PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Abebaw, A; Tesera, H; Belachew, T; Mihiretie, GD				Abebaw, Abtie; Tesera, Hiwot; Belachew, Teshome; Mihiretie, Gebreselassie Demeke			The bacterial profile and antibiotic susceptibility pattern among patients with suspected bloodstream infections, Gondar, north-west Ethiopia	PATHOLOGY AND LABORATORY MEDICINE INTERNATIONAL			English	Article						bacteremia; drug susceptibility; sepsis; resistant	BACTEREMIA; PROGNOSIS; ETIOLOGY; CULTURE	Background: The bacteria most likely to cause bacteremia include Staphylococcus, Streptococcus, Enterococcus, Escherichia, Klebsiella, Pseudomonas, Enterobacter, Haemophilus, and Neisseria genera. Bloodstream infections remain one of the most important causes of morbidity and mortality throughout the world. Drug-resistant pathogens are becoming the most challenging problem and they have different economic and social impacts around the world. Objective: To study the bacterial profile and antibiotic susceptibility among bacteremia-suspected patients in the University of Gondar Teaching Hospital from September 2003 to February 2013. Materials and method: This retrospective cross-sectional study was conducted from March to May 2013 at the University of Gondar. Data were collected and extracted manually from the microbiology registration books of the hospital laboratory using checklists and were checked for its completeness and consistency. Result: Among a total of 856 blood samples analyzed, 169 (19.7%) cases were bacteremia confirmed. From the confirmed cases, 98 (58%) were male and 71 (42%) female. Culture positivity rate was highest (44%) in the age group of <= 28 days followed by the age group of 29 days-5 years. Conclusion: In our study, coagulase-negative staphylococci were the most common causative agent for bacteremia among the Gram-positive isolates. The overall antimicrobial susceptibility pattern of the Gram-positive isolates was an intermediate level of resistance (60%-80%), but Gram-negative bacteria showed a high level of resistance (>80%) against ampicillin and amoxicillin.	[Abebaw, Abtie; Mihiretie, Gebreselassie Demeke] Debre Markos Univ, Coll Med & Hlth Sci, Dept Med Lab Sci, POB 269, Debre Markos, Ethiopia; [Tesera, Hiwot] Univ Gondar, Coll Med & Hlth Sci, Dept Med Lab Sci, Gondar, Ethiopia; [Belachew, Teshome] Bahirdar Univ, Coll Med & Hlth Sci, Dept Med Lab Sci, Bahir Dar, Ethiopia	Mihiretie, GD (reprint author), Debre Markos Univ, Coll Med & Hlth Sci, Dept Med Lab Sci, POB 269, Debre Markos, Ethiopia.	gebredemeke@yahoo.com	Shiferaw, Abtie Ababaw/I-5040-2019	Belachew, Teshome/0000-0003-4350-9803			Ali H, 2008, MED J BABYLON, V5, P385; Ali Jemal, 2008, Ethiop Med J, V46, P155; Asrat D, 2001, ETHIOPIAN MED J, V39, P97; Bachou H, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-160; BARBER M, 1961, J CLIN PATHOL, V14, P385, DOI 10.1136/jcp.14.4.385; BENNETT IL, 1954, YALE J BIOL MED, V26, P241; Bhat YR, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-32; BRYAN CS, 1989, CLIN MICROBIOL REV, V2, P329; Cheesbrough M., 2000, DISTRICT LAB PRACT 2, P62; Clinical and Laboratory Standards Institute, 2005, CLSI PUBL; Forbes BA, 2007, BAILEY SCOTTS DIAGNO, P778; Garg A, 2007, J INDIAN ACAD CLIN M, V8, P139; Horieh S, 2012, 30 ANN M EUR SOC PAE; Javaloyas M, 2002, SCAND J INFECT DIS, V34, P436, DOI 10.1080/00365540110080629; Kalantar E, 2008, JUNDISHAPUR J NAT PH, V3, P1; Karlowsky James A, 2004, Ann Clin Microbiol Antimicrob, V3, P7, DOI 10.1186/1476-0711-3-7; Karunakaran Rina, 2007, Journal of Microbiology Immunology and Infection, V40, P432; Kuppermann N, 1999, PEDIATR CLIN N AM, V46, P1073, DOI 10.1016/S0031-3955(05)70176-0; Mehdinejad M., 2009, Journal of Biological Sciences, V9, P249, DOI 10.3923/jbs.2009.249.253; Panceri ML, 2004, EPIDEMIOL INFECT, V132, P647, DOI 10.1017/S0950268803001080; Pedersen G, 2003, CLIN MICROBIOL INFEC, V9, P793, DOI 10.1046/j.1469-0691.2003.00599.x; Pourakbari B, 2012, J INFECT DEV COUNTR, V6, P120, DOI 10.3855/jidc.1517; Worku S., 2003, ETHIOP J HEALTH DEV, V17, P111; Zenebe T, 2011, ETHIOP J HEALTH SCI, V21, P1	24	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND		1179-2698		PATHOL LAB MED INT	Pathol. Lab. Med. Int.		2018	10						1	7		10.2147/PLMI.S153444			7	Pathology	Pathology	GC9FA	WOS:000430101700001		DOAJ Gold			2019-10-28	
J	Sidawy, MK; Wojcik, EM				Sidawy, Mary K.; Wojcik, Eva M.			New Names for Old Entities-A Potpouri of Newly Defined Tumors	AJSP-REVIEWS AND REPORTS			English	Editorial Material									[Sidawy, Mary K.] MedStar Georgetown Univ Hosp, Dept Pathol, Washington, DC USA; [Wojcik, Eva M.] Loyola Univ Med Ctr, Dept Pathol & Lab Med, Pathol & Urol, Maywood, IL 60153 USA	Sidawy, MK (reprint author), MedStar Georgetown Univ Hosp, Dept Pathol, Washington, DC USA.							0	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JAN-FEB	2018	23	1					1	2		10.1097/PCR.0000000000000228			2	Pathology	Pathology	GB8DA	WOS:000429304100001					2019-10-28	
J	Rossi, ED; LiVolsi, VA; Baloch, Z				Rossi, Esther Diana; LiVolsi, Virginia A.; Baloch, Zubair			Noninvasive Follicular Neoplasm of Thyroid With Papillary Like Nuclear Features: A Redefined Indolent Neoplasm of the Thyroid Gland	AJSP-REVIEWS AND REPORTS			English	Review						fine-needle aspiration cytology; I-FVPC; NIFTPs; thyroid lesions	YOUNG INVESTIGATOR CHALLENGE; NEEDLE-ASPIRATION-CYTOLOGY; MOLECULAR CLASSIFICATION; INDETERMINATE CYTOLOGY; OBSERVER VARIATION; RAS MUTATIONS; CARCINOMA; VARIANT; DIAGNOSIS; NODULES	Follicular variant of papillary thyroid carcinoma (FVPC) represents approximately 30% of all papillary thyroid carcinomas and includes encapsulated, both invasive and noninvasive forms (E-FVPC), and infiltrative FVPCs with different biological behaviors and molecular profiles. The E-FVPC exhibits very low regional recurrence and metastatic potential with a biological behavior similar to that of follicular adenomas. In 2015, a panel of endocrine pathologists, endocrinologists, surgeons, and patient advocates recommended the revision of the diagnostic terminology for cases of noninvasive E-FVPC to rename them as "noninvasive follicular thyroid neoplasm with papillary-like nuclear features." This revised term was defined by a specific set of morphological features characterized by a noninvasive follicular patterned neoplasm with nuclear features of papillary thyroid carcinoma, scant nuclear pseudoinclusions, and lack of papillary structures and psammoma bodies. The downgrading of noninvasive follicular thyroid neoplasms with papillary-like nuclear features to "not cancer" influences not only the histologic diagnosis but also the preoperative fine-needle aspiration diagnosis and the associated malignancy risk of various diagnostic categories used in the reporting of thyroid fine-needle aspiration specimens. The case presented here with follow-up discussion highlights the pathologic features, potential controversies, and management of patients with this diagnosis.	[Rossi, Esther Diana] Univ Cattolica Sacro Cuore, Div Anat Pathol & Histol, Fdn Policlin Univ A Gemelli, Rome, Italy; [LiVolsi, Virginia A.; Baloch, Zubair] Hosp Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, 3400 Spruce St, Philadelphia, PA 19104 USA	Baloch, Z (reprint author), Hosp Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, 3400 Spruce St, Philadelphia, PA 19104 USA.	zubair.baloch2@uphs.upenn.edu					Alexander EK, 2012, NEW ENGL J MED, V367, P705, DOI 10.1056/NEJMoa1203208; Ali SZ, 2011, ACTA CYTOL, V55, P4, DOI 10.1159/000322365; [Anonymous], 2015, CANCER DISCOV, V5, P5, DOI 10.1158/2159-8290.CD-NB2014-165; Asa SL, 2015, THYROID, V25, P1, DOI 10.1089/thy.2014.0540; Baloch Z, 2002, AM J CLIN PATHOL, V118, P603; Baloch ZW, 2007, J CLIN PATHOL, V60, P244, DOI 10.1136/jcp.2006.038604; Baloch ZW, 2010, ENDOCR PRACT, V16, P952, DOI 10.4158/EP10060.OR; Bizzarro T, 2016, CANCER CYTOPATHOL, V124, P699, DOI 10.1002/cncy.21777; Borrelli N, 2016, CANCER CYTOPATHOL, V124, P340, DOI 10.1002/cncy.21681; Chan JKC, 2002, AM J CLIN PATHOL, V117, P16; Cho U, 2017, MODERN PATHOL, V30, P810, DOI 10.1038/modpathol.2017.9; Chudova D, 2010, J CLIN ENDOCR METAB, V95, P5296, DOI 10.1210/jc.2010-1087; Duick DS, 2012, THYROID, V22, P996, DOI 10.1089/thy.2012.0180; Elsheikh TM, 2008, AM J CLIN PATHOL, V130, P736, DOI 10.1309/AJCPKP2QUVN4RCCP; Faquin WC, 2016, CANCER CYTOPATHOL, V124, P181, DOI 10.1002/cncy.21631; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Gupta N, 2013, J CLIN ENDOCR METAB, V98, pE914, DOI 10.1210/jc.2012-3396; Hahn SY, 2017, AM J NEURORADIOL, V38, P777, DOI 10.3174/ajnr.A5075; Hirokawa M, 2002, AM J SURG PATHOL, V26, P1508, DOI 10.1097/00000478-200211000-00014; Howitt BE, 2015, AM J CLIN PATHOL, V144, P850, DOI 10.1309/AJCPEIE12POICULI; Ibrahim AA, 2016, AM J CLIN PATHOL, V146, P373, DOI [10.1093/AJCP/AQW126, 10.1093/ajcp/aqw126]; Jiang XY, 2016, CANCER CYTOPATHOL, V124, P893, DOI 10.1002/cncy.21802; Lee SE, 2017, THYROID, V27, P802, DOI 10.1089/thy.2016.0547; Liu J, 2006, CANCER-AM CANCER SOC, V107, P1255, DOI 10.1002/cncr.22138; Lloyd RV, 2004, AM J SURG PATHOL, V28, P1336, DOI 10.1097/01.pas.0000135519.34847.f6; Logani S, 2000, DIAGN CYTOPATHOL, V23, P380, DOI 10.1002/1097-0339(200012)23:6<380::AID-DC3>3.0.CO;2-0; Maletta F, 2016, HUM PATHOL, V54, P134, DOI 10.1016/j.humpath.2016.03.014; Na DG, 2017, KOREAN J RADIOL, V18, P217, DOI 10.3348/kjr.2017.18.1.217; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Nikiforov YE, 2014, CANCER-AM CANCER SOC, V120, P3627, DOI 10.1002/cncr.29038; Nikiforova MN, 2013, J CLIN ENDOCR METAB, V98, pE1852, DOI 10.1210/jc.2013-2292; Ohori NP, 2017, CANCER CYTOPATHOL, V125, P292, DOI 10.1002/cncy.21830; Ohori NP, 2010, CANCER CYTOPATHOL, V118, P17, DOI 10.1002/cncy.20063; Paulson VA, 2017, THYROID, V27, P506, DOI 10.1089/thy.2016.0583; Piana S, 2010, AM J SURG PATHOL, V34, P868, DOI 10.1097/PAS.0b013e3181dbee07; Renshaw AA, 2002, AM J CLIN PATHOL, V117, P19; Rivera M, 2009, THYROID, V19, P119, DOI 10.1089/thy.2008.0303; Rosario PW, 2016, ENDOCR-RELAT CANCER, V23, P893, DOI 10.1530/ERC-16-0379; Strickland KC, 2015, THYROID, V25, P987, DOI 10.1089/thy.2014.0612; Ustun B, 2014, ENDOCR PATHOL, V25, P257, DOI 10.1007/s12022-014-9301-3; Valderrabano P, 2017, ENDOCR-RELAT CANCER, V24, P127, DOI 10.1530/ERC-16-0512; Vivero M, 2013, THYROID, V23, P273, DOI 10.1089/thy.2012.0369; Williams ED, 2000, INT J SURG PATHOL, V8, P181, DOI 10.1177/106689690000800304; Witt RL, 2013, LARYNGOSCOPE, V123, P1059, DOI 10.1002/lary.23838; Wu HHJ, 2003, DIAGN CYTOPATHOL, V29, P262, DOI 10.1002/dc.10388; Xu B, 2015, HUM PATHOL, V46, P1789, DOI 10.1016/j.humpath.2015.08.015; Yang GCH, 2017, DIAGN CYTOPATHOL, V45, P533, DOI 10.1002/dc.23709; Zhao LN, 2017, CANCER CYTOPATHOL, V125, P323, DOI 10.1002/cncy.21839	48	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JAN-FEB	2018	23	1					3	7		10.1097/PCR.0000000000000225			5	Pathology	Pathology	GB8DA	WOS:000429304100002					2019-10-28	
J	Ongkeko, M; Zeck, J; de Brito, P				Ongkeko, Martin; Zeck, Jay; de Brito, Pedro			Molecular Testing Uncovers an Adamantinoma-Like Ewing Family of Tumors in the Thyroid: Case Report and Review of Literature	AJSP-REVIEWS AND REPORTS			English	Review						adamantinoma-like Ewing family of tumors; EWSR-FLI1; thyroid	SPINDLE EPITHELIAL TUMOR; NUT MIDLINE CARCINOMA; NEUROECTODERMAL TUMOR; SARCOMA; ELEMENTS; NECK; DIFFERENTIATION; HISTOGENESIS; DIAGNOSIS; ANTIBODY	Adamantinoma-like Ewing family of tumors (EFT) is a rare and unique variant of the Ewing family. Like all entities within this family, adamantinoma-like EFTs harbor the characteristic translocation between the EWS gene and one of several transcription factors in the ETS family. This tumor was named because of resemblance to adamantinoma and was first described in bone. Adamantinoma-like EFT is a mesenchymal tumor but exhibits an epithelioid morphology and immunoprofile. The rarity of this tumor, along with its unusual morphologic characteristics, makes it a particularly challenging diagnosis. We present a case of a malignant neoplasm of the thyroid showing epithelioid and basaloid nests with metastases to cervical lymph nodes and pancreas. This case was initially classified as a poorly differentiated thyroid carcinoma. Following an extended molecular analysis of the tumor, reverse transcriptase-polymerase chain reaction detected the hallmark EWSR:FLI1 gene fusion. This case was subsequently reclassified as adamantinoma-like EFT. In cases of basaloid or undifferentiated epithelioid tumors, the possibility of adamantinoma-like EFT should be included in a working differential diagnosis. Testing for CD99 and EWSR: FLI1 gene fusion is confirmatory.	[Ongkeko, Martin; Zeck, Jay; de Brito, Pedro] MedStar Georgetown Univ Hosp, Dept Pathol, 3900 Reservoir Rd NW,Med Dent Bldg South West, Washington, DC 20007 USA	Ongkeko, M (reprint author), MedStar Georgetown Univ Hosp, Dept Pathol, 3900 Reservoir Rd NW,Med Dent Bldg South West, Washington, DC 20007 USA.	martin.s.ongkeko@gunet.georgetown.edu					Adapa P, 2009, PEDIATR RADIOL, V39, P1365, DOI 10.1007/s00247-009-1388-1; Ahmad R, 1999, CANCER, V85, P725, DOI 10.1002/(SICI)1097-0142(19990201)85:3<725::AID-CNCR23>3.0.CO;2-2; Bishop JA, 2015, AM J SURG PATHOL, V39, P1267, DOI 10.1097/PAS.0000000000000460; Biswas G, 2005, ORAL ONCOL EXTRA, V42, P198; Bridge JA, 1999, AM J SURG PATHOL, V23, P159, DOI 10.1097/00000478-199902000-00004; Chan JM, 2013, HEAD NECK-J SCI SPEC, V35, pE346, DOI 10.1002/hed.23240; Chetty R, 1998, HISTOPATHOLOGY, V33, P71, DOI 10.1046/j.1365-2559.1998.00441.x; Chirila M, 2013, ENT-EAR NOSE THROAT, V92, P3; Choi EYK, 2014, SEMIN DIAGN PATHOL, V31, P39, DOI 10.1053/j.semdp.2014.01.002; Cruz J, 2011, INT J SURG PATHOL, V19, P620, DOI 10.1177/1066896911405320; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; de Alava Enrique, 2017, Surg Pathol Clin, V10, P575, DOI 10.1016/j.path.2017.04.001; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DeLellis R.A, 2004, PATHOLOGY GENETICS T, P73; Ehrlich Y, 2010, ANN ONCOL, V21, P1846, DOI 10.1093/annonc/mdq045; El Hachem G, 2017, J CLIN REV CASE REP, V1, P1; Eloy C, 2014, INT J SURG PATHOL, V22, P579, DOI 10.1177/1066896913486697; Eloy C, 2014, INT J SURG PATHOL, V22, P260, DOI 10.1177/1066896913486696; Ewing J., 1921, P NEW YORK PATHOL S, V21, P17; Folpe AL, 2005, AM J SURG PATHOL, V29, P1025; French C, 2014, NAT REV CANCER, V14, P149, DOI 10.1038/nrc3659; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; JONES JE, 1995, ARCH OTOLARYNGOL, V121, P1392; Khoury JD, 2005, ADV ANAT PATHOL, V12, P212, DOI 10.1097/01.pap.0000175114.55541.52; Llombart-Bosch A, 2009, VIRCHOWS ARCH, V455, P397, DOI 10.1007/s00428-009-0842-7; Machado I, 2011, VIRCHOWS ARCH, V458, P281, DOI 10.1007/s00428-010-1023-4; Maldi E, 2012, PATHOL RES PRACT, V208, P356, DOI 10.1016/j.prp.2012.03.005; Mhawech-Fauceglia P, 2007, J CLIN PATHOL, V60, P694, DOI 10.1136/jcp.2006.039230; Misra RK, 2013, ACTA CYTOL, V57, P303, DOI 10.1159/000346704; Natale R, 2013, RARE TUMORS, V5, DOI 10.4081/rt.2013.e20; ORDONEZ NG, 1991, AM J CLIN PATHOL, V96, P15, DOI 10.1093/ajcp/96.1.15; Pinto Alfredo, 2011, Sarcoma, DOI 10.1155/2011/856190; Pusztaszeri MP, 2014, ADV ANAT PATHOL, V21, P26, DOI 10.1097/PAP.0000000000000004; Ragazzi M, 2014, INT J ENDOCRINOL, DOI 10.1155/2014/790834; Ryu CH, 2011, CLIN EXP OTORHINOLAR, V4, P204, DOI 10.3342/ceo.2011.4.4.204; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; USHIGOME S, 2002, WHO CLASSIFICATION T, P298; Volante M, 2007, AM J SURG PATHOL, V31, P1256, DOI 10.1097/PAS.0b013e3180309e6a; Wang YF, 2015, AM J CLIN PATHOL, V143, P223, DOI 10.1309/AJCPB7PS6QHWEFRK; Weinreb I, 2008, AM J SURG PATHOL, V32, P1742, DOI 10.1097/PAS.0b013e3181706252; Yerly S, 2010, ACTA CYTOL, V54, P911	41	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JAN-FEB	2018	23	1					8	12		10.1097/PCR.0000000000000227			5	Pathology	Pathology	GB8DA	WOS:000429304100003					2019-10-28	
J	Rooper, LM; Westra, WH				Rooper, Lisa M.; Westra, William H.			A Protein Lost, a Diagnosis Gained: A Review of SMARCB1-Deficient Sinonasal Carcinomas	AJSP-REVIEWS AND REPORTS			English	Review						INI1; sinonasal carcinomas; SMARCB1	SINGLE-INSTITUTION EXPERIENCE; UNDIFFERENTIATED CARCINOMA; EPITHELIOID SARCOMA; INI1 EXPRESSION; MYOEPITHELIAL-CARCINOMAS; RHABDOID TUMORS; TRACT; FEATURES; MUTATIONS; CANCER	In recent years, improved molecular techniques have allowed for extensive reclassification of sinonasal tumors, particularly those previously diagnosed as sinonasal undifferentiated carcinomas. SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily B, member 1-deficient sinonasal carcinoma is one such recently described entity defined by loss of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily B, member 1 (INI1) protein expression by immunohistochemistry. This review characterizes the clinical, histologic, molecular, and immunohistochemical features of this novel entity with an emphasis on its differential diagnosis.	[Rooper, Lisa M.; Westra, William H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Westra, William H.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Westra, William H.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA	Westra, WH (reprint author), Johns Hopkins Med Inst, 401 N Broadway,Weinberg Bldg,Suite 2242, Baltimore, MD 21231 USA.	wwestra@jhmi.edu					Agaimy A, 2017, AM J SURG PATHOL, V41, P458, DOI 10.1097/PAS.0000000000000797; Agaimy A, 2017, AM J SURG PATHOL, V41, P253, DOI 10.1097/PAS.0000000000000787; Agaimy A, 2016, AM J SURG PATHOL, V40, P544, DOI 10.1097/PAS.0000000000000554; Agaimy A, 2015, MODERN PATHOL, V28, P248, DOI 10.1038/modpathol.2014.100; Agaimy A, 2014, AM J SURG PATHOL, V38, P1274, DOI 10.1097/PAS.0000000000000236; Allison DB, 2016, DIAGN CYTOPATHOL, V44, P700, DOI 10.1002/dc.23503; Arnold MA, 2013, HUM PATHOL, V44, P881, DOI 10.1016/j.humpath.2012.08.014; Barresi V, 2016, NEUROPATHOLOGY, V36, P283, DOI 10.1111/neup.12271; Bell D, 2015, VIRCHOWS ARCH, V467, P649, DOI 10.1007/s00428-015-1853-1; Biegel JA, 2002, CLIN CANCER RES, V8, P3461; Biegel JA, 1999, CANCER RES, V59, P74; Bishop JA, 2017, AM J SURG PATHOL; Bishop JA, 2015, AM J SURG PATHOL, V39, P1267, DOI 10.1097/PAS.0000000000000460; Bishop JA, 2014, AM J SURG PATHOL, V38, P1282, DOI 10.1097/PAS.0000000000000285; Bishop JA, 2013, AM J SURG PATHOL, V37, P836, DOI 10.1097/PAS.0b013e31827b1cd6; Bishop JA, 2012, AM J SURG PATHOL, V36, P1216, DOI 10.1097/PAS.0b013e318254ce54; Cheng JX, 2008, MODERN PATHOL, V21, P647, DOI 10.1038/modpathol.2008.44; Dogan S, 2017, J PATHOL, V242, P400, DOI 10.1002/path.4915; FRIERSON HF, 1986, AM J SURG PATHOL, V10, P771, DOI 10.1097/00000478-198611000-00004; Hasselblatt M, 2009, J NEUROPATH EXP NEUR, V68, P1249, DOI 10.1097/NEN.0b013e3181c06a51; Hollmann TJ, 2011, AM J SURG PATHOL, V35, pE47, DOI 10.1097/PAS.0b013e31822b325b; Hornick JL, 2009, AM J SURG PATHOL, V33, P542, DOI 10.1097/PAS.0b013e3181882c54; Jamshidi F, 2014, ONCOLOGIST, V19, P623, DOI 10.1634/theoncologist.2013-0390; Jo VY, 2017, AM J SURG PATHOL, V41, P1013, DOI 10.1097/PAS.0000000000000849; Jo VY, 2017, MODERN PATHOL, V30, P650, DOI 10.1038/modpathol.2016.239; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kohashi K, 2017, CANCER SCI, V108, P547, DOI 10.1111/cas.13173; Laco J, 2017, PATHOL RES PRACT, V213, P133, DOI 10.1016/j.prp.2016.10.012; Le Loarer F, 2014, GENE CHROMOSOME CANC, V53, P475, DOI 10.1002/gcc.22159; Lewis JS, 2017, WHO CLASSIFICATION H, P18; Myers LL, 2002, LARYNGOSCOPE, V112, P1964, DOI 10.1097/00005537-200211000-00010; Rekhi B, 2017, APMIS, V125, P679, DOI 10.1111/apm.12702; Rooper Lisa M, 2017, Surg Pathol Clin, V10, P103, DOI 10.1016/j.path.2016.10.005; Shatzkes DR, 2016, AJNR AM J NEURORADIO; Stelow EB, 2008, AM J SURG PATHOL, V32A, P828, DOI 10.1097/PAS.0b013e31815a3900; Strehl JD, 2015, ANN DIAGN PATHOL, V19, P198, DOI 10.1016/j.anndiagpath.2015.04.001; Sullivan LM, 2013, MODERN PATHOL, V26, P385, DOI 10.1038/modpathol.2012.175; Thompson LDR, 2017, VIRCHOWS ARCH; Thompson LDR, 2017, MODERN PATHOL, V30, pS1, DOI 10.1038/modpathol.2016.119; Turner JH, 2012, HEAD NECK-J SCI SPEC, V34, P877, DOI 10.1002/hed.21830; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang J, 2016, HUM PATHOL, V55, P83, DOI 10.1016/j.humpath.2016.04.018; Wasserman JK, 2017, HEAD NECK PATHOL, V11, P256, DOI 10.1007/s12105-016-0752-3; Zeng M, 2016, INT J CLIN EXP PATHO, V9, P3454	44	1	1	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JAN-FEB	2018	23	1					13	18		10.1097/PCR.0000000000000222			6	Pathology	Pathology	GB8DA	WOS:000429304100004					2019-10-28	
J	Jo, VY; Krane, JF				Jo, Vickie Y.; Krane, Jeffrey F.			Clinicopathologic Features of Secretory Carcinoma of Salivary Gland: An Updated Review	AJSP-REVIEWS AND REPORTS			English	Review						mammary analog secretory carcinoma; parotid; salivary gland; secretory carcinoma	ACINIC CELL-CARCINOMA; ETV6-NTRK3 GENE FUSION; HIGH-GRADE TRANSFORMATION; CYTOPATHOLOGIC FEATURES; CYTOLOGICAL FEATURES; DUCT CARCINOMA; THYROID-GLAND; IMMUNOHISTOCHEMISTRY; EXPRESSION; DIAGNOSIS	Secretory carcinoma of the salivary gland was first recognized in 2010 and has since been characterized by clinical, pathologic, and genetic means. Tumors share morphologic, immunophenotypic, and genetic features with primary breast secretory carcinoma, which facilitated its recognition as a distinct salivary entity. Definitive diagnosis is based on the characteristic immunophenotype of S100 and mammaglobin positivity and the presence of the ETV6-NTRK3 fusion gene; these features have allowed reclassification of tumors most frequently originally classified as acinic cell carcinoma variants. We present a case of secretory carcinoma that was reclassified from cystadenocarcinoma using immunohistochemical andmolecular testing and present an updated review of the clinicopathologic features with discussion of differential diagnosis.	[Jo, Vickie Y.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA	Jo, VY (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	vjo@bwh.harvard.edu					Amin SM, 2016, AM J DERMATOPATH, V38, P842, DOI 10.1097/DAD.0000000000000590; Baghai F, 2017, PATHOL RES PRACT, V213, P1112, DOI 10.1016/j.prp.2017.07.017; Bishop JA, 2017, AM J SURG PATHOL, V41, P62, DOI 10.1097/PAS.0000000000000734; Bishop JA, 2013, HUM PATHOL, V44, P1982, DOI 10.1016/j.humpath.2013.03.017; Bishop JA, 2013, AM J SURG PATHOL, V37, P1053, DOI 10.1097/PAS.0b013e3182841554; Bishop JA, 2013, CANCER CYTOPATHOL, V121, P228, DOI 10.1002/cncy.21245; Bishop JA, 2013, HEAD NECK PATHOL, V7, P35, DOI 10.1007/s12105-013-0429-0; Chang MD, 2016, J CUTAN PATHOL, V43, P1045, DOI 10.1111/cup.12788; Chenevert J, 2012, MODERN PATHOL, V25, P919, DOI 10.1038/modpathol.2012.57; Chiosea SI, 2012, HISTOPATHOLOGY, V61, P387, DOI 10.1111/j.1365-2559.2012.04232.x; Chiosea SI, 2012, AM J SURG PATHOL, V36, P343, DOI 10.1097/PAS.0b013e318242a5b0; Cipriani NA, 2017, INT J SURG PATHOL, V25, P613, DOI 10.1177/1066896917709350; Connor A, 2012, AM J SURG PATHOL, V36, P27, DOI 10.1097/PAS.0b013e318231542a; Dettloff J, 2017, HEAD NECK PATHOL, V11, P124, DOI 10.1007/s12105-016-0741-6; Dogan S, 2016, MODERN PATHOL, V29, P985, DOI 10.1038/modpathol.2016.115; Drilon A, 2016, ANN ONCOL, V27, P920, DOI 10.1093/annonc/mdw042; Drilon AD, 2008, CANCER-AM CANCER SOC, V113, P3364, DOI 10.1002/cncr.23978; Griffith C, 2011, VIRCHOWS ARCH, V459, P117, DOI 10.1007/s00428-011-1098-6; Griffith CC, 2013, CANCER CYTOPATHOL, V121, P234, DOI 10.1002/cncy.21249; Guilmette J, 2017, HEAD NECK PATHOL, V11, P419, DOI 10.1007/s12105-017-0784-3; Hechtman JF, 2017, AM J SURG PATHOL, V41, P1547, DOI 10.1097/PAS.0000000000000911; Higuchi K, 2014, DIAGN CYTOPATHOL, V42, P846, DOI 10.1002/dc.23139; Hsieh MS, 2016, HUM PATHOL, V56, P134, DOI 10.1016/j.humpath.2016.05.021; Hsieh MS, 2016, HISTOPATHOLOGY, V68, P641, DOI 10.1111/his.12792; Ito Y, 2015, AM J SURG PATHOL, V39, P602, DOI 10.1097/PAS.0000000000000392; Jung MJ, 2015, DIAGN CYTOPATHOL, V43, P287, DOI 10.1002/dc.23208; Jung MJ, 2013, KOREAN J PATHOL, V47, P36, DOI 10.4132/KoreanJPathol.2013.47.1.36; Kawahara A, 2015, CANCER CYTOPATHOL, V123, P603, DOI 10.1002/cncy.21594; Khurram SA, 2016, OR SURG OR MED OR PA, V122, P731, DOI 10.1016/j.oooo.2016.07.008; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kralik JM, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-19; Kratochvil FJ, 2012, OR SURG OR MED OR PA, V114, P630, DOI 10.1016/j.oooo.2012.07.480; Luk PP, 2015, PATHOLOGY, V47, P659, DOI 10.1097/PAT.0000000000000322; Luo WY, 2014, INT J CLIN EXP PATHO, V7, P9008; Mariano FV, 2016, HEAD NECK PATHOL, V10, P429, DOI 10.1007/s12105-016-0718-5; Ngouajio AL, 2017, INT J PEDIATR OTORHI, V100, P187, DOI 10.1016/j.ijporl.2017.07.004; Patel KR, 2013, HUM PATHOL, V44, P2501, DOI 10.1016/j.humpath.2013.06.010; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; Samulski TD, 2014, CYTOJOURNAL, V11, DOI 10.4103/1742-6413.139726; Schwartz LE, 2013, HEAD NECK PATHOL, V7, P311, DOI 10.1007/s12105-013-0442-3; Shah AA, 2015, HEAD NECK PATHOL, V9, P85, DOI 10.1007/s12105-014-0557-1; Skalova A, 2016, AM J SURG PATHOL, V40, P3, DOI 10.1097/PAS.0000000000000537; Skalova A, 2014, AM J SURG PATHOL, V38, P23, DOI 10.1097/PAS.0000000000000088; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Stevens TM, 2015, MODERN PATHOL, V28, P1084, DOI 10.1038/modpathol.2015.64; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Wu EY, 2017, HISTOPATHOLOGY, V71, P665, DOI 10.1111/his.13268	47	0	0	2	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JAN-FEB	2018	23	1					19	24		10.1097/PCR.0000000000000230			6	Pathology	Pathology	GB8DA	WOS:000429304100005					2019-10-28	
J	Shelman, NR; Kyrillos, AM; deBrito, PA; Zeck, JC				Shelman, Nathan R.; Kyrillos, Alexandra M.; deBrito, Pedro A.; Zeck, Jay C.			NUT Midline Carcinoma: An Underdiagnosed and Often Misunderstood Entity	AJSP-REVIEWS AND REPORTS			English	Review						BRD4; head and neck; NUT; NUT midline carcinoma; undifferentiated carcinoma	ALPHA-FETOPROTEIN; FEATURES; TUMOR; DIFFERENTIATION; INHIBITOR; ELEVATION; OUTCOMES	NUT (nuclear protein in testis) midline carcinoma (NMC) is a rare and aggressive poorly differentiated squamous carcinoma that typically presents in midline regions, most often involving the mediastinum and head and neck. An entity previously thought to impact only pediatric and young-adult populations, NMC has been accepted more recently as impacting all ages. It is thought that NMC remains underdiagnosed, likely due to lack of awareness and the misconception of a pediatric-only presentation. Recent development of a NUT-specific monoclonal antibody has made confirming the diagnosis less problematic; however, this test is not widely available. Management of NMC is difficult, although recent developments in targeted therapeutics have shown promise. We present a case of presumed metastatic NUT midline carcinoma from our institution, as well as a review of NMC, focusing on clinical, histopathologic, and immunohistochemical features, and a brief discussion of the molecular aberrations characteristic of this entity.	[Shelman, Nathan R.; deBrito, Pedro A.; Zeck, Jay C.] MedStar Georgetown Univ Hosp, Dept Pathol, 3800 Reservoir Rd NW,Med Dent Bldg, Washington, DC 20007 USA; [Kyrillos, Alexandra M.] Georgetown Univ, Sch Med, Washington, DC USA	Shelman, NR (reprint author), MedStar Georgetown Univ Hosp, Dept Pathol, 3800 Reservoir Rd NW,Med Dent Bldg, Washington, DC 20007 USA.	Nathan.R.Shelman@gunet.georgetown.edu					Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Bishop JA, 2016, CANCER CYTOPATHOL, V124, P901, DOI 10.1002/cncy.21761; Bishop JA, 2014, AM J SURG PATHOL, V38, P1282, DOI 10.1097/PAS.0000000000000285; Chau NG, 2016, CANCER-AM CANCER SOC, V122, P3632, DOI 10.1002/cncr.30242; D'Ambrosio L, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3262-0; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2013, HEAD NECK PATHOL, V7, P11, DOI 10.1007/s12105-013-0428-1; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; French CA, 2003, CANCER RES, V63, P304; French CA, 2012, ANNU REV PATHOL-MECH, V7, P247, DOI 10.1146/annurev-pathol-011811-132438; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Harada Y, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2944-3; Harms A, 2015, LUNG CANCER, V90, P484, DOI 10.1016/j.lungcan.2015.10.001; KEES UR, 1991, AM J PEDIAT HEMATOL, V13, P459; KUBONISHI I, 1991, CANCER RES, V51, P3327; Lemelle L, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26693; Maher OM, 2015, PEDIATR BLOOD CANCER, V62, P715, DOI 10.1002/pbc.25350; Mertens F, 2007, PEDIATR BLOOD CANCER, V49, P1015, DOI 10.1002/pbc.20755; Nakamura H, 2015, PATHOL RES PRACT, V211, P92, DOI 10.1016/j.prp.2014.07.006; Perkins Crystal, 2017, World J Nucl Med, V16, P247, DOI 10.4103/1450-1147.207284; Raza A, 2015, EXPERT REV ANTICANC, V15, P1199, DOI 10.1586/14737140.2015.1082909; Schwartz BE, 2011, CANCER RES, V71, P2686, DOI 10.1158/0008-5472.CAN-10-3513; Shehata BM, 2010, PEDIATR DEVEL PATHOL, V13, P481, DOI 10.2350/09-10-0727-CR.1; Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335; Tanaka M, 2012, AM J SURG PATHOL, V36, P381, DOI 10.1097/PAS.0b013e31824230a8; Torre M, 2017, CANCER CYTOPATHOL, V125, P70, DOI 10.1002/cncy.21794; Travis WD, 2015, WHO CLASSIFICATION T, V7; Vargas SO, 2001, CANCER, V92, P1195, DOI 10.1002/1097-0142(20010901)92:5<1195::AID-CNCR1438>3.0.CO;2-3; Wang R, 2017, P NATL ACAD SCI USA, V114, pE5361; Wartchow EP, 2012, ULTRASTRUCT PATHOL, V36, P280, DOI 10.3109/01913123.2012.664613; Wasserman JK, 2016, INT J SURG PATHOL, V24, P85, DOI 10.1177/1066896915606970	31	0	0	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JAN-FEB	2018	23	1					25	29		10.1097/PCR.0000000000000223			5	Pathology	Pathology	GB8DA	WOS:000429304100006					2019-10-28	
J	Picken, MM; Jones, CH; Turk, TMT				Picken, Maria M.; Jones, Carolyn H.; Turk, Thomas M. T.			Benign Mixed Epithelial and Stromal Tumor of the Kidney With Cytogenetic Alterations-Advances and Controversies in Classification of Biphasic Cystic Renal Tumors	AJSP-REVIEWS AND REPORTS			English	Review						cytogenetics; differential diagnosis; mixed epithelial and stromal tumor of the kidney	OF-THE-LITERATURE; 1ST CASE-REPORT; DICER1 MUTATIONS; SYNOVIAL SARCOMA; NEPHROMA; ADULT; MEST; DIFFERENTIATION; ANGIOMYOLIPOMA; FEATURES	We present a case of benignmixed epithelial and stromal tumor of the kidney (MEST) with some unusual features, such as a partially exophytic growth, relatively solid tumor architecture, and negative stains for estrogen/progesterone receptors. We also report the results of cytogenetic studies and discuss the differential diagnosis of the MEST family of tumors in the context of other biphasic cystic renal lesions. Based on the molecular studies thus far published, MEST and adult cystic nephroma are similar to each other but different from other kidney lesions, including morphologically similar cystic and biphasic pediatric lesions. The discovery of the molecular signatures of several cystic renal lesions has led to their proper classification. However, with regard to the MEST family of tumors, the search for a "signature" molecular abnormality continues, and at present, molecular studies focus on the exclusion of abnormalities diagnostic of morphologically overlapping lesions. At present, patient age seems to be the most useful factor in the classification of morphologically similar lesions. Although the term mixed epithelial and stromal tumor family is all inclusive, retention of the term cystic nephroma, for both pediatric and adult lesions, will continue to create confusion. Although most MEST lesions are benign, caution is advised in the management of patients with limited tumor sampling, such as occurs in core biopsy or cytology. It is also prudent to ensure adequate resection specimen sampling and a negative margin because malignant transformation can occur, accompanied by a dismal prognosis, whereas incomplete tumor resection can lead to recurrence.	[Picken, Maria M.] Loyola Univ Med Ctr, Dept Pathol, Bldg 110,Rm 2242,2160 S First Ave, Maywood, IL 60153 USA; [Jones, Carolyn H.] Rush Univ, Dept Pediat, Chicago, IL 60612 USA; [Turk, Thomas M. T.] Rush Univ, Dept Urol, Chicago, IL 60612 USA	Picken, MM (reprint author), Loyola Univ Med Ctr, Dept Pathol, Bldg 110,Rm 2242,2160 S First Ave, Maywood, IL 60153 USA.	mpicken@lumc.edu					Adsay NV, 2000, AM J SURG PATHOL, V24, P958, DOI 10.1097/00000478-200007000-00007; Antic T, 2006, ARCH PATHOL LAB MED, V130, P80; Antic T, 2006, AJSP-REV REP, V11, P173, DOI 10.1097/01.pcr.0000227462.98588.47; Argani P, 2000, AM J SURG PATHOL, V24, P1087, DOI 10.1097/00000478-200008000-00006; Cajaiba MM, 2016, HUM PATHOL, V48, P81, DOI 10.1016/j.humpath.2015.08.022; Calio A, 2016, AM J SURG PATHOL, V40, P1538, DOI 10.1097/PAS.0000000000000733; Chaudhri AA, 2013, INT J SURG PATHOL, V21, P153, DOI 10.1177/1066896912453851; Chu PGG, 2009, VIRCHOWS ARCH, V455, P389, DOI 10.1007/s00428-009-0831-x; Colombo P, 2008, UROLOGY, V71, DOI 10.1016/j.urology.2007.09.057; Comperat E, 2005, PATHOL RES PRACT, V200, P865, DOI 10.1016/j.prp.2004.05.004; Doros LA, 2014, MODERN PATHOL, V27, P1267, DOI 10.1038/modpathol.2013.242; Farias JA, 2016, UROL ANNALS, V8, P114, DOI 10.4103/0974-7796.171493; Fine SW, 2006, AM J SURG PATHOL, V30, P593, DOI 10.1097/01.pas.0000194298.19839.b4; Hara N, 2005, PATHOL INT, V55, P670, DOI 10.1111/j.1440-1827.2005.01888.x; Jung SJ, 2008, HUM PATHOL, V39, P463, DOI 10.1016/j.humpath.2007.08.008; Karafin M, 2011, AM J SURG PATHOL, V35, P1264, DOI 10.1097/PAS.0b013e31822539a1; Kum JBJ, 2011, AM J SURG PATHOL, V35, P1114, DOI 10.1097/PAS.0b013e3182233fb6; Kuroda N, 2008, APMIS, V116, P1013, DOI 10.1111/j.1600-0463.2008.01063.x; LeRoy MA, 2016, ARCH PATHOL LAB MED, V140, P594, DOI 10.5858/arpa.2015-0170-RS; Li YJ, 2017, AM J SURG PATHOL, V41, P472, DOI 10.1097/PAS.0000000000000816; Mai KT, 2007, PATHOLOGY, V39, P235, DOI 10.1080/00313020701230799; Michal M, 2004, VIRCHOWS ARCH, V445, P359, DOI 10.1007/s00428-004-1060-y; Michal M, 1998, PATHOL RES PRACT, V194, P445, DOI 10.1016/S0344-0338(98)80038-1; Michal M, 2016, WHO CLASSIFICATION T, P70; Michal M, 2017, HUM PATHOL, V61, P199, DOI 10.1016/j.humpath.2016.09.020; Moch H, 2016, WORLD HEALTH ORGANIZ; Montironi R, 2008, EUR UROL, V54, P1237, DOI 10.1016/j.eururo.2007.10.040; Mudaliar KM, 2014, INT J SURG PATHOL, V22, P266, DOI 10.1177/1066896913488823; Parikh P, 2005, ARCH PATHOL LAB MED, V129, P910; Picken MM, 2005, ULTRASTRUCT PATHOL, V29, P283, DOI 10.1080/01913120590951275; Pierson CR, 2001, HUM PATHOL, V32, P513, DOI 10.1053/hupa.2001.24323; Poizat F, 2012, VIRCHOWS ARCH, V461, P379, DOI 10.1007/s00428-012-1307-y; Reikie BA, 2015, ADV ANAT PATHOL, V22, P113, DOI 10.1097/PAP.0000000000000057; Smith NE, 2015, HUM PATHOL, V46, P894, DOI 10.1016/j.humpath.2015.02.003; Sountoulides P, 2012, CUAJ-CAN UROL ASSOC, V6, pE23, DOI 10.5489/cuaj.11042; Sukov WR, 2007, HUM PATHOL, V38, P1432, DOI 10.1016/j.humpath.2007.03.022; Sun BL, 2015, INT J SURG PATHOL, V23, P238, DOI 10.1177/1066896914563391; Suzuki T, 2013, INT J UROL, V20, P448, DOI 10.1111/j.1442-2042.2012.03155.x; Svec A, 2001, VIRCHOWS ARCH, V439, P700, DOI 10.1007/s004280100518; Tajima S, 2015, INT J CLIN EXP PATHO, V8, P989; Tan MH, 2004, CURR MOL MED, V4, P895, DOI 10.2174/1566524043359719; Teklali Y, 2010, J PEDIATR UROL, V6, P320, DOI 10.1016/j.jpurol.2009.10.010; Turbiner J, 2007, AM J SURG PATHOL, V31, P489, DOI 10.1097/PAS.0b013e31802bdd56; Vanecek T, 2017, APPL IMMUNOHISTO M M, V25, P117, DOI 10.1097/PAI.0000000000000262; Yang Y, 2005, VIRCHOWS ARCH, V447, P669, DOI 10.1007/s00428-005-1269-4; Yap YS, 2004, LANCET ONCOL, V5, P747, DOI 10.1016/S1470-2045(04)01651-1; Zhou M, 2009, AM J SURG PATHOL, V33, P72, DOI 10.1097/PAS.0b013e3181852105; Zou L, 2014, INT J CLIN EXP PATHO, V7, P2658	48	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JAN-FEB	2018	23	1					44	50		10.1097/PCR.0000000000000226			7	Pathology	Pathology	GB8DA	WOS:000429304100009					2019-10-28	
J	Yousef, PG; Gabril, MY				Yousef, Peter G.; Gabril, Manal Y.			An update on the molecular pathology of urinary bladder tumors	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Urothelial carcinoma; Molecular biomarkers; Molecular pathways	TRANSITIONAL-CELL CARCINOMA; IN-SITU; UROTHELIAL CARCINOMA; PROSPECTIVE MULTICENTER; PROSTATE-CANCER; STEM-CELLS; MARKERS; VALIDATION; RECURRENCE; CYTOLOGY	Urothelial carcinoma is the fourth most common tumors after prostate cancer, lung, and colorectal carcinoma but the second most common urologic malignancy. Urothelial carcinoma composed more than 90% of bladder tumors while squamous cell carcinoma and adenocarcinomas composed 5% and 2% respectively. The intense research involving the different molecular aspects of bladder cancer has provided a great insight into identifying more about molecular profiling and pathways of bladder cancer. In this review, we will highlight the general concepts of the molecular features; profiling and classification as well as the molecular pathways for bladder carcinomas, especially urothelial carcinoma. Also, we will discuss the advances of molecular biomarkers for screening, early diagnosis, surveillance and potential prognosis of urothelial carcinoma of the bladder. Studies showed that accumulation of genetic alterations involving the clonal expansion of altered cells with growth advantages through sequential multi-step pathways results in progression of bladder tumors. The accumulated research data from literature has revealed that the genomic signatures of urothelial carcinoma are required to subclassify bladder cancer into genetically distinct subgroups. These findings could improve the understating of pathogenesis as well as will provide new therapeutic modules e.g. targeted therapy.	[Yousef, Peter G.; Gabril, Manal Y.] Western Univ, London Hlth Sci Ctr, Pathol & Lab Med, London, ON, Canada	Gabril, MY (reprint author), Western Univ, London Hlth Sci Ctr, Pathol & Lab Med, Univ Hosp, 339 Windermere Rd, London, ON N6A 5A5, Canada.	manal.gabril@lhsc.on.ca					Adams J, 2005, CANCER LETT, V220, P137, DOI 10.1016/j.canlet.2004.06.052; Alva A, 2015, J UROLOGY, V194, P790, DOI 10.1016/j.juro.2015.02.2951; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Chan MWY, 2002, CLIN CANCER RES, V8, P464; Cheng LA, 2011, HUM PATHOL, V42, P455, DOI 10.1016/j.humpath.2010.07.007; Cronin M, 2007, CLIN CHEM, V53, P1084, DOI 10.1373/clinchem.2006.076497; Dyrskjot L, 2017, EUR UROL, V72, P461, DOI 10.1016/j.eururo.2017.05.040; Fendler A, 2011, CLIN CHEM, V57, P954, DOI 10.1373/clinchem.2010.157727; Friedrich MG, 2004, CLIN CANCER RES, V10, P7457, DOI 10.1158/1078-0432.CCR-04-0930; Guo Baihong, 2011, Can Urol Assoc J, V5, pE129, DOI 10.5489/cuaj.09118; Hafner C, 2002, INT J CANCER, V101, P1, DOI 10.1002/ijc.10544; Hanke M, 2010, UROL ONCOL-SEMIN ORI, V28, P655, DOI 10.1016/j.urolonc.2009.01.027; Hartmann A, 2002, CANCER RES, V62, P809; Hausladen DA, 2003, J UROLOGY, V170, P230, DOI 10.1097/01.ju.0000063685.29339.24; Hautmann S, 2004, EUR UROL, V46, P466, DOI 10.1016/j.eururo.2004.06.006; Ho PL, 2012, NAT REV UROL, V9, P583, DOI 10.1038/nrurol.2012.142; Hurst CD, 2012, CLIN CANCER RES, V18, P5865, DOI 10.1158/1078-0432.CCR-12-1807; Kattan M. W., 2006, J UROLOGY, V6, P2108; Kattan MW, 2006, J UROLOGY, V175, P2103, DOI 10.1016/S0022-5347(06)00313-2; Kattan MW, 1998, JNCI-J NATL CANCER I, V90, P766, DOI 10.1093/jnci/90.10.766; Knowles MA, 2005, CANCER LETT, V225, P121, DOI 10.1016/j.canlet.2004.10.047; Kompier LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013821; Konety BR, 2001, J UROLOGY, V165, P600, DOI 10.1097/00005392-200102000-00081; Lokeshwar VB, 2005, UROLOGY, V66, P35, DOI 10.1016/j.urology.2005.08.064; Lokeshwar VB, 2001, J UROLOGY, V165, P1067, DOI 10.1016/S0022-5347(05)66428-2; Mallmann P, 1991, ACTA OBSTET GYN SCAN, V70, P35, DOI 10.3109/00016349109006175; Matsushita K, 2011, INT J UROL, V18, P616, DOI 10.1111/j.1442-2042.2011.02809.x; McConkey DJ, 2010, UROL ONCOL-SEMIN ORI, V28, P429, DOI 10.1016/j.urolonc.2010.04.008; McKenney JK, 2001, AM J SURG PATHOL, V25, P1074, DOI 10.1097/00000478-200108000-00013; Mian C, 2006, CANCER CYTOPATHOL, V108, P60, DOI 10.1002/cncr.21712; Mian C, 2005, ANTICANCER RES, V25, P3641; Moonen PMJ, 2007, EUR UROL, V51, P1275, DOI 10.1016/j.eururo.2006.10.044; Moussa O, 2006, J UROLOGY, V175, P2312, DOI 10.1016/S0022-5347(06)00254-0; Nezos A, 2011, CANCER TREAT REV, V37, P284, DOI 10.1016/j.ctrv.2010.10.002; Piaton E, 2003, LAB INVEST, V83, P845, DOI 10.1097/01.LAB.0000074893.70675.2E; Reinert T, 2012, ADV UROL, DOI 10.1155/2012/503271; Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659; Retz M, 2003, J UROLOGY, V169, P86, DOI 10.1097/01.ju.0000039900.41604.a2; Schaefer A, 2010, NAT REV UROL, V7, P286, DOI 10.1038/nrurol.2010.45; Sethi S, 2013, AM J TRANSL RES, V5, P200; Shariat SF, 2008, CANCER, V112, P315, DOI 10.1002/cncr.23162; Shariat SF, 2006, J UROLOGY, V176, P2414, DOI 10.1016/j.juro.2006.08.004; Shariat SF, 2006, J UROLOGY, V176, P919, DOI 10.1016/j.juro.2006.04.017; Simon R, 2001, CANCER RES, V61, P355; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; Takihana Y, 2006, INT J UROL, V13, P401, DOI 10.1111/j.1442-2042.2006.01300.x; Tomlinson DC, 2007, J PATHOL, V213, P91, DOI 10.1002/path.2207; van Rhijn BSW, 2004, CANCER RES, V64, P1911, DOI 10.1158/0008-5472.CAN-03-2421; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Yoder BJ, 2007, AM J CLIN PATHOL, V127, P295, DOI 10.1309/ADJL7E810U1H42BJ; Zellweger T, 2006, INT J CANCER, V119, P1660, DOI 10.1002/ijc.21704; Zuiverloon TCM, 2012, BJU INT, V109, P941, DOI 10.1111/j.1464-410X.2011.10428.x; Zuiverloon TCM, 2010, CLIN CANCER RES, V16, P3011, DOI 10.1158/1078-0432.CCR-09-3013	55	5	6	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					1	6		10.1016/j.prp.2017.11.00:3			6	Pathology	Pathology	GB5EN	WOS:000429086000001	29254798				2019-10-28	
J	Laedrach, C; Salhia, B; Cihoric, N; Zlobec, I; Tapia, C				Laedrach, C.; Salhia, B.; Cihoric, N.; Zlobec, I.; Tapia, C.			Immunophenotypic profile of tumor buds in breast cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Tumor budding; Breast cancer; Hormone receptors; Her2	EPITHELIAL-MESENCHYMAL TRANSITION; INDEPENDENT PROGNOSTIC-FACTOR; EMT; MICROENVIRONMENT; METASTASIS; MARKERS; GROWTH; CELLS	Background: Tumor buds are associated with lympho-vascular invasion and lymph node metastases leading to the assumption that they are involved in the early metastatic process. Hence, it would be important to know if tumor buds can be targeted with the most widely used targeted therapies in breast cancer (BC) and if changes in hormone and Her2 status occur. The aim of this study was to answer these questions by determining whether hormone receptor (HR) and Her2 status are expressed in the tumor buds of a large cohort of BCs. Design: We constructed a tumor bud next-generation tissue microarray (ngTMA) consisting of n = 199 BCs of non-special type. Generally, two 1 mm punches were taken from the tumor bud areas in the periphery (PTB) and within the tumor center (ITB). HR and Her2 status was assessed using immunohistochemistry and fluorescence in situ hybridization, respectively. HR status was positive if 1% of tumor bud cells were positive. Her2 status was considered positive if bud cells showed strong complete membranous Her2 over-expression or Her2 amplification. Results: Most tumor buds were positive for estrogen (ER) (PTB: 86%; ITB: 88.3) and progesterone receptor (PgR) (PTB: 72%; ITB: 72.8%) and Her2 was positive in: PTB 11.5% and ITB 11%. A difference between the main tumor mass and tumor buds (PTB and ITB) was seen for PgR in 3.5% of cases (n = 7). No differences were seen for ER and Her2 between tumor buds and main tumor mass. Conclusion: Most tumor buds (96.5%) share the same HR and Her2 expression profile of the main tumor mass, implying that tumor buds relay on the same pathways as the main tumor mass and might be equally responsive to targeted therapies.	[Laedrach, C.; Zlobec, I.; Tapia, C.] Univ Bern, Inst Pathol, Bern, Switzerland; [Salhia, B.] USC, Keck Sch Med, Dept Translat Genom, Los Angeles, CA USA; [Cihoric, N.] Inselspital Bern, Dept Radiooncol, Bern, Switzerland; [Cihoric, N.; Tapia, C.] Inselspital Bern, Breast Ctr, Bern, Switzerland; [Tapia, C.] UT MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX USA; [Tapia, C.] UT MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA	Tapia, C (reprint author), UT MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Dept Translat Mol Pathol, 2130 W Holcombe Blvd, Houston, TX 77030 USA.	CTapia1@mdanderson.org			Claudia von Schilling Foundation for Breast Cancer Research, Germany	This study was funded by the Claudia von Schilling Foundation for Breast Cancer Research, Germany.	Bill R, 2015, FEBS LETT, V589, P1577, DOI 10.1016/j.febslet.2015.05.002; Burandt E, 2014, GENE CHROMOSOME CANC, V53, P228, DOI 10.1002/gcc.22130; Centeno I, 2017, VIRCHOWS ARCH, V470, P341, DOI 10.1007/s00428-017-2071-9; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cheung SY, 2015, BREAST CANCER RES TR, V152, P489, DOI 10.1007/s10549-015-3485-1; Dawson H, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00011; Grogg A, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1897-2; Gujam FJA, 2015, BRIT J CANCER, V113, P1066, DOI 10.1038/bjc.2015.287; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Heerboth S, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-015-0048-3; Ingthorsson S, 2016, ONCOGENE, V35, P4244, DOI 10.1038/onc.2015.489; Jang MH, 2015, HUM PATHOL, V46, P1267, DOI 10.1016/j.humpath.2015.05.010; Jimenez-Salazar JE, 2014, HORM CANCER-US, V5, P161, DOI 10.1007/s12672-014-0180-3; Jing YY, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-29; Kadota K, 2015, CHEST, V148, P711, DOI 10.1378/chest.14-3005; Karamitopoulou E, 2013, EUR J CANCER, V49, P1032, DOI 10.1016/j.ejca.2012.10.022; Karamitopoulou E, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00221; Liang FL, 2013, PATHOL RES PRACT, V209, P269, DOI 10.1016/j.prp.2013.01.009; Lugli A., 2017, MODERN PATHOL, P1; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Purdie CA, 2014, BRIT J CANCER, V110, P565, DOI 10.1038/bjc.2013.756; Salhia B, 2015, BREAST CANCER RES TR, V150, P363, DOI 10.1007/s10549-015-3333-3; Santamaria PG, 2017, MOL ONCOL, V11, P718, DOI 10.1002/1878-0261.12091; Sarioglu S, 2010, PATHOL RES PRACT, V206, P88, DOI 10.1016/j.prp.2009.09.006; Seki M., 2016, HEAD NECK S1, pE1582; Tapia C, 2007, MODERN PATHOL, V20, P192, DOI 10.1038/modpathol.3800729; Thies S, 2016, HUM PATHOL, V52, P1, DOI 10.1016/j.humpath.2016.01.016; Ueno H, 2004, GUT, V53, P581, DOI 10.1136/gut.2003.028365; Wang YY, 2009, CLIN CANCER RES, V15, P5784, DOI 10.1158/1078-0432.CCR-09-0814; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Zlobec I, 2007, J PATHOL, V212, P260, DOI 10.1002/path.2164; Zlobec Inti, 2014, J Vis Exp, P51893, DOI 10.3791/51893; Zlobec I, 2010, ONCOTARGET, V1, P651, DOI 10.18632/oncotarget.199; Zuo LA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2588	34	1	1	1	1	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					25	29		10.1016/j.prp.2017.11.0211			5	Pathology	Pathology	GB5EN	WOS:000429086000004	29254793				2019-10-28	
J	Santos, EMS; da Rocha, RG; Santos, HO; Guimaraes, TA; Fraga, CAD; da Silveira, LH; Batista, PR; de Oliveira, PSL; Melo, GA; Santos, SH; de Paula, AMB; Guimaraes, ALS; Farias, LC				Sobrinho Santos, Eliane Macedo; da Rocha, Rogerio Goncalves; Santos, Hercules Otacilio; Guimaraes, Talita Antunes; de Carvalho Fraga, Carlos Alberto; da Silveira, Luiz Henrique; Batista, Paulo Ricardo; Lopes de Oliveira, Paulo Sergio; Melo, Geraldo Aclecio; Santos, Sergio Henrique; Batista de Paula, Alfredo Mauricio; Sena Guimaraes, Andre Luiz; Farias, Lucyana Conceicao			Gallic acid modulates phenotypic behavior and gene expression in oral squamous cell carcinoma cells by interfering with leptin pathway	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Leptin; Gallic acid; Oral squamous cell carcinoma; Cell proliferation; Cell migration; Angiogenesis	BREAST-CANCER CELLS; HYPOXIC CONDITIONS; APOPTOSIS; RECEPTOR; LINES; DEATH; OSTEOSARCOMA; PROGRESSION; ACTIVATION; INDUCTION	Gallic acid is a polyphenolic compost appointed to interfere with neoplastic cells behavior. Evidence suggests an important role of leptin in carcinogenesis pathways, inducing a proliferative phenotype. We investigated the potential of gallic acid to modulate leptin-induced cell proliferation and migration of oral squamous cell carcinoma cell lines. The gallic acid effect on leptin secretion by oral squamous cell carcinoma cells, as well as the underlying molecular mechanisms, was also assessed. For this, we performed proliferation, migration, immunocytochemical and qPCR assays. The expression levels of cell migration-related genes (MMP2, MMP9, CoI1A1, and E-cadherin), angiogenesis (HIF-1 alpha, mir210), leptin signaling (LepR, p44/42 MAPK), apoptosis (casp-3), and secreted leptin levels by oral squamous cell carcinoma cells were also measured. Gallic acid decreased proliferation and migration of leptin-treated oral squamous cell carcinoma cells, and reduced mRNA expression of MMP2, MMP9, Co11A1, mir210, but did not change HIF-l alpha. Gallic acid decreased levels of leptin secreted by oral squamous cell carcinoma cells, accordingly with downregulation of p44/42 MAPK expression. Thus, gallic acid appears to break down neoplastic phenotype of oral squamous cell carcinoma cells by interfering with leptin pathway.	[Sobrinho Santos, Eliane Macedo; da Rocha, Rogerio Goncalves; Guimaraes, Talita Antunes; da Silveira, Luiz Henrique; Batista de Paula, Alfredo Mauricio; Sena Guimaraes, Andre Luiz; Farias, Lucyana Conceicao] Univ Estadual Montes Claros, Dept Dent, Montes Claros, MG, Brazil; [Sobrinho Santos, Eliane Macedo] Inst Fed Norte Minas Gerais, Campus Aracuai, Montes Claros, MG, Brazil; [Santos, Hercules Otacilio; de Carvalho Fraga, Carlos Alberto] Inst Fed Norte Minas Gerais, Campus Salinas, Montes Claros, MG, Brazil; [de Carvalho Fraga, Carlos Alberto] Univ Fed Alagoas, Arapiraca, Alagoas, Brazil; [Batista, Paulo Ricardo] Fundacao Oswaldo Cruz, Programa Comp Cient, Rio De Janeiro, Brazil; [Lopes de Oliveira, Paulo Sergio] Natl Biosci Lab LNBio, Campinas, SP, Brazil; [Melo, Geraldo Aclecio] Univ Estadual Montes Claros, Dept Biol, Montes Claros, MG, Brazil; [Santos, Sergio Henrique] Univ Fed Minas Gerais, Food Engn Coll, Inst Agr Sci, Belo Horizonte, MG, Brazil	Farias, LC (reprint author), Univ Estadual Montes Claros, Hosp Univ Clemente Faris, Lab Pesquisa Saude, Ave Cula Mangabeira 562, BR-39401001 Montes Claros, MG, Brazil.	Incyanacfarias@gmail.com	Guimaraes, Andre Luiz Sena/D-8122-2011; Fraga, Carlos/C-1328-2013; Oliveira, Paulo/K-5588-2013; Batista, Paulo Ricardo/E-8883-2013	Guimaraes, Andre Luiz Sena/0000-0002-3162-3206; Fraga, Carlos/0000-0002-9564-9595; Goncalves da Rocha, Rogerio/0000-0003-1468-2754; Batista, Paulo Ricardo/0000-0002-3399-174X	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for Scientific and Technological Development (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), BrazilMinas Gerais State Research Foundation (FAPEMIG)	This study was supported by grants from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), Brazil. Dr. Guimaraes and Dr. De Paula are research fellows of the CNPq. We thank Exame Ltda. Laboratory - Montes Claros/MG - Brazil.	Ando S, 2012, NAT REV ENDOCRINOL, V8, P263, DOI 10.1038/nrendo.2011.184; Bruno A, 2005, J IMMUNOL, V174, P8090, DOI 10.4049/jimmunol.174.12.8090; Bruno A, 2009, J ALLERGY CLIN IMMUN, V124, P230, DOI 10.1016/j.jaci.2009.04.032; Carpagnano GE, 2007, ONCOL RES, V16, P375; Carpenter B, 2012, STRUCTURE, V20, P487, DOI 10.1016/j.str.2012.01.019; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Dolinsky TJ, 2004, NUCLEIC ACIDS RES, V32, pW665, DOI 10.1093/nar/gkh381; Dolinsky TJ, 2007, NUCLEIC ACIDS RES, V35, pW522, DOI 10.1093/nar/gkm276; Elmquist JK, 1998, NAT NEUROSCI, V1, P445, DOI 10.1038/2164; Faried A, 2007, INT J ONCOL, V30, P605; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Garofalo C, 2006, J CELL PHYSIOL, V207, P12, DOI 10.1002/jcp.20472; Gharote HP, 2010, J ORAL PATHOL MED, V39, P69, DOI 10.1111/j.1600-0714.2009.00808.x; Giordano C, 2013, MOL ONCOL, V7, P379, DOI 10.1016/j.molonc.2012.11.002; Guimaraes TA, 2016, ANTI-CANCER DRUG, V27, P407, DOI 10.1097/CAD.0000000000000342; Guimaraes TA, 2016, ONCOTARGET, V7, P55057, DOI 10.18632/oncotarget.10842; Han YH, 2009, ONCOL RES, V18, P315, DOI 10.3727/096504010X1262118079949; He ZP, 2016, ONCOL REP, V35, P291, DOI 10.3892/or.2015.4354; Hsu CL, 2007, BRIT J NUTR, V98, P727, DOI 10.1017/S000711450774686X; Hussain SR, 2015, TUMOR BIOL, V36, P6515, DOI 10.1007/s13277-015-3342-1; INOUE M, 1994, BIOCHEM BIOPH RES CO, V204, P898, DOI 10.1006/bbrc.1994.2544; Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+; Ivan M, 2014, ADV EXP MED BIOL, V772, P205, DOI 10.1007/978-1-4614-5915-6_10; Kang MK, 2009, ANN NY ACAD SCI, V1171, P514, DOI 10.1111/j.1749-6632.2009.04728.x; Kasibhatla S, 2006, CSH PROTOC, V2006; Kaur J, 2016, CLIN ORAL INVEST, V20, P39, DOI 10.1007/s00784-015-1472-x; Kuhn M, 2014, NUCLEIC ACIDS RES, V42, pD401, DOI 10.1093/nar/gkt1207; Kuo CL, 2014, ONCOL REP, V32, P355, DOI 10.3892/or.2014.3209; Lang K, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-27; Li H, 2005, PROTEINS, V61, P704, DOI 10.1002/prot.20660; Liang CZ, 2012, CANCER BIOTHER RADIO, V27, P701, DOI 10.1089/cbr.2012.1245; Locatelli C, 2009, CHEM-BIOL INTERACT, V181, P175, DOI 10.1016/j.cbi.2009.06.019; Lu YC, 2016, ANTICANCER RES, V36, P697; Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v; Park YK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109344; Petersen C, 2000, CLIN CANCER RES, V6, P2513; Raina K, 2008, MOL CANCER THER, V7, P1258, DOI 10.1158/1535-7163.MCT-07-2220; Ren H, 2014, CANCER LETT, V354, P172, DOI 10.1016/j.canlet.2014.08.001; Samuel-Mendelsohn S, 2011, PROSTATE, V71, P929, DOI 10.1002/pros.21309; Sangle NA, 2012, ARCH PATHOL LAB MED, V136, P572, DOI 10.5858/arpa.2011-0204-RS; Santos E. M., 2016, J APPL BIOINFORM COM, V5; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Serrano A, 1998, ARCH BIOCHEM BIOPHYS, V350, P49, DOI 10.1006/abbi.1997.0474; Shi GZ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-97; Taliaferro-Smith L, 2013, NEOPLASIA, V15, P23, DOI 10.1593/neo.121502; Toth Marta, 2012, Methods Mol Biol, V878, P121, DOI 10.1007/978-1-61779-854-2_8; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Weng SW, 2015, ANTICANCER RES, V35, P2077; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Ye Y, 2011, MOL CANCER THER, V10, P1667, DOI 10.1158/1535-7163.MCT-11-0123; Yoshioka K, 2000, ONCOL REP, V7, P1221; You BR, 2011, MOL CELL BIOCHEM, V357, P295, DOI 10.1007/s11010-011-0900-8; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0	53	2	2	1	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					30	37		10.1016/j.prp.2017.11.022			8	Pathology	Pathology	GB5EN	WOS:000429086000005	29254802				2019-10-28	
J	Zhang, JH; Chen, SN; Chen, WL; Huang, YM; Lin, RH; Huang, MY; Wu, YS; Zheng, LP; Li, ZF; Liao, NS; Ye, JX; Liu, XX				Zhang, Jiahui; Chen, Sainan; Chen, Wenlie; Huang, Yunmei; Lin, Ruhui; Huang, Meiya; Wu, Yinsheng; Zheng, Liangpu; Li, Zuanfang; Liao, Naishun; Ye, Jinxia; Liu, Xianxiang			Ultrastructural change of the subchondral bone increases the severity of cartilage damage in osteoporotic osteoarthritis of the knee in rabbits	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Osteoarthritis; Osteoporosis; Subchondral bone; Cartilage; Scanning electron microscopy	TOUGU XIAOTONG CAPSULE; ARTICULAR-CARTILAGE; EXPERIMENTAL-MODEL; PATHOGENESIS; PREVALENCE; MORPHOLOGY; HIP	Osteoporotic osteoarthritis is a phenotype of osteoarthritis (OA) manifested as fragile and osteoporotic subchondral bone. However, the ultrastructural features of subchondral bone in osteoporosis OA have not been determined. The study was aimed to investigate the ultrastructural dynamic changes of subchondral bone in osteoporotic OA model and how the ultrastructural damage in the subchondral bone caused by osteoporosis deteriorated the cartilage damage in OA. Eighteen rabbits were equally randomized to three groups, including the control, the OA and the osteoporotic OA groups. The structural changes of cartilage were evaluated by HE and safranin-O fast green staining, the Mankin's grading system was used to assess the stage of OA progression. And microstructural or ultrastructural changes in subchondral bone were assessed by micro-computed tomography or by scanning electron microscopy. According to the changes of cartilage histopathology, the OA group was in the early pathological stage of OA while the osteoporotic OA group was in the middle stage of OA based on Mankin's grading system. In addition, the damage of cartilage surface, reduction in the number of chondrocytes and the matrix staining were more increased in the osteoporotic OA group compared to the OA group. Compared to the OA group, the subchondral bone in the microstructure and ultrastructure in the osteoporotic OA group showed more microfracture changes in trabecular bone with more destructions of the tree-like mesh. Moreover, the collagen fibers were random rough with a fewer amount of bone lacunae in subchondral cortical plate in the osteoporotic OA group compared to the OA group. These findings indicated that the subchondral bone ultrastructure in the osteoporotic OA model was characterized by the destruction of the network structure and collagen fibers. The subchondral bone ultrastructural damage caused by osteoporosis may change mechanical properties of the upper cartilage and aggravate OA cartilage. Therefore, early diagnosis and treatment of osteoporosis is of great significance to prevent early OA from further developing osteoporotic OA.	[Zhang, Jiahui; Chen, Sainan; Chen, Wenlie; Huang, Yunmei; Huang, Meiya; Li, Zuanfang; Liao, Naishun; Liu, Xianxiang] Fujian Univ Tradit Chinese Med, Fuzhou 350122, Fujian, Peoples R China; [Zhang, Jiahui; Chen, Wenlie; Lin, Ruhui; Huang, Meiya; Zheng, Liangpu; Ye, Jinxia; Liu, Xianxiang] Fujian Acad Integrat Med, Fuzhou 350122, Fujian, Peoples R China; [Chen, Sainan] Fujian Acad Tradit Chinese Med, Fuzhou 350003, Fujian, Peoples R China; [Chen, Wenlie; Huang, Yunmei; Lin, Ruhui; Wu, Yinsheng] Natl Lab Tradit Chinese Med Pharmacol Cell Struct, Fuzhou 350003, Fujian, Peoples R China; [Wu, Yinsheng; Zheng, Liangpu; Li, Zuanfang; Ye, Jinxia] Fujian Univ Tradit Chinese Med, Fujian Key Lab Integrat Med Geriatr, Fuzhou 350122, Fujian, Peoples R China; [Liao, Naishun] Fujian Med Univ, Mengchao Hepatobiliary Hosp, United Innovat Mengchao Hepatobiliary Technol Key, Fuzhou 350001, Fujian, Peoples R China	Chen, WL (reprint author), Fujian Univ Tradit Chinese Med, Fujian Acad Integrat Med, Fuzhou 350122, Fujian, Peoples R China.	chen.wl@163.com		Liao, Naishun/0000-0002-2781-4229	Natural Science Foundation of Fujian Province of ChinaNatural Science Foundation of Fujian Province [2014J01356, 2015J01690]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81573801]; Fundamental Research Project for Common Wealth Scientific Institutes in Fujian Province [2017R1035-4]	This work was supported by the Natural Science Foundation of Fujian Province of China, (Nos. 2014J01356, 2015J01690), the National Natural Science Foundation of China (Nos. 81573801), the Fundamental Research Project for Common Wealth Scientific Institutes in Fujian Province(Nos. 2017R1035-4).	Al-Daghri NM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005780; Bellido M, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3103; Bera B, 2011, MICRON, V42, P412, DOI 10.1016/j.micron.2010.12.002; Bobinac D, 2013, OSTEOARTHR CARTILAGE, V21, P1724, DOI 10.1016/j.joca.2013.06.030; Braidotti P, 2000, J BIOMECH, V33, P1153, DOI 10.1016/S0021-9290(00)00074-9; Calvo E, 2007, OSTEOARTHR CARTILAGE, V15, P69, DOI 10.1016/j.joca.2006.06.006; Castaneda S, 2008, J BONE MINER METAB, V26, P53, DOI 10.1007/s00774-007-0797-1; Chapurlat RD, 2007, J BONE MINER RES, V22, P1502, DOI 10.1359/JBMR.070609; Chen SN, 2016, MOL MED REP, V13, P419, DOI 10.3892/mmr.2015.4547; Dancevic CM, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0429-9; Domingues VR, 2015, ACTA ORTOP BRAS, V23, P34, DOI 10.1590/1413-78522015230100981; Georgiadis M, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2016.0088; Geusens PP, 2016, CURR OPIN RHEUMATOL, V28, P97, DOI 10.1097/BOR.0000000000000256; Goldring MB, 2010, ANN NY ACAD SCI, V1192, P230, DOI 10.1111/j.1749-6632.2009.05240.x; Goudarzi M, 2016, SCI REP-UK, V6, DOI 10.1038/srep32539; Herrero-Beaumont G, 2013, NAT REV RHEUMATOL, V9, P448, DOI 10.1038/nrrheum.2013.113; Iijima H, 2016, OSTEOARTHR CARTILAGE, V24, P354, DOI 10.1016/j.joca.2015.09.001; Iijima H, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-101; Im GI, 2014, J BONE MINER METAB, V32, P101, DOI 10.1007/s00774-013-0531-0; Lajeunesse D, 2003, CURR OPIN RHEUMATOL, V15, P628, DOI 10.1097/00002281-200309000-00018; Li BF, 2010, ACTA ORTHOP, V81, P396, DOI 10.3109/17453674.2010.483986; Li GY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4405; Li P, 2012, OSTEOARTHR CARTILAGE, V20, P1336, DOI 10.1016/j.joca.2012.07.004; Li XH, 2013, INT J MOL MED, V31, P1349, DOI 10.3892/ijmm.2013.1341; Lingard EA, 2010, AGE AGEING, V39, P234, DOI 10.1093/ageing/afp222; Liu Xian-xiang, 2005, Zhongguo Zhong Xi Yi Jie He Za Zhi, V25, P1104; Lv HC, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0530-5; MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623-197153030-00009; Mohan G, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3543; Neogi T, 2010, ANN RHEUM DIS, V69, P841, DOI 10.1136/ard.2009.110114; RADIN EL, 1986, CLIN ORTHOP RELAT R, P34; Ribbens C, 2002, ANN RHEUM DIS, V61, P161, DOI 10.1136/ard.61.2.161; Roman-Blas JA, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0494-0; Sahar ND, 2005, MICRON, V36, P617, DOI 10.1016/j.micron.2005.07.006; Sambrook P, 1997, BAILLIERE CLIN RHEUM, V11, P695, DOI 10.1016/S0950-3579(97)80005-2; Sharma AR, 2013, INT J MOL SCI, V14, P19805, DOI 10.3390/ijms141019805; Shen Y, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-35; Southard TE, 2000, ORAL SURG ORAL MED O, V89, P244, DOI 10.1067/moe.2000.102223; Vestergaard P, 2009, CALCIFIED TISSUE INT, V84, P249, DOI 10.1007/s00223-009-9224-z; Wang CJ, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4601	40	0	0	4	13	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					38	43		10.1016/j.prp.2017.11.018			6	Pathology	Pathology	GB5EN	WOS:000429086000006	29263013				2019-10-28	
J	Perez-Ramirez, C; Canadas-Garre, M; Alnatsha, A; Villar, E; Delgado, JR; Calleja-Hernandez, MA; Faus-Dader, MJ				Perez-Ramirez, Cristina; Canadas-Garre, Marisa; Alnatsha, Ahmed; Villar, Eduardo; Delgado, Juan Ramon; Calleja-Hernandez, Miguel Angel; Faus-Dader, Maria Jose			Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Non-small cell lung cancer; Risk; Polymorphisms; DNA repair pathway; Folate metabolism pathway; Glutathione metabolism pathway	PLATINUM-BASED CHEMOTHERAPY; METHYLENETETRAHYDROFOLATE REDUCTASE; S-TRANSFERASES; XUAN-WEI; ASSOCIATION; ENDONUCLEASE; EPIGENETICS; LYS751GLN; P1	Lung cancer, particularly non-small cell lung cancer (NSCLC) subtype, is the leading cause of cancer-related death related worldwide. Numerous gene polymorphisms in DNA repair, folate and glutathione pathways have been associated with susceptibility of NSCLC. We conducted this study to evaluate the effects of ERCC1, ERCC2, ERCC5, XRCC1, XRCC3, MTHFR, MTR, MTHFD1, SLC19A1 and GSTP1 gene polymorphisms on risk of NSCLC. No association between these gene polymorphisms and susceptibility of NSCLC were found in our patients, suggesting that genetic variations in genes involved in DNA repair, folate and glutathione metabolism pathways may not influence the risk of NSCLC.	[Perez-Ramirez, Cristina] Complejo Hosp Univ Granada, Inst Invest Biosanit Granada, UGC Prov Farm Granada, Pharmacogenet Unit, Avda Fuerzas Armadas 2, Granada, Spain; [Perez-Ramirez, Cristina; Faus-Dader, Maria Jose] Univ Granada, Fac Pharm, Dept Biochem, Campus Univ Cartuja S-N, E-18071 Granada, Spain; [Canadas-Garre, Marisa] Queens Univ Belfast, Ctr Publ Hlth, Nephrol Res Grp, Belfast City Hosp,Reg Genet Ctr, Level A,Tower Block,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland; [Alnatsha, Ahmed] Univ Tubingen, Fac Med, Dept Mol Med, Geissweg 5, D-72076 Tubingen, Germany; [Villar, Eduardo] Complejo Hosp Univ Granada, Inst Invest Biosanitaria Granada, UGC Anat Patol, Pathol Serv, Avda Fuerzas Armadas 2, Granada 18014, Spain; [Delgado, Juan Ramon] Complejo Hosp Univ Granada, Inst Invest Biosanitaria Granada, UGC Oncol Med, Med Oncol Serv, Avda Fuerzas Armadas 2, Granada 18014, Spain; [Calleja-Hernandez, Miguel Angel] Univ Granada, Fac Pharm, Dept Pharmacol, Campus Univ Cartuja S-N, E-18071 Granada, Spain	Canadas-Garre, M (reprint author), Queens Univ Belfast, Ctr Publ Hlth, Nephrol Res Grp, Belfast City Hosp,Reg Genet Ctr, Level A,Tower Block,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	cperezramirez87@gmail.com; marisacgarre@gmail.corn; r.j.b-man@hotmail.com; eduardovillar6@gmail.com; juanramondelgado@gmail.com; mangel.calleja.sspa@juntadeandalucia.es; mfaus@ugr.es			Instituto de Salud Carlos III, Ministerio de Economia y Competitividad [CA12/00097]; Ministerio de Education, Cultura y Deporte [FPU12/04722]; FEDER funds (EU) from the Instituto de Salud Carlos III [PT13/0010/0039]	This work was partly supported by a contract for Marisa Canadas-Garre (Tecnicos de Apoyo Subprogram. CA12/00097) from Instituto de Salud Carlos III, Ministerio de Economia y Competitividad and a research grant for Cristina Perez-Ramirez (FPU12/04722), from Ministerio de Education, Cultura y Deporte. The Hospital Universitario Virgen de las Nieves Biobank was supported by grants cofinanced by FEDER funds (EU) from the Instituto de Salud Carlos III (PT13/0010/0039).	Ansari J, 2016, TRANSL LUNG CANCER R, V5, P155, DOI 10.21037/tlcr.2016.02.02; ANTTILA S, 1993, CANCER RES, V53, P5643; Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; Catana A, 2015, ONCOTARGETS THER, V8, P3533, DOI 10.2147/OTT.S92361; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; Cui LH, 2011, PHARMACOGENOMICS, V12, P797, DOI [10.2217/pgs.11.27, 10.2217/PGS.11.27]; de Laat WL, 1998, J BIOL CHEM, V273, P7835, DOI 10.1074/jbc.273.14.7835; Dixon K, 2004, SEMIN CANCER BIOL, V14, P441, DOI 10.1016/j.semcancer.2004.06.007; Edge S, 2010, AJCC CANC STAGING MA, P649; Edge SB, 2010, AJCC CANC STAGING MA, P648; Feng X., 2013, MOL BIOL REP, V40, P9; Garcia-Campelo R, 2005, EXPERT OPIN PHARMACO, V6, P2015, DOI 10.1517/14656566.6.12.2015; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hou ZJ, 2014, CURR TOP MEMBR, V73, P175, DOI 10.1016/B978-0-12-800223-0.00004-9; Huang XY, 2016, J CANCER, V7, P144, DOI 10.7150/jca.13303; Jacques PF, 1996, CIRCULATION, V93, P7, DOI 10.1161/01.CIR.93.1.7; Jimenez-Varo E, 2014, THROMB HAEMOSTASIS, V112, P522, DOI 10.1160/TH13-11-0941; Kiyohara Chikako, 2007, Int J Med Sci, V4, P59; Li XM, 2015, J CANCER RES THER, V11, P565, DOI 10.4103/0973-1482.163788; Liu B, 2015, B CANCER, V102, P332, DOI 10.1016/j.bulcan.2015.02.003; Liu HL, 2008, LUNG CANCER, V61, P21, DOI 10.1016/j.lungcan.2007.12.001; Mao RF, 2008, J HUM GENET, V53, P340, DOI 10.1007/s10038-008-0262-6; Marshall AL, 2013, CARCINOGENESIS, V34, P487, DOI 10.1093/carcin/bgt016; Molina J.R., 2008, MAYO CLIN P, V83, P1367; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; R. C. Team, 2013, R LANG ENV STAT COMP; Risch A, 2008, INT J CANCER, V123, P1, DOI 10.1002/ijc.23605; Ryberg D, 1997, CARCINOGENESIS, V18, P1285, DOI 10.1093/carcin/18.7.1285; Saarikoski S.T., 1995, INT J CANCER, V77, P516; Sancar A, 1995, ANNU REV GENET, V29, P69, DOI 10.1146/annurev.ge.29.120195.000441; Shen M, 2005, LUNG CANCER-J IASLC, V49, P299, DOI 10.1016/j.lungcan.2005.04.002; Shen M, 2005, INT J CANCER, V116, P768, DOI 10.1002/ijc.21117; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Singh S, 2015, CANCER CHEMOTH PHARM, V75, P1, DOI 10.1007/s00280-014-2566-x; Tan X, 2014, TWIN RES HUM GENET, V17, P99, DOI 10.1017/thg.2014.4; Wang YD, 2009, CANCER LETT, V285, P134, DOI 10.1016/j.canlet.2009.05.005; Wang YF, 2003, LUNG CANCER-J IASLC, V40, P25, DOI 10.1016/S0169-5002(02)00537-8; Wei QY, 2003, CANCER EPIDEM BIOMAR, V12, P963; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Xu TP, 2013, GENE, V526, P265, DOI 10.1016/j.gene.2013.05.021; Zhan P, 2010, J THORAC ONCOL, V5, P1337, DOI 10.1097/JTO.0b013e3181e7fe2a; Zhou B, 2016, GENET MOL RES, V15; Zhu N, 2013, YONSEI MED J, V54, P1384, DOI 10.3349/ymj.2013.54.6.1384; Zienolddiny S, 2006, CARCINOGENESIS, V27, P560, DOI 10.1093/carcin/bgi232	46	3	3	1	6	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					44	52		10.1016/j.prp.2017.11.015			9	Pathology	Pathology	GB5EN	WOS:000429086000007	29254785	Green Published			2019-10-28	
J	Zhu, M; Qiu, SL; Zhang, XW; Wang, YC; Souraka, TDM; Wen, X; Liang, CZ; Tu, JC				Zhu, Man; Qiu, Shili; Zhang, Xianwei; Wang, Yingchao; Souraka, Tapara D. M.; Wen, Xue; Liang, Chunzi; Tu, Jiancheng			The associations between CYP24A1 polymorphisms and cancer susceptibility: A meta-analysis and trial sequential analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Cancer; CYP24A1; Vitamin D; Polymorphism; Meta-analysis	VITAMIN-D PATHWAY; PLASMA 25-HYDROXYVITAMIN D; D-RELATED GENES; BREAST-CANCER; RISK; VARIANTS; CYP27B1; PROGNOSIS; VDR	Purpose: Published data have shown that vitamin D may have a protective effect on cancer development. CYP24A1, the main enzyme responsible for the degradation of active vitamin D, plays an important role in many cancer related cellular processes. Up to now, relationships between CYP24A1 polymorphisms and cancer susceptibility have been widely investigated, whereas the results are inconsistent. The aim of present meta-analysis was to explore the associations between CYP24A1 polymorphisms and cancer susceptibility. Methods: We searched on EMBASE, Web of Science, PubMed and China National Knowledge Infrastructure (CNKI) electronic databases (up to July 1, 2017) for relevant studies. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to make the evaluation clear. Results: Twenty-nine studies published in eight publications involving 20,593 cases and 25,458 controls were included. Five CYP24A1 gene polymorphisms were evaluated: rs2181874, rs2585428, rs4809960, rs6022999, and rs6068816. Our analyses suggested that rs2585428 and rs4809960 polymorphisms were significantly associated with overall cancer risk. Stratification analyses of ethnicity indicated that rs2585428 and rs4809960 polymorphisms decreased the risk of cancer among Caucasians. When studies were stratified by cancer type, our results indicated that rs2585428 significantly decreased the risk of pancreas cancer, while rs4809960 significantly decreased the risk of breast cancer. There were no associations of rs2181874, rs6022999, or rs6068816 with overall cancer risks. Conclusion: Associations between CYP24A1 polymorphisms and cancer risks were examined, and additional multi-center studies with large samples are necessary to validate our results.	[Zhu, Man; Qiu, Shili; Zhang, Xianwei; Wang, Yingchao; Souraka, Tapara D. M.; Liang, Chunzi; Tu, Jiancheng] Wuhan Univ, Zhongnan Hosp, Dept Clin Lab Med, Wuhan 430071, Hubei, Peoples R China; [Zhu, Man; Qiu, Shili; Zhang, Xianwei; Wang, Yingchao; Souraka, Tapara D. M.; Liang, Chunzi; Tu, Jiancheng] Wuhan Univ, Zhongnan Hosp, Ctr Gene Diag, Wuhan 430071, Hubei, Peoples R China; [Wen, Xue] Wuhan Univ, Zhongnan Hosp, Ctr Reprod Med, Wuhan 430071, Hubei, Peoples R China	Liang, CZ; Tu, JC (reprint author), Wuhan Univ, Zhongnan Hosp, Dept Clin Lab Med, Wuhan 430071, Hubei, Peoples R China.; Liang, CZ; Tu, JC (reprint author), Wuhan Univ, Zhongnan Hosp, Ctr Gene Diag, Wuhan 430071, Hubei, Peoples R China.	cliang1873@outlook.com; jianchengtu@whu.edu.cn			US-China Biomedical Cooperation Projection [81261120403]; National Basic Research Program of China (973 Program)National Basic Research Program of China [2012CB720605]	This study was supported by 2012 US-China Biomedical Cooperation Projection (81261120403); National Basic Research Program of China (973 Program) (2012CB720605).	Anderson LN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066768; Anderson LN, 2011, CANCER EPIDEM BIOMAR, V20, P1708, DOI 10.1158/1055-9965.EPI-11-0300; Azad AK, 2013, INT J CANCER, V132, P2520, DOI 10.1002/ijc.27946; Barry EL, 2014, J CLIN ENDOCR METAB, V99, pE2133, DOI 10.1210/jc.2014-1389; Bokhari AA, 2016, ONCOTARGET, V7, P77576, DOI 10.18632/oncotarget.12725; Chen GA, 2011, CLIN CANCER RES, V17, P817, DOI 10.1158/1078-0432.CCR-10-1789; Clendenen TV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140478; Dong LM, 2009, CANCER EPIDEM BIOMAR, V18, P2540, DOI 10.1158/1055-9965.EPI-09-0228; Feldman D, 2014, NAT REV CANCER, V14, P342, DOI 10.1038/nrc3691; Garcia-Closas M, 2013, NAT GENET, V45, P392, DOI 10.1038/ng.2561; Holick CN, 2007, CANCER EPIDEM BIOMAR, V16, P1990, DOI 10.1158/1055-9965.EPI-07-0487; Holt SK, 2009, CANCER EPIDEM BIOMAR, V18, P1929, DOI 10.1158/1055-9965.EPI-09-0113; Kim Y, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-29; Kimball S, 2008, CRIT REV CL LAB SCI, V45, P339, DOI 10.1080/10408360802165295 ; Mehta RG, 2013, CANCER LETT, V334, P95, DOI 10.1016/j.canlet.2012.10.034; Mondul AM, 2013, CANCER EPIDEM BIOMAR, V22, P688, DOI 10.1158/1055-9965.EPI-13-0007-T; Muindi JR, 2013, HORM CANCER-US, V4, P242, DOI 10.1007/s12672-013-0139-9; Pibiri F, 2014, CANCER CAUSE CONTROL, V25, P561, DOI 10.1007/s10552-014-0361-y; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Reimers LL, 2015, CANCER CAUSE CONTROL, V26, P187, DOI 10.1007/s10552-014-0497-9; Scarmo S, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3390; Schafer A, 2012, ARCH DERMATOL RES, V304, P353, DOI 10.1007/s00403-012-1243-3; Stolzenberg-Solomon RZ, 2010, AM J EPIDEMIOL, V172, P81, DOI 10.1093/aje/kwq120; Sun HY, 2016, HUM PATHOL, V50, P101, DOI 10.1016/j.humpath.2015.11.008; Thorne J, 2008, P NUTR SOC, V67, P115, DOI 10.1017/S0029665108006964; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang J, 2014, CANCER CAUSE CONTROL, V25, P819, DOI 10.1007/s10552-014-0383-5; Whitlatch LW, 2002, J STEROID BIOCHEM, V81, P135, DOI 10.1016/S0960-0760(02)00053-5; Wolpin BM, 2012, CANCER EPIDEM BIOMAR, V21, P82, DOI 10.1158/1055-9965.EPI-11-0836; Wu X., 2016, J MOL SCI, V17, P10; Yao S, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3162; Zhalehjoo N, 2017, MOL MED REP, V15, P467, DOI 10.3892/mmr.2016.5992	32	3	3	0	1	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					53	63		10.1016/j.prp.2017.11.014			11	Pathology	Pathology	GB5EN	WOS:000429086000008	29254801				2019-10-28	
J	Azambuja, DB; Leguisamo, NM; Gloria, HC; Kalil, AN; Rhoden, E; Saffi, J				Azambuja, Daniel B.; Leguisamo, Natalia M.; Gloria, Helena C.; Kalil, Antonio Nocchi; Rhoden, Ernani; Saffi, Jenifer			Prognostic impact of changes in base excision repair machinery in sporadic colorectal cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Colorectal cancer; Base excision repair; TNM staging; Prognosis; Disease-free survival	DNA-POLYMERASE-BETA; POLYPOSIS-COLI PROTEIN; FLAP ENDONUCLEASE-1; GLYCOSYLASE; DAMAGE; FEN1; APC; OVEREXPRESSION; SENSITIVITY; MUTATIONS	Objective: to evaluate the prognostic value of base excision repair proteins in sporadic colorectal cancer. Methods: Pre-treatment tumor samples from 72 patients with sporadic colorectal adenocarcinoma were assessed for APC, MPG, Pol beta, XRCC1 and Fenl expression by immunohistochemistry. The associations of molecular data were analyzed in relation to clinical features and TNM staging as a prognosis predictor and disease-free survival. Results: Higher levels of MPG, Pol beta and XRCC1, but not Fenl, were associated with unfavorable pathological outcomes, such as poor cellular differentiation, advanced TNM stages, presence of lymphatic and perineural invasions and metastatic lymph nodes. MPG and Pol beta overexpression were associated with right-sided CRC. However, only MPG high expression is associated with shorter disease-free survival in CRC patients. Conclusions: Our results suggest that increased expression of MPG, Pol beta and XRCC1 are more likely to evolve to poor pathological outcomes, but only the elevated expression of MPG protein predicts recurrence. The BER proteins appear to be suitable candidates to refine the TNM current staging of colorectal cancer.	[Azambuja, Daniel B.; Kalil, Antonio Nocchi] Santa Casa Misericordia Porto Alegre ISCMPA, Dept Colorectal Surg, BR-90050170 Porto Alegre, RS, Brazil; [Azambuja, Daniel B.; Leguisamo, Natalia M.; Gloria, Helena C.; Saffi, Jenifer] UFCSPA, Lab Genet Toxicol, BR-9005017 Porto Alegre, RS, Brazil; [Leguisamo, Natalia M.] Fundacao Univ Cardiol Rio Grande Sul IC FUC, Inst Cardiol, Mol & Celular Cardiol Lab, BR-90040371 Porto Alegre, RS, Brazil; [Rhoden, Ernani] Santa Casa Misericordia Porto Alegre ISCMPA, Dept Surg, BR-90050170 Porto Alegre, RS, Brazil	Leguisamo, NM (reprint author), UFCSPA, Lab Genet Toxicol, BR-9005017 Porto Alegre, RS, Brazil.	dazambuja@uol.com.br; nmleguisamo@gmail.com; helenadecastroegloria@gmail.com; ankalil@terra.com.br; ernanirhoden@ufespa.edu.br; jenifers@ufcspa.edu.br			FAPERGS (Fundacao de Apoio a Pesquisa do Rio Grande do Sul)Foundation for Research Support of the State of Rio Grande do Sul (FAPERGS); CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)CAPES; CNPq (Conselho Nacional de Pesquisa)National Council for Scientific and Technological Development (CNPq)	We thank to FAPERGS (Fundacao de Apoio a Pesquisa do Rio Grande do Sul), CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) and CNPq (Conselho Nacional de Pesquisa) for financial support.	Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cuneo MJ, 2010, P NATL ACAD SCI USA, V107, P6805, DOI 10.1073/pnas.0914077107; David SS, 2007, NATURE, V447, P941, DOI 10.1038/nature05978; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Dianova II, 2004, NUCLEIC ACIDS RES, V32, P2550, DOI 10.1093/nar/gkh567; Donigan KA, 2012, J BIOL CHEM, V287, P23830, DOI 10.1074/jbc.M111.324947; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Hegde ML, 2008, CELL RES, V18, P27, DOI 10.1038/cr.2008.8; Henneke G, 2003, TRENDS BIOCHEM SCI, V28, P384, DOI 10.1016/S0968-0004(03)00138-5; Horton JK, 2008, CELL RES, V18, P48, DOI 10.1038/cr.2008.7; Jaiswal AS, 2008, CANCER LETT, V271, P272, DOI 10.1016/j.canlet.2008.06.024; Jaiswal AS, 2006, BIOCHEMISTRY-US, V45, P15903, DOI 10.1021/bi0607958; Jaiswal AS, 2012, NEOPLASIA, V14, P495, DOI 10.1593/neo.12680; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kim Yun-Jeong, 2012, Curr Mol Pharmacol, V5, P3; Lange SS, 2011, NAT REV CANCER, V11, P96, DOI 10.1038/nrc2998; Leguisamo NM, 2017, ONCOTARGET, V8, P54199, DOI 10.18632/oncotarget.14909; Lieberman DA, 2012, GASTROENTEROLOGY, V143, P844, DOI 10.1053/j.gastro.2012.06.001; Maguire A, 2014, WORLD J GASTROENTERO, V20, P9850, DOI 10.3748/wjg.v20.i29.9850; Maynard S, 2009, CARCINOGENESIS, V30, P2, DOI 10.1093/carcin/bgn250; McManus KJ, 2009, P NATL ACAD SCI USA, V106, P3276, DOI 10.1073/pnas.0813414106; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Nieuwenhuis MH, 2007, CRIT REV ONCOL HEMAT, V61, P153, DOI 10.1016/j.critrevonc.2006.07.004; Nikolova T, 2009, ANTICANCER RES, V29, P2453; Paik J, 2005, CANCER RES, V65, P10472, DOI 10.1158/0008-5472.CAN-05-1495; Petrelli F, 2017, JAMA ONCOL, V3, P211, DOI 10.1001/jamaoncol.2016.4227; Pino MS, 2011, EXPERT REV GASTROENT, V5, P385, DOI [10.1586/EGH.11.25, 10.1586/egh.11.25]; Qin Qiong, 2017, Chronic Dis Transl Med, V3, P51, DOI 10.1016/j.cdtm.2017.02.004; Rinne ML, 2005, NUCLEIC ACIDS RES, V33, P2859, DOI 10.1093/nar/gki601; Roos WP, 2016, NAT REV CANCER, V16, P20, DOI 10.1038/nrc.2015.2; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Shen BH, 2005, BIOESSAYS, V27, P717, DOI 10.1002/bies.20255; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Smith SA, 2000, NUCLEIC ACIDS RES, V28, P3294, DOI 10.1093/nar/28.17.3294; Sobol RW, 2002, P NATL ACAD SCI USA, V99, P6860, DOI 10.1073/pnas.092662499; Trivedi RN, 2008, MOL PHARMACOL, V74, P505, DOI 10.1124/mol.108.045112; Wallace SS, 2014, DNA REPAIR, V19, P14, DOI 10.1016/j.dnarep.2014.03.030; Wallace SS, 2012, CANCER LETT, V327, P73, DOI 10.1016/j.canlet.2011.12.038; Wang K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-573; Wyatt MD, 2009, CELL MOL LIFE SCI, V66, P788, DOI 10.1007/s00018-008-8557-5; Zheng L, 2011, NUCLEIC ACIDS RES, V39, P781, DOI 10.1093/nar/gkq884	44	2	2	0	1	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					64	71		10.1016/j.prp.2017.11.012			8	Pathology	Pathology	GB5EN	WOS:000429086000009	29254784				2019-10-28	
J	Wu, JH; Zhang, YH; Sun, L; Zhai, QL				Wu, Jianghua; Zhang, Yanhui; Sun, Lin; Zhai, Qiongli			Cyclin D1 expression by histiocytes may mimic cyclin D1-positive proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Cyclin D1; Chronic lymphocytic leukaemia/Small; lymphocytic lymphoma; Histiocytes	MANTLE CELL LYMPHOMA; IMMUNOHISTOCHEMISTRY; DIAGNOSIS; LEUKEMIA; TISSUES	Aims: Cyclin D1, generally considered to be absent in chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL), has been reported in the proliferation centres (PCs) of recent CLL/SLL cases. Cyclin D1 immunostaining in CLL/SLL may lead to diagnostic confusion. The objective of this study was to identify the types of stained cells and the impact on diagnosis. Methods: Cyclin D1 expression was assessed by immunostaining samples from 46 cases of CLL/SLL. CD68 and double immunostaining with CD20/CyclinD1, CD68/CyclinD1, and CD163/CyclinD1 were then performed in cases of CLL/SLL positive for cyclinD1 in the PCs. Results: Dim-positive cyclin D1 staining in randomly scattered cells in the CLL/SLLs were observed in 38/46 cases (82.6%). In five (10.9%) cases, more than 50 cyclin D1-positive cells per high-power field were detected within the PCs in CLL/SLL with weak to moderate intensity. Double immunochemical staining in these cases showed that cyclin D1 in these positive cells was mostly co-expressed with CD68 and CD163 and the cells were negative for CD20. Conclusions: The cyclin D1-positive CLL/SLL cells in this study were mostly histiocytes. The expression of cyclin D1 by histiocytes may mimic cyclin D1 + CLL/SLL; thus, the recognition of cyclin D1 expression by non-lymphoid cells in lymphoma is important.	[Wu, Jianghua; Zhang, Yanhui; Sun, Lin; Zhai, Qiongli] Tianjin Med Univ, Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Dept Pathol,Natl Clin Res Ctr Canc,Tianjin Clin R, Tianjin, Peoples R China	Zhai, QL (reprint author), Tianjin Med Univ, Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Dept Pathol,Natl Clin Res Ctr Canc, Tianjin 30060, Peoples R China.	zhaigiongli@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81272361]; Science and Technology Fund of Tianjin Bureau of Public Health [2014KZ084]	This work was supported by the National Natural Science Foundation of China (Grant No. 81272361) and the Science and Technology Fund of Tianjin Bureau of Public Health (NO. 2014KZ084).	Abboudi Z, 2009, EUR J HAEMATOL, V83, P203, DOI 10.1111/j.1600-0609.2009.01276.x; Abdulla Z, 2014, APMIS, V122, P183, DOI 10.1111/apm.12123; Asaad Nancy Yousef, 2005, J Egypt Natl Canc Inst, V17, P279; Athanasiou E, 2001, MODERN PATHOL, V14, P62, DOI 10.1038/modpathol.3880257; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; Belaud-Rotureau MA, 2002, MODERN PATHOL, V15, P517, DOI 10.1038/modpathol.3880556; Chan JKC, 1999, HISTOPATHOLOGY, V34, P266; Cheuk W, 2004, AM J SURG PATHOL, V28, P801, DOI 10.1097/01.pas.0000126054.95798.94; deBoer CJ, 1996, ANN ONCOL, V7, P251; Gradowski JF, 2012, AM J CLIN PATHOL, V138, P132, DOI 10.1309/AJCPIVKZRMPF93ET; Lau SK, 2004, AM J CLIN PATHOL, V122, P794, DOI 10.1309/QHD6YFN81KQXUUH6; Meyerson HJ, 2006, AM J CLIN PATHOL, V125, P241, DOI 10.1309/7C2W961960RMLHD; Mitterlechner T, 2006, J CLIN PATHOL, V59, P48, DOI 10.1136/jcp.2005.026815; Muller-Hermelink HK, 2008, WHO CLASSIFICATION T, P180; O'Malley DP, 2005, ARCH PATHOL LAB MED, V129, P92; Padhi S, 2013, INDIAN J MED PAEDIAT, V34, P283, DOI 10.4103/0971-5851.125246; Pileri SA, 1997, J PATHOL, V183, P116; Sabatini E, 2010, PATHOLOGICA, V102, P83; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Swerdlow SH, 2008, WHO CLASSIFICATION T, P229; Troussard X, 2000, Hematol J, V1, P181, DOI 10.1038/sj.thj.6200025	21	2	2	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					72	75		10.1016/j.prp.2017.11.010			4	Pathology	Pathology	GB5EN	WOS:000429086000010	29254788				2019-10-28	
J	Jeffreys, M; Jeffus, SK; Herfs, M; Quick, CM				Jeffreys, Matthew; Jeffus, Susanne K.; Herfs, Michael; Quick, Charles Matthew			Accentuated p53 staining in usual type vulvar dysplasia-A potential diagnostic pitfall	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Differentiated; VIN; p53; p16; Vulva	INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; CARCINOMA; LESIONS; HPV	Evaluation of vulvar intraepithelial neoplasia (VIN) may be difficult due to overlapping histologic features seen in both usual (UVIN) and differentiated vulvar intraepithelial neoplasia (DVIN). DVIN represents a diagnostic challenge; poor inter-observer agreement is well documented. P53 has been described as a potentially helpful adjunct in some cases; however, intricacies in its interpretation remain. This study evaluated 41 consecutive cases which consisted of 23 keratinizing dysplasias that were morphologically suggestive of DVIN and 18 UVINs. All cases were stained with p16 and p53. Our results revealed that 22 of 41 (54%) VINs showed novel accentuated wild type (WT) staining with non-linear basal staining for p53, including 12 (52%) cases histologically suggestive of DVIN and 10 (56%) described as UVIN. P16 was positive in 100% of the accentuated wild type cases, consistent with a diagnosis of UVIN. Positive p53 and negative p16 staining was seen in 4 (17%) cases histologically suggestive of DVIN. Of these, 75% progressed to carcinoma, whereas only 1 of 35 (3%) patients with UVIN progressed to carcinoma. In conclusion, DVIN is difficult to diagnose due to potential histologic overlap with UVIN, especially the warty, or keratinizing, subtype. Accentuated WT p53 in absence of concurrent p16 staining may lead to misdiagnosis of DVIN, especially in small biopsy samples. P16/p53 staining should be performed in tandem with strict adherence to patterns considered positive, as patients with UVIN have significantly less risk of progression.	[Jeffreys, Matthew; Jeffus, Susanne K.; Quick, Charles Matthew] Univ Arkansas Med Sci, Dept Pathol, 4301 West Markham St,Slot 517, Little Rock, AR 72205 USA; [Herfs, Michael] Univ Liege, Lab Expt Pathol, GIGA Canc, 13 Ave Hippocrate, B-4000 Liege, Belgium	Quick, CM (reprint author), Univ Arkansas Med Sci, Dept Pathol, 4301 West Markham St,Slot 517, Little Rock, AR 72205 USA.	Quickcharlesm@uams.edu					Darragh TM, 2013, INT J GYNECOL PATHOL, V32, P76, DOI 10.1097/PGP.0b013e31826916c7; del Pino M, 2013, HISTOPATHOLOGY, V62, P161, DOI 10.1111/his.12034; Fox H, 2003, HISTOPATHOLOGY, V42, P209, DOI 10.1046/j.1365-2559.2003.01578.x; Hart WR, 2001, INT J GYNECOL PATHOL, V20, P16, DOI 10.1097/00004347-200101000-00003; Herfs M, 2017, J PATHOL, V241, P522, DOI 10.1002/path.4858; Hoang LN, 2016, PATHOLOGY, V48, P291, DOI 10.1016/j.pathol.2016.02.015; Kocjan BJ, 2011, J VIROL METHODS, V175, P117, DOI [10.1016/j.jviromet.2011.34.006, 10.1016/j.jviromet.2011.04.006]; Mulvany NJ, 2008, INT J GYNECOL PATHOL, V27, P125, DOI 10.1097/pgp.0b0318134ea34; Pinto AP, 2013, MODERN PATHOL, V26, P1498, DOI 10.1038/modpathol.2013.85; Podoll MB, 2017, INT J GYNECOL PATHOL, V36, P273, DOI 10.1097/PGP.0000000000000317; Stewart CJR, 2014, J CLIN PATHOL, V67, P319, DOI 10.1136/jclinpath-2013-201920; van de Nieuwenhof HP, 2009, CANCER EPIDEM BIOMAR, V18, P2061, DOI 10.1158/1055-9965.EPI-09-0209; van den Einden LCG, 2013, MODERN PATHOL, V26, P874, DOI 10.1038/modpathol.2012.235; Watkins JC, 2017, MODERN PATHOL, V30, P448, DOI 10.1038/modpathol.2016.187; Yang B, 2000, AM J SURG PATHOL, V24, P429, DOI 10.1097/00000478-200003000-00013	15	2	2	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					76	79		10.1016/j.prp.2017.11.009			4	Pathology	Pathology	GB5EN	WOS:000429086000011	29254796				2019-10-28	
J	Shimasaki, M; Kanazawa, Y; Sato, K; Tsuchiya, H; Ueda, Y				Shimasaki, Miyako; Kanazawa, Yoshimitsu; Sato, Katsuaki; Tsuchiya, Hiroyuki; Ueda, Yoshimichi			Aquaporin-1 and-5 are involved in the invasion and proliferation of soft tissue sarcomas	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Soft tissue sarcoma; Aquaporin-1; Aquaporin-5; Invasion and metastasis; Cell proliferation	WATER-CHANNEL; EXPRESSION; METASTASIS; CANCER; EZRIN; CELLS; INHIBITOR; MIGRATION; SURVIVAL; GROWTH	Background and aim: Recent studies of several carcinomas have reported that aquaporin possesses novel oncogenie properties. The aim of this study was to clarify the involvement of aquaporin-1 and 5 in the proliferation, invasion and metastasis of soft tissue sarcomas. Materials and methods: The expression of aquaporin-1 and -5 was immunohistochemically examined in 73 soft tissue sarcomas as well as in benign, locally aggressive soft tissue tumors, and in soft tissues of adult humans and human fetuses. The mRNA and protein expression of aquaporin-1 and -5 genes were quantified in 19 sarcoma tissues. Results: Aquaporin-1 was expressed in the tumor cells of 37 (51%) and aquaporin-5 in 29 (40%) of 73 soft tissue sarcomas. Two expression patterns were identified: a differentiation-dependent pattern, similar to their expression in adult human soft tissue and in benign soft tissue tumors, and an aggressiveness-related pattern, that is similar to their expression in the mesenchymal cells of the developing fetal limb. The latter expression pattern proved to be an independent prognostic factor for patients with soft tissue sarcoma, in which aquaporin-1 was related to the invasiveness, and aquaporin-5 to the proliferation of soft tissue sarcoma cells. Conclusion: These results indicate pivotal roles for aquaporin-1 and -5 in the aggressive growth and metastatic potential of soft tissue sarcomas, suggesting that they are promising targets for the treatment of patients with intractable soft tissue sarcoma.	[Shimasaki, Miyako; Sato, Katsuaki; Ueda, Yoshimichi] Kanazawa Med Univ, Dept Pathol, Daigaku 1-1, Uchinada, Ishikawa 9200293, Japan; [Kanazawa, Yoshimitsu; Tsuchiya, Hiroyuki] Kanazawa Univ, Grad Sch Med Sci, Dept Orthoped Surg, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan	Ueda, Y (reprint author), Kanazawa Med Univ, Dept Pathol, Daigaku 1-1, Uchinada, Ishikawa 9200293, Japan.	z-ueda@kanazawa-med.ac.jp			Japanese Ministry of Education, Culture, Sports, Science, and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [22590323]; Kanazawa Medical University [SR2012-01]	This study was supported by the grant 22590323 (Y.U.) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology and the grant SR2012-01 (Y.U.) from Kanazawa Medical University.	Agre Peter, 2006, Proc Am Thorac Soc, V3, P5, DOI 10.1513/pats.200510-109JH; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; Carneiro A, 2011, J CLIN PATHOL, V64, P689, DOI 10.1136/jcp.2011.089805; Coindre P., 2001, CANCER, V91, P1914; Demetri GD, 2013, J CLIN ONCOL, V31, P2485, DOI 10.1200/JCO.2012.45.5766; Endo M, 2013, CLIN CANCER RES, V19, P450, DOI 10.1158/1078-0432.CCR-12-1067; Fletcher C. D. M., 2012, WHO CLASSIFICATION T; Francis P, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-73; Gao HW, 2006, GLIA, V53, P783, DOI 10.1002/glia.20336; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hasegawa T. S., 2002, CANCER, V5, P813; Hu J, 2006, FASEB J, V20, P1892, DOI 10.1096/fj.06-5930fje; Italiano A, 2011, CANCER-AM CANCER SOC, V117, P1049, DOI 10.1002/cncr.25538; Jiang Y, 2009, IUBMB LIFE, V61, P1001, DOI 10.1002/iub.243; Jung J. Y., 2011, PLOS ONE, V6; Kang SK, 2008, AM J PATHOL, V173, P518, DOI 10.2353/ajpath.2008.071198; Kao SCH, 2012, CANCER-AM CANCER SOC, V118, P2952, DOI 10.1002/cncr.26497; Machida Y, 2011, HUM PATHOL, V42, P669, DOI 10.1016/j.humpath.2010.07.022; Matsuzaki T, 2005, ACTA HISTOCHEM CYTOC, V38, P37, DOI 10.1267/ahc.38.37; Mertens F, 2010, VIRCHOWS ARCH, V456, P129, DOI 10.1007/s00428-009-0736-8; Monzani E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006167; Mosbasheri A, 2004, AM J PHYSIOL-CELL PH, V286, pC529, DOI 10.1152/ajpcell.00408.2003; Oda Y, 2009, INT J CANCER, V124, P1852, DOI 10.1002/ijc.24128; Papadopoulos MC, 2008, PFLUG ARCH EUR J PHY, V456, P693, DOI 10.1007/s00424-007-0357-5; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125; Skowronski MT, 2012, REPROD BIOL, V12, P81, DOI 10.1016/S1642-431X(12)60079-5; Verkman AS, 2008, J MOL MED, V86, P523, DOI 10.1007/s00109-008-0303-9; Verkman AS, 2009, J EXP BIOL, V212, P1707, DOI 10.1242/jeb.024125; Wang LP, 2016, TECHNOL CANCER RES T, V15, P821, DOI 10.1177/1533034615607693; Weng WH, 2005, CLIN CANCER RES, V11, P6198, DOI 10.1158/1078-0432.CCR-05-0548; Woo J, 2008, CANCER LETT, V264, P54, DOI 10.1016/j.canlet.2008.01.029; Wu Z, 2015, CANCER BIOL THER, V16, P1332, DOI 10.1080/15384047.2015.1070983; Yool AJ, 2010, CLIN EXP PHARMACOL P, V37, P403, DOI 10.1111/j.1440-1681.2009.05244.x; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zhang ZQ, 2010, J PATHOL, V221, P210, DOI 10.1002/path.2702	37	1	1	0	0	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					80	88		10.1016/j.prp.2017.11.006			9	Pathology	Pathology	GB5EN	WOS:000429086000012	29258764	Other Gold			2019-10-28	
J	Gamberi, G; Morandi, L; Benini, S; Resca, A; Cocchi, S; Magagnoli, G; Donati, DM; Righi, A; Gambarotti, M				Gamberi, Gabriella; Morandi, Luca; Benini, Stefania; Resca, Anna; Cocchi, Stefania; Magagnoli, Giovanna; Donati, Davide Maria; Righi, Alberto; Gambarotti, Marco			Detection of H3F3A p.G35W and p.G35R in giant cell tumor of bone by Allele Specific Locked Nucleic Acid quantitative PCR (ASLNAqPCR)	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Giant cell tumor; H3F3A gene; Allele specific locked nucleic acid quantitative; PCR	RECEPTOR ACTIVATOR; MUTATION; LIGAND	Giant Cell Tumor (GCT) represents about 20% of benign bone tumors, is locally aggressive although malignant transformation is extremely rare, < I% of cases but 2-3% give pulmonary metastasis. Age at onset is between 20 and 40 years with a slight predominance for the female gender. GCT is characterized by specific mutations in H3F3A gene encoding the protein histone 3.3. The study of these mutations is important for the differential diagnosis with giant cell rich sarcomas, chondroblastoma and aneurysmal bone cyst. To identify the most frequent H3F3A mutations we developed a novel allele specific Real Time Polymerase Chain Reaction method, based on Allele Specific Locked Nucleic Acid (ASLNAqPCR) that is here described. Molecular analyses were performed on 20 GCT and 2 osteosarcoma arising on a previous GCT. All cases were verified by Sanger sequencing. We demonstrated that ASLNAqPCR is a quick, sensitive and reliable method to identify mutations of the H3F3A gene, in giant cell tumor of bone, to support diagnosis in morphologically ambiguous cases.	[Gamberi, Gabriella; Benini, Stefania; Resca, Anna; Cocchi, Stefania; Magagnoli, Giovanna; Righi, Alberto; Gambarotti, Marco] Rizzoli Inst, Dept Pathol, Via Barbiano 1-10, I-40136 Bologna, Italy; [Gamberi, Gabriella; Morandi, Luca; Donati, Davide Maria] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy; [Morandi, Luca] Bellaria Hosp, Unit Anat Pathol, Bologna, Italy; [Donati, Davide Maria] Rizzoli Inst, Orthopaed Oncol Surg Unit, Bologna, Italy	Gamberi, G (reprint author), Rizzoli Inst, Dept Pathol, Via Barbiano 1-10, I-40136 Bologna, Italy.	gabriella.gamberi@ior.it; luca.morandi2@unibo.it; stefania.benini@ior.it; annaresca27@gmail.com; stefania.cucchi@ior.it; giovanna.magagnoli@ior.it; davidemaria.donati@ior.it; alberto.righi@ior.it; marco.gambarotti@ior.it	Righi, Alberto/J-6028-2016; COCCHI, STEFANIA/D-1725-2019; Magagnoli, Giovanna/D-1723-2019; Gambarotti, Marco/C-6878-2019	Righi, Alberto/0000-0002-1074-0155; COCCHI, STEFANIA/0000-0001-6853-4621; Magagnoli, Giovanna/0000-0002-6430-1318; Gambarotti, Marco/0000-0002-8080-4484			Alberghini M, 2010, VIRCHOWS ARCH, V456, P97, DOI 10.1007/s00428-009-0863-2; Amanatullah DF, 2014, ORTHOPEDICS, V37, P158, DOI 10.3928/01477447-20140225-51; Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859; Athanasou NA, 2013, WHO CLASSIFICATION T, P321; Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814; Bertoni F, 2003, CANCER, V97, P2520, DOI 10.1002/cncr.11359; Cleven AHG, 2015, AM J SURG PATHOL, V39, P1576, DOI 10.1097/PAS.0000000000000512; Dominkus M, 2006, INT ORTHOP, V30, P499, DOI 10.1007/s00264-006-0204-x; Errani C, 2010, CANCER TREAT REV, V36, P1, DOI 10.1016/j.ctrv.2009.09.002; Girolami I, 2016, J CLIN PATHOL, V69, P240, DOI 10.1136/jclinpath-2015-203248; Gong LH, 2012, VIRCHOWS ARCH, V460, P327, DOI 10.1007/s00428-012-1198-y; Harness NG, 2004, J HAND SURG-AM, V29A, P188, DOI 10.1016/j.jhsa.2003.11.003; Kervarrec T, 2017, MODERN PATHOL, V30, P393, DOI 10.1038/modpathol.2016.212; Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P591, DOI 10.1007/s11999-010-1501-7; Lang S, 2008, Pathologe, V29 Suppl 2, P245, DOI 10.1007/s00292-008-1090-3; Latorra D, 2003, HUM MUTAT, V22, P79, DOI 10.1002/humu.10228; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luke J, 2017, HISTOPATHOLOGY, V71, P125, DOI 10.1111/his.13190; Morandi L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036084; Morgan T, 2005, AM J PATHOL, V167, P117, DOI 10.1016/S0002-9440(10)62959-8; Muheremu A, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-261; Nielsen GP, 2013, DIAGNOSTIC PATHOLOGY; Ogura K, 2017, GENE CHROMOSOME CANC, V56, P711, DOI 10.1002/gcc.22469; Presneau N, 2015, J PATHOL CLIN RES, V1, P113, DOI 10.1002/cjp2.13; Roux S, 2002, AM J CLIN PATHOL, V117, P210; Szenker E, 2011, CELL RES, V21, P421, DOI 10.1038/cr.2011.14; Werner M, 2006, INT ORTHOP, V30, P484, DOI 10.1007/s00264-006-0215-7; Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102	28	1	1	1	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					89	94		10.1016/j.prp.2017.10.023			6	Pathology	Pathology	GB5EN	WOS:000429086000013	29254795				2019-10-28	
J	Park, WY; Lee, SJ; Kim, YK; Kim, A; Park, DY; Lee, BE; Song, GA; Kim, GH				Park, Won-Young; Lee, So-Jeong; Kim, Young-Keum; Kim, Ahrong; Park, Do Youn; Lee, Bong-Eun; Song, Geun-Am; Kim, Gwang Ha			Occurrence of metachronous or synchronous lesions after endoscopic treatment of gastric epithelia dysplasia- impact of histologic features of background mucosa	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Stomach; Gastric epithelial dysplasia; Crypt dysplasia; Intestinal metaplasia; Atrophy; Multiple lesions	TERM-FOLLOW-UP; INTESTINAL METAPLASIA; SUBMUCOSAL DISSECTION; PIT DYSPLASIA; RESECTION; CANCER; RISK; CLASSIFICATION; RECURRENCE; PATHOLOGY	Aims: Endoscopic resection is a safe and effective method to treat gastric epithelia dysplasia (GED). However, the development of metachronous and synchronous lesions after treatment has become a major concern. In this study, we investigated clinicopathologic features of 105 GED lesions from endoscopic resections between January 2008 and December 2009. Our goal is to find histologic factors that predict synchronous and metachronous lesions after ESD treatment. We assessed the degree of intestinal metaplasia (IM) and atrophy, type of IM, presence of gastritis cystica profunda, and crypt dysplasia in the adjacent mucosa. Methods and results: We divided 105 GED lesions into three groups: a single group without metachronous or synchronous GED or adenocarcinoma (n = 35); a multiple synchronous group (n = 30, group with synchronous occurrence of GED or adenocarcinoma after treatment); and a multiple metachronous group (n = 40, group with metachronous occurrence of GED or adenocarcinoma after treatment). The multiple metachronous and synchronous groups showed larger sizes (p = 0.003) and higher grades (p = 0.021) as compared with the single group. Furthermore, marked IM and atrophy in adjacent mucosa were more easily seen in the multiple metachronous and synchronous groups as compared with the single group (p < 0.0001). Interestingly, the presence of incomplete type of IM (p = 0.025) and crypt dysplasia (p < 0.0001) in background mucosa was associated with occurrence of metachronous and synchronous lesions following endoscopic resection of GED. Conclusions: The histological features of background mucosa, such as intestinal metaplasia, atrophy, and crypt dysplasia could be used as indicators of occurrence of metachronous and synchronous lesions after endoscopic treatment of GED.	[Park, Won-Young; Lee, So-Jeong; Kim, Young-Keum; Kim, Ahrong; Park, Do Youn] Pusan Natl Univ Hosp, Dept Pathol, 1-10 Ami Dong, Busan 602739, South Korea; [Park, Won-Young; Lee, So-Jeong; Kim, Young-Keum; Kim, Ahrong; Park, Do Youn; Lee, Bong-Eun; Song, Geun-Am; Kim, Gwang Ha] Pusan Natl Univ, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea; [Park, Won-Young; Lee, So-Jeong; Kim, Young-Keum; Kim, Ahrong; Park, Do Youn; Lee, Bong-Eun; Song, Geun-Am; Kim, Gwang Ha] Pusan Natl Univ Hosp, Biomed Res Inst, Pusan, South Korea; [Lee, Bong-Eun; Song, Geun-Am; Kim, Gwang Ha] Pusan Natl Univ Hosp, Dept Gastroenterol, Pusan, South Korea	Park, DY (reprint author), Pusan Natl Univ Hosp, Dept Pathol, 1-10 Ami Dong, Busan 602739, South Korea.; Park, DY (reprint author), Pusan Natl Univ, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea.	pdy220@pusan.ac.kr			National R & D Program for Cancer Control, Ministry for Health, Welfare, and Family Affairs, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [0920050]; Ministry of Health, Welfare and Family AffairsMinistry of Health & Welfare, Republic of Korea	This study was supported by a grant (0920050) from the National R & D Program for Cancer Control, Ministry for Health, Welfare, and Family Affairs, Republic of Korea. The biospecimens for this study were provided by Pusan National University Hospital, a member of the National Biobank of Korea, which is supported by the Ministry of Health, Welfare and Family Affairs. All samples derived from the National Biobank of Korea were obtained with informed consent under institutional review board-approved protocols.	Abraham SC, 2002, AM J SURG PATHOL, V26, P1276, DOI 10.1097/01.PAS.0000024542.83286.45; Agoston AT, 2014, HUM PATHOL, V45, P446, DOI 10.1016/j.humpath.2013.10.032; Arima N, 1999, J CLIN GASTROENTEROL, V29, P44, DOI 10.1097/00004836-199907000-00011; Baek DH, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0249-7; Bang CS, 2015, J KOREAN MED SCI, V30, P749, DOI 10.3346/jkms.2015.30.6.749; Correa P, 2010, AM J GASTROENTEROL, V105, P493, DOI 10.1038/ajg.2009.728; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Gonzalez CA, 2010, INT J CANCER, V127, P2654, DOI 10.1002/ijc.25273; Han JS, 2011, SCAND J GASTROENTERO, V46, P1099, DOI 10.3109/00365521.2011.591427; Jang MY, 2013, KOREAN J INTERN MED, V28, P687, DOI 10.3904/kjim.2013.28.6.687; Jung DH, 2015, J GASTRIC CANCER, V15, P246, DOI 10.5230/jgc.2015.15.4.246; Lauwers GY, 2003, J CLIN GASTROENTEROL, V36, pS37, DOI 10.1097/00004836-200305001-00007; LEWIN KJ, 1996, ATLAS TUMOR PATHOL, P245; Li Y, 2013, HUM PATHOL, V44, P578, DOI 10.1016/j.humpath.2012.07.002; Lim JH, 2015, GASTRIC CANCER, V18, P817, DOI 10.1007/s10120-014-0438-z; Moon Sun You, 2010, Korean J Gastroenterol, V55, P325; Nakajima Takeshi, 2006, Gastric Cancer, V9, P93, DOI 10.1007/s10120-006-0372-9; Niwa T, 2005, J HISTOCHEM CYTOCHEM, V53, P75, DOI 10.1369/jhc.4A6443.2005; Park DY, 2008, AM J SURG PATHOL, V32, P524, DOI 10.1097/PAS.0b013e31815b890e; Rugge M, 2002, ALIMENT PHARM THERAP, V16, P1249, DOI 10.1046/j.1365-2036.2002.01301.x; Shin N, 2011, AM J SURG PATHOL, V35, P1021, DOI 10.1097/PAS.0b013e31821ec495; Shin S. H., 2015, PLOS ONE, V18; Tava F, 2006, HUM PATHOL, V37, P1489, DOI 10.1016/j.humpath.2006.05.012; Yoo JH, 2013, J CLIN GASTROENTEROL, V47, pE17, DOI 10.1097/MCG.0b013e31825c0b69	24	2	2	1	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					95	99		10.1016/j.prp.2017.10.022			5	Pathology	Pathology	GB5EN	WOS:000429086000014	29103763				2019-10-28	
J	del Arco, CD; Taxonera, C; Olivares, D; Acenero, MJF				Diaz del Arco, Cristina; Taxonera, Carlos; Olivares, David; Fernandez Acenero, Ma Jesus			Eosinophilic colitis: Case series and literature review	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Eosinophilic; Colitis; Eosinophil; Large; Bowel	GASTROENTERITIS; INFANTS; CHILDREN; DISEASE; IBD	Introduction: Primary eosinophilic colitis (EC) in adults is a rare and poorly studied disease, with 3 case series, 2 database-based studies and 52 case reports published to date. Methods: Retrospective study of all adult EC cases diagnosed in a large tertiary hospital (Hospital Clinico San Carlos, Madrid) between 2006 and 2016. We included all cases with a histopathological diagnosis of EC and we selected only those cases that were clinically recognized primary EC. We report their clinical, endoscopic and histopathological features and review the literature on this topic. Results: We identified 22 primary EC cases. Patients were mostly women (77%) with a mean age of 41 years. 4 patients (18%) had coexistent allergic diseases. Most patients consulted with diarrhea (86%) and 3 patients also suffered from rectal bleeding. Blood tests showed peripheral eosinophilia in 4 cases (18%). 19 patients had no endoscopic lesions, 2 had features of unspecific colitis and one showed features suggestive of IBD. Mean and maximum number of eosinophils per high power field ranged from 16 to 199 and 20 to 253 (mean: 48 and 70). They were mainly located in the lamina propria and most cases were associated with signs of eosinophil activation. Most patients were treated by corticosteroids, diet or budesonide and the result of treatment was generally good. No complications or recurrences were reported. Conclusions: EC etiology and pathogenesis is unknown. Its clinical, endoscopical and imaging features are not specific, and clear histopathological criteria are lacking. Identification of signs of eosinophilic activation could be helpful.	[Diaz del Arco, Cristina; Fernandez Acenero, Ma Jesus] Hosp Clin Madrid, Dept Surg Pathol, C Prof Martin Lagos S-N, Madrid 28040, Spain; [Taxonera, Carlos; Olivares, David] Hosp Clin Madrid, Dept Gastroenterol, Madrid, Spain	del Arco, CD (reprint author), Hosp Clin Madrid, Dept Surg Pathol, C Prof Martin Lagos S-N, Madrid 28040, Spain.	crisdelarco@gmail.com		Fernandez-Acenerp/0000-0002-2439-3553			Alfadda AA, 2011, BRIT MED BULL, V100, P59, DOI 10.1093/bmb/ldr045; Alfadda Abdulrahman A, 2011, Therap Adv Gastroenterol, V4, P301, DOI 10.1177/1756283X10392443; Bates AWH, 2012, SCIENTIFICA, DOI 10.6064/2012/682576; Bischoff SC, 2010, CURR OPIN ALLERGY CL, V10, P238, DOI 10.1097/ACI.0b013e32833982c3; Brandon JL, 2013, PEDIATR RADIOL, V43, P697, DOI 10.1007/s00247-012-2615-8; Dionisio de Sousa Isabel Jose, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2016-214496; Gaertner WB, 2011, GASTROENT RES PRACT, DOI 10.1155/2011/857508; Jensen ET, 2016, J PEDIATR GASTR NUTR, V62, P36, DOI 10.1097/MPG.0000000000000865; Katsanos KH, 2011, J CROHNS COLITIS, V5, P256, DOI 10.1016/j.crohns.2011.02.009; KLEIN NC, 1970, MEDICINE, V49, P299, DOI 10.1097/00005792-197007000-00003; Lozinsky AC, 2014, J PEDIAT-BRAZIL, V90, P16, DOI 10.1016/j.jped.2013.03.024; Okpara N, 2009, WORLD J GASTROENTERO, V15, P2975, DOI 10.3748/wig.15.2975; Shifflet A, 2009, J FORMOS MED ASSOC, V108, P834, DOI 10.1016/S0929-6646(09)60414-9; Torrente F, 2014, J PEDIATR GASTR NUTR, V59, P300, DOI 10.1097/MPG.0000000000000432; Turner D, 2013, J PEDIATR GASTR NUTR, V56, P492, DOI 10.1097/MPG.0b013e3182801e60; Turner K. O., 2016, AM J SURG PATHOL, P1; Uppal V, 2016, CLIN REV ALLERG IMMU, V50, P175, DOI 10.1007/s12016-015-8489-4; Villanueva MS, 2015, CLIN COLON RECT SURG, V28, P118, DOI 10.1055/s-0035-1549365; Yamada Y, 2011, INT ARCH ALLERGY IMM, V155, P40, DOI 10.1159/000327264; Yang M, 2015, NUTRIENTS, V7, P1817, DOI 10.3390/nu7031817; Yen EF, 2012, BEST PRACT RES CL GA, V26, P611, DOI 10.1016/j.bpg.2012.11.012	21	4	4	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					100	104		10.1016/j.prp.2017.09.029			5	Pathology	Pathology	GB5EN	WOS:000429086000015	29103770				2019-10-28	
J	Xian, ZH; Qin, C; Cong, WM				Xian, Zhi-Hong; Qin, Chun; Cong, Wen -Ming			KRAS mutation and immunohistochemical profile in intraductal papillary neoplasm of the intrahepatic bile ducts	PATHOLOGY RESEARCH AND PRACTICE			English	Article						KRAS mutation; Immunohistochemical profile; Intraductal papillary neoplasm of bile duct; Malignant progression	BILIARY INTRAEPITHELIAL NEOPLASIA; MUCINOUS NEOPLASM; CLINICOPATHOLOGICAL FEATURES; TRACT CHOLANGIOCARCINOMA; PROGRESSION; GNAS; FREQUENCY; PANCREAS; EXPRESSION; P53	Intraductal papillary neoplasm of bile duct (IPNB) is characterized by a spectrum of diseases ranging from low-grade intraepithelial neoplasia to invasive carcinoma. In the present study, we aimed to investigate immunophenotypic features and KRAS mutations in relation to pathological subtypes and grades in Chinese patients with IPNBs. A total of 46 patients with IPNBs and 11 invasive adenocarcinomas arising in IPNBs (invasive IPNBs) were enrolled and clinicopathological data were analyzed. It was found that CK7 was expressed in 42 of the 46 neoplastic lesions. HepPar1 was expressed in 11 of the 46 noninvasive IPNBs, but not in invasive IPNBs. Additionally, CK19 was frequently expressed in both noninvasive IPNBs and invasive IPNBs. The intestinal-type IPNBs had a significantly higher percentage of MUC2 expression relative to the pancreaticobiliary (P = 0.015) and gastric-type IPNBs (P < 0.001). High-grade IPNBs and invasive IPNBs showed increased expression of cyclin D1, Ki-67, p53, mCEA, and CA19-9. The rate of KRAS mutation was significantly higher in high-grade IPNBs (P = 0.001) and invasive IPNBs (P = 0.006) than that in low- to intermediate-grade IPNBs. Additionally, KRAS mutation was significantly associated with tumor size, and Ki-67 expression. In conclusion, the expression of cyclin D, Ki-67, p53, mCEA and CA19-9 and KRAS mutation status are significantly correlated with histological grades of IPNBs.	[Xian, Zhi-Hong; Qin, Chun; Cong, Wen -Ming] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Pathol, Shanghai, Peoples R China	Xian, ZH (reprint author), Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Pathol, Shanghai, Peoples R China.	xianzh2015@163.com					Abraham SC, 2003, HUM PATHOL, V34, P902, DOI 10.1016/S0046-8177(03)00337-X; Ang C, 2015, J GASTROEN HEPATOL, V30, P1116, DOI 10.1111/jgh.12916; Borad MJ, 2015, CURR OPIN GASTROEN, V31, P264, DOI 10.1097/MOG.0000000000000171; Farshidfar F, 2017, CELL REP, V18, P2780, DOI 10.1016/j.celrep.2017.02.033; Furukawa T, 2005, VIRCHOWS ARCH, V447, P794, DOI 10.1007/s00428-005-0039-7; Hsu M, 2013, CANCER-AM CANCER SOC, V119, P1669, DOI 10.1002/cncr.27955; Huang WC, 2017, J FORMOS MED ASSOC, V116, P464, DOI 10.1016/j.jfma.2016.07.015; Itatsu K, 2007, LIVER INT, V27, P1174, DOI 10.1111/j.1478-3231.2007.01577.x; Ji Y, 2008, HISTOL HISTOPATHOL, V23, P41, DOI 10.14670/HH-23.41; Jung G, 2012, J HEPATOL, V57, P787, DOI 10.1016/j.jhep.2012.05.008; Kim KM, 2012, AM J GASTROENTEROL, V107, P118, DOI 10.1038/ajg.2011.316; Kloek JJ, 2011, HUM PATHOL, V42, P824, DOI 10.1016/j.humpath.2010.09.017; Matsubara T, 2012, HUM PATHOL, V43, P2177, DOI 10.1016/j.humpath.2012.03.007; Matthaei H, 2012, HPB, V14, P677, DOI 10.1111/j.1477-2574.2012.00504.x; Nakanuma Y, 2010, WHO CLASSIFICATION T, P217; Nakanuma Y, 2016, HUM PATHOL, V51, P103, DOI 10.1016/j.humpath.2015.12.022; Nakanuma Y, 2010, J HEPATO-BIL-PAN SCI, V17, P211, DOI 10.1007/s00534-009-0158-7; O'Dell M. R., 2012, CANCER RES, V72, P1081; Perea J, 2017, HUM PATHOL, V61, P221, DOI 10.1016/j.humpath.2016.07.039; Rizvi S, 2013, GASTROENTEROLOGY, V145, P1215, DOI 10.1053/j.gastro.2013.10.013; Robertson S, 2013, HUM PATHOL, V44, P2768, DOI 10.1016/j.humpath.2013.07.026; Sasaki M, 2015, HUM PATHOL, V46, P202, DOI 10.1016/j.humpath.2014.09.016; Sasaki M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081706; Schabath MB, 2016, ONCOGENE, V35, P3209, DOI 10.1038/onc.2015.375; Schlitter AM, 2014, MODERN PATHOL, V27, P73, DOI 10.1038/modpathol.2013.112; Sclabas GM, 2012, J AM COLL SURGEONS, V214, P27, DOI 10.1016/j.jamcollsurg.2011.09.025; Shimonishi T, 2002, HUM PATHOL, V33, P503, DOI 10.1053/hupa.2002.124030; Tsai JH, 2017, HISTOPATHOLOGY, V70, P756, DOI 10.1111/his.13125; Tsai JH, 2013, AM J SURG PATHOL, V37, P1862, DOI 10.1097/PAS.0b013e3182986bb5; Xiao HD, 2011, J PATHOL, V224, P508, DOI 10.1002/path.2875; Yang J, 2012, DIGEST LIVER DIS, V44, P251, DOI 10.1016/j.dld.2011.08.014; Yasri S, 2017, J FORMOS MED ASSOC, V116, P214, DOI 10.1016/j.jfma.2016.11.008; Zen Y, 2006, HEPATOLOGY, V44, P1333, DOI 10.1002/hep.21387	33	1	1	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					105	111		10.1016/j.prp.2017.10.017			7	Pathology	Pathology	GB5EN	WOS:000429086000016	29103773				2019-10-28	
J	Ben, ZY; Gong, LL; Qiu, YH				Ben, Zhiyun; Gong, Leilei; Qiu, Yuhua			High expression of VRK1 is related to poor prognosis in glioma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Glioma; VRK1; Proliferation; Apoptosis; Prognosis	VACCINIA-RELATED KINASE-1; THREONINE PROTEIN-KINASE; HEPATOCELLULAR-CARCINOMA; ADJUVANT TEMOZOLOMIDE; SURVIVAL; PHOSPHORYLATION; PROLIFERATION; GLIOBLASTOMA; RADIOTHERAPY; CONCOMITANT	Vaccinia-related kinase 1 (VRK1) is a member of the vaccinia-related kinase (VRK) family of serine/threonine protein kinases, which phosphorylates several transcription factors and has been postulated to be involved in regulation of cell proliferation. However, it remains unclear whether aberrant expression of VRK1 is related to the development of glioma. In this study, we aimed to investigate the clinical significance of VRK1 expression in human glioma and its biological function in glioma cells. Western blot and immunohistochemical analysis revealed that VRK1 was highly expressed in glioma tissues and cell lines. In addition, the expression level of VRK1 was positively correlated with glioma pathological grade, as well as Ki-67 expression. Kaplan-Meier analysis revealed that patients with high VRK1 expression was associated with a poorer prognosis. To determine whether VRK1 could regulate the proliferation of glioma cells, we transfected glioma cells with interfering RNA target VRK1, then investigated cell proliferation with cell counting kit (CCK) -8, flow cytometry assays and colony formation analyses. Our results indicated that knockdown of VRK1 would inhibit the proliferation of glioma cells. Besides, reduced expression of VRK1 could induce the apoptosis of glioma cells. On the basis of these findings, we suggested that VRK1 might be a promising prognostic biomarker of glioma.	[Ben, Zhiyun; Qiu, Yuhua] Soochow Univ, Sch Biol & Basic Med Sci, Dept Immunol, Suzhou 215123, Jiangsu, Peoples R China; [Gong, Leilei] Nantong Univ, Jiangsu Key Lab Neuroregenerat, Nantong 226001, Jiangsu, Peoples R China	Qiu, YH (reprint author), Soochow Univ, Sch Biol & Basic Med Sci, Dept Immunol, Suzhou 215123, Jiangsu, Peoples R China.	qiuyuhuasd@126.com					Auffinger Brenda, 2012, F1000 Med Rep, V4, P18; BANHAM AH, 1992, VIROLOGY, V191, P803, DOI 10.1016/0042-6822(92)90256-O; Bauer R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111219; Huang W, 2016, PATHOL RES PRACT, V212, P171, DOI 10.1016/j.prp.2015.11.015; Inagawa S, 2002, CLIN CANCER RES, V8, P450; Kang TH, 2008, J CELL SCI, V121, P3035, DOI 10.1242/jcs.026757; LIN SQ, 1992, J VIROL, V66, P2717; Liu Q, 2015, INT J CLIN EXP MED, V8, P22073; Lopez-Borges S, 2000, ONCOGENE, V19, P3656, DOI 10.1038/sj.onc.1203709; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; Ni WK, 2013, J CELL BIOCHEM, V114, P2120, DOI 10.1002/jcb.24560; Nichols RJ, 2004, J BIOL CHEM, V279, P7934, DOI 10.1074/jbc.M310813200; Omar AI, 2014, JOVE-J VIS EXP, DOI 10.3791/51638; Piccioni DE, 2013, EXPERT REV ANTICANC, V13, P1297, DOI 10.1586/14737140.2013.851160; Salzano M, 2014, ONCOTARGET, V5, P1770, DOI 10.18632/oncotarget.1678; Santos CR, 2006, MOL CANCER RES, V4, P177, DOI 10.1158/1541-7786.MCR-05-0212; Sevilla A, 2004, ONCOGENE, V23, P8950, DOI 10.1038/sj.onc.1208015; Sevilla A, 2004, J BIOL CHEM, V279, P27458, DOI 10.1074/jbc.M401009200; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Valbuena A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001642; Valbuena A, 2007, LUNG CANCER, V58, P303, DOI 10.1016/j.lungcan.2007.06.023; Valbuena A, 2011, CELL SIGNAL, V23, P1267, DOI 10.1016/j.cellsig.2011.04.002; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Vega FM, 2004, MOL CELL BIOL, V24, P10366, DOI 10.1128/MCB.24.23.10366-10380.2004; Wang HX, 2015, NEOPLASIA, V17, P239, DOI 10.1016/j.neo.2015.02.002; Zelko I, 1998, ARCH BIOCHEM BIOPHYS, V352, P31, DOI 10.1006/abbi.1998.0582	28	2	3	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					112	118		10.1016/j.prp.2017.10.014			7	Pathology	Pathology	GB5EN	WOS:000429086000017	29103766				2019-10-28	
J	Sun, YP; Mei, H; Xu, C; Tang, HJ; Wei, W				Sun, Yongpan; Mei, Hong; Xu, Chuan; Tang, Hongjun; Wei, Wei			Circulating microRNA-339-5p and-21 in plasma as an early detection predictors of lung adenocarcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						miR-339-5p; miR-21; Lung adenocarcinoma; Plasma; Biomarker; Diagnosis	DIAGNOSTIC-VALUE; CANCER; BIOMARKERS; SERUM; RNA; IDENTIFICATION; MIR-339-5P; PROGNOSIS; CARCINOMA; PATHWAY	Background: Many studies have shown that differentially expressed miRs in body fluids can serve as biomarkers in non-invasive detection of the cancers. However, the clinical significance of plasma miRs in the diagnosis of lung adenocarcinoma (LA) is still not clear. Therefore, we examined the LA-specific miRs in plasma, which could be utilized to diagnosis and monitor LA in routine clinical practice. Methods: Twenty-eight LA cases and twenty-eight healthy controls were recruited to our study. MiRs differential expression in plasma was measured by miRNA Microarray assay and revalidated by using qRT-PCR based absolute quantification methods The diagnostic power of circulating miRs in LA was evaluated using the receiver operating characteristics (ROC) curves and the area under the ROC curves (AUC). Results: Tumor tissues and plasma levels of miR-339-5p were significantly down-regulated in LA patients compared with those in the control group, whereas the levels of miR-21 in LA patients were significantly higher than control group. ROC analysis showed that miR-339-5p and miR-21 could distinguish LA patients from healthy controls with high AUC (0.900 and 0.880, respectively), sensitivity (0.821 and 0.821, respectively) and specificity (0.929 and 0.964, respectively). Importantly, the combination of miR-339-5p and miR-21 markedly improved AUC (0.963), sensitivity (0.929) and specificity (0.929). Conclusion: Plasma miR-339-5p or miR-21 could serve as a potential biomarker for diagnosis of LA, however, the combination of miR-339-5p and miR-21 was more efficient for LA detection.	[Sun, Yongpan; Mei, Hong; Xu, Chuan; Tang, Hongjun; Wei, Wei] Guizhou Prov Peoples Hosp, Dept Thorac Surg, 83 East Zhongshan Rd, Guiyang 550002, Guizhou, Peoples R China	Mei, H (reprint author), Guizhou Prov Peoples Hosp, Dept Thorac Surg, 83 East Zhongshan Rd, Guiyang 550002, Guizhou, Peoples R China.	meihhxx1@163.com					Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282; Cinegaglia NC, 2016, ONCOTARGET, V7, P28920, DOI 10.18632/oncotarget.8713; El-Hefnawy T, 2004, CLIN CHEM, V50, P564, DOI 10.1373/clinchem.2003.028506; Gallach S, 2017, ONCOTARGET, V8, P56143, DOI 10.18632/oncotarget.18603; Gan TQ, 2017, MED SCI MONITOR, V23, P2453, DOI 10.12659/MSM.901460; Gao F, 2014, ONCOL REP, V31, P351, DOI 10.3892/or.2013.2830; Geng Q, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0149-3; Imamura T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06137-8; Jansson MD, 2015, ONCOGENE, V34, P1908, DOI 10.1038/onc.2014.130; Jiang M, 2013, MOL CELL BIOCHEM, V383, P67, DOI 10.1007/s11010-013-1755-y; Kosaka Nobuyoshi, 2010, Silence, V1, P7, DOI 10.1186/1758-907X-1-7; Liu XG, 2012, MED ONCOL, V29, P618, DOI 10.1007/s12032-011-9923-y; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mansouri L, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0576-8; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Navickas R, 2016, CARDIOVASC RES, V111, P322, DOI 10.1093/cvr/cvw174; Okamura K, 2013, LUNG CANCER, V80, P45, DOI 10.1016/j.lungcan.2013.01.002; Osipova J, 2014, J CLIN ENDOCR METAB, V99, pE1661, DOI 10.1210/jc.2013-3868; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Patnaik SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046045; Peng H, 2016, LIFE SCI, V151, P235, DOI 10.1016/j.lfs.2016.03.002; Peng Z, 2017, ONCOTARGET, V8, P64143, DOI 10.18632/oncotarget.19358; Pu MF, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006896; Raitoharju E, 2014, MOL CELL ENDOCRINOL, V391, P41, DOI 10.1016/j.mce.2014.04.013; Tong YS, 2015, MOL CANCER, V14, DOI 10.1186/1476-4598-14-3; Tsai MM, 2016, EUR J CANCER, V64, P137, DOI 10.1016/j.ejca.2016.05.007; Wang YH, 2017, ONCOTARGET, V8, P20133, DOI 10.18632/oncotarget.15448; Wang Y, 2016, ONCOTARGET, V7, P26070, DOI 10.18632/oncotarget.8429; Wang YL, 2016, CLIN RES HEPATOL GAS, V40, P51, DOI 10.1016/j.clinre.2015.05.022; Wu ZS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-542; Yuan J, 2012, J INT MED RES, V40, P2090, DOI 10.1177/030006051204000606; Zhang H, 2017, ONCOL LETT, V13, P669, DOI [10.3892/o1.2016.5462, 10.3892/ol.2016.5462]; Zhang J, 2012, BBA-REV CANCER, V1826, P32, DOI 10.1016/j.bbcan.2012.03.001; Zhou X, 2017, ONCOTARGET, V8, P6513, DOI 10.18632/oncotarget.14311	35	2	2	1	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					119	125		10.1016/j.prp.2017.10.011			7	Pathology	Pathology	GB5EN	WOS:000429086000018	29103767				2019-10-28	
J	Lounglaithong, K; Bychkov, A; Sampatanukul, P				Lounglaithong, Kowit; Bychkov, Andrey; Sampatanukul, Pichet			Aberrant promoter methylation of the PAQR3 gene is associated with prostate cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						PAQR3; Promoter methylation; Prostate cancer; Benign prostatic hyperplasia	MEMBRANE PROGESTIN RECEPTOR; TUMOR-SUPPRESSOR; CELL CARCINOMA; PROGRESSION; EXPRESSION; RKTG; IDENTIFICATION; TUMORIGENESIS; METASTASIS; PROGNOSIS	Methylation markers are promising tools for diagnosis, prognosis and targeted treatment of cancer. In prostate carcinoma, aberrant promoter hypermethylation occurs earlier in the disease course and more consistently than recurrent somatic mutations. PAQR3, a tumor suppressor gene, was recently found to be downregulated in prostate cancer cell lines. We hypothesized that promoter methylation could be responsible for PAQR3 silencing in prostate cancer tissues. We aimed to investigate PAQR3 promoter methylation in prostate cancer by comparing it to benign prostatic hyperplasia (BPH). A total of 154 human prostate tissue samples, including 92 cases with prostate cancer and 62 cases with BPH, were examined by methylation-specific PCR. Clinicopathological correlation between PAQR3 promoter methylation and prognostically relevant variables was studied by statistical analysis. Promoter methylation of PAQR3 was significantly more frequent in prostate carcinoma compared to BPH (73.9% vs. 25.8%, p < 0.01). The high prevalence of PAQR3 methylation in cancer foci was also confirmed with microdissection technique in 12 samples of prostate adenocarcinoma. PAQR3 hypermethylation was associated with perineural invasion (p = 0.03), an adverse clinicopathological feature of prostate cancer. We concluded that PAQR3 can be a promising methylation marker candidate for the detection and monitoring of prostate cancer.	[Lounglaithong, Kowit; Bychkov, Andrey; Sampatanukul, Pichet] Chulalongkorn Univ, Dept Pathol, Fac Med, Rama 4 Rd, Bangkok 10330, Thailand	Sampatanukul, P (reprint author), Chulalongkorn Univ, Dept Pathol, Fac Med, Rama 4 Rd, Bangkok 10330, Thailand.	kowit.lung@hotmail.co.th; andrey.b@chula.ac.th; fmedpst@gmail.com	Bychkov, Andrey/N-1884-2019	Bychkov, Andrey/0000-0002-4203-5696			Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Chen JP, 2016, ONCOL REP, V36, P1612, DOI 10.3892/or.2016.4951; Feng L, 2007, P NATL ACAD SCI USA, V104, P14348, DOI 10.1073/pnas.0701298104; Ferlay J, 2013, GLOBOCAN 2012 V1 0; Gioeli D, 1999, CANCER RES, V59, P279; Gonez LJ, 2008, MOL MED, V14, P697, DOI 10.2119/2008-00072.Gonez; Greene KL, 2009, J UROLOGY, V182, P2232, DOI 10.1016/j.juro.2009.07.093; Guo WW, 2016, CARCINOGENESIS, V37, P397, DOI 10.1093/carcin/bgw013; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hsing AW, 2006, FRONT BIOSCI-LANDMRK, V11, P1388, DOI 10.2741/1891; Huang W, 2016, ONCOTARGET; Jiang YH, 2011, CANCER RES, V71, P2959, DOI 10.1158/0008-5472.CAN-10-4077; Li RH, 2016, ONCOL LETT, V12, P1773, DOI 10.3892/ol.2016.4843; Li ZH, 2015, ONCOTARGET, V6, P12357, DOI 10.18632/oncotarget.3657; Ling ZQ, 2014, ANN ONCOL, V25, P1363, DOI 10.1093/annonc/mdu168; Loeb S, 2010, BJU INT, V105, P1510, DOI 10.1111/j.1464-410X.2009.08845.x; Luo X, 2008, BIOCHEM J, V414, P399, DOI 10.1042/BJ20080948; Ma ZQ, 2015, TUMOR BIOL, V36, P3319, DOI 10.1007/s13277-014-2964-z; Park JY, 2015, METHODS MOL BIOL, V1238, P607, DOI 10.1007/978-1-4939-1804-1_32; Strand SH, 2014, INT J MOL SCI, V15, P16544, DOI 10.3390/ijms150916544; Tang YT, 2005, J MOL EVOL, V61, P372, DOI 10.1007/s00239-004-0375-2; Wang X, 2012, CARCINOGENESIS, V33, P2228, DOI 10.1093/carcin/bgs245; Weber MJ, 2004, J CELL BIOCHEM, V91, P13, DOI 10.1002/jcb.10683; Wu HG, 2014, ONCOL REP, V32, P2687, DOI 10.3892/or.2014.3532; Wu Q, 2016, TUMOR BIOL, V37, P561, DOI 10.1007/s13277-015-3770-y; Xiu YC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109734; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Zhang Y, 2010, ONCOGENE, V29, P5404, DOI 10.1038/onc.2010.270; Zhou F, 2017, ONCOL RES, V25, P663, DOI 10.3727/096504016X14761384026719; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	32	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					126	129		10.1016/j.prp.2017.10.010			4	Pathology	Pathology	GB5EN	WOS:000429086000019	29122400				2019-10-28	
J	Shahrabi-Farahani, M; Karimi, E; Mostaan, LV; Saba, S; Yazdani, N; Arnoli, MM				Shahrabi-Farahani, Maryam; Karimi, Ebrahim; Mostaan, Leila Vazifeh; Saba, Sadaf; Yazdani, Nasrin; Arnoli, Mahsa M.			Association between epstein barr virus and tongue squamous cell carcinoma in iranian patients	PATHOLOGY RESEARCH AND PRACTICE			English	Article						EBV; Tongue SCC	CANCER; PREVALENCE; CARCINOGENESIS; EPIDEMIOLOGY; EXPRESSION; HEAD	Detection of Epstein-Barr virus in oral squamous cell carcinoma suggests its involvement in the carcinogenesis of oral cavity. But, there are few studies on the incidence of EBV genome in squamous cell carcinomas at specific locations in the oral cavity like tongue and with different tumor progression. In this study the presence of EBV genome in tongue Squamous Cell Carcinoma (TSCC) in Iranian patients were investigated. Accordingly, a total of 94 cases with TSCC were firstly analyzed for the presence of viral genome through Nested PCR. Patients were divided into different groups based on their gender and the size, nodal involvement, grade and stage of their tumor. Results showed the presence of EBV genome in 72.3% of TSCCs with no significant difference between two genders, although slightly higher in females. Interestingly, PCR products of EBV genome showed a statistically significant higher distribution in TSCCs at IVa stage (p = 0.04), while a considerable low involvement of EBV genome was seen in T1-sized tumors. The result of this study further emphasizes the role of EBV in oral SCCs - mainly at tongue. This is the first investigation to clarify the association between EBV genome and different tumor size and stage in TSCCs; however, more studies in different regions and larger populations should be performed to be able to draw a firmed conclusion.	[Shahrabi-Farahani, Maryam; Saba, Sadaf; Arnoli, Mahsa M.] Univ Tehran Med Sci, Endocrinol & Metab Mol Cellular Sci Inst, Metab Disorders Res Ctr, Tehran, Iran; [Karimi, Ebrahim; Yazdani, Nasrin] Univ Tehran Med Sci, Amir Alam Hosp, Dept Otolaryngol Head & Neck Surg, Otorhinolaryngol Res Ctr, Tehran, Iran; [Mostaan, Leila Vazifeh] Mashhad Univ Med Sci, Canc Res Ctr, Mashhad, Iran	Arnoli, MM (reprint author), Dr Shariati Hosp, North Karegar St, Tehran 14114, Iran.; Yazdani, N (reprint author), AmirAlam Hosp, Otorhinolaryngol Res Ctr, North Saadi Ave,POB 11457-65111, Tehran, Iran.	N_Yazdani@tums.ac.ir; amolimm@tums.ac.ir	Karimi, Ebrahim/V-1253-2019	Karimi, Ebrahim/0000-0002-8168-7304			Acharya S, 2015, J ORAL PATHOL MED, V44, P252, DOI 10.1111/jop.12231; Banko A, 2014, ARCH BIOL SCI, V66, P537, DOI 10.2298/ABS1402537B; Cruz I, 2000, INT J CANCER, V86, P356, DOI 10.1002/(SICI)1097-0215(20000501)86:3<356::AID-IJC9>3.0.CO;2-W; Funk GF, 2002, HEAD NECK-J SCI SPEC, V24, P165, DOI 10.1002/hed.10004; Goldenberg D, 2001, AM J OTOLARYNG, V22, P197, DOI 10.1053/ajot.2001.23429; Gonzalez-Moles MA, 2002, LARYNGOSCOPE, V112, P482, DOI 10.1097/00005537-200203000-00014; Gupta K., 2013, PATHOL RES INT, V2013; Higa M, 2002, J CLIN PATHOL, V55, P414, DOI 10.1136/jcp.55.6.414; HORIUCHI K, 1995, ORAL SURG ORAL MED O, V79, P57, DOI 10.1016/S1079-2104(05)80075-7; Jalouli J, 2012, ANTICANCER RES, V32, P571; Kis A, 2009, EUR J ORAL SCI, V117, P536, DOI 10.1111/j.1600-0722.2009.00660.x; Laborde RR, 2010, EUR J CANCER, V46, P1153, DOI 10.1016/j.ejca.2010.01.026; Metgud R, 2012, ONCOL REV, V6, P164, DOI 10.4081/oncol.2012.e21; Moore SR, 1999, ORAL DIS, V5, P185; Mostaan LV, 2013, GENET TEST MOL BIOMA, V17, P74, DOI 10.1089/gtmb.2012.0210; Polz-Gruszka D., 2014, J PRECLIN CLIN RES, V8; Rao SVK, 2013, ASIAN PAC J CANCER P, V14, P5567, DOI 10.7314/APJCP.2013.14.10.5567; Sand L, 2014, MICROBES INFECT, V16, P371, DOI 10.1016/j.micinf.2014.02.009; Sand LP, 2002, ORAL SURG ORAL MED O, V93, P586, DOI 10.1067/moe.2002.124462; Saravani S, 2014, INT J PREVENTIVE MED, V5; Schantz SP, 2002, ARCH OTOLARYNGOL, V128, P268, DOI 10.1001/archotol.128.3.268; Shah KM, 2009, CLIN MICROBIOL INFEC, V15, P982, DOI 10.1111/j.1469-0691.2009.03033.x; Shimakage M, 2002, HUM PATHOL, V33, P608, DOI 10.1053/hupa.2002.129786; Tsai MH, 2013, CELL REP, V5, P458, DOI 10.1016/j.celrep.2013.09.012; Yen C.-Y., 2009, BIOMED RES INT	25	0	0	0	0	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					130	133		10.1016/j.prp.2017.10.006			4	Pathology	Pathology	GB5EN	WOS:000429086000020	29103768				2019-10-28	
J	Loo, SK; Hamid, SSA; Musa, M; Wong, KK				Loo, Suet Kee; Hamid, Suzina Sheikh Ab.; Musa, Mustaffa; Wong, Kah Keng			DNMT1 is associated with cell cycle and DNA replication gene sets in diffuse large B-cell lymphoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Diffuse large B-cell lymphoma; DNMT1; Cell cycle; DNA replication; Gene set enrichment analysis	METHYLTRANSFERASE 1; R-CHOP; DRUG-RESISTANCE; BREAST-CANCER; EXPRESSION; METHYLATION; LINES; PHOSPHORYLATION; SURVIVAL; THERAPY	Dysregulation of DNA (cytosine-5)-methyltransferase 1 (DNMT1) is associated with the pathogenesis of various types of cancer. It has been previously shown that DNMT1 is frequently expressed in diffuse large B-cell lymphoma (DLBCL), however its functions remain to be elucidated in the disease. In this study, we gene expression profiled (GEP) shRNA targeting DNMT1(shDNMT1)-treated germinal center B-cell-like DLBCL (GCB-DLBCL)-derived cell line (Le. HT) compared with non-silencing shRNA (control shRNA)-treated HT cells. Independent gene set enrichment analysis (GSEA) performed using GEPs of shRNA-treated HT cells and primary GCB-DLBCL cases derived from two publicly-available datasets (i.e. GSE10846 and GSE31312) produced three separate lists of enriched gene sets for each gene sets collection from Molecular Signatures Database (MSigDB). Subsequent Venn analysis identified 268, 145 and six consensus gene sets from analyzing gene sets in C2 collection (curated gene sets), C5 sub-collection [gene sets from gene ontology (GO) biological process ontology] and Hallmark collection, respectively to be enriched in positive correlation with DNMT1 expression profiles in shRNA-treated HT cells, GSE10846 and GSE31312 datasets [false discovery rate (FDR) < 0.05]. Cell cycle progression and DNA replication were among the significantly enriched biological processes (FDR < 0.05). Expression of genes involved in the activation of cell cycle and DNA replication (e.g. CDK1, CCNAZ E2F2, PCNA, RFC5 and POLD3) were highly correlated (r > 0.8) with DNMT1 expression and significantly downregulated (log fold-change < -1.35; p < 0.05) following DNMT1 silencing in HT cells. These results suggest the involvement of DNMT1 in the activation of cell cycle and DNA replication in DLBCL cells.	[Loo, Suet Kee; Musa, Mustaffa; Wong, Kah Keng] Univ Sains Malaysia, Sch Med Sci, Dept Immunol, Kubang Kerian 16150, Kelantan, Malaysia; [Hamid, Suzina Sheikh Ab.] Univ Sains Malaysia, Sch Med Sci, Tissue Bank Unit, Kubang Kerian 16150, Kelantan, Malaysia	Wong, KK (reprint author), Univ Sains Malaysia, Sch Med Sci, Dept Immunol, Kubang Kerian 16150, Kelantan, Malaysia.	kahkeng@usm.my		Wong, Kah Keng/0000-0001-7359-6202	Universiti Sains MalaysiaUniversiti Sains Malaysia [1001/PPSP/813054]	This work was supported by Research University grant (1001/PPSP/813054), Universiti Sains Malaysia, awarded to K.K.W.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Arsic N, 2012, J CELL BIOL, V196, P147, DOI 10.1083/jcb.201102085; Azad NS, 2017, ONCOTARGET, V8, P35326, DOI 10.18632/oncotarget.15108; Bai J, 2016, ONCOTARGET, V7, P44129, DOI 10.18632/oncotarget.9866; Barra V, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-2; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Broske AM, 2009, NAT GENET, V41, P1207, DOI 10.1038/ng.463; Chen SJ, 2014, J MED CHEM, V57, P9028, DOI 10.1021/jm501134e; Chuang L. S., 1997, SCIENCE, V277, P1021; Clozel T, 2013, CANCER DISCOV, V3, P1002, DOI 10.1158/2159-8290.CD-13-0117; Das DS, 2016, LEUKEMIA, V30, P2187, DOI 10.1038/leu.2016.96; De Falco G, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1661-7; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; El-Cheikh J, 2017, BONE MARROW TRANSPL, V52, P918, DOI 10.1038/bmt.2017.31; Ertel A, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-55; Fagan RL, 2013, J BIOL CHEM, V288, P23858, DOI 10.1074/jbc.M113.480517; Florean C, 2016, ONCOTARGET, V7, P24027, DOI 10.18632/oncotarget.8210; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gillet JP, 2011, P NATL ACAD SCI USA, V108, P18708, DOI 10.1073/pnas.1111840108; Glickman JF, 1997, J BIOL CHEM, V272, P17851, DOI 10.1074/jbc.272.28.17851; Gomes XV, 2001, J BIOL CHEM, V276, P34768, DOI 10.1074/jbc.M011631200; Goyal R, 2007, EPIGENETICS, V2, P155, DOI 10.4161/epi.2.3.4768; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Iida T, 2002, GENES CELLS, V7, P997, DOI 10.1046/j.1365-2443.2002.00584.x; Knox JD, 2000, J BIOL CHEM, V275, P17986, DOI 10.1074/jbc.C900894199; Lavoie G, 2011, BIOCHEM BIOPH RES CO, V409, P187, DOI 10.1016/j.bbrc.2011.04.115; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Loo SK, 2017, PATHOLOGY, V49, P731, DOI 10.1016/j.pathol.2017.08.009; Lyu SW, 2013, PLACENTA, V34, P133, DOI 10.1016/j.placenta.2012.12.003; Majka J, 2004, PROG NUCLEIC ACID RE, V78, P227, DOI 10.1016/S0079-6603(04)78006-X; Margot JB, 2001, J CELL BIOCHEM, V83, P373, DOI 10.1002/jcb.1236; Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200; Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Perry AM, 2016, HAEMATOLOGICA, V101, P1244, DOI 10.3324/haematol.2016.148809; Peters SL, 2013, MOL CELL BIOL, V33, P4321, DOI 10.1128/MCB.00776-13; Rao AV, 2009, J CLIN ONCOL, V27, P5580, DOI 10.1200/JCO.2009.22.2547; Sandberg R, 2005, P NATL ACAD SCI USA, V102, P2052, DOI 10.1073/pnas.0408105102; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shaknovich R, 2011, BLOOD, V118, P3559, DOI 10.1182/blood-2011-06-357996; Shaknovich R, 2010, BLOOD, V116, pE81, DOI 10.1182/blood-2010-05-285320; Shikata K, 2001, J BIOCHEM-TOKYO, V129, P699, DOI 10.1093/oxfordjournals.jbchem.a002909; Singhal G, 2013, J VIROL, V87, P8767, DOI 10.1128/JVI.00879-13; Stein WD, 2004, CANCER RES, V64, P2805, DOI 10.1158/0008-5472.CAN-03-3383; Suarez-Alvarez B, 2012, TRENDS GENET, V28, P506, DOI 10.1016/j.tig.2012.06.005; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Takahashi T, 2009, ONCOL REP, V21, P451, DOI 10.3892/or_00000244; Tang HL, 2014, MOL CANCER THER, V13, P3185, DOI 10.1158/1535-7163.MCT-14-0243; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; Visco C, 2012, LEUKEMIA, V26, P2103, DOI 10.1038/leu.2012.83; Vispe S, 2015, ONCOTARGET, V6, P15265, DOI 10.18632/oncotarget.3317; Wada N, 2012, HISTOPATHOLOGY, V60, P313, DOI 10.1111/j.1365-2559.2011.04096.x; Wang XJ, 2017, ONCOTARGETS THER, V10, P1865, DOI 10.2147/OTT.S130022; Wilding JL, 2014, CANCER RES, V74, P2377, DOI 10.1158/0008-5472.CAN-13-2971; Wong KK, 2014, LEUKEMIA, V28, P362, DOI 10.1038/leu.2013.224; Wong KK, 2015, EXP MOL PATHOL, V99, P537, DOI 10.1016/j.yexmp.2015.08.019; Xiang Y, 2014, ONCOGENE, V33, P378, DOI 10.1038/onc.2012.575; Xie CR, 2015, MOL MED REP, V12, P4250, DOI 10.3892/mmr.2015.3974; Xu M, 2010, MOL MED REP, V3, P699, DOI 10.3892/mmr_00000320; Zhang CY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023849; Zhang WJ, 2015, MOL MED REP, V12, P141, DOI 10.3892/mmr.2015.3402	70	5	5	3	7	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					134	143		10.1016/j.prp.2017.10.005			10	Pathology	Pathology	GB5EN	WOS:000429086000021	29137822				2019-10-28	
J	Tao, LP; Fan, XP; Fan, YC; Zhao, J; Gao, S; Wang, K				Tao, Li-Ping; Fan, Xiao-Peng; Fan, Yu-Chen; Zhao, Jing; Gao, Shuai; Wang, Kai			Combined detection of insulin-like growth factor-binding protein 7 promoter methylation improves the diagnostic efficacy of AFP in hepatitis B virus-associated hepatocellular carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Hepatocellular carcinoma; Insulin-like growth factor-binding protein 7; Methylation; MethyLight; Promoter	ELEMENT DNA METHYLATION; QUANTITATIVE-ANALYSIS; ALPHA-FETOPROTEIN; GENE-EXPRESSION; CANCER-PATIENTS; SERUM; TUMOR; PLASMA; IGFBP7; METHYLIGHT	This study quantitatively assessed serum insulin-like growth factor-binding protein 7 (IGFBP7) promoter methylation in hepatocellular carcinoma (HCC), and explored its clinical value. A total of 80 patients with hepatitis B virus-associated HCC, 35 patients with chronic hepatitis B (CHB), and 20 healthy controls (HC) were enrolled. MethyLight was used to quantitatively assess the methylation levels of serum IGFBP7 promoter. A logistic regression model was established for the combined evaluation of AFP and serum IGFBP7 promoter methylation. The results showed that mean methylation levels of serum IGFBP7 promoter were significantly higher in HCC (5.33%, interquartile range [IQR] 1.14-15.70%) patients than in individuals with CHB (1.54%, IQR 0.64-2.45%; P < 0.01) and HC (0.63%, IQR 0.22-0.98%; P < 0.01). In HCC subgroups, patients with vascular invasion, tumor size > 3 cm and advanced tumor node metastasis (TNM) showed higher methylation levels compared with the remaining groups (P < 0.05). Compared with AFP alone, combined determination based on logistic regression analysis significantly improved the area under the receiver operating characteristic (ROC) curve (AUC) (0.759 vs 0.623, P < 0.05). In addition, the Youden index was increased from 5.71%, 11.25% and 15.18%, when considering AFP alone at cut-off values of 20, 200, and 400 ng/ml, respectively, to 45.71% with IGFBP7 promoter methylation taken into consideration (all P < 0.05). These results suggested that combined quantitative measurement of serum IGFBP7 promoter methylation could enhance the diagnostic ability of AFP in distinguishing hepatitis B virus-associated HCC from CHB.	[Tao, Li-Ping; Fan, Xiao-Peng; Fan, Yu-Chen; Zhao, Jing; Gao, Shuai; Wang, Kai] Shandong Univ, Dept Hepatol, Qilu Hosp, Wenhuaxi Rd 107, Jinan 250012, Shandong, Peoples R China; [Tao, Li-Ping] Wenzhou Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Wenzhou 325000, Peoples R China; [Fan, Xiao-Peng; Fan, Yu-Chen; Zhao, Jing; Gao, Shuai; Wang, Kai] Shandong Univ, Inst Hepatol, Wenhuaxi Rd 107, Jinan 250012, Shandong, Peoples R China	Wang, K (reprint author), Shandong Univ, Dept Hepatol, Qilu Hosp, Wenhuaxi Rd 107, Jinan 250012, Shandong, Peoples R China.; Wang, K (reprint author), Shandong Univ, Inst Hepatol, Wenhuaxi Rd 107, Jinan 250012, Shandong, Peoples R China.	wangdoc876@126.com		Wang, Kai/0000-0002-6297-0147	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81371832]; Chinese Ministry of Science and TechnologyMinistry of Science and Technology, China [2012ZX10002007, 2013ZX10002001]; Science and Technology Development Plan of Shandong Province [2015GSF118145]; Qingdao people's Livelihood Science and technology project [15-9-2-91-NSH]; Fundamental Research Funds of Shandong University-Clinical Research Project of Qilu Hospital [2014QLKY11]	This work was supported by grants from the National Natural Science Foundation of China (81371832), Key Project of Chinese Ministry of Science and Technology (2012ZX10002007 and 2013ZX10002001), Science and Technology Development Plan of Shandong Province (2015GSF118145), Qingdao people's Livelihood Science and technology project (15-9-2-91-NSH), and the Fundamental Research Funds of Shandong University-Clinical Research Project of Qilu Hospital (2014QLKY11).	[Anonymous], 2010, HEPATOL INT, V4, P439; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Chan KCA, 2008, CLIN CHEM, V54, P1528, DOI 10.1373/clinchem.2008.104653; Chen D, 2013, MOL THER, V21, P758, DOI 10.1038/mt.2012.282; Chen D, 2011, CLIN CANCER RES, V17, P6693, DOI 10.1158/1078-0432.CCR-10-2774; Chen Y, 2007, J PATHOL, V211, P431, DOI 10.1002/path.2132; De Masi S, 2005, DIGEST LIVER DIS, V37, P260, DOI 10.1016/j.dld.2004.11.005; Farinati F, 2006, AM J GASTROENTEROL, V101, P524, DOI 10.1111/j.1572-0241.2006.00443.x; Fernando WC, 2014, GASTROENT RES PRACT, DOI 10.1155/2014/374926; Fong ZV, 2014, CANCER-AM CANCER SOC, V120, P2824, DOI 10.1002/cncr.28730; Gao S, 2015, ALIMENT PHARM THER, V42, P319, DOI 10.1111/apt.13271; Hernandez HG, 2013, BIOTECHNIQUES, V55, P181, DOI 10.2144/000114087; Huang GM, 2014, CLIN CHEM LAB MED, V52, P899, DOI 10.1515/cclm-2013-0885; Huang ZH, 2011, EXP MOL PATHOL, V91, P702, DOI 10.1016/j.yexmp.2011.08.004; Hwa V, 2006, J CLIN ENDOCR METAB, V91, P1826, DOI 10.1210/jc.2005-2842; International Agency for Research on Cancer (GLOBOCAN), 2012, EST CANC INC MORT PR; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; LEON SA, 1977, CANCER RES, V37, P646; Li F, 2014, GENE CHROMOSOME CANC, V53, P90, DOI 10.1002/gcc.22120; Lin J, 2007, J PATHOL, V212, P83, DOI 10.1002/path.2144; Lok AS, 2010, GASTROENTEROLOGY, V138, P493, DOI 10.1053/j.gastro.2009.10.031; Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190; Nishida N, 2013, ONCOLOGY-BASEL, V84, P82, DOI 10.1159/000345895; Ogino S, 2006, J MOL DIAGN, V8, P209, DOI 10.2353/jmoldx.2006.050135; Sun FK, 2013, DIGEST DIS SCI, V58, P1010, DOI 10.1007/s10620-012-2462-3; Tamura K, 2009, EUR J PHARMACOL, V610, P61, DOI 10.1016/j.ejphar.2009.01.045; Tomimaru Y, 2010, BRIT J CANCER, V102, P1483, DOI 10.1038/sj.bjc.6605669; Tomimaru Y, 2012, INT J CANCER, V130, P319, DOI 10.1002/ijc.25994; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Wang JH, 2006, CLIN BIOCHEM, V39, P344, DOI 10.1016/j.clinbiochem.2006.01.008; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; Wojdacz TK, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm013; Wong IHN, 1999, CANCER RES, V59, P71; Wong IHN, 2000, CLIN CANCER RES, V6, P3516; Wu HC, 2012, CARCINOGENESIS, V33, P1946, DOI 10.1093/carcin/bgs201; Yeo W, 2005, LIVER INT, V25, P266, DOI 10.1111/j.1478-3231.2005.01084.x; Zhang F, 2014, J VIRAL HEPATITIS, V21, P241, DOI 10.1111/jvh.12136; Zhang YJ, 2007, CLIN CANCER RES, V13, P2378, DOI 10.1158/1078-0432.CCR-06-1900; Zhu JD, 2009, INT J BIOCHEM CELL B, V41, P147, DOI 10.1016/j.biocel.2008.09.003	41	0	0	0	7	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					144	150		10.1016/j.prp.2017.10.004			7	Pathology	Pathology	GB5EN	WOS:000429086000022	29108923				2019-10-28	
J	Chu, XQ; Wang, J; Chen, GX; Zhang, GQ; Zhang, DY; Cai, YY				Chu, Xian-Qun; Wang, Jing; Chen, Guang-Xiang; Zhang, Guan-Qi; Zhang, De-Yong; Cai, Yong-Yan			Overexpression of microRNA-495 improves the intestinal mucosal barrier function by targeting STAT3 via inhibition of the JAK/STAT3 signaling pathway in a mouse model of ulcerative colitis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						MircoRNA-495; STAT3; JAK/STAT3 signaling pathway; Ulcerative colitis; Intestinal mucosal barrier	INFLAMMATORY-BOWEL-DISEASE; MESSENGER-RNA; PROTEIN-LEVEL; EXPRESSION; CELLS; CANCER; CLAUDIN-1; COLON; PROLIFERATION; POLYMORPHISM	We aim to investigate the role of microRNA-495 (miR-495) in the intestinal mucosa] barrier by indirectly targeting signal transducer and activator of transcription 3 (STAT3) through the Janus kinase-signal transducer and activator of transcription (JAK)/STAT3 signaling pathway in a mouse model of ulcerative colitis (UC). BALB/c mice were selected for establishing mice model of UC, and intestinal tissues of normal and UC mice were collected. ELISA was conducted for detecting levels of TNF-alpha, IL-6, IFN-gamma and IL-10. The levels of SOD, MPO, MDA and NO were tested in the intestinal tissues. Dual luciferase reporter gene assay was applied to determine whether miR-495 directly targets STAT3. Cells were cultured, transfected and assigned into: normal group, blank group, NC group, miR-495 mimic group, miR-495 inhibitor group, siRNA-STAT3 group and miR-495 inhibitor + siRNA-STAT3 group. MTT was used for testing cell proliferation, flow cytometry for cell cycle and apoptosis. Northern blotting and Western blotting were performed to detect miR-495 expression and expressions of STAT3, JAK and Claudin-1. Results show that the UC group had higher expression levels of TNF-alpha, IL-6, IFN-gamma, MPO, MDA, NO, STAT3 and JAK and lower expression levels of IL-10, SOD, miR-495 and Claudin-1, compared to the normal group. Dual luciferase reporter gene assay confirmed that STAT3 was the target gene of miR-495. The miR-495 mimic and siRNA-STAT3 groups had higher expressions of Claudin-1, higher cell proliferation and increased amount of cells in S phase, but lower expressions of STAT3 and JAK, decreased amount of cells in G0/G1 phase and cell apoptotic rate compared with the blank, NC groups. We also found that the miR-495 inhibitor + siRNA-STAT3 group had reduced miR-495 expression. No significant differences were found in mRNA and protein expressions of STAT3, JAK and Claudin-1, cell proliferation, apoptosis and cycle amongst the miR-495 inhibitor + siRNA-STAT3 groups. Our study provides evidence that miR-495 improves the intestinal mucosal barrier function by targeting STAT3 through inhibiting the JAK/STAT3 signaling pathway in UC mice.	[Chu, Xian-Qun; Wang, Jing; Chen, Guang-Xiang; Zhang, De-Yong] Jining 1 Peoples Hosp, Dept Gastrointestinal Surg, 6 Jiankang Rd, Jining 272011, Shandong, Peoples R China; [Zhang, Guan-Qi] Hubei Prov Peoples Hosp, Dept Hepatobiliary Surg, Wuhan 430060, Hubei, Peoples R China; [Cai, Yong-Yan] Cangzhou Cent Hosp, Dept Pediat Med 1, Cangzhou 061000, Peoples R China	Zhang, DY (reprint author), Jining 1 Peoples Hosp, Dept Gastrointestinal Surg, 6 Jiankang Rd, Jining 272011, Shandong, Peoples R China.	zhangdeyong_zdy@163.com					Ai C, 2015, TUMOR BIOL, V36, P729, DOI 10.1007/s13277-014-2687-1; Akiho Hirotada, 2015, World J Gastrointest Pathophysiol, V6, P219, DOI 10.4291/wjgp.v6.i4.219; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Blikslager AT, 2007, PHYSIOL REV, V87, P545, DOI 10.1152/physrev.00012.2006; Cai B, 2015, INFLAMMATION, V38, P1599, DOI 10.1007/s10753-015-0135-z; Camilleri M, 2012, NEUROGASTROENT MOTIL, V24, P503, DOI 10.1111/j.1365-2982.2012.01921.x; Chang Q, 2013, NEOPLASIA, V15, P848, DOI 10.1593/neo.13706; Chang TL, 2010, GASTROENTEROLOGY, V138, P255, DOI 10.1053/j.gastro.2009.08.044; Chen HL, 2017, ONCOL LETT, V13, P2021, DOI 10.3892/ol.2017.5727; Chen YH, 2011, EMBO REP, V12, P534, DOI 10.1038/embor.2011.65; Chen Z, 2010, GENES IMMUN, V11, P573, DOI 10.1038/gene.2010.16; Chen Zhi-tao, 2010, Zhonghua Yixue Yichuanxue Zazhi, V27, P603, DOI 10.3760/cma.j.issn.1003-9406.2010.06.001; Chen ZT, 2013, INT J COLORECTAL DIS, V28, P1351, DOI 10.1007/s00384-013-1671-3; Chuang AY, 2014, INFLAMM BOWEL DIS, V20, P126, DOI 10.1097/01.MIB.0000436954.70596.9b; Cichon C, 2014, TISSUE BARRIERS, V2, DOI 10.4161/21688362.2014.944446; COLLIN SP, 1989, VISION RES, V29, P765, DOI 10.1016/0042-6989(89)90089-8; da Silva BC, 2014, WORLD J GASTROENTERO, V20, P9458, DOI 10.3748/wjg.v20.i28.9458; Da-Silva N, 2010, DIGEST LIVER DIS, V42, P544, DOI 10.1016/j.dld.2009.12.005; Danese S, 2011, NEW ENGL J MED, V365, P1713, DOI 10.1056/NEJMra1102942; Deng XM, 2013, CURR PHARM DESIGN, V19, P17; Eyking A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156871; Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002; Garud Sagar, 2009, Therap Adv Gastroenterol, V2, P99, DOI 10.1177/1756283X09102329; Gaulke CA, 2014, J VIROL, V88, P6268, DOI 10.1128/JVI.00097-14; Haghikia Arash, 2012, JAKSTAT, V1, P143, DOI 10.4161/jkst.19573; Isik A, 2017, SURG LAPARO ENDO PER, V27, P154, DOI 10.1097/SLE.0000000000000389; Koukos G, 2013, GASTROENTEROLOGY, V145, P842, DOI 10.1053/j.gastro.2013.07.001; Kufer TA, 2006, ANN NY ACAD SCI, V1072, P19, DOI 10.1196/annals.1326.020; Li Y, 2010, GUT, V59, P227, DOI 10.1136/gut.2009.184176; Li ZR, 2012, CANCER LETT, V323, P41, DOI 10.1016/j.canlet.2012.03.029; Lin L, 2011, CANCER RES, V71, P7226, DOI 10.1158/0008-5472.CAN-10-4660; Lissner D, 2013, DIGEST DIS, V31, P91, DOI 10.1159/000347194; Liu D, 2015, THROMB RES, V135, P146, DOI 10.1016/j.thromres.2014.10.027; Mattioli G, 2015, J CROHNS COLITIS, V9, P558, DOI 10.1093/ecco-jcc/jjv065; Mudter J, 2007, INFLAMM BOWEL DIS, V13, P1016, DOI 10.1002/ibd.20148; Ordas I, 2012, LANCET, V380, P1606, DOI 10.1016/S0140-6736(12)60150-0; Qiu W, 2011, J CLIN INVEST, V121, P1722, DOI 10.1172/JCI42917; Reinisch W, 2011, GUT, V60, P780, DOI 10.1136/gut.2010.221127; Resnick MB, 2005, MODERN PATHOL, V18, P511, DOI 10.1038/modpathol.3800301; de Medina FS, 2014, INFLAMM BOWEL DIS, V20, P2394, DOI 10.1097/MIB.0000000000000204; Shao YJ, 2013, POULTRY SCI, V92, P1764, DOI 10.3382/ps.2013-03029; Sugimoto K, 2008, WORLD J GASTROENTERO, V14, P5110, DOI 10.3748/wjg.14.5110; Tjandra K, 2002, DIGEST DIS SCI, V47, P1216, DOI 10.1023/A:1015330809095; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; Verma R, 2013, EUR CYTOKINE NETW, V24, P130, DOI 10.1684/ecn.2013.0343; Wang HS, 2017, MED SCI MONITOR, V23, P640, DOI 10.12659/MSM.898740; Wang XM, 2012, WORLD J GASTROENTERO, V18, P6819, DOI 10.3748/wjg.v18.i46.6819; Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405; Yang W, 2008, J BIOL CHEM, V283, P8643, DOI 10.1074/jbc.M709824200; Zhao J, 2013, MOL MED REP, V7, P565, DOI 10.3892/mmr.2012.1225	50	3	3	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					151	162		10.1016/j.prp.2017.10.003			12	Pathology	Pathology	GB5EN	WOS:000429086000023	29129493				2019-10-28	
J	Steiner, I; Stejskal, V; Zacek, P				Steiner, Ivo; Stejskal, Vaclav; Zacek, Pavel			Mast cells in calcific aortic stenosis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Calcific aortic stenosis; Mast cells; CD117; Pathogenesis	VALVE STENOSIS; CARDIAC VALVES; BONE-FORMATION; INFLAMMATION; HEART	In developed countries, calcific aortic stenosis (CAS) has become the most common acquired valvular disease and reason for aortic valve replacement. It is considered a form of atherosclerosis and, like the latter, of inflammatory origin, with presence in the calcified aortic valves of blood vessels, lymphatics, lymphocytes, plasma cells, histiocytes, and sometimes also of metaplastic bone tissue. This study is aimed at examining the presence of CD117 - positive mast cells in CAS. In 56 examined calcified aortic valves excised by cardiac surgery, mast cells were constantly present as a part of the polymorphous cellular infiltrate; in individual cases, their numbers were 1-90 (median 24). The numbers were significantly higher in the congenitally malformed/bicuspid valves (median 40) than in the tricuspid ones (median 20). In valves with presence of metaplastic bone, mast cells were significantly more numerous (median 42) than in those without metaplasia (median 20). In 12 normal aortic valves obtained at autopsies, the numbers of mast cells were 4-21 (median 11). Discussed is a possible role of mast cells in pathogenesis of CAS.	[Steiner, Ivo; Stejskal, Vaclav] Charles Univ Prague, Fingerland Dept Pathol, Fac Med, Hradec Kralove, Czech Republic; [Steiner, Ivo; Stejskal, Vaclav; Zacek, Pavel] Fac Hosp, Hradec Kralove, Czech Republic; [Zacek, Pavel] Charles Univ Prague, Dept Cardiosurg, Fac Med, Hradec Kralove, Czech Republic	Steiner, I (reprint author), Fac Hosp, Fingerland Dept Pathol, Hradec Kralove 50005, Czech Republic.	steiner@lfhk.cuni.cz			Ministry of Education, Youth, and Sports, Czech RepublicMinistry of Education, Youth & Sports - Czech RepublicCzech Republic Government [BBMRI_CZ LM 2015089, Progres Q40/11, CZ.02.1.01/0.0/0.0/16_013/0001674]	This study was supported by grants BBMRI_CZ LM 2015089, and Progres Q40/11, Ministry of Education, Youth, and Sports, Czech Republic CZ.02.1.01/0.0/0.0/16_013/0001674.	Anvari MS, 2012, INT J SURG PATHOL, V20, P474, DOI 10.1177/1066896912440820; Ehrlich P., 1878, THESIS; Galeone A, 2013, SCI WORLD J, DOI [10.1155/2013/875363, 10.1007/978-1-4614-3900-4]; Galeone A, 2013, INT J CARDIOL, V169, P296, DOI 10.1016/j.ijcard.2013.09.012; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; Gotlieb A. I., 2011, CARDIOVASC PATHOL, P420; Kritikou E, 2016, EUR J PHARMACOL, V778, P103, DOI 10.1016/j.ejphar.2015.04.050; Krystel-Whittemore M, 2016, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00620; Laine P, 1999, CIRCULATION, V99, P361, DOI 10.1161/01.CIR.99.3.361; Metz M, 2007, IMMUNOL REV, V217, P304, DOI 10.1111/j.1600-065X.2007.00520.x; Mohler ER, 2004, AM J CARDIOL, V94, P1396, DOI 10.1016/j.amjcard.2004.08.013; Mohler ER, 2001, CIRCULATION, V103, P1522; Moreno PR, 2011, J THORAC CARDIOV SUR, V142, P895, DOI 10.1016/j.jtcvs.2011.03.002; Morita H, 2016, SEMIN IMMUNOPATHOL, V38, P623, DOI 10.1007/s00281-016-0566-0; Rajamannan NM, 2011, CIRCULATION, V124, P1783, DOI 10.1161/CIRCULATIONAHA.110.006767; Reid AC, 2007, IMMUNOL REV, V217, P123, DOI 10.1111/j.1600-065X.2007.00514.x; Ribatti D, 2013, IMMUNOL LETT, V152, P83, DOI 10.1016/j.imlet.2013.05.003; Steiner I, 2010, Cesk Patol, V46, P33; Steiner I, 2007, VIRCHOWS ARCH, V450, P653, DOI 10.1007/s00428-007-0430-7; Steiner I, 2012, PATHOL RES PRACT, V208, P231, DOI 10.1016/j.prp.2012.02.009; Torre M, 2016, CARDIOVASC PATHOL, V25, P18, DOI 10.1016/j.carpath.2015.08.008; Veinot JP, 2006, CARDIOVASC PATHOL, V15, P36, DOI 10.1016/j.carpath.2005.08.005; Wypasek E, 2012, INFLAMMATION, V35, P429, DOI 10.1007/s10753-011-9332-6; Yip CYY, 2011, CARDIOVASC PATHOL, V20, P177, DOI 10.1016/j.carpath.2010.12.001	24	2	2	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					163	168		10.1016/j.prp.2017.07.016			6	Pathology	Pathology	GB5EN	WOS:000429086000024	29157538				2019-10-28	
J	Zhang, TJ; Guo, H; Zhou, JD; Li, XX; Zhang, W; Ma, JC; Wen, XM; Yao, XY; Lin, J; Qian, J				Zhang, Ting-juan; Guo, Hong; Zhou, Jing-dong; Li, Xi-xi; Zhang, Wei; Ma, Ji-chun; Wen, Xiang-mei; Yao, Xin-yu; Lin, Jiang; Qian, Jun			Bone marrow miR-10a overexpression is associated with genetic events but not affects clinical outcome in acute myeloid leukemia	PATHOLOGY RESEARCH AND PRACTICE			English	Article						miR-10; AML; NPM1; t(15;17)		Background: Accumulating studies have linked the disruptions of microRNA-10 (miR-10) to acute myeloid leukemia (AML) with NPM1 mutation. However, miR-10 expression and its clinical implication in AML remain poorly defined. Although a recent report showed high serum level of miR-10a was associated with adverse prognosis in AML, herein, we found bone marrow (BM) miR-10 overexpression was not a prognostic biomarker in AML. Methods: BM miR-10 expression was examined by real-time quantitative PCR in BM mononuclear cells in 115 de novo AML patients and 45 controls. Results: BM miR-10 (mill-10a/b) expression was significantly up-regulated in AML patients, and was positively correlated with each other. Overexpression of miR-10a was associated with lower percentage of BM blasts, whereas miR-10b overexpression tended to correlate with higher percentage of BM blasts. Importantly, miR-10a overexpression was significantly associated with FAB-M3/t(15;17) subtypes and NPM1 mutation, meanwhile, overexpression of miR-10b was correlated with NPM1 and DNMT3A mutations. However, miR-10a/b over expression was not associated with complete remission rate, and did not have an impact on both leukemia free survival and overall survival time in non-M3 AML patients without NPMI mutation. Conclusions: BM miR-10 overexpression is associated with genetic events but not affects clinical outcome in AML.	[Zhang, Ting-juan; Zhou, Jing-dong; Li, Xi-xi; Zhang, Wei; Yao, Xin-yu; Qian, Jun] Jiangsu Univ, Dept Hematol, Affiliated Peoples Hosp, 8 Dianli Rd, Zhenjiang 212002, Jiangsu, Peoples R China; [Guo, Hong; Ma, Ji-chun; Wen, Xiang-mei; Lin, Jiang] Jiangsu Univ, Lab Ctr, Affiliated Peoples Hosp, 8 Dianli Rd, Zhenjiang 212002, Jiangsu, Peoples R China; [Zhang, Ting-juan; Guo, Hong; Zhou, Jing-dong; Li, Xi-xi; Zhang, Wei; Ma, Ji-chun; Wen, Xiang-mei; Lin, Jiang; Qian, Jun] Key Lab Precis Diag & Treatment Zhenjiang City, Zhenjiang, Jiangsu, Peoples R China; [Zhang, Ting-juan; Zhou, Jing-dong; Li, Xi-xi; Yao, Xin-yu] Jiangsu Univ, Sch Med, Zhenjiang, Jiangsu, Peoples R China	Qian, J (reprint author), Jiangsu Univ, Dept Hematol, Affiliated Peoples Hosp, 8 Dianli Rd, Zhenjiang 212002, Jiangsu, Peoples R China.; Lin, J (reprint author), Jiangsu Univ, Lab Ctr, Affiliated Peoples Hosp, 8 Dianli Rd, Zhenjiang 212002, Jiangsu, Peoples R China.	linjiangmail@sina.com; qianjun0007@hotmail.com			National Natural Science foundation of ChinaNational Natural Science Foundation of China [81270630]; Special Funds of "Ke Jiao Qiang Wei" Project of Jiangsu Province; 333 Project of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BRA2016131]; Six Talent Peaks Project in Jiangsu Province [2015-WSN-115]; Medical Innovation Team of Jiangsu Province [CXTDB2017002]; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX17_1821]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2016M601748]; Social Development Foundation of Zhenjiang [SH2015058, SH2016045, SH2016046]; Key Medical Talent Program of Zhenjiang City	This work was supported by National Natural Science foundation of China (81270630), Special Funds of "Ke Jiao Qiang Wei" Project of Jiangsu Province, 333 Project of Jiangsu Province (BRA2016131), Six Talent Peaks Project in Jiangsu Province (2015-WSN-115), Medical Innovation Team of Jiangsu Province (CXTDB2017002), Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX17_1821), China Postdoctoral Science Foundation funded project (2016M601748), Social Development Foundation of Zhenjiang (SH2015058, SH2016045, SH2016046), Key Medical Talent Program of Zhenjiang City.	Agirre X, 2008, MOL CANCER RES, V6, P1830, DOI 10.1158/1541-7786.MCR-08-0167; Bryant A, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-8; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Garzon R, 2006, P NATL ACAD SCI USA, V103, P5078, DOI 10.1073/pnas.0600587103; Georgantas RW, 2007, P NATL ACAD SCI USA, V104, P2750, DOI 10.1073/pnas.0610983104; Gregory TK, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-23; Havelange V, 2014, BLOOD, V123, P2412, DOI 10.1182/blood-2013-10-532374; Jin P, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-39; Jongen-Lavrencic M, 2008, BLOOD, V111, P5078, DOI 10.1182/blood-2008-01-133355; Liao Q, 2017, ONCOTARGET, V8, P3666, DOI 10.18632/oncotarget.12343; Lund AH, 2010, CELL DEATH DIFFER, V17, P209, DOI 10.1038/cdd.2009.58; Mrozek K, 2004, BLOOD REV, V18, P115, DOI 10.1016/S0268-960X(03)00040-7; Zhang T. J., 2017, J CELL PHYSL; Zhi YJ, 2015, INT J HEMATOL, V102, P296, DOI 10.1007/s12185-015-1829-6; Zhou JD, 2017, J CELL MOL MED, V21, P1468, DOI 10.1111/jcmm.13073	15	1	1	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					169	173		10.1016/j.prp.2017.11.019			5	Pathology	Pathology	GB5EN	WOS:000429086000025	29254789				2019-10-28	
J	Li, L; Yu, Q; Liang, WM				Li, Li; Yu, Qiong; Liang, Weimin			Use of 2,3,5-triphenyltetrazolium chloride-stained brain tissues for immunofluorescence analyses after focal cerebral ischemia in rats	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Ischemic stroke; Middle cerebral artery occlusion (MCAO); TTC staining; Penumbra and infarct	STROKE; NEUROGENESIS; PRECURSORS; MICROGLIA; APOPTOSIS; OCCLUSION; PROTEIN; INJURY; AREAS; CELLS	The middle cerebral artery occlusion (MCAO) model in rodents has been widely used as model for studying brain ischemic stroke. TTC (2,3,5-triphenyltetrazolium chloride) staining in fresh tissues is used to evaluate the size of the infarct in MCAO model, and TTC-stained brain tissues are considered to be possible to bring a damage to the anatomical structure of neuronal cells and unsuitable for immunofluorescence analyses of cytology, and discarded after evaluation of infarct volume. Another group of models with in vivo fixation was required to the pathological or histological analyses of the infarct brains, which lead to double the numbers of animals in researches. However, some evidences indicate that if we properly optimized staining protocol, TTC-stained brain tissues might be suitable for cytological analyses. In this work, we have optimized the immunofluorescent staining methods of TTC-stained brain slices, and found that TTC-stained brain tissues are suitable for quantitative and qualitative analyses of microglia, astrocytes and neuroblasts, the morphology of theses cell were nearly identical to the in-vivo fixed models. Our optimized-protocol provide two advantages over traditional methods one of them is providing the precise the infarct region, which reduces the differences within groups, the other one is decreasing the total number of animals in research dramatically.	[Li, Li; Yu, Qiong; Liang, Weimin] Fudan Univ, Huashan Hosp, Dept Anesthesiol, Shanghai 200040, Peoples R China	Liang, WM (reprint author), Fudan Univ, Huashan Hosp, Dept Anesthesiol, Shanghai 200040, Peoples R China.	chiefliang@sina.com			Zhuo xue plan, Fudan University; Huajingplan, huashan hospital; Science and outstanding leaders scientific research projects in Shanghai [14XD1402900]	This study was supported by Zhuo xue plan, Fudan University; Huajingplan, huashan hospital. Science and outstanding leaders scientific research projects in Shanghai (14XD1402900).	Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Benedek A, 2006, BRAIN RES, V1116, P159, DOI 10.1016/j.brainres.2006.07.123; Chiba T, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/759103; Gleichman AJ, 2014, NEUROSCI LETT, V565, P47, DOI 10.1016/j.neulet.2013.10.055; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Kettenmann H, 2007, NATURE, V446, P987, DOI 10.1038/nature05713; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Khan SNH, 2000, J NEUROSCI METH, V98, P43, DOI 10.1016/S0165-0270(00)00185-0; Kharlamov A, 2009, J NEUROSCI METH, V182, P205, DOI 10.1016/j.jneumeth.2009.06.014; Kramer M, 2010, J NEUROSCI METH, V187, P84, DOI 10.1016/j.jneumeth.2009.12.020; Lee MH, 2003, LIFE SCI, V73, P2455, DOI 10.1016/S0024-3205(03)00655-6; LI Y, 1995, J NEUROL SCI, V128, P134, DOI 10.1016/0022-510X(94)00228-G; Ohira K, 2010, NAT NEUROSCI, V13, P173, DOI 10.1038/nn.2473; Paciaroni M, 2009, EUR NEUROL, V61, P321, DOI 10.1159/000210544; Shimada IS, 2010, STROKE, V41, pE552, DOI 10.1161/STROKEAHA.110.589010; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sun HS, 2015, EXP NEUROL, V263, P161, DOI [10.1016/j.expneurol.2014.10.003, 10.1016/j.expneuro1.2014.10.003]; Sun YY, 2012, J NEUROSCI METH, V203, P122, DOI 10.1016/j.jneumeth.2011.09.029; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006	23	1	1	0	6	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					174	179		10.1016/j.prp.2017.11.016			6	Pathology	Pathology	GB5EN	WOS:000429086000026	29254786				2019-10-28	
J	Adrian, S; Clemens, C; Elisabeth, SW; Sylvia, S				Adrian, Schmidt; Clemens, Caspar; Elisabeth, Schmidt-Weiss; Sylvia, Stadlmann			Clinicohistopathological Characteristics of Malignant Melanoma in the Gall Bladder: A Case Report and Review of the Literature	CASE REPORTS IN PATHOLOGY			English	Review							DYSPLASTIC NEVUS SYNDROME; METASTATIC MELANOMA; GALLBLADDER	Objective. Primary gall bladder melanoma is a rare and controversial entity. So far, only 36 cases are documented in the literature. Metastatic melanoma targeting the gall bladder, however, has been reported to occur in about 15-20% of melanoma patients and is much more common. Methods. Based on the case of a 58-year-old woman presenting with multiple melanoma nodules in the gall bladder, we searched in the available literature in PubMed for articles describing a "primary melanoma of the gallbladder" regardless of language used. Results. We detected 33 papers that described 36 cases of primary gall bladder melanoma between 1907 and 2017. From different criteria distinguishing primary and secondary gall bladder melanoma, generally, the following were accepted: (1) exclusion of previous primary melanoma, (2) absence of synchronous involvement of other sites, (3) unicity of the lesion, (4) polypoid or papillary shape of the lesion, and (5) presence of junctional melanocitary component. Review of the 36 published cases revealed that only about one-fourth of them fulfilled all the five criteria. Conclusion. Primary gall bladder melanoma is even rarer than described in the literature, and the question whether this entity really exists remains open.	[Adrian, Schmidt] Triemli Hosp, Div Med Oncol & Hematol, Dept Internal Med, Birmensdorferstr 497, CH-8063 Zurich, Switzerland; [Clemens, Caspar] Cantonal Hosp Baden, Div Med Oncol & Hematol, Dept Internal Med, Ergel 1, CH-5404 Baden, Switzerland; [Elisabeth, Schmidt-Weiss] Univ Hosp Zurich, Clin Med Oncol, Ctr Hematol & Oncol, Ramistr 100, CH-8091 Zurich, Switzerland; [Sylvia, Stadlmann] Cantonal Hosp Baden, Div Pathol, Ergel 1, CH-5404 Baden, Switzerland	Adrian, S (reprint author), Triemli Hosp, Div Med Oncol & Hematol, Dept Internal Med, Birmensdorferstr 497, CH-8063 Zurich, Switzerland.	adrian.schmidt@bluewin.ch					ALLEN AC, 1953, CANCER-AM CANCER SOC, V6, P1, DOI 10.1002/1097-0142(195301)6:1<1::AID-CNCR2820060102>3.0.CO;2-C; ANDERSON JB, 1983, POSTGRAD MED J, V59, P390, DOI 10.1136/pgmj.59.692.390; Baumann C., 1982, REV MED SUISSE ROMAN, P102; BORJA SR, 1984, CANCER, V54, P929, DOI 10.1002/1097-0142(19840901)54:5<929::AID-CNCR2820540530>3.0.CO;2-7; CARLE G, 1981, CANCER-AM CANCER SOC, V48, P2318, DOI 10.1002/1097-0142(19811115)48:10<2318::AID-CNCR2820481030>3.0.CO;2-Y; DASGUPTA T, 1964, CANCER, V17, P1323; De Simone P, 2000, Surg Endosc, V14, P593; Debiec H., 1966, PRZEGL LEK, P463; Dong XD, 1999, CANCER-AM CANCER SOC, V85, P32, DOI 10.1002/(SICI)1097-0142(19990101)85:1<32::AID-CNCR5>3.0.CO;2-Z; Gligorijevic J, 2011, TURK J GASTROENTEROL, V22, P626, DOI 10.4318/tjg.2011.0278; Guerini A., 1990, ARCH ANATOMIE CYTOLO, P168; Habeck Joerg-Olaf, 1993, Zentralblatt fuer Pathologie, V139, P367; Haskaraca M. F., 2012, CASE REPORTS SURG, V2012; HATAE Y, 1978, PATHOL RES PRACT, V163, P281, DOI 10.1016/S0344-0338(78)80021-1; HATANAKA N, 1993, SURG TODAY, V23, P1023, DOI 10.1007/BF00308983; HEATH DI, 1988, J CLIN PATHOL, V41, P1073, DOI 10.1136/jcp.41.10.1073; Higgins CM, 1995, PATHOLOGY, V27, P312, DOI 10.1080/00313029500169203; JONES CH, 1961, J PATHOL BACTERIOL, V81, P423, DOI 10.1002/path.1700810215; Longwitz D, 1996, ULTRASCHALL MED, V17, P195, DOI 10.1055/s-2007-1003180; MEYER JE, 1978, CANCER, V42, P127, DOI 10.1002/1097-0142(197807)42:1<127::AID-CNCR2820420122>3.0.CO;2-Z; Middleton MR, 2000, J CLIN ONCOL, V18, P158, DOI 10.1200/JCO.2000.18.1.158; NAGUIB SE, 1984, AM J DERMATOPATH, V6, P231; PAUTLER EE, 1951, AMA ARCH PATHOL, V51, P238; PEISON B, 1976, CANCER, V37, P2448, DOI 10.1002/1097-0142(197605)37:5<2448::AID-CNCR2820370538>3.0.CO;2-Q; Pitlovic V, 2011, MED GLAS, V8, P71; RAFFENSPERGER EC, 1963, AM J DIG DIS, V8, P356, DOI 10.1007/BF02237710; Ricci R, 2001, VIRCHOWS ARCH, V438, P159, DOI 10.1007/s004280000336; ROSENTHAL SOL ROY, 1931, AMER JOUR CANCER, V15, P2288; RUDOLPH A, 1985, CHIRURG, V56, P469; Safioleas M, 2006, WORLD J GASTROENTERO, V12, P4259, DOI 10.3748/wjg.v12.i26.4259; SEUL B, 1984, CHIRURG, V55, P179; SIERRACALLEJAS JL, 1976, VIRCHOWS ARCH A, V370, P233, DOI 10.1007/BF00427583; Simard C. I., 1966, J CHIRURGIE, P51; Simonenko V. B., 2004, KLINICHESKAIA MEDITS, P69; VELEZ AF, 1995, AM SURGEON, V61, P1095; VERBANCK JJ, 1986, GASTROENTEROLOGY, V91, P214, DOI 10.1016/0016-5085(86)90461-0; WALSH TS, 1956, CANCER, V9, P518, DOI 10.1002/1097-0142(195605/06)9:3<518::AID-CNCR2820090313>3.0.CO;2-3; Wieting, 1907, BEITR PATHOL ANAT AL, V42, P23	38	1	1	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									6471923	10.1155/2018/6471923			4	Pathology	Pathology	GB2GW	WOS:000428870700001	29750128	DOAJ Gold, Green Published			2019-10-28	
J	Johannesen, E; Nguyen, V				Johannesen, Eric; Van Nguyen			Massive Ovarian Edema in a Girl with Hemoglobin SC Disease	CASE REPORTS IN PATHOLOGY			English	Article								Massive ovarian edema is a benign tumor like lesion of the ovary. The widely accepted mechanism is disruption of vascular drainage resulting in accumulation of fluid within the stroma and enlargement of the ovary. We report a case of massive ovarian edema in a teenage girl with hemoglobin SC disease. A 16-year-old female with hemoglobin SC disease was admitted with right lower quadrant pain. An ultrasound and CT scan showed a large, heterogeneous solid, and cystic pelvic mass. Due to the size and the possibility of malignancy, the patient underwent a salpingo-oophorectomy. The mass was an 8.3 cm hemorrhagic cyst with some solid areas. Histologic exam showed diffuse edema with scattered entrapped follicles and a narrow rim of normal appearing ovarian stroma. Dilated and occluded capillaries were seen along with hemorrhage and sickled red blood cells but no necrosis was identified. These histologic features were consistent with massive ovarian edema. Massive ovarian edema is thought to be caused by disturbance of the vascular outflow resulting in fluid buildup in the stroma. It is most often attributed to intermittent ovarian torsion that disrupts capillary and venous flow, but arterial flow is maintained. Rare cases of massive ovarian edema caused by tumor emboli or external compression by tumors have been reported, but this is the first case of a patient with hemoglobin SC disease developing vasoocclusions resulting in this lesion.	[Johannesen, Eric; Van Nguyen] Univ Missouri, Dept Pathol & Anat Sci, Columbia, MO 65203 USA	Johannesen, E (reprint author), Univ Missouri, Dept Pathol & Anat Sci, Columbia, MO 65203 USA.	johannesene@missouri.edu					Bazot M, 2003, GYNECOL ONCOL, V91, P648, DOI 10.1016/j.ygyno.2003.08.016; Brown HM, 2014, HUM REPROD UPDATE, V20, P29, DOI 10.1093/humupd/dmt049; Callen AL, 2017, EMERG RADIOL, V24, P215, DOI 10.1007/s10140-016-1436-8; Chen G, 2014, BLOOD, V123, P3818, DOI 10.1182/blood-2013-10-529982; Colella MP, 2015, HAEMATOLOGICA, V100, P469, DOI 10.3324/haematol.2014.114587; Guvenal T, 2001, EUR J OBSTET GYN R B, V97, P258, DOI 10.1016/S0301-2115(00)00536-4; Hannemann A, 2011, ANEMIA, DOI 10.1155/2011/248527; Harrison BT, 2014, INT J GYNECOL PATHOL, V33, P418, DOI 10.1097/PGP.0b013e31829d76ee; Nagel RL, 2003, BLOOD REV, V17, P167, DOI 10.1016/S0268-960X(03)00003-1; Praveen R. S., 2013, ECANCER, V7, P1; Rees DC, 2010, LANCET, V376, P2018, DOI 10.1016/S0140-6736(10)61029-X; Thomas RL, 2012, OBSTET GYNECOL, V120, P473, DOI 10.1097/AOG.0b013e3182572654; Zhang DC, 2016, BLOOD, V127, P801, DOI 10.1182/blood-2015-09-618538; Zhou Z, 2011, ANEMIA, DOI 10.1155/2011/918916	14	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									4193248	10.1155/2018/4193248			3	Pathology	Pathology	GA6MC	WOS:000428446100001	29725550	DOAJ Gold, Green Published			2019-10-28	
J	Agrawal, R				Agrawal, Ranjan			From Editor's desk	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material									[Agrawal, Ranjan] Rohilkhand Med Coll & Hosp, Dept Pathol, Bareilly, Uttar Pradesh, India	Agrawal, R (reprint author), Rohilkhand Med Coll & Hosp, Dept Pathol, Bareilly, Uttar Pradesh, India.	chiefeditor.ijpm@gmail.com					Agarwal S, 2018, INDIAN J PATHOL MICR, V61, P39, DOI 10.4103/IJPM.IJPM_791_16; Modkharkar S, 2018, INDIAN J PATHOL MICR, V61, P58, DOI 10.4103/IJPM.IJPM_56_17; Sungu N, 2018, INDIAN J PATHOL MICR, V61, P22, DOI 10.4103/IJPM.IJPM_85_17; Verma D, 2018, INDIAN J PATHOL MICR, V61, P31, DOI 10.4103/IJPM.IJPM_393_16; Vyas M, 2018, INDIAN J PATHOL MICR, V61, P2, DOI 10.4103/IJPM.IJPM_578_17	5	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					1	1		10.4103/0377-4929.228204			1	Pathology	Pathology	GA6JJ	WOS:000428438900001	29567876	DOAJ Gold			2019-10-28	
J	Vyas, M; Jain, D				Vyas, Monika; Jain, Dhanpat			A practical diagnostic approach to hepatic masses	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Review						Adenoma; carcinoma; cholangiocarcinoma; hepatocellular	FOCAL NODULAR HYPERPLASIA; BILE-DUCT ADENOMA; PATHOLOGY-CONSENSUS-CONFERENCE; BENIGN HEPATOCELLULAR NODULES; FATTY LIVER-DISEASE; PRACTICES RECOMMENDATIONS; CLINICOPATHOLOGICAL FEATURES; IMMUNOHISTOCHEMICAL MARKERS; HEPATOBILIARY CYSTADENOMA; MALIGNANT-TRANSFORMATION	The differential diagnosis of hepatic mass lesions is broad and arriving at the right diagnosis can be challenging, especially on needle biopsies. The differential diagnosis of liver tumors in children is different from adults and is beyond the scope of this review. In adults, the approach varies depending on the age, gender, and presence of background liver disease. The lesions can be divided broadly into primary and metastatic (secondary), and the primary lesions can be further divided into those of hepatocellular origin and nonhepatocellular origin. The first category consists of benign and malignant lesions arising from hepatocytes, while the second category includes biliary, mesenchymal, hematopoietic, and vascular tumors. Discussion of nonepithelial neoplasms is beyond the scope of this review. The hepatocytic lesions comprise dysplastic nodules, focal nodular hyperplasia, hepatic adenoma, and hepatocellular carcinoma, and the differential diagnosis can be challenging requiring clinicopathological correlation and application of immunohistochemical (IHC) markers. Liver is a common site for metastasis, sometimes presenting with an unknown primary site, and proper workup is the key to arriving at the correct diagnosis. The correct diagnosis in this setting requires a systematic approach with attention to histologic features, imaging findings, clinical presentation, and judicious use of IHC markers. The list of antibodies that can be used for this purpose keeps on growing continually. It is important for pathologists to be up to date with the sensitivity and specificity of these markers and their diagnostic role and clinical implications. The purpose of this review is to outline the differential diagnosis of hepatic masses in adults and discuss an algorithmic approach to make a right diagnosis.	[Vyas, Monika; Jain, Dhanpat] Yale Sch Med, Dept Pathol, 310 Cedar St, New Haven, CT 06510 USA	Jain, D (reprint author), Yale Sch Med, Dept Pathol, 310 Cedar St, New Haven, CT 06510 USA.	dhanpat.jain@yale.edu		Vyas, Monika/0000-0002-7020-9948			Acosta AM, 2016, ARCH PATHOL LAB MED, V140, P1157, DOI 10.5858/arpa.2015-0102-RS; Ahmad I, 2009, HUM PATHOL, V40, P726, DOI 10.1016/j.humpath.2008.10.018; Albores-Saavedra J, 2001, AM J SURG PATHOL, V25, P956, DOI 10.1097/00000478-200107000-00016; Aljiffry M, 2009, WORLD J GASTROENTERO, V15, P4240, DOI 10.3748/wjg.15.4240; ALLAIRE GS, 1988, AM J SURG PATHOL, V12, P708, DOI 10.1097/00000478-198809000-00007; Alshenawy HA, 2015, PATHOL ONCOL RES, V21, P893, DOI 10.1007/s12253-015-9898-7; Altavilla G, 1999, Adv Clin Path, V3, P139; Amin MB, 2014, AM J SURG PATHOL, V38, pE20, DOI 10.1097/PAS.0000000000000240; An SL, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0014-x; Arena V, 2006, HISTOPATHOLOGY, V49, P318, DOI 10.1111/j.1365-2559.2006.02441.x; Arnason T, 2013, HISTOPATHOLOGY, V62, P458, DOI 10.1111/his.12032; Bacq Y, 2003, GASTROENTEROLOGY, V125, P1470, DOI 10.1053/S0016-5085(03)01357-X; Balabaud C, 2015, HUM PATHOL, V46, P634, DOI 10.1016/j.humpath.2014.10.029; Bellanne-Chantelot C, 2008, DIABETES, V57, P503, DOI 10.2337/db07-0859; Bhathal PS, 1996, AM J SURG PATHOL, V20, P858, DOI 10.1097/00000478-199607000-00009; Bioulac-Sage P, 2007, J HEPATOL, V46, P521, DOI 10.1016/j.jhep.2006.12.007; Bioulac-Sage P, 2005, GASTROENTEROLOGY, V128, P1211, DOI 10.1053/j.gastro.2005.02.004; Bioulac-Sage P, 2010, GASTROEN CLIN BIOL, V34, P355, DOI 10.1016/j.gcb.2010.03.014; Bioulac-Sage P, 2011, DIAGNOSTIC HISTOPATH, V17, P521; Bioulac-Sage P, 2008, HEPATOL INT, V2, P316, DOI 10.1007/s12072-008-9075-0; Bioulac-Sage P, 2007, HEPATOLOGY, V46, P740, DOI 10.1002/hep.21743; Bioulac-Sage P, 2011, SEMIN LIVER DIS, V31, P91, DOI 10.1055/s-0031-1272837; Bioulac-Sage P, 2010, DIGEST SURG, V27, P39, DOI 10.1159/000268406; Bioulac-Sage P, 2009, HEPATOLOGY, V50, P481, DOI 10.1002/hep.22995; Bioulac-Sage P, 2009, LIVER INT, V29, P459, DOI 10.1111/j.1478-3231.2008.01849.x; Blonski Wojciech, 2006, Curr Gastroenterol Rep, V8, P38, DOI 10.1007/s11894-006-0062-0; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Brunt E M, 2001, Clin Liver Dis, V5, P1, DOI 10.1016/S1089-3261(05)70151-3; Buscarini E, 2004, ULTRASOUND MED BIOL, V30, P1089, DOI 10.1016/j.ultrasmedbio.2004.08.004; Buza N, 2017, ARCH PATHOL LAB MED, V141, P1052, DOI 10.5858/arpa.2016-0541-RA; Chan ES, 2012, AM J SURG PATHOL, V36, P737, DOI 10.1097/PAS.0b013e31824aba59; Chan ES, 2010, CLIN LIVER DIS, V14, P687, DOI 10.1016/j.cld.2010.10.001; Cho SJ, 2016, HUM PATHOL, V50, P135, DOI 10.1016/j.humpath.2015.12.002; Choi WT, 2017, HUM PATHOL, V63, P1, DOI 10.1016/j.humpath.2016.12.025; Chu PG, 2003, AM J CLIN PATHOL, V120, P64, DOI 10.1309/48KC17WAU69BTBXQ; De Gaetano AM, 2004, ABDOM IMAGING, V29, P455, DOI 10.1007/s00261-003-0131-x; DEVANEY K, 1994, AM J SURG PATHOL, V18, P1078, DOI 10.1097/00000478-199411000-00002; Dhingra S, 2014, ARCH PATHOL LAB MED, V138, P1090, DOI 10.5858/arpa.2013-0183-RA; Di Tommaso L, 2017, FRONT MED-LAUSANNE, V4, DOI [10.3389/fmed.2017.00010, 10.3389/fmed2017.00010]; Di Tommaso L, 2011, HEPATOLOGY, V53, P1549, DOI 10.1002/hep.24218; Epstein JI, 2014, AM J SURG PATHOL, V38, pE6, DOI 10.1097/PAS.0000000000000238; Fischer S, 2008, ARCH PATHOL LAB MED, V132, P359, DOI 10.1043/1543-2165(2008)132[359:AOITTN]2.0.CO;2; Forner A, 2008, HEPATOLOGY, V47, P97, DOI 10.1002/hep.21966; FOSTER JH, 1994, ARCH SURG-CHICAGO, V129, P712; Fujiwara M, 2012, CANCER CYTOPATHOL, V120, P230, DOI 10.1002/cncy.21190; Gatto M, 2010, DIGEST LIVER DIS, V42, P253, DOI 10.1016/j.dld.2009.12.008; Graham RP, 2015, MODERN PATHOL, V28, P822, DOI 10.1038/modpathol.2015.4; Henriet E, 2017, HEPATOLOGY, V66, P2016, DOI 10.1002/hep.29336; HIATT JR, 1986, WESTERN J MED, V144, P609; Inamura K, 2005, AM J SURG PATHOL, V29, P660, DOI 10.1097/01.pas.0000160438.00652.8b; Iyer A, 2008, HUM PATHOL, V39, P1370, DOI 10.1016/j.humpath.2008.01.015; Joseph NM, 2014, MODERN PATHOL, V27, P62, DOI 10.1038/modpathol.2013.114; Kakar S, 2007, ARCH PATHOL LAB MED, V131, P1648; Karabork A, 2010, PATHOL RES PRACT, V206, P572, DOI 10.1016/j.prp.2010.03.004; Klein WM, 2005, AM J CLIN PATHOL, V124, P512, DOI 10.1309/TT0R7KAL32228E99; Kojiro M, 1999, SEMIN LIVER DIS, V19, P287, DOI 10.1055/s-2007-1007118; Kojiro M, 2009, HEPATOLOGY, V49, P658, DOI 10.1002/hep.22709; Kong CS, 2000, ACTA CYTOL, V44, P218, DOI 10.1159/000326363; Lau SK, 2004, AM J CLIN PATHOL, V122, P61, DOI 10.1309/9R6673QEC06D86Y4; Lee JH, 2002, J KOREAN MED SCI, V17, P415, DOI 10.3346/jkms.2002.17.3.415; Leung C, 2015, WORLD J GASTROENTERO, V21, P1189, DOI 10.3748/wjg.v21.i4.1189; Libbrecht L, 2006, AM J GASTROENTEROL, V101, P2341, DOI 10.1111/j.1572-0241.2006.00783.x; Marginean Esmeralda Celia, 2013, Surg Pathol Clin, V6, P333, DOI 10.1016/j.path.2013.03.005; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Mitchell K, 2008, DIAGN HISTOPATHOL, V14, P598; Mittal K, 2008, ARCH PATHOL LAB MED, V132, P402, DOI 10.1043/1543-2165(2008)132[402:AOITGP]2.0.CO;2; Mortele Koenraad J, 2002, Clin Liver Dis, V6, P119, DOI 10.1016/S1089-3261(03)00069-2; Nakanuma YY, 2000, WHO CLASSIFICATION T, V2000, P173; Nault JC, 2017, GASTROENTEROLOGY, V152, P880, DOI 10.1053/j.gastro.2016.11.042; Niu ZS, 2016, WORLD J GASTROENTERO, V22, P3305, DOI 10.3748/wjg.v22.i12.3305; Ordonez NG, 2012, ADV ANAT PATHOL, V19, P66, DOI 10.1097/PAP.0b013e31823e472e; Paradis V, 2004, GASTROENTEROLOGY, V126, P1323, DOI 10.1053/j.gastro.2004.02.005; Paradis V, 1997, HEPATOLOGY, V26, P891; Paradis Valerie, 2013, Surg Pathol Clin, V6, P311, DOI 10.1016/j.path.2013.03.008; Park YN, 1998, AM J SURG PATHOL, V22, P656, DOI 10.1097/00000478-199806000-00002; Park YN, 2007, CANCER, V109, P915, DOI 10.1002/cncr.22460; Park YN, 2011, ARCH PATHOL LAB MED, V135, P704, DOI 10.1043/2010-0524-RA.1; Perumpail RB, 2015, DIGEST DIS SCI, V60, P3142, DOI 10.1007/s10620-015-3821-7; Poomphakwaen K, 2009, ASIAN PAC J CANCER P, V10, P251; Quaglia A, 2003, HISTOPATHOLOGY, V42, P14, DOI 10.1046/j.1365-2559.2003.01550.x; Rebouissou S, 2008, J HEPATOL, V48, P163, DOI [10.1016/j.jhep.2007.10.003, 10.1016/j.jhep.2008.02.001]; Rebouissou S, 2016, HEPATOLOGY, V64, P2047, DOI 10.1002/hep.28638; Reznik Y, 2004, J CLIN ENDOCR METAB, V89, P1476, DOI 10.1210/jc.2003-031552; de Lope CR, 2012, J HEPATOL, V56, pS75, DOI 10.1016/S0168-8278(12)60009-9; Roncalli M, 2016, CLIN MOL HEPATOL, V22, P199, DOI 10.3350/cmh.2016.0101; Roncalli M, 2011, DIGEST LIVER DIS, V43, pS361, DOI 10.1016/S1590-8658(11)60592-6; Ross HM, 2011, MODERN PATHOL, V24, P390, DOI 10.1038/modpathol.2010.207; Ryu HS, 2012, TUMORI, V98, P478, DOI 10.1700/1146.12643; Saad RS, 2004, AM J CLIN PATHOL, V122, P421, DOI 10.1309/UMF715KRG2V198YD; Schraml C, 2015, DIAGNOSTICS, V5, P513, DOI 10.3390/diagnostics5040513; Shafizadeh Nafis, 2013, Surg Pathol Clin, V6, P367, DOI 10.1016/j.path.2013.03.007; Sherman M, 2014, SEMIN LIVER DIS, V34, P389, DOI 10.1055/s-0034-1394139; Sherman M, 2010, SEMIN LIVER DIS, V30, P3, DOI 10.1055/s-0030-1247128; Srivastava A, 2009, AM J SURG PATHOL, V33, P626, DOI 10.1097/PAS.0b013e31818d7d8b; Suriawinata Arief A, 2002, Clin Liver Dis, V6, P527, DOI 10.1016/S1089-3261(02)00005-3; Tang A, 2015, ADV ANAT PATHOL, V22, P314, DOI 10.1097/PAP.0000000000000089; Tang Y, 1999, Radiat Med, V17, P265; Torbenson M, 2007, ADV ANAT PATHOL, V14, P217, DOI 10.1097/PAP.0b013e3180504913; Ulbright TM, 2014, AM J SURG PATHOL, V38, pE50, DOI 10.1097/PAS.0000000000000233; van Meer S, 2016, EUR J GASTROEN HEPAT, V28, P955, DOI 10.1097/MEG.0000000000000641; Walther Z, 2011, PATHOLOG RES INT, V2011, DOI DOI 10.4061/2011/403929]; Wang FM, 2012, AM J CLIN PATHOL, V137, P937, DOI 10.1309/AJCP0KZZ5DSIGMNY; Werling RW, 2003, AM J SURG PATHOL, V27, P303, DOI 10.1097/00000478-200303000-00003; Yang M, 2010, MODERN PATHOL, V23, P654, DOI 10.1038/modpathol.2010.38; Yu FC, 2008, J GASTROINTEST LIVER, V17, P203; Zhang F, 2008, HISTOPATHOLOGY, V52, P224, DOI 10.1111/j.1365-2559.2007.02929.x	108	1	1	1	2	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					2	17		10.4103/IJPM.IJPM_578_17			16	Pathology	Pathology	GA6JJ	WOS:000428438900002	29567877	DOAJ Gold			2019-10-28	
J	Aksakalli, N				Aksakalli, Nihan			Evaluation of the osteopontin in oral peripheral and central giant cell granuloma	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Central giant cell granuloma; integrin alpha(v); Ki-67; osteopontin; peripheral giant cell granuloma	BONE SIALOPROTEIN; EXPRESSION; JAWS; LESIONS; INTEGRIN; RESORPTION; CD44V6; KI-67	Aim: Peripheral giant cell granuloma (PGCG) and central giant cell granuloma (CGCG) of the jaws are benign proliferations of spindle-shaped mesenchymal cells and multinucleated giant cells. Despite the histopathologic similarities, they have markedly different clinical behavior. PGCG shows low recurrence rate whereas CGCG shows a variable clinical behavior ranging from nonaggressive lesions to aggressive lesions characterizing by pain, rapid growth, and high recurrence rate. Therefore, the aim of the study was to compare CGCG with PGCG by immunohistochemistry using Ki-67, osteopontin (OPN), and integrin alpha(v) antibodies. Subjects and Methods: Twenty PGCG and 20 CGCG were selected for immunohistochemical evaluation of OPN, integrin alpha(v), and Ki-67 in multinucleated giant cells and mononucleated cells of PGCG and CGCG. Results: PGCG showed higher Ki-67 immunoreactivity in mononucleated cells compared to CGCG (P < 0.05). There was no reactivity with Ki-67 in multinucleated giant cells of both groups. Mononucleated cells in CGCGs demonstrated increased OPN and integrin alpha(v) expressions in comparison with PGCGs (P < 0.05). Conclusions: The clinic behavior of CGCG being more aggressive than PGCG might be explained by the high expression of OPN and integrin alpha(v). Further studies are necessary to evaluate the other OPN receptors and their role on the biologic behavior of these lesions.	[Aksakalli, Nihan] Istanbul Univ, Inst Oncol, Dept Tumor Pathol, Block A,Floor 2 Capa, TR-34093 Istanbul, Turkey	Aksakalli, N (reprint author), Istanbul Univ, Inst Oncol, Dept Tumor Pathol, Block A,Floor 2 Capa, TR-34093 Istanbul, Turkey.	nihanaksakalli@gmail.com					Carlinfante G, 2003, CLIN EXP METASTAS, V20, P437, DOI 10.1023/A:1025419708343; Chen Q, 2014, STEM CELLS, V32, P327, DOI 10.1002/stem.1567; Chien CY, 2009, ORAL ONCOL, V45, P798, DOI 10.1016/j.oraloncology.2008.12.006; Florez-Moreno GA, 2008, ORAL SURG ORAL MED O, V105, P625, DOI 10.1016/j.tripleo.2007.08.032; Itonaga I, 2003, J ORAL PATHOL MED, V32, P224, DOI 10.1034/j.1600-0714.2003.00069.x; Kruse-Losler B, 2006, ORAL SURG ORAL MED O, V101, P346, DOI 10.1016/j.tripleo.2005.02.060; Liu B, 2003, J ORAL PATHOL MED, V32, P367, DOI 10.1034/j.1600-0714.2003.00126.x; Martinez C, 2010, EXP MOL PATHOL, V88, P272, DOI 10.1016/j.yexmp.2009.12.008; MIYAUCHI A, 1993, OSTEOPOROSIS INT, V3, pS132; Neville BW, 2009, ORAL MAXILLOFACIAL P, P520; Papanicolaou P, 2012, MED ORAL PATOL ORAL, V17, pE56, DOI 10.4317/medoral.17205; ROSS FP, 1993, J BIOL CHEM, V268, P9901; Salehinejad J, 2012, PATHOL RES PRACT, V208, P410, DOI 10.1016/j.prp.2012.04.005; Schack L, 2009, J IMMUNOL, V182, P6943, DOI 10.4049/jimmunol.0900065; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279, DOI 10.1177/10454411000110030101; Sodek J, 2006, J DENT RES, V85, P404, DOI 10.1177/154405910608500503; Souza PEA, 2000, ORAL DIS, V6, P35; Sun ZJ, 2009, SKELETAL RADIOL, V38, P903, DOI 10.1007/s00256-009-0740-8; Wang YP, 2009, ORAL ONCOL, V45, P538, DOI 10.1016/j.oraloncology.2008.07.015; Wang YP, 2009, J FORMOS MED ASSOC, V108, P286, DOI 10.1016/S0929-6646(09)60068-1	21	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					18	21		10.4103/IJPM.IJPM_214_16			4	Pathology	Pathology	GA6JJ	WOS:000428438900003	29567878	DOAJ Gold			2019-10-28	
J	El Jabbour, T; Dalvi, SD; Kim, S; Sheehan, C; Ross, JS				El Jabbour, Tony; Dalvi, Siddhartha Dilip; Kim, Sungeun; Sheehan, Christine; Ross, Jeffrey S.			Myeloid cell leukemia-1 protein expression and myeloid cell leukemia-1 gene amplification in non small cell lung cancer	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Adenocarcinoma; myeloid cell leukemia-1 amplification; myeloid cell leukemia-1 immunohistochemistry; nonsmall cell lung carcinoma	CHRONIC LYMPHOCYTIC-LEUKEMIA; MCL-1 EXPRESSION; BREAST-CANCER; IN-VITRO; SURVIVAL; CARCINOMA; APOPTOSIS; THERAPY; BCL-2	Background: Myeloid cell leukemia-1 (Mcl-1) is a member of the B-cell lymphoma 2 family known to play a significant role in the regulation of apoptosis. Mcl-1 expression has been studied in nonsmall cell lung cancer (NSCLC) cell lines but has not been previously evaluated as a prognostic factor in clinical samples. Materials and Methods: Formalin-fixed, paraffin-embedded sections from 119 NSCLC, including 33 squamous cell carcinomas (SCC), 55 adenocarcinomas (AC), and 31 either pure adenocarcinoma in situ (AIS) or AC with lepidic features were immunostained by an automated method with rabbit polyclonal Mcl-1. Cytoplasmic Mcl-1 (cMcl-1) immunoreactivity was scored based on intensity and percentage of positive tumor cells in both tumor and adjacent benign epithelium in each case. MCL1 amplification was determined by hybrid capture-based comprehensive genomic profiling (CGP) on a separate cohort of 9393 NSCLC samples. Results: Intense diffuse cMcl-1 overexpression was noted in 35/119 (29%) tumors overall and correlated with tumor type (52% AIS vs. 31% AC vs. 6% SCC, P < 0.0001), tumor grade (48% grade 1 vs. 14% grade 2 vs. 31% grade 3, P = 0.007), small tumor size (36% <= 3.0 cm vs. 16% > 3.0 cm, P = 0.016), and lengthened survival within the AIS subgroup (100% alive vs. 42% expired, P = 0.018) while showing a trend toward correlation with nonrecurrent disease overall (32% nonrecurrent vs. 11% recurrent, P = 0.072) and within the AC subgroup (33% nonrecurrent vs. 0% recurrent, P = 0.092). MCL1 amplification was identified in 569 (6%) of 9393 NSCLC by CGP. Conclusions: cMcl-1 overexpression appears to occur independently from MCL1 gene amplification in NSCLC and correlates with AIS histologic type, lower tumor grade, smaller tumor size, nonrecurrent disease, and increased survival.	[El Jabbour, Tony; Dalvi, Siddhartha Dilip; Kim, Sungeun; Sheehan, Christine; Ross, Jeffrey S.] Albany Med Ctr, Dept Pathol, 43 New Scotland Ave, Albany, NY 12208 USA	Dalvi, SD (reprint author), Albany Med Ctr, Dept Pathol, 43 New Scotland Ave, Albany, NY 12208 USA.	dalvis@mail.amc.edu		Dalvi, Siddhartha/0000-0002-0738-4567			Akgul C, 2009, CELL MOL LIFE SCI, V66, P1326, DOI 10.1007/s00018-008-8637-6; Ali SM, 2016, CASE REP ONCOL, V9, P112, DOI 10.1159/000443371; [Anonymous], 2016, CANC FACTS FIG; Booy EP, 2011, ONCOGENE, V30, P2367, DOI 10.1038/onc.2010.616; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Brunner M, 2008, MODERN PATHOL, V21, P876, DOI 10.1038/modpathol.2008.63; Crawford M, 2009, BIOCHEM BIOPH RES CO, V388, P483, DOI 10.1016/j.bbrc.2009.07.143; Ding QQ, 2007, CANCER RES, V67, P4564, DOI 10.1158/0008-5472.CAN-06-1788; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379.3379_3379_3389; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Pepper C, 2008, BLOOD, V112, P3807, DOI 10.1182/blood-2008-05-157131; Perciavalle RM, 2013, TRENDS CELL BIOL, V23, P22, DOI 10.1016/j.tcb.2012.08.011; Sieghart W, 2006, J HEPATOL, V44, P151, DOI 10.1016/j.jhep.2005.09.010; Song LX, 2005, CANCER BIOL THER, V4, P267, DOI 10.4161/cbt.4.3.1496; Thomas LW, 2010, FEBS LETT, V584, P2981, DOI 10.1016/j.febslet.2010.05.061; Wang LK, 2009, J SURG ONCOL, V100, P396, DOI 10.1002/jso.21344; Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784; Zhang T, 2012, MED ONCOL, V29, P1985, DOI 10.1007/s12032-011-0005-y; Zhuang LQ, 2007, MODERN PATHOL, V20, P416, DOI 10.1038/modpathol.3800750	20	1	1	1	1	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					27	30		10.4103/IJPM.IJPM_731_16			4	Pathology	Pathology	GA6JJ	WOS:000428438900005	29567880	DOAJ Gold			2019-10-28	
J	Verma, D; Agarwal, K; Tudu, SK				Verma, Deepti; Agarwal, Kiran; Tudu, Sanjeev Kumar			Expression of breast cancer type 1 and its relation with expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2/neu in breast carcinoma on trucut biopsy specimens	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Breast cancer type 1; breast carcinoma; trucut biopsy	BRCA1 EXPRESSION; FAMILIAL BREAST; PROGNOSTIC-SIGNIFICANCE; OVARIAN-CANCER; PROTEIN EXPRESSION; GENE; MUTATIONS; CARRIERS; LINKAGE; TISSUE	Objective: (1) The objective is to study the immunohistochemical expression of Breast cancer type 1 (BRCA1) in breast carcinoma on trucut biopsy specimens and (2) To relate its expression with that of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER-2)/neu and the clinicopathological parameters. Settings and Design: A cross-sectional hospital-based study was performed in Lady Hardinge Medical College and Shrimati Sucheta Kriplani Hospital, New Delhi, with collaboration of the Departments of Pathology and Surgery from the period of November 2008 to March 2010. Materials and Methods: The study group included 54 cytologically proven cases of breast carcinoma. The immunohistochemical expression of BRCA1 was studied and related with expression of ER, PR, and HER-2/neu on their trucut biopsies. Results: The altered expression of BRCA1 (i.e., reduced or absent expression) was seen in 44.4% cases of breast carcinoma while 55.6% had positive expression. About 83% of breast carcinomas with altered BRCA1 expression were larger than 3 cm in size. The breast carcinomas showing altered expression were found to be mostly high grade (63.6%). This was statistically significant. The ER and PR negativity were seen in 62.5% and 79.2% breast carcinomas with altered BRCA1 expression, respectively. The score 3 positivity of HER-2/neu was more common among carcinomas with altered BRCA1 expression (21% vs. 16.7%). The triple negativity was found in 41.7% breast carcinomas having altered BRCA1 expression. This was statistically significant. Conclusion: The combination of immunohistochemical expression of BRCA1, ER, PR, and HER-2/neu and clinicopathological details may be helpful in predicting the individuals more likely to carry BRCA1 mutations and thus selecting the candidate and family members for genetic screening for BRCA1 mutations.	[Verma, Deepti] Lady Hardinge Med Coll & Hosp, Dr Lal Path Labs, Dept Histopathol, New Delhi, India; [Agarwal, Kiran] Lady Hardinge Med Coll & Hosp, Dept Histopathol, Dept Pathol, New Delhi, India; [Tudu, Sanjeev Kumar] Lady Hardinge Med Coll & Hosp, Dept Histopathol, Dept Surg, New Delhi, India	Verma, D (reprint author), Dr Lal Path Labs, Sect 18, New Delhi 89, India.	vermadeepti09@rediffmail.com					Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z; Comanescu M, 2009, ROM J MORPHOL EMBRYO, V50, P419; EASTON DF, 1993, AM J HUM GENET, V52, P678; Fletcher DM, 2007, DIAGNOSTIC HISTOPATH, P948; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Hedau S, 2015, J CANCER RES THER, V11, P158, DOI 10.4103/0973-1482.140985; Hilakivi-Clarke L, 2000, CANCER RES, V60, P4993; Hosni HN, 2014, ACAD J CANC RES, V7, P1; James CR, 2007, ONCOLOGIST, V12, P142, DOI 10.1634/theoncologist.12-2-142; Kennedy RD, 2002, LANCET, V360, P1007, DOI 10.1016/S0140-6736(02)11087-7; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lambie H, 2003, J PATHOL, V200, P207, DOI 10.1002/path.1348; Lee WY, 1999, HISTOPATHOLOGY, V34, P106; Mangia A, 2009, HISTOL HISTOPATHOL, V24, P69, DOI 10.14670/HH-24.69; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mitrovic O, 2013, ARCH BIOL SCI, V65, P511, DOI 10.2298/ABS1302511M; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; Palacios J, 2003, CLIN CANCER RES, V9, P3606; Perez-Valles A, 2001, J CLIN PATHOL, V54, P476, DOI 10.1136/jcp.54.6.476; Rakha EA, 2008, HUM PATHOL, V39, P857, DOI 10.1016/j.humpath.2007.10.011; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaz FH, 2007, J HISTOCHEM CYTOCHEM, V55, P1105, DOI 10.1369/jhc.7A7209.2007; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yang QF, 2001, CANCER-AM CANCER SOC, V92, P54, DOI 10.1002/1097-0142(20010701)92:1<54::AID-CNCR1291>3.0.CO;2-8; Yoshikawa K, 1999, CLIN CANCER RES, V5, P1249	27	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					31	38		10.4103/IJPM.IJPM_393_16			8	Pathology	Pathology	GA6JJ	WOS:000428438900006	29567881	DOAJ Gold			2019-10-28	
J	Agarwal, S; Singh, A; Bagga, PK				Agarwal, Sonal; Singh, Amarjit; Bagga, Permeet Kaur			Immunohistochemical evaluation of lymphovascular invasion in carcinoma breast with CD34 and D2-40 and its correlation with other prognostic markers	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Carcinoma breast; CD34/D2-40; lymph node ratio; lymphovascular invasion; Nottingham prognostic index; retraction artifacts	INFILTRATING DUCT CARCINOMA; TUMOR SIZE; CANCER; LYMPHANGIOGENESIS; SURVIVAL; RETRACTION; MASTECTOMY; DIAGNOSIS; ARTIFACT; CRITERIA	Background: Carcinoma breast is ever-evolving and becoming increasingly prevalent in India. Numerous prognostic factors based on morphology and immunohistochemistry (IHC) have been established which need to be interconnected to give patients best possible treatment. Aims: This study aims to confirm and analyze lymphovascular invasion (LVI) detected by hematoxylin and eosin (H and E) using IHC with CD34 and D2-40 and its correlation with other biologic and morphologic prognostic markers. Settings and Design: This was a prospective study. Materials and Methods: Fifty mastectomy specimens diagnosed as infiltrating ductal carcinoma breast on histopathology selected for the study. Evaluation of formalin-fixed paraffin-embedded sections was done using H and E and IHC for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 HER2/neu receptors, CD34, and D2-40 endothelial markers. Correlation of LVI done with prognostic markers of Carcinoma Breast, namely, age of the patient, tumor size, Nottingham grade, lymph node ratio (LNR), Nottingham prognostic index (NPI), ER/PR status, and HER2/neu status. CD34 and D2-40 utilized to distinguish blood vessel, lymph vessel, and retraction artifacts and to calculate lymphatic microvessel density (LMVD) and blood microvessel density (BMVD). Statistical Analysis Used: SPSS Software Package. Results: LVI was associated with younger age (P = 0.001), greater tumor size (P = 0.007), higher Nottingham grade (P = 0.001), higher LNR (P = 0.001), higher NPI (P = 0.001), Negative ER Status (P = 0.001), Negative PR Status (P = 0.002), Positive HER2/neu status (P = 0.021), Higher Intratumoral BMVD (P = 0.016), Peritumoral BMVD (P = 0.001), and Intratumoral LMVD (P = 0.009). Blood vessels more commonly invaded than lymph vessels. Retraction artifacts can be mistaken for LVI without IHC. Conclusions: D2-40 is a promising marker for lymphatic endothelium. LVI is a poor prognostic marker hence should be evaluated imperatively in all cases of carcinoma breast.	[Agarwal, Sonal; Singh, Amarjit; Bagga, Permeet Kaur] Govt Med Coll, Dept Pathol, Amritsar, Punjab, India	Bagga, PK (reprint author), Govt Med Coll, Dept Pathol, Amritsar, Punjab, India.	permeetbagga18@yahoo.co.in					Acs G, 2007, AM J SURG PATHOL, V31, P129, DOI 10.1097/01.pas.0000213316.59176.9b; Agarwal B, 2005, AM J SURG PATHOL, V29, P1449, DOI 10.1097/01.pas.0000174269.99459.9d; Alieldin NH, 2014, J EGYPT NATL CANCER, V26, P23, DOI 10.1016/j.jnci.2013.08.005; Andea AA, 2002, CANCER, V94, P1383, DOI 10.1002/cncr.10331; [Anonymous], TRENDS IND; Arapantoni-Dadioti P, 2012, J BUON, V17, P277; Azizun-Nisa, 2008, ASIAN PAC J CANCER P, V9, P553; Bleyer A, 2006, NIH PUBLICATION, V06-5767; Cork DMW, 2012, TUMOR BIOL, V33, P2329, DOI 10.1007/s13277-012-0495-z; Deger A, 2015, INT J CLIN EXP PATHO, V8, P9772; El-Gohary YM, 2008, AM J CLIN PATHOL, V129, P578, DOI 10.1309/2HGNJ1GU57JMBJAQ; Gurleyik G, 2007, ACTA CHIR BELG, V107, P284, DOI 10.1080/00015458.2007.11680057; Irie J, 2007, INT J SURG PATHOL, V15, P53, DOI 10.1177/1066896906295690; Jagsi R, 2005, INT J RADIAT ONCOL, V62, P1035, DOI 10.1016/j.ijrobp.2004.12.014; Kim KJ, 2005, JPN J CLIN ONCOL, V35, P126, DOI 10.1093/jjcolyhi039; Krishnamurthy J, 2016, INDIAN J CANCER, V53, P34, DOI 10.4103/0019-509X.180834; Kuru B, 2003, J SURG ONCOL, V83, P167, DOI 10.1002/jso.10264; Lalloo F, 2006, EUR J CANCER, V42, P1143, DOI 10.1016/j.ejca.2005.11.032; Marinho VFZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-64; Mohammed RAA, 2011, J PATHOL, V223, P358, DOI 10.1002/path.2810; Mohammed ZMA, 2013, BMC CLIN PATHOL, V13, DOI 10.1186/1472-6890-13-31; Panagiotopoulos N, 2016, J BUON, V21, P1082; Rakha EA, 2012, CANCER-AM CANCER SOC, V118, P3670, DOI 10.1002/cncr.26711; ROSEN PP, 1983, PATHOL ANNU, V18, P215; SAY CC, 1974, CANCER, V34, P468, DOI 10.1002/1097-0142(197408)34:2<468::AID-CNCR2820340235>3.0.CO;2-X; Schoppmann SF, 2004, ANN SURG, V240, P306, DOI 10.1097/01.sla.0000133355.48672.22; Song YJ, 2011, J BREAST CANCER, V14, P198, DOI 10.4048/jbc.2011.14.3.198; Truong PT, 2005, J AM COLL SURGEONS, V200, P912, DOI 10.1016/j.jamcollsurg.2005.02.010; Vleugel MM, 2004, J CLIN PATHOL, V57, P746, DOI 10.1136/jcp.2003.014480; Yang CC, 2012, INT J SURG PATHOL, V20, P546, DOI 10.1177/1066896912451323	30	2	2	0	3	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					39	44		10.4103/IJPM.IJPM_791_16			6	Pathology	Pathology	GA6JJ	WOS:000428438900007	29567882	DOAJ Gold			2019-10-28	
J	Kumar, M; Katiyar, S; Sagar, M; Kumari, M; Goel, MM				Kumar, Madhu; Katiyar, Shweta; Sagar, Mala; Kumari, Malti; Goel, Madhu Mati			Liquid-based cytology versus conventional cytology in fine-needle aspirates of salivary gland neoplasms	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Conventional cytology; fine-needle aspiration cytology; liquid-based cytology; salivary gland neoplasms	THINPREP(R) TECHNIQUE; DIAGNOSTIC PITFALLS; FNA SAMPLES; BIOPSY; EXPERIENCE; ARTIFACTS; SMEARS	Background: Liquid-based cytology (LBC) is a method of retrieving and processing of cytological material for the assessment of both gynecological and nongynecological cases introduced in 1996. Mostly conventional smears (CS) are prepared in Indian scenario; however, due to increasing popularity of LBC in nongynecology specimens, LBC is also used in few centers for diagnosing salivary gland neoplasm. Aim: The aim of this study is to compare CS and LBC in fine-needle aspiration cytology (FNAC) of the salivary gland neoplasms in terms of cytomorphological details, adequacy, ease of interpretation, pitfalls, and diagnostic efficiency. Materials and Methods: We conducted a prospective, observational, comparative study which included 64 salivary gland neoplasms. Both CS and LBC (SurePath) were prepared as per standard protocols and examined. Results and Conclusion: In our study, specificity and positive predictive value of both the techniques (conventional and LBC) were found to be 100%. Sensitivity of both the techniques was found to be similar (66.7%). Negative predictive value and diagnostic accuracy of conventional technique were found to be almost similar to that of LBC technique (97.6% vs. 97.2% and 97.7% vs. 97.4%). In terms of adequacy and cellularity, CSs were better than LBC. Ease of interpretation was better with CSs due to abundant chondromyxoid stroma, an important clue in the diagnosis of pleomorphic adenoma. Nuclear details and background were better in LBC as compared to CS. Hence, we conclude that in salivary gland FNAC, both CS and LBC have similar diagnostic efficiency. however, interpretation of conventional smears is easier than Liquid Based Cytology especially in cases of pleomorphic adenoma. However, some advantages of LBC in respect to conventional cytology, with better-preserved morphology obtained from LBC becomes furthermore obligatory.	[Kumar, Madhu; Katiyar, Shweta; Sagar, Mala; Kumari, Malti; Goel, Madhu Mati] King Georges Med Univ, Dept Pathol, Lucknow 226003, Uttar Pradesh, India	Kumar, M (reprint author), King Georges Med Univ, Dept Pathol, Lucknow 226003, Uttar Pradesh, India.	k_madhu2010@rediffmail.com					Al-Khafaji BM, 2001, ACTA CYTOL, V45, P567, DOI 10.1159/000327866; Anand VH, 2014, SE ASIAN J CASE REP, V3, P609; BISCOTTI CV, 1995, AM J CLIN PATHOL, V104, P150; Cajulis RS, 1997, ACTA CYTOL, V41, P1412, DOI 10.1159/000332852; Chacho MS, 2003, CANCER CYTOPATHOL, V99, P135, DOI 10.1002/cncr.11102; Fadda G, 2011, ACTA CYTOL, V55, P389, DOI 10.1159/000329029; Gandhi S H, 2013, NATL J INTEGR RES ME, V4, P70; Hipp J, 2015, DIAGN CYTOPATHOL, V43, P98, DOI 10.1002/dc.23188; Hoda RS, 2007, DIAGN CYTOPATHOL, V35, P621, DOI 10.1002/dc.20698; Jain R, 2013, CYTOJOURNAL, V10, DOI 10.4103/1742-6413.109547; JAYARAM N, 1989, DIAGN CYTOPATHOL, V5, P349, DOI 10.1002/dc.2840050402; Leung CS, 1997, DIAGN CYTOPATHOL, V16, P368, DOI 10.1002/(SICI)1097-0339(199704)16:4<368::AID-DC14>3.3.CO;2-H; MAVEC P, 1964, Acta Otolaryngol, V58, P471, DOI 10.3109/00016486409121406; Michael CW, 2000, DIAGN CYTOPATHOL, V23, P6, DOI 10.1002/1097-0339(200007)23:1<6::AID-DC2>3.0.CO;2-F; Mygdakos N, 2009, ROM J MORPHOL EMBRYO, V50, P245; ODWYER P, 1986, CANCER, V57, P554, DOI 10.1002/1097-0142(19860201)57:3<554::AID-CNCR2820570325>3.0.CO;2-G; Parfitt JR, 2007, CANCER CYTOPATHOL, V111, P123, DOI 10.1002/cncr.22575; Pusztaszeri MP, 2015, SEMIN DIAGN PATHOL, V32, P264, DOI 10.1053/j.semdp.2014.12.008; Rana DN, 2001, CYTOPATHOLOGY, V12, P390, DOI 10.1046/j.1365-2303.2001.00351.x; Rarick JM, 2014, ACTA CYTOL, V58, P552, DOI 10.1159/000364854; Ren SY, 2014, ACTA CYTOL, V58, P522, DOI 10.1159/000363123; Tripathy K, 2015, J CYTOL, V32, P17, DOI 10.4103/0970-9371.155225; Vikram Y, 2015, INDIAN J APPL RES, V5, P529	23	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					45	49		10.4103/IJPM.IJPM_729_16			5	Pathology	Pathology	GA6JJ	WOS:000428438900008	29567883	DOAJ Gold			2019-10-28	
J	Poongodi, R; Varma, N; Naseem, S; Parveen, B; Varma, S				Poongodi, R.; Varma, Neelam; Naseem, Shano; Parveen, Bose; Varma, Subhash			Utility of CD200 expression and CD20 antibody binding capacity in differentiating chronic lymphocytic leukemia from other chronic lymphoproliferative disorders	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						CD20 antibody binding capacity; CD200; chronic lymphoproliferative disorders	FLOW-CYTOMETRY; CELL; DIAGNOSIS; ANTIGEN; MALIGNANCIES; NEOPLASMS; CLL	Background: Chronic lymphoproliferative disorders (CLPDs) are heterogeneous group of disorders with variable clinical presentations and outcomes. Therefore, accurate classification is crucial for treatment planning. At present, flow cytometry immunophenotyping (FCM-IPT) is a useful tool for diagnosing these diseases. However, overlapping immunophenotypes do exist. Recently, differential expression of CD200 and variation in number of CD20 antibody bound per cell (ABC) in different CLPDs has been reported. Materials and Methods: Seventy-seven CLPD cases were analyzed by FCM-IPT for CD200 expression, and Quantibrite bead was used to calculate CD20 ABC. Results: Variability in CD200 expression can help in the differentiation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL) from other CLPDs. CD200 was brightly expressed in 100% CLL cases, having homogenous bright (2+) intensity. On the contrary, CD200 was uniformly negative in all Mantle cell lymphoma cases except 1, in which the intensity was dim, and the mean fluorescence intensity was significantly lower than CLL. Furthermore, all HCL cases showed bright expression of CD200, thereby making it useful in differentiation from other CLPD with villous lymphocytes. Evaluation of CD20 ABC showed that it differs among various CLPD and was significantly lowest in CLL and highest in HCL both on peripheral blood and bone marrow samples. Conclusion: Our results support the fact that CD200 can be added to routine CLPD panel as it is useful in subcategorizing them. However, inclusion of CD20 ABC to routine panel does not seem plausible but may be done for difficult diagnostic cases or where anti-CD20 therapy is planned.	[Poongodi, R.] Postgrad Inst Med Educ & Res, Dept Pathol, Chandigarh, India; [Varma, Neelam; Naseem, Shano; Parveen, Bose] Postgrad Inst Med Educ & Res, Dept Hematol, Sect 12, Chandigarh 160012, India; [Varma, Subhash] Postgrad Inst Med Educ & Res, Dept Internal Med, Chandigarh, India	Varma, N (reprint author), Postgrad Inst Med Educ & Res, Dept Hematol, Sect 12, Chandigarh 160012, India.	varmaneelam@yahoo.com					Alapat D, 2012, AM J CLIN PATHOL, V137, P93, DOI 10.1309/AJCP59UORCYZEVQO; Brunetti L, 2009, BRIT J HAEMATOL, V145, P665, DOI 10.1111/j.1365-2141.2009.07644.x; Dorfman DM, 2010, AM J CLIN PATHOL, V134, P726, DOI 10.1309/AJCP38XRRUGSQOVC; El Desoukey NA, 2012, J INVEST MED, V60, P56, DOI 10.2310/JIM.0b013e31823908f9; Ginaldi L, 1998, J CLIN PATHOL, V51, P364, DOI 10.1136/jcp.51.5.364; Huh YO, 2001, AM J CLIN PATHOL, V116, P437, DOI 10.1309/438N-E0FH-A5PR-XCAC; MATUTES E, 1994, LEUKEMIA, V8, P1640; Matutes E, 2010, BEST PRACT RES CL HA, V23, P3, DOI 10.1016/j.beha.2010.01.001; McWhirter JR, 2006, P NATL ACAD SCI USA, V103, P1041, DOI 10.1073/pnas.0510081103; Olejniczak SH, 2006, IMMUNOL INVEST, V35, P93, DOI 10.1080/08820130500496878; Palumbo GA, 2009, LEUKEMIA RES, V33, P1212, DOI 10.1016/j.leukres.2009.01.017; Prevodnik VK, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-33; Rossmann ED, 2007, CYTOM PART B-CLIN CY, V72B, P450, DOI 10.1002/cyto.b.20359; Sandes AF, 2014, CYTOM PART B-CLIN CY, V86, P98, DOI 10.1002/cyto.b.21128; Swerdlow SH, 2008, WHO CLASSIFICATION T; van Dongen JJM, 2012, LEUKEMIA, V26, P1908, DOI 10.1038/leu.2012.120; Yi Shuhua, 2014, Zhonghua Xue Ye Xue Za Zhi, V35, P337, DOI 10.3760/cma.j.issn.0253-2727.2014.04.019	17	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					50	57		10.4103/IJPM.IJPM_267_17			8	Pathology	Pathology	GA6JJ	WOS:000428438900009	29567884	DOAJ Gold			2019-10-28	
J	Modkharkar, S; Navale, P; Amare, PK; Chougule, A; Patkar, N; Tembhare, P; Menon, H; Sengar, M; Khattry, N; Banavali, S; Arora, B; Narula, G; Laskar, S; Khanna, N; Muckaden, MA; Rangarajan, V; Agrawal, A; Shet, T; Epari, S; Subramanian, PG; Gujral, S				Modkharkar, Sushil; Navale, Pooja; Amare, Pratibha Kadam; Chougule, Anuradha; Patkar, Nikhil; Tembhare, Prashant; Menon, Hari; Sengar, Manju; Khattry, Navin; Banavali, Shripad; Arora, Brijesh; Narula, Gaurav; Laskar, Siddhartha; Khanna, Nehal; Muckaden, Mary Ann; Rangarajan, Venkatesh; Agrawal, Archi; Shet, Tanuja; Epari, Sridhar; Subramanian, P. G.; Gujral, Sumeet			Applicability of 2008 World Health Organization classification system of hematolymphoid neoplasms: Learning experiences	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Extranodal lymphomas; hematolymphoid neoplasms; leukemia; lymphoma; pediatric hematolymphoid neoplasms; World Health Organization classification	LANGERHANS CELL HISTIOCYTOSIS; NON-HODGKINS-LYMPHOMA; CHRONIC MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOLOGIC MALIGNANCIES; EPIDEMIOLOGY; REGISTRY; INDIA; CHILDHOOD; DIAGNOSIS	Background: 2008 World Health Organization (WHO) classification of hematolymphoid neoplasms (HLN) has classified them based on morphology, results of various ancillary techniques, and clinical features.([1]) There are no studies looking at the applicability of WHO classification. Aims: The aim of the study was to calculate proportions of all HLN subtypes seen during 1-year period based on 2008 WHO classification of HLN and study applicability and also shortcomings of practices in a tertiary care center in India. Materials and Methods: This was a 1-year retrospective study (January 1st, to December 31st, 2010) where cases were identified using hospital/laboratory electronic records. Old follow-up and referral cases were excluded from the study. Only newly diagnosed cases classified into categories laid down by 2008 WHO classification of HLN included. Results: Out of 2118 newly diagnosed classifiable cases, 1602 (75.6%) cases were of lymphoid neoplasms, 489 (23.1%) cases of myeloid neoplasms, 16 (0.8%) cases of histiocytic and dendritic cell neoplasms, and 11 (0.5%) cases of acute leukemias of ambiguous lineage. Overall, most common HLN subtype was diffuse large B-cell lymphoma (n = 361, 17.0%). Precursor B-lymphoblastic leukaemia/lymphoma (n = 177, 48.2%) was the most common subtype within pediatric age group. Conclusions: All major subtypes of HLN were seen at our center and showed trends almost similar to those seen in other Indian studies. Molecular/cytogenetic studies could not be performed on a significant number of cases owing to logistic reasons (unavailability of complete panels and also cost-related issues) and such cases could not be classified as per the WHO classification system.	[Modkharkar, Sushil; Navale, Pooja; Shet, Tanuja; Epari, Sridhar; Gujral, Sumeet] Tata Mem Hosp, Dept Pathol, Bombay, Maharashtra, India; [Amare, Pratibha Kadam] Tata Mem Hosp, Dept Canc Cytogenet, Bombay, Maharashtra, India; [Menon, Hari; Sengar, Manju; Khattry, Navin; Banavali, Shripad; Arora, Brijesh; Narula, Gaurav] Tata Mem Hosp, Dept Med Oncol, Bombay, Maharashtra, India; [Laskar, Siddhartha; Khanna, Nehal] Tata Mem Hosp, Dept Radiat Oncol, Bombay, Maharashtra, India; [Muckaden, Mary Ann] Tata Mem Hosp, Dept Palliat Med, Bombay, Maharashtra, India; [Rangarajan, Venkatesh; Agrawal, Archi] Tata Mem Hosp, Dept Radiol & Nucl Med, Bombay, Maharashtra, India; [Chougule, Anuradha; Patkar, Nikhil; Tembhare, Prashant; Subramanian, P. G.] Tata Mem Hosp, Hematopathol Lab, Dept Pathol, Bombay, Maharashtra, India	Gujral, S (reprint author), Tata Mem Hosp, Hematopathol Lab, 727,7th Floor,Annexe Bldg,Dr Ernest Borges Rd, Bombay 400012, Maharashtra, India.	s_gujral@outlook.com	TEMBHARE, PRASHANT R/J-6813-2019; Narula, Gaurav/S-7761-2019	Narula, Gaurav/0000-0002-8539-295X; Patkar, Nikhil/0000-0001-9234-2857			ALTMAN AJ, 1988, PEDIATR CLIN N AM, V35, P765; Anderson JR, 1998, ANN ONCOL, V9, P717, DOI 10.1023/A:1008265532487; Aquino Victor M, 2002, Curr Probl Pediatr Adolesc Health Care, V32, P50, DOI 10.1067/mps.2002.121791; Arora N, 2013, LEUKEMIA LYMPHOMA, V54, P1004, DOI 10.3109/10428194.2012.729056; Baccarani M, 2012, ANN ONCOL, V23, P72, DOI 10.1093/annonc/mds228; Belgaumi AF, 2010, HAEMATOL-HEMATOL J, V95, P1211, DOI 10.3324/haematol.2009.015180; Bhatia S, 1997, J PEDIATR-US, V130, P774, DOI 10.1016/S0022-3476(97)80021-2; BROADBENT V, 1994, BRIT J CANCER, V70, pS11; Campo E, 2011, BLOOD, V117, P5019, DOI 10.1182/blood-2011-01-293050; Chan WC, 1997, ANN ONCOL, V8, P973; Deschler B, 2006, CANCER-AM CANCER SOC, V107, P2099, DOI 10.1002/cncr.22233; Ghimire P, 2011, WORLD J GASTROENTERO, V17, P697, DOI 10.3748/wjg.v17.i6.697; Gualco G, 2010, CLINICS, V65, P1267, DOI 10.1590/S1807-59322010001200008; Gujral S, 2009, LEUKEMIA, V23, P978, DOI 10.1038/leu.2008.327; Hochberg J, 2009, BRIT J HAEMATOL, V144, P24, DOI 10.1111/j.1365-2141.2008.07393.x; Howarth DM, 1999, CANCER-AM CANCER SOC, V85, P2278, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2278::AID-CNCR25>3.0.CO;2-U; Jarrett RF, 2003, J CLIN PATHOL, V56, P811, DOI 10.1136/jcp.56.11.811; Jayasekara H, 2010, LEUKEMIA LYMPHOMA, V51, P456, DOI 10.3109/10428190903552104; Kaatsch P, 2010, CANCER TREAT REV, V36, P277, DOI 10.1016/j.ctrv.2010.02.003; Khung S, 2013, INSIGHTS IMAGING, V4, P569, DOI 10.1007/s13244-013-0271-7; Krol ADG, 2003, ANN ONCOL, V14, P131, DOI 10.1093/annonc/mdg004; Kumar C Chandra, 2011, Genes Cancer, V2, P95, DOI 10.1177/1947601911408076; Lee JP, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-30; Linabery AM, 2008, CANCER, V112, P416, DOI 10.1002/cncr.23169; Perez-Saldivar ML, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-355; Maynadie M, 2011, HAEMATOL-HEMATOL J, V96, P55, DOI 10.3324/haematol.2010.026252; Morton LM, 2006, BLOOD, V107, P265, DOI 10.1182/blood-2005-06-2508; Mrozek K, 2009, HEMATOL ONCOL CLIN N, V23, P991, DOI 10.1016/j.hoc.2009.07.001; Muller AMS, 2005, ANN HEMATOL, V84, P1, DOI 10.1007/s00277-004-0939-7; Naresh KN, 2004, LEUKEMIA LYMPHOMA, V45, P1569, DOI 10.1080/10428190410001683679; Novelli S, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-70; Osca-Gelis G, 2013, HAEMATOLOGICA, V98, pE95, DOI 10.3324/haematol.2013.084061; Patkar N., 2008, Indian Journal of Cancer, V45, P59; Rohrbacher M, 2009, BEST PRACT RES CL HA, V22, P295, DOI 10.1016/j.beha.2009.07.007; Safaei A, 2013, IRAN J MED SCI, V38, P301; Sant M, 2010, BLOOD, V116, P3724, DOI 10.1182/blood-2010-05-282632; Shenoy Pareen, 2011, Adv Hematol, V2011, P725219, DOI 10.1155/2011/725219; Sun J, 2012, AM J CLIN PATHOL, V138, P429, DOI 10.1309/AJCP7YLTQPUSDQ5C; Swerdlow SH, 2008, WHO CLASSIFICATION T; Yang QP, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-77; Yoon SO, 2010, AM J HEMATOL, V85, P760, DOI 10.1002/ajh.21824; Zucca E, 1997, ANN ONCOL, V8, P727, DOI 10.1023/A:1008282818705	42	1	1	0	1	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					58	65		10.4103/IJPM.IJPM_56_17			8	Pathology	Pathology	GA6JJ	WOS:000428438900010	29567885	DOAJ Gold			2019-10-28	
J	Jeyamani, L; Jayarajan, J; Leelakrishnan, V; Swaminathan, M				Jeyamani, Lavanya; Jayarajan, Jayalakshmi; Leelakrishnan, Venkatakrishnan; Swaminathan, Mukundan			CagA and VacA genes of Helicobacter pylori and their clinical relevance	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						CagA; Helicobacter pylori; vacA; virulence factor	VACUOLATING CYTOTOXIN ALLELES; BIOPSY SPECIMENS; ASSOCIATION	Context: Helicobacter pylori is associated with the development of a variety of gastroduodenal diseases which varies with ethnicity and the type of strains that infect the population. Aims: This study aims to evaluate the prevalence of H. pylori cagA and vacA genotypes in our region and to determine their relationship to the severity of the lesions that they cause. Settings and Design: This study was an observational cross-sectional study. Subjects and Methods: DNA was extracted from 165 gastric biopsies from patients evaluated for dyspepsia. PCR was used to detect cagA and vacA (s1, s2, m1, m2) genes of H. pylori. Statistical analysis of associations was performed between endoscopy findings and virulence genes. Statistical Analysis Used: Pearson Chi-square test and Fischer's exact test. Results: The prevalence of H. pylori infection was 37% and the dominant genotypes was vacA s1 cagA-positive strain (54.1%) in this study. The vacAs1 subtype was found in all patients with peptic ulcer disease (PUD). The entire normal study group had VacA s2 variant only. This clearly shows that vacA s1 is a significant virulence marker and patients harboring s1 strains are more prone to develop ulcers (P = 0.007). There was a significant association of cagA with s1 strain rather than s2. Variation in VacA m genotype did not seem to have any association with disease status. There was a statistically significant association between the presence of cagA gene and PUD rather than the nonulcer dyspepsia (P = 0.027). Conclusion: The predominant genotype in our population was cagA positive vacA s1, which was found to be significantly associated with patients with gastric diseases, especially PUD. VacA s1 can serve as a single best virulence marker of the disease manifestation.	[Jeyamani, Lavanya] PSG Inst Med Sci & Res, Dept Microbiol, Karpagam Fac Med Sci & Res, Coimbatore, Tamil Nadu, India; [Jayarajan, Jayalakshmi; Leelakrishnan, Venkatakrishnan; Swaminathan, Mukundan] PSG Inst Med Sci & Res, Dept Microbiol & Gastroenterol, Coimbatore, Tamil Nadu, India	Jeyamani, L (reprint author), 197-13,7th Ave, Madras 600101, Tamil Nadu, India.	jlavanya152@gmail.com			PSGIMSR through PSG Prime Funds	This study was financially supported by PSGIMSR through PSG Prime Funds.	Alfizah H, 2013, WORLD J GASTROENTERO, V19, P1283, DOI 10.3748/wjg.v19.i8.1283; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; Atherton JC, 1999, J CLIN MICROBIOL, V37, P2979; Chattopadhyay S, 2004, J CLIN MICROBIOL, V42, P2821, DOI 10.1128/JCM.42.6.2821-2824.2004; Doosti A., 2009, Research Journal of Biological Sciences, V4, P11; Erdogdu C, 2014, TURK J MED SCI, V44, P126, DOI 10.3906/sag-1209-72; Estrada UN, 2013, AFR J MICROBIOL RES, V7, P1409; Farshad Shohreh, 2007, Pak J Biol Sci, V10, P1185; GOODWIN CS, 1989, INT J SYST BACTERIOL, V39, P397, DOI 10.1099/00207713-39-4-397; Hunt RH, 2010, GASTROENTEROLOGY ORG; Hussein NR, 2008, J CLIN MICROBIOL, V46, P1774, DOI 10.1128/JCM.01737-07; Refaay HA, 2006, EGYPT J MED MICROBIO, V15, P751; Udhayakumar G, 2009, CAN J MICROBIOL, V55, P126, DOI [10.1139/W08-108, 10.1139/w08-108]; Xue FB, 2001, WORLD J GASTROENTERO, V7, P801, DOI 10.3748/wjg.v7.i6.801; Yakoob J, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-87	15	3	3	1	1	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					66	69		10.4103/IJPM.IJPM_234_17			4	Pathology	Pathology	GA6JJ	WOS:000428438900011	29567886	DOAJ Gold			2019-10-28	
J	Kumar, A; Hatwal, D; Batra, N; Verma, N				Kumar, Arvind; Hatwal, Deepa; Batra, Neha; Verma, Nidhi			Role of nm23H1 in predicting metastases in prostatic carcinoma	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Adenocarcinoma; metastases; nm23H1; prostate	CANCER-CELLS; SUPPRESSOR NM23-H1; EXPRESSION; STATISTICS; SURVIVAL; RECEPTOR; GROWTH; TISSUE; GENES; INDIA	Background: Non-metastatic nm23H1 gene is thought to play a critical role in cell proliferation. Studies of nm23H1 have been done in many other malignancies. But none of these studies took up nm23H1 gene as predictor in the metastases of prostatic carcinoma. Aims and Objectives: To study the expression of nm23H1 in prostatic lesion and to correlate nm23H1 expression with presence of metastases, tumour stage, tumour grade and with PSA level serum. Setting and Design: Tertiary hospital based retrospective and prospective study done in a period of one year from thirty patients having prostatic lesion confirmed by biopsy. Material and Methods: Immunohistochemistry for nm23H1 was performed on unstained coated sections of prostatic lesions to study the relation with prostatic lesion and their correlation with age, PSA level, tumour stage, grading. Clinical data was collected from medical records. Statistical Analysis: SPSS Version 15 analysis software was used. The value were presented in number(%) and Mean +/- SD. Results: Majority of patients belong to age group 61 to 70yrs. Gleason score >7 were seen in 55% of patients of adenocarcinoma with and without metastasis. The difference in PSA levels between BPH and adenocarcinoma was significant (P < 0.001). IHC expression for nm23H1 gene showed positive findings in all the cases (P = 1). PSA values >20ng/ml showed maximum % mean expression (98.64%) as compared to PSA levels < 10 ng/ml (96.91%). Conclusion: IHC expression of nm23H1 is not an effective tool to distinguish among the cases of BPH, adenocarcinoma of prostate with and without metastasis. Hence nm23H1 gene does not behave like an antimetastatic gene in prostatic lesions.	[Kumar, Arvind; Hatwal, Deepa; Batra, Neha] Govt Med Sci & Res Inst, Dept Pathol, Veer Chandra Singh Garhwali, Garhwal, Uttarakhand, India; [Verma, Nidhi] MAMC, Dept Pathol, New Delhi, India	Hatwal, D (reprint author), Care Of Hatwal SK, Hlth Care Ctr, Garhwal, Uttarakhand, India.	dhatwal@yahoo.com					Andolfo I, 2011, N-S ARCH PHARMACOL, V384, P489, DOI 10.1007/s00210-011-0645-7; Andriole GL, 2009, NEW ENGL J MED, V360, P1310, DOI 10.1056/NEJMoa0810696; Banerjee S, 2015, N-S ARCH PHARMACOL, V388, P207, DOI 10.1007/s00210-014-1043-8; Boissan M, 2010, CANCER RES, V70, P7710, DOI 10.1158/0008-5472.CAN-10-1887; Carotenuto M, 2015, N-S ARCH PHARMACOL, V388, P257, DOI 10.1007/s00210-014-1035-8; Carter HB, 2006, JNCI-J NATL CANCER I, V98, P506, DOI 10.1093/jnci/djj155; Cherry JP, 1998, J UROLOGY, V160, P2223, DOI 10.1016/S0022-5347(01)62300-0; Ding Guo Fang, 2006, Fen Zi Xi Bao Sheng Wu Xue Bao, V39, P544; Goh LK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091666; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hariharan K, 2016, INDIAN J UROL, V32, P103, DOI 10.4103/0970-1591.174774; Huang YW, 2009, ANTICANCER RES, V29, P2179; Igawa M, 1996, EUR UROL, V30, P383; IGAWA M, 1994, CANCER RES, V54, P1313; Jain S, 2014, META GENE, V2, P596, DOI 10.1016/j.mgene.2014.07.007; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kandil MA, 2000, J EGYP NAT CANC I, V12, P199; Kauffman EC, 2003, J UROLOGY, V169, P1122, DOI 10.1097/01.ju.0000051580.89109.4b; KONISHI N, 1993, JPN J CANCER RES, V84, P1050, DOI 10.1111/j.1349-7006.1993.tb02800.x; Koo KC, 2015, PROSTATE INT, V3, P10, DOI 10.1016/j.prnil.2015.02.006; Lapek JD, 2015, N-S ARCH PHARMACOL, V388, P161, DOI 10.1007/s00210-014-1063-4; Leav I, 2010, AM J PATHOL, V176, P393, DOI 10.2353/ajpath.2010.090521; Lee JH, 2009, MOL CELL BIOCHEM, V329, P141, DOI 10.1007/s11010-009-0124-3; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Marino N, 2013, CANCER RES, V73, P5949, DOI 10.1158/0008-5472.CAN-13-0368; Marino N, 2012, CANCER METAST REV, V31, P593, DOI 10.1007/s10555-012-9374-8; Narizhneva NV, 2009, CELL CYCLE, V8, P4155, DOI 10.4161/cc.8.24.10316; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Prowatke I, 2007, BRIT J CANCER, V96, P82, DOI 10.1038/sj.bjc.6603490; Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Stravodimos K, 2000, ANTICANCER RES, V20, P3823; Tong Y, 2015, CANCER LETT, V361, P207, DOI 10.1016/j.canlet.2015.02.050; Watanabe S, 2010, J CANCER RES CLIN, V136, P787, DOI 10.1007/s00432-009-0718-x; Yadav VK, 2014, NUCLEIC ACIDS RES, V42, P764, DOI 10.1093/nar/gkt946; Yang ZS, 2014, MOLECULES, V19, P6851, DOI 10.3390/molecules19056851; You DJ, 2014, J BIOL CHEM, V289, P17709, DOI 10.1074/jbc.M114.553552	38	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					70	75		10.4103/IJPM.IJPM_520_16			6	Pathology	Pathology	GA6JJ	WOS:000428438900012	29567887	DOAJ Gold			2019-10-28	
J	Rizvi, M; Sultan, A; Chowdhry, M; Azam, M; Khan, F; Shukla, I; Khan, HM				Rizvi, Meher; Sultan, Asfia; Chowdhry, Madhav; Azam, Mohd; Khan, Fatima; Shukla, Indu; Khan, Haris M.			Prevalence of scrub typhus in pyrexia of unknown origin and assessment of interleukin-8, tumor necrosis factor-alpha, and interferon-gamma levels in scrub typhus-positive patients	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						ELISA; Orientia tsutsugamushi; pyrexia of unknown origin; scrub typhus	RICKETTSIAL INFECTIONS; SEROLOGICAL EVIDENCE; SPOTTED-FEVER; INDIA; DIAGNOSIS; OUTBREAK; DISEASES	Background: Scrub typhus is lesser known cause of fever of unknown origin in India. Even if there have been reports documenting the prevalence of scrub typhus in different parts of India, it is still an unknown entity, and clinicians usually do not consider it as differential diagnosis. The present study was performed to document the prevalence of scrub typhus among febrile patients in western part of Uttar Pradesh and to assess the clinical profile of infected patients on the one hand and knowledge, attitude, and practices among clinicians on the other. Materials and Methods: A total of 357 adult patients with fever of more than 5-day duration were recruited. All patients underwent complete physical examination, and detailed clinical history was elicited as per predesigned pro forma. After primary screening to rule out malaria, enteric fever, and leptospirosis infection, secondary screening for scrub typhus was done by rapid screen test and IgM ELISA. Results: Scrub typhus infection was positive in 91 (25.5%) cases. The most common symptoms among the patients were fever (100%), pain in abdomen (79.1%), pedal edema 56 (61.5%), rash 44 (48.3%), headache 44 (48.3%), vomiting 42 (46.1%), constipation 33 (36.2%), cough 28 (30.7%), and lymphadenopathy 20 (21.9%). The median values of interleukin-8, interferon-gamma, and tumor necrosis factor-alpha in healthy controls were 15.54 pg/ml, 7.77 pg/ml, and 54.1 pg/ml, respectively, while the median values of these cytokines in scrub typhus-positive patients were 21.04 pg/ml, 8.74 pg/ml, and 73.8 pg/ml, respectively. Conclusion: Our results highlight that scrub typhus infection is an important cause of pyrexia of unknown origin, and active surveillance is necessary to assess the exact magnitude and distribution of the disease.	[Rizvi, Meher; Sultan, Asfia; Chowdhry, Madhav; Azam, Mohd; Khan, Fatima; Shukla, Indu; Khan, Haris M.] Aligarh Muslim Univ, JN Med Coll, Dept Microbiol, Aligarh, Uttar Pradesh, India	Sultan, A (reprint author), Aligarh Muslim Univ, JN Med Coll, Dept Microbiol, Aligarh, Uttar Pradesh, India.	drasfia@gmail.com					Bakken Johan S., 2006, Morbidity and Mortality Weekly Report, V55, P1; Batra HV, 2007, INDIAN J MED RES, V126, P101; Bithu R, 2014, INDIAN J MED MICROBI, V32, P387, DOI 10.4103/0255-0857.142241; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BROWN GW, 1976, T ROY SOC TROP MED H, V70, P444, DOI 10.1016/0035-9203(76)90127-9; Chierakul W, 2004, CLIN IMMUNOL, V113, P140, DOI 10.1016/j.clim.2004.08.006; Chugh TD, 2008, J BIOSCIENCES, V33, P549, DOI 10.1007/s12038-008-0073-0; Cinco M, 1996, FEMS MICROBIOL LETT, V138, P211, DOI 10.1016/0378-1097(96)00109-7; Hun L, 2012, RES REP TROP MED, V3, P47, DOI 10.2147/RRTM.S24753; Kawamura A. J, 1995, TSUTSUGAMUSHI DIS, P1; Mahajan S K, 2006, J Assoc Physicians India, V54, P619; Mathai E, 2001, ANN TROP MED PARASIT, V95, P395, DOI 10.1080/00034980120065804; Mittal V, 2012, INDIAN J MED RES, V135, P538; PALMER BA, 1984, INFECT IMMUN, V46, P237; Rathi N, 2010, INDIAN PEDIATR, V47, P157, DOI 10.1007/s13312-010-0024-3; Rizvi M, 2011, ANN TROP MED PARASIT, V105, P499, DOI 10.1179/1364859411Y.0000000041; Sharma A, 2005, JPN J INFECT DIS, V58, P208; Sonthayanon P, 2006, AM J TROP MED HYG, V75, P1099, DOI 10.4269/ajtmh.2006.75.1099; Sonthayanon P, 2009, J CLIN MICROBIOL, V47, P430, DOI 10.1128/JCM.01927-08; Sundhindra BK, 2004, NATL MED J INDIA, V17, P51; Varghese GM, 2013, INT J INFECT DIS, V17, pE981, DOI 10.1016/j.ijid.2013.05.017; Vivekanandan M, 2010, J Assoc Physicians India, V58, P24	22	1	1	0	2	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					76	80		10.4103/IJPM.IJPM_644_16			5	Pathology	Pathology	GA6JJ	WOS:000428438900013	29567888	DOAJ Gold			2019-10-28	
J	Charles, MVP; Kalaivani, R; Venkatesh, S; Kali, A; Seetha, KS				Charles, Marie Victor Pravin; Kalaivani, Ramakrishnan; Venkatesh, Soma; Kali, Arunava; Seetha, Kunigal Srinivasiah			Evaluation of procalcitonin as a diagnostic marker in neonatal sepsis	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						C-reactive protein; neonatal sepsis; procalcitonin	C-REACTIVE PROTEIN; INFECTION; COUNT	Context: Neonatal sepsis is an early infection occurring within 28 days of the postnatal life. It has nonspecific signs and symptoms which make the diagnosis cumbersome. It inflicts an increase in morbidity and mortality among neonates. Procalcitonin (PCT) is yet another acute phase reactant, which is synthesized by the C-cells of thyroid gland. Aims: The aim of our study is to evaluate PCT as a diagnostic marker of neonatal sepsis in comparison with C-reactive protein (CRP). Subjects and Methods: A prospective cross-sectional study was conducted at our tertiary care hospital in Puducherry. The study was conducted over a period of 5 months from November 2015 to 2016. The study included all neonates with clinical signs of sepsis. The neonates were assigned into three groups as proven sepsis, suspected sepsis, and no sepsis group. The CRP level and PCT level were compared between the three groups, and their sensitivity and specificity were calculated. Statistical Analysis Used: The mean, standard deviation, and standard error of mean were calculated. The groups were compared using one-way ANOVA. The diagnostic test efficiency was evaluated by receiver operating characteristic curve analysis. Results: A total of 75 neonates were included in our study. There were 9 (12%) neonates with proven clinical sepsis, 47 (62.6%) neonates with suspected clinical sepsis, and 19 (25.3%) neonates with no sepsis. The mean and standard error of mean were calculated for CRP and PCT in all the three groups. The results showed a sensitivity of 88.90% for both CRP and PCT and specificity of 89.40% for CRP and 80.30% for PCT. The common organisms isolated from culture-positive group were Escherichia coli (22.2%), Pseudomonas aeruginosa (22.2%), and Candida albicans (22.2%), followed by Klebsiella pneumoniae, Acinetobacter baumannii, and methicillin-resistant Staphylococcus aureus. Conclusions: PCT may not be sufficiently used as a sole marker of sepsis in neonates compared to CRP. PCT in conjunction with CRP and other tests for septic screen can aid in better diagnosis of neonatal sepsis.	[Charles, Marie Victor Pravin; Kalaivani, Ramakrishnan; Kali, Arunava; Seetha, Kunigal Srinivasiah] Mahatma Gandhi Med Coll & Res Inst, Dept Med Microbiol, Pondicherry, India; [Venkatesh, Soma] Mahatma Gandhi Med Coll & Res Inst, Dept Pediat, Pondicherry, India	Charles, MVP (reprint author), Mahatma Gandhi Med Coll & Res Inst, Cuddalore Main Rd, Pillaiyarkupam 607403, Puducherry, India.	dr_mvpravincharles@yahoo.com			Sri Balaji Vidyapeeth University	The study was financially supported by Sri Balaji Vidyapeeth University.	ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N; Auriti C, 2012, ARCH DIS CHILD-FETAL, V97, pF368, DOI 10.1136/fetalneonatal-2010-194100; Boo NY, 2008, SINGAP MED J, V49, P204; Chiesa C, 1998, CLIN INFECT DIS, V26, P664, DOI 10.1086/514576; DANDONA P, 1994, J CLIN ENDOCR METAB, V79, P1605, DOI 10.1210/jc.79.6.1605; Hatherill M, 1999, ARCH DIS CHILD, V81, P417, DOI 10.1136/adc.81.5.417; Hornik CP, 2012, PEDIATR INFECT DIS J, V31, P799, DOI 10.1097/INF.0b013e318256905c; Lapillonne A, 1998, LANCET, V351, P1211, DOI 10.1016/S0140-6736(05)79165-0; Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6; Lopez Sastre Jose B, 2006, BMC Pediatr, V6, P16; Meena J, 2015, AUSTRALAS MED J, V8, P263, DOI 10.4066/AMJ.2015.2460; Monneret G, 1997, ACTA PAEDIATR, V86, P209, DOI 10.1111/j.1651-2227.1997.tb08870.x; Park In Ho, 2014, Korean J Pediatr, V57, P451, DOI 10.3345/kjp.2014.57.10.451; Sakha K, 2008, Pak J Biol Sci, V11, P1785; *UNICEF, 2009, STAT WORLDS HLTH 200; VIGUSHIN DM, 1993, J CLIN INVEST, V91, P1351, DOI 10.1172/JCI116336; Whicher J, 2001, ANN CLIN BIOCHEM, V38, P483, DOI 10.1258/0004563011901299	17	2	2	0	2	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					81	84		10.4103/IJPM.IJPM_820_16			4	Pathology	Pathology	GA6JJ	WOS:000428438900014	29567889	DOAJ Gold			2019-10-28	
J	Utpat, K; Desai, UD; Amonkar, G; Joshi, JM				Utpat, Ketaki; Desai, Unnati D.; Amonkar, Gayathri; Joshi, Jyotsna M.			A perplexing primary novel hilar lesion: Remember the pneumonic PPNHL!	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Computed tomography; flexible fiberoptic bronchoscopy; primary pulmonary non-Hodgkin's lymphoma	NON-HODGKINS-LYMPHOMA; LUNG-CANCER; ENDOBRONCHIAL ULTRASOUND; BRONCHOSCOPY; DIAGNOSIS	A 60-year-old female presented with dyspnea, cough, and chest pain with a left hilar mass lesion. In our case, clinicoradiological correlation, bronchoscopy, and computed tomography-guided biopsy revealed the diagnosis of primary pulmonary non-Hodgkin's lymphoma (PPNHL) on histopathology and immunohistochemistry. We discuss the approach to hilar masses. PPNHL is a rare malignant lymphoma most common being mucosa-associated lymphoid tissue lymphoma. Various therapeutic options are available. The chemotherapy regimen consisting of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) is preferred.	[Utpat, Ketaki; Desai, Unnati D.; Joshi, Jyotsna M.] TNMC & BYL Nair Hosp, Dept Pulm Med, 2nd Floor,OPD Bldg,Al Nair Rd, Bombay 400008, Maharashtra, India; [Amonkar, Gayathri] TNMC & BYL Nair Hosp, Dept Pathol, Bombay, Maharashtra, India	Joshi, JM (reprint author), TNMC & BYL Nair Hosp, Dept Pulm Med, 2nd Floor,OPD Bldg,Al Nair Rd, Bombay 400008, Maharashtra, India.	drjoshijm@gmail.com					Balamugesh T, 2009, LUNG INDIA, V26, P17, DOI 10.4103/0970-2113.45199; Chhajed PN, 2006, ANN THORAC SURG, V81, P1839, DOI 10.1016/j.athoracsur.2005.11.054; El-Bayoumi E, 2008, SEMIN RESP CRIT CARE, V29, P261, DOI 10.1055/s-2008-1076746; Falcone F, 2003, RESPIRATION, V70, P179, DOI 10.1159/000070066; Juanpere S, 2013, INSIGHTS IMAGING, V4, P29, DOI 10.1007/s13244-012-0201-0; Kanashiki M, 2012, ONCOL LETT, V4, P513, DOI 10.3892/ol.2012.780; Kim JH, 2004, JPN J CLIN ONCOL, V34, P510, DOI 10.1093/jjco/hyh095; Kocaturk CI, 2012, TUBERK TORAK, V60, P246, DOI 10.5578/tt.3482; Olak J, 1996, ONCOLOGIST, V1, P201; Parr L H, 1969, J Natl Med Assoc, V61, P153; Petty TL, 2003, CURR OPIN PULM MED, V9, P309, DOI 10.1097/00063198-200307000-00011; Savage KJ, 2006, ONCOLOGIST, V11, P488, DOI 10.1634/theoncologist.11-5-488; THORNTON TF, 1944, SURG GYNECOL OBSTET, V78, P364; TSUBOI E, 1967, CANCER-AM CANCER SOC, V20, P687, DOI 10.1002/1097-0142(1967)20:5<687::AID-CNCR2820200521>3.0.CO;2-K; Winer-Muram HT, 2006, RADIOLOGY, V239, P34, DOI 10.1148/radiol.2391050343	15	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					85	89		10.4103/IJPM.IJPM_71_17			5	Pathology	Pathology	GA6JJ	WOS:000428438900015	29567890	DOAJ Gold			2019-10-28	
J	Patil, B; Shivkumar, V; Gangane, N				Patil, Bharat; Shivkumar, Vitaladevuni; Gangane, Nitin			Utility of MOC-31 monoclonal antibody in differentiating metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cytology	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Adenocarcinoma cells; effusion cytology; MOC 31; reactive mesothelial cells	BODY CAVITY FLUIDS; IMMUNOCYTOCHEMICAL PANEL; DIAGNOSIS	In effusion cytology, a clear distinction between reactive mesothelial cells and metastatic adenocarcinoma cells is sometimes challenging mainly due to similarities in the cytomorphological features. In such cases for definitive diagnosis, paraffin-embedded cell block examination and immunohistochemistry are helpful in making this distinction. MOC-31 is one of the proposed immunomarker for adenocarcinoma cells. We undertook to evaluate the role of MOC-31 as a marker for identifying adenocarcinoma cells in effusion specimen. A total of 185 paraffin-embedded cell blocks of effusion samples were identified, of these 111 cases were of metastatic adenocarcinoma. MOC-31 was positive in 101 of the 111 cases of metastatic adenocarcinoma. Minimal focal cytoplasmic staining was also seen in 7 of the 74 cases of reactive mesothelial cells, but these were taken negative as they did not show membrane positivity. The sensitivity and specificity of MOC-31 for metastatic adenocarcinoma cells were 92.5%, and 100% respectively, positive and negative predictive value (NPV) was 100% and 91.14%, respectively. MOC-31 can be used as a reliable marker in effusions for distinguishing metastatic adenocarcinoma from reactive mesothelial cases.	[Patil, Bharat; Shivkumar, Vitaladevuni; Gangane, Nitin] Mahatma Gandhi Inst Med Sci, Dept Pathol, Wardha 442102, Maharashtra, India	Shivkumar, V (reprint author), Mahatma Gandhi Inst Med Sci, Dept Pathol, Wardha 442102, Maharashtra, India.	shivkumar@mgims.ac.in					Butnor KJ, 2006, J CLIN PATHOL, V59, P564, DOI 10.1136/jcp.2005.029652; EDWARDS C, 1995, J CLIN PATHOL, V48, P626, DOI 10.1136/jcp.48.7.626; Hecht JL, 2006, CANCER CYTOPATHOL, V108, P56, DOI 10.1002/cncr.21426; Kim JH, 2009, DIAGN CYTOPATHOL, V37, P258, DOI 10.1002/dc.20986; Kundu UR, 2011, CANCER CYTOPATHOL, V119, P272, DOI 10.1002/cncy.20164; Milner A, 1987, CYTOLOGY TECHNICAL M; Morgan RL, 1999, CANCER CYTOPATHOL, V87, P390, DOI 10.1002/(SICI)1097-0142(19991225)87:6<390::AID-CNCR10>3.0.CO;2-4; Nathan NA, 2000, AM J CLIN PATHOL, V114, P599, DOI 10.1309/G035-P2MM-D1TM-T5QE; Ordonez NG, 2007, HUM PATHOL, V38, P1, DOI 10.1016/j.humpath.2006.08.010; Ordonez NG, 2006, MODERN PATHOL, V19, P34, DOI 10.1038/modpathol.3800471; Politi E, 2005, DIAGN CYTOPATHOL, V32, P151, DOI 10.1002/dc.20203; RUITENBEEK T, 1994, ARCH PATHOL LAB MED, V118, P265; Saleh HA, 2009, DIAGN CYTOPATHOL, V37, P324, DOI 10.1002/dc.21006; Su XY, 2011, DIAGN CYTOPATHOL, V39, P900, DOI 10.1002/dc.21489; Ueda J, 2006, DIAGN CYTOPATHOL, V34, P6, DOI 10.1002/dc.20391	15	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					90	93		10.4103/IJPM.IJPM_86_17			4	Pathology	Pathology	GA6JJ	WOS:000428438900016	29567891	DOAJ Gold			2019-10-28	
J	Wang, XK; Su, F; Zhou, FF; Feng, MH				Wang, Xiaokang; Su, Fei; Zhou, Fenfang; Feng, Maohui			Sporadic lymphangioleiomyomatosis with multiple atypical features: A case report and literature review	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Review						Extrapulmonary; HMB-45 negative; lymphangioleiomyomatosis; man	PULMONARY LYMPHANGIOLEIOMYOMATOSIS	Lymphangioleiomyomatosis (LAM) is a rare, genetically determined, progressive interstitial lung disease, which almost exclusively affects women, especially at the childbearing age. The initial symptoms and radiographic changes in a patient with LAM are always associated with the respiratory system. Here, we present a case of mediastinal and abdominal LAM of a 22-year-old male, where LAM cells are negative for human melanoma black-45 (HMB-45). The report of this uncharacterized LAM case will make a significant contribution to the realization of LAM associated clinical features, diagnostic approaches, and its afterward treatments.	[Wang, Xiaokang; Zhou, Fenfang; Feng, Maohui] Wuhan Univ, Zhongnan Hosp, Dept Oncol, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China; [Su, Fei] Lanzhou Univ, Affiliated Hosp 1, Dept Oncol, Lanzhou, Gansu, Peoples R China	Feng, MH (reprint author), Wuhan Univ, Zhongnan Hosp, Dept Oncol, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.	fengmh5690@163.com			Research Foundation of Health and Family Planning Commission of Hubei Province [WJ2015MA010]	This research was supported in part by grants from Research Foundation of Health and Family Planning Commission of Hubei Province (grant number WJ2015MA010).	Aubry MC, 2000, AM J RESP CRIT CARE, V162, P749, DOI 10.1164/ajrccm.162.2.9911006; Carel H, 2010, BMJ-BRIT MED J, V340, P848; Fiore Maria Grazia, 2005, Ann Diagn Pathol, V9, P96, DOI 10.1016/j.anndiagpath.2004.12.007; Jaiswal VR, 2003, ARCH PATHOL LAB MED, V127, P879; Johnson S, 1999, THORAX, V54, P254, DOI 10.1136/thx.54.3.254; KANG H W, 1991, Journal of Korean Medical Science, V6, P83; Kim NR, 2003, PATHOL INT, V53, P231, DOI 10.1046/j.1320-5463.2003.01460.x; McCormack FX, 2008, CHEST, V133, P507, DOI 10.1378/chest.07-0898; Schiavina M, 2007, AM J RESP CRIT CARE, V176, P96, DOI 10.1164/rccm.200610-1408CR; Wakida K, 2015, ANN THORAC SURG, V100, P1105, DOI 10.1016/j.athoracsur.2014.11.069	10	0	0	0	1	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					94	97		10.4103/IJPM.IJPM_843_16			4	Pathology	Pathology	GA6JJ	WOS:000428438900017	29567892	DOAJ Gold			2019-10-28	
J	Fernandes, H; Umashankar, T; Richie, AJ; Hegde, S				Fernandes, Hilda; Umashankar, T.; Richie, Anto J.; Hegde, Sunayana			Coats' disease - disease of the eye rarely encountered by pathologists	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Coats' disease; leukocoria; retinal detachment		Coats' Disease is an idiopathic condition of the eye affecting young children although it can be seen in adults. Most patients present early in life with unilateral decreased vision, strabismus or leukocoria. The most important differential diagnosis is unilateral retinoblastoma. In this study we report a case of coat's disease in an young girl, and evaluate histopathological and clinical findings.	[Fernandes, Hilda; Umashankar, T.] Fr Muller Med Coll, Dept Pathol, Mangalore 575002, Karnataka, India; [Richie, Anto J.] Fr Muller Med Coll, Dept Radiol, Mangalore, Karnataka, India; [Hegde, Sunayana] Fr Muller Med Coll, Dept Ophthalmol, Mangalore, Karnataka, India	Fernandes, H (reprint author), Fr Muller Med Coll, Dept Pathol, Mangalore 575002, Karnataka, India.	hilda67@rediffmail.com					Coats G., 1908, ROYAL LONDON OPHTH H, V17, P440; Fernandes BF, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-24; Ghorbanian S, 2012, OPHTHALMOLOGICA, V227, P175, DOI 10.1159/000336906; Grant M, 2013, COATS DIS RETINAL TE; Haller JA, 2006, COATS DIS RETINAL TE; KREMER I, 1985, BRIT J OPHTHALMOL, V69, P32, DOI 10.1136/bjo.69.1.32; Rishi E, 2016, INDIAN J OPHTHALMOL, V64, P518, DOI 10.4103/0301-4738.190141; Shields CL, 2006, J PEDIAT OPHTH STRAB, V43, P313; Shields JA, 2002, RETINA-J RET VIT DIS, V22, P80, DOI 10.1097/00006982-200202000-00014	9	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					98	100		10.4103/IJPM.IJPM_826_16			3	Pathology	Pathology	GA6JJ	WOS:000428438900018	29567893	DOAJ Gold			2019-10-28	
J	Anand, MS; Krishnamurthy, S; Ravindranath, S; Ranganathan, J				Anand, Murthy S.; Krishnamurthy, Shantha; Ravindranath, Suvarna; Ranganathan, Jyothi			Merkel cell carcinoma with seborrheic keratosis: A unique association	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Merkel; neuroendocrine; polyoma; seborrheic; skin		Merkel cell carcinoma (MCC) is a rare, clinically aggressive neuroendocrine carcinoma of the skin; MCC is 40 times less common as compared to melanoma. The most frequently reported sites have been the head and neck, extremities, and trunk. Potential mimics include malignant melanoma, lymphoma, or metastatic small cell (neuroendocrine) carcinomas. Histopathology of MCC resembles small cell carcinoma both morphologically and on IHC. The possible cell of origin was proposed as the Merkel cell, which functions as a mechanoreceptor. It has a high chance of local recurrence, regional and distant spread. In recent times, Merkel cell polyomavirus has been implicated as the causative agent for this tumor. The same agent has a reported etiologic association with other skin lesions, including seborrheic keratosis.	[Anand, Murthy S.; Krishnamurthy, Shantha; Ravindranath, Suvarna; Ranganathan, Jyothi] SRL Reference Lab, Dept Pathol, Bengaluru, Karnataka, India	Anand, MS (reprint author), 52,34th Cross,11th Main,4th T Block, Bengaluru 560041, Karnataka, India.	anandmurthy81@yahoo.co.in					Allen PJ, 2005, J CLIN ONCOL, V23, P2300, DOI 10.1200/JCO.2005.02.329; Andres C, 2010, J CUTAN PATHOL, V37, P28, DOI 10.1111/j.1600-0560.2009.01352.x; Heath M, 2008, J AM ACAD DERMATOL, V58, P375, DOI 10.1016/j.jaad.2007.11.020; Houben R, 2010, J VIROL, V84, P7064, DOI 10.1128/JVI.02400-09; McFalls J, 2017, J CUTAN PATHOL, V44, P480, DOI 10.1111/cup.12908; Moens U, 2007, CELL MOL LIFE SCI, V64, P1656, DOI 10.1007/s00018-007-7020-3	6	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					101	102		10.4103/IJPM.IJPM_659_16			2	Pathology	Pathology	GA6JJ	WOS:000428438900019	29567894	DOAJ Gold			2019-10-28	
J	Mishra, S; Shelly, D; Gupta, D; Bharadwaj, R				Mishra, Shashank; Shelly, Divya; Gupta, Divya; Bharadwaj, Reena			Invasive cutaneous mucormycosis in a preterm neonate presenting as a vesicobullous lesion	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Mucormycosis; neonate; prematurity	WOODEN TONGUE DEPRESSORS; ZYGOMYCOSIS; INFECTIONS; CHILDREN; INFANTS	Mucormycosis is a relatively rare fungal infection seen in immunocompromised patients. Very few cases of invasive cutaneous mucormycosis occurring in neonates have been reported in literature. It is an aggressive disease with a mortality rate of around 64% in neonates, so a high index of suspicion is essential for rapid diagnosis and definitive treatment with broad-spectrum antifungals such as Amphotericin B. We present a case of a premature infant born at 25 weeks of gestation who developed vesicobullous lesions all over the body on day 5 of life. Biopsy from the vesicles confirmed the presence of angioinvasive fungal hyphae of mucormycosis which were highlighted on Periodic acid-Schiff and Grocott stain.	[Mishra, Shashank; Shelly, Divya; Gupta, Divya; Bharadwaj, Reena] Armed Forces Med Coll, Dept Pathol, Sholapur Rd, Pune 411040, Maharashtra, India	Shelly, D (reprint author), Armed Forces Med Coll, Dept Pathol, Sholapur Rd, Pune 411040, Maharashtra, India.	dshelly13@gmail.com					Darmstadt GL, 2000, PEDIATRICS, V105, P438, DOI 10.1542/peds.105.2.438; DENNIS JE, 1980, J PEDIATR-US, V96, P824, DOI 10.1016/S0022-3476(80)80550-6; Enright AM, 2004, PEDIATR CLIN N AM, V51, P889, DOI 10.1016/j.pcl.2004.03.005; GELLER JD, 1993, J AM ACAD DERMATOL, V29, P462, DOI 10.1016/0190-9622(93)70211-B; Maravi-Poma E, 2004, INTENS CARE MED, V30, P724, DOI 10.1007/s00134-003-2132-1; MARCHEVSKY AM, 1980, HUM PATHOL, V11, P457, DOI 10.1016/S0046-8177(80)80054-2; Mitchell SJ, 1996, LANCET, V348, P441, DOI 10.1016/S0140-6736(96)05059-3; Oh D, 2002, J PEDIATR SURG, V37, P1607, DOI 10.1053/jpsu.2002.36193; Roilides E, 2009, CLIN MICROBIOL INFEC, V15, P50, DOI 10.1111/j.1469-0691.2009.02981.x; RYAN ME, 1982, PEDIATR INFECT DIS J, V1, P110, DOI 10.1097/00006454-198203000-00009	10	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					103	105		10.4103/IJPM.IJPM_796_16			3	Pathology	Pathology	GA6JJ	WOS:000428438900020	29567895	DOAJ Gold			2019-10-28	
J	Wang, FF; Wu, YT; Zheng, ZC; Bai, YP				Wang, Feifei; Wu, Yatong; Zheng, Zhancai; Bai, Yanping			Syringocystadenoma papilliferum and trichoblastoma arising in the nevus sebaceous	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Nevus sebaceous; syringocystadenoma papilliferum; trichoblastoma	SECONDARY NEOPLASMS; JADASSOHN	Nevus sebaceous (NS) is a clinically common benign tumor and has a high potential to develop into a great diversity of neoplasms of epidermal and adnexal origins. However, it is a rare phenomenon of the coexistence in a single NS with two or more skin tumors. We report a case of a 58-year-old woman with two kinds of neoplastic proliferation including syringocystadenoma papilliferum and trichoblastoma arising in NS on the scalp.	[Wang, Feifei] Beijing Univ Chinese Med, Sch Grad, Beijing, Peoples R China; [Wu, Yatong; Zheng, Zhancai; Bai, Yanping] China Japan Friendship Hosp, Dept Dermatol & Venerol, Beijing, Peoples R China	Bai, YP (reprint author), 2 Yinghua East St, Beijing 100029, Peoples R China.	ffreewong@163.com					Aslam A, 2014, CLIN EXP DERMATOL, V39, P1, DOI 10.1111/ced.12209; Dore E, 2015, J CUTAN PATHOL, V42, P645, DOI 10.1111/cup.12489; Gozel S, 2013, KOREAN J PATHOL, V47, P569, DOI 10.4132/KoreanJPathol.2013.47.6.569; Hsu MC, 2016, J DERMATOL, V43, P175, DOI 10.1111/1346-8138.13070; Idriss MH, 2014, J AM ACAD DERMATOL, V70, P332, DOI 10.1016/j.jaad.2013.10.004; Kamyab-Hesari K, 2016, INT J DERMATOL, V55, P193, DOI 10.1111/ijd.12845; Nascimento BAM, 2015, AN BRAS DERMATOL, V90, P900, DOI 10.1590/abd1806-4841.20153862; Pitarch G, 2015, ACTAS DERMO-SIFILOGR, V106, pE45, DOI 10.1016/j.ad.2015.01.017; Premalata CS, 2007, INT J DERMATOL, V46, P306, DOI 10.1111/j.1365-4632.2007.03151.x	9	0	0	0	1	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					106	108		10.4103/IJPM.IJPM_613_16			3	Pathology	Pathology	GA6JJ	WOS:000428438900021	29567896	DOAJ Gold			2019-10-28	
J	Sharifdini, M; Hesari, A; Mahdavi, SA; Alipour, A; Kia, EB				Sharifdini, Meysam; Hesari, Aniseh; Mahdavi, Seif Ali; Alipour, Akram; Kia, Eshrat Beigom			Strongyloides stercoralis hyperinfection in an unconscious diabetic patient with dermatomyositis	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Dermatomyositis; diabetes mellitus; immunosuppression; Strongyloides stercoralis; strongyloidiasis hyperinfection; threadworm	MAZANDARAN PROVINCE; FECAL SAMPLES; NORTHERN IRAN; INFECTION; EOSINOPHILIA; DIAGNOSIS; LEUKEMIA	A case of Strongyloides stercoralis hyperinfection in a patient with dermatomyositis and diabetes mellitus is herein reported. The case was a 60-year-old female admitted due to watery diarrhea and unconsciousness. She had a 10-year history of chronic immunosuppressive therapy including methotrexate and prednisolone for dermatomyositis. Stool parasitological examination revealed numerous rhabditiform larvae of threadworm "S. stercoralis." Larva in stool sample was characterized by sequencing of mitochondrial DNA. After treatment with ivermectin, the patient recovered without evidence of S. stercoralis in follow-up stool samples. In endemic areas, stool examination for detection of S. stercoralis should be performed on a regular basis for all patients receiving immunosuppressive therapy, as early detection and treatment are necessary to minimize complications of severe strongyloidiasis.	[Sharifdini, Meysam] Guilan Univ Med Sci, Sch Med, Dept Med Parasitol & Mycol, Rasht, Iran; [Hesari, Aniseh] Social Secur Org, Emam Reza Hosp, Qom Med Ctr, Emergency Dept, Qom, Iran; [Mahdavi, Seif Ali] Mazandaran Univ Med Sci, Amol Fac Paramed, Dept Med Parasitol & Mycol, Sari, Iran; [Alipour, Akram; Kia, Eshrat Beigom] Univ Tehran Med Sci, Ctr Res Endem Parasites Iran, Tehran, Iran; [Alipour, Akram; Kia, Eshrat Beigom] Univ Tehran Med Sci, Sch Publ Hlth, Dept Med Parasitol & Mycol, POB 14155-6446, Tehran, Iran	Kia, EB (reprint author), Univ Tehran Med Sci, Sch Publ Hlth, Dept Med Parasitol & Mycol, POB 14155-6446, Tehran, Iran.	keiaeshr@tums.ac.ir	Mahdavi, Seif Ali/F-6862-2017	Mahdavi, Seif Ali/0000-0003-1522-7796; sharifdini, meysam/0000-0003-2686-7748	Tehran University of Medical Sciences, Tehran, IranTehran University of Medical Sciences [91-01-160-17294]	The financial support of this study was partly provided by Deputy of Research, Tehran University of Medical Sciences, Tehran, Iran through grant no 91-01-160-17294.	Ashrafi K, 2010, IRAN J PARASITOL, V5, P40; Basile A, 2010, J AM ACAD DERMATOL, V63, P896, DOI 10.1016/j.jaad.2009.09.037; BEREZHNAYA V G, 1991, Meditsinskaya Parazitologiya i Parazitarnye Bolezni, P26; DASILVA OA, 1981, AM J TROP MED HYG, V30, P69, DOI 10.4269/ajtmh.1981.30.69; Fakhar M., 2010, Comparative Clinical Pathology, V19, P621, DOI 10.1007/s00580-010-0995-4; GENTA RM, 1993, CLIN INFECT DIS, V16, pS122, DOI 10.1093/clinids/16.Supplement_2.S122; Gotuzzo E, 1999, AM J TROP MED HYG, V60, P146, DOI 10.4269/ajtmh.1999.60.146; Hamilton KW, 2011, TRANSPLANTATION, V91, P1019, DOI 10.1097/TP.0b013e3182115b7b; Hays R, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw029; Hunter Catherine J, 2008, J Med Case Rep, V2, P156, DOI 10.1186/1752-1947-2-156; KANE MG, 1984, DIGEST DIS SCI, V29, P768, DOI 10.1007/BF01312953; Keiser PB, 2004, CLIN MICROBIOL REV, V17, P208, DOI 10.1128/CMR.17.1.208-217.2004; Kia EB, 2008, IRAN J PARASITOL, V3, P21; Kia EB, 2008, KOREAN J PARASITOL, V46, P261, DOI 10.3347/kjp.2008.46.4.261; Mejia R, 2012, CURR OPIN INFECT DIS, V25, P458, DOI 10.1097/QCO.0b013e3283551dbd; Nesheli HM, 2011, IRAN J PEDIATR, V21, P549; Olsen A, 2009, T ROY SOC TROP MED H, V103, P967, DOI 10.1016/j.trstmh.2009.02.013; Rios JT, 2015, REV ASSOC MED BRAS, V61, P311, DOI 10.1590/1806-9282.61.04.311; Romero-Cabello R, 2012, BMJ CASE REP, V2012, P1; Saraei M, 2014, INFECTION, V42, P1039, DOI 10.1007/s15010-014-0637-x; Sharifdini M, 2017, KOREAN J PARASITOL, V55, P279, DOI 10.3347/kjp.2017.55.3.279; Sharifdini M, 2015, AM J TROP MED HYG, V93, P1285, DOI 10.4269/ajtmh.15-0309; Sharifdini M, 2014, IRAN J PARASITOL, V9, P155; Siddiqui AA, 2001, CLIN INFECT DIS, V33, P1040, DOI 10.1086/322707; Verweij JJ, 2009, T ROY SOC TROP MED H, V103, P342, DOI 10.1016/j.trstmh.2008.12.001	25	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					109	112		10.4103/IJPM.IJPM_734_16			4	Pathology	Pathology	GA6JJ	WOS:000428438900022	29567897	DOAJ Gold			2019-10-28	
J	Jain, J; Banait, S; Tiewsoh, I; Choudhari, M				Jain, Jyoti; Banait, Shashank; Tiewsoh, Iadarilang; Choudhari, Madhura			Kikuchi's disease (histiocytic necrotizing lymphadenitis): A rare presentation with acute kidney injury, peripheral neuropathy, and aseptic meningitis with cutaneous involvement	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Fever of unknown origin; histiocytic necrotizing lymphadenitis; Kikuchi's disease; Kikuchi-Fujimoto disease; lympadenopathy	FUJIMOTO-DISEASE; UNKNOWN ORIGIN; FEVER	Kikuchi's disease (KD) also known as histiocytic necrotizing lymphadenitis is rare, idiopathic, generally self-limited cause of lymphadenitis. We present a case of twenty year young female who presented in critically ill state with fever, cervical and axillary lymphadenopathy, rash, vomiting and altered sensorium and found to have neurological, hepatic, renal and dermatological involvement. Kikuchi's disease should be considered in differential diagnosis of fever and lymphadenopathy and though benign can sometimes present with multi-organ involvement. It is because of rarity of this disease with unusual complications, present case is reported.	[Jain, Jyoti; Tiewsoh, Iadarilang; Choudhari, Madhura] Mahatma Gandhi Inst Med Sci, Dept Med, Wardha 442102, Maharashtra, India; [Banait, Shashank] Jawaharlal Nehru Med Coll, Dept Ophthalmol, Wardha, Maharashtra, India	Jain, J (reprint author), Mahatma Gandhi Inst Med Sci, Dept Med, Wardha 442102, Maharashtra, India.	jyotijain@mgims.ac.in					Avkan-Oguz V, 2010, INTERNAL MED, V49, P1823, DOI 10.2169/internalmedicine.49.3633; Bennie MJ, 2003, BRIT J RADIOL, V76, P656, DOI 10.1259/bjr/67899714; CHAD D, 1982, NEUROLOGY, V32, P725, DOI 10.1212/WNL.32.7.725; Dumas G, 2014, MEDICINE, V93, P372, DOI 10.1097/MD.0000000000000220; Graham LE, 2002, ANN RHEUM DIS, V61, P475, DOI 10.1136/ard.61.5.475; Mauleon C, 2012, J DERMATOL CASE REP, V6, P82, DOI 10.3315/jdcr.2012.1108; Noursadeghi M, 2005, CLIN INFECT DIS, V41, pE80, DOI 10.1086/444563; Parappil A, 2004, CLIN INFECT DIS, V39, P138, DOI 10.1086/421267; Primrose William J, 2009, Ulster Med J, V78, P134; Yoshioka K, 2010, INTERNAL MED, V49, P2267, DOI 10.2169/internalmedicine.49.3919	10	1	1	0	4	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					113	115		10.4103/IJPM.IJPM_256_17			3	Pathology	Pathology	GA6JJ	WOS:000428438900023	29567898	DOAJ Gold			2019-10-28	
J	Misra, P; Ghosh, AK; Jassar, A				Misra, Pratibha; Ghosh, Arijit Kumar; Jassar, Aneeta			Autopsy findings in an atypical case of occult massive fatal pulmonary embolism in a backdrop of hyperhomocysteinemia	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Autopsy; hyperhomocysteinemia; massive pulmonary thromboembolism		A 43-year-old apparently healthy male presented with fever and presyncope. He was suspected to have massive pulmonary thromboembolism based on the clinico-biochemical profile. Despite aggressive thrombolytic therapy, he succumbed to his illness within 12 h of admission. Postmortem examination showed massive pulmonary thromboembolism and hyperhomocysteinemia with low high-density lipoproteins (HDL) cholesterol with antemortem blood sample. Herein, we report autopsy findings in a rare case of a young male with occult massive pulmonary thromboembolism without deep vein thrombosis, who had an atypical clinical presentation and was found to have underlying hyperhomocysteinemia and decreased HDLc. An acute, massive PE can present a diagnostic challenge due to the rate and severity of decompensation seen in afflicted patients. A high index of suspicion is required for early detection of pulmonary embolism in a young patient with atypical presentation and without obvious risk factors.	[Misra, Pratibha; Jassar, Aneeta] Mil Hosp, Dept Pathol & Lab Med, Jalandhar, Punjab, India; [Ghosh, Arijit Kumar] Mil Hosp, Dept Med & Cardiol, Jalandhar, Punjab, India	Jassar, A (reprint author), Mil Hosp, Dept Pathol, Jalandhar 144005, Punjab, India.	draneetajassar@gmail.com					Bok Yoo HH, 2004, J BRAS PNEUMOL, V30, P426; Brilakis ES, 1999, MAYO CLIN PROC, V74, P609, DOI 10.4065/74.6.609; Choi Won-Ho, 2009, Korean Journal of Internal Medicine, V24, P123, DOI 10.3904/kjim.2009.24.2.123; Feied CF, 2002, ROSENS EMERGENCY MED, V2, P1210; Hainaut P, 2002, THROMB RES, V106, P121, DOI 10.1016/S0049-3848(02)00096-8; Karalezli A, 2011, CLIN APPL THROMB-HEM, V17, pE186, DOI 10.1177/1076029610395570; Kariyappa M, 2014, J IND COLL CARDIOL, V4, P239; Laack TA, 2004, EMERG MED CLIN N AM, V22, P961, DOI 10.1016/j.emc.2004.05.011; Lankeit M, 2011, CRIT CARE CLIN, V27, P953, DOI 10.1016/j.ccc.2011.09.008; MORGENTHALER TI, 1995, MAYO CLIN PROC, V70, P417, DOI 10.4065/70.5.417; Susec O, 1997, ACAD EMERG MED, V4, P891; Sweet PH, 2013, JRSM SHORT REP, V4, DOI 10.1177/204253331348982424040503	12	1	1	0	1	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					116	119		10.4103/IJPM.IJPM_165_17			4	Pathology	Pathology	GA6JJ	WOS:000428438900024	29567899	DOAJ Gold			2019-10-28	
J	Jayaram, A; Manipadam, MT; Jacob, PM				Jayaram, Ananthvikas; Manipadam, Marie Therese; Jacob, Paul Mazhuvanchary			Anastomosing hemangioma with extensive fatty stroma in the retroperitoneum	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Anastomosing hemangioma; capillaries; hobnail; sinusoidal	MIMICKING-ANGIOSARCOMA; GENITOURINARY TRACT; KIDNEY	Anastomosing hemangiomas are a recently recognized benign vascular neoplasm, first described by Montgomery and Epstein in 2009. A few cases have been described in the genitourinary tract, especially in the renal hilum. These are fairly well-demarcated lesions with lobules of sinusoidal-like capillaries lined by hobnail endothelial cells containing eosinophilic hyaline globules in the cytoplasm. Extramedullary hematopoiesis has been described in a few cases, along with large feeding vessels. A predominant adipocytic component has been described in only one case.([9]) We describe a case of a retroperitoneal anastomosing hemangioma occurring in an extrarenal site in a 53-year-old female, followed by a review of the current literature.	[Jayaram, Ananthvikas; Manipadam, Marie Therese] Christian Med Coll & Hosp, Dept Pathol, Vellore 632004, Tamil Nadu, India; [Jacob, Paul Mazhuvanchary] Christian Med Coll & Hosp, Dept Endocrine Surg, Vellore, Tamil Nadu, India	Jayaram, A (reprint author), Christian Med Coll & Hosp, Dept Pathol, Vellore 632004, Tamil Nadu, India.	ananthvikas@gmail.com	SOUNDRARAJAN, JOYSON/I-1779-2019				He H, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-261; Heidegger I, 2014, INT J UROL, V21, P836, DOI 10.1111/iju.12433; Kryvenko ON, 2013, ARCH PATHOL LAB MED, V137, P251, DOI 10.5858/arpa.2011-0615-OA; Kryvenko ON, 2011, AM J CLIN PATHOL, V136, P450, DOI 10.1309/AJCPJPW34QCQYTMT; LANE RH, 1989, AM J ROENTGENOL, V152, P83, DOI 10.2214/ajr.152.1.83; Lin JM, 2013, AM J SURG PATHOL, V37, P1761, DOI 10.1097/PAS.0b013e3182967e6c; Montgomery E, 2009, AM J SURG PATHOL, V33, P1364, DOI 10.1097/PAS.0b013e3181ad30a7; POWIS SJA, 1972, BRIT J SURG, V59, P74, DOI 10.1002/bjs.1800590121; Tran TA, 2012, CENT EUR J UROL, V65, P40, DOI 10.5173/ceju.2012.01.art13; Zhao M, 2013, INT J CLIN EXP PATHO, V6, P757	10	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					120	122		10.4103/IJPM.IJPM_259_16			3	Pathology	Pathology	GA6JJ	WOS:000428438900025	29567900	DOAJ Gold			2019-10-28	
J	Khadilkar, UN; Basavaiah, SH; Prabhu, GGL; Tapadia, R; Rakesh, BH				Khadilkar, Urmila N.; Basavaiah, Sridevi H.; Prabhu, G. G. Laxman; Tapadia, Rohit; Rakesh, B. H.			Mixed epithelial and stromal tumor - A solid-cystic renal neoplasm undergoing malignant transformation: A rare case report	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Immunohistochemistry; malignant transformation; mixed epithelial; solid-cystic; stromal tumor	MESOBLASTIC NEPHROMA; KIDNEY	We present a case of 53-year-old female who came with the complaints of mass on the right side of the abdomen noticed 3 weeks back. There was no history of localized swelling or rise of temperature, no history of weight loss, or evening rise of temperature. On examination, there was a flank mass which was bimanually palpable and tender. Routine laboratory investigations were within normal limits, except for the presence of hematuria in routine urinalysis. Computed tomography scan abdomen revealed a large multiloculated solid-cystic mass lesion with septation in the right-sided kidney. Cystic renal cell carcinoma was suspected and conventional open right radical nephrectomy was done. Grossly, the tumor was solid-cystic containing blood-tinged fluid. Microscopy revealed a complex tumor with both epithelial and stromal proliferation and with the aid of immunohistochemistry a diagnosis of mixed epithelial and stromal tumor undergoing malignant transformation was concluded.	[Khadilkar, Urmila N.; Basavaiah, Sridevi H.; Tapadia, Rohit] Manipal Acad Higher Educ, Kasturba Med Coll, Dept Pathol, Manipal, Karnataka, India; [Prabhu, G. G. Laxman; Rakesh, B. H.] Manipal Acad Higher Educ, Kasturba Med Coll, Dept Urol, Manipal, Karnataka, India	Basavaiah, SH (reprint author), Manipal Acad Higher Educ, Kasturba Med Coll, Dept Pathol, Manipal, Karnataka, India.	drsri.20@gmail.com					Adsay NV, 2000, AM J SURG PATHOL, V24, P958, DOI 10.1097/00000478-200007000-00007; Hou Chen-Pang, 2010, Chang Gung Med J, V33, P693; Jung SJ, 2008, HUM PATHOL, V39, P463, DOI 10.1016/j.humpath.2007.08.008; Mohanty SK, 2009, ARCH PATHOL LAB MED, V133, P1483, DOI 10.1043/1543-2165-133.9.1483; Moslemi MK, 2010, UROL J, V7, P141; Pierson CR, 2001, HUM PATHOL, V32, P513, DOI 10.1053/hupa.2001.24323; Ramya G, 2013, INT J RECENT TRENDS, V9, P303; Shannon BA, 2005, ARCH PATHOL LAB MED, V129, P238; Turbiner J, 2007, AM J SURG PATHOL, V31, P489, DOI 10.1097/PAS.0b013e31802bdd56	9	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					123	126		10.4103/IJPM.IJPM_627_16			4	Pathology	Pathology	GA6JJ	WOS:000428438900026	29567901	DOAJ Gold			2019-10-28	
J	Thakur, A; Malhotra, V; Sachan, S; Aggarwal, A				Thakur, Abha; Malhotra, Veena; Sachan, Seema; Aggarwal, Aanchal			Uterine tumor resembling ovarian sex cord tumor: Histomorphological features	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Biological behavior; histological features; immunohistochemical profile; uterine tumors resembling ovarian sex cord tumor	UTROSCT	Uterine tumors resembling ovarian sex cord tumors are rare neoplasms with varied histological and immunophenotypic profile, uncertain histiogenesis and biological behavior. A critical evaluation of histological features is essential for diagnosis and management of these cases.	[Thakur, Abha; Malhotra, Veena; Sachan, Seema] BLK Superspecial Hosp, Dept Histopathol, New Delhi, India; [Aggarwal, Aanchal] BLK Superspecial Hosp, Dept IVF & Reprod Med, New Delhi, India	Malhotra, V (reprint author), BLK Hosp, Dept Histopathol, Pusa Rd, New Delhi, India.	veena.malhotra@blkhospital.com					Bakula-Zalewska E, 2014, ANN DIAGN PATHOL, V18, P329, DOI 10.1016/j.anndiagpath.2014.08.009; Berretta R, 2009, INT J GYNECOL CANCER, V19, P808, DOI 10.1111/IGC.0b013e3181a417b4; Blake EA, 2014, EUR J OBSTET GYN R B, V181, P163, DOI 10.1016/j.ejogrb.2014.07.050; Blinman P, 2009, INTERN MED J, V39, P617, DOI 10.1111/j.1445-5994.2009.01998.x; CLEMENT PB, 1976, AM J CLIN PATHOL, V66, P512; de Leval L, 2010, AM J SURG PATHOL, V34, P1749, DOI 10.1097/PAS.0b013e3181f8120c; Pradhan D, 2013, ARCH PATHOL LAB MED, V137, P1832, DOI 10.5858/arpa.2012-0634-RS; Staats PN, 2009, AM J SURG PATHOL, V33, P1206, DOI 10.1097/PAS.0b013e3181a7b9cf; Umeda S, 2014, INT J CLIN EXP PATHO, V7, P1051; Wang JZ, 2003, DIAGN MOL PATHOL, V12, P174, DOI 10.1097/00019606-200309000-00009	10	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					131	133		10.4103/IJPM.IJPM_702_16			3	Pathology	Pathology	GA6JJ	WOS:000428438900028	29567903	DOAJ Gold			2019-10-28	
J	Vanidassane, I; Kumar, S; Gunasekar, S; Mathur, SR; Phulware, R; Rastogi, S				Vanidassane, Ilavarasi; Kumar, Sunil; Gunasekar, Sudhakar; Mathur, Sandeep R.; Phulware, Ravi; Rastogi, Sameer			Primary rhabdomyosarcoma in ovary - Pathologist clinches it all	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Ovarian tumors; rhabdomyosarcoma; sarcoma		Sarcomas are extremely complex and heterogeneous group of malignancies. However, exact categorization of the type of sarcoma is essential for the individualized approach for a given patient. It is mandatory that sarcomas should be treated in tertiary care centers with good pathology support and expertise. Here, we present an apt example of a young girl with large abdominal mass which was diagnosed as ovarian rhabdomyosarcoma (RMS). Besides, her excellent response to RMS regimen further reinforces the findings.	[Vanidassane, Ilavarasi] All India Inst Med Sci, Dept Med Oncol, New Delhi, India; [Kumar, Sunil; Gunasekar, Sudhakar] All India Inst Med Sci, Dept Surg Oncol, New Delhi, India; [Mathur, Sandeep R.; Phulware, Ravi] All India Inst Med Sci, Dept Pathol, New Delhi, India; [Rastogi, Sameer] All India Inst Med Sci, Dr BRA Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi, India	Rastogi, S (reprint author), All India Inst Med Sci, Dr BRA Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi, India.	samdoc_mamc@yahoo.com		Vanidassane, Ilavarasi/0000-0001-7678-3361			Cribbs RK, 2008, PEDIATR SURG INT, V24, P593, DOI 10.1007/s00383-007-2075-7; Ezem BU, 2011, AFRIMEDIC J, V2, P35; GUERARD MJ, 1983, GYNECOL ONCOL, V15, P325, DOI 10.1016/0090-8258(83)90050-1; Gulia S, 2017, J GLOB ONCOL, V3, P271, DOI 10.1200/JGO.2015.001818; Nielsen GP, 1998, INT J GYNECOL PATHOL, V17, P113, DOI 10.1097/00004347-199804000-00003; Qureshi A, 2011, BMJ CASE REP, V2011; Sangwan N, 2012, J GYNECOL SURG, V28, P428, DOI 10.1089/gyn.2010.0120	7	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					134	136		10.4103/IJPM.IJPM_548_16			3	Pathology	Pathology	GA6JJ	WOS:000428438900029	29567904	DOAJ Gold			2019-10-28	
J	Mohanty, SK; Thakral, D; Gupta, D; Kumar, P; Mitra, DK				Mohanty, Supreet Kumar; Thakral, Deepshi; Gupta, Devika; Kumar, Prabin; Mitra, Dipendra Kumar			Diminished CD40L expression on T-cells in a case of disseminated cryptococcosis	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Disseminated cryptococcosis; hyperimmunoglobulin M syndrome; immunodeficiency	PRIMARY IMMUNODEFICIENCIES; DEFICIENCY	X-linked hyperimmunoglobulin M (HIGM) syndrome may increase the susceptibility of patients to disseminated cryptococcal infections primarily due to CD40L deficiency that causes defective cross talk between T- and B-cells, thus preventing class switching. In HIGM syndrome, serum IgM levels are elevated with severe reduction in serum immunoglobulin G (IgG) and IgA levels. In addition, the expression of CD40L (CD154) on in vitro-activated T-cells is severely reduced or absent. Here, we describe a rare, and perhaps, the first reported case in India of a 3-year-old male child with X-linked HIGM immunodeficiency syndrome who developed disseminated Cryptococcosis. Evaluation of the serum IgG profile of the patient revealed increased serum IgM levels with reduced IgG and IgA levels. Both the frequency and the function of T-cells, primarily CD40L on activated T-cells, showed weak expression suggestive of HIGM syndrome.	[Mohanty, Supreet Kumar; Thakral, Deepshi; Gupta, Devika; Kumar, Prabin; Mitra, Dipendra Kumar] All India Inst Med Sci, Dept Transplant Immunol & Immunogenet, New Delhi, India	Mitra, DK (reprint author), All India Inst Med Sci, Dept Transplant Immunol & Immunogenet, New Delhi, India.	salilmitra2@gmail.com					Bousfiha A, 2015, J CLIN IMMUNOL, V35, P727, DOI 10.1007/s10875-015-0198-5; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; Gupta S, 2012, ANN NY ACAD SCI, V1250, P73, DOI 10.1111/j.1749-6632.2011.06353.x; MAYER L, 1986, NEW ENGL J MED, V314, P409, DOI 10.1056/NEJM198602133140703; Nandan Devki, 2014, J Lab Physicians, V6, P114, DOI 10.4103/0974-2727.141510; Notarangelo LD, 2000, CLIN EXP IMMUNOL, V120, P399, DOI 10.1046/j.1365-2249.2000.01142.x; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; ROSEN FS, 1961, PEDIATRICS, V28, P182; Shah Ira, 2013, J Family Med Prim Care, V2, P206, DOI 10.4103/2249-4863.117429; Yehia Baligh Ramzi, 2009, Cases J, V2, P170, DOI 10.1186/1757-1626-2-170	10	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					137	140		10.4103/IJPM.IJPM_761_16			4	Pathology	Pathology	GA6JJ	WOS:000428438900030	29567905	DOAJ Gold			2019-10-28	
J	Shah, I; Shah, F				Shah, Ira; Shah, Forum			Nontuberculous mycobacterial empyema in an immunocompetent child	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Children; empyema; immunocompetent; nontuberculous mycobacteria	INFECTIONS	Nontuberculous mycobacterium (NTM) species are mycobacterial species other than those belonging to the Mycobacterium Tuberculosis complex and Mycobacterium leprae. There are very few reports of NTM in immunocompetent children causing empyema. In this article, we report a 9-year-old immunocompetent girl who presented with Mycobacterium avium-intracellulare empyema.	[Shah, Ira; Shah, Forum] BJ Wadia Hosp Children, Pediat TB Clin, Dept Pediat, Bombay, Maharashtra, India	Shah, I (reprint author), 1-B Saguna,271-B St Francis Rd, Bombay 400056, Maharashtra, India.	irashah@pediatriconcall.com					Baquero-Artigao F, 2005, An Pediatr (Barc), V62, P458, DOI 10.1157/13074620; Holland SM, 2001, AM J MED SCI, V321, P49, DOI 10.1097/00000441-200101000-00008; Jenkins PA, 2001, THORAX, V56, P167; Katoch VM, 2004, INDIAN J MED RES, V120, P290; Kurashima Atsuyuki, 2007, Kekkaku, V82, P195; Martins Andrea Barral, 2005, Braz J Infect Dis, V9, P173, DOI 10.1590/S1413-86702005000200009; Ogawa Kenji, 2013, Kekkaku, V88, P355; Parrish SC, 2008, POSTGRAD MED, V120, P78, DOI 10.3810/pgm.2008.11.1942; Vu Thien-Tuong-Vi, 2005, J Otolaryngol, V34 Suppl 1, pS40; Wali S, 2009, ANN THORAC MED, V4, P213, DOI 10.4103/1817-1737.56004	10	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					141	142		10.4103/IJPM.IJPM_586_16			2	Pathology	Pathology	GA6JJ	WOS:000428438900031	29567906	DOAJ Gold			2019-10-28	
J	Jain, A; Arava, S				Jain, Akanksha; Arava, Sudheer			Chondroid syringoma with extensive cystic change and focal syringometaplasia: A rare histomorphological finding	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material									[Jain, Akanksha; Arava, Sudheer] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India	Arava, S (reprint author), All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.	aravaaiims@gmail.com					Abbas O, 2016, INT J DERMATOL, V55, P142, DOI 10.1111/ijd.13040; Bhasin TS, 2010, J CLIN DIAGN RES, V4, P2641; Cyralyk H, 2007, ACTA DERMATOVEN ALP, V16, P177; Khan Kalyan, 2013, Indian J Dermatol, V58, P157, DOI 10.4103/0019-5154.108072	4	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					143	144		10.4103/IJPM.IJPM_539_16			2	Pathology	Pathology	GA6JJ	WOS:000428438900032	29567907	DOAJ Gold			2019-10-28	
J	Agnihotri, M; Vaideeswar, P				Agnihotri, Mona; Vaideeswar, Pradeep			Diffuse esophageal submucosal retention cysts: An autopsy happenstance	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material									[Agnihotri, Mona; Vaideeswar, Pradeep] Seth GS Med Coll, Dept Pathol, Cardiovasc & Thorac Div, Bombay 400012, Maharashtra, India	Vaideeswar, P (reprint author), Seth GS Med Coll, Dept Pathol, Cardiovasc & Thorac Div, Bombay 400012, Maharashtra, India.	shreeprajai@yahoo.co.in					EDGIN R, 1981, J CLIN GASTROENTEROL, V3, P57, DOI 10.1097/00004836-198100031-00012; FARMAN J, 1977, AM J ROENTGENOL, V128, P495, DOI 10.2214/ajr.128.3.495; Goodman Philip, 1994, Dysphagia, V9, P199, DOI 10.1007/BF00341265; HOVER AR, 1982, J CLIN GASTROENTEROL, V4, P209, DOI 10.1097/00004836-198206000-00003; Nie L, 2017, DIS ESOPHAGUS, V30, DOI 10.1111/dote.12442; Tano S, 2011, ENDOSCOPY, V43, pE262, DOI 10.1055/s-0030-1256531	6	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					145	146		10.4103/IJPM.IJPM_346_17			2	Pathology	Pathology	GA6JJ	WOS:000428438900033	29567908	DOAJ Gold			2019-10-28	
J	Gupta, A; Goyal, M; Aribandi, A				Gupta, Anurag; Goyal, Manu; Aribandi, Anil			Hypernucleate plasma cell: A rare morphological finding	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material							MULTIPLE-MYELOMA		[Gupta, Anurag; Goyal, Manu] AmPath, Dept Hematopathol & Genet, Hyderabad 500019, Telangana, India; [Aribandi, Anil] Amer Oncol Inst, Dept Clin Haematol, Hyderabad, Telangana, India	Gupta, A (reprint author), AmPath, Dept Hematopathol & Genet, Hyderabad 500019, Telangana, India.	dranuraggupta30@gmail.com	Goyal, Manu/N-5073-2019				Erkut N, 2011, TURK J HEMATOL, V28, P158, DOI 10.5152/tjh.2011.38; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Ribourtout B., 2015, Morphologie, V99, P38, DOI 10.1016/j.morpho.2015.02.001; Shumate M, 2009, BLOOD, V114, P4904	4	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					147	148		10.4103/IJPM.IJPM_374_17			2	Pathology	Pathology	GA6JJ	WOS:000428438900034	29567909	DOAJ Gold			2019-10-28	
J	Mallik, N; Nampoothiri, RV; Sreedharanunni, S; Sachdeva, MUS; Malhotra, P; Varma, N				Mallik, Nabhajit; Nampoothiri, Ram Vasudevan; Sreedharanunni, Sreejesh; Sachdeva, Man Updesh Singh; Malhotra, Pankaj; Varma, Neelam			Multiple myeloma or lymphoma? The increasing role of flow cytometry and serum-free light chain assay	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material									[Mallik, Nabhajit; Nampoothiri, Ram Vasudevan; Sreedharanunni, Sreejesh; Sachdeva, Man Updesh Singh; Malhotra, Pankaj; Varma, Neelam] Postgrad Inst Med Educ & Res, Dept Hematol & Internal Med Clin Hematol, Chandigarh, India	Sreedharanunni, S (reprint author), Postgrad Inst Med Educ & Res, Dept Hematol, 5th Floor,Res Block A, Chandigarh 160012, India.	sreejesh.s@pgimer.edu.in					Dupuis MM, 2016, ONCOTARGETS THER, V9, P7583, DOI 10.2147/OTT.S122241; Fonseca R, 2002, BLOOD, V99, P3735, DOI 10.1182/blood.V99.10.3735; Heerema-McKenney A, 2010, AM J CLIN PATHOL, V133, P265, DOI 10.1309/AJCPUS3PRRT5ZXVS; Larson D, 2012, NEW ENGL J MED, V367, P580, DOI 10.1056/NEJMc1206740; Sidana S, 2014, BLOOD, V124, P5708; SMITH DB, 1986, HEMATOL ONCOL, V4, P307, DOI 10.1002/hon.2900040407	6	0	0	1	1	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					149	150		10.4103/IJPM.IJPM_381_17			2	Pathology	Pathology	GA6JJ	WOS:000428438900035	29567910	DOAJ Gold			2019-10-28	
J	Malhotra, P; Bhardwaj, M				Malhotra, Purnima; Bhardwaj, Minakshi			Intestinal spirochetosis: The hue is the cue	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material									[Malhotra, Purnima; Bhardwaj, Minakshi] Dr Ram Manohar Lohia Hosp, Dept Pathol, PGIMER, New Delhi, India	Malhotra, P (reprint author), Dr Ram Manohar Lohia Hosp, Dept Pathol, PGIMER, New Delhi, India.	purnimapaliwal@gmail.com					Esteve M, 2006, J GASTROEN HEPATOL, V21, P1326, DOI 10.1111/j.1440-1746.2006.04150.x; HARLAND WA, 1967, BRIT MED J, V3, P718, DOI 10.1136/bmj.3.5567.718; HOVINDHOUGEN K, 1982, J CLIN MICROBIOL, V16, P1127; Lin RK, 2006, J CLIN PATHOL, V59, P1100, DOI 10.1136/jcp.2005.034900; Teglbjaerg P S, 1990, Curr Top Pathol, V81, P247; Weisheit B, 2007, SCAND J GASTROENTERO, V42, P1422, DOI 10.1080/00365520701245629	6	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					151	152		10.4103/IJPM.IJPM_740_16			2	Pathology	Pathology	GA6JJ	WOS:000428438900036	29567911	DOAJ Gold			2019-10-28	
J	Mulay, HD; Reddy, AK; Yelikar, BR				Mulay, Himanshu Dilip; Reddy, Anil K.; Yelikar, Balasaheb R.			Mobile whole slide imaging with Indian twist	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							PATHOLOGY		[Mulay, Himanshu Dilip; Reddy, Anil K.; Yelikar, Balasaheb R.] BLDE Univ, Shri BM Patil Med Coll, Dept Pathol, Solapur Rd, Vijayapura 586103, Karnataka, India	Mulay, HD (reprint author), BLDE Univ, Shri BM Patil Med Coll, Dept Pathol, Solapur Rd, Vijayapura 586103, Karnataka, India.	himanshumulay@gmail.com					Auguste L, 2015, BMJ INNOV, P1; Rojo MG, 2006, INT J SURG PATHOL, V14, P285, DOI 10.1177/1066896906292274; Pantanowitz L, 2013, ARCH PATHOL LAB MED, V137, P1710, DOI 10.5858/arpa.2013-0093-CP	3	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					153	154		10.4103/IJPM.IJPM_603_16			2	Pathology	Pathology	GA6JJ	WOS:000428438900037	29567912	DOAJ Gold			2019-10-28	
J	Liu, HP; Zhang, D				Liu, Hai-Peng; Zhang, Duo			An unusual presentation of multiple congenital melanocytic nevi with a whole-body distribution	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter									[Liu, Hai-Peng; Zhang, Duo] Jilin Univ, Bethune Hosp 1, Dept Plast & Reconstruct Surg, 71 Xin Min St, Changchun 130021, Jilin, Peoples R China	Zhang, D (reprint author), Jilin Univ, Bethune Hosp 1, Dept Plast & Reconstruct Surg, 71 Xin Min St, Changchun 130021, Jilin, Peoples R China.	zhangduo2002@hotmail.com					KOPF AW, 1979, J AM ACAD DERMATOL, V1, P123, DOI 10.1016/S0190-9622(79)70009-0; Lin YT, 1997, DERMATOLOGY, V194, P362, DOI 10.1159/000246140; Lyon VB, 2010, PEDIATR CLIN N AM, V57, P1155, DOI 10.1016/j.pcl.2010.07.005; Marghoob AA, 2004, ARCH DERMATOL, V140, P171, DOI 10.1001/archderm.140.2.171; Ruiz-Maldonado R, 2004, PEDIATR DERMATOL, V21, P178, DOI 10.1111/j.0736-8046.2004.21222.x	5	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					155	+		10.4103/IJPM.IJPM_477_16			2	Pathology	Pathology	GA6JJ	WOS:000428438900038	29567913	DOAJ Gold			2019-10-28	
J	Mukherjee, U; Patil, N; Khurana, A				Mukherjee, Urmi; Patil, Nayana; Khurana, Anuj			Suprasellar schwannoma: A rare occurence	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter									[Mukherjee, Urmi; Patil, Nayana; Khurana, Anuj] Max Super Special Hosp, Dept Lab Med, New Delhi, India; [Patil, Nayana] Max Super Special Hosp, Dept Pathol, New Delhi 110017, India	Patil, N (reprint author), Max Super Special Hosp, Dept Pathol, New Delhi 110017, India.	dr.nayana04@gmail.com					Honegger J, 2005, BRIT J NEUROSURG, V19, P432, DOI 10.1080/02688690500390391; Mohammed S, 2010, ACTA NEUROCHIR, V152, P885, DOI 10.1007/s00701-009-0527-7; Park HW, 2009, J KOREAN NEUROSURG S, V45, P375, DOI 10.3340/jkns.2009.45.6.375	3	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					156	157		10.4103/IJPM.IJPM_819_16			2	Pathology	Pathology	GA6JJ	WOS:000428438900039	29567914	DOAJ Gold			2019-10-28	
J	Sharma, S; Kaur, R; Bal, A; Mohindra, S; Aggarwal, R				Sharma, Sudha; Kaur, Rajwant; Bal, Amanjit; Mohindra, Sandeep; Aggarwal, Ritu			Primary orbital plasmacytoma: An unusual presentation in an adolescent	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							EXTRAMEDULLARY PLASMACYTOMA; SOLITARY PLASMACYTOMA; BONE		[Sharma, Sudha; Kaur, Rajwant; Aggarwal, Ritu] Postgrad Inst Med Educ & Res, Dept Immunopathol, Res Block A,4th Floor, Chandigarh 160012, India; [Bal, Amanjit] Postgrad Inst Med Educ & Res, Dept Histopathol, Chandigarh, India; [Mohindra, Sandeep] Postgrad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, India	Aggarwal, R (reprint author), Postgrad Inst Med Educ & Res, Dept Immunopathol, Res Block A,4th Floor, Chandigarh 160012, India.	ritu_immunopath@yahoo.co.in					Brannan PA, 2009, ORBIT, V28, P71, DOI 10.1080/01676830802594540; Chattapadhyay S, 2013, CLIN CANCER INVESTIG, V2, P163, DOI 10.4103/2278-0513.113643; Misra A, 2017, INDIAN J PATHOL MICR, V60, P303, DOI 10.4103/IJPM.IJPM_375_16; Pasch W, 2012, INT J CLIN EXP PATHO, V5, P463; Soutar R, 2004, BRIT J HAEMATOL, V124, P717, DOI 10.1111/j.1365-2141.2004.04834.x	5	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					158	+		10.4103/IJPM.IJPM_378_17			2	Pathology	Pathology	GA6JJ	WOS:000428438900040	29567915	DOAJ Gold			2019-10-28	
J	Pandey, V; Khatib, Y; Khade, AL; Pandey, R; Khare, MS				Pandey, Vinita; Khatib, Yasmeen; Khade, Archana Laxman; Pandey, Rahul; Khare, Manisha S.			Clear cell myeloma artefactual or real	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter									[Pandey, Vinita; Khatib, Yasmeen; Khade, Archana Laxman; Khare, Manisha S.] HBT Med Coll, Dept Pathol, C Wing,1st Floor,Hosp Bldg, Bombay 400056, Maharashtra, India; [Pandey, Vinita; Khatib, Yasmeen] Dr RN Cooper Hosp, Bombay, Maharashtra, India; [Khade, Archana Laxman; Khare, Manisha S.] Dr RN Cooper Municipal Gen Hosp, Bombay 400056, Maharashtra, India; [Pandey, Rahul] Tata Mem Hosp, Dept Pathol, Bombay, Maharashtra, India	Khade, AL (reprint author), HBT Med Coll, Dept Pathol, C Wing,1st Floor,Hosp Bldg, Bombay 400056, Maharashtra, India.; Khade, AL (reprint author), Dr RN Cooper Municipal Gen Hosp, Bombay 400056, Maharashtra, India.	arck115@gmail.com					Banerjee SS, 2004, HISTOPATHOLOGY, V44, P2, DOI 10.1111/j.1365-2559.2004.01763.x; CHEN KTK, 1985, AM J SURG PATHOL, V9, P149, DOI 10.1097/00000478-198502000-00011; Koduri PR, 2014, INDIAN J HEMATOL BLO, V30, pS86, DOI 10.1007/s12288-013-0259-y; Kotru M, 2009, INDIAN J HEMATOL BLO, V25, P84, DOI 10.1007/s12288-009-0020-8; Svec A, 2010, J HEMATOP, V3, P155	5	2	2	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					159	+		10.4103/IJPM.IJPM_326_17			3	Pathology	Pathology	GA6JJ	WOS:000428438900041	29567916	DOAJ Gold			2019-10-28	
J	Chowdhry, M; Makroo, RN; Thakur, Y; Agrawal, S; Mishra, M; Rani, D				Chowdhry, Mohit; Makroo, Raj Nath; Thakur, Yogita; Agrawal, Soma; Mishra, Manoj; Rani, Deepika			Hyperheptaploidy in idiopathic thrombocytopenic purpura	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter									[Chowdhry, Mohit; Makroo, Raj Nath; Thakur, Yogita; Agrawal, Soma; Mishra, Manoj; Rani, Deepika] Indraprastha Apollo Hosp, Dept Transplant Immunol Mol Biol & Transfus Med, New Delhi, India	Chowdhry, M (reprint author), Apollo Hosp, Dept Transplant Immunol Mol Biol & Transfus Med, Delhi Mathura Rd, New Delhi 110076, India.	mohit_c@apollohospitalsdelhi.com	Agrawal, Soma/W-9176-2019				Hwang Y, 2010, KOREAN J LAB MED, V30, P105, DOI 10.3343/kjlm.2010.30.2.105; KWONG YL, 1993, CANCER GENET CYTOGEN, V65, P74, DOI 10.1016/0165-4608(93)90063-R; Makroo R N, 2011, Indian J Hum Genet, V17, P238, DOI 10.4103/0971-6866.92091; Shaffer IG, 2009, ISCN INT SYSTEM HUMA; Vaidya Shantashri, 2012, Indian J Hum Genet, V18, P379, DOI 10.4103/0971-6866.108055	5	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					161	+		10.4103/IJPM.IJPM_225_17			2	Pathology	Pathology	GA6JJ	WOS:000428438900042	29567917	DOAJ Gold			2019-10-28	
J	Chougule, A; Garg, R; Dey, P				Chougule, Abhijit; Garg, Rashi; Dey, Pranab			Undiagnosed tubal high-grade serous carcinoma metastatic to synchronous benign ovarian Brenner tumor	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter									[Chougule, Abhijit; Garg, Rashi; Dey, Pranab] Postgrad Inst Med Educ & Res, Dept Cytol & Gynaecol Pathol, Chandigarh 160012, India	Garg, R (reprint author), Postgrad Inst Med Educ & Res, Dept Cytol & Gynaecol Pathol, Chandigarh 160012, India.	rashiigarg@gmail.com					Alvarado-Cabrero I, 2013, ANN DIAGN PATHOL, V17, P159, DOI 10.1016/j.anndiagpath.2012.10.001; Gomes FV, 2015, INSIGHTS IMAGING, V6, P431, DOI 10.1007/s13244-015-0416-y; Seidman JD, 2008, ARCH PATHOL LAB MED, V132, P1753, DOI 10.1043/1543-2165-132.11.1753; Singh N, 2016, GYNECOL ONCOL, V141, P195, DOI 10.1016/j.ygyno.2015.10.022; Vang R, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P529, DOI 10.1007/978-1-4419-0489-8_11	5	0	0	0	4	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					162	+		10.4103/IJPM.IJPM_600_16			3	Pathology	Pathology	GA6JJ	WOS:000428438900043	29567918	DOAJ Gold			2019-10-28	
J	Mishra, T; Karegar, MM; Rojekar, AV; Joshi, AS				Mishra, Toshi; Karegar, Manjusha M.; Rojekar, Amey V.; Joshi, Amita S.			Multilocular peritoneal inclusion cyst, rare occurrence in men: A case report	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							MESOTHELIOMA		[Mishra, Toshi; Karegar, Manjusha M.; Rojekar, Amey V.; Joshi, Amita S.] Seth GS Med Coll, Dept Pathol, Bombay, Maharashtra, India	Mishra, T (reprint author), Seth GS Med Coll, Dept Pathol, Bombay, Maharashtra, India.	toshi.mishra@gmail.com					MENNEMEYER R, 1979, CANCER, V44, P692, DOI 10.1002/1097-0142(197908)44:2<692::AID-CNCR2820440242>3.0.CO;2-6; ROMERO JA, 1994, GYNECOL ONCOL, V54, P377, DOI 10.1006/gyno.1994.1227; ROSS MJ, 1989, CANCER-AM CANCER SOC, V64, P1336, DOI 10.1002/1097-0142(19890915)64:6<1336::AID-CNCR2820640628>3.0.CO;2-X; Safioleas MC, 2006, WORLD J GASTROENTERO, V12, P5739, DOI 10.3748/wjg.v12.i35.5739; Stojsic Z, 2012, J PEDIATR SURG, V47, pE45, DOI 10.1016/j.jpedsurg.2012.06.029; WEISS SW, 1988, AM J SURG PATHOL, V12, P737, DOI 10.1097/00000478-198810000-00001	6	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					164	166		10.4103/IJPM.IJPM_480_16			3	Pathology	Pathology	GA6JJ	WOS:000428438900044	29567919	DOAJ Gold			2019-10-28	
J	Prior, J; Couturier, OF				Prior, J. O.; Couturier, O. -F.			Editorial	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			English	Editorial Material									[Prior, J. O.] Lausanne Univ Hosp, Nucl Med & Mol Imaging Dept, Lausanne, Switzerland; [Couturier, O. -F.] French Polynesia Hosp Ctr Taaone, Isotop Med Unit, Tahiti, French Polynesi, France	Prior, J (reprint author), Lausanne Univ Hosp, Nucl Med & Mol Imaging Dept, Lausanne, Switzerland.	john.prior@chuv.ch					Bera G, 2018, MED NUCL; Blaire T, 2018, MED NUCL; Galinier I, 2018, MED NUCL; Lacoeuille F, 2018, MED NUCL; Lussey-Lepoutre C, 2018, MED NUCL	5	0	0	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JAN-FEB	2018	42	1					1	2		10.1016/j.mednuc.2018.01.001			2	Pathology	Pathology	GA5FI	WOS:000428357800001					2019-10-28	
J	Blaire, T; Bailliez, A; Ben Bouallegue, F; Bellevre, D; Agostini, D; Manrique, A				Blaire, T.; Bailliez, A.; Ben Bouallegue, F.; Bellevre, D.; Agostini, D.; Manrique, A.			Simultaneous dual-isotope I-123/Tc-99m acquisition using CZT-based cameras: Toward a one-stop-shop SPECT in heart failure patients	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			English	Review						CZT; HMR; MIBG; Dual-isotope; LVEF	CARDIAC SYMPATHETIC INNERVATION; PROGNOSTIC VALUE; GAMMA-CAMERA; DILATED CARDIOMYOPATHY; CLINICAL VALIDATION; COLLIMATOR CHOICE; PHANTOM; MIBG; PERFORMANCE; ASSOCIATION	The CZT-cameras (DNM 530c and DSPECT) have only recently been introduced, and the impact of the increased energy resolution remains unknown. This paper summarizes the evidence on the assessment of: (i) the left ventricular function, (ii) the I-123/Tc-99m mismatch, and (iii) the heart-to-mediastinum ratio (HMR) of I-123-metaiodobenzylguanidine (MIBG) uptake under dual-isotope conditions (Tc-99m and I-123) using cadmium-zinc-telluride (CZT) technology. The diagnostic accuracy of CZT cameras for myocardial sympathetic innervation imaging, left ventricular function and perfusion assessment using perfusion-gated SPECT have only been established in a few studies, under single-isotope conditions. Limited evidence is available regarding simultaneous dual-isotope acquisition using CZT-cameras. However, recently reported data have shown that CZT cameras allow, in dual-isotope (I-123 and Tc-99m) acquisitions and under routine conditions: (i) a simultaneous and accurate segmental study of myocardial innervation and perfusion (match and mismatch), (ii) the ventricular function assessment (EDV, ESV and LVEF), and (iii) the determination of the late HMR of cardiac I-123-MIBG uptake in patients with heart failure. However, this latter should be performed using transaxial reconstructed images and a linear correction based on phantom data acquisitions. Conclusion. With an increased energy resolution, the CZT cameras should become the one-stop shop SPECT for simultaneous dual-isotope I-123/Tc-99m acquisitions in heart failure patients, permitting to perform LV function, myocardial perfusion and innervation. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Blaire, T.; Bailliez, A.] Inst Catholique Lille, Grp Hop, UF 5881, Dept Nucl Med, Lomme Les Lille, France; [Blaire, T.; Bailliez, A.; Agostini, D.; Manrique, A.] Normandie Univ, UNICAEN, Signalisat Electrophysiol & Imagerie Les Ischemie, F-14000 Caen, France; [Blaire, T.; Bailliez, A.] Hop Prive Le Bois, IRIS, Dept Nucl Med, Lille, France; [Ben Bouallegue, F.] CHU Montpellier, Dept Nucl Med, Montpellier, France; [Bellevre, D.; Agostini, D.; Manrique, A.] CHU Cote Nacre, Dept Nucl Med, Caen, France	Blaire, T (reprint author), Inst Catholique Lille, Grp Hop, UF 5881, Dept Nucl Med, Lomme Les Lille, France.	Blaire.Tanguy@ghicl.net		Blaire, Tanguy/0000-0002-8834-7281			Agostini D, 2016, EUR J NUCL MED MOL I, V43, P2423, DOI 10.1007/s00259-016-3467-5; Bailliez A, 2016, J NUCL MED, V57, P1370, DOI 10.2967/jnumed.115.168575; Bailliez A, 2014, J NUCL CARDIOL, V21, P712, DOI 10.1007/s12350-014-9899-z; Bellevre D, 2015, EUR J NUCL MED MOL I, V42, P1912, DOI 10.1007/s00259-015-3141-3; Blaire T, 2017, J NUCL CARDIOL; Blaire T, 2017, J NUCL MED; Blaire T, 2016, EJNMMI PHYS, V3, DOI 10.1186/s40658-016-0163-2; Bocher M, 2010, EUR J NUCL MED MOL I, V37, P1887, DOI 10.1007/s00259-010-1488-z; Cochet H, 2013, J NUCL MED, V54, P556, DOI 10.2967/jnumed.112.110577; D'estanque E, 2017, J NUCL CARDIOL, V24, P1361, DOI 10.1007/s12350-016-0524-1; Erlandsson K, 2009, PHYS MED BIOL, V54, P2635, DOI 10.1088/0031-9155/54/9/003; Flotats A, 2010, EUR J NUCL MED MOL I, V37, P1802, DOI 10.1007/s00259-010-1491-4; Gimelli A, 2014, EUR HEART J-CARD IMG, V15, P575, DOI 10.1093/ehjci/jet258; Gimelli A, 2014, EUR J NUCL MED MOL I, V41, P946, DOI 10.1007/s00259-013-2640-3; Imbert L, 2012, J NUCL MED, V53, P1897, DOI 10.2967/jnumed.112.107417; Inoue Y, 2003, J NUCL CARDIOL, V10, P623, DOI 10.1016/S1071-3581(03)00652-4; Jacobson AF, 2010, J AM COLL CARDIOL, V55, P2212, DOI 10.1016/j.jacc.2010.01.014; Kacperski K, 2011, PHYS MED BIOL, V56, P1397, DOI 10.1088/0031-9155/56/5/012; Leo WR, 1994, TECHNIQUES NUCL PART; Manrique A, 2008, EUR J NUCL MED MOL I, V35, P2074, DOI 10.1007/s00259-008-0889-8; MERLET P, 1992, J NUCL MED, V33, P471; Merlet P, 1999, J NUCL MED, V40, P917; Nakata T, 1998, J NUCL CARDIOL, V5, P579, DOI 10.1016/S1071-3581(98)90112-X; Takahashi Y, 2013, ANN NUCL MED, V27, P11, DOI 10.1007/s12149-012-0653-9; Tinti E, 2014, EUR J NUCL MED MOL I, V41, P167, DOI 10.1007/s00259-013-2549-x; Veltman CE, 2012, EUR J NUCL MED MOL I, V39, P1599, DOI 10.1007/s00259-012-2180-2; Verberne HJ, 2005, EUR J NUCL MED MOL I, V32, P1100, DOI 10.1007/s00259-005-1810-3; Wakabayashi T, 2001, J NUCL MED, V42, P1757	28	0	0	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JAN-FEB	2018	42	1					3	8		10.1016/j.mednuc.2017.11.002			6	Pathology	Pathology	GA5FI	WOS:000428357800002					2019-10-28	
J	Galinier, I; Cazeau, AL				Galinier, I.; Cazeau, A. -L.			FDG PET indications in oncology: Update according to the European and American clinical practice guidelines	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Review						Guidelines; FDG PET; ESMO; NCCN; GBU	POSITRON-EMISSION-TOMOGRAPHY; PRIMARY BREAST-CANCER; CELL LUNG-CANCER; HODGKIN-LYMPHOMA; FAILURE	[18F]-Fluoro-2-Deoxy-D-Glucose-Positon Emission Tomography (PET) is a powerful tool which availability increases in France. The oncological PET indications are plentiful and are increasing. Yet, its cost is significant. Thus, it is important to use PET in validated indications and/or in situations in which it can improve the patient management. The first part of this work reviews the PET indications in oncology, according to the international clinical practice guidelines (European Society for Medical Oncology [ESMO] and National Comprehensive Cancer Network [NCCN]), and compares those with the French guidelines (Guide de bon usage [GBU] des examens d'imagerie medicate). The second part assesses the indication distribution of 400 consecutive PET-CT studies in an against cancer center, according to the cancer type and confronts those with the guidelines. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Galinier, I.] Hop Carcassonne, Serv Med Nucl, 1060 Chemin Madeleine, F-11000 Carcassonne, France; [Cazeau, A. -L.] Inst Bergonie, Serv Med Nucl, 229 Cours Argonne, F-33000 Bordeaux, France	Galinier, I (reprint author), Hop Carcassonne, Serv Med Nucl, 1060 Chemin Madeleine, F-11000 Carcassonne, France.	isabelle.galinier@ch-carcassonne.fr					Barrington SF, 2013, J CLIN ONCOL, V53, P5229, DOI DOI 10.1200/JC0.2013.53.5229; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Cheson BD, 2011, J CLIN ONCOL, V29, P1844, DOI 10.1200/JCO.2010.32.5225; Farma JM, 2008, ANN SURG ONCOL, V15, P2465, DOI 10.1245/s10434-008-9992-0; Fuster D, 2008, J CLIN ONCOL, V26, P4746, DOI 10.1200/JCO.2008.17.1496; Hutchings M, 2005, ANN ONCOL, V16, P1160, DOI 10.1093/annonc/mdi200; MacManus M, 2009, RADIOTHER ONCOL, V91, P85, DOI 10.1016/j.radonc.2008.11.008; Pavlidis N, 2012, ANN ONCOL, V23, P7, DOI 10.1093/annonc/mds222; Pieterman RM, 2000, NEW ENGL J MED, V343, P254, DOI 10.1056/NEJM200007273430404; Prior JO, 2009, J CLIN ONCOL, V27, P439, DOI 10.1200/JCO.2008.17.2742; Riegger C, 2012, EUR J NUCL MED MOL I, V39, P852, DOI 10.1007/s00259-012-2077-0; Siva S, 2013, J NUCL MED, V54, P1223, DOI 10.2967/jnumed.112.116814; Takeda A, 2013, LUNG CANCER, V79, P248, DOI 10.1016/j.lungcan.2012.11.008; Zhu AX, 2010, LANCET ONCOL, V11, P48, DOI 10.1016/S1470-2045(09)70333-X	14	0	0	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JAN-FEB	2018	42	1					9	31		10.1016/j.mednuc.2017.11.004			23	Pathology	Pathology	GA5FI	WOS:000428357800003					2019-10-28	
J	Lacoeuille, F; Arlicot, N; Faivre-Chauvet, A				Lacoeuille, F.; Arlicot, N.; Faivre-Chauvet, A.			Targeted alpha and beta radiotherapy: An overview of radiopharmaceutical and clinical aspects	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			English	Review						Targeted radiotherapy; Radiopharmaceutical; Clinical	RECEPTOR RADIONUCLIDE THERAPY; IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY; RADIOLABELED SOMATOSTATIN ANALOGS; RESISTANT PROSTATE-CANCER; STEM-CELL TRANSPLANTATION; REFRACTORY LOW-GRADE; PHASE-I TRIAL; MONOCLONAL-ANTIBODIES; NEUROENDOCRINE TUMORS; MEMBRANE ANTIGEN	For many years, the role of internal radiotherapy has remained limited to certain historical indications such as thyroid cancers or to academic medical research. However, the recent recognition of theranostics and targeted therapies as one of the cornerstones of the modern concept of personalized medicine, has participated in the promotion of new developments for beta and alpha radiotherapy. In this paper, we will review the emerging radionuclides, radiopharmaceutical developments and advances, as well as the clinical successes that have been made in past few years. The results obtained, for some very promising, could herald in a new era for nuclear medicine. However, as presented in this review, in order to fully exploit its potential, and not to remain static as a promising or emerging therapy, the entire field of nuclear medicine must invest in the implementation of well-designed prospective and comparative studies for targeted radiotherapy. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Lacoeuille, F.] Univ Angers, Univ Nantes, CRCINA, CHU Angers, F-49000 Angers, France; [Arlicot, N.] Univ Tours, CHRU Tours, INSERM, UMR,U930, F-37000 Tours, France; [Faivre-Chauvet, A.] Univ Nantes, CHU Nantes, CRCINA, F-44000 Nantes, France	Lacoeuille, F (reprint author), Univ Angers, Univ Nantes, CRCINA, CHU Angers, F-49000 Angers, France.	FrLacoeuille@chu-angers.fr	LACOEUILLE, Franck/K-4430-2015; Arlicot, Nicolas/E-4929-2013	LACOEUILLE, Franck/0000-0002-7070-7664; Arlicot, Nicolas/0000-0001-7087-2312	French National Agency for Research ("Investissements d'Avenir"), Labex IRONFrench National Research Agency (ANR) [ANR-11-LABX-0018-01]	This work was supported by the French National Agency for Research ("Investissements d'Avenir" No. ANR-11-LABX-0018-01), Labex IRON.	Abou DS, 2017, APPL RADIAT ISOTOPES, V119, P36, DOI 10.1016/j.apradiso.2016.10.015; Afshar-Oromieh A, 2016, J NUCL MED, V57, p79S, DOI 10.2967/jnumed.115.170720; Ahmadzadehfar H, 2016, ONCOTARGET, V7, P12477, DOI 10.18632/oncotarget.7245; Apostolidis C, 2005, APPL RADIAT ISOTOPES, V62, P383, DOI 10.1016/j.apradiso.2004.06.013; ATCHER RW, 1988, APPL RADIAT ISOTOPES, V39, P283, DOI 10.1016/0883-2889(88)90016-0; Ballot S, 2006, EUR J NUCL MED MOL I, V33, P602, DOI 10.1007/s00259-005-0007-0; Bander NH, 2005, J CLIN ONCOL, V23, P4591, DOI 10.1200/JCO.2005.05.160; Banerjee S, 2015, CHEM REV, V115, P2934, DOI 10.1021/cr500171e; Benesova M, 2015, J NUCL MED, V56, P914, DOI 10.2967/jnumed.114.147413; Bleeker G, 2013, EUR J NUCL MED MOL I, V40, P1711, DOI 10.1007/s00259-013-2510-z; Bodei L, 2004, CANCER BIOTHER RADIO, V19, P65, DOI 10.1089/108497804773391694; Bodet-Milin C, 2016, SEMIN NUCL MED, V46, P135, DOI 10.1053/j.semnuclmed.2015.10.007; Boll RA, 2005, APPL RADIAT ISOTOPES, V62, P667, DOI 10.1016/j.apradiso.2004.12.003; Boschi A, 2017, PHARMACEUTICALS, V10, DOI 10.3390/ph10010012; Bouchelouche K, 2011, SEMIN NUCL MED, V41, P29, DOI 10.1053/j.semnuclmed.2010.08.005; Bouchelouche K, 2010, CURR OPIN ONCOL, V22, P274, DOI 10.1097/CCO.0b013e3283373d5c; Brechbiel MW, 2008, Q J NUCL MED MOL IM, V52, P166; Callison J Clay Jr, 2011, J Lung Cancer, V10, P69; Cives M, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0567-8; Cordier D, 2010, EUR J NUCL MED MOL I, V37, P1335, DOI 10.1007/s00259-010-1385-5; Cordier D, 2016, SEMIN NUCL MED, V46, P243, DOI 10.1053/j.semnuclmed.2016.01.009; Cordier D, 2010, J NEURO-ONCOL, V100, P129, DOI 10.1007/s11060-010-0153-5; Crawford JR, 2017, NUCL MED BIOL, V48, P31, DOI 10.1016/j.nucmedbio.2017.01.011; Dadachova E, 2002, NUCL MED BIOL, V29, P13, DOI 10.1016/S0969-8051(01)00279-7; Dalm SU, 2016, J NUCL MED, V57, P260, DOI 10.2967/jnumed.115.167007; de Kraker J, 2008, EUR J CANCER, V44, P551, DOI 10.1016/j.ejca.2008.01.010; De Kruijff RM, 2015, PHARMACEUTICALS, V8, P321, DOI 10.3390/ph8020321; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; DEKRAKER J, 1995, EUR J CANCER, V31A, P600, DOI 10.1016/0959-8049(95)00063-O; Delacroix D, 2004, GUIDE PRATIQUE RADIO; Denis-Bacelar AM, 2017, EUR J NUCL MED MOL I, V44, P620, DOI 10.1007/s00259-016-3543-x; DEUTSCH E, 1986, NUCL MED BIOL, V13, P465, DOI 10.1016/0883-2897(86)90027-9; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Ehrhardt GJ, 1998, APPL RADIAT ISOTOPES, V49, P295, DOI 10.1016/S0969-8043(97)00038-9; Eustatia-Rutten CFA, 2006, J CLIN ENDOCR METAB, V91, P313, DOI 10.1210/jc.2005-1322; Evans-Axelsson S, 2016, SEMIN NUCL MED, V46, P165, DOI 10.1053/j.semnuclmed.2015.10.005; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GEERLINGS MW, 1993, NUCL MED COMMUN, V14, P121, DOI 10.1097/00006231-199302000-00009; Gopal AK, 2011, BLOOD, V118, P1132, DOI 10.1182/blood-2010-12-324392; Gordon LI, 2004, BLOOD, V103, P4429, DOI 10.1182/blood-2003-11-3883; Gordon LI, 2002, SEMIN ONCOL, V29, P87, DOI 10.1053/sonc.2002.30148; Gut rard F, 2013, CANCER BIOTHER RADI, V28, P1; HATTNER RS, 1984, AM J ROENTGENOL, V143, P373, DOI 10.2214/ajr.143.2.373; HENNIG IM, 1995, INT J CANCER, V61, P786, DOI 10.1002/ijc.2910610608; Henriksen G, 2003, J NUCL MED, V44, P252; Hosseini SF, 2017, APPL RADIAT ISOTOPES, V127, P137, DOI 10.1016/j.apradiso.2017.05.024; Ianniello A, 2016, EUR J NUCL MED MOL I, V43, P1040, DOI 10.1007/s00259-015-3262-8; Imhof A, 2011, J CLIN ONCOL, V29, P2416, DOI 10.1200/JCO.2010.33.7873; ISRAELI RS, 1994, CANCER RES, V54, P1807; Jurcic Joseph G, 2014, Am Soc Clin Oncol Educ Book, pe126, DOI 10.14694/EdBook_AM.2014.34.e126; Khan S, 2011, J NUCL MED, V52, P1361, DOI 10.2967/jnumed.111.087932; Kim SJ, 2015, EUR J NUCL MED MOL I, V42, P1964, DOI 10.1007/s00259-015-3155-x; Knapp FF, 2016, RADIOPHARMACEUTICALS; Kneifel S, 2006, CLIN CANCER RES, V12, P3843, DOI 10.1158/1078-0432.CCR-05-2820; Knut Liepe, 2015, World J Nucl Med, V14, P10, DOI 10.4103/1450-1147.150509; Kolsky KL, 1998, APPL RADIAT ISOTOPES, V49, P1541, DOI 10.1016/S0969-8043(98)00016-5; Kotzerke J, 1998, NUCL MED COMMUN, V19, P795, DOI 10.1097/00006231-199808000-00011; Kraeber-Bodere F, 2015, INT J MOL SCI, V16, P3932, DOI 10.3390/ijms16023932; Kraeber-Bodere F, 2014, SEMIN ONCOL, V41, P613, DOI 10.1053/j.seminoncol.2014.07.004; Kratochwil C, 2015, MOL IMAGING BIOL, V17, P313, DOI 10.1007/s11307-014-0795-3; Kratochwil C, 2016, J NUCL MED, V57, P1170, DOI 10.2967/jnumed.115.171397; Kratochwil C, 2015, EUR J NUCL MED MOL I, V42, P987, DOI 10.1007/s00259-014-2978-1; KRENNING EP, 1994, ANN NY ACAD SCI, V733, P496, DOI 10.1111/j.1749-6632.1994.tb17300.x; Kulkarni HR, 2014, PET CLIN, V9, P91, DOI 10.1016/j.cpet.2013.08.016; Kwekkeboom DJ, 2008, J CLIN ONCOL, V26, P2124, DOI 10.1200/JCO.2007.15.2553; Kwekkeboom DJ, 2010, ENDOCR-RELAT CANCER, V17, pR53, DOI 10.1677/ERC-09-0078; Larsen R, 2003, Patent US, Patent No. 20030206857; Lehenberger S, 2011, NUCL MED BIOL, V38, P917, DOI 10.1016/j.nucmedbio.2011.02.007; Lepareur N, 2005, DALTON T, P2866, DOI 10.1039/b503938j; Lepareur N, 2012, INT J MOL IMAGING, V2012; Lewin J, 2015, EUR J NUCL MED MOL I, V42, P25, DOI 10.1007/s00259-014-2888-2; Liu H, 1997, CANCER RES, V57, P3629; Liu H, 1998, CANCER RES, V58, P4055; Lumbroso J, 1991, J Nucl Biol Med, V35, P220; Madan RA, 2016, LANCET ONCOL, V17, P1186, DOI 10.1016/S1470-2045(16)30248-0; Maguire WF, 2014, J NUCL MED, V55, P1492, DOI 10.2967/jnumed.114.138347; Matthews DC, 1999, BLOOD, V94, P1237, DOI 10.1182/blood.V94.4.1237.416k34_1237_1247; Mausner LF, 1998, APPL RADIAT ISOTOPES, V49, P285, DOI 10.1016/S0969-8043(97)00040-7; McCluskey AG, 2005, CLIN CANCER RES, V11, P7929, DOI 10.1158/1078-0432.CCR-05-0982; McDevitt MR, 1999, APPL RADIAT ISOTOPES, V50, P895, DOI 10.1016/S0969-8043(98)00151-1; McDevitt MR, 1999, J NUCL MED, V40, P1722; McLaughlin MF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054531; Miederer M, 2008, ADV DRUG DELIVER REV, V60, P1371, DOI 10.1016/j.addr.2008.04.009; Miederer M, 2008, CLIN CANCER RES, V14, P3555, DOI 10.1158/1078-0432.CCR-07-4647; Milner C, 2012, J NUCL MED, V53, P1951; Moustapha ME, 2006, NUCL MED BIOL, V33, P81, DOI 10.1016/j.nucmedbio.2005.09.006; Muller C, 2014, EUR J NUCL MED MOL I, V41, P476, DOI 10.1007/s00259-013-2563-z; Nicolas GP, 2017, J NUCL MED, V58, P1435, DOI 10.2967/jnumed.117.191684; Nijsen JFW, 2004, RADIOLOGY, V231, P491, DOI 10.1148/radiol.2312030594; Nijsen JFW, 1999, EUR J NUCL MED, V26, P699, DOI 10.1007/s002590050440; Parisi MT, 2016, SEMIN NUCL MED, V46, P184, DOI 10.1053/j.semnuclmed.2016.02.002; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Phillips WT, 2012, NEURO-ONCOLOGY, V14, P416, DOI 10.1093/neuonc/nos060; Pouget JP, 2011, NAT REV CLIN ONCOL, V8, P720, DOI 10.1038/nrclinonc.2011.160; Rahbar K, 2017, EUR J NUCL MED MOL I, P1; Rajguru Saurabh, 2014, Clin Adv Hematol Oncol, V12, P509; Ringhoffer M, 2005, BRIT J HAEMATOL, V130, P604, DOI 10.1111/j.1365-2141.2005.05663.x; Rizzieri D, 2016, CRIT REV ONCOL HEMAT, V105, P5, DOI 10.1016/j.critrevonc.2016.07.008; Rosenblat TL, 2010, CLIN CANCER RES, V16, P5303, DOI 10.1158/1078-0432.CCR-10-0382; Saad F, 2016, LANCET ONCOL, V17, P1306, DOI 10.1016/S1470-2045(16)30173-5; Salavati A, 2016, SEMIN NUCL MED, V46, P215, DOI 10.1053/j.semnuclmed.2016.01.010; SCHEINBERG DA, 1991, J CLIN ONCOL, V9, P478, DOI 10.1200/JCO.1991.9.3.478; Scholz CW, 2013, J CLIN ONCOL, V31, P308, DOI 10.1200/JCO.2011.41.1553; Seidl C, 2014, IMMUNOTHERAPY-UK, V6, P431, DOI 10.2217/imt.14.16; Selwyn RG, 2007, APPL RADIAT ISOTOPES, V65, P318, DOI 10.1016/j.apradiso.2006.08.009; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Shimoni A, 2016, SEMIN NUCL MED, V46, P119, DOI 10.1053/j.semnuclmed.2015.10.009; SISSON JC, 1981, NEW ENGL J MED, V305, P12, DOI 10.1056/NEJM198107023050103; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smith-Jones PM, 2004, Q J NUCL MED MOL IM, V48, P297; Soderquist CZ, 2012, CURR RADIOPHARM, V5, P244, DOI 10.2174/1874471011205030244; Sollini M, 2013, J THORAC ONCOL, V8, P1095, DOI 10.1097/JTO.0b013e318293f051; SPENCER RP, 1987, NUCL MED BIOL, V14, P537, DOI 10.1016/0883-2897(87)90022-5; Strebhardt K, 2008, NAT REV CANCER, V8, P473, DOI 10.1038/nrc2394; Strosberg J, 2017, NEW ENGL J MED, V376, P125, DOI 10.1056/NEJMoa1607427; Strosberg JR, 2013, J CLIN ONCOL, V31, P420, DOI 10.1200/JCO.2012.44.5924; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tagawa ST, 2013, CLIN CANCER RES, V19, P5182, DOI 10.1158/1078-0432.CCR-13-0231; Taggart D, 2008, Q J NUCL MED MOL IM, V52, P403; Tarasov VA, 2015, CURR RADIOPHARM, V8, P95, DOI 10.2174/1874471008666150312161942; Tartarone A, 2016, SEMIN NUCL MED, V46, P239, DOI 10.1053/j.semnuclmed.2015.12.004; Vaidyanathan G, 2008, CURR RADIOPHARM, V1, P177, DOI 10.2174/1874471010801030177; Valkema R, 2006, SEMIN NUCL MED, V36, P147, DOI 10.1053/j.semnuclmed.2006.01.001; Van Essen M, 2007, ACTA ONCOL, V46, P723, DOI 10.1080/0284160701441848; Vanpouille-Box C, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00136; Vanpouille-Box C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016926; Verburg FA, 2014, EUR J NUCL MED MOL I, V41, P199, DOI 10.1007/s00259-013-2609-2; Verger E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164626; Versari A, 2014, THYROID, V24, P715, DOI 10.1089/thy.2013.0225; von Mehren M, 2003, ANNU REV MED, V54, P343, DOI 10.1146/annurev.med.54.101601.152442; Waldherr C, 2002, J NUCL MED, V43, P610; Wang G, 2014, APPL RADIAT ISOTOPES, V85, P45, DOI 10.1016/j.apradiso.2013.12.008; WIELAND DM, 1980, J NUCL MED, V21, P349; Wild D, 2014, J NUCL MED, V55, P1248, DOI 10.2967/jnumed.114.138834; Witzig TE, 2002, J CLIN ONCOL, V20, P3262, DOI 10.1200/JCO.2002.11.017; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Witzig TE, 2015, BRIT J HAEMATOL, V170, P679, DOI 10.1111/bjh.13493; Woodward J, 2011, BIOCONJUGATE CHEM, V22, P766, DOI 10.1021/bc100574f; Wright C. L., 2015, BIOMED RES INT, V2015; Wright CL, 2017, EUR J NUCL MED MOL I, V44, P1194, DOI 10.1007/s00259-017-3694-4; Yanik GA, 2015, BIOL BLOOD MARROW TR, V21, P673, DOI 10.1016/j.bbmt.2014.12.008; Yavari K, 2016, J LABELLED COMPD RAD, V59, P24, DOI 10.1002/jlcr.3366; Zalutsky MR, 2011, CURR RADIOPHARM, V4, P177, DOI 10.2174/1874471011104030177; ZALUTSKY MR, 1989, P NATL ACAD SCI USA, V86, P7149, DOI 10.1073/pnas.86.18.7149; Zalutsky MR, 2000, CURR PHARM DESIGN, V6, P1433, DOI 10.2174/1381612003399275	145	4	4	3	12	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JAN-FEB	2018	42	1					32	44		10.1016/j.mednuc.2017.12.002			13	Pathology	Pathology	GA5FI	WOS:000428357800004					2019-10-28	
J	Bera, G; Soret, M; Maisonobe, JA; Giron, A; Garnier, JM; Habert, MO; Kas, A				Bera, G.; Soret, M.; Maisonobe, J. -A.; Giron, A.; Garnier, J. -M.; Habert, M. -O.; Kas, A.			Equivalent dose rate from patients after whole-body FDG-PET/CT	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			English	Article						Radiation protection; Dose rate; FDG-PET/CT		Introduction. - F-18-fluorodeoxyglucose PET/CT (FDG-PET/CT) is an imaging modality routinely used in oncology, hematology, as well as in infectious and inflammatory diseases. Frequently, patients and their accompanying persons may be apprehensive concerning risks of radiation exposure after performing this examination, particularly when it concerns nearby young adolescents or pregnant women. Our objective was to clearly explain about radiation protection instructions for patients after performing whole-body FDG-PET/CT based on the Equivalent Dose Rate (EDR) estimation at our nuclear medicine department. Methods. - We measured the dosage rates from 14 patients after undergoing whole-body FDG-PET/CT performed on two different PET/CT systems, with and without Time-of-Flight technology (TOF), in the Pitie Salpetriere Charles Foix Hospital Group. The patients explored, using the TOF PET/CT system (group 1, n = 7), had a FDG injected dose (FDG-ID) of 3.7 MBq/kg whereas those explored using the non-TOF PET/CT system (group 2, n = 7) had a FDG-ID of 5 MBq/kg. Measurements of the EDR at 0.8 m (EDR-0.8 m) from the sternum were obtained immediately after PET/CT completion. Results. - Patients did not differ in terms of body mass index, mean +/- SD 27.2 +/- 7.1 kg/m(2) and 27.9 +/- 8.1 kg/m(2), for group 1 and 2 respectively. The median administrated activity was not significantly different between the two groups: 263 MBq [187-362] for group 1 and 377 MBq [228-608] for group 2. The median delay of EDR-0.8 m measurement after FDG-injection was lower for group 1 (85 min [70-118]) (P = 0.03). The median of EDR-0.8 m did not differ between the 2 groups, 27 mu Sv/h [22-42] and 34 mu Sv/h [28-82] for group 1 and 2 respectively as well as the EDR-8 m normalized to the FDG-ID, 0.13 mu Sv/h/MBq [0.07-0.15] and 0.08 mu Sv//h/MBq [0.06-0.15], for group 1 and 2 respectively. Conclusion. - The present study confirmed the low values of EDR from patients after whole-body FDG-PET/CT. This suggests that patients and their accompanying persons can be reassured about potential risks of radiation exposure after this examination and that cautionary advice is unnecessary at our Hospital Group. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Bera, G.; Soret, M.; Maisonobe, J. -A.; Garnier, J. -M.; Habert, M. -O.; Kas, A.] Grp Hosp Pitie Salpetriere Charles Foix, AP HP, Serv Med Nucl, 47-83,Blvd Hop, F-75651 Paris 13, France; [Giron, A.; Habert, M. -O.; Kas, A.] Sorbonne Univ, Lab Imagerie Biomed, INSERM, U1146, Paris, France; [Giron, A.; Habert, M. -O.; Kas, A.] Univ Pierre & Marie Curie Paris 6, Paris, France	Bera, G (reprint author), Grp Hosp Pitie Salpetriere Charles Foix, AP HP, Serv Med Nucl, 47-83,Blvd Hop, F-75651 Paris 13, France.	berageraldine@gmail.com					Calais PJ, 2014, ANN NUCL MED, V28, P531, DOI 10.1007/s12149-014-0843-8; Cronin B, 1999, EUR J NUCL MED, V26, P121, DOI 10.1007/s002590050367; Demir M, 2011, RADIAT PROT DOSIM, V147, P528, DOI 10.1093/rpd/ncq497; Fayad E, 2015, MED NUCL, V39, P380, DOI 10.1016/j.mednuc.2015.05.003; Zhang-Yin J, 2017, J NUCL MED, V58, P1230, DOI 10.2967/jnumed.116.187138	5	2	2	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JAN-FEB	2018	42	1					45	48		10.1016/j.mednuc.2017.11.003			4	Pathology	Pathology	GA5FI	WOS:000428357800005					2019-10-28	
J	Lussey-Lepoutre, C; Tresallet, C; Ghander, C; Morelec, I; Najah, H; Kasereka-kisenge, F; Bozetto, J; Taieb, D; Hindie, E				Lussey-Lepoutre, C.; Tresallet, C.; Ghander, C.; Morelec, I.; Najah, H.; Kasereka-kisenge, F.; Bozetto, J.; Taieb, D.; Hindie, E.			The role of imaging in the preoperative management of primary hyperparathyroidism: A current up-date	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			English	Article							HYPERFUNCTIONING PARATHYROID-GLANDS; 4TH INTERNATIONAL WORKSHOP; JAW TUMOR SYNDROME; F-18-FLUOROCHOLINE PET/CT; C-11-METHIONINE PET/CT; SECONDARY HYPERPARATHYROIDISM; SESTAMIBI SCINTIGRAPHY; C-11-CHOLINE PET/CT; COMPUTED-TOMOGRAPHY; SUCCESS RATE		[Lussey-Lepoutre, C.] Hop La Pitie Salpetriere, Nucl Med, 47-83,Blvd Hop, F-75013 Paris, France; [Tresallet, C.; Najah, H.; Kasereka-kisenge, F.] Hop La Pitie Salpetriere, Endocrine Surg, F-75013 Paris, France; [Ghander, C.] Hop La Pitie Salpetriere, Thyroid & Endocrine Tumour Dept, F-75013 Paris, France; [Morelec, I.; Bozetto, J.] Hosp Civiles Lyon, Lyon Sud Hosp, Nucl Med, F-69310 Lyon, France; [Taieb, D.] Aix Marseille Univ, CERIMED, La Timone Univ Hosp, Nucl Med, F-13005 Marseille, France; [Hindie, E.] Univ Bordeaux, Haut Leveque Hosp, Nucl Med, F-33604 Bordeaux, France	Lussey-Lepoutre, C (reprint author), Hop La Pitie Salpetriere, Nucl Med, 47-83,Blvd Hop, F-75013 Paris, France.	charlotte.lussey@inserm.fr					AKERSTROM G, 1984, SCAND J UROL NEPHROL, V18, P75, DOI 10.3109/00365598409182168; AKERSTROM G, 1984, SURGERY, V95, P14; Bergenfelz AOJ, 2009, LANGENBECK ARCH SURG, V394, P761, DOI 10.1007/s00423-009-0533-5; Bilezikian JP, 2014, J CLIN ENDOCR METAB, V99, P3561, DOI 10.1210/jc.2014-1413; Boury S, 2017, MED NUCL, V41, P322, DOI 10.1016/j.mednuc.2017.06.010; Bradley KJ, 2005, J INTERN MED, V257, P18, DOI 10.1111/j.1365-2796.2004.01421.x; Bricaire L, 2013, J CLIN ENDOCR METAB, V98, pE403, DOI 10.1210/jc.2012-2789; Cakal E, 2012, CLIN IMAG, V36, P688, DOI 10.1016/j.clinimag.2012.01.038; Calabria F, 2017, NUCL MED BIOL, V51, P40, DOI 10.1016/j.nucmedbio.2017.04.004; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Casara D, 2001, EUR J NUCL MED, V28, P1351, DOI 10.1007/s002590100564; Caveny SA, 2012, J NUCL MED TECHNOL, V40, P104, DOI 10.2967/jnmt.111.098400; Cazaentre T, 2014, CLIN NUCL MED, V39, pE328, DOI 10.1097/RLU.0b013e3182a77b62; Cheung K, 2012, ANN SURG ONCOL, V19, P577, DOI 10.1245/s10434-011-1870-5; Ciappuccini R, 2012, CLIN NUCL MED, V37, P223, DOI 10.1097/RLU.0b013e31823362e5; Deandreis D, 2015, EUR J NUCL MED MOL I, V42, P1941, DOI 10.1007/s00259-015-3130-6; Fraser WD, 2009, LANCET, V374, P145, DOI 10.1016/S0140-6736(09)60507-9; Ginsburg M, 2015, J VASC INTERV RADIOL, V26, P79, DOI 10.1016/j.jvir.2014.09.019; Greenspan BS, 2012, J NUCL MED TECHNOL, V40, P111, DOI 10.2967/jnmt.112.105122; Grosfeld JL, 1996, SURGERY, V120, P650, DOI 10.1016/S0039-6060(96)80012-2; Guerin C, 2015, EUR J ENDOCRINOL; Hassler S, 2014, CLIN NUCL MED, V39, P32, DOI 10.1097/RLU.0000000000000272; Hayakawa N, 2015, NUCL MED COMMUN, V36, P53, DOI 10.1097/MNM.0000000000000216; Henry JF, 2010, LANGENBECK ARCH SURG, V395, P103, DOI 10.1007/s00423-009-0560-2; Hessman O, 2008, WORLD J SURG, V32, P82; Hessman O, 2008, WORLD J SURG, V32, P774, DOI 10.1007/s00268-008-9537-5; Hindie E, 1998, J NUCL MED, V39, P1100; Hindie E, 2000, ARCH SURG-CHICAGO, V135, P1461, DOI 10.1001/archsurg.135.12.1461; Hindie E, 1997, RADIOLOGY, V204, P221, DOI 10.1148/radiology.204.1.9205251; Hindie E, 2009, EUR J NUCL MED MOL I, V36, P1201, DOI 10.1007/s00259-009-1131-z; Hocevar M, 2017, EJSO-EUR J SURG ONC, V43, P133, DOI 10.1016/j.ejso.2016.09.016; Hodolic M, 2014, RADIOL ONCOL, V48, P228, DOI 10.2478/raon-2013-0075; Karakas E, 2013, LANGENBECK ARCH SURG, V398, P99, DOI 10.1007/s00423-012-1004-y; Kelly HR, 2014, AM J NEURORADIOL, V35, P176, DOI 10.3174/ajnr.A3615; Klingensmith WC, 2013, J NUCL MED TECHNOL, V41, P99, DOI 10.2967/jnmt.112.118208; Kluijfhout WP, 2017, RADIOLOGY, V284, P460, DOI 10.1148/radiol.2016160768; Kluijfhout WP, 2016, NUCL MED COMMUN, V37, P1246, DOI 10.1097/MNM.0000000000000595; Kluijfhout WP, 2016, LANGENBECK ARCH SURG, V401, P925, DOI 10.1007/s00423-016-1425-0; Krakauer M, 2016, CLIN NUCL MED, V41, P93, DOI 10.1097/RLU.0000000000000988; Krishnamurthy VD, 2017, SURGERY, V161, P1651, DOI 10.1016/j.surg.2016.11.019; Kukar M, 2015, ANN SURG ONCOL, V22, P139, DOI 10.1245/s10434-014-3940-y; LEVIN KE, 1989, ARCH SURG-CHICAGO, V124, P911; Levin KE, 1989, ARCH SURG-CHICAGO, V124, P4; Lezaic L, 2014, EUR J NUCL MED MOL I, V41, P2083, DOI 10.1007/s00259-014-2837-0; Madorin CA, 2013, JAMA SURG, V148, P500, DOI 10.1001/jamasurg.2013.57; Mapelli P, 2012, CLIN NUCL MED, V37, P593, DOI 10.1097/RLU.0b013e31824c5ffc; Martin D, 1996, AM J SURG, V172, P633, DOI 10.1016/S0002-9610(96)00030-X; Martinez-Rodriguez I, 2014, REV ESP MED NUCL IMA, V33, P93, DOI 10.1016/j.remn.2013.08.002; Michaud L, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001701; Michaud L, 2014, J CLIN ENDOCR METAB, V99, P4531, DOI 10.1210/jc.2014-2821; Michel L, 2013, ACTA CHIR BELG, V113, P112, DOI 10.1080/00015458.2013.11680896; Molinari AS, 1996, SURGERY, V120, P934, DOI 10.1016/S0039-6060(96)80036-5; Neumann DR, 2008, J NUCL MED, V49, P2012, DOI 10.2967/jnumed.108.054858; Nichols KJ, 2012, NUCL MED COMMUN, V33, P43, DOI 10.1097/MNM.0b013e32834bfeb1; Orevi M, 2014, CLIN NUCL MED, V39, P1033, DOI 10.1097/RLU.0000000000000607; Otto D, 2004, EUR J NUCL MED MOL I, V31, P1405, DOI 10.1007/s00259-004-1610-1; Phitayakorn R, 2006, AM J SURG, V191, P418, DOI 10.1016/j.amjsurg.2005.10.049; Quak E, 2013, J CLIN ENDOCR METAB, V98, P3111, DOI 10.1210/jc.2013-2084; Rep S, 2015, RADIOL ONCOL, V49, P327, DOI 10.1515/raon-2015-0016; Roy M, 2013, WORLD J SURG, V37, P102, DOI 10.1007/s00268-012-1773-z; Ruda JM, 2005, OTOLARYNG HEAD NECK, V132, P359, DOI 10.1016/j.otohns.2004.10.005; RUSSELL CF, 1982, BRIT J SURG, V69, P244, DOI 10.1002/bjs.1800690503; Schalin-Jantti C, 2013, J NUCL MED, V54, P739, DOI 10.2967/jnumed.112.109561; Shon IAH, 2008, NUCL MED COMMUN, V29, P949, DOI 10.1097/MNM.0b013e328309789e; Sundin A, 1996, J NUCL MED, V37, P1766; TAILLEFER R, 1992, J NUCL MED, V33, P1801; Thakker RV, 2016, J INTERN MED, V280, P574, DOI 10.1111/joim.12523; Traub-Weidinger T, 2014, J CLIN ENDOCR METAB, V99, P4199, DOI 10.1210/jc.2014-1267; Tunninen Virpi, 2013, Int J Mol Imaging, V2013, P921260, DOI 10.1155/2013/921260; Udelsman R, 2014, J CLIN ENDOCR METAB, V99, P3595, DOI 10.1210/jc.2014-2000; Udelsman R, 2009, J CLIN ENDOCR METAB, V94, P366, DOI 10.1210/jc.2008-1761; Weber T, 2013, ANN SURG, V257, P1124, DOI 10.1097/SLA.0b013e318289b345; Wermers RA, 2006, J BONE MINER RES, V21, P171, DOI 10.1359/JBMR.050910; Yuan LL, 2017, ACTA RADIOL, V58, P558, DOI 10.1177/0284185116661878	74	1	1	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JAN-FEB	2018	42	1					49	58		10.1016/j.mednuc.2017.12.001			10	Pathology	Pathology	GA5FI	WOS:000428357800006					2019-10-28	
J	Shah, SI; Dyer, L; Stanek, J				Shah, Sujal I.; Dyer, Lisa; Stanek, Jerzy			Placental Histomorphology in a Case of Double Trisomy 48,XXX,+18	CASE REPORTS IN PATHOLOGY			English	Article							PRENATAL-DIAGNOSIS; ABORTIONS; FEATURES; GESTATION; KARYOTYPE; HISTOLOGY	Background. Approximately 50% of early spontaneous abortions are found to have chromosomal abnormalities. In these cases, certain histopathologic abnormalities are suggestive of, although not diagnostic for, the presence of chromosomal abnormalities. However, placental histomorphology in cases of complex chromosomal abnormalities, including double trisomies, is virtually unknown. Case Report. We present the case of a 27-year-old G3P22002 female presenting at 19 weeks and 1 day of gestation by last menstrual period for scheduled prenatal visit. Ultrasound revealed a single fetus without heart tones and adequate amniotic fluid. Limited fetal measurements were consistent with estimated gestational age of 17 weeks. Labor was induced with misoprostol due to fetal demise. Autopsy revealed an immature female fetus with grade 1-2 maceration. The ears were low-set and posteriorly rotated. The fingers were short bilaterally, and the right foot showed absence of the second and third digits. Evaluation of the organs showed predominantly marked autolysis consistent with retained stillbirth. Placental examination revealed multiple findings, including focal pseudovillous papilliform trophoblastic proliferation of the undersurface of the chorionic plate and clustering of perpendicularly oriented sclerotic chorionic villi in the chorion laeve, which have not been previously reported in cases of chromosomal abnormalities. Karyotype of placental tissue revealed a 48,XXX,+18 karyotype and the same double trisomy of fetal thymic tissue by FISH. Conclusion. In addition to convoluted outlines of chorionic villi, villous trophoblastic pseudoinclusions, and clusters of villous cytotrophoblasts, the previously unreported focal pseudovillous papilliform trophoblastic proliferation of the undersurface of the chorionic plate and clustering of perpendicularly oriented sclerotic chorionic villi in the chorion laeve were observed in this double trisomy case. More cases have to be examined to show if the histology is specific for this double trisomy.	[Shah, Sujal I.; Stanek, Jerzy] Univ Cincinnati, Med Ctr, Dept Pathol & Lab Med, Cincinnati, OH 45220 USA; [Shah, Sujal I.; Stanek, Jerzy] Cincinnati Childrens Hosp Med Ctr, Div Pathol & Lab Med, Cincinnati, OH 45229 USA; [Dyer, Lisa] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA; [Dyer, Lisa] Univ Cincinnati, Coll Med, Cincinnati, OH USA	Stanek, J (reprint author), Univ Cincinnati, Med Ctr, Dept Pathol & Lab Med, Cincinnati, OH 45220 USA.; Stanek, J (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Pathol & Lab Med, Cincinnati, OH 45229 USA.	jerzy.stanek@cchmc.org					Arizawa M, 2014, PLACENTA, V35, pA20; Baergen RN, 2011, MANUAL OF PATHOLOGY OF THE HUMAN PLACENTA, SECOND EDITION, P1, DOI 10.1007/978-1-4419-7494-5; Chen CP, 2000, PRENATAL DIAG, V20, P750, DOI 10.1002/1097-0223(200009)20:9<750::AID-PD900>3.0.CO;2-E; Dezerega V, 2005, J ULTRAS MED, V24, P717, DOI 10.7863/jum.2005.24.5.717; Diego-Alvarez D, 2006, HUM REPROD, V21, P958, DOI 10.1093/humrep/dei406; GENEST DR, 1995, HUM PATHOL, V26, P201, DOI 10.1016/0046-8177(95)90038-1; Hassold T, 2007, HUM MOL GENET, V16, pR203, DOI 10.1093/hmg/ddm243; HONORE LH, 1976, TERATOLOGY, V14, P151, DOI 10.1002/tera.1420140206; JARURATANASIRIKUL S, 1994, AM J MED GENET, V49, P207, DOI 10.1002/ajmg.1320490210; Jiang ZY, 2015, WORLD J PEDIATR, V11, P83, DOI 10.1007/s12519-015-0005-7; KUHLMANN RS, 1990, AM J OBSTET GYNECOL, V163, P1264, DOI 10.1016/0002-9378(90)90704-B; Reddy KS, 1997, HUM GENET, V101, P339, DOI 10.1007/s004390050638; Roberts L, 2000, PLACENTA, V21, P678, DOI 10.1053/plac.2000.0553; ROSENFELD W, 1981, AM J MED GENET, V8, P67, DOI 10.1002/ajmg.1320080109; SONODA T, 1987, Acta Paediatrica Japonica, V29, P173; Spencer K, 2013, PRENATAL DIAG, V33, P1105, DOI 10.1002/pd.4192; Stanek J, 2010, PATHOLOGY, V42, P499, DOI 10.3109/00313025.2010.494296; Tartaglia NR, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-8; VANLIJNSCHOTEN G, 1994, PLACENTA, V15, P765, DOI 10.1016/0143-4004(94)90039-6; VANLIJNSCHOTEN G, 1993, HISTOPATHOLOGY, V22, P25	20	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									2839765	10.1155/2018/2839765			5	Pathology	Pathology	FZ6XW	WOS:000427744900001	29707399	DOAJ Gold, Green Published			2019-10-28	
J	Lauwers, GY; Langner, C				Lauwers, Gregory Y.; Langner, Cord			Inflammatory and infectious pathology of the gastrointestinal tract: an introduction	VIRCHOWS ARCHIV			English	Editorial Material									[Lauwers, Gregory Y.] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL USA; [Lauwers, Gregory Y.] Univ S Florida, Dept Oncol Sci, Tampa, FL 33620 USA; [Langner, Cord] Med Univ Graz, Inst Pathol, Graz, Austria	Lauwers, GY (reprint author), H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL USA.; Lauwers, GY (reprint author), Univ S Florida, Dept Oncol Sci, Tampa, FL 33620 USA.	Gregory.Lauwers@Moffitt.org; cord.langner@medunigraz.at						0	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JAN	2018	472	1					1	2		10.1007/s00428-017-2284-y			2	Pathology	Pathology	FZ3FX	WOS:000427473200001	29282536	Bronze			2019-10-28	
J	Brown, I; Kumarasinghe, MP				Brown, Ian; Kumarasinghe, Marian Priyanthi			Granulomas in the gastrointestinal tract: deciphering the Pandora's box	VIRCHOWS ARCHIV			English	Article						Crohn's disease; Sarcoidosis; Chronic granulomatous disease; Drug reaction; Granulomatous appendicitis; Gastrointestinal infection	INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; INTESTINAL TUBERCULOSIS; CLINICOPATHOLOGICAL ANALYSIS; PERICRYPTAL GRANULOMAS; CRYPTOLYTIC LESIONS; HELICOBACTER-PYLORI; BIOPSY SPECIMENS; GASTRITIS; COLITIS	Granulomas are organised collection of activated histiocytes induced by a persistent antigen stimulus. A wide variety of antigens encountered by the gastrointestinal tract are of this nature and hence the resulting granulomatous inflammation represents a tissue reaction pattern. The potential causes can be broadly classified as infections or non-infectious immune reactions. There is also a group where a cause is never identified. Granulomas may be of varying morphological appearance, most commonly epithelioid, foreign body type, suppurative and necrotizing. This may provide a clue as to the aetiology; however, in most cases, the cause requires further inquiry. Pathologists may need to cut deeper levels to look for foreign material and apply special stains to look for microorganisms. Pathologists also need to be certain that the process is a true granuloma and not a mimic. The site of occurrence in the gastrointestinal tract and the clinical setting is often paramount in establishing the aetiology. For instance, infections are more likely the cause in developing countries or when there is immunosuppression. Similarly, granulomas in the stomach are usually due to Crohn's disease; however, it is only rarely the cause of granulomas isolated to the appendix.	[Brown, Ian] Envoi Pathol, 5-38 Bishop St, Brisbane, Qld 4059, Australia; [Brown, Ian] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia; [Kumarasinghe, Marian Priyanthi] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA, Australia; [Kumarasinghe, Marian Priyanthi] Queen Elizabeth II Med Ctr, PathWest Lab Med, Nedlands, WA, Australia	Brown, I (reprint author), Envoi Pathol, 5-38 Bishop St, Brisbane, Qld 4059, Australia.; Brown, I (reprint author), Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia.	ianbrown@envoi.com.au	Brown, Ian/R-7763-2016	Brown, Ian/0000-0001-6329-2547			AbdullGaffar B, 2010, INT J SURG PATHOL, V18, P14, DOI 10.1177/1066896909349246; Alimchandani M, 2013, AM J SURG PATHOL, V37, P1365, DOI 10.1097/PAS.0b013e318297427d; Almadi MA, 2011, NAT REV GASTRO HEPAT, V8, P455, DOI 10.1038/nrgastro.2011.115; Almadi MA, 2009, AM J GASTROENTEROL, V104, P1003, DOI 10.1038/ajg.2008.162; Arnold CA, 2013, AM J SURG PATHOL, V37, P38, DOI 10.1097/PAS.0b013e31826a523e; BAERT F, 1995, AM J GASTROENTEROL, V90, P1871; Bojic D, 2011, ANN GASTROENTEROL, V24, P271; Bronner MP, 2004, SEMIN DIAGN PATHOL, V21, P98, DOI 10.1053/j.semdp.2004.12.001; Brown IS, 2016, VIRCHOWS ARCH, V469, P515, DOI 10.1007/s00428-016-2009-7; CARNEY JA, 1973, GASTROENTEROLOGY, V65, P316; Caso F, 2015, RMD OPEN, V20, P1; Colombat M, 2001, HISTOPATHOLOGY, V38, P21, DOI 10.1046/j.1365-2559.2001.01063.x; Daniels JA, 2007, AM J SURG PATHOL, V31, P1800, DOI 10.1097/PAS.0b013e3180cab60c; DHILLON AP, 1989, APMIS, V97, P723, DOI 10.1111/j.1699-0463.1989.tb00468.x; Dilauro Steven, 2010, Curr Gastroenterol Rep, V12, P249, DOI 10.1007/s11894-010-0112-5; DUDLEY TH, 1993, HUM PATHOL, V24, P595, DOI 10.1016/0046-8177(93)90238-C; Ebert EC, 2008, AM J GASTROENTEROL, V103, P3184, DOI 10.1111/j.1572-0241.2008.02202.x; ECTORS NL, 1993, HISTOPATHOLOGY, V23, P55, DOI 10.1111/j.1365-2559.1993.tb01183.x; Elbaz T, 2013, J ADV RES, V4, P445, DOI 10.1016/j.jare.2012.12.001; ELLIS H, 1994, ANN ROY COLL SURG, V76, P5; FAHIMI HD, 1963, GASTROENTEROLOGY, V45, P161; Franco Diana L, 2014, Case Rep Gastroenterol, V8, P329, DOI 10.1159/000369129; Gan HT, 2002, AM J GASTROENTEROL, V97, P1446, DOI 10.1016/S0002-9270(02)04042-X; Ghrenassia E, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004279; Goldstein NS, 2000, AM J SURG PATHOL, V24, P668, DOI 10.1097/00000478-200005000-00005; Gonzalez RS, 2017, HISTOPATHOLOGY, V70, P223, DOI 10.1111/his.13068; Guo GM, 2003, AM J SURG PATHOL, V27, P1147, DOI 10.1097/00000478-200308000-00013; Gupta A, 2016, HISTOPATHOLOGY, V68, P938, DOI 10.1111/his.12875; Gupta NK, 2013, AM J SURG PATHOL, V37, P1109, DOI 10.1097/PAS.0b013e31828a827a; Gutierrez Y, 1996, AM J SURG PATHOL, V20, P603, DOI 10.1097/00000478-199605000-00007; HAWORTH SJ, 1984, GUT, V25, P1296, DOI 10.1136/gut.25.11.1296; Heresbach D, 2005, GUT, V54, P215, DOI 10.1136/gut.2004.041715; Hizawa K, 1996, J CLIN GASTROENTEROL, V23, P78, DOI 10.1097/00004836-199607000-00025; Holland SM, 2013, HEMATOL ONCOL CLIN N, V27, P89, DOI 10.1016/j.hoc.2012.11.002; Hussain N, 2006, CLIN GASTROENTEROL H, V4, P73, DOI 10.1016/S1542-3565(05)00858-X; Kamani L, 2008, SINGAP MED J, V49, pE222; Koreishi A, 2007, AM J SURG PATHOL, V31, P1469, DOI 10.1097/PAS.0b013e318032c473; Kumar Vinay, 2014, ROBBINS COTRAN PATHO, P96; Lamps LW, 2007, HISTOPATHOLOGY, V50, P55, DOI 10.1111/j.1365-2559.2006.02544.x; Lamps LW, 2001, AM J SURG PATHOL, V25, P508, DOI 10.1097/00000478-200104000-00011; Lauwers GY, 2010, J GASTROENTEROL, V45, P131, DOI 10.1007/s00535-009-0146-3; Lee FD, 1997, J CLIN PATHOL, V50, P148, DOI 10.1136/jcp.50.2.148; Lorenzi L, 2012, J CROHNS COLITIS, V6, P800, DOI 10.1016/j.crohns.2012.03.009; Maeng L, 2004, AM J SURG PATHOL, V28, P941, DOI 10.1097/00000478-200407000-00015; Mahadeva U, 2002, HISTOPATHOLOGY, V41, P50, DOI 10.1046/j.1365-2559.2002.01416.x; Makharia GK, 2010, AM J GASTROENTEROL, V105, P642, DOI 10.1038/ajg.2009.585; Marks DJB, 2009, AM J GASTROENTEROL, V104, P117, DOI 10.1038/ajg.2008.72; Miyamoto M, 2003, J GASTROENTEROL, V38, P371, DOI 10.1007/s005350300066; Molnar T, 2005, WORLD J GASTROENTERO, V11, P3118, DOI 10.3748/wjg.v11.i20.3118; MOONEY EE, 1995, J CLIN PATHOL, V48, P335, DOI 10.1136/jcp.48.4.335; Nowacki NB, 2015, AM J SURG PATHOL, V39, P84, DOI 10.1097/PAS.0000000000000308; Oberhuber G, 1997, GASTROENTEROLOGY, V112, P698, DOI 10.1053/gast.1997.v112.pm9041230; Ozturk Y, 2004, J PEDIATR GASTR NUTR, V39, P286, DOI 10.1097/00005176-200409000-00011; Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X; Pulimood AB, 1999, GUT, V45, P537, DOI 10.1136/gut.45.4.537; Renault M, 2010, J CLIN PATHOL, V63, P347, DOI 10.1136/jcp.2009.074161; Richards ML, 1997, J AM COLL SURGEONS, V185, P13, DOI 10.1016/S1072-7515(01)00875-4; Rose CD, 2011, CURR OPIN RHEUMATOL, V23, P411, DOI 10.1097/BOR.0b013e328349c430; ROTTERDAM H, 1977, AM J CLIN PATHOL, V67, P550; Rubio CA, 2007, J CLIN PATHOL, V60, P1268, DOI 10.1136/jcp.2006.045336; Seve P, 2005, J INTERN MED, V258, P191, DOI 10.1111/j.1365-2796.2005.01525.x; Simillis C, 2010, DIS COLON RECTUM, V53, P177, DOI 10.1007/DCR.0b013e3181b7bfb0; SINNIAH B, 1991, ANN TROP MED PARASIT, V85, P625, DOI 10.1080/00034983.1991.11812618; Skef W, 2015, WORLD J GASTROENTERO, V21, P3801, DOI 10.3748/wjg.v21.i13.3801; Sood Ajit, 2014, Curr Gastroenterol Rep, V16, P418, DOI 10.1007/s11894-014-0418-9; Srivastava A, 2007, HISTOPATHOLOGY, V50, P15, DOI 10.1111/j.1365-2559.2006.02553.x; Thomson ABR, 2012, WORLD J GASTROENTERO, V18, P4823, DOI 10.3748/wjg.v18.i35.4823; WAKEFIELD AJ, 1991, GASTROENTEROLOGY, V100, P1279; Warren BF, 1997, J CLIN PATHOL, V50, P880, DOI 10.1136/jcp.50.10.880-b; Wright CL, 1998, AM J SURG PATHOL, V22, P383, DOI 10.1097/00000478-199804000-00001; Yantiss RK, 2006, HISTOPATHOLOGY, V48, P116, DOI 10.1111/j.1365-2559.2005.02248.x; Ye ZY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002157	72	2	2	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JAN	2018	472	1					3	14		10.1007/s00428-017-2210-3			12	Pathology	Pathology	FZ3FX	WOS:000427473200002	28776106				2019-10-28	
J	McCarthy, AJ; Sheahan, K				McCarthy, Aoife J.; Sheahan, Kieran			Classification of eosinophilic disorders of the small and large intestine	VIRCHOWS ARCHIV			English	Review						Colitis; Enteritis; Eosinophilic; Eosinophils; Gastroenteritis; Intestine	MYELOPROLIFERATIVE VARIANT; GASTROINTESTINAL DISORDERS; LYMPHOCYTIC COLITIS; FOOD ALLERGIES; MAST-CELLS; GASTROENTERITIS; PATHOLOGY; DISEASE; ESOPHAGITIS; TRACT	Eosinophilic gastrointestinal diseases (EGIDs), including eosinophilic gastroenteritis and eosinophilic colitis, have been increasing in prevalence in Western countries in recent years. Eosinophils are normally scanty in the gastrointestinal tract, and increased numbers of eosinophils can denote pathology. Normal values for tissue eosinophils vary widely between different segments of the colon, thus location of the biopsy is critically important for the interpretation of findings. However, no standard diagnostic criteria have been proposed for the diagnosis of eosinophilic gastroenteritis or eosinophilic colitis. Gut eosinophilia encompasses entitites that are predominantly immunoglobulin E (IgE)-mediated, the primary EGIDs and those that are secondary and not IgE-mediated. A final diagnosis of eosinophilic gastrointestinal diseases requires careful pathological assessment, clinical correlation and exclusion of several differential diagnoses.	[McCarthy, Aoife J.; Sheahan, Kieran] St Vincents Univ Hosp, Dept Histopathol, Elm Pk, Dublin 4, Ireland; [McCarthy, Aoife J.; Sheahan, Kieran] Univ Coll Dublin, Sch Med, Dublin, Ireland	McCarthy, AJ (reprint author), St Vincents Univ Hosp, Dept Histopathol, Elm Pk, Dublin 4, Ireland.; McCarthy, AJ (reprint author), Univ Coll Dublin, Sch Med, Dublin, Ireland.	aoifejmccarthy@hotmail.com		McCarthy, Aoife J./0000-0003-0806-0924			Aceves S, 2012, SEMIN IMMUNOPATHOL, V34, P715, DOI 10.1007/s00281-012-0324-x; Ahmad M, 2000, J CLIN GASTROENTEROL, V30, P242, DOI 10.1097/00004836-200004000-00007; Al-Haddad S, 2005, GUT, V54, P1674, DOI 10.1136/gut.2005.072595; Alfadda AA, 2014, COLORECTAL DIS, V16, P123, DOI 10.1111/codi.12464; Alfadda AA, 2011, BRIT MED BULL, V100, P59, DOI 10.1093/bmb/ldr045; Alfadda Abdulrahman A, 2011, Therap Adv Gastroenterol, V4, P301, DOI 10.1177/1756283X10392443; ANTTILA VJ, 1992, EPILEPSIA, V33, P119, DOI 10.1111/j.1528-1157.1992.tb02293.x; Barbie DA, 2004, J CLIN GASTROENTEROL, V38, P883, DOI 10.1097/00004836-200411000-00010; Bass JA, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0359-2; Bates WH, 2012, SCI CAIRO; Behm CA, 2000, PARASITOL TODAY, V16, P202, DOI 10.1016/S0169-4758(99)01620-8; BOLINN GW, 1985, J CLIN INVEST, V75, P1559, DOI 10.1172/JCI111861; BRIDGES AJ, 1990, AM J MED, V89, P526, DOI 10.1016/0002-9343(90)90386-R; Brown IS, 2012, AM J CLIN PATHOL, V138, P42, DOI 10.1309/AJCPE89ZPVJTSPWL; Carvalho ATP, 2003, J CLIN GASTROENTEROL, V36, P120, DOI 10.1097/00004836-200302000-00006; Chen MJ, 2003, WORLD J GASTROENTERO, V9, P2813; Cherian S, 2006, ARCH DIS CHILD, V91, P1000, DOI 10.1136/adc.2006.100974; Cianferoni A, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0558-5; Ciani S, 2000, PATHOL RES PRACT, V196, P89, DOI 10.1016/S0344-0338(00)80038-2; CLOUSE RE, 1992, GASTROENTEROLOGY, V103, P168, DOI 10.1016/0016-5085(92)91110-P; Conner JR, 2017, HISTOPATHOLOGY, V71, P177, DOI 10.1111/his.13228; DABBS DJ, 1993, AM J SURG PATHOL, V17, P497, DOI 10.1097/00000478-199305000-00009; De Maeyer N, 2011, ACTA GASTRO-ENT BELG, V74, P570; DeBrosse CW, 2006, PEDIATR DEVEL PATHOL, V9, P210, DOI 10.2350/11-05-0130.1; DESCHRYVERKECSKEMETI K, 1984, AM J SURG PATHOL, V8, P171, DOI 10.1097/00000478-198403000-00002; Fernandez Salazar L I, 2013, J Crohns Colitis, V7, pe20, DOI 10.1016/j.crohns.2012.06.013; Foroughi S, 2007, J ALLERGY CLIN IMMUN, V120, P594, DOI 10.1016/j.jaci.2007.06.015; Friedberg J W, 1995, Ann Clin Psychiatry, V7, P97, DOI 10.3109/10401239509149034; GOLDMAN H, 1986, AM J SURG PATHOL, V10, P75, DOI 10.1097/00000478-198602000-00001; Gonsalves N, 2007, GASTROENTEROL CLIN N, V36, P75, DOI 10.1016/j.gtc.2007.01.003; Guajardo JR, 2002, J PEDIATR-US, V141, P576, DOI 10.1067/mpd.2002.127663; Hong ST, 2003, J KOREAN MED SCI, V18, P429, DOI 10.3346/jkms.2003.18.3.429; Inamura H, 2006, Allergol Immunopathol (Madr), V34, P228, DOI 10.1157/13094031; Ingle SB, 2013, WORLD J GASTROENTERO, V19, P5061, DOI 10.3748/wjg.v19.i31.5061; Jawairia M, 2012, ISRN GASTROENTEROL; Jeziorska M, 2001, J PATHOL, V194, P484, DOI 10.1002/path.904; Jimenez-Saenz M, 2006, J CLIN GASTROENTEROL, V40, P84; Jimenez-Saenz M, 2006, CLIN ALERT, V44, P1; Kato M, 1998, ANAT REC, V252, P418, DOI 10.1002/(SICI)1097-0185(199811)252:3<418::AID-AR10>3.0.CO;2-1; Khan Seema, 2002, Paediatr Drugs, V4, P563; Klion AD, 2004, BLOOD, V103, P473, DOI 10.1182/blood-2003-08-2798; Klion AD, 2003, BLOOD, V101, P4660, DOI 10.1182/blood-2003-01-0006; Lampinen M, 2005, GUT, V54, P1714, DOI 10.1136/gut.2005.066423; LANGE P, 1994, LANCET, V344, P1296, DOI 10.1016/S0140-6736(94)90782-X; LEE CM, 1993, AM J GASTROENTEROL, V88, P70; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Lowichik A, 1996, MODERN PATHOL, V9, P110; Lucendo AJ, 2010, SCAND J GASTROENTERO, V45, P1013, DOI 10.3109/00365521003690251; MARTIN DM, 1981, GASTROENTEROLOGY, V80, P1567; Matsushita T, 2015, AM J SURG PATHOL, V39, P521, DOI 10.1097/PAS.0000000000000370; MILLS LR, 1993, DIGEST DIS SCI, V38, P1147, DOI 10.1007/BF01295734; Minematsu H, 2011, DIGESTION, V83, P210, DOI 10.1159/000321812; Mueller S, 2006, J CLIN PATHOL, V59, P1175, DOI 10.1136/jcp.2005.031922; Mueller S, 2008, BEST PRACT RES CL GA, V22, P425, DOI 10.1016/j.bpg.2007.12.008; NAYLOR AR, 1985, DIS COLON RECTUM, V28, P615; NOLTE H, 1990, GUT, V31, P791, DOI 10.1136/gut.31.7.791; ODZE RD, 1995, J PEDIATR-US, V126, P163, DOI 10.1016/S0022-3476(95)70540-6; ODZE RD, 1993, HUM PATHOL, V24, P668, DOI 10.1016/0046-8177(93)90248-F; Oh HE, 2008, J GASTROENTEROL, V43, P741, DOI 10.1007/s00535-008-2230-5; Pascal RR, 1997, MODERN PATHOL, V10, P363; Polydorides AD, 2008, HUM PATHOL, V39, P832, DOI 10.1016/j.humpath.2007.10.012; Ronkainen J, 2007, GUT, V56, P615, DOI 10.1136/gut.2006.107714; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Roufosse FE, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-37; Rubio CA, 2003, PATHOL RES PRACT, V199, P145, DOI 10.1078/0344-0338-00367; Saad AG, 2011, PEDIATR DEVEL PATHOL, V14, P294, DOI 10.2350/10-07-0878-OA.1; Saeed SA, 2006, PEDIATR TRANSPLANT, V10, P730, DOI 10.1111/j.1399-3046.2006.00538.x; Schwab D, 2003, AM J GASTROENTEROL, V98, P1525, DOI 10.1016/S0002-9270(03)00259-4; Solans R, 2001, RHEUMATOLOGY, V40, P763, DOI 10.1093/rheumatology/40.7.763; Stein ML, 2008, J ALLERGY CLIN IMMUN, V121, P1473, DOI 10.1016/j.jaci.2008.02.033; Straumann A, 2008, BEST PRACT RES CL GA, V22, P481, DOI 10.1016/j.bpg.2007.09.001; Talley NJ, 2007, CLIN GASTROENTEROL H, V5, P1175, DOI 10.1016/j.cgh.2007.05.015; TALLEY NJ, 1990, GUT, V31, P54, DOI 10.1136/gut.31.1.54; Tanaka M, 2003, SCAND J GASTROENTERO, V38, P594, DOI 10.1080/00365520310000564; Tanaka M, 2002, SCAND J GASTROENTERO, V37, P200, DOI 10.1080/003655202753416885; Tsibouris P, 2005, DIGEST DIS SCI, V50, P2389, DOI 10.1007/s10620-005-3069-8; Turner KO, 2017, AM J SURG PATHOL, V41, P225, DOI 10.1097/PAS.0000000000000760; Uppal V, 2016, CLIN REV ALLERG IMMU, V50, P175, DOI 10.1007/s12016-015-8489-4; Uzunismail Hulya, 2006, Turk J Gastroenterol, V17, P53; Velchuru VR, 2007, J GASTROINTEST SURG, V11, P1373, DOI 10.1007/s11605-006-0055-1; Villanacci V, 2014, J CROHNS COLITIS, V8, P1438, DOI 10.1016/j.crohns.2014.05.003; WALKER NI, 1995, AM J SURG PATHOL, V19, P328, DOI 10.1097/00000478-199503000-00011; Weidenhiller M, 2005, GUT, V54, P312, DOI 10.1136/gut.2004.049767; WELLER PF, 1994, BLOOD, V83, P2759, DOI 10.1182/blood.V83.10.2759.2759; WINTER HS, 1990, MODERN PATHOL, V3, P5; Xu X, 2004, SCAND J GASTROENTERO, V39, P440, DOI 10.1080/00365520310008566; Yan BM, 2009, GUT, V58, P721, DOI 10.1136/gut.2008.165894; Yantiss RK, 2015, MODERN PATHOL, V28, pS7, DOI 10.1038/modpathol.2014.132; Yun MY, 2007, WORLD J GASTROENTERO, V13, P1758, DOI 10.3748/wjg.v13.i11.1758; Zezos P, 2014, COLORECTAL DIS, V16, pO420, DOI 10.1111/codi.12725	90	2	2	2	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JAN	2018	472	1					15	28		10.1007/s00428-017-2249-1			14	Pathology	Pathology	FZ3FX	WOS:000427473200003	29127496				2019-10-28	
J	Johncilla, ME; Srivastava, A				Johncilla, Melanie E.; Srivastava, Amitabh			Esophagitis unrelated to reflux disease: current status and emerging diagnostic challenges	VIRCHOWS ARCHIV			English	Review						Esophagus; Inflammation; Histopathology; Eosinophilic esophagitis; Lymphocytic esophagitis; Leukoplakia	ORAL LICHEN-PLANUS; EOSINOPHILIC ESOPHAGITIS; LYMPHOCYTIC ESOPHAGITIS; GASTROINTESTINAL-TRACT; SLOUGHING ESOPHAGITIS; CONSENSUS RECOMMENDATIONS; SWALLOWED FLUTICASONE; EPIDERMOID METAPLASIA; PEMPHIGUS-VULGARIS; HOST-DISEASE	There has been much progress in our understanding of esophageal inflammatory disorders in the past few years. This is particularly true about esophageal eosinophilia and PPI responsiveness, lymphocytic esophagitis and motility disorders, and short-term risk of neoplasia in esophageal leukoplakia. The current review will summarize esophageal injury patterns that primarily occur due to non-reflux causes, with a focus on usual pitfalls in biopsy diagnosis and recent advances in our knowledge of the more common forms of esophagitis.	[Johncilla, Melanie E.] Weill Cornell Med Coll, Dept Pathol, New York, NY USA; [Srivastava, Amitabh] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA	Srivastava, A (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	asrivastava@bwh.harvard.edu					Abraham SC, 2000, AM J SURG PATHOL, V24, P1678, DOI 10.1097/00000478-200012000-00014; Abraham SC, 1999, AM J SURG PATHOL, V23, P1241, DOI 10.1097/00000478-199910000-00009; Abraham SC, 1999, MODERN PATHOL, V12, P1152; Ahmadi Bahram, 2003, American Journal of Gastroenterology, V98, pS214, DOI 10.1016/j.amjgastroenterol.2003.09.016; Basseri Benjamin, 2013, Gastroenterol Hepatol (N Y), V9, P505; Baum S, 2014, AUTOIMMUN REV, V13, P482, DOI 10.1016/j.autrev.2014.01.047; Boyce HW, 1998, GASTROINTEST ENDOSC, V47, P547, DOI 10.1016/S0016-5107(98)70264-0; BRIGGS GW, 1961, ANN INTERN MED, V55, P943, DOI 10.7326/0003-4819-55-6-943; Carmack SW, 2009, AM J SURG PATHOL, V33, P1789, DOI 10.1097/PAS.0b013e3181b7ce21; Chang S, 2014, CLIN ENDOSC, V47, P452, DOI 10.5946/ce.2014.47.5.452; Chen Z, 2009, J CLIN PATHOL, V62, P113, DOI 10.1136/jcp.2008.058263; Chryssostalis A, 2008, ENDOSCOPY, V40, P764, DOI 10.1055/s-2008-1077357; Cohen S, 2012, J CLIN GASTROENTEROL, V46, P828, DOI 10.1097/MCG.0b013e3182500de8; Collins MH, 2014, GASTROENTEROL CLIN N, V43, P257, DOI 10.1016/j.gtc.2014.02.007; COSTIGAN DJ, 1983, DIGEST DIS SCI, V28, P763, DOI 10.1007/BF01312569; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; Dellon ES, 2013, AM J GASTROENTEROL, V108, P1854, DOI 10.1038/ajg.2013.363; Ebach DR, 2011, INFLAMM BOWEL DIS, V17, P45, DOI 10.1002/ibd.21347; Ezoe Y, 2011, HEPATO-GASTROENTEROL, V58, P809; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; GOLDBERG NS, 1989, J AM ACAD DERMATOL, V21, P1115, DOI 10.1016/S0190-9622(89)70309-1; Graham DY, 2002, DIGEST DIS SCI, V47, P1665, DOI 10.1023/A:1016495221567; Haque S, 2012, GUT, V61, P1108, DOI 10.1136/gutjnl-2011-301014; Hirano I, 2013, GUT, V62, P489, DOI 10.1136/gutjnl-2011-301817; Ip S, 2016, DIGEST DIS SCI, V61, P2351, DOI 10.1007/s10620-016-4142-1; Isomoto H, 2004, AM J GASTROENTEROL, V99, P1063, DOI 10.1111/j.1572-0241.2004.30847.x; Iwakura N, 2015, ALIMENT PHARM THER, V41, P776, DOI 10.1111/apt.13141; Katzka DA, 2010, CLIN GASTROENTEROL H, V8, P777, DOI 10.1016/j.cgh.2010.04.024; Kay M, 2009, CURR OPIN PEDIATR, V21, P651, DOI 10.1097/MOP.0b013e32832e2764; KAYE MD, 1987, GASTROINTEST ENDOSC, V33, P254, DOI 10.1016/S0016-5107(87)71576-4; Kia L, 2015, NAT REV GASTRO HEPAT, V12, P379, DOI 10.1038/nrgastro.2015.75; Lazaraki G, 2009, DIS ESOPHAGUS, V22, pE21, DOI 10.1111/j.1442-2050.2008.00903.x; LEE FD, 1994, HISTOPATHOLOGY, V25, P303, DOI 10.1111/j.1365-2559.1994.tb01347.x; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lucendo AJ, 2016, CLIN GASTROENTEROL H, V14, P13, DOI 10.1016/j.cgh.2015.07.041; LUND WS, 1976, J LARYNGOL OTOL, V90, P105, DOI 10.1017/S0022215100081810; Maiorana A, 2003, HUM PATHOL, V34, P1331, DOI 10.1016/j.humpath.2003.08.005; Millar AJW, 2015, PEDIATR SURG INT, V31, P111, DOI 10.1007/s00383-014-3642-3; Moawad FJ, 2013, AM J GASTROENTEROL, V108, P366, DOI 10.1038/ajg.2012.443; Molina-Infante J, 2014, ALIMENT PHARM THER, V40, P955, DOI 10.1111/apt.12914; Molina-Infante J, 2011, CLIN GASTROENTEROL H, V9, P110, DOI 10.1016/j.cgh.2010.09.019; NOVAK JM, 1979, J CLIN GASTROENTEROL, V1, P9, DOI 10.1097/00004836-197903000-00003; Parfitt JR, 2007, HUM PATHOL, V38, P527, DOI 10.1016/j.humpath.2007.01.014; Peterson KA, 2010, DIGEST DIS SCI, V55, P1313, DOI 10.1007/s10620-009-0859-4; POSTLETHWAIT RW, 1974, J THORAC CARDIOV SUR, V68, P953; Purdy JK, 2008, AM J CLIN PATHOL, V130, P508, DOI 10.1309/D3PCF6D6YYMQRX9A; Purdy JK, 2012, MODERN PATHOL, V25, P767, DOI 10.1038/modpathol.2011.204; Putra J, 2016, AM J SURG PATHOL, V40, P1679, DOI 10.1097/PAS.0000000000000712; Quispel R, 2009, ENDOSCOPY, V41, P187, DOI 10.1055/s-0028-1119590; Riffat F, 2009, DIS ESOPHAGUS, V22, P89, DOI 10.1111/j.1442-2050.2008.00867.x; RUBINOW A, 1983, AM J MED, V75, P951, DOI 10.1016/0002-9343(83)90874-4; Rubio CA, 2017, J CLIN PATHOL, V70, P208, DOI 10.1136/jclinpath-2016-203782; Rubio CA, 2006, AM J CLIN PATHOL, V125, P432, DOI 10.1309/7LABLGY08UEM3H26; Salaria SN, 2013, AM J SURG PATHOL, V37, P1889, DOI 10.1097/PAS.0b013e31829dff19; Sayej WN, 2009, J PEDIATR GASTR NUTR, V49, P393, DOI 10.1097/MPG.0b013e31819c4b3e; SCHULLY C, 1985, J ORAL PATHOL MED, V14, P431, DOI 10.1111/j.1600-0714.1985.tb00516.x; SEAMAN WB, 1957, RADIOLOGY, V68, P534, DOI 10.1148/68.4.534; SILVERMAN S, 1985, ORAL SURG ORAL MED O, V60, P30, DOI 10.1016/0030-4220(85)90210-5; SILVERMAN S, 1991, ORAL SURG ORAL MED O, V72, P665, DOI 10.1016/0030-4220(91)90007-Y; Singhi AD, 2014, MODERN PATHOL, V27, P38, DOI 10.1038/modpathol.2013.100; Straumann A, 2012, ALLERGY, V67, P477, DOI 10.1111/j.1398-9995.2012.02787.x; Sutton LM, 2014, INFLAMM BOWEL DIS, V20, P1324, DOI 10.1097/MIB.0000000000000100; TADA S, 1990, GASTROINTEST ENDOSC, V36, P10, DOI 10.1016/S0016-5107(90)70913-3; Taggart MW, 2013, HISTOPATHOLOGY, V63, P463, DOI 10.1111/his.12195; Trabulo D, 2015, WORLD J GASTROENTERO, V21, P9217, DOI 10.3748/wjg.v21.i30.9217; Uygun I, 2012, ACTA CHIR BELG, V112, P346; Warners MJ, 2015, EUR J GASTROEN HEPAT, V27, P506, DOI 10.1097/MEG.0000000000000331; Wen T, 2015, J ALLERGY CLIN IMMUN, V135, P187, DOI 10.1016/j.jaci.2014.08.043; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Wishingrad M, 1999, GASTROINTEST ENDOSC, V50, P845, DOI 10.1016/S0016-5107(99)70172-0; Xue Y, 2015, AM J SURG PATHOL, V39, P1558, DOI 10.1097/PAS.0000000000000493; Zerbib F, 2015, J CLIN GASTROENTEROL, V49, P451, DOI 10.1097/MCG.0000000000000317	72	1	1	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JAN	2018	472	1					29	41		10.1007/s00428-017-2238-4			13	Pathology	Pathology	FZ3FX	WOS:000427473200004	29034419				2019-10-28	
J	Biswas, S; Quante, M; Leedham, S; Jansen, M				Biswas, Sujata; Quante, Michael; Leedham, Simon; Jansen, Marnix			The metaplastic mosaic of Barrett's oesophagus	VIRCHOWS ARCHIV			English	Review						Metaplasia; Barrett's oesophagus; Inflammation; Lineage tracing	INTESTINAL METAPLASIA; COLUMNAR EPITHELIUM; GASTRIC CARDIA; GOBLET CELLS; ADENOCARCINOMA; RISK; DIFFERENTIATION; POPULATION; EXPRESSION; REGENERATION	Barrett's oesophagus surveillance biopsies represent a significant share of the daily workload for a busy histopathology department. Given the emphasis on endoscopic detection and dysplasia grading, it is easy to forget that the benefits of these screening programs remain unproven. The majority of patients are at low risk of progression to oesophageal adenocarcinoma, and periodic surveillance of these patients is burdensome and costly. Here, we investigate the parallels in the development of Barrett's oesophagus and other scenarios of wound healing in the intestine. There is now increased recognition of the full range of glandular phenotypes that can be found in patients' surveillance biopsies, and emerging evidence suggests parallel pathways to oesophageal adenocarcinoma. Greater understanding of the conditions that favour progression to cancer in the distal oesophagus will allow us to focus resources on patients at increased risk.	[Biswas, Sujata; Leedham, Simon] Univ Oxford, Nuffield Dept Med, Oxford, England; [Quante, Michael] Tech Univ Munich, Klinikum Rechts Isar, Med Klin 2, Munich, Germany; [Jansen, Marnix] UCL, Inst Canc, London, England; [Jansen, Marnix] Univ Coll London Hosp, London, England	Leedham, S (reprint author), Univ Oxford, Nuffield Dept Med, Oxford, England.; Jansen, M (reprint author), UCL, Inst Canc, London, England.; Jansen, M (reprint author), Univ Coll London Hosp, London, England.	simonl@well.ox.ac.uk; m.jansen@ucl.ac.uk	BISWAS, SUJATA/N-6521-2016	BISWAS, SUJATA/0000-0002-0700-7286	Cancer Research UKCancer Research UK [A22745]; Medical Research CouncilMedical Research Council UK (MRC) [MR/L016508/1]		Aida J, 2015, AM J SURG PATHOL, V39, P188, DOI 10.1097/PAS.0000000000000350; Bhat S, 2011, J NATL CANCER I, V103, P1049, DOI 10.1093/jnci/djr203; CAMERON AJ, 1992, GASTROENTEROLOGY, V103, P1241, DOI 10.1016/0016-5085(92)91510-B; Cancer Research UK, 2016, TEST TIM COM EV PATH, P1; Choi E, 2014, GUT, V63, P1711, DOI 10.1136/gutjnl-2013-305964; Clemons NJ, 2012, AM J PHYSIOL-GASTR L, V303, pG1335, DOI 10.1152/ajpgi.00291.2012; Cooper GS, 2009, AM J GASTROENTEROL, V104, P1356, DOI 10.1038/ajg.2009.159; Corley DA, 2009, GUT, V58, P182, DOI 10.1136/gut.2008.163360; Corley DA, 2013, GASTROENTEROLOGY, V145, P312, DOI 10.1053/j.gastro.2013.05.004; Derakhshan MH, 2015, AM J GASTROENTEROL, V110, P1505, DOI 10.1038/ajg.2015.288; di Pietro M, 2015, GASTROENTEROLOGY, V148, P912, DOI 10.1053/j.gastro.2015.02.012; Dunbar KB, 2016, JAMA-J AM MED ASSOC, V315, P2104, DOI 10.1001/jama.2016.5657; Erichsen R, 2017, ALIMENT PHARM THER, V45, P973, DOI 10.1111/apt.13962; Fitzgerald RC, 2014, GUT, V63, P7, DOI 10.1136/gutjnl-2013-305372; Gaddam S, 2013, GASTROENTEROLOGY, V145, P548, DOI 10.1053/j.gastro.2013.05.040; Going JJ, 2004, NEOPLASIA, V6, P85; Hahn HP, 2009, AM J SURG PATHOL, V33, P1006, DOI 10.1097/PAS.0b013e31819f57e9; HAMILTON SR, 1977, GASTROENTEROLOGY, V72, P669; Harrison R, 2007, AM J GASTROENTEROL, V102, P1154, DOI 10.1111/j.1572-0241.2007.01230.x; Humphries A, 2008, NAT REV CANCER, V8, P415, DOI 10.1038/nrc2392; Hur C, 2012, CANCER, V119, P1149; Hvid-Jensen F, 2011, NEW ENGL J MED, V365, P1375, DOI 10.1056/NEJMoa1103042; Kelty CJ, 2007, SCAND J GASTROENTERO, V42, P1271, DOI 10.1080/00365520701420735; Khor TS, 2012, AM J SURG PATHOL, V36, P331, DOI 10.1097/PAS.0b013e31823d08d6; Kostadinov RL, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003553; Lavery DL, 2016, GUT, V65, P907, DOI 10.1136/gutjnl-2015-310748; Lavery DL, 2014, GUT, V63, P1854, DOI 10.1136/gutjnl-2013-306508; Li X, 2015, CANCER PREV RES, V8, P845, DOI 10.1158/1940-6207.CAPR-15-0130; Liu W, 2009, AM J GASTROENTEROL, V104, P816, DOI 10.1038/ajg.2009.85; McDonald SAC, 2015, CELL MOL GASTROENTER, V1, P41, DOI 10.1016/j.jcmgh.2014.10.001; Miyoshi H, 2012, SCIENCE, V338, P108, DOI 10.1126/science.1223821; Palles C, 2015, GASTROENTEROLOGY, V148, P367, DOI 10.1053/j.gastro.2014.10.041; PAULL A, 1976, NEW ENGL J MED, V295, P476, DOI 10.1056/NEJM197608262950904; Pohl H, 2005, J NATL CANCER I, V97, P142, DOI 10.1093/jnci/dji024; Quante M, 2017, GASTROENTEROLOGY; Quante M, 2012, CANCER CELL, V21, P36, DOI 10.1016/j.ccr.2011.12.004; Reis CA, 1999, CANCER RES, V59, P1003; Reveiller M, 2012, ANN SURG, V255, P1113, DOI 10.1097/SLA.0b013e3182512af9; Riddell RH, 2009, AM J GASTROENTEROL, V104, P2588, DOI 10.1038/ajg.2009.390; Robertson EV, 2013, GASTROENTEROLOGY, V145, P730, DOI 10.1053/j.gastro.2013.06.038; Ronkainen J, 2005, GASTROENTEROLOGY, V129, P1825, DOI 10.1053/j.gastro.2005.08.053; Rubenstein JH, 2015, GASTROENTEROLOGY, V149, P302, DOI 10.1053/j.gastro.2015.04.053; Schellnegger R, 2017, CANCER PREV RES, V10, P55, DOI 10.1158/1940-6207.CAPR-16-0117; Spechler SJ, 2014, NEW ENGL J MED, V371, P836, DOI 10.1056/NEJMra1314704; Spechler SJ, 2011, GASTROENTEROLOGY, V140, pE18, DOI 10.1053/j.gastro.2011.01.031; Srivastava A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133403; Sturmer R, 2014, CELL PHYSIOL BIOCHEM, V33, P895, DOI 10.1159/000358662; Takubo K, 2009, HUM PATHOL, V40, P65, DOI 10.1016/j.humpath.2008.06.008; Theodorou D, 2012, J GASTROINTEST SURG, V16, P469, DOI 10.1007/s11605-011-1776-3; Vaughan TL, 2015, NAT REV GASTRO HEPAT, V12, P243, DOI 10.1038/nrgastro.2015.24; Vaughan TL, 2005, LANCET ONCOL, V6, P945, DOI 10.1016/S1470-2045(05)70431-9; Welch HG, 2010, J NATL CANCER I, V102, P605, DOI 10.1093/jnci/djq099; Wright NA, 1998, PHILOS T R SOC B, V353, P925, DOI 10.1098/rstb.1998.0257; Yantiss RK, 2010, ARCH PATHOL LAB MED, V134, P1589, DOI 10.1043/2009-0547-RAR1.1	54	0	1	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JAN	2018	472	1					43	54		10.1007/s00428-018-2317-1			12	Pathology	Pathology	FZ3FX	WOS:000427473200005	29500519	Green Published			2019-10-28	
J	Umetsu, SE; Brown, I; Langner, C; Lauwers, GY				Umetsu, Sarah E.; Brown, Ian; Langner, Cord; Lauwers, Gregory Y.			Autoimmune enteropathies	VIRCHOWS ARCHIV			English	Review						Autoimmune disease; Immunodeficiency; Drug induced; Inherited disease; Enteritis; Colitis	OLMESARTAN-ASSOCIATED ENTEROPATHY; COMMON VARIABLE IMMUNODEFICIENCY; INFLAMMATORY-BOWEL-DISEASE; IMMUNE DYSREGULATION; SENSITIVE ENTEROPATHY; PROTRACTED DIARRHEA; VILLOUS ATROPHY; POLYENDOCRINOPATHY; BLOCKADE; GUT	Autoimmune enteropathy (AIE) is a rare condition characterized by intractable diarrhea and immune-mediated injury of the intestinal mucosa. As the clinical and histopathologic manifestations of this disease are highly variable, its diagnosis is challenging for both clinicians and pathologists. In fact, the term autoimmune enteropathies is likely more appropriate since the clinicopathologic manifestations are observed in association with a heterogeneous group of disorders. The pathophysiology of AIE has not been fully elucidated. It appears to result from dysregulation of intestinal immunity and particularly in children, often presents in association with immunodeficiency. The overarching histopathologic changes seen in AIE include mucosal inflammation and epithelial injury, although this can manifest in the form of different patterns. Recognition of the clinical settings and of the various histologic patterns can aid the pathologist in establishing the correct diagnosis.	[Umetsu, Sarah E.] Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave,Room M551A,Box 0102, San Francisco, CA 94143 USA; [Brown, Ian] Envoi Pathol, Kelvin Grove, Qld, Australia; [Langner, Cord] Med Univ Graz, Inst Pathol, Graz, Austria; [Lauwers, Gregory Y.] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL USA	Umetsu, SE (reprint author), Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave,Room M551A,Box 0102, San Francisco, CA 94143 USA.	sarah.umetsu@ucsf.edu	Brown, Ian/R-7763-2016	Brown, Ian/0000-0001-6329-2547			Abdel-Rahman O, 2015, IMMUNOTHERAPY-UK, V7, P1213, DOI 10.2217/imt.15.87; Agarwal S, 2009, CURR ALLERGY ASTHM R, V9, P347, DOI 10.1007/s11882-009-0051-0; Akram S, 2007, CLIN GASTROENTEROL H, V5, P1282, DOI 10.1016/j.cgh.2007.05.013; Bacchetta R, 2016, ANN N Y ACAD SCI; Bamias G, 2017, CANCER INVEST, V35, P443, DOI 10.1080/07357907.2017.1324032; Bennett CL, 2001, CURR OPIN PEDIATR, V13, P533, DOI 10.1097/00008480-200112000-00007; Biagi F, 2009, AM J GASTROENTEROL, V104, P3112, DOI 10.1038/ajg.2009.511; Catassi C, 1999, J PEDIATR GASTR NUTR, V29, P63, DOI 10.1097/00005176-199907000-00016; Collins M, 2017, J CROHNS COLITIS, V11, pS237; Corazza GR, 1997, LANCET, V350, P106, DOI 10.1016/S0140-6736(97)01042-8; Coutzac C, 2017, J CROHNS COLITIS, V11, P1238, DOI 10.1093/ecco-jcc/jjx081; Dahan S, 2007, IMMUNOL REV, V215, P243, DOI 10.1111/j.1600-065X.2006.00484.x; de Serre NPM, 2009, MODERN PATHOL, V22, P95, DOI 10.1038/modpathol.2008.161; Elwing JE, 2005, DIGEST DIS SCI, V50, P928, DOI 10.1007/s10620-005-2666-x; Esteve M, 2016, DIGEST LIVER DIS, V48, P154, DOI 10.1016/j.dld.2015.09.014; FIOCCHI C, 1989, ANN INTERN MED, V110, P786, DOI 10.7326/0003-4819-110-10-786; FONTAINE JL, 1975, ARCH DIS CHILD, V50, P357, DOI 10.1136/adc.50.5.357; Genre J, 2009, CLIN IMMUNOL, V132, P215, DOI 10.1016/j.clim.2009.03.519; Gentile Nicole M, 2012, Curr Gastroenterol Rep, V14, P380, DOI 10.1007/s11894-012-0276-2; Geyer M, 2014, PEDIATRICS, V134, pE1720, DOI 10.1542/peds.2013-3308; Gonzalez RS, 2017, HISTOPATHOLOGY, V70, P223, DOI 10.1111/his.13068; Goulet OJ, 1998, J PEDIATR GASTR NUTR, V26, P151, DOI 10.1097/00005176-199802000-00006; Kambayashi T, 2014, NAT REV IMMUNOL, V14, P719, DOI 10.1038/nri3754; Kisand K, 2015, J CLIN IMMUNOL, V35, P463, DOI 10.1007/s10875-015-0176-y; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Lagana SM, 2015, J CLIN PATHOL, V68, P29, DOI 10.1136/jclinpath-2014-202615; Leon F, 2004, AM J GASTROENTEROL, V99, P1563, DOI 10.1111/j.1572-0241.2004.40039.x; Lohr NJ, 2010, AM J HUM GENET, V86, P447, DOI 10.1016/j.ajhg.2010.01.028; Louie CY, 2015, AM J SURG PATHOL, V39, P1653, DOI 10.1097/PAS.0000000000000525; Mais DD, 1999, AM J CLIN PATHOL, V112, P810; MALUENDA C, 1984, J PEDIATR GASTR NUTR, V3, P349, DOI 10.1097/00005176-198406000-00008; Marietta EV, 2015, ALIMENT PHARM THER, V42, P1303, DOI 10.1111/apt.13413; Marthey L, 2014, ALIMENT PHARM THER, V40, P1103, DOI 10.1111/apt.12937; MARTINVILLA JM, 1993, LANCET, V342, P380, DOI 10.1016/0140-6736(93)91531-P; Masia R, 2014, AM J SURG PATHOL, V38, P1319, DOI 10.1097/PAS.0000000000000317; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; MIRAKIAN R, 1988, J AUTOIMMUN, V1, P263, DOI 10.1016/0896-8411(88)90032-7; Montalto M, 2009, SCAND J GASTROENTERO, V44, P1029, DOI 10.1080/00365520902783691; Moran CJ, 2012, AM J SURG PATHOL, V36, P1339, DOI 10.1097/PAS.0b013e318254f413; Oble DA, 2008, AM J SURG PATHOL, V32, P1130, DOI 10.1097/PAS.0b013e31817150e3; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Reynoso ED, 2009, J IMMUNOL, V182, P2102, DOI 10.4049/jimmunol.0802769; Rubio-Tapia A, 2012, MAYO CLIN PROC, V87, P732, DOI 10.1016/j.mayocp.2012.06.003; Ruemmele FM, 2004, CURR OPIN GASTROEN, V20, P587, DOI 10.1097/00001574-200411000-00014; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Scialom S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125024; Singhi AD, 2014, MODERN PATHOL, V27, P543, DOI 10.1038/modpathol.2013.150; SKOGH T, 1982, J CLIN LAB IMMUNOL, V9, P147; Tegtmeyer D, 2017, PEDIAT ALLERG IMM-UK, V28, P412, DOI 10.1111/pai.12734; UNSWORTH DJ, 1985, J PEDIATR GASTR NUTR, V4, P375, DOI 10.1097/00005176-198506000-00009; Uzel G, 2013, J ALLERGY CLIN IMMUN, V131, P1611, DOI 10.1016/j.jaci.2012.11.054; Verbsky JW, 2013, CURR OPIN PEDIATR, V25, P708, DOI 10.1097/MOP.0000000000000029; Volta U, 2006, DIGEST LIVER DIS, V38, P926, DOI 10.1016/j.dld.2006.02.003; Volta Umberto, 2016, Gastroenterol Hepatol Bed Bench, V9, P140; WALKERSMITH JA, 1982, LANCET, V1, P566; Walter JE, 2016, J ALLER CL IMM-PRACT, V4, P1089, DOI 10.1016/j.jaip.2016.08.004; Weidner AS, 2015, AM J SURG PATHOL, V39, P1661, DOI 10.1097/PAS.0000000000000522; Wurm P, 2017, CRIT CARE MED, V45, pE600, DOI 10.1097/CCM.0000000000002310	58	4	4	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JAN	2018	472	1					55	66		10.1007/s00428-017-2243-7			12	Pathology	Pathology	FZ3FX	WOS:000427473200006	29022145				2019-10-28	
J	Patil, DT; Odze, RD				Patil, Deepa T.; Odze, Robert D.			Biopsy diagnosis of colitis: an algorithmic approach	VIRCHOWS ARCHIV			English	Review						Colitis; Algorithm; Endoscopic biopsies; Pattern of injury	INFLAMMATORY-BOWEL-DISEASE; TREATED ULCERATIVE-COLITIS; GASTROINTESTINAL-TRACT; CLINICAL-SIGNIFICANCE; MORPHOLOGIC FINDINGS; SKIP LESION; ILEITIS; FEATURES; INJURY; GASTROENTERITIS	Certain types of colitides, such as collagenous colitis, lymphocytic colitis, and ischemic colitis, have distinct histologic features that allow for a specific diagnosis. However, in most colonic biopsy specimens, a definite diagnosis cannot be established on the basis of histology alone. Thus, in most cases of colitis, it is helpful to utilize a systematic approach in order to recognize patterns of injury. This information in conjunction with clinical and laboratory findings may help pathologists narrow the differential diagnosis and/or establish a more definite etiology for the patient's illness in order to guide clinical management. We provide general guidelines to distinguish variations in normal mucosa and biopsy procedure-related artifacts from true inflammatory conditions. Inflammatory conditions may be further categorized into those with predominantly lymphoplasmacytic inflammation (with or without neutrophils), predominantly neutrophilic inflammation, predominantly eosinophilic inflammation, or paucicellular colitis, since each of these patterns of inflammation are associated with a distinct differential diagnosis. This review will focus on a pattern-based algorithmic approach to evaluating biopsies of patients who present to physicians with signs and symptoms of colitis.	[Patil, Deepa T.] Cleveland Clin, Dept Pathol, Cleveland, OH 44106 USA; [Odze, Robert D.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA	Patil, DT (reprint author), Cleveland Clin, Dept Pathol, Cleveland, OH 44106 USA.	patild@ccf.org					Alberto L, 2006, GASTROENTEROLOGY, V130, P1588, DOI 10.1053/j.gastro.2006.02.004; Arnold CA, 2013, AM J SURG PATHOL, V37, P38, DOI 10.1097/PAS.0b013e31826a523e; Ayata G, 2002, AM J SURG PATHOL, V26, P1414, DOI 10.1097/00000478-200211000-00003; BERNSTEIN CN, 1995, GASTROINTEST ENDOSC, V42, P232, DOI 10.1016/S0016-5107(95)70097-8; DAVISON AM, 1990, HISTOPATHOLOGY, V16, P93, DOI 10.1111/j.1365-2559.1990.tb01069.x; De Petris G, 2017, PATHOLOGICA, V109, P97; DHaens G, 1997, AM J GASTROENTEROL, V92, P1275; Dilauro Steven, 2010, Curr Gastroenterol Rep, V12, P249, DOI 10.1007/s11894-010-0112-5; Doyle LA, 2014, AM J SURG PATHOL, V38, P832, DOI 10.1097/PAS.0000000000000190; Dubeau MF, 2013, INFLAMM BOWEL DIS, V19, P445, DOI 10.1002/ibd.22990; Geboes K, 1998, AM J GASTROENTEROL, V93, P201, DOI 10.1111/j.1572-0241.1998.00201.x; Glickman JN, 2004, AM J SURG PATHOL, V28, P190, DOI 10.1097/00000478-200402000-00006; GROISMAN GM, 1994, MODERN PATHOL, V7, P322; Hamilton MJ, 2016, INFLAMM BOWEL DIS, V22, P2448, DOI 10.1097/MIB.0000000000000911; Haskell H, 2005, AM J SURG PATHOL, V29, P1472, DOI 10.1097/01.pas.0000176435.19197.88; HEPPELL J, 1986, DIS COLON RECTUM, V29, P789, DOI 10.1007/BF02555345; Horny HP, 2008, WHO CLASSIFICATION T, V2, P54; Ikeuchi H, 2006, WORLD J GASTROENTERO, V12, P5913, DOI 10.3748/wjg.v12.i36.5913; Kim B, 1999, AM J GASTROENTEROL, V94, P3258, DOI 10.1111/j.1572-0241.1999.01533.x; Kleer CG, 1998, AM J SURG PATHOL, V22, P983, DOI 10.1097/00000478-199808000-00008; KLEIN NC, 1970, MEDICINE, V49, P299, DOI 10.1097/00005792-197007000-00003; Lengeling RW, 2003, CLIN GASTROENTEROL H, V1, P160, DOI 10.1053/jcgh.2003.50024; Lin JM, 2010, AM J SURG PATHOL, V34, P1672, DOI 10.1097/PAS.0b013e3181f3de93; Lynch JP, 2011, SEMIN RESP CRIT CARE, V32, P494, DOI 10.1055/s-0031-1283287; Mahadeva U, 2002, HISTOPATHOLOGY, V41, P50, DOI 10.1046/j.1365-2559.2002.01416.x; Marginean EC, 2016, ARCH PATHOL LAB MED, V140, P748, DOI 10.5858/arpa.2015-0451-RA; MARKOWITZ J, 1993, AM J GASTROENTEROL, V88, P2034; McCarthy AJ, 2015, HISTOPATHOLOGY, V66, P15, DOI 10.1111/his.12598; MCCREADY FJ, 1949, NEW ENGL J MED, V240, P119, DOI 10.1056/NEJM194901272400401; ODZE R, 1993, AM J SURG PATHOL, V17, P869, DOI 10.1097/00000478-199309000-00002; Okawa K, 1998, AM J GASTROENTEROL, V93, P2405, DOI 10.1016/S0002-9270(98)00576-0; Pascal RR, 1997, MODERN PATHOL, V10, P363; Patil DT, 2017, AM J GASTROENTEROL, V112, P1211, DOI 10.1038/ajg.2017.182; Quigley EMM, 2014, CURR OPIN GASTROEN, V30, P141, DOI 10.1097/MOG.0000000000000040; RILEY SA, 1991, GUT, V32, P174, DOI 10.1136/gut.32.2.174; SALTZSTEIN SL, 1963, AM J CLIN PATHOL, V40, P610; Selbst MK, 2009, MODERN PATHOL, V22, P737, DOI 10.1038/modpathol.2009.44; Star KV, 2013, AM J SURG PATHOL, V37, P1319, DOI 10.1097/PAS.0b013e31829ab1ef; Tobin JM, 2001, J PEDIATR GASTR NUTR, V32, P443, DOI 10.1097/00005176-200104000-00010; Valdez R, 2000, AM J SURG PATHOL, V24, P1407, DOI 10.1097/00000478-200010000-00011; Vieth M, 2017, VIRCHOWS ARCH, V470, P245, DOI 10.1007/s00428-017-2077-3; Washington K, 2002, AM J SURG PATHOL, V26, P1441, DOI 10.1097/00000478-200211000-00006; Yang SK, 1999, GASTROINTEST ENDOSC, V49, P743, DOI 10.1016/S0016-5107(99)70293-2; Yantiss RK, 2006, AM J SURG PATHOL, V30, P165, DOI 10.1097/01.pas.0000189178.00440.bf; Yantiss RK, 2004, AM J SURG PATHOL, V28, P999, DOI 10.1097/01.pas.0000126758.35603.8d; Yao K, 2000, AM J GASTROENTEROL, V95, P1967	46	1	1	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JAN	2018	472	1					67	80		10.1007/s00428-017-2274-0			14	Pathology	Pathology	FZ3FX	WOS:000427473200007	29177895				2019-10-28	
J	Loughrey, MB; Shepherd, NA				Loughrey, Maurice B.; Shepherd, Neil A.			Diagnostic dilemmas in chronic inflammatory bowel disease	VIRCHOWS ARCHIV			English	Review						Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; Biopsy pathology; Infective colitis; Diverticular colitis; Dysplasia	POUCH-ANAL ANASTOMOSIS; FOCALLY ENHANCED GASTRITIS; ULCERATIVE-COLITIS; CROHNS-DISEASE; INDETERMINATE COLITIS; CLINICAL-SIGNIFICANCE; RESTORATIVE PROCTOCOLECTOMY; COLORECTAL NEOPLASIA; ACTIVE COLITIS; LYMPHOGRANULOMA-VENEREUM	Histopathological assessment of biopsy and resection specimens of chronic inflammatory bowel disease (CIBD), or possible CIBD, forms a significant component of the routine workload in most tissue pathology laboratories. In this review, we have chosen selected areas of particular diagnostic difficulty in CIBD pathology, providing key advice for pathology reporting. Those mimics of CIBD which have the greatest potential for misdiagnosis are discussed, particularly the wide range of infectious colitides which represent possible diagnostic pitfalls. The most important distinguishing features between the two main forms of CIBD, ulcerative colitis and Crohn's disease, are addressed, first in relation to resection specimens, and then with emphasis on features which may also be diagnostically useful in endoscopic biopsy material. The importance of assessment of the index endoscopic specimen is stressed, before treatment has been instigated, along with careful correlation with clinical and endoscopic features. Problems in the assessment of post-surgical CIBD specimens are described and then the role of upper gastrointestinal pathology specimens in diagnosing both Crohn's disease and ulcerative colitis, with increased recognition of upper gastrointestinal tract involvement in the latter condition. Finally, with recent developments in endoscopic surveillance techniques and local excision options, modern approaches to reporting and managing neoplasia complicating CIBD are reviewed.	[Loughrey, Maurice B.] Royal Victoria Hosp, Dept Histopathol, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland; [Shepherd, Neil A.] Cheltenham Gen Hosp, Gloucestershire Cellular Pathol Lab, Sandford Rd, Cheltenham GL53 7AN, Glos, England	Shepherd, NA (reprint author), Cheltenham Gen Hosp, Gloucestershire Cellular Pathol Lab, Sandford Rd, Cheltenham GL53 7AN, Glos, England.	maurice.loughrey@belfasttrust.hscni.net; neil.a.shepherd@nhs.net					Adamczyk L, INFLAMMATOR IN PRESS; Almadi MA, 2009, AM J GASTROENTEROL, V104, P1003, DOI 10.1038/ajg.2008.162; Annese V, 2013, J CROHNS COLITIS, V7, P982, DOI 10.1016/j.crohns.2013.09.016; Arnold CA, 2013, AM J SURG PATHOL, V37, P38, DOI 10.1097/PAS.0b013e31826a523e; Ayata G, 2002, AM J SURG PATHOL, V26, P1414, DOI 10.1097/00000478-200211000-00003; Bell AJ, 2006, COLORECTAL DIS, V8, P402, DOI 10.1111/j.1463-1318.2006.00954.x; Cairns SR, 2010, GUT, V59, P666, DOI 10.1136/gut.2009.179804; Castellaneta SP, 2004, J PEDIATR GASTR NUTR, V39, P257, DOI 10.1097/00005176-200409000-00006; CHAMBERS TJ, 1979, GUT, V20, P269, DOI 10.1136/gut.20.4.269; CHOI PM, 1994, GUT, V35, P950, DOI 10.1136/gut.35.7.950; Crohn UB, 1925, AM J MED SCI, V170, P220; de Vrieze NHN, 2014, EXPERT REV ANTI-INFE, V12, P697, DOI 10.1586/14787210.2014.901169; Dejaco C, 2003, ENDOSCOPY, V35, P1004, DOI 10.1055/s-2003-44593; Denoya P, 2011, COLORECTAL DIS, V13, P1142, DOI 10.1111/j.1463-1318.2010.02421.x; DHaens G, 1997, AM J GASTROENTEROL, V92, P1275; ElZimaity H. M., 2013, MORSON DAWSONS GASTR, P110; Farraye FA, 2010, GASTROENTEROLOGY, V138, P746, DOI [10.1053/j.gastro.2009.12.035, 10.1053/j.gastro.2009.12.037]; Feakins RM, 2013, J CLIN PATHOL, V66, P1005, DOI 10.1136/jclinpath-2013-201885; Glickman JN, 2004, AM J SURG PATHOL, V28, P190, DOI 10.1097/00000478-200402000-00006; Goldstein N, 2006, AM J CLIN PATHOL, V126, P365, DOI 10.1309/UAXMW3428PGNHJ3; Goldstein NS, 1997, AM J SURG PATHOL, V21, P1343, DOI 10.1097/00000478-199711000-00009; Greenson JK, 1997, HUM PATHOL, V28, P729, DOI 10.1016/S0046-8177(97)90183-0; Guindi M, 2004, J CLIN PATHOL, V57, P1233, DOI 10.1136/jcp.2003.015214; Gupta RB, 2007, GASTROENTEROLOGY, V133, P1099, DOI 10.1053/j.gastro.2007.08.001; Haque S, 2012, GUT, V61, P1108, DOI 10.1136/gutjnl-2011-301014; Harpaz N, 2001, MODERN PATHOL, V14, p86A; Haskell H, 2005, AM J SURG PATHOL, V29, P1472, DOI 10.1097/01.pas.0000176435.19197.88; Jain D, 2013, MORSON DAWSONS GASTR, P552; Joo M, 2010, AM J SURG PATHOL, V34, P689, DOI 10.1097/PAS.0b013e3181db84cd; Kim B, 1999, AM J GASTROENTEROL, V94, P3258, DOI 10.1111/j.1572-0241.1999.01533.x; KNILLJONES RP, 1970, Q J MED, V39, P287; Koulaouzidis A, 2011, WORLD J GASTROENTERO, V17, P4157, DOI 10.3748/wjg.v17.i37.4157; Ladefoged K, 2005, SCAND J GASTROENTERO, V40, P1192, DOI 10.1080/00365520510023305; Laine L, 2015, GASTROINTEST ENDOSC, V81, P489, DOI 10.1016/j.gie.2014.12.009; Lamps LW, 2015, HISTOPATHOLOGY, V66, P3, DOI 10.1111/his.12582; Lamps LW, 2001, AM J SURG PATHOL, V25, P508, DOI 10.1097/00000478-200104000-00011; Langner C, 2014, VIRCHOWS ARCH, V464, P511, DOI 10.1007/s00428-014-1543-4; Lemberg DA, 2005, J GASTROEN HEPATOL, V20, P1696, DOI 10.1111/j.1440-1746.2005.03954.x; Levi GS, 2006, AM J SURG PATHOL, V30, P1022, DOI 10.1097/00000478-200608000-00014; Magro F, 2013, J CROHNS COLITIS, V7, P827, DOI 10.1016/j.crohns.2013.06.001; Martland GT, 2007, HISTOPATHOLOGY, V50, P83, DOI 10.1111/j.1365-2559.2006.02545.x; Meucci G, 1999, EUR J GASTROEN HEPAT, V11, P909, DOI 10.1097/00042737-199908000-00018; Oberhuber G, 1997, GASTROENTEROLOGY, V112, P698, DOI 10.1053/gast.1997.v112.pm9041230; ODZE R, 1993, AM J SURG PATHOL, V17, P869, DOI 10.1097/00000478-199309000-00002; Odze RD, 2002, MODERN PATHOL, V15, P379, DOI 10.1038/modpathol.3880534; Odze RD, 2015, MODERN PATHOL, V28, pS30, DOI 10.1038/modpathol.2014.131; RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0; Rioux KP, 2006, J CLIN GASTROENTEROL, V40, P260, DOI 10.1097/00004836-200603000-00019; Roka K, 2013, J CROHNS COLITIS, V7, P797, DOI 10.1016/j.crohns.2012.11.003; Rubio CA, 1997, DIS COLON RECTUM, V40, P1072, DOI 10.1007/BF02050932; Rubio CA, 2006, AM J CLIN PATHOL, V125, P432, DOI 10.1309/7LABLGY08UEM3H26; Rutter M, 2004, GASTROENTEROLOGY, V126, P451, DOI 10.1053/j.gastro.2003.11.010; Rutter MD, 2004, GASTROINTEST ENDOSC, V60, P334, DOI 10.1016/S0016-5107(04)01710-9; SANDBORN WJ, 1994, MAYO CLIN PROC, V69, P409, DOI 10.1016/S0025-6196(12)61634-6; Shelley-Fraser G, 2012, HISTOPATHOLOGY, V60, P1034, DOI 10.1111/j.1365-2559.2011.03911.x; Shen B, 2001, INFLAMM BOWEL DIS, V7, P301, DOI 10.1097/00054725-200111000-00004; SHEPHERD NA, 1987, J CLIN PATHOL, V40, P601, DOI 10.1136/jcp.40.6.601; SHEPHERD NA, 1987, HUM PATHOL, V18, P50, DOI 10.1016/S0046-8177(87)80193-4; SHEPHERD NA, 1991, J CLIN PATHOL, V44, P726, DOI 10.1136/jcp.44.9.726; Shetty S, 2011, HISTOPATHOLOGY, V59, P850, DOI 10.1111/j.1365-2559.2011.04019.x; Singh R, 2015, INDIAN J PATHOL MICR, V58, P427, DOI 10.4103/0377-4929.168880; Sofo L, 2016, WORLD J GASTRO SURG, V8, P556, DOI 10.4240/wjgs.v8.i8.556; Soucy G, 2012, MODERN PATHOL, V25, P295, DOI 10.1038/modpathol.2011.120; Swan NC, 1998, DIS COLON RECTUM, V41, P1511, DOI 10.1007/BF02237298; ten Hove JR, 2017, CLIN GASTROENTEROL H, V15, P222, DOI 10.1016/j.cgh.2016.08.035; Thompson-Fawcett MW, 1999, DIS COLON RECTUM, V42, P348, DOI 10.1007/BF02236352; Valdez R, 2000, AM J SURG PATHOL, V24, P1407, DOI 10.1097/00000478-200010000-00011; VANTRAPPEN G, 1977, GASTROENTEROLOGY, V72, P220; Voltaggio L, 2014, ADV ANAT PATHOL, V21, P83, DOI 10.1097/PAP.0000000000000014; Wanders LK, 2014, CLIN GASTROENTEROL H, V12, P756, DOI 10.1016/j.cgh.2013.07.024; WARREN BF, 1993, GUT, V34, P514, DOI 10.1136/gut.34.4.514; Wright CL, 1998, AM J SURG PATHOL, V22, P383, DOI 10.1097/00000478-199804000-00001; Xin W, 2004, AM J SURG PATHOL, V28, P1347, DOI 10.1097/01.pas.0000138182.97366.b4; Xin W, 2003, AM J SURG PATHOL, V27, P1134, DOI 10.1097/00000478-200308000-00011; Yantiss RK, 2006, AM J SURG PATHOL, V30, P165, DOI 10.1097/01.pas.0000189178.00440.bf	75	0	0	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JAN	2018	472	1					81	97		10.1007/s00428-017-2235-7			17	Pathology	Pathology	FZ3FX	WOS:000427473200008	29103205				2019-10-28	
J	Pai, RK; Geboes, K				Pai, Rish K.; Geboes, Karel			Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology?	VIRCHOWS ARCHIV			English	Article						Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; Mucosal healing	POSTOPERATIVE ENDOSCOPIC RECURRENCE; CONTROLLED THERAPEUTIC TRIAL; ULCERATIVE-COLITIS PATIENTS; CROHNS-DISEASE; CLINICAL REMISSION; RISK-FACTOR; HISTOLOGIC ABNORMALITIES; COLORECTAL NEOPLASIA; INFLIXIMAB TREATMENT; RESECTION MARGINS	Histologic evaluation of disease activity in the setting of inflammatory bowel disease is gaining interest within the gastroenterology community. Recent data suggests that histologic measurements of inflammation in ulcerative colitis are more sensitive at detecting disease activity and perform better than endoscopic measurements in predicting clinical outcomes. Histologic measurements are also increasingly used in ulcerative colitis clinical trials to assess response to new therapies. Histologic measurements of disease activity are less well studied in Crohn's disease, but are gaining attention. Current published treatment algorithms in inflammatory bowel disease do not take into consideration histologic activity; however, this may change in the near future. In order for histologic measurements to be included in clinical decision-making, validated, reliable, and responsive histologic scoring systems are needed. In this review, the recent literature on the significance of histologic activity in both ulcerative colitis and Crohn's disease is summarized. Histologic scoring systems are also briefly discussed.	[Pai, Rish K.] Mayo Clin Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA; [Geboes, Karel] Univ Leuven, Leuven, Belgium	Pai, RK (reprint author), Mayo Clin Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	pai.rish@mayo.edu					Agnholt J, 2003, ALIMENT PHARM THERAP, V17, P703, DOI 10.1046/j.0269-2813.2003.01487.x; Anseline PF, 1997, BRIT J SURG, V84, P78; Baars JE, 2012, INFLAMM BOWEL DIS, V18, P1634, DOI 10.1002/ibd.21925; Bessissow T, 2012, AM J GASTROENTEROL, V107, P1684, DOI 10.1038/ajg.2012.301; Bitton A, 2001, GASTROENTEROLOGY, V120, P13, DOI 10.1053/gast.2001.20912; Brennan GT, 2017, J CLIN GASTROENTEROL, V51, P43, DOI 10.1097/MCG.0000000000000507; Bressenot A, 2015, INFLAMM BOWEL DIS, V21, P468, DOI 10.1097/MIB.0000000000000224; Bryant RV, 2014, J CROHNS COLITIS, V8, P1582, DOI 10.1016/j.crohns.2014.08.011; Bryant RV, 2016, GUT, V65, P408, DOI 10.1136/gutjnl-2015-309598; Christensen B, 2017, CLIN GASTROENTEROL H, V15, P1557, DOI 10.1016/j.cgh.2017.02.016; Christensen Britt, 2016, Curr Gastroenterol Rep, V18, P5, DOI 10.1007/s11894-015-0477-6; Colombel JF, 2006, GUT, V55, P1561, DOI 10.1136/gut.2005.084301; D'Haens G, 2007, GASTROENTEROLOGY, V132, P763, DOI 10.1053/j.gastro.2006.12.038; D'Haens GR, 1998, GASTROENTEROLOGY, V114, P262, DOI 10.1016/S0016-5085(98)70476-7; Decousus S, 2016, DIGEST LIVER DIS, V48, P753, DOI 10.1016/j.dld.2016.02.023; Denoya P, 2011, COLORECTAL DIS, V13, P1142, DOI 10.1111/j.1463-1318.2010.02421.x; Fazio VW, 1996, ANN SURG, V224, P563, DOI 10.1097/00000658-199610000-00014; Feagan BG, 2005, NEW ENGL J MED, V352, P2499, DOI 10.1056/NEJMoa042982; Feagins LA, 2013, INFLAMM BOWEL DIS, V19, P1477, DOI 10.1097/MIB.0b013e318281f4ae; Geboes K, 2000, GUT, V47, P404, DOI 10.1136/gut.47.3.404; Geboes K, 2005, CURR MED RES OPIN, V21, P1741, DOI 10.1185/030079905X65457; Gross V, 2006, ALIMENT PHARM THERAP, V23, P303, DOI 10.1111/j.1365-2036.2006.02743.x; Gross V, 2011, J CROHNS COLITIS, V5, P129, DOI 10.1016/j.crohns.2010.11.006; Gupta RB, 2007, GASTROENTEROLOGY, V133, P1099, DOI 10.1053/j.gastro.2007.08.001; Iacucci M, 2016, DIGEST DIS, V34, P160, DOI 10.1159/000443133; Jauregui-Amezaga A, 2017, J CROHNS COLITIS, V11, P305, DOI 10.1093/ecco-jcc/jjw154; Kleer CG, 1998, AM J SURG PATHOL, V22, P983, DOI 10.1097/00000478-199808000-00008; Korelitz BI, 2014, WORLD J GASTROENTERO, V20, P4980, DOI 10.3748/wjg.v20.i17.4980; KOTANAGI H, 1991, DIS COLON RECTUM, V34, P909, DOI 10.1007/BF02049707; Kruis W, 2009, GUT, V58, P233, DOI 10.1136/gut.2008.154302; Lemmens B, 2017, J CROHNS COLITIS, V11, P212, DOI 10.1093/ecco-jcc/jjw135; Lemmens B, 2013, INFLAMM BOWEL DIS, V19, P1194, DOI 10.1097/MIB.0b013e318280e75f; Magro F, 2016, J CROHNS COLITIS, V10, P1407, DOI 10.1093/ecco-jcc/jjw112; Mantzaris GJ, 2009, INFLAMM BOWEL DIS, V15, P375, DOI 10.1002/ibd.20777; Marchal-Bressenot A, 2016, GUT, V65, P1919, DOI 10.1136/gutjnl-2016-312722; Marchal-Bressenot A, 2017, GUT, V66, P43, DOI 10.1136/gutjnl-2015-310187; Mojtahed A, 2014, INFLAMM BOWEL DIS, V20, P2092, DOI 10.1097/MIB.0000000000000155; Molander P, 2013, J CROHNS COLITIS, V7, P730, DOI 10.1016/j.crohns.2012.10.018; Mosli MH, 2017, GUT, V66, P50, DOI 10.1136/gutjnl-2015-310393; Mosli MH, 2014, INFLAMM BOWEL DIS, V20, P564, DOI 10.1097/01.MIB.0000437986.00190.71; Naini BV, 2012, HUM PATHOL, V43, P2187, DOI 10.1016/j.humpath.2012.03.008; Park S, 2016, AM J GASTROENTEROL, V111, P1692, DOI 10.1038/ajg.2016.418; Peyrin-Biroulet L, 2015, AM J GASTROENTEROL, V110, P1324, DOI 10.1038/ajg.2015.233; Rahier JF, 2013, INFLAMM BOWEL DIS, V19, P2084, DOI 10.1097/MIB.0b013e3182971cec; Reinisch W, 2017, J CROHNS COLITIS, V11, P425, DOI 10.1093/ecco-jcc/jjw178; RILEY SA, 1991, GUT, V32, P174, DOI 10.1136/gut.32.2.174; Rubin DT, 2007, GASTROENTEROLOGY, V132, pA19; Rutter M, 2004, GASTROENTEROLOGY, V126, P451, DOI 10.1053/j.gastro.2003.11.010; Sandborn WJ, 2016, NEW ENGL J MED, V374, P1754, DOI 10.1056/NEJMoa1513248; SAVERYMUTTU SH, 1986, GASTROENTEROLOGY, V90, P1121, DOI 10.1016/0016-5085(86)90376-8; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; Sherlock ME, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007698.pub3; Silva MA, 2003, PEDIATR RES, V54, P456, DOI 10.1203/01.PDR.0000083002.91602.40; Sipponen T, 2008, ALIMENT PHARM THER, V28, P1221, DOI 10.1111/j.1365-2036.2008.03835.x; Sokol H, 2009, GUT, V58, P1218, DOI 10.1136/gut.2009.177782; TRUELOVE SC, 1956, BRIT MED J, V1, P1315, DOI 10.1136/bmj.1.4979.1315; TRUELOVE SC, 1958, BRIT MED J, V2, P1072, DOI 10.1136/bmj.2.5104.1072; Walsh AJ, 2016, NAT REV GASTRO HEPAT, V13, P567, DOI 10.1038/nrgastro.2016.128; WOLFF BG, 1983, DIS COLON RECTUM, V26, P239, DOI 10.1007/BF02562486; Wolff S, 2013, INFLAMM BOWEL DIS, V19, P2611, DOI 10.1097/01.MIB.0000437044.43961.00; WOLFSON DM, 1982, GASTROENTEROLOGY, V83, P405; WRIGHT R, 1966, AM J DIG DIS, V11, P847, DOI 10.1007/BF02233941; Zenlea T, 2016, AM J GASTROENTEROL, V111, P685, DOI 10.1038/ajg.2016.50	63	6	6	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JAN	2018	472	1					99	110		10.1007/s00428-017-2156-5			12	Pathology	Pathology	FZ3FX	WOS:000427473200009	28555281				2019-10-28	
J	Ensari, A; Kelsen, J; Russo, P				Ensari, Arzu; Kelsen, Judith; Russo, Pierre			Newcomers in paediatric GI pathology: childhood enteropathies including very early onset monogenic IBD	VIRCHOWS ARCHIV			English	Article						Enteropathy; Inflammatory bowel disease; Children; Histopathology	INFLAMMATORY-BOWEL-DISEASE; MICROVILLOUS INCLUSION DISEASE; GOBLET-CELL ANTIBODIES; CONGENITAL DIARRHEAL DISORDERS; X-LINKED SYNDROME; AUTOIMMUNE ENTEROPATHY; TUFTING ENTEROPATHY; PROTRACTED DIARRHEA; IMMUNE DYSREGULATION; INTRACTABLE DIARRHEA	Childhood enteropathies are a group of diseases causing severe chronic (> 2-3 weeks) diarrhoea often starting in the first week of life with the potential for fatal complications for the affected infant. Early identification and accurate classification of childhood enteropathies are, therefore, crucial for making treatment decisions to prevent life-threatening complications. Childhood enteropathies are classified into four groups based on the underlying pathology: (i) conditions related to defective digestion, absorption and transport of nutrients and electrolytes; (ii) disorders related to enterocyte differentiation and polarization; (iii) defects of enteroendocrine cell differentiation; and (iv) disorders associated with defective modulation of intestinal immune response. While the intestinal mucosa is usually normal in enteropathies related to congenital transport or enzyme deficiencies, the intestinal biopsy in other disorders may reveal a wide range of abnormalities varying from normal villous architecture to villous atrophy and/or inflammation, or features specific to the underlying disorder including epithelial abnormalities, lipid vacuolization in the enterocytes, absence of plasma cells, lymphangiectasia, microorganisms, and mucosal eosinophilic or histiocytic infiltration. This review intends to provide an update on small intestinal biopsy findings in childhood enteropathies, the "newcomers", including very early onset monogenic inflammatory bowel disease (IBD), in particular, for the practicing pathologist.	[Ensari, Arzu] Ankara Univ, Sch Med, Dept Pathol, TR-06100 Ankara, Turkey; [Kelsen, Judith] Univ Penn, Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, Perelman Sch, 3401 Civ Ctr Blvd,5 NW26, Philadelphia, PA 19104 USA; [Russo, Pierre] Univ Penn, Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Perelman Sch Med, 3401 Civ Ctr Blvd,5 NW26, Philadelphia, PA 19104 USA	Ensari, A (reprint author), Ankara Univ, Sch Med, Dept Pathol, TR-06100 Ankara, Turkey.	ensariarzu@gmail.com; kelsen@email.chop.edu; russo@email.chop.edu			NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K23 DK100461]		Akram S, 2007, CLIN GASTROENTEROL H, V5, P1282, DOI 10.1016/j.cgh.2007.05.013; Ashton JJ, 2016, INFLAMM BOWEL DIS, V22, P2317, DOI 10.1097/MIB.0000000000000890; AVERY GB, 1968, PEDIATRICS, V41, P712; Aydin SE, 2015, J CLIN IMMUNOL, V35, P189, DOI 10.1007/s10875-014-0126-0; Bennett CL, 2001, NAT GENET, V27, P20; Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; Betterle C, 1998, J CLIN ENDOCR METAB, V83, P1049, DOI 10.1210/jc.83.4.1049; Biagi F, 2009, AM J GASTROENTEROL, V104, P3112, DOI 10.1038/ajg.2009.511; Bianco AM, 2014, GUT, V63, P1367, DOI 10.1136/gutjnl-2013-306555; Canani RB, 2010, J PEDIATR GASTR NUTR, V50, P360, DOI 10.1097/MPG.0b013e3181d135ef; Cannioto Z, 2009, EUR J PEDIATR, V168, P149, DOI 10.1007/s00431-008-0721-2; CHARRITAT JL, 1987, ANN PEDIATR-PARIS, V34, P195; Cheng LE, 2009, CLIN IMMUNOL, V132, P124, DOI 10.1016/j.clim.2009.03.514; Collins MH, 2009, IMMUNOL ALLERGY CLIN, V29, P109, DOI 10.1016/j.iac.2008.10.005; Cortina G, 2007, HUM PATHOL, V38, P570, DOI 10.1016/j.humpath.2006.10.014; Cutz E, 1997, PEDIATR RADIOL, V27, P523; Daniels JA, 2007, AM J SURG PATHOL, V31, P1800, DOI 10.1097/PAS.0b013e3180cab60c; DAVIDSON GP, 1979, ACTA PAEDIATR SCAND, V68, P181, DOI 10.1111/j.1651-2227.1979.tb04986.x; DAVIDSON GP, 1978, GASTROENTEROLOGY, V75, P783; de Serre NPM, 2009, MODERN PATHOL, V22, P95, DOI 10.1038/modpathol.2008.161; Egritas O, 2011, TURK J GASTROENTEROL, V22, P260, DOI 10.4318/tjg.2011.0211; Ensari A, 2014, PATHOBIOLOGY OF HUMAN DISEASE: A DYNAMIC ENCYCLOPEDIA OF DISEASE MECHANISMS, P1266, DOI 10.1016/B978-0-12-386456-7.03804-1; Folwaczny C, 1997, GASTROENTEROLOGY, V113, P101, DOI 10.1016/S0016-5085(97)70085-4; Gambarara M, 2003, TRANSPLANT P, V35, P3052, DOI 10.1016/j.transproceed.2003.10.053; Gentile Nicole M, 2012, Curr Gastroenterol Rep, V14, P380, DOI 10.1007/s11894-012-0276-2; Glocker E, 2012, CELL MOL LIFE SCI, V69, P41, DOI 10.1007/s00018-011-0837-9; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Goulet O, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-20; Groisman GM, 2002, AM J SURG PATHOL, V26, P902, DOI 10.1097/00000478-200207000-00008; Guerrerio AL, 2010, J PEDIATR GASTR NUTR, V51, P548, DOI 10.1097/MPG.0b013e3181efe56b; Heyman MB, 2005, J PEDIATR-US, V146, P35, DOI 10.1016/j.jpeds.2004.08.043; Hogenauer C, 2001, NEW ENGL J MED, V344, P270, DOI 10.1056/NEJM200101253440405; Hurrell JM, 2011, ADV ANAT PATHOL, V18, P335, DOI 10.1097/PAP.0b013e318229bfe2; Jones B, 2003, NAT GENET, V34, P29, DOI 10.1038/ng1145; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Justinich CJ, 2000, CURR OPIN PEDIATR, V12, P456, DOI 10.1097/00008480-200010000-00006; Kahvecioglu D, 2014, TURKISH J PEDIATR, V56, P440; Kammermeier J, 2014, J MED GENET, V51, P748, DOI 10.1136/jmedgenet-2014-102624; Kampe O, 2009, J INTERN MED, V265, P511, DOI 10.1111/j.1365-2796.2009.02094.x; Kato K, 2011, INT J HEMATOL, V94, P479, DOI 10.1007/s12185-011-0932-6; Kelsen JR, 2015, CELL MOL GASTROENTER, V1, P462, DOI 10.1016/j.jcmgh.2015.06.010; Khan S, 2008, GASTROENTEROL CLIN N, V37, P333, DOI 10.1016/j.gtc.2008.02.003; Khatun I, 2013, J LIPID RES, V54, P1541, DOI 10.1194/jlr.M031658; Khubchandani SR, 2011, ULTRASTRUCT PATHOL, V35, P87, DOI 10.3109/01913123.2010.537438; KLEIN NC, 1970, MEDICINE, V49, P299, DOI 10.1097/00005792-197007000-00003; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kuloglu Z, 2012, RHEUMATOL INT, V32, P783, DOI 10.1007/s00296-009-1326-4; Lampasona V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078664; Lancu TC, 2007, ULTRASTRUCT PATHOL, V31, P173, DOI 10.1080/01913120701350712; Lemale J, 2011, J PEDIATR GASTR NUTR, V52, P734, DOI 10.1097/MPG.0b013e31820731db; Martin BA, 2014, AM J SURG PATHOL, V38, P1387, DOI 10.1097/PAS.0000000000000314; MARTINVILLA JM, 1993, LANCET, V342, P380, DOI 10.1016/0140-6736(93)91531-P; Masia R, 2014, AM J SURG PATHOL, V38, P1319, DOI 10.1097/PAS.0000000000000317; MIRAKIAN R, 1986, BRIT MED J, V293, P1132, DOI 10.1136/bmj.293.6555.1132; Montalto M, 2009, SCAND J GASTROENTERO, V44, P1029, DOI 10.1080/00365520902783691; MOORE L, 1995, HUM PATHOL, V26, P1162, DOI 10.1016/0046-8177(95)90283-X; Mora AJ, 2011, J CLIN GASTROENTEROL, V45, P700, DOI 10.1097/MCG.0b013e3181fd2742; MORELL A, 1972, J PEDIATR-US, V80, P960, DOI 10.1016/S0022-3476(72)80007-6; Muller T, 2008, NAT GENET, V40, P1163, DOI 10.1038/ng.225; Murch SH, 2002, J PEDIATR GASTR NUTR, V34, pS4, DOI 10.1097/01.MPG.0000017288.92960.BB; Ochs HD, 2007, IMMUNOL RES, V38, P112, DOI 10.1007/s12026-007-0022-2; Ochs HD, 2007, ADV EXP MED BIOL, V601, P27; Pautler D, 2008, J PEDIATR GASTR NUTR, V46, P355, DOI 10.1097/MPG.0b013e3181677082; Pedersen J, 2014, TRENDS MOL MED, V20, P652, DOI 10.1016/j.molmed.2014.09.006; Peretti N, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-24; Posovszky C, 2012, J CLIN ENDOCR METAB, V97, pE292, DOI 10.1210/jc.2011-2044; POWELL BR, 1982, J PEDIATR-US, V100, P731, DOI 10.1016/S0022-3476(82)80573-8; REIFEN RM, 1994, J PEDIATR GASTR NUTR, V18, P379, DOI 10.1097/00005176-199404000-00022; Rogahn D, 1999, J ROY SOC MED, V92, P311, DOI 10.1177/014107689909200615; Rosenzweig SD, 2008, J CLIN IMMUNOL, V28, pS67, DOI 10.1007/s10875-007-9160-5; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Russo P, 2014, PATHOLOGY PEDIAT GAS, P99; Russo PA, 1999, PEDIATR DEVEL PATHOL, V2, P65, DOI 10.1007/s100249900092; Russo Pierre, 2013, Adv Pediatr, V60, P217, DOI 10.1016/j.yapd.2013.04.010; SAVAGE MO, 1985, J PEDIATR GASTR NUTR, V4, P187, DOI 10.1097/00005176-198504000-00006; Schnell U, 2013, HUM MOL GENET, V22, P2566, DOI 10.1093/hmg/ddt105; Shaker M, 2009, CURR OPIN PEDIATR, V21, P667, DOI 10.1097/MOP.0b013e32833069a8; Sherman PM, 2004, J PEDIATR GASTR NUTR, V38, P16, DOI 10.1097/00005176-200401000-00007; Singhi AD, 2014, MODERN PATHOL, V27, P543, DOI 10.1038/modpathol.2013.150; Sivagnanam M, 2008, GASTROENTEROLOGY, V135, P429, DOI 10.1053/j.gastro.2008.05.036; Szperl AM, 2011, J PEDIATR GASTR NUTR, V52, P307, DOI 10.1097/MPG.0b013e3181eea177; Talmon G, 2012, INT J SURG PATHOL, V20, P252, DOI 10.1177/1066896911430959; Terrin G, 2012, INT J MOL SCI, V13, P4168, DOI 10.3390/ijms13044168; Uhlig HH, 2013, GUT, V62, P1795, DOI 10.1136/gutjnl-2012-303956; UHNOO IS, 1990, PEDIATR RES, V27, P153, DOI 10.1203/00006450-199002000-00014; UNSWORTH J, 1982, J PEDIATR GASTR NUTR, V1, P503, DOI 10.1097/00005176-198212000-00010; Verbsky JW, 2013, CURR OPIN PEDIATR, V25, P708, DOI 10.1097/MOP.0000000000000029; Wang JF, 2006, NEW ENGL J MED, V355, P270, DOI 10.1056/NEJMoa054288; Wiegerinck CL, 2014, GASTROENTEROLOGY, V147, P65, DOI 10.1053/j.gastro.2014.04.002; Worthey EA, 2011, GENET MED, V13, P255, DOI 10.1097/GIM.0b013e3182088158; Yee Eric U, 2013, Surg Pathol Clin, V6, P523, DOI 10.1016/j.path.2013.05.006; Yong PL, 2008, J CLIN IMMUNOL, V28, P581, DOI 10.1007/s10875-008-9196-1	92	2	2	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JAN	2018	472	1					111	123		10.1007/s00428-017-2197-9			13	Pathology	Pathology	FZ3FX	WOS:000427473200010	28718031	Green Accepted			2019-10-28	
J	Slavik, T; Lauwers, GY				Slavik, Tomas; Lauwers, Gregory Y.			Navigating the jungles of tropical infectious gastrointestinal pathology: a pattern-based approach to the endoscopic biopsy	VIRCHOWS ARCHIV			English	Article						Gastrointestinal tract; Tropical infections; Histopathology; Patterns	INFLAMMATORY BOWEL-DISEASE; SELF-LIMITED COLITIS; TRAVELERS DIARRHEA; RECTAL BIOPSY; GRANULOMATOUS APPENDICITIS; YERSINIA-ENTEROCOLITICA; DEVELOPING-COUNTRIES; HELICOBACTER-PYLORI; CLINICAL MANAGEMENT; TYPHOID-FEVER	International travels and global human migration have had the unforeseen consequence of increasing the exposure of histopathologists in developed countries to the pathology of tropical infectious disease. The gastrointestinal tract (GIT) is often the primary site of infection due to the faecal-oral route of transmission and the high risk of exposure to contaminated water, food or soil when travelling to these regions. Whilst current microbiologic techniques are far more sensitive than histology in detecting infectious pathogens, the histopathologist nonetheless retains a pivotal role in diagnosing tropical GIT disease. This role entails evaluating endoscopic biopsies for any characteristic inflammatory pattern, identifying pathogens which may be present and excluding other look-alike pathologies. Recent advances in commercially available diagnostic modalities, including molecular techniques, have further broadened the scope of the histopathologist's armamentarium. This review outlines a practical pattern-based approach to diagnosing tropical GIT infections in endoscopic material, so as to assist pathologists less familiar with this spectrum of pathology.	[Slavik, Tomas] Ampath Pathol Labs, Pretoria, South Africa; [Slavik, Tomas] Univ Pretoria, Dept Anat Pathol, Fac Hlth Sci, Pretoria, South Africa; [Slavik, Tomas] Private Bag X9,Highveld Pk, ZA-0067 Pretoria, South Africa; [Lauwers, Gregory Y.] H Lee Moffitt Canc Ctr & Res Inst, Dept Anat Pathol, Tampa, FL USA	Slavik, T (reprint author), Ampath Pathol Labs, Pretoria, South Africa.; Slavik, T (reprint author), Univ Pretoria, Dept Anat Pathol, Fac Hlth Sci, Pretoria, South Africa.; Slavik, T (reprint author), Private Bag X9,Highveld Pk, ZA-0067 Pretoria, South Africa.	slavikt@ampath.co.za					Ackers J P, 1997, Semin Gastrointest Dis, V8, P33; ALLISON MC, 1987, Q J MED, V65, P985; ANAND BS, 1986, GASTROENTEROLOGY, V90, P654, DOI 10.1016/0016-5085(86)91120-0; Ansari AA, 2014, J AUTOIMMUN, V55, P1, DOI 10.1016/j.jaut.2014.09.001; Azad AK, 1997, AM J TROP MED HYG, V56, P490, DOI 10.4269/ajtmh.1997.56.490; Bal A M, 2005, J Postgrad Med, V51, P179; Beeching NJ, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7348; Blacklock A, 2015, GLOBAL HEALTH ACTION, V8, DOI 10.3402/gha.v8.25266; Brandt H, 1970, Hum Pathol, V1, P351; COOK GC, 1984, LANCET, V1, P721; Curry A, 1998, PARASITOLOGY, V117, pS143; DUDLEY TH, 1993, HUM PATHOL, V24, P595, DOI 10.1016/0046-8177(93)90238-C; ELMASRY NA, 1986, J TROP MED HYG, V89, P13; Fayer R, 2015, CLIN MICROBIOL REV, V28, P295, DOI 10.1128/CMR.00113-14; Fenwick A, 2012, PUBLIC HEALTH, V126, P233, DOI 10.1016/j.puhe.2011.11.015; Field V, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-330; Fletcher SM, 2013, J PUBLIC HEALTH RES, V2, P42, DOI 10.4081/jphr.2013.e9; Fritz EL, 2006, J CLIN MICROBIOL, V44, P1692, DOI 10.1128/JCM.44.5.1692-1696.2006; GASCON J, 1993, EUR J EPIDEMIOL, V9, P217, DOI 10.1007/BF00158796; Geboes K, 2013, MORSON DAWSONS GASTR, P315; Ghoshal UC, 2003, J GASTROEN HEPATOL, V18, P540, DOI 10.1046/j.1440-1746.2003.03006.x; Giddings SL, 2016, MED CLIN N AM, V100, P317, DOI 10.1016/j.mcna.2015.08.017; GLEASON TH, 1982, AM J SURG PATHOL, V6, P347, DOI 10.1097/00000478-198206000-00007; Goodgame Richard, 2003, Curr Infect Dis Rep, V5, P66, DOI 10.1007/s11908-003-0067-x; Greenwood Z, 2008, J TRAVEL MED, V15, P221, DOI 10.1111/j.1708-8305.2008.00203.x; GREER GJ, 1988, J PARASITOL, V74, P471, DOI 10.2307/3282058; Haghighi P, 1997, CRIT REV CL LAB SCI, V34, P313, DOI 10.3109/10408369708998096; Hardin RE, 2007, WORLD J GASTROENTERO, V13, P5659, DOI 10.3748/wjg.v13.i42.5659; Hassan HA, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-91; HEYMANN DL, 2008, CONTROL COMMUNICABLE; Hibbett DS, 2007, MYCOL RES, V111, P509, DOI 10.1016/j.mycres.2007.03.004; Hogenauer C, 2006, NEW ENGL J MED, V355, P2418, DOI 10.1056/NEJMoa054765; Hotez PJ, 2008, J CLIN INVEST, V118, P1311, DOI 10.1172/JCI34261; JORENS PG, 1991, DIS COLON RECTUM, V34, P194, DOI 10.1007/BF02049998; KELLY J, 1990, AM J SURG PATHOL, V14, P87, DOI 10.1097/00000478-199001000-00010; Khan MS, 2016, LANCET INFECT DIS, V16, pE173, DOI 10.1016/S1473-3099(16)30134-7; Koo HL, 2010, J CLIN MICROBIOL, V48, P1673, DOI 10.1128/JCM.02072-09; Kraus MD, 1999, MODERN PATHOL, V12, P949; LaBeaud AD, 2016, UPTODATE; Lamps LW, 2007, HISTOPATHOLOGY, V50, P55, DOI 10.1111/j.1365-2559.2006.02544.x; Lamps LW, 2015, HISTOPATHOLOGY, V66, P3, DOI 10.1111/his.12582; Lamps LW, 2009, SURGICAL PATHOLOGY OF THE GASTROINTESTINAL SYSTEM: BACTERIAL, FUNGAL, VIRAL, AND PARASITIC INFECTIONS, P37, DOI 10.1007/978-1-4419-0861-2_7; Lamps LW, 2001, AM J SURG PATHOL, V25, P508, DOI 10.1097/00000478-200104000-00011; Leder K, 2015, AUST FAM PHYSICIAN, V44, P34; Leder K, 2013, EMERG INFECT DIS, V19, P1049, DOI 10.3201/eid1907.121573; Lee JH, 2005, AM J ROENTGENOL, V185, P1084, DOI 10.2214/AJR.04.1680; Legrand F, 2001, BONE MARROW TRANSPL, V27, P621, DOI 10.1038/sj.bmt.1702820; LINDKVIST P, 1995, J INFECT DIS, V172, P1135, DOI 10.1093/infdis/172.4.1135; MALLOUH AA, 1987, PEDIATR INFECT DIS J, V6, P527, DOI 10.1097/00006454-198706000-00007; MATHAN MM, 1986, DIGEST DIS SCI, V31, P586, DOI 10.1007/BF01318689; Oberhuber G, 1997, SCAND J GASTROENTERO, V32, P48, DOI 10.3109/00365529709025062; Oliveira Fabricio Marcus Silva, 2015, Trop Parasitol, V5, P9, DOI 10.4103/2229-5070.149887; Page AV, 2013, MED CLIN N AM, V97, P681, DOI 10.1016/j.mcna.2013.04.001; PASTORE G, 1976, AM J DIG DIS, V21, P613, DOI 10.1007/BF01071953; Pawlowski SW, 2009, GASTROENTEROLOGY, V136, P1874, DOI 10.1053/j.gastro.2009.02.072; Qu ZH, 2009, HUM PATHOL, V40, P572, DOI 10.1016/j.humpath.2008.10.008; Rovery C, 2008, EMERG INFECT DIS, V14, P1360, DOI 10.3201/eid1409.071133; Shakoor S, 2012, INFECT DIS CLIN N AM, V26, P437, DOI 10.1016/j.idc.2012.02.002; Slavik T, 2012, ARCH PATHOL LAB MED, V136, P305, DOI 10.5858/arpa.2011-0332-RA; Soentjens P, 2016, CLIN INFECT DIS, V63, P1626, DOI 10.1093/cid/ciw493; SURAWICZ CM, 1988, AM J SURG PATHOL, V12, P82; SURAWICZ CM, 1984, GASTROENTEROLOGY, V86, P104; Swaminathan A, 2009, J INFECTION, V59, P19, DOI 10.1016/j.jinf.2009.05.008; Tate JE, 2009, PEDIATRICS, V124, P465, DOI 10.1542/peds.2008-3528; Thwaites Phoebe A, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr-2016-218185; TODD IP, 1969, GUT, V10, P1009, DOI 10.1136/gut.10.12.1009; VARIYAM EP, 1989, DIGEST DIS SCI, V34, P732, DOI 10.1007/BF01540345; Vieira S, 2016, AM J TROP MED HYG, V94, P699, DOI 10.4269/ajtmh.15-0798; Vila J, 2003, EMERG INFECT DIS, V9, P552, DOI 10.3201/eid0905.020451; Zboromyrska Y, 2014, CLIN MICROBIOL INFEC, V20, pO753, DOI 10.1111/1469-0691.12621	70	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JAN	2018	472	1					135	147		10.1007/s00428-017-2166-3			13	Pathology	Pathology	FZ3FX	WOS:000427473200012	28589386				2019-10-28	
J	Jawale, R; Lai, KK; Lamps, LW				Jawale, Rahul; Lai, Keith K.; Lamps, Laura W.			Sexually transmitted infections of the lower gastrointestinal tract	VIRCHOWS ARCHIV			English	Review						Sexually transmitted infections (STIs); Pathogens; Inflammatory bowel disease (IBD)	EUROPEAN GUIDELINE; SAN-FRANCISCO; DIAGNOSIS; MEN; PROCTOCOLITIS; CHLAMYDIA; ESOPHAGITIS; PREVALENCE; APPEARANCE; GONORRHEA	The World Health Organization estimates that there is greater than one million new cases of sexually transmitted infections (STIs) every day. In many countries, STIs are at an unprecedented high, including the USA, where nearly 20 million new cases were reported in 2016. Although morbidity associated with STIs is usually seen in the context of genitourinary disease, these pathogens may also affect the gastrointestinal tract and cause anal pain, abdominal pain, or diarrhea. It is important to recognize patterns of injury associated with these pathogens, especially those that may mimic other gastrointestinal diseases, such as idiopathic inflammatory bowel disease (IBD). This review focuses upon STIs of the lower gastrointestinal tract, organized by the most common site of involvement: the anus, rectum, and colon.	[Jawale, Rahul] Baystate Med Ctr, Dept Pathol, Springfield, MA USA; [Lai, Keith K.] Cleveland Clin, Dept Anat Pathol, 9500 Euclid Ave,L-25, Cleveland, OH 44195 USA; [Lamps, Laura W.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	Lai, KK (reprint author), Cleveland Clin, Dept Anat Pathol, 9500 Euclid Ave,L-25, Cleveland, OH 44195 USA.	laik2@ccf.org					Al-Tawfiq JA, 2000, SEX TRANSM DIS, V27, P111, DOI 10.1097/00007435-200002000-00009; Arnold CA, 2013, AM J SURG PATHOL, V37, P38, DOI 10.1097/PAS.0b013e31826a523e; BeckSague CM, 1996, SEX TRANSM DIS, V23, P342, DOI 10.1097/00007435-199607000-00014; Carrington M, 2005, J EXP MED, V201, P1069, DOI 10.1084/jem.20042158; Ceovic R, 2015, INFECT DRUG RESIST, V8, P39, DOI [10.2147/IDR.S57540, 10.2147/DR.557540]; Charles P, 2016, J CLIN VIROL, V78, P12, DOI 10.1016/j.jcv.2016.02.023; Cortes-Bratti X, 1999, J CLIN INVEST, V103, P107, DOI 10.1172/JCI3831; Cosentino LA, 2012, J CLIN MICROBIOL, V50, P2005, DOI 10.1128/JCM.00185-12; Cunha CB, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2002-0; Darragh TM, 2012, ARCH PATHOL LAB MED, V136, P1266, DOI 10.5858/arpa.LGT200570; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; DELAMONTE SM, 1985, HUM PATHOL, V16, P1025, DOI 10.1016/S0046-8177(85)80280-X; Esteve M, 2006, J GASTROEN HEPATOL, V21, P1326, DOI 10.1111/j.1440-1746.2006.04150.x; Foschi Claudio, 2014, BMC Res Notes, V7, P225, DOI 10.1186/1756-0500-7-225; Furman DL, 2008, GASTROINTEST ENDOSC, V67, P161, DOI 10.1016/j.gie.2007.07.020; Gangaiah D, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003918; Garland SM, 2009, J INFECT DIS, V199, P805, DOI 10.1086/597071; Ghinai R, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003496; GOODELL SE, 1983, NEW ENGL J MED, V308, P868, DOI 10.1056/NEJM198304143081503; GREENSON JK, 1991, HUM PATHOL, V22, P541, DOI 10.1016/0046-8177(91)90230-M; Hamlyn E, 2006, POSTGRAD MED J, V82, P733, DOI 10.1136/pmj.2006.048488; Harrison Tucker, 2016, Proc (Bayl Univ Med Cent), V29, P418; Hoentjen F, 2012, DIGEST DIS SCI, V57, P269, DOI 10.1007/s10620-011-1935-0; Hoie S, 2011, SCAND J GASTROENTERO, V46, P503, DOI 10.3109/00365521.2010.537681; Johnson KM, 2009, J VIROL, V83, P2067, DOI 10.1128/JVI.02190-08; Kato S, 2005, DIS ESOPHAGUS, V18, P340, DOI 10.1111/j.1442-2050.2005.00510.x; Kent CK, 2005, CLIN INFECT DIS, V41, P67, DOI 10.1086/430704; Lamb CA, 2013, FRONTLINE GASTROENTE, V4, P32, DOI 10.1136/flgastro-2012-100274; Lewis DA, 2014, EXPERT REV ANTI-INFE, V12, P687, DOI 10.1586/14787210.2014.892414; Lewis DA, 2012, SEX TRANSM DIS, V39, P880, DOI 10.1097/OLQ.0b013e318269cf90; Lowy DR, 2006, J CLIN INVEST, V116, P1167, DOI 10.1172/JCI28607; Magro CM, 1996, HUM PATHOL, V27, P1066, DOI 10.1016/S0046-8177(96)90285-3; Marcus JL, 2010, SEX TRANSM DIS, V37, P59, DOI 10.1097/OLQ.0b013e3181b76c42; MCBANE RD, 1991, GASTROINTEST ENDOSC, V37, P600, DOI 10.1016/S0016-5107(91)70862-6; McMillan A, 2007, INT J STD AIDS, V18, P514, DOI 10.1258/095646207781439739; Miller KE, 2006, AM FAM PHYSICIAN, V73, P1779; Moreno-Ribera N, 2016, ACTAS DERMO-SIFILOGR, V107, P235, DOI 10.1016/j.ad.2015.10.007; Velho PENF, 2008, BRAZ J INFECT DIS, V12, P521, DOI 10.1590/S1413-86702008000600015; O'Farrell N, 2002, SEX TRANSM INFECT, V78, P452, DOI 10.1136/sti.78.6.452; O'Farrell N, 2016, INT J STD AIDS, V27, P605, DOI 10.1177/0956462416633626; Pathela P, 2013, CLIN INFECT DIS, V57, P1203, DOI 10.1093/cid/cit437; Peterman TA, 2014, PUBLIC HEALTH REP, V129, P164, DOI 10.1177/003335491412900210; Plummer M, 2007, J INFECT DIS, V195, P1582, DOI 10.1086/516784; Rompalo AM, 1999, CLIN INFECT DIS, V28, pS84, DOI 10.1086/514721; RUTHER U, 1990, ENDOSCOPY, V22, P237, DOI 10.1055/s-2007-1012857; Shelton Andrew A, 2004, Clin Colon Rectal Surg, V17, P231, DOI 10.1055/s-2004-836943; Suay-Garcia B, 2017, EUR J CLIN MICROBIOL, V36, P1065, DOI 10.1007/s10096-017-2931-x; Ussher JE, 2007, CLIN INFECT DIS, V44, pE85, DOI 10.1086/515404; van Liere GAFS, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-274; Voltaggio L, 2014, ADV ANAT PATHOL, V21, P83, DOI 10.1097/PAP.0000000000000014; Wang SS, 2003, J NATL CANC I MONOGR, V35	51	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JAN	2018	472	1					149	158		10.1007/s00428-017-2261-5			10	Pathology	Pathology	FZ3FX	WOS:000427473200013	29124332				2019-10-28	
J	Gorkiewicz, G; Moschen, A				Gorkiewicz, Gregor; Moschen, Alexander			Gut microbiome: a new player in gastrointestinal disease	VIRCHOWS ARCHIV			English	Review						Gut microbiome; Spatial microbiome organization; Dysbiosis; Inflammation; Carcinogenesis; Fecal microbiome transplantation	INFLAMMATORY-BOWEL-DISEASE; VERSUS-HOST-DISEASE; HELICOBACTER-PYLORI INFECTION; STEM-CELL TRANSPLANTATION; CHAIN FATTY-ACIDS; INTESTINAL MICROBIOTA; CROHNS-DISEASE; FUSOBACTERIUM-NUCLEATUM; CELIAC-DISEASE; COLORECTAL-CANCER	The gastrointestinal (GI) tract harbors a diverse and host-specific gut microbial community. Whereas host-microbe interactions are based on homeostasis and mutualism, the microbiome also contributes to disease development. In this review, we summarize recent findings connecting the GI microbiome with GI disease. Starting with a description of biochemical factors shaping microbial compositions in each gut segment along the longitudinal axis, improved histological techniques enabling high resolution visualization of the spatial microbiome structure are highlighted. Subsequently, inflammatory and neoplastic diseases of the esophagus, stomach, and small and large intestines are discussed and the respective changes in microbiome compositions summarized. Finally, approaches aiming to restore disturbed microbiome compositions thereby promoting health are discussed.	[Gorkiewicz, Gregor] Med Univ Graz, Inst Pathol, Neue Stiftingtalstr 6, A-8010 Graz, Austria; [Moschen, Alexander] Med Univ Innsbruck, Christian Doppler Lab Mucosal Immunol, Peter Mayr Str 1, A-6020 Innsbruck, Austria; [Moschen, Alexander] Med Univ Innsbruck, Div Internal Med 1, Dept Med, Peter Mayr Str 1, A-6020 Innsbruck, Austria	Gorkiewicz, G (reprint author), Med Univ Graz, Inst Pathol, Neue Stiftingtalstr 6, A-8010 Graz, Austria.	gregor.gorkiewicz@medunigraz.at; alexander.moschen@i-med.ac.at		Gorkiewicz, Gregor/0000-0003-1149-4782	Austrian Science Foundation (FWF)Austrian Science Fund (FWF) [W1241-B18]; BioTechMed Graz; Christian Doppler research foundation; Austrian Federal Ministry of Science, Research and Economy; National Foundation for Research, Technology and Development	The work in the laboratory of GG is supported by the Austrian Science Foundation (FWF W1241-B18) and BioTechMed Graz. The work in the laboratory of AM is supported by the Christian Doppler research foundation. The financial support by the Austrian Federal Ministry of Science, Research and Economy and the National Foundation for Research, Technology and Development is gratefully acknowledged.	Abed J, 2016, CELL HOST MICROBE, V20, P215, DOI 10.1016/j.chom.2016.07.006; Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647; Albenberg L, 2014, GASTROENTEROLOGY, V147, P1055, DOI 10.1053/j.gastro.2014.07.020; Arnold IC, 2011, J CLIN INVEST, V121, P3088, DOI 10.1172/JCI45041; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820; Atherton JC, 2006, ANNU REV PATHOL-MECH, V1, P63, DOI 10.1146/annurev.pathol.1.110304.100125; Atherton JC, 2009, J CLIN INVEST, V119, P2475, DOI 10.1172/JCI38605; Backhed F, 2015, CELL HOST MICROBE, V17, P852, DOI 10.1016/j.chom.2015.05.012; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Becker C, 2015, ILAR J, V56, P192, DOI 10.1093/ilar/ilv030; Benitez AJ, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0085-6; Berry D, 2013, P NATL ACAD SCI USA, V110, P4720, DOI 10.1073/pnas.1219247110; Bik EM, 2006, P NATL ACAD SCI USA, V103, P732, DOI 10.1073/pnas.0506655103; Blackett KL, 2013, ALIMENT PHARM THER, V37, P1084, DOI 10.1111/apt.12317; Bokulich NA, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7121; Bonder MJ, 2016, NAT GENET, V48, P1407, DOI 10.1038/ng.3663; Bonnet M, 2014, CLIN CANCER RES, V20, P859, DOI 10.1158/1078-0432.CCR-13-1343; Bordenstein SR, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002226; Borrelli O, 2006, CLIN GASTROENTEROL H, V4, P744, DOI 10.1016/j.cgh.2006.03.010; Buffie CG, 2015, NATURE, V517, P205, DOI 10.1038/nature13828; Caminero A, 2016, GASTROENTEROLOGY, V151, P670, DOI 10.1053/j.gastro.2016.06.041; Castano-Rodriguez N, 2017, GUT, V66, P235, DOI 10.1136/gutjnl-2015-310545; Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111; Chassaing B, 2015, NATURE, V519, P92, DOI 10.1038/nature14232; Chow J, 2011, CURR OPIN IMMUNOL, V23, P473, DOI 10.1016/j.coi.2011.07.010; Coker O. O., 2017, GUT; Cullen TW, 2015, SCIENCE, V347, P170, DOI 10.1126/science.1260580; D'Haens GR, 1998, GASTROENTEROLOGY, V114, P262, DOI 10.1016/S0016-5085(98)70476-7; Desai MS, 2016, CELL, V167, P1339, DOI 10.1016/j.cell.2016.10.043; Devkota S, 2012, NATURE, V487, P104, DOI 10.1038/nature11225; Di Pilato V, 2016, ANN NY ACAD SCI, V1381, P21, DOI 10.1111/nyas.13127; Dominguez-Bello MG, 2016, NAT MED, V22, P250, DOI 10.1038/nm.4039; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; El-Gazzar A, 2013, J IMMUNOL, V191, P1509, DOI 10.4049/jimmunol.1301071; Falush D, 2003, SCIENCE, V299, P1582, DOI 10.1126/science.1080857; Feng Q, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7528; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gallo RL, 2012, NAT REV IMMUNOL, V12, P503, DOI 10.1038/nri3228; Garcia-Gonzalez AP, 2017, CELL, V169, P431, DOI 10.1016/j.cell.2017.03.046; Garrett WS, 2015, SCIENCE, V348, P80, DOI 10.1126/science.aaa4972; Gevers D, 2014, CELL HOST MICROBE, V15, P382, DOI 10.1016/j.chom.2014.02.005; Goodrich JK, 2016, CELL HOST MICROBE, V19, P731, DOI 10.1016/j.chom.2016.04.017; Goodrich JK, 2014, CELL, V159, P789, DOI 10.1016/j.cell.2014.09.053; Gopalakrishnan V, 2017, SCIENCE; Gorkiewicz G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055817; Guerra N, 2013, CLIN IMMUNOL, V149, P432, DOI 10.1016/j.clim.2013.09.003; Gur C, 2015, IMMUNITY, V42, P344, DOI 10.1016/j.immuni.2015.01.010; Halme L, 2006, WORLD J GASTROENTERO, V12, P3668, DOI 10.3748/wjg.v12.i23.3668; Halwachs B, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00180; Harris JK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128346; Hogenauer C, 2006, NEW ENGL J MED, V355, P2418, DOI 10.1056/NEJMoa054765; Hogenauer C, 1998, CLIN INFECT DIS, V27, P702, DOI 10.1086/514958; Holler E, 2014, BIOL BLOOD MARROW TR, V20, P640, DOI 10.1016/j.bbmt.2014.01.030; Hue S, 2004, IMMUNITY, V21, P367, DOI 10.1016/j.immuni.2004.06.018; Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668; Hunt RH, 2017, GASTROENTEROL CLIN N, V46, P121, DOI 10.1016/j.gtc.2016.09.009; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Ivarsson A, 2000, ACTA PAEDIATR, V89, P165, DOI 10.1080/080352500750028771; Jager S, 2010, INT J INFLAMM, DOI 10.4061/2010/910283; Johansson MEV, 2011, P NATL ACAD SCI USA, V108, P4659, DOI 10.1073/pnas.1006451107; JONES JM, 1971, RADIAT RES, V45, P577, DOI 10.2307/3573066; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225; Kelly CJ, 2015, CELL HOST MICROBE, V17, P662, DOI 10.1016/j.chom.2015.03.005; Kienesberger S, 2016, CELL REP, V14, P1395, DOI 10.1016/j.celrep.2016.01.017; Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007; Kump P, 2017, ALIMENT PHARM THER; Kusters JG, 2006, CLIN MICROBIOL REV, V19, P449, DOI 10.1128/CMR.00054-05; Lawley TD, 2013, IMMUNOLOGY, V138, P1, DOI 10.1111/j.1365-2567.2012.03616.x; Lebwohl B, 2013, AM J EPIDEMIOL, V178, P1721, DOI 10.1093/aje/kwt234; Lees CW, 2011, GUT, V60, P1739, DOI 10.1136/gut.2009.199679; Leffler DA, 2015, NEW ENGL J MED, V372, P1539, DOI 10.1056/NEJMra1403772; Lertpiriyapong K, 2014, GUT, V63, P54, DOI 10.1136/gutjnl-2013-305178; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Li XX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007985; Liang QY, 2017, CLIN CANCER RES, V23, P2061, DOI 10.1158/1078-0432.CCR-16-1599; Liu N, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-130; Lofgren JL, 2011, GASTROENTEROLOGY, V140, P210, DOI 10.1053/j.gastro.2010.09.048; Lopez-Soto A, 2015, INT J CANCER, V136, P1741, DOI 10.1002/ijc.28775; Luciano L, 1996, CELL TISSUE RES, V286, P81, DOI 10.1007/s004410050677; Lynch SV, 2016, NEW ENGL J MED, V375, P2369, DOI 10.1056/NEJMra1600266; Macfarlane S, 2007, CLIN INFECT DIS, V45, P29, DOI 10.1086/518578; Macia L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7734; Maldonado-Contreras A, 2011, ISME J, V5, P574, DOI 10.1038/ismej.2010.149; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Matsuo K, 1997, GUT, V40, P782, DOI 10.1136/gut.40.6.782; Maynard CL, 2012, NATURE, V489, P231, DOI 10.1038/nature11551; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Meresse B, 2004, IMMUNITY, V21, P357, DOI 10.1016/j.immuni.2004.06.020; MEUCCI G, 1992, GASTROENTEROLOGY, V103, P514, DOI 10.1016/0016-5085(92)90841-L; Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101; Molodecky NA, 2012, GASTROENTEROLOGY, V142, P46, DOI 10.1053/j.gastro.2011.10.001; Monstein HJ, 2000, J MED MICROBIOL, V49, P817, DOI 10.1099/0022-1317-49-9-817; Montalban-Arques A, 2016, J PATHOL, V240, P425, DOI 10.1002/path.4782; Moschen AR, 2016, CELL HOST MICROBE, V19, P455, DOI 10.1016/j.chom.2016.03.007; Nakatsu G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9727; Nardone G, 2017, LANCET GASTROENTEROL, V2, P298, DOI 10.1016/S2468-1253(16)30108-X; Nieuwdorp M, 2014, GASTROENTEROLOGY, V146, P1525, DOI 10.1053/j.gastro.2014.02.008; Norman JM, 2015, CELL, V160, P447, DOI 10.1016/j.cell.2015.01.002; Noto JM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006573; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; Park HE, 2017, VIRCHOWS ARCH, V471, P329, DOI 10.1007/s00428-017-2171-6; Pedron T, 2012, MBIO, V3, DOI 10.1128/mBio.00116-12; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Quince C, 2015, AM J GASTROENTEROL, V110, P1718, DOI 10.1038/ajg.2015.357; Raffatellu M, 2009, CELL HOST MICROBE, V5, P476, DOI 10.1016/j.chom.2009.03.011; Raulet DH, 2013, ANNU REV IMMUNOL, V31, P413, DOI 10.1146/annurev-immunol-032712-095951; Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012; Sassone-Corsi M, 2016, NATURE, V540, P280, DOI 10.1038/nature20557; Schaubeck M, 2016, GUT, V65, P225, DOI 10.1136/gutjnl-2015-309333; Schneditz G, 2014, P NATL ACAD SCI USA, V111, P13181, DOI 10.1073/pnas.1403274111; Sender R, 2016, CELL, V164, P337, DOI 10.1016/j.cell.2016.01.013; Simon D, 2016, ALLERGY, V71, P611, DOI 10.1111/all.12846; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Sjoberg V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053414; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Sonnenburg JL, 2016, NATURE, V535, P56, DOI 10.1038/nature18846; Spindelboeck W, 2017, HAEMATOLOGICA, V102, pE210, DOI 10.3324/haematol.2016.154351; Staffas A, 2017, BLOOD, V129, P927, DOI 10.1182/blood-2016-09-691394; Targan SR, 2016, AM J GASTROENTEROL, V111, P1599, DOI 10.1038/ajg.2016.298; Taur Y, 2014, BLOOD, V124, P1174, DOI 10.1182/blood-2014-02-554725; Tilg H, 2015, GASTROENTEROLOGY, V148, P1107, DOI 10.1053/j.gastro.2014.12.036; Tropini C, 2017, CELL HOST MICROBE, V21, P433, DOI 10.1016/j.chom.2017.03.010; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Turpin W, 2016, NAT GENET, V48, P1413, DOI 10.1038/ng.3693; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; VANBEKKU.DW, 1974, J NATL CANCER I, V52, P401, DOI 10.1093/jnci/52.2.401; von Rosenvinge EC, 2013, ISME J, V7, P1354, DOI 10.1038/ismej.2013.33; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; Wang J, 2016, NAT GENET, V48, P1396, DOI 10.1038/ng.3695; Wlodarska M, 2015, CELL HOST MICROBE, V17, P577, DOI 10.1016/j.chom.2015.04.008; Wurm P, 2017, CRIT CARE MED, V45, pE600, DOI 10.1097/CCM.0000000000002310; Yang I, 2013, FEMS MICROBIOL REV, V37, P736, DOI 10.1111/1574-6976.12027; Yang LY, 2009, GASTROENTEROLOGY, V137, P588, DOI 10.1053/j.gastro.2009.04.046; Yang Y, 2014, NATURE, V510, P152, DOI 10.1038/nature13279; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008	138	3	3	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JAN	2018	472	1					159	172		10.1007/s00428-017-2277-x			14	Pathology	Pathology	FZ3FX	WOS:000427473200014	29243124	Green Published			2019-10-28	
J	Tang, BM; Shojaei, M; Branley, J; McLean, A				Tang, Benjamin M.; Shojaei, Maryam; Branley, James; McLean, Anthony			Biomarkers for high-risk influenza patients: what are the next steps?	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Editorial Material						Influenza; biomarkers; host response; risk stratification	INFECTION		[Tang, Benjamin M.; Shojaei, Maryam; McLean, Anthony] Nepean Hosp, Dept Intens Care Med, Sydney, NSW, Australia; [Tang, Benjamin M.; Shojaei, Maryam] Westmead Inst Med Res, Ctr Immunol & Allergy Res, Sydney, NSW, Australia; [Tang, Benjamin M.] Marie Bashir Inst Infect Dis & Biosecur, Resp Virus Infect Res, Sydney, NSW, Australia; [Branley, James] Nepean Hosp, Dept Microbiol, Sydney, NSW, Australia	Tang, BM (reprint author), Nepean Hosp, Great Western Highway, Sydney, NSW, Australia.						Andres-Terre M, 2015, IMMUNITY, V43, P1199, DOI 10.1016/j.immuni.2015.11.003; Brandes M, 2013, CELL, V154, P197, DOI 10.1016/j.cell.2013.06.013; Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496; La Gruta NL, 2007, IMMUNOL CELL BIOL, V85, P85, DOI 10.1038/sj.icb.7100026; Morgan DJ, 2017, JAMA-J AM MED ASSOC, V318, P607, DOI 10.1001/jama.2017.8531; Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013; Oshansky CM, 2014, AM J RESP CRIT CARE, V189, P449, DOI 10.1164/rccm.201309-1616OC; Peteranderl C, 2016, SEMIN RESP CRIT CARE, V37, P487, DOI 10.1055/s-0036-1584801; Rello J, 2017, LANCET RESP MED, V5, P91, DOI 10.1016/S2213-2600(17)30005-X; Tang BM, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02098-2016	10	0	0	0	0	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	3					205	206		10.1080/14737159.2018.1420475			2	Pathology	Pathology	FY5ZM	WOS:000426918100001	29264948	Bronze			2019-10-28	
J	Fleece, ME; Pholwat, S; Mathers, AJ; Houpt, ER				Fleece, Molly E.; Pholwat, Suporn; Mathers, Amy J.; Houpt, Eric R.			Molecular diagnosis of antimicrobial resistance in Escherichia coli	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Molecular diagnostics; mechanisms of resistance; Escherichia coli; antimicrobial resistance; whole genome sequencing; extended-spectrum beta-lactamase; carbapenemase; PCR; microarray	MEDIATED QUINOLONE RESISTANCE; SPECTRUM-BETA-LACTAMASE; GRAM-NEGATIVE BACILLI; CARBA-R ASSAY; CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE; MODIFIED HODGE TEST; ACRAB EFFLUX PUMP; ANTIBIOTIC-RESISTANCE; KLEBSIELLA-PNEUMONIAE; EXTENDED-SPECTRUM	Introduction: Antimicrobial resistance is a growing global public health threat. The complexities of antimicrobial resistance in gram-negative bacteria such as Escherichia coli pose significant diagnostic and therapeutic challenges. Molecular diagnostics are emerging in this field.Areas covered: The authors review the clinical importance of pathogenic E. coli and discuss the mechanisms of resistance to common antibiotics used to treat these infections. We review the literature on antimicrobial susceptibility testing and discuss the current state of phenotypic as well as molecular methodologies. Clinical vignettes are presented to highlight how molecular diagnostics may be used for patient care.Expert commentary: The future use of molecular diagnostics for detection of antimicrobial resistance will be tailored to the context, whether hospital epidemiology, infection control, antibiotic stewardship, or clinical care. Further clinical research is needed to understand how to best apply molecular diagnostics to these settings.	[Fleece, Molly E.; Pholwat, Suporn; Mathers, Amy J.; Houpt, Eric R.] Univ Virginia, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA	Houpt, ER (reprint author), Univ Virginia, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA.	erh6k@virginia.edu					Abbott A, 2015, MANUAL CLIN MICROBIO, P1379; Adachi JA, 2001, CLIN INFECT DIS, V32, P1706, DOI 10.1086/320756; Aires JR, 2005, J BACTERIOL, V187, P1923, DOI 10.1128/JB.187.6.1923-1929.2005; Al-Hasan MN, 2009, J ANTIMICROB CHEMOTH, V64, P169, DOI 10.1093/jac/dkp162; AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; Angus DC, 2013, NEW ENGL J MED, V369, P840, DOI 10.1056/NEJMra1208623; Arroyo MA, 2017, J CLIN MICROBIOL, V55, P2708, DOI 10.1128/JCM.00692-17; Azucena E, 2001, DRUG RESIST UPDATE, V4, P106, DOI 10.1054/drup.2001.0197; Bajaj P, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00417; BAKER CN, 1991, J CLIN MICROBIOL, V29, P533; Baron S, 2016, INT J ANTIMICROB AG, V48, P583, DOI 10.1016/j.ijantimicag.2016.06.023; Blair JMA, 2015, NAT REV MICROBIOL, V13, P42, DOI 10.1038/nrmicro3380; Bryce A, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i939; Bush K, 2010, ANTIMICROB AGENTS CH, V54, P969, DOI 10.1128/AAC.01009-09; Canton R, 2006, CURR OPIN MICROBIOL, V9, P466, DOI 10.1016/j.mib.2006.08.011; Castanheira M, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00567-17, 10.1128/aac.00567-17]; Cattoir V, 2009, CURR MED CHEM, V16, P1028, DOI 10.2174/092986709787581879; Chaurasia S, 2016, LANCET GLOB HEALTH, V4, pE752, DOI 10.1016/S2214-109X(16)30148-6; CLSI, 2016, M100S26 CLSI; Conrad S, 1996, J ANTIMICROB CHEMOTH, V38, P443, DOI 10.1093/jac/38.3.443; Dalhoff Axel, 2012, Interdiscip Perspect Infect Dis, V2012, P976273, DOI 10.1155/2012/976273; Dodemont M, 2014, J CLIN MICROBIOL, V52, P3085, DOI 10.1128/JCM.01099-14; DUPONT HL, 1993, NEW ENGL J MED, V328, P1821; Ellington MJ, 2017, CLIN MICROBIOL INFEC, V23, P2, DOI 10.1016/j.cmi.2016.11.012; Erb A, 2007, EUR J CLIN MICROBIOL, V26, P83, DOI 10.1007/s10096-006-0248-2; Friedman SM, 2001, ANTIMICROB AGENTS CH, V45, P2378, DOI 10.1128/AAC.45.8.2378-2380.2001; Gao RS, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005957; Girlich D, 2012, J CLIN MICROBIOL, V50, P477, DOI 10.1128/JCM.05247-11; Goldstein EJC, 2004, J ANTIMICROB CHEMOTH, V53, P29, DOI 10.1093/jac/dkh201; Hawser SP, 2009, ANTIMICROB AGENTS CH, V53, P3280, DOI 10.1128/AAC.00426-09; Hayakawa K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181548; Hilborn ED, 1999, ARCH INTERN MED, V159, P1758, DOI 10.1001/archinte.159.15.1758; Hombach M, 2013, CLIN MICROBIOL INFEC, V19, pE59, DOI 10.1111/1469-0691.12090; Humphries RM, 2016, CLIN INFECT DIS, V63, P83, DOI 10.1093/cid/ciw201; Huovinen P, 2001, CLIN INFECT DIS, V32, P1608; Jacoby GA, 2005, NEW ENGL J MED, V352, P380, DOI 10.1056/NEJMra041359; Jacoby GA, 2005, CLIN INFECT DIS, V41, pS120, DOI 10.1086/428052; Jacoby GA, 2009, CLIN MICROBIOL REV, V22, P161, DOI 10.1128/CMR.00036-08; Jean SS, 2011, INT J ANTIMICROB AG, V37, P291, DOI 10.1016/j.ijantimicag.2011.01.009; Johnson JR, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/aac.00732-17, 10.1128/AAC.00732-17]; Jorgensen J, 2015, MANUAL CLIN MICROBIO, P1253, DOI DOI 10.1128/9781555817381.CH71; Kahlmeter G, 2014, UPSALA J MED SCI, V119, P78, DOI 10.3109/03009734.2014.901446; Karlowski JA, 2015, MANUAL CLIN MICROBIO, P1274; Kaur J, 2013, J CLIN DIAGN RES, V7, P229, DOI 10.7860/JCDR/2013/4619.2734; Kim JS, 2016, BIOMED RES INT, V2016; Ku LC, 2015, CLIN PERINATOL, V42, P29, DOI 10.1016/j.clp.2014.10.004; LECLERCQ R, 1991, ANTIMICROB AGENTS CH, V35, P1273, DOI 10.1128/AAC.35.7.1273; Leclercq R, 2002, CLIN INFECT DIS, V34, P482, DOI 10.1086/324626; Ledeboer N. A., 2011, Journal of Clinical Microbiology, V49, pS20, DOI 10.1128/JCM.00771-11; Ledeboer NA, 2015, J CLIN MICROBIOL, V53, P2460, DOI 10.1128/JCM.00581-15; Li XZ, 2015, CLIN MICROBIOL REV, V28, P337, DOI 10.1128/CMR.00117-14; Lindgren PK, 2003, ANTIMICROB AGENTS CH, V47, P3222, DOI 10.1128/AAC.47.10.3222-3232.2003; Liu YY, 2016, LANCET INFECT DIS, V16, P161, DOI 10.1016/S1473-3099(15)00424-7; Mathers AJ, 2015, CLIN MICROBIOL REV, V28, P565, DOI 10.1128/CMR.00116-14; Mathers AJ, 2013, J CLIN MICROBIOL, V51, P1291, DOI 10.1128/JCM.03240-12; Matsumura Y, 2016, EXPERT REV MOL DIAGN, V16, P783, DOI 10.1586/14737159.2016.1172964; McMullen AR, 2017, CLIN CHEM, V63, P723, DOI 10.1373/clinchem.2016.264804; Miller SA, 2017, J CLIN MICROBIOL, V55, P1827, DOI 10.1128/JCM.00157-17; Moore NM, 2017, J CLIN MICROBIOL, V55, P2268, DOI [10.1128/JCM.00137-17, 10.1128/jcm.00137-17]; Nguyen MCP, 2009, EMERG INFECT DIS, V15, P1648, DOI 10.3201/eid1510.090696; O'Neill J, 2014, REV ANTIMICROBIAL RE; Oethinger M, 2000, ANTIMICROB AGENTS CH, V44, P10, DOI 10.1128/AAC.44.1.10-13.2000; Ojo KK, 2004, ANTIMICROB AGENTS CH, V48, P3451, DOI 10.1128/AAC.48.9.3451-3456.2004; Okusu H, 1996, J BACTERIOL, V178, P306, DOI 10.1128/jb.178.1.306-308.1996; Olaitan AO, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00643; Opal SM, 2003, CLIN INFECT DIS, V37, P50, DOI 10.1086/375593; ORAM M, 1991, ANTIMICROB AGENTS CH, V35, P387, DOI 10.1128/AAC.35.2.387; Pasteran F, 2009, J CLIN MICROBIOL, V47, P1631, DOI 10.1128/JCM.00130-09; Patel JB, 2015, MANUAL CLIN MICROBIO, P1212; Piddock LJV, 1999, DRUGS, V58, P11, DOI 10.2165/00003495-199958002-00003; Pierce VM, 2017, J CLIN MICROBIOL, V55, P2321, DOI 10.1128/JCM.00193-17; Poirel L, 2006, ANTIMICROB AGENTS CH, V50, P1525, DOI 10.1128/AAC.50.4.1525-1527.2006; Poirel L, 2012, J ANTIMICROB CHEMOTH, V67, P1597, DOI 10.1093/jac/dks121; Poole K, 2005, J ANTIMICROB CHEMOTH, V56, P20, DOI 10.1093/jac/dki171; Ramirez MS, 2010, DRUG RESIST UPDATE, V13, P151, DOI 10.1016/j.drup.2010.08.003; Ranieri VM, 2012, NEW ENGL J MED, V366, P2055, DOI 10.1056/NEJMoa1202290; Reuter S, 2013, JAMA INTERN MED, V173, P1397, DOI 10.1001/jamainternmed.2013.7734; Roberts MC, 1999, ANTIMICROB AGENTS CH, V43, P2823, DOI 10.1128/AAC.43.12.2823; Robicsek A, 2006, LANCET INFECT DIS, V6, P629, DOI 10.1016/S1473-3099(06)70599-0; Rosenberg EY, 2000, J BACTERIOL, V182, P1754, DOI 10.1128/JB.182.6.1754-1756.2000; Salimnia H, 2016, J CLIN MICROBIOL, V54, P687, DOI 10.1128/JCM.01679-15; Shelburne SA, 2017, CLIN INFECT DIS, V65, P738, DOI 10.1093/cid/cix417; Siu GKH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139728; Skold O, 2001, VET RES, V32, P261, DOI 10.1051/vetres:2001123; Skold O, 2000, DRUG RESIST UPDATE, V3, P155, DOI 10.1054/drup.2000.0146; Sogaard M, 2011, CLIN INFECT DIS, V52, P61, DOI 10.1093/cid/ciq069; Stoesser N, 2013, J ANTIMICROB CHEMOTH, V68, P2234, DOI 10.1093/jac/dkt180; Stoesser N, 2016, MBIO, V7, DOI 10.1128/mBio.02162-15; Tadesse DA, 2012, EMERG INFECT DIS, V18, P741, DOI 10.3201/eid1805.111153; Talan DA, 2016, EMERG INFECT DIS, V22, P1594, DOI 10.3201/eid2209.160148; Tanner H, 2017, J HOSP INFECT, V97, P254, DOI 10.1016/j.jhin.2017.06.029; Tato M, 2016, J CLIN MICROBIOL, V54, P1814, DOI 10.1128/JCM.00341-16; Thomson KS, 2001, EMERG INFECT DIS, V7, P333, DOI 10.3201/eid0702.010238; Tijet Nathalie, 2013, Antimicrob Agents Chemother, V57, P4578, DOI 10.1128/AAC.00878-13; Tran JH, 2002, P NATL ACAD SCI USA, V99, P5638, DOI 10.1073/pnas.082092899; Turnidge J, 2006, CLIN MICROBIOL INFEC, V12, P418, DOI 10.1111/j.1469-0691.2006.01377.x; Turnidge JD, 2015, MANUAL CLIN MICROBIO, P1246; Turnidge J, 2007, CLIN MICROBIOL REV, V20, P391, DOI 10.1128/CMR.00047-06; U.S. FDA, 2009, CLASS 2 SPEC CONTR G; Valsesia G, 2015, J CLIN MICROBIOL, V53, P1812, DOI 10.1128/JCM.03506-14; van Belkum A, 2013, J CLIN MICROBIOL, V51, P2018, DOI 10.1128/JCM.00313-13; von Baum H, 2005, INT J MED MICROBIOL, V295, P503, DOI 10.1016/j.ijmm.2005.07.002; Walsh TR, 2005, CLIN MICROBIOL REV, V18, P306, DOI 10.1128/CMR.18.2.306-325.2005; Wang P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026356; Ward C, 2015, EUR J CLIN MICROBIOL, V34, P487, DOI 10.1007/s10096-014-2252-2; Weiner LM, 2016, INFECT CONT HOSP EP, V37, P1288, DOI 10.1017/ice.2016.174; World Health Organization, 2017, GLOB PRIOR LIST ANT; Xavier BB, 2016, EUROSURVEILLANCE, V21, P8, DOI 10.2807/1560-7917.ES.2016.21.27.30280; Yang JY, 2011, INT J ANTIMICROB AG, V38, P348, DOI 10.1016/j.ijantimicag.2011.04.021; YOSHIDA H, 1990, ANTIMICROB AGENTS CH, V34, P1271, DOI 10.1128/AAC.34.6.1271; Zankari E, 2013, J ANTIMICROB CHEMOTH, V68, P771, DOI 10.1093/jac/dks496; Zhanel GG, 2013, DRUGS, V73, P159, DOI 10.1007/s40265-013-0013-7; Zhong P, 2000, DRUG RESIST UPDATE, V3, P325, DOI 10.1054/drup.2000.0175	113	3	3	3	14	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	3					207	217		10.1080/14737159.2018.1439381			11	Pathology	Pathology	FY5ZM	WOS:000426918100002	29431523				2019-10-28	
J	Basile, AO; Ritchie, MD				Basile, Anna Okula; Ritchie, Marylyn DeRiggi			Informatics and machine learning to define the phenotype	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Cluster analysis; complex traits; dimensionality reduction; electronic health records (EHRs); heterogeneity; machine learning; missing data; phenotype; topological analysis; unsupervised analysis	ELECTRONIC MEDICAL-RECORDS; HEALTH RECORDS; CLUSTER-ANALYSIS; DATA QUALITY; SAMPLE-SIZE; LARGE-SCALE; HETEROGENEITY; ASSOCIATION; BIOBANK; DISEASE	Introduction: For the past decade, the focus of complex disease research has been the genotype. From technological advancements to the development of analysis methods, great progress has been made. However, advances in our definition of the phenotype have remained stagnant. Phenotype characterization has recently emerged as an exciting area of informatics and machine learning. The copious amounts of diverse biomedical data that have been collected may be leveraged with data-driven approaches to elucidate trait-related features and patterns.Areas covered: In this review, the authors discuss the phenotype in traditional genetic associations and the challenges this has imposed.Approaches for phenotype refinement that can aid in more accurate characterization of traits are also discussed. Further, the authors highlight promising machine learning approaches for establishing a phenotype and the challenges of electronic health record (EHR)-derived data.Expert commentary: The authors hypothesize that through unsupervised machine learning, data-driven approaches can be used to define phenotypes rather than relying on expert clinician knowledge. Through the use of machine learning and an unbiased set of features extracted from clinical repositories, researchers will have the potential to further understand complex traits and identify patient subgroups. This knowledge may lead to more preventative and precise clinical care.	[Basile, Anna Okula; Ritchie, Marylyn DeRiggi] Penn State Univ, Dept Biochem & Mol Biol, State Coll, PA 16801 USA; [Ritchie, Marylyn DeRiggi] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA	Ritchie, MD (reprint author), Penn State Univ, Dept Biochem & Mol Biol, State Coll, PA 16801 USA.; Ritchie, MD (reprint author), Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA.	marylyn@upenn.edu			Pennsylvania Department of Health [SAP 4100070267]; Biomedical Big Data to Knowledge (B2D2K) Pre-doctoral Training Program from the National Library of Medicine [1T32 LM012415-01]	This project is funded, in part, under a grant with the Pennsylvania Department of Health (#SAP 4100070267). The Department specifically disclaims responsibility for any analyses, interpretations or conclusions. This work is also supported by the Biomedical Big Data to Knowledge (B2D2K) Pre-doctoral Training Program from the National Library of Medicine (1T32 LM012415-01).	Ahlqvist E, 2017, BIORXIV; Ananthakrishnan AN, 2013, INFLAMM BOWEL DIS, V19, P1411, DOI 10.1097/MIB.0b013e31828133fd; Beaulieu-Jones BK, 2017, BIORXIV; Beaulieu-Jones BK, 2016, PAC S BIOCOMPUT PAC, V22, P207; Botsis Taxiarchis, 2010, Summit Transl Bioinform, V2010, P1; BROWNELL KD, 1991, BEHAV THER, V22, P153, DOI 10.1016/S0005-7894(05)80174-1; Burgel PR, 2010, EUR RESPIR J, V36, P531, DOI 10.1183/09031936.00175109; Burgel PR, 2014, BIOMED RES INT, DOI 10.1155/2014/420134; Buyske S, 2009, HUM HERED, V67, P287, DOI 10.1159/000194981; Cantor-Rivera D, 2015, COMPUT MED IMAG GRAP, V41, P14, DOI 10.1016/j.compmedimag.2014.07.002; Carey DJ, 2016, GENET MED, V18, P906, DOI 10.1038/gim.2015.187; Carlsson G, 2009, B AM MATH SOC, V46, P255, DOI 10.1090/S0273-0979-09-01249-X; Cassel M., 2006, 12 IEEE INT LIN TEST; Cunningham JP, 2015, J MACH LEARN RES, V16, P2859; de Burgos-Lunar C, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-146; Deliu Matea, 2016, Pulm Ther, V2, P19; Do R, 2012, HUM MOL GENET, V21, pR1, DOI 10.1093/hmg/dds387; Docampo E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074873; Edwards BJ, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-18; Faulconer Edwin R, 2004, Inform Prim Care, V12, P243; Fens N, 2013, COPD, V10, P277, DOI 10.3109/15412555.2012.744388; Gaziano JM, 2016, J CLIN EPIDEMIOL, V70, P214, DOI 10.1016/j.jclinepi.2015.09.016; Georgiades S, 2013, J CHILD PSYCHOL PSYC, V54, P206, DOI 10.1111/j.1469-7610.2012.02588.x; Gidea M, 2017, ARXIV170304385PHYSQF; Gordon D, 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1085; Gottesman O, 2013, GENET MED, V15, P761, DOI 10.1038/gim.2013.72; Green MA, 2016, J PUBLIC HEALTH-UK, V38, P258, DOI 10.1093/pubmed/fdv040; Hashem IAT, 2015, INFORM SYST, V47, P98, DOI 10.1016/j.is.2014.07.006; Hersh WR, 2013, MED CARE, V51, pS30, DOI 10.1097/MLR.0b013e31829b1dbd; Hormozdiari F, 2016, AM J HUM GENET, V99, P89, DOI 10.1016/j.ajhg.2016.04.013; Huilei Xu, 2011, Information Quality in e-Health. Proceedings 7th Conference of the Workgroup Human-Computer Interaction and Usability Engineering of the Austrian Computer Society, USAB 2011, P15, DOI 10.1007/978-3-642-25364-5_2; Ji F, 2005, STAT APPL GENET MOL, V4; Kafieh Rahele, 2013, J Med Signals Sens, V3, P22; Kirby JC, 2016, J AM MED INFORM ASSN, V23, P1046, DOI 10.1093/jamia/ocv202; Kortelainen J, 2011, IEEE T NEUR SYS REH, V19, P113, DOI 10.1109/TNSRE.2010.2098420; Kyeong S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182603; Lee S, 2014, AM J HUM GENET, V95, P5, DOI 10.1016/j.ajhg.2014.06.009; Lewis JD, 2004, PHARMACOEPIDEM DR S, V13, P437, DOI 10.1002/pds.902; Li L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9364; Liao KP, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1885; Liao KP, 2010, ARTHRIT CARE RES, V62, P1120, DOI 10.1002/acr.20184; Linder JA, 2009, MED CARE, V47, P208, DOI 10.1097/MLR.0b013e318189375f; Lo Re V, 2009, PHARMACOEPIDEM DR S, V18, P807, DOI 10.1002/pds.1784; Lum PY, 2013, SCI REP-UK, V3, DOI 10.1038/srep01236; Maher B, 2008, NATURE, V456, P18, DOI 10.1038/456018a; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Margulis AV, 2009, PHARMACOEPIDEM DR S, V18, P900, DOI 10.1002/pds.1787; McCarty CA, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-13; McLaughlin T, 2012, Int J Obes Suppl, V2, pS8; Nicolau M, 2011, P NATL ACAD SCI USA, V108, P7265, DOI 10.1073/pnas.1102826108; Paoletti M, 2009, J BIOMED INFORM, V42, P1013, DOI 10.1016/j.jbi.2009.05.008; Pathak J, 2013, J AM MED INFORM ASSN, V20, pE206, DOI 10.1136/amiajnl-2013-002428; Paul R, 2010, 2010 Fifth International Conference on Digital Information Management (ICDIM 2010), P44, DOI 10.1109/ICDIM.2010.5664638; Pendergrass S A, 2015, Curr Genet Med Rep, V3, P92; Perlis RH, 2012, PSYCHOL MED, V42, P41, DOI 10.1017/S0033291711000997; Porter SC, 1999, J AM MED INFORM ASSN, P354; Richesson RL, 2013, J AM MED INFORM ASSN, V20, pE319, DOI 10.1136/amiajnl-2013-001952; Ritchie MD, 2015, NAT REV GENET, V16, P85, DOI 10.1038/nrg3868; Roden DM, 2008, CLIN PHARMACOL THER, V84, P362, DOI 10.1038/clpt.2008.89; Rosenblum L. J., 1984, OCEANS '84 Conference and Exposition. Conference Record. `Industry, Government, Education - Designs for the Future' (Cat. No. 84CH2066-9), P100, DOI 10.1109/OCEANS.1984.1152328; Roukema J, 2006, PEDIATRICS, V117, P15, DOI 10.1542/peds.2004-2741; Schildcrout JS, 2010, J BIOMED INFORM, V43, P914, DOI 10.1016/j.jbi.2010.07.011; Singh N, 2014, INT J COMPUT APPL, V92, P7; Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779; Sutherland ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036631; Thornton-Wells TA, 2004, TRENDS GENET, V20, P640, DOI 10.1016/j.tig.2004.09.007; Thornton-Wells TA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-204; Tsai F. S., 2010, J ARTIFICIAL INTELLI, V3, P119, DOI DOI 10.3923/JAI.2010.119.134; van de Weygaert R, 2013, ARXIV13063640ASTROPH; van den Berge MJC, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00115; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Verma A, 2016, BIOCOMPUT-PAC SYM, P168; Verma A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160573; Wagner MJ, 2013, PHARMACOGENOMICS, V14, P413, DOI [10.2217/PGS.13.36, 10.2217/pgs.13.36]; Wasserman L, 2016, ARXIV160908227STAT; Weiskopf NG, 2013, J AM MED INFORM ASSN, V20, P144, DOI 10.1136/amiajnl-2011-000681; Wu LT, 2013, J PSYCHIATR RES, V47, P555, DOI 10.1016/j.jpsychires.2012.12.009	77	1	1	0	7	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	3					219	226		10.1080/14737159.2018.1439380			8	Pathology	Pathology	FY5ZM	WOS:000426918100003	29431517	Green Accepted			2019-10-28	
J	Mittal, S; Brown, NJ; Holen, I				Mittal, Suruchi; Brown, Nicola J.; Holen, Ingunn			The breast tumor microenvironment: role in cancer development, progression and response to therapy	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Breast cancer; bone; microenvironment; bone metastases; bone targeted agents	REGULATORY T-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; NEUTROPHIL-LYMPHOCYTE RATIO; MAMMARY-GLAND DEVELOPMENT; EXTRACELLULAR-MATRIX; MAMMOGRAPHIC DENSITY; TGF-BETA; INFILTRATING LYMPHOCYTES; NEOADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS	Introduction: Numerous clinical and pre-clinical studies have provided ample evidence supporting that the tumor microenvironment plays a significant role during breast cancer development, progression and in determining the therapeutic response.Areas covered: This review focuses on the evolving concept of the microenvironment as the critical participant in each step of the multi-stage process of malignant progression. Currently, only a small number of molecules form part of routine molecular diagnostics in breast caner, but microenvironment-derived biomarkers are potential additions to existing predictive and prognostic marker panels. The authors discuss the dependency of the breast tumor cells on different components of the microenvironment for their survival, dissemination, dormancy and establishment in secondary sites to form overt metastasis, as well as the potential as a therapeutic target to improve breast cancer outcome.Expert commentary: Despite the importance in the development of breast cancer, the contribution of the microenvironment is not considered in routine diagnostic testing or informing therapeutic decisions. However, introduction of immunotherapy will increasingly require patient selection based on the stromal composition of the primary breast tumor. Better understanding of the role of specific microenvironment-derived molecules is likely to inform personalized therapy, leading to improved patient outcome.	[Mittal, Suruchi; Brown, Nicola J.; Holen, Ingunn] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England	Holen, I (reprint author), Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.	I.Holen@Sheffield.ac.uk			Breast Cancer Now UK [2016NovPCC006]	S Mittal is funded by a project grant from Breast Cancer Now UK, Grant number 2016NovPCC006.	Aalders KC, 2017, CANCER TREAT REV, V53, P98, DOI 10.1016/j.ctrv.2016.12.009; Aapro MS, 2012, BREAST, V21, P8, DOI 10.1016/j.breast.2011.08.138; Acerbi I, 2015, INTEGR BIOL-UK, V7, P1120, DOI 10.1039/c5ib00040h; ADAMS EF, 1988, BREAST CANCER RES TR, V11, P165, DOI 10.1007/BF01805840; Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Al-Raawi D, 2011, INT J CLIN EXP MED, V4, P265; Alix-Panabieres C, 2017, FEBS LETT, V591, P2241, DOI 10.1002/1873-3468.12662; Allen MD, 2011, J PATHOL, V223, P646, DOI 10.1002/path.2833; Alonso-Escolano D, 2004, BRIT J PHARMACOL, V141, P241, DOI 10.1038/sj.bjp.0705606; Alonso-Escolano D, 2006, J PHARMACOL EXP THER, V318, P373, DOI 10.1124/jpet.106.103358; Amornsupak K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-955; Andarawewa KL, 2005, CANCER RES, V65, P10862, DOI 10.1158/0008-5472.CAN-05-1231; Asano Y, 2016, BRIT J SURG, V103, P845, DOI 10.1002/bjs.10127; Awolaran O, 2016, BREAST, V30, P156, DOI 10.1016/j.breast.2016.09.017; Baeriswyl V, 2009, SEMIN CANCER BIOL, V19, P329, DOI 10.1016/j.semcancer.2009.05.003; Balz LM, 2012, J PATHOL, V227, P234, DOI 10.1002/path.3991; Bambace NM, 2011, J THROMB HAEMOST, V9, P237, DOI 10.1111/j.1538-7836.2010.04131.x; Barone I, 2012, CANCER RES, V72, P1416, DOI 10.1158/0008-5472.CAN-11-2558; Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584; Beckwee D, 2017, SUPPORT CARE CANCER, V25, P1673, DOI 10.1007/s00520-017-3613-z; Bendell JC, 2003, CANCER, V97, P2972, DOI 10.1002/cncr.11436; Bergenfelz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127028; Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x; Blucher C, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00293; Bohling SD, 2008, MODERN PATHOL, V21, P1527, DOI 10.1038/modpathol.2008.160; Bos PD, 2013, J EXP MED, V210, P2435, DOI 10.1084/jem.20130762; Boucharaba A, 2009, ONCOL RES, V18, P173, DOI 10.3727/096504009790217399; Boudreau A, 2012, CELL ADHES MIGR, V6, P236, DOI 10.4161/cam.20880; Boyd NF, 2002, NEW ENGL J MED, V347, P886, DOI 10.1056/NEJMoa013390; Boyd NF, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2942; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Brueggemeier RW, 2005, ENDOCR REV, V26, P331, DOI 10.1210/er.2004-0015; Buchsbaum RJ, 2016, CANCERS, V8, P2; Burstein HJ, 2005, J CLIN ONCOL, V23, P8340, DOI 10.1200/JCO.2005.02.8621; Burugu S, 2017, BREAST CANCER-TOKYO, V24, P3, DOI 10.1007/s12282-016-0698-z; Caine GJ, 2004, THROMB HAEMOSTASIS, V92, P185, DOI 10.1160/TH03-11-0679; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; Camacho L, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0598-8; Cameron MD, 2000, CANCER RES, V60, P2541; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carmichael AR, 2006, BJOG-INT J OBSTET GY, V113, P1160, DOI 10.1111/j.1471-0528.2006.01021.x; Castano Z, 2011, INT J DEV BIOL, V55, P889, DOI 10.1387/ijdb.113366zc; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chang PH, 2012, CANCER RES, V72, P4652, DOI 10.1158/0008-5472.CAN-12-0877; Chen J, 2015, FEBS OPEN BIO, V5, P502, DOI 10.1016/j.fob.2015.05.003; Chen YL, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0408-0; Chin AR, 2016, CLIN CANCER RES, V22, P3725, DOI 10.1158/1078-0432.CCR-16-0028; Cichon MA, 2010, J MAMMARY GLAND BIOL, V15, P389, DOI 10.1007/s10911-010-9195-8; Cole S, 2009, 32 ANN CTRC AACR SAN; Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140-6736(15)60908-4; Conklin MW, 2011, AM J PATHOL, V178, P1221, DOI 10.1016/j.ajpath.2010.11.076; Cox TR, 2015, NATURE, V522, P106, DOI 10.1038/nature14492; Cuzick J, 2003, LANCET, V361, P296, DOI 10.1016/S0140-6736(03)12342-2; Cuzick J, 2011, J NATL CANCER I, V103, P744, DOI 10.1093/jnci/djr079; D'Oronzo S, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12725; Demers M, 2012, P NATL ACAD SCI USA, V109, P13076, DOI 10.1073/pnas.1200419109; Demicheli R, 1996, BREAST CANCER RES TR, V41, P177, DOI 10.1007/BF01807163; Demir L, 2013, CLIN EXP METASTAS, V30, P1047, DOI 10.1007/s10585-013-9602-9; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4; Dirat B, 2011, CANCER RES, V71, P2455, DOI 10.1158/0008-5472.CAN-10-3323; Dirat B, 2010, ENDOCR DEV, V19, P45, DOI 10.1159/000316896; Dowling RJO, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0540-0; Drabsch Y, 2011, J MAMMARY GLAND BIOL, V16, P97, DOI 10.1007/s10911-011-9217-1; Dumont N, 2013, NEOPLASIA, V15, P249, DOI 10.1593/neo.121950; Engel J, 2003, EUR J CANCER, V39, P1794, DOI 10.1016/S0959-8049(03)00422-2; Ethier JL, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-016-0794-1; Fang YZ, 2013, JNCI-J NATL CANCER I, V105, P47, DOI 10.1093/jnci/djs485; Fang ZX, 2017, ONCOTARGET, V8, P54173, DOI 10.18632/oncotarget.17013; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; FERRIERE JP, 1985, AM J HEMATOL, V19, P47, DOI 10.1002/ajh.2830190107; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FIDLER IJ, 1976, JNCI-J NATL CANCER I, V57, P1199, DOI 10.1093/jnci/57.5.1199; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Folgueira MA, 2013, BIOSCI REP, V33; Francia G, 2011, NAT REV CANCER, V11, P135, DOI 10.1038/nrc3001; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gao MQ, 2010, J CELL SCI, V123, P3507, DOI 10.1242/jcs.072900; Garcia-Mendoza MG, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0703-7; Gehler S, 2013, CRIT REV EUKAR GENE, V23, P139, DOI 10.1615/CritRevEukarGeneExpr.2013006647; Gobert M, 2009, CANCER RES, V69, P2000, DOI 10.1158/0008-5472.CAN-08-2360; Goodwin PJ, 2015, JNCI-J NATL CANCER I, P107; Goss PE, 2016, NEW ENGL J MED, V375, P209, DOI 10.1056/NEJMoa1604700; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; GRIGNANI G, 1989, INVAS METAST, V9, P298; Gwak JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125728; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayashi M, 2012, ANN SURG ONCOL, V19, P3042, DOI 10.1245/s10434-012-2343-1; Hendrix A, 2011, INT J DEV BIOL, V55, P879, DOI 10.1387/ijdb.113391ah; Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778; Holle AW, 2016, ADV DRUG DELIVER REV, V97, P270, DOI 10.1016/j.addr.2015.10.007; HOLLIDAY DL, 2009, BREAST CANCER RES, V11; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hosseini H, 2016, NATURE; Hugo HJ, 2012, CANCER MICROENVIRON, V5, P83, DOI 10.1007/s12307-012-0098-7; Humtsoe JO, 2010, ONCOGENE, V29, P1214, DOI 10.1038/onc.2009.419; Huo CW, 2014, BREAST CANCER RES TR, V144, P479, DOI 10.1007/s10549-014-2901-2; Iyengar P, 2005, J CLIN INVEST, V115, P1163, DOI 10.1172/JCI200523424; Jhaveri K, 2016, CLIN BREAST CANCER, V16, P113, DOI 10.1016/j.clbc.2015.11.006; Jordan NV, 2016, NATURE, V537, P102, DOI 10.1038/nature19328; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Kimbung S, 2015, SEMIN CANCER BIOL, V35, P85, DOI 10.1016/j.semcancer.2015.08.009; Kimijima I, 2000, ONCOLOGY-BASEL, V59, P25, DOI 10.1159/000055284; Kitamura T, 2015, J EXP MED, V212, P1043, DOI 10.1084/jem.20141836; Koh CH, 2015, BRIT J CANCER, V113, P150, DOI 10.1038/bjc.2015.183; Kohn JC, 2015, BIOPHYS J, V108, P471, DOI 10.1016/j.bpj.2014.12.023; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Kroemer G, 2015, NAT MED, V21, P1128, DOI 10.1038/nm.3944; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Kuznetsov HS, 2012, CANCER DISCOV, V2, P1150, DOI 10.1158/2159-8290.CD-12-0216; Labelle M, 2012, CANCER DISCOV, V2, P1091, DOI 10.1158/2159-8290.CD-12-0329; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Lamy M, 2017, NEW BIOTECHNOL, V39, P215, DOI 10.1016/j.nbt.2017.08.004; Lapeire L, 2014, CANCER RES, V74, P6806, DOI 10.1158/0008-5472.CAN-14-0160; Largillier R, 2008, ANN ONCOL, V19, P2012, DOI 10.1093/annonc/mdn424; Leblanc R, 2014, BLOOD, V124, P3141, DOI 10.1182/blood-2014-04-568683; Li T, 2005, CANCER EPIDEM BIOMAR, V14, P343, DOI 10.1158/1055-9965.EPI-04-0490; Linde N, 2016, ADV CANCER RES, V132, P45, DOI 10.1016/bs.acr.2016.07.002; LOCHTER A, 1995, SEMIN CANCER BIOL, V6, P165, DOI 10.1006/scbi.1995.0017; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Lopez JI, 2011, INTEGR BIOL-UK, V3, P910, DOI 10.1039/c1ib00043h; Luo HJ, 2014, ENDOCR-RELAT CANCER, V21, P355, DOI 10.1530/ERC-13-0237; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Majed B, 2008, BREAST CANCER RES TR, V111, P329, DOI 10.1007/s10549-007-9785-3; Martens JWM, 2003, THROMB HAEMOSTASIS, V89, P393; Martin LJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1831; Martinez-Outschoorn UE, 2011, CANCER BIOL THER, V12, P924, DOI 10.4161/cbt.12.10.17780; Mastro AM, 2003, CLIN EXP METASTAS, V20, P275, DOI 10.1023/A:1022995403081; Mazouni C, 2008, BRIT J CANCER, V99, P68, DOI 10.1038/sj.bjc.6604443; McAllister SS, 2014, NAT CELL BIOL, V16, P717, DOI 10.1038/ncb3015; McCormack VA, 2006, CANCER EPIDEM BIOMAR, V15, P1159, DOI 10.1158/1055-9965.EPI-06-0034; McIntyre A, 2015, EMBO MOL MED, V7, P368, DOI 10.15252/emmm.201404271; Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Miyashita M, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0632-x; Mohamed MM, 2014, INT J BIOCHEM CELL B, V46, P138, DOI 10.1016/j.biocel.2013.11.015; Mohammed ZMA, 2012, BRIT J CANCER, V107, P864, DOI 10.1038/bjc.2012.347; Montero AJ, 2012, BREAST CANCER RES TR, V132, P215, DOI 10.1007/s10549-011-1889-0; Moraes LA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17622-5; Mouw JK, 2014, NAT MED, V20, P360, DOI 10.1038/nm.3497; MROWIEC ZR, 1995, BLOOD CELL MOL DIS, V21, P25, DOI 10.1006/bcmd.1995.0005; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nouh MA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-1; Nutter F, 2014, ENDOCR-RELAT CANCER, V21, P327, DOI 10.1530/ERC-13-0158; Ozbek S, 2010, MOL BIOL CELL, V21, P4300, DOI 10.1091/mbc.E10-03-0251; Ohara M, 2009, CANCER IMMUNOL IMMUN, V58, P441, DOI 10.1007/s00262-008-0570-x; OLEKSOWICZ L, 1991, J IMMUNOTHER, V10, P363, DOI 10.1097/00002371-199110000-00008; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Ottewell PD, 2016, J BONE ONCOL, V5, P124, DOI 10.1016/j.jbo.2016.03.007; Ottewell PD, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.10; Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078-0432.CCR-13-1246; PACCHIARINI L, 1991, INVAS METAST, V11, P102; Palmieri C, 2003, J ENDOCRINOL, V177, P65, DOI 10.1677/joe.0.1770065; Pang MF, 2016, CANCER RES, V76, P5277, DOI 10.1158/0008-5472.CAN-16-0579; Pantel K, 2016, ONCOGENE, V35, P1216, DOI 10.1038/onc.2015.192; Park J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1711; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Plitas G, 2016, IMMUNITY, V45, P1122, DOI 10.1016/j.immuni.2016.10.032; Pocock S J, 1982, Stat Med, V1, P93, DOI 10.1002/sim.4780010202; Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562; Rabbani SA, 2007, CANCER METAST REV, V26, P663, DOI 10.1007/s10555-007-9085-8; Radisky D, 2002, CANCER INVEST, V20, P139, DOI 10.1081/CNV-120000374; Rausch LK, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00211; RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736; Santagata S, 2014, J CLIN INVEST, V124, P859, DOI 10.1172/JCI70941; Savas P, 2016, NAT REV CLIN ONCOL, V13, P228, DOI 10.1038/nrclinonc.2015.215; Sawant A, 2013, CANCER RES, V73, P4606, DOI 10.1158/0008-5472.CAN-13-0305; Schedin P., 2011, COLD SPRING HARB PER, V3, DOI DOI 10.1101/CSHPERSPECT.A003228; Schewe DM, 2008, P NATL ACAD SCI USA, V105, P10519, DOI 10.1073/pnas.0800939105; Schneider JG, 2011, BONE, V48, P54, DOI 10.1016/j.bone.2010.09.016; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Shekhar MPV, 2007, AM J PATHOL, V170, P1546, DOI 10.2353/ajpath.2007.061004; Shekhar MPV, 2001, CANCER RES, V61, P1320; Sickles EA, 2007, RADIOL CLIN N AM, V45, P765, DOI 10.1016/j.rcl.2007.06.002; Sieminski AL, 2004, EXP CELL RES, V297, P574, DOI 10.1016/j.yexcr.2004.03.035; Sierko E, 2004, SEMIN THROMB HEMOST, V30, P95; Sierra A, 1997, LAB INVEST, V77, P357; Sleeman JP, 2015, J MOL MED, V93, P1173, DOI 10.1007/s00109-015-1351-6; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Soni A, 2015, AM J CLIN PATHOL, V143, P471, DOI 10.1309/AJCPYO5FSV3UPEXS; Soon PSH, 2013, ENDOCR-RELAT CANCER, V20, P1, DOI 10.1530/ERC-12-0227; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Spiegel A, 2016, CANCER DISCOV, V6, P630, DOI 10.1158/2159-8290.CD-15-1157; Staton CA, 2007, J PATHOL, V212, P237, DOI 10.1002/path.2182; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; Tan JX, 2011, INT J DEV BIOL, V55, P851, DOI 10.1387/ijdb.113365jt; Taucher S, 2003, THROMB HAEMOSTASIS, V15, P1098; Taylor NA, 2017, J CLIN INVEST, V127, P3478, DOI 10.1172/JCI90499; Teo NB, 2002, BRIT J CANCER, V86, P905, DOI 10.1038/sj/bjc/6600053; Thorat MA, 2017, BREAST, V34, pS47, DOI 10.1016/j.breast.2017.06.027; Tice JA, 2008, ANN INTERN MED, V148, P337, DOI 10.7326/0003-4819-148-5-200803040-00004; Tokyol C, 2009, UPSALA J MED SCI, V114, P108, DOI 10.1080/03009730902761797; Tominaga N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7716; Tyan SW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035128; Ursin G, 2005, BREAST CANCER RES, V7, pR605, DOI 10.1186/bcr1260; Uzzan B, 2004, CANCER RES, V64, P2941, DOI 10.1158/0008-5472.CAN-03-1957; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Viale G, 2012, ANN ONCOL, V23, P207, DOI 10.1093/annonc/mds326; Vona-Davis L, 2007, ENDOCR-RELAT CANCER, V14, P189, DOI 10.1677/ERC-06-0068; Waight JD, 2013, J CLIN INVEST, V123, P4464, DOI 10.1172/JCI68189; Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017; Weaver VM, 1996, BIOCHEM CELL BIOL, V74, P833, DOI 10.1139/o96-089; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Weber CE, 2015, ONCOGENE, V34, P4821, DOI 10.1038/onc.2014.410; Wei BJ, 2016, ONCOTARGETS THER, V9, P5567, DOI 10.2147/OTT.S108419; Weil RJ, 2005, AM J PATHOL, V167, P913, DOI 10.1016/S0002-9440(10)61180-7; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Whittaker CA, 2006, DEV BIOL, V300, P252, DOI 10.1016/j.ydbio.2006.07.044; WICHA MS, 1980, DEV BIOL, V80, P253, DOI 10.1016/0012-1606(80)90402-9; Wolfe AR, 2016, ONCOTARGET, V7, P82482, DOI 10.18632/oncotarget.12694; WOLFE JN, 1976, AM J ROENTGENOL, V126, P1130, DOI 10.2214/ajr.126.6.1130; Woodard PK, 1998, ONCOLOGY-NY, V12, P431; Woodard PK, 1998, ONCOLOGY WILLISTON P, V12, P444; Woodard PK, 1998, ONCOLOGY, V12, P441; Xu K, 2010, ONCOGENE, V29, P6533, DOI 10.1038/onc.2010.385; Yamaguchi J, 2008, AM J CLIN PATHOL, V130, P382, DOI 10.1309/MX6KKA1UNJ1YG8VN; Yang J, 2015, INT J CLIN EXP PATHO, V8, P6656; Yang M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2411-1; Yoneda T, 2013, WORLD J ORTHOP, V4, P178, DOI 10.5312/wjo.v4.i4.178; Yu JP, 2014, J IMMUNOL, V193, P2574, DOI 10.4049/jimmunol.1400833; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yu Y, 2014, BRIT J CANCER, V110, P724, DOI 10.1038/bjc.2013.768; Yuan ZY, 2014, ONCOTARGETS THER, V7, P1, DOI 10.2147/OTT.S61838; Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076147; Zhao XX, 2017, ONCOTARGET, V8, P30576, DOI 10.18632/oncotarget.15736; Zhou Y, 2017, J CANCER, V8, P4098, DOI 10.7150/jca.21030; Zhu JQ, 2014, HISTOL HISTOPATHOL, V29, P1083, DOI 10.14670/HH-29.1083	246	6	6	1	17	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	3					227	243		10.1080/14737159.2018.1439382			17	Pathology	Pathology	FY5ZM	WOS:000426918100004	29424261	Green Accepted			2019-10-28	
J	Upchurch, E; Isabelle, M; Lloyd, GR; Kendall, C; Barr, H				Upchurch, Emma; Isabelle, Martin; Lloyd, Gavin Rhys; Kendall, Catherine; Barr, Hugh			An update on the use of Raman spectroscopy in molecular cancer diagnostics: current challenges and further prospects	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Molecular changes; Raman spectroscopy; biomarkers; early diagnosis; dysplasia; early cancer	BODY-MASS INDEX; IN-VIVO DIAGNOSIS; TREATMENT-RELATED TOXICITY; LABEL-FREE DETECTION; LOW-GRADE DYSPLASIA; BARRETTS-ESOPHAGUS; BREAST-CANCER; CELL CARCINOMA; COLON-CANCER; P53 PROTEIN	Introduction: Cancer is responsible for an extraordinary burden of disease, affecting 90.5 million people worldwide in 2015. Outcomes for these patients are improved when the disease is diagnosed at an early, or even precancerous, stage. Raman spectroscopy is demonstrating results that show its ability to detect the molecular changes that are diagnostic of precancerous and cancerous tissue. This review highlights the new advances occurring in this domain.Areas covered: PubMed searches were undertaken to identify new research in the utilisation of Raman spectroscopy in cancer diagnostics. The areas in which Raman spectroscopy is showing promise are covered, including improving the accuracy of identifying precancerous changes, using the technology in real time, in vivo modalities, the search for a biomarker to aid potential screening and predicting the response of the cancer to the treatment regimen.Expert commentary: Many of the examples in this review are focused on Barrett's oesophagus and oesophageal adenocarcinoma as this is my area of expertise and perfectly exemplifies where Raman spectroscopy could be utilised in clinical practise. The authors discuss the areas where they believe current knowledge is lacking and how Raman spectroscopy could answer the dilemmas that are still faced in the management of cancer.	[Upchurch, Emma; Barr, Hugh] Gloucestershire Royal Hosp, Dept Upper GI Surg, Gloucester, England; [Upchurch, Emma; Kendall, Catherine; Barr, Hugh] Gloucestershire Royal Hosp, Biophoton Res Unit, Gloucester, England; [Isabelle, Martin] Renishaw Plc, Wooton Under Edge, England; [Lloyd, Gavin Rhys] Univ Birmingham, Sch Biosci, Phenome Ctr Birmingham, Birmingham, W Midlands, England	Upchurch, E (reprint author), Gloucestershire Royal Hosp, Dept Upper GI Surg, Gloucester, England.; Upchurch, E (reprint author), Gloucestershire Royal Hosp, Biophoton Res Unit, Gloucester, England.	emma.upchurch@nhs.net	Lloyd, Gavin/P-4212-2019	Lloyd, Gavin/0000-0001-7989-6695			Aguiar RP, 2013, PHOTOMED LASER SURG, V31, P595, DOI 10.1089/pho.2012.3460; ALBRECHT MG, 1977, J AM CHEM SOC, V99, P5215, DOI 10.1021/ja00457a071; Alfano R. R., 1991, LASERS LIFE SCI, V4, P23; Almond LM, 2014, GASTROINTEST ENDOSC, V79, P37, DOI 10.1016/j.gie.2013.05.028; Almond LM, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.8.081421; Almond LM, 2011, J BIOPHOTONICS, V4, P685, DOI 10.1002/jbio.201100041; Balogh GA, 2006, INT J ONCOL, V28, P995; Barkur S, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.8.085001; Beljebbar A, 2009, CRIT REV ONCOL HEMAT, V72, P255, DOI 10.1016/j.critrevonc.2009.09.004; Bergholt MS, 2011, TECHNOL CANCER RES T, V10, P103, DOI 10.7785/tcrt.2012.500185; Bergholt MS, 2014, GASTROENTEROLOGY, V146, P27, DOI 10.1053/j.gastro.2013.11.002; Bergholt MS, 2011, INT J CANCER, V128, P2673, DOI 10.1002/ijc.25618; Bird-Lieberman EL, 2012, NAT MED, V18, P315, DOI 10.1038/nm.2616; BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; Boustany NN, 1999, LAB INVEST, V79, P1201; Brozek-Pluska B, 2015, ANALYST, V140, P2134, DOI 10.1039/c4an01877j; Burggraaf J, 2015, NAT MED, V21, P955, DOI 10.1038/nm.3641; Byrne AM, 2012, GLYCOBIOLOGY, V22, P638, DOI 10.1093/glycob/cwr190; Chan AKP, 2005, INT J RADIAT ONCOL, V61, P665, DOI 10.1016/j.ijrobp.2004.06.026; Chatelain D, 2003, VIRCHOWS ARCH, V442, P18, DOI 10.1007/s00428-002-0674-1; Chen N, 2017, INT J NANOMED, V12, P5399, DOI 10.2147/IJN.S137756; Chen Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093906; Chowdary MVP, 2007, PHOTOMED LASER SURG, V25, P269, DOI 10.1089/pho.2006.2066; Corsetti S, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201700166; Crow P, 2005, UROLOGY, V65, P1126, DOI 10.1016/j.urology.2004.12.058; Crow P, 2004, BJU INT, V93, P1232, DOI 10.1111/j.1464-410X.2004.04852.x; Day JCC, 2009, PHYS MED BIOL, V54, P7077, DOI 10.1088/0031-9155/54/23/003; de Campos-Lobato LF, 2011, ANN SURG ONCOL, V18, P1590, DOI 10.1245/s10434-010-1506-1; de Jong BWD, 2006, ANAL CHEM, V78, P7761, DOI 10.1021/ac061417b; De Jong BWD, 2002, J UROLOGY, V168, P1771, DOI 10.1097/01.ju.0000030059.28948.c6; Del Mistro G, 2015, ANAL BIOANAL CHEM, V407, P3271, DOI 10.1007/s00216-015-8610-9; Dignam JJ, 2006, J NATL CANCER I, V98, P1647, DOI 10.1093/jnci/djj442; Dochow S, 2015, ANAL BIOANAL CHEM, V407, P8291, DOI 10.1007/s00216-015-8800-5; Domenici F, 2012, ANAL BIOCHEM, V421, P9, DOI 10.1016/j.ab.2011.10.010; Duits LC, 2015, GUT, V64, P700, DOI 10.1136/gutjnl-2014-307278; El Far MA, 2006, CLIN CHEM LAB MED, V44, P653, DOI 10.1515/CCLM.2006.091; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FELD MS, 1995, P SOC PHOTO-OPT INS, V2388, P99, DOI 10.1117/12.208468; Feng SY, 2011, BIOSENS BIOELECTRON, V26, P3167, DOI 10.1016/j.bios.2010.12.020; Feng SY, 2010, BIOSENS BIOELECTRON, V25, P2414, DOI 10.1016/j.bios.2010.03.033; FRANK CJ, 1995, ANAL CHEM, V67, P777, DOI 10.1021/ac00101a001; Gaddam S, 2011, AM J GASTROENTEROL, V106, P1961, DOI 10.1038/ajg.2011.294; Gahan PB, 2010, EPMA J, V1, P503, DOI 10.1007/s13167-010-0021-6; Garcia-Aguilar J, 2011, ANN SURG, V254, P97, DOI 10.1097/SLA.0b013e3182196e1f; Gniadecka M, 1997, PHOTOCHEM PHOTOBIOL, V66, P418, DOI 10.1111/j.1751-1097.1997.tb03167.x; Grimbergen MCM, 2009, PROC SPIE, V7161, DOI 10.1117/12.807811; Grimbergen MCM, 2009, J PHOTOCH PHOTOBIO B, V95, P170, DOI 10.1016/j.jphotobiol.2009.03.002; Guerrero S, 2000, CANCER RES, V60, P6750; Haka AS, 2005, P NATL ACAD SCI USA, V102, P12371, DOI 10.1073/pnas.0501390102; Haka AS, 2002, CANCER RES, V62, P5375; Han HW, 2009, APPL PHYS B-LASERS O, V94, P667, DOI 10.1007/s00340-008-3299-5; Huang ZW, 2009, OPT LETT, V34, P758, DOI 10.1364/OL.34.000758; Huang ZW, 2003, INT J CANCER, V107, P1047, DOI 10.1002/ijc.11500; Hutchings J, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3512244; Hutchings J, 2009, J BIOPHOTONICS, V2, P91, DOI 10.1002/jbio.200810070; Ito H, 2014, NANOMED-NANOTECHNOL, V10, P599, DOI 10.1016/j.nano.2013.09.006; Kalkanis SN, 2014, J NEURO-ONCOL, V116, P477, DOI 10.1007/s11060-013-1326-9; Kallaway C, 2013, PHOTODIAGN PHOTODYN, V10, P207, DOI 10.1016/j.pdpdt.2013.01.008; Kast RE, 2008, BIOPOLYMERS, V89, P235, DOI 10.1002/bip.20899; Kawabata T, 2008, J GASTROENTEROL, V43, P283, DOI 10.1007/s00535-008-2160-2; Kendall C, 2011, FARADAY DISCUSS, V149, P279, DOI 10.1039/c005379a; Kendall C, 2010, ANALYST, V135, P3038, DOI 10.1039/c0an00536c; Kendall C, 2009, ANALYST, V134, P1029, DOI 10.1039/b822130h; Kerkhof M, 2007, HISTOPATHOLOGY, V50, P920, DOI 10.1111/j.1365-2559.2007.02706.x; Kneipp J, 2003, VIB SPECTROSC, V32, P67, DOI 10.1016/S0924-2031(03)00048-1; Koljenovic S, 2005, ANAL CHEM, V77, P7958, DOI 10.1021/ac0512599; Koljenovic S, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1922307; Krafft C, 2006, J RAMAN SPECTROSC, V37, P367, DOI 10.1002/jrs.1450; Krafft C, 2005, ANALYST, V130, P1070, DOI 10.1039/b419232j; Krafft C, 2015, ANAL BIOANAL CHEM, V407, P699, DOI 10.1007/s00216-014-8311-9; LAIRD AK, 1964, BRIT J CANCER, V18, P490, DOI 10.1038/bjc.1964.55; Lau DP, 2003, LASER SURG MED, V37(30, P192; Lee YC, 2010, ENDOSCOPY, V42, P699, DOI 10.1055/s-0030-1255629; LEON SA, 1977, CANCER RES, V37, P646; Leslie DG, 2012, PEDIATR NEUROSURG, V48, P109, DOI 10.1159/000343285; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li SX, 2014, LASER PHYS LETT, V11, DOI 10.1088/1612-2011/11/6/065603; Li SX, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.2.027008; Li SX, 2014, APPL PHYS LETT, V105, DOI 10.1063/1.4892667; Li XZ, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.3.037003; Li Z., 2014, LASER PHYS LETT, V11; Lin D, 2014, SCI REP-UK, V4, DOI 10.1038/srep04751; Lin D, 2014, J BIOMED NANOTECHNOL, V10, P478, DOI 10.1166/jbn.2014.1750; LIU CH, 1992, J PHOTOCH PHOTOBIO B, V16, P187, DOI 10.1016/1011-1344(92)80008-J; LUO JC, 1994, J OCCUP ENVIRON MED, V36, P155, DOI 10.1097/00043764-199402000-00010; Mahadevan-Jansen A, 1998, PHOTOCHEM PHOTOBIOL, V68, P123, DOI 10.1111/j.1751-1097.1998.tb03262.x; Maheedhar K, 2008, PHOTOMED LASER SURG, V26, P83, DOI 10.1089/pho.2007.2128; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Malviya V, 2004, UROL RES, V32, P391, DOI 10.1007/s00240-004-0415-9; Manoharan R, 1998, PHOTOCHEM PHOTOBIOL, V67, P15, DOI 10.1111/j.1751-1097.1998.tb05160.x; Manoharan R, 1994, LASERS LIFE SCI, V6, P1; Matousek P, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2718934; Meyerhardt JA, 2003, CANCER, V98, P484, DOI 10.1002/cncr.11544; Meyerhardt JA, 2004, J CLIN ONCOL, V22, P648, DOI 10.1200/JCO.2004.07.121; MIZUNO A, 1994, J RAMAN SPECTROSC, V25, P25, DOI 10.1002/jrs.1250250105; Molckovsky A, 2003, GASTROINTEST ENDOSC, V57, P396, DOI 10.1067/mge.2003.105; Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; Nijssen A, 2002, J INVEST DERMATOL, V119, P64, DOI 10.1046/j.1523-1747.2002.01807.x; Odes EJ, 2016, S AFR J SCI, V112, P100, DOI 10.17159/sajs.2016/20150471; Ogino S, 2008, J MOL DIAGN, V10, P13, DOI 10.2353/jmoldx.2008.070082; Ogino S, 2009, CANCER EPIDEM BIOMAR, V18, P2513, DOI 10.1158/1055-9965.EPI-09-0451; Ogino S, 2009, AM J GASTROENTEROL, V104, P2047, DOI 10.1038/ajg.2009.281; Ogino S, 2008, J CLIN ONCOL, V26, P5713, DOI 10.1200/JCO.2008.18.2675; Ogino S, 2009, CANCER EPIDEM BIOMAR, V18, P1849, DOI 10.1158/1055-9965.EPI-09-0181; Pantel K, 2010, TRENDS MOL MED, V16, P398, DOI 10.1016/j.molmed.2010.07.001; Paterson AL, 2017, HISTOPATHOLOGY, V70, P203, DOI 10.1111/his.13039; Pohl H, 2010, CLIN GASTROENTEROL H, V8, P858, DOI 10.1016/j.cgh.2010.06.028; Raman C.V., 1928, Indian Journal of Physics, V2, P387; Rehman S, 2007, J RAMAN SPECTROSC, V38, P1345, DOI 10.1002/jrs.1774; Rothschild BM, 2003, NATURWISSENSCHAFTEN, DOI [10.1038/news031020-2, DOI 10.1038/NEWS031020-2]; Salman A., 2001, CELL MOL BIOL, V47, P159; Shafer-Peltier KE, 2002, J RAMAN SPECTROSC, V33, P552, DOI 10.1002/jrs.877; Shetty G, 2006, BRIT J CANCER, V94, P1460, DOI 10.1038/sj.bjc.6603102; Shim MG, 2000, PHOTOCHEM PHOTOBIOL, V72, P146, DOI 10.1562/0031-8655(2000)072<0146:IVNIRS>2.0.CO;2; Shim MG, 1999, APPL SPECTROSC, V53, P619, DOI 10.1366/0003702991947225; Singh R, 2007, GUT LIVER, V1, P93, DOI 10.5009/gnl.2007.1.2.93; SMEKAL A, 1923, NATURWISSENSCHAFTEN, V11, P873, DOI DOI 10.1007/BF01576902; Smith KD, 2010, ANN SURG, V251, P261, DOI 10.1097/SLA.0b013e3181bdfc27; Song LMWK, 2005, P SOC PHOTO-OPT INS, V5692, P140, DOI 10.1117/12.584986; Stone N, 2004, FARADAY DISCUSS, V126, P141, DOI 10.1039/b304992b; Stone N, 2002, J RAMAN SPECTROSC, V33, P564, DOI 10.1002/jrs.882; Stone N, 2000, LARYNGOSCOPE, V110, P1756, DOI 10.1097/00005537-200010000-00037; Stone N, 2011, CHEM SCI, V2, P776, DOI 10.1039/c0sc00570c; Suwa H, 1997, GUT, V40, P647, DOI 10.1136/gut.40.5.647; Tamakoshi K, 2004, INT J OBESITY, V28, P551, DOI 10.1038/sj.ijo.0802603; Teh SK, 2008, BRIT J CANCER, V98, P457, DOI 10.1038/sj.bjc.6604176; Thakur JS, 2007, J RAMAN SPECTROSC, V38, P127, DOI 10.1002/jrs.1565; Upchurch E, 2017, ROLE RAMAN SPECTROSC; Vieth M, 2004, ENDOSCOPY, V36, P776, DOI 10.1055/s-2004-825802; Vos T, 2016, LANCET, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6; Wagner RP, 1999, GENETICS, V151, P917; Wang H, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3369002; Wang JF, 2015, SCI REP-UK, V5, DOI 10.1038/srep12957; Wang L, 2014, ANALYST, V139, P455, DOI 10.1039/c3an01381b; Wang L, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.8.087001; Wang L, 2012, SPECTROSC SPECT ANAL, V32, P123, DOI 10.3964/j.issn.1000-0593(2012)01-0123-04; Wang Y, 2009, IEEE ENG MED BIO, P885, DOI 10.1109/IEMBS.2009.5333131; Weston AP, 2001, AM J GASTROENTEROL, V96, P1355, DOI 10.1111/j.1572-0241.2001.03851.x; WHO, 2015, WORLD CANC REPORT 20; Wills H, 2009, J PEDIATR SURG, V44, P386, DOI 10.1016/j.jpedsurg.2008.10.095; Wu M, 2010, MOL BIOL REP, V37, P339, DOI 10.1007/s11033-009-9744-7; Yang TX, 2014, ACS APPL MATER INTER, V6, P20985, DOI 10.1021/am5057536; Yang YL, 2011, BIOMED OPT EXPRESS, V2, P2160, DOI 10.1364/BOE.2.002160; Zhang Q, 2015, ANALYST, V140, P6163, DOI 10.1039/c5an01074h; Zhou Y, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.11.116021	145	6	6	1	13	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	3					245	258		10.1080/14737159.2018.1439739			14	Pathology	Pathology	FY5ZM	WOS:000426918100005	29431541				2019-10-28	
J	Volpi, CC; Gualeni, AV; Pietrantonio, F; Vaccher, E; Carbone, A; Gloghini, A				Volpi, Chiara C.; Gualeni, Ambra V.; Pietrantonio, Filippo; Vaccher, Emanuela; Carbone, Antonino; Gloghini, Annunziata			Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Bright-field in situ hybridization; DNA detection; gene amplification; gene rearrangements; RNA detection; diagnostic precision; personalized treatment	SQUAMOUS-CELL CARCINOMA; EPSTEIN-BARR-VIRUS; PAPILLOMAVIRUS-RELATED HEAD; PRIMARY COLORECTAL-CANCER; POLYMERASE-CHAIN-REACTION; OF-AMERICAN-PATHOLOGISTS; TREATMENT DE-ESCALATION; BREAST-CANCER; COPY NUMBER; NASOPHARYNGEAL CARCINOMA	Introduction: Bright-field in situ hybridization (ISH) methods detect gene alterations that may improve diagnostic precision and personalized management of cancer patients.Areas covered: This review focuses on some bright-field ISH techniques for detection of gene amplification or viral infection that have already been introduced in tumor pathology, research and diagnostic practice. Other emerging ISH methods, for the detection of translocation, mRNA and microRNA have recently been developed and need both an optimization and analytical validation. The review also deals with their clinical applications and implications on the management of cancer patients.Expert commentary: The technology of bright-field ISH applications has advanced significantly in the last decade. For example, an automated dual-color assay was developed as a clinical test for selecting cancer patients that are candidates for personalized therapy. Recently an emerging bright-field gene-protein assay has been developed. This method simultaneously detects the protein, gene and centromeric targets in the context of tissue morphology, and might be useful in assessing the HER2 status particularly in equivocal cases or samples with heterogeneous tumors. The application of bright-field ISH methods has become the gold standard for the detection of tumor-associated viral infection as diagnostic or prognostic factors.	[Volpi, Chiara C.; Gualeni, Ambra V.; Gloghini, Annunziata] Fdn IRCCS, Dept Pathol & Lab Med, Ist Nazl Tumori, Milan, Italy; [Pietrantonio, Filippo] Fdn IRCCS, Dept Med Oncol, Ist Nazl Tumori, Milan, Italy; [Vaccher, Emanuela] Natl Canc Inst, Dept Med Oncol, Ctr Riferimento Oncol, IRCCS, Aviano, Italy; [Carbone, Antonino] Natl Canc Inst, Dept Pathol, Ctr Riferimento Oncol, IRCCS, Aviano, Italy	Gloghini, A (reprint author), Fdn IRCCS, Dept Diagnost Pathol & Lab Med, Ist Nazl Tumori, Via G Venezian 1, I-20133 Milan, Italy.	annunziata.gloghini@istitutotumori.mi.it	Carbone, Antonino/AAA-2217-2019; Pietrantonio, Filippo/C-2180-2017; Gloghini, Annunziata/AAB-4809-2019	Carbone, Antonino/0000-0003-2211-639X; Pietrantonio, Filippo/0000-0002-8530-8420; Gloghini, Annunziata/0000-0002-7226-1942	Fondazione IRCCS, Istituto Nazionale dei Tumori Milano; Associazione Italiana per la Ricerca sul Cancro (AIRC), Milano, ItalyAssociazione Italiana per la Ricerca sul Cancro (AIRC) [IG 19206]; Institutional Grant derived from the National fund 5x1000	CC Volpi is recipient of a fellowship supported by an Institutional grant from Fondazione IRCCS, Istituto Nazionale dei Tumori Milano for a project on 'Identification of head and neck cancer and HPV-related infections by profiling volatile organic compounds in exhaled breath'. AV Gualeni is recipient of a fellowship supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Milano, Italy, for a project on 'Pseudomyxoma peritonei: optimizing the multimodality treatment and exploring the connection between oncogenes deregulation, host inflammatory response and mucin production', IG 19206. The funders have no role in the writing of the review or decision to submit it for publication. This work was supported in part by an Institutional Grant derived from the National fund 5x1000 to the Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, for a project on "Molecular Pathology" (to A Carbone).	Ahn S, 2016, MODERN PATHOL, V29, P1095, DOI 10.1038/modpathol.2016.96; Ang KK, 2014, J CLIN ONCOL, V32, P2940, DOI 10.1200/JCO.2013.53.5633; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Bang YJ, 2010, LANCET, V376, P1302; Banizs AB, 2014, INT J NANOMED, V9, P4223, DOI 10.2147/IJN.S64267; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Bartley AN, 2017, J CLIN ONCOL, V35, P446, DOI 10.1200/JCO.2016.69.4836; Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969; Blanchard P, 2015, LANCET ONCOL, V16, P645, DOI 10.1016/S1470-2045(15)70126-9; Blondal T, 2013, METHODS, V59, pS1, DOI 10.1016/j.ymeth.2012.09.015; Bozzi F, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0475-z; Bozzi F, 2016, ONCOTARGET, V7, P75503, DOI 10.18632/oncotarget.12262; Bradley CA, 2017, NAT REV CLIN ONCOL, V14, P562, DOI 10.1038/nrclinonc.2017.40; Braun M, 2012, J MOL DIAGN, V14, P322, DOI 10.1016/j.jmoldx.2012.01.017; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Cappuzzo F, 2009, J CLIN ONCOL, V27, P1667, DOI 10.1200/JCO.2008.19.1635; Carbone A, 2012, J CLIN PATHOL, V65, P680, DOI 10.1136/jclinpath-2012-200717; Carbone A, 2011, AM J HEMATOL, V86, pE66, DOI 10.1002/ajh.22169; Carbone A, 2008, J MOL DIAGN, V10, P527, DOI 10.2353/jmoldx.2008.080052; Casadevall D, 2015, ONCOTARGET, V6, P16215, DOI 10.18632/oncotarget.3976; CHAN JKC, 2008, WHO CLASSIFICATION T, P285; Chang JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105524; Chaturvedi AK, 2016, ORAL ONCOL, V60, P61, DOI 10.1016/j.oraloncology.2016.06.006; Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870; Chen YP, 2015, ANN ONCOL, V26, P205, DOI 10.1093/annonc/mdu507; Chia WK, 2014, MOL THER, V22, P132, DOI 10.1038/mt.2013.242; Choi J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111658; Chua MLK, 2016, LANCET, V387, P1012, DOI 10.1016/S0140-6736(15)00055-0; Ciniselli CM, 2016, HUM PATHOL, V47, P157, DOI 10.1016/j.humpath.2015.06.026; Cleary C, 2016, CLIN ONCOL-UK, V28, P467, DOI 10.1016/j.clon.2016.03.001; Colaco RJ, 2013, CLIN ONCOL-UK, V25, P171, DOI 10.1016/j.clon.2012.10.006; Comoli P, 2005, J CLIN ONCOL, V23, P8942, DOI 10.1200/JCO.2005.02.6195; Cortelazzi B, 2015, J ORAL PATHOL MED, V44, P734, DOI 10.1111/jop.12301; Crawford A, 2009, CURR OPIN IMMUNOL, V21, P179, DOI 10.1016/j.coi.2009.01.010; Darnell DK, 2010, RNA, V16, P632, DOI 10.1261/rna.1775610; de Azambuja E, 2014, LANCET ONCOL, V15, P1137, DOI 10.1016/S1470-2045(14)70320-1; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Delecluse HJ, 2007, J CLIN PATHOL, V60, P1358, DOI 10.1136/jcp.2006.044586; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; Dogan V, 2018, CLIN OTOLARYNGOL, V43, P13, DOI 10.1111/coa.12895; Elsheikh S, 2008, BREAST CANCER RES TR, V109, P325, DOI 10.1007/s10549-007-9659-8; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fakhry C, 2014, J CLIN ONCOL, V32, P3365, DOI 10.1200/JCO.2014.55.1937; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Finocchiaro G, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.43; Fu KK, 2000, INT J RADIAT ONCOL, V48, P7, DOI 10.1016/S0360-3016(00)00663-5; Gandrillon O, 1996, MOL CELL PROBE, V10, P51, DOI 10.1006/mcpr.1996.0007; Gasparini P, 2014, ONCOTARGET, V5, P1174, DOI 10.18632/oncotarget.1682; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Gillison ML, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.5510; Gillison ML, 2008, JNCI-J NATL CANCER I, V100, P407, DOI 10.1093/jnci/djn025; Gillison ML, 2015, J CLIN ONCOL, V33, P3235, DOI 10.1200/JCO.2015.61.6995; Gleave ME, 2005, NAT REV CANCER, V5, P468, DOI 10.1038/nrc1631; Gloghini A, 2015, WORLD CANCER RES J, V2; Gomez-Martin C, 2013, J CLIN ONCOL, V31, P4445, DOI 10.1200/JCO.2013.48.9070; Gooi Z, 2017, HEAD NECK-J SCI SPEC, V39, P201, DOI 10.1002/hed.24635; Grabinski TM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120120; Graziano F, 2011, J CLIN ONCOL, V29, P4789, DOI 10.1200/JCO.2011.36.7706; Gualeni AV, 2015, J CLIN PATHOL, V68, P661, DOI 10.1136/jclinpath-2015-203005; Ha SY, 2013, MODERN PATHOL, V26, P1632, DOI 10.1038/modpathol.2013.108; Han N, 2015, PATHOBIOLOGY, V82, P269, DOI 10.1159/000441149; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanker AB, 2017, CLIN CANCER RES, V23, P4323, DOI 10.1158/1078-0432.CCR-16-2287; Hierro C, 2017, ANN ONCOL, V28, P1207, DOI 10.1093/annonc/mdx081; Hirsch FR, 2008, J CLIN ONCOL, V26, P3351, DOI 10.1200/JCO.2007.14.0111; Holten-Rossing H, 2015, BREAST CANCER RES TR, V152, P367, DOI 10.1007/s10549-015-3475-3; Huang SH, 2012, INT J RADIAT ONCOL, V82, P276, DOI 10.1016/j.ijrobp.2010.08.031; Huang W, 2013, HUM PATHOL, V44, P29, DOI 10.1016/j.humpath.2012.05.009; Hunt JL, 2008, ARCH PATHOL LAB MED, V132, P248, DOI 10.1043/1543-2165(2008)132[248:MPIAPP]2.0.CO;2; Izquierdo M, 2005, CANCER GENE THER, V12, P217, DOI 10.1038/sj.cgt.7700791; Jiang T, 2015, LUNG CANCER, V87, P1, DOI 10.1016/j.lungcan.2014.11.009; Jorgensen S, 2010, METHODS, V52, P375, DOI 10.1016/j.ymeth.2010.07.002; Kang H, 2015, NAT REV CLIN ONCOL, V12, P11, DOI 10.1038/nrclinonc.2014.192; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Kim HR, 2017, ANN ONCOL, V28, P1250, DOI 10.1093/annonc/mdx098; Kim H, 2011, J THORAC ONCOL, V6, P1359, DOI 10.1097/JTO.0b013e31821cfc73; Kim KY, 2017, INT J RADIAT ONCOL, V98, P996, DOI 10.1016/j.ijrobp.2017.03.018; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; Koh YW, 2011, MODERN PATHOL, V24, P794, DOI 10.1038/modpathol.2011.9; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kwak EL, 2015, CANCER DISCOV, V5, P1271, DOI 10.1158/2159-8290.CD-15-0748; Kwak Y, 2015, PATHOBIOLOGY, V82, P76, DOI 10.1159/000398807; Laakso M, 2006, J PATHOL, V210, P3, DOI 10.1002/path.2022; Laschi S, 2009, BIOELECTROCHEMISTRY, V76, P214, DOI 10.1016/j.bioelechem.2009.02.012; Lee AWM, 2015, J CLIN ONCOL, V33, P3356, DOI 10.1200/JCO.2015.60.9347; Lee HE, 2012, BRIT J CANCER, V107, P325, DOI 10.1038/bjc.2012.237; Lee HM, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00178; Leung SF, 2006, J CLIN ONCOL, V24, P5414, DOI 10.1200/JCO.2006.07.7982; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lim MY, 2016, HEAD NECK-J SCI SPEC, V38, P1139, DOI 10.1002/hed.24429; Lin CL, 2002, CANCER RES, V62, P6952; Lydiatt WM, 2017, CA-CANCER J CLIN, V67, P122, DOI 10.3322/caac.21389; Martin V, 2014, FUTURE ONCOL, V10, P1469, DOI [10.2217/fon.14.19, 10.2217/FON.14.19]; Marur S, 2017, J CLIN ONCOL, V35, P490, DOI 10.1200/JCO.2016.68.3300; Metzger ML, 2016, HISTOPATHOLOGY, V68, P241, DOI 10.1111/his.12745; Mills AM, 2017, AM J SURG PATHOL, V41, P607, DOI 10.1097/PAS.0000000000000800; Mirghani H, 2015, INT J CANCER, V136, P1494, DOI 10.1002/ijc.28847; Mirghani H, 2016, ORAL ONCOL, V62, P101, DOI 10.1016/j.oraloncology.2016.10.009; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; Moeini A, 2016, CLIN CANCER RES, V22, P291, DOI 10.1158/1078-0432.CCR-14-3296; Necchi A, EUR UROL FOCUS, DOI [10.1016/j, DOI 10.1016/J]; Neparidze Natalia, 2014, Clin Adv Hematol Oncol, V12, P358; Nielsen SL, 2017, APPL IMMUNOHISTO M M, V25, P320, DOI 10.1097/PAI.0000000000000463; Nitta H, 2016, PATHOL INT, V66, P313, DOI 10.1111/pin.12407; Nitta H, 2013, J THORAC ONCOL, V8, P1019, DOI 10.1097/JTO.0b013e31829ebb4d; Nitta H, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-60; Nitta H, 2010, METHODS, V52, P352, DOI 10.1016/j.ymeth.2010.07.005; Nitta H, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-41; O'Sullivan B, 2016, LANCET ONCOL, V17, P440, DOI 10.1016/S1470-2045(15)00560-4; O'Sullivan B, 2013, J CLIN ONCOL, V31, P543, DOI 10.1200/JCO.2012.44.0164; Oddo D, 2017, BRIT J CANCER, V117, P347, DOI 10.1038/bjc.2017.196; Paik PK, 2017, CLIN CANCER RES, V23, P5366, DOI 10.1158/1078-0432.CCR-17-0645; Pan JJ, 2016, CANCER-AM CANCER SOC, V122, P546, DOI 10.1002/cncr.29795; Pantanowitz L, 2013, ARCH PATHOL LAB MED, V137, P1710, DOI 10.5858/arpa.2013-0093-CP; Park YS, 2015, AM J CLIN PATHOL, V143, P865, DOI 10.1309/AJCPNFLSMWWPP8DR; Pasini E, 2009, INT J CANCER, V125, P1358, DOI 10.1002/ijc.24515; Pearson A, 2016, CANCER DISCOV, V6, P838, DOI 10.1158/2159-8290.CD-15-1246; Perrone F, 2006, CLIN CANCER RES, V12, P6643, DOI 10.1158/1078-0432.CCR-06-1759; Perrone F, 2011, AM J SURG PATHOL, V35, P774, DOI 10.1097/PAS.0b013e3182116a45; Petersson B, 2017, WHO CLASSIFICATION H, P65; Pichler M, 2015, BRIT J CANCER, V113, P569, DOI 10.1038/bjc.2015.253; Pietrantonio F, 2017, CLIN CANCER RES, V23, P2414, DOI 10.1158/1078-0432.CCR-16-1863; Pietrantonio F, 2016, CANCER DISCOV, V6, P963, DOI 10.1158/2159-8290.CD-16-0297; Posner MR, 2011, ANN ONCOL, V22, P1071, DOI 10.1093/annonc/mdr006; Psyrri A, 2014, ANN ONCOL, V25, P2101, DOI 10.1093/annonc/mdu265; Rieger JM, 2006, INT J ORAL MAX SURG, V35, P581, DOI 10.1016/j.ijom.2006.03.026; Rietbergen MM, 2013, ANN ONCOL, V24, P2740, DOI 10.1093/annonc/mdt319; Rimassa L, 2017, WORLD J GASTROENTERO, V23, P2448, DOI 10.3748/wjg.v23.i13.2448; Rischin D, 2010, J CLIN ONCOL, V28, P2989, DOI 10.1200/JCO.2009.27.4449; Rogers TM, 2015, J THORAC ONCOL, V10, P611, DOI 10.1097/JTO.0000000000000465; Rooper LM, 2016, ORAL ONCOL, V55, P11, DOI 10.1016/j.oraloncology.2016.02.008; Rosenthal DI, 2016, J CLIN ONCOL, V34, P1300, DOI 10.1200/JCO.2015.62.5970; Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9; Sartore-Bianchi A, 2012, J CLIN PATHOL, V65, P218, DOI 10.1136/jclinpath-2011-200353; Saylor PJ, 2017, CLIN CANCER RES, V23, P363, DOI 10.1158/1078-0432.CCR-16-0237; Schildhaus HU, 2015, CLIN CANCER RES, V21, P907, DOI 10.1158/1078-0432.CCR-14-0450; Schildhaus HU, 2013, MODERN PATHOL, V26, P1468, DOI 10.1038/modpathol.2013.95; Schildhaus HU, 2012, MODERN PATHOL, V25, P1473, DOI 10.1038/modpathol.2012.102; Seiwert TY, 2014, J CLIN ONCOL, V32, P3914, DOI 10.1200/JCO.2014.57.9268; Seo AN, 2015, TUMOR BIOL, V36, P9813, DOI 10.1007/s13277-015-3726-2; Serup-Hansen E, 2014, J CLIN ONCOL, V32, P1812, DOI 10.1200/JCO.2013.52.3464; Shahabipour F, 2017, J CELL PHYSIOL, V232, P1660, DOI 10.1002/jcp.25766; Shi ZG, 2012, J ONCOL, DOI 10.1155/2012/903581; Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Spagnuolo RD, 2016, ONCOTARGET, V7, P45015, DOI 10.18632/oncotarget.7523; Su X, 2014, BRIT J CANCER, V110, P967, DOI 10.1038/bjc.2013.802; Swain SM, 2015, NEW ENGL J MED, V372, P724, DOI 10.1056/NEJMoa1413513; Tanner M, 2000, AM J PATHOL, V157, P1467, DOI 10.1016/S0002-9440(10)64785-2; Tos APD, 2000, J PATHOL, V190, P531; Tran TN, 2013, LUNG CANCER, V81, P462, DOI 10.1016/j.lungcan.2013.05.015; Tsao SW, 2015, J PATHOL, V235, P323, DOI 10.1002/path.4448; Tubbs R, 2004, J MOL HISTOL, V35, P589; Tubbs R, 2002, AM J PATHOL, V160, P1589, DOI 10.1016/S0002-9440(10)61106-6; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; Ukpo OC, 2011, AM J SURG PATHOL, V35, P1343, DOI 10.1097/PAS.0b013e318220e59d; Valtorta E, 2015, MODERN PATHOL, V28, P1481, DOI 10.1038/modpathol.2015.98; van Rijk A, 2010, HAEMATOL-HEMATOL J, V95, P247, DOI 10.3324/haematol.2009.011635; Varella-Garcia M, 2009, J CLIN PATHOL, V62, P970, DOI 10.1136/jcp.2009.066548; Varella-Garcia M, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-19; Varga Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105961; Vergani E, 2016, ONCOTARGET, V7, P4428, DOI 10.18632/oncotarget.6599; Vojtechova Z, 2016, INT J CANCER, V138, P386, DOI 10.1002/ijc.29712; Volpi CC, 2017, HUM PATHOL, P6, DOI [10.1016/j, DOI 10.1016/J]; Wagner F, 2014, J CLIN PATHOL, V67, P403, DOI 10.1136/jclinpath-2013-201974; Wagner S, 2017, ONCOL RES TREAT, V40, P334, DOI 10.1159/000477252; Wang CC, 2010, INT J RADIAT ONCOL, V78, P1111, DOI 10.1016/j.ijrobp.2009.09.021; Wang J, 1998, BIOSENS BIOELECTRON, V13, P757, DOI 10.1016/S0956-5663(98)00039-6; Westra WH, 2014, ORAL ONCOL, V50, P771, DOI 10.1016/j.oraloncology.2014.05.004; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Wong DD, 2016, PATHOLOGY, V48, P203, DOI 10.1016/j.pathol.2016.02.007; Wulf MA, 2012, AM J SURG PATHOL, V36, P1801, DOI 10.1097/PAS.0b013e31826ff153; Xie FJ, 2016, ONCOTARGETS THER, V9, DOI 10.2147/OTT.S91848; Xu T, 2013, CURR ONCOL, V20, pE406, DOI 10.3747/co.20.1456; Yamaguchi M, 2017, J CLIN EXP HEMATOP, V57, P98, DOI 10.3960/jslrt.17018; Yoshida A, 2011, J THORAC ONCOL, V6, P1677, DOI 10.1097/JTO.0b013e3182286d25; Zhang BL, 2015, ORAL ONCOL, V51, P1041, DOI 10.1016/j.oraloncology.2015.08.005; Zhang L, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-558; Zhang LH, 2013, SCI REP-UK, V3, DOI 10.1038/srep02992; Zhang WJ, 2011, APPL IMMUNOHISTO M M, V19, P54, DOI 10.1097/PAI.0b013e3181ee8e14	184	3	3	2	3	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	3					259	277		10.1080/14737159.2018.1440210			19	Pathology	Pathology	FY5ZM	WOS:000426918100006	29431533				2019-10-28	
J	Patil, PD; Burotto, M; Velcheti, V				Patil, Pradnya D.; Burotto, Mauricio; Velcheti, Vamsidhar			Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Immune related adverse events; biomarkers; checkpoint inhibitor toxicity	SYSTEMIC-LUPUS-ERYTHEMATOSUS; REGULATORY T-CELLS; ADVERSE EVENTS; GENE POLYMORPHISMS; CTLA-4 BLOCKADE; METASTATIC MELANOMA; AUTOIMMUNE-DISEASES; MULTIPLE-SCLEROSIS; ADDISONS-DISEASE; CANCER-PATIENTS	Introduction: Immune checkpoint pathways are key immune regulatory pathways that play a physiologic role in maintaining immune-homeostasis and are often co-opted by cancer cells to evade the host immune system. Recent developments in cancer immunotherapy, mainly drugs blocking the immune checkpoint pathways, have revolutionized the treatment paradigm for many solid tumors. A wide spectrum of immune-related adverse events (irAEs) have been described with the use of these agents which necessitate treatment with immunosuppression, lead to disruption of therapy and can on occasion be life-threatening. There are currently no clinically validated biomarkers to predict the risk of irAEs.Areas covered: In this review, the authors describe the current progress in identifying biomarkers for irAEs and potential future directions. Literature search was conducted using PubMed-MEDLINE, Embase and Scopus. In addition, abstracts from major conference proceedings were reviewed for relevant content.Expert commentary: The discovery of biomarkers for irAEs is currently in its infancy, however there are a lot of promising candidate biomarkers that are currently being investigated. Biomarkers that can identify patients at a higher risk of developing irAEs or lead to early detection of autoimmune toxicities are crucial to optimize patient selection for immune-oncology agents and to minimize toxicity with their use.	[Patil, Pradnya D.; Velcheti, Vamsidhar] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Oncol, Cleveland, OH 44106 USA; [Burotto, Mauricio] Clin Alemana Santiago, Dept Med Oncol, Vitacura, Chile	Velcheti, V (reprint author), Cleveland Clin, Ctr Immunooncol Res, Taussig Canc Inst, Dept Hematol Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA.; Velcheti, V (reprint author), Cleveland Clin, Lerner Coll Med, Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	velchev@ccf.org					Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Bertsias GK, 2009, ARTHRITIS RHEUM-US, V60, P207, DOI 10.1002/art.24227; Blomhoff A, 2004, J CLIN ENDOCR METAB, V89, P3474, DOI 10.1210/jc.2003-031854; Bour-Jordan H, 2003, NAT IMMUNOL, V4, P182, DOI 10.1038/ni884; Bour-Jordan H, 2009, IMMUNOL REV, V229, P41, DOI 10.1111/j.1600-065X.2009.00775.x; Bruck P, 2008, J HUM GENET, V53, P559, DOI 10.1007/s10038-008-0286-y; Burnet F M, 1971, Transplant Rev, V7, P3; Buttmann M, 2008, J NEUROGENET, V22, P181, DOI 10.1080/01677060802179287; Chaput N, 2017, ANN ONCOL, V28, P1368, DOI 10.1093/annonc/mdx108; Chen TW, 2015, ANN ONCOL, V26, P1824, DOI 10.1093/annonc/mdv182; De Simone M, 2016, IMMUNITY, V45, P1135, DOI 10.1016/j.immuni.2016.10.021; De Velasco G, 2017, CANCER IMMUNOL RES, V5, P312, DOI 10.1158/2326-6066.CIR-16-0237; Dubin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10391; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Ehrlich P., 1909, NED TIJDSCHR GENEES, V5, P273; Ermann J, 2015, NAT REV RHEUMATOL, V11, P541, DOI 10.1038/nrrheum.2015.71; Faith JJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008051; Freeman-Keller M, 2016, CLIN CANCER RES, V22, P886, DOI 10.1158/1078-0432.CCR-15-1136; Ganesan Vinitha, 2016, BioMolecular Concepts, V7, P133, DOI 10.1515/bmc-2016-0007; Gowen M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.9559; Hou XL, 2016, GENES IMMUN, V17, P153, DOI 10.1038/gene.2016.9; Hudson LL, 2002, HUM GENET, V111, P452, DOI 10.1007/s00439-002-0807-2; Jaber SH, 2006, ARCH DERMATOL, V142, P166, DOI 10.1001/archderm.142.2.166; Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214; Judd J, 2017, ONCOLOGIST, V22, P1232, DOI 10.1634/theoncologist.2017-0133; Khoja L, 2017, ANN ONCOL, V28, P2377, DOI 10.1093/annonc/mdx286; Kroner A, 2005, ANN NEUROL, V58, P50, DOI 10.1002/ana.20514; Lee YH, 2015, Z RHEUMATOL, V74, P230, DOI 10.1007/s00393-014-1415-y; Li Z, 2016, ONCOTARGET, V7, P26168, DOI 10.18632/oncotarget.8435; Liu J, 2016, CANCER RES, V76, P5288, DOI 10.1158/0008-5472.CAN-16-0194; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794; Mitchell AL, 2009, J CLIN ENDOCR METAB, V94, P5139, DOI 10.1210/jc.2009-1404; Nishimura H, 2000, J EXP MED, V191, P891, DOI 10.1084/jem.191.5.891; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; O'Mahony C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000112; Oh DY, 2017, CANCER RES, V77, P1322, DOI 10.1158/0008-5472.CAN-16-2324; Oosterwegel MA, 1999, J IMMUNOL, V163, P2634; Perret RE, 2017, INT J DERMATOL, V56, P527, DOI 10.1111/ijd.13540; Pitt JM, 2016, CANCER RES, V76, P4602, DOI 10.1158/0008-5472.CAN-16-0448; Pizarro C, 2014, DIABETES-METAB RES, V30, P761, DOI 10.1002/dmrr.2552; Prokunina L, 2002, NAT GENET, V32, P666, DOI 10.1038/ng1020; Reuben JM, 2006, CANCER, V106, P2437, DOI 10.1002/cncr.21854; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Schindler K, 2014, ASCO M, V32, P9096, DOI DOI 10.1200/JC0.2014.32.15; Shi VJ, 2016, JAMA DERMATOL, V152, P1128, DOI 10.1001/jamadermatol.2016.2226; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Song GG, 2013, HUM IMMUNOL, V74, P1214, DOI 10.1016/j.humimm.2013.05.014; Subudhi SK, 2016, P NATL ACAD SCI USA, V113, P11919, DOI 10.1073/pnas.1611421113; Sun Jingjing, 2008, Cancer Immun, V8, P9; Tarhini AA, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0081-1; Telenti A, 2016, P NATL ACAD SCI USA, V113, P11901, DOI 10.1073/pnas.1613365113; Tu YQ, 2017, ONCOTARGET, V8, P98993, DOI 10.18632/oncotarget.20114; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Vaidya B, 2002, RHEUMATOLOGY, V41, P180, DOI 10.1093/rheumatology/41.2.180; Vandenbroeck K, 2012, J INTERF CYTOK RES, V32, P139, DOI 10.1089/jir.2011.0103; Velcheti Vamsidhar, 2016, Am Soc Clin Oncol Educ Book, V35, P298, DOI 10.14694/EDBK_156572; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Weidhaas JB, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3040; Wells KR, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3041	65	5	6	0	3	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	3					297	305		10.1080/14737159.2018.1440209			9	Pathology	Pathology	FY5ZM	WOS:000426918100008	29430978				2019-10-28	
J	Bao, WX; He, FP; Gao, J; Meng, FX; Zou, H; Luo, BY				Bao, Wangxiao; He, Fangping; Gao, Jian; Meng, Fanxia; Zou, Hai; Luo, Benyan			Alpha-1-antitrypsin: a novel predictor for long-term recovery of chronic disorder of consciousness	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Alpha-1-antitrypsin; chronic disorder of consciousness; iTRAQ; proteomics; plasma	TRAUMATIC BRAIN-INJURY; VEGETATIVE STATE; CEREBROSPINAL-FLUID; COMPLEMENT-SYSTEM; SERUM; PROTEIN; BIOMARKERS; PROTEOMICS; MICE; RATS	Background: The aim of this manuscript was to explore the molecular basis and identify novel biomarkers for the diagnosis and prognosis of patients with chronic disorder of consciousness.Methods: A coupled isobaric tag for relative and absolute quantitation-based approach was used to screen differentially expressed proteins (DEPs) between patients with chronic disorder of consciousness and healthy individuals. Candidate proteins were identified and measured. The Coma Recovery Scale-Revised (CRS-R) score was used to quantify the severity, and long-term recovery was assessed by Glasgow Outcome Scale (GOS).Results: Between patients and controls, a total of 77 DEPs were identified. Based on the DEPs, a network containing 50 nodes and 207 edges was built, and alpha-1-antitrypsin was marked as the hub protein. The results indicated that alpha-1-antitrypsin correlated with the CRS-R score with a correlation coefficient of 0.631, and an outcome at 12months (8.52.1ng/ml in patients with GOS 1-2 vs. 6.8 +/- 1.6ng/ml in those with GOS 3-5, p=0.002).Conclusions: The data confirm the diagnostic and prognostic potential of alpha-1-antitrypsin in chronic disorder of consciousness, which may contribute to the development of novel therapeutic agents.	[Bao, Wangxiao; He, Fangping; Meng, Fanxia; Luo, Benyan] Zhejiang Univ, Affiliated Hosp 1, Dept Neurol, Collaborat Innovat Ctr Brain Sci,Sch Med, Hangzhou 310003, Zhejiang, Peoples R China; [Gao, Jian] Hangzhou Hosp Zhejiang CAPR, Dept Rehabil, Hangzhou, Zhejiang, Peoples R China; [Zou, Hai] Zhejiang Prov Peoples Hosp, Dept Cardiol, Hangzhou 310003, Zhejiang, Peoples R China; [Zou, Hai] Hangzhou Med Coll, Peoples Hosp, Hangzhou, Zhejiang, Peoples R China	Luo, BY (reprint author), Zhejiang Univ, Affiliated Hosp 1, Dept Neurol, Collaborat Innovat Ctr Brain Sci,Sch Med, Hangzhou 310003, Zhejiang, Peoples R China.; Zou, H (reprint author), Zhejiang Prov Peoples Hosp, Dept Cardiol, Hangzhou 310003, Zhejiang, Peoples R China.	haire1993@163.com; luobenyan@zju.edu.cn			Science and Technology Plan of Zhejiang Province [2017C03011]	This work was supported by grants from the Science and Technology Plan of Zhejiang Province [2017C03011].	Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Altermann E, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-60; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; Demertzi A, 2014, CORTEX, V52, P35, DOI 10.1016/j.cortex.2013.11.005; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dhingra V, 2005, INT J PHARM, V299, P1, DOI 10.1016/j.ijpharm.2005.04.010; Echan LA, 2005, PROTEOMICS, V5, P3292, DOI 10.1002/pmic.200401228; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Gao WM, 2014, PEDIATR RES, V76, P280, DOI 10.1038/pr.2014.86; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Hannawi Y, 2015, NEUROLOGY, V84, P1272, DOI 10.1212/WNL.0000000000001404; Hardwick J, 2008, ISBT SCI SER, V3, P148, DOI 10.1111/j.1751-2824.2008.00195.x; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Li YS, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-52; Lizhnyak PN, 2015, EXPERT REV PROTEOMIC, V12, P75, DOI 10.1586/14789450.2015.1000869; LLEWELLYNJONES CG, 1994, BBA-MOL BASIS DIS, V1227, P155, DOI 10.1016/0925-4439(94)90089-2; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Ma H, 2010, DIABETOLOGIA, V53, P2198, DOI 10.1007/s00125-010-1829-2; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; Moldthan HL, 2014, J STROKE CEREBROVASC, V23, pE355, DOI 10.1016/j.jstrokecerebrovasdis.2013.12.029; Monti MM, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3765; MORNEX JF, 1986, J CLIN INVEST, V77, P1952, DOI 10.1172/JCI112524; Orsini F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00380; Pfeifer R, 2005, RESUSCITATION, V65, P49, DOI 10.1016/j.resuscitation.2004.10.011; Rich MC, 2016, NEUROSCI LETT, V617, P188, DOI 10.1016/j.neulet.2016.02.025; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Ruseva MM, 2015, P NATL ACAD SCI USA, V112, P14319, DOI 10.1073/pnas.1513698112; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Takahata Keisuke, 2016, Brain Nerve, V68, P849, DOI 10.11477/mf.1416200517; Thelin EP, 2018, BEHAV BRAIN RES, V340, P71, DOI 10.1016/j.bbr.2016.08.058; Troakes C, 2017, NEUROPATHOLOGY, V37, P12, DOI 10.1111/neup.12320; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wade DT, 1999, BMJ-BRIT MED J, V319, P841, DOI 10.1136/bmj.319.7213.841; Welch RD, 2017, J NEUROTRAUM, V34, P1957, DOI 10.1089/neu.2016.4772; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zhang P, 2016, J PROTEOMICS, V133, P93, DOI 10.1016/j.jprot.2015.12.014; Zhu H, 2017, EXP BIOL MED, V243	45	0	0	0	6	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	3					307	313		10.1080/14737159.2018.1438192			7	Pathology	Pathology	FY5ZM	WOS:000426918100009	29419340				2019-10-28	
J	Ura, A; Ogura, K; Sakaguchi, A; Onagi, H; Ogishima, D; Sugimori, Y; Hamamura, K; Fukunaga, M; Matsumoto, T				Ura, Ayako; Ogura, Kanako; Sakaguchi, Asumi; Onagi, Hiroko; Ogishima, Daiki; Sugimori, Yayoi; Hamamura, Kensuke; Fukunaga, Masaharu; Matsumoto, Toshiharu			Coexistence of Cervical Leiomyosarcoma and Gastric-Type Adenocarcinoma In Situ with Extensive Extension to the Endometrium and Fallopian Tube	CASE REPORTS IN PATHOLOGY			English	Article							UTERINE CERVIX; SARCOMAS; TRACT	Cervical leiomyosarcoma is known to be rare from the previous reviews of a large number of malignant cervical tumors. The patient was a 66-year-old woman with irregular vaginal bleeding. She underwent modified radical hysterectomy and bilateral salpingooophorectomy. Histopathologically, we diagnosed the coexistence of uterine cervical leiomyosarcoma and cervical gastric-type adenocarcinoma in situ with endometrial lesions that had continuous and skip patterns and fallopian tubal lesions with a partial lesion. To the best of our knowledge, cases of synchronous leiomyosarcoma and cancers have not often been reported; only two cases of synchronous cervical leiomyosarcoma and cervical squamous cell carcinoma have been published. This case is the first presentation of coincidental primary cervical leiomyosarcoma and cervical gastric-type adenocarcinoma in situ. Additionally, we considered cervical gastric-type adenocarcinoma in situ with continuous lesions on the endometrium and skip lesions on the left fallopian tube.	[Ura, Ayako; Ogura, Kanako; Sakaguchi, Asumi; Onagi, Hiroko; Matsumoto, Toshiharu] Juntendo Univ, Nerima Hosp, Dept Diagnost Pathol, Tokyo, Japan; [Ogishima, Daiki; Sugimori, Yayoi; Hamamura, Kensuke] Juntendo Univ, Nerima Hosp, Dept Gynecol, Tokyo, Japan; [Fukunaga, Masaharu] Shin Yurigaoka Gen Hosp, Dept Diagnost Pathol, Kawasaki, Kanagawa, Japan	Ura, A (reprint author), Juntendo Univ, Nerima Hosp, Dept Diagnost Pathol, Tokyo, Japan.	a-ura@juntendo.ac.jp		Ogishima, Daiki/0000-0002-0725-7613			Amalinei C, 2008, GENET MOL BIOL, V9, P1; Dudzik K, 2017, MENOPAUSE REV, V16, P23, DOI 10.5114/pm.2017.67367; Ekici AID, 2006, INT J GYNECOL CANCER, V16, P1947, DOI 10.1111/j.1525-1438.2006.00704.x; Katie K., 2016, INT J SURG CASE REPO, V22, P32; Khosla D, 2012, INT J GYNECOL CANCER, V22, P1026, DOI 10.1097/IGC.0b013e31825a97f6; Kojima A, 2007, AM J SURG PATHOL, V31, P664, DOI 10.1097/01.pas.0000213434.91868.b0; Kurman RJ, 2014, WHO CLASSIFICATION T; Mikami Y, 2013, ADV ANAT PATHOL, V20, P227, DOI 10.1097/PAP.0b013e31829c2d66; Saatli B, 2014, GINEKOL POL, V85, P441; Sheyn I, 2000, ARCH PATHOL LAB MED, V124, P1539; Talia KL, 2017, AM J SURG PATHOL, V41, P1023, DOI 10.1097/PAS.0000000000000855; Tong SY, 2008, EUR J OBSTET GYN R B, V136, P78, DOI 10.1016/j.ejogrb.2006.09.010; Wiston B., 1969, OBSTET GYNECOLOGY, V33; Wright JD, 2005, GYNECOL ONCOL, V99, P348, DOI 10.1016/j.ygyno.2005.06.021; Zielinski GD, 2003, J PATHOL, V201, P535, DOI 10.1002/path.1480	15	0	0	1	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									5848629	10.1155/2018/5848629			6	Pathology	Pathology	FY4IM	WOS:000426786000001	29670794	DOAJ Gold, Green Published			2019-10-28	
J	Al Abdulmohsen, S; Ayoubi, A; Al-Dandan, S				Al Abdulmohsen, Sally; Ayoubi, Ayman; Al-Dandan, Sadeq			Respiratory Epithelial Orbital Cyst: A Case Report and Literature Review	CASE REPORTS IN PATHOLOGY			English	Review								A 44-year-old male with schizophrenia presented with progressive right proptosis for one year and conjunctivitis for two months. An orbital cyst was seen in the superotemporal region on computerized tomography and was surgically removed. There was no history or radiological signs of paranasal sinus disease or previous trauma. Histopathologic evaluation revealed a cyst lined with respiratory epithelium. Respiratory choristomatous cysts of the orbit are considered rare in both pediatric and adult patients. We review the literature of respiratory orbital cysts and conclude that they tend to present in adults and should be considered in the differential diagnoses of orbital cysts.	[Al Abdulmohsen, Sally; Al-Dandan, Sadeq] King Fahad Med City, Dept Anat Pathol, Riyadh, Saudi Arabia; [Ayoubi, Ayman] King Fahad Med City, Dept Ophthalmol, Riyadh, Saudi Arabia	Al Abdulmohsen, S (reprint author), King Fahad Med City, Dept Anat Pathol, Riyadh, Saudi Arabia.	sally.abdullah@gmail.com		Al-Dandan, Sadeq/0000-0003-3373-7327			Eggert J E, 1988, Ophthalmic Plast Reconstr Surg, V4, P101, DOI 10.1097/00002341-198804020-00008; Goh RLZ, 2016, ORBIT, V35, P245, DOI 10.1080/01676830.2016.1176219; Gunalp I, 1997, INT OPHTHALMOL, V20, P273; Jakobiec FA, 2016, OPHTHAL PLAST RECONS, V32, pE15, DOI 10.1097/IOP.0000000000000373; Kemp PS, 2014, J PEDIAT OPHTH STRAB, V51, pE19, DOI 10.3928/01913913-20140225-04; LEVENTER DB, 1994, OPHTHALMOLOGY, V101, P1614; MANSOUR AM, 1989, SURV OPHTHALMOL, V33, P339, DOI 10.1016/0039-6257(89)90011-8; Mee JJ, 2002, CLIN EXP OPHTHALMOL, V30, P356, DOI 10.1046/j.1442-9071.2002.00556.x; Morris WR, 2001, OPHTHALMIC PLAST REC, V17, P462, DOI 10.1097/00002341-200111000-00016; Neves RB, 1998, AM J OPHTHALMOL, V125, P879, DOI 10.1016/S0002-9394(98)00050-6; NEWTON C, 1985, OPHTHALMOLOGY, V92, P1754; Shields JA, 2004, SURV OPHTHALMOL, V49, P281, DOI 10.1016/j.survophthal.2004.02.001; Tay E, 2014, OPHTHAL PLAST RECONS, V30, pE116, DOI 10.1097/IOP.0b013e3182a64f6b; Thanos A, 2014, SURV OPHTHALMOL, V59, P328, DOI 10.1016/j.survophthal.2013.07.001; Weegerink N, 2016, B-ENT, V12, P77; West JA, 1997, AUST NZ J OPHTHALMOL, V25, P117, DOI 10.1111/j.1442-9071.1997.tb01292.x	16	0	0	1	2	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									7256871	10.1155/2018/7256871			4	Pathology	Pathology	FX6FI	WOS:000426178300001	29651357	DOAJ Gold, Green Published			2019-10-28	
J	Halima, A; Pannunzio, AM; Erstine, EM; Ko, JS; Bergfeld, WF; Malaya, RM; Frankel, MB; Calhoun, BC; Sturgis, CD				Halima, A.; Pannunzio, A. M.; Erstine, E. M.; Ko, J. S.; Bergfeld, W. F.; Malaya, R. M.; Frankel, M. B.; Calhoun, B. C.; Sturgis, C. D.			Cutaneous Adnexal Cylindroma of Breast: Epithelial Immunoreactivities for GATA-3, Mammaglobin, and E-Cadherin Do Not Equate to a Mammary Ductal Neoplasm	CASE REPORTS IN PATHOLOGY			English	Article							ADENOID CYSTIC CARCINOMA; DERMAL ANALOG TUMOR; TRANSCRIPTION FACTOR; SOLITARY CYLINDROMA; MYB; SKIN; EXPRESSION; DIFFERENTIATION; VARIANTS; UPDATE	Cylindromas are benign epithelial neoplasms derived from cutaneous eccrine adnexal structures. These tumors are most commonly encountered on the head, neck, and scalp of older women. In rare instances, solitary cylindromas may arise at other body sites. In the current case, a cylindroma of the skin of the breast was diagnosed by complete excision. Immunohistochemical studies confirmed the tumor cells to be immunoreactive with cytokeratin AE1/3, cytokeratin 5/6, cytokeratin 7, p63, and SOX10. The neoplastic cells were also noted to be immunoreactive with markers typically expected to be positive in ductal epithelium of the breast including GATA3, mammaglobin, and E-cadherin. The case emphasizes the importance of correlating clinical setting, imaging studies, patient history, and careful microscopic evaluation in arriving at an accurate diagnosis. This case also illustrates the point that not all "breast" tumors that are confirmed to be positive for GATA3, mammaglobin, and E-cadherin are derived from mammary ducts.	[Halima, A.; Pannunzio, A. M.; Erstine, E. M.; Ko, J. S.; Bergfeld, W. F.; Calhoun, B. C.; Sturgis, C. D.] Cleveland Clin, Med Inst, RJ Tomsich Pathol & Lab, Cleveland, OH 44106 USA; [Malaya, R. M.] Cleveland Clin, Gen Surg, Cleveland, OH 44106 USA; [Frankel, M. B.] Cleveland Clin, Diagnost Radiol, Cleveland, OH 44106 USA	Sturgis, CD (reprint author), Cleveland Clin, Med Inst, RJ Tomsich Pathol & Lab, Cleveland, OH 44106 USA.	sturgic@ccf.org		Erstine, Emily M/0000-0002-0126-7028			Aggarwal Roopak, 2013, Int J Trichology, V5, P83, DOI 10.4103/0974-7753.122967; Albores-Saavedra J, 2005, AM J CLIN PATHOL, V123, P866, DOI 10.1309/CRWUA3K0MPQHC4W; Chae YK, 2015, ONCOTARGET, V6, P37117, DOI 10.18632/oncotarget.5076; Corda G, 2016, J PATHOL, V239, P391, DOI 10.1002/path.4746; COTTON DWK, 1984, BRIT J DERMATOL, V111, P53, DOI 10.1111/j.1365-2133.1984.tb04016.x; Danialan R, 2015, J CLIN PATHOL, V68, P992, DOI 10.1136/jclinpath-2015-203228; Dubois A, 2017, DERMATOL CLIN, V35, P61, DOI 10.1016/j.det.2016.08.002; Evangelista MTP, 2017, J CUTAN PATHOL, V44, P444, DOI 10.1111/cup.12904; Ferrarotto R, 2016, CURR OPIN ONCOL, V28, P195, DOI 10.1097/CCO.0000000000000280; Foschini MP, 2017, PATHOLOGY, V49, P215, DOI 10.1016/j.pathol.2016.10.011; FUJITA M, 1992, ARCH DERMATOL RES, V284, P159, DOI 10.1007/BF00372710; Fusco N, 2016, HISTOPATHOLOGY, V68, P262, DOI 10.1111/his.12735; George OL, 2014, CANCERS, V6, P2049, DOI 10.3390/cancers6042049; GERRETSEN AL, 1993, CANCER-AM CANCER SOC, V72, P1618, DOI 10.1002/1097-0142(19930901)72:5<1618::AID-CNCR2820720521>3.0.CO;2-5; Gokaslan ST, 2001, AM J SURG PATHOL, V25, P823, DOI 10.1097/00000478-200106000-00017; Jordao C, 2015, INT J DERMATOL, V54, P275, DOI 10.1111/ijd.12600; Kazakov DV, 2016, HEAD NECK PATHOL, V10, P125, DOI 10.1007/s12105-016-0705-x; Mahmoud A, 2009, DIAGN PATHOL, V4, DOI 10.1186/1746-1596-4-30; Mertens RB, 2015, AM J DERMATOPATH, V37, P885, DOI 10.1097/DAD.0000000000000306; Miyai Kosuke, 2014, World J Clin Cases, V2, P732, DOI 10.12998/wjcc.v2.i12.732; Nagy N, 2015, EUR J MED GENET, V58, P271, DOI 10.1016/j.ejmg.2015.02.010; Nakai T, 2016, VIRCHOWS ARCH, V469, P213, DOI 10.1007/s00428-016-1963-4; Nonaka D, 2004, AM J SURG PATHOL, V28, P1070, DOI 10.1097/01.pas.0000126774.27698.27; Obaidat NA, 2007, J CLIN PATHOL, V60, P145, DOI 10.1136/jcp.2006.041608; Pardal J, 2017, AM J DERMATOPATH, V39, P279, DOI 10.1097/DAD.0000000000000634; PENNEYS NS, 1993, J CUTAN PATHOL, V20, P40, DOI 10.1111/j.1600-0560.1993.tb01247.x; Rajan N, 2016, J PATHOL, V239, P197, DOI 10.1002/path.4717; Rakha EA, 2006, J PATHOL, V208, P495, DOI 10.1002/path.1916; Rakha EA, 2015, PATHOBIOLOGY, V82, P172, DOI 10.1159/000433600; Singh DD, 2013, J CRANIO MAXILL SURG, V41, P516, DOI 10.1016/j.jcms.2012.11.016; Sjodin A, 2003, J INVEST DERMATOL, V121, P428, DOI 10.1046/j.1523-1747.2003.12374.x; Taghipour S., 2013, BMJ CASE REPORTS, V2013, P1; Uttarkar S, 2017, EXP HEMATOL, V47, P31, DOI 10.1016/j.exphem.2016.12.003; Vujhini SK, 2011, INDIAN J PATHOL MICR, V54, P204, DOI 10.4103/0377-4929.77407; Wang N, 2004, ACTA CYTOL, V48, P853, DOI 10.1159/000326457; Weedon D., 2002, EDINBURGH CHURCHILL, P890	36	0	0	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									4039545	10.1155/2018/4039545			7	Pathology	Pathology	FX6FH	WOS:000426178100001	29651355	DOAJ Gold, Green Published			2019-10-28	
J	Torrent, E; Pastor, J; Fresno, L; Vigueras, I; Casanova, MI; Ramis, A; Solano-Gallego, L				Torrent, E.; Pastor, J.; Fresno, L.; Vigueras, I.; Casanova, M. I.; Ramis, A.; Solano-Gallego, L.			Laryngeal Granuloma due to Leishmania spp. Infection in a Dog	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						dog; granuloma; larynx; leishmaniosis	LOCALIZED MUCOSAL LEISHMANIASIS; CANINE LEISHMANIASIS; VISCERAL LEISHMANIASIS; INFANTUM; INVOLVEMENT; GLOSSITIS; DIAGNOSIS; LESIONS	A French bulldog with a previous history of leishmaniosis was presented due to respiratory distress associated with a laryngeal mass. The mass was excised and cytological and histopathological examination revealed pyogranulomatous inflammation with Leishmania spp. amastigotes. After surgery, the respiratory condition resolved; however, 3 months later the dog developed clinicopathological signs of leishmaniosis, which improved with systemic treatment. This case shows an atypical presentation of leishmaniosis with a focal tumour-like mass in the vocal folds as the only clinical sign. (C) 2017 Elsevier Ltd. All rights reserved.	[Torrent, E.; Fresno, L.; Vigueras, I.] Univ Autonoma Barcelona, Fdn Hosp Clin Vet, Edif 5,Campus UAB, Bellaterra, Spain; [Torrent, E.; Pastor, J.; Fresno, L.; Vigueras, I.; Solano-Gallego, L.] Univ Autonoma Barcelona, Fac Vet, Dept Med & Cirurgia Anim, Edif 5,Campus UAB, Bellaterra, Spain; [Casanova, M. I.; Ramis, A.] Univ Autonoma Barcelona, Serv Diagnost Patol Vet, Dept Sanitat & Anat Anim, Edif 5,Campus UAB, Bellaterra, Spain	Torrent, E (reprint author), Univ Autonoma Barcelona, Fdn Hosp Clin Vet, Edif 5,Campus UAB, Bellaterra, Spain.; Torrent, E; Solano-Gallego, L (reprint author), Univ Autonoma Barcelona, Fac Vet, Dept Med & Cirurgia Anim, Edif 5,Campus UAB, Bellaterra, Spain.	esthertorrent@yahoo.com; laia.solano@uab.cat			Spanish ministry grant; Ministerio de Economia y CompetitividadSpanish Ministry of Economy & Competitiveness; fondos FEDEREuropean Union (EU) [AGL2012-32498]; Ministerio de Ciencia e Innovacion (Spain)Ministry of Science and Innovation, Spain (MICINN); European Social FundEuropean Social Fund (ESF)	The authors thank the veterinarians and technicians of the HCV who were involved in the care of this dog, especially C. Torrente. The authors are also grateful to L. Feo and L. Ordeix for helping collect information about the case. Analytical tests performed in this study were supported partially by a Spanish ministry grant, Ministerio de Economia y Competitividad and fondos FEDER (AGL2012-32498). L. Solano-Gallego held a Ramon y Cajal senior researcher contract awarded by the Ministerio de Ciencia e Innovacion (Spain) and the European Social Fund.	Aliaga L, 2003, MEDICINE, V82, P147, DOI 10.1097/00005792-200305000-00001; Alvar J, 2004, ADV PARASIT, V57, P1, DOI 10.1016/S0065-308X(04)57001-X; Baneth G, 2008, TRENDS PARASITOL, V24, P324, DOI 10.1016/j.pt.2008.04.001; Baneth G, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-118; Barroso PA, 2015, AM J TROP MED HYG, V93, P334, DOI 10.4269/ajtmh.14-0267; Bernaerts F, 2010, VET J, V183, P95, DOI 10.1016/j.tvjl.2008.09.009; Ciaramella P, 1997, VET REC, V141, P539, DOI 10.1136/vr.141.21.539; Cincura C, 2017, AM J TROP MED HYG, V97, P761, DOI 10.4269/ajtmh.16-0349; Cobo F, 2016, INT J INFECT DIS, V50, P54, DOI 10.1016/j.ijid.2016.08.003; Darcis G, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2571-x; FERRER L, 1995, VET REC, V136, P514, DOI 10.1136/vr.136.20.514; Ferro S, 2013, VET PATHOL, V50, P749, DOI 10.1177/0300985813480192; Font A, 1996, J AM ANIM HOSP ASSOC, V32, P131, DOI 10.5326/15473317-32-2-131; Gazozai Sanaullah, 2010, Pak J Pharm Sci, V23, P363; Koutinas AF, 2014, VET PATHOL, V51, P527, DOI 10.1177/0300985814521248; Koutinas AF, 1999, J AM ANIM HOSP ASSOC, V35, P376, DOI 10.5326/15473317-35-5-376; Lamothe J, 2002, VET REC, V151, P182, DOI 10.1136/vr.151.6.182; Maia C, 2009, VET J, V179, P142, DOI 10.1016/j.tvjl.2007.08.009; Manzillo VF, 2005, VET REC, V156, P213, DOI 10.1136/vr.156.7.213; Marino G, 2012, J SMALL ANIM PRACT, V53, P323, DOI 10.1111/j.1748-5827.2012.01201.x; Mignogna MD, 2015, ORAL DIS, V21, pE70, DOI 10.1111/odi.12268; Esteve LO, 2015, VET PARASITOL, V209, P157, DOI 10.1016/j.vetpar.2015.03.004; Oryan A, 2013, PARASITOL RES, V112, P1799, DOI 10.1007/s00436-012-3240-z; Palatnik-de-Sousa CB, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-197; Paltrinieri S, 2016, VET CLIN PATHOL, V45, P1; Parpaglia MLP, 2007, J VET MED A, V54, P414, DOI 10.1111/j.1439-0442.2007.00994.x; Salam MA, 2013, J HEALTH POPUL NUTR, V31, P294; Shirian S, 2013, PATHOG GLOB HEALTH, V107, P267, DOI 10.1179/2047773213Y.0000000098; Solano-Gallego L, 2009, VET PARASITOL, V165, P1, DOI 10.1016/j.vetpar.2009.05.022; Solano-Gallego L, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1519-0; Tangalidi MK, 2016, VET CLIN PATH, V45, P710, DOI 10.1111/vcp.12416; Taranto N. J., 2000, Revista Argentina de Microbiologia, V32, P129; Torres M, 2011, VET J, V188, P346, DOI 10.1016/j.tvjl.2010.05.025; Viegas C, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-120	34	2	2	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JAN	2018	158	1					6	11		10.1016/j.jcpa.2017.10.174			6	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FX6VV	WOS:000426226300002	29422317				2019-10-28	
J	Teh, APP; Izzati, UZ; Diep, NV; Hirai, T; Yamaguchi, R				Teh, A. P. P.; Izzati, U. Z.; Diep, N. V.; Hirai, T.; Yamaguchi, R.			Merkel Cell Carcinoma in a Steer	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						adrenocorticotropic hormone; Merkel cell carcinoma; nestin; steer	NEUROENDOCRINE CARCINOMA; TUMORS; SKIN; DOG; DIAGNOSIS; LINEAGE; CAT	Merkel cell carcinoma is a rare and aggressive cutaneous neuroendocrine tumour reported only in man, dogs and cats. A 20-month-old Japanese black fattening steer was presented with necrotic protruding skin masses over the left thoracic area and a 20 x 25 cm subcutaneous mass in the left abdominal area. Microscopical evaluation of the masses revealed cords of small to medium-sized round tumour cells with marked anisocytosis and anisokaryosis and clear and vacuolated cytoplasm, which were separated by a delicate fibrovascular stroma and arranged in a trabecular and nested pattern. Necropsy examination revealed multiple solid white nodular masses in the lungs. Immunohistochemistry (IHC) for cytokeratin (CK) 20 and CKAE1/3 revealed focal perinuclear labelling of tumour cells. IHC for the neuroendocrine markers chromogranin A and neuron specific enolase, the neuroepithelial stem cell marker nestin and the hormonal markers adrenocorticotropic hormone and calcitonin revealed diffuse cytoplasmic labelling of all tumour cells. Ultrastructurally, the tumour cells contained few neurosecretory granules and abundant glycogen pools. The tumours were diagnosed as Merkel cell carcinoma with pulmonary metastases and this case represents the first such diagnosis in cattle. (C) 2017 Elsevier Ltd. All rights reserved.	[Teh, A. P. P.; Izzati, U. Z.; Diep, N. V.; Hirai, T.; Yamaguchi, R.] Univ Miyazaki, Fac Agr, Dept Vet Pathol, Gakuen Kibanadai Nishi 1-1, Miyazaki, Japan	Yamaguchi, R (reprint author), Univ Miyazaki, Fac Agr, Dept Vet Pathol, Gakuen Kibanadai Nishi 1-1, Miyazaki, Japan.	a0d402u@cc.miyazaki-u.ac.jp		Diep, Nguyen Van/0000-0002-8833-1693; Uda Zahli, Izzati/0000-0001-6635-7561			Anzai S, 2000, J Dermatol, V27, P397; Bagnasco G, 2003, VET DERMATOL, V14, P111, DOI 10.1046/j.1365-3164.2003.00321.x; Cheng JW, 2013, J VIROL, V87, P6118, DOI 10.1128/JVI.00385-13; Dohata A, 2015, VET PATHOL, V52, P1012, DOI 10.1177/0300985815570484; GLICK AD, 1983, VET PATHOL, V20, P761, DOI 10.1177/030098588302000610; Godlewski J, 2013, FOLIA HISTOCHEM CYTO, V51, P168, DOI 10.5603/FHC.2013.0015; Hargis AM, 2017, PATHOLOGIC BASIS VET, P1009; IWASAKI H, 1981, CANCER, V48, P753, DOI 10.1002/1097-0142(19810801)48:3<753::AID-CNCR2820480315>3.0.CO;2-9; Jaeger T, 2012, J SKIN CANCER, DOI 10.1155/2012/983421; Joiner KS, 2010, VET PATHOL, V47, P1090, DOI 10.1177/0300985810375945; Konno A, 1998, VET PATHOL, V35, P538, DOI 10.1177/030098589803500609; Lighezan R, 2009, ROM J MORPHOL EMBRYO, V50, P613; MAULDIN EA, 2016, JUBB KENNEDY PALMERS, V1, P509; Morrison KM, 2009, DEV BIOL, V336, P76, DOI 10.1016/j.ydbio.2009.09.032; Motoyama T, 1988, J JAPANESE SOC CLIN, V27, P593; Ozaki K, 2009, J VET MED SCI, V71, P1093, DOI 10.1292/jvms.71.1093; Patnaik AK, 2001, VET PATHOL, V38, P553, DOI 10.1354/vp.38-5-553; PILOTTI S, 1982, AM J SURG PATHOL, V6, P243, DOI 10.1097/00000478-198204000-00006; Szeder V, 2003, DEV DYNAM, V228, P623, DOI 10.1002/dvdy.10403; Ulbright TM, 2005, MODERN PATHOL, V18, pS61, DOI 10.1038/modpathol.3800310; Voog E, 1999, CANCER, V85, P2589, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2589::AID-CNCR15>3.0.CO;2-F; WHITELEY LO, 1987, VET PATHOL, V24, P570, DOI 10.1177/030098588702400618; Woo SH, 2010, DEVELOPMENT, V137, P3965, DOI 10.1242/dev.055970	23	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JAN	2018	158	1					17	21		10.1016/j.jcpa.2017.10.177			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FX6VV	WOS:000426226300004	29422311				2019-10-28	
J	Diaz, PU; Rey, F; Gareis, NC; Notaro, US; Matiller, V; Belotti, EM; Stassi, AF; Salvetti, NR; Ortega, HH				Diaz, P. U.; Rey, F.; Gareis, N. C.; Notaro, U. S.; Matiller, V.; Belotti, E. M.; Stassi, A. F.; Salvetti, N. R.; Ortega, H. H.			Altered Expression of Anti-Mullerian Hormone during the Early Stage of Bovine Persistent Ovarian Follicles	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						anti-Mullerian hormone; cow; cystic ovarian disease; follicular persistence	THECA CELL TUMORS; DAIRY-COWS; FOLLICULAR CYSTS; INHIBITING SUBSTANCE; BETA SUPERFAMILY; MOUSE OVARY; GROWTH; PROGESTERONE; FOLLICULOGENESIS; RECEPTORS	Anti-Mullerian hormone (AMH) is a homodimeric glycoprotein expressed exclusively in the gonads. This hormone is an important regulator of the early growth of follicles through inhibitory effects on the recruitment of primordial follicles into the pool of growing follicles and on granulosa cell proliferation. Cystic ovarian disease (COD) is an important disorder affecting the fertility of dairy cattle. In the present study, we evaluated the expression of AMH in granulosa cells and AMH secretion into follicular fluid in pre-ovulatory follicles from control cows, animals with spontaneously arising COD and during the development of the disease, at 5, 10 and 15 days of follicular persistence. To this end, after an oestrous synchronization protocol, low doses of progesterone was administered for 5, 10 and 15 days after the expected day of ovulation (day 0 of follicular persistence) in treated cows (groups P5, P10 and P15, respectively), using an intravaginal progesterone-releasing device. Results showed a decrease in the expression of AMH in granulosa cells throughout folliculogenesis (P < 0.05) and in the spontaneously arising follicular cysts and persistent follicles related to the control group (P < 0.05). There was also a higher concentration of AMH in the follicular fluid of persistent follicles at 10 and 15 days of follicular persistence (P < 0.05). Together, these results may indicate an alteration in AMH expression and secretion, which occurs early in folliculogenesis and incipiently during the development of COD, and which could contribute to the recurrence of this disease in cattle. (C) 2017 Elsevier Ltd. All rights reserved.	[Diaz, P. U.; Rey, F.; Gareis, N. C.; Notaro, U. S.; Matiller, V.; Belotti, E. M.; Stassi, A. F.; Salvetti, N. R.; Ortega, H. H.] Univ Nacl Litoral, Consejo Nacl Invest Cient & Tecn, Inst Ciencias Vet Litoral, Lab Biol Celular & Mol Aplicada, RP Kreder 2805, Esperanza, Santa Fe, Argentina	Diaz, PU (reprint author), Univ Nacl Litoral, Consejo Nacl Invest Cient & Tecn, Inst Ciencias Vet Litoral, Lab Biol Celular & Mol Aplicada, RP Kreder 2805, Esperanza, Santa Fe, Argentina.	pablourield@hotmail.com			Argentine National Agency for the Promotion of Science and Technology (ANPCyT)ANPCyT [PICT 2010-2315, 2011-1274, 2013-2279]	This study was supported by a grant from the Argentine National Agency for the Promotion of Science and Technology (ANPCyT) (PICT 2010-2315, 2011-1274 and 2013-2279). We are grateful to the staff of the Hospital de Salud Animal of the Facultad de Ciencias Veterinarias de la Universidad Nacional del Litoral for animal care and help with the generation of experimental animals and collection of samples, We also acknowledge the staff members of the Laboratorio de Biologia Celular y Molecular Aplicada (ICiVet-Litoral, UNL-CONICET) for technical support in processing of slides. We thank J. Bertoli and F. Barberis for assistance with the animal care and Biogenesis-Bago and Zoovet Laboratories for providing the drugs used in the protocols. The first two authors contributed equally to this work.	Ali HE, 2013, THERIOGENOLOGY, V80, P940, DOI 10.1016/j.theriogenology.2013.07.022; Amweg AN, 2013, DOMEST ANIM ENDOCRIN, V45, P126, DOI 10.1016/j.domaniend.2013.07.001; Ashley RL, 2006, ENDOCRINOLOGY, V147, P4151, DOI 10.1210/en.2006-0002; Bartolome JA, 2005, JAVMA-J AM VET MED A, V227, P1409, DOI 10.2460/javma.2005.227.1409; Bello NM, 2006, J DAIRY SCI, V89, P3413, DOI 10.3168/jds.S0022-0302(06)72378-5; BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376; Braw-Tal R, 2009, THERIOGENOLOGY, V72, P690, DOI 10.1016/j.theriogenology.2009.04.027; BrawTal R, 1997, J REPROD FERTIL, V109, P165; de Vet A, 2002, FERTIL STERIL, V77, P357, DOI 10.1016/S0015-0282(01)02993-4; Diaz PU, 2016, REPRODUCTION, V152, P333, DOI 10.1530/REP-15-0315; Diaz PU, 2015, THERIOGENOLOGY, V84, P1149, DOI 10.1016/j.theriogenology.2015.06.015; DICLEMENTE N, 1994, ENDOCRINE, V2, P553; Durlinger ALL, 2002, ENDOCRINOLOGY, V143, P1076, DOI 10.1210/en.143.3.1076; Durlinger ALL, 1999, ENDOCRINOLOGY, V140, P5789, DOI 10.1210/en.140.12.5789; Durlinger ALL, 2002, REPRODUCTION, V124, P601, DOI 10.1530/rep.0.1240601; Durlinger ALL, 2001, ENDOCRINOLOGY, V142, P4891, DOI 10.1210/en.142.11.4891; Field SL, 2014, MOL REPROD DEV, V81, P284, DOI 10.1002/mrd.22285; Gruijters MJG, 2003, MOL CELL ENDOCRINOL, V211, P85, DOI 10.1016/j.mce.2003.09.024; Gumienny TL, 2002, TRENDS ENDOCRIN MET, V13, P295, DOI 10.1016/S1043-2760(02)00615-X; Josso N, 2001, MOL CELL ENDOCRINOL, V179, P25, DOI 10.1016/S0303-7207(01)00467-1; KIM JH, 1992, J CLIN ENDOCR METAB, V75, P911, DOI 10.1210/jc.75.3.911; Kitahara G, 2012, J REPROD DEVELOP, V58, P98, DOI 10.1262/jrd.11-101T; Knight PG, 2006, REPRODUCTION, V132, P191, DOI 10.1530/rep.1.01074; La Marca A, 2006, CLIN ENDOCRINOL, V64, P603, DOI 10.1111/j.1365-2265.2006.02533.x; Manuck TA, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.03.048; Marelli BE, 2014, REPROD BIOL, V14, P276, DOI 10.1016/j.repbio.2014.08.002; Matiller V, 2014, REPROD DOMEST ANIM, V49, P813, DOI 10.1111/rda.12373; Monniaux D, 2008, BIOL REPROD, V79, P387, DOI 10.1095/biolreprod.107.065847; Ortega HH, 2016, CURR PHARM DESIGN, V22, P5634, DOI 10.2174/1381612822666160804100941; Ortega HH, 2015, REPRODUCTION, V149, pR251, DOI 10.1530/REP-14-0618; Ortega HH, 2009, REPRODUCTION, V137, P865, DOI 10.1530/REP-08-0491; Polat IM, 2015, THERIOGENOLOGY, V84, P1043, DOI 10.1016/j.theriogenology.2015.06.003; PURSLEY JR, 1995, THERIOGENOLOGY, V44, P915, DOI 10.1016/0093-691X(95)00279-H; Rico C, 2009, BIOL REPROD, V80, P50, DOI 10.1095/biolreprod.108.072157; Rico C, 2011, BIOL REPROD, V84, P560, DOI 10.1095/biolreprod.110.088187; SEIFER DB, 1993, J CLIN ENDOCR METAB, V76, P711, DOI 10.1210/jc.76.3.711; Silvia WJ, 2002, DOMEST ANIM ENDOCRIN, V23, P167, DOI 10.1016/S0739-7240(02)00154-6; UENO S, 1989, ENDOCRINOLOGY, V125, P1060, DOI 10.1210/endo-125-2-1060; Visser JA, 2005, MOL CELL ENDOCRINOL, V234, P81, DOI 10.1016/j.mce.2004.09.008	39	1	1	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JAN	2018	158	1					22	31		10.1016/j.jcpa.2017.10.175			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FX6VV	WOS:000426226300005	29422312				2019-10-28	
J	Coleto, AF; Wilson, TM; Soares, NP; Gundim, LE; Castro, IP; Guimaraes, EC; Bandarra, MB; Medeiros-Ronchi, AA				Coleto, A. F.; Wilson, T. M.; Soares, N. P.; Gundim, L. E.; Castro, I. P.; Guimaraes, E. C.; Bandarra, M. B.; Medeiros-Ronchi, A. A.			Prognostic Value of Occult Isolated Tumour Cells within Regional Lymph Nodes of Dogs with Malignant Mammary Tumours	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						dog; immunohistochemistry; mammary tumour; metastasis	BREAST-CANCER; GLAND TUMORS; CONSENSUS; MICROMETASTASES	Canine mammary tumours (CMTs) are the most common type of neoplasm in bitches. As in women, the presence of metastasis in regional lymph nodes is an important prognostic factor in bitches with mammary carcinomas, but the clinical significance of occult isolated tumour cells (ITCs) within lymph nodes is still undefined in this species. The effectiveness of immunohistochemistry (IHC) in identifying occult ITCs and micrometastasis (MIC) was compared with that of the conventional haematoxylin and eosin staining technique. The relationship between tumour size, histological type, histological grade and the presence of metastasis was evaluated. The overall survival (OS) of female dogs with occult mammary carcinomas and ITCs within lymph nodes was analysed. Fragments of mammary carcinoma and regional lymph nodes of 59 female dogs were also evaluated. Histological sections of mammary carcinoma and lymph node samples were studied for tumour diagnosis and lymph node samples were tested by IHC using a pan-cytokeratin antibody. It was found that 35.2% of occult ITCs and 2.8% of hidden MIC were detected when IHC was used. There was a good correlation between the size of the tumour and metastasis to the lymph nodes (P = 0.77). ITCs were observed more frequently in the medullary region (60.7%) and metastases in the cortical region (44.4%). There was no significant difference in the OS between female dogs with occult ITCs and lymph nodes without ITCs. IHC can detect occult tumour cells in lymph nodes that are negative by histopathological examination. Female dogs with nodal ITCs do not have lower survival. (C) 2017 Elsevier Ltd. All rights reserved.	[Coleto, A. F.; Wilson, T. M.; Soares, N. P.; Gundim, L. E.; Castro, I. P.; Bandarra, M. B.; Medeiros-Ronchi, A. A.] Univ Fed Uberlandia, Fac Vet Med, Lab Vet Pathol, Uberlandia, MG, Brazil; [Guimaraes, E. C.] Univ Fed Uberlandia, Fac Math, Uberlandia, MG, Brazil	Coleto, AF (reprint author), Univ Fed Uberlandia, Fac Vet Med, Lab Vet Pathol, Uberlandia, MG, Brazil.	arlindacoleto@hotmail.com	Coleto, Arlinda/R-2544-2019	Wilson, Tais/0000-0002-0404-9499	Coordination for the Improvement of Higher Education Personnel (CAPES)CAPES [APQ-01816-14]	The authors appreciate the technical support provided by the Veterinary Hospital of the Federal University of Uberlandia in providing access to the cases. We acknowledge the assistance of Prof E. Ferreira with statistical analysis. The work was supported partially by a PhD scholarship financed by the Coordination for the Improvement of Higher Education Personnel (CAPES, APQ-01816-14).	Ahmed SS, 2014, J CLIN PATHOL, V67, DOI 10.1136/jclinpath-2013-201771; Beserra HEO, 2016, ADV BREAST CANC RES, V5, P58, DOI DOI 10.4236/ABCR.2016.52006; Callegari-Jacques S. M., 2003, BIOESTATISTICA PRINC, P255; Carvalho MI, 2016, VET PATHOL, V53, P1138, DOI 10.1177/0300985816646429; Casey KM, 2017, VET COMP ONCOL, V15, P785, DOI 10.1111/vco.12219; Chang SC, 2005, JAVMA-J AM VET MED A, V227, P1625, DOI 10.2460/javma.2005.227.1625; Coelho VS, 2014, THESIS; Cummings MC, 2002, AM J SURG PATHOL, V26, P1286, DOI 10.1097/01.PAS.0000027303.89469.E2; de Araujo MR, 2015, J VET INTERN MED, V29, P1360, DOI 10.1111/jvim.13576; Edge SB, 2010, AJCC CANC STAGING MA; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966; Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322; Goldschmidt M. H., 2017, Tumors in domestic animals, P723; Gundim LF, 2016, CAN J VET RES, V80, P318; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; MacPhail CM, 2015, CIRURGIA PEQUENOS AN, P809; Matos AJF, 2006, VET REC, V158, P626, DOI 10.1136/vr.158.18.626; Misdorp W., 1999, WHO INT HISTOLOGICAL, P18; OKEEFE D. A., 1997, TRATADO MED INTERNA, P2344; Oliveira JC, 2010, PESQUISA VET BRASIL, V30, P177, DOI 10.1590/S0100-736X2010000200014; Owen LN, 1980, TNM CLASSIFICATION T, P10; Pena L, 2014, VET PATHOL, V51, P127, DOI 10.1177/0300985813509388; Queiroga F., 2002, P C CIENC VET OEIR, P183; Ramos-Vara J. A., 2017, Tumors in domestic animals, P44; Rasotto R, 2012, VET PATHOL, V49, P330, DOI 10.1177/0300985811409253; Reed Wenche, 2004, Breast J, V10, P174, DOI 10.1111/j.1075-122X.2004.21328.x; Sorenmo KU, 2011, VET PATHOL, V48, P85, DOI 10.1177/0300985810389480; Sorenmo KU, 2009, VET COMP ONCOL, V7, P162, DOI 10.1111/j.1476-5829.2009.00184.x; SORENMO K. U, 2013, WITHROW MACEWENS SMA, P553; Stromberg P. C., 2017, Tumors in domestic animals, P27; Szczubial M, 2011, VET COMP ONCOL, V9, P296, DOI 10.1111/j.1476-5829.2011.00268.x; van Deurzen CHM, 2008, ANN SURG ONCOL, V15, P1309, DOI 10.1245/s10434-007-9803-z	33	0	0	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JAN	2018	158	1					32	38		10.1016/j.jcpa.2017.11.001			7	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FX6VV	WOS:000426226300006	29422313				2019-10-28	
J	Evenhuis, JV; Zisman, I; Kass, PH; Verstraete, FJM				Evenhuis, J. V.; Zisman, I.; Kass, P. H.; Verstraete, F. J. M.			Dental Pathology of the Grey Fox (Urocyon cinereoargenteus)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						dental pathology; grey fox (Urocyon cinereoargenteus); temporomandibular joint pathology	TEMPOROMANDIBULAR-JOINT PATHOLOGY; GRAY FOXES; VULPES-VULPES; RED FOXES; LYNX-RUFUS; CALIFORNIA; COYOTES; POPULATION; MORTALITY; ANOMALIES	Museum specimens from 637 grey foxes (Urocyon cinereoargenteus) were examined macroscopically according to predefined criteria. Of the 637 specimens, 569 were included for further examination. The study population included more males (n = 261, 45.9%) than females (n = 196, 34.4%) and animals of unknown sex (n = 112, 19.7%). Additionally, 481 (84.5%) adults, 67 (11.8%) young adults and 21 (3.7%) individuals of unknown age comprised the study population, with juveniles and neonates excluded. The number of teeth present for examination was 23,066 (96.5%) with 624 (2.6%) absent artefactually, 15 (0.06%) absent congenitally and 193 (0.8%) lost ante mortem through acquired tooth loss. No persistent deciduous teeth or temporomandibular joint osteoarthritis were found in any of the specimens. Ten supernumerary teeth from nine (1.6%) specimens were encountered. Teeth with extra roots were found in 61 individuals (10.7%), with 0.4% of all teeth affected. Of the alveoli examined, 1,529 (6.4%) displayed bony changes suggestive of periodontitis, with 276 (48.7%) of individuals affected. Significantly more adults were affected by bony changes associated with stage 3 periodontitis than young adults. All specimens displaying stage 4 periodontitis were adults. Fractures affected 446 (78.4%) of the specimens examined and 3,554 (15.4%) of teeth present. Almost half (n = 10,856, 47.1%) of the teeth available for examination and most specimens (n = 487, 85.6%) displayed some degree of attrition or abrasion. Two individuals (0.4%) exhibited periapical lesions. Traumatic skull injuries affected 56 (9.8%) specimens. Characterizing the dental pathology in the grey fox provides key insight into the ecology of the species and factors contributing to fitness. (C) 2017 Elsevier Ltd. All rights reserved.	[Evenhuis, J. V.; Zisman, I.; Verstraete, F. J. M.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA; [Kass, P. H.] Univ Calif Davis, Sch Vet Med, Dept Populat Hlth & Reprod, Davis, CA 95616 USA	Verstraete, FJM (reprint author), Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA.	fjverstraete@ucdavis.edu	Verstraete, Frank/I-3120-2019	Verstraete, Frank/0000-0002-7677-3654; Evenhuis, Janny/0000-0003-2953-376X	Academic Senate Research Grant; Merial (Boehringer-Ingleheim) Veterinary Scholars Programme	The authors thank M. Flannery and R. Bandar of the Department of Ornithology and Mammalogy, California Academy of Sciences, San Francisco, and C. Conroy of the Museum of Vertebrate Zoology, University of California, Berkeley, for making their U. cinereoargenteus collections available for this study. This research was funded by an Academic Senate Research Grant to F. J. M. Verstraete, University of California, and by the Merial (Boehringer-Ingleheim) Veterinary Scholars Programme, which had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the manuscript or in the decision to submit the manuscript for publication.	Abbott C, 2005, J COMP PATHOL, V132, P169, DOI 10.1016/j.jcpa.2004.09.007; Aghashani A, 2017, J COMP PATHOL, V156, P251, DOI 10.1016/j.jcpa.2016.11.269; Aghashani A, 2016, J COMP PATHOL, V154, P329, DOI 10.1016/j.jcpa.2016.03.001; Aguirre AA, 2009, PARASITE VECTOR, V2, DOI 10.1186/1756-3305-2-S1-S7; Beineke A, 2015, ONE HEALTH, V1, P49, DOI 10.1016/j.onehlt.2015.09.002; BOUWMEESTER J, 1989, J ZOOL, V219, P123, DOI 10.1111/j.1469-7998.1989.tb02571.x; Bozarth CA, 2011, J MAMMAL, V92, P283, DOI 10.1644/10-MAMM-A-141.1; Chamberlain MJ, 2005, AM MIDL NAT, V153, P171, DOI 10.1674/0003-0031(2005)153[0171:OISUAB]2.0.CO;2; Clark EJ, 2017, J COMP PATHOL, V156, P240, DOI 10.1016/j.jcpa.2016.11.267; Collins Paul W., 1993, P351; Cypher Brian L., 1993, Transactions of the Illinois State Academy of Science, V86, P139; DAVIDSON WR, 1992, J WILDLIFE DIS, V28, P581, DOI 10.7589/0090-3558-28.4.581; EASTERLA D A, 1968, Southwestern Naturalist, V13, P362, DOI 10.2307/3669234; ENGLUND J, 1982, J WILDLIFE MANAGE, V46, P1113, DOI 10.2307/3808254; Farias V, 2005, J ZOOL, V266, P249, DOI 10.1017/S0952836905006850; FRITZELL E K, 1982, Mammalian Species, P1, DOI 10.2307/3503957; Gisburne TJ, 2005, ACTA THERIOL, V50, P515, DOI 10.1007/BF03192644; Gomez-Ortiz Y, 2015, ZOOL STUD, V54, DOI 10.1186/s40555-014-0102-7; Hall ER, 1940, J DENT RES, V19, P103, DOI DOI 10.1177/00220345400190020101; Hamp SE, 1997, J PERIODONTAL RES, V32, P589, DOI 10.1111/j.1600-0765.1997.tb00936.x; HARRISON RL, 1993, SOUTHWEST NAT, V38, P352, DOI 10.2307/3671614; Harrison RL, 1997, J WILDLIFE MANAGE, V61, P112, DOI 10.2307/3802420; HOCKMAN JG, 1983, AM MIDL NAT, V110, P276, DOI 10.2307/2425269; Kelly TR, 2003, J WILDLIFE DIS, V39, P467, DOI 10.7589/0090-3558-39.2.467; Nentvichova M, 2008, ACTA THERIOL, V53, P217, DOI 10.1007/BF03193118; ONDERKA DK, 1990, WILDLIFE SOC B, V18, P175; PAVLINOV I Y, 1975, Acta Theriologica, V20, P507; Pavlovc Dubravka, 2007, Veterinarski Arhiv, V77, P291; Riley SPD, 2004, J WILDLIFE DIS, V40, P11, DOI 10.7589/0090-3558-40.1.11; Roemer G, 2016, IUCN RED LIST THREAT; Shafer WG, 1983, TXB ORAL PATHOLOGY, P318; Szuma E, 2002, J ZOOL, V256, P243, DOI 10.1017/S0952836902000286; Verstraete FJM, 1996, J COMP PATHOL, V115, P265, DOI 10.1016/S0021-9975(96)80084-3; Verstraete FM, 2003, SEMIN AVIAN EXOT PET, V12, P37, DOI 10.1053/saep.2003.127877; Wilson DE, 2005, MAMMAL SPECIES WORLD, P582; Wood J. E., 1958, Journal of Mammalogy, V39, P74, DOI 10.2307/1376612	36	2	2	4	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JAN	2018	158	1					39	50		10.1016/j.jcpa.2017.11.002			12	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FX6VV	WOS:000426226300007	29422314				2019-10-28	
J	Mander, KA; Finnie, JW				Mander, K. A.; Finnie, J. W.			Loss of Endothelial Barrier Antigen Immunoreactivity in Rat Retinal Microvessels is Correlated with Clostridium perfringens Type D Epsilon Toxin-induced Damage to the Blood-Retinal Barrier	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						Clostridium perfringens type D epsilon toxin; endothelial barrier antigen; microvascular injury; rat retina	BRAIN-BARRIER; MICROVASCULAR DAMAGE; EXPRESSION; NEUROPATHOLOGY; HETEROGENEITY; EBA	Clostridium perfringens type D epsilon toxin (ETX) is a potent neurotoxin producing a severe, and often fatal, neurological disorder in ruminant livestock. Microvascular damage appears to be the fundamental action of ETX in the brain and, recently, similar vascular injury, with subsequent severe vasogenic oedema, has been reported in the retina of rats given ETX. Endothelial barrier antigen (EBA) is a useful marker of an intact blood brain barrier in rats and it has been shown that loss of EBA immunoreactivity is correlated with ETX-induced cerebral microvascular damage in this species. This paper reports, for the first time, that loss of EBA immunoexpression also occurs in rat retinal microvessels exposed to ETX, the marked reduction in EBA immunopositivity acting as a useful marker for blood-retinal barrier breakdown produced by this neurotoxin. (C) 2017 Elsevier Ltd. All rights reserved.	[Mander, K. A.; Finnie, J. W.] Univ Adelaide, Adelaide Med Sch, Discipline Anat & Pathol, Frome Rd, Adelaide, SA, Australia; [Finnie, J. W.] SA Pathol, Hanson Inst, Ctr Neurol Dis, Frome Rd, Adelaide, SA, Australia	Mander, KA (reprint author), Univ Adelaide, Adelaide Med Sch, Discipline Anat & Pathol, Frome Rd, Adelaide, SA, Australia.	Kimberley.mander@adelaide.edu.au					Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Bolon B, 2008, TOXICOL PATHOL, V36, P871, DOI 10.1177/0192623308322313; Campbell M, 2013, ADV EXP MED BIOL, V763, P70; Dartt DA, 2011, IMMUNOLOGY INFLAMMAT, P229; Finnie JW, 2014, J COMP PATHOL, V151, P153, DOI 10.1016/j.jcpa.2014.04.010; Finnie JW, 2014, J VET DIAGN INVEST, V26, P470, DOI 10.1177/1040638714530127; Finnie JW, 2004, ANAEROBE, V10, P145, DOI 10.1016/j.anaerobe.2003.08.003; Garcia JP, 2015, VET PATHOL, V52, P465, DOI 10.1177/0300985814540543; Ghabriel MN, 2002, BRAIN RES, V934, P140, DOI 10.1016/S0006-8993(02)02416-2; Jin XL, 2014, BRAIN RES, V1558, P84, DOI 10.1016/j.brainres.2014.02.032; Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003; LAWRENSON JG, 1995, BRIT J OPHTHALMOL, V79, P462, DOI 10.1136/bjo.79.5.462; Macdonald JA, 2010, J NEUROSCI RES, V88, P1457, DOI 10.1002/jnr.22316; Mander KA, 2016, 5 COLD SPRING HARB B; Pelz J, 2013, EUR J HISTOCHEM, V57, P255, DOI 10.4081/ejh.2013.e38; Runkle EA, 2011, METHODS MOL BIOL, V686, P133, DOI 10.1007/978-1-60761-938-3_5; Saubamea B, 2012, J CEREBR BLOOD F MET, V32, P81, DOI 10.1038/jcbfm.2011.109; STERNBERGER NH, 1987, P NATL ACAD SCI USA, V84, P8169, DOI 10.1073/pnas.84.22.8169; Tamai E, 2003, INFECT IMMUN, V71, P5371, DOI 10.1128/IAI.71.9.5371-5375.2003; Uzal FA, 2016, CLOSTRIDIAL DIS ANIM, V2016, P157, DOI DOI 10.1002/9781118728291.CH13; Wilhelm I, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1143544; Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6; Zhu C, 2001, EXP NEUROL, V169, P72, DOI 10.1006/exnr.2001.7652	23	1	1	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JAN	2018	158	1					51	55		10.1016/j.jcpa.2017.11.003			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FX6VV	WOS:000426226300008	29422315				2019-10-28	
J	Ordeix, L; Silva, JED; Llull, J; Quirola, P; Montserrat-Sangra, S; Martinez-Orellana, P; Solano-Gallego, L				Ordeix, L.; Silva, J. E. dos S.; Llull, J.; Quirola, P.; Montserrat-Sangra, S.; Martinez-Orellana, P.; Solano-Gallego, L.			Histological and Immunological Description of the Leishmanin Skin Test in Ibizan Hounds	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						dog; Leishmania infantum; leishmanin skin test; Toll-like receptor 2	CANINE LEISHMANIASIS; CELLULAR-IMMUNITY; DOGS; INFANTUM; INFECTION; BLOOD; RESPONSES; INSIGHTS; ANTIGEN	The leishmanin skin test (LST), a delayed-type hypersensitivity (DTH) reaction to Leishmania infantum, can specifically identify dogs that have made a cell-mediated immune response to L. infantum infection. The Ibizan hound appears to be more resistant to L. it infection than other breeds of dog. The aim of this study was to describe the histological and immunohistochemical changes induced by the LST in Ibizan hounds living in an area highly endemic for leishmaniosis. The majority of dogs were apparently healthy, lacked serum antibody to L. infantum. and blood parasitaemia, but had marked specific interferon gamma production after in-vitro blood stimulation with L. infantum. Leishmanin (3 x 10(8) killed promastigotes of L. infantum/ml) was injected intradermally and biopsy samples were obtained from a positive reaction at 72 h from nine Ibizan hounds. A moderate to intense, perivascular to interstitial dermatitis and panniculitis characterized the inflammatory response at the injection site. In addition, three samples had diffuse inflammation in the deep dermis and panniculus. Oedema and necrosis were present in the deep dermis and panniculus. Congestion and haemorrhage were observed in five biopsies. T lymphocytes (CD3(+)) and large mononuclear cells (lysozyme(-)) were the most prevalent cells. CD3(+) cells were significantly more numerous than CD20(+) B cells and lysozyme(+) cells. B cells were sparsely distributed, especially in the deep dermis and panniculus. Rare neutrophils and macrophages (lysozyme+) were observed with few eosinophils. Toll-like receptor (TLR)-2 protein was expressed in large mononuclear cells mainly located in the superficial dermis. Leishmania immunohistochemistry was negative and quantitative polymerase chain reaction was positive in all cases. The intradermal injection of killed L. infantum promastigotes in Ibizan hounds causes similar histological and immunohistochemical findings to those described for human subjects and are indicative of a DTH response. Moreover, TLR2 protein is expressed in inflammatory cells similar to findings in clinically affected skin biopsy samples. (C) 2017 Elsevier Ltd. All rights reserved.	[Ordeix, L.; Silva, J. E. dos S.; Quirola, P.; Montserrat-Sangra, S.; Martinez-Orellana, P.; Solano-Gallego, L.] Univ Autonoma Barcelona, Fac Med, Dept Med & Cirurgia Anim, Bellaterra, Spain; [Ordeix, L.] Univ Autonoma Barcelona, Fac Med, Fdn Hosp Clin Vet, Bellaterra, Spain; [Ordeix, L.; Solano-Gallego, L.] Hosp MonVet, Manacor, Mallorca, Spain	Ordeix, L; Solano-Gallego, L (reprint author), Univ Autonoma Barcelona, Fac Med, Dept Med & Cirurgia Anim, Bellaterra, Spain.; Ordeix, L (reprint author), Univ Autonoma Barcelona, Fac Med, Fdn Hosp Clin Vet, Bellaterra, Spain.; Ordeix, L; Solano-Gallego, L (reprint author), Hosp MonVet, Manacor, Mallorca, Spain.	laura.ordeix@uab.cat; laia.solano@uab.cat			Ministerio de Economia y CompetitividadSpanish Ministry of Economy & Competitiveness [AGL2012-32498]; European Society of Veterinary Dermatology; Spanish ministry grant	The authors are grateful to A. S. Tur for technical help and image capture. We thank B. Perez and A. Neira for technical assistance with TLR2 IHC and L. Serrano and L. Altet for technical help with molecular analysis. The current affiliation of J. E. dos Santos Silva and P. Quirola is Faculdade de Medicina Veterinaria de Aracatuba, Universidade Estadual Paulista, Brazil and Institute Nacional de Investigacion en Salud Pnblica del Ecuador, Ecuador, respectively. This study was supported by a Spanish ministry grant, Ministerio de Economia y Competitividad (AGL2012-32498) and the European Society of Veterinary Dermatology (Research Major Grant 2012).	Abbas AK, 2015, CELLULAR MOL IMMUNOL, P399; Aslan H, 2016, J INFECT DIS, V213, P1752, DOI 10.1093/infdis/jiw022; Baneth G, 2008, TRENDS PARASITOL, V24, P324, DOI 10.1016/j.pt.2008.04.001; Bourdoiseau G, 2009, VET IMMUNOL IMMUNOP, V128, P71, DOI 10.1016/j.vetimm.2008.10.309; Cardoso L, 1998, VET PARASITOL, V79, P213, DOI 10.1016/S0304-4017(98)00169-1; Fernandez-Bellon H, 2005, VET IMMUNOL IMMUNOP, V107, P163, DOI 10.1016/j.vetimm.2005.04.002; Ferrer L, 2003, ADV VET DERMATOLOGY, P92; GENARO O, 1992, MEM I OSWALDO CRUZ, V87, P163, DOI 10.1590/S0074-02761992000100025; Guarín Nora, 2006, Biomédica, V26, P38; Hosein S, 2017, PARASITOLOGY, V144, P95, DOI 10.1017/S003118201600055X; Hosein S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140325; Kumar H, 2009, BIOCHEM BIOPH RES CO, V388, P621, DOI 10.1016/j.bbrc.2009.08.062; Lombardo G, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-120; Martinez-Orellana P, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2062-3; MAYRINK W, 1989, REV INST MED TROP SP, V31, P256, DOI 10.1590/S0036-46651989000400008; Montserrat-Sangra S, 2016, VET PARASITOL, V228, P172, DOI 10.1016/j.vetpar.2016.09.005; Esteve LO, 2015, VET PARASITOL, V209, P157, DOI 10.1016/j.vetpar.2015.03.004; Ordeix L, 2005, VET DERMATOL, V16, P187, DOI 10.1111/j.1365-3164.2005.00454.x; Ordeix L, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2051-6; Rodriguez-Cortes A, 2010, AM J TROP MED HYG, V82, P251, DOI 10.4269/ajtmh.2010.09-0366; Sacchi L, 2006, J COMP PATHOL, V135, P17, DOI 10.1016/j.jcpa.2006.02.009; Solano-Gallego L, 2009, VET PARASITOL, V165, P1, DOI 10.1016/j.vetpar.2009.05.022; Solano-Gallego L, 2001, VET PARASITOL, V102, P163, DOI 10.1016/S0304-4017(01)00527-1; Solano-Gallego L, 2000, VET PARASITOL, V90, P37, DOI 10.1016/S0304-4017(00)00223-5; Solano-Gallego L, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1598-y; Solano-Gallego L, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1519-0; Solano-Gallego L, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-111; Strauss-Ayali D, 2005, INT J PARASITOL, V35, P63, DOI 10.1016/j.ijpara.2004.10.015; Tafuri W L, 1993, Rev Soc Bras Med Trop, V26, P11	29	1	1	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JAN	2018	158	1					56	65		10.1016/j.jcpa.2017.11.004			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FX6VV	WOS:000426226300009	29422316				2019-10-28	
J	Vessieres, F; Rasotto, R; Peters, I; Villiers, E; Berlato, D; Cian, F				Vessieres, F.; Rasotto, R.; Peters, I.; Villiers, E.; Berlato, D.; Cian, F.			Assessment of Lymphoid Molecular Clonality in Canine Thymoma	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						clonality; dog; polymerase chain reaction for antigen receptor rearrangement; thymoma	MEDIASTINAL MASSES; DOGS; REARRANGEMENTS; DIAGNOSIS; FELINE; ASSAY	The aim of this study was to document the molecular clonality of lymphoid cells in canine thymoma using polymerase chain reaction for antigen receptor rearrangement (PARR). Fifteen formalin-fixed and paraffin wax-embedded samples of canine thymoma were analyzed for T- and B-cell receptor clonality. Two of these 15 cases were excluded from the study due to insufficient DNA concentration. Twelve of the 13 remaining samples (92.3%) showed a polyclonal lymphoid component and in one case the lymphoid component was monoclonal (T-cell clonality). PARR could therefore be a useful tool for differentiating canine thymoma from canine mediastinal lymphoma. (C) 2017 Elsevier Ltd. All rights reserved.	[Vessieres, F.; Rasotto, R.; Berlato, D.; Cian, F.] Anim Hlth Trust, Lanwades Pk, Newmarket, Suffolk, England; [Peters, I.] Univ Exeter, Innovat Ctr, Unit G, TDDS Lab, Rennes Dr, Exeter, Devon, England; [Villiers, E.] Dick White Referrals, Stn Farm, London Rd, Six Mile Bottom, Cambs, England; [Vessieres, F.] Anderson Moores Vet Specialists, Poles Lane, Hursley SO21 2LL, Hants, England	Vessieres, F (reprint author), Anim Hlth Trust, Lanwades Pk, Newmarket, Suffolk, England.; Vessieres, F (reprint author), Anderson Moores Vet Specialists, Poles Lane, Hursley SO21 2LL, Hants, England.	florence.vessieres@andersonmoores.com	; Rasotto, Roberta/L-2552-2018	Berlato, Davide/0000-0001-7951-428X; Rasotto, Roberta/0000-0001-7079-1838	Animal Health Trust, Newmarket, UK	The authors thank S. Isaacson (Animal Health Trust, UK) for technical assistance and Bridge Pathology (Bristol, UK) for providing some of the case material. This work was supported by the Animal Health Trust, Newmarket, UK. The corresponding author's current address is Anderson Moores Veterinary Specialists, Hursley, UK. An abstract of this study was presented as an oral communication at the EC-VIM/ECVCP congress in Lisbon, Portugal, on 12th September 2015.	ATWATER SW, 1994, J AM VET MED ASSOC, V205, P1007; Burnett RC, 2003, VET PATHOL, V40, P32, DOI 10.1354/vp.40-1-32; De Mello Souza CH, 2013, WITHROW MACEWENS SMA, P686; Keller SM, 2012, VET IMMUNOL IMMUNOP, V145, P410, DOI 10.1016/j.vetimm.2011.12.019; Lana S, 2006, J VET INTERN MED, V20, P1161, DOI 10.1892/0891-6640(2006)20[1161:DOMMID]2.0.CO;2; Nolan T, 2006, ANAL BIOCHEM, V351, P308, DOI 10.1016/j.ab.2006.01.051; Olivero D, 2011, VET IMMUNOL IMMUNOP, V144, P337, DOI 10.1016/j.vetimm.2011.08.011; Peters IR, 2007, VET IMMUNOL IMMUNOP, V117, P55, DOI 10.1016/j.vetimm.2007.01.011; Pintore L, 2014, J SMALL ANIM PRACT, V55, P28, DOI 10.1111/jsap.12161; Qurollo BA, 2013, J VET INTERN MED, V27, P1251, DOI 10.1111/jvim.12148; Vernau W, 1999, VET IMMUNOL IMMUNOP, V69, P145, DOI 10.1016/S0165-2427(99)00051-3; Yoon J, 2004, VET RADIOL ULTRASOUN, V45, P542, DOI 10.1111/j.1740-8261.2004.04093.x	12	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JAN	2018	158	1					66	70		10.1016/j.jcpa.2017.12.001			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FX6VV	WOS:000426226300010	29422318				2019-10-28	
J	Jungwirth, N; Puff, C; Koster, K; Mischke, R; Meyer, H; Stark, A; Thoma, B; Zoller, G; Seehusen, F; Hewicker-Trautwein, M; Beineke, A; Baumgartner, W; Wohlsein, P				Jungwirth, N.; Puff, C.; Koester, K.; Mischke, R.; Meyer, H.; Stark, A.; Thoma, B.; Zoeller, G.; Seehusen, F.; Hewicker-Trautwein, M.; Beineke, A.; Baumgaertner, W.; Wohlsein, P.			Atypical Cowpox Virus Infection in a Series of Cats	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						cat; cowpox; orthopox; unusual presentation	POXVIRUS INFECTION; HUMAN TRANSMISSION; DOMESTIC CAT	Within 4 weeks, five cats with skin lesions affecting the hindlimbs and mainly consisting of oedema, hyperaemia and plaque-like alterations were presented to the same veterinary clinic. The cats were suffering from lameness, trauma, renal insufficiency or complicated tail amputation. Although the lesions seemed unusual for a poxvirus infection, microscopical examination of biopsy samples or specimens taken during necropsy examination revealed ballooning degeneration of keratinocytes with eosinophilic, cytoplasmic inclusion bodies indicative of an orthopoxvirus infection. Cowpox virus infection was verified using immunohistochemistry and virus isolation. Molecular analysis revealed identical haemagglutinin gene sequences in four cases and spatiotemporal circumstances in some cases pointed to hospital-acquired transmission. Unusual manifestations of feline cowpox may have an unexpected risk for human infection. (C) 2017 Elsevier Ltd. All rights reserved.	[Jungwirth, N.; Puff, C.; Seehusen, F.; Hewicker-Trautwein, M.; Beineke, A.; Baumgaertner, W.; Wohlsein, P.] Univ Vet Med Hannover, Dept Pathol, Hannover, Germany; [Koester, K.; Mischke, R.] Univ Vet Med Hannover, Small Anim Clin, Hannover, Germany; [Meyer, H.; Zoeller, G.] Bundeswehr Inst Microbiol, Dept Viruses & Intracellular Agents, Munich, Germany; [Stark, A.; Thoma, B.] Bundeswehr Inst Microbiol, Cent Diagnost Lab Div, Munich, Germany; [Jungwirth, N.; Beineke, A.; Baumgaertner, W.] Ctr Syst Neurosci, Hannover, Germany	Wohlsein, P (reprint author), Univ Vet Med Hannover, Dept Pathol, Hannover, Germany.	peter.wohlsein@tiho-hannover.de			European Union's Horizon research and innovation programme [643476]	The authors thank B. Buck, P. Griinig, C. Schutz, C. Namneck and C. Hermann for excellent technical assistance. The current address for B. Thoma is Medizinische Laboratorien Dusseldorf, Dusseldorf, Germany. This study received part funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 643476.	Appl C, 2013, BERL MUNCH TIERARZTL, V126, P55, DOI 10.2376/0005-9366-126-55; Bennett M, 1996, J MED MICROBIOL, V45, P157, DOI 10.1099/00222615-45-3-157; BENNETT M, 1986, VET REC, V118, P387, DOI 10.1136/vr.118.14.387; Carroll DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023086; Chantrey J, 1999, EPIDEMIOL INFECT, V122, P455, DOI 10.1017/S0950268899002423; Dabrowski PW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079953; Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603; Essbauer S, 2010, VET MICROBIOL, V140, P229, DOI 10.1016/j.vetmic.2009.08.026; Godfrey DR, 2004, J SMALL ANIM PRACT, V45, P202, DOI 10.1111/j.1748-5827.2004.tb00225.x; Hemmer CJ, 2010, INT J INFECT DIS, V14, pE338, DOI 10.1016/j.ijid.2010.03.005; Herder V, 2011, VET DERMATOL, V22, P220, DOI 10.1111/j.1365-3164.2010.00947.x; Hnilica K, 2016, SMALL ANIMAL DERMATO, P181; Jager K, 2016, TIERAERZTL PRAX K H, V44, P273, DOI 10.15654/TPK-150712; Kurth A, 2008, EMERG INFECT DIS, V14, P670, DOI 10.3201/eid1404.070817; Lawn R, 2010, VET REC, V166, P631, DOI 10.1136/vr.c2505; Matz-Rensing K, 2006, VET PATHOL, V43, P212, DOI 10.1354/vp.43-2-212; Mauldin AE, 2016, JUBB KENNEDY PALMERS, V1, P619; Olson VA, 2004, J CLIN MICROBIOL, V42, P1940, DOI 10.1128/JCM.42.5.1940-1946.2004; PFEIFF B, 1991, HAUTARZT, V42, P293; SCARFF D, 1990, VET REC, V127, P459; Schaudien D, 2007, J COMP PATHOL, V137, P151, DOI 10.1016/j.jcpa.2007.05.007; Schoniger S, 2007, VET REC, V160, P522, DOI 10.1136/vr.160.15.522; von Bomhard W, 2011, VET DERMATOL, V22, P111, DOI 10.1111/j.1365-3164.2010.00923.x	23	1	1	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JAN	2018	158	1					71	76		10.1016/j.jcpa.2017.12.003			6	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FX6VV	WOS:000426226300011	29422319				2019-10-28	
J	Steenkamp, G; Boy, SC; van Staden, PJ; Bester, MN				Steenkamp, G.; Boy, S. C.; van Staden, P. J.; Bester, M. N.			Oral, Maxillofacial and Dental Diseases in Captive Cheetahs (Acinonyx jubatus)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						cheetah; maxillofacial; oral cavity; teeth	TOOTH RESORPTION; CATS; MALOCCLUSION; PLEISTOCENE; CARNIVORES; PATHOLOGY; BREAKAGE; LESIONS; LION	Descriptions of several oral, maxillofacial and dental conditions/diseases exist for a variety of captive large felids, but little is reported on the pathology of free roaming large felids. Apart from focal palatine erosions (FPEs) as initially described by Fitch and Fagan (1982) and some reference to absent incisor teeth, few data exist on diseases affecting the oral, maxillofacial and dental structures of cheetahs (Acinonyx jubatus), regardless of their captivity status. This study reports 18 different conditions affecting the teeth, bone and oral cavity soft tissue of cheetahs, based on initial assessment of 256 animals over 11 years (2002-2012) in South Africa and Namibia. This report excludes oral tumours or FPEs, but includes several acquired and developmental conditions never described before. (C) 2017 Elsevier Ltd. All rights reserved.	[Steenkamp, G.; Bester, M. N.] Univ Pretoria, Mammal Res Inst, Fac Nat & Agr Sci, Private Bag X20, Hatfield, South Africa; [Steenkamp, G.] Univ Pretoria, Fac Vet Sci, Dept Compan Anim Clin Studies, Pretoria, South Africa; [Boy, S. C.] Sefako Makgatho Hlth Sci Univ, Sch Oral Hlth Sci, Dept Oral Pathol, Ga Rankuwa, South Africa; [van Staden, P. J.] Univ Pretoria, Fac Nat & Agr Sci, Dept Stat, Pretoria, South Africa	Steenkamp, G (reprint author), Univ Pretoria, Mammal Res Inst, Fac Nat & Agr Sci, Private Bag X20, Hatfield, South Africa.; Steenkamp, G (reprint author), Univ Pretoria, Fac Vet Sci, Dept Compan Anim Clin Studies, Pretoria, South Africa.	Gerhard.steen.kamp@up.ac.za	van Staden, Paul J/B-3861-2011; Bester, Marthan N/E-5387-2010	van Staden, Paul J/0000-0002-5710-5984; Steenkamp, Gerhard/0000-0001-8428-7309			Barycka E, 2007, J VET DENT, V24, P172, DOI 10.1177/089875640702400305; BEEBE BF, 1988, CAN J VET RES, V52, P468; Berger M., 1996, Journal of Veterinary Dentistry, V13, P13; Bertolini F, 2016, MAMM GENOME, V27, P144, DOI 10.1007/s00335-016-9623-1; Boy S, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00009; Brettschneider H, 2015, P 13 WORLD VET DENT; Caro TM, 1994, CHEETAHS SERENGETI P, P15; COOK RA, 1986, J AM VET MED ASSOC, V189, P1082; De Simoi A, 2006, J VET DENT, V23, P89, DOI 10.1177/089875640602300205; Fitch H.M., 1982, Zoo Biology, V1, P295, DOI 10.1002/zoo.1430010403; Floyd M R, 1991, J Vet Dent, V8, P18; Gorrel C, 2015, J FELINE MED SURG, V17, P37, DOI 10.1177/1098612X14560098; HEUSCHELE W P, 1959, J Am Vet Med Assoc, V134, P365; Ingham KE, 2001, J SMALL ANIM PRACT, V42, P439, DOI 10.1111/j.1748-5827.2001.tb02497.x; Kertesz P, 1993, COLOUR ATLAS VET DEN, P215; Langley L, 2007, 43 INT S DIS ZOO WIL, P213; Levin J, 1996, 10 ANN DENT FORUM, P212; Longley L., 2011, International Zoo Yearbook, V45, P91, DOI 10.1111/j.1748-1090.2010.00125.x; Miles AEW, 1990, COLYERS VARIATIONS D, P62; Mitsouras K, 2011, BMC VET RES, V7, DOI 10.1186/1746-6148-7-38; Nicmiec BA, 2010, COLOUR HDB SMALL ANI, P272; Niemiec BA, 2008, TOP COMPANION ANIM M, V23, P59, DOI 10.1053/j.tcam.2008.02.002; Rector A, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r57; Reiter AM, 2005, VET CLIN N AM-SMALL, V35, P913, DOI 10.1016/j.cvsm.2005.03.006; Roux P, 2009, J VET DENT, V26, P16, DOI 10.1177/089875640902600106; Schuurs A, 2013, PATHOLOGY HARD DENT, P42; Steenkamp G, 2017, THESIS; Sundberg JP, 2000, VET PATHOL, V37, P1, DOI 10.1354/vp.37-1-1; Sykes JM, 2007, J ZOO WILDLIFE MED, V38, P300, DOI 10.1638/1042-7260(2007)038[0300:OEGITP]2.0.CO;2; Uribe LMM, 2015, ORTHOD CRANIOFAC RES, V18, P91, DOI 10.1111/ocr.12083; van Foreest A, 1997, J Vet Dent, V14, P131; van Foreest AW, 1999, TIJDSCHR DIERGENEESK, V124, P251; VANVALKENBURGH B, 1988, AM NAT, V131, P291, DOI 10.1086/284790; VANVALKENBURGH B, 1993, SCIENCE, V261, P456, DOI 10.1126/science.261.5120.456; VanValkenburgh B, 1996, J MAMMAL, V77, P240, DOI 10.2307/1382725; Verstraete FJM, 1998, AM J VET RES, V59, P692; Verstraete FJM, 1996, J COMP PATHOL, V115, P283, DOI 10.1016/S0021-9975(96)80085-5; Wiggs RB, 1997, VET DENT PRINCIPLES, P280; Willis G, 1983, Alumni Bull Sch Dent Indiana Univ, P18; Wrogemann N, 1975, CHEETAH SUN, P91	40	1	2	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JAN	2018	158	1					77	89		10.1016/j.jepa.2017.12.004			13	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FX6VV	WOS:000426226300012	29422320				2019-10-28	
J	Day, MJ				Day, M. J.			The Journal of Comparative Pathology Educational Trust 2017 Awards	JOURNAL OF COMPARATIVE PATHOLOGY			English	Editorial Material									[Day, M. J.] Murdoch Univ, Sch Vet & Life Sci, Murdoch, WA, Australia	Day, MJ (reprint author), Murdoch Univ, Sch Vet & Life Sci, Murdoch, WA, Australia.	profmjday@gmail.com						0	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JAN	2018	158	1					90	91		10.1016/j.jcpa.2017.10.173			2	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FX6VV	WOS:000426226300013	29129310				2019-10-28	
J	Jiang, JJ; Jiang, TJ; Xu, JL; Shen, J; Gao, F				Jiang, Jingjing; Jiang, Tiejia; Xu, Jialu; Shen, Jue; Gao, Feng			Novel Mutation of the Dystrophin Gene in a Child with Duchenne Muscular Dystrophy	FETAL AND PEDIATRIC PATHOLOGY			English	Article						DMD; children; gene mutation; high-throughput Sequencing; muscle biopsy	DIAGNOSIS; DELETIONS; DUPLICATIONS; MLPA; DMD; DNA	Introduction: Duchenne muscular dystrophy (DMD) is an X-linked autosomal recessive genetic disorder caused by mutations in DMD gene. Approximately 70% of the mutations are caused by deletions or duplications of DMD exons, while the remaining were minor mutations. Case report: We present a 5-year-old boy with typical clinical features of DMD. A novel mutation was identified as a c.9358_9359insA of DMD gene by next-generation sequencing. This mutation which was origined from mother, generated a frameshift mutation and resulted in abnormal synthesis of protein polypeptide chains. Conclusion: We demonstrated a novel mutation of DMD gene and expanded the spectrum of mutations causing DMD.	[Jiang, Jingjing; Jiang, Tiejia; Xu, Jialu; Shen, Jue; Gao, Feng] Zhejiang Univ, Childrens Hosp, Sch Med, 3333 BinSheng Rd, Hangzhou 310058, Zhejiang, Peoples R China	Gao, F (reprint author), Zhejiang Univ, Childrens Hosp, Sch Med, 3333 BinSheng Rd, Hangzhou 310058, Zhejiang, Peoples R China.	epilepsy@zju.edu.cn					Aartsma-Rus A, 2006, MUSCLE NERVE, V34, P135, DOI 10.1002/mus.20586; Bello Luca, 2016, Acta Myol, V35, P122; Bushby K, 2010, LANCET NEUROL, V9, P77, DOI 10.1016/S1474-4422(09)70271-6; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; Fortina P, 1997, CLIN CHEM, V43, P745; Janssen B, 2005, NEUROGENETICS, V6, P29, DOI 10.1007/s10048-004-0204-1; Jones KJ, 1997, J PAEDIATR CHILD H, V33, P195, DOI 10.1111/j.1440-1754.1997.tb01579.x; KUNKEL LM, 1986, NATURE, V322, P73, DOI 10.1038/322073a0; Lai KKS, 2006, CLIN BIOCHEM, V39, P367, DOI 10.1016/j.clinbiochem.2005.11.019; Lee SH, 1998, MOL HUM REPROD, V4, P345, DOI 10.1093/molehr/4.4.345; Mamanova L, 2010, NAT METHODS, V7, P111, DOI 10.1038/nmeth.1419; Mercuri E, 2013, CURR OPIN PEDIATR, V25, P701, DOI 10.1097/MOP.0b013e328365ace5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WAPENAAR M C, 1988, Genomics, V2, P101, DOI 10.1016/0888-7543(88)90090-0	14	1	1	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	1					1	6		10.1080/15513815.2017.1369201			6	Pathology; Pediatrics	Pathology; Pediatrics	FW9ZF	WOS:000425696300001	29336709				2019-10-28	
J	Matynia, AP; Perkins, SL; Li, D				Matynia, Anna Paulina; Perkins, Sherrie L.; Li, David			Lymphomatoid Granulomatosis in a 14-Year-Old Boy with Trisomy 21 and History of B-Lymphoblastic Leukemia/Lymphoma	FETAL AND PEDIATRIC PATHOLOGY			English	Article						lymphomatoid granulomatosis; pediatric; B-lymphoblastic leukemia/lymphoma; trisomy 21	LEUKEMIA; REMISSION; CHILD	Background: Lymphomatoid granulomatosis is a EBV-driven lymphoproliferative disorder that has been reported in association with immunodeficiency, but only exceptionally in patients with hematopoietic malignancy. Case report: A 14-year-old boy with trisomy-21 and a history of B-lymphoblastic leukemia/lymphoma (B-ALL) diagnosed 1.5years prior, on maintenance chemotherapy, presented with fever and respiratory symptoms. Chest X-ray revealed right-lower-lobe consolidation. He was treated for pneumonia but continued to be febrile with worsening respiratory status, with development of additional pulmonary and liver nodules. No infectious etiology was identified. Following nondiagnostic lung and liver biopsies, the largest pulmonary mass was resected. The histopathologic findings were diagnostic of lymphomatoid granulomatosis. There was no residual B-ALL. The patient's status continued to deteriorate and he died shortly thereafter. Conclusion: Relative immunosuppression due to maintenance therapy for B-ALL can lead to lymphomatoid granulomatosis.	[Matynia, Anna Paulina; Perkins, Sherrie L.; Li, David] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA	Matynia, AP (reprint author), Univ Utah, Dept Pathol, ARUP Labs, 500 ChipetaWay,Mail Code 115-J13, Salt Lake City, UT 84108 USA.	anna.matynia@hsc.utah.edu					[Anonymous], 1987, N Engl J Med, V317, P879; BEKASSY AN, 1985, AM J PEDIAT HEMATOL, V7, P377; COHEN SR, 1978, ANN OTO RHINOL LARYN, V87, P5; Colby TV, 2012, MODERN PATHOL, V25, pS39, DOI 10.1038/modpathol.2011.149; Drut R, 2005, J CLIN PATHOL, V58, P550, DOI 10.1136/jcp.2004.022475; DRUT R, 1988, Pediatric Pathology, V8, P395; KATZENSTEIN ALA, 1979, CANCER, V43, P360, DOI 10.1002/1097-0142(197901)43:1<360::AID-CNCR2820430151>3.0.CO;2-8; Katzenstein ALA, 2010, AM J SURG PATHOL, V34, pE35, DOI 10.1097/PAS.0b013e3181fd8781; LIEBOW AA, 1972, HUM PATHOL, V3, P457, DOI 10.1016/S0046-8177(72)80005-4; Moertel CL, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.5.e82; Oren H, 2003, J PEDIAT HEMATOL ONC, V25, P163, DOI 10.1097/00043426-200302000-00016; Pittaluga S., 2008, WHO CLASSIFICATION T, V4, P247; SHEN SC, 1981, HUM PATHOL, V12, P276, DOI 10.1016/S0046-8177(81)80130-X; Tacke ZCA, 2014, J PEDIAT HEMATOL ONC, V36, pE416, DOI 10.1097/MPH.0000000000000090	14	1	1	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	1					7	14		10.1080/15513815.2017.1379042			8	Pathology; Pediatrics	Pathology; Pediatrics	FW9ZF	WOS:000425696300002	29336635				2019-10-28	
J	Sun, Y; Hu, XY; Song, JQ; Hu, YY; Liu, CH; Li, GM				Sun, Yan; Hu, Xuyun; Song, Jiqing; Hu, Yanyan; Liu, Caihong; Li, Guimei			Novel RNASET2 Pathogenic Variants in an East Asian Child with Delayed Psychomotor Development	FETAL AND PEDIATRIC PATHOLOGY			English	Article						RNASET2; mutation; intelligence disability; leukoencephalopathy	AICARDI-GOUTIERES-SYNDROME; GENOME-WIDE ASSOCIATION; CYSTIC LEUKOENCEPHALOPATHY; SUSCEPTIBILITY LOCI; BRAIN INFECTION; DISEASE; EXPRESSION; MUTATIONS; PURIFICATION; SAMHD1	Introduction: RNASET2 mutation has been reported in patients with cystic leukoencephalopathy without megalencephaly and the Aicardi-Goutieres syndrome. Both disorders are Mendelian mimics of congenital cytomegalovirus infection with overlapping features, including leukoencephalopathy, white matter alterations, intracranial calcification, delayed psychomotor development, intelligence disability and seizures. Only eight families with RNASET2 mutation have been previously reported. Methods: Whole exome sequencing was performed and copy number variants were described by read-depth strategy. Results: We identified a novel nonsense variant c.128G>A (p. W43*) and a 430 Kb 6q27 microdeletion encompassing RNASET2. Our patient did not show anterior temporal lobe subcortical cysts, hearing loss, dystonia or extra-neurological features. Conclusion: Our results provided further genetic and phenotypic information of RNASET2 mutation in Chinese patients and highlighted the importance for physicians to consider RNASET2-related disorders when diagnosing patients with congenital brain infection-like phenotypes.	[Sun, Yan; Hu, Yanyan; Liu, Caihong; Li, Guimei] Shandong Univ, Shandong Prov Hosp, Dept Pediat, Jinan, Shandong, Peoples R China; [Hu, Xuyun] Guangxi Maternal & Child Hlth Hosp, Genet & Metab Cent Lab, Nanning, Guangxi, Peoples R China; [Hu, Xuyun] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Shanghai 200127, Peoples R China; [Song, Jiqing] Shandong Univ, Shandong Prov Hosp, Dept Radiol, Jinan, Shandong, Peoples R China	Hu, XY (reprint author), Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Shanghai 200127, Peoples R China.; Li, GM (reprint author), Shandong Univ, Shandong Prov Hosp, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China.	hu_xuyun@126.com; liguimei2013@126.com			Shandong Provincial Natural Science FoundationNatural Science Foundation of Shandong Province [ZR2013HQ034]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81500020]; China Scholarship CouncilChina Scholarship Council	This work is partially funded by Shandong Provincial Natural Science Foundation (ZR2013HQ034) and National Natural Science Foundation of China (81500020) and China Scholarship Council.	Acquati F, 2005, INT J ONCOL, V26, P1159; Campomenosi P, 2006, ARCH BIOCHEM BIOPHYS, V449, P17, DOI 10.1016/j.abb.2006.02.022; Chen XJ, 2015, BMC MED GENET, V16, DOI 10.1186/s12881-015-0150-9; Chu X, 2011, NAT GENET, V43, P897, DOI 10.1038/ng.898; Crow YJ, 2006, NAT GENET, V38, P910, DOI 10.1038/ng1842; Crow YJ, 2015, AM J MED GENET A, V167, P296, DOI 10.1002/ajmg.a.36887; Gabrielsen ISM, 2016, HUM MOL GENET, V25, P3117, DOI 10.1093/hmg/ddw152; Gomes A L, 2001, Eur J Paediatr Neurol, V5, P121, DOI 10.1053/ejpn.2001.0482; Gonsky R, 2017, GASTROENTEROLOGY, V153, P219, DOI 10.1053/j.gastro.2017.04.002; Haud N, 2011, P NATL ACAD SCI USA, V108, P1099, DOI 10.1073/pnas.1009811107; Henneke M, 2005, NEUROLOGY, V64, P1411, DOI 10.1212/01.WNL.0000158472.82823.01; Henneke M, 2009, NAT GENET, V41, P773, DOI 10.1038/ng.398; Ishii KJ, 2005, INT J CANCER, V117, P517, DOI 10.1002/ijc.21402; Lualdi M, 2015, MOL BIOTECHNOL, V57, P513, DOI 10.1007/s12033-015-9845-6; Nesiel-Nuttman L, 2014, ONCOTARGET, V5, P11464, DOI 10.18632/oncotarget.2562; Olivier M, 1998, NEUROPEDIATRICS, V29, P225, DOI 10.1055/s-2007-973566; Orcesi S, 2009, BRIT MED BULL, V89, P183, DOI 10.1093/bmb/ldn049; Quan C, 2010, NAT GENET, V42, P614, DOI 10.1038/ng.603; Rice G, 2007, AM J HUM GENET, V81, P713, DOI 10.1086/521373; Rice GI, 2013, LANCET NEUROL, V12, P1159, DOI 10.1016/S1474-4422(13)70258-8; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Roiz Levava, 2016, Oncoscience, V3, P71; Smirnoff P, 2006, CANCER, V107, P2760, DOI 10.1002/cncr.22327; Tonduti D, 2016, EUR J PAEDIATR NEURO, V20, P604, DOI 10.1016/j.ejpn.2016.03.009; Vidalino L, 2012, BIOL CELL, V104, P13, DOI 10.1111/boc.201100092; Wang Q, 2015, J NANOMATER, DOI 10.1155/2015/408634; Yang SK, 2014, GUT, V63, P80, DOI 10.1136/gutjnl-2013-305193; Zhang Q, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22258; Zhu H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167212	29	0	0	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	1					15	21		10.1080/15513815.2017.1388456			7	Pathology; Pediatrics	Pathology; Pediatrics	FW9ZF	WOS:000425696300003	29336640				2019-10-28	
J	Still, GG; Li, S; Wilson, M; Sammut, P				Still, Gordon Gray; Li, Shuo; Wilson, Mark; Sammut, Paul			Persistent Pulmonary Hypertension Without Underlying Cardiac Disease as a Presentation of Pulmonary Interstitial Glycogenosis	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Pulmonary interstitial glycogenosis; persistent pulmonary hypertension; corticosteroid therapy; radiopathologic correlation; lung biopsy	LUNG-DISEASE; CLASSIFICATION; CHILDREN; INFANT	Introduction: Pulmonary interstitial glycogenosis (PIG) is an idiopathic lung condition that remains clinically underrecognized despite a growing body of literature. Case report: We present a case of PIG with pulmonary hypertension without underlying cardiac disease. This patient presented with respiratory distress and spontaneous pneumothorax at 6months of age. Laboratory and imaging investigations demonstrated nonspecific features, but refractory pulmonary hypertension was confirmed on cardiac catheterization. Lung tissue histopathology showed glycogen positive staining of the interstitial cells, consistent with PIG. Conclusion: This unique case demonstrates that pulmonary hypertension can be seen in the setting of PIG without associated cardiac anomalies, and persists despite treatment in an otherwise self-limited condition.	[Still, Gordon Gray] Univ Nebraska Med Ctr, Dept Pediat, Omaha, NE USA; [Li, Shuo; Wilson, Mark; Sammut, Paul] Yale New Haven Hlth Bridgeport Hosp, Dept Radiol, Bridgeport, CT USA	Li, S (reprint author), 267 Grant St, Bridgeport, CT 06610 USA.	dr.shuo.li@gmail.com		/0000-0003-0511-8545			Alkhorayyef A, 2013, PEDIATR CARDIOL, V34, P462, DOI 10.1007/s00246-012-0311-y; Canakis AM, 2002, AM J RESP CRIT CARE, V165, P1557, DOI 10.1164/rccm.2105139; Castillo M, 2010, PEDIATR RADIOL, V40, P1562, DOI 10.1007/s00247-010-1670-2; Deutsch GH, 2007, AM J RESP CRIT CARE, V176, P1120, DOI 10.1164/rccm.200703-393OC; Deutsch GH, 2010, PEDIATR RADIOL, V40, P1471, DOI 10.1007/s00247-010-1730-7; Deutsch GH, 2009, PEDIATR DEVEL PATHOL, V12, P475, DOI 10.2350/08-12-0575.1; Ehsan Z, 2014, PEDIATR PULM, V49, pE17, DOI 10.1002/ppul.22738; Fan LL, 1997, AM J RESP CRIT CARE, V156, P939, DOI 10.1164/ajrccm.156.3.9703051; Jiskoot-Ermers MEC, 2015, AJP REP, V5, pE136, DOI 10.1055/s-0035-1551674; King BA, 2011, PEDIATR PULM, V46, P1142, DOI 10.1002/ppul.21486; Kurland G, 2013, AM J RESP CRIT CARE, V188, P376, DOI 10.1164/rccm.201305-0923ST; Lanfranchi M, 2010, PEDIATR RADIOL, V40, P361, DOI 10.1007/s00247-009-1455-7; Onland W, 2005, PEDIATR PULM, V40, P362, DOI 10.1002/ppul.20255; Poplar J, 2012, CHEST, V142, P774, DOI 10.1378/chest.12-0492; Radman MR, 2013, PEDIATR CARDIOL, V34, P1254, DOI 10.1007/s00246-012-0371-z; Sanchez-de-Toledo J, 2015, WORLD J PEDIATR CONG, V6, P480, DOI 10.1177/2150135115577433	16	1	1	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	1					22	26		10.1080/15513815.2017.1397071			5	Pathology; Pediatrics	Pathology; Pediatrics	FW9ZF	WOS:000425696300004	29336713				2019-10-28	
J	Becerra-Solano, LE; Castaneda-Cisneros, G; Corona-Rivera, JR; Diaz-Rodriguez, M; Figuera, LE; Lopez-Munoz, E; Nastasi-Catanese, JA; Toscano-Flores, JJ; Ramirez-Duenas, MD; Garcia-Ortiz, JE				Eduardo Becerra-Solano, Luis; Castaneda-Cisneros, Gema; Roman Corona-Rivera, Jorge; Diaz-Rodriguez, Manuel; Eduardo Figuera, Luis; Lopez-Munoz, Eunice; Antonio Nastasi-Catanese, Jose; Jesus Toscano-Flores, Jose; de Lourdes Ramirez-Duenas, Maria; Elias Garcia-Ortiz, Jose			Severe Craniofacial Involvement due to Amniotic Band Sequence	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Amniotic band sequence; disruptive sequence; limb-body wall defects; facial clefts	ASSOCIATION; ANOMALIES; RUPTURE; HYPOTHESIS; PREGNANCY; DEFECTS; COMPLEX; MODEL	Background: Disruptive amniotic band sequence (DABS) is a sporadic, non-familial disorder with unclear etiology. Diagnosis is based on clinical features because there is currently no reliable laboratory diagnostic tests. Objective: We describe six cases of DABS with severe craniofacial deformations, three with and three without classical constrictive limb deformation. Results: The craniofacial deformities were delimited by peripheral sharply demarcated scarring. Conclusion: When a sharply demarcated linear disruptive craniofacial lesion is observed, DABS should be considered despite the absence of constrictive limb scarring.	[Eduardo Becerra-Solano, Luis] Inst Mexicano Seguro Social, Med Res Unit, Guadalajara, Mexico; [Eduardo Becerra-Solano, Luis] Hosp Ginecol Obstetricia & 4 Luis Castelazo Ayal, Med Res Unit Reprod Med, Mexico City, DF, Mexico; [Castaneda-Cisneros, Gema] Hosp Especialidades Ctr Med Nacl Occidente IMSS, Dept Neurosurg, Belisario Dominguez 771, Guadalajara, Jalisco, Mexico; [Roman Corona-Rivera, Jorge] Hosp Civil Guadalajara, Div Pediat, Serv Genet, Salvador Quevedo & Zubieta 750, Guadalajara, Jalisco, Mexico; [Diaz-Rodriguez, Manuel; Eduardo Figuera, Luis; Jesus Toscano-Flores, Jose] Ctr Investi Biomed Occidente, Div Genet, Sierra Mojada 800, Guadalajara, Jalisco, Mexico; [Lopez-Munoz, Eunice] Inst Mexicano Seguro Social, Unidada Invest Med Medicina Reproduct, Rio Margdalena 289, Mexico City, DF, Mexico; [Antonio Nastasi-Catanese, Jose] Fdn Clin Valle del Lili, Dept Patol & Med Lab, Lab Genet Humana, Bogota, Colombia; [de Lourdes Ramirez-Duenas, Maria; Elias Garcia-Ortiz, Jose] Inst Mexicano Seguro Social, Ctr Invest Biomed Occidente, Div Genet, Sierra Mojada 800, Guadalajara, Jalisco, Mexico; [Elias Garcia-Ortiz, Jose] Hosp Ginecol & Obstetricia, Ctr Med Nacl Occidente, Direcc Educ Salud & Invest, Belisario Dominguez 771, Guadalajara, Jalisco, Mexico	Garcia-Ortiz, JE (reprint author), IMSS, Ctr Med Nacl Occidente, Ctr Invest Biomed Occidente, Div Genet, Sierra Mojada 800, Guadalajara 44340, Jalisco, Mexico.	jose.garciaor@imss.gob.mx	; Figuera, Luis/V-8429-2017	Corona-Rivera, Jorge/0000-0002-4626-148X; GARCIA-ORTIZ, JOSE ELIAS/0000-0003-1504-1457; Figuera, Luis/0000-0002-6096-4579; Ramirez-Duenas, Maria de Lourdes/0000-0001-5752-1841			Bamforth J S, 1993, Birth Defects Orig Artic Ser, V29, P279; BAMFORTH JS, 1992, AM J MED GENET, V44, P280, DOI 10.1002/ajmg.1320440304; Castilla EE, 1999, AM J MED GENET, V86, P9, DOI 10.1002/(SICI)1096-8628(19990903)86:1<9::AID-AJMG3>3.0.CO;2-X; Coady MSE, 1998, PLAST RECONSTR SURG, V101, P640, DOI 10.1097/00006534-199803000-00010; Davies BR, 2007, FETAL PEDIATR PATHOL, V26, P87, DOI 10.1080/15513810701448466; Davies BR, 2001, ARCH MED RES, V32, P48, DOI 10.1016/S0188-4409(00)00260-5; DONNAI D, 1989, J MED GENET, V26, P421, DOI 10.1136/jmg.26.7.421; Galvan A, 2012, FETAL PEDIATR PATHOL, V31, P300, DOI 10.3109/15513815.2012.659387; Gellis S S, 1977, Birth Defects Orig Artic Ser, V13, P259; Guzman-Huerta ME, 2013, REV INVEST CLIN, V65, P300; Hunter AGW, 2011, AM J MED GENET A, V155A, P2045, DOI 10.1002/ajmg.a.34161; Lowry RB, 2017, AM J MED GENET A, V173, P299, DOI 10.1002/ajmg.a.38016; Luehr B, 2002, J Matern Fetal Neonatal Med, V12, P132, DOI 10.1080/713605615; ORAHILLY R, 1975, ANAT EMBRYOL, V148, P1, DOI 10.1007/BF00315559; Orioli IM, 2003, AM J MED GENET A, V118A, P135, DOI 10.1002/ajmg.a.10194; Rayan GM, 2001, PLAST RECONSTR SURG, V107, P1000, DOI 10.1097/00006534-200104010-00015; SCHIEVE LA, 1994, AM J PUBLIC HEALTH, V84, P405, DOI 10.2105/AJPH.84.3.405; Taub PJ, 2003, AM J MED GENET A, V120A, P256, DOI 10.1002/ajmg.a.20240; TORPIN R, 1965, AM J OBSTET GYNECOL, V91, P65, DOI 10.1016/0002-9378(65)90588-0; van der Meulen JC, 1999, PLAST RECONSTR SURG, V103, P1087, DOI 10.1097/00006534-199903000-00068; VISCARELLO RR, 1992, OBSTET GYNECOL, V80, P523; Werler MM, 2003, BIRTH DEFECTS RES A, V67, P68, DOI 10.1002/bdra.10001; Winer N, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.09.030; YANG SS, 1984, AM J SURG PATHOL, V8, P117, DOI 10.1097/00000478-198402000-00005	24	1	1	1	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	1					27	37		10.1080/15513815.2017.1392663			11	Pathology; Pediatrics	Pathology; Pediatrics	FW9ZF	WOS:000425696300005	29336649				2019-10-28	
J	Yang, RQ; Li, R; Liu, XJ; Fan, LM; Zhang, JL; Wang, LB; Teng, H				Yang, Ruiqi; Li, Rui; Liu, Xuejuan; Fan, Limei; Zhang, Jialing; Wang, Libo; Teng, Hong			Measurement of Fetal Mesencephalon and Pons Via Ultrasonographic Cross Sectional Imagining	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Fetal central nervous system development; mesencephalon; pons; cross-sectional imaging; ultrasonography	MALFORMATIONS; CLASSIFICATION; HINDBRAIN; DIAGNOSIS; MIDBRAIN	Objectives. This study evaluated the feasibility of measuring the fetal mesencephalon and pons by ultrasonographic cross sectional imaging to detect fetal central nervous system developmental abnormalities. Materials and Methods. Fetal ultrasonographic measurements included: Fetal mesencephalon anteroposterior diameters (MAD), mesencephalon transverse diameters (MTD), pons anteroposterior diameter (PAD) and proximal transverse diameters (PTD). Results. Nine-hundred ninety fetuses were imaged. Thirty-eight fetuses (observation group) presented central nervous system abnormalities; 952 fetuses without imaged abnormalities were utilized as the reference (control) group. Fetal MAD, MTD, PAD, and PTD in control fetuses showed a linear correlation with gestational age. Thirty-eight fetuses had 40 abnormal measurements (8 MAD, 8 MTD, 14 PAD, and 10 PTD), 16 in mesencephalon, and 24 in pons. All data fell below the 95% confidence intervals' lower limits for the corresponding gestational age. Conclusion. Using normative data based on 957 fetuses allows detection of size abnormalities of the pons and midbrain during fetal life.	[Yang, Ruiqi; Fan, Limei; Zhang, Jialing; Teng, Hong] Jinlin Univ, Hosp 2, Dept Obstet & Gynecol, Changchun, Jilin, Peoples R China; [Li, Rui] Changchun Univ Chinese Med, Affiliated Hosp, Emergency Dept, Changchun, Jilin, Peoples R China; [Liu, Xuejuan] Jilin Univ, Hosp 1, Dept Pathol, Changchun, Jilin, Peoples R China; Jilin Maternal & Child Hlth Hosp, Dept Elect Diag, Changchun, Jilin, Peoples R China	Teng, H (reprint author), Jilin Univ, Hosp 2, Dept Obstet & Gynecol, 218 Zi Qiang St, Changchun 130021, Jilin, Peoples R China.	tenghong_jl@sina.cn					Achiron R, 2004, ULTRASOUND OBST GYN, V24, P506, DOI 10.1002/uog.1731; BENDA CE, 1954, J NEUROPATH EXP NEUR, V13, P14, DOI 10.1093/jnen/13.1.14; Boddaert N, 2003, NEURORADIOLOGY, V45, P320, DOI 10.1007/s00234-003-0980-6; CARDOZA JD, 1988, RADIOLOGY, V169, P711, DOI 10.1148/radiology.169.3.3055034; Doherty D, 2013, LANCET NEUROL, V12, P381, DOI 10.1016/S1474-4422(13)70024-3; FILLY RA, 1991, RADIOLOGY, V181, P1; Gaglioti P, 2005, ULTRASOUND OBST GYN, V25, P372, DOI 10.1002/uog.1857; Ghi T, 2003, ULTRASOUND OBST GYN, V22, P121, DOI 10.1002/uog.191; Graham E, 2001, J Matern Fetal Med, V10, P258; HEISERMAN J, 1991, J ULTRAS MED, V10, P121; Jacobsen P, 1996, ACTA OBSTET GYN SCAN, V75, P620, DOI 10.3109/00016349609054685; Karadeniz L, 2011, J CHIN MED ASSOC, V74, P134, DOI 10.1016/j.jcma.2011.01.029; MCARDLE CB, 1987, RADIOLOGY, V162, P230, DOI 10.1148/radiology.162.1.3786768; PAPP Z, 1992, ATLAS FETAL DIAGNOSI, P117; Parisi MA, 2003, MOL GENET METAB, V80, P36, DOI 10.1016/j.ymgme.2003.08.010; Patel S, 2002, AM J NEURORADIOL, V23, P1074; Paul LK, 2007, NAT REV NEUROSCI, V8, P287, DOI 10.1038/nrn2107; Ross ME, 2001, NEUROPEDIATRICS, V32, P256, DOI 10.1055/s-2001-19120; Sasidharan C. K., 2004, Indian Journal of Pediatrics, V71, P459, DOI 10.1007/BF02725643; Tanaka H, 2000, HUM REPROD, V15, P1407, DOI 10.1093/humrep/15.6.1407	20	0	0	2	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	1					38	48		10.1080/15513815.2017.1397069			11	Pathology; Pediatrics	Pathology; Pediatrics	FW9ZF	WOS:000425696300006	29336643				2019-10-28	
J	Aggarwal, S; Tandon, A; Das Bhowmik, A; Safarulla, JMNJ; Dalal, A				Aggarwal, Shagun; Tandon, Ashwani; Das Bhowmik, Aneek; Safarulla, Jamal Mohamed Nurul Jain; Dalal, Ashwin			A Dysmorphology Based Systematic Approach Toward Perinatal Genetic Diagnosis in a Fetal Autopsy Series	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Fetal autopsy; fetal dysmorphology; fetal pathology; birth defects; exome sequencing	PRENATAL-DIAGNOSIS; PREGNANCY LOSS; ABNORMALITIES; ULTRASOUND; MICROARRAY; PREVALENCE; STILLBIRTH; DISORDERS; PHENOTYPE; KARYOTYPE	Background. This retrospective study assesses the contribution of genetic disorders in fetuses undergoing postmortem evaluation and the performance of a clinical dysmorphology based systematic approach toward genetic diagnosis. Materials and Methods. Ninety fetuses, including spontaneous losses and terminated pregnancies, underwent a postmortem evaluation including dysmorphological examination, radiological studies, and histopathological examination. Genetic testing including karyotyping, biochemical testing, Sanger sequencing, and exome sequencing were performed selectively. Results. A genetic etiology was concluded in 48 fetuses (55%). As a standalone test, dysmorphological examination was able to ascertain a definite genetic diagnosis in sixteen cases, histopathology in six; and karyotyping, biochemical testing and exome sequencing in two cases each (Total 28). Additionally, dysmorphology findings indicated possible genetic disorder in 20 cases. Conclusion. Genetic etiologies contribute significantly to fetuses undergoing autopsy in this series. A systematic approach to postmortem fetal evaluation guided by dysmorphological examination provides high diagnostic yield toward perinatal genetic diagnosis.	[Aggarwal, Shagun] Nizams Inst Med Sci, Dept Med Genet, 4th Floor,Specialty Block, Hyderabad 500082, Telangana, India; [Aggarwal, Shagun; Das Bhowmik, Aneek; Safarulla, Jamal Mohamed Nurul Jain; Dalal, Ashwin] Ctr DNA Fingerprinting & Diagnost, Diagnost Div, Hyderabad, Telangana, India; [Tandon, Ashwani] Nizams Inst Med Sci, Dept Pathol, Hyderabad, Telangana, India	Aggarwal, S (reprint author), Nizams Inst Med Sci, Dept Med Genet, 4th Floor,Specialty Block, Hyderabad 500082, Telangana, India.	shagun.genetics@gmail.com	Das Bhowmik, Aneek/H-3481-2016	Das Bhowmik, Aneek/0000-0003-3318-8268			Abdalla EM, 2015, TURKISH J PEDIATR, V57, P146; Aggarwal S, 2016, AM J MED GENET A, V170, P1868, DOI 10.1002/ajmg.a.37654; Alamillo CL, 2015, PRENATAL DIAG, V35, P1073, DOI 10.1002/pd.4648; Rodriguez MA, 2014, PRENATAL DIAG, V34, P784, DOI 10.1002/pd.4368; Barkova E, 2015, CLIN GENET, V87, P330, DOI 10.1111/cge.12434; Beke A, 2005, J REPROD MED, V50, P675; Bellini C, 2015, AM J MED GENET A, V167, P1082, DOI 10.1002/ajmg.a.36988; Brajenovic-Milic B, 1998, FETAL DIAGN THER, V13, P187, DOI 10.1159/000020836; Carss KJ, 2014, HUM MOL GENET, V23, P3269, DOI 10.1093/hmg/ddu038; Czeizel Andrew E, 2005, Int J Med Sci, V2, P91; Daniel A, 2003, AUST NZ J OBSTET GYN, V43, P16, DOI 10.1046/j.0004-8666.2003.00025.x; Das Bhowmik A, 2015, GENE, V572, P303, DOI 10.1016/j.gene.2015.08.053; de Wit MC, 2014, ULTRASOUND OBST GYN, V43, P139, DOI 10.1002/uog.12575; Desilets V, 2011, J OBSTET GYNAECOL CA, V33, P1047, DOI 10.1016/S1701-2163(16)35055-1; Devisme L, 2012, BRAIN, V135, P469, DOI 10.1093/brain/awr357; Drury S, 2015, PRENATAL DIAG, V35, P1010, DOI 10.1002/pd.4675; Ernst LM, 2015, SEMIN PERINATOL, V39, P55, DOI 10.1053/j.semperi.2014.10.008; Filges I, 2014, CLIN GENET, V86, P220, DOI 10.1111/cge.12301; Filges I, 2015, PRENATAL DIAG, V35, P1005, DOI 10.1002/pd.4464; Fletcher E, 2017, PEDIATR DEVEL PATHOL, V20, P288, DOI 10.1177/1093526617693104; Forrester MB, 2004, AM J MED GENET A, V128A, P383, DOI 10.1002/ajmg.a.30205; Gripp KW, 2016, AM J MED GENET A, V170, P1754, DOI 10.1002/ajmg.a.37672; Hebbar M, 2016, AM J MED GENET A, V170, P2486, DOI 10.1002/ajmg.a.37794; Javed A, 2014, NAT METHODS, V11, P935, DOI [10.1038/NMETH.3046, 10.1038/nmeth.3046]; Kumari N, 2008, J PERINATOL, V28, P736, DOI 10.1038/jp.2008.93; Lyon A, 2004, ARCH DIS CHILD, V89, pF284, DOI 10.1136/adc.2003.037333; McPherson E, 2016, AM J MED GENET A, V170, P1174, DOI 10.1002/ajmg.a.37606; Medina Castro D, 2012, GINECOL OBSTET MEX, V80, P313; Nayak SS, 2015, PRENATAL DIAG, V35, P685, DOI 10.1002/pd.4592; Reddy UM, 2012, NEW ENGL J MED, V367, P2185, DOI 10.1056/NEJMoa1201569; Reddy UM, 2012, PRENATAL DIAG, V32, P371, DOI 10.1002/pd.3825; Reutter H, 2016, PEDIATR NEPHROL, V31, P2025, DOI 10.1007/s00467-016-3335-3; Romero ST, 2015, ULTRASOUND OBST GYN, V45, P89, DOI 10.1002/uog.14713; Rosenfeld JA, 2015, ULTRASOUND OBST GYN, V46, P478, DOI 10.1002/uog.14866; Stoll C, 2003, ULTRASOUND OBST GYN, V21, P543, DOI 10.1002/uog.125; Vimercati Antonella, 2012, J Prenat Med, V6, P13; Vogt C, 2012, ULTRASOUND OBST GYN, V39, P666, DOI 10.1002/uog.10106; Wapner RJ, 2012, NEW ENGL J MED, V367, P2175, DOI 10.1056/NEJMoa1203382; Weichert J, 2010, FETAL DIAGN THER, V27, P142, DOI 10.1159/000304735	39	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	1					49	68		10.1080/15513815.2017.1397070			20	Pathology; Pediatrics	Pathology; Pediatrics	FW9ZF	WOS:000425696300007	29336636				2019-10-28	
J	Fathollahi, A; Massoud, A; Amirzargar, AA; Aghili, B; Esfahani, EN; Rezaei, N				Fathollahi, Anwar; Massoud, Ahmad; Amirzargar, Ali Akbar; Aghili, Babak; Esfahani, Ensieh Nasli; Rezaei, Nima			sICAM-1, sVCAM-1 and sE-Selectin Levels in Type 1 Diabetes	FETAL AND PEDIATRIC PATHOLOGY			English	Article						cell adhesion molecules; sICAM-1; sVCAM-1; sE-selectin; type 1 diabetes	CELL-ADHESION MOLECULE-1; ELEVATED CONCENTRATIONS; MELLITUS; DISEASE; ANGIOGENESIS; RECEPTORS; ETIOLOGY; NIDDM	Background/Objective: This study was performed to compare soluble levels of adhesion molecules between diabetic patients and controls and to assess their possible association with long-term complications of type 1 diabetes (T1D). Methods: Forty-eight patients with T1D and 39 healthy controls were enrolled in this study. The plasma level of adhesion molecules was measured by sandwich enzyme-linked immunosorbent assay technique. Results: Higher sVCAM 1 (soluble vascular cell adhesion molecule 1) levels correlated with older age of onset of T1D. The plasma level of sICAM 1 (soluble intercellular adhesion molecule 1) was significantly increased, while sE selectin was significantly decreased in patients with T1D, compared to controls. There was no significant relationship between these plasma-level variations and the long-term complications of T1D. Conclusion: Although plasma levels of cell adhesion molecules are different in T1D patients and healthy controls, they might not be good candidate markers for prognosis of disease.	[Fathollahi, Anwar; Massoud, Ahmad; Amirzargar, Ali Akbar; Aghili, Babak; Rezaei, Nima] Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran, Iran; [Amirzargar, Ali Akbar] Univ Tehran Med Sci, Mol Immunol Res Ctr, Tehran, Iran; [Esfahani, Ensieh Nasli] Univ Tehran Med Sci, Diabet Res Ctr, Endocrinol & Metab Clin Sci Inst, Tehran, Iran; [Esfahani, Ensieh Nasli] Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Endocrinol & Metab Res Inst, Tehran, Iran; [Rezaei, Nima] Univ Tehran Med Sci, Childrens Med Ctr, Res Ctr Immunodeficiencies, Tehran, Iran; [Rezaei, Nima] USERN, NIIMA, Boston, MA USA	Rezaei, N (reprint author), Childrens Med Ctr Hosp, Res Ctr Immunodeficiencies, Dr Qarib St,Keshavarz Blvd, Tehran 14194, Iran.	rezaei_nima@tums.ac.ir	Rezaei, Nima/B-4245-2008; Massoud, Ahmed/R-7174-2017	Rezaei, Nima/0000-0002-3836-1827; Massoud, Ahmed/0000-0001-9343-469X; Fathollahi, Anwar/0000-0002-9303-2479	Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran	This study was supported by a grant from Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.	Akerblom HK, 2002, AM J MED GENET, V115, P18, DOI 10.1002/ajmg.10340; ALBELDA SM, 1990, FASEB J, V4, P2868; Albertini JP, 1998, DIABETES CARE, V21, P1008, DOI 10.2337/diacare.21.6.1008; Bannan S, 1998, DIABETOLOGIA, V41, P460, DOI 10.1007/s001250050930; Ceriello A, 1998, HORM METAB RES, V30, P146, DOI 10.1055/s-2007-978854; Clausen P, 2000, DIABETIC MED, V17, P644, DOI 10.1046/j.1464-5491.2000.00347.x; Dong AL, 2011, P NATL ACAD SCI USA, V108, P14614, DOI 10.1073/pnas.1012859108; Fasching P, 1996, J CLIN ENDOCR METAB, V81, P4313, DOI 10.1210/jc.81.12.4313; Gho YS, 1999, CANCER RES, V59, P5128; Giarratana N, 2004, J IMMUNOL, V173, P2280, DOI 10.4049/jimmunol.173.4.2280; Jude EB, 1998, DIABETOLOGIA, V41, P330, DOI 10.1007/s001250050911; Jude EB, 2002, EUR J INTERN MED, V13, P185, DOI DOI 10.1016/S0953-6205(02)00014-6; Ley K, 2003, TRENDS MOL MED, V9, P263, DOI 10.1016/S1471-4914(03)00071-6; Martin A, 2003, MED RES REV, V23, P117, DOI 10.1002/med.10024; McMurray RW, 1996, SEMIN ARTHRITIS RHEU, V25, P215, DOI 10.1016/S0049-0172(96)80034-5; Mohamed-Ali V, 2001, J INTERN MED, V250, P415, DOI 10.1046/j.1365-2796.2001.00900.x; Nahrendorf M, 2006, CIRCULATION, V114, P1504, DOI 10.1161/CIRCULATIONAHA.106.646380; Paterson AD, 2009, ARTERIOSCL THROM VAS, V29, P1958, DOI 10.1161/ATVBAHA.109.192971; Polverini PJ, 1996, AM J PATHOL, V148, P1023; Schroder C, 2011, J CANCER RES CLIN, V137, P1193, DOI 10.1007/s00432-011-0984-2; Smith CW, 2008, J ALLERGY CLIN IMMUN, V121, pS375, DOI 10.1016/j.jaci.2007.07.030; Soltesz G, 2003, DIABETOLOGIA, V46, P447, DOI 10.1007/s00125-003-1101-0; Todd JA, 2001, IMMUNITY, V15, P387, DOI 10.1016/S1074-7613(01)00202-3; Van Belle TL, 2011, PHYSIOL REV, V91, P79, DOI 10.1152/physrev.00003.2010; Wai Wong C, 2012, INT J CELL BIOL	25	2	3	2	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	1					69	73		10.1080/15513815.2017.1405467			5	Pathology; Pediatrics	Pathology; Pediatrics	FW9ZF	WOS:000425696300008	29336634				2019-10-28	
J	Rahmoun, N; El Mecherfi, KE; Bouchetara, A; Hetraf, SL; Amira, CD; Neggaz, LA; Boudjema, A; Zemani-Fodil, F; Kheroua, O				Rahmoun, Nesrine; El Mecherfi, Kamel Eddine; Bouchetara, Assia; Hetraf, Sara Lardjem; Amira, Chahinez Dahmani; Neggaz, Leila Adda; Boudjema, Abdallah; Zemani-Fodil, Faouzia; Kheroua, Omar			Association of REL Polymorphism with Cow's Milk Proteins Allergy in Pediatric Algerian Population	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Cow's milk proteins allergy; IL4; FoxP3; REL; polymorphisms	GENE POLYMORPHISMS; IL4 GENES; ASTHMA; INTERLEUKIN-4; RISK; IL-4; SUSCEPTIBILITY; VARIANTS; RHINITIS; INFANTS	Introduction: Cow's milk proteins allergy (CMPA) pathogenesis involves complex immunological mechanisms with the participation of several cells and molecules involved in food allergy. The association of polymorphisms in the interleukin 4, Forkhead box P3 and the avian reticuloendotheliosis genes was investigated in an infant population with CMPA of Western Algeria. Materials and methods: We obtained DNA and clinical data from milk allergic subjects during active phase and from a group of non-atopic control subjects. Results: Our findings showed that the allele G of the cRel gene intronic polymorphism at +7883 positions was significantly higher among cow's milk proteins allergic patients compared to control subjects. Conclusion: The results of this study suggest a possible association of CMPA with cRel G+7883T polymorphism.	[Rahmoun, Nesrine; Hetraf, Sara Lardjem; Amira, Chahinez Dahmani; Boudjema, Abdallah; Zemani-Fodil, Faouzia] USTOMB, Lab Genet Mol & Cellulaire, Oran, Algeria; [Rahmoun, Nesrine; El Mecherfi, Kamel Eddine; Hetraf, Sara Lardjem; Amira, Chahinez Dahmani; Neggaz, Leila Adda; Boudjema, Abdallah; Zemani-Fodil, Faouzia] USTOMB, Fac Sci & Vie, Dept Genet Mol Appl, Oran, Algeria; [El Mecherfi, Kamel Eddine; Kheroua, Omar] Univ Oran 1 Ahmed Benbella, Lab Physiol Nutr & Secur Alimentaire, Oran, Algeria; [Bouchetara, Assia] EHS Boukhroufa Abdelkader, Dept Malad Infect, Canastel, Oran, Algeria	El Mecherfi, KE (reprint author), USTO MB, BP 1505, Bir El Djir 31000, Oran, Algeria.	elmecherfi@gmail.com	SAIDI, Djamel/P-7438-2016	SAIDI, Djamel/0000-0002-3253-7414			Adjers K, 2005, INT ARCH ALLERGY IMM, V138, P251, DOI 10.1159/000088726; Akdis M, 2005, J ALLERGY CLIN IMMUN, V116, P961, DOI 10.1016/j.jaci.2005.09.004; ALI FR, 2013, J DERMATOL, V168, P864, DOI DOI 10.1111/BJD.12106; Battle NC, 2007, AM J RESP CRIT CARE, V175, P881, DOI 10.1164/rccm.200607-992OC; Baye TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016522; Beghe B, 2003, CLIN EXP ALLERGY, V33, P1111, DOI 10.1046/j.1365-2222.2003.01731.x; Bekada A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138453; BISHOP JM, 1990, J PEDIATR-US, V116, P862, DOI 10.1016/S0022-3476(05)80641-9; Black S, 2009, ALLERGY, V64, P1172, DOI 10.1111/j.1398-9995.2009.01988.x; Boughellout H, 2010, ANNABA ALGERIE, V24, P62; Burks AW, 2012, J ALLERGY CLIN IMMUN, V129, P906, DOI 10.1016/j.jaci.2012.02.001; [陈芸 CHEN Yun], 2011, [免疫学杂志, Immunological Journal], V27, P416; Cho JH, 2011, GASTROENTEROLOGY, V140, P1704, DOI 10.1053/j.gastro.2011.02.046; Curotto LMA, 2009, IMMUNITY, V30, P626, DOI [10.1016/j.immuni.2009.05.002, DOI 10.1016/J.IMMUNI.2009.05.002]; Denis M, 2012, ARCH PEDIATRIE, V19, P305, DOI 10.1016/j.arcped.2011.12.002; Deo SS, 2010, LUNG INDIA, V27, P66, DOI 10.4103/0970-2113.63609; Donovan CE, 1999, J IMMUNOL, V163, P6827; Dutau G, 2007, REV FR ALLERGOL, V47, P102, DOI 10.1016/j.allerg.2007.01.008; Enciso-Mora V, 2010, NAT GENET, V42, P1126, DOI 10.1038/ng.696; Eyre S, 2010, ANN RHEUM DIS, V69, P1572, DOI 10.1136/ard.2009.122887; Fiocchi A, 2010, PEDIAT ALLERG IMM-UK, V21, P1, DOI 10.1111/j.1399-3038.2010.01068.x; Gervaziev YV, 2006, INT ARCH ALLERGY IMM, V141, P257, DOI 10.1159/000095295; Gilmore Thomas D, 2011, Genes Cancer, V2, P695, DOI 10.1177/1947601911421925; Gregersen PK, 2009, NAT GENET, V41, P820, DOI 10.1038/ng.395; He JQ, 2003, GENES IMMUN, V4, P385, DOI 10.1038/sj.gene.6363985; HILL DJ, 1994, CLIN EXP ALLERGY, V24, P1137, DOI 10.1111/j.1365-2222.1994.tb03319.x; Holloway JW, 2010, J ALLERGY CLIN IMMUN, V125, pS81, DOI 10.1016/j.jaci.2009.10.071; Hong XM, 2009, CURR OPIN PEDIATR, V21, P770, DOI 10.1097/MOP.0b013e32833252dc; Ibsaine O, 2014, ARCH PEDIATR, V55, DOI [10.1016/S0929-693X(14)72107-4, DOI 10.1016/S0929-693X(14)72107-4]; Isidoro-Garcia Maria, 2005, Clin Mol Allergy, V3, P15, DOI 10.1186/1476-7961-3-15; Johnston LK, 2014, J IMMUNOL, V192, P2529, DOI 10.4049/jimmunol.1303026; Kvenshagen B, 2008, ACTA PAEDIATR, V97, P196, DOI 10.1111/j.1651-2227.2007.00599.x; Li GS, 2007, HUM MUTAT, V28, P950, DOI 10.1002/humu.20543; Lin PI, 2007, AM J HUM GENET, V80, P531, DOI 10.1086/512133; Long MX, 2009, IMMUNITY, V31, P921, DOI 10.1016/j.immuni.2009.09.022; Martorell-Aragones A, 2015, ALLERGOL IMMUNOPATH, V43, P507, DOI 10.1016/j.aller.2015.01.003; Menard S, 2010, MUCOSAL IMMUNOL, V3, P247, DOI 10.1038/mi.2010.5; Micheal S, 2013, J INVEST ALLERG CLIN, V23, P107; Movahedi M, 2013, AM J OTOLARYNG, V34, P676, DOI 10.1016/j.amjoto.2013.05.002; Noguchi E, 1998, CLIN EXP ALLERGY, V28, P449; Paparo L, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0252-z; Rance F, 2005, HORS SERIE, V1; Rance F, 2009, REV FR ALLERGOL S1, V49, P28, DOI DOI 10.1016/S1877-0320(09)72481-9; Rautava S, 2004, J PEDIATR GASTR NUTR, V39, P529, DOI 10.1097/00005176-200411000-00015; Renauld JC, 2002, LOUVAIN MED, V121, P241; Ruan QG, 2009, IMMUNITY, V31, P932, DOI 10.1016/j.immuni.2009.10.006; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; SCHRANDER JJP, 1993, EUR J PEDIATR, V152, P640, DOI 10.1007/BF01955238; Shohei H, 2010, J IMMUNOL, V40, P664; Suzuki I, 2000, CLIN EXP ALLERGY, V30, P1746, DOI 10.1046/j.1365-2222.2000.00983.x; Trynka G, 2009, GUT, V58, P1078, DOI 10.1136/gut.2008.169052; Varade J, 2011, ANN RHEUM DIS, V70, P711, DOI 10.1136/ard.2010.134593; Venter C, 2006, J ALLERGY CLIN IMMUN, V117, P1118, DOI 10.1016/j.jaci.2005.12.1352; Walley AJ, 1996, J MED GENET, V33, P689, DOI 10.1136/jmg.33.8.689; Wang JY, 2009, J CLIN IMMUNOL, V29, P205, DOI 10.1007/s10875-008-9256-6; Wu XH, 2010, J ASTHMA, V47, P238, DOI 10.3109/02770900903509099; Yang HJ, 2013, J INVESTIG ALLERGOL, P114; Yang XX, 2011, ASIAN PAC J ALLERGY, V29, P273; Zamorano J., 2003, IMMUNOLOGIA, V22, P215	59	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	1					74	83		10.1080/15513815.2017.1405468			10	Pathology; Pediatrics	Pathology; Pediatrics	FW9ZF	WOS:000425696300009	29336650				2019-10-28	
J	Sreenivasan, S; Sawant, V; Ghoshal, J				Sreenivasan, Srividya; Sawant, Vishnu; Ghoshal, Joy			Post Mortem Diagnosis of Blake's Pouch Cyst: A Presentation of Distended Cyst at Necropsy	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Blake's pouch cyst; cerebellar vermis; fetus; posterior fossa		Background: Blake's pouch cyst forms from non-permeabilization of Blake's pouch. It is difficult to visualize at necropsy as the cyst ruptures easily into the 4th ventricle during dissection. Case report: Based upon prenatal imaging, delicate dissection allowed post-mortem confirmation of the Blake's pouch cyst. Conclusions: This highlights the importance of utilizing premortem imaging to help guide the postmortem dissection and documentation of a posterior fossa cyst.	[Sreenivasan, Srividya; Sawant, Vishnu; Ghoshal, Joy] DY Patil Univ, Sch Med, Dept Anat, Navi Mumbai 400706, Maharashtra, India	Sreenivasan, S (reprint author), DY Patil Univ, Sch Med, Dept Anat, Navi Mumbai 400706, Maharashtra, India.	srividyasreenivasan@yahoo.com					Blake JA, 1900, J COMP NEUROL, V10, P79, DOI 10.1002/cne.910100104; BROCKLEH.G, 1969, J ANAT, V105, P467; Cornips EMJ, 2010, CHILD NERV SYST, V26, P1057, DOI 10.1007/s00381-010-1085-2; Nelson MD, 2004, PEDIATR RADIOL, V34, P720, DOI 10.1007/s00247-004-1253-1; O'Rahilly R, 2001, HUMAN EMBRYOLOGY TER; Paladini D, 2012, ULTRASOUND OBST GYN, V39, P279, DOI 10.1002/uog.10138; Wilson JT, 1937, J ANAT, V71, P423	7	0	0	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	1					84	88		10.1080/15513815.2017.1392664			5	Pathology; Pediatrics	Pathology; Pediatrics	FW9ZF	WOS:000425696300010	29336637				2019-10-28	
J	Donaduzzi, LC; Reinheimer, A; da Silva, MAR; de Noronha, L; Johann, ACBR; Franco, A; Couto, SDB; Souza, PHC				Donaduzzi, Liziane Cattelan; Reinheimer, Angelica; Ramires da Silva, Maria Augusta; de Noronha, Lucia; Batista Rodrigues Johann, Aline Cristina; Franco, Ademir; Berti Couto, Soraya de Azambuja; Couto Souza, Paulo Henrique			Primary Diffuse Large B Cell Lymphoma Mimicking Hyperplastic Reactive Lesion (Lymphoma of the Oral Cavity)	CASE REPORTS IN PATHOLOGY			English	Article							NON-HODGKINS-LYMPHOMA; MALIGNANT-LYMPHOMA; CLASSIFICATION	Objective. To report a case of a challenging oral diagnosis involving a primary diffuse large B cell lymphoma of the oral cavity mimicking a hyperplastic reactive lesion. Case Report. A 72-year-old male patient was referred to the Department of Stomatology presenting a proliferative nodular lesion in the anterior region of the mandible involving the anterior teeth. The clinical examination revealed anterior teeth affected by periodontal disease, suggesting the nodular cession hyperplastic reaction. Incisional biopsy was performed under local anesthesia. The histopathological examination revealed a diffuse proliferation of atypical large lymphoid cells. The tumor cells showed immunopositivity for CD20 and Ki67 (100%) and negativity for CD3, CD30, and CD15. The diagnosis of diffuse large B cell lymphoma was established. The patient underwent chemotherapy and progressed to death after nine months. Conclusion. Lymphomas of the oral cavity are rare and may have nonspecific clinical features, mimicking inflammatory and reactive lesions. Therefore, a detailed clinical evaluation associated with histopathological and immunohistochemical analysis should be performed to enable early and accurate diagnoses in suspected oral lesions.	[Donaduzzi, Liziane Cattelan; Reinheimer, Angelica; Ramires da Silva, Maria Augusta; Batista Rodrigues Johann, Aline Cristina; Franco, Ademir; Berti Couto, Soraya de Azambuja; Couto Souza, Paulo Henrique] Pontificia Univ Catolica Parana, Dept Dent, Sch Life Sci, Curitiba, PR, Brazil; [de Noronha, Lucia] Pontificia Univ Catolica Parana, Sch Med, Curitiba, PR, Brazil	Johann, ACBR (reprint author), Pontificia Univ Catolica Parana, Dept Dent, Sch Life Sci, Curitiba, PR, Brazil.	aline.johann@pucpr.br	Franco, Ademir/D-6665-2017; Johann, Aline C B R/G-7190-2012	Franco, Ademir/0000-0002-1417-2781; Johann, Aline C B R/0000-0002-1678-9363			Alexander DD, 2007, INT J CANCER, P1, DOI 10.1002/ijc.22719; Basavaraj K F, 2012, J Nat Sci Biol Med, V3, P189, DOI 10.4103/0976-9668.101913; Bhattacharyya I, 2010, HEAD NECK PATHOL, V4, P181, DOI 10.1007/s12105-010-0184-4; Castellarin P, 2010, J ONCOL, DOI 10.1155/2010/202305; Chan WC, 1997, BLOOD, V89, P3909; Coiffier B, 2005, J CLIN ONCOL, V23, P6387, DOI 10.1200/JCO.2005.05.015; Epstein JB, 2001, ORAL SURG ORAL MED O, V92, P519, DOI 10.1067/moe.2001.116062; Inchingolo F, 2011, HEAD NECK ONCOL, V3, DOI 10.1186/1758-3284-3-1; Jayakrishnan R., 2008, Journal of Oral and Maxillofacial Pathology, V12, P85; Manjunatha B S, 2011, J Indian Soc Periodontol, V15, P418, DOI 10.4103/0972-124X.92584; Marrelli M, 2012, INT J MED SCI, V9, P47, DOI 10.7150/ijms.9.47; Nogai H, 2011, J CLIN ONCOL, V29, P1803, DOI 10.1200/JCO.2010.33.3252; Rozza-de-Menezes R. E., 2013, CASE REPORTS DENT, V2013, P1; Shah GH, 2011, INDIAN J MED PAEDIAT, V32, P76, DOI 10.4103/0971-5851.89776; Souto G.-R., 2013, J CLIN EXPT DENT, V5, P287; Swerdlow SH, 2008, WHO CLASSIFICATION T; Tatullo M, 2015, J CANCER, V6, P976, DOI 10.7150/jca.11936; Yin HF, 1999, VIRCHOWS ARCH, V435, P400, DOI 10.1007/s004280050417; Zapater E, 2010, ORAL DIS, V16, P119, DOI 10.1111/j.1601-0825.2009.01586.x	19	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									2981689	10.1155/2018/2981689			4	Pathology	Pathology	FW6UX	WOS:000425455400001	29552368	DOAJ Gold, Green Published			2019-10-28	
J	Evans, AJ				Evans, Andrew J.			Treatment effects in prostate cancer	MODERN PATHOLOGY			English	Article							INTENSITY FOCUSED ULTRASOUND; TARGETED PHOTODYNAMIC THERAPY; NEOADJUVANT HORMONAL-THERAPY; ESTRO-SIOG GUIDELINES; FOLLOW-UP; RADICAL PROSTATECTOMY; RADIATION-THERAPY; ANDROGEN BLOCKADE; FOCAL THERAPY; CARCINOMA	Nonsurgical treatments for prostate cancer include androgen-deprivation therapy (ADT), radiation therapy (RT), ablative therapies, chemotherapy, and newly emerging immunotherapies. These approaches can be used alone or in combination depending on the clinical scenario. ADT is typically reserved for high-risk locally or systemically advanced disease that is not amenable to curative surgery. Radiation therapy can be used instead of surgery as primary therapy with curative intent for low-intermediate-risk disease as well as for control of locally advanced disease not suitable for surgery. Ablative therapies can be used as primary therapy for low-intermediate-risk disease or as salvage therapy for clinically localized disease where RT has failed. Chemotherapy and immune-based therapies are currently used for androgen-independent disease, although the indications for these approaches may well change as new data from clinical trials accrue. Pathologists should be able to recognize tissue changes associated with these treatments to provide information that will optimize patient management. This is particularly true in situations where clinical history of recent or remote nonsurgical treatment is not provided with the specimen. In the absence of this information, pathologists encountering the features described herein are encouraged to review patient records or communicate directly with clinical colleagues to determine how a given patient was treated and when.	[Evans, Andrew J.] Univ Hlth Network, Toronto Gen Hosp, Dept Lab Informat Support Syst, 11 Eaton 223,200 Elizabeth St, Toronto, ON M5G 2C4, Canada	Evans, AJ (reprint author), Univ Hlth Network, Toronto Gen Hosp, Dept Lab Informat Support Syst, 11 Eaton 223,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	andrew.evans@uhn.ca					Alberti C, 2010, G CHIR, V31, P568; Azzouzi AR, 2017, LANCET ONCOL, V18, P181, DOI 10.1016/S1470-2045(16)30661-1; BOCKING A, 1987, DIAGN CYTOPATHOL, V3, P108, DOI 10.1002/dc.2840030204; Bostwick DG, 2007, ARCH PATHOL LAB MED, V131, P360; Brown JA, 2004, J LAPAROENDOSC ADV A, V14, P335; Chen RC, 2016, J CLIN ONCOL, V34, P2182, DOI 10.1200/JCO.2015.65.7759; Cornford P, 2017, EUR UROL, V71, P630, DOI 10.1016/j.eururo.2016.08.002; Crook JM, 1997, CANCER-AM CANCER SOC, V79, P328, DOI 10.1002/(SICI)1097-0142(19970115)79:2<328::AID-CNCR16>3.0.CO;2-2; Crook JM, 2009, CANCER, V115, P673, DOI 10.1002/cncr.24020; Efstathiou E, 2010, EUR UROL, V57, P1030, DOI 10.1016/j.eururo.2009.10.020; Eggener SE, 2016, J UROLOGY, V196, P1670, DOI 10.1016/j.juro.2016.07.074; Elterman DS, 2011, CAN J UROL, V18, P6037; Evans AJ, 2006, AM J SURG PATHOL, V30, P684, DOI 10.1097/00000478-200606000-00003; Evans AJ, 2011, ADV ANAT PATHOL, V18, P281, DOI 10.1097/PAP.0b013e318220f5b1; Fine SW, 2012, ADV ANAT PATHOL, V19, P204, DOI 10.1097/PAP.0b013e31825c6b92; Francini E, 2017, CANCER-AM CANCER SOC, V123, P29, DOI 10.1002/cncr.30329; Golabek T, 2016, CENT EUR J UROL, V69, P131, DOI 10.5173/ceju.2016.812; Gravis G, 2017, CANCER TREAT REV, V55, P211, DOI 10.1016/j.ctrv.2016.09.008; Kincaide LF, 1996, AM J VET RES, V57, P1225; Kollermann J, 2003, UROLOGY, V62, P476, DOI 10.1016/S0090-4295(03)00351-0; Lawrentschuk N, 2011, J UROLOGY, V185, P862, DOI 10.1016/j.juro.2010.10.080; Lindner U, 2010, NAT REV UROL, V7, P562, DOI 10.1038/nrurol.2010.142; Lindner U, 2010, EUR UROL, V57, P1111, DOI 10.1016/j.eururo.2010.03.008; Lorente D, 2016, EUR UROL FOCUS, V2, P488, DOI 10.1016/j.euf.2016.10.008; Lucia MS, 2007, J NATL CANCER I, V99, P1375, DOI 10.1093/jnci/djm117; Madan RA, 2017, CURR OPIN SUPPORT PA, V11, P225, DOI 10.1097/SPC.0000000000000278; Mazzucchelli R, 2013, INT J IMMUNOPATH PH, V26, P291, DOI 10.1177/039463201302600202; Mizokami A, 2017, INT J UROL, V24, P566, DOI 10.1111/iju.13372; Morash C, 2015, CUAJ-CAN UROL ASSOC, V9, P171, DOI 10.5489/cuaj.2806; Mottet N, 2017, EUR UROL, V71, P618, DOI 10.1016/j.eururo.2016.08.003; Naghavi AO, 2015, INT J CLIN ONCOL, V20, P598, DOI 10.1007/s10147-014-0745-8; O'Brien C, 2010, AM J CLIN PATHOL, V133, P654, DOI 10.1309/AJCP8EL5FTZSOBIH; Oelke M, 2013, EUR UROL, V64, P118, DOI 10.1016/j.eururo.2013.03.004; Perera M, 2016, NAT REV UROL, V13, P641, DOI 10.1038/nrurol.2016.177; Rijnders M, 2017, EUR UROL, V72, P411, DOI 10.1016/j.eururo.2017.06.012; Ryan P, 2012, J CLIN PATHOL, V65, P729, DOI 10.1136/jclinpath-2011-200460; Serfling R, 2007, J UROLOGY, V177, P2352, DOI 10.1016/j.juro.2007.01.116; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Srigley JR, 2012, HISTOPATHOLOGY, V60, P153, DOI 10.1111/j.1365-2559.2011.04079.x; ter Haar GR, 2001, ECHOCARDIOGR-J CARD, V18, P317, DOI 10.1046/j.1540-8175.2001.00317.x; Tetu B, 2008, BEST PRACT RES CL EN, V22, P271, DOI 10.1016/j.beem.2008.01.005; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Trachtenberg J, 2007, J UROLOGY, V178, P1974, DOI 10.1016/j.juro.2007.07.036; Trachtenberg J, 2008, BJU INT, V102, P556, DOI 10.1111/j.1464-410X.2008.07753.x; van den Bos W, 2015, UROL ONCOL-SEMIN ORI, V33, DOI 10.1016/j.urolonc.2015.06.015; van der Kwast TH, 1999, UROLOGY, V53, P523, DOI 10.1016/S0090-4295(98)00542-1; Van Leenders GJLH, 2000, J CLIN PATHOL, V53, P391, DOI 10.1136/jcp.53.5.391; Veereman G, 2015, EUR UROL FOCUS, V1, P158, DOI 10.1016/j.euf.2015.04.006; Warmuth M, 2010, EUR UROL, V58, P803, DOI 10.1016/j.eururo.2010.09.009; Woodrum DA, 2017, CLIN RADIOL, V72, P665, DOI 10.1016/j.crad.2017.02.010; Yacoubian A, 2016, CURR UROL REP, V17, DOI 10.1007/s11934-016-0637-8; Yee DS, 2010, BJU INT, V105, P185, DOI 10.1111/j.1464-410X.2009.08698.x; Yeku O, 2016, CANCER J, V22, P334, DOI 10.1097/PPO.0000000000000223; Zaorsky NG, 2017, NAT REV UROL, V14, P415, DOI 10.1038/nrurol.2017.76	54	1	1	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31			1			S110	S121		10.1038/modpathol.2017.158			12	Pathology	Pathology	FW3PC	WOS:000425219700009	29297495				2019-10-28	
J	Fine, SW				Fine, Samson W.			Neuroendocrine tumors of the prostate	MODERN PATHOLOGY			English	Article							SMALL-CELL-CARCINOMA; NEOPLASTIC HUMAN PROSTATE; PROGNOSTIC-SIGNIFICANCE; ANDROGEN RECEPTOR; ACID-PHOSPHATASE; RADICAL PROSTATECTOMY; INCREASED SURVIVAL; CANCER; DIFFERENTIATION; ADENOCARCINOMA	Neuroendocrine (NE) differentiation in tumors of the prostate or in the setting of prostate cancer (PCa) is rare. A survey of these lesions is presented, including usual PCa with focal NE marker-positive cells, Paneth cell-like change, prostatic 'carcinoid', high-grade NE carcinoma, as well as other tumors that do not fit neatly into these categories. The most significant clinical and pathologic features, emerging molecular evidence and the importance of differentiating NE tumors involving the prostate from secondary involvement are highlighted.	[Fine, Samson W.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave,Room C502, New York, NY 10065 USA	Fine, SW (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave,Room C502, New York, NY 10065 USA.	fines@mskcc.org					Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; ABRAHAMSSON PA, 1993, J ANDROL, V14, P307; ABRAHAMSSON PA, 1989, PATHOL RES PRACT, V185, P373, DOI 10.1016/S0344-0338(89)80016-0; Abrahamsson PA, 1998, PROSTATE, P37; Agoff SN, 2000, MODERN PATHOL, V13, P238, DOI 10.1038/modpathol.3880044; ALMAGRO UA, 1985, CANCER, V55, P608, DOI 10.1002/1097-0142(19850201)55:3<608::AID-CNCR2820550322>3.0.CO;2-S; AMATO RJ, 1992, J UROLOGY, V147, P935, DOI 10.1016/S0022-5347(17)37427-X; ANSARI MA, 1981, AM J CLIN PATHOL, V76, P94; Aparicio AM, 2013, CLIN CANCER RES, V19, P3621, DOI 10.1158/1078-0432.CCR-12-3791; APRIKIAN AG, 1994, J UROLOGY, V151, P914, DOI 10.1016/S0022-5347(17)35121-2; APRIKIAN AG, 1993, CANCER, V71, P3952, DOI 10.1002/1097-0142(19930615)71:12<3952::AID-CNCR2820711226>3.0.CO;2-X; AZUMI N, 1984, AM J SURG PATHOL, V8, P545, DOI 10.1097/00000478-198407000-00007; AZUMI N, 1991, AM J SURG PATHOL, V15, P785, DOI 10.1097/00000478-199108000-00009; AZZOPARDI JG, 1971, J PATHOL, V104, P247, DOI 10.1002/path.1711040406; Beltran H, 2014, CLIN CANCER RES, V20, P2846, DOI 10.1158/1078-0432.CCR-13-3309; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bonkhoff H, 2001, ANN ONCOL, V12, pS141, DOI 10.1093/annonc/12.suppl_2.S141; BONKHOFF H, 1994, HUM PATHOL, V25, P42, DOI 10.1016/0046-8177(94)90169-4; BONKHOFF H, 1993, VIRCHOWS ARCH A, V423, P291, DOI 10.1007/BF01606893; Casella R, 1998, J UROLOGY, V160, P406, DOI 10.1016/S0022-5347(01)62909-4; CHRISTOPHER ME, 1991, J UROLOGY, V146, P382, DOI 10.1016/S0022-5347(17)37800-X; COHEN RJ, 1991, BRIT J UROL, V68, P258, DOI 10.1111/j.1464-410X.1991.tb15318.x; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; DISANTAGNESE PA, 1984, HUM PATHOL, V15, P1034; DISANTAGNESE PA, 1985, ARCH PATHOL LAB MED, V109, P607; DISANTAGNESE PA, 1988, ARCH PATHOL LAB MED, V112, P1097; DISANTAGNESE PA, 1992, CANCER-AM CANCER SOC, V70, P254, DOI 10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E; Epstein JI, 2014, AM J SURG PATHOL, V38, P756, DOI 10.1097/PAS.0000000000000208; Evans AJ, 2006, AM J SURG PATHOL, V30, P684, DOI 10.1097/00000478-200606000-00003; Fernandes R C, 2001, Rev Hosp Clin Fac Med Sao Paulo, V56, P153, DOI 10.1590/S0041-87812001000500005; FETISSOF F, 1983, VIRCHOWS ARCH B, V42, P53, DOI 10.1007/BF02890370; Galanis E, 1997, CANCER-AM CANCER SOC, V79, P1729, DOI 10.1002/(SICI)1097-0142(19970501)79:9<1729::AID-CNCR14>3.0.CO;2-#; GHALI VS, 1984, CANCER, V54, P1043, DOI 10.1002/1097-0142(19840915)54:6<1043::AID-CNCR2820540619>3.0.CO;2-U; Ghannoum JE, 2004, INT J SURG PATHOL, V12, P167, DOI 10.1177/106689690401200214; Goulet-Salmon B, 2004, J ENDOCRINOL INVEST, V27, P570, DOI 10.1007/BF03347481; Guo CC, 2011, HUM PATHOL, V42, P11, DOI 10.1016/j.humpath.2010.05.026; Han B, 2009, MODERN PATHOL, V22, P1176, DOI 10.1038/modpathol.2009.79; Hansel DE, 2009, PROSTATE, V69, P603, DOI 10.1002/pros.20910; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Huang JT, 2006, PROSTATE, V66, P1399, DOI 10.1002/pros.20434; Klimstra David S, 2015, Am Soc Clin Oncol Educ Book, P92, DOI 10.14694/EdBook_AM.2015.35.92; Krijnen JLM, 1997, J UROLOGY, V158, P171, DOI 10.1097/00005392-199707000-00054; KRIJNEN JLM, 1993, HISTOCHEMISTRY, V100, P393, DOI 10.1007/BF00268938; Lotan TL, 2011, MODERN PATHOL, V24, P820, DOI 10.1038/modpathol.2011.7; MATZKIN H, 1987, J UROLOGY, V138, P1129, DOI 10.1016/S0022-5347(17)43524-5; McWilliam LJ, 1997, BRIT J UROL, V80, P287, DOI 10.1046/j.1464-410X.1997.00300.x; Moch H, 2016, WHO CLASSIFICATION T; Mosquera JM, 2013, NEOPLASIA, V15, P1, DOI 10.1593/neo.121550; Murali R, 2006, ARCH PATHOL LAB MED, V130, P1693; NOORDZIJ MA, 1995, INT J CANCER, V62, P252, DOI 10.1002/ijc.2910620304; Papandreou CN, 2002, J CLIN ONCOL, V20, P3072, DOI 10.1200/JCO.2002.12.065; Park K, 2014, HUM PATHOL, V45, P2136, DOI 10.1016/j.humpath.2014.06.008; PATEL S, 1985, UROLOGY, V25, P627, DOI 10.1016/0090-4295(85)90297-3; PEARSE AGE, 1969, J HISTOCHEM CYTOCHEM, V17, P303, DOI 10.1177/17.5.303; Prendeville S, 2017, MODERN PATHOL, V30, p249A; Pretl K, 1944, VIRCHOWS ARCH A, V312, P392, DOI 10.1007/BF02655955; Priemer DS, 2016, ENDOCR PATHOL, V27, P123, DOI 10.1007/s12022-016-9421-z; RATZENHOFER M, 1965, Z ZELLFORSCH MIK ANA, V67, P113, DOI 10.1007/BF00339280; RO JY, 1987, CANCER, V59, P977, DOI 10.1002/1097-0142(19870301)59:5<977::AID-CNCR2820590521>3.0.CO;2-G; Rubenstein JH, 1997, AM J CLIN ONCOL-CANC, V20, P376, DOI 10.1097/00000421-199708000-00011; Scheble VJ, 2010, HISTOPATHOLOGY, V56, P937, DOI 10.1111/j.1365-2559.2010.03564.x; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; SCHRON DS, 1984, CANCER, V53, P2478, DOI 10.1002/1097-0142(19840601)53:11<2478::AID-CNCR2820531119>3.0.CO;2-Q; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; So JS, 2014, HUM PATHOL, V45, P2388, DOI 10.1016/j.humpath.2014.08.004; SOBIN LH, 1986, CANCER, V58, P136, DOI 10.1002/1097-0142(19860701)58:1<136::AID-CNCR2820580124>3.0.CO;2-S; Srigley J, 2002, LAB INVEST, V82, p182A; Steineck G, 2002, ACTA ONCOL, V41, P668, DOI 10.1080/028418602321028292; Tamas EF, 2006, AM J SURG PATHOL, V30, P980, DOI 10.1097/00000478-200608000-00008; Tan HL, 2014, CLIN CANCER RES, V20, P890, DOI 10.1158/1078-0432.CCR-13-1982; Tash JA, 2002, J UROLOGY, V167, P2526, DOI 10.1016/S0022-5347(05)65024-0; TETU B, 1987, CANCER, V59, P1803, DOI 10.1002/1097-0142(19870515)59:10<1803::AID-CNCR2820591019>3.0.CO;2-X; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; Udager AM, 2014, PROSTATE, V74, P1199, DOI 10.1002/pros.22836; Wang W, 2008, AM J SURG PATHOL, V32, P65, DOI 10.1097/PAS.0b013e318058a96b; WEAVER MG, 1992, AM J SURG PATHOL, V16, P62, DOI 10.1097/00000478-199201000-00009; Weinstein MH, 1996, HUM PATHOL, V27, P683, DOI 10.1016/S0046-8177(96)90398-6; WENK RE, 1977, CANCER, V40, P773, DOI 10.1002/1097-0142(197708)40:2<773::AID-CNCR2820400226>3.0.CO;2-I; WHELAN T, 1995, J UROLOGY, V153, P1080, DOI 10.1016/S0022-5347(01)67648-1; Williamson SR, 2011, MODERN PATHOL, V24, P1120, DOI 10.1038/modpathol.2011.56; Wu CX, 2012, J PATHOL, V227, P53, DOI 10.1002/path.3987; Wynn SS, 2000, ARCH PATHOL LAB MED, V124, P1074; Yao JL, 2006, AM J SURG PATHOL, V30, P705, DOI 10.1097/00000478-200606000-00005; Yuan TC, 2007, ENDOCR-RELAT CANCER, V14, P531, DOI 10.1677/ERC-07-0061	85	5	5	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31			1			S122	S132		10.1038/modpathol.2017.164			11	Pathology	Pathology	FW3PC	WOS:000425219700010	29297494				2019-10-28	
J	Grignon, DJ				Grignon, David J.			Prostate cancer reporting and staging: needle biopsy and radical prostatectomy specimens	MODERN PATHOLOGY			English	Article							ISUP CONSENSUS CONFERENCE; POSITIVE SURGICAL MARGINS; SEMINAL-VESICLE INVOLVEMENT; BLADDER NECK INVOLVEMENT; EXTRAPROSTATIC EXTENSION; PERINEURAL INVASION; PROGNOSTIC-SIGNIFICANCE; INTERNATIONAL SOCIETY; UROLOGICAL PATHOLOGY; LYMPHOVASCULAR INVASION	Prostatic adenocarcinoma remains the most common cancer affecting men. A substantial majority of patients have the diagnosis made on thin needle biopsies, most often in the absence of a palpable abnormality. Treatment choices ranging from surveillance to radical prostatectomy or radiation therapy are largely driven by the pathologic findings in the biopsy specimen. The first part of this review focuses on important morphologic parameters in needle biopsy specimens that are not covered in the accompanying articles. This includes tumor quantification as well as other parameters such a extraprostatic extension, seminal vesicle invasion, perineural invasion, and lymphovascular invasion. For those men who undergo radical prostatectomy, pathologic stage and other parameters are critical in prognostication and in determining the appropriateness of adjuvant therapy. Staging parameters, including extraprostatic extension, seminal vesicle invasion, and lymph node status are discussed here. Surgical margin status is also an important parameter and definitions and reporting of this feature are detailed. Throughout the article the current reporting guidelines published by the College of American Pathologists and the International Collaboration on Cancer Reporting are highlighted.	[Grignon, David J.] Indiana Univ Sch Med, Dept Pathol & Lab Med, IUH Pathol Lab, 300 West Eleventh St, Indianapolis, IN 46202 USA	Grignon, DJ (reprint author), Indiana Univ Sch Med, Dept Pathol & Lab Med, IUH Pathol Lab, 300 West Eleventh St, Indianapolis, IN 46202 USA.	dgrignon@iupui.edu					Alkhateeb S, 2010, J UROLOGY, V183, P145, DOI 10.1016/j.juro.2009.08.132; Amin BB, 2017, AJCC CANC STAGING MA; Amin MB, 2014, ARCH PATHOL LAB MED, V138, P1387, DOI 10.5858/arpa.2014-0219-SA; Aoun F, 2017, THER ADV UROL, V9, P73, DOI 10.1177/1756287217697661; Arias-Stella JA, 2015, AM J SURG PATHOL, V39, P281, DOI 10.1097/PAS.0000000000000344; AYALA AG, 1989, AM J SURG PATHOL, V13, P21, DOI 10.1097/00000478-198901000-00003; Babaian RJ, 2001, CANCER, V91, P1414; Berney DM, 2011, MODERN PATHOL, V24, P39, DOI 10.1038/modpathol.2010.160; Billis AR, 2004, HUM PATHOL, V35, P525, DOI 10.1016/j.humpath.2003.12.005; Billis Athanase, 2004, International Urology and Nephrology, V36, P363, DOI 10.1007/s11255-004-0922-1; Bismar TA, 2003, AM J SURG PATHOL, V27, P432, DOI 10.1097/00000478-200304000-00002; Boormans JL, 2008, BJU INT, V102, P1589, DOI 10.1111/j.1464-410X.2008.07904.x; Brimo F, 2008, HISTOPATHOLOGY, V53, P177, DOI 10.1111/j.1365-2559.2008.03087.x; Brimo F, 2010, UROLOGY, V76, P1206, DOI 10.1016/j.urology.2010.03.090; Cao DF, 2011, UROLOGY, V77, P1409, DOI 10.1016/j.urology.2010.10.059; Cao DF, 2010, AM J SURG PATHOL, V34, P994, DOI 10.1097/PAS.0b013e3181e103bf; Cheng L, 2005, J UROLOGY, V174, P2181, DOI 10.1097/01.ju.0000181215.41607.c3; Cheng L, 1998, AM J SURG PATHOL, V22, P1491, DOI 10.1097/00000478-199812000-00006; Chuang AY, 2007, J UROLOGY, V178, P1306, DOI 10.1016/j.juro.2007.05.159; Cohen RJ, 1998, HUM PATHOL, V29, P424, DOI 10.1016/S0046-8177(98)90129-0; D'Amico AV, 2002, CANCER, V95, P281, DOI 10.1002/cncr.10657; D'Amico AV, 2002, INT J RADIAT ONCOL, V53, P581, DOI 10.1016/S0360-3016(02)02797-9; Dash A, 2002, UROLOGY, V60, P276, DOI 10.1016/S0090-4295(02)01727-2; Davis BJ, 1999, CANCER, V85, P2630; DeLancey JO, 2013, UROLOGY, V81, P354, DOI 10.1016/j.urology.2012.09.034; Dess RT, 2017, CURR UROL REP, V18, DOI 10.1007/s11934-017-0700-0; Dvorak T, 2005, UROLOGY, V66, P1024, DOI 10.1016/j.urology.2005.05.037; Eastham JA, 2007, UROLOGY, V70, DOI 10.1016/j.urology.2007.08.040; Edge SB, 2010, AJCC CANC STAGING MA; Egevad L, 2017, PROSTATE CORE NEEDLE; Egevad L, 2017, PROSTATE CANC RADICA; Eichelberger LE, 2005, MODERN PATHOL, V18, P886, DOI 10.1038/modpathol.3800405; Ekici S, 2003, SCAND J UROL NEPHROL, V37, P387, DOI 10.1080/00365590310014535; Emerson RE, 2005, AM J SURG PATHOL, V29, P225, DOI 10.1097/01.pas.0000146008.47191.76; Epstein JI, 1997, J UROLOGY, V157, P241, DOI 10.1016/S0022-5347(01)65336-9; EPSTEIN JI, 1993, J UROLOGY, V150, P135, DOI 10.1016/S0022-5347(17)35415-0; Epstein JI, 2000, UROLOGY, V56, P283, DOI 10.1016/S0090-4295(00)00640-3; Evans AJ, 2008, AM J SURG PATHOL, V32, P1503, DOI 10.1097/PAS.0b013e31817fb3a0; Fajkovic H, 2016, UROL ONCOL, V34; Fleshner NE, 2010, UROL ONCOL-SEMIN ORI, V28, P197, DOI 10.1016/j.urolonc.2009.08.015; Galiabovitch E, 2017, BJU INT, V119, P567, DOI 10.1111/bju.13594; Gupta R, 2015, BJU INT, V116, P343, DOI 10.1111/bju.12911; Harnden P, 2007, CANCER, V109, P13, DOI 10.1002/cncr.22388; HUMPHREY PA, 1990, HUM PATHOL, V21, P799, DOI 10.1016/0046-8177(90)90048-A; Joshi A, 2009, HISTOPATHOLOGY, V54, P912, DOI 10.1111/j.1365-2559.2009.03299.x; Kang M, 2016, ANN SURG ONCOL, V23, P2699, DOI 10.1245/s10434-016-5153-z; Kang YJ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3307-4; Karram S, 2011, AM J SURG PATHOL, V35, P1351, DOI 10.1097/PAS.0b013e3182217b79; Kench JG, 2013, HISTOPATHOLOGY, V62, P203, DOI 10.1111/his.12042; Kozal S, 2015, UROL ONCOL, V33; Kryvenko ON, 2012, AM J SURG PATHOL, V36, P1865, DOI 10.1097/PAS.0b013e318262c3d0; Loeb S, 2010, BJU INT, V105, P1510, DOI 10.1111/j.1464-410X.2009.08845.x; Luchini C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02577-4; Magi-Galluzzi C, 2011, MODERN PATHOL, V24, P26, DOI 10.1038/modpathol.2010.158; MCNEAL JE, 1981, PROSTATE, V2, P35, DOI 10.1002/pros.2990020105; Miller JS, 2010, BJU INT, V106, P330, DOI 10.1111/j.1464-410X.2009.09110.x; Moreira DM, 2015, J UROLOGY, V194, P1258, DOI 10.1016/j.juro.2015.04.113; Nazeer T, 2009, HUM PATHOL, V40, P538, DOI 10.1016/j.humpath.2008.10.004; OHORI M, 1993, AM J SURG PATHOL, V17, P1252, DOI 10.1097/00000478-199312000-00006; OHORI M, 1995, J UROLOGY, V154, P1818, DOI 10.1016/S0022-5347(01)66792-2; Osunkoya AO, 2012, SEMIN DIAGN PATHOL, V29, P154, DOI 10.1053/j.semdp.2011.10.001; Park YH, 2016, SCI REP-UK, V6, DOI 10.1038/srep25419; Passoni NM, 2014, BJU INT, V114, P503, DOI 10.1111/bju.12342; Pettus JA, 2004, J UROLOGY, V172, P129, DOI 10.1097/01.ju.0000132160.68779.96; Pierorazio PM, 2010, J UROLOGY, V183, P151, DOI 10.1016/j.juro.2009.08.138; Ploussard G, 2010, BJU INT, V105, P776, DOI 10.1111/j.1464-410X.2009.08957.x; Poulos CK, 2004, CANCER-AM CANCER SOC, V101, P1563, DOI 10.1002/cncr.20551; Poulos CK, 2004, CANCER, V101, P527, DOI 10.1002/cncr.20415; Preston MA, 2011, EUR UROL, V59, P613, DOI 10.1016/j.eururo.2010.12.005; RAVERY V, 1994, UROLOGY, V44, P371, DOI 10.1016/S0090-4295(94)80095-2; Sadimin ET, 2016, HUM PATHOL, V49, P10, DOI 10.1016/j.humpath.2015.10.010; Saether T, 2008, SCAND J UROL NEPHROL, V42, P514, DOI 10.1080/00365590802299585; Salomon L, 2003, EUR UROL, V43, P39, DOI 10.1016/S0302-2838(02)00493-1; Samaratunga H, 2011, MODERN PATHOL, V24, P6, DOI 10.1038/modpathol.2010.178; Sammon JD, 2013, UROL ONCOL-SEMIN ORI, V31, P1470, DOI 10.1016/j.urolonc.2012.03.013; Savdie R, 2017, UROL ONCOL-SEMIN ORI, V35, DOI 10.1016/j.urolonc.2017.06.048; Savdie R, 2012, BJU INT, V109, P1794, DOI 10.1111/j.1464-410X.2011.10572.x; Schultz L, 2013, AM J SURG PATHOL, V37, P1831, DOI 10.1097/PAS.0000000000000112; Sebo TJ, 2000, J UROLOGY, V163, P174, DOI 10.1016/S0022-5347(05)67998-0; SGRIGNOLI AR, 1994, J UROLOGY, V152, P1077, DOI 10.1016/S0022-5347(17)32507-7; Shuford MD, 2004, J UROLOGY, V172, P119, DOI 10.1097/01.ju.0000132137.02846.ec; Sofer M, 2002, J UROLOGY, V167, P2453, DOI 10.1016/S0022-5347(05)65003-3; Sohayda C, 2000, UROLOGY, V55, P382, DOI 10.1016/S0090-4295(99)00458-6; Sooriakumaran P, 2015, BJU INT, V115, P106, DOI 10.1111/bju.12483; Srigley J, 2017, PROTOCOL EXAMINATION; Stamey TA, 1999, JAMA-J AM MED ASSOC, V281, P1395, DOI 10.1001/jama.281.15.1395; Stavrinides V, 2017, CANCER TREAT REV, V58, P14, DOI 10.1016/j.ctrv.2017.05.004; Sung MT, 2007, AM J SURG PATHOL, V31, P311, DOI 10.1097/01.pas.0000213359.26003.37; Sung MT, 2006, PATHOLOGY, V38, P309, DOI 10.1080/00313020600820914; Tan PH, 2011, MODERN PATHOL, V24, P48, DOI 10.1038/modpathol.2010.155; Tefilli MV, 1998, J UROLOGY, V160, P802, DOI 10.1016/S0022-5347(01)62791-5; Trpkov C, 2014, UROLOGY, V84, P149, DOI 10.1016/j.urology.2014.04.007; Truong M, 2017, HUM PATHOL, V66, P206, DOI 10.1016/j.humpath.2017.06.017; van den Ouden D, 1998, UROL INT, V60, P17, DOI 10.1159/000030197; van der Kwast TH, 2011, MODERN PATHOL, V24, P16, DOI 10.1038/modpathol.2010.156; van der Kwast TH, 2006, VIRCHOWS ARCH, V449, P428, DOI 10.1007/s00428-006-0254-x; van Veggel BAMH, 2011, HISTOPATHOLOGY, V59, P692, DOI 10.1111/j.1365-2559.2011.03986.x; Wheeler TM, 1998, HUM PATHOL, V29, P856, DOI 10.1016/S0046-8177(98)90457-9; Yossepowitch O, 2002, J UROLOGY, V168, P2011, DOI 10.1097/01.ju.0000033909.09204.c6; Zhou M, 2009, MODERN PATHOL, V22, P385, DOI 10.1038/modpathol.2008.190	100	1	1	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31			1			S96	S109		10.1038/modpathol.2017.167			14	Pathology	Pathology	FW3PC	WOS:000425219700008	29297497	Bronze			2019-10-28	
J	Humphrey, PA				Humphrey, Peter A.			Variants of acinar adenocarcinoma of the prostate mimicking benign conditions	MODERN PATHOLOGY			English	Article							METHYLACYL-COA-RACEMASE; FOAMY GLAND CARCINOMA; PSEUDOHYPERPLASTIC ADENOCARCINOMA; GRANULOMATOUS PROSTATITIS; RADICAL PROSTATECTOMY; ATROPHIC FEATURES; NEEDLE BIOPSIES; GLEASON-GRADE; CANCER; DIAGNOSIS	Histological variants of acinar adenocarcinoma of the prostate may be of significance due to difficulty in diagnosis or due to differences in prognosis compared to usual acinar adenocarcinoma. The 2016 World Health Organization classification of acinar adenocarcinoma includes four variants that are deceptively benign in histological appearance, such that a misdiagnosis of a benign condition may be made. These four variants are atrophic pattern adenocarcinoma, pseudohyperplastic adenocarcinoma, microcystic adenocarcinoma, and foamy gland adenocarcinoma. They differ from usual small acinar adenocarcinoma in architectural glandular structure and/or cytoplasmic and nuclear alterations. The variants are often admixed, in variable proportions, with usual small acinar adenocarcinoma that is often Gleason pattern 3 but may be high-grade pattern 4 in a minority of cases. Atrophic pattern adenocarcinoma can be identified in a sporadic setting or after radiation or hormonal therapy. This variant is characterized by cytoplasmic volume loss and can resemble benign glandular atrophy, an extremely common benign process in the prostate. The glands of pseudohyperplastic adenocarcinoma simulate usual epithelial hyperplasia, with gland complexity that is not typical of small acinar adenocarcinoma. These complex growth configurations include papillary infoldings, luminal undulations, and branching. Microcystic adenocarcinoma is characterized by cystic dilation of prostatic glands to a size that is much more commonly observed in cystic change in benign prostatic glands. Finally, the cells in foamy gland adenocarcinoma display cytoplasmic vacuolization and nuclear pyknosis, features that can found in benign glands and macrophages. Three of the four variants (atrophic, pseudohyperplastic, and microcystic) are assigned low-grade Gleason pattern 3. Of significance, foamy gland adenocarcinoma can be Gleason pattern 3 but can also be high-grade pattern 4 or 5. Diagnostic awareness of the existence of these deceptively benign-appearing variants of acinar adenocarcinoma is essential so that an accurate diagnosis of prostate cancer may be rendered.	[Humphrey, Peter A.] Yale Sch Med, Dept Pathol, Box 208023,310 Cedar St, New Haven, CT 06520 USA	Humphrey, PA (reprint author), Yale Sch Med, Dept Pathol, Box 208023,310 Cedar St, New Haven, CT 06520 USA.	peter.humphrey@yale.edu					Adley BP, 2006, AM J CLIN PATHOL, V126, P849, DOI 10.1309/F3R88U2574Q8G1J3; Amin MB, 1999, AM J SURG PATHOL, V23, P925, DOI 10.1097/00000478-199908000-00010; Arista-Nasr J, 2003, PATHOL ONCOL RES, V9, P232, DOI 10.1007/BF02893383; Arista-Nasr J, 2016, INT J SURG PATHOL, V24, P477, DOI 10.1177/1066896916640360; Arista-Nasr J, 2015, ANN DIAGN PATHOL, V19, P253, DOI 10.1016/j.anndiagpath.2015.04.009; Berman DM, 2000, AM J SURG PATHOL, V24, P140, DOI 10.1097/00000478-200001000-00018; Bonkhoff H, 2016, PROSTATE, V76, P369, DOI 10.1002/pros.23128; Brimo F, 2012, HUM PATHOL, V43, P313, DOI 10.1016/j.humpath.2011.11.005; Carswell BM, 2006, HISTOPATHOLOGY, V48, P668, DOI 10.1111/j.1365-2559.2006.02409.x; Chuang AY, 2007, AM J SURG PATHOL, V31, P1225, DOI 10.1097/PAS.0b013e31802be3c2; Cina SJ, 1997, AM J SURG PATHOL, V21, P289, DOI 10.1097/00000478-199703000-00004; Egan AJM, 1997, AM J SURG PATHOL, V21, P931, DOI 10.1097/00000478-199708000-00007; Egevad L, 2016, WHO CLASSIFICATION T, P166; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Farinola MA, 2004, HUM PATHOL, V35, P1272, DOI 10.1016/j.humpath.2004.06.015; FOX H, 1966, J UROLOGY, V96, P372, DOI 10.1016/S0022-5347(17)63272-5; Hameed O, 2005, SEMIN DIAGN PATHOL, V22, P88, DOI 10.1053/j.semdp.2005.11.001; Hameed O, 2005, AM J SURG PATHOL, V29, P579, DOI 10.1097/01.pas.0000157936.93999.18; HEDRICK L, 1989, AM J SURG PATHOL, V13, P389, DOI 10.1097/00000478-198905000-00006; Hudson J, 2012, HUM PATHOL, V43, P974, DOI 10.1016/j.humpath.2011.09.009; Humphrey PA, 1998, AM J SURG PATHOL, V22, P1239, DOI 10.1097/00000478-199810000-00009; Humphrey PA, 2014, NEOPLASTIC MIMICS GE, P140; Humphrey PA, 2016, WHO CLASSIFICATION T, P138; Humphrey PA, 2014, PATHOL NEOPLAST MIM, P11; Humphrey PA, 2014, J UROLOGY, V191, P1416, DOI 10.1016/j.juro.2014.02.041; Kaleem Z, 1998, AM J CLIN PATHOL, V109, P695; Koca SB, 2014, ANN DIAGN PATHOL, V18, P271, DOI 10.1016/j.anndiagpath.2014.07.002; Kojima F, 2017, ANN DIAGN PATHOL, V27, P7, DOI 10.1016/j.anndiagpath.2016.12.002; Lee TK, 2010, PATHOLOGY, V42, P319, DOI 10.3109/00313021003767314; MIEKOS E, 1986, International Urology and Nephrology, V18, P433, DOI 10.1007/BF02084115; Nelson RS, 1996, AM J SURG PATHOL, V20, P419, DOI 10.1097/00000478-199604000-00004; Oppenheimer JR, 1997, ARCH PATHOL LAB MED, V121, P724; Paner GP, 2016, AM J SURG PATHOL, V40, P886, DOI 10.1097/PAS.0000000000000618; PRESTI B, 1991, AM J CLIN PATHOL, V95, P330, DOI 10.1093/ajcp/95.3.330; Przybycin CG, 2008, AM J SURG PATHOL, V32, P58, DOI 10.1097/PAS.0b013e318093e3f6; Reuter VE, 1997, UROLOGY, V49, P16, DOI 10.1016/S0090-4295(97)00164-7; SEBO TJ, 1994, HUM PATHOL, V25, P386, DOI 10.1016/0046-8177(94)90147-3; Smith SC, 2014, AM J SURG PATHOL, V38, P615, DOI 10.1097/PAS.0000000000000090; So JS, 2014, AM J SURG PATHOL, V38, P852, DOI 10.1097/PAS.0000000000000193; Srigley JR, 2012, HISTOPATHOLOGY, V60, P153, DOI 10.1111/j.1365-2559.2011.04079.x; Tran TT, 2001, AM J SURG PATHOL, V25, P618, DOI 10.1097/00000478-200105000-00008; Wang WL, 2008, AM J SURG PATHOL, V32A, P851, DOI 10.1097/PAS.0b013e31815a0508; Warrick JI, 2013, AM J SURG PATHOL, V37, P1709, DOI 10.1097/PAS.0b013e318293d85b; Wolf AN, 2000, AM J SURG PATHOL, V24, P1039; Wolters T, 2010, AM J SURG PATHOL, V34, P35, DOI 10.1097/PAS.0b013e3181c3ece9; Yaskiv O, 2011, AM J SURG PATHOL, V35, P1062, DOI 10.1097/PAS.0b013e318215cc03; Yaskiv O, 2010, AM J SURG PATHOL, V34, P556, DOI 10.1097/PAS.0b013e3181d2a549; Zhou M, 2003, AM J SURG PATHOL, V27, P772, DOI 10.1097/00000478-200306000-00007	48	4	4	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31			1			S64	S70		10.1038/modpathol.2017.137			7	Pathology	Pathology	FW3PC	WOS:000425219700005	29297496				2019-10-28	
J	Kristiansen, G				Kristiansen, Glen			Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer	MODERN PATHOLOGY			English	Article							METHYLACYL-COA RACEMASE; CYCLE PROGRESSION-SCORE; PITX2 DNA METHYLATION; NEEDLE-BIOPSY COHORT; EARLY PSA RECURRENCE; RADICAL PROSTATECTOMY; GENE-EXPRESSION; GENOMIC CLASSIFIER; PROTEIN EXPRESSION; ERG EXPRESSION	Molecular diagnostics is a rapidly evolving area of surgical pathology, that is gradually beginning to transform our diagnostical procedures for a variety of tumors. Next to molecular prognostication that has begun to complement our histological diagnosis in breast cancer, additional testing to detect targets and to predict therapy response has become common practice in breast and lung cancer. Prostate cancer is a bit slower in this respect, as it is still largely diagnosed and classified on morphological grounds. Our diagnostic immunohistochemical armamentarium of basal cell markers and positive markers of malignancy now allows to clarify the majority of lesions, if applied to the appropriate morphological context (and step sections). Prognostic immunohistochemistry remains a problematic and erratic yet tempting research field that provides information on tumor relevance of proteins, but little hard data to integrate into our diagnostic workflow. Main reasons are various issues of standardization that hamper the reproducibility of cut-off values to delineate risk categories. Molecular testing of DNA-methylation or transcript profiling may be much better standardized and this review discusses a couple of commercially available tests: The ConfirmDX test measures DNA-methylation to estimate the likelihood of cancer detection on a repeat biopsy and may help to reduce unnecessary biopsies. The tests Prolaris, OncotypeDX Prostate, and Decipher all are transcript tests that have shown to provide prognostic data independent of clinico-pathological parameters and that may aid in therapy planning. However, further validation and more comparative studies will be needed to clarify the many open questions concerning sampling bias and tumor heterogeneity.	[Kristiansen, Glen] Univ Hosp Bonn, Inst Pathol, Sigmund Freud Str 25, D-53127 Bonn, Germany	Kristiansen, G (reprint author), Univ Hosp Bonn, Inst Pathol, Sigmund Freud Str 25, D-53127 Bonn, Germany.	Glen.Kristiansen@ukbonn.de					ABLIN RJ, 1970, J IMMUNOL, V104, P1329; Ahearn TU, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv346; Ahmad AS, 2016, ONCOTARGET, V7, P71833, DOI 10.18632/oncotarget.12377; Andriole GL, 2009, NEW ENGL J MED, V360, P1310, DOI 10.1056/NEJMoa0810696; Attard G, 2008, ONCOGENE, V27, P253, DOI 10.1038/sj.onc.1210640; Banez LL, 2010, J UROLOGY, V184, P149, DOI 10.1016/j.juro.2010.03.012; Barresi V, 2016, APMIS, V124, P188, DOI 10.1111/apm.12483; Bastian PJ, 2005, CLIN CANCER RES, V11, P4097, DOI 10.1158/1078-0432.CCR-04-1832; BATES RJ, 1982, J UROLOGY, V127, P574, DOI 10.1016/S0022-5347(17)53915-4; Berg KD, 2014, EUR UROL, V66, P851, DOI 10.1016/j.eururo.2014.02.058; Berg KD, 2016, DAN MED J, V16, P63; Bowen C, 2000, CANCER RES, V60, P6111; BRAWER MK, 1985, CANCER RES, V45, P3663; Buus R, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw149; Capitanio U, 2015, EUR UROL FOCUS, V1, P127, DOI 10.1016/j.euf.2015.05.002; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Christgen M, 2015, HUM PATHOL, V46, P1341, DOI 10.1016/j.humpath.2015.05.016; Cooperberg MR, 2013, J CLIN ONCOL, V31, P1428, DOI 10.1200/JCO.2012.46.4396; Cullen J, 2015, EUR UROL, V68, P123, DOI 10.1016/j.eururo.2014.11.030; Cuzick J, 2015, BRIT J CANCER, V113, P382, DOI 10.1038/bjc.2015.223; Cuzick J, 2013, BRIT J CANCER, V108, P2582, DOI 10.1038/bjc.2013.248; Cuzick J, 2012, BRIT J CANCER, V106, P1095, DOI 10.1038/bjc.2012.39; Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3; Cyll K, 2017, BRIT J CANCER, V117, P367, DOI 10.1038/bjc.2017.171; Demichelis F, 2007, ONCOGENE, V26, P4596, DOI 10.1038/sj.onc.1210237; Den RB, 2016, PROSTATE CANCER P D, V19, P374, DOI 10.1038/pcan.2016.38; Denkert C, 2015, BREAST, V24, pS67, DOI 10.1016/j.breast.2015.07.017; Deocampo N D, 2003, Minerva Endocrinol, V28, P145; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Dietrich D, 2013, J MOL DIAGN, V15, P270, DOI 10.1016/j.jmoldx.2012.11.002; Edwards S, 2005, BRIT J CANCER, V92, P376, DOI 10.1038/sj.bjc.6602261; Epstein JI, 2014, AM J SURG PATHOL, V38, pE6, DOI 10.1097/PAS.0000000000000238; Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855; Esgueva R, 2010, MODERN PATHOL, V23, P539, DOI 10.1038/modpathol.2009.193; Ferraldeschi R, 2015, EUR UROL, V67, P795, DOI 10.1016/j.eururo.2014.10.027; FitzGerald LM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-230; FRANKEL AE, 1982, CANCER RES, V42, P3714; Freedland SJ, 2013, INT J RADIAT ONCOL, V86, P848, DOI 10.1016/j.ijrobp.2013.04.043; Fritzsche FR, 2010, BMC UROL, V10, DOI 10.1186/1471-2490-10-4; Fritzsche Florian Rudolf, 2008, BMC Urol, V8, P15, DOI 10.1186/1471-2490-8-15; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Goltz D, 2015, PATHOLOGY, V47, P629, DOI 10.1097/PAT.0000000000000320; Gunia S, 2008, VIRCHOWS ARCH, V453, P165, DOI 10.1007/s00428-008-0638-1; Halvorsen OJ, 2003, CLIN CANCER RES, V9, P1474; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He HY, 2011, AM J SURG PATHOL, V35, P608, DOI 10.1097/PAS.0b013e31820bcd2d; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; HEDRICK L, 1989, AM J SURG PATHOL, V13, P389, DOI 10.1097/00000478-198905000-00006; Henshall SM, 2003, CANCER RES, V63, P4196; Herawi M, 2005, AM J SURG PATHOL, V29, P874, DOI 10.1097/01.pas.0000159520.36806.3e; Holmes EE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093933; Hoogland AM, 2012, MODERN PATHOL, V25, P471, DOI 10.1038/modpathol.2011.176; Huber F, 2015, BRIT J CANCER, V112, P140, DOI 10.1038/bjc.2014.588; Jeronimo C, 2011, EUR UROL, V60, P753, DOI 10.1016/j.eururo.2011.06.035; Jiang Z, 2001, AM J SURG PATHOL, V25, P1397, DOI 10.1097/00000478-200111000-00007; Jiang Z, 2003, HUM PATHOL, V34, P792, DOI 10.1016/S0046-8177(03)00268-5; Kalos M, 2004, PROSTATE, V60, P246, DOI 10.1002/pros.20043; Karnes RJ, 2017, EUR UROL; Kesch C, 2017, CURR OPIN UROL, DOI [10.1097/MOU.0000000000000461, DOI 10.1097/MOU.0000000000000461]; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Klein EA, 2017, J UROLOGY, V197, P122, DOI 10.1016/j.juro.2016.08.091; Klein EA, 2016, UROLOGY, V90, P148, DOI 10.1016/j.urology.2016.01.012; Klein EA, 2014, EUR UROL, V66, P550, DOI 10.1016/j.eururo.2014.05.004; Knezevic D, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-690; Kretschmer A, 2017, UROLOGE, V56, P933, DOI 10.1007/s00120-017-0418-0; Kristiansen G, 2008, BRIT J CANCER, V99, P939, DOI 10.1038/sj.bjc.6604614; Kristiansen G, 2005, J PATHOL, V205, P359, DOI 10.1002/path.1676; Kristiansen G, 2009, Pathologe, V30 Suppl 2, P146, DOI 10.1007/s00292-009-1230-4; Kristiansen G, 2012, HISTOPATHOLOGY, V60, P125, DOI 10.1111/j.1365-2559.2011.04083.x; Kristiansen I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061151; Krohn A, 2012, AM J PATHOL, V181, P401, DOI 10.1016/j.ajpath.2012.04.026; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Li WZ, 2012, UROLOGY, V80, DOI 10.1016/j.urology.2012.06.017; Litovkin K, 2014, J CANCER RES CLIN, V140, P1849, DOI 10.1007/s00432-014-1738-8; Lotan TL, 2017, ONCOTARGET, V8, P65566, DOI 10.18632/oncotarget.19217; Luan ZM, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15026750; Luo J, 2002, CANCER RES, V62, P2220; Magi-Galluzzi C, 2003, AM J SURG PATHOL, V27, P1128, DOI 10.1097/00000478-200308000-00010; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; McMenamin ME, 1999, CANCER RES, V59, P4291; McShane LM, 2005, JNCI-J NATL CANCER I, V97, P1180, DOI 10.1093/jnci/dji237; Minner S, 2013, MODERN PATHOL, V26, P106, DOI 10.1038/modpathol.2012.130; Minner S, 2011, CLIN CANCER RES, V17, P5878, DOI 10.1158/1078-0432.CCR-11-1251; Moch H, 2016, WHO CLASSIFICATION T; Na R, 2016, ASIAN J ANDROL, V18, P575, DOI 10.4103/1008-682X.175096; Nakagawa T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002318; Nguyen PL, 2017, EUR UROL, V72, P845, DOI 10.1016/j.eururo.2017.05.009; Oderda M, 2017, UROLOGY, V102, P73, DOI 10.1016/j.urology.2016.11.038; Ohl F, 2005, J MOL MED, V83, P1014, DOI 10.1007/s00109-005-0703-z; Osunkoya AO, 2008, AM J SURG PATHOL, V32, P461, DOI 10.1097/PAS.0b013e318157020e; Partin AW, 2014, J UROLOGY, V192, P1081, DOI 10.1016/j.juro.2014.04.013; Peng Z, 2014, PROSTATE CANCER P D, V17, P81, DOI 10.1038/pcan.2013.57; Pettersson A, 2012, CANCER EPIDEM BIOMAR, V21, P1497, DOI 10.1158/1055-9965.EPI-12-0042; Polley MYC, 2013, JNCI-J NATL CANCER I, V105, P1897, DOI 10.1093/jnci/djt306; Queisser A, 2015, MODERN PATHOL, V28, P138, DOI 10.1038/modpathol.2014.77; Riener MO, 2009, HEPATOLOGY, V49, P1602, DOI 10.1002/hep.22843; Sailer V, 2015, HISTOPATHOLOGY, V67, P577, DOI 10.1111/his.12671; Sailer V, 2014, APMIS, V122, P690, DOI 10.1111/apm.12291; Sailer V, 2013, HISTOPATHOLOGY, V63, P50, DOI 10.1111/his.12116; Sboner A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-8; Schmitz M, 2007, INT J CANCER, V120, P1284, DOI 10.1002/ijc.22359; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Schroder FH, 2014, LANCET, V384, P2027, DOI 10.1016/S0140-6736(14)60525-0; Schultz M, 2007, INT J CANCER, V121, P2591, DOI 10.1002/ijc.23073; Sekula P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178531; Sheridan T, 2007, AM J SURG PATHOL, V31, P1351, DOI 10.1097/PAS.0b013e3180536678; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sommariva S, 2016, EUR UROL, V69, P107, DOI 10.1016/j.eururo.2014.11.038; Stewart GD, 2013, J UROLOGY, V189, P1110, DOI 10.1016/j.juro.2012.08.219; Tischler V, 2010, HISTOPATHOLOGY, V56, P811, DOI 10.1111/j.1365-2559.2010.03535.x; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Torenbeek R, 1998, HISTOPATHOLOGY, V32, P20, DOI 10.1046/j.1365-2559.1998.00328.x; Tosoian JJ, 2017, BJU INT, V120, P808, DOI 10.1111/bju.13911; TOTTEN RS, 1953, AMA ARCH PATHOL, V55, P131; Tretiakova MS, 2004, AM J SURG PATHOL, V28, P69, DOI 10.1097/00000478-200401000-00007; Trock BJ, 2016, MODERN PATHOL, V29, P764, DOI 10.1038/modpathol.2016.63; Trock BJ, 2012, BJU INT, V110, P56, DOI 10.1111/j.1464-410X.2011.10718.x; Uchida K, 2015, HUM PATHOL, V46, P384, DOI 10.1016/j.humpath.2014.11.011; Uhl B, 2017, J MOL DIAGN, V19, P107, DOI 10.1016/j.jmoldx.2016.08.008; Vanaja DK, 2009, CANCER INVEST, V27, P549, DOI 10.1080/07357900802620794; Varga Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058483; Varinot J, 2016, VIRCHOWS ARCH, V468, P619, DOI 10.1007/s00428-016-1917-x; Varinot J, 2013, VIRCHOWS ARCH, V463, P803, DOI 10.1007/s00428-013-1495-0; Vasiljevic N, 2014, BIOMARK MED, V8, P1143, DOI [10.2217/bmm.14.41, 10.2217/BMM.14.41]; Verma S, 2017, RADIOLOGY, V285, P343, DOI 10.1148/radiol.2017161684; Wei L, 2017, EUR UROL, V71, P183, DOI 10.1016/j.eururo.2016.07.008; Wei SZ, 2008, PROSTATE, V68, P1387, DOI 10.1002/pros.20806; Weiss G, 2009, J UROLOGY, V181, P1678, DOI 10.1016/j.juro.2008.11.120; Wilt TJ, 2017, NEW ENGL J MED, V377, P132, DOI 10.1056/NEJMoa1615869; Woodrum DA, 2017, CLIN RADIOL, V72, P665, DOI 10.1016/j.crad.2017.02.010; Wu CL, 2004, HUM PATHOL, V35, P1008, DOI 10.1016/j.humpath.2004.03.019; Xu JC, 2000, CANCER RES, V60, P1677; Xu JC, 2001, CANCER RES, V61, P1563; Yin M, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-41; Zabalza CV, 2015, ONCOTARGET, V6, P12822, DOI 10.18632/oncotarget.3431; Zhou M, 2002, AM J SURG PATHOL, V26, P926, DOI 10.1097/00000478-200207000-00012	139	4	4	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31			1			S143	S155		10.1038/modpathol.2017.168			13	Pathology	Pathology	FW3PC	WOS:000425219700012	29297492				2019-10-28	
J	Magi-Galluzzi, C				Magi-Galluzzi, Cristina			Prostate cancer: diagnostic criteria and role of immunohistochemistry	MODERN PATHOLOGY			English	Article							METHYLACYL-COA-RACEMASE; NEEDLE-BIOPSY SPECIMENS; SMALL ACINAR PROLIFERATION; INTRAEPITHELIAL NEOPLASIA; RADICAL-PROSTATECTOMY; INTRALUMINAL CRYSTALLOIDS; LIMITED ADENOCARCINOMA; MINIMAL ADENOCARCINOMA; HISTOLOGIC FEATURES; SURGICAL PATHOLOGY	The diagnosis of prostate cancer is based on microscopic criteria. Presently, prostate needle biopsy interpretation can be a challenge for the pathologist due to the increased number of specimens with limited amount of suspicious glands and minimal atypia. It is critical for the pathologist to have an organized methodical approach when considering the morphological features enabling a definitive diagnosis of prostate cancer. Although several diagnostic criteria and supportive features have been advocated, only few findings are absolutely specific and diagnostic of prostate cancer. The diagnosis of prostate cancer relies on a combination of architectural and cytological features that are reviewed in detail herein. Infiltrative growth pattern, prominent nucleoli and lack of basal cells are the most useful diagnostic criteria. Perineural invasion, glomerulation and mucinous fibroplasia are pathognomonic features of prostate cancer, although uncommon on small prostate cancer foci. The role of immunohistochemistry in establishing a diagnosis of limited prostate is addressed.	[Magi-Galluzzi, Cristina] Cleveland Clin, Lerner Coll Med, Dept Pathol, Cleveland, OH 44195 USA; [Magi-Galluzzi, Cristina] Cleveland Clin, RT Pathol & Lab Med Inst, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA	Magi-Galluzzi, C (reprint author), Cleveland Clin, RT Pathol & Lab Med Inst, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA.	magic@ccf.org					Algaba F, 1996, CANCER, V78, P376, DOI 10.1002/(SICI)1097-0142(19960715)78:2<376::AID-CNCR32>3.0.CO;2-R; Ali TZ, 2008, AM J SURG PATHOL, V32, P1890, DOI 10.1097/PAS.0b013e31817ce994; Andrews C, 2014, AM J SURG PATHOL, V38, P1007, DOI 10.1097/PAS.0000000000000205; Anton RC, 1998, AM J SURG PATHOL, V22, P446, DOI 10.1097/00000478-199804000-00009; Armah HB, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-34; Baisden BL, 1999, AM J SURG PATHOL, V23, P918, DOI 10.1097/00000478-199908000-00009; Bostwick D G, 1997, Ann Diagn Pathol, V1, P104, DOI 10.1016/S1092-9134(97)80015-9; BOSTWICK DG, 1995, ARCH PATHOL LAB MED, V119, P444; Cheville JC, 1997, AM J CLIN PATHOL, V108, P633; Egevad L, 2006, MODERN PATHOL, V19, P180, DOI 10.1038/modpathol.3800522; EPSTEIN JI, 1995, AM J SURG PATHOL, V19, P873, DOI 10.1097/00000478-199508000-00002; Epstein JI, 2004, MODERN PATHOL, V17, P307, DOI 10.1038/modpathol.3800050; EPSTEIN JI, 1995, HUM PATHOL, V26, P223, DOI 10.1016/0046-8177(95)90041-1; Epstein JI, 1998, AM J SURG PATHOL, V22, P1430, DOI 10.1097/00000478-199811000-00016; EPSTEIN JI, 1992, HUM PATHOL, V23, P1321, DOI 10.1016/0046-8177(92)90049-9; EPSTEIN JI, 1992, AM J SURG PATHOL, V16, P1205, DOI 10.1097/00000478-199212000-00007; Epstein JI, 2014, AM J SURG PATHOL, V38, pE6, DOI 10.1097/PAS.0000000000000238; Farinola MA, 2004, HUM PATHOL, V35, P1272, DOI 10.1016/j.humpath.2004.06.015; FURUSATO M, 1989, PROSTATE, V15, P259, DOI 10.1002/pros.2990150306; GAUDIN PB, 1995, AM J SURG PATHOL, V19, P737, DOI 10.1097/00000478-199507000-00001; Giannico GA, 2013, AM J SURG PATHOL, V37, P1401, DOI 10.1097/PAS.0b013e31828d5c32; Hameed O, 2005, SEMIN DIAGN PATHOL, V22, P88, DOI 10.1053/j.semdp.2005.11.001; HELPAP B, 1988, HISTOPATHOLOGY, V13, P203, DOI 10.1111/j.1365-2559.1988.tb02025.x; Henneberry JM, 1997, AM J SURG PATHOL, V21, P725, DOI 10.1097/00000478-199706000-00014; Iczkowski KA, 1997, AM J SURG PATHOL, V21, P1489, DOI 10.1097/00000478-199712000-00012; Iczkowski KA, 2000, ARCH PATHOL LAB MED, V124, P98; KELEMEN PR, 1990, CANCER, V65, P1017, DOI 10.1002/1097-0142(19900215)65:4<1017::AID-CNCR2820650429>3.0.CO;2-F; Kovi J, 1985, Pathol Annu, V20 Pt 1, P157; KRAMER CE, 1993, HUM PATHOL, V24, P618, DOI 10.1016/0046-8177(93)90241-8; Kruslin B, 2003, VIRCHOWS ARCH, V443, P524, DOI 10.1007/s00428-003-0862-7; Lee SL, 2015, APPL IMMUNOHISTO M M, V23, P499, DOI 10.1097/PAI.0000000000000119; Leroy X, 2003, J CLIN PATHOL, V56, P230, DOI 10.1136/jcp.56.3.230; Magi-Galluzzi C, 2003, AM J SURG PATHOL, V27, P1128, DOI 10.1097/00000478-200308000-00010; MOSTOFI FK, 1992, HUM PATHOL, V23, P223, DOI 10.1016/0046-8177(92)90103-A; Nelson RS, 1996, AM J SURG PATHOL, V20, P419, DOI 10.1097/00000478-199604000-00004; Osunkoya AO, 2008, AM J SURG PATHOL, V32, P461, DOI 10.1097/PAS.0b013e318157020e; Pacelli A, 1998, HUM PATHOL, V29, P543, DOI 10.1016/S0046-8177(98)90073-9; RO JY, 1988, PROSTATE, V13, P233, DOI 10.1002/pros.2990130305; Shah R. B., 2012, PROSTATE BIOPSY INTE; SRIGLEY JR, 1988, SEMIN DIAGN PATHOL, V5, P254; Thorson P, 1998, MODERN PATHOL, V11, P543; Thorson P, 2000, AM J CLIN PATHOL, V114, P896; TOTTEN RS, 1953, AMA ARCH PATHOL, V55, P131; Trpkov K, 2009, AM J CLIN PATHOL, V132, P211, DOI 10.1309/AJCPGFJP83IXZEUR; Ulamec M, 2007, J CLIN PATHOL, V60, P1098, DOI 10.1136/jcp.2006.044784; Varma M, 2002, ARCH PATHOL LAB MED, V126, P554; Worschech A, 2009, ANAL QUANT CYTOL, V31, P424; Wu A, 2013, ARCH PATHOL LAB MED, V137, P1179, DOI 10.5858/arpa.2013-0254-CR; Wu CL, 2004, HUM PATHOL, V35, P1008, DOI 10.1016/j.humpath.2004.03.019; Yaskiv O, 2012, AM J CLIN PATHOL, V138, P803, DOI 10.1309/AJCP3K5VUFALZTKC; Zhou M, 2004, AM J SURG PATHOL, V28, P239, DOI 10.1097/00000478-200402000-00012; Zhou M, 2003, AM J SURG PATHOL, V27, P772, DOI 10.1097/00000478-200306000-00007	52	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31			1			S12	S21		10.1038/modpathol.2017.139			10	Pathology	Pathology	FW3PC	WOS:000425219700002	29297490				2019-10-28	
J	McKenney, JK				McKenney, Jesse K.			Mesenchymal tumors of the prostate	MODERN PATHOLOGY			English	Article							SOLITARY FIBROUS TUMOR; SPECIALIZED STROMAL TUMORS; URINARY-BLADDER; SCLEROSING ADENOSIS; SEMINAL-VESICLE; SARCOMATOID CARCINOMA; NUCLEAR EXPRESSION; PSMA-EXPRESSION; UTERINE CERVIX; FOLLOW-UP	Mesenchymal tumors of the prostate are rare but often cause considerable diagnostic difficulty when encountered. These may be either benign or malignant and can arise within the prostate gland or in adjacent tissues. This review covers prostatic stromal proliferations (prostatic stromal tumor of uncertain malignant potential and stromal sarcoma), solitary fibrous tumor, myofibroblastic proliferations, smooth muscle neoplasms (leiomyoma and leiomyosarcoma), gastrointestinal stromal tumor, schwannoma, rhabdomyosarcoma, sarcomatoid carcinoma, postradiation sarcoma, and mixed epithelial stromal tumor of the seminal vesicle. Differential diagnostic considerations are emphasized, including descriptions of helpful histological and/or clinical clues and the use of adjuvant diagnostic techniques.	[McKenney, Jesse K.] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Anat Pathol, 9500 Euclid Ave,L15, Cleveland, OH 44195 USA	McKenney, JK (reprint author), Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Anat Pathol, 9500 Euclid Ave,L15, Cleveland, OH 44195 USA.	mckennj@ccf.org					Bostwick DG, 2004, J UROLOGY, V172, P894, DOI 10.1097/01.ju.0000134580.71261.57; Cheah AL, 2014, PATHOLOGY, V46, P389, DOI 10.1097/PAT.0000000000000122; Cheng L, 2010, HISTOPATHOLOGY, V56, P627, DOI 10.1111/j.1365-2559.2010.03525.x; Cheville J, 2016, WHO CLASSIFICATION T, P175; Children's Oncology Group, RHABD; Creytens D, 2015, APPL IMMUNOHISTO M M, V23, P462, DOI 10.1097/PAI.0000000000000081; DAYA DA, 1988, GYNECOL ONCOL, V29, P290, DOI 10.1016/0090-8258(88)90228-4; Demicco EG, 2017, MODERN PATHOL, V30, P1433, DOI 10.1038/modpathol.2017.54; Demicco EG, 2012, MODERN PATHOL, V25, P1298, DOI 10.1038/modpathol.2012.83; Din NU, 2016, ANN DIAGN PATHOL, V20, P24, DOI 10.1016/j.anndiagpath.2015.10.009; Doyle LA, 2014, MODERN PATHOL, V27, P1231, DOI 10.1038/modpathol.2013.247; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Fletcher CDM, 2013, WHO CLASSIFICATION T, P80; Gaudin PB, 1998, AM J SURG PATHOL, V22, P148, DOI 10.1097/00000478-199802000-00002; Gharaee-Kermani M, 2014, AM J PATHOL, V184, P732, DOI 10.1016/j.ajpath.2013.11.024; Guner G, 2016, HUM PATHOL, V54, P184, DOI 10.1016/j.humpath.2016.03.011; Hansel DE, 2006, AM J SURG PATHOL, V30, P1316, DOI 10.1097/01.pas.0000209838.92842.bf; Harel M, 2016, UROL ONCOL-SEMIN ORI, V34, P103, DOI 10.1016/j.urolonc.2015.09.013; He R, 2012, J ANDROL, V33, P798, DOI 10.2164/jandrol.111.015917; Hemminger J, 2012, HISTOPATHOLOGY, V61, P170, DOI 10.1111/j.1365-2559.2011.04150.x; Herawi M, 2006, AM J SURG PATHOL, V30, P1389, DOI 10.1097/01.pas.0000209847.59670.c8; Herawi M, 2006, AM J SURG PATHOL, V30, P694, DOI 10.1097/00000478-200606000-00004; Hossain D, 2008, ANN DIAGN PATHOL, V12, P328, DOI 10.1016/j.anndiagpath.2008.02.009; Hsieh KL, 2016, CASE REP UROL, V2016; HUANG WL, 1990, J UROLOGY, V143, P824, DOI 10.1016/S0022-5347(17)40110-8; Iyer A, 2012, HISTOPATHOLOGY, V60, P522, DOI 10.1111/j.1365-2559.2011.04066.x; Jana M, 2011, INDIAN J UROL, V27, P415, DOI 10.4103/0970-1591.85454; JONES EC, 1991, AM J SURG PATHOL, V15, P1171, DOI 10.1097/00000478-199112000-00008; Kanthan GL, 2016, CLIN NUCL MED, V41, P703, DOI 10.1097/RLU.0000000000001281; KULMALA RV, 1994, SCAND J UROL NEPHROL, V28, P429, DOI 10.3109/00365599409180527; LASKIN WB, 1988, CANCER-AM CANCER SOC, V62, P2330, DOI 10.1002/1097-0142(19881201)62:11<2330::AID-CNCR2820621113>3.0.CO;2-2; Latchamsetty Kalyan C, 2002, Urology, V60, P515, DOI 10.1016/S0090-4295(02)01815-0; Lee TK, 2010, AM J SURG PATHOL, V34, P502, DOI 10.1097/PAS.0b013e3181cf326d; Lopez-Beltran A, 2005, ARCH PATHOL LAB MED, V129, P683; Mavrogenis AF, 2012, J SURG ONCOL, V105, P570, DOI 10.1002/jso.22122; McKenney JK, 2005, ADV ANAT PATHOL, V12, P312, DOI 10.1097/01.pap.0000194626.12760.4e; Miettinen MM, 2013, WHO CLASSIFICATION T, P164; Montgomery EA, 2006, AM J SURG PATHOL, V30, P1502, DOI 10.1097/01.pas.0000213280.35413.1b; Nagar M, 2011, AM J SURG PATHOL, V35, P898, DOI 10.1097/PAS.0b013e318214f2f2; OESTERLING JE, 1990, CANCER-AM CANCER SOC, V66, P1836, DOI 10.1002/1097-0142(19901015)66:8<1836::AID-CNCR2820660832>3.0.CO;2-Y; Ortiz-Rey JA, 2015, APPL IMMUNOHISTO M M, V23, P161, DOI 10.1097/PAI.0000000000000016; Pan CC, 2006, HISTOPATHOLOGY, V48, P321, DOI 10.1111/j.1365-2559.2005.02236.x; Pan CC, 2013, MODERN PATHOL, V26, P1536, DOI 10.1038/modpathol.2013.99; Paner GP, 2016, AM J SURG PATHOL, V40, P886, DOI 10.1097/PAS.0000000000000618; Perez Valcarcel J, 2006, Actas Urol Esp, V30, P1031; PERRONE T, 1990, MED PEDIATR ONCOL, V18, P72, DOI 10.1002/mpo.2950180116; PROPPE KH, 1984, AM J SURG PATHOL, V8, P101, DOI 10.1097/00000478-198402000-00003; Rames RA, 1999, J UROLOGY, V162, P165, DOI 10.1097/00005392-199907000-00045; RANE A, 1995, BRIT J UROL, V75, P683, DOI 10.1111/j.1464-410X.1995.tb07440.x; Reikie BA, 2015, ADV ANAT PATHOL, V22, P113, DOI 10.1097/PAP.0000000000000057; Rischpler C, 2016, EUR J NUCL MED MOL I, V43, P193, DOI 10.1007/s00259-015-3235-y; Ristau BT, 2011, CAN J UROL, V18, P5914; RO JY, 1993, HUM PATHOL, V24, P1203, DOI 10.1016/0046-8177(93)90217-5; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Ronchi A, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0640-5; Sadimin ET, 2016, HUM PATHOL, V52, P68, DOI 10.1016/j.humpath.2016.01.002; Salas S, 2017, ANN ONCOL, V28, P1979, DOI 10.1093/annonc/mdx250; Serizawa RR, 2011, BMC UROL, V11, DOI 10.1186/1471-2490-11-4; SHANNON RL, 1992, CANCER, V69, P2676, DOI 10.1002/1097-0142(19920601)69:11<2676::AID-CNCR2820691109>3.0.CO;2-P; Tsuzuki T, 2004, AM J SURG PATHOL, V28, P1609, DOI 10.1097/00000478-200412000-00009; Ullman D, 2017, APPL IMMUNOHISTOCHEM; Wang G, 2016, CUAJ-CAN UROL ASSOC, V10, pE197, DOI 10.5489/cuaj.3220; Wang WL, 2009, UROL ONCOL-SEMIN ORI, V27, P525, DOI 10.1016/j.urolonc.2008.04.007; WICK MR, 1989, AM J CLIN PATHOL, V92, P131, DOI 10.1093/ajcp/92.2.131; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137; YOUNG RH, 1987, ARCH PATHOL LAB MED, V111, P363	66	3	3	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31			1			S133	S142		10.1038/modpathol.2017.155			10	Pathology	Pathology	FW3PC	WOS:000425219700011	29297486				2019-10-28	
J	Osunkoya, AO				Osunkoya, Adeboye O.			Mucinous and secondary tumors of the prostate	MODERN PATHOLOGY			English	Article							TRANSITIONAL-CELL-CARCINOMA; GASTROINTESTINAL STROMAL TUMOR; UROTHELIAL-TYPE ADENOCARCINOMA; PATHOLOGY-CONSENSUS-CONFERENCE; OF-THE-LITERATURE; PTEN PROTEIN LOSS; INTERNATIONAL-SOCIETY; PRACTICES RECOMMENDATIONS; RADICAL PROSTATECTOMY; LUNG-CANCER	Primary mucinous tumors and secondary tumors involving the prostate gland are relatively uncommon, however they have important diagnostic, therapeutic, and prognostic implications. The primary mucinous tumors of the prostate include mucinous (colloid) adenocarcinoma of the prostate, prostatic adenocarcinoma with mucinous features, and mucinous adenocarcinoma of the prostatic urethra (mucin-producing urothelial-type adenocarcinoma of the prostate). Mucinous adenocarcinoma of the prostate is defined as a primary prostatic acinar tumor characterized by the presence of at least 25% of the tumor composed of glands with extraluminal mucin. This diagnosis can only be made in radical prostatectomy specimens. Recent studies have shown that these tumors have a similar or in some cases better prognosis than conventional prostatic adenocarcinoma treated by radical prostatectomy. The preferred terminology for tumors that are composed of <25% extraluminal mucinous component in radical prostatectomy specimens is 'prostatic adenocarcinoma with mucinous features.' All cases of prostatic adenocarcinoma with extraluminal mucinous components in prostate needle core biopsies or transurethral resection of the prostate specimens are also referred to as 'prostatic adenocarcinoma with mucinous features.' Mucinous adenocarcinoma of the prostatic urethra (mucin-producing urothelial-type adenocarcinoma of the prostate) as the name implies, does not arise from prostatic acini or ducts, and is a distinct entity that arises from the prostatic urethra usually from urethritis glandularis or glandular metaplasia with malignant transformation, and is analogous to adenocarcinoma with mucinous differentiation arising from the urinary bladder. This tumor is aggressive and has a relatively poor prognosis. The most common secondary tumors that arise from adjacent organs and spread (direct extension or metastasis) to the prostate gland, include urothelial carcinoma of the bladder and colorectal adenocarcinoma. Other secondary tumors that may involve the prostate include metastatic epithelial tumors from several other sites, malignant melanoma and soft tissue tumors.	[Osunkoya, Adeboye O.] Emory Univ, Dept Pathol, Sch Med, Suite H174,1364 Clifton Road NE, Atlanta, GA 30322 USA; [Osunkoya, Adeboye O.] Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA; [Osunkoya, Adeboye O.] Vet Affairs Med Ctr, Dept Pathol, Atlanta, GA 30033 USA; [Osunkoya, Adeboye O.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA	Osunkoya, AO (reprint author), Emory Univ, Dept Pathol, Sch Med, Suite H174,1364 Clifton Road NE, Atlanta, GA 30322 USA.	adeboye.osunkoya@emory.edu					ABESHOUSE B S, 1958, South Med J, V51, P994, DOI 10.1097/00007611-195808000-00009; Adsay NV, 2003, AM J SURG PATHOL, V27, P571, DOI 10.1097/00000478-200305000-00002; Alsharif M, 2008, DIAGN CYTOPATHOL, V36, P734, DOI 10.1002/dc.20881; Amin MB, 2014, AM J SURG PATHOL, V38, pE20, DOI 10.1097/PAS.0000000000000240; Amin MB, 2014, AM J SURG PATHOL, V38, P1017, DOI 10.1097/PAS.0000000000000254; Amin MB, 2017, AJCC CANC STAGING MA; Anagnostou E, 2011, INT J SURG PATHOL, V19, P632, DOI 10.1177/1066896911408304; ARAI Y, 1988, J UROLOGY, V139, P382, DOI 10.1016/S0022-5347(17)42426-8; BAMBERGER MH, 1990, UROLOGY, V35, P445, DOI 10.1016/0090-4295(90)80090-A; Abad JB, 2010, ACTAS UROL ESP, V34, P918, DOI 10.1016/j.acuro.2010.03.033; Bates AW, 2002, VIRCHOWS ARCH, V440, P392, DOI 10.1007/s004280100505; Beach R, 2002, AM J SURG PATHOL, V26, P1588, DOI 10.1097/00000478-200212000-00006; BERMAN JR, 1993, UROLOGY, V41, P150, DOI 10.1016/0090-4295(93)90169-B; Bertsch EC, 2016, APPL IMMUNOHISTOCHEM; Bohman KD, 2012, ADV ANAT PATHOL, V19, P374, DOI 10.1097/PAP.0b013e318271a361; Chastain EC, 2012, PATHOLOGY, V44, P199, DOI 10.1097/PAT.0b013e3283511c73; Chuang AY, 2007, AM J SURG PATHOL, V31, P1246, DOI 10.1097/PAS.0b013e31802f5d33; CIHAK RW, 1980, J UROLOGY, V123, P791, DOI 10.1016/S0022-5347(17)56135-2; Cobo Dols Manuel, 2005, Clin Transl Oncol, V7, P409; Curtis MW, 2005, MODERN PATHOL, V18, P585, DOI 10.1038/modpathol.3800317; de la Roza G, 2009, CAN J UROL, V16, P4502; Dickson BC, 2008, CAN J UROL, V15, P4112; Dobbs RW, 2012, CAN J UROL, V19, P6471; EPSTEIN JI, 1985, AM J SURG PATHOL, V9, P299, DOI 10.1097/00000478-198504000-00006; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Epstein JI, 2014, AM J SURG PATHOL, V38, pE6, DOI 10.1097/PAS.0000000000000238; Esrig D, 1996, J UROLOGY, V156, P1071, DOI 10.1016/S0022-5347(01)65705-7; Farnham SB, 2005, UROLOGY, V66, pE28, DOI 10.1016/j.urology.2005.01.058; Fichtenbaum EJ, 2012, AM J CLIN PATHOL, V138, P190, DOI 10.1309/AJCP5ZC4GQVNWTYR; Fokt RM, 2009, UROL INT, V83, P122, DOI 10.1159/000224882; FRANKS LM, 1964, CANCER, V17, P983, DOI 10.1002/1097-0142(196408)17:8<983::AID-CNCR2820170804>3.0.CO;2-R; Fusco N, 2016, ADV ANAT PATHOL, V23, P170, DOI 10.1097/PAP.0000000000000115; Greene GF, 2005, UROLOGY, V65, pE23, DOI 10.1016/j.urology.2004.12.049; Gupta Tejpal, 2004, Indian J Gastroenterol, V23, P114; Gurel B, 2008, ADV ANAT PATHOL, V15, P319, DOI 10.1097/PAP.0b013e31818a5c19; Gurel B, 2010, AM J SURG PATHOL, V34, P1097, DOI 10.1097/PAS.0b013e3181e6cbf3; Han B, 2009, MODERN PATHOL, V22, P1176, DOI 10.1038/modpathol.2009.79; Harari SE, 2016, HUM PATHOL, V47, P132, DOI 10.1016/j.humpath.2015.09.014; Herawi M, 2006, AM J SURG PATHOL, V30, P1389, DOI 10.1097/01.pas.0000209847.59670.c8; Huh JS, 2014, WORLD J MENS HEALTH, V32, P184, DOI 10.5534/wjmh.2014.32.3.184; JOHNSON DE, 1974, J UROLOGY, V112, P507, DOI 10.1016/S0022-5347(17)59776-1; Johnson H, 2013, HUM PATHOL, V44, P2241, DOI 10.1016/j.humpath.2013.05.006; KING DHC, 1995, UROLOGY, V46, P722, DOI 10.1016/S0090-4295(99)80310-0; Lane BR, 2006, UROLOGY, V68, P825, DOI 10.1016/j.urology.2006.04.028; Lerner SP, 2008, UROL ONCOL-SEMIN ORI, V26, P481, DOI 10.1016/j.urolonc.2008.03.002; LOO KT, 1992, ARCH PATHOL LAB MED, V116, P976; Lotan TL, 2015, MODERN PATHOL, V28, P128, DOI 10.1038/modpathol.2014.85; Lotan TL, 2013, MODERN PATHOL, V26, P587, DOI 10.1038/modpathol.2012.201; Lotan TL, 2011, CLIN CANCER RES, V17, P6563, DOI 10.1158/1078-0432.CCR-11-1244; MADERSBACHER S, 1994, EUR UROL, V26, P267; Mai KT, 2002, TUMORI, V88, P341; Marcus DM, 2012, PROSTATE CANCER P D, V15, P283, DOI 10.1038/pcan.2012.4; McMenamin ME, 1999, CANCER RES, V59, P4291; Moch H, 2016, WHO CLASSIFICATION T; Leite KRM, 2008, ANN DIAGN PATHOL, V12, P260, DOI 10.1016/j.anndiagpath.2007.11.001; MOTLEY RC, 1986, J UROLOGY, V135, P801, DOI 10.1016/S0022-5347(17)45860-5; Oliva IV, 2011, HUM PATHOL, V42, P51, DOI 10.1016/j.humpath.2010.06.013; Osunkoya AO, 2008, MODERN PATHOL, V21, P789, DOI 10.1038/modpathol.2008.47; Osunkoya AO, 2008, AM J SURG PATHOL, V32, P468, DOI 10.1097/PAS.0b013e3181589f72; Osunkoya AO, 2007, HUM PATHOL, V38, P1836, DOI 10.1016/j.humpath.2007.04.021; Osunkoya AO, 2012, SEMIN DIAGN PATHOL, V29, P154, DOI 10.1053/j.semdp.2011.10.001; Osunkoya AO, 2012, PATHOLOGY, V44, P391, DOI 10.1097/PAT.0b013e32835657cf; Owens CL, 2007, ARCH PATHOL LAB MED, V131, P599; Plummer ER, 2000, CLIN ONCOL-UK, V12, P229, DOI 10.1053/clon.2000.9159; Reinke DA, 2016, J GASTROINTEST ONCOL, V7, pS71, DOI 10.3978/j.issn.2078-6891.2015.023; Revelo MP, 2004, J UROLOGY, V171, P646, DOI 10.1097/01.ju.0000107380.40481.bc; RO JY, 1990, HUM PATHOL, V21, P593, DOI 10.1016/S0046-8177(96)90004-0; Rodriguez A, 2006, UROLOGY, V67, DOI 10.1016/j.urology.2005.09.058; Roshni S, 2014, J GASTRIC CANCER, V14, P135, DOI 10.5230/jgc.2014.14.2.135; SAGALOWSKY AI, 1986, CANCER, V57, P1060, DOI 10.1002/1097-0142(19860301)57:5<1060::AID-CNCR2820570533>3.0.CO;2-X; Sakamoto N, 2005, INT J UROL, V12, P509, DOI 10.1111/j.1442-2042.2005.01072.x; SCHELLHAMMER PF, 1977, J UROLOGY, V118, P399, DOI 10.1016/S0022-5347(17)58039-8; Schips L, 2002, J UROLOGY, V168, P641, DOI 10.1016/S0022-5347(05)64701-5; Schowinsky JT, 2006, AM J SURG PATHOL, V30, P866, DOI 10.1097/01.pas.0000213274.60962.63; Shen SS, 2006, HUM PATHOL, V37, P726, DOI 10.1016/j.humpath.2006.01.027; SILVERMAN ML, 1981, CANCER, V47, P1398, DOI 10.1002/1097-0142(19810315)47:6<1398::AID-CNCR2820470626>3.0.CO;2-S; SMEDLEY HM, 1983, POSTGRAD MED J, V59, P371, DOI 10.1136/pgmj.59.692.371; Sunkoya AO, 2007, AM J SURG PATHOL, V31, P1323; Torelli Tullio, 2013, Tumori, V99, pe203, DOI 10.1700/1377.15315; WATSON CJE, 1990, BRIT J UROL, V66, P431, DOI 10.1111/j.1464-410X.1990.tb14969.x; Yoo JH, 2009, RESPIROLOGY, V14, P772, DOI 10.1111/j.1440-1843.2009.01545.x; Youssef Fady R, 2011, J Med Case Rep, V5, P223, DOI 10.1186/1752-1947-5-223; ZEIN TA, 1985, J UROLOGY, V133, P615, DOI 10.1016/S0022-5347(17)49111-7; Zhang P, 2010, J RADIOL CASE REP, V4, P35, DOI 10.3941/jrcr.v4i3.355	84	4	5	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31			1			S80	S95		10.1038/modpathol.2017.132			16	Pathology	Pathology	FW3PC	WOS:000425219700007	29297488				2019-10-28	
J	Rubin, MA; Demichelis, F				Rubin, Mark A.; Demichelis, Francesca			The Genomics of Prostate Cancer: emerging understanding with technologic advances	MODERN PATHOLOGY			English	Article							IN-SITU HYBRIDIZATION; ANDROGEN-RECEPTOR GENE; TUMOR-SUPPRESSOR GENE; ALLELIC LOSS; NEUROENDOCRINE DIFFERENTIATION; CELL-LINE; MOLECULAR CHARACTERIZATION; CHROMOSOMAL-ANOMALIES; RETINOBLASTOMA GENE; HOMOZYGOUS DELETION	With the advent of next-generation sequencing technologies and large whole-exome and genome studies in prostate and other cancers, our understanding of the landscape of genomic alterations has dramatically been refined. In additional to well-known alterations in genomic regions involving 8p, 8q, 10q23, common ETS translocations and androgen receptor amplifications, newer technology have uncovered recurrent mutations in SPOP, FOXA1, MED12, IDH and complex large scale genomic alterations (eg, chromoplexy). This review surveys the enhanced landscape of genomic alterations in clinically localized and advanced prostate cancer.	[Rubin, Mark A.; Demichelis, Francesca] Weill Cornell Med Coll, New York Presbyterian Hosp, Inst Precis Med, New York, NY USA; [Rubin, Mark A.] Weill Cornell Med Coll, Sandra & Edward Meyer Canc Ctr, New York, NY USA; [Rubin, Mark A.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA; [Rubin, Mark A.] Univ Bern, Dept Biomed Res, Murlenstr 35, CH-3008 Bern, Switzerland; [Demichelis, Francesca] Univ Trento, Ctr Integrat Biol, Via Sommar 9, I-38123 Trento, Italy	Rubin, MA (reprint author), Univ Bern, Dept Biomed Res, Murlenstr 35, CH-3008 Bern, Switzerland.; Demichelis, F (reprint author), Univ Trento, Ctr Integrat Biol, Via Sommar 9, I-38123 Trento, Italy.	mark.rubin@dbmr.unibe.ch; f.demichelis@unitn.it		Rubin, Mark/0000-0002-8321-9950			Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; An J, 2014, CELL REP, V6, P657, DOI 10.1016/j.celrep.2014.01.013; Arora R, 2004, CANCER-AM CANCER SOC, V100, P2362, DOI 10.1002/cncr.20243; ARPS S, 1993, CANCER GENET CYTOGEN, V66, P93, DOI 10.1016/0165-4608(93)90234-D; Aryee MJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005211; ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; ATKIN NB, 1985, NEW ENGL J MED, V312, P315; Attard G, 2009, J CLIN PATHOL, V62, P373, DOI 10.1136/jcp.2008.061515; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Barry M, 2007, UROLOGY, V70, P630, DOI 10.1016/j.urology.2007.08.032; Bastos DA, 2014, ONCOLOGY-NY, V28, P693; Bastus NC, 2010, CANCER RES, V70, P9544, DOI 10.1158/0008-5472.CAN-10-1638; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2013, EUR UROL, V63, P920, DOI 10.1016/j.eururo.2012.08.053; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; Blattner M, 2017, CANCER CELL, V31, P436, DOI 10.1016/j.ccell.2017.02.004; Blattner M, 2014, NEOPLASIA, V16, P14, DOI 10.1593/neo.131704; Bluemn EG, 2012, CURR OPIN ONCOL, V24, P251, DOI 10.1097/CCO.0b013e32835105b3; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; BOVA GS, 1993, CANCER RES, V53, P3869; Boysen G, 2015, ELIFE, V4, DOI 10.7554/eLife.09207; Brocks D, 2014, CELL REP, V8, P798, DOI 10.1016/j.celrep.2014.06.053; BROOKS JD, 1995, PROSTATE, V26, P35, DOI 10.1002/pros.2990260108; Bubendorf L, 1999, CANCER RES, V59, P803; Burchardt T, 1999, J UROLOGY, V162, P1800, DOI 10.1016/S0022-5347(05)68241-9; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005; Cheng L, 1998, J NATL CANCER I, V90, P233, DOI 10.1093/jnci/90.3.233; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; Clegg NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017449; Cooper CS, 2015, NAT GENET, V47, P367, DOI 10.1038/ng.3221; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Deng XH, 2008, CANCER RES, V68, P9663, DOI 10.1158/0008-5472.CAN-08-2229; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; EMMERTBUCK MR, 1995, CANCER RES, V55, P2959; Esgueva R, 2010, MOD PATHOL; FLEMING WH, 1986, CANCER RES, V46, P1535; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Furusato B, 2010, PROSTATE CANCER P D, V13, P228, DOI 10.1038/pcan.2010.23; Furusato B, 2008, MODERN PATHOL, V21, P67, DOI 10.1038/modpathol.3800981; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Geng C, 2014, CANCER RES, V74, P5631, DOI 10.1158/0008-5472.CAN-14-0476; Geng C, 2013, P NATL ACAD SCI USA, V110, P6997, DOI 10.1073/pnas.1304502110; GIBAS Z, 1984, CANCER GENET CYTOGEN, V11, P399, DOI 10.1016/0165-4608(84)90020-7; Gonzalez-Billalabeitia E, 2014, CANCER DISCOV, V4, P896, DOI 10.1158/2159-8290.CD-13-0230; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; GRAY IC, 1995, CANCER RES, V55, P4800; Groner AC, 2016, CANCER CELL, V29, P846, DOI 10.1016/j.ccell.2016.04.012; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347; Haffner MC, 2010, NAT GENET, V42, P668, DOI 10.1038/ng.613; Han B, 2008, CANCER RES, V68, P7629, DOI 10.1158/0008-5472.CAN-08-2014; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Hieronymus H, 2014, P NATL ACAD SCI USA, V111, P11139, DOI 10.1073/pnas.1411446111; Hong MKH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7605; Hovelson DH, 2015, NEOPLASIA, V17, P385, DOI 10.1016/j.neo.2015.03.004; Hughes IA, 2012, LANCET, V380, P1419, DOI 10.1016/S0140-6736(12)60071-3; Huijbers IJ, 2014, EMBO MOL MED, V6, P212, DOI 10.1002/emmm.201303297; ISAACS WB, 1991, CANCER RES, V51, P4716; Jenkins RB, 1997, CANCER RES, V57, P524; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kobayashi M, 2008, PROSTATE, V68, P1715, DOI 10.1002/pros.20832; KONIG JJ, 1989, UROL RES, V17, P79; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Kumar A, 2011, P NATL ACAD SCI USA, V108, P17087, DOI 10.1073/pnas.1108745108; Kunju LP, 2014, APPL IMMUNOHISTO M M, V22, pE32, DOI 10.1097/PAI.0000000000000095; Kypta RM, 2012, NAT REV UROL, V9, P418, DOI 10.1038/nrurol.2012.116; LAI SL, 1995, ANTICANCER RES, V15, P225; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Lee JK, 2016, CANCER CELL, V29, P536, DOI 10.1016/j.ccell.2016.03.001; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin CR, 2009, CELL, V139, P1069, DOI 10.1016/j.cell.2009.11.030; Lin D, 2014, CANCER RES, V74, P1272, DOI 10.1158/0008-5472.CAN-13-2921-T; Lindberg J, 2015, EUR UROL, V67, P819, DOI 10.1016/j.eururo.2014.09.006; Lindberg J, 2013, EUR UROL, V63, P347, DOI 10.1016/j.eururo.2012.03.050; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MACOSKA JA, 1992, J UROLOGY, V147, P1142, DOI 10.1016/S0022-5347(17)37504-3; MACOSKA JA, 1994, CANCER RES, V54, P3824; Maher CA, 2009, P NATL ACAD SCI USA, V106, P12353, DOI 10.1073/pnas.0904720106; Mani RS, 2010, NAT REV GENET, V11, P819, DOI 10.1038/nrg2883; Mani RS, 2009, SCIENCE, V326, P1230, DOI 10.1126/science.1178124; MASSENKEIL G, 1994, ANTICANCER RES, V14, P2785; MATSUYAMA H, 1994, ONCOGENE, V9, P3071; Mehra R, 2008, CANCER RES, V68, P3584, DOI 10.1158/0008-5472.CAN-07-6154; Mehra R, 2007, CANCER RES, V67, P7991, DOI 10.1158/0008-5472.CAN-07-2043; Meiers I, 2007, UROLOGY, V70, P3, DOI 10.1016/j.urology.2007.06.1129; Mertz KD, 2007, NEOPLASIA, V9, P200, DOI 10.1593/neo.07103; Mosquera JM, 2013, NEOPLASIA, V15, P1, DOI 10.1593/neo.121550; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Mullins JK, 2012, J UROLOGY, V188, P2219, DOI 10.1016/j.juro.2012.08.028; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; NEWMARK JR, 1992, P NATL ACAD SCI USA, V89, P6319, DOI 10.1073/pnas.89.14.6319; Nickerson ML, 2013, HUM MUTAT, V34, P1231, DOI 10.1002/humu.22346; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Perner S, 2010, UROLOGY, V75, P762, DOI 10.1016/j.urology.2009.10.010; Pflueger D, 2009, NEOPLASIA, V11, P804, DOI 10.1593/neo.09572; PHILLIPS SMA, 1994, BRIT J CANCER, V70, P1252, DOI 10.1038/bjc.1994.482; Pierce WK, 2015, J MOL BIOL; Pinthus JH, 2000, CANCER RES, V60, P6563; Prandi D, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0439-6; QIAN JQ, 1995, CANCER RES, V55, P5408; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Rajan P, 2014, EUR UROL, V66, P32, DOI 10.1016/j.eururo.2013.08.011; Richter E, 2007, PROSTATE CANCER P D, V10, P114, DOI 10.1038/sj.pcan.4500936; Rickman DS, 2017, NAT MED, V23, P664, DOI 10.1038/nm.4341; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Romanel A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00046-0; Rubin MA, 2000, HUM PATHOL, V31, P504, DOI 10.1053/hp.2000.6713; Rubin MA, 2016, EUR UROL, V69, P557, DOI 10.1016/j.eururo.2015.10.040; Rudin CM, 2014, CANCER DISCOV, V4, P273, DOI 10.1158/2159-8290.CD-14-0069; SAKR WA, 1994, CANCER RES, V54, P3273; Shukla GC, 2016, ANDROLOGY-US, V4, P366, DOI 10.1111/andr.12167; Smith SC, 2014, AM J SURG PATHOL, V38, P615, DOI 10.1097/PAS.0000000000000090; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Teicher BA, 2014, BIOCHEM PHARMACOL, V87, P211, DOI 10.1016/j.bcp.2013.09.014; Theurillat JPP, 2014, SCIENCE, V346, P85, DOI 10.1126/science.1250255; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; TRAPMAN J, 1994, CANCER RES, V54, P6061; True LD, 2002, AM J PATHOL, V161, P705, DOI 10.1016/S0002-9440(10)64226-5; VanderWeele DJ, 2014, CANCER SCI, V105, P1079, DOI 10.1111/cas.12460; VANHAAFTENDAY C, 1987, PROSTATE, V11, P271, DOI 10.1002/pros.2990110307; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; VISAKORPI T, 1995, CANCER RES, V55, P342; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Young A, 2012, AM J CLIN PATHOL, V138, P685, DOI 10.1309/AJCPU7PPWUPYG8OH; YUNIS JJ, 1978, AM J DIS CHILD, V132, P161, DOI 10.1001/archpedi.1978.02120270059012	149	6	6	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31			1			S1	S11		10.1038/modpathol.2017.166			11	Pathology	Pathology	FW3PC	WOS:000425219700001	29297493				2019-10-28	
J	Trpkov, K				Trpkov, Kiril			Benign mimics of prostatic adenocarcinoma	MODERN PATHOLOGY			English	Article							ATYPICAL ADENOMATOUS HYPERPLASIA; NEEDLE-BIOPSY SPECIMENS; METHYLACYL-COA RACEMASE; BASAL-CELL HYPERPLASIA; MUCOSAL GLAND HYPERPLASIA; ISUP CONSENSUS CONFERENCE; NEPHROGENIC ADENOMA; SCLEROSING ADENOSIS; PROSTATECTOMY SPECIMENS; HISTOLOGIC FEATURES	Benign mimics present either as common challenges in daily routine practice or may cause diagnostic dilemmas because some are less commonly seen and one may be less familiar in recognizing them. There are a multitude of mimics of prostatic adenocarcinoma, which may represent normal gland structures, benign proliferations, atrophic lesions, hyperplastic or metaplastic changes, and inflammatory processes. Some of them are preferentially found in certain anatomic areas of the prostate, either confined to the prostate, or outside of the gland. Various benign mimics of prostatic carcinoma may be also evaluated based on their morphologic similarity to Gleason patterns 3-5 of prostatic adenocarcinoma. Most of the mimics are easily recognizable in larger specimens, such as TUR of the prostate or radical prostatectomy specimens, but they may pose diagnostic problems when the evaluation is done on limited tissue, such as needle-core biopsies or if prostate specimens are infrequently encountered in practice. Therefore, before signing out a report with a diagnosis of prostatic carcinoma, pathologists should carefully consider and rule out the various benign lesions that may mimic carcinoma. This is particularly relevant in the current prostate biopsy practice which relies on using extended biopsy core templates. The awareness and familiarity with the characteristic features of the mimics and judicial use of additional ancillary tests, including immunohistochemistry can prevent overdiagnosis and false-positive interpretation. This review provides a contemporary update on the broad spectrum of the benign prostatic lesions that can mimic prostate adenocarcinoma, outlines their key morphologic and immunohistochemical diagnostic features, and provides a diagnostic, pattern-based approach in establishing a correct diagnosis and distinguishing them reliably from prostatic adenocarcinoma.	[Trpkov, Kiril] Univ Calgary, Calgary Lab Serv, Dept Pathol & Lab Med, 7007 14 St, Calgary, AB T2V 1P9, Canada; [Trpkov, Kiril] Univ Calgary, Rockyview Gen Hosp, 7007 14 St, Calgary, AB T2V 1P9, Canada	Trpkov, K (reprint author), Univ Calgary, Calgary Lab Serv, Dept Pathol & Lab Med, 7007 14 St, Calgary, AB T2V 1P9, Canada.; Trpkov, K (reprint author), Univ Calgary, Rockyview Gen Hosp, 7007 14 St, Calgary, AB T2V 1P9, Canada.	kiril.trpkov@cls.ab.ca					Agostinho AD, 1998, UROL INT, V61, P47, DOI 10.1159/000030284; Algaba F, 2015, ANAL QUANT CYTOPATHO, V37, P57; ALGUACILGARCIA A, 1986, AM J SURG PATHOL, V10, P795, DOI 10.1097/00000478-198611000-00007; Ali TZ, 2005, AM J SURG PATHOL, V29, P1159, DOI 10.1097/01.pas.0000160980.62586.05; Allan CH, 2001, AM J SURG PATHOL, V25, P802, DOI 10.1097/00000478-200106000-00013; Amin MB, 1999, AM J SURG PATHOL, V23, P925, DOI 10.1097/00000478-199908000-00010; AYALA AG, 1986, AM J SURG PATHOL, V10, P665, DOI 10.1097/00000478-198610000-00001; Billis A, 1998, MODERN PATHOL, V11, P47; Billis A, 2010, INT BRAZ J UROL, V36, P401, DOI 10.1590/S1677-55382010000400003; Bohman KD, 2012, ADV ANAT PATHOL, V19, P374, DOI 10.1097/PAP.0b013e318271a361; Bostwick DG, 2003, MODERN PATHOL, V16, P630, DOI 10.1097/01.MP.0000074733.10777.78; BOSTWICK DG, 1993, HUM PATHOL, V24, P819, DOI 10.1016/0046-8177(93)90131-Y; CARSTENS PHB, 1980, J UROLOGY, V123, P686; Chen YB, 2011, AM J SURG PATHOL, V35, P1054, DOI 10.1097/PAS.0b013e318218df97; Cheng L, 2010, HISTOPATHOLOGY, V56, P627, DOI 10.1111/j.1365-2559.2010.03525.x; CHEVILLE JC, 1995, AM J SURG PATHOL, V19, P1068, DOI 10.1097/00000478-199509000-00011; Chuang AY, 2007, AM J SURG PATHOL, V31, P1225, DOI 10.1097/PAS.0b013e31802be3c2; Chughtai B, 2005, INT J ANDROL, V28, P74, DOI 10.1111/j.1365-2605.2005.00499.x; Cina SJ, 1997, AM J SURG PATHOL, V21, P550, DOI 10.1097/00000478-199705000-00007; Cina SJ, 1997, AM J SURG PATHOL, V21, P289, DOI 10.1097/00000478-199703000-00004; CRAMER SF, 1981, AM J CLIN PATHOL, V75, P854, DOI 10.1093/ajcp/75.6.854; De Marzo AM, 2006, AM J SURG PATHOL, V30, P1281, DOI 10.1097/01.pas.0000213289.50660.be; Egan AJM, 1997, AM J SURG PATHOL, V21, P931, DOI 10.1097/00000478-199708000-00007; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Farinola MA, 2004, HUM PATHOL, V35, P1272, DOI 10.1016/j.humpath.2004.06.015; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P617, DOI 10.1002/path.1700680234; FRAUENHOFFER EE, 1991, AM J CLIN PATHOL, V95, P446, DOI 10.1093/ajcp/95.4.446; GAGUCAS RJ, 1995, AM J SURG PATHOL, V19, P30, DOI 10.1097/00000478-199501000-00004; Garcia JJ, 2008, AM J SURG PATHOL, V32, P1709, DOI 10.1097/PAS.0b013e318172ee97; GARDNER WA, 1987, J UROLOGY, V137, P53, DOI 10.1016/S0022-5347(17)43869-9; Gaudin PB, 1995, AM J CLIN PATHOL, V104, P620; GAUDIN PB, 1994, AM J SURG PATHOL, V18, P863, DOI 10.1097/00000478-199409000-00001; GAUDIN PB, 1995, AM J SURG PATHOL, V19, P737, DOI 10.1097/00000478-199507000-00001; GIKAS PW, 1993, AM J SURG PATHOL, V17, P454, DOI 10.1097/00000478-199305000-00003; Green WM, 2013, HUM PATHOL, V44, P1895, DOI 10.1016/j.humpath.2013.02.019; GRIGNON DJ, 1992, AM J SURG PATHOL, V16, P383, DOI 10.1097/00000478-199204000-00007; Grignon DJ, 1996, EUR UROL, V30, P206; GRIGNON DJ, 1993, AM J SURG PATHOL, V17, P287, DOI 10.1097/00000478-199303000-00009; Gupta A, 2004, AM J SURG PATHOL, V28, P1224, DOI 10.1097/01.pas.0000131544.18266.a4; Hameed O, 2010, ARCH PATHOL LAB MED, V134, P427, DOI 10.1043/1543-2165-134.3.427; Harik LR, 2012, ARCH PATHOL LAB MED, V136, P721, DOI 10.5858/arpa.2011-0584-RA; Herawi M, 2005, AM J SURG PATHOL, V29, P874, DOI 10.1097/01.pas.0000159520.36806.3e; Hoster GA, 2005, HUM PATHOL, V36, P480, DOI 10.1016/j.humpath.2005.02.015; Howarth SM, 2005, HISTOPATHOLOGY, V47, P114, DOI 10.1111/j.1365-2559.2005.02043.x; Hudson J, 2012, HUM PATHOL, V43, P974, DOI 10.1016/j.humpath.2011.09.009; Humphrey PA, 1998, AM J SURG PATHOL, V22, P1239, DOI 10.1097/00000478-199810000-00009; JONES EC, 1991, AM J SURG PATHOL, V15, P1171, DOI 10.1097/00000478-199112000-00008; Kawabata K, 1997, ARCH PATHOL LAB MED, V121, P515; KRAMER CE, 1993, HUM PATHOL, V24, P618, DOI 10.1016/0046-8177(93)90241-8; Kunju LP, 2010, ARCH PATHOL LAB MED, V134, P1455, DOI 10.1043/2010-0226-CR.1; Leroy X, 2003, AM J SURG PATHOL, V27, P519, DOI 10.1097/00000478-200304000-00013; Levi AW, 2000, AM J SURG PATHOL, V24, P1039, DOI 10.1097/00000478-200008000-00001; Lotan TL, 2008, AM J SURG PATHOL, V32, P1360, DOI 10.1097/PAS.0b013e318169eed7; Luque Rafael J, 2003, Arch Pathol Lab Med, V127, pe14; Maniar KP, 2011, INT J SURG PATHOL, V19, P772, DOI 10.1177/1066896911414567; Mazal PR, 2002, NEW ENGL J MED, V347, P653, DOI 10.1056/NEJMoa013413; MCINTIRE TL, 1986, J UROLOGY, V135, P507, DOI 10.1016/S0022-5347(17)45710-7; Medlicott S, 2016, ANN DIAGN PATHOL, V22, P33, DOI 10.1016/j.anndiagpath.2016.03.004; Nelson RS, 1996, AM J SURG PATHOL, V20, P419, DOI 10.1097/00000478-199604000-00004; Netto George J, 2008, Surg Pathol Clin, V1, P1, DOI 10.1016/j.path.2008.07.008; OLIVA E, 1995, MODERN PATHOL, V8, P722; Oppenheimer JR, 1997, ARCH PATHOL LAB MED, V121, P724; Oppenheimer JR, 1998, AM J SURG PATHOL, V22, P440, DOI 10.1097/00000478-199804000-00008; OSTROWSKI ML, 1994, AM J SURG PATHOL, V18, P412, DOI 10.1097/00000478-199404000-00009; Postma R, 2005, UROLOGY, V65, P745, DOI 10.1016/j.urology.2004.10.046; PRESTI B, 1991, AM J CLIN PATHOL, V95, P330, DOI 10.1093/ajcp/95.3.330; Przybycin CG, 2008, AM J SURG PATHOL, V32, P58, DOI 10.1097/PAS.0b013e318093e3f6; Quick CM, 2010, HUM PATHOL, V41, P1145, DOI 10.1016/j.humpath.2010.01.010; Repassy Denes L., 2002, Pathology & Oncology Research, V8, P202; Rioux-Leclercq NC, 2002, AM J SURG PATHOL, V26, P237, DOI 10.1097/00000478-200202000-00011; Ruska KM, 1998, AM J SURG PATHOL, V22, P1073, DOI 10.1097/00000478-199809000-00005; Saboorian MH, 1997, AM J SURG PATHOL, V21, P1069, DOI 10.1097/00000478-199709000-00011; SAKAMOTO N, 1991, AM J SURG PATHOL, V15, P660, DOI 10.1097/00000478-199107000-00007; Sarma HN, 1996, SCAND J UROL NEPHROL, V30, P155, DOI 10.3109/00365599609180909; Schowinsky JT, 2006, AM J SURG PATHOL, V30, P866, DOI 10.1097/01.pas.0000213274.60962.63; SEBO TJ, 1994, HUM PATHOL, V25, P386, DOI 10.1016/0046-8177(94)90147-3; Skinnider BF, 2004, AM J SURG PATHOL, V28, P701, DOI 10.1097/01.pas.0000126759.43227.d9; So JS, 2014, AM J SURG PATHOL, V38, P852, DOI 10.1097/PAS.0000000000000193; Srigley JR, 2004, MODERN PATHOL, V17, P328, DOI 10.1038/modpathol.3800055; Thorson P, 2003, MODERN PATHOL, V16, P598, DOI 10.1097/01.MP.0000073526.59270.6E; Tran TT, 2001, AM J SURG PATHOL, V25, P618, DOI 10.1097/00000478-200105000-00008; Trpkov K, 2009, AM J CLIN PATHOL, V132, P211, DOI 10.1309/AJCPGFJP83IXZEUR; Wagner D, 2007, INT J SURG PATHOL, V15, P86, DOI 10.1177/1066896906295892; Wang HLL, 2002, AM J SURG PATHOL, V26, P1066, DOI 10.1097/01.PAS.0000020460.78859.86; Wang WL, 2008, AM J SURG PATHOL, V32A, P851, DOI 10.1097/PAS.0b013e31815a0508; Yang XMJ, 2003, HUM PATHOL, V34, P462, DOI 10.1016/S0046-8177(03)00121-7; Yang XMJ, 2002, AM J SURG PATHOL, V26, P921, DOI 10.1097/00000478-200207000-00011; Zhao J, 2009, AM J SURG PATHOL, V33, P583, DOI 10.1097/PAS.0b013e31818a5c6c	89	3	3	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31			1			S22	S46		10.1038/modpathol.2017.136			25	Pathology	Pathology	FW3PC	WOS:000425219700003	29297489				2019-10-28	
J	Aljoghaiman, M; Taha, MS; Abdulkader, MM				Aljoghaiman, Majid; Taha, Mahmoud S.; Abdulkader, Marwah M.			Cerebellar Medulloblastoma in Middle-to-Late Adulthood	CASE REPORTS IN PATHOLOGY			English	Article							TUMORS	Medulloblastoma is a malignant brain tumor that is typically seen in children. It is classified as an embryonal tumor, classically located within the posterior fossa. When it involves the fourth ventricle, the patient commonly presents with signs and symptoms of raised intracranial pressure secondary to obstructive hydrocephalus. It is exceedingly rare for Medulloblastoma to occur in middle and late adulthood. In this paper, we present a case of a 51-year-old man who presented with a posterior fossa mass that was diagnosed later as Medulloblastoma.	[Aljoghaiman, Majid] King Faisal Univ, Dept Neurosurg, Al Hasa, Saudi Arabia; [Taha, Mahmoud S.] King Fahad Specialist Hosp, Dept Neurosci, Dammam, Saudi Arabia; [Abdulkader, Marwah M.] King Fahad Specialist Hosp, Dept Pathol & Lab Med, Dammam, Saudi Arabia	Aljoghaiman, M (reprint author), King Faisal Univ, Dept Neurosurg, Al Hasa, Saudi Arabia.	majed_saj@hotmail.com		Aljoghaiman, Majid/0000-0002-3381-3564			Agamanolis D P, NEUROPATHOLOGY; BLOOM HJG, 1990, INT J RADIAT ONCOL, V18, P763, DOI 10.1016/0360-3016(90)90395-Z; CERVONI L, 1994, J NEURO-ONCOL, V19, P169, DOI 10.1007/BF01306459; Jaiswal AK, 2000, NEUROL INDIA, V48, P178; KEPES JJ, 1987, NEUROSURGERY, V21, P81, DOI 10.1227/00006123-198707000-00017; Le QT, 1997, CANCER J SCI AM, V3, P238; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Raat J, 1944, ARCH NEURO PSYCHIATR, V52, P163; RAMSAY DA, 1995, CLIN NEUROPATHOL, V14, P337; Rutka J T, 1997, Clin Neurosurg, V44, P571; Sajko T, 2004, ACTA CLIN CROAT, V43, P45; SKOLYSZEWSKI J, 1989, INT J RADIAT ONCOL, V16, P479; Smoll NR, 2012, J CLIN NEUROSCI, V19, P1541, DOI 10.1016/j.jocn.2012.04.009; Yong RL, 2006, CAN J NEUROL SCI, V33, P101, DOI 10.1017/S0317167100004789	14	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									5425398	10.1155/2018/5425398			4	Pathology	Pathology	FV8UL	WOS:000424862400001	29651356	DOAJ Gold, Green Published			2019-10-28	
J	Puvabanditsin, S; Abellar, R; Madubuko, A; Mehta, R; Walzer, L				Puvabanditsin, Surasak; Abellar, Rosanna; Madubuko, Adaora; Mehta, Rajeev; Walzer, Lauren			Pulmonary Vasculitis and a Horseshoe Kidney in Noonan Syndrome	CASE REPORTS IN PATHOLOGY			English	Article							DISORDERS; MUTATIONS	We report a term male neonate with congenital myeloproliferative disorder, thrombocytopenia, a horseshoe kidney, feeding difficulty secondary to dysphagia/foregut dysmotility, and respiratory failure. Prenatal molecular genetic analysis revealed a fetus carrying c.184T>G (p.Tyr62Asp) pathogenic variant in PTPN11. The infant eventually succumbed to respiratory failure. Bacterial and viral cultures/studies were all no growth/negative. Pulmonary capillaritis and vasculitis were noted at autopsy. This report presents a new case of Noonan syndrome with unusual associated disorders and a review of the literature.	[Puvabanditsin, Surasak; Madubuko, Adaora; Mehta, Rajeev; Walzer, Lauren] Rutgers Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ 08903 USA; [Abellar, Rosanna] Columbia Univ, Dept Pathol, Med Ctr, New York, NY USA	Puvabanditsin, S (reprint author), Rutgers Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ 08903 USA.	surasak1@aol.com					Agha A, 2012, CURR RHEUMATOL REP, V14, P526, DOI 10.1007/s11926-012-0281-3; Allanson JE, 2016, GENEREVIEWS; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; Choong K, 1999, J PEDIAT HEMATOL ONC, V21, P523, DOI 10.1097/00043426-199911000-00014; Gripp KW, 2016, AM J MED GENET A, V170, P2237, DOI 10.1002/ajmg.a.37781; Gupta A, 2009, CLIN EXP NEPHROL, V13, P531, DOI 10.1007/s10157-009-0183-5; Hasle H, 2009, HORM RES, V72, P8, DOI 10.1159/000243773; JAMIESON CR, 1994, NAT GENET, V8, P357, DOI 10.1038/ng1294-357; Kleta R, 2000, NEPHROL DIAL TRANSPL, V15, P1094, DOI 10.1093/ndt/15.7.1094-b; LONGLEY S, 1986, AM J MED, V80, P1027, DOI 10.1016/0002-9343(86)90660-1; NOONAN JA, 1963, J PEDIATR-US, V63, P468; Prendiville TW, 2014, ARCH DIS CHILD, V99, P629, DOI 10.1136/archdischild-2013-305047; Roberts AE, 2013, LANCET, V381, P333, DOI 10.1016/S0140-6736(12)61023-X; Romano AA, 2010, PEDIATRICS, V126, P746, DOI 10.1542/peds.2009-3207; Shah N, 1999, ARCH DIS CHILD, V81, P28, DOI 10.1136/adc.81.1.28; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tidyman WE, 2016, HUM MOL GENET, V25, pR123, DOI 10.1093/hmg/ddw191	17	0	0	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									6829586	10.1155/2018/6829586			4	Pathology	Pathology	FV8UM	WOS:000424862500001	29670795	DOAJ Gold, Green Published			2019-10-28	
J	Resta, IT; Singh, A; Gilbert, BC; Rojiani, MV; Alleyne, C; Rojiani, AM				Resta, Isabella Tondi; Singh, Arminder; Gilbert, Bruce C.; Rojiani, Mumtaz V.; Alleyne, Cargill; Rojiani, Amyn M.			Suprasellar Ganglioglioma: Expanding the Differential Diagnosis	CASE REPORTS IN PATHOLOGY			English	Article							OPTIC CHIASM; FOLLOW-UP	This case study describes a young man with symptoms suggestive of the presence of a space-occupying lesion within the cranial cavity. Imaging studies confirmed a lesion in the suprasellar region and surgical intervention to remove the tumor yielded an unexpected diagnosis. Neuroimaging characteristics and histopathology including immunohistochemistry are described. Gangliogliomas are uncommon CNS neoplasms and are most commonly found in the temporal and frontal lobes of young, male adults. They are rarely seen in the suprasellar region and only a handful of cases have been reported to date. The differential diagnoses associated with these suprasellar region lesions can be dependent on the age of the patient and neuroimaging characteristics. The present report highlights the importance of histopathological examination and the need to consider a wide range of diagnostic entities in the differential diagnosis of lesions in this topographic distribution, including rarely encountered tumors such as gangliogliomas.	[Resta, Isabella Tondi; Rojiani, Mumtaz V.; Rojiani, Amyn M.] Augusta Univ, Med Coll Georgia, Dept Pathol, 1120 Fifteenth St, Augusta, GA 30912 USA; [Singh, Arminder] Augusta Univ, Med Coll Georgia, Dept Neurol, 1120 Fifteenth St, Augusta, GA 30912 USA; [Gilbert, Bruce C.] Augusta Univ, Med Coll Georgia, Dept Radiol, 1120 Fifteenth St, Augusta, GA 30912 USA; [Rojiani, Mumtaz V.] Augusta Univ, Med Coll Georgia, Dept Med, 1120 Fifteenth St, Augusta, GA 30912 USA; [Alleyne, Cargill] Augusta Univ, Med Coll Georgia, Dept Neurosurg, 1120 Fifteenth St, Augusta, GA 30912 USA	Rojiani, AM (reprint author), Augusta Univ, Med Coll Georgia, Dept Pathol, 1120 Fifteenth St, Augusta, GA 30912 USA.	arojiani@augusta.edu					Becker A. J., 2016, WHO CLASSIFICATION T; Blumcke I, 1999, ACTA NEUROPATHOL, V97, P481, DOI 10.1007/s004010051017; Gupta R, 2010, CHILD NERV SYST, V26, P255, DOI 10.1007/s00381-009-0989-1; KALYANRAMAN UP, 1987, NEUROSURGERY, V20, P428, DOI 10.1227/00006123-198703000-00012; Liu GT, 1996, NEUROLOGY, V46, P1669, DOI 10.1212/WNL.46.6.1669; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Luyken C, 2004, CANCER, V101, P146, DOI 10.1002/cncr.20332; Nishio S, 2001, NEUROSURG REV, V24, P14, DOI 10.1007/PL00011960; Shuangshoti S, 2000, AM J NEURORADIOL, V21, P1486; Tandon Vivek, 2016, Asian J Neurosurg, V11, P407; ZENTNER J, 1994, J NEUROL NEUROSUR PS, V57, P1497, DOI 10.1136/jnnp.57.12.1497	11	1	1	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									9486064	10.1155/2018/9486064			4	Pathology	Pathology	FV8UN	WOS:000424862600001	29487755	DOAJ Gold, Green Published			2019-10-28	
S	Pinn, VW	Galli, SJ	Abbas, AK; Aster, JC		Pinn, Vivian W.	Galli, SJ		Perspectives from a Pathologist: My Journey on the Path to Women's Health Research, Sex and Gender Policy, and Practice Implications	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						women in pathology; renal pathology; women's health research; career development	IDIOPATHIC NEPHROTIC SYNDROME; INSTITUTES-OF-HEALTH; PATHOGENESIS; DISEASE; NIH	These words reflect my recollections of major transition points in my life and career: as I first became dedicated to becoming a physician, being introduced to the field of pathology and research, and then transitioning to a somewhat different career focus by becoming the first director of the National Institutes of Health Office of Research on Women's Health. Many of the experiences that I gained during my years in pathology served me well as I made efforts to establish women's health research and sex and gender based studies as scientific endeavors. Participating in research and teaching as an academic pathologist, setting funding priorities, and supporting and encouraging research careers through governmental office programs have been the essence of my more than 50 years as a pathologist and physician.	[Pinn, Vivian W.] NIH, Off Res Womens Hlth, Bethesda, MD 20892 USA	Pinn, VW (reprint author), NIH, Off Res Womens Hlth, Bethesda, MD 20892 USA.	vwpinn@gmail.com					ABRASS CK, 1980, KIDNEY INT, V17, P545, DOI 10.1038/ki.1980.63; ACOSTA JM, 1973, ARCH SURG-CHICAGO, V106, P844; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701; [Anonymous], 1988, N ENGL J MED, V318, P924; Association of American Medical Colleges, 2014, STAT WOM AC MED PIP; Baker RB, 2008, JAMA-J AM MED ASSOC, V300, P306, DOI 10.1001/jama.300.3.306; BARNES BENJAMIN A., 1966, TRANSPLANTATION, V4, P154, DOI 10.1097/00007890-196603000-00004; CHAD D, 1982, NEUROLOGY, V32, P725, DOI 10.1212/WNL.32.7.725; Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a; Coggins C H, 1986, Trans Am Clin Climatol Assoc, V97, P18; COGGINS CH, 1979, NEW ENGL J MED, V301, P1301; Coggins CH, 1979, NEPHRON, V24, P10; Committee on Maximizing the Potential of Women in Academic Science and Engineering, 2007, BIAS BARR FULF POT W; Cope O, 1997, BREAST ITS PROBLEMS; COSYNS JP, 1982, KIDNEY INT, V22, P177, DOI 10.1038/ki.1982.150; D Grady, 2003, PUBLICATION AGENCY H; GOLDBERG MJ, 1982, GASTROENTEROLOGY, V83, P677; GUPTA PK, 1969, ACTA CYTOL, V13, P373; Hultgren S, 2008, NAT REV MICROBIOL, V6, P254, DOI 10.1038/nrmicro1875; Institute of Medicine, 2010, WOM HLTH RES PROGR P; Institute of Medicine, 2001, EXPL BIOL CONTR HUM; Institute of Medicine (US) Board on Population Health and Public Health Practice, 2012, SEX SPEC REP SCI RES; JEANNET M, 1970, NEW ENGL J MED, V282, P111, DOI 10.1056/NEJM197001152820301; Kelty M, 2012, PRINCIPLES PRACTICE, P147; Legato M J, 2000, J Gend Specif Med, V3, P15; Louis DN, 2011, KEEN MINDS EXPLORE D; LYONS H, 1973, NEW ENGL J MED, V288, P124, DOI 10.1056/NEJM197301182880304; Mastroianni AC, 1994, WOMEN HLTH RES ETHIC, VI; MCCAULEY RGK, 1979, AM J DIS CHILD, V133, P1174, DOI 10.1001/archpedi.1979.02130110082015; Nadal MV, 1990, NATL I HLTH PROBLEMS; National Institutes of Health, 1994, FED REGISTER, V59, P11146; Natl. Inst. Health, 2012, CAUS FACT INT WORKSH; Natl. Inst. Health Intramural Res, NIH WORK LIF RES; Natl. Inst. Health (NIH), 2011, NIH FAM FRIENDL IN; Natl. Inst. Health (NIH), 1999, RFAOD99088 NIH; Natl. Inst. Health (NIH), 2010, HIGHL NIH WOM HLTH S; Natl. Inst. Health (NIH), 2001, RFAOD02002 NIH; Natl. Inst. Health (NIH), 1994, WOM BIOM CAR DYN CHA; NEATON JD, 1987, CONTROL CLIN TRIALS, V8, pS41; Off. Res. Women's Health Natl. Inst. Health, 1992, REP NAT I HLTH OPP R, V1; Off. Res. Women's Health Natl. Inst. Health, 1992, REP NAT I HLTH OPP R, V2; Office of Research on Women's Health, 1999, AG RES WOM HLTH 21 C; Office of Research on Women's Health, 2010, MOV FUT NEW DIM STRA; Pinn VW, 2011, INT LIBR ETH LAW NEW, V48, P53, DOI 10.1007/978-94-007-0931-7_4; Pinn VW, 2011, J DENT EDUC, V75, pS11; Pinn VW, 2010, J WOMENS HEALTH, V19, P1603, DOI 10.1089/jwh.2010.2386; Pinn Vivian W, 2005, Gend Med, V2, P121, DOI 10.1016/S1550-8579(05)80039-7; Pinn Vivian W., 1999, J AM MED WOMEN ASSOC, V54, P15; Pinn VW, 2005, JAMA-J AM MED ASSOC, V294, P1407, DOI 10.1001/jama.294.11.1407; PINN VW, 1994, ACAD MED, V69, P698, DOI 10.1097/00001888-199409000-00003; Pinn VW, 2010, AM SOC CELL BIOL NEW, V33, P13; Pinn VW, 2011, SEARCH LEGACY USPHS, P1; PINNWIGGINS VW, 1987, TRANSPL P, V19, P49; Plank-Bazinet JL, 2016, ACAD MED, V91, P1057, DOI 10.1097/ACM.0000000000001239; Pohlhaus JR, 2011, ACAD MED, V86, P759, DOI 10.1097/ACM.0b013e31821836ff; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Rossouw J E, 1995, J Am Med Womens Assoc (1972), V50, P50; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321; Spec. Collections Res. Cent, 2015, GUID NANC E WARN PAP; The multiple risk factor intervention trial (MRFIT), 1976, JAMA-J AM MED ASSOC, V235, P825; US Public Health Serv, 1985, PUBLIC HLTH REP, V1, P76; Wenger NK, 2004, CIRCULATION, V109, P558, DOI 10.1161/01.CIR.0000117292.19349.D0; Wood SF, 2011, WOMEN HEALTH ISS, V21, P99, DOI 10.1016/j.whi.2011.01.003	63	0	0	0	1	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						1	25		10.1146/annurev-pathol-020117-044020			25	Pathology	Pathology	BJ3ZK	WOS:000424631200001	29414246	Bronze			2019-10-28	
S	Al-Samkari, H; Berliner, N	Galli, SJ	Abbas, AK; Aster, JC		Al-Samkari, Hanny; Berliner, Nancy	Galli, SJ		Hemophagocytic Lymphohistiocytosis	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						hemophagocytic lymphohistiocytosis; hemophagocytosis; macrophage activation syndrome; immune activation; reactive hemophagocytic syndrome	MACROPHAGE ACTIVATION SYNDROME; JUVENILE RHEUMATOID-ARTHRITIS; STEM-CELL TRANSPLANTATION; CLINICAL-FEATURES; ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS; CUTANEOUS MANIFESTATIONS; SCAVENGER RECEPTOR; ADULT PATIENTS; PERFORIN GENE; DEP REGIMEN	Hemophagocytic lymphohistiocytosis is a life-threatening disorder characterized by unbridled activation of cytotoxic T lymphocytes, natural killer (NK) cells, and macrophages resulting in hypercytokinemia and immune-mediated injury of multiple organ systems. It is seen in both children and adults and is recognized as primary (driven by underlying genetic mutations that abolish critical proteins required for normal function of cytotoxic T cells and NK cells) or secondary (resulting from a malignant, infectious, or autoimmune stimulus without an identifiable underlying genetic trigger). Clinical and laboratory manifestations include fever, splenomegaly, neurologic dysfunction, coagulopathy, liver dysfunction, cytopenias, hypertriglyceridemia, hyperferritinemia, hemophagocytosis, and diminished NK cell activity. It is treated with immune suppressants, etoposide, and allogeneic hematopoietic stem cell transplantation; more than 50% of children who undergo transplant survive, but adults have quite poor outcomes even with aggressive management. Newer agents directed at subduing the uncontrolled immune response in a targeted fashion offer promise in this highly morbid disease.	[Al-Samkari, Hanny] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Berliner, Nancy] Brigham & Womens Hosp, Boston, MA 02115 USA	Al-Samkari, H (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.	hal-samkari@partners.org; nberliner@partners.org		Al-Samkari, Hanny/0000-0001-6175-1383			Akel T, 2017, ANN CLIN MICROB ANTI, V16, DOI 10.1186/s12941-017-0179-z; AKIMA M, 1984, HUM PATHOL, V15, P161, DOI 10.1016/S0046-8177(84)80057-X; Allen CE, 2008, PEDIATR BLOOD CANCER, V50, P1227, DOI 10.1002/pbc.21423; Allen CE, 2015, HEMATOL-AM SOC HEMAT, P177, DOI 10.1182/asheducation-2015.1.177; AMBRUSO DR, 1980, CANCER, V45, P2516, DOI 10.1002/1097-0142(19800515)45:10<2516::AID-CNCR2820451008>3.0.CO;2-V; Ammann S, 2017, EUR J IMMUNOL, V47, P364, DOI 10.1002/eji.201646686; Arca M, 2015, BRIT J HAEMATOL, V168, P63, DOI 10.1111/bjh.13102; Asano T, 2012, PEDIATR BLOOD CANCER, V59, P110, DOI 10.1002/pbc.23384; Batu ED, 2017, SCAND J RHEUMATOL, V46, P44, DOI 10.3109/03009742.2016.1167951; Brito-Zeron P, 2016, SEMIN ARTHRITIS RHEU, V45, P391, DOI 10.1016/j.semarthrit.2015.07.004; Campo M, 2015, HEMATOL ONCOL CLIN N, V29, P915, DOI 10.1016/j.hoc.2015.06.009; Cannella S, 2007, CANCER-AM CANCER SOC, V109, P2566, DOI 10.1002/cncr.22718; Chandrakasan S, 2013, J PEDIATR-US, V163, P1253, DOI 10.1016/j.jpeds.2013.06.053; Chung SM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006159; Cohen LA, 2010, BLOOD, V116, P1574, DOI 10.1182/blood-2009-11-253815; Colomba C, 2016, INFECTION, V44, P391, DOI 10.1007/s15010-016-0881-3; Cote M, 2009, J CLIN INVEST, V119, P3765, DOI 10.1172/JCI40732; Cron RQ, 2015, J RHEUMATOL, V42, P1078, DOI 10.3899/jrheum.150108; Debaugnies F, 2016, AM J CLIN PATHOL, V145, P862, DOI [10.1093/AJCP/AQW076, 10.1093/ajcp/aqw076]; Drori A, 2015, J CLIN VIROL, V68, P6, DOI 10.1016/j.jcv.2015.04.013; Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01-690636, 10.1182/blood-2016-01690636]; Ericson KG, 2001, AM J HUM GENET, V68, P590, DOI 10.1086/318796; Fardet L, 2010, BRIT J DERMATOL, V162, P547, DOI 10.1111/j.1365-2133.2009.09549.x; Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690; FARQUHAR JW, 1952, ARCH DIS CHILD, V27, P519, DOI 10.1136/adc.27.136.519; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Feldmann J, 2002, BRIT J HAEMATOL, V117, P965, DOI 10.1046/j.1365-2141.2002.03534.x; Filipovich AH, 2011, CURR OPIN ALLERGY CL, V11, P512, DOI 10.1097/ACI.0b013e32834c22f5; FISCHER A, 1986, J PEDIATR-US, V108, P267, DOI 10.1016/S0022-3476(86)81002-2; FISCHER A, 1985, PEDIATRICS, V76, P263; Fisgin NT, 2008, AM J HEMATOL, V83, P73, DOI 10.1002/ajh.20969; FUJIWARA F, 1993, AM J PEDIAT HEMATOL, V15, P92; Grom AA, 2003, J PEDIATR-US, V142, P292, DOI 10.1067/mpd.2003.110; HADCHOUEL M, 1985, J PEDIATR-US, V106, P561, DOI 10.1016/S0022-3476(85)80072-X; Haddad E, 1997, BLOOD, V89, P794, DOI 10.1182/blood.V89.3.794; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Henter JI, 2002, BLOOD, V100, P2367, DOI 10.1182/blood-2002-01-0172; HENTER JI, 1991, ACTA PAEDIATR SCAND, V80, P428, DOI 10.1111/j.1651-2227.1991.tb11878.x; HENTER JI, 1991, BLOOD, V78, P2918; Henter JI, 1997, J PEDIATR-US, V130, P358, DOI 10.1016/S0022-3476(97)70196-3; HENTER JI, 1986, LANCET, V2, P1402; Ho C, 2014, AM J CLIN PATHOL, V141, P62, DOI 10.1309/AJCPMD5TJEFOOVBW; Hui Yee Man Tracy, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2014-208220; Ikumi K, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000247; JANKA GE, 1983, EUR J PEDIATR, V140, P221, DOI 10.1007/BF00443367; Jin YK, 2016, EXP THER MED, V12, P2729, DOI 10.3892/etm.2016.3668; Jordan MB, 2004, BLOOD, V104, P735, DOI 10.1182/blood-2003-10-3413; Jordan M, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.LBA-3.LBA-3; Jordan MB, 2011, BLOOD, V118, P4041, DOI 10.1182/blood-2011-03-278127; Kaplan RM, 2016, DIAGN MICR INFEC DIS, V86, P327, DOI 10.1016/j.diagmicrobio.2016.08.007; KOMP DM, 1989, BLOOD, V73, P2128; KOMP DM, 1989, PEDIATR HEMAT ONCOL, V6, P253, DOI 10.3109/08880018909034295; Le Joncour A, 2016, CLIN INFECT DIS, V62, P804, DOI 10.1093/cid/civ999; Lehmberg K, 2015, BRIT J HAEMATOL, V170, P539, DOI 10.1111/bjh.13462; Li F, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0902-y; Li J, 2014, MEDICINE, V93, P100, DOI 10.1097/MD.0000000000000022; Lin TF, 2011, PEDIATR BLOOD CANCER, V56, P154, DOI 10.1002/pbc.22774; MA AD, 2012, BLOOD, V120; Marabelle A, 2010, J PEDIATR-US, V157, P511, DOI 10.1016/j.jpeds.2010.02.064; Marsh RA, 2010, BLOOD, V116, P5824, DOI 10.1182/blood-2010-04-282392; Maschalidi S, 2016, BLOOD, V128, P60, DOI 10.1182/blood-2016-02-700013; Minoia F, 2014, ARTHRITIS RHEUMATOL, V66, P3160, DOI 10.1002/art.38802; Mohyuddin GR, 2016, CASE REP HEMATOL, V2016; Morimoto A, 2016, PEDIATR INT, V58, P817, DOI 10.1111/ped.13064; Morrell DS, 2002, ARCH DERMATOL, V138, P1208, DOI 10.1001/archderm.138.9.1208; Munoz J, 2012, CYTOMEGALOVIRUS INDU; Niece JA, 2010, PEDIATR BLOOD CANCER, V54, P424, DOI 10.1002/pbc.22359; Nikiforow S, 2015, HEMATOL-AM SOC HEMAT, P183, DOI 10.1182/asheducation-2015.1.183; Nikiforow S, 2015, HEMATOL ONCOL CLIN N, V29, P943, DOI 10.1016/j.hoc.2015.06.011; Ohadi M, 1999, AM J HUM GENET, V64, P165, DOI 10.1086/302187; Osugi Y, 1997, BLOOD, V89, P4100, DOI 10.1182/blood.V89.11.4100; Pagel J, 2012, BLOOD, V119, P6016, DOI 10.1182/blood-2011-12-398958; Parikh SA, 2014, MAYO CLIN PROC, V89, P484, DOI 10.1016/j.mayocp.2013.12.012; Ramos-Casals M, 2014, LANCET, V383, P1503, DOI 10.1016/S0140-6736(13)61048-X; Ravelli A, 2005, J PEDIATR-US, V146, P598, DOI 10.1016/j.jpeds.2004.12.016; Ravelli A, 2015, HEMATOL ONCOL CLIN N, V29, P927, DOI 10.1016/j.hoc.2015.06.010; Riviere S, 2014, AM J MED, V127, P1118, DOI 10.1016/j.amjmed.2014.04.034; Salle V, 2014, MED MALADIES INFECT, V44, P437, DOI 10.1016/j.medmal.2014.07.002; Schaer DJ, 2006, BLOOD, V107, P373, DOI 10.1182/blood-2005-03-1014; Schaer DJ, 2005, EUR J HAEMATOL, V74, P6, DOI 10.1111/j.1600-0609.2004.00318.x; Schram AM, 2016, BRIT J HAEMATOL, V172, P412, DOI 10.1111/bjh.13837; Schram AM, 2015, BLOOD, V125, P2908, DOI 10.1182/blood-2015-01-551622; Schram AM, 2015, BLOOD, V125, P1548, DOI 10.1182/blood-2014-10-602607; Schram AM, 2014, BLOOD, V124, P4104; Scott RB, 1939, LANCET, V2, P194; Sieni E, 2011, J MED GENET, V48, P343, DOI 10.1136/jmg.2010.085456; Smith MC, 2014, INT J CLIN EXP PATHO, V7, P5738; STEPHAN JL, 1993, BLOOD, V82, P2319; STEPHAN JL, 1993, CLIN EXP RHEUMATOL, V11, P451; Sung Pil Soo, 2011, Chonnam Med J, V47, P173, DOI 10.4068/cmj.2011.47.3.173; Takada H, 2001, LEUKEMIA LYMPHOMA, V42, P21, DOI 10.3109/10428190109097673; Tang YM, 2008, BRIT J HAEMATOL, V143, P84, DOI 10.1111/j.1365-2141.2008.07298.x; ten Bosch JEV, 2009, PEDIATR BLOOD CANCER, V53, P226, DOI 10.1002/pbc.22041; Trizzino A, 2008, J MED GENET, V45, P15, DOI 10.1136/jmg.2007.052670; Trottestam H, 2011, BLOOD, V118, P4577, DOI 10.1182/blood-2011-06-356261; Tseng YT, 2011, J MICROBIOL IMMUNOL, V44, P191, DOI 10.1016/j.jmii.2011.01.027; Tsuji T, 2014, ANN HEMATOL, V93, P821, DOI 10.1007/s00277-013-1925-8; Ueda I, 2006, PEDIATR BLOOD CANCER, V46, P482, DOI 10.1002/pbc.20511; Untanu RV, 2016, CASE REP INFECT DIS, DOI 10.1155/2016/1358742; van der Ven AJAM, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00004; Wang JS, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0317-7; Wang YN, 2015, BLOOD, V126, P2186, DOI 10.1182/blood-2015-05-644914; Zhang KJ, 2014, BLOOD, V124, P1331, DOI 10.1182/blood-2014-05-573105; zur Stadt U, 2005, HUM MOL GENET, V14, P827, DOI 10.1093/hmg/ddi076	104	12	14	1	5	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						27	49		10.1146/annurev-pathol-020117-043625			23	Pathology	Pathology	BJ3ZK	WOS:000424631200002	28934563				2019-10-28	
S	Fu, DJ; Miller, AD; Southard, TL; Flesken-Nikitin, A; Ellenson, LH; Nikitin, AY	Galli, SJ	Abbas, AK; Aster, JC		Fu, Dah-Jiun; Miller, Andrew D.; Southard, Teresa L.; Flesken-Nikitin, Andrea; Ellenson, Lora H.; Nikitin, Alexander Yu.	Galli, SJ		Stem Cell Pathology	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						cancer; mouse models; disease pathogenesis; stem cell biology; stem cell niches; tissue evaluation	LABEL-RETAINING CELLS; PROSTATE-CANCER; ADULT STEM; ALDEHYDE DEHYDROGENASE; PROXIMAL REGION; HAIR FOLLICLE; OF-ORIGIN; SQUAMOCOLUMNAR JUNCTION; EPITHELIAL-CELLS; CLONAL ANALYSIS	Rapid advances in stem cell biology and regenerative medicine have opened new opportunities for better understanding disease pathogenesis and the development of new diagnostic, prognostic, and treatment approaches. Many stem cell niches are well defined anatomically, thereby allowing their routine pathological evaluation during disease initiation and progression. Evaluation of the consequences of genetic manipulations in stem cells and investigation of the roles of stem cells in regenerative medicine and pathogenesis of various diseases such as cancer require significant expertise in pathology for accurate interpretation of novel findings. Therefore, there is an urgent need for developing stem cell pathology as a discipline to facilitate stem cell research and regenerative medicine. This review provides examples of anatomically defined niches suitable for evaluation by diagnostic pathologists, describes neoplastic lesions associated with them, and discusses further directions of stem cell pathology.	[Fu, Dah-Jiun; Miller, Andrew D.; Southard, Teresa L.; Flesken-Nikitin, Andrea; Nikitin, Alexander Yu.] Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA; [Fu, Dah-Jiun; Miller, Andrew D.; Southard, Teresa L.; Flesken-Nikitin, Andrea; Nikitin, Alexander Yu.] Cornell Univ, Cornell Stem Cell Program, Ithaca, NY 14853 USA; [Ellenson, Lora H.] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10021 USA	Nikitin, AY (reprint author), Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA.; Nikitin, AY (reprint author), Cornell Univ, Cornell Stem Cell Program, Ithaca, NY 14853 USA.	an58@cornell.edu			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA182413, R01 CA197160]; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD052471]		Abou-Kheir WG, 2010, STEM CELLS, V28, P2129, DOI 10.1002/stem.538; Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V7, P656, DOI 10.1016/j.stem.2010.11.016; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; BETTON GR, 1988, TOXICOL PATHOL, V16, P288, DOI 10.1177/019262338801600222; Bjerknes M, 1999, GASTROENTEROLOGY, V116, P7, DOI 10.1016/S0016-5085(99)70222-2; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Blanpain C, 2014, SCIENCE, V344, P1243, DOI 10.1126/science.1242281; BONKHOFF H, 1993, VIRCHOWS ARCH A, V422, P35, DOI 10.1007/BF01605130; BONKHOFF H, 1995, HUM PATHOL, V26, P167, DOI 10.1016/0046-8177(95)90033-0; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; Buczacki SJA, 2013, NATURE, V495, P65, DOI 10.1038/nature11965; Burger PE, 2009, STEM CELLS, V27, P2220, DOI 10.1002/stem.135; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; CAIRNIE AB, 1965, EXP CELL RES, V39, P528, DOI 10.1016/0014-4827(65)90055-8; Cheng CY, 2014, CELL REP, V6, P1000, DOI 10.1016/j.celrep.2014.02.023; Cheng CY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060905; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; Clayton E, 2007, NATURE, V446, P185, DOI 10.1038/nature05574; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Cohnheim J., 1867, VIRCHOWS ARCH, V40, P1, DOI DOI 10.1007/BF02968135; Corti S, 2006, STEM CELLS, V24, P975, DOI 10.1634/stemcells.2005-0217; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; Crabb DW, 2004, P NUTR SOC, V63, P49, DOI 10.1079/PNS2003327; Day CP, 2015, CELL, V163, P39, DOI 10.1016/j.cell.2015.08.068; Dimou L, 2014, PHYSIOL REV, V94, P709, DOI 10.1152/physrev.00036.2013; Doulatov S, 2013, SCIENCE, V342, P700, DOI 10.1126/science.1238363; Dow LE, 2012, CELL, V148, P1099, DOI 10.1016/j.cell.2012.02.023; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Fafilek B, 2013, GASTROENTEROLOGY, V144, P381, DOI 10.1053/j.gastro.2012.10.048; Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181; Flesken-Nikitin A, 2014, MOL CELL ONCOL, V1, DOI 10.4161/23723548.2014.963435; Flesken-Nikitin A, 2013, NATURE, V495, P241, DOI 10.1038/nature11979; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Gamwell LF, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.100347; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goto K, 2006, STEM CELLS, V24, P1859, DOI 10.1634/stemcells.2005-0585; Gracz AD, 2014, AM J PHYSIOL-GASTR L, V307, pG260, DOI 10.1152/ajpgi.00066.2014; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Hachiya A, 2004, AM J PATHOL, V165, P2099, DOI 10.1016/S0002-9440(10)63260-9; Hayakawa Y, 2015, CANCER CELL, V28, P800, DOI 10.1016/j.ccell.2015.10.003; Hayakawa Y, 2015, GUT, V64, P544, DOI 10.1136/gutjnl-2014-307190; Herfs M, 2013, J PATHOL, V229, P460, DOI 10.1002/path.4110; Herfs M, 2012, P NATL ACAD SCI USA, V109, P10516, DOI 10.1073/pnas.1202684109; HogenEsch H, 2012, J CONTROL RELEASE, V164, P183, DOI 10.1016/j.jconrel.2012.02.031; Horsley V, 2006, CELL, V126, P597, DOI 10.1016/j.cell.2006.06.048; Hsu YC, 2012, NAT REV MOL CELL BIO, V13, P103, DOI 10.1038/nrm3272; Huse JT, 2009, BRAIN PATHOL, V19, P132, DOI 10.1111/j.1750-3639.2008.00234.x; Ishimoto T, 2010, CANCER SCI, V101, P673, DOI 10.1111/j.1349-7006.2009.01430.x; Jensen UB, 1999, DEVELOPMENT, V126, P2409; Kaiser J, 2015, SCIENCE, V347, P226, DOI 10.1126/science.347.6219.226; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; Kittel B, 2004, EXP TOXICOL PATHOL, V55, P413, DOI 10.1078/0940-2993-00349; Kloepper JE, 2008, EXP DERMATOL, V17, P592, DOI 10.1111/j.1600-0625.2008.00720.x; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Ksander BR, 2014, NATURE, V511, P353, DOI 10.1038/nature13426; Latendresse JR, 2002, TOXICOL PATHOL, V30, P524, DOI 10.1080/01926230290105721; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; LeBlanc AK, 2016, NEURO-ONCOLOGY, V18, P1209, DOI 10.1093/neuonc/now051; LEBLOND CP, 1948, ANAT REC, V100, P357, DOI 10.1002/ar.1091000306; Legg J, 2003, DEVELOPMENT, V130, P6049, DOI 10.1242/dev.00837; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Levin TG, 2010, GASTROENTEROLOGY, V139, P2072, DOI 10.1053/j.gastro.2010.08.053; Li X M, 2016, 2016 INT C ADV MECH, V2016, P26, DOI DOI 10.1007/S10096-016-2674-0; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Matsuo J, 2017, GASTROENTEROLOGY, V152, P218, DOI 10.1053/j.gastro.2016.09.018; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; McKelvie PA, 2002, BRIT J OPHTHALMOL, V86, P168, DOI 10.1136/bjo.86.2.168; McKernan R, 2013, NAT BIOTECHNOL, V31, P875, DOI 10.1038/nbt.2710; Mcnairn AJ, 2011, EUR J DERMATOL, V21, P21, DOI 10.1684/ejd.2011.1267; Medema JP, 2011, NATURE, V474, P318, DOI 10.1038/nature10212; Montgomery RK, 2011, P NATL ACAD SCI USA, V108, P179, DOI 10.1073/pnas.1013004108; MOOLENBEEK C, 1981, LAB ANIM, V15, P57, DOI 10.1258/002367781780958577; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Nasti TH, 2012, PHOTOCHEM PHOTOBIOL, V88, P1111, DOI 10.1111/j.1751-1097.2012.01182.x; Ng A, 2014, NAT CELL BIOL, V16, P745, DOI 10.1038/ncb3000; Niemann C, 2002, TRENDS CELL BIOL, V12, P185, DOI 10.1016/S0962-8924(02)02263-8; Nikitin AY, 2009, CANCER DRUG DISCOV D, P199, DOI 10.1007/978-1-60327-933-8_16; O'Neil A, 2017, J HISTOCHEM CYTOCHEM, V65, P47, DOI 10.1369/0022155416678182; Obokata H, 2011, NAT PROTOC, V6, P1053, DOI 10.1038/nprot.2011.356; Odze RD, 2005, SEMIN DIAGN PATHOL, V22, P256, DOI 10.1053/j.semdp.2006.04.007; Ohyama M, 2006, J CLIN INVEST, V116, P249, DOI 10.1172/JCI26043; Okano H, 2008, PHILOS T R SOC B, V363, P2111, DOI 10.1098/rstb.2008.2264; Osawa M., 2009, STEMBOOK; Ousset M, 2012, NAT CELL BIOL, V14, P1130, DOI 10.1038/ncb2600; Pellegrini G, 1999, J CELL BIOL, V145, P769, DOI 10.1083/jcb.145.4.769; Petignat P, 2007, BMJ-BRIT MED J, V335, P765, DOI 10.1136/bmj.39337.615197.80; Potten CS, 2009, CELL PROLIFERAT, V42, P731, DOI 10.1111/j.1365-2184.2009.00642.x; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; Powell AE, 2012, CELL, V149, P146, DOI 10.1016/j.cell.2012.02.042; Qiao XT, 2007, GASTROENTEROLOGY, V133, P1989, DOI 10.1053/j.gastro.2007.09.031; Quante M, 2012, CANCER CELL, V21, P36, DOI 10.1016/j.ccr.2011.12.004; REID BJ, 1987, ANNU REV MED, V38, P477, DOI 10.1146/annurev.me.38.020187.002401; Rompolas P, 2016, SCIENCE, V352, P1471, DOI 10.1126/science.aaf7012; Runck LA, 2010, CELL CYCLE, V9, P3039, DOI 10.4161/cc.9.15.12437; Rycaj K, 2015, CANCER RES, V75, P4003, DOI 10.1158/0008-5472.CAN-15-0798; Sada A, 2016, NAT CELL BIOL, V18, P619, DOI 10.1038/ncb3359; Salm SN, 2005, J CELL BIOL, V170, P81, DOI 10.1083/jcb.200412015; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; Schmoeckel E, 2017, MODERN PATHOL, V30, P1241, DOI 10.1038/modpathol.2017.53; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Seidman JD, 2015, INT J GYNECOL PATHOL, V34, P112, DOI 10.1097/PGP.0000000000000123; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Shi Y, 2017, NAT REV DRUG DISCOV, V16, P115, DOI 10.1038/nrd.2016.245; SHIH IM, 1994, AM J PATHOL, V145, P837; Snippert HJ, 2011, EMBO REP, V12, P113, DOI 10.1038/embor.2010.216; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Stange DE, 2013, CELL, V155, P357, DOI 10.1016/j.cell.2013.09.008; Storms RW, 1999, P NATL ACAD SCI USA, V96, P9118, DOI 10.1073/pnas.96.16.9118; Stylli SS, 2015, J CLIN NEUROSCI, V22, P619, DOI 10.1016/j.jocn.2014.10.013; SUGIMURA Y, 1986, BIOL REPROD, V34, P961, DOI 10.1095/biolreprod34.5.961; Szotek PP, 2008, P NATL ACAD SCI USA, V105, P12469, DOI 10.1073/pnas.0805012105; Takeda N, 2011, SCIENCE, V334, P1420, DOI 10.1126/science.1213214; Trudgill NJ, 2003, J CLIN PATHOL-MOL PA, V56, P313, DOI 10.1136/mp.56.6.313; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Van der Flier LG, 2009, GASTROENTEROLOGY, V137, P15, DOI 10.1053/j.gastro.2009.05.035; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wang GM, 2007, PROSTATE, V67, P968, DOI 10.1002/pros.20582; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Wang X, 2011, CELL, V145, P1023, DOI 10.1016/j.cell.2011.05.026; Wang YZ, 2001, DIFFERENTIATION, V68, P270, DOI 10.1046/j.1432-0436.2001.680414.x; Wang ZA, 2013, NAT CELL BIOL, V15, P274, DOI 10.1038/ncb2697; WARING GO, 1984, AM J OPHTHALMOL, V97, P547, DOI 10.1016/0002-9394(84)90371-4; White AC, 2015, TRENDS CELL BIOL, V25, P11, DOI 10.1016/j.tcb.2014.08.008; Wu J, 2016, NATURE, V540, P51, DOI 10.1038/nature20573; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Yamanaka S, 2010, NATURE, V465, P704, DOI 10.1038/nature09229; Zhou ZX, 2007, CANCER RES, V67, P5683, DOI 10.1158/0008-5472.CAN-07-0768; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	138	0	0	0	5	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						71	92		10.1146/annurev-pathol-020117-043935			22	Pathology	Pathology	BJ3ZK	WOS:000424631200004	29059010	Green Accepted			2019-10-28	
S	Farley, MM; Watkins, TA	Galli, SJ	Abbas, AK; Aster, JC		Farley, Madeline M.; Watkins, Trent A.	Galli, SJ		Intrinsic Neuronal Stress Response Pathways in Injury and Disease	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						neurodegeneration; axon regeneration; dual leucine zipper kinase; integrated stress response; PERK	LEUCINE-ZIPPER KINASE; UNFOLDED PROTEIN RESPONSE; RETINAL GANGLION-CELLS; NERVE GROWTH-FACTOR; TRANSCRIPTION FACTOR BRN3B; HYPERTENSION RAT MODEL; AXON GROWTH; TRANSLATION ARREST; EIF2-ALPHA KINASES; PARKINSONS-DISEASE	From injury to disease to aging, neurons, like all cells, may face various insults that can impact their function and survival. Although the consequences are substantially dictated by the type, context, and severity of insult, distressed neurons are far from passive. Activation of cellular stress responses aids in the preservation or restoration of nervous system function. However, stress responses themselves can further advance neuropathology and contribute significantly to neuronal dysfunction and neurodegeneration. Here we explore the recent advances in defining the cellular stress responses within neurodegenerative diseases and neuronal injury, and we emphasize axonal injury as a well-characterized model of neuronal insult. We highlight key findings and unanswered questions about neuronal stress response pathways, from the initial detection of cellular insults through the underlying mechanisms of the responses to their ultimate impact on the fates of distressed neurons.	[Farley, Madeline M.; Watkins, Trent A.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Watkins, TA (reprint author), Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.	trentw@bcm.edu					Abe N, 2008, CURR OPIN NEUROBIOL, V18, P276, DOI 10.1016/j.conb.2008.06.005; Aime P, 2015, J NEUROSCI, V35, P10731, DOI 10.1523/JNEUROSCI.0614-15.2015; Anderson P, 2008, TRENDS BIOCHEM SCI, V33, P141, DOI 10.1016/j.tibs.2007.12.003; Asiimwe N, 2016, OXID MED CELL LONGEV, DOI 10.1155/2016/7205747; Aulas A, 2017, J CELL SCI, V130, P927, DOI 10.1242/jcs.199240; B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563; Baleriola J, 2014, CELL, V158, P1159, DOI 10.1016/j.cell.2014.07.001; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Bellato HM, 2016, CYTOSKELETON, V73, P551, DOI 10.1002/cm.21294; Ben-Yaakov K, 2012, EMBO J, V31, P1350, DOI 10.1038/emboj.2011.494; Benowitz LI, 2017, EXP NEUROL, V287, P365, DOI 10.1016/j.expneurol.2015.12.015; Bentmann E, 2013, FEBS J, V280, P4348, DOI 10.1111/febs.12287; BERKELAAR M, 1994, J NEUROSCI, V14, P4368; Biswas SC, 2007, J BIOL CHEM, V282, P29368, DOI 10.1074/jbc.M702634200; Buckingham BP, 2008, J NEUROSCI, V28, P2735, DOI 10.1523/JNEUROSCI.4443-07.2008; Calabrese V, 2010, ANTIOXID REDOX SIGN, V13, P1763, DOI 10.1089/ars.2009.3074; Casas-Tinto S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10022; Cavalli V, 2005, J CELL BIOL, V168, P775, DOI 10.1083/jcb.200410136; Chen MF, 2016, SCI REP-UK, V6, DOI 10.1038/srep31482; Chen XQ, 2008, J NEUROSCI, V28, P672, DOI 10.1523/JNEUROSCI.2132-07.2008; Chung SH, 2016, P NATL ACAD SCI USA, V113, pE2852, DOI 10.1073/pnas.1600564113; DeGracia DJ, 2007, NEUROSCIENCE, V146, P562, DOI 10.1016/j.neuroscience.2007.01.050; DeGracia DJ, 2007, J CEREBR BLOOD F MET, V27, P875, DOI 10.1038/sj.jcbfm.9600388; Fan AC, 2016, ADV EXP MED BIOL, V907, P263, DOI 10.1007/978-3-319-29073-7_11; Fernandes KJL, 1999, J COMP NEUROL, V414, P495, DOI 10.1002/(SICI)1096-9861(19991129)414:4<495::AID-CNE6>3.0.CO;2-S; Ferraris D, 2013, FUTURE MED CHEM, V5, P1923, DOI [10.4155/fmc.13.150, 10.4155/FMC.13.150]; Frade JM, 2015, CELL CYCLE, V14, P712, DOI 10.1080/15384101.2015.1004937; Fujita Y, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00338; Garcia-Huerta P, 2016, BRAIN RES, V1649, P173, DOI 10.1016/j.brainres.2016.02.052; Gerdts J, 2016, NEURON, V89, P449, DOI 10.1016/j.neuron.2015.12.023; Ghosh AS, 2011, J CELL BIOL, V194, P751, DOI 10.1083/jcb.201103153; Ghosh-Roy A, 2010, J NEUROSCI, V30, P3175, DOI 10.1523/JNEUROSCI.5464-09.2010; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Guo M, 2013, NAT CHEM BIOL, V9, P145, DOI [10.1038/NCHEMBIO.1158, 10.1038/nchembio.1158]; Guo X, 2013, J CLIN INVEST, V123, P5371, DOI 10.1172/JCI70911; Hammarlund M, 2009, SCIENCE, V323, P802, DOI 10.1126/science.1165527; Hao Y, 2016, ELIFE, V5, DOI 10.7554/eLife.14048; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; Hart AM, 2002, EXP BRAIN RES, V142, P308, DOI 10.1007/s00221-001-0929-0; Henriques A, 2015, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00464; Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124; Hirai S, 2005, GENE EXPR PATTERNS, V5, P517, DOI 10.1016/j.modgep.2004.12.002; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; Holland SM, 2017, J NEUROSCI RES, V95, P1528, DOI 10.1002/jnr.24003; Holland SM, 2016, P NATL ACAD SCI USA, V113, P763, DOI 10.1073/pnas.1514123113; Hollis ER, 2015, EXP NEUROL, V265, P30, DOI 10.1016/j.expneurol.2014.12.004; Hu Y, 2016, NEURAL REGEN RES, V11, P1557, DOI 10.4103/1673-5374.193225; Hu Y, 2012, NEURON, V73, P445, DOI 10.1016/j.neuron.2011.11.026; Huang YA, 2017, CELL, V168, P427; Huntwork-Rodriguez S, 2013, J CELL BIOL, V202, P747, DOI 10.1083/jcb.201303066; Itoh K, 2013, TRENDS CELL BIOL, V23, P64, DOI 10.1016/j.tcb.2012.10.006; Jamison JT, 2008, NEUROSCIENCE, V154, P504, DOI 10.1016/j.neuroscience.2008.03.057; Johnson IP, 2013, NEUROSCIENCE, V228, P163, DOI 10.1016/j.neuroscience.2012.10.015; Kalinski AL, 2015, J NEUROSCI, V35, P10357, DOI 10.1523/JNEUROSCI.1249-15.2015; Kanaan NM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127768; Karuppagounder SS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aac6008; Kedersha N, 2002, MOL BIOL CELL, V13, P195, DOI 10.1091/mbc.01-05-0221; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; Kirchner S, 2015, NAT REV GENET, V16, P98, DOI 10.1038/nrg3861; Kirkpatrick LL, 2001, J NEUROSCI, V21, P2288; Koss DJ, 2017, BEHAV PHARMACOL, V28, P161, DOI 10.1097/FBP.0000000000000299; Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984; Kukekov NV, 2006, J BIOL CHEM, V281, P15517, DOI 10.1074/jbc.M601056200; Kwon MJ, 2015, J NEUROSCI, V35, P15934, DOI 10.1523/JNEUROSCI.1924-15.2015; Lanni C, 2012, FREE RADICAL BIO MED, V52, P1727, DOI 10.1016/j.freeradbiomed.2012.02.034; Larhammar M, 2017, ELIFE, V6, DOI 10.7554/eLife.20725; Le Pichon CE, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag0394; LEAH JD, 1991, BRAIN RES, V566, P198, DOI 10.1016/0006-8993(91)91699-2; Liu J, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00177; Ma T, 2013, NAT NEUROSCI, V16, P1299, DOI 10.1038/nn.3486; Ma TC, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00043; Majd S, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0211-1; Maor-Nof M, 2016, NEURON, V92, P991, DOI 10.1016/j.neuron.2016.10.061; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; Mason MRJ, 2003, EUR J NEUROSCI, V18, P789, DOI 10.1046/j.1460-9568.2003.02809.x; Mattson MP, 2008, HUM EXP TOXICOL, V27, P155, DOI 10.1177/0960327107083417; Mattson MP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3114pe10; McInerney GM, 2005, MOL BIOL CELL, V16, P3753, DOI 10.1091/mbc.E05-02-0124; McKernan DP, 2007, J NEUROCHEM, V102, P922, DOI 10.1111/j.1471-4159.2007.04573.x; Miller FD, 2000, CELL DEATH DIFFER, V7, P880, DOI 10.1038/sj.cdd.4400736; Moisse K, 2009, BRAIN RES, V1249, P202, DOI 10.1016/j.brainres.2008.10.021; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; Nielson JL, 2010, J NEUROSCI, V30, P11516, DOI 10.1523/JNEUROSCI.1433-10.2010; Niemi JP, 2016, EXP NEUROL, V275, P25, DOI 10.1016/j.expneurol.2015.09.018; Niemi JP, 2013, J NEUROSCI, V33, P16236, DOI 10.1523/JNEUROSCI.3319-12.2013; Nihalani D, 2003, J BIOL CHEM, V278, P28694, DOI 10.1074/jbc.M304212200; Norambuena A, 2017, ALZHEIMERS DEMENT, V13, P152, DOI 10.1016/j.jalz.2016.08.015; Norsworthy MW, 2017, NEURON, V94, P1112, DOI 10.1016/j.neuron.2017.05.035; Ohn T, 2008, NAT CELL BIOL, V10, P1224, DOI 10.1038/ncb1783; Ohno M, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00022; Ohri SS, 2013, NEUROBIOL DIS, V58, P29, DOI 10.1016/j.nbd.2013.04.021; Orsini F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00380; Pak W, 2004, CELL, V119, P567, DOI 10.1016/j.cell.2004.10.026; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; Paschen W, 2007, CURR PHARM DESIGN, V13, P1887; Pasini S, 2015, CELL REP, V11, P183, DOI 10.1016/j.celrep.2015.03.025; Patel VP, 2011, INT J CLIN EXP PATHO, V4, P215; Perlson E, 2009, J NEUROSCI, V29, P9903, DOI 10.1523/JNEUROSCI.0813-09.2009; Perry RB, 2014, DEV NEUROBIOL, V74, P210, DOI 10.1002/dneu.22115; Perry RB, 2012, NEURON, V75, P294, DOI 10.1016/j.neuron.2012.05.033; Phatak NR, 2016, MOL VIS, V22, P1048; Poehler AM, 2014, AUTOPHAGY, V10, P2171, DOI 10.4161/auto.36436; Popugaeva E, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00029; Pozniak CD, 2013, J EXP MED, V210, P2553, DOI 10.1084/jem.20122832; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Ren XC, 2017, OXID MED CELL LONGEV, DOI 10.1155/2017/4175353; RICH KM, 1989, J NEUROCYTOL, V18, P569, DOI 10.1007/BF01187077; RICHARDSON PM, 1984, NATURE, V309, P791, DOI 10.1038/309791a0; Rishal I, 2014, NAT REV NEUROSCI, V15, P32, DOI 10.1038/nrn3609; Saleem S, 2017, J BIOL CHEM, V292, P2571, DOI 10.1074/jbc.M116.744730; Segev Y, 2015, J NEUROSCI, V35, P12986, DOI 10.1523/JNEUROSCI.5241-14.2015; Sevastou I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157754; Shah SZA, 2015, J MOL NEUROSCI, V57, P529, DOI 10.1007/s12031-015-0633-3; Shin JE, 2012, NEURON, V74, P1015, DOI 10.1016/j.neuron.2012.04.028; Sidrauski C, 2013, ELIFE, V2, DOI 10.7554/eLife.00498; Soto I, 2008, J NEUROSCI, V28, P548, DOI 10.1523/JNEUROSCI.3714-07.2008; Srinivasan K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11295; Stankiewicz TR, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00314; Stankowska DL, 2015, INVEST OPHTH VIS SCI, V56, P893, DOI 10.1167/iovs.14-15008; Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810; Stone MC, 2014, CELL REP, V6, P247, DOI 10.1016/j.celrep.2013.12.022; Sweeney P, 2017, TRANSL NEURODEGENER, V6, DOI 10.1186/s40035-017-0077-5; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Taylor RC, 2014, NAT REV MOL CELL BIO, V15, P211, DOI 10.1038/nrm3752; Tedeschi A, 2013, EMBO REP, V14, P605, DOI 10.1038/embor.2013.64; Tu HP, 2006, CELL, V126, P981, DOI 10.1016/j.cell.2006.06.059; Twiss JL, 2016, NEURAL REGEN RES, V11, P1365, DOI 10.4103/1673-5374.191193; Valakh V, 2015, NEUROBIOL DIS, V77, P13, DOI 10.1016/j.nbd.2015.02.014; Valakh V, 2013, J NEUROSCI, V33, P17863, DOI 10.1523/JNEUROSCI.2196-13.2013; Valenzuela V, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.8; Vanderweyde T, 2012, J NEUROSCI, V32, P8270, DOI 10.1523/JNEUROSCI.1592-12.2012; Verma P, 2005, J NEUROSCI, V25, P331, DOI 10.1523/JNEUROSCI.3073-04.2005; Vieira FG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135570; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Walker LJ, 2017, ELIFE, V6, DOI 10.7554/eLife.22540; Wang DH, 2010, IEEE PEDG 2010: THE 2ND INTERNATIONAL SYMPOSIUM ON POWER ELECTRONICS FOR DISTRIBUTED GENERATION SYSTEMS, P1, DOI 10.1109/PEDG.2010.5545769; Wang L., 2014, DISCRETE DYN NAT SOC, V2014, P1, DOI DOI 10.1002/ASL2.454; Wang L, 2014, NAT HAZARDS, V71, P85, DOI 10.1007/s11069-013-0901-x; Watkins TA, 2013, P NATL ACAD SCI USA, V110, P4039, DOI 10.1073/pnas.1211074110; Welsbie DS, 2017, NEURON, V94, P1142, DOI 10.1016/j.neuron.2017.06.008; Welsbie DS, 2013, P NATL ACAD SCI USA, V110, P4045, DOI 10.1073/pnas.1211284110; Wu FG, 2015, P NATL ACAD SCI USA, V112, pE1559, DOI 10.1073/pnas.1421535112; Xiang CC, 2017, APOPTOSIS, V22, P1, DOI 10.1007/s10495-016-1296-4; Xiong X, 2010, J CELL BIOL, V191, P211, DOI 10.1083/jcb.201006039; Yan D, 2012, NEURON, V76, P534, DOI 10.1016/j.neuron.2012.08.043; Yan D, 2009, CELL, V138, P1005, DOI 10.1016/j.cell.2009.06.023; Yang J, 2015, CELL, V160, P161, DOI 10.1016/j.cell.2014.11.053; Ying ZX, 2015, J NEUROSCI, V35, P14557, DOI 10.1523/JNEUROSCI.0012-15.2015; You SW, 2000, INVEST OPHTH VIS SCI, V41, P3165; Zeke A, 2016, MICROBIOL MOL BIOL R, V80, P793, DOI 10.1128/MMBR.00043-14	150	10	10	1	10	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						93	116		10.1146/annurev-pathol-012414-040354			24	Pathology	Pathology	BJ3ZK	WOS:000424631200005	29414247				2019-10-28	
S	Kuszak, AJ; Espey, MG; Falk, MJ; Holmbeck, MA; Manfredi, G; Shadel, GS; Vernon, HJ; Zolkipli-Cunningham, Z	Galli, SJ	Abbas, AK; Aster, JC		Kuszak, Adam J.; Espey, Michael Graham; Falk, Marni J.; Holmbeck, Marissa A.; Manfredi, Giovanni; Shadel, Gerald S.; Vernon, Hilary J.; Zolkipli-Cunningham, Zarazuela	Galli, SJ		Nutritional Interventions for Mitochondrial OXPHOS Deficiencies: Mechanisms and Model Systems	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						primary mitochondrial OXPHOS disorders; nutritional interventions; electron transport chain; metabolism	COMPLEX-I DEFICIENCY; ALPHA-LIPOIC ACID; CEREBRAL FOLATE-DEFICIENCY; TRANSCRIPTION FACTORS B1; CYTOCHROME-C-OXIDASE; OXIDATIVE-PHOSPHORYLATION; MOUSE MODELS; KETOGENIC DIET; DNA MUTATIONS; TRANSMITOCHONDRIAL MICE	Multisystem metabolic disorders caused by defects in oxidative phosphorylation (OXPHOS) are severe, often lethal, conditions. Inborn errors of OXPHOS function are termed primary mitochondrial disorders (PMDs), and the use of nutritional interventions is routine in their supportive management. However, detailed mechanistic understanding and evidence for efficacy and safety of these interventions are limited. Preclinical cellular and animal model systems are important tools to investigate PMD metabolic mechanisms and therapeutic strategies. This review assesses the mechanistic rationale and experimental evidence for nutritional interventions commonly used in PMDs, including micronutrients, metabolic agents, signaling modifiers, and dietary regulation, while highlighting important knowledge gaps and impediments for randomized controlled trials. Cellular and animal model systems that recapitulate mutations and clinical manifestations of specific PMDs are evaluated for their potential in determining pathological mechanisms, elucidating therapeutic health outcomes, and investigating the value of nutritional interventions for mitochondrial disease conditions.	[Kuszak, Adam J.] NIH, Off Dietary Supplements, Bethesda, MD 20852 USA; [Espey, Michael Graham] NCI, Div Canc Biol, Rockville, MD 20850 USA; [Falk, Marni J.] Childrens Hosp Philadelphia, Dept Pediat, Div Human Genet, Philadelphia, PA 19104 USA; [Falk, Marni J.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Holmbeck, Marissa A.; Shadel, Gerald S.] Yale Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Manfredi, Giovanni] Weill Cornell Med, Feil Family Brain & Mind Res Inst, New York, NY 10065 USA; [Shadel, Gerald S.] Yale Sch Med, Dept Genet, New Haven, CT 06520 USA; [Vernon, Hilary J.] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; [Zolkipli-Cunningham, Zarazuela] Childrens Hosp Philadelphia, Div Neurol, Dept Pediat, Philadelphia, PA 19104 USA	Kuszak, AJ (reprint author), NIH, Off Dietary Supplements, Bethesda, MD 20852 USA.	kuszakaj@mail.nih.gov; SP@nih.gov; falkm@email.chop.edu; marissa.holmbeck@yale.edu; gim2004@med.cornell.edu; gerald.shadel@yale.edu; hvernon1@jhmi.edu; ZolkipliZ@email.chop.edu		Falk, Marni/0000-0002-1723-6728; Vernon, Hilary/0000-0001-9940-9866	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F32 AG052995]; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM120762]		Acehan D, 2011, J BIOL CHEM, V286, P899, DOI 10.1074/jbc.M110.171439; ADES LC, 1993, AM J MED GENET, V45, P327, DOI 10.1002/ajmg.1320450309; Ahola-Erkkila S, 2013, MITOCHONDRION, V13, P911, DOI 10.1016/j.mito.2013.07.036; Ahola-Erkkila S, 2010, HUM MOL GENET, V19, P1974, DOI 10.1093/hmg/ddq076; Alfadhel M, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-83; Anderson PR, 2005, HUM MOL GENET, V14, P3397, DOI 10.1093/hmg/ddi367; [Anonymous], 1998, SCIENCE, V282, P2012, DOI DOI 10.1126/SCIENCE.282.5396.2012; Artuch R, 1998, J INHERIT METAB DIS, V21, P837, DOI 10.1023/A:1005470702369; Bar-Meir M, 2001, J PEDIATR-US, V139, P868, DOI 10.1067/mpd.2001.118885; Barrientos A, 2003, IUBMB LIFE, V55, P83, DOI 10.1080/1521654031000098122; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Baruffini E, 2007, BBA-MOL BASIS DIS, V1772, P1225, DOI 10.1016/j.bbadis.2007.10.002; Bassett DE, 1996, NATURE, V379, P589, DOI 10.1038/379589a0; Bayat V, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001288; Beher D, 2009, CHEM BIOL DRUG DES, V74, P619, DOI 10.1111/j.1747-0285.2009.00901.x; Belenky P, 2007, TRENDS BIOCHEM SCI, V32, P12, DOI 10.1016/j.tibs.2006.11.006; BERNSEN PLJA, 1993, J NEUROL SCI, V118, P181, DOI 10.1016/0022-510X(93)90108-B; Bogan KL, 2008, ANNU REV NUTR, V28, P115, DOI 10.1146/annurev.nutr.28.061807.155443; Bonawitz ND, 2006, MOL CELL, V24, P813, DOI 10.1016/j.molcel.2006.11.024; Bonnefoy N, 2001, METHOD CELL BIOL, V65, P381, DOI 10.1016/S0091-679X(01)65022-2; Borowczyk K, 2015, BIOANALYSIS, V7, P1785, DOI [10.4155/BIO.15.95, 10.4155/bio.15.95]; Bosch AM, 2011, J INHERIT METAB DIS, V34, P159, DOI 10.1007/s10545-010-9242-z; Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; BRENNER S, 1974, GENETICS, V77, P71; Broughton RE, 2001, GENOME RES, V11, P1958, DOI 10.1101/gr.156801; Brown G, 2014, J INHERIT METAB DIS, V37, P577, DOI 10.1007/s10545-014-9712-9; Budde SMS, 2003, J INHERIT METAB DIS, V26, P813, DOI 10.1023/B:BOLI.0000010003.14113.af; Bugiani M, 2006, BRAIN DEV-JPN, V28, P576, DOI 10.1016/j.braindev.2006.04.001; BULDER CJE, 1964, ANTON VAN LEE J M S, V30, P442, DOI 10.1007/BF02046758; Camp KM, 2016, MOL GENET METAB, V119, P187, DOI 10.1016/j.ymgme.2016.09.002; Chai JS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163634; Chen Z, 2015, MOL BIOL CELL, V26, P674, DOI 10.1091/mbc.E14-11-1513; Cheng WC, 2008, BBA-MOL CELL RES, V1783, P1272, DOI 10.1016/j.bbamcr.2008.04.012; Chinnery P, 2006, COCHRANE DB SYST REV, V2006; Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426; Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779; Claypool SM, 2008, MOL BIOL CELL, V19, P5143, DOI 10.1091/mbc.E08-09-0896; Coppola M, 2000, GENOMICS, V66, P48, DOI 10.1006/geno.2000.6136; Costa AL, 2014, HUM MOL GENET, V23, P2106, DOI 10.1093/hmg/ddt603; Cotney J, 2009, HUM MOL GENET, V18, P2670, DOI 10.1093/hmg/ddp208; Curt MJC, 2015, BIOCHIMIE, V119, P146, DOI 10.1016/j.biochi.2015.10.022; D'Aurelio M, 2001, J BIOL CHEM, V276, P46925, DOI 10.1074/jbc.M106429200; Da-Re C, 2014, J BIOL CHEM, V289, P29235, DOI 10.1074/jbc.M114.602938; Dai DF, 2010, AGING CELL, V9, P536, DOI 10.1111/j.1474-9726.2010.00581.x; Davis RL, 2013, NEUROLOGY, V81, P1819, DOI 10.1212/01.wnl.0000436068.43384.ef; DeBrosse C, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88207; Desquiret-Dumas V, 2012, BBA-MOL BASIS DIS, V1822, P1019, DOI 10.1016/j.bbadis.2012.01.010; DiMauro S, 2006, MUSCLE NERVE, V34, P265, DOI 10.1002/mus.20598; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Dorsam B, 2016, CANCER LETT, V371, P12, DOI 10.1016/j.canlet.2015.11.019; Duncan AJ, 2005, CLIN CHEM, V51, P2380, DOI 10.1373/clinchem.2005.054643; El-Hattab AW, 2015, MOL GENET METAB, V116, P107, DOI 10.1016/j.ymgme.2015.09.004; El-Hattab AW, 2013, META GENE, V1, P8, DOI 10.1016/j.mgene.2013.09.001; El-Hattab AW, 2012, MOL GENET METAB, V105, P607, DOI 10.1016/j.ymgme.2012.01.016; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; Falk MJ, 2008, MOL GENET METAB, V93, P388, DOI 10.1016/j.ymgme.2007.11.007; Falk MJ, 2011, EMBO MOL MED, V3, P410, DOI 10.1002/emmm.201100149; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; Fan WW, 2008, SCIENCE, V319, P958, DOI 10.1126/science.1147786; Felici R, 2015, MOL PHARMACOL, V87, P965, DOI 10.1124/mol.114.097204; Ferreira C, 2014, GENEREVIEWS; FISHER RP, 1985, J BIOL CHEM, V260, P1330; Folmes CDL, 2013, STEM CELLS, V31, P1298, DOI 10.1002/stem.1389; Garone C, 2013, JAMA NEUROL, V70, P1177, DOI 10.1001/jamaneurol.2013.3197; Garrido-Maraver J, 2012, BRIT J PHARMACOL, V167, P1311, DOI 10.1111/j.1476-5381.2012.02086.x; Gerards M, 2011, BRAIN, V134, P210, DOI 10.1093/brain/awq273; Gineste C, 2015, HUM MOL GENET, V24, P6580, DOI 10.1093/hmg/ddv361; Gomes MB, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-80; Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362; Grad LI, 2006, BBA-BIOENERGETICS, V1757, P115, DOI 10.1016/j.bbabio.2005.11.009; Green P, 2010, AM J HUM GENET, V86, P485, DOI 10.1016/j.ajhg.2010.02.006; Haas RH, 2007, MITOCHONDRION, V7, pS136, DOI 10.1016/j.mito.2007.03.008; Hamalainen Riikka H, 2016, Methods Mol Biol, V1353, P65, DOI 10.1007/7651_2015_258; Hamalainen RH, 2015, CELL REP, V11, P1614, DOI 10.1016/j.celrep.2015.05.009; Hansson A, 2004, P NATL ACAD SCI USA, V101, P3136, DOI 10.1073/pnas.0308710100; Haraguchi M, 2002, MOL CELL BIOL, V22, P5212, DOI 10.1128/MCB.22.14.5212-5221.2002; Hargreaves I P, 2014, Int J Biochem Cell Biol, V49, P105, DOI 10.1016/j.biocel.2014.01.020; HARRIS RC, 1992, CLIN SCI, V83, P367, DOI 10.1042/cs0830367; Hartman PS, 2001, MECH AGEING DEV, V122, P1187, DOI 10.1016/S0047-6374(01)00259-7; Hatakeyama H, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0227-x; Hick A, 2013, DIS MODEL MECH, V6, P608, DOI 10.1242/dmm.010900; Hofer A, 2014, HUM MOL GENET, V23, P2400, DOI 10.1093/hmg/ddt631; Holmbeck MA, 2015, DIS MODEL MECH, V8, P843, DOI 10.1242/dmm.019323; Horvath R, 2012, J INHERIT METAB DIS, V35, P679, DOI 10.1007/s10545-011-9434-1; Huang Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128561; Hwang WY, 2013, NAT BIOTECHNOL, V31, P227, DOI 10.1038/nbt.2501; Hyland K, 2010, J INHERIT METAB DIS, V33, P563, DOI 10.1007/s10545-010-9159-6; Ingraham CA, 2009, MITOCHONDRION, V9, P204, DOI 10.1016/j.mito.2009.02.001; Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826; Iommarini L, 2015, MITOCHONDRION, V22, P96, DOI 10.1016/j.mito.2015.01.008; Ishikawa K, 2009, METHOD ENZYMOL, V457, P335, DOI 10.1016/S0076-6879(09)05019-8; Jardim FR, 2017, MOL NEUROBI IN PRESS; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Johnson SC, 2013, SCIENCE, V342, P1524, DOI 10.1126/science.1244360; Jun AS, 1996, MOL CELL BIOL, V16, P771; Kaese S, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00345; Kang HC, 2007, EPILEPSIA, V48, P82, DOI 10.1111/j.1528-1167.2006.00906.x; Karaa A, 2016, MOL GENET METAB, V119, P100, DOI 10.1016/j.ymgme.2016.07.005; Karamanlidis G, 2013, CELL METAB, V18, P239, DOI 10.1016/j.cmet.2013.07.002; Kasahara A, 2006, HUM MOL GENET, V15, P871, DOI 10.1093/hmg/ddl005; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kauppila JHK, 2016, CELL REP, V16, P2980, DOI 10.1016/j.celrep.2016.08.037; Kerscher SJ, 2000, BBA-BIOENERGETICS, V1459, P274, DOI 10.1016/S0005-2728(00)00162-6; Khan NA, 2014, EMBO MOL MED, V6, P721, DOI 10.1002/emmm.201403943; Kiebish MA, 2013, J LIPID RES, V54, P1312, DOI 10.1194/jlr.M034728; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145; Koga Y, 2010, ANN NY ACAD SCI, V1201, P104, DOI 10.1111/j.1749-6632.2010.05624.x; Kossoff EH, 2012, CURR OPIN NEUROL, V25, P173, DOI 10.1097/WCO.0b013e3283515e4a; Kruse SE, 2008, CELL METAB, V7, P312, DOI 10.1016/j.cmet.2008.02.004; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kuwabara PE, 2001, J INHERIT METAB DIS, V24, P127, DOI 10.1023/A:1010306731764; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/3033; Larsson NG, 2001, TRENDS MOL MED, V7, P578, DOI 10.1016/S1471-4914(01)02167-0; Lass A, 1999, FREE RADICAL BIO MED, V26, P1375, DOI 10.1016/S0891-5849(98)00330-X; Lasserre JP, 2015, DIS MODEL MECH, V8, P509, DOI 10.1242/dmm.020438; Lattanzi L, 1998, J CLIN INVEST, V101, P2119, DOI 10.1172/JCI1505; Lehtonen J, 2015, MITOCHONDRION, V24, pS45; Levy SE, 1999, TRANSGENIC RES, V8, P137, DOI 10.1023/A:1008967412955; Li H, 2000, P NATL ACAD SCI USA, V97, P3467, DOI 10.1073/pnas.97.7.3467; Li JL, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-32; Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303; Lopez LC, 2014, MOL SYNDROMOL, V5, P163, DOI 10.1159/000360494; Lopez LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011897; Lopez LC, 2009, HUM MOL GENET, V18, P714, DOI 10.1093/hmg/ddn401; Lopez LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023; Ma H, 2015, NATURE, V524, P234, DOI 10.1038/nature14546; Maglioni S, 2016, MITOCHONDRION, V30, P117, DOI 10.1016/j.mito.2016.02.003; Makky K, 2008, J BIOMOL SCREEN, V13, P960, DOI 10.1177/1087057108326080; Marchington DR, 1999, NAT MED, V5, P957, DOI 10.1038/11403; Mashkevich G, 1997, J BIOL CHEM, V272, P14356, DOI 10.1074/jbc.272.22.14356; MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872; MATTHEWS PM, 1993, NEUROLOGY, V43, P884, DOI 10.1212/WNL.43.5.884; Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103; McCormack S, 2015, MITOCHONDRION, V22, P45, DOI 10.1016/j.mito.2015.02.005; McCulloch V, 2002, MOL CELL BIOL, V22, P1116, DOI 10.1128/MCB.22.4.1116-1125.2002; McDaniel SS, 2011, EPILEPSIA, V52, pe7, DOI 10.1111/j.1528-1167.2011.02981.x; McKay SE, 2015, AM J PATHOL, V185, P3132, DOI 10.1016/j.ajpath.2015.08.014; Meiklejohn CD, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003238; Metodiev MD, 2009, CELL METAB, V9, P386, DOI 10.1016/j.cmet.2009.03.001; Morris SM, 2007, J NUTR, V137, p1602S, DOI 10.1093/jn/137.6.1602S; Moullan N, 2015, CELL REP, V10, P1681, DOI 10.1016/j.celrep.2015.02.034; Mullen AR, 2014, CELL REP, V7, P1679, DOI 10.1016/j.celrep.2014.04.037; Nakada K, 2004, BIOCHEM BIOPH RES CO, V323, P175, DOI 10.1016/j.bbrc.2004.08.073; Nakano K, 2005, MITOCHONDRION, V5, P426, DOI 10.1016/j.mito.2005.10.002; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Nikkanen J, 2016, CELL METAB, V23, P635, DOI 10.1016/j.cmet.2016.01.019; Nissim I, 2014, J BIOL CHEM, V289, P9710, DOI 10.1074/jbc.M113.544726; Ogilvie I, 2005, J CLIN INVEST, V115, P2784, DOI 10.1172/JCI26020; Olsen RKJ, 2007, BRAIN, V130, P2045, DOI 10.1093/brain/awm135; Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016; Parikh S, 2015, GENET MED, V17, P689, DOI 10.1038/gim.2014.177; Parikh S, 2009, CURR TREAT OPTION N, V11, P414, DOI 10.1007/s11940-009-0046-0; Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788; Park SJ, 2012, CELL, V148, P421, DOI 10.1016/j.cell.2012.01.017; Pashaj A, 2015, CAN J PHYSIOL PHARM, V93, P1029, DOI 10.1139/cjpp-2014-0480; Peng M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000061; PENN AMW, 1992, NEUROLOGY, V42, P2147, DOI 10.1212/WNL.42.11.2147; Pesah Y, 2004, DEVELOPMENT, V131, P2183, DOI 10.1242/dev.01095; PETROVABENEDICT R, 1992, J INHERIT METAB DIS, V15, P943, DOI 10.1007/BF01800243; Pfeffer G, 2012, COCHRANE DB SYST REV, V2012; Phoon CKL, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.111.000455; Pineda M, 2006, ANN NEUROL, V59, P394, DOI 10.1002/ana.20746; Pinkert CA, 2002, METHODS, V26, P348, DOI 10.1016/S1046-2023(02)00041-5; Powers C, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00074; Prigione A, 2011, STEM CELLS, V29, P1338, DOI 10.1002/stem.683; Quintana A, 2010, P NATL ACAD SCI USA, V107, P10996, DOI 10.1073/pnas.1006214107; Quinzii CM, 2007, MITOCHONDRION, V7, pS122, DOI 10.1016/j.mito.2007.03.004; Quinzii CM, 2013, FASEB J, V27, P612, DOI 10.1096/fj.12-209361; Raimundo N, 2012, CELL, V148, P716, DOI 10.1016/j.cell.2011.12.027; RAUCHOVA H, 1995, PHYSIOL RES, V44, P209; Rea SL, 2010, DEV DISABIL RES REV, V16, P200, DOI 10.1002/ddrr.114; REID GA, 1982, J BIOL CHEM, V257, P3062; Ribas GS, 2014, GENE, V533, P469, DOI 10.1016/j.gene.2013.10.017; Rochette L, 2015, CAN J PHYSIOL PHARM, V93, P1021, DOI 10.1139/cjpp-2014-0353; Rochette L, 2013, MOL NUTR FOOD RES, V57, P114, DOI 10.1002/mnfr.201200608; Rodan LH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127066; Rodriguez MC, 2007, MUSCLE NERVE, V35, P235, DOI 10.1002/mus.20688; Saada A, 2014, INT J BIOCHEM CELL B, V48, P60, DOI [10.1016/j.bioce1.2013.12.010, 10.1016/j.biocel.2013.12.010]; Safdar A, 2011, P NATL ACAD SCI USA, V108, P4135, DOI 10.1073/pnas.1019581108; Sager JJ, 2010, BRAIN STRUCT FUNCT, V214, P285, DOI 10.1007/s00429-009-0237-1; Saiki R, 2008, AM J PHYSIOL-RENAL, V295, pF1535; Saleem A, 2015, MITOCHONDRION, V21, P19, DOI 10.1016/j.mito.2014.12.001; Sander JD, 2011, NAT BIOTECHNOL, V29, P697, DOI 10.1038/nbt.1934; Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240; Sato A, 2005, P NATL ACAD SCI USA, V102, P16765, DOI 10.1073/pnas.0506197102; SCALORI V, 1990, INT J TISSUE REACT, V12, P149; SCHATZ G, 1963, BIOCHEM BIOPH RES CO, V12, P448, DOI 10.1016/0006-291X(63)90313-9; Schwimmer Christine, 2006, Biotechnology Journal, V1, P270, DOI 10.1002/biot.200500053; Sen A, 2017, CURR TOP DEV BIOL, V121, P1, DOI 10.1016/bs.ctdb.2016.07.001; Serrano M, 2012, DRUG DISCOV TODAY, V17, P1299, DOI 10.1016/j.drudis.2012.07.008; Sgarbi G, 2009, ARCH NEUROL-CHICAGO, V66, P951, DOI 10.1001/archneurol.2009.134; Shabalina IG, 2017, AGING-US, V9, P315, DOI 10.18632/aging.101174; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; Shadel GS, 1999, AM J HUM GENET, V65, P1230, DOI 10.1086/302630; Shimizu A, 2015, BIOCHEM BIOPH RES CO, V459, P66, DOI 10.1016/j.bbrc.2015.02.070; Shimizu A, 2014, P NATL ACAD SCI USA, V111, P3104, DOI 10.1073/pnas.1318109111; Siddiq I, 2015, NEUROLOGY, V85, P197, DOI 10.1212/WNL.0000000000001726; Sligh JE, 2000, P NATL ACAD SCI USA, V97, P14461, DOI 10.1073/pnas.250491597; Sonnhammer ELL, 1997, GENOMICS, V46, P200, DOI 10.1006/geno.1997.4989; Soustek MS, 2015, J INHERIT METAB DIS, V38, P915, DOI 10.1007/s10545-015-9834-8; Soustek MS, 2011, HUM GENE THER, V22, P865, DOI 10.1089/hum.2010.199; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Stanley CA, 2004, ANN NY ACAD SCI, V1033, P42, DOI 10.1196/annals.1320.004; Steele SL, 2014, TRANSL RES, V163, P79, DOI 10.1016/j.trsl.2013.08.008; Stewart AM, 2014, TRENDS NEUROSCI, V37, P264, DOI 10.1016/j.tins.2014.02.011; Suen DF, 2010, P NATL ACAD SCI USA, V107, P11835, DOI 10.1073/pnas.0914569107; Sugden MC, 2010, J ENDOCRINOL, V204, P93, DOI 10.1677/JOE-09-0359; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI [10.1016/S1474-4422(11)70155-2, 10.1016/S1474-4422(11)70155-7]; Suzuki T, 2015, TOHOKU J EXP MED, V236, P225, DOI 10.1620/tjem.236.225; Tabarki B, 2013, NEUROLOGY, V80, P261, DOI 10.1212/WNL.0b013e31827deb4c; Tarnopolsky MA, 2008, ADV DRUG DELIVER REV, V60, P1561, DOI 10.1016/j.addr.2008.05.001; Tarnopolsky MA, 1999, MUSCLE NERVE, V22, P1228, DOI 10.1002/(SICI)1097-4598(199909)22:9<1228::AID-MUS9>3.3.CO;2-Y; Tischner C, 2015, MITOCHONDRION, V24, P32, DOI 10.1016/j.mito.2015.06.002; Toivonen JM, 2001, GENETICS, V159, P241; Torraco A, 2015, MITOCHONDRION, V21, P76, DOI 10.1016/j.mito.2015.01.009; Torraco A, 2009, BBA-MOL CELL RES, V1793, P171, DOI 10.1016/j.bbamcr.2008.06.003; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005; Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102; Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310; Tyynismaa H, 2009, EMBO REP, V10, P137, DOI 10.1038/embor.2008.242; Ugalde C, 2004, HUM MOL GENET, V13, P659, DOI 10.1093/hmg/ddh071; Valentino ML, 2004, ANN NEUROL, V56, P631, DOI 10.1002/ana.20236; Valsecchi F, 2012, BBA-BIOENERGETICS, V1817, P1925, DOI 10.1016/j.bbabio.2012.03.006; Vempati UD, 2008, METHODS, V46, P241, DOI 10.1016/j.ymeth.2008.09.008; Verkaart S, 2007, BBA-MOL BASIS DIS, V1772, P1041, DOI 10.1016/j.bbadis.2007.05.004; Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95; Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988; Viscomi C, 2015, BBA-BIOENERGETICS, V1847, P544, DOI 10.1016/j.bbabio.2015.03.001; Volkoff H, 2006, ZEBRAFISH, V3, P131, DOI 10.1089/zeb.2006.3.131; Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156; Yadak R, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00031; Yamanashi H, 2014, EXP ANIM TOKYO, V63, P459, DOI 10.1538/expanim.14-0038; Yokota M, 2010, FEBS LETT, V584, P3943, DOI 10.1016/j.febslet.2010.07.048; Zhang Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069282	241	3	3	1	5	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						163	191		10.1146/annurev-pathol-020117-043644			29	Pathology	Pathology	BJ3ZK	WOS:000424631200008	29099651	Green Accepted			2019-10-28	
S	Elenitoba-Johnson, KSJ; Lim, MS	Galli, SJ	Abbas, AK; Aster, JC		Elenitoba-Johnson, Kojo S. J.; Lim, Megan S.	Galli, SJ		New Insights into Lymphoma Pathogenesis	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						lymphoma; pathogenesis; spliceosome; mutations; metabolism; circulating tumor DNA	B-CELL LYMPHOMA; IDENTIFIES RECURRENT MUTATIONS; GERMINAL-CENTER FORMATION; T-CELL; STAT3 MUTATIONS; ACTIVATING MUTATIONS; TUMOR-SUPPRESSOR; UBIQUITIN LIGASE; HODGKIN LYMPHOMA; SPLICING FACTOR	Lymphomas represent clonal proliferations of lymphocytes that are broadly classified based upon their maturity (peripheral or mature versus precursor) and lineage (B cell, T cell, and natural killer cell). Insights into the pathogenetic mechanisms involved in lymphoma impact the classification of lymphoma and have significant implications for the diagnosis and clinical management of patients. Serial scientific and technologic advances over the last 30 years in immunology, cytogenetics, molecular biology, gene expression profiling, mass spectrometry-based proteomics, and, more recently, next-generation sequencing have contributed to greatly enhance our understanding of the pathogenetic mechanisms in lymphoma. Novel and emerging concepts that challenge our previously accepted paradigms about lymphoma biology and how these impact diagnosis, molecular testing, disease monitoring, drug development, and personalized and precision medicine for lymphoma are discussed.	[Elenitoba-Johnson, Kojo S. J.; Lim, Megan S.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Elenitoba-Johnson, Kojo S. J.] Univ Penn, Ctr Personalized Diagnost, Philadelphia, PA 19104 USA; [Elenitoba-Johnson, Kojo S. J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lim, Megan S.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Philadelphia, PA 19104 USA	Elenitoba-Johnson, KSJ (reprint author), Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.; Elenitoba-Johnson, KSJ (reprint author), Univ Penn, Ctr Personalized Diagnost, Philadelphia, PA 19104 USA.; Elenitoba-Johnson, KSJ (reprint author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.	kojo.elenitoba-johnson@uphs.upenn.edu; megan.lim@uphs.upenn.edu		Elenitoba-Johnson, Kojo/0000-0002-1082-1545; Lim, Megan/0000-0002-0415-2867			Abate F, 2017, P NATL ACAD SCI USA, V114, P764, DOI 10.1073/pnas.1608839114; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Amarnath S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003130; Amir RE, 2004, ONCOGENE, V23, P2540, DOI 10.1038/sj.onc.1207366; Andersson EI, 2016, BLOOD, V128, P2465, DOI 10.1182/blood-2016-06-724856; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Battistella M, 2015, J INVEST DERMATOL, V135, P1659, DOI 10.1038/jid.2015.27; Beguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011; Biamonti G, 2014, SEMIN CELL DEV BIOL, V32, P30, DOI 10.1016/j.semcdb.2014.03.016; Boddicker RL, 2016, BLOOD, V128, P1234, DOI 10.1182/blood-2016-03-707141; Boddicker RL, 2016, SMALL GTPAS IN PRESS; Bonnal S, 2012, NAT REV DRUG DISCOV, V11, P847, DOI 10.1038/nrd3823; Bradley WD, 2014, CHEM BIOL, V21, P1463, DOI 10.1016/j.chembiol.2014.09.017; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Brown PJ, 2008, BLOOD, V111, P2816, DOI 10.1182/blood-2007-09-115113; Busino L, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003408; Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463; Caro P, 2012, CANCER CELL, V22, P547, DOI 10.1016/j.ccr.2012.08.014; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Cea M, 2016, CLIN CANCER RES, V22, P6099, DOI 10.1158/1078-0432.CCR-16-0630; Challa-Malladi M, 2011, CANCER CELL, V20, P728, DOI 10.1016/j.ccr.2011.11.006; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Chiba Shigeru, 2015, Small GTPases, V6, P100, DOI 10.4161/21541248.2014.988088; Choi J, 2015, NAT GENET, V47, P1011, DOI 10.1038/ng.3356; Chong LC, 2016, BLOOD, V128, P1206, DOI 10.1182/blood-2015-11-683003; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Easterfield AJ, 2003, IMMUNOGENETICS, V55, P344, DOI 10.1007/s00251-003-0584-7; Elliott NE, 2011, BLOOD, V118, P3911, DOI 10.1182/blood-2010-12-319467; Fischer ES, 2014, NATURE, V512, P49, DOI 10.1038/nature13527; Garcia PD, 2014, CLIN CANCER RES, V20, P1834, DOI 10.1158/1078-0432.CCR-13-2062; Gopalakrishnan R, 2016, ONCOGENE, V35, P1797, DOI 10.1038/onc.2015.245; Greaves P, 2013, BLOOD, V121, P734, DOI 10.1182/blood-2012-10-385591; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Gribben JG, 2015, J CLIN ONCOL, V33, P2803, DOI 10.1200/JCO.2014.59.5363; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Hopfinger G, 2013, CANCER-AM CANCER SOC, V119, P2258, DOI 10.1002/cncr.27972; Hsu TYT, 2015, NATURE, V525, P384, DOI 10.1038/nature14985; Isono K, 2005, GENE DEV, V19, P536, DOI 10.1101/gad.1284605; Jaffe ES, 2017, HEMATOPATHOLOGY; Jerez A, 2013, BLOOD, V122, P2453, DOI 10.1182/blood-2013-04-494930; Jerez A, 2012, BLOOD, V120, P3048, DOI 10.1182/blood-2012-06-435297; Jiang YW, 2017, CANCER DISCOV, V7, P38, DOI 10.1158/2159-8290.CD-16-0975; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; Kiel MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9470; Kiel MJ, 2014, BLOOD, V124, P1460, DOI 10.1182/blood-2014-03-559542; Kiel MJ, 2012, J EXP MED, V209, P1553, DOI 10.1084/jem.20120910; Koskela HLM, 2012, NEW ENGL J MED, V366, P1905, DOI 10.1056/NEJMoa1114885; Koues OI, 2015, IMMUNITY, V42, P186, DOI 10.1016/j.immuni.2014.12.021; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kucuk C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7025; Lettice LA, 2011, HUM MUTAT, V32, P1492, DOI 10.1002/humu.21615; Lewinsohn M, 2016, BLOOD, V127, P1017, DOI 10.1182/blood-2015-10-676098; Liu J, 2014, ONCOTARGET, V5, P1026, DOI 10.18632/oncotarget.1675; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Martin MJ, 2016, ONCOTARGET, V7, P86313, DOI 10.18632/oncotarget.13388; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; MATUTES E, 1991, BLOOD, V78, P3269; McDonnell SRP, 2013, BLOOD, V122, P958, DOI 10.1182/blood-2013-01-482026; McKinney M, 2017, CANCER DISCOV, V7, P369, DOI 10.1158/2159-8290.CD-16-0330; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Muralidharan G, 2005, ANTIMICROB AGENTS CH, V49, P220, DOI 10.1128/AAC.49.1.220-229.2005; Nakagawa M, 2014, J EXP MED, V211, P2497, DOI 10.1084/jem.20140987; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Naylor TL, 2011, CANCER RES, V71, P2643, DOI 10.1158/0008-5472.CAN-10-2525; Nie ZL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6908; Norberg E, 2017, CELL DEATH DIFFER, V24, P251, DOI 10.1038/cdd.2016.116; Ohgami RS, 2013, LEUKEMIA, V27, P2244, DOI 10.1038/leu.2013.104; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Padgett RA, 2012, TRENDS GENET, V28, P147, DOI 10.1016/j.tig.2012.01.001; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Park J, 2017, BLOOD, V130, P1430, DOI 10.1182/blood-2017-02-768234; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Paulus A, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.93; Pekarsky Y, 1999, P NATL ACAD SCI USA, V96, P2949, DOI 10.1073/pnas.96.6.2949; Polprasert C, 2015, CANCER CELL, V27, P658, DOI 10.1016/j.ccell.2015.03.017; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Quesada V, 2012, NAT GENET, V44, P47, DOI 10.1038/ng.1032; Rajala HLM, 2013, BLOOD, V121, P4541, DOI 10.1182/blood-2012-12-474577; Ravi D, 2016, CANCER RES, V76, P3319, DOI 10.1158/0008-5472.CAN-15-2477; Roberti A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12602; Roemer MGM, 2016, J CLIN ONCOL, V34, P2690, DOI 10.1200/JCO.2016.66.4482; Rosebeck Shaun, 2016, World J Biol Chem, V7, P128, DOI 10.4331/wjbc.v7.i1.128; Rosebeck S, 2011, SCIENCE, V331, P468, DOI 10.1126/science.1198946; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Rossi D, 2011, BLOOD, V118, P6904, DOI 10.1182/blood-2011-08-373159; Ryan RJH, 2015, CANCER DISCOV, V5, P1058, DOI 10.1158/2159-8290.CD-15-0370; Sahasrabuddhe AA, 2015, ONCOGENE, V34, P445, DOI 10.1038/onc.2013.571; Sahasrabuddhe AA, 2015, CURR OPIN HEMATOL, V22, P369, DOI 10.1097/MOH.0000000000000156; Sahasrabuddhe AA, 2015, IMMUNOL REV, V263, P224, DOI 10.1111/imr.12236; Sakata-Yanagimoto M, 2014, NAT GENET, V46, P171, DOI 10.1038/ng.2872; Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011; Schneider C, 2016, BLOOD, V128, P660, DOI 10.1182/blood-2015-11-684357; Schneider M, 2015, GENE CHROMOSOME CANC, V54, P638, DOI 10.1002/gcc.22276; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Steidl C, 2011, BLOOD, V118, P2659, DOI 10.1182/blood-2011-05-326538; Steidl C, 2011, NATURE, V471, P377, DOI 10.1038/nature09754; STERN MH, 1993, ONCOGENE, V8, P2475; Sur I, 2016, NAT REV CANCER, V16, P483, DOI 10.1038/nrc.2016.62; Swerdlow SH, 2008, WHO CLASSIFICATION T; Twa DDW, 2014, BLOOD, V123, P2062, DOI 10.1182/blood-2013-10-535443; Vallois D, 2016, BLOOD, V128, P1490, DOI 10.1182/blood-2016-02-698977; Van Roosbroeck K, 2016, GENE CHROMOSOME CANC, V55, P428, DOI 10.1002/gcc.22345; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Voena C, 2015, CANCER IMMUNOL RES, V3, P1333, DOI 10.1158/2326-6066.CIR-15-0089; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Webb TR, 2013, DRUG DISCOV TODAY, V18, P43, DOI 10.1016/j.drudis.2012.07.013; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilson WH, 2015, NAT MED, V21, P922, DOI 10.1038/nm.3884; Xu YK, 2005, IMMUNITY, V22, P9, DOI 10.1016/j.immuni.2004.12.004; Yamamoto R, 2009, CANCER SCI, V100, P2093, DOI 10.1111/j.1349-7006.2009.01302.x; Yang FM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170896; Young RM, 2015, SEMIN HEMATOL, V52, P77, DOI 10.1053/j.seminhematol.2015.01.008; Zhang JY, 2017, CANCER DISCOV, V7, P322, DOI 10.1158/2159-8290.CD-16-1417; Zhang LH, 2013, BRIT J HAEMATOL, V160, P487, DOI 10.1111/bjh.12172; Zhou Jianbiao, 2017, Stem Cell Investig, V4, P6, DOI 10.21037/sci.2017.01.06	125	1	1	0	5	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						193	217		10.1146/annurev-pathol-020117-043803			25	Pathology	Pathology	BJ3ZK	WOS:000424631200009	29140757				2019-10-28	
S	Perkey, E; Maillard, I	Galli, SJ	Abbas, AK; Aster, JC		Perkey, Eric; Maillard, Ivan	Galli, SJ		New Insights into Graft-Versus-Host Disease and Graft Rejection	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						transplantation; rejection; graft-versus-host disease; allogeneic; cytokines; Notch	INNATE LYMPHOID-CELLS; PLASMACYTOID DENDRITIC CELLS; FIBROBLASTIC RETICULAR CELLS; ANTIGEN-PRESENTING CELLS; REGULATORY T-CELLS; DELTA-LIKE 4; B-CELLS; MARROW-TRANSPLANTATION; NOTCH LIGAND; ACUTE GVHD	Allogeneic transplantation of foreign organs or tissues has lifesaving potential, but can lead to serious complications. After solid organ transplantation, immune-mediated rejection mandates the use of prolonged global immunosuppression and limits the life span of transplanted allografts. After bone marrow transplantation, donor-derived immune cells can trigger life-threatening graft-versus-host disease. T cells are central mediators of alloimmune complications and the target of most existing therapeutic interventions. We review recent progress in identifying multiple cell types in addition to T cells and new molecular pathways that regulate pathogenic alloreactivity. Key discoveries include the cellular subsets that function as potential sources of alloantigens, the cross talk of innate lymphoid cells with damaged epithelia and with the recipient microbiome, the impact of the alarmin interleukin-33 on alloreactivity, and the role of Notch ligands expressed by fibroblastic stromal cells in alloimmunity. While refining our understanding of transplantation immunobiology, these findings identify new therapeutic targets and new areas of investigation.	[Perkey, Eric; Maillard, Ivan] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; [Maillard, Ivan] Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; [Maillard, Ivan] Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; [Maillard, Ivan] Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; [Maillard, Ivan] Univ Penn, Perelman Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	Perkey, E (reprint author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	eperkey@umich.edu; imaillar@pennmedicine.upenn.edu		Maillard, Ivan/0000-0003-1312-6748; Perkey, Eric/0000-0003-3275-3181			Abe J, 2014, J IMMUNOL, V193, P1636, DOI 10.4049/jimmunol.1302946; Abrahimi P, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85293; Ahmed EB, 2011, AM J TRANSPLANT, V11, P936, DOI 10.1111/j.1600-6143.2011.03476.x; Alexander KA, 2014, J CLIN INVEST, V124, P4266, DOI 10.1172/JCI75935; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Anderson BE, 2005, BLOOD, V105, P2227, DOI 10.1182/blood-2004-08-3032; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Auderset F, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002560; Backer RA, 2014, NAT IMMUNOL, V15, P1143, DOI 10.1038/ni.3027; Bailis W, 2013, IMMUNITY, V39, P148, DOI 10.1016/j.immuni.2013.07.006; Baker RJ, 2001, J IMMUNOL, V167, P7199, DOI 10.4049/jimmunol.167.12.7199; Beelen DW, 1999, BLOOD, V93, P3267, DOI 10.1182/blood.V93.10.3267.410k22_3267_3275; Beilhack A, 2005, BLOOD, V106, P1113, DOI 10.1182/blood-2005-02-0509; BENICHOU G, 1994, J IMMUNOL, V153, P938; BENICHOU G, 1992, J EXP MED, V175, P305, DOI 10.1084/jem.175.1.305; Bjorklund AK, 2016, NAT IMMUNOL, V17, P451, DOI 10.1038/ni.3368; Botha P, 2008, TRANSPLANTATION, V85, P771, DOI 10.1097/TP.0b013e31816651de; Brunner SM, 2011, TRANSPL INT, V24, P1027, DOI 10.1111/j.1432-2277.2011.01306.x; Calderon L, 2012, CELL, V149, P159, DOI 10.1016/j.cell.2012.01.049; Chai Q, 2013, IMMUNITY, V38, P1013, DOI 10.1016/j.immuni.2013.03.012; Charbonnier LM, 2015, NAT IMMUNOL, V16, P1162, DOI 10.1038/ni.3288; Chong AS, 2015, TRANSPLANTATION, V99, P21, DOI 10.1097/TP.0000000000000545; Chung J, 2017, J CLIN INVEST, V127, P1574, DOI 10.1172/JCI89535; CLIFT RA, 1990, BLOOD, V76, P1867; Colf LA, 2007, CELL, V129, P135, DOI 10.1016/j.cell.2007.01.048; Corbitt N, 2013, AM J PATHOL, V182, P180, DOI 10.1016/j.ajpath.2012.09.010; Couturier M, 2013, LEUKEMIA, V27, P1527, DOI 10.1038/leu.2013.39; Dickson RP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097214; Dubrot J, 2014, J EXP MED, V211, P1153, DOI 10.1084/jem.20132000; Dudakov JA, 2015, ANNU REV IMMUNOL, V33, P747, DOI 10.1146/annurev-immunol-032414-112123; Dudakov JA, 2012, SCIENCE, V336, P91, DOI 10.1126/science.1218004; Duffner UA, 2004, J IMMUNOL, V172, P7393, DOI 10.4049/jimmunol.172.12.7393; Eriguchi Y, 2012, BLOOD, V120, P223, DOI 10.1182/blood-2011-12-401166; Fasnacht N, 2014, J EXP MED, V211, P2265, DOI 10.1084/jem.20132528; Ferrara JLM, 2011, BLOOD, V118, P6702, DOI 10.1182/blood-2011-08-375006; Fletcher AL, 2010, J EXP MED, V207, P689, DOI 10.1084/jem.20092642; Fricke WF, 2014, AM J TRANSPLANT, V14, P416, DOI 10.1111/ajt.12588; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Hanash AM, 2012, IMMUNITY, V37, P339, DOI 10.1016/j.immuni.2012.05.028; Heeger PS, 1999, J IMMUNOL, V163, P2267; Hepworth MR, 2015, SCIENCE, V348, P1031, DOI 10.1126/science.aaa4812; Herranz D, 2014, NAT MED, V20, P1130, DOI 10.1038/nm.3665; Herrera OB, 2004, J IMMUNOL, V173, P4828, DOI 10.4049/jimmunol.173.8.4828; Hershberg RM, 1998, J CLIN INVEST, V102, P792, DOI 10.1172/JCI3201; Highfill SL, 2010, BLOOD, V116, P5738, DOI 10.1182/blood-2010-06-287839; Hill GR, 1997, BLOOD, V90, P3204, DOI 10.1182/blood.V90.8.3204; Hoyne GF, 2000, INT IMMUNOL, V12, P177, DOI 10.1093/intimm/12.2.177; Hozumi K, 2008, J EXP MED, V205, P2507, DOI 10.1084/jem.20080134; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Illigens BM, 2002, HUM IMMUNOL, V63, P912, DOI 10.1016/S0198-8859(02)00449-4; Jenq RR, 2015, BIOL BLOOD MARROW TR, V21, P1373, DOI 10.1016/j.bbmt.2015.04.016; Jenq RR, 2012, J EXP MED, V209, P902, DOI 10.1084/jem.20112408; Jones SC, 2003, J CLIN INVEST, V112, P1880, DOI 10.1172/JCI200319427; Karahan GE, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00686; Koch U, 2008, J EXP MED, V205, P2515, DOI 10.1084/jem.20080829; Kovall RA, 2017, DEV CELL, V41, P228, DOI 10.1016/j.devcel.2017.04.001; Koyama M, 2015, J EXP MED, V212, P1303, DOI 10.1084/jem.20150329; Koyama M, 2012, NAT MED, V18, P135, DOI 10.1038/nm.2597; Koyama M, 2009, BLOOD, V113, P2088, DOI 10.1182/blood-2008-07-168609; KUNDIG TM, 1995, SCIENCE, V268, P1343, DOI 10.1126/science.7761853; Laky K, 2015, IMMUNITY, V42, P80, DOI 10.1016/j.immuni.2014.12.027; LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31; Lei YM, 2016, J CLIN INVEST, V126, P2736, DOI 10.1172/JCI85295; Leveque-El Mouttie L, 2016, BLOOD, V128, P794, DOI 10.1182/blood-2015-11-680876; Levine JE, 2013, BLOOD, V122, P1505, DOI 10.1182/blood-2013-02-485813; Li HM, 2012, J IMMUNOL, V188, P3804, DOI 10.4049/jimmunol.1102795; Li HM, 2011, J IMMUNOL, V186, P230, DOI 10.4049/jimmunol.1002965; Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95; LINDAHL KF, 1977, J EXP MED, V145, P500, DOI 10.1084/jem.145.3.500; Lindemans CA, 2015, NATURE, V528, P560, DOI 10.1038/nature16460; Liu Q, 2016, J CLIN INVEST, V126, P2805, DOI 10.1172/JCI84577; Macdonald WA, 2009, IMMUNITY, V31, P897, DOI 10.1016/j.immuni.2009.09.025; Malhotra D, 2012, NAT IMMUNOL, V13, P499, DOI 10.1038/ni.2262; Marino J, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8759; Markey KA, 2014, J IMMUNOL, V192, P5426, DOI 10.4049/jimmunol.1302490; Markey KA, 2009, BLOOD, V113, P5644, DOI 10.1182/blood-2008-12-191833; Martin PJ, 2017, BLOOD, V129, P791, DOI 10.1182/blood-2016-09-737700; Mathews LR, 2016, AM J TRANSPLANT, V16, P938, DOI 10.1111/ajt.13542; Mathewson ND, 2016, NAT IMMUNOL, V17, P505, DOI 10.1038/ni.3400; Matta BM, 2016, BLOOD, V128, P427, DOI 10.1182/blood-2015-12-684142; Matta BM, 2014, J IMMUNOL, V193, P4010, DOI 10.4049/jimmunol.1400481; Matte CC, 2004, NAT MED, V10, P987, DOI 10.1038/nm1089; Matte-Martone C, 2008, BLOOD, V111, P3884, DOI 10.1182/blood-2007-11-125294; MAYER L, 1987, J EXP MED, V166, P1471, DOI 10.1084/jem.166.5.1471; Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209; MICONNET I, 1995, EUR J IMMUNOL, V25, P364, DOI 10.1002/eji.1830250209; Minter LM, 2005, NAT IMMUNOL, V6, P680, DOI 10.1038/ni1209; Mochizuki K, 2013, J IMMUNOL, V190, P3772, DOI 10.4049/jimmunol.1202820; Molofsky AB, 2015, IMMUNITY, V42, P1005, DOI 10.1016/j.immuni.2015.06.006; Ochando JC, 2006, NAT IMMUNOL, V7, P652, DOI 10.1038/ni1333; Oh PL, 2012, AM J TRANSPLANT, V12, P753, DOI 10.1111/j.1600-6143.2011.03860.x; Pascual-Figal DA, 2011, ANN THORAC SURG, V92, P2118, DOI 10.1016/j.athoracsur.2011.07.048; Pinchuk IV, 2008, GASTROENTEROLOGY, V135, P1228, DOI 10.1053/j.gastro.2008.07.016; Poe JC, 2017, BLOOD, V130, P2131, DOI 10.1182/blood-2017-05-782466; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Radtke F, 2013, NAT REV IMMUNOL, V13, P427, DOI 10.1038/nri3445; Reichenbach DK, 2015, BLOOD, V125, P3183, DOI 10.1182/blood-2014-10-606830; Reshef R, 2012, NEW ENGL J MED, V367, P135, DOI 10.1056/NEJMoa1201248; Reynolds ND, 2011, J IMMUNOL, V187, P2803, DOI 10.4049/jimmunol.1100160; Riella LV, 2011, J IMMUNOL, V187, P4629, DOI 10.4049/jimmunol.1004076; Roderick JE, 2013, J EXP MED, V210, P1311, DOI 10.1084/jem.20112615; Saada JI, 2006, J IMMUNOL, V177, P5968, DOI 10.4049/jimmunol.177.9.5968; Sandy AR, 2013, J IMMUNOL, V190, P5818, DOI 10.4049/jimmunol.1203452; Sarantopoulos S, 2015, BLOOD, V125, P1703, DOI 10.1182/blood-2014-12-567834; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shin HM, 2006, EMBO J, V25, P129, DOI 10.1038/sj.emboj.7600902; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Shono Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2311; Silva IA, 2010, BIOL BLOOD MARROW TR, V16, P598, DOI 10.1016/j.bbmt.2009.12.007; Sivaganesh S, 2013, J IMMUNOL, V190, P5829, DOI 10.4049/jimmunol.1300458; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Spierings E, 2013, BIOL BLOOD MARROW TR, V19, P1244, DOI 10.1016/j.bbmt.2013.06.001; SPRENT J, 1986, J EXP MED, V163, P998, DOI 10.1084/jem.163.4.998; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/S0092-8674(05)80090-X; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Stolp J, 2014, NAT REV NEPHROL, V10, P389, DOI 10.1038/nrneph.2014.80; STORB R, 1983, NEW ENGL J MED, V308, P302, DOI 10.1056/NEJM198302103080602; Suenaga F, 2015, J IMMUNOL, V194, P398, DOI 10.4049/jimmunol.1401022; Takashima S, 2011, J EXP MED, V208, P285, DOI 10.1084/jem.20101559; Takemoto SK, 2000, NEW ENGL J MED, V343, P1078, DOI 10.1056/NEJM200010123431504; Talayero P, 2016, AM J TRANSPLANT, V16, P72, DOI 10.1111/ajt.13435; Tawara I, 2010, J IMMUNOL, V185, P3866, DOI 10.4049/jimmunol.1001625; Teshima T, 2002, NAT MED, V8, P575, DOI 10.1038/nm0602-575; Teshima T, 2002, BLOOD, V99, P1825, DOI 10.1182/blood.V99.5.1825; Toubai T, 2012, BLOOD, V119, P3844, DOI 10.1182/blood-2011-10-384057; Tran IT, 2013, J CLIN INVEST, V123, P1590, DOI 10.1172/JCI65477; Turnquist HR, 2011, J IMMUNOL, V187, P4598, DOI 10.4049/jimmunol.1100519; Vaishnava S, 2011, SCIENCE, V334, P255, DOI 10.1126/science.1209791; VANBEKKU.DW, 1974, J NATL CANCER I, V52, P401, DOI 10.1093/jnci/52.2.401; Vander Lugt MT, 2013, NEW ENGL J MED, V369, P529, DOI 10.1056/NEJMoa1213299; Varelias A, 2017, BLOOD, V129, P2172, DOI 10.1182/blood-2016-08-732628; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Vigouroux S, 2003, J VIROL, V77, P10872, DOI 10.1128/JVI.77.20.10872-10880.2003; Wang HF, 2014, P NATL ACAD SCI USA, V111, P705, DOI 10.1073/pnas.1315023111; Wang T, 2010, AM J TRANSPLANT, V10, P1524, DOI 10.1111/j.1600-6143.2010.03066.x; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640; Weber D, 2016, BONE MARROW TRANSPL, V51, P1087, DOI 10.1038/bmt.2016.66; Weber D, 2017, BIOL BLOOD MARROW TR, V23, P845, DOI 10.1016/j.bbmt.2017.02.006; Weber M, 2014, BIOL BLOOD MARROW TR, V20, P1696, DOI 10.1016/j.bbmt.2014.08.005; Weiner J, 2017, TRANSPLANTATION, V101, P2449, DOI 10.1097/TP.0000000000001593; Westendorf AM, 2009, GUT, V58, P211, DOI 10.1136/gut.2008.151720; Wikstrom ME, 2015, BLOOD, V126, P1503, DOI 10.1182/blood-2015-01-622837; Willner DL, 2013, AM J RESP CRIT CARE, V187, P640, DOI 10.1164/rccm.201209-1680OC; Wong KK, 2003, J CLIN INVEST, V112, P1741, DOI 10.1172/JCI200318020; Wood S, 2015, J IMMUNOL, V194, P2899, DOI 10.4049/jimmunol.1402034; Yin H, 2010, TRANSPLANTATION, V89, P1189, DOI 10.1097/TP.0b013e3181d720af; Yvon ES, 2003, BLOOD, V102, P3815, DOI 10.1182/blood-2002-12-3826; Zhang JL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0166; Zhang Y, 2002, J CLIN INVEST, V109, P1335, DOI 10.1172/JCI200214989; Zhang Y, 2011, BLOOD, V117, P299, DOI 10.1182/blood-2010-03-271940; Zhao K, 2014, J INTERF CYTOK RES, V34, P707, DOI 10.1089/jir.2013.0099; Zhuang Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12623	154	3	3	2	3	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						219	245		10.1146/annurev-pathol-020117-043720			27	Pathology	Pathology	BJ3ZK	WOS:000424631200010	29099650				2019-10-28	
S	Webb, GJ; Hirschfield, GM; Krawitt, EL; Gershwin, ME	Galli, SJ	Abbas, AK; Aster, JC		Webb, G. J.; Hirschfield, G. M.; Krawitt, E. L.; Gershwin, M. E.	Galli, SJ		Cellular and Molecular Mechanisms of Autoimmune Hepatitis	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						autoimmune hepatitis; autoimmunity; hepatocyte; cirrhosis; T cells; autoantibodies	REGULATORY T-CELLS; PRIMARY BILIARY-CIRRHOSIS; CHRONIC ACTIVE HEPATITIS; INDUCED LIVER-INJURY; PRIMARY SCLEROSING CHOLANGITIS; NECROSIS-FACTOR-ALPHA; MAJOR HISTOCOMPATIBILITY COMPLEX; SMOOTH-MUSCLE ANTIBODIES; NATURAL-KILLER-CELLS; EPSTEIN-BARR-VIRUS	Autoimmune hepatitis is an uncommon idiopathic syndrome of immune-mediated destruction of hepatocytes, typically associated with autoantibodies. The disease etiology is incompletely understood but includes a clear association with human leukocyte antigen (HLA) variants and other non-HLA gene variants, female sex, and the environment. Pathologically, there is a CD4+ T cell-rich lymphocytic inflammatory infiltrate with variable hepatocyte necrosis and subsequent hepatic fibrosis. Attempts to understand pathogenesis are informed by several monogenetic syndromes that may include autoimmune liver injury, by several drug and environmental agents that have been identified as triggers in a minority of cases, by human studies that point toward a central role for CD4+ effector and regulatory T cells, and by animal models of the disease. Nonspecific immunosuppression is the current standard therapy. Further understanding of the disease's cellular and molecular mechanisms may assist in the design of better-targeted therapies, aid the limitation of adverse effects from therapy, and inform individualized risk assessment and prognostication.	[Webb, G. J.; Hirschfield, G. M.] Univ Birmingham, Inst Immunol & Immunotherapy, Liver Biomed Res Ctr, Natl Inst Hlth Res, Birmingham B15 2TT, W Midlands, England; [Krawitt, E. L.] Univ Vermont, Dept Med, Burlington, VT 05405 USA; [Krawitt, E. L.] Dartmouth Coll, Dept Med, Hanover, NH 03755 USA; [Gershwin, M. E.] Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95817 USA	Webb, GJ (reprint author), Univ Birmingham, Inst Immunol & Immunotherapy, Liver Biomed Res Ctr, Natl Inst Hlth Res, Birmingham B15 2TT, W Midlands, England.	g.j.webb@bham.ac.uk; g.hirschfield@bham.ac.uk; edward.krawitt@med.uvm.edu; megershwin@ucdavis.edu			Medical Research CouncilMedical Research Council UK (MRC) [MR/M001911/1]		Adar Tomer, 2010, J Clin Gastroenterol, V44, pe20, DOI 10.1097/MCG.0b013e3181a745e7; Agarwal K, 2007, TISSUE ANTIGENS, V69, P227, DOI 10.1111/j.1399-0039.2006.00794.x; Agarwal K, 2000, J HEPATOL, V32, P538, DOI 10.1016/S0168-8278(00)80213-5; Agarwal K, 2000, HEPATOLOGY, V31, P49, DOI 10.1002/hep.510310110; AHONEN P, 1987, J CLIN ENDOCR METAB, V64, P494, DOI 10.1210/jcem-64-3-494; Akimova T, 2012, AM J TRANSPLANT, V12, P3449, DOI 10.1111/j.1600-6143.2012.04269.x; ALWABEL A, 1993, J ALLERGY CLIN IMMUN, V92, P902, DOI 10.1016/0091-6749(93)90068-Q; Amarapurkar D N, 2003, J Assoc Physicians India, V51, P967; ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; Aoki N, 2011, GASTROENTEROLOGY, V140, P1322, DOI 10.1053/j.gastro.2011.01.002; Appleyard Sally, 2010, J Med Case Rep, V4, P311, DOI 10.1186/1752-1947-4-311; Arenz M, 1998, J HEPATOL, V28, P70, DOI 10.1016/S0168-8278(98)80204-3; BACH N, 1992, HEPATOLOGY, V15, P572, DOI 10.1002/hep.1840150403; BALLARDINI G, 1984, LANCET, V2, P1009; Bank I, 2003, J LAB CLIN MED, V141, P33, DOI 10.1067/mlc.2003.1; Behairy BE, 2016, ANN HEPATOL, V15, P682, DOI 10.5604/16652681.1212319; Bei R, 1999, CANCER RES, V59, P5471; Beland K, 2015, HEPATOLOGY, V62, P1511, DOI 10.1002/hep.27991; Beldi G, 2008, HEPATOLOGY, V48, P841, DOI 10.1002/hep.22401; Berardi S, 2007, GUT, V56, P237, DOI 10.1136/gut.2006.092064; Bittencourt PL, 2008, J CLIN GASTROENTEROL, V42, P300, DOI 10.1097/MCG.0b013e31802dbdfc; Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906; Bjornsson E, 2010, HEPATOLOGY, V51, P2040, DOI 10.1002/hep.23588; Bjornsson ES, 2013, GASTROENTEROLOGY, V144, P1419, DOI 10.1053/j.gastro.2013.02.006; Bonder CS, 2005, IMMUNITY, V23, P153, DOI 10.1016/j.immuni.2005.06.007; Bonito AJ, 2013, J CLIN INVEST, V123, P3510, DOI 10.1172/JCI65414; BOTTAZZO GF, 1976, J CLIN PATHOL, V29, P403, DOI 10.1136/jcp.29.5.403; BOURDI M, 1994, MOL PHARMACOL, V45, P1287; Braley-Mullen H, 1999, J AUTOIMMUN, V12, P157, DOI 10.1006/jaut.1999.0272; Burak KW, 2013, CAN J GASTROENTEROL, V27, P273, DOI 10.1155/2013/512624; BUTLER RC, 1984, BRIT J EXP PATHOL, V65, P509; Cai P, 2008, TOXICOL APPL PHARM, V228, P68, DOI 10.1016/j.taap.2007.11.031; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; CANTOR HM, 1967, NATURE, V215, P744, DOI 10.1038/215744a0; Carambia A, 2014, J HEPATOL, V61, P594, DOI 10.1016/j.jhep.2014.04.027; Castellote J, 2001, MED CLIN-BARCELONA, V117, P76, DOI 10.1016/S0025-7753(01)72016-7; Chang JJ, 2007, IMMUNOL CELL BIOL, V85, P16, DOI 10.1038/sj.icb.7100009; Chapman MH, 2010, NEW ENGL J MED, V362, P1642, DOI 10.1056/NEJMc0908038; CHAPMAN RW, 1988, GUT, V29, P422, DOI 10.1136/gut.29.4.422; Chen YY, 2016, HEPATOLOGY, V64, P138, DOI 10.1002/hep.28517; Chernavsky AC, 2004, HUM IMMUNOL, V65, P683, DOI 10.1016/j.humimm.2004.03.004; Clemente-Casares X, 2016, NATURE, V530, P434, DOI 10.1038/nature16962; CLIFFORD BD, 1995, HEPATOLOGY, V21, P613, DOI 10.1002/hep.1840210302; COCHRANE AMG, 1976, LANCET, V1, P441; Cooper GS, 2003, AUTOIMMUN REV, V2, P119, DOI 10.1016/S1568-9972(03)00006-5; Corrigan M, 2015, BRIT MED BULL, V114, P181, DOI 10.1093/bmb/ldv021; Corse E, 2013, J IMMUNOL, V190, P526, DOI 10.4049/jimmunol.1202621; Crispe IN, 2009, ANNU REV IMMUNOL, V27, P147, DOI 10.1146/annurev.immunol.021908.132629; Crispe IN, 2000, IMMUNOL REV, V174, P47, DOI 10.1034/j.1600-0528.2002.017412.x; Csepregi A, 2002, SCAND J IMMUNOL, V56, P623, DOI 10.1046/j.1365-3083.2002.01165.x; Czaja AJ, 1997, HEPATOLOGY, V25, P317; Czaja AJ, 1999, J HEPATOL, V30, P394, DOI 10.1016/S0168-8278(99)80096-8; Czaja AJ, 1999, GASTROENTEROLOGY, V117, P645, DOI 10.1016/S0016-5085(99)70458-0; Czaja AJ, 2002, AM J GASTROENTEROL, V97, P413; Czaja AJ, 2001, HEPATOLOGY, V34, P659, DOI 10.1053/jhep.2001.27562; CZAJA AJ, 1993, GASTROENTEROLOGY, V105, P1824, DOI 10.1016/0016-5085(93)91081-R; Czaja AJ, 2000, DIGEST DIS SCI, V45, P1028, DOI 10.1023/A:1005506031717; Daniel V, 2016, HUM IMMUNOL, V77, P146, DOI 10.1016/j.humimm.2015.11.006; Daniels JA, 2009, AM J CLIN PATHOL, V131, P243, DOI 10.1309/AJCP8WHR0IEVUUOJ; De Biasio MB, 2006, J CLIN PATHOL, V59, P417, DOI 10.1136/jcp.2005.028613; de Boer YS, 2014, GASTROENTEROLOGY, V147, P443, DOI 10.1053/j.gastro.2014.04.022; De Luca-Johnson J, 2016, DIGEST DIS SCI, V61, P2710, DOI 10.1007/s10620-016-4213-3; Deane KD, 2014, NAT REV RHEUMATOL, V10, P212, DOI 10.1038/nrrheum.2014.6; Derkow K, 2007, HEPATOLOGY, V46, P1155, DOI 10.1002/HEP.21796; Devlin J, 1998, HEPATOLOGY, V27, P926, DOI 10.1002/hep.510270406; Dhaliwal HK, 2015, AM J GASTROENTEROL, V110, P993, DOI 10.1038/ajg.2015.139; Dickinson RE, 2014, BLOOD, V123, P863, DOI 10.1182/blood-2013-07-517151; DIENES HP, 1987, HEPATOLOGY, V7, P1317, DOI 10.1002/hep.1840070623; DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311; Dong ZJ, 2004, J HEPATOL, V41, P966, DOI 10.1016/j.jhep.2004.08.021; Dugan CM, 2010, J PHARMACOL EXP THER, V333, P364, DOI 10.1124/jpet.109.164541; Dyson JK, 2015, J HEPATOL, V62, P208, DOI 10.1016/j.jhep.2014.09.010; EGGINK HF, 1982, CLIN EXP IMMUNOL, V50, P17; Ehser J, 2013, J AUTOIMMUN, V42, P39, DOI 10.1016/j.jaut.2012.11.001; Eipel C, 2010, WORLD J GASTROENTERO, V16, P6046, DOI 10.3748/wjg.v16.i48.6046; Ellebrecht CT, 2016, SCIENCE, V353, P179, DOI 10.1126/science.aaf6756; Erhardt A, 2007, HEPATOLOGY, V45, P475, DOI 10.1002/hep.21498; Fainboim L, 2001, HEPATOLOGY, V33, P1512, DOI 10.1053/jhep.2001.24562; Fattovich G, 1996, J HEPATOL, V24, P38, DOI 10.1016/S0168-8278(96)80184-X; Fernando MMA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000024; FERRAN C, 1990, EUR J IMMUNOL, V20, P509, DOI 10.1002/eji.1830200308; FERRANTE A, 1989, INT ARCH ALLER A IMM, V88, P348, DOI 10.1159/000234823; Ferri S, 2010, HEPATOLOGY, V52, P999, DOI 10.1002/hep.23792; Fontana RJ, 2014, GASTROENTEROLOGY, V146, P914, DOI 10.1053/j.gastro.2013.12.032; Fox CK, 2001, LIVER, V21, P272, DOI 10.1034/j.1600-0676.2001.021004272.x; FRANCO A, 1988, HEPATOLOGY, V8, P449, DOI 10.1002/hep.1840080302; Fujinami RS, 2006, CLIN MICROBIOL REV, V19, P80, DOI 10.1128/CMR.19.1.80-94.2006; Gagliani N, 2015, NATURE, V523, P221, DOI 10.1038/nature14452; Gao X, 2013, J EXP MED, V210, P2833, DOI 10.1084/jem.20130733; GARCIABUEY L, 1995, GASTROENTEROLOGY, V108, P1770, DOI 10.1016/0016-5085(95)90139-6; Gautam M, 2006, LIVER TRANSPLANT, V12, P1813, DOI 10.1002/lt.20910; Germano V, 2005, ANN RHEUM DIS, V64, P1519, DOI 10.1136/ard.2004.032821; Gil-Farina I, 2016, J IMMUNOL, V197, P2145, DOI 10.4049/jimmunol.1600228; Gilbert K. M, 2010, HEPAT RES TREAT, V2010, DOI DOI 10.1155/2010/248157]; GODFREY VL, 1991, AM J PATHOL, V138, P1379; Goodnow CC, 2007, CELL, V130, P25, DOI 10.1016/j.cell.2007.06.033; Gorham JD, 2001, J IMMUNOL, V166, P6413, DOI 10.4049/jimmunol.166.10.6413; Goris A, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007260; Gough A, 1996, BRIT MED J, V312, P169; Gough SCL, 2007, CURR GENOMICS, V8, P453, DOI 10.2174/138920207783591690; Graff JN, 2014, CANCER IMMUNOL RES, V2, P399, DOI 10.1158/2326-6066.CIR-13-0193; Granito A, 2008, AM J GASTROENTEROL, V103, P1313, DOI 10.1111/j.1572-0241.2007.01782_7.x; Grant AJ, 2002, AM J PATHOL, V160, P1445, DOI 10.1016/S0002-9440(10)62570-9; Grant AJ, 2001, HEPATOLOGY, V33, P1065, DOI 10.1053/jhep.2001.24231; Grant CR, 2014, HEPATOLOGY, V59, P1007, DOI 10.1002/hep.26583; Gregorio GV, 2003, CLIN EXP IMMUNOL, V133, P404, DOI 10.1046/j.1365-2249.2003.02229.x; Gregorio GV, 1997, HEPATOLOGY, V25, P541, DOI 10.1002/hep.510250308; Gregorio GV, 1999, J IMMUNOL, V162, P1802; Griffin JM, 2000, TOXICOL SCI, V57, P345, DOI 10.1093/toxsci/57.2.345; Gromme M, 2002, MOL IMMUNOL, V39, P181, DOI 10.1016/S0161-5890(02)00101-3; Groribaek L, 2014, J HEPATOL, V60, P612, DOI 10.1016/j.jhep.2013.10.020; Gunther C, 2016, J CLIN INVEST, V126, P4346, DOI 10.1172/JCI87545; GUT J, 1995, TOXICOLOGY, V97, P199, DOI 10.1016/0300-483X(94)03010-Y; Hardtke-Wolenski M, 2015, HEPATOLOGY, V61, P1295, DOI 10.1002/hep.27639; Hardtke-Wolenski M, 2013, HEPATOLOGY, V58, P718, DOI 10.1002/hep.26380; HASHIMOTO E, 1993, MAYO CLIN PROC, V68, P1049, DOI 10.1016/S0025-6196(12)60897-0; Heneghan MA, 2001, GUT, V48, P97, DOI 10.1136/gut.48.1.97; Herkel J, 2003, HEPATOLOGY, V37, P1079, DOI 10.1053/jhep.2003.50191; Heymann F, 2015, HEPATOLOGY, V62, P279, DOI 10.1002/hep.27793; Hirschfield GM, 2013, ANNU REV PATHOL-MECH, V8, P303, DOI 10.1146/annurev-pathol-020712-164014; Holdener M, 2008, J EXP MED, V205, P1409, DOI 10.1084/jem.20071859; HOMBERG JC, 1984, CLIN EXP IMMUNOL, V55, P561; Huang R, 2016, DISCOV MED, V21, P25; Hubscher SG, 2014, DIAGN HISTOPATHOL, V20, P109; Hudspeth K, 2016, J AUTOIMMUN, V66, P40, DOI 10.1016/j.jaut.2015.08.011; HUPPERTZ HI, 1995, J HEPATOL, V23, P204, DOI 10.1016/0168-8278(95)80336-X; HUSSAIN MJ, 1994, J HEPATOL, V21, P816, DOI 10.1016/S0168-8278(94)80244-0; Ichiki Y, 2005, AUTOIMMUN REV, V4, P315, DOI 10.1016/j.autrev.2005.01.005; Illing PT, 2012, NATURE, V486, P554, DOI 10.1038/nature11147; Ito H, 2009, J IMMUNOL, V182, P391, DOI 10.4049/jimmunol.182.1.391; Iwamoto S, 2013, CLIN IMMUNOL, V146, P15, DOI 10.1016/j.clim.2012.10.008; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Jara P, 2009, NEW ENGL J MED, V361, P1359, DOI 10.1056/NEJMoa0901075; Jeffery HC, 2017, CLIN EXP IMMUNOL, V188, P394, DOI 10.1111/cei.12940; JENSEN DM, 1978, NEW ENGL J MED, V299, P1, DOI 10.1056/NEJM197807062990101; Jiang W, 2005, P NATL ACAD SCI USA, V102, P17077, DOI 10.1073/pnas.0504570102; John B, 2004, J IMMUNOL, V172, P5222, DOI 10.4049/jimmunol.172.9.5222; Kamijo A, 2011, HEPATOL RES, V41, P350, DOI 10.1111/j.1872-034X.2011.00773.x; KANEDA K, 1984, HEPATOLOGY, V4, P955, DOI 10.1002/hep.1840040529; Kasper HU, 2009, APMIS, V117, P779, DOI 10.1111/j.1600-0463.2009.02540.x; Katayama H, 2014, EUR J IMMUNOL, V44, P1622, DOI 10.1002/eji.201343883; Kido M, 2008, GASTROENTEROLOGY, V135, P1333, DOI 10.1053/j.gastro.2008.06.042; Kim KW, 2013, INVEST NEW DRUG, V31, P1071, DOI 10.1007/s10637-013-9939-6; Kirstein MM, 2015, HEPATOLOGY, V62, P1524, DOI 10.1002/hep.27983; Kisand K, 2010, J EXP MED, V207, P299, DOI 10.1084/jem.20091669; Kisand KE, 2001, J GASTROENTEROL, V36, P248, DOI 10.1007/s005350170111; Klatzmann D, 2015, NAT REV IMMUNOL, V15, P283, DOI 10.1038/nri3823; Klein I, 2006, J EXP MED, V203, P437, DOI 10.1084/jem.20051775; Klocke K, 2016, P NATL ACAD SCI USA, V113, pE2383, DOI 10.1073/pnas.1603892113; Konig IR, 2011, BRIEF BIOINFORM, V12, P253, DOI 10.1093/bib/bbq074; Kubitz R, 2015, CLIN REV ALLERG IMMU, V48, P273, DOI 10.1007/s12016-014-8457-4; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; KURIKI J, 1983, GASTROENTEROLOGY, V84, P596; Kurokohchi K, 2006, WORLD J GASTROENTERO, V12, P2523, DOI 10.3748/wjg.v12.i16.2523; Kwon HJ, 2014, HEPATOLOGY, V59, P1094, DOI 10.1002/hep.26748; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Lan RYZ, 2009, J AUTOIMMUN, V32, P43, DOI 10.1016/j.jaut.2008.11.001; Lan RY, 2006, HEPATOLOGY, V43, P729, DOI 10.1002/hep.21123; Landi A, 2014, J INTERF CYTOK RES, V34, P204, DOI 10.1089/jir.2013.0075; Lankisch TO, 2005, J PEDIATR-US, V146, P839, DOI 10.1016/j.jpeds.2005.01.050; Lapierre P, 2006, J AUTOIMMUN, V26, P82, DOI 10.1016/j.jaut.2005.11.001; Lapierre P, 2004, HEPATOLOGY, V39, P1066, DOI 10.1002/hep.20109; Lapierre P, 2012, HEPATOLOGY, V56, p702A; LASKIN CA, 1990, AM J MED, V89, P129, DOI 10.1016/0002-9343(90)90288-O; LECOEUR S, 1994, CHEM RES TOXICOL, V7, P434, DOI 10.1021/tx00039a023; Lecoeur S, 1996, MOL PHARMACOL, V50, P326; Lee S, 2016, J ALLERGY CLIN IMMUN, V137, P327, DOI 10.1016/j.jaci.2015.08.036; Leslie D, 2001, J CLIN INVEST, V108, P1417, DOI 10.1172/JCI14452; Liberal R, 2016, EXPERT REV GASTROENT, V10, P1163, DOI 10.1080/17474124.2016.1193004; Liberal R, 2015, HEPATOLOGY, V62, P863, DOI 10.1002/hep.27884; Liberal R, 2013, J AUTOIMMUN, V41, P126, DOI 10.1016/j.jaut.2012.11.002; Liberal R, 2012, HEPATOLOGY, V56, P677, DOI 10.1002/hep.25682; Lied GA, 2011, SCAND J IMMUNOL, V73, P1, DOI 10.1111/j.1365-3083.2010.02470.x; Lin JT, 2005, LAB INVEST, V85, P550, DOI 10.1038/labinvest.3700246; Liu XM, 2015, HEPATOLOGY, V62, P1563, DOI 10.1002/hep.28001; Lleo A, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0098-9; Lleo A, 2012, HEPATOLOGY, V55, P153, DOI 10.1002/hep.24630; LOEPER J, 1993, GASTROENTEROLOGY, V104, P203, DOI 10.1016/0016-5085(93)90853-5; LOHR H, 1991, CLIN EXP IMMUNOL, V84, P297; LOHR HF, 1994, LIVER, V14, P161; Lohse AW, 2015, J HEPATOL, V63, P971, DOI 10.1016/j.jhep.2015.06.030; LOHSE AW, 1995, Z GASTROENTEROL, V33, P527; LOHSE AW, 1990, HEPATOLOGY, V11, P24, DOI 10.1002/hep.1840110106; Longhi MS, 2008, HEPATOLOGY, V47, P581, DOI 10.1002/hep.22071; Longhi MS, 2007, HEPATOLOGY, V46, P472, DOI 10.1002/hep.21658; Longhi MS, 2006, J IMMUNOL, V176, P4484, DOI 10.4049/jimmunol.176.7.4484; Longhi MS, 2012, GASTROENTEROLOGY, V142, P1526, DOI 10.1053/j.gastro.2012.02.041; Longhi MS, 2011, HEPATOLOGY, V53, P536, DOI 10.1002/hep.24039; Longhi MS, 2009, HEPATOLOGY, V50, P130, DOI 10.1002/hep.22914; Longhi MS, 2005, J AUTOIMMUN, V25, P63, DOI 10.1016/j.jaut.2005.05.001; Longhi MS, 2004, J HEPATOL, V41, P31, DOI 10.1016/j.jhep.2004.03.008; Lu QJ, 2013, J AUTOIMMUN, V41, P1, DOI 10.1016/j.jaut.2013.01.010; Ma Y, 2002, HEPATOLOGY, V35, P658, DOI 10.1053/jhep.2002.32092; Ma Y, 2006, GASTROENTEROLOGY, V130, P868, DOI 10.1053/j.gastro.2005.12.020; MAGGIORE G, 1995, J PEDIATR GASTR NUTR, V20, P23, DOI 10.1097/00005176-199501000-00005; Maldonado RA, 2015, P NATL ACAD SCI USA, V112, pE156, DOI 10.1073/pnas.1408686111; MANNS M, 1990, HEPATOLOGY, V12, P127, DOI 10.1002/hep.1840120120; MANNS M, 1987, LANCET, V1, P292; Manns MP, 2010, HEPATOLOGY, V51, P2193, DOI 10.1002/hep.23584; Marquardt N, 2015, J IMMUNOL, V194, P2467, DOI 10.4049/jimmunol.1402756; MARTINI E, 1988, HEPATOLOGY, V8, P1662, DOI 10.1002/hep.1840080632; Martins EBG, 1996, HEPATOLOGY, V23, P988; Maruoka R, 2013, GASTROENTEROLOGY, V145, P209, DOI 10.1053/j.gastro.2013.03.011; Metushi IG, 2015, HEPATOLOGY, V61, P1332, DOI 10.1002/hep.27549; MEYERZUM.KH, 1972, CLIN EXP IMMUNOL, V11, P99; Miao Q, 2015, CLIN REV ALLERG IMMU, V48, P226, DOI 10.1007/s12016-014-8432-0; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Mieli-Vergani G, 2011, NAT REV GASTRO HEPAT, V8, P320, DOI 10.1038/nrgastro.2011.69; MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529; Monshi MM, 2013, HEPATOLOGY, V57, P727, DOI 10.1002/hep.26077; Montano-Loza AJ, 2009, LIVER TRANSPLANT, V15, P1254, DOI [10.1002/lt.21796, 10.1002/It.21796]; Morita M, 2010, AM J TRANSPLANT, V10, P40; NAGAKAWA J, 1990, GASTROENTEROLOGY, V99, P758, DOI 10.1016/0016-5085(90)90965-4; Nagasaki F, 2005, TOHOKU J EXP MED, V206, P173, DOI 10.1620/tjem.206.173; Navarro V, 2006, LIVER TRANSPLANT, V12, P652, DOI 10.1002/lt.20680; NEUBERGER J, 1981, GUT, V22, P669, DOI 10.1136/gut.22.8.669; Neumeister P, 2000, LANCET, V355, P1334, DOI 10.1016/S0140-6736(00)02120-6; NISHIGUCHI S, 1992, ANN INTERN MED, V116, P21, DOI 10.7326/0003-4819-116-1-21; Nobili V, 2003, PEDIATR INFECT DIS J, V22, P387; Norris S, 1998, J HEPATOL, V28, P84, DOI 10.1016/S0168-8278(98)80206-7; O'Leary Jacqueline G, 2008, Clin Infect Dis, V46, pe12, DOI 10.1086/524082; Obermayer-Straub P, 2001, GASTROENTEROLOGY, V121, P668, DOI 10.1053/gast.2001.27103; Obermayer-Straub P, 2000, CLIN REV ALLERG IMMU, V18, P167, DOI 10.1385/CRIAI:18:2:167; Oertelt S, 2006, J IMMUNOL, V177, P1655, DOI 10.4049/jimmunol.177.3.1655; Ogawa S, 2000, J GASTROEN HEPATOL, V15, P69, DOI 10.1046/j.1440-1746.2000.02044.x; Ohta A, 2000, J IMMUNOL, V165, P956, DOI 10.4049/jimmunol.165.2.956; Oo YH, 2012, J HEPATOL, V57, P6, DOI 10.1016/j.jhep.2012.04.005; Oo YH, 2010, J IMMUNOL, V184, P2886, DOI 10.4049/jimmunol.0901216; Oo YH, 2012, J HEPATOL, V57, P1044, DOI 10.1016/j.jhep.2012.07.008; Palmer MT, 2010, NAT IMMUNOL, V11, P36, DOI 10.1038/ni.1802; Pando M, 1999, HEPATOLOGY, V30, P1374, DOI 10.1002/hep.510300611; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Peiseler M, 2012, J HEPATOL, V57, P125, DOI 10.1016/j.jhep.2012.02.029; Pensati L, 1997, GASTROENTEROLOGY, V113, P1384, DOI 10.1053/gast.1997.v113.pm9322534; Peterson P, 2008, NAT REV IMMUNOL, V8, P948, DOI 10.1038/nri2450; Portmann B, 2012, HISTOPATHOLOGY, V60, P236, DOI 10.1111/j.1365-2559.2011.03853.x; Purswani S, 2014, IMMUNOLOGY, V143, P70; Qin BD, 2013, J GASTROEN HEPATOL, V28, P543, DOI 10.1111/jgh.12040; Rajoriya N, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00400; Ramsey C, 2002, HUM MOL GENET, V11, P397, DOI 10.1093/hmg/11.4.397; RODMAN JS, 1976, AM J MED, V60, P941, DOI 10.1016/0002-9343(76)90564-7; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; Rudner LA, 2003, J IMMUNOL, V170, P4785, DOI 10.4049/jimmunol.170.9.4785; SCHLAAK JF, 1993, CLIN EXP IMMUNOL, V94, P168; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; SCULLY LJ, 1993, DIGEST DIS SCI, V38, P744, DOI 10.1007/BF01316809; SENALDI G, 1992, ARCH DIS CHILD, V67, P1447, DOI 10.1136/adc.67.12.1447; Simpson N, 2006, TRANSPLANTATION, V82, P1298, DOI 10.1097/01.tp.0000241104.58576.e6; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Skoog SM, 2002, AM J GASTROENTEROL, V97, P1568, DOI 10.1016/S0002-9270(02)04107-2; Sneller MC, 1997, BLOOD, V89, P1341, DOI 10.1182/blood.V89.4.1341; Snowden JA, 1997, BRIT J DERMATOL, V137, P130; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; STINISSEN P, 1995, J IMMUNOL, V154, P4883; Strassburg CP, 1996, GASTROENTEROLOGY, V111, P1576, DOI 10.1016/S0016-5085(96)70020-3; Strettell MDJ, 1997, GASTROENTEROLOGY, V112, P2028, DOI 10.1053/gast.1997.v112.pm9178696; Su GL, 2002, AM J PHYSIOL-GASTR L, V283, pG256, DOI 10.1152/ajpgi.00550.2001; Suzuki Y, 2004, J GASTROENTEROL, V39, P649, DOI 10.1007/s00535-003-1360-z; Takaba H, 2015, CELL, V163, P975, DOI 10.1016/j.cell.2015.10.013; Tamaki S, 2005, CLIN IMMUNOL, V117, P280, DOI 10.1016/j.clim.2005.08.010; Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139; Tang R, 2017, GUT IN PRESS; Taubert R, 2014, J HEPATOL, V61, P1106, DOI 10.1016/j.jhep.2014.05.034; Tay SS, 2014, J IMMUNOL, V193, P2087, DOI 10.4049/jimmunol.1400037; Tedesco D, 2017, HEPATOLOGY, V65, P661, DOI 10.1002/hep.28894; Tian ZG, 2013, HEPATOLOGY, V57, P1654, DOI 10.1002/hep.26115; TIEGS G, 1992, J CLIN INVEST, V90, P196, DOI 10.1172/JCI115836; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Toda G, 1997, J HEPATOL, V26, P1207, DOI 10.1016/S0168-8278(97)80453-9; Tordjmann T, 1998, LIVER, V18, P391; TOYONAGA T, 1994, P NATL ACAD SCI USA, V91, P614, DOI 10.1073/pnas.91.2.614; Tsuda M, 2010, J AUTOIMMUN, V35, P265, DOI 10.1016/j.jaut.2010.06.017; van Gerven NMF, 2015, GENES IMMUN, V16, P247, DOI 10.1038/gene.2014.82; van Gerven NMF, 2016, J GASTROINTEST LIVER, V25, P9, DOI 10.15403/jgld.2014.1121.251.hpe; van Gerven NMF, 2014, SCAND J GASTROENTERO, V49, P1245, DOI 10.3109/00365521.2014.946083; van Gerven NMF, 2013, J HEPATOL, V58, P141, DOI 10.1016/j.jhep.2012.09.009; Vazquez-Garcia MN, 1998, J HEPATOL, V28, P985, DOI 10.1016/S0168-8278(98)80347-4; VENTO S, 1995, LANCET, V346, P608, DOI 10.1016/S0140-6736(95)91438-2; VENTO S, 1991, LANCET, V337, P1183, DOI 10.1016/0140-6736(91)92858-Y; Verdonk RC, 2007, INFLAMM BOWEL DIS, V13, P703, DOI 10.1002/ibd.20087; VERGANI D, 1980, NEW ENGL J MED, V303, P66, DOI 10.1056/NEJM198007103030202; Vergani D, 2004, J HEPATOL, V41, P677, DOI 10.1016/j.jhep.2004.08.002; VERGANI D, 1987, LIVER, V7, P307; VERGANI GM, 1979, CLIN EXP IMMUNOL, V38, P16; Vieira CL, 2013, WORLD J HEPATOL, V5, P152, DOI 10.4254/wjh.v5.i3.152; Villasenor J, 2005, IMMUNOL REV, V204, P156, DOI 10.1111/j.0105-2896.2005.00246.x; Vogel A, 2002, HEPATOLOGY, V35, P126, DOI 10.1053/jhep.2002.30084; Waldenstrom J, 1950, DTSCH GES VERDAU STO, V15, P113; Walker LSK, 2011, NAT REV IMMUNOL, V11, P852, DOI 10.1038/nri3108; Wang J, 2006, J HEPATOL, V44, P446, DOI 10.1016/j.jhep.2005.08.015; Wang QX, 2016, J AUTOIMMUN, V66, P98, DOI 10.1016/j.jaut.2015.10.006; Warren A, 2006, HEPATOLOGY, V44, P1182, DOI 10.1002/hep.21378; Washington MK, 2012, MACSWEENS PATHOLOGY, P467; WATANABE Y, 1987, CLIN EXP IMMUNOL, V67, P105; Webb GJ, 2016, J AUTOIMMUN, V66, P25, DOI 10.1016/j.jaut.2015.08.016; Webb GJ, 2015, J AUTOIMMUN, V64, P42, DOI 10.1016/j.jaut.2015.07.004; Webb G, 2016, HEPATOLOGY, V64, p702A; Webb G, 2016, J HEPATOL, V64, P1190, DOI 10.1016/j.jhep.2016.01.017; Weiler-Normann C, 2013, J HEPATOL, V58, P529, DOI 10.1016/j.jhep.2012.11.010; WEN L, 1990, LANCET, V336, P1527, DOI 10.1016/0140-6736(90)93306-A; WEN L, 1992, CLIN EXP IMMUNOL, V89, P78; Werner M, 2008, SCAND J GASTROENTERO, V43, P1232, DOI 10.1080/00365520802130183; Wies I, 2000, LANCET, V355, P1510, DOI 10.1016/S0140-6736(00)02166-8; Wong GW, 2017, LIVER INT, V37, P449, DOI 10.1111/liv.13236; Worth A, 2006, BRIT J HAEMATOL, V133, P124, DOI 10.1111/j.1365-2141.2006.05993.x; Wynn TA, 2004, IMMUNOL REV, V201, P156, DOI 10.1111/j.0105-2896.2004.00176.x; Xing LZ, 2014, NAT MED, V20, P1043, DOI 10.1038/nm.3645; Yachida M, 1999, CLIN EXP IMMUNOL, V116, P140; Yang CY, 2014, HEPATOLOGY, V59, P1944, DOI 10.1002/hep.26979; Yang SY, 2015, SCIENCE, V348, P589, DOI 10.1126/science.aaa7017; Yasumi Y, 2007, HEPATOL RES, V37, P248, DOI 10.1111/j.1872-034X.2007.00040.x; Ye F, 2009, IMMUNOL LETT, V122, P198, DOI 10.1016/j.imlet.2009.01.005; Yoshizawa K, 1999, HUM IMMUNOL, V60, P806, DOI 10.1016/S0198-8859(99)00058-0; Yoshizawa K, 2005, J HEPATOL, V42, P578, DOI 10.1016/j.jhep.2004.12.019; You Q, 2010, TOXICOL LETT, V194, P79, DOI 10.1016/j.toxlet.2010.02.009; Yuksel M, 2016, CLIN EXP IMMUNOL, V186, P164, DOI 10.1111/cei.12843; Yuksel M, 2015, HEPATOLOGY, V62, P1536, DOI 10.1002/hep.27998; Zachou K., 2004, J AUTOIMMUNE DIS, V1, P2, DOI DOI 10.1186/1740-2557-1-2; Zachou K, 2011, J HEPATOL, V55, P636, DOI 10.1016/j.jhep.2011.01.012; Zauli D, 1997, HEPATOLOGY, V25, P1105, DOI 10.1002/hep.510250510; Zhang WC, 2009, HEPATOLOGY, V49, P545, DOI 10.1002/hep.22651; Zhao L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018909; Zhernakova A, 2010, AM J HUM GENET, V86, P970, DOI 10.1016/j.ajhg.2010.05.004; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154; Zwolak A, 2016, HUM EXP TOXICOL, V35, P799, DOI 10.1177/0960327115607078	325	13	13	4	10	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						247	292		10.1146/annurev-pathol-020117-043534			46	Pathology	Pathology	BJ3ZK	WOS:000424631200011	29140756				2019-10-28	
S	Pizzi, M; Margolskee, E; Inghirami, G	Galli, SJ	Abbas, AK; Aster, JC		Pizzi, Marco; Margolskee, Elizabeth; Inghirami, Giorgio	Galli, SJ		Pathogenesis of Peripheral T Cell Lymphoma	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						peripheral T cell lymphoma; PTCL; signaling pathways; genetic defects; microenvironment; cell transformation; cell progression; target therapies	EPSTEIN-BARR-VIRUS; GRANULAR LYMPHOCYTIC-LEUKEMIA; JAK-STAT PATHWAY; DEATH-LIGAND 1; LYMPHOPROLIFERATIVE DISORDERS; HEMATOLOGICAL MALIGNANCIES; ACTIVATING MUTATIONS; C-MYC; PROLYMPHOCYTIC LEUKEMIA; LYMPHOBLASTIC LYMPHOMA	Peripheral T cell lymphomas (PTCLs) are highly heterogeneous tumors, displaying distinct clinical and biological features. The pathogenesis and normal counterpart of such entities have been elusive for decades. Recent studies have, however, disclosed key mechanisms of peripheral T cell transformation, including (a) the deregulation of signaling pathways controlling T cell development, differentiation, and maturation; (b) the remodeling of the peritumor microenvironment; and (c) the virus-mediated rewiring of T cell biology. Uncovering the molecular mechanisms of T cell transformation will help elucidate the peculiar clinical and pathological features of each PTCL entity and will lead to the characterization of novel antitumor therapies. These therapies will combine conventional and new-generation compounds with immune-modulating agents to ablate both the neoplastic cells and the tumor-supporting microenvironment. This review addresses the pathogenic mechanisms of PTCLs, with special attention paid to novel therapeutic strategies for the clinical management of such aggressive tumors.	[Pizzi, Marco; Margolskee, Elizabeth; Inghirami, Giorgio] Cornell Univ, Dept Pathol & Lab Med, Weill Cornell Med Coll, New York, NY 10021 USA; [Pizzi, Marco] Univ Padua, Dept Med DIMED, Surg Pathol & Cytopathol Unit, I-35121 Padua, Italy; [Inghirami, Giorgio] Univ Torino, Dept Mol Biotechnol & Hlth Sci, I-10126 Turin, Italy; [Inghirami, Giorgio] Univ Torino, Ctr Expt Res & Med Studies CeRMS, I-10126 Turin, Italy; [Inghirami, Giorgio] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Inghirami, Giorgio] NYU, Sch Med, NYU Canc Ctr, New York, NY 10016 USA	Inghirami, G (reprint author), Cornell Univ, Dept Pathol & Lab Med, Weill Cornell Med Coll, New York, NY 10021 USA.; Inghirami, G (reprint author), Univ Torino, Dept Mol Biotechnol & Hlth Sci, I-10126 Turin, Italy.; Inghirami, G (reprint author), Univ Torino, Ctr Expt Res & Med Studies CeRMS, I-10126 Turin, Italy.; Inghirami, G (reprint author), NYU, Sch Med, Dept Pathol, New York, NY 10016 USA.; Inghirami, G (reprint author), NYU, Sch Med, NYU Canc Ctr, New York, NY 10016 USA.	ggi9001@med.cornell.edu		Margolskee, Elizabeth/0000-0001-8597-0636			Abate F, 2017, P NATL ACAD SCI USA, V114, P764, DOI 10.1073/pnas.1608839114; Adelaide J, 2006, LEUKEMIA, V20, P536, DOI 10.1038/sj.leu.2404104; Ambrogio C, 2009, CANCER RES, V69, P8611, DOI 10.1158/0008-5472.CAN-09-2655; Aster JC, 2012, J CLIN ONCOL, V30, P2418, DOI 10.1200/JCO.2012.42.0992; Attygalle AD, 2013, AM J SURG PATHOL, V37, P1456, DOI 10.1097/PAS.0b013e3182991415; Bellanger D, 2014, LEUKEMIA, V28, P417, DOI 10.1038/leu.2013.271; Boddicker RL, 2016, BLOOD, V128, P1234, DOI 10.1182/blood-2016-03-707141; Borowiak M, 2013, CARCINOGENESIS, V34, P2664, DOI 10.1093/carcin/bgt221; Bouchekioua A, 2014, LEUKEMIA, V28, P338, DOI 10.1038/leu.2013.157; Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-76; Bustelo X. R, 2014, SMALL GTPASES, V5; CAI QC, 2013, BLOOD, V122; Cairns RA, 2012, BLOOD, V119, P1901, DOI 10.1182/blood-2011-11-391748; Chanmee T, 2014, CANCERS, V6, P1670, DOI 10.3390/cancers6031670; Chen B., 2013, SCI WORLD J, V2013, P1, DOI DOI 10.1158/1078-0432.CCR-13-0855; CHEN J, 2017, CYTOKINE, V114, P3975, DOI DOI 10.1073/PNAS.1700682114; Chen Jiezhong, 2012, World J Virol, V1, P154, DOI 10.5501/wjv.v1.i6.154; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Chen Q, 2013, NATURE, V493, P561, DOI 10.1038/nature11742; Coude MM, 2015, ONCOTARGET, V6, P17698, DOI 10.18632/oncotarget.4131; Crescenzo R, 2015, CANCER CELL, V27, P516, DOI 10.1016/j.ccell.2015.03.006; Croft M, 2009, NAT REV IMMUNOL, V9, P271, DOI 10.1038/nri2526; de Leval L, 2007, BLOOD, V109, P4952, DOI 10.1182/blood-2006-10-055145; Deng CC, 2013, CLIN CANCER RES, V19, P22, DOI 10.1158/1078-0432.CCR-12-0290; Deplus R, 2013, EMBO J, V32, P645, DOI 10.1038/emboj.2012.357; dos Santos NR, 2007, BLOOD, V109, P3972, DOI 10.1182/blood-2006-09-048801; Dow LE, 2015, NAT BIOTECHNOL, V33, P390, DOI 10.1038/nbt.3155; Ehrentraut S, 2016, ONCOTARGET, V7, P34201, DOI 10.18632/oncotarget.9077; Fanale MA, 2007, DRUGS, V67, P333, DOI 10.2165/00003495-200767030-00002; Fasan A, 2013, LEUKEMIA, V27, P1598, DOI 10.1038/leu.2012.350; Feldman AL, 2011, BLOOD, V117, P915, DOI 10.1182/blood-2010-08-303305; Ferrajoli A, 2006, CURR CANCER DRUG TAR, V6, P671, DOI 10.2174/156800906779010227; Gallo RC, 2011, BEST PRACT RES CL HA, V24, P559, DOI 10.1016/j.beha.2011.09.012; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; Green MR, 2012, CLIN CANCER RES, V18, P1611, DOI 10.1158/1078-0432.CCR-11-1942; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Gupta M, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.844.844; Haney SL, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006334; Hanna S, 2013, CELL SIGNAL, V25, P1955, DOI 10.1016/j.cellsig.2013.04.009; Hasegawa H, 2005, BRIT J HAEMATOL, V128, P253, DOI 10.1111/j.1365-2141.2004.05289.x; Hu H, 2016, PLAST RECONSTR SURG, V137, P1659, DOI 10.1097/PRS.0000000000002010; Huang X, 2009, BLOOD, V114, P126; Inghirami G, 2015, IMMUNOL REV, V263, P124, DOI 10.1111/imr.12248; Inghirami G, 2011, SEMIN DIAGN PATHOL, V28, P190, DOI 10.1053/j.semdp.2011.03.002; Iqbal J, 2016, BLOOD REV, V30, P89, DOI 10.1016/j.blre.2015.08.003; Iqbal J, 2014, BLOOD, V123, P2915, DOI 10.1182/blood-2013-11-536359; Iqbal J, 2010, BLOOD, V115, P1026, DOI 10.1182/blood-2009-06-227579; Jackow CM, 1997, BLOOD, V89, P32; Jeong M, 2014, NAT GENET, V46, P17, DOI 10.1038/ng.2836; Jerez A, 2013, BLOOD, V122, P2453, DOI 10.1182/blood-2013-04-494930; Jiang L, 2015, NAT GENET, V47, P1061, DOI 10.1038/ng.3358; Jo JC, 2017, ANN HEMATOL, V96, P25, DOI 10.1007/s00277-016-2818-4; Josefowicz SZ, 2013, IMMUNOLOGY, V139, P299, DOI 10.1111/imm.12115; Kamstrup MR, 2014, LEUKEMIA LYMPHOMA, V55, P639, DOI 10.3109/10428194.2013.807510; Karwacz K, 2011, EMBO MOL MED, V3, P581, DOI 10.1002/emmm.201100165; Kasprzycka M, 2006, P NATL ACAD SCI USA, V103, P9964, DOI 10.1073/pnas.0603507103; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; Kelly JA, 2003, J EXP MED, V198, P79, DOI 10.1084/jem.20021548; Kiel MJ, 2014, BLOOD, V124, P1460, DOI 10.1182/blood-2014-03-559542; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim WY, 2009, ANN ONCOL, V20, P1688, DOI 10.1093/annonc/mdp056; Koo GC, 2012, CANCER DISCOV, V2, P591, DOI 10.1158/2159-8290.CD-12-0028; Kucuk C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7025; Laimer D, 2012, NAT MED, V18, P1699, DOI 10.1038/nm.2966; Lee H, 2012, P NATL ACAD SCI USA, V109, P7765, DOI 10.1073/pnas.1205132109; Lesokhin AM, 2016, J CLIN ONCOL, V34, P2698, DOI 10.1200/JCO.2015.65.9789; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lin ZX, 2012, MED ONCOL, V29, P3522, DOI 10.1007/s12032-012-0244-6; Ma GY, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0249-x; Ma H, 2017, INT J CLIN ONCOL, V22, P18, DOI 10.1007/s10147-016-1045-2; Macaire H, 2012, J BIOL CHEM, V287, P21357, DOI 10.1074/jbc.M112.340992; Malissen B, 2014, NAT IMMUNOL, V15, P790, DOI 10.1038/ni.2959; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; Miyauchi K, 2011, CANCER SCI, V102, P1236, DOI 10.1111/j.1349-7006.2011.01924.x; Nagata Y, 2016, BLOOD, V127, P596, DOI 10.1182/blood-2015-06-644948; Nagato T, 2017, CANCER IMMUNOL IMMUN, V66, P877, DOI 10.1007/s00262-017-1987-x; Nairismagi ML, 2016, LEUKEMIA, V30, P1311, DOI 10.1038/leu.2016.13; Nakayama T, 2008, ONCOGENE, V27, P3221, DOI 10.1038/sj.onc.1210984; Newton RH, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00151; Nguyen TB, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2016.122; NICKOLOFF BJ, 1994, BLOOD, V83, P2580; Nicolae A, 2016, LEUKEMIA, V30, P2245, DOI 10.1038/leu.2016.178; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Odejide O, 2014, BLOOD, V123, P1293, DOI 10.1182/blood-2013-10-531509; Ohgami RS, 2013, LEUKEMIA, V27, P2244, DOI 10.1038/leu.2013.104; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Pancewicz J, 2010, P NATL ACAD SCI USA, V107, P16619, DOI 10.1073/pnas.1010722107; Pechloff K, 2010, J EXP MED, V207, P1031, DOI 10.1084/jem.20092042; Perry AM, 2013, BLOOD, V122, P3599, DOI 10.1182/blood-2013-07-512830; Philip S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004040; Piccaluga PP, 2014, LEUKEMIA, V28, P1687, DOI 10.1038/leu.2014.50; Piccaluga PP, 2007, CANCER RES, V67, P10703, DOI 10.1158/0008-5472.CAN-07-1708; Piccaluga PP, 2011, SEMIN DIAGN PATHOL, V28, P234, DOI 10.1053/j.semdp.2011.02.007; Pike KA, 2016, CYTOKINE, V82, P52, DOI 10.1016/j.cyto.2015.12.025; Pizzi M, 2017, CURR OPIN HEMATOL, V24, P384, DOI 10.1097/MOH.0000000000000349; Polakowski N, 2014, J VIROL, V88, P13482, DOI 10.1128/JVI.02285-14; Roderick JE, 2014, BLOOD, V123, P1040, DOI 10.1182/blood-2013-08-522698; Rohr J, 2016, LEUKEMIA, V30, P1062, DOI 10.1038/leu.2015.357; Roncero AM, 2016, LEUKEMIA, V30, P94, DOI 10.1038/leu.2015.202; Rowe M, 2014, J VIROL, V88, P12065, DOI 10.1128/JVI.01431-14; Russler-Germain DA, 2014, CANCER CELL, V25, P442, DOI 10.1016/j.ccr.2014.02.010; Sabattini E, 2013, HAEMATOLOGICA, V98, pE81, DOI 10.3324/haematol.2013.084913; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Sakata-Yanagimoto M, 2015, INT J HEMATOL, V102, P523, DOI 10.1007/s12185-015-1738-8; Sakata-Yanagimoto M, 2014, NAT GENET, V46, P171, DOI 10.1038/ng.2872; Scarfo I, 2016, BLOOD, V127, P221, DOI 10.1182/blood-2014-12-614503; Schiefer Ana-Iris, 2015, Front Biosci (Schol Ed), V7, P226; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Sommer VH, 2004, LEUKEMIA, V18, P1288, DOI 10.1038/sj.leu.2403385; Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013; SUNDARAM M, 1993, GENETICS, V135, P765; Swerdlow SH, 2017, WHO CLASSIFICATION T; Tabbo F, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00041; Tabiasco J, 2003, J IMMUNOL, V170, P5993, DOI 10.4049/jimmunol.170.12.5993; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Takahara M, 2006, INT J CANCER, V119, P2775, DOI 10.1002/ijc.22139; Tiemessen MM, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001430; Tosello V, 2013, THER ADV HEMATOL, V4, P199, DOI 10.1177/2040620712471368; Vainchenker W, 2013, ONCOGENE, V32, P2601, DOI 10.1038/onc.2012.347; Vallois D, 2016, BLOOD, V128, P1490, DOI 10.1182/blood-2016-02-698977; Vaque JP, 2014, BLOOD, V123, P2034, DOI 10.1182/blood-2013-05-504308; Velusamy T, 2014, BLOOD, V124, P3768, DOI 10.1182/blood-2014-07-588434; Waldmann TA, 2017, ANNU REV IMMUNOL, V35, P533, DOI 10.1146/annurev-immunol-110416-120628; Wang C, 2015, BLOOD, V126, P1741, DOI 10.1182/blood-2015-05-644591; Wang J, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-50; Watatani Y, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.2927.2927; WEISSMAN IL, 1982, CURR TOP MICROBIOL, V98, P103; Wilcox RA, 2016, AM J HEMATOL, V91, P113, DOI 10.1002/ajh.24203; Wilcox RA, 2009, BLOOD, V114, P2149, DOI 10.1182/blood-2009-04-216671; Wright DG, 2016, ONCOTARGET, V7, P1687, DOI 10.18632/oncotarget.6424; Yang LB, 2015, NAT REV CANCER, V15, P152, DOI 10.1038/nrc3895; Yeh CH, 2016, P NATL ACAD SCI USA, V113, P6731, DOI 10.1073/pnas.1601537113; Yoo HY, 2016, HAEMATOLOGICA, V101, pE271, DOI 10.3324/haematol.2016.148015; Younes A, 2010, NEW ENGL J MED, V363, P1812, DOI 10.1056/NEJMoa1002965; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Ysebaert L, 2014, CURR OPIN ONCOL, V26, P463, DOI 10.1097/CCO.0000000000000114; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zhang Q, 2014, J IMMUNOL, V192, P2913, DOI 10.4049/jimmunol.1302951; Zhang W, 2017, BIOMARK RES, V5, DOI 10.1186/s40364-017-0081-z; Zhao TJ, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00247; Zhao WL, 2004, LAB INVEST, V84, P1512, DOI 10.1038/labinvest.3700145; Zheng Z, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0088-y	149	6	6	0	2	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						293	320		10.1146/annurev-pathol-020117-043821			28	Pathology	Pathology	BJ3ZK	WOS:000424631200012	29414251				2019-10-28	
S	Russell, JO; Monga, SP	Galli, SJ	Abbas, AK; Aster, JC		Russell, Jacquelyn O.; Monga, Satdarshan P.	Galli, SJ		Wnt/beta-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						hepatocyte; cholangiocyte; liver stem cell; regeneration; zonation; hepatocellular cancer; hepatoblastoma; liver tumors	HEPATIC STELLATE-CELLS; SINUSOIDAL ENDOTHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; BETA-CATENIN; RAT-LIVER; KUPFFER CELLS; STEM-CELLS; PROGENITOR CELLS; OVAL CELLS; IN-VITRO	The liver is an organ that performs a multitude of functions, and its health is pertinent and indispensable to survival. Thus, the cellular and molecular machinery driving hepatic functions is of utmost relevance. The Wnt signaling pathway is one such signaling cascade that enables hepatic homeostasis and contributes to unique hepatic attributes such as metabolic zonation and regeneration. The Wnt/beta-catenin pathway plays a role in almost every facet of liver biology. Furthermore, its aberrant activation is also a hallmark of various hepatic pathologies. In addition to its signaling function, beta-catenin also plays a role at adherens junctions. Wnt/beta-catenin signaling also influences the function of many different cell types. Due to this myriad of functions, Wnt/beta-catenin signaling is complex, context-dependent, and highly regulated. In this review, we discuss the Wnt/beta-catenin signaling pathway, its role in cell-cell adhesion and liver function, and the cell type-specific roles of Wnt/beta-catenin signaling as it relates to liver physiology and pathobiology.	[Russell, Jacquelyn O.; Monga, Satdarshan P.] Univ Pittsburgh, Sch Med, Div Expt Pathol, Dept Pathol, Pittsburgh, PA 15261 USA; [Monga, Satdarshan P.] Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Dept Med, Pittsburgh, PA 15261 USA; [Monga, Satdarshan P.] Univ Pittsburgh, Sch Med, Pittsburgh Liver Res Ctr, Pittsburgh, PA 15261 USA	Monga, SP (reprint author), Univ Pittsburgh, Sch Med, Div Expt Pathol, Dept Pathol, Pittsburgh, PA 15261 USA.; Monga, SP (reprint author), Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Dept Med, Pittsburgh, PA 15261 USA.; Monga, SP (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh Liver Res Ctr, Pittsburgh, PA 15261 USA.	smonga@pitt.edu		Monga, Satdarshan/0000-0002-8437-3378	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA204586]; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [T32 EB001026]; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [F31 DK115017, R01 DK100287, R01 DK095498, R01 DK062277]		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Acebron SP, 2016, TRENDS CELL BIOL, V26, P956, DOI 10.1016/j.tcb.2016.07.009; Acebron SP, 2014, MOL CELL, V54, P663, DOI 10.1016/j.molcel.2014.04.014; Akhurst B, 2001, HEPATOLOGY, V34, P519, DOI 10.1053/jhep.2001.26751; Alison M, 1997, J HEPATOL, V26, P343, DOI 10.1016/S0168-8278(97)80051-7; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Apte U, 2008, HEPATOLOGY, V47, P288, DOI 10.1002/hep.21973; Apte U, 2009, AM J PATHOL, V175, P1056, DOI 10.2353/ajpath.2009.080976; Audard V, 2007, J PATHOL, V212, P345, DOI 10.1002/path.2169; Austinat M, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-21; Banziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049; Barbera JPM, 2000, DEVELOPMENT, V127, P2433; Barrott JJ, 2011, P NATL ACAD SCI USA, V108, P12752, DOI 10.1073/pnas.1006437108; Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Behari J, 2010, EXPERT REV GASTROENT, V4, P745, DOI 10.1586/EGH.10.74; Behari J, 2010, AM J PATHOL, V176, P744, DOI 10.2353/ajpath.2010.090667; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bell Danielle, 2017, Gene Expression, V17, P141, DOI 10.3727/105221616X693639; Benhamouche S, 2006, DEV CELL, V10, P759, DOI 10.1016/j.devcel.2006.03.015; Berg T, 2010, J SURG RES, V164, P276, DOI 10.1016/j.jss.2009.10.033; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bort R, 2006, DEV BIOL, V290, P44, DOI 10.1016/j.ydbio.2005.11.006; Bossard P, 1998, DEVELOPMENT, V125, P4909; Boulter L, 2012, NAT MED, V18, P572, DOI 10.1038/nm.2667; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Calmont A, 2006, DEV CELL, V11, P339, DOI 10.1016/j.devcel.2006.06.015; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Carpentier R, 2011, GASTROENTEROLOGY, V141, P1432, DOI 10.1053/j.gastro.2011.06.049; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Cheng JH, 2008, AM J PHYSIOL-GASTR L, V294, pG39, DOI 10.1152/ajpgi.00263.2007; Cieply B, 2009, HEPATOLOGY, V49, P821, DOI 10.1002/hep.22695; Clotman F, 2002, DEVELOPMENT, V129, P1819; Coffinier C, 2002, DEVELOPMENT, V129, P1829; Colnot S, 2004, P NATL ACAD SCI USA, V101, P17216, DOI 10.1073/pnas.0404761101; Corbett L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142794; Cordi S, 2016, DIFFERENTIATION, V91, P42, DOI 10.1016/j.diff.2016.02.001; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; De Zanger R, 1982, SINUSOIDAL LIVER CEL, P6976; Decaens T, 2008, HEPATOLOGY, V47, P247, DOI 10.1002/hep.21952; Delgado E, 2015, J HEPATOL, V62, P380, DOI 10.1016/j.jhep.2014.10.021; Ding BS, 2010, NATURE, V468, P310, DOI 10.1038/nature09493; Dixon LJ, 2013, COMPR PHYSIOL, V3, P785, DOI 10.1002/cphy.c120026; Dong S, 2015, CLIN LAB, V61, P537, DOI 10.7754/Clin.Lab.2014.141127; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; Duncan AW, 2009, GASTROENTEROLOGY, V137, P466, DOI 10.1053/j.gastro.2009.05.044; Espanol-Suner R, 2012, GASTROENTEROLOGY, V143, P1564, DOI 10.1053/j.gastro.2012.08.024; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; EVARTS RP, 1989, CANCER RES, V49, P1541; Fausto N, 2003, MECH DEVELOP, V120, P117, DOI 10.1016/S0925-4773(02)00338-6; Fitamant J, 2015, CELL REP, V10, P1692, DOI 10.1016/j.celrep.2015.02.027; FOX ES, 1987, INFECT IMMUN, V55, P2962; Friedman SL, 2008, PHYSIOL REV, V88, P125, DOI 10.1152/physrev.00013.2007; Fuentealba LC, 2007, CELL, V131, P980, DOI 10.1016/j.cell.2007.09.027; GARD AL, 1985, J NEUROIMMUNOL, V8, P359, DOI 10.1016/S0165-5728(85)80073-4; Ge WS, 2014, MOL MED REP, V9, P2145, DOI 10.3892/mmr.2014.2099; GEBHARDT R, 1992, PHARMACOL THERAPEUT, V53, P275, DOI 10.1016/0163-7258(92)90055-5; Go GW, 2014, CELL METAB, V19, P209, DOI 10.1016/j.cmet.2013.11.023; Goessling W, 2008, DEV BIOL, V320, P161, DOI 10.1016/j.ydbio.2008.05.526; Gordillo M, 2015, DEVELOPMENT, V142, P2094, DOI 10.1242/dev.114215; Gougelet A, 2014, HEPATOLOGY, V59, P2344, DOI 10.1002/hep.26924; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Harada N, 2004, CANCER RES, V64, P48, DOI 10.1158/0008-5472.CAN-03-2123; Harada N, 2002, CANCER RES, V62, P1971; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hinson Jack A, 2010, Handb Exp Pharmacol, P369, DOI 10.1007/978-3-642-00663-0_12; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; Huch M, 2015, CELL, V160, P299, DOI 10.1016/j.cell.2014.11.050; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Hunter MP, 2007, DEV BIOL, V308, P355, DOI 10.1016/j.ydbio.2007.05.028; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Isse K, 2013, HEPATOLOGY, V57, P1632, DOI 10.1002/hep.26131; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jiang F, 2006, J HEPATOL, V45, P401, DOI 10.1016/j.jhep.2006.03.016; Ju C, 2002, CHEM RES TOXICOL, V15, P1504, DOI 10.1021/tx0255976; JUNGERMANN K, 1989, PHYSIOL REV, V69, P708; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; KEMPKA G, 1988, EXP CELL RES, V176, P38, DOI 10.1016/0014-4827(88)90118-8; Kim H, 2015, CELL REP, V11, P1151, DOI 10.1016/j.celrep.2015.04.048; Kim NG, 2009, P NATL ACAD SCI USA, V106, P5165, DOI 10.1073/pnas.0810185106; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Kinoshita M, 2010, J HEPATOL, V53, P903, DOI 10.1016/j.jhep.2010.04.037; KLEIN A, 1994, J LEUKOCYTE BIOL, V55, P248; Knolle PA, 1997, CLIN EXP IMMUNOL, V107, P555, DOI 10.1046/j.1365-2249.1997.d01-959.x; Knolle PA, 2016, CELL MOL IMMUNOL, V13, P347, DOI 10.1038/cmi.2016.5; Koch A, 1999, CANCER RES, V59, P269; Koch S, 2015, CELL, V163, P1225, DOI 10.1016/j.cell.2015.10.029; Kojima Takashi, 2003, Medical Electron Microscopy, V36, P157, DOI 10.1007/s00795-003-0220-5; Kolios G, 2006, WORLD J GASTROENTERO, V12, P7413, DOI 10.3748/wjg.v12.i46.7413; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Kordes C, 2008, BIOCHEM BIOPH RES CO, V367, P116, DOI 10.1016/j.bbrc.2007.12.085; Kordes C, 2013, J CLIN INVEST, V123, P1874, DOI 10.1172/JCI66027; Lee DH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11961; Lehwald N, 2012, GASTROENTEROLOGY, V143, P754, DOI 10.1053/j.gastro.2012.05.048; Lehwald N, 2011, GASTROENTEROLOGY, V141, P707, DOI 10.1053/j.gastro.2011.04.051; Lemaigre FP, 2009, GASTROENTEROLOGY, V137, P62, DOI 10.1053/j.gastro.2009.03.035; Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009; Limaye PB, 2008, LAB INVEST, V88, P865, DOI 10.1038/labinvest.2008.56; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu HJ, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001249; Lokmane L, 2008, DEVELOPMENT, V135, P2777, DOI 10.1242/dev.023010; Lorent K, 2004, DEVELOPMENT, V131, P5753, DOI 10.1242/dev.01411; Lu WY, 2015, NAT CELL BIOL, V17, P971, DOI 10.1038/ncb3203; Luedde T, 2014, GASTROENTEROLOGY, V147, P765, DOI 10.1053/j.gastro.2014.07.018; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; MAGNUSSON S, 1989, BIOCHEM J, V257, P651, DOI 10.1042/bj2570651; Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370; Mclin VA, 2007, DEVELOPMENT, V134, P2207, DOI 10.1242/dev.001230; MEYER DH, 1990, BIOCHEM BIOPH RES CO, V171, P1122, DOI 10.1016/0006-291X(90)90801-S; Michalopoulos GK, 2015, GASTROENTEROLOGY, V149, P876, DOI 10.1053/j.gastro.2015.08.004; Michalopoulos GK, 2005, HEPATOLOGY, V41, P535, DOI 10.1002/hep.20600; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Micsenyi A, 2004, GASTROENTEROLOGY, V126, P1134, DOI 10.1053/j.gastro.2003.12.047; Monga SP, 2015, GASTROENTEROLOGY, V148, P1294, DOI 10.1053/j.gastro.2015.02.056; Monga SPS, 2006, CELL TISSUE RES, V323, P71, DOI 10.1007/s00441-005-0045-8; Monga SPS, 2003, GASTROENTEROLOGY, V124, P202, DOI 10.1053/gast.2003.50000; Monga SPS, 2001, HEPATOLOGY, V33, P1098, DOI 10.1053/jhep.2001.23786; Monga SPS, 2002, CANCER RES, V62, P2064; Nejak-Bowen Kari, 2017, Gene Expression, V17, P219, DOI 10.3727/105221617X695762; Nejak-Bowen Kari, 2008, Organogenesis, V4, P92; Nejak-Bowen KN, 2010, HEPATOLOGY, V51, P1603, DOI 10.1002/hep.23538; Nelsen CJ, 2001, CANCER RES, V61, P8564; Nguyen-Lefebvre AT, 2015, J ENZYMOL METAB, V1, P101; Nishita M, 2010, TRENDS CELL BIOL, V20, P346, DOI 10.1016/j.tcb.2010.03.001; Ober EA, 2006, NATURE, V442, P688, DOI 10.1038/nature04888; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Okabe H, 2016, HEPATOLOGY, V64, P1652, DOI 10.1002/hep.28774; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Pellicoro A, 2014, NAT REV IMMUNOL, V14, P181, DOI 10.1038/nri3623; Pez F, 2013, J HEPATOL, V59, P1107, DOI 10.1016/j.jhep.2013.07.001; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Planas-Paz L, 2016, NAT CELL BIOL, V18, P467, DOI 10.1038/ncb3337; Purcell R, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-96; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; RAMADORI G, 1990, VIRCHOWS ARCH B, V59, P349, DOI 10.1007/BF02899424; Raynaud P, 2011, INT J BIOCHEM CELL B, V43, P245, DOI 10.1016/j.biocel.2009.07.020; Rivera CA, 2001, AM J PHYSIOL-GASTR L, V281, pG200; Rocha AS, 2015, CELL REP, V13, P1757, DOI 10.1016/j.celrep.2015.10.049; Rodrigo-Torres D, 2014, HEPATOLOGY, V60, P1367, DOI 10.1002/hep.27078; Rossi JM, 2001, GENE DEV, V15, P1998, DOI 10.1101/gad.904601; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Sastre-Perona Ana, 2012, Front Endocrinol (Lausanne), V3, P31, DOI 10.3389/fendo.2012.00031; Schaub JR, 2014, CELL REP, V8, P933, DOI 10.1016/j.celrep.2014.07.003; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schuppan D, 2013, J GASTROEN HEPATOL, V28, P68, DOI 10.1111/jgh.12212; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Sekine S, 2006, HEPATOLOGY, V43, P817, DOI 10.1002/hep.21131; Shin S, 2015, GASTROENTEROLOGY, V148, P192, DOI 10.1053/j.gastro.2014.09.039; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Son S, 2009, CELL BIOL, V131, P411; Stanulovic VS, 2007, HEPATOLOGY, V45, P433, DOI 10.1002/hep.21456; Suzuki T, 2006, MOL CELL BIOL, V26, P6149, DOI 10.1128/MCB.00298-06; Tabibian JH, 2013, COMPR PHYSIOL, V3, P541, DOI 10.1002/cphy.c120019; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tan XP, 2008, HEPATOLOGY, V47, P1667, DOI 10.1002/hep.22225; Tan XP, 2006, GASTROENTEROLOGY, V131, P1561, DOI 10.1053/j.gastro.2006.08.042; Tan XP, 2005, GASTROENTEROLOGY, V129, P285, DOI 10.1053/j.gastro.2005.04.013; Tanimizu N, 2009, MOL BIOL CELL, V20, P2486, DOI 10.1091/mbc.E08-02-0177; Tao J, 2016, HEPATOLOGY, V65, P158; Tao JY, 2016, HEPATOLOGY, V64, P1587, DOI 10.1002/hep.28601; Tao JY, 2014, GASTROENTEROLOGY, V147, P690, DOI 10.1053/j.gastro.2014.05.004; Tarlow BD, 2014, CELL STEM CELL, V15, P605, DOI 10.1016/j.stem.2014.09.008; Tarlow BD, 2014, HEPATOLOGY, V60, P278, DOI 10.1002/hep.27084; Thompson MD, 2010, AM J PATHOL, V177, P1812, DOI 10.2353/ajpath.2010.100173; Thorgeirsson SS, 1996, FASEB J, V10, P1249; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Uhrig A, 2005, J LEUKOCYTE BIOL, V77, P626, DOI 10.1189/jlb.0604332; Van Hul N, 2011, AM J PATHOL, V179, P1839, DOI 10.1016/j.ajpath.2011.06.042; Vinas O, 2003, HEPATOLOGY, V38, P919, DOI 10.1053/jhep.2003.50392; Vincan E, 2008, CLIN EXP METASTAS, V25, P657, DOI 10.1007/s10585-008-9156-4; Vinyoles M, 2014, MOL CELL, V53, P444, DOI 10.1016/j.molcel.2013.12.010; WAKE K, 1971, AM J ANAT, V132, P429, DOI 10.1002/aja.1001320404; Wang B, 2015, NATURE, V524, P180, DOI 10.1038/nature14863; Wang X, 2003, P NATL ACAD SCI USA, V100, P11881, DOI 10.1073/pnas.1734199100; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Wells JM, 2000, DEVELOPMENT, V127, P1563; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wickline ED, 2013, NEOPLASIA, V15, P421, DOI 10.1593/neo.122098; Wickline ED, 2011, J HEPATOL, V55, P1256, DOI 10.1016/j.jhep.2011.03.014; WISSE E, 1970, J ULTRA MOL STRUCT R, V31, P125, DOI 10.1016/S0022-5320(70)90150-4; Xiang S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035180; Xu C, 2009, CELL CYCLE, V8, P4032, DOI 10.4161/cc.8.24.10111; Xu J, 2013, NATL VITAL STAT REP, V64, P1; Yang J, 2015, AM J PATHOL, V185, P2194, DOI 10.1016/j.ajpath.2015.04.021; Yang J, 2014, HEPATOLOGY, V60, P964, DOI 10.1002/hep.27082; Yanger K, 2014, CELL STEM CELL, V15, P340, DOI 10.1016/j.stem.2014.06.003; Yanger K, 2013, GENE DEV, V27, P719, DOI 10.1101/gad.207803.112; Yeh TH, 2010, HEPATOLOGY, V52, P1410, DOI 10.1002/hep.23801; Yimlamai D, 2014, CELL, V157, P1324, DOI 10.1016/j.cell.2014.03.060; Yin CY, 2013, J CLIN INVEST, V123, P1902, DOI 10.1172/JCI66369; YOKOI Y, 1984, HEPATOLOGY, V4, P709, DOI 10.1002/hep.1840040425; Zaher H, 1998, TOXICOL APPL PHARM, V152, P193, DOI 10.1006/taap.1998.8501; Zeng G, 2006, EXP CELL RES, V312, P3620, DOI 10.1016/j.yexcr.2006.08.003; Zhai L, 2004, J BIOL CHEM, V279, P33220, DOI 10.1074/jbc.M403407200; Zhang XF, 2010, HEPATOLOGY, V52, P954, DOI 10.1002/hep.23747; Zucman-Rossi J, 2007, ONCOGENE, V26, P774, DOI 10.1038/sj.onc.1209824	205	27	30	6	22	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						351	378		10.1146/annurev-pathol-020117-044010			28	Pathology	Pathology	BJ3ZK	WOS:000424631200014	29125798	Green Accepted			2019-10-28	
J	Latham, B; Harrison, M; Graves, D				Latham, Bruce; Harrison, Michael; Graves, Debra			Pathology enters its golden era	PATHOLOGY			English	Editorial Material									[Latham, Bruce; Harrison, Michael; Graves, Debra] Royal Coll Pathologists Australasia, Durham Hall,207 Albion St, Darlinghurst, NSW 2010, Australia; [Latham, Bruce] Pathwest Fiona Stanley Hosp Network Lab, Dept Anat Pathol, Murdoch, WA, Australia; [Harrison, Michael] Sullivan Nicolaides Pathol, Indooroopilly, Qld, Australia	Graves, D (reprint author), Royal Coll Pathologists Australasia, Durham Hall,207 Albion St, Darlinghurst, NSW 2010, Australia.	debrag@rcpa.edu.au					Conyers RAJ, 2006, PATHOLOGY PROFESSION, P33; Delahunt B, 2009, PATHOLOGY, V41, P103, DOI 10.1080/00313020802587741; GUNZ FW, 1982, PATHOLOGY, V14, P1; Gunz FW, 1984, PATHOLOGY, V16, P231; Hackett E, 1969, PATHOLOGY, V1, pi; Lee CS, 2008, PATHOLOGY, V40, P1, DOI 10.1080/00313020701757106; Magarey F, 1977, PATHOLOGY, V9, P279; Nelson David Selwyn, 1990, PATHOLOGY, V22, P51; NELSON DS, 1986, PATHOLOGY, V18, P1; Vincent PC, 2000, PATHOLOGY, V32, P165; Vincent PC, 1997, PATHOLOGY, V29, P1; Vincent PC, 1996, PATHOLOGY, V28, P1; VINCENT PC, 1991, PATHOLOGY, V23, P80; WARREN BA, 1993, PATHOLOGY, V25, pU1; Warren BA, 1988, PATHOLOGY, V20, P209; Winton R, 1982, NATURE THINGS HIST R, P48	17	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JAN	2018	50	1					1	2		10.1016/j.pathol.2017.10.001			2	Pathology	Pathology	FU6MY	WOS:000423967900001					2019-10-28	
J	Delahunt, B; Neill, B				Delahunt, Brett; Neill, Belinda			Pathology 50 years on	PATHOLOGY			English	Editorial Material									[Delahunt, Brett; Neill, Belinda] Royal Coll Pathologists Australasia, Pathol Editorial Off, Durham Hall, Surry Hills, NSW, Australia; [Delahunt, Brett] Univ Otago, Wellington Sch Med & Hlth Sci, Dept Pathol & Mol Med, POB 7343, Wellington, New Zealand	Delahunt, B (reprint author), Univ Otago, Wellington Sch Med & Hlth Sci, Dept Pathol & Mol Med, POB 7343, Wellington, New Zealand.	brett.delahunt@otago.ac.nz					Asa SL, 2018, PATHOLOGY, V50, P111, DOI 10.1016/j.pathol.2017.09.003; Colebatch AJ, 2018, PATHOLOGY, V50, P16, DOI 10.1016/j.pathol.2017.09.002; Eble JN, 2018, PATHOLOGY, V50, P24, DOI 10.1016/j.pathol.2017.09.005; Egevad L, 2018, PATHOLOGY, V50, P60, DOI 10.1016/j.pathol.2017.09.008; Li SY, 2018, PATHOLOGY, V50, P74, DOI 10.1016/j.pathol.2017.09.006; Ma HY, 2018, PATHOLOGY, V50, P49, DOI 10.1016/j.pathol.2017.09.004; Rakha EA, 2018, PATHOLOGY, V50, P100, DOI 10.1016/j.pathol.2017.10.005; Schaefer IM, 2018, PATHOLOGY, V50, P37, DOI 10.1016/j.pathol.2017.07.007; Ulbright TM, 2018, PATHOLOGY, V50, P88, DOI 10.1016/j.pathol.2017.07.013; World Health Organization, 2016, CLASS TUM UR SYST MA; Young RH, 2018, PATHOLOGY, V50, P5, DOI 10.1016/j.pathol.2017.09.007	11	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JAN	2018	50	1					3	4		10.1016/j.pathol.2017.10.002			2	Pathology	Pathology	FU6MY	WOS:000423967900002		Bronze			2019-10-28	
J	Young, RH				Young, Robert H.			Ovarian sex cord-stromal tumours and their mimics	PATHOLOGY			English	Review						Ovary; tumours; sex cord-stromal	SERTOLI-LEYDIG-CELL; PEUTZ-JEGHERS SYNDROME; CLINICOPATHOLOGICAL ANALYSIS; GRANULOSA-CELL; HETEROLOGOUS ELEMENTS; ANNULAR TUBULES; PREGNANCY; DISTINCTION; MUTATIONS; DIAGNOSIS	Sex cord-stromal tumours of the ovary include many of the most morphologically intriguing ovarian neoplasms and albeit many of them are rare, they factor into the differential diagnosis more often than their frequency might suggest. The most common malignant form, the adult granulosa cell tumour, may grossly simulate various surface epithelial neoplasms. Microscopically, confusion with endometrioid carcinoma may occur because the cords and microfollicles of the granulosa cell tumour may be mimicked by endometrioid carcinoma and the latter may have pale nuclei with nuclear grooves. Thorough sampling generally resolves this differential and if not immunohistochemistry aids. Although the adult granulosa cell tumour typically has cells with scant cytoplasm in some cases the tumour cells are luteinised and others have cells with abundant pale cytoplasm. A reticulum stain may be of great aid in indicating whether cells of the type just noted are of granulosa or theca nature. Variations in the morphology of the juvenile variant of granulosa cell tumour that can be diagnostically challenging include those that have a macronodular pattern with scant follicular differentiation, those with marked sclerosis, and those that are unusually pleomorphic. The uncommon but histologically varied Sertoli-Leydig cell tumour is considered, emphasis being placed on the most recently described variant, the retiform pattern, with its potential to mimic surface epithelial neoplasms and even mixed mesodermal tumours. Considering the usual young age of the patient may be paramount in making this tumour come to the mind of the pathologist. The rare pure Sertoli cell tumour is briefly noted as is the sex cord tumour with annular tubules, well known because of its association in some cases with Peutz-Jeghers syndrome. Most do not have that association, however, but have their own interesting features including a greater than average risk, among sex cord stromal tumours, of nodal metastasis and progesterone production, and an occasional development from them of an otherwise typical Sertoli cell tumour. The stromal family includes the common fibroma which is challenging when it is cellular with some mitotic activity and the approach to such neoplasms is reviewed. Emphasis in the consideration of thecoma is placed on its typical cytological features and the overlap with what may be seen in some adult granulosa cell tumours. The review concludes with three fascinating pure stromal tumours all described within the last several decades: the sclerosing stromal tumour, the unusual luteinised thecoma associated with sclerosing peritonitis and the microcystic stromal tumour. The first is sometimes misdiagnosed when pure stromal neoplasms of other types are vascular and may have pseudolobules and it is essential that the pseudolobules of the sclerosing stromal tumour contain a haphazard admixture of fibroblasts and weakly luteinised cells. The remarkable tumours associated with peritonitis exhibit brisk mitotic activity but appear not to have a metastatic potential; they can cause significant problems because of the sclerosing peritonitis. The microcystic stromal tumour may mimic a steroid cell tumour or thecoma but unlike them is inhibin and calretinin negative, and stains for CD10 and beta-catenin. It often shows bizarre nuclei atypia but limited mitotic activity and appears to be clinically benign on the basis of still limited experience.	[Young, Robert H.] Harvard Med Sch, Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA	Young, RH (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA.	rhyoung@partners.org					Ahmed E, 1999, AM J SURG PATHOL, V23, P1089, DOI 10.1097/00000478-199909000-00012; Bennett JA, 2015, INT J GYNECOL PATHOL, V34, P357, DOI 10.1097/PGP.0000000000000163; Burandt E, 2014, AM J SURG PATHOL, V38, P1023, DOI 10.1097/PAS.0000000000000252; Burandt E, 2014, AM J SURG PATHOL, V38, P239, DOI 10.1097/PAS.0000000000000100; Dallenbach-Hellweg G, 2001, INT J GYNECOL PATHOL, V20, P289, DOI 10.1097/00004347-200107000-00014; Ganesan R, 2011, INT J GYNECOL PATHOL, V30, P452, DOI 10.1097/PGP.0b013e318214b17f; Irving JA, 2008, AM J SURG PATHOL, V32, P581, DOI 10.1097/PAS.0b013e31815c186f; Irving JA, 2006, AM J SURG PATHOL, V30, P929, DOI 10.1097/00000478-200608000-00001; Irving JA, 2015, AM J SURG PATHOL, V39, P1420, DOI 10.1097/PAS.0000000000000482; Irving JA, 2009, AM J SURG PATHOL, V33, P367, DOI 10.1097/PAS.0b013e31818479c3; Kiyokawa T, 2006, AM J SURG PATHOL, V30, P277; McCluggage WG, 2007, AM J SURG PATHOL, V31, P592; McCluggage WG, 2013, AM J SURG PATHOL, V37, P1450, DOI 10.1097/PAS.0b013e31828e4f55; Morris JM, 1958, ENDOCRINE PATHOLOGY; Oliva E, 2005, AM J SURG PATHOL, V29, P143, DOI 10.1097/01.pas.0000149692.21205.9c; PRAT J, 1982, CANCER, V50, P2465, DOI 10.1002/1097-0142(19821201)50:11<2465::AID-CNCR2820501135>3.0.CO;2-U; Ravishankar S, 2016, INT J SURG PATHOL, V24, P269, DOI 10.1177/1066896915620663; Schultz KAP, 2011, GYNECOL ONCOL, V122, P246, DOI 10.1016/j.ygyno.2011.03.024; Schulz KAP, 2017, GYNECOL ONCOL; Scully R., 1996, TUMORS OVARY MALDEVE; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Staats PN, 2008, AM J SURG PATHOL, V32, P1273, DOI 10.1097/PAS.0b013e3181666a5f; SZYFELBEIN WM, 1995, AM J SURG PATHOL, V19, P21, DOI 10.1097/00000478-199501000-00003; YOUNG RH, 1982, CANCER, V50, P1384, DOI 10.1002/1097-0142(19821001)50:7<1384::AID-CNCR2820500726>3.0.CO;2-5; Young RH, 2001, SEMIN DIAGN PATHOL, V18, P161; YOUNG RH, 1994, AM J SURG PATHOL, V18, P1102, DOI 10.1097/00000478-199411000-00004; YOUNG RH, 1982, AM J SURG PATHOL, V6, P513, DOI 10.1097/00000478-198209000-00003; YOUNG RH, 1982, CANCER, V50, P2448, DOI 10.1002/1097-0142(19821201)50:11<2448::AID-CNCR2820501133>3.0.CO;2-T; YOUNG RH, 1983, AM J SURG PATHOL, V7, P755, DOI 10.1097/00000478-198307080-00005; YOUNG RH, 1983, INT J GYNECOL PATHOL, V1, P325, DOI 10.1097/00004347-198301040-00002; YOUNG RH, 1984, AM J SURG PATHOL, V8, P575, DOI 10.1097/00000478-198408000-00002; YOUNG RH, 1983, INT J GYNECOL PATHOL, V2, P227, DOI 10.1097/00004347-198303000-00001; YOUNG RH, 1985, AM J SURG PATHOL, V9, P543, DOI 10.1097/00000478-198508000-00001; YOUNG RH, 1994, INT J GYNECOL PATHOL, V13, P302, DOI 10.1097/00004347-199410000-00003; YOUNG RH, 1984, GYNECOL ONCOL, V18, P181, DOI 10.1016/0090-8258(84)90026-X; Young RH, 2016, MAGIC MOL ILLUSTRATE; Young RH, 2007, PATHOLOGY, V39, P6, DOI 10.1080/00313020601153281; Young RH, 2017, INT J GYNECOL PATHOL, V36, P2, DOI 10.1097/PGP.0000000000000371; Young RH, 2014, SEMIN DIAGN PATHOL, V31, P382, DOI 10.1053/j.semdp.2014.08.001; ZALOUDEK C, 1982, AM J SURG PATHOL, V6, P503, DOI 10.1097/00000478-198209000-00002	40	7	8	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JAN	2018	50	1					5	15		10.1016/j.pathol.2017.09.007			11	Pathology	Pathology	FU6MY	WOS:000423967900003	29132723	Bronze			2019-10-28	
J	Colebatch, AJ; Scolyer, RA				Colebatch, Andrew J.; Scolyer, Richard A.			Trajectories of premalignancy during the journey from melanocyte to melanoma	PATHOLOGY			English	Review						Melanoma; pathology; naevus; diagnosis; tumour progression; carcinogenesis	TERT PROMOTER MUTATIONS; CUTANEOUS MALIGNANT-MELANOMA; DYSPLASTIC NEVUS; ULTRAVIOLET-RADIATION; GENETIC EVOLUTION; BRAF MUTATIONS; SUN EXPOSURE; ASSOCIATION; HETEROGENEITY; PATHOGENESIS	A stepwise progression from melanocytic precursors to cutaneous melanoma is a well-established model, based on decades of careful observation and morphological analysis. The steps identified are benign melanocytic naevus, dysplastic naevus, 'radial growth phase' melanoma (including melanoma in situ) and 'vertical growth phase' melanoma (also termed tumourigenic melanoma). Recent genomic data have refined the understanding of the steps of melanoma development and their relationship to one another. These data support the existence of dysplastic naevi as distinct lesions; suggest the importance of clonal dynamics in the precursor steps of melanoma; and confirm the carcinogenic role of ultraviolet radiation throughout early melanoma development and progression. In this review, the steps of melanoma development and progression are summarised and discussed in the context of recent genomic studies. This new understanding of melanoma pathogenesis that has been facilitated through careful correlation of morphological and molecular features will allow the identification and development of robust biomarkers to assist in more accurate diagnosis and prognostication of melanocytic tumours.	[Colebatch, Andrew J.; Scolyer, Richard A.] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Camperdown, NSW 2050, Australia; [Colebatch, Andrew J.; Scolyer, Richard A.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia; [Colebatch, Andrew J.; Scolyer, Richard A.] Univ Sydney, Sydney Med Sch, Discipline Pathol, Sydney, NSW, Australia	Colebatch, AJ (reprint author), Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Camperdown, NSW 2050, Australia.	andrew.colebatch@health.nsw.gov.au		Scolyer, Richard/0000-0002-8991-0013			Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; BARNHILL RL, 1991, CANCER, V67, P3157, DOI 10.1002/1097-0142(19910615)67:12<3157::AID-CNCR2820671237>3.0.CO;2-6; Bastian BC, 2000, CANCER RES, V60, P1968; BLACK WC, 1988, CANCER, V62, P163, DOI 10.1002/1097-0142(19880701)62:1<163::AID-CNCR2820620126>3.0.CO;2-N; Borah S, 2015, SCIENCE, V347, P1006, DOI 10.1126/science.1260200; Brochez L, 2002, J PATHOL, V196, P459, DOI 10.1002/path.1061; Chen S, 2010, AM J DERMATOPATH, V32, P858, DOI 10.1097/DAD.0b013e3181dc0fda; CLARK WH, 1978, ARCH DERMATOL, V114, P732, DOI 10.1001/archderm.114.5.732; CLARK WH, 1969, CANCER RES, V29, P705; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; CLEMENTE C, 1991, HUM PATHOL, V22, P313, DOI 10.1016/0046-8177(91)90078-4; Colebatch AJ, 2016, ONCOTARGET, V7, P66569, DOI 10.18632/oncotarget.11892; Cook MG, 1996, HISTOPATHOLOGY, V28, P497, DOI 10.1046/j.1365-2559.1996.d01-464.x; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DURAY PH, 1987, ARCH DERMATOL, V123, P80, DOI 10.1001/archderm.123.1.80; Elder DE, 2016, PATHOLOGY, V48, P147, DOI 10.1016/j.pathol.2015.12.002; ELDER DE, 1980, CANCER, V46, P1787, DOI 10.1002/1097-0142(19801015)46:8<1787::AID-CNCR2820460816>3.0.CO;2-S; Elmore JG, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2813; Gerami P, 2009, AM J SURG PATHOL, V33, P1783, DOI 10.1097/PAS.0b013e3181ba6db6; Giglia-Mari G, 2003, HUM MUTAT, V21, P217, DOI 10.1002/humu.10179; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; Glatz K, 2010, AM J DERMATOPATH, V32, P643, DOI 10.1097/DAD.0b013e3181d7ce6f; Green A, 2007, INT J CANCER, V120, P1116, DOI 10.1002/ijc.22453; Green AC, 2012, J CLIN ONCOL, V30, P1462, DOI 10.1200/JCO.2011.38.8561; Griewank KG, 2014, JNCI-J NATL CANCER I, P106, DOI DOI 10.1093/JNCI/DJU246; Han DL, 2013, J CLIN ONCOL, V31, P4387, DOI 10.1200/JCO.2013.50.1114; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbst K, 2016, CANCER RES, V76, P4765, DOI 10.1158/0008-5472.CAN-15-3476; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Heidenreich B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4401; HOLMAN CDJ, 1983, JNCI-J NATL CANCER I, V71, P651; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; HUSAIN Z, 1991, CANCER RES, V51, P4964; Kakavand H, 2014, PATHOLOGY, V46, P193, DOI 10.1097/PAT.0000000000000077; LANCASTER H O, 1956, Med J Aust, V43, P1082; LEW RA, 1983, J DERMATOL SURG ONC, V9, P981, DOI 10.1111/j.1524-4725.1983.tb01051.x; Lin WM, 2015, J AM ACAD DERMATOL, V72, P54, DOI 10.1016/j.jaad.2014.09.028; Magro CM, 2006, MODERN PATHOL, V19, pS41, DOI 10.1038/modpathol.3800516; Mar VJ, 2013, CLIN CANCER RES, V19, P4589, DOI 10.1158/1078-0432.CCR-13-0398; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; McGovern VJ, 1983, MELANOMA HISTOLOGICA; McKinnon JG, 2003, CANCER, V98, P1223, DOI 10.1002/cncr.11624; Melamed RD, 2017, J INVEST DERMATOL, V137, P905, DOI 10.1016/j.jid.2016.11.017; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mroz EA, 2013, CANCER-AM CANCER SOC, V119, P3034, DOI 10.1002/cncr.28150; Murugaesu N, 2015, CANCER DISCOV, V5, P821, DOI 10.1158/2159-8290.CD-15-0412; O'Rourke EA, 2013, AM J DERMATOPATH, V35, P30, DOI 10.1097/DAD.0b013e3182587ef8; Oliveria SA, 2006, ARCH DIS CHILD, V91, P131, DOI 10.1136/adc.2005.086918; Plasmeijer EI, 2017, J INVEST DERMATOL, V137, P2017, DOI 10.1016/j.jid.2017.03.040; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; RHODES AR, 1983, J AM ACAD DERMATOL, V9, P563, DOI 10.1016/S0190-9622(83)70171-4; Sanborn JZ, 2015, P NATL ACAD SCI USA, V112, P10995, DOI 10.1073/pnas.1508074112; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shitara D, 2015, BRIT J DERMATOL, V173, P671, DOI 10.1111/bjd.13829; Tsao H, 2003, ARCH DERMATOL, V139, P282, DOI 10.1001/archderm.139.3.282; Tuthill RJ, 2007, SEMIN ONCOL, V34, P467, DOI 10.1053/j.seminoncol.2007.09.014; Unna PG, 1893, BERL KLIN WOCHENSCHR, V30, P14; Vilain RE, 2016, PATHOLOGY, V48, P108, DOI 10.1016/j.pathol.2015.12.009; Viros A, 2014, NATURE, V511, P478, DOI 10.1038/nature13298; Wang Y, 2009, P NATL ACAD SCI USA, V106, P6279, DOI 10.1073/pnas.0812401106; Worret WI, 1998, AM J DERMATOPATH, V20, P135, DOI 10.1097/00000372-199804000-00005; Yeh I, 2013, JNCI-J NATL CANCER I, V105, P917, DOI 10.1093/jnci/djt119; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930	65	6	6	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JAN	2018	50	1					16	23		10.1016/j.pathol.2017.09.002			8	Pathology	Pathology	FU6MY	WOS:000423967900004	29132722				2019-10-28	
J	Eble, JN; Delahunt, B				Eble, John N.; Delahunt, Brett			Emerging entities in renal cell neoplasia: thyroid-like follicular renal cell carcinoma and multifocal oncocytoma-like tumours associated with oncocytosis	PATHOLOGY			English	Review						Kidney; carcinoma	OF-THE-LITERATURE; HOGG-DUBE-SYNDROME; MITOCHONDRIAL-DNA MUTATIONS; MOUSE MONOCLONAL-ANTIBODY; HEREDITARY LEIOMYOMATOSIS; EPITHELIAL NEOPLASMS; PAPILLARY CARCINOMA; DIAGNOSTIC UTILITY; ATROPHIC KIDNEY; CYSTIC-DISEASE	The list of accepted entities of renal cell neoplasia has burgeoned since the turn of the century through recognition of rare tumour types and the discovery of genetic mutations driving renal neoplasia syndromes. This growth has not finished and in this report we present examples of each of these types which were not included in the 2016 World Health Organization classification of renal neoplasia, but are candidates for inclusion in the next edition of the classification. Thyroid-like follicular renal cell carcinoma is a rare tumour type with a distinctive microscopic appearance resembling follicles of the thyroid gland. Thirty-nine cases have been described and the findings have been reasonably consistent. Oncocytoma-like tumours associated with oncocytosis arise as a result of somatic mutations in the mitochondrial genome. The differential diagnosis is mainly with the renal lesions of the Birt-Hogg-Dube syndrome, which is the result of germline mutations in the folliculin gene. Patients with oncocytoma-like tumours associated with oncocytosis are at great risk of developing renal failure as the proliferating lesions replace the renal parenchyma. Oncocytoma-like tumours have never been found to metastasise.	[Eble, John N.] Indiana Univ Hlth, Cent Pathol Lab, Indianapolis, IN USA; [Delahunt, Brett] Univ Otago, Wellington Sch Med & Hlth Sci, Dept Pathol & Mol Med, Wellington, New Zealand	Eble, JN (reprint author), IU Hlth Cent Pathol Lab, 350 W 11th St, Indianapolis, IN 46202 USA.	jeble@iupui.edu					Ac'h S, 2003, UROL INT, V70, P241, DOI 10.1159/000068760; Adamy A, 2011, J UROLOGY, V185, P795, DOI 10.1016/j.juro.2010.10.068; Alessandrini L, 2012, VIRCHOWS ARCH, V461, P345, DOI 10.1007/s00428-012-1298-8; Amin MB, 2009, AM J SURG PATHOL, V33, P393, DOI 10.1097/PAS.0b013e31818cb8f5; Amin MB, 1997, AM J SURG PATHOL, V21, P1, DOI 10.1097/00000478-199701000-00001; Ariaratnam N, 2009, ABDOM IMAGING, V34, P261, DOI 10.1007/s00261-008-9375-9; Bainvcaretse J, 1996, ROZHL CHIR, V75, P573; Bender BU, 1997, NEPHROL DIAL TRANSPL, V12, P1034, DOI 10.1093/ndt/12.5.1034; Benusiglio PR, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0163-z; Berens S, 2014, PATHOLOGE, V35, P83, DOI 10.1007/s00292-013-1772-3; Bhatt K, 2014, J UROLOGY, V192, P1225, DOI 10.1016/j.juro.2014.07.018; BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; Cameron BR, 2003, J OTOLARYNGOL, V32, P319, DOI 10.2310/7070.2003.11429; Chen F, 2016, MOL CLIN ONCOL, V4, P143, DOI 10.3892/mco.2015.682; Chen TS, 2003, INT J SURG PATHOL, V11, P325, DOI 10.1177/106689690301100415; Chen X, 2016, Zhonghua Bing Li Xue Za Zhi, V45, P687, DOI 10.3760/cma.j.issn.0529-5807.2016.10.004; Chen YB, 2014, AM J SURG PATHOL, V38, P627, DOI 10.1097/PAS.0000000000000163; Cimino-Mathews A, 2011, AM J SURG PATHOL, V35, P757, DOI 10.1097/PAS.0b013e3182147fa8; Cossu Rocca P, 2008, MODERN PATHOL, V21, P498; Cudazzo E, 1998, Minerva Chir, V53, P769; DAVILA RM, 1988, ARCH PATHOL LAB MED, V112, P51; Dawane R, 2015, AM J CLIN PATHOL, V144, P796, DOI 10.1309/AJCP6P0STAAHOTTG; Dechet CB, 1999, J UROLOGY, V162, P40, DOI 10.1097/00005392-199907000-00010; Delahunt B, 1997, MODERN PATHOL, V10, P537; Delahunt B, 2001, HUM PATHOL, V32, P590, DOI 10.1053/hupa.2001.24984; Dhillon J, 2014, DIAGN CYTOPATHOL, V42, P273, DOI 10.1002/dc.22930; Dhillon J, 2011, HUM PATHOL, V42, P146, DOI 10.1016/j.humpath.2010.01.026; Dimashkieh HH, 2004, ARCH PATHOL LAB MED, V128, P817; Dong L, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003314; El Jammal Abbas, 2015, Ugeskr Laeger, V177, P122; Farkas LM, 1999, NEPHROL DIAL TRANSPL, V14, P2262, DOI 10.1093/ndt/14.9.2262; Val-Bernal JF, 2011, PATHOL RES PRACT, V207, P733, DOI 10.1016/j.prp.2011.09.002; Fiske J, 2005, UROLOGY, V66, P132011, DOI 10.1016/j.urlology.2005.06.122; Fukuzawa Shigeki, 1993, Acta Urologica Japonica, V39, P163; Furuya M, 2016, CLIN GENET, V90, P403, DOI 10.1111/cge.12807; Gasparre G, 2008, HUM MOL GENET, V17, P986, DOI 10.1093/hmg/ddm371; Ghaouti M, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0186-8; Giunchi F, 2016, PATHOLOGY, V48, P41, DOI 10.1016/j.pathol.2015.11.009; Gobbo S, 2010, AM J SURG PATHOL, V34, P620, DOI 10.1097/PAS.0b013e3181d73293; Gonzalez Resina Raquel, 2007, Arch Esp Urol, V60, P802; Gryn A, 2014, PROG UROL, V24, P138, DOI 10.1016/j.purol.2013.05.011; Gudbjartsson T, 2005, BJU INT, V96, P1275, DOI 10.1111/j.1464-410X.2005.05827.x; GUPTA RK, 1991, ACTA CYTOL, V35, P742; HARA M, 1982, J UROLOGY, V128, P576, DOI 10.1016/S0022-5347(17)53052-9; HARACH HR, 1988, HISTOPATHOLOGY, V13, P43, DOI 10.1111/j.1365-2559.1988.tb02002.x; Hartman TR, 2009, ONCOGENE, V28, P1594, DOI 10.1038/onc.2009.14; Hes O, 2016, WHO CLASSIFICATION T, P43; Hes O, 2014, ANN DIAGN PATHOL, V18, P82, DOI 10.1016/j.anndiagpath.2013.12.003; Hu YH, 2012, J CLIN PATHOL, V65, P254, DOI 10.1136/jclinpath-2011-200508; Huang JT, 2009, INT J CLIN EXP PATHO, V2, P583; HUNT HA, 1983, J UROLOGY, V129, P1220, DOI 10.1016/S0022-5347(17)52651-8; Insabato L, 2003, TUMORI, V89, P99; ISRAELI RS, 1995, UROLOGY, V46, P873, DOI 10.1016/S0090-4295(99)80362-8; Ito Katsuhiro, 2017, Hinyokika Kiyo, V63, P145, DOI 10.14989/ActaUrolJap_63_4_145; Ivey BS, 2010, CAN J UROL, V17, P5131; Janssen M, 2016, UROLOGE, V55, P941, DOI 10.1007/s00120-016-0058-9; Jennette JC, 2015, HEPTINSTALLS PATHOLO, P91; Jung SJ, 2006, AM J SURG PATHOL, V30, P411; KADESKY KT, 1993, J UROLOGY, V150, P1227, DOI 10.1016/S0022-5347(17)35737-3; Katz DS, 1996, AM J KIDNEY DIS, V27, P579, DOI 10.1016/S0272-6386(96)90170-5; Khoja HA, 2012, INT J SURG PATHOL, V20, P411, DOI 10.1177/1066896911429942; Klomp JA, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-59; Kluger N, 2010, BRIT J DERMATOL, V162, P527, DOI 10.1111/j.1365-2133.2009.09517.x; LABERKE HG, 1983, PATHOL RES PRACT, V176, P284, DOI 10.1016/S0344-0338(83)80018-1; Lam KY, 2001, EUR J SURG ONCOL, V27, P631, DOI 10.1053/ejso.2001.1203; Lang M, 2015, MODERN PATHOL, V28, P1458, DOI 10.1038/modpathol.2015.101; Leroy X, 2001, ARCH PATHOL LAB MED, V125, P683; Li CC, 2015, ANN CLIN LAB SCI, V45, P707; Li X, 2013, XIAN DAI MI NIAO WAI, V18, P162; Lin YZ, 2014, ONCOL LETT, V7, P1796, DOI 10.3892/ol.2014.2027; Makis W, 2011, NUCL MED MOLEC IMAG, V45, P308, DOI 10.1007/s13139-011-0090-z; Malde S, 2013, CASE REP PATHOL, DOI 10.1155/2013/687427; Martin SM, 2010, ACTAS UROL ESP, V34, P390, DOI 10.1016/j.acuro.2009.09.002; Matei DV, 2003, ANTICANCER RES, V23, P561; Mayr JA, 2008, CLIN CANCER RES, V14, P2270, DOI 10.1158/1078-0432.CCR-07-4131; Mazzucchelli R, 2008, APMIS, V116, P934, DOI 10.1111/j.1600-0463.2008.01090.x; MEAD GO, 1990, CLIN IMAG, V14, P231, DOI 10.1016/0899-7071(90)90080-U; Menendez CL, 2007, VIRCHOWS ARCH, V450, P365, DOI 10.1007/s00428-006-0324-0; Moisin L, 1998, Rontgenpraxis, V51, P43; MOURA ACF, 1982, J UROLOGY, V127, P311, DOI 10.1016/S0022-5347(17)53757-X; Muscara MJ, 2017, INT J SURG PATHOL, V25, P73, DOI 10.1177/1066896916662153; NADASDY T, 1994, HUM PATHOL, V25, P22, DOI 10.1016/0046-8177(94)90166-X; Nagashima Y, 2005, PATHOL INT, V55, P210, DOI 10.1111/j.1440-1827.2005.01813.x; Nath V, 2015, CASE REP PATHOL, DOI 10.1155/2015/701413; Nonaka D, 2008, MODERN PATHOL, V21, P192, DOI 10.1038/modpathol.3801002; Oji Y, 2003, CANCER SCI, V94, P606, DOI 10.1111/j.1349-7006.2003.tb01490.x; Ordonez NG, 2012, ADV ANAT PATHOL, V19, P401, DOI 10.1097/PAP.0b013e318271a382; Oshiro Y, 2014, PATHOL INT, V64, P478, DOI 10.1111/pin.12193; Ozcan A, 2011, MODERN PATHOL, V24, P751, DOI 10.1038/modpathol.2011.3; Pavlovich CP, 2005, J UROLOGY, V173, P1482, DOI 10.1097/01.ju.0000154629.45832.30; PerezOrdonez B, 1997, AM J SURG PATHOL, V21, P871, DOI 10.1097/00000478-199708000-00001; Ploussard G, 2009, PROG UROL, V19, P142, DOI 10.1016/j.purol.2008.10.001; Robboy SJ, 2009, INT J GYNECOL PATHOL, V28, P405, DOI 10.1097/PGP.0b013e3181a27777; Sanchez-Chapado Manuel, 1995, Archivos Espanoles de Urologia, V48, P909; Seyedzadeh A, 2003, PEDIATR NEPHROL, V18, P1286, DOI 10.1007/s00467-003-1257-3; SHAH I, 1983, UROLOGY, V22, P314, DOI 10.1016/S0090-4295(83)80027-2; Sharma SG, 2010, APPL IMMUNOHISTO M M, V18, P494, DOI 10.1097/PAI.0b013e3181e78ff8; Shin M, 2014, JPN J RADIOL, V32, P556, DOI 10.1007/s11604-014-0334-9; SIDDINS M, 1995, AUST NZ J SURG, V65, P216, DOI 10.1111/j.1445-2197.1995.tb00611.x; Sydor A, 2009, CLIN NEPHROL, V71, P433; Tang JQ, 2013, LINCHUANG YU SHIYAN, V29, P447; Teh BT, 1998, GENE CHROMOSOME CANC, V21, P260, DOI 10.1002/(SICI)1098-2264(199803)21:3<260::AID-GCC12>3.0.CO;2-T; Tickoo SK, 1999, AM J SURG PATHOL, V23, P1094, DOI 10.1097/00000478-199909000-00013; Tomoda C, 2003, THYROID, V13, P291, DOI 10.1089/105072503321582105; Toriyama A, 2014, HISTOPATHOLOGY, V65, P465, DOI 10.1111/his.12405; Toro JR, 1999, ARCH DERMATOL, V135, P1195, DOI 10.1001/archderm.135.10.1195; Tosi AL, 2012, TUMORI, V98, P79; Trpkov K, 2016, AM J SURG PATHOL, V40, P865, DOI 10.1097/PAS.0000000000000617; Tryggvason G, 2001, SCAND J UROL NEPHROL, V35, P150; Tweed EJ, 2011, CLIN KIDNEY J, V4, P126, DOI 10.1093/ndtplus/sfr019; Ulrich S, 1999, PATHOLOGE, V20, P189, DOI 10.1007/s002920050343; Vernadakis S, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-119; VIALE G, 1989, AM J SURG PATHOL, V13, P1034, DOI 10.1097/00000478-198912000-00005; Vicens RA, 2014, ABDOM IMAGING, V39, P388, DOI 10.1007/s00261-013-0053-1; Pena AV, 2007, PROG UROL, V17, P997; Volavsek M, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-108; WARFEL KA, 1982, J UROLOGY, V127, P1179, DOI 10.1016/S0022-5347(17)54285-8; Wentzel SW, 2012, RARE TUMORS, V4, P175, DOI 10.4081/rt.2012.e54; William S, 2008, VIRCHOWS ARCH, V452, P91, DOI 10.1007/s00428-007-0486-4; World Health Organization, 2016, CLASS TUM UR SYST MA; World Health Organization, 2004, CLASS TUM PATH GEN T; Wu Huan-wen, 2013, Zhonghua Bing Li Xue Za Zhi, V42, P37, DOI 10.3760/cma.j.issn.0529-5807.2013.01.008; Wu WW, 2014, CASE REP PATHOL, DOI 10.1155/2014/313974; Wu Xiu-zhen, 2013, Zhonghua Bing Li Xue Za Zhi, V42, P622; [吴秀贞 Wu Xiuzhen], 2013, [中华泌尿外科杂志, Chinese Journal of Urology], V34, P14; [徐缓 XU Huan], 2010, [诊断病理学杂志, Chinese Journal of Diagnostic Pathology], V17, P46; Yamashita M, 2010, J CLIN NEUROSCI, V17, P269, DOI 10.1016/j.jocn.2009.04.024; Zhai QJ, 2010, APPL IMMUNOHISTO M M, V18, P323, DOI 10.1097/PAI.0b013e3181d712ef; ZHANG G, 1985, J UROLOGY, V133, P84, DOI 10.1016/S0022-5347(17)48798-2; Zhang XC, 2010, ARCH PATHOL LAB MED, V134, P786, DOI 10.1043/1543-2165-134.5.786	130	10	10	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JAN	2018	50	1					24	36		10.1016/j.pathol.2017.09.005			13	Pathology	Pathology	FU6MY	WOS:000423967900005	29132724				2019-10-28	
J	Schaefer, IM; Fletcher, CDM				Schaefer, Inga-Marie; Fletcher, Christopher D. M.			Recent advances in the diagnosis of soft tissue tumours	PATHOLOGY			English	Review						Sarcoma; soft tissue; genomic alteration; immunohistochemical marker; classification	GASTROINTESTINAL STROMAL TUMORS; ROUND-CELL SARCOMAS; NERVE SHEATH TUMORS; CARNEY-STRATAKIS-SYNDROME; HIGHLY SENSITIVE MARKER; EPITHELIOID HEMANGIOENDOTHELIOMA; SUCCINATE-DEHYDROGENASE; PSEUDOMYOGENIC HEMANGIOENDOTHELIOMA; NEUROFIBROMATOSIS TYPE-1; WILD-TYPE	Soft tissue tumours are relatively rare, but are diagnostically challenging as they comprise a large spectrum of diagnostic entities. Substantial advances have been made in recent years in identifying the underlying recurrent chromosomal and genomic alterations in a significant subset of soft tissue tumours, and this continues to enrich our understanding of the biological mechanisms of tumour development and progression. Ongoing validation and integration of these findings into existing pathological-diagnostic algorithms has led to re- or subclassification of diagnostic categories and will continue to shape a more nuanced (and hopefully clinically relevant) tumour classification system in the future. This review provides a selective overview of recent diagnostic or conceptual advances in the categories of peripheral nerve sheath tumours, vascular and adipocytic tumours, round cell and myogenic sarcomas, and gastrointestinal stromal tumours, as well as their underlying molecular mechanisms, some of which have been translated successfully into useful immunohistochemical stains. A thorough and critical validation of newly identified diagnosticmarkers-acknowledging the fact that some genetic alterationsmay not necessarily be tumour-specific- and ongoing correlation with clinical and prognostic implications will be necessary in this regard.	[Fletcher, Christopher D. M.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA	Fletcher, CDM (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	cfletcher@bwh.harvard.edu		, Inga-Marie/0000-0001-9710-5500			Agaimy A, 2008, AM J SURG PATHOL, V32A, P867, DOI 10.1097/PAS.0b013e31815c0417; Agaimy A, 2007, AM J SURG PATHOL, V31, P113, DOI 10.1097/01.pas.0000213307.05811.f0; Agaram NP, 2014, GENE CHROMOSOME CANC, V53, P779, DOI 10.1002/gcc.22187; Antonescu CR, 2017, AM J SURG PATHOL, V41, P941, DOI 10.1097/PAS.0000000000000846; Antonescu CR, 2014, GENE CHROMOSOME CANC, V53, P951, DOI 10.1002/gcc.22206; Antonescu CR, 2014, GENE CHROMOSOME CANC, V53, P183, DOI 10.1002/gcc.22132; Antonescu CR, 2013, GENE CHROMOSOME CANC, V52, P775, DOI 10.1002/gcc.22073; Beert E, 2011, GENE CHROMOSOME CANC, V50, P1021, DOI 10.1002/gcc.20921; Belinsky MG, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00117; Boikos SA, 2016, JAMA ONCOL, V2, P922, DOI 10.1001/jamaoncol.2016.0256; Busam KJ, 2017, AM J SURG PATHOL, V41, P396, DOI 10.1097/PAS.0000000000000769; Chen BJ, 2012, AM J SURG PATHOL, V36, P1119, DOI 10.1097/PAS.0b013e31825d532d; Cleven AHG, 2016, MODERN PATHOL, V29, P582, DOI 10.1038/modpathol.2016.45; Cohen-Gogo S, 2014, PEDIATR BLOOD CANCER, V61, P2191, DOI 10.1002/pbc.25210; Creytens D, 2014, VIRCHOWS ARCH, V465, P97, DOI 10.1007/s00428-014-1568-8; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; Deyrup AT, 2013, AM J SURG PATHOL, V37, P1373, DOI 10.1097/PAS.0b013e31829562ed; Doyle LA, 2016, AM J SURG PATHOL, V40, P94, DOI 10.1097/PAS.0000000000000511; Doyle LA, 2012, HISTOPATHOLOGY, V61, P801, DOI 10.1111/j.1365-2559.2012.04300.x; Errani C, 2012, CANCER GENET-NY, V205, P12, DOI 10.1016/j.cancergen.2011.10.008; Errani C, 2011, GENE CHROMOSOME CANC, V50, P644, DOI 10.1002/gcc.20886; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Folpe AL, 2005, AM J SURG PATHOL, V29, P1025; Gasparotto D, 2017, CLIN CANCER RES, V23, P273, DOI 10.1158/1078-0432.CCR-16-0152; Haller F, 2014, ENDOCR-RELAT CANCER, V21, P567, DOI 10.1530/ERC-14-0254; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hoang LN, 2017, AM J SURG PATHOL, V41, P12, DOI 10.1097/PAS.0000000000000721; Hornick JL, 2011, AM J SURG PATHOL, V35, P190, DOI 10.1097/PAS.0b013e3181ff0901; Huang SC, 2015, AM J SURG PATHOL, V39, P1313, DOI 10.1097/PAS.0000000000000469; Hung YP, 2017, AM J SURG PATHOL, V41, P596, DOI 10.1097/PAS.0000000000000795; Hung YP, 2016, MODERN PATHOL, V29, P1324, DOI 10.1038/modpathol.2016.140; Hung YP, 2016, MODERN PATHOL, V29, P370, DOI 10.1038/modpathol.2016.31; Italiano A, 2012, GENE CHROMOSOME CANC, V51, P207, DOI 10.1002/gcc.20945; Janeway KA, 2007, CANCER RES, V67, P9084, DOI 10.1158/0008-5472.CAN-07-1938; Janeway KA, 2011, P NATL ACAD SCI USA, V108, P314, DOI 10.1073/pnas.1009199108; Jo VY, 2017, AM J SURG PATHOL, V41, P1013, DOI 10.1097/PAS.0000000000000849; Jo VY, 2015, AM J SURG PATHOL, V39, P673, DOI 10.1097/PAS.0000000000000379; Kao YC, 2016, AM J SURG PATHOL, V40, P1670, DOI 10.1097/PAS.0000000000000697; Killian JK, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009961; Kohsaka S, 2014, NAT GENET, V46, P595, DOI 10.1038/ng.2969; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Marino-Enriquez A, 2017, AM J SURG PATHOL, V41, P234, DOI 10.1097/PAS.0000000000000770; Mason EF, 2016, AM J SURG PATHOL, V40, P1616, DOI 10.1097/PAS.0000000000000685; Matyakhina L, 2007, J CLIN ENDOCR METAB, V92, P2938, DOI 10.1210/jc.2007-0797; Mendlick MR, 2001, AM J SURG PATHOL, V25, P684, DOI 10.1097/00000478-200105000-00019; Mentzel T, 2010, MODERN PATHOL, V23, P729, DOI 10.1038/modpathol.2010.66; MIETTINEN M, 1995, AM J SURG PATHOL, V19, P207, DOI 10.1097/00000478-199502000-00009; Miettinen M, 2006, SEMIN DIAGN PATHOL, V23, P70, DOI 10.1053/j.semdp.2006.09.001; Miettinen MM, 2017, HUM PATHOL; Mosquera JM, 2013, GENE CHROMOSOME CANC, V52, P538, DOI 10.1002/gcc.22050; Mussi C, 2008, CLIN CANCER RES, V14, P4550, DOI 10.1158/1078-0432.CCR-08-0086; Pasini B, 2008, EUR J HUM GENET, V16, P79, DOI 10.1038/sj.ejhg.5201904; PEREZATAYDE AR, 1993, AM J SURG PATHOL, V17, P706, DOI 10.1097/00000478-199307000-00008; Pierron G, 2012, NAT GENET, V44, P461, DOI 10.1038/ng.1107; Prieto-Granada CN, 2016, AM J SURG PATHOL, V40, P479, DOI 10.1097/PAS.0000000000000564; Rohrich M, 2016, ACTA NEUROPATHOL, V131, P877, DOI 10.1007/s00401-016-1540-6; Santiago T, 2017, MODERN PATHOL, V30, P884, DOI 10.1038/modpathol.2017.12; Sarlomo-Rikala M, 1998, MODERN PATHOL, V11, P728; Schaefer IM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14674; Schaefer IM, 2016, HISTOPATHOLOGY, V69, P702, DOI 10.1111/his.12972; Schaefer IM, 2016, MODERN PATHOL, V29, P4, DOI 10.1038/modpathol.2015.134; Specht K, 2016, AM J SURG PATHOL, V40, P433, DOI 10.1097/PAS.0000000000000591; Specht K, 2014, GENE CHROMOSOME CANC, V53, P622, DOI 10.1002/gcc.22172; Stratakis CA, 2009, J INTERN MED, V266, P43, DOI 10.1111/j.1365-2796.2009.02110.x; Szuhai K, 2014, J PATHOL, V232, P300, DOI 10.1002/path.4307; Tanas MR, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002409; van IJzendoorn DGP, 2015, GENE CHROMOSOME CANC, V54, P565, DOI 10.1002/gcc.22269; Walther C, 2014, J PATHOL, V232, P534, DOI 10.1002/path.4322; Wang YX, 2014, NAT GENET, V46, P601, DOI 10.1038/ng.2974; Zou CY, 2009, ANN SURG, V249, P1014, DOI 10.1097/SLA.0b013e3181a77e9a	71	5	5	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JAN	2018	50	1					37	48		10.1016/j.pathol.2017.07.007			12	Pathology	Pathology	FU6MY	WOS:000423967900006	28950990				2019-10-28	
J	Ma, HY; Brosens, LAA; Offerhaus, GJA; Giardiello, FM; de Leng, WWJ; Montgomery, EA				Ma, Huiying; Brosens, Lodewijk A. A.; Offerhaus, G. Johan A.; Giardiello, Francis M.; de Leng, Wendy W. J.; Montgomery, Elizabeth A.			Pathology and genetics of hereditary colorectal cancer	PATHOLOGY			English	Review						Familial colon cancer; hereditary polyposis syndrome; genetic defect	PEUTZ-JEGHERS-SYNDROME; FAMILIAL ADENOMATOUS POLYPOSIS; MUTYH-ASSOCIATED POLYPOSIS; MULTIPLE INTESTINAL NEOPLASIA; LARGE GENOMIC DELETIONS; TUMOR-SUPPRESSOR GENE; STEM-CELL DYNAMICS; OF-THE-LITERATURE; LYNCH-SYNDROME; JUVENILE POLYPOSIS	Colorectal cancer (CRC) accounts for over 8% of all deaths annually worldwide. Between 2 and 5% of all CRCs occur due to inherited syndromes, including Lynch syndrome, familial adenomatous polyposis, MUTYHassociated polyposis, Peutz-Jeghers syndrome, juvenile polyposis and Cowden/PTEN hamartoma syndrome. In addition, serrated polyposis is a clinically defined condition characterised by multiple colorectal serrated polyps and an increased risk of CRC but the genetics are not known. In most hereditary CRC syndromes, polyps undergo carcinogenesis, but the exact route to carcinoma seems to differ between the conditions. Discovery of the key germline mutations in these syndromes has been instrumental to our understanding of the underlying molecular mechanisms of colorectal carcinogenesis. This review summarises the genetic and pathological alterations in hereditary CRC syndromes.	[Ma, Huiying; Brosens, Lodewijk A. A.; Offerhaus, G. Johan A.; de Leng, Wendy W. J.] Univ Med Ctr Utrecht, Dept Pathol, NL-3584 CX Utrecht, Netherlands; [Giardiello, Francis M.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Montgomery, Elizabeth A.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Ma, HY (reprint author), Univ Med Ctr Utrecht, Dept Pathol, NL-3584 CX Utrecht, Netherlands.	h.ma@umcutrecht.nl	Brosens, Lodewijk/E-8792-2018		China Scholarship Council (CSC)China Scholarship Council	Huiying Ma acknowledges financial support from the China Scholarship Council (CSC). The authors state that there are no conflicts of interest to disclose.	Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Amos CI, 2004, J MED GENET, V41, P327, DOI 10.1136/jmg.2003.010900; Andrew AS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030535; Aretz S, 2007, J MED GENET, V44, P702, DOI 10.1136/jmg.2007.052506; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bassi C, 2013, SCIENCE, V341, P395, DOI 10.1126/science.1236188; Belchetz LA, 1996, DIS COLON RECTUM, V39, P384, DOI 10.1007/BF02054051; Binder H, 2017, J PATHOL, V243, P242, DOI 10.1002/path.4948; Boon EMJ, 2004, BRIT J CANCER, V90, P224, DOI 10.1038/sj.bjc.6601505; Boparai KS, 2010, GUT, V59, P1094, DOI 10.1136/gut.2009.185884; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Brosens LAA, 2016, INT J SURG PATHOL, V24, P185, DOI 10.1177/1066896915620013; Brosens LAA, 2015, SURG CLIN N AM, V95, P1067, DOI 10.1016/j.suc.2015.05.004; Buchanan DD, 2017, GUT, V66, P1170, DOI 10.1136/gutjnl-2016-312773; Buecher B, 2013, DIGEST LIVER DIS, V45, P441, DOI 10.1016/j.dld.2012.10.006; Carulli AJ, 2014, INTEGR BIOL-UK, V6, P243, DOI 10.1039/c3ib40163d; Castillejo A, 2014, EUR J CANCER, V50, P2241, DOI 10.1016/j.ejca.2014.05.022; Christie M, 2013, ONCOGENE, V32, P4675, DOI 10.1038/onc.2012.486; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Crowder CD, 2012, AM J SURG PATHOL, V36, P1178, DOI 10.1097/PAS.0b013e3182597f41; de la Chapelle A, 2010, J CLIN ONCOL, V28, P3380, DOI 10.1200/JCO.2009.27.0652; de Leng WWJ, 2007, GUT, V56, P1475, DOI 10.1136/gut.2007.128132; Delnatte C, 2006, AM J HUM GENET, V78, P1066, DOI 10.1086/504301; Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033; Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415; Dunlop MG, 2002, GUT, V51, pV21, DOI 10.1136/gut.51.suppl_5.v21; Edelstein DL, 2015, CLIN GASTROENTEROL H, V13, P1697, DOI 10.1016/j.cgh.2015.02.003; Eng C, 1998, AM J HUM GENET, V62, P1020, DOI 10.1086/301847; Engel C, 2010, CLIN GASTROENTEROL H, V8, P174, DOI 10.1016/j.cgh.2009.10.003; Farin HF, 2016, NATURE, V530, P340, DOI 10.1038/nature16937; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fogarty S, 2016, MOL CANCER RES, V14, P683, DOI 10.1158/1541-7786.MCR-15-0479; Fumagalli A, 2017, P NATL ACAD SCI USA, V114, pE2357, DOI 10.1073/pnas.1701219114; Gala MK, 2014, GASTROENTEROLOGY, V146, P520, DOI 10.1053/j.gastro.2013.10.045; Gammon A, 2009, BEST PRACT RES CL GA, V23, P219, DOI 10.1016/j.bpg.2009.02.007; Giardiello FM, 2014, AM J GASTROENTEROL, V109, P1159, DOI 10.1038/ajg.2014.186; Giuffre G, 2005, J MOL DIAGN, V7, P160, DOI 10.1016/S1525-1578(10)60542-9; Grover S, 2012, JAMA-J AM MED ASSOC, V308, P485, DOI 10.1001/jama.2012.8780; Guarinos C, 2014, CLIN CANCER RES, V20, P1158, DOI 10.1158/1078-0432.CCR-13-1490; Hamilton SR, 2000, PATHOLOGY GENETICS T; Hampel H, 2008, J CLIN ONCOL, V26, P5783, DOI 10.1200/JCO.2008.17.5950; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Hearle N, 2006, CLIN CANCER RES, V12, P3209, DOI 10.1158/1078-0432.CCR-06-0083; Hernegger GS, 2002, DIS COLON RECTUM, V45, P127; Howe JR, 1998, ANN SURG ONCOL, V5, P751, DOI 10.1007/BF02303487; IARC and WHO, 2012, GLOBOCAN 2012 EST CA; IJspeert JEG, 2016, ENDOSC INT OPEN, V4, pE73, DOI 10.1055/s-0034-1393361; Jacob LS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001225; Jansen M, 2006, GUT, V55, P1, DOI 10.1136/gut.2005.069062; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Jasperson KW, 2010, GASTROENTEROLOGY, V138, P2044, DOI 10.1053/j.gastro.2010.01.054; Jones S, 2002, HUM MOL GENET, V11, P2961, DOI 10.1093/hmg/11.23.2961; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Katajisto P, 2008, NAT GENET, V40, P455, DOI 10.1038/ng.98; Kim B, 2011, BEST PRACT RES CL GA, V25, P607, DOI 10.1016/j.bpg.2011.08.002; Kim J, 2017, NATURE, V546, P168, DOI 10.1038/nature22359; Kim KM, 2004, AM J PATHOL, V164, P1369, DOI 10.1016/S0002-9440(10)63223-3; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kloor M, 2012, LANCET ONCOL, V13, P598, DOI 10.1016/S1470-2045(12)70109-2; Klumpen HJ, 2011, J CLIN ONCOL, V29, pE150, DOI 10.1200/JCO.2010.32.7825; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Koo BK, 2015, P NATL ACAD SCI USA, V112, P7548, DOI 10.1073/pnas.1508113112; Korsse SE, 2013, CARCINOGENESIS, V34, P1611, DOI 10.1093/carcin/bgt068; Kottakis F, 2016, NATURE, V539, P390, DOI 10.1038/nature20132; Lamberti C, 1999, GUT, V44, P839, DOI 10.1136/gut.44.6.839; Lamlum H, 1999, NAT MED, V5, P1071; Landon M, 2015, CLIN GENET, V87, P368, DOI 10.1111/cge.12375; Langeveld D, 2012, GUT, V61, P839, DOI 10.1136/gutjnl-2011-300622; Langeveld D, 2010, CLIN CANCER RES, V16, P4126, DOI 10.1158/1078-0432.CCR-10-0168; Leslie A, 2002, BRIT J SURG, V89, P845, DOI 10.1046/j.1365-2168.2002.02120.x; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Ligtenberg MJL, 2009, NAT GENET, V41, P112, DOI 10.1038/ng.283; Lim W, 2004, GASTROENTEROLOGY, V126, P1788, DOI 10.1053/j.gastro.2004.03.014; LINOS DA, 1981, ARCH SURG-CHICAGO, V116, P1182; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; Lubbe SJ, 2009, J CLIN ONCOL, V27, P3975, DOI 10.1200/JCO.2008.21.6853; Lucci-Cordisco E, 2013, AM J MED GENET A, V161, P2777, DOI 10.1002/ajmg.a.36253; Lynch HT, 2009, CLIN GENET, V76, P1, DOI 10.1111/j.1399-0004.2009.01230.x; Ma HY, 2016, J GASTROENTEROL, V51, P841, DOI 10.1007/s00535-016-1211-3; Markkanen Enni, 2013, Frontiers in Genetics, V4, P18, DOI 10.3389/fgene.2013.00018; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MILLER LJ, 1983, DIGEST DIS SCI, V28, P1047, DOI 10.1007/BF01311735; Minde DP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-101; Minoo P, 2006, GUT, V55, DOI 10.1136/gut.2005.082859; Moller P, 2017, GUT; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Mulvihill J J, 1983, Prog Clin Biol Res, V115, P61; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Ngeow J, 2017, ENDOCRIN METAB CLIN, V46, P503, DOI 10.1016/j.ecl.2017.01.013; Nielsen M, 2009, GASTROENTEROLOGY, V136, P471, DOI 10.1053/j.gastro.2008.10.056; Nieuwenhuis MH, 2007, CRIT REV ONCOL HEMAT, V61, P153, DOI 10.1016/j.critrevonc.2006.07.004; Nucci MR, 1997, HUM PATHOL, V28, P1396, DOI 10.1016/S0046-8177(97)90230-6; Oka A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004301; Parsons MT, 2012, J MED GENET, V49, P151, DOI 10.1136/jmedgenet-2011-100714; PETERSEN GM, 1991, GASTROENTEROLOGY, V100, P1658, DOI 10.1016/0016-5085(91)90666-9; Pezzolesi MG, 2008, AM J HUM GENET, V82, P1141, DOI 10.1016/j.ajhg.2008.04.005; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; Pino MS, 2009, J MOL DIAGN, V11, P238, DOI 10.2353/jmoldx.2009.080142; Preston SL, 2003, CANCER RES, V63, P3819; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rosty C, 2011, PATHOLOG RES INT, V2011, DOI DOI 10.4061/2011/157073; Rustgi AK, 2007, GENE DEV, V21, P2525, DOI 10.1101/gad.1593107; Salloch H, 2010, INT J COLORECTAL DIS, V25, P97, DOI 10.1007/s00384-009-0793-0; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Scheper MA, 2006, ORAL SURG ORAL MED O, V101, P625, DOI 10.1016/j.tripleo.2005.06.026; Schreibman IR, 2005, AM J GASTROENTEROL, V100, P476, DOI 10.1111/j.1572-0241.2005.40237.x; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Sekine S, 2017, MODERN PATHOL, V30, P1144, DOI 10.1038/modpathol.2017.39; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; SHEPHERD NA, 1987, AM J SURG PATHOL, V11, P743, DOI 10.1097/00000478-198710000-00001; Snippert HJ, 2014, EMBO REP, V15, P62, DOI 10.1002/embr.201337799; Snover DC, 2010, WHO CLASSIFICATION T, P160; Soravia C, 2000, DIS COLON RECTUM, V43, P363, DOI 10.1007/BF02258303; Spicer J, 2003, ONCOGENE, V22, P4752, DOI 10.1038/sj.onc.1206669; Stoffel EM, 2014, CLIN GASTROENTEROL H, V12, P1059, DOI 10.1016/j.cgh.2013.08.015; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tamguney T, 2007, J CELL SCI, V120, P4071, DOI 10.1242/jcs.015230; Teresi RE, 2007, AM J HUM GENET, V81, P756, DOI 10.1086/521051; Tsou HC, 1997, AM J HUM GENET, V61, P1036, DOI 10.1086/301607; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Valle L, 2017, CLIN GASTROENTEROL H, V15, P809, DOI 10.1016/j.cgh.2016.09.148; Van Hattem WA, 2008, GUT, V57, P623, DOI 10.1136/gut.2007.142927; van Hattem WA, 2011, AM J SURG PATHOL, V35, P530, DOI 10.1097/PAS.0b013e318211cae1; van Lier MGF, 2010, AM J GASTROENTEROL, V105, P1258, DOI 10.1038/ajg.2009.725; Vasen HFA, 2013, GUT, V62, P812, DOI 10.1136/gutjnl-2012-304356; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Vermeulen L, 2013, SCIENCE, V342, P995, DOI 10.1126/science.1243148; Wachsmannova-Matelova L, 2009, NEOPLASMA, V56, P486, DOI 10.4149/neo_2009_06_486; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Watts JL, 2000, DEVELOPMENT, V127, P1467; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Westerman AM, 1999, LANCET, V353, P1211, DOI 10.1016/S0140-6736(98)08018-0; Yan HHN, 2017, GUT, V66, P1645, DOI 10.1136/gutjnl-2016-311849; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Young J, 2001, AM J PATHOL, V159, P2107, DOI 10.1016/S0002-9440(10)63062-3; Zhou XP, 2001, LANCET, V358, P210, DOI 10.1016/S0140-6736(01)05412-5	149	20	21	4	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JAN	2018	50	1					49	59		10.1016/j.pathol.2017.09.004			11	Pathology	Pathology	FU6MY	WOS:000423967900007	29169633				2019-10-28	
J	Egevad, L; Delahunt, B; Kristiansen, G; Samaratunga, H; Varma, M				Egevad, Lars; Delahunt, Brett; Kristiansen, Glen; Samaratunga, Hemamali; Varma, Murali			Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations	PATHOLOGY			English	Review						Pathology; prostate carcinoma; prognosis; intraductal carcinoma; grade; stage; biomarkers	ISUP CONSENSUS-CONFERENCE; RECURRENCE-FREE SURVIVAL; GLEASON GRADE 4/5; SEMINAL-VESICLE INVASION; CIRCULATING TUMOR-CELLS; PTEN PROTEIN LOSS; RADICAL-PROSTATECTOMY; PERINEURAL INVASION; INTRADUCTAL CARCINOMA; NEEDLE-BIOPSY	Prognostic assessment is a key element in the management of patients with prostate cancer as it informs both treatment, follow-up and outcome prediction. Tumour grade should be based upon the novel and evidence-based recommendations of the International Society of Urological Pathology (ISUP) Consensus Conference of 2014, with ISUP grades 1-5 being derived from 2005 ISUP modified Gleason grading, i.e., ISUP grade 1 (3 + 3 = 6), grade 2 (3 + 4 = 7), grade 3 (4 + 3 = 7), grade 4 (3 + 5 = 8, 5 + 3 = 8, 4 + 4 = 8), and grade 5 (4 + 5 = 9 5 + 4 = 9, 5 + 5 = 10). Reporting the percentage of pattern 4 present is somewhat controversial. It does appear to have value for cases of ISUP grade 2 tumours where only small volumes of pattern 4 tumour are present, as this may assist in determining if a patient is appropriate for active surveillance. It is currently recommended that pure intraductal carcinoma (IDCP) not be graded. Here we here propose that atypical intraductal proliferation, indeterminate for high-grade prostatic intraepithelial neoplasia (PIN) and IDCP, should be reported as atypical proliferation suspicious for IDCP (ASID) with a note that the lesion is non-diagnostic. Pathological staging is dependent on tumour spread with the key factors being tumour volume, tumour extent including extraprostatic extension (focal and established), as well as seminal vesicle and pelvic lymph node involvement. Perineural infiltration in needle biopsies and lymphovascular invasion are evolving parameters that should be included in the pathology report. The identification of prognostic biomarkers is in evolution although a variety of transcription signatures have been shown to have utility in outcome assessment. Other molecular markers showing promise as prognostic indicators are PTEN, androgen receptors, PARP and tumour promoter (GST-pi, RASSF1, PITX2) methylation.	[Egevad, Lars] Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden; [Delahunt, Brett] Univ Otago, Wellington Sch Med & Hlth Sci, Dept Pathol & Mol Med, Wellington, New Zealand; [Kristiansen, Glen] Univ Hosp Bonn, Inst Pathol, Bonn, Germany; [Samaratunga, Hemamali] Aquesta Uropathol, Brisbane, Qld, Australia; [Samaratunga, Hemamali] Univ Queensland, Brisbane, Qld, Australia; [Varma, Murali] Univ Hosp Wales, Dept Cellular Pathol, Cardiff, S Glam, Wales	Egevad, L (reprint author), Karolinska Univ Hosp, Karolinska Inst, Dept Oncol Pathol, Radiumhemmet P1 02, S-17176 Stockholm, Sweden.	lars.egevad@ki.se	Samaratunga, Hemamali M L/D-1559-2013	Samaratunga, Hemamali M L/0000-0001-5796-1791			Al-Hussain T, 2011, J UROLOGY, V186, P470, DOI 10.1016/j.juro.2011.03.119; Amin MB, 2014, ARCH PATHOL LAB MED, V138, P1387, DOI 10.5858/arpa.2014-0219-SA; Antonarakis ES, 2017, J CLIN ONCOL, V35, P2149, DOI 10.1200/JCO.2016.70.1961; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Attard G, 2008, ONCOGENE, V27, P253, DOI 10.1038/sj.onc.1210640; Ball MW, 2015, UROLOGY, V85, P161, DOI 10.1016/j.urology.2014.08.025; Banez LL, 2010, J UROLOGY, V184, P149, DOI 10.1016/j.juro.2010.03.012; Berg KD, 2014, EUR UROL, V66, P851, DOI 10.1016/j.eururo.2014.02.058; Bernemann C, 2017, WORLD J UROL, V35, P1625, DOI 10.1007/s00345-017-2024-6; Bernemann C, 2017, EUR UROL, V71, P1, DOI 10.1016/j.eururo.2016.07.021; Berney DM, 2011, MODERN PATHOL, V24, P39, DOI 10.1038/modpathol.2010.160; Bismar TA, 2003, AM J SURG PATHOL, V27, P432, DOI 10.1097/00000478-200304000-00002; Brimo F, 2008, HISTOPATHOLOGY, V53, P177, DOI 10.1111/j.1365-2559.2008.03087.x; Brinker DA, 1999, J UROLOGY, V162, P2036, DOI 10.1016/S0022-5347(05)68094-9; Buus R, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw149; Carlsson SV, 2013, J UROLOGY, V189, P1314, DOI 10.1016/j.juro.2012.10.027; Carvalhal GF, 2000, CANCER, V89, P1308, DOI 10.1002/1097-0142(20000915)89:6<1308::AID-CNCR16>3.0.CO;2-3; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Castiglione F, 2017, PROSTATE, V77, P3, DOI 10.1002/pros.23242; Chen ME, 2003, AM J SURG PATHOL, V27, P1291, DOI 10.1097/00000478-200310000-00001; Cheng L, 2005, J UROLOGY, V174, P2181, DOI 10.1097/01.ju.0000181215.41607.c3; Cullen J, 2015, EUR UROL, V68, P123, DOI 10.1016/j.eururo.2014.11.030; Cuzick J, 2013, BRIT J CANCER, V108, P2582, DOI 10.1038/bjc.2013.248; Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3; Daniunaite K, 2014, J UROLOGY, V192, P1849, DOI 10.1016/j.juro.2014.06.075; Danneman D, 2015, BJU INT, V115, P248, DOI 10.1111/bju.12671; Danneman D, 2013, HISTOPATHOLOGY, V63, P580, DOI 10.1111/his.12199; Dawkins HJS, 2000, PROSTATE, V44, P265; de la Taille A, 2000, EUR UROL, V38, P79, DOI 10.1159/000020256; DEJTER SW, 1989, UROLOGY, V33, P361, DOI 10.1016/0090-4295(89)90026-5; Delahunt B, 2015, PATHOLOGY, V47, P520, DOI 10.1097/PAT.0000000000000318; Demichelis F, 2007, ONCOGENE, V26, P4596, DOI 10.1038/sj.onc.1210237; Dietrich D, 2014, CRIT REV CL LAB SCI, V51, P173, DOI 10.3109/10408363.2014.906130; Dietrich D, 2013, J MOL DIAGN, V15, P270, DOI 10.1016/j.jmoldx.2012.11.002; Dong F, 2012, AM J SURG PATHOL, V36, P838, DOI 10.1097/PAS.0b013e3182486faf; Egan AJM, 1997, AM J SURG PATHOL, V21, P1496, DOI 10.1097/00000478-199712000-00013; Egevad L, 2002, J UROLOGY, V168, P509, DOI 10.1016/S0022-5347(05)64669-1; Egevad L, 2017, PROSTATE CORE NEEDLE; Egevad L, 2017, PROSTATE CANC RADICA; Egevad L, 2017, HISTOPATHOLOGY, V71, P677, DOI 10.1111/his.13313; Egevad L, 2016, AM J SURG PATHOL, V40, P858, DOI 10.1097/PAS.0000000000000642; Eichelberger LE, 2005, MODERN PATHOL, V18, P886, DOI 10.1038/modpathol.3800405; Elharram M, 2012, CAN J UROL, V19, P6567; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; EPSTEIN JI, 1993, J UROLOGY, V150, P135, DOI 10.1016/S0022-5347(17)35415-0; Epstein JI, 2017, AM J SURG PATHOL, V41, pE1, DOI 10.1097/PAS.0000000000000820; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855; Ferraldeschi R, 2015, EUR UROL, V67, P795, DOI 10.1016/j.eururo.2014.10.027; Ferrari MK, 2004, UROLOGY, V64, P749, DOI 10.1016/j.urology.2004.04.070; Glaessgen A, 2004, J UROLOGY, V171, P664, DOI 10.1097/01.ju.0000108198.98598.00; Glaessgen A, 2002, J UROLOGY, V168, P2006, DOI 10.1097/01.ju.0000034255.95952.df; GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125; Gopalan A, 2009, CANCER RES, V69, P1400, DOI 10.1158/0008-5472.CAN-08-2467; Guo CC, 2006, MODERN PATHOL, V19, P1528, DOI 10.1038/modpathol.3800702; Harnden P, 2007, CANCER, V109, P13, DOI 10.1002/cncr.22388; Herman CM, 2000, AM J SURG PATHOL, V24, P859, DOI 10.1097/00000478-200006000-00012; Huber F, 2015, BRIT J CANCER, V112, P140, DOI 10.1038/bjc.2014.588; Hull GW, 2002, J UROLOGY, V167, P528, DOI 10.1016/S0022-5347(01)69079-7; Iczkowski KA, 2014, ANN DIAGN PATHOL, V18, P333, DOI 10.1016/j.anndiagpath.2014.08.010; Jeong BC, 2015, EUR UROL, V67, P342, DOI 10.1016/j.eururo.2014.06.015; Joshi A, 2009, HISTOPATHOLOGY, V54, P912, DOI 10.1111/j.1365-2559.2009.03299.x; Karnes RJ, 2017, EUR UROL; Kato M, 2016, MODERN PATHOL, V29, P166, DOI 10.1038/modpathol.2015.146; Kench J, 2014, PROSTATE CANC CORE N; Khani F, 2015, AM J SURG PATHOL, V39, P1383, DOI 10.1097/PAS.0000000000000465; Kikuchi E, 2004, J UROLOGY, V172, P508, DOI 10.1097/01.ju.0000130481.04082.1a; Kimura K, 2014, PROSTATE, V74, P680, DOI 10.1002/pros.22786; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Klein EA, 2014, EUR UROL, V66, P550, DOI 10.1016/j.eururo.2014.05.004; Knezevic D, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-690; Kristiansen A, 2013, HISTOPATHOLOGY, V62, P1049, DOI 10.1111/his.12104; Krohn A, 2012, AM J PATHOL, V181, P401, DOI 10.1016/j.ajpath.2012.04.026; Kweldam CF, 2016, HISTOPATHOLOGY, V69, P441, DOI 10.1111/his.12976; Kweldam CF, 2016, MODERN PATHOL, V29, P630, DOI 10.1038/modpathol.2016.49; Lalonde E, 2014, LANCET ONCOL, V15, P1521, DOI 10.1016/S1470-2045(14)71021-6; Lindberg J, 2015, EUR UROL, V67, P819, DOI 10.1016/j.eururo.2014.09.006; Loeb S, 2010, BJU INT, V105, P1510, DOI 10.1111/j.1464-410X.2009.08845.x; Lokman U, 2017, EUR UROL FOCUS; Lotan TL, 2011, CLIN CANCER RES, V17, P6563, DOI 10.1158/1078-0432.CCR-11-1244; Lubig S, 2018, PATHOLOGY, V50, P298, DOI 10.1016/j.pathol.2017.09.013; Maccio L, 2016, INTERN EMERG MED, V11, P399, DOI 10.1007/s11739-015-1375-5; Magi-Galluzzi C, 2011, MODERN PATHOL, V24, P26, DOI 10.1038/modpathol.2010.158; Huynh MA, 2016, EUR UROL, V69, P976, DOI 10.1016/j.eururo.2015.08.054; Mai KT, 2003, PATHOL RES PRACT, V199, P599, DOI 10.1078/0344-0338-00467; Maru N, 2001, HUM PATHOL, V32, P828, DOI 10.1053/hupa.2001.26456; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; McKenney JK, 2016, AM J SURG PATHOL, V40, P1439, DOI 10.1097/PAS.0000000000000736; McNeal JE, 1996, AM J SURG PATHOL, V20, P802, DOI 10.1097/00000478-199607000-00003; Merrilees AD, 2008, MODERN PATHOL, V21, P1095, DOI 10.1038/modpathol.2008.81; Meyer CP, 2017, WORLD J UROL, V35, P199, DOI 10.1007/s00345-016-1861-z; Miller JS, 2010, BJU INT, V106, P330, DOI 10.1111/j.1464-410X.2009.09110.x; Moch H, 2016, WHO CLASSIFICATION T; Morash C, 2015, CUAJ-CAN UROL ASSOC, V9, P171, DOI 10.5489/cuaj.2806; Moreira DM, 2015, J UROLOGY, V194, P1258, DOI 10.1016/j.juro.2015.04.113; MUKAMEL E, 1990, BRIT J UROL, V65, P46, DOI 10.1111/j.1464-410X.1990.tb14660.x; Na R, 2016, ASIAN J ANDROL, V18, P575, DOI 10.4103/1008-682X.175096; Nakagawa T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002318; Nazeer T, 2009, HUM PATHOL, V40, P538, DOI 10.1016/j.humpath.2008.10.004; Ng JC, 2004, J UROLOGY, V172, P2249, DOI 10.1097/01.ju.0000143973.22897.f8; Noguchi M, 2000, CANCER, V89, P1056, DOI 10.1002/1097-0142(20000901)89:5<1056::AID-CNCR15>3.0.CO;2-U; O'Brien BA, 2011, BJU INT, V107, P389, DOI 10.1111/j.1464-410X.2010.09539.x; O'Brien C, 2010, AM J CLIN PATHOL, V133, P654, DOI 10.1309/AJCP8EL5FTZSOBIH; Oderda M, 2017, UROLOGY, V102, P73, DOI 10.1016/j.urology.2016.11.038; OHORI M, 1993, AM J SURG PATHOL, V17, P1252, DOI 10.1097/00000478-199312000-00006; Oxley JD, DATASET HISTOPATHOLO; Ozcan F, 2001, EUR UROL, V40, P308, DOI 10.1159/000049791; PARTIN AW, 1989, J UROLOGY, V141, P341, DOI 10.1016/S0022-5347(17)40761-0; Perry-Keene J, 2014, HISTOPATHOLOGY, V64, P399, DOI 10.1111/his.12262; Pettersson A, 2012, CANCER EPIDEM BIOMAR, V21, P1497, DOI 10.1158/1055-9965.EPI-12-0042; Polley MYC, 2015, MODERN PATHOL, V28, P778, DOI 10.1038/modpathol.2015.38; Qian JQ, 1997, MODERN PATHOL, V10, P1113; Quinn DI, 2003, CANCER-AM CANCER SOC, V97, P1884, DOI 10.1002/cncr.11263; Quintal MMQ, 2011, INT UROL NEPHROL, V43, P697, DOI 10.1007/s11255-011-9901-5; Rajan P, 2016, EUR UROL FOCUS; Rauscher I, 2016, J NUCL MED, V57, P1713, DOI 10.2967/jnumed.116.173492; Renshaw AA, 1997, AM J CLIN PATHOL, V107, P704; Rimar KJ, 2017, CANCER-AM CANCER SOC, V123, P1912, DOI 10.1002/cncr.30631; Robinson BD, 2010, J UROLOGY, V184, P1328, DOI 10.1016/j.juro.2010.06.017; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Salomon L, 2003, EUR UROL, V43, P39, DOI 10.1016/S0302-2838(02)00493-1; Samaratunga H, 2015, PATHOLOGY, V47, P515, DOI 10.1097/PAT.0000000000000315; Samaratunga H, 2011, MODERN PATHOL, V24, P6, DOI 10.1038/modpathol.2010.178; Samaratunga H, 2010, PATHOLOGY, V42, P330, DOI 10.3109/00313021003767330; Saraon P, 2011, CLIN CHEM, V57, P1366, DOI 10.1373/clinchem.2011.165977; Sauter G, 2016, EUR UROL, V69, P592, DOI 10.1016/j.eururo.2015.10.029; Schatz P, 2010, J MOL DIAGN, V12, P345, DOI 10.2353/jmoldx.2010.090088; Sebo TJ, 2000, J UROLOGY, V163, P174, DOI 10.1016/S0022-5347(05)67998-0; Shah RB, 2017, HISTOPATHOLOGY, V71, P693, DOI 10.1111/his.13273; Shin SJ, 2016, VIRCHOWS ARCH, V469, P305, DOI 10.1007/s00428-016-1971-4; Srigley J, 2017, PROTOCOL EXAMINATION; Srigley JR, 2006, ARCH PATHOL LAB MED, V130, P303; Stamey TA, 1999, JAMA-J AM MED ASSOC, V281, P1395, DOI 10.1001/jama.281.15.1395; Terada N, 2017, THER ADV MED ONCOL, V9, P565, DOI 10.1177/1758834017719215; Tosoian JJ, 2017, BJU INT; Trpkov C, 2014, UROLOGY, V84, P149, DOI 10.1016/j.urology.2014.04.007; Trudel D, 2014, EUR J CANCER, V50, P1610, DOI 10.1016/j.ejca.2014.03.009; Turner RM, 2017, UROLOGY, V102, P173, DOI 10.1016/j.urology.2016.11.011; Van der Kwast T, 2012, EUR J CANCER, V48, P1318, DOI 10.1016/j.ejca.2012.02.003; van der Kwast TH, 2011, MODERN PATHOL, V24, P16, DOI 10.1038/modpathol.2010.156; Varga Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058483; Varma M, 2017, HISTOPATHOLOGY, V71, P837, DOI 10.1111/his.13300; Varma M, 2017, HISTOPATHOLOGY, V70, P504, DOI 10.1111/his.13081; Varma M, 2016, J CLIN PATHOL, V69, P852, DOI 10.1136/jclinpath-2016-203658; Watts K, 2013, HISTOPATHOLOGY, V63, P574, DOI 10.1111/his.12198; Wei L, 2017, EUR UROL, V71, P183, DOI 10.1016/j.eururo.2016.07.008; Weiss G, 2009, J UROLOGY, V181, P1678, DOI 10.1016/j.juro.2008.11.120; Wheeler TM, 1998, HUM PATHOL, V29, P856, DOI 10.1016/S0046-8177(98)90457-9; Wittschieber D, 2010, PATHOL ONCOL RES, V16, P479, DOI 10.1007/s12253-010-9270-x; Yamamoto Shinya, 2015, Clin Breast Cancer, V15, pe35, DOI 10.1016/j.clbc.2014.09.005; Yee DS, 2011, BJU INT, V108, P502, DOI 10.1111/j.1464-410X.2010.09848.x; Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x; Yoshimoto M, 2007, BRIT J CANCER, V97, P678, DOI 10.1038/sj.bjc.6603924; Yu HHM, 2007, UROLOGY, V70, P111, DOI 10.1016/j.urology.2007.03.020; Zhou M, 2015, AM J SURG PATHOL, V39, P1331, DOI 10.1097/PAS.0000000000000457	155	10	11	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JAN	2018	50	1					60	73		10.1016/j.pathol.2017.09.008			14	Pathology	Pathology	FU6MY	WOS:000423967900008	29199015				2019-10-28	
J	Li, SY; Young, KH; Medeiros, LJ				Li, Shaoying; Young, Ken H.; Medeiros, L. Jeffrey			Diffuse large B-cell lymphoma	PATHOLOGY			English	Review						Diffuse large B-cell lymphoma; diagnostic work-up; morphology; immunohistochemistry; molecular diagnostics	CHOP CONSORTIUM PROGRAM; DOUBLE-HIT LYMPHOMA; NON-HODGKIN-LYMPHOMA; POOR-PROGNOSIS; MYC REARRANGEMENT; GENE-EXPRESSION; CD30 EXPRESSION; P53 EXPRESSION; INFERIOR SURVIVAL; BURKITT-LYMPHOMA	Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide, representing approximately 30-40% of all cases in different geographic regions. Patients most often present with a rapidly growing tumour mass in single or multiple, nodal or extranodal sites. The most common type of DLBCL, designated as not otherwise specified, represents 80-85% of all cases and is the focus of this review. There are also rare types of lymphoma composed of large B-cells, in aggregate about 15-20% of all neoplasms that are sufficiently distinctive to recognise separately. DLBCL not otherwise specified (referred to henceforth as DLBCL) is a heterogeneous entity in terms of clinical presentation, genetic findings, response to therapy, and prognosis. A major advance was the application of gene expression profiling (GEP) to the study of DLBCL which further clarified this heterogeneity and provided a rationale for subdividing cases into groups. The most popular system divides cases of DLBCL according to cell-of-origin into germinal centre B-cell like (GCB) and activated B-cell like (ABC) subtypes, with about 10-15% of cases being unclassifiable. Patients with the GCB subtype usually have better prognosis than patients with the ABC subtype. Although cell-of-origin is useful for predicting outcome, the GCB and ABC subtypes remain heterogeneous, with better and worse prognostic subsets within each group. Next generation sequencing (NGS) analysis of DLBCL has facilitated global identification of numerous and diverse genetic abnormalities in these neoplasms and has shown that GCB and ABC tumours have different mutation profiles. Although the therapy of patients with DLBCL is an active area of research, the current 5-year overall survival rate is 60-70% using standard-of-care frontline therapy. A precision medicine approach for the design of new therapies based on molecular findings in DLBCL is likely the best path forward. As pathologists, our role has expanded beyond diagnosis. We must perform a complete work-up of DLBCL cases. In addition to our traditional role in establishing the diagnosis, we need to analyse markers that provide information regarding prognosis and potential therapeutic targets. We also must ensure that adequate tissue is triaged for molecular studies which are essential for designing therapy regimens, particularly in the setting of disease relapse.	[Li, Shaoying; Young, Ken H.; Medeiros, L. Jeffrey] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	Medeiros, LJ (reprint author), MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd,Unit 72, Houston, TX 77030 USA.	ljmedeiros@mdanderson.org	Medeiros, L. Jeffrey/AAB-1018-2019				Alinari L, 2016, AM J HEMATOL, V91, P395, DOI 10.1002/ajh.24299; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Aukema SM, 2014, HAEMATOLOGICA, V99, P726, DOI 10.3324/haematol.2013.091827; Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; Barrans S, 2010, J CLIN ONCOL, V28, P3360, DOI 10.1200/JCO.2009.26.3947; Bhatt G, 2016, CURR HEMATOL MALIG R, V11, P480, DOI 10.1007/s11899-016-0345-y; Bohers E, 2015, LEUKEMIA LYMPHOMA, V56, P1213, DOI 10.3109/10428194.2014.941836; Brudno J, 2016, BLOOD, V127, P965, DOI 10.1182/blood-2015-06-651968; Chen WY, 2006, BLOOD, V107, P2477, DOI 10.1182/blood-2005-07-2950; Choi WWL, 2009, CLIN CANCER RES, V15, P5494, DOI 10.1158/1078-0432.CCR-09-0113; Clipson A, 2015, J PATHOL CLIN RES, V1, P125, DOI 10.1002/cjp2.10; Clozel T, 2013, CANCER DISCOV, V3, P1002, DOI 10.1158/2159-8290.CD-13-0117; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Copie-Bergman C, 2015, BLOOD, V126, P2466, DOI 10.1182/blood-2015-05-647602; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Dybkaer K, 2015, J CLIN ONCOL, V33, P1379, DOI 10.1200/JCO.2014.57.7080; Epperla N, 2017, HEMATOL ONCOL STEM C; Epperla N, 2017, CANCER-AM CANCER SOC, V123, P4411, DOI 10.1002/cncr.30895; Gary-Gouy H, 2002, BLOOD, V100, P4537, DOI 10.1182/blood-2002-05-1525; Gary-Gouy H, 2002, J IMMUNOL, V168, P232, DOI 10.4049/jimmunol.168.1.232; Gebauer N, 2015, LEUKEMIA LYMPHOMA, V56, P179, DOI 10.3109/10428194.2014.907896; Georgiou K, 2016, BLOOD, V127, P3026, DOI 10.1182/blood-2015-12-686550; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Herrera AF, 2016, BRIT J HAEMATOL, V175, P841, DOI 10.1111/bjh.14311; Horn H, 2015, AM J SURG PATHOL, V39, P61, DOI 10.1097/PAS.0000000000000319; Horn H, 2013, BLOOD, V121, P2253, DOI 10.1182/blood-2012-06-435842; Hu SM, 2013, BLOOD, V121, P4021, DOI 10.1182/blood-2012-10-460063; Hu SM, 2013, BLOOD, V121, P2715, DOI 10.1182/blood-2012-10-461848; Ichikawa A, 1997, NEW ENGL J MED, V337, P529, DOI 10.1056/NEJM199708213370804; JAFFE ES, 1974, NEW ENGL J MED, V290, P813, DOI 10.1056/NEJM197404112901501; Johnson NA, 2012, J CLIN ONCOL, V30, P3452, DOI 10.1200/JCO.2011.41.0985; Johnson NA, 2009, BLOOD, V114, P2273, DOI 10.1182/blood-2009-03-212191; Kanungo A, 2006, MODERN PATHOL, V19, P25, DOI 10.1038/modpathol.3800500; Karmali R, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0449-1; Karube K, 2017, LEUKEMIA; Kerbauy FR, 2004, LEUKEMIA LYMPHOMA, V45, P2071, DOI 10.1080/10428190410001713170; Korkolopoulou P, 2016, ADV ANAT PATHOL, V23, P202, DOI 10.1097/PAP.0000000000000117; Kramer MHH, 1998, BLOOD, V92, P3152, DOI 10.1182/blood.V92.9.3152.421a07_3152_3162; Landsburg DJ, 2017, J CLIN ONCOL, V35, P2260, DOI 10.1200/JCO.2017.72.2157; Landsburg DJ, 2016, BRIT J HAEMATOL, V175, P631, DOI 10.1111/bjh.14282; Landsburg DJ, 2016, CANCER-AM CANCER SOC, V122, P559, DOI 10.1002/cncr.29781; Le Gouill S, 2007, HAEMATOL-HEMATOL J, V92, P1335, DOI 10.3324/haematol.11305; Lee JH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01998-5; LENNERT K, 1975, BRIT J CANCER, V31, P29; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Li MY, 2017, AM J SURG PATHOL, V41, P1322, DOI 10.1097/PAS.0000000000000836; Li SY, 2016, ONCOTARGET, V7, P38122, DOI 10.18632/oncotarget.9473; Li SY, 2016, HISTOPATHOLOGY, V68, P1090, DOI 10.1111/his.12884; Li SY, 2016, AM J SURG PATHOL, V40, P253, DOI 10.1097/PAS.0000000000000542; Li SY, 2015, MODERN PATHOL, V28, P208, DOI 10.1038/modpathol.2014.95; Li SY, 2012, MODERN PATHOL, V25, P145, DOI 10.1038/modpathol.2011.147; Lin P, 2007, HAEMATOL-HEMATOL J, V92, P1297, DOI 10.3324/haematol.11263; Lin P, 2012, CANCER-AM CANCER SOC, V118, P1566, DOI 10.1002/cncr.26433; Loddenkemper C, 2004, J PATHOL, V202, P60, DOI 10.1002/path.1485; Lu TX, 2015, ONCOTARGET, V6, P18374, DOI 10.18632/oncotarget.4073; LUKES RJ, 1974, CANCER, V34, P1488, DOI 10.1002/1097-0142(197410)34:8+<1488::AID-CNCR2820340822>3.0.CO;2-C; Nguyen L, 2017, GENES-BASEL, V8, DOI 10.3390/genes8040116; Martelli M, 2013, CRIT REV ONCOL HEMAT, V87, P146, DOI 10.1016/j.critrevonc.2012.12.009; Meyer PN, 2011, J CLIN ONCOL, V29, P200, DOI 10.1200/JCO.2010.30.0368; Monti S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004-07-2947; Moore EM, 2017, AM J SURG PATHOL, V41, P1155, DOI 10.1097/PAS.0000000000000818; Morin RD, 2013, BLOOD, V122, P1256, DOI 10.1182/blood-2013-02-483727; Muris JJF, 2006, J PATHOL, V208, P714, DOI 10.1002/path.1924; Naeini YB, 2016, ANN DIAGN PATHOL, V25, P7, DOI 10.1016/j.anndiagpath.2016.07.008; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Niitsu N, 2009, LEUKEMIA, V23, P777, DOI 10.1038/leu.2008.344; Nyman H, 2007, BLOOD, V109, P4930, DOI 10.1182/blood-2006-09-047068; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; Oki Y, 2014, BRIT J HAEMATOL, V166, P891, DOI 10.1111/bjh.12982; Ott G, 2010, BLOOD, V116, P4916, DOI 10.1182/blood-2010-03-276766; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Pedersen MO, 2014, EUR J HAEMATOL, V92, P42, DOI 10.1111/ejh.12212; Pedersen MO, 2012, EUR J HAEMATOL, V89, P63, DOI 10.1111/j.1600-0609.2012.01787.x; Perry AM, 2016, HAEMATOLOGICA, V101, P1244, DOI 10.3324/haematol.2016.148809; Perry AM, 2012, BLOOD, V120, P2290, DOI 10.1182/blood-2012-05-430389; Petrich AM, 2014, BLOOD, V124, P2354, DOI 10.1182/blood-2014-05-578963; Pillai RK, 2013, AM J SURG PATHOL, V37, P323, DOI 10.1097/PAS.0b013e31826cebad; Pizzi M, 2014, FRONT BIOSCI-LANDMRK, V19, P1088, DOI 10.2741/4269; Quesada AE, 2017, MOD PATHOL; Rappaport H., 1966, TUMORS HEMATOPOEITIC; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Rossi D, 2017, BLOOD, V129, P1947, DOI 10.1182/blood-2016-05-719641; Schmidt-Hansen M, 2017, LEUKEMIA LYMPHOMA, V58, P2403, DOI 10.1080/10428194.2017.1287364; Scott DW, 2014, BLOOD, V123, P1214, DOI 10.1182/blood-2013-11-536433; SHIPP MA, 1993, NEW ENGL J MED, V329, P987; Slack GW, 2014, BRIT J HAEMATOL, V167, P608, DOI 10.1111/bjh.13085; SMITH JL, 1973, LANCET, V1, P74; Swerdlow SH, 2008, WHO CLASSIFICATION T; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tagawa H, 2006, BLOOD, V107, P3052; Taylor CR, 2011, VIRCHOWS ARCH, V458, P637, DOI 10.1007/s00428-011-1083-0; Teras LR, 2016, CA-CANCER J CLIN, V66, P443, DOI 10.3322/caac.21357; Thakral B, 2017, EUR J HAEMATOL, V98, P415, DOI 10.1111/ejh.12847; Tomita N, 2009, HAEMATOL-HEMATOL J, V94, P935, DOI 10.3324/haematol.2008.005355; Turakhia SK, 2014, AM J CLIN PATHOL, V142, P339, DOI 10.1309/AJCPBWVHTF7RRSA4; Visco C, 2012, LEUKEMIA, V26, P2103, DOI 10.1038/leu.2012.83; Visco C, 2013, HAEMATOLOGICA, V98, P255, DOI 10.3324/haematol.2012.066209; Wang W, 2015, AM J SURG PATHOL, V39, P1132, DOI 10.1097/PAS.0000000000000434; Wang XJ, 2017, MODERN PATHOL, V30, P194, DOI 10.1038/modpathol.2016.178; Wang XJ, 2016, EUR J HAEMATOL, V97, P39, DOI 10.1111/ejh.12680; Wang XJ, 2015, AM J SURG PATHOL, V39, P1250, DOI 10.1097/PAS.0000000000000433; Wiestner A, 2013, J CLIN ONCOL, V31, P128, DOI 10.1200/JCO.2012.44.4281; Xie Y, 2014, AM J CLIN PATHOL, V141, P593, DOI 10.1309/AJCPPHMZ6VHF0WQV; Xu J, 2017, HUM PATHOL, V60, P160, DOI 10.1016/j.humpath.2016.10.009; Xu-Monette ZY, 2015, ONCOTARGET, V6, P5615, DOI 10.18632/oncotarget.3479; Xu-Monette ZY, 2012, BLOOD, V120, P3986, DOI 10.1182/blood-2012-05-433334; Xu-Monette ZY, 2012, BLOOD, V119, P3668, DOI 10.1182/blood-2011-11-366062; Yamaguchi M, 2002, BLOOD, V99, P815, DOI 10.1182/blood.V99.3.815; Yao Z, 2017, LEUKEMIA; Young KH, 2007, BLOOD, V110, P4396, DOI 10.1182/blood-2007-02-072082; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110; Zhou Z, 2014, BLOOD, V123, P837, DOI 10.1182/blood-2013-09-524108	114	31	33	8	37	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JAN	2018	50	1					74	87		10.1016/j.pathol.2017.09.006			14	Pathology	Pathology	FU6MY	WOS:000423967900009	29167021				2019-10-28	
J	Ulbright, TM				Ulbright, Thomas M.			Pitfalls in the interpretation of specimens from patients with testicular tumours, with an emphasis on variant morphologies	PATHOLOGY			English	Review						Testicular neoplasm; germ cell tumour; seminoma; embryonal carcinoma; yolk sac tumour; trophoblastic tumour; teratoma; Sertoli cell tumour; post-chemotherapy resection; sarcomatoid yolk sac tumour; immunohistochemistry	GERM-CELL TUMORS; CYSTIC TROPHOBLASTIC TUMOR; SOFT-TISSUE SARCOMAS; YOLK-SAC TUMOR; SPERMATOCYTIC SEMINOMA; EMBRYONAL CARCINOMA; TESTIS; CHEMOTHERAPY; FEATURES; GLYPICAN-3	Accurate diagnosis of primary and metastatic tumours is essential in testicular cancer. While many cases are straightforward, some pose difficulties, especially when variant morphologies occur. Seminoma with 'atypical' features, including increased nuclear pleomorphism and crowding and greater cytoplasmic density with loss of membrane definition, mimics embryonal carcinoma, although ancillary features (fibrous septa, lymphocytes) and immunohistochemistry are of great help. Other deceptive seminoma features include prominent to exclusive intertubular growth, microcystic/tubular patterns, and signet-ring tumour cells. Conversely, embryonal carcinomas may have 'seminoma-like' foci, as may Sertoli cell tumours with diffuse growth and pale cytoplasm. Solid pattern yolk sac tumour mimics seminoma and, conversely, microcytic seminoma resembles yolk sac tumour. Other architectural patterns, ancillary yolk sac tumour features (intercellular basement membrane deposits, hyaline cytoplasmic globules) and immunohistochemistry aid in distinction from seminoma. Embryonal carcinomas may show, in addition to 'seminoma-like' foci, pseudoendodermal sinus-like structures, sieve-like patterns, endometrioid-like morphology and prominent zones of stratified columnar tumour cells. These may cause confusion with yolk sac tumour and teratoma, although careful attention to cytological features usually suffices for accurate diagnosis. Recent work has defined 'new' primary trophoblastic tumours, i.e., cystic trophoblastic tumour and epithelioid trophoblastic tumour. The newly termed 'spermatocytic tumour' occasionally consists mostly of a monotonous proliferation of intermediate-sized tumour cells with prominent nucleoli, thereby simulating either seminoma or embryonal carcinoma. Prostatic adenocarcinoma remains the most common tumour to metastasise to the testis and can cause confusion with rete carcinomas and primary germ cell tumours. Post-chemotherapy resections pose their own challenges. Effete tumour cells in areas of necrosis and prominent fibroxanthomatous reactions should not be interpreted as persistent, viable germ cell tumour. 'Fibrosis' often has atypical widely scattered spindle tumour cells in a densely collagenous background but does not merit additional treatment apart from excision. The marked cytological atypia that may occur in metastatic teratoma may be disconcerting but, again, the proper treatment is complete surgical excision rather than more chemotherapy. Glandular and sarcomatoid yolk sac tumours, which are almost exclusively seen after chemotherapy, resemble adenocarcinomas and sarcomas, respectively. Unlike de novo malignancies, they are mostly seen in sites expected for metastases.	[Ulbright, Thomas M.] Indiana Univ Sch Med, Indiana Univ Hlth, Dept Pathol & Lab Med, Pathol Lab, Indianapolis, IN 46202 USA	Ulbright, TM (reprint author), IU Hlth Pathol Lab, Room 4014,350 W 11th St, Indianapolis, IN 46202 USA.	tulbrigh@iupui.edu					AlboresSaavedra J, 1996, HUM PATHOL, V27, P650, DOI 10.1016/S0046-8177(96)90393-7; Beck SDW, 2002, J UROLOGY, V168, P1402, DOI 10.1097/01.ju.0000027902.28824.71; Cancer Research UK, 2014, TEST CANC SURV STAT; Cheng L, 2007, J PATHOL, V213, P65, DOI 10.1002/path.2202; Clevenger JA, 2009, MODERN PATHOL, V22, P1361, DOI 10.1038/modpathol.2009.108; Coindre JM, 2006, ARCH PATHOL LAB MED, V130, P1448; DAVEY DD, 1987, CANCER, V59, P533, DOI 10.1002/1097-0142(19870201)59:3<533::AID-CNCR2820590329>3.0.CO;2-X; EINHORN LH, 1977, ANN INTERN MED, V87, P293, DOI 10.7326/0003-4819-87-3-293; FRIEDMAN N B, 1946, Mil Surg, V99, P573; Gondim DD, 2017, AM J SURG PATHOL, V41, P788, DOI 10.1097/PAS.0000000000000830; Henley JD, 2002, AM J SURG PATHOL, V26, P541, DOI 10.1097/00000478-200205000-00001; Henley JD, 2004, AM J SURG PATHOL, V28, P1163, DOI 10.1097/01.pas.0000132742.12221.82; Howitt BE, 2015, AM J SURG PATHOL, V39, P251, DOI 10.1097/PAS.0000000000000322; Idrees MT, 2015, AM J SURG PATHOL, V39, P1468, DOI 10.1097/PAS.0000000000000509; Jones TD, 2004, AM J SURG PATHOL, V28, P935, DOI 10.1097/00000478-200407000-00014; Kao CS, 2014, AM J SURG PATHOL, V38, P689, DOI 10.1097/PAS.0000000000000171; Kao CS, 2012, AM J SURG PATHOL, V36, P360, DOI 10.1097/PAS.0b013e31823c510b; Looijenga LHJ, 2003, CANCER RES, V63, P2244; Magers MJ, 2014, AM J SURG PATHOL, V38, P1396, DOI 10.1097/PAS.0000000000000262; Michael H, 1997, AM J SURG PATHOL, V21, P896, DOI 10.1097/00000478-199708000-00003; Mosbech CH, 2014, VIRCHOWS ARCH, V465, P567, DOI 10.1007/s00428-014-1635-1; Nazeer T, 1998, ONCOL REP, V5, P1425; Nochomovitz LE, 1994, J UROL PATHOL, V2, P1; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; Ota S, 2006, VIRCHOWS ARCH, V449, P308, DOI 10.1007/s00428-006-0238-x; Pavic M, 2006, UROLOGY, V67, P84611, DOI 10.1016/j.urology.2005.10.039; Rice KR, 2014, J UROLOGY, V192, P1403, DOI 10.1016/j.juro.2014.05.118; SCULLY RE, 1961, CANCER-AM CANCER SOC, V14, P788, DOI 10.1002/1097-0142(199007/08)14:4<788::AID-CNCR2820140414>3.0.CO;2-3; SRIGLEY JR, 1988, ULTRASTRUCT PATHOL, V12, P67, DOI 10.3109/01913128809048477; Tickoo SK, 2002, INT J SURG PATHOL, V10, P23, DOI 10.1177/106689690201000105; TROJANI M, 1984, INT J CANCER, V33, P37, DOI 10.1002/ijc.2910330108; Ulbright T. M, 2016, WHO CLASSIFICATION T, P189; Ulbright TM, 2008, AM J SURG PATHOL, V32, P1683, DOI 10.1097/PAS.0b013e3181788516; Ulbright TM, 2008, AM J SURG PATHOL, V32, P1175, DOI 10.1097/PAS.0b013e31816597b0; Ulbright TM, 2014, AM J SURG PATHOL, V38, pE50, DOI 10.1097/PAS.0000000000000233; ULBRIGHT TM, 1990, PATHOL ANNU, V25, P313; Ulbright TM, 2005, AM J SURG PATHOL, V29, P500, DOI 10.1097/01.pas.0000155146.60670.3f; Ulbright TM, 2004, AM J SURG PATHOL, V28, P1212, DOI 10.1097/01.pas.0000128675.56664.f7; Ulbright TM, 2013, TUMORS TESTIS ADJACE; Zynger DL, 2006, AM J SURG PATHOL, V30, P1570, DOI 10.1097/01.pas.0000213322.89670.48	40	3	4	2	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JAN	2018	50	1					88	99		10.1016/j.pathol.2017.07.013			12	Pathology	Pathology	FU6MY	WOS:000423967900010	29129333				2019-10-28	
J	Rakha, EA; Ellis, IO				Rakha, Emad A.; Ellis, Ian O.			Diagnostic challenges in papillary lesions of the breast	PATHOLOGY			English	Review						Breast cancer; papillary lesions; diagnosis; challenges	TALL CELL VARIANT; THYROID-CARCINOMA; INVASIVE TUMOR; MANAGEMENT; CANCER; NEOPLASMS; PATTERNS; MARKERS; PROFILE; BIOPSY	Papillary lesions of the breast comprise a heterogeneous group of diseases ranging from benign and atypical lesions to malignant tumours including non-invasive and invasive entities. Although diagnosis of papillary lesions featuring typical histological features is straightforward, a proportion shows overlapping features, posing diagnostic challenges. In addition to being uncommon, the excellent behaviour of papillary tumours reduces the distinguishing value of individual histological features and increases the subjectivity of interpretation of various diagnostic features. Therefore the overall categorisation, which is based on a constellation of subjective features, may vary with subsequent management implications. Concordance studies revealed that recognition of papillary carcinomas (PC) as a malignant entity by pathologists is high, but concordance of its classification into in situ and invasive disease can be problematic, as can assessment of prognostic and predictive factors in the invasive component. Identification of low nuclear grade atypia within benign papillary lesions and its classification into atypia or in situ carcinoma may also pose a diagnostic challenge. Although immunohistochemistry is helpful in evaluation of benign and atypical lesions it has a limited utility in differentiating the majority of PC as non-invasive or invasive disease. Pathologists should be aware of the various entities and the differential diagnosis of each entity, the existence of lesions with overlapping features and should follow the updated guideline recommendation for their diagnosis and management. These rare lesions usually require additional diagnostic work-up and difficult cases should trigger consensus opinion or expert referral.	Univ Nottingham, Sch Med, Div Canc & Stem Cells, Nottingham, England; Nottingham Univ Hosp NHS Trust, City Hosp, Nottingham, England	Rakha, EA (reprint author), Nottingham Univ Hosp NHS Trust, Dept Histopathol, City Hosp Campus,Hucknall Rd, Nottingham NG5 1PB, England.	emad.rakha@nottingham.ac.uk	Rakha, Emad/Q-5554-2019	Rakha, Emad/0000-0002-5009-5525; Ellis, Ian/0000-0001-5292-8474			Anderson WF, 2004, CANCER EPIDEM BIOMAR, V13, P1128; Cameselle-Teijeiro J, 2006, INT J SURG PATHOL, V14, P79, DOI 10.1177/106689690601400116; CARTER D, 1983, CANCER, V52, P14, DOI 10.1002/1097-0142(19830701)52:1<14::AID-CNCR2820520104>3.0.CO;2-N; Chiang S, 2016, CANCER RES, V76, P7118, DOI 10.1158/0008-5472.CAN-16-0298; Collins L, 2012, WHO CLASSIFICATION T; Collins LC, 2008, HISTOPATHOLOGY, V52, P20, DOI 10.1111/j.1365-2559.2007.02898.x; Collins LC, 2006, AM J SURG PATHOL, V30, P1002, DOI 10.1097/00000478-200608000-00011; Cserni G, 2012, APMIS, V120, P249, DOI 10.1111/j.1600-0463.2011.02840.x; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; Eberle CA, 2016, HISTOPATHOLOGY, V68, P1030, DOI 10.1111/his.12897; Ellis IO, 2016, PATHOLOGY REPORTING, P160; Eusebi V, 2003, AM J SURG PATHOL, V27, P1114, DOI 10.1097/00000478-200308000-00008; Fayanju OM, 2007, AM J SURG, V194, P497, DOI 10.1016/j.amjsurg.2007.06.016; Foschini MP, 2017, AM J SURG PATHOL, V41, P887, DOI 10.1097/PAS.0000000000000853; Grabowski J, 2008, CANCER, V113, P916, DOI 10.1002/cncr.23723; Grin A, 2009, AM J SURG PATHOL, V33, P1615, DOI 10.1097/PAS.0b013e3181aec446; Gurbuz Y, 2003, J CLIN PATHOL, V56, P552, DOI 10.1136/jcp.56.7.552; Hameed O, 2009, MODERN PATHOL, V22, P1236, DOI 10.1038/modpathol.2009.91; Harris KP, 1999, BRIT J SURG, V86, P1274, DOI 10.1046/j.1365-2168.1999.01254.x; Hill CB, 2005, AM J CLIN PATHOL, V123, P36, DOI 10.1309/XG7TPQ16DMJAV8P1; Koerner F, 2010, SEMIN DIAGN PATHOL, V27, P13, DOI 10.1053/j.semdp.2009.12.004; LEFKOWITZ M, 1994, HUM PATHOL, V25, P802, DOI 10.1016/0046-8177(94)90250-X; Lewis JT, 2006, AM J SURG PATHOL, V30, P665, DOI 10.1097/00000478-200606000-00001; Li CI, 2005, BRIT J CANCER, V93, P1046, DOI 10.1038/sj.bjc.6602787; Louwman MWJ, 2007, INT J CANCER, V121, P127, DOI 10.1002/ijc.22625; MacGrogan G, 2012, WHO CLASSIFICATION T; Masood S, 2012, ADV ANAT PATHOL, V19, P108, DOI 10.1097/PAP.0b013e318249d090; Mulligan AM, 2007, INT J SURG PATHOL, V15, P143, DOI 10.1177/1066896906299119; Nagi C, 2005, ARCH PATHOL LAB MED, V129, P1465; Nassar H, 2006, AM J SURG PATHOL, V30, P501, DOI 10.1097/00000478-200604000-00011; Nicolas MM, 2007, HISTOPATHOLOGY, V51, P657, DOI 10.1111/j.1365-2559.2007.02849.x; O'Malley FP, 2012, WHO CLASSIFICATION T; Pal SK, 2010, BREAST CANCER RES TR, V122, P637, DOI 10.1007/s10549-010-0961-5; Rakha EA, 2017, HISTOPATHOLOGY, V70, P632, DOI 10.1111/his.13117; Rakha EA, 2016, HISTOPATHOLOGY, V69, P862, DOI 10.1111/his.13009; Rakha EA, 2016, PATHOBIOLOGY, V83, P221, DOI 10.1159/000442884; Rakha EA, 2016, HISTOPATHOLOGY, V68, P45, DOI 10.1111/his.12861; Rakha EA, 2015, HISTOPATHOLOGY, V66, P740, DOI 10.1111/his.12591; Rakha EA, 2012, J CLIN PATHOL, V65, P710, DOI 10.1136/jclinpath-2012-200710; Rakha EA, 2011, AM J SURG PATHOL, V35, P1093, DOI 10.1097/PAS.0b013e31821b3f65; Rosen PP, 2009, ROSENS BREAST PATHOL; Seal M, 2009, VIRCHOWS ARCH, V455, P477, DOI 10.1007/s00428-009-0834-7; Solorzano CC, 2002, AM J SURG, V184, P364, DOI 10.1016/S0002-9610(02)00941-8; Tan PH, 2015, HISTOPATHOLOGY, V66, P761, DOI 10.1111/his.12463; Tavassoli F, 1999, PATHOLOGY BREAST, P325; Tavassoli FA, 2003, PATHOLOGY GENETICS T; Tosi AL, 2007, INT J SURG PATHOL, V15, P14, DOI 10.1177/1066896906295689; Tramm T, 2011, AM J SURG PATHOL, V35, P202, DOI 10.1097/PAS.0b013e31820598a2; Tsang WYW, 1996, AM J SURG PATHOL, V20, P921, DOI 10.1097/00000478-199608000-00002; Tse G, 2012, WHO CLASSIFICATION T; Ueng SH, 2009, ARCH PATHOL LAB MED, V133, P893, DOI 10.1043/1543-2165-133.6.893; Visscher D, 2012, WHO CLASSIFICATION T; Wei Bing, 2006, Zhonghua Bing Li Xue Za Zhi, V35, P589	53	5	5	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JAN	2018	50	1					100	110		10.1016/j.pathol.2017.10.005			11	Pathology	Pathology	FU6MY	WOS:000423967900011	29179906	Bronze			2019-10-28	
J	Asa, SL; Mete, O				Asa, Sylvia L.; Mete, Ozgur			Endocrine pathology: past, present and future	PATHOLOGY			English	Review						Endocrine pathology; history; biomarkers; genetics; epidemiology	KI67 PROLIFERATIVE INDEX; NEUROENDOCRINE TUMORS; GENOMIC CHARACTERIZATION; THYROID-CANCER; DIAGNOSIS; LESIONS	Endocrine pathology is the subspecialty of diagnostic pathology which deals with the diagnosis and characterisation of neoplastic and non-neoplastic diseases of the endocrine system. This relatively young subspecialty was initially focused mainly on thyroid and parathyroid pathology, with some participants also involved in studies of the pituitary, the endocrine pancreas, and the adrenal glands. However, the endocrine system involves much more than these traditional endocrine organs and the discipline has grown to encompass lesions of the dispersed neuroendocrine cells, including neuroendocrine tumours (NETs) of the lungs, gastrointestinal tract, thymus, breast and prostate, as well as paraganglia throughout the body, not just in the adrenals. Indeed, the production of hormones is the hallmark of the endocrine system, and some aspects of gynecological/testicular, bone and liver pathology also fall into the realm of this specialty. Many of the lesions that are the focus of this discipline are increasing in incidence and their pathology is becoming more complex with increased understanding of molecular pathology and a high incidence of familial disease. The future of endocrine pathology will demand a depth of understanding of structure, function, prognosis and prediction as pathologists play a key role in the multidisciplinary care team of patients with endocrine diseases. It is anticipated that new technologies will allow increased subspecialisation in pathology and growth of this important area of expertise.	Univ Hlth Network, Lab Med Program, Dept Pathol, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	Asa, SL (reprint author), 200 Elizabeth St,11th Floor, Toronto, ON M5G 2M9, Canada.	sylvia.asa@uhn.ca		Asa, Sylvia/0000-0001-8418-5054			Addison T, 1855, CONSTITUTIONAL LOCAL, P201; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Asa SL, 2005, ENDOCR PATHOL, V16, P295, DOI 10.1385/EP:16:4:295; Asa SL, 2016, ENDOCRINE PATHOLOGY; Asa SL, 2011, TUMORS PITUITARY GLA; Asa SL, 2017, PATHOLOGY, V49, P229, DOI 10.1016/j.pathol.2017.01.001; Asa SL, 2016, EXPERT REV ENDOCRINO, V11, P149, DOI 10.1586/17446651.2016.1153422; Asa SL, 2015, THYROID, V25, P1, DOI 10.1089/thy.2014.0540; Banting FG, 1922, J LAB CLIN MED, V7, P464; Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P325; Bernard C, 1849, COMPT REND SOC BIOL, V1, P60; Boerner SL, 2017, BIOPSY INTERPRETATIO; Brastianos PK, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv310; Brown-Sequard C E, 1893, Br Med J, V1, P1145; Cheung CC, 2001, MODERN PATHOL, V14, P338, DOI 10.1038/modpathol.3880312; Chou A, 2015, AM J SURG PATHOL, V39, P652, DOI 10.1097/PAS.0000000000000368; Cushing H, 1932, B JOHNS HOPKINS HOSP, V50, P137; Descartes R., 1649, DES PASSIONS DE LAME; Duan K, ENDOCRINE PATHOLOGY; Duan K, 2017, AJSP-REV REP, V22, P246, DOI 10.1097/PCR.0000000000000206; Erdheim J, 1903, BEITR PATHOL ANAT AL, V33, P158; Erovic BM, 2012, ENDOCR PATHOL, V23, P221, DOI 10.1007/s12022-012-9222-y; Fishbein L, 2017, CANCER CELL, V31, P181, DOI 10.1016/j.ccell.2017.01.001; Flajani G., 1802, COLLEZIONE OSSERVAZI, V3, P270; Gomez-Hernandez K, 2016, ENDOCRINE PATHOLOGY; Graves RJ, 1835, LOND MED SURG J 2, V7, P516; Gucer H, 2013, VIRCHOWS ARCH, V463, P593, DOI 10.1007/s00428-013-1465-6; Hafezi-Bakthiari S, 2016, ENDOCRINE PATHOLOGY; HARRIS GW, 1948, PHYSIOL REV, V28, P139; Juhlin CC, 2010, ENDOCR PATHOL, V21, P166, DOI 10.1007/s12022-010-9121-z; Klein M, 1968, Arch Anat Histol Embryol, V51, P379; Kovacs K, 2014, ENDOCR PATHOL, V25, P2, DOI 10.1007/s12022-013-9249-8; Kulke MH, 2011, J CLIN ONCOL, V29, P934, DOI 10.1200/JCO.2010.33.2056; Kultschitzky N., 1897, Archiv fuer Mikroskopische Anatomie, Vxlix, P7; Laguesse E, 1895, J ANAT PHYSL, V31, P475; Langerhans P, 1869, BEITRAGE MIKROSKOPIS; LEMBECK F, 1953, NATURE, V172, P910, DOI 10.1038/172910a0; Lyssikatos C, 2016, ENDOCRINE PATHOLOGY; Marie P, 1886, REV MED-PARIS, V6, P297; McCall CM, 2013, AM J SURG PATHOL, V37, P1671, DOI 10.1097/PAS.0000000000000089; Mete O, 2017, AM J SURG PATHOL; Mete O, 2013, PATHOLOGY, V45, P316, DOI 10.1097/PAT.0b013e32835f45c5; Minkowski O, 1887, BERL KLIN WOCHENSCHR, V24, P371; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Nonaka D, 2011, AM J SURG PATHOL, V35, P145, DOI 10.1097/PAS.0b013e31820371e4; Obendorfer S, 1907, FRANKFURT Z PATHOL, V1, P425; Oishi N, 2016, HUM PATHOL, V53, P51, DOI 10.1016/j.humpath.2016.02.008; Ordonez NG, 2014, APPL IMMUNOHISTO M M, V22, P756, DOI 10.1097/PAI.0000000000000007; Oudijk L, 2016, ENDOCRINE PATHOLOGY; Papathomas TG, 2016, AM J SURG PATHOL, V40, P569, DOI 10.1097/PAS.0000000000000574; Parry CH, 1825, COLLECTIONS ME UNPUB; Pearse A G, 1974, Pathol Annu, V9, P27; Pellegriti G, 2013, J CANCER EPIDEMIOL, DOI 10.1155/2013/965212; Reagh J, 2017, AM J SURG PATHOL, V41, P75, DOI 10.1097/PAS.0000000000000740; SANGER F, 1953, BIOCHEM J, V53, P353, DOI 10.1042/bj0530353; Sheehan HL, 1937, J PATHOL BACTERIOL, V45, P189, DOI 10.1002/path.1700450118; Simmonds M, 1914, DEUT MED WOCHENSCHR, V40, P322, DOI 10.1055/s-0029-1190185; Singh S, 2014, EJSO-EUR J SURG ONC, V40, P1517, DOI 10.1016/j.ejso.2014.06.016; Singh S, 2016, CANCER TREAT REV, V47, P32, DOI 10.1016/j.ctrv.2016.05.003; Tang LH, 2012, AM J SURG PATHOL, V36, P1761, DOI 10.1097/PAS.0b013e318263207c; Testa AG, 1810, MALATTIE CUORE LORO; Toledo RA, 2017, NAT REV ENDOCRINOL, V13, P233, DOI 10.1038/nrendo.2016.185; Vigneri R, 2015, CURR OPIN ONCOL, V27, P1, DOI 10.1097/CCO.0000000000000148; Volynskaya Z, 2017, ARCH PATHOL LAB MED; Volynskaya Z, 2017, ADV ANAT PATHOL, V24, P215, DOI 10.1097/PAP.0000000000000153; Von Basedow KA, 1840, WOCHENSCHRIFT GESAMM, V6, P197; Von Mering J, 1889, ZBL KLIN MED, V10, P393; WERMER P, 1954, AM J MED, V16, P363, DOI 10.1016/0002-9343(54)90353-8; Winer S, 2016, ENDOCRINE PATHOLOGY; Zander R., 1890, BEITR PATH ANAT, V7, P439; Zheng SY, 2016, CANCER CELL, V29, P723, DOI 10.1016/j.ccell.2016.04.002	71	4	4	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	JAN	2018	50	1					111	118		10.1016/j.pathol.2017.09.003			8	Pathology	Pathology	FU6MY	WOS:000423967900012	29132721				2019-10-28	
J	Gulumian, M; Andraos, C				Gulumian, Mary; Andraos, Charlene			In Search of a Converging Cellular Mechanism in Nanotoxicology and Nanomedicine in the Treatment of Cancer	TOXICOLOGIC PATHOLOGY			English	Review						nanotoxicology; nanomedicine; cancer treatment; lysosomal membrane permeabilization; autophagy dysfunction; inflammasome activation	LYSOSOMAL MEMBRANE PERMEABILIZATION; NLRP3 INFLAMMASOME ACTIVATION; DOUBLE-EDGED-SWORD; OXIDATIVE STRESS; AUTOPHAGOSOME ACCUMULATION; MALIGNANT-TRANSFORMATION; SILVER NANOPARTICLES; TUMOR SUPPRESSION; T-LYMPHOCYTES; BREAST-CANCER	Multiple applications of nanomaterials have raised concern with regard to their toxicity. With increasing research into nanomaterial safety, mechanisms involved in the toxic effects of nanomaterials have begun to emerge. The importance of nanomaterial-induced lysosomal membrane permeabilization through overloading or direct damage of the lysosomal compartment, resulting in the blockade of autophagosome-lysosome fusion and autophagy dysfunction, as well as inflammasome activation were cited as emerging mechanisms of nanomaterial toxicity. It has recently been proposed that these very mechanisms leading to nanomaterial toxicity may be utilized in nanotherapeutics. This review discusses these nanomaterial-induced mechanisms in detail and how it has been exploited in cancer research. This review also addresses certain considerations that need to be kept in mind when using nanomaterials in therapeutics.	[Gulumian, Mary; Andraos, Charlene] Natl Inst Occupat Hlth, POB 4788, ZA-2000 Johannesburg, South Africa; [Gulumian, Mary] Univ Witwatersrand, Sch Pathol, Haematol & Mol Med Dept, Johannesburg, South Africa	Gulumian, M (reprint author), Natl Inst Occupat Hlth, POB 4788, ZA-2000 Johannesburg, South Africa.	mary.gulumian@nioh.nhls.ac.za					Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Anding AL, 2015, CURR TOP DEV BIOL, V114, P67, DOI 10.1016/bs.ctdb.2015.07.012; Appelqvist H, 2013, J MOL CELL BIOL, V5, P214, DOI 10.1093/jmcb/mjt022; Auberger P, 2017, BLOOD, V129, P547, DOI 10.1182/blood-2016-07-692707; Baker B, 2015, J BIOL CHEM, V290, P6670, DOI 10.1074/jbc.M114.611442; Baron L, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.576; Bhattacharyya K, 2012, OPT LETT, V37, P4474, DOI 10.1364/OL.37.004474; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Biswas R, 2014, J IMMUNOL RES, DOI 10.1155/2014/304180; Blomgran R, 2007, J LEUKOCYTE BIOL, V81, P1213, DOI 10.1189/jlb.0506359; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Boya P, 2012, ANTIOXID REDOX SIGN, V17, P766, DOI 10.1089/ars.2011.4405; Cho WS, 2011, PART FIBRE TOXICOL, V8, DOI 10.1186/1743-8977-8-27; Clark AJ, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957-4484/27/6/065101; Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738; Ding FA, 2014, INT J NANOMED, V9, P4317, DOI 10.2147/IJN.S68685; Domenech M, 2013, ACS NANO, V7, P5091, DOI 10.1021/nn4007048; Erdal H, 2005, P NATL ACAD SCI USA, V102, P192, DOI 10.1073/pnas.0408592102; Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005; Fehrenbacher N, 2005, CANCER RES, V65, P2993, DOI 10.1158/0008-5472.CAN-05-0476; Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194; Futerman AH, 2004, NAT REV MOL CELL BIO, V5, P554, DOI 10.1038/nrm1423; Galluzzi L, 2017, NAT REV CLIN ONCOL, V14, P247, DOI 10.1038/nrclinonc.2016.183; Galluzzi L, 2016, MOL CELL, V62, P473, DOI 10.1016/j.molcel.2016.05.001; Galluzzi L, 2016, TRENDS CELL BIOL, V26, P1, DOI 10.1016/j.tcb.2015.11.001; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Gao W, 2014, CHEM COMMUN, V50, P8117, DOI 10.1039/c4cc03793f; Gary-Bobo M, 2013, CURR MED CHEM, V20, P1946, DOI 10.2174/0929867311320150002; Gattorno M, 2013, ARTHRITIS RHEUM-US, V65, P1137, DOI 10.1002/art.37882; Gillies LA, 2014, J CELL BIOCHEM, V115, P632, DOI 10.1002/jcb.24709; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Guo BC, 2016, SCI REP-UK, V6, DOI 10.1038/srep36107; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Gurung P, 2015, SCI REP-UK, V5, DOI 10.1038/srep14488; Hamilton RF, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-57; Hamilton RF, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-35; Hapuarachchige S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156294; Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018-009-0053-z; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Hu B, 2011, CELL CYCLE, V10, P1936, DOI 10.4161/cc.10.12.16008; Huang DT, 2015, SCI REP-UK, V5, DOI 10.1038/srep14361; Huang LW, 2017, BIOSENS BIOELECTRON, V92, P724, DOI 10.1016/j.bios.2016.10.004; Jo EK, 2016, CELL MOL IMMUNOL, V13, P148, DOI 10.1038/cmi.2015.95; Johansson AC, 2010, APOPTOSIS, V15, P527, DOI 10.1007/s10495-009-0452-5; Johnson-Lyles DN, 2010, TOXICOL APPL PHARM, V248, P249, DOI 10.1016/j.taap.2010.08.008; Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje; Katsnelson MA, 2016, AM J PHYSIOL-CELL PH, V311, pC83, DOI 10.1152/ajpcell.00298.2015; Keliher EJ, 2013, NEOPLASIA, V15, P684, DOI 10.1593/neo.13276; Kenzaoui BH, 2012, BIOCHEM J, V441, P813, DOI 10.1042/BJ20111252; Kepp O, 2010, EUR J IMMUNOL, V40, P627, DOI 10.1002/eji.200940160; Khan MI, 2012, BIOMATERIALS, V33, P1477, DOI 10.1016/j.biomaterials.2011.10.080; Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008; Kolb R, 2014, PROTEIN CELL, V5, P12, DOI 10.1007/s13238-013-0001-4; Kos J, 2014, FUTURE MED CHEM, V6, P1355, DOI [10.4155/FMC.14.73, 10.4155/fmc.14.73]; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kroemer G, 2010, CURR OPIN CELL BIOL, V22, P121, DOI 10.1016/j.ceb.2010.02.003; Kundu JK, 2012, FREE RADICAL BIO MED, V52, P2013, DOI 10.1016/j.freeradbiomed.2012.02.035; Lamkanfi M, 2011, NAT REV IMMUNOL, V11, P213, DOI 10.1038/nri2936; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li HY, 2011, NAT NANOTECHNOL, V6, P645, DOI [10.1038/nnano.2011.153, 10.1038/NNANO.2011.153]; Li Q, 2015, ADV DIFFER EQU-NY, DOI 10.1186/s13662-015-0377-y; Li W., 2015, PHARM ANAL ACTA, V6, P368, DOI [10. 4172/2153-2435. 1000368, DOI 10.4172/2153-2435.1000368]; Li Y, 2016, NANOMEDICINE-UK, V11, P269, DOI 10.2217/nnm.15.196; Lin C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00271; Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913; Lindqvist LM, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.36; Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Lu Y, 2013, ADV FUNCT MATER, V23, P1534, DOI 10.1002/adfm.201202233; Luzio JP, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016840; Ma XW, 2011, ACS NANO, V5, P8629, DOI 10.1021/nn202155y; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Maynadier M, 2013, J CONTROL RELEASE, V171, P251, DOI 10.1016/j.jconrel.2013.07.017; Michallet MC, 2004, J IMMUNOL, V172, P5405, DOI 10.4049/jimmunol.172.9.5405; Mishra AR, 2016, TOXICOL SCI, V150, P473, DOI 10.1093/toxsci/kfw011; Mittal S, 2017, PART FIBRE TOXICOL, V14, DOI 10.1186/s12989-017-0194-4; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Morselli E, 2011, ANTIOXID REDOX SIGN, V14, P2251, DOI 10.1089/ars.2010.3478; Mridha AR, 2017, J HEPATOL, V66, P1037, DOI 10.1016/j.jhep.2017.01.022; Oberle C, 2010, CELL DEATH DIFFER, V17, P1167, DOI 10.1038/cdd.2009.214; Ono K, 2003, MOL CELL BIOL, V23, P665, DOI 10.1128/MCB.23.2.665-676.2003; Ostenfeld MS, 2008, AUTOPHAGY, V4, P487, DOI 10.4161/auto.5774; Peeters PM, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-3; Peynshaert K, 2014, CHEM REV, V114, P7581, DOI 10.1021/cr400372p; Piao SF, 2016, ANN NY ACAD SCI, V1371, P45, DOI 10.1111/nyas.12953; Pietrocola F, 2016, AUTOPHAGY, V12, P1962, DOI 10.1080/15548627.2016.1214778; Puri C, 2013, CELL, V154, P1285, DOI 10.1016/j.cell.2013.08.044; Repnik U, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008755; Repnik U, 2012, BBA-PROTEINS PROTEOM, V1824, P22, DOI 10.1016/j.bbapap.2011.08.016; Sayan M, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0162-4; Serrano-Puebla A, 2016, ANN NY ACAD SCI, V1371, P30, DOI 10.1111/nyas.12966; Simard JC, 2015, J BIOL CHEM, V290, P5926, DOI 10.1074/jbc.M114.610899; Small DM, 2013, INT J CANCER, V133, P2102, DOI 10.1002/ijc.28238; Stern ST, 2008, TOXICOL SCI, V106, P140, DOI 10.1093/toxsci/kfn137; Stern ST, 2008, TOXICOL SCI, V101, P4, DOI 10.1093/toxsci/kfm169; Stern ST, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-20; Turk B, 2009, J BIOL CHEM, V284, P21783, DOI 10.1074/jbc.R109.023820; Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002; Vegerhof A, 2016, MATERIALS, V9, DOI 10.3390/ma9110943; Wang LM, 2011, NANO LETT, V11, P772, DOI 10.1021/nl103992v; Wang YL, 2016, ONCOL REP, V35, P2053, DOI 10.3892/or.2016.4569; Wei PF, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/49/495101; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Wilson SP, 2010, POSTGRAD MED, V122, P125, DOI 10.3810/pgm.2010.09.2209; Withana NP, 2012, CANCER RES, V72, P1199, DOI 10.1158/0008-5472.CAN-11-2759; Wolfram J, 2015, CURR DRUG TARGETS, V16, P1671, DOI 10.2174/1389450115666140804124808; Wu YN, 2011, BIOMATERIALS, V32, P4565, DOI 10.1016/j.biomaterials.2011.03.006; Yamashita T, 2012, MATERIALS, V5, P350, DOI 10.3390/ma5020350; Yang EJ, 2012, BIOMATERIALS, V33, P6858, DOI 10.1016/j.biomaterials.2012.06.016; Yang M, 2013, SMALL, V9, P4194, DOI 10.1002/smll.201300481; Yazdi AS, 2010, P NATL ACAD SCI USA, V107, P19449, DOI 10.1073/pnas.1008155107; Yuan H, 2009, AM J PHYSIOL-HEART C, V296, pH470, DOI 10.1152/ajpheart.01051.2008; Zabirnyk O, 2007, AUTOPHAGY, V3, P278, DOI 10.4161/auto.3916; Zarschler K, 2016, NANOMED-NANOTECHNOL, V12, P1663, DOI 10.1016/j.nano.2016.02.019; Zavodszky E, 2013, FEBS LETT, V587, P1988, DOI 10.1016/j.febslet.2013.04.025; Zhang Q, 2009, AUTOPHAGY, V5, P1107, DOI 10.4161/auto.5.8.9842; Zhang WQ, 2013, ACS APPL MATER INTER, V5, P9856, DOI 10.1021/am4033857; Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x; Zhu WP, 2016, P NATL ACAD SCI USA, V113, P12374, DOI 10.1073/pnas.1605030113; Zhu YL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050607; Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224	125	2	2	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JAN	2018	46	1			SI		4	13		10.1177/0192623317735776			10	Pathology; Toxicology	Pathology; Toxicology	FU4FB	WOS:000423807800001	29034767	Bronze			2019-10-28	
J	Yanamala, N; Orandle, MS; Kodali, VK; Bishop, L; Zeidler-Erdely, PC; Roberts, JR; Castranova, V; Erdely, A				Yanamala, Naveena; Orandle, Marlene S.; Kodali, Vamsi K.; Bishop, Lindsey; Zeidler-Erdely, Patti C.; Roberts, Jenny R.; Castranova, Vincent; Erdely, Aaron			Sparse Supervised Classification Methods Predict and Characterize Nanomaterial Exposures: Independent Markers of MWCNT Exposures	TOXICOLOGIC PATHOLOGY			English	Article						fibrosis markers; computational toxicology; nanotoxicology; predictive models; support vector machines	CARBON NANOTUBE; INHALATION EXPOSURE; GENE SELECTION; MOUSE LUNG; IN-VIVO; CANCER CLASSIFICATION; ASPIRATION EXPOSURE; NALP3 INFLAMMASOME; FIBROSIS; EXPRESSION	Recent experimental evidence indicates significant pulmonary toxicity of multiwalled carbon nanotubes (MWCNTs), such as inflammation, interstitial fibrosis, granuloma formation, and carcinogenicity. Although numerous studies explored the adverse potential of various CNTs, their comparability is often limited. This is due to differences in administered dose, physicochemical characteristics, exposure methods, and end points monitored. Here, we addressed the problem through sparse classification method, a supervised machine learning approach that can reduce the noise contained in redundant variables for discriminating among MWCNT-exposed and MWCNT-unexposed groups. A panel of proteins measured from bronchoalveolar lavage fluid (BAL) samples was used to predict exposure to various MWCNT and determine markers that are attributable to MWCNT exposure and toxicity in mice. Using sparse support vector machine-based classification technique, we identified a small subset of proteins clearly distinguishing each exposure. Macrophage-derived chemokine (MDC/CCL22), in particular, was associated with various MWCNT exposures and was independent of exposure method employed, that is, oropharyngeal aspiration versus inhalation exposure. Sustained expression of some of the selected protein markers identified also suggests their potential role in MWCNT-induced toxicity and proposes hypotheses for future mechanistic studies. Such approaches can be used more broadly for nanomaterial risk profiling studies to evaluate decisions related to dose/time-response relationships that could delineate experimental variables from exposure markers.	[Yanamala, Naveena] NIOSH, Exposure Assessment Branch, Hlth Effects Lab Div, Morgantown, WV USA; [Orandle, Marlene S.; Kodali, Vamsi K.; Bishop, Lindsey; Zeidler-Erdely, Patti C.; Erdely, Aaron] NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV USA; [Roberts, Jenny R.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Morgantown, WV USA; [Castranova, Vincent] West Virginia Univ, Dept Pharmaceut Sci, Morgantown, WV USA	Yanamala, N (reprint author), NIOSH, Exposure Assessment Branch, MS 3030,1095 Willowdale Rd, Morgantown, WV 26505 USA.	nyanamala@cdc.gov	Kodali, Vamsi/D-2497-2009	Kodali, Vamsi/0000-0001-6177-0568	National Institute for Occupational Safety and Health (NIOSH)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [939051E]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by National Institute for Occupational Safety and Health (NIOSH) 939051E.	Ahsen ME, 2012, IEEE DECIS CONTR P, P2976, DOI 10.1109/CDC.2012.6426819; Ahsen ME, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3604-y; Arora S, 2012, TOXICOL APPL PHARM, V258, P151, DOI 10.1016/j.taap.2011.11.010; Belperio JA, 2002, AM J RESP CELL MOL, V27, P419, DOI 10.1165/rcmb.2002-0009OC; Bevilacqua V, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S7-S9; Bishop L, 2017, ACS NANO, V11, P8849, DOI 10.1021/acsnano.7b03038; Bradley P. S., 1998, Machine Learning. Proceedings of the Fifteenth International Conference (ICML'98), P82; Caplan-Shaw CE, 2011, J OCCUP ENVIRON MED, V53, P981, DOI 10.1097/JOM.0b013e31822fff60; Cassel SL, 2008, P NATL ACAD SCI USA, V105, P9035, DOI 10.1073/pnas.0803933105; Chen L, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-161; Chensue SW, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00043; Chiu BC, 2003, AM J RESP CELL MOL, V29, P106, DOI 10.1165/rcmb.2002-0241OC; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411; Dahm MM, 2015, ANN OCCUP HYG, V59, P705, DOI 10.1093/annhyg/mev020; Dolinay T, 2012, AM J RESP CRIT CARE, V185, P1225, DOI 10.1164/rccm.201201-0003OC; Dong J, 2016, ARCH TOXICOL, V90, P2231, DOI 10.1007/s00204-016-1711-1; Dong J, 2016, ARCH TOXICOL, V90, P385, DOI 10.1007/s00204-015-1589-3; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Duan KB, 2005, IEEE T NANOBIOSCI, V4, P228, DOI 10.1109/TNB.2005.853657; Dymacek J, 2015, TOXICOL SCI, V144, P51, DOI 10.1093/toxsci/kfu262; Erdely A, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-53; Erdely A, 2009, NANO LETT, V9, P36, DOI 10.1021/nl801828z; Frankenberger M, 2011, MOL MED, V17, P762, DOI 10.2119/molmed.2010.00202; Guo NL, 2014, CANCER INFORM, V13, P37, DOI 10.4137/CIN.S14054; Guo NL, 2012, J TOXICOL ENV HEAL A, V75, P1129, DOI 10.1080/15287394.2012.699852; Guyon I, 2002, MACH LEARN, V46, P389, DOI 10.1023/A:1012487302797; Huang LK, 2013, CANCER INFORM, V12, P143, DOI 10.4137/CIN.S10212; Inoue T, 2004, EUR RESPIR J, V24, P49, DOI 10.1183/09031936.04.00110203; Johnston HJ, 2010, NANOTOXICOLOGY, V4, P207, DOI 10.3109/17435390903569639; Kim V, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0103-2; Kinaret P, 2017, ACS NANO, V11, P291, DOI 10.1021/acsnano.6b05652; Kodali V. K., 2016, TOXICOLOGICAL SCI S, V150; Ma-Hock L, 2009, TOXICOL SCI, V112, P468, DOI 10.1093/toxsci/kfp146; Maulik U, 2014, IEEE T NANOBIOSCI, V13, P152, DOI 10.1109/TNB.2014.2312132; Meinshausen N, 2010, J R STAT SOC B, V72, P417, DOI 10.1111/j.1467-9868.2010.00740.x; Mercer RR, 2011, PART FIBRE TOXICOL, V8, DOI 10.1186/1743-8977-8-21; Misganaw B, 2015, CANCER INFORM, V14, P45, DOI 10.4137/CIN.S30803; Nikota J, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0137-5; Nolan A, 2012, CHEST, V142, P412, DOI [10.1378/chest.11-1202, 10.1378/chest.11-1.202]; Oberdorster G, 2015, J TOXICOL ENV HEAL B, V18, P121, DOI 10.1080/10937404.2015.1051611; Pacurari M, 2011, TOXICOL APPL PHARM, V255, P18, DOI 10.1016/j.taap.2011.05.012; Palomaki J, 2011, ACS NANO, V5, P6861, DOI 10.1021/nn200595c; Pauluhn J, 2010, TOXICOL SCI, V113, P226, DOI 10.1093/toxsci/kfp247; Porter DW, 2010, TOXICOLOGY, V269, P136, DOI 10.1016/j.tox.2009.10.017; Rao GVS, 2003, J TOXICOL ENV HEAL A, V66, P1441, DOI 10.1080/15287390390201839; Ritter M, 2005, BIOCHEM BIOPH RES CO, V334, P254, DOI 10.1016/j.bbrc.2005.06.084; Roberts J. R., 2016, TOXICOLOGICAL SCI S, V150; Roco MC, 2011, J NANOPART RES, V13, P427, DOI 10.1007/s11051-010-0192-z; Ryman-Rasmussen JP, 2009, AM J RESP CELL MOL, V40, P349, DOI 10.1165/rcmb.2008-0276OC; Schulte PA, 2012, TOXICOL LETT, V213, P91, DOI 10.1016/j.toxlet.2011.03.027; Shinoda H, 2009, RESPIRATION, V78, P285, DOI 10.1159/000207617; Shvedova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL552, DOI 10.1152/ajplung.90287.2008; Shvedova AA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150628; Snyder-Talkington BN, 2016, J TOXICOL ENV HEAL A, V79, P352, DOI 10.1080/15287394.2016.1159635; Snyder-Talkington BN, 2016, J APPL TOXICOL, V36, P161, DOI 10.1002/jat.3157; Snyder-Talkington BN, 2013, TOXICOL APPL PHARM, V272, P476, DOI 10.1016/j.taap.2013.06.026; Sundaramurthy G, 2015, COMPUT BIOL MED, V67, P29, DOI 10.1016/j.compbiomed.2015.07.029; Tabet L, 2011, PART FIBRE TOXICOL, V8, DOI 10.1186/1743-8977-8-3; Tajima S, 2007, EXP LUNG RES, V33, P81, DOI 10.1080/01902140701198583; Vapnik V., 1982, ESTIMATION DEPENDENC; Veropoulos K., 1999, P INT JOINT C ART IN, P55; Vidyasagar M, 2014, P ROY SOC A-MATH PHY, V470, DOI 10.1098/rspa.2014.0081; Weiden MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040016; Wick P, 2007, TOXICOL LETT, V168, P121, DOI 10.1016/j.toxlet.2006.08.019; Wick P, 2011, CHEMSUSCHEM, V4, P905, DOI 10.1002/cssc.201100161; Wu MX, 2010, ENVIRON HEALTH PERSP, V118, P499, DOI 10.1289/ehp.0901159; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412	67	1	1	2	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JAN	2018	46	1			SI		14	27		10.1177/0192623317730575			14	Pathology; Toxicology	Pathology; Toxicology	FU4FB	WOS:000423807800002	28934917	Bronze			2019-10-28	
J	Mercer, RR; Scabilloni, JF; Wang, LY; Battelli, LA; Antonini, JM; Roberts, JR; Qian, Y; Sisler, JD; Castranova, V; Porter, DW; Hubbs, AF				Mercer, Robert R.; Scabilloni, James F.; Wang, Liying; Battelli, Lori A.; Antonini, James M.; Roberts, Jenny R.; Qian, Yong; Sisler, Jennifer D.; Castranova, Vincent; Porter, Dale W.; Hubbs, Ann F.			The Fate of Inhaled Nanoparticles: Detection and Measurement by Enhanced Dark-field Microscopy	TOXICOLOGIC PATHOLOGY			English	Article						fibrosis; inhalation; nanoparticles; nanotechnology; pathology; toxicology	WALLED CARBON NANOTUBES; CARDIOVASCULAR-RESPONSES; OXIDE NANOPARTICLES; OXIDATIVE STRESS; CERIUM OXIDE; PULMONARY; LUNG; INHALATION; RATS; TRANSLOCATION	Assessing the potential health risks for newly developed nanoparticles poses a significant challenge. Nanometer-sized particles are not generally detectable with the light microscope. Electron microscopy typically requires high-level doses, above the physiologic range, for particle examination in tissues. Enhanced dark-field microscopy (EDM) is an adaption of the light microscope that images scattered light. Nanoparticles scatter light with high efficiency while normal tissues do not. EDM has the potential to identify the critical target sites for nanoparticle deposition and injury in the lungs and other organs. This study describes the methods for EDM imaging of nanoparticles and applications. Examples of EDM application include measurement of deposition and clearance patterns. Imaging of a wide variety of nanoparticles demonstrated frequent situations where nanoparticles detected by EDM were not visible by light microscopy. EDM examination of colloidal gold nanospheres (10-100 nm diameter) demonstrated a detection size limit of approximately 15 nm in tissue sections. EDM determined nanoparticle volume density was directly proportional to total lung burden of exposed animals. The results confirm that EDM can determine nanoparticle distribution, clearance, transport to lymph nodes, and accumulation in extrapulmonary organs. Thus, EDM substantially improves the qualitative and quantitative microscopic evaluation of inhaled nanoparticles.	[Mercer, Robert R.; Scabilloni, James F.; Battelli, Lori A.; Sisler, Jennifer D.; Porter, Dale W.; Hubbs, Ann F.] NIOSH, Pathol & Physiol Res Branch, HELD, 1095 Willowdale Dr, Morgantown, WV 26505 USA; [Mercer, Robert R.; Porter, Dale W.] West Virginia Univ, Dept Physiol & Pharmacol, Morgantown, WV USA; [Wang, Liying; Antonini, James M.; Roberts, Jenny R.; Qian, Yong] NIOSH, Allergy & Clin Immunol Branch, HELD, Morgantown, WV USA; [Wang, Liying; Antonini, James M.; Roberts, Jenny R.; Qian, Yong; Castranova, Vincent] West Virginia Univ, Dept Pharmaceut Sci, Morgantown, WV USA	Mercer, RR (reprint author), NIOSH, Pathol & Physiol Res Branch, HELD, 1095 Willowdale Dr, Morgantown, WV 26505 USA.	rmercer@cdc.gov			Intramural CDC HHS [CC999999]		Alexander J S, 2010, Pathophysiology, V17, P315, DOI 10.1016/j.pathophys.2009.09.003; Badireddy AR, 2012, ENVIRON SCI TECHNOL, V46, P10081, DOI 10.1021/es204140s; BARRY BE, 1988, EXP LUNG RES, V14, P225, DOI 10.3109/01902148809115126; BARRY BE, 1985, CRC CR REV TOXICOL, V14, P1, DOI 10.3109/10408448509023763; Chen BT, 2012, INHAL TOXICOL, V24, P798, DOI 10.3109/08958378.2012.720741; Choi HS, 2010, NAT BIOTECHNOL, V28, P1300, DOI 10.1038/nbt.1696; CRAPO JD, 1984, J TOXICOL ENV HEALTH, V13, P301, DOI 10.1080/15287398409530500; Dillon JCK, 2017, MICROSC RES TECHNIQ, V80, P462, DOI 10.1002/jemt.22816; Dixon JB, 2010, ANN NY ACAD SCI, V1207, pE52, DOI 10.1111/j.1749-6632.2010.05716.x; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; ELIAS H, 1983, GUIDE PRACTICAL STER; FLORENCE AT, 1995, J DRUG TARGET, V3, P65, DOI 10.3109/10611869509015936; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; HARMSEN AG, 1985, SCIENCE, V230, P1277, DOI 10.1126/science.4071052; Hillard JE, 1962, MET SOC AIME T, V224, P906; Hyde DM, 2007, TOXICOL PATHOL, V35, P41, DOI 10.1080/01926230601059977; LAUWERYNS JM, 1974, ANN NY ACAD SCI, V221, P244, DOI 10.1111/j.1749-6632.1974.tb28225.x; LOUD AV, 1978, LAB INVEST, V38, P586; Ma J, 2015, TOXICOL APPL PHARM, V288, P63, DOI 10.1016/j.taap.2015.07.012; Ma JYC, 2014, TOXICOL APPL PHARM, V278, P135, DOI 10.1016/j.taap.2014.04.019; Ma XY, 2003, PHYS MED BIOL, V48, P4165, DOI 10.1088/0031-9155/48/24/013; McKinney W, 2012, INHAL TOXICOL, V24, P447, DOI 10.3109/08958378.2012.685111; Mercer RR, 2008, AM J PHYSIOL-LUNG C, V294, pL87, DOI 10.1152/ajplung.00186.2007; Mercer RR, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-38; Mercer RR, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-33; Mercer RR, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-28; MERCER RR, 1994, J APPL PHYSIOL, V77, P1060; MERCER RR, 1994, AM J RESP CELL MOL, V10, P613, DOI 10.1165/ajrcmb.10.6.8003339; MERCER RR, 1987, J APPL PHYSIOL, V62, P1480; Porter DW, 2017, NANOIMPACT, V6, P1, DOI 10.1016/j.impact.2017.01.004; Porter DW, 2013, NANOTOXICOLOGY, V7, P1179, DOI 10.3109/17435390.2012.719649; Porter DW, 2010, TOXICOLOGY, V269, P136, DOI 10.1016/j.tox.2009.10.017; Porter DW, 2004, TOXICOL SCI, V79, P370, DOI 10.1093/toxsci/kfh110; Roberts J. R., 2011, TOXICOLOGIST, V120, P377; Roberts JR, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0145-5; Roberts JR, 2013, J TOXICOL ENV HEAL A, V76, P651, DOI 10.1080/15287394.2013.792024; Roth GA, 2015, JOVE-J VIS EXP, DOI 10.3791/53317; Russ J. C., 2000, PRACTICAL STEREOLGOY; SCHERLE W, 1970, Mikroskopie, V26, P57; Shvedova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL552, DOI 10.1152/ajplung.90287.2008; Sisler JD, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0155-3; Sisler JD, 2016, TOXICOL SCI, V150, P418, DOI 10.1093/toxsci/kfw005; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; STONE KC, 1992, AM J RESP CELL MOL, V6, P235, DOI 10.1165/ajrcmb/6.2.235; Vallyathan V, 2007, J TOXICOL ENV HEAL A, V70, P95, DOI 10.1080/15287390600747825; van de Hulst J. C., 1957, LIGHT SCATTERING SMA; Verebes GS, 2013, J BIOPHOTONICS, V6, P960, DOI 10.1002/jbio.201300067; Wang T, 2004, SECURITIES FRAUD EC, P1; Weibel E. R., 1979, STEREOLOGICAL METHOD; Weibel ER, 1963, MORPHOMETRY HUMAN LU; WOODY D, 1980, J MICROSC-OXFORD, V118, P421, DOI 10.1111/j.1365-2818.1980.tb00291.x; YEH HC, 1976, ENVIRON HEALTH PERSP, V15, P147, DOI 10.2307/3428398; Zhang HY, 2012, ACS NANO, V6, P4349, DOI 10.1021/nn3010087	53	7	7	1	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JAN	2018	46	1			SI		28	46		10.1177/0192623317732321			19	Pathology; Toxicology	Pathology; Toxicology	FU4FB	WOS:000423807800003	28929951	Green Accepted			2019-10-28	
J	Graham, UM; Yokel, RA; Dozier, AK; Drummy, L; Mahalingam, K; Tseng, MT; Birch, E; Fernback, J				Graham, Uschi M.; Yokel, Robert A.; Dozier, Alan K.; Drummy, Lawrence; Mahalingam, Krishnamurthy; Tseng, Michael T.; Birch, Eileen; Fernback, Joseph			Analytical High-resolution Electron Microscopy Reveals Organ-specific Nanoceria Bioprocessing	TOXICOLOGIC PATHOLOGY			English	Article						bioprocessing; ions; liver; nanoceria; nanoparticles; spleen; transformation	CERIUM OXIDE NANOPARTICLES; OXIDATIVE STRESS; BIOMEDICAL APPLICATIONS; PROTECT; RATS; MECHANISMS; BIODEGRADATION; BIOPERSISTENCE; NANOMATERIALS; HYPERTENSION	This is the first utilization of advanced analytical electron microscopy methods, including high-resolution transmission electron microscopy, high-angle annular dark field scanning transmission electron microscopy, electron energy loss spectroscopy, and energy-dispersive X-ray spectroscopy mapping to characterize the organ-specific bioprocessing of a relatively inert nanomaterial (nanoceria). Liver and spleen samples from rats given a single intravenous infusion of nanoceria were obtained after prolonged (90 days) in vivo exposure. These advanced analytical electron microscopy methods were applied to elucidate the organ-specific cellular and subcellular fate of nanoceria after its uptake. Nanoceria is bioprocessed differently in the spleen than in the liver.	[Graham, Uschi M.; Yokel, Robert A.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 1525 Bull Lea Rd,Ste 10, Lexington, KY 40515 USA; [Graham, Uschi M.; Dozier, Alan K.; Birch, Eileen; Fernback, Joseph] NIOSH, Cincinnati, OH 45226 USA; [Drummy, Lawrence; Mahalingam, Krishnamurthy] US Air Force Res Lab, Dayton, OH USA; [Tseng, Michael T.] Univ Louisville, Coll Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA	Graham, UM (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 1525 Bull Lea Rd,Ste 10, Lexington, KY 40515 USA.	graham@topasol.com	Yokel, Robert/P-6310-2019	Yokel, Robert/0000-0001-5188-3972	U.S. Environmental Protection Agency Science to Achieve ResultsUnited States Environmental Protection Agency [RD-833772]; National Institute of General Medical Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM109195]; United States Environmental Protection Agency through STARUnited States Environmental Protection Agency [RD-833772]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research reported in this publication was supported by U.S. Environmental Protection Agency Science to Achieve Results (grant number RD-833772) and the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R01GM109195. Although the research described in this article has been funded wholly or in part by the United States Environmental Protection Agency through STAR Grant RD-833772, it has not been subjected to the Agency's required peer and policy review and therefore does not necessarily reflect the views of the agency, and no official endorsement should be inferred.	Alpaslan E, 2017, SCI REP-UK, V7, DOI 10.1038/srep45859; Arts JHE, 2015, REGUL TOXICOL PHARM, V71, pS1, DOI 10.1016/j.yrtph.2015.03.007; Arya A, 2013, INT J NANOMED, V8, P4507, DOI 10.2147/IJN.S53032; Berry JP, 1997, MICROSC RES TECHNIQ, V36, P313, DOI 10.1002/(SICI)1097-0029(19970215)36:4<313::AID-JEMT9>3.0.CO;2-M; Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91; Chigurupati S, 2013, BIOMATERIALS, V34, P2194, DOI 10.1016/j.biomaterials.2012.11.061; Cho WS, 2012, TOXICOL SCI, V126, P469, DOI 10.1093/toxsci/kfs006; Colon J, 2010, NANOMED-NANOTECHNOL, V6, P698, DOI 10.1016/j.nano.2010.01.010; Crook M. A., 2012, CLIN BIOCHEM; Dozier D., 2017, PROC MICROS MICRO 20; Gao Y, 2014, ONCOTARGETS THER, V7, P835, DOI 10.2147/OTT.S62057; Geraets L, 2012, TOXICOL SCI, V127, P463, DOI 10.1093/toxsci/kfs113; Giri S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054578; Graham U. M., 2017, P MICR MICR 2017 M A; Graham Uschi M, 2017, Adv Exp Med Biol, V947, P71, DOI 10.1007/978-3-319-47754-1_4; Graham UM, 2014, CHEMPLUSCHEM, V79, P1083, DOI 10.1002/cplu.201402080; Gu MA, 2016, MOL PLANT, V9, P396, DOI 10.1016/j.molp.2015.12.012; Hardas SS, 2014, NANOTOXICOLOGY, V8, P155, DOI 10.3109/17435390.2013.868059; He XA, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/28/285103; Heckman KL, 2013, ACS NANO, V7, P10582, DOI 10.1021/nn403743b; Hijaz M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2206-4; Janos P, 2017, ENVIRON SCI-NANO, V4, P1283, DOI 10.1039/c7en00119c; Keller J, 2014, ARCH TOXICOL, V88, P2033, DOI 10.1007/s00204-014-1349-9; Kim CK, 2012, ANGEW CHEM INT EDIT, V51, P11039, DOI 10.1002/anie.201203780; Kolli MB, 2014, BIOMATERIALS, V35, P9951, DOI 10.1016/j.biomaterials.2014.08.037; Konduru N, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/s12989-014-0055-3; Laux P, 2017, NANOIMPACT, V6, P69, DOI 10.1016/j.impact.2017.03.003; Lee JH, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-36; Lee PW, 2010, BIOMATERIALS, V31, P1316, DOI 10.1016/j.biomaterials.2009.11.010; Levy M, 2011, BIOMATERIALS, V32, P3988, DOI 10.1016/j.biomaterials.2011.02.031; Liu YB, 2016, LANGMUIR, V32, P13276, DOI 10.1021/acs.langmuir.6b03342; Mazuel F, 2016, ACS NANO, V10, P7627, DOI 10.1021/acsnano.6b02876; Minarchick VC, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00339; Molina RM, 2014, ENVIRON-SCI NANO, V1, P561, DOI 10.1039/c4en00034j; Navaei-Nigjeh M, 2012, ASIAN J ANIM VET ADV, V7, P605, DOI 10.3923/ajava.2012.605.612; Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/NMAT2442, 10.1038/nmat2442]; Niu JL, 2007, CARDIOVASC RES, V73, P549, DOI 10.1016/j.cardiores.2006.11.031; Nunes A, 2012, NANOMEDICINE-UK, V7, P1485, DOI [10.2217/NNM.12.33, 10.2217/nnm.12.33]; Oberdorster G., 2000, 96 HLTH EFF I; Oro D, 2016, J HEPATOL, V64, P691, DOI 10.1016/j.jhep.2015.10.020; Popov AL, 2016, RSC ADV, V6, P106141, DOI 10.1039/c6ra18566e; Prasad R., 2013, NANO BIOMED ENG, V5, P46, DOI DOI 10.5101/nbe.v5i1.p46-49.1; Pulido-Reyes G, 2017, ENVIRON TOXICOL CHEM, V36, P3181, DOI 10.1002/etc.3924; Reed K, 2014, ENVIRON SCI-NANO, V1, P390, DOI 10.1039/c4en00079j; Rocca A, 2015, NANOMED-NANOTECHNOL, V11, P1725, DOI 10.1016/j.nano.2015.05.001; SCHMIDT EE, 1993, SCANNING MICROSCOPY, V7, P613; Selvaraj V, 2015, BIOMATERIALS, V59, P160, DOI 10.1016/j.biomaterials.2015.04.025; Shvedova AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030923; Sisler JD, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0155-3; Soenen SJ, 2015, CHEM REV, V115, P2109, DOI 10.1021/cr400714j; Steiniger B, 2011, J HISTOCHEM CYTOCHEM, V59, P639, DOI 10.1369/0022155411408315; Tseng MT, 2014, TOXICOL PATHOL, V42, P984, DOI 10.1177/0192623313505780; Tseng MT, 2012, TOXICOL APPL PHARM, V260, P173, DOI 10.1016/j.taap.2012.02.008; Turner S, 2011, NANOSCALE, V3, P3385, DOI 10.1039/c1nr10510h; Vlasova II, 2016, TOXICOL APPL PHARM, V299, P58, DOI 10.1016/j.taap.2016.01.002; Walkey C, 2015, ENVIRON SCI-NANO, V2, P33, DOI 10.1039/c4en00138a; Wohlleben W, 2013, J CERAM SCI TECHNOL, V4, P93, DOI 10.4416/JCST2012-00045; Yokel R. A., 2013, NANOMEDICINE, V9, P98; Yokel RA, 2014, ENVIRON SCI-NANO, V1, P549, DOI 10.1039/c4en00035h; Yokel RA, 2012, TOXICOL SCI, V127, P256, DOI 10.1093/toxsci/kfs067	60	3	3	2	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JAN	2018	46	1			SI		47	61		10.1177/0192623317737254			15	Pathology; Toxicology	Pathology; Toxicology	FU4FB	WOS:000423807800004	29145781	Green Accepted, Bronze			2019-10-28	
J	Hamilton, RF; Tsuruoka, S; Wu, NQ; Wolfarth, M; Porter, DW; Bunderson-Schelvan, M; Holian, A				Hamilton, Raymond F., Jr.; Tsuruoka, Shuji; Wu, Nianqiang; Wolfarth, Michael; Porter, Dale W.; Bunderson-Schelvan, Melisa; Holian, Andrij			Length, but Not Reactive Edges, of Cup-stack MWCNT Is Responsible for Toxicity and Acute Lung Inflammation	TOXICOLOGIC PATHOLOGY			English	Article						MWCNT; macrophage; NLRP3 inflammasome; ROS; nanomaterials	MULTIWALLED CARBON NANOTUBES; NLRP3 INFLAMMASOME; ACTIVATION; NIGERICIN; FIBROSIS; DAMAGE; MICE; FUNCTIONALIZATION; NANOMATERIALS; PURIFICATION	Multiwalled carbon nanotube (MWCNT) toxicity after inhalation has been associated with size, aspect ratio, rigidity, surface modification, and reactive oxygen species production. In this study, we investigated a series of cup-stacked MWCNT prepared as variants of the Creos 24PS. Mechanical chopping produced a short version (AR10) and graphitization to remove active reaction sites by extreme heat (2,800 degrees C; Creos 24HT) to test the contribution of length and alteration of potential reaction sites to toxicity. The 3 MWCNT variants were tested in vitro in a human macrophage-like cell model and with C57BL/6 alveolar macrophages for dose-dependent toxicity and NLRP3 inflammasome activation. The 24PS and 24HT variants showed significant dose-dependent toxicity and inflammasome activation. In contrast, the AR10 variant showed no toxicity or bioactivity at any concentration tested. The in vivo results reflected those observed in vitro, with the 24PS and 24HT variants resulting in acute inflammation, including elevated polymorphonuclear counts, Interleukin (IL)-18, cathepsin B, and lactate dehydrogenase in isolated lung lavage fluid from mice exposed to 40 mu g MWCNT. Taken together, these data indicate that length, but not the absence of proposed reaction sites, on the MWCNT influences particle bioactivity.	[Hamilton, Raymond F., Jr.; Bunderson-Schelvan, Melisa; Holian, Andrij] Univ Montana, Ctr Environm Hlth Sci, Dept Biomed & Pharmaceut Sci, 32 Campus Dr,280 Skaggs, Missoula, MT 59812 USA; [Tsuruoka, Shuji] Shinshu Univ, Inst Carbon Sci & Technol, Nagano, Japan; [Wu, Nianqiang] West Virginia Univ, Dept Mech & Aerosp Engn, Morgantown, WV USA; [Wolfarth, Michael; Porter, Dale W.] NIOSH, Morgantown, WV USA	Holian, A (reprint author), Univ Montana, Ctr Environm Hlth Sci, Dept Biomed & Pharmaceut Sci, 32 Campus Dr,280 Skaggs, Missoula, MT 59812 USA.	andrij.holian@umontana.edu	Wu, Nianqiang/K-1122-2019; Wu, Nianqiang/B-9798-2015	Wu, Nianqiang/0000-0002-8888-2444; Wu, Nianqiang/0000-0002-8888-2444	Center of Innovation Program, "Global Aqua Innovation Center for Improving Living Standards and Water-sustainability" from Japan Science and Technology Agency, JST	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Shuji Tsuruoka was supported by the Center of Innovation Program, "Global Aqua Innovation Center for Improving Living Standards and Water-sustainability" from Japan Science and Technology Agency, JST.	Alarifi S, 2015, INT J TOXICOL, V34, P258, DOI 10.1177/1091581815584799; Antonopoulos C, 2015, J BIOL CHEM, V290, P20167, DOI 10.1074/jbc.M115.652321; Arend WP, 2008, IMMUNOL REV, V223, P20, DOI 10.1111/j.1600-065X.2008.00624.x; Aslan-Sungur G, 2016, SCI TOTAL ENVIRON, V554, P192, DOI 10.1016/j.scitotenv.2016.02.153; Bevensee MO, 1999, J MEMBRANE BIOL, V169, P131, DOI 10.1007/s002329900525; Bissinger R, 2016, BASIC CLIN PHARMACOL, V118, P381, DOI 10.1111/bcpt.12503; BUDUNOVA IV, 1992, CELL BIOL TOXICOL, V8, P63, DOI 10.1007/BF00119295; Bunderson-Schelvan M, 2016, BIOL EFFECTS FIBROUS, P51; Donaldson K, 2006, TOXICOL SCI, V92, P5, DOI 10.1093/toxsci/kfj130; Donaldson K, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-5; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Fenoglio I, 2012, CHEM RES TOXICOL, V25, P74, DOI 10.1021/tx200255h; Grailer JJ, 2014, J IMMUNOL, V192, P5974, DOI 10.4049/jimmunol.1400368; Guey B, 2014, P NATL ACAD SCI USA, V111, P17254, DOI 10.1073/pnas.1415756111; Hamilton Raymond F.  Jr., 2013, International Journal of Biomedical Nanoscience and Nanotechnology, V3, P107, DOI 10.1504/IJBNN.2013.054509; Hamilton RF, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/s12989-014-0043-7; Hamilton RF, 2014, INT J MOL SCI, V15, P6815, DOI 10.3390/ijms15046815; Hamilton RF, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-57; Hamilton RF, 2013, INHAL TOXICOL, V25, P199, DOI 10.3109/08958378.2013.775197; Hamilton RF, 2012, INHAL TOXICOL, V24, P995, DOI 10.3109/08958378.2012.745633; Hamilton RF, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-35; Hedmer M, 2014, ANN OCCUP HYG, V58, P355, DOI 10.1093/annhyg/met072; Heid ME, 2013, J IMMUNOL, V191, P5230, DOI 10.4049/jimmunol.1301490; Jackson P, 2015, ENVIRON MOL MUTAGEN, V56, P183, DOI 10.1002/em.21922; Jessop F, 2015, NANOTOXICOLOGY, V9, P365, DOI 10.3109/17435390.2014.933904; Ji Z, 2012, ACS NANO, V6, P5366, DOI 10.1021/nn3012114; Katsnelson MA, 2015, J IMMUNOL, V194, P3937, DOI 10.4049/jimmunol.1402658; Kusaka T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092634; Lee JW, 2016, AQUAT TOXICOL, V171, P9, DOI 10.1016/j.aquatox.2015.12.005; Lee JS, 2015, NANOTOXICOLOGY, V9, P802, DOI 10.3109/17435390.2014.978404; Lehman JH, 2011, CARBON, V49, P2581, DOI 10.1016/j.carbon.2011.03.028; Liu X, 2008, CARBON, V46, P489, DOI 10.1016/j.carbon.2007.12.018; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Menendez JA, 1996, LANGMUIR, V12, P4404, DOI 10.1021/la9602022; Mercer RR, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-28; Murphy FA, 2013, NANOTOXICOLOGY, V7, P1157, DOI 10.3109/17435390.2012.713527; Murphy FA, 2011, AM J PATHOL, V178, P2587, DOI 10.1016/j.ajpath.2011.02.040; Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397; Nomura J, 2015, J IMMUNOL, V195, P5718, DOI 10.4049/jimmunol.1402512; Ono-Ogasawara M, 2011, IND HEALTH, V49, P726, DOI 10.2486/indhealth.MS1279; Palomaki J, 2011, ACS NANO, V5, P6861, DOI 10.1021/nn200595c; Poland CA, 2012, NANOTOXICOLOGY, V6, P899, DOI 10.3109/17435390.2011.626535; Porter D, 2008, NANOTOXICOLOGY, V2, P144, DOI 10.1080/17435390802318349; Porter DW, 2013, NANOTOXICOLOGY, V7, P1179, DOI 10.3109/17435390.2012.719649; Porter DW, 2010, TOXICOLOGY, V269, P136, DOI 10.1016/j.tox.2009.10.017; Qu GB, 2009, CARBON, V47, P2060, DOI 10.1016/j.carbon.2009.03.056; Rajavel K, 2014, LANGMUIR, V30, P592, DOI 10.1021/la403332b; Sager TM, 2014, NANOTOXICOLOGY, V8, P317, DOI 10.3109/17435390.2013.779757; Sayan M, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0162-4; Sun BB, 2015, SMALL, V11, P2087, DOI 10.1002/smll.201402859; Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725; Tsuruoka S, 2013, J PHYS CONF SER, V429, DOI 10.1088/1742-6596/429/1/012029; Tsuruoka S, 2015, CARBON, V95, P302, DOI 10.1016/j.carbon.2015.08.048; Tsuruoka S, 2015, CARBON, V83, P232, DOI 10.1016/j.carbon.2014.10.009; Wang X, 2011, ACS NANO, V5, P9772, DOI 10.1021/nn2033055; Xia T, 2013, ENVIRON HEALTH PERSP, V121, P683, DOI 10.1289/ehp.1306561; Yang M, 2014, TOXICOL APPL PHARM, V280, P117, DOI 10.1016/j.taap.2014.07.022; Yang WL, 2015, INT J CLIN EXP PATHO, V8, P13209; Yaron JR, 2016, BIOCHEM BIOPH RES CO, V472, P545, DOI 10.1016/j.bbrc.2016.03.021; Zar J. H., 2010, BIOSTATISTICAL ANAL	60	4	4	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JAN	2018	46	1			SI		62	74		10.1177/0192623317732303			13	Pathology; Toxicology	Pathology; Toxicology	FU4FB	WOS:000423807800005	28946794	Green Accepted, Bronze			2019-10-28	
J	Hopkins, LE; Laing, EA; Peake, JL; Uyeminami, D; Mack, SM; Li, XT; Smiley-Jewell, S; Pinkerton, KE				Hopkins, Laurie E.; Laing, Emilia A.; Peake, Janice L.; Uyeminami, Dale; Mack, Savannah M.; Li, Xueting; Smiley-Jewell, Suzette; Pinkerton, Kent E.			Repeated Iron-Soot Exposure and Nose-to-brain Transport of Inhaled Ultrafine Particles	TOXICOLOGIC PATHOLOGY			English	Article						nose; brain; olfactory epithelium; ultrafine combustion particles; iron; soot	MOUSE-BRAIN; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; NANOPARTICLES; MICROGLIA; INFLAMMATION; ACTIVATION; DELIVERY; RATS; NEURODEGENERATION	Particulate exposure has been implicated in the development of a number of neurological maladies such as multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, and idiopathic Parkinson's disease. Only a few studies have focused on the olfactory pathway as a portal through which combustion-generated particles may enter the brain. The primary objective of this study was to define the deposition, uptake, and transport of inhaled ultrafine iron-soot particles in the nasal cavities of mice to determine whether combustion-generated nanoparticles reach the olfactory bulb via the olfactory epithelium and nerve fascicles. Adult female C57B6 mice were exposed to iron-soot combustion particles at a concentration of 200 g/m(3), which included 40 g/m(3) of iron oxide nanoparticles. Mice were exposed for 6 hr/day, 5 days/week for 5 consecutive weeks (25 total exposure days). Our findings visually demonstrate that inhaled ultrafine iron-soot reached the brain via the olfactory nerves and was associated with indicators of neural inflammation.	[Hopkins, Laurie E.; Laing, Emilia A.; Peake, Janice L.; Uyeminami, Dale; Mack, Savannah M.; Li, Xueting; Smiley-Jewell, Suzette; Pinkerton, Kent E.] Univ Calif Davis, Ctr Hlth & Environm, Davis, CA 95616 USA; [Li, Xueting] Columbia Univ, Inst Human Nutr, New York, NY 10032 USA	Pinkerton, KE (reprint author), Univ Calif Davis, Ctr Hlth & Environm, Davis, CA 95616 USA.	kepinkerton@ucdavis.edu			National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [U01ES027288, P30ES023513]; National Institute for Occupational Safety and HealthUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [US4 0H07550]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P51 OD011107]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the National Institute of Environmental Health Sciences (U01ES027288, P30ES023513), the National Institute for Occupational Safety and Health (US4 0H07550), and the National Institute of Health (P51 OD011107).	Ahmad N, 2016, INT J BIOL MACROMOL, V91, P640, DOI 10.1016/j.ijbiomac.2016.06.001; Cameron B, 2010, NEUROBIOL DIS, V37, P503, DOI 10.1016/j.nbd.2009.10.006; Chakraborty S, 2010, J NEUROSCI RES, V88, P1615, DOI 10.1002/jnr.22343; Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053; Connor Neil, 2015, TELEGRAPH; Czlonkowska A, 2011, J NEUROIMMUNOL, V231, P78, DOI 10.1016/j.jneuroim.2010.09.020; Doty RL, 2008, ANN NEUROL, V63, P7, DOI 10.1002/ana.21327; Gao HL, 2016, ACTA PHARM SIN B, V6, P268, DOI 10.1016/j.apsb.2016.05.013; Gotz J, 2004, INT J DEV NEUROSCI, V22, P453, DOI 10.1016/j.ijdevneu.2004.07.013; Hao JF, 2016, COLLOID SURFACE B, V147, P376, DOI 10.1016/j.colsurfb.2016.08.011; HAUKE C, 1993, J NEUROSCI METH, V50, P273, DOI 10.1016/0165-0270(93)90034-O; Heusinkveld HJ, 2016, NEUROTOXICOLOGY, V56, P94, DOI 10.1016/j.neuro.2016.07.007; Hopkins LE, 2014, NANOTOXICOLOGY, V8, P885, DOI 10.3109/17435390.2013.842267; Hughes LS, 1998, ENVIRON SCI TECHNOL, V32, P1153, DOI 10.1021/es970280r; Jasinski J, 2006, MICROSC MICROANAL, V12, P424, DOI 10.1017/S1431927606060491; Kim YS, 2006, EXP MOL MED, V38, P333, DOI 10.1038/emm.2006.40; Kovacs T, 2004, AGEING RES REV, V3, P215, DOI 10.1016/j.arr.2003.10.003; Kreyling WG, 2002, J TOXICOL ENV HEAL A, V65, P1513, DOI 10.1080/00984100290071649; Kumar V, 2009, ARCH TOXICOL, V83, P965, DOI 10.1007/s00204-009-0455-6; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Linse S, 2007, P NATL ACAD SCI USA, V104, P8691, DOI 10.1073/pnas.0701250104; Majde JA, 2010, MED HYPOTHESES, V75, P204, DOI 10.1016/j.mehy.2010.02.023; Mistry A, 2009, INT J PHARMACEUT, V379, P146, DOI 10.1016/j.ijpharm.2009.06.019; Mombaerts P, 2006, ANNU REV CELL DEV BI, V22, P713, DOI 10.1146/annurev.cellbio.21.012804.093915; Muntimadugu E, 2016, EUR J PHARM SCI, V92, P224, DOI 10.1016/j.ejps.2016.05.012; Ngo MA, 2010, CALIF AGR, V64, P12, DOI 10.3733/ca.v064n01p12; Oberdorster G, 2004, INHAL TOXICOL, V16, P437, DOI 10.1080/08958370490439597; Patchin ES, 2016, ENVIRON HEALTH PERSP, V124, P1870, DOI 10.1289/EHP234; Pinkerton KE, 2006, CLIN EXP PHARMACOL P, V33, P269, DOI 10.1111/j.1440-1681.2006.04357.x; Pinkerton Kent E, 2008, Res Rep Health Eff Inst, P3; Godoy MCP, 2008, BRAIN, V131, P1880, DOI 10.1093/brain/awn101; Pui DYH, 2014, PARTICUOLOGY, V13, P1, DOI 10.1016/j.partic.2013.11.001; Rao DB, 2003, TOXICOL APPL PHARM, V193, P116, DOI 10.1016/S0041-008X(03)00340-5; Shaftel SS, 2007, J NEUROSCI, V27, P9301, DOI 10.1523/JNEUROSCI.1418-07.2007; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; Thornton P, 2010, CURR NEUROVASC RES, V7, P330, DOI 10.2174/156720210793180800; WierzbaBobrowicz T, 1997, FOLIA NEUROPATHOL, V35, P29; Yang GS, 2001, AEROSOL SCI TECH, V35, P759, DOI 10.1080/02786820152546806; Zhong CY, 2010, J TOXICOL ENV HEAL A, V73, P837, DOI 10.1080/15287391003689366; Zhou YM, 2003, ENVIRON TOXICOL, V18, P227, DOI 10.1002/tox.10119; Zhou YM, 2003, TOXICOL APPL PHARM, V190, P157, DOI 10.1016/S0041-008X(03)00157-1	41	4	4	1	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JAN	2018	46	1			SI		75	84		10.1177/0192623317729222			10	Pathology; Toxicology	Pathology; Toxicology	FU4FB	WOS:000423807800006	28914166	Green Accepted			2019-10-28	
J	Chamanza, R; Darville, N; van Heerden, M; De Jonghe, S				Chamanza, Ronnie; Darville, Nicolas; van Heerden, Marjolein; De Jonghe, Sandra			Comparison of the Local Tolerability to 5 Long-acting Drug Nanosuspensions with Different Stabilizing Excipients, Following a Single Intramuscular Administration in the Rat	TOXICOLOGIC PATHOLOGY			English	Article						nanoparticles; stabilizing excipient; polysorbate 80; long-acting injectable intramuscular administration; histopathology; inflammation	RELEASE; NANOCRYSTALS; MACROPHAGE; DELIVERY	To investigate the effects of common nanosuspension-stabilizing excipients on the nature and temporal evolution of histopathological changes at intramuscular (i.m.) administration sites, 5 groups of 39 male rats per group received a single injection of 1 of the 5 analogous crystalline drug nanosuspensions containing 200 mg/ml of an antiviral compound with particle sizes of +/- 200 nm and identical vehicle compositions, except for the type of nanosuspension stabilizer. The investigated stabilizers were poloxamer 338, poloxamer 407, d--tocopherol polyethylene glycol 1,000-succinate (TPGS), polysorbate 80, and polysorbate 80 combined with egg phosphatidylglycerol. Histopathology and immunohistochemistry revealed progressive inflammatory changes at the i.m. administration sites and the draining lymph nodes that differed according to the time point of sacrifice and the type of stabilizer. Although the overall time course of inflammatory changes was similar across the groups, differences in the nature, severity, and timing of the inflammatory response were observed between animals injected with poloxamer- or TPGS-containing nanosuspensions and those injected with formulations containing polysorbate 80. A more severe and prolonged active inflammatory phase, the presence of multinucleate giant cells, prolonged macrophage infiltration of the formulation depot, and more persistent histiocytic infiltrates in the lymph nodes were observed in the polysorbate 80-containing nanosuspension groups. Such vehicle-mediated effects could influence the overall tolerability profile of long-acting nanosuspensions.	[Chamanza, Ronnie; Darville, Nicolas; van Heerden, Marjolein; De Jonghe, Sandra] Johnson & Johnson, Janssen Pharmaceut Co, Janssen Res & Dev, Preclin Dev & Safety, Beerse, Belgium	Chamanza, R (reprint author), Johnson & Johnson, Janssen Pharmaceut Co, Janssen Res & Dev, Preclin Dev & Safety,Toxicol Pathol, Turnhoutseweg 30, B-2340 Beerse, Belgium.	rchamanz@its.jnj.com			Agency for Innovation by Science and Technology in Flanders/Flanders Innovation & Entrepreneurship agency, Belgium (IWT OO/AIO RD) [IWT150002]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Financial support was provided by the Agency for Innovation by Science and Technology in Flanders/Flanders Innovation & Entrepreneurship agency, Belgium (IWT O&O/AIO R&D grant no. IWT150002).	Akers MJ, 2002, J PHARM SCI-US, V91, P2283, DOI 10.1002/jps.10154; Burgess DJ, 2012, ADV DEL SCI TECHNOL, P1, DOI 10.1007/978-1-4614-0554-2_1; Chistiakov DA, 2017, LAB INVEST, V97, P4, DOI 10.1038/labinvest.2016.116; Darville N, 2016, J CONTROL RELEASE, V230, P95, DOI 10.1016/j.jconrel.2016.03.041; Darville N, 2016, TOXICOL PATHOL, V44, P189, DOI 10.1177/0192623315618291; Darville N, 2014, J PHARM SCI-US, V103, P2072, DOI 10.1002/jps.24014; de Beer MC, 2003, J LIPID RES, V44, P674, DOI 10.1194/jlr.M200444-JLR200; Edagwa B, 2017, EXPERT OPIN DRUG DEL, V14, P1281, DOI 10.1080/17425247.2017.1288212; Gnanadhas DP, 2017, J CLIN INVEST, V127, P857, DOI 10.1172/JCI90025; Kumar S, 2012, ADV DEL SCI TECHNOL, P239, DOI 10.1007/978-1-4614-0554-2_13; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Pramanick S., 2013, PHARM TIMES, V45, P65; Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494; Remenar JF, 2014, MOL PHARMACEUT, V11, P1739, DOI 10.1021/mp500070m; Shegokar R, 2010, INT J PHARMACEUT, V399, P129, DOI 10.1016/j.ijpharm.2010.07.044; Sun B, 2012, CURR OPIN SOLID ST M, V16, P295, DOI 10.1016/j.cossms.2012.10.004	16	0	0	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JAN	2018	46	1			SI		85	100		10.1177/0192623317737295			16	Pathology; Toxicology	Pathology; Toxicology	FU4FB	WOS:000423807800007	29096596	Bronze			2019-10-28	
J	Lafond, JF; Shimoji, M; Ramaswamy, B; Shukoor, MI; Malik, P; Shapiro, B; Depireux, DA				Lafond, Jean-Francois; Shimoji, Mika; Ramaswamy, Bharath; Shukoor, Mohammed I.; Malik, Pulkit; Shapiro, Benjamin; Depireux, Didier A.			Middle Ear Histopathology Following Magnetic Delivery to the Cochlea of Prednisolone-loaded Iron Oxide Nanoparticles in Rats	TOXICOLOGIC PATHOLOGY			English	Article						histopathology; preclinical research and development; preclinical safety-assessment; risk management; special senses; otopathology; nanoparticles; magnetic delivery		Delivery of therapy to the cochlea is a challenge and limits the efficacy of therapies meant to treat hearing loss, reverse tinnitus, and protect hearing from chemotherapy regimens. Magnetic injection is a technique that uses magnetic fields to inject nanoparticles from the middle ear into the cochlea, where they can then elute therapy to treat hearing disorders. To evaluate the safety of this treatment in the middle ear, 30 rats were subdivided into 6 groups and treated by single or multiple intratympanic injections of saline, prednisolone, nanoparticles, or nanoparticles loaded with prednisolone. A specially designed magnet array was used to magnetically inject the particles from the middle ear to the cochlea. Treatment began at study day 0, and animals were euthanized on study day 2, 30, or 90. Temporal bones were collected and prepared for histopathological examination. Intratympanic administration of magnetic nanoparticles and/or prednisolone resulted in minimal to mild inflammatory changes in all treated groups. The incidence and severity of the inflammatory changes observed appeared slightly increased in animals administered nanoparticles, with or without prednisolone, when compared to animals administered prednisolone alone. At study day 90, there was partial reversibility of the findings noted at study day 2 and 30. Repeat administration did not appear to cause greater inflammatory changes.	[Lafond, Jean-Francois] Charles River Labs Inc, Senneville, PQ, Canada; [Shimoji, Mika; Shukoor, Mohammed I.; Shapiro, Benjamin; Depireux, Didier A.] Otomagnetics LLC, Rockville, MD USA; [Ramaswamy, Bharath; Malik, Pulkit; Shapiro, Benjamin; Depireux, Didier A.] Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA; [Shapiro, Benjamin; Depireux, Didier A.] Univ Maryland, ISR, College Pk, MD 20742 USA; [Depireux, Didier A.] Univ Maryland, Dept Otorhinolaryngol Head & Neck Surg, Baltimore, MD 21201 USA	Lafond, JF (reprint author), Charles River Labs, 22022 Transcanadienne, Senneville, PQ H9X 3R3, Canada.	jean-francois.lafond@crl.com			Action on Hearing Loss in the UK; Congressionally Directed Medical Research Program (CDMRP)United States Department of Defense; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Maryland Innovation Initiative at the Maryland Technology Development Corporation (TEDCO); Maryland Industrial Partnerships (MIPS) program in the State of Maryland; Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center, in Washington DC	The author(s) received the following financial support for the research, authorship, and/or publication of this article: Funding is gratefully acknowledged from Action on Hearing Loss in the UK, from the Congressionally Directed Medical Research Program (CDMRP), from the National Institutes of Health (NIH), from the Maryland Innovation Initiative at the Maryland Technology Development Corporation (TEDCO) and the Maryland Industrial Partnerships (MIPS) program in the State of Maryland, as well as from the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center, in Washington DC.	Lee JJ, 2018, LARYNGOSCOPE, V128, P189, DOI 10.1002/lary.26562; Meyer T, 2013, NOISE HEALTH, V15, P83, DOI 10.4103/1463-1741.110285; Ramaswamy B., 2017, FRONTIE IN PRESS SEP; Rask-Andersen H, 2012, ANAT REC, V295, P1791, DOI 10.1002/ar.22599; Salt AN, 2012, HEARING RES, V283, P14, DOI 10.1016/j.heares.2011.11.012; Sarwar A, 2013, IEEE T MAGN, V49, P440, DOI 10.1109/TMAG.2012.2221456; Shapiro B, 2014, ANNU REV BIOMED ENG, V16, P455, DOI 10.1146/annurev-bioeng-071813-105206; Sharon JD, 2015, CURR TREAT OPTION NE, V17, DOI 10.1007/s11940-015-0341-x; Spear SA, 2011, OTOLARYNG HEAD NECK, V145, P534, DOI 10.1177/0194599811419466	9	2	2	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JAN	2018	46	1			SI		101	106		10.1177/0192623317732028			6	Pathology; Toxicology	Pathology; Toxicology	FU4FB	WOS:000423807800008	28992726	Bronze			2019-10-28	
J	Rashid, S; Akhtar, M				Rashid, Sameera; Akhtar, Mohammed			Sarcomatoid Variant of Urothelial Carcinoma of the Renal Pelvis with Inferior Vena Cava Tumour Thrombus: A Case Report and Literature Review	CASE REPORTS IN PATHOLOGY			English	Review							TRANSITIONAL-CELL CARCINOMA; CARCINOSARCOMAS	Sarcomatoid variant of urothelial carcinoma (SVUC) of the renal pelvis is a rare entity. To the best of our knowledge, around 25 cases of this neoplasm have been reported in the literature to date, most of which were of high stage. The inferior vena cava tumour thrombus, which is a hallmark of renal cell carcinoma (RCC), may rarely be found in urothelial carcinoma of renal pelvis. In this report, a case of SVUC associated with tumour extension to inferior vena cava is documented. This association has been encountered in only one previously reported case. The possibility of urothelial carcinoma of the renal pelvis should therefore be included in the differential diagnosis of tumour thrombus of the inferior vena cava.	[Rashid, Sameera; Akhtar, Mohammed] Hamad Med Corp, Dept Lab Med & Pathol, Doha, Qatar	Rashid, S (reprint author), Hamad Med Corp, Dept Lab Med & Pathol, Doha, Qatar.	srashid2@hamad.qa		Rashid, Sameera/0000-0003-0608-4746			Arita N, 2013, ONCOL LETT, V5, P49, DOI 10.3892/ol.2012.990; BLOXHAM CA, 1990, HISTOPATHOLOGY, V16, P63, DOI 10.1111/j.1365-2559.1990.tb01062.x; Canacci AM, 2006, J UROLOGY, V175, P1906, DOI 10.1016/S0022-5347(06)00431-9; Chen GM, 2011, CHINESE MED J-PEKING, V124, P2074, DOI 10.3760/cma.j.issn.0366-6999.2011.13.028; Diaz RR, 2014, KOREAN J UROL, V55, P624, DOI 10.4111/kju.2014.55.9.624; DIDIER D, 1987, RADIOLOGY, V162, P83, DOI 10.1148/radiology.162.1.3024211; Eble J. N., 2004, WHO CLASSICATION TUM, V1; Hisataki T, 2001, INT J UROL, V8, P704, DOI 10.1046/j.1442-2042.2001.00396.x; Howlader N, 2017, SEER CANC STAT UNPUB; Keskin SK, 2017, J UROLOGY, V198, P530, DOI 10.1016/j.juro.2017.04.067; Kim J. K., 2017, UROL ONCOL-SEMIN ORI, V35, P458; Li MY, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-1041-z; LopezBeltran A, 1996, PATHOL RES PRACT, V192, P1218, DOI 10.1016/S0344-0338(96)80154-3; Perez-Montiel D, 2006, MODERN PATHOL, V19, P494, DOI 10.1038/modpathol.3800559; Psutka SP, 2015, THER ADV UROL, V7, P216, DOI 10.1177/1756287215576443; SUSTER S, 1989, ARCH PATHOL LAB MED, V113, P404; Thiel DD, 2006, UROLOGY, V67, DOI 10.1016/j.urology.2005.09.026; Tian XQ, 2014, ONCOL LETT, V8, P1208, DOI 10.3892/ol.2014.2240; Venyo A. K.-G., 2014, INT SCHOLARLY RES NO, V2014, P1; Wang XD, 2011, UROLOGY, V77, P836, DOI 10.1016/j.urology.2010.09.028; WICK MR, 1993, SEMIN DIAGN PATHOL, V10, P118; Zhai QJ, 2007, ARCH PATHOL LAB MED, V131, P1244	22	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									1837510	10.1155/2018/1837510			5	Pathology	Pathology	FU1JE	WOS:000423604700001	29581908	DOAJ Gold, Green Published			2019-10-28	
J	Gu, LQ; Gates, KS; Wang, MX; Li, GF				Gu, Li-Qun; Gates, Kent S.; Wang, Michael X.; Li, Guangfu			What is the potential of nanolock- and nanocross-nanopore technology in cancer diagnosis?	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Editorial Material						Cancer diagnostics; nanopore; nanolock; nanocross; biosensor; driver mutation; single nucleotide polymorphism (SNP); Point-of-care; precision oncology; Precision medicine	SINGLE-NUCLEOTIDE RESOLUTION; MISMATCHED BASE-PAIRS; CELL LUNG-CANCER; REAL-TIME PCR; METASTATIC MELANOMA; BRAF MUTATION; ABASIC SITES; DNA DUPLEXES; MOLECULES; DISCRIMINATION		[Gu, Li-Qun] Univ Missouri, Dept Bioengn, Columbia, MO 65211 USA; [Gu, Li-Qun] Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO 65211 USA; [Gates, Kent S.] Univ Missouri, Dept Chem, Columbia, MO 65211 USA; [Gates, Kent S.] Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; [Wang, Michael X.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Li, Guangfu] Univ Missouri, Dept Surg, Columbia, MO USA; [Li, Guangfu] Univ Missouri, Ellis Fischel Canc Ctr, Columbia, MO USA	Gu, LQ (reprint author), Univ Missouri, Dept Bioengn, Columbia, MO 65211 USA.; Gu, LQ (reprint author), Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO 65211 USA.; Gates, KS (reprint author), Univ Missouri, Dept Chem, Columbia, MO 65211 USA.; Gates, KS (reprint author), Univ Missouri, Dept Biochem, Columbia, MO 65211 USA.	gul@missouri.edu; gatesk@missouri.edu		Gu, Li-Qun/0000-0002-8710-6160; Li, Guangfu/0000-0002-9817-568X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ES021007, GM114204, HG009338]	The manuscript was supported by the National Institutes of Health (ES021007 to KS Gates, GM114204 to LQ Gu, and HG009338 to KS Gates and LQ Gu).	An N, 2014, P NATL ACAD SCI USA, V111, P14325, DOI 10.1073/pnas.1415944111; An N, 2012, P NATL ACAD SCI USA, V109, P11504, DOI 10.1073/pnas.1201669109; Ang YS, 2012, ACS NANO, V6, P8815, DOI 10.1021/nn302636z; Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Cao C, 2016, NAT NANOTECHNOL, V11, P713, DOI [10.1038/nnano.2016.66, 10.1038/NNANO.2016.66]; Cherf GM, 2012, NAT BIOTECHNOL, V30, P344, DOI 10.1038/nbt.2147; Chu D, 2017, VIRCHOWS ARCH, V471, P147, DOI 10.1007/s00428-017-2137-8; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cornelis S, 2017, SCI REP-UK, V7, DOI 10.1038/srep41759; Couch FJ, 2014, SCIENCE, V343, P1466, DOI 10.1126/science.1251827; Fang ZC, 2009, ANAL CHEM, V81, P612, DOI 10.1021/ac801890f; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Granzhan A, 2014, CHEM SOC REV, V43, P3630, DOI 10.1039/c3cs60455a; Greninger AL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0220-9; Halait H, 2012, DIAGN MOL PATHOL, V21, P1, DOI 10.1097/PDM.0b013e31823b216f; Hornblower B, 2007, NAT METHODS, V4, P315, DOI 10.1038/NMETH1021; Huber F, 2013, NAT NANOTECHNOL, V8, P125, DOI [10.1038/nnano.2012.263, 10.1038/NNANO.2012.263]; Jain M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1103-0; Kamps R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020308; Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770; Kong JL, 2017, CHEM COMMUN, V53, P436, DOI 10.1039/c6cc08621g; Kumar K, 2011, LANGMUIR, V27, P10920, DOI 10.1021/la2019132; Lee JS, 2016, BMB REP, V49, P607, DOI 10.5483/BMBRep.2016.49.11.145; Lu CH, 2015, ANGEW CHEM INT EDIT, V54, P12212, DOI 10.1002/anie.201503054; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Manrao EA, 2012, NAT BIOTECHNOL, V30, P349, DOI 10.1038/nbt.2171; Matsuda K, 2017, ADV CLIN CHEM, V80, P45, DOI 10.1016/bs.acc.2016.11.002; Miyake Y, 2006, J AM CHEM SOC, V128, P2172, DOI 10.1021/ja056354d; Nejad MI, 2017, CHEMBIOCHEM, V18, P1383, DOI 10.1002/cbic.201700204; Olmedillas-Lopez S, 2017, MOL DIAGN THER, V21, P493, DOI 10.1007/s40291-017-0278-8; Ono A, 2011, CHEM SOC REV, V40, P5855, DOI 10.1039/c1cs15149e; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pi C, 2017, EXPERT REV MOL DIAGN, V17, P1089, DOI 10.1080/14737159.2017.1395701; Price NE, 2014, J AM CHEM SOC, V136, P3483, DOI 10.1021/ja410969x; Purnell RF, 2009, ACS NANO, V3, P2533, DOI 10.1021/nn900441x; Rosen CB, 2014, NAT BIOTECHNOL, V32, P179, DOI 10.1038/nbt.2799; Sapio MR, 2006, EUR J ENDOCRINOL, V154, P341, DOI 10.1530/eje.1.02072; Sato Y, 2011, CHEM COMMUN, V47, P5885, DOI 10.1039/c1cc11370d; Schmidt K, 2017, J ANTIMICROB CHEMOTH, V72, P104, DOI 10.1093/jac/dkw397; Shin SH, 2017, NPJ PRECIS ONCOL, V1:28; Speicher MR, 2014, NAT BIOTECHNOL, V32, P441, DOI 10.1038/nbt.2897; Starostik P, 2017, ANTI-CANCER DRUG, V28, P1, DOI 10.1097/CAD.0000000000000427; Torigoe H, 2011, NUCLEOS NUCLEOT NUCL, V30, P149, DOI 10.1080/15257770.2011.553210; Torigoe Hidetaka, 2007, Nucleic Acids Symp Ser (Oxf), P185, DOI 10.1093/nass/nrm093; Vercoutere W, 2001, NAT BIOTECHNOL, V19, P248, DOI 10.1038/85696; Villanueva M Teresa, 2014, Nat Rev Clin Oncol, V11, P179, DOI 10.1038/nrclinonc.2014.32; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wallace EVB, 2010, CHEM COMMUN, V46, P8195, DOI 10.1039/c0cc02864a; Wang GH, 2013, J PHYS CHEM B, V117, P4763, DOI 10.1021/jp309541h; Wang SY, 2013, ACS NANO, V7, P9814, DOI 10.1021/nn404435v; Wang Y, 2017, ACS SENSORS, V2, P975, DOI 10.1021/acssensors.7b00235; Wang Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05883; Wang Y, 2011, NAT NANOTECHNOL, V6, P668, DOI [10.1038/NNANO.2011.147, 10.1038/nnano.2011.147]; Wolfe AJ, 2007, J AM CHEM SOC, V129, P14034, DOI 10.1021/ja0749340; Wu CC, 2009, BIOSENS BIOELECTRON, V25, P820, DOI 10.1016/j.bios.2009.08.031; Yohe S, 2017, ARCH PATHOL LAB MED, V141, P1544, DOI 10.5858/arpa.2016-0501-RA; Zeglis BM, 2007, NAT PROTOC, V2, P357, DOI 10.1038/nprot.2007.22; Zhang XY, 2015, ACS NANO, V9, P11812, DOI 10.1021/acsnano.5b03923; Zhao Q, 2007, NANO LETT, V7, P1680, DOI 10.1021/nl070668c	60	1	1	0	11	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	2					113	117		10.1080/14737159.2018.1410060			5	Pathology	Pathology	FU3KC	WOS:000423748800001	29171309	Bronze, Green Accepted			2019-10-28	
J	Zaporozhchenko, IA; Ponomaryova, AA; Rykova, EY; Laktionov, PP				Zaporozhchenko, Ivan A.; Ponomaryova, Anastasia A.; Rykova, Elena Yu; Laktionov, Pavel P.			The potential of circulating cell-free RNA as a cancer biomarker: challenges and opportunities	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Circulating cell-free RNA; mRNA; miRNA; lncRNA; plasma; serum; urine; cancer; biomarkers; liquid biopsy	LONG NONCODING RNAS; PIWI-INTERACTING RNAS; SMALL NUCLEOLAR RNAS; MESSENGER-RNA; PROSTATE-CANCER; CLINICAL UTILITY; NUCLEIC-ACIDS; PLASMA; MICRORNAS; EXPRESSION	Introduction: Cancer statistics show that recent improvements in cancer management are only mildly effective in the absence of reliable biomarkers for the detection, diagnosis and monitoring of malignant disease. Recently circulating nucleic acids have been suggested as potential biomarker candidates to fill this role.Areas covered: This review focuses on the different types of circulating RNA biomarkers under investigation, describing the latest advances in their development and application to clinical settings, as well as challenges that researchers face in the process. Immediate perspectives of the field are outlined, and authors' recommendations on the best progression path are provided.Expert commentary: The development of RNA-based cancer biomarkers is a thriving area of biomedical research that has progressed significantly over the last decade. However, it seems that it is now at the point, where unless several key issues are resolved, no significant progress can be made further. Currently several areas of biomarker research require re-assessment, as indicated by the latest findings regarding the biology of circulating nucleic acids and the accumulated data of their analysis using various techniques. Additionally, regulating agencies need to be working alongside researchers to facilitate faster and easier adoption of new effective biomarkers into the clinical practice.	[Zaporozhchenko, Ivan A.; Rykova, Elena Yu; Laktionov, Pavel P.] SB RAS, Inst Chem Biol & Fundamental Med, Mol Med Lab, Novosibirsk, Russia; [Zaporozhchenko, Ivan A.; Rykova, Elena Yu; Laktionov, Pavel P.] EN Meshalkin Siberian Fed Biomed Res Ctr, Ctr New Surg Technol, Lab Biomed Technol, Novosibirsk, Russia; [Ponomaryova, Anastasia A.] SB RAMS, Tomsk Canc Res Inst, Lab Immunol, Tomsk, Russia; [Ponomaryova, Anastasia A.] Natl Res Tomsk Polytech Univ, Dept Appl Phys, Tomsk, Russia	Laktionov, PP (reprint author), SB RAS, Inst Chem Biol & Fundamental Med, Mol Med Lab, Novosibirsk, Russia.; Laktionov, PP (reprint author), EN Meshalkin Siberian Fed Biomed Res Ctr, Ctr New Surg Technol, Lab Biomed Technol, Novosibirsk, Russia.	lakt@niboch.nsc.ru			Russian Science FoundationRussian Science Foundation (RSF) [16-15-00124]	This review was supported by a grant from the Russian Science Foundation (No: 16-15-00124).	Ainsztein AM, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27493; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Assumpcao CB, 2015, EPIGENOMICS-UK, V7, P975, DOI 10.2217/epi.15.37; Balatti V, 2017, P NATL ACAD SCI USA, V114, P8071, DOI 10.1073/pnas.1706908114; Baraniskin A, 2013, INT J CANCER, V132, pE48, DOI 10.1002/ijc.27791; Beatty M, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-933; Boeri M, 2011, P NATL ACAD SCI USA, V108, P3713, DOI 10.1073/pnas.1100048108; Bosl A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183458; Bolha L, 2017, DIS MARKERS, DOI 10.1155/2017/7243968; Brodtkorb M, 2014, BLOOD, V123, P1051, DOI 10.1182/blood-2013-07-512392; Brunet-Vega A, 2015, ANAL BIOCHEM, V488, P28, DOI 10.1016/j.ab.2015.07.018; Bryzgunova OE, 2015, ACTA NATURAE, V7, P48, DOI 10.32607/20758251-2015-7-3-48-54; Byron SA, 2016, NAT REV GENET, V17, P257, DOI 10.1038/nrg.2016.10; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Cann GM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049144; Chen SY, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0959-5; Cheng GF, 2015, ADV DRUG DELIVER REV, V81, P75, DOI 10.1016/j.addr.2014.09.001; Cornu JN, 2013, PROSTATE, V73, P242, DOI 10.1002/pros.22563; Crescitelli R, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20677; Danielson KM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0164644; de Souza MF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184094; Deng H, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317706332; Deniz E, 2017, FUNCT INTEGR GENOMIC, V17, P135, DOI 10.1007/s10142-016-0524-x; Dhahbi Joseph M, 2014, Biomark Cancer, V6, P37, DOI 10.4137/BIC.S20764; Diamandis EP, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-87; Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102; Du WW, 2017, CELL DEATH DIFFER, V24, P357, DOI 10.1038/cdd.2016.133; Durand X, 2011, EXPERT REV MOL DIAGN, V11, P137, DOI [10.1586/erm.10.122, 10.1586/ERM.10.122]; ENCODE, 2013, NATURE, V489, P57; Fayda M, 2016, TUMOR BIOL, V37, P3969, DOI 10.1007/s13277-015-4189-1; Feng HJ, 2013, CANCER LETT, V340, P179, DOI 10.1016/j.canlet.2012.11.010; Fernandez-Mercado M, 2015, J CELL MOL MED, V19, P2307, DOI 10.1111/jcmm.12625; Fleischhacker M, 2007, BBA-REV CANCER, V1775, P181, DOI 10.1016/j.bbcan.2006.10.001; Gallo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030679; Gallo A, 2017, HUM GENET, V136, P1265, DOI 10.1007/s00439-017-1837-0; Garcia JM, 2008, RNA, V14, P1424, DOI 10.1261/rna.755908; Garcia V, 2008, CANCER LETT, V263, P312, DOI 10.1016/j.canlet.2008.01.008; Glinge C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0167969; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Goldvaser H, 2017, BRIT J CANCER, V117, P353, DOI 10.1038/bjc.2017.166; Gordon BL, 2015, J SURG ONCOL, V111, P24, DOI 10.1002/jso.23778; Grossman RL, 2017, CLIN PHARMACOL THER, V101, P589, DOI 10.1002/cpt.666; Guo Y, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1929-y; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hasselmann DO, 2001, CLIN CHEM, V47, P1488; He YQ, 2015, CLIN CHEM, V61, P1138, DOI 10.1373/clinchem.2015.241190; Huang M, 2017, WORLD J GASTROENTERO, V23, P6330, DOI 10.3748/wjg.v23.i34.6330; Huang WY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096490; Huang XY, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-319; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; HYNIE I, 1975, CLIN CHEM, V21, P1383; Isin M, 2014, CLIN CHIM ACTA, V431, P255, DOI 10.1016/j.cca.2014.02.010; Jahr S, 2001, CANCER RES, V61, P1659; Javidi MA, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0295-y; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jin HY, 2014, CELL CYCLE, V13, P495, DOI 10.4161/cc.27784; Kaczkowski B, 2016, CANCER RES, V76, P216, DOI 10.1158/0008-5472.CAN-15-0484; Kartha RV, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00008; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kim YK, 2012, MOL CELL, V46, P893, DOI 10.1016/j.molcel.2012.05.036; Kingston RE, 2010, CURR PROTOC MOL BIOL, DOI [10.1002/0471142727.mb0400s58, DOI 10.1002/0471142727.MB0400S58]; Kishikawa T, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86646; Kishikawa T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13006; Kishikawa T, 2015, WORLD J GASTROENTERO, V21, P8527, DOI 10.3748/wjg.v21.i28.8527; Koczera P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081278; Kohler J, 2016, J CANCER RES CLIN, V142, P795, DOI 10.1007/s00432-015-2095-y; Kristensen LS, 2018, ONCOGENE, V37, P555, DOI 10.1038/onc.2017.361; Kuhlmann JD, 2014, CLIN CHEM, V60, P206, DOI 10.1373/clinchem.2013.213066; Lanzos A, 2017, SCI REP-UK, V7, DOI 10.1038/srep41544; Larrea E, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050627; Lawrie CH, 2008, BRIT J HAEMATOL, V141, P672, DOI 10.1111/j.1365-2141.2008.07077.x; Lazaro-Ibanez E, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3087-x; Leyten GHJM, 2014, EUR UROL, V65, P534, DOI 10.1016/j.eururo.2012.11.014; Li PF, 2015, CLIN CHIM ACTA, V444, P132, DOI 10.1016/j.cca.2015.02.018; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Liang WJ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004608; Liao JP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-198; Liu Y, 2016, ONCOL LETT, V12, P2289, DOI 10.3892/ol.2016.4996; Liz J, 2016, BBA-GENE REGUL MECH, V1859, P169, DOI 10.1016/j.bbagrm.2015.06.015; Lo KW, 1999, CLIN CHEM, V45, P1292; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; LUTHJE J, 1987, CLIN CHIM ACTA, V164, P275, DOI 10.1016/0009-8981(87)90302-0; Majewski IJ, 2011, NAT MED, V17, P304, DOI 10.1038/nm.2311; Mannoor K, 2012, BBA-REV CANCER, V1826, P121, DOI 10.1016/j.bbcan.2012.03.005; March-Villalba JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043470; Marchese FP, 2014, EPIGENETICS-US, V9, P21, DOI 10.4161/epi.27472; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Marsh JB, 2000, CURR OPIN LIPIDOL, V11, P261, DOI 10.1097/00041433-200006000-00006; Martinez VD, 2015, SCI REP-UK, V5, DOI 10.1038/srep10423; McKiernan J, 2016, JAMA ONCOL, V2, P882, DOI 10.1001/jamaoncol.2016.0097; Memczak S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141214; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Mestdagh P, 2014, NAT METHODS, V11, P809, DOI [10.1038/NMETH.3014, 10.1038/nmeth.3014]; Modelska A, 2015, BRIEF BIOINFORM, V16, P1000, DOI 10.1093/bib/bbv013; Moldovan L, 2014, J CELL MOL MED, V18, P371, DOI 10.1111/jcmm.12236; Montani F, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv063; Moret I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082753; Munker R, 2011, CLIN SCI, V121, P141, DOI 10.1042/CS20110005; Nagayasu K, 2013, MOL CLIN ONCOL, V1, P668, DOI 10.3892/mco.2013.109; Ng KW, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0491-9; Nientiedt M, 2018, EUR UROL FOCUS, V4, P260, DOI 10.1016/j.euf.2016.08.004; Nilsson J, 2009, BRIT J CANCER, V100, P1603, DOI 10.1038/sj.bjc.6605058; Ohashi A, 2015, J THROMB HAEMOST, V13, P575; Ozsolak F, RNA SEQUENCING ADV C, DOI [10.1038/nrg2934, DOI 10.1038/NRG2934]; Page K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077963; Parkinson DR, 2014, CLIN CANCER RES, V20, P1428, DOI 10.1158/1078-0432.CCR-13-2961; Pavlou MP, 2013, CLIN CHEM, V59, P147, DOI 10.1373/clinchem.2012.184614; Pease J, 2013, NAT METH, V10, pi, DOI [10.1038/nmeth.f.366, DOI 10.1038/NMETH.F.366]; Pekarsky Y, 2016, P NATL ACAD SCI USA, V113, P5071, DOI 10.1073/pnas.1604266113; Pellegrini KL, 2015, MOL ASPECTS MED, V45, P37, DOI 10.1016/j.mam.2015.05.003; Pon JR, 2015, ANNU REV PATHOL-MECH, V10, P25, DOI 10.1146/annurev-pathol-012414-040312; Ponnusamy M, 2017, EUR J CELL BIOL, V96, P746, DOI 10.1016/j.ejcb.2017.09.004; Poon IKH, 2014, NAT REV IMMUNOL, V14, P166, DOI 10.1038/nri3607; Prensner JR, 2013, NAT GENET, V45, P1392, DOI 10.1038/ng.2771; Previdi MC, 2017, FUTURE ONCOL, V13, P443, DOI 10.2217/fon-2016-0253; Pritchard CC, 2012, NAT REV GENET, V13, P358, DOI 10.1038/nrg3198; Pritchard CC, 2012, CANCER PREV RES, V5, P492, DOI 10.1158/1940-6207.CAPR-11-0370; Qi P, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0524-4; Qiu XN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151345; Quinn JF, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27495; Rapisuwon S, 2016, COMPUT STRUCT BIOTEC, V14, P211, DOI 10.1016/j.csbj.2016.05.004; Rivas A, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-37; Rong DW, 2017, ONCOTARGET, V8, P73271, DOI 10.18632/oncotarget.19154; Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392; Rupaimoole R, 2016, CANCER DISCOV, V6, P235, DOI 10.1158/2159-8290.CD-15-0893; Russo F, 2018, NUCLEIC ACIDS RES, V46, pD354, DOI 10.1093/nar/gkx854; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Saus E, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00054; Schou Jakob Vasehus, 2016, Non-Coding RNA, V2, P5, DOI 10.3390/ncrna2020005; Shi T, 2016, DIS MARKERS, DOI 10.1155/2016/9085195; Shin H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091041; Siddiqi S, 2012, J CELL BIOCHEM, V113, P373, DOI 10.1002/jcb.23363; Smyth T, 2015, J CONTROL RELEASE, V199, P145, DOI 10.1016/j.jconrel.2014.12.013; Sokilde R, 2014, J MOL DIAGN, V16, P106, DOI 10.1016/j.jmoldx.2013.10.001; Sourvinou IS, 2013, J MOL DIAGN, V15, P827, DOI 10.1016/j.jmoldx.2013.07.005; Sozzi G, 2014, TRANSL LUNG CANCER R, V3, P139, DOI 10.3978/j.issn.2218-6751.2014.06.04; Sozzi G, 2014, J CLIN ONCOL, V32, P768, DOI 10.1200/JCO.2013.50.4357; Spencer JD, 2014, KIDNEY INT, V85, P1179, DOI 10.1038/ki.2013.395; Stepanov GA, 2015, BIOMED RES INT, DOI 10.1155/2015/206849; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; STROUN M, 1978, CANCER RES, V38, P3546; Su J, 2015, ONCOTARGET, V7; Sun CX, 2018, CANCER LETT, V414, P16, DOI 10.1016/j.canlet.2017.10.031; Suzuki Ryusuke, 2012, Frontiers in Genetics, V3, DOI 10.3389/fgene.2012.00204; Takahashi Y, 2013, J BIOTECHNOL, V165, P77, DOI 10.1016/j.jbiotec.2013.03.013; Tang HK, 2013, MOL MED REP, V7, P761, DOI 10.3892/mmr.2012.1254; Thorenoor N, 2015, TUMOR BIOL, V36, P41, DOI 10.1007/s13277-014-2818-8; Tolkach Y, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3746-y; Tsui NBY, 2002, CLIN CHEM, V48, P1647; Wagner J, 2013, ARTERIOSCL THROM VAS, V33, P1392, DOI 10.1161/ATVBAHA.112.300741; Wang FL, 2016, AM J CANCER RES, V6, P1167; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wang WT, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0086-0; Watts GF, 2000, METABOLISM, V49, P1204, DOI 10.1053/meta.2000.8621; Weber Daniel Gilbert, 2013, BMC Res Notes, V6, P518, DOI 10.1186/1756-0500-6-518; Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405; Witwer KW, 2015, CLIN CHEM, V61, P56, DOI 10.1373/clinchem.2014.221341; Witwer KW, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20360; Wu XY, 2012, GENE, V500, P10, DOI 10.1016/j.gene.2012.03.021; Yang W, 2016, ONCOGENE, V35, P3919, DOI 10.1038/onc.2015.460; Yuan TZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19413; Zhang KC, 2017, THERANOSTICS, V7, P213, DOI 10.7150/thno.16044	163	7	7	2	17	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	2					133	145		10.1080/14737159.2018.1425143			13	Pathology	Pathology	FU3KC	WOS:000423748800003	29307231				2019-10-28	
J	Choi, JJ; McCarthy, MW				Choi, Justin J.; McCarthy, Matthew W.			The prognostic value of mid-regional pro-adrenomedullin in the evaluation of acute dyspnea	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Biomarker; acute dyspnea; risk stratification; chronic obstructive pulmonary disease; community acquired pneumonia; pulmonary embolism; adrenomedullin; mid-regional pro-adrenomedullin; acute heart failure	COMMUNITY-ACQUIRED PNEUMONIA; PROATRIAL NATRIURETIC PEPTIDE; NONMASSIVE PULMONARY-EMBOLISM; C-REACTIVE PROTEIN; HEART-FAILURE; RISK STRATIFICATION; MR-PROADM; PLASMA ADRENOMEDULLIN; CARDIAC TROPONIN; PREDICTIVE-VALUE	Introduction: Acute dyspnea is a common chief complaint among patients who visit an emergency room and presents diagnostic challenges for clinicians in both identifying the etiology and determining the clinical severity. The study of biomarkers in the prognostication and risk stratification of these patients has been increasing, including the investigation of the prognostic value for mid-regional pro-adrenomedullin (MR-proADM).Areas covered: In this review, the authors cover what is known about MR-proADM testing in patients presenting with acute dyspnea and the supporting evidence of its prognostic value in common conditions in medical patients with acute dyspnea, including acute heart failure, community acquired pneumonia, acute exacerbation of chronic obstructive pulmonary disease, and acute pulmonary embolism.Expert commentary: Numerous studies have proposed MR-proADM as a more accurate, prognostic tool in the evaluation of acute dyspnea than other biomarkers and consensus risk scores such as Sequential Organ Failure Assessment (SOFA) and quick SOFA (qSOFA). The authors review recent prospective studies, systematic reviews, and meta-analyses that demonstrate its prognostic value and role in risk stratification, including its use in biomarker-based triage algorithms as part of the diagnostic evaluation of the acutely dyspneic patient.	[Choi, Justin J.] Weill Cornell Med Coll, Dept Med, New York, NY USA; [McCarthy, Matthew W.] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Gen Internal Med, New York, NY USA	Choi, JJ (reprint author), Weill Cornell Med Coll, 525 East 68th St,Box 331, New York, NY 10065 USA.	juc9107@med.cornell.edu					Acosta S, 2017, ANGIOLOGY, DOI 3319717723255; Adams HP, 2008, STROKE, V39, P87, DOI 10.1161/STROKEAHA.106.476648; Al Shuaibi M, 2013, CLIN INFECT DIS, V56, P943, DOI 10.1093/cid/cis1029; Alan M, 2015, J INTERN MED, V278, P174, DOI 10.1111/joim.12341; Albrich WC, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-112; Angeletti S, 2013, CLIN CHEM LAB MED, V51, P1059, DOI 10.1515/cclm-2012-0595; Ara-Somohano C, 2017, MINERVA ANESTESIOL, V83, P824, DOI 10.23736/S0375-9393.17.10882-5; Aujesky D, 2008, CLIN INFECT DIS, V47, pS133, DOI 10.1086/591394; Bahrmann P, 2016, EUR HEART J-ACUTE CA, V5, P568, DOI 10.1177/2048872615612455; Bajaj A, 2015, HEART LUNG, V44, P327, DOI 10.1016/j.hrtlng.2015.03.007; Bauer TT, 2006, J INTERN MED, V260, P93, DOI 10.1111/j.1365-2796.2006.01657.x; Becattini C, 2007, CIRCULATION, V116, P427, DOI 10.1161/CIRCULATIONAHA.106.680421; Bello S, 2012, EUR RESPIR J, V39, P1144, DOI 10.1183/09031936.00080411; Bernasconi M, 2011, CHEST, V140, P91, DOI 10.1378/chest.10-1353; Boyer Brent, 2012, Congest Heart Fail, V18, P91, DOI 10.1111/j.1751-7133.2011.00256.x; Brusse-Keizer M, 2015, RESP MED, V109, P734, DOI 10.1016/j.rmed.2015.02.013; Bustamante A, 2017, J NEUROIMMUNOL, V312, P19, DOI 10.1016/j.jneuroim.2017.08.012; Cantor WJ, 2009, NEW ENGL J MED, V360, P2705, DOI 10.1056/NEJMoa0808276; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; Choi JJ, 2018, EXPERT REV MOL DIAGN, V18, P27, DOI 10.1080/14737159.2018.1407244; Christ-Crain M, 2005, CRIT CARE, V9, pR816, DOI 10.1186/cc3885; Christ-Crain M, 2010, CRIT CARE, V14, DOI 10.1186/cc8155; Courtais C, 2013, AM J EMERG MED, V31, P215, DOI 10.1016/j.ajem.2012.07.017; De La Torre-Prados MV, 2016, MINERVA ANESTESIOL, V82, P760; Douketis JD, 2002, ARCH INTERN MED, V162, P79, DOI 10.1001/archinte.162.1.79; Dres M, 2017, INT J CHRONIC OBSTR, V12, P1047, DOI 10.2147/COPD.S126400; Enguix-Armada A, 2016, CLIN CHEM LAB MED, V54, P163, DOI 10.1515/cclm-2015-0243; Espana PP, 2015, J INFECTION, V70, P457, DOI 10.1016/j.jinf.2014.12.003; Eto T, 2001, PEPTIDES, V22, P1693, DOI 10.1016/S0196-9781(01)00513-7; Fedorowski A, 2013, J INTERN MED, V273, P359, DOI 10.1111/joim.12043; Fernandez-Susavila H, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.007329; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Funke-Kaiser A, 2014, ANN MED, V46, P155, DOI 10.3109/07853890.2013.874662; Gegenhuber A, 2007, J CARD FAIL, V13, P42, DOI 10.1016/j.cardfail.2006.09.004; Geraci JM, 2006, SUPPORT CARE CANCER, V14, P1038, DOI 10.1007/s00520-006-0053-6; Gille J, 2017, J BURN CARE RES, V38, P290, DOI 10.1097/BCR.0000000000000508; Goliasch G, 2017, EUR HEART J; Gorissen C, 2007, CLIN CHEM LAB MED, V45, P678, DOI 10.1515/CCLM.2007.119; Gruenberger JB, 2017, INT J CHRONIC OBSTR, V12, P937, DOI 10.2147/COPD.S123744; Haaf P, 2013, INT J CARDIOL, V168, P1048, DOI 10.1016/j.ijcard.2012.10.025; Hausfater P, 2017, BIOMARKERS, V22, P28, DOI 10.1080/1354750X.2016.1201541; Huang DT, 2009, CHEST, V136, P823, DOI 10.1378/chest.08-1981; Jaff MR, 2011, CIRCULATION, V123, P1788, DOI 10.1161/CIR.0b013e318214914f; Ji QY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14888-7; Jimenez D, 2009, CHEST, V136, P974, DOI 10.1378/chest.09-0608; Kato J, 1996, J CLIN ENDOCR METAB, V81, P180, DOI 10.1210/jc.81.1.180; Khan SQ, 2007, J AM COLL CARDIOL, V49, P1525, DOI 10.1016/j.jacc.2006.12.038; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V194, P720, DOI 10.1006/bbrc.1993.1881; KITAMURA K, 1994, FEBS LETT, V341, P288, DOI 10.1016/0014-5793(94)80474-5; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; KUNITOH H, 1994, ANN ALLERGY, V72, P250; Kunitoh H, 1996, J ASTHMA, V33, P105, DOI 10.3109/02770909609054538; Kutz A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168076; Legramante JM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187702; Lenferink A, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011682.pub2; Lewis LK, 1998, CLIN CHEM, V44, P571; Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377; Liu D, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1566-3; Lundberg OHM, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1361-y; Maisel A, 2011, J AM COLL CARDIOL, V58, P1057, DOI 10.1016/j.jacc.2011.06.006; Maisel A, 2010, J AM COLL CARDIOL, V55, P2062, DOI 10.1016/j.jacc.2010.02.025; Meeran K, 1997, J CLIN ENDOCR METAB, V82, P95, DOI 10.1210/jc.82.1.95; Meng DQ, 2014, RESP CARE, V59, P1542, DOI 10.4187/respcare.03046; Meyer G, 2014, NEW ENGL J MED, V370, P1402, DOI 10.1056/NEJMoa1302097; Minami J, 2002, AM J HYPERTENS, V15, P994, DOI 10.1016/S0895-7061(02)02997-7; Mockel M, 2013, EMERG MED J, V30, P633, DOI 10.1136/emermed-2012-201530; Morbach C, 2017, EUR J HEART FAIL, V19, P1166, DOI 10.1002/ejhf.859; Nagaya N, 1999, AM J PHYSIOL-REG I, V276, pR213; Nakamura M, 1997, CIRCULATION, V95, P1214; Nishikimi T, 2001, J HYPERTENS, V19, P765, DOI 10.1097/00004872-200104000-00014; NISHIKIMI T, 1995, J AM COLL CARDIOL, V26, P1424, DOI 10.1016/0735-1097(95)00338-X; NISHIKIMI T, 1994, HYPERTENSION, V24, P600, DOI 10.1161/01.HYP.24.5.600; Nishikimi T, 2007, CURR MED CHEM, V14, P1689, DOI 10.2174/092986707780830943; Nishikimi Toshio, 2005, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V3, P231, DOI 10.2174/1568016054368241; Nishikimi T, 2018, HEART FAIL CLIN, V14, P49, DOI 10.1016/j.hfc.2017.08.006; Nishikimi T, 2013, CURR PROTEIN PEPT SC, V14, P256, DOI 10.2174/13892037113149990045; Nishikimi T, 2009, CIRC J, V73, P892, DOI 10.1253/circj.CJ-08-0487; Nishio K, 1997, CRIT CARE MED, V25, P953, DOI 10.1097/00003246-199706000-00010; O'Malley RG, 2014, J AM COLL CARDIOL, V63, P1644, DOI 10.1016/j.jacc.2013.12.034; Pang PS, 2018, CARDIOL CLIN, V36, P63, DOI [10.1016/j.ccl.2017.09.003, 10.1016/j.cc12017.09.003]; Peacock WF, 2008, NEW ENGL J MED, V358, P2117, DOI 10.1056/NEJMoa0706824; Pedowska-Wloszek J, 2013, THROMB RES, V132, P506, DOI 10.1016/j.thromres.2013.08.008; Pezzilli R, 2012, PANMINERVA MED, V54, P211; Puskarich MA, 2011, RESUSCITATION, V82, P1289, DOI 10.1016/j.resuscitation.2011.06.015; Rasmussen MB, 2017, EUR HEART J-ACUTE CA, V6; Rooney KD, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0692-9; Ruan W, 2016, ANN ACAD MED SINGAP, V45, P18; Schrier RW, 1999, NEW ENGL J MED, V341, P577, DOI 10.1056/NEJM199908193410806; Schuetz P, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1098-z; Shah RV, 2012, EUR HEART J, V33, P2197, DOI 10.1093/eurheartj/ehs136; Spoto S, 2017, SHOCK; Stolz D, 2008, CHEST, V134, P263, DOI 10.1378/chest.08-0047; Stolz D, 2007, CHEST, V131, P1058, DOI 10.1378/chest.06-2336; Stolz D, 2014, EUR RESPIR J, V43, P397, DOI 10.1183/09031936.00058713; Struck J, 2004, PEPTIDES, V25, P1369, DOI 10.1016/j.peptides.2004.06.019; SUGO S, 1994, BIOCHEM BIOPH RES CO, V201, P1160, DOI 10.1006/bbrc.1994.1827; SUGO S, 1994, BIOCHEM BIOPH RES CO, V203, P719, DOI 10.1006/bbrc.1994.2241; Taboulet P, 2005, ANN BIOL CLIN-PARIS, V63, P377; Travaglino F, 2014, AM J EMERG MED, V32, P334, DOI 10.1016/j.ajem.2013.12.045; Travaglino F, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-184; Tzikas S, 2013, HEART, V99, P388, DOI 10.1136/heartjnl-2012-302956; Valenzuela-Sanchez F, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.08.65; Vari RC, 1996, P SOC EXP BIOL MED, V211, P178; von Haehling S, 2010, EUR J HEART FAIL, V12, P484, DOI 10.1093/eurjhf/hfq031; Vuilleumier N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155973; Wu AHB, 2007, CLIN CHEM, V53, P2086, DOI 10.1373/clinchem.2007.095679; Xue Y, 2013, EUR J HEART FAIL, V15, P1343, DOI 10.1093/eurjhf/hft116	108	0	0	0	0	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	2					147	153		10.1080/14737159.2018.1427069			7	Pathology	Pathology	FU3KC	WOS:000423748800004	29319365				2019-10-28	
J	Bastos, DA; Antonarakis, ES				Bastos, Diogo A.; Antonarakis, Emmanuel S.			CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						AR-V7; prognostic; predictive; biomarker; castration-resistant prostate cancer	CIRCULATING TUMOR-CELLS; IN-SITU HYBRIDIZATION; SPLICE VARIANT 7; THERAPEUTIC RESISTANCE; ANDROGEN DEPRIVATION; HORMONAL THERAPIES; INCREASED SURVIVAL; ABIRATERONE; ENZALUTAMIDE; MEN	Introduction: Prostate cancer is a highly heterogeneous disease, with remarkably different prognosis across all stages. Increased circulating tumor cell (CTC) count ( 5) using the CellSearch assay has been identified as one of the markers that can be used to predict survival, with added value beyond currently available prognostic factors. Recently, androgen receptor splice variant 7 (AR-V7) detection has been associated with worse outcomes for patients with castration-resistant prostate cancer (CRPC) treated with novel androgen receptor-signaling (ARS) inhibitors such as abiraterone and enzalutamide but not taxane chemotherapies.Areas covered: In this manuscript, the authors review the available biomarkers in CRPC and discuss emerging data on the value of CTC-derived AR-V7 status to assess prognosis and its potential role to guide treatment selection for patients with advanced prostate cancer.Expert commentary: Current evidence supports AR-V7 status as a prognostic biomarker and also as a potential predictive biomarker for patients with mCRPC. The authors expect that the incorporation of AR-V7 status and other biomarkers (e.g. AR mutations) in the sequential assessment of patients with advanced prostate cancer will lead to a more rational use of available and future therapies, with significant improvements in outcomes for our patients.	[Bastos, Diogo A.] Hosp Sirio Libanes, Dept Oncol, Sao Paulo, Brazil; [Antonarakis, Emmanuel S.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MA USA; [Antonarakis, Emmanuel S.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Urol, Baltimore, MA USA	Antonarakis, ES (reprint author), Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB1-1M45, Baltimore, MA USA.	eantona1@jhmi.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 CA185297, P30 CA006973]; Prostate Cancer Foundation	This article was funded by NIH Grants R01 CA185297 and P30 CA006973 and the Prostate Cancer Foundation.	Antonarakis ES, 2016, PROSTATE CANCER P D, V19, P231, DOI 10.1038/pcan.2016.17; Antonarakis ES, 2017, J CLIN ONCOL, V35, P2149, DOI 10.1200/JCO.2016.70.1961; Antonarakis ES, 2017, EUR UROL, V71, P4, DOI 10.1016/j.eururo.2016.08.038; Antonarakis ES, 2015, JAMA ONCOL, V1, P582, DOI 10.1001/jamaoncol.2015.1341; Antonarakis ES, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.7_suppl.138; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Aparicio AM, 2016, CLIN CANCER RES, V22, P1520, DOI 10.1158/1078-0432.CCR-15-1259; Armstrong AJ, 2012, EUR UROL, V61, P549, DOI 10.1016/j.eururo.2011.11.009; Azad AA, 2015, CLIN CANCER RES, V21, P2315, DOI 10.1158/1078-0432.CCR-14-2666; Bastos DA, 2016, DRUG DES DEV THER, V10, DOI 10.2147/DDDT.S93941; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Beltran H, 2016, CLIN CANCER RES, V22, P1510, DOI 10.1158/1078-0432.CCR-15-0137; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Bernemann C, 2017, EUR UROL, V71, P1, DOI 10.1016/j.eururo.2016.07.021; Danila DC, 2007, CLIN CANCER RES, V13, P7053, DOI 10.1158/1078-0432.CCR-07-1506; de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Del Re M, 2017, EUR UROL, V71, P680, DOI 10.1016/j.eururo.2016.08.012; FDA NIH Biomarker Working Group, 2016, BEST BIOM ENDP OTH T; Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174; Goldkorn A, 2014, J CLIN ONCOL, V32, P1136, DOI 10.1200/JCO.2013.51.7417; Guedes LB, 2016, CLIN CANCER RES, V22, P4651, DOI 10.1158/1078-0432.CCR-16-0205; Halabi S, 2016, J CLIN ONCOL, V34, P1652, DOI 10.1200/JCO.2015.65.7270; Halabi S, 2014, J CLIN ONCOL, V32, P671, DOI 10.1200/JCO.2013.52.3696; Handy CE, 2016, CURR TREAT OPTION ON, V17, DOI 10.1007/s11864-016-0438-9; Heller G, 2017, CLIN CANCER RES, V23, P1967, DOI 10.1158/1078-0432.CCR-16-1224; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Hussain M, 2013, NEW ENGL J MED, V368, P1314, DOI 10.1056/NEJMoa1212299; James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Li H, 2017, EUROPEAN UROLOGY FOC; Ma YF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081264; Markowski MC, 2017, JCO PRECIS ONCOL, V1; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Nakazawa M, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0568-7; Nakazawa M, 2014, HORM CANCER-US, V5, P265, DOI 10.1007/s12672-014-0190-1; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Pomerantz MM, 2017, CANCER-AM CANCER SOC, V123, P3532, DOI 10.1002/cncr.30808; Qu FF, 2017, CLIN CANCER RES, V23, P726, DOI 10.1158/1078-0432.CCR-16-1070; Rescigno P, 2016, EUR UROL, V70, P724, DOI 10.1016/j.eururo.2016.02.055; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Romanel A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac9511; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Ryan CJ, 2011, J CLIN ONCOL, V29, P3651, DOI 10.1200/JCO.2011.35.2005; Saylor PJ, 2017, CLIN CANCER RES, V23, P363, DOI 10.1158/1078-0432.CCR-16-0237; Scher HI, 2017, CANCER RES, V77, P5687, DOI 10.1158/0008-5472.CAN-17-1353; Scher HI, 2016, JAMA ONCOL, V2, P1441, DOI 10.1001/jamaoncol.2016.1828; Scher HI, 2015, J CLIN ONCOL, V33, P1348, DOI 10.1200/JCO.2014.55.3487; Scher HI, 2013, NAT REV CLIN ONCOL, V10, P225, DOI 10.1038/nrclinonc.2013.30; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Seitz AK, 2017, EUR UROL, V72, P828, DOI 10.1016/j.eururo.2017.07.024; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Steinestel J, 2017, EUR UROL, V71, P6, DOI 10.1016/j.eururo.2016.08.071; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Taplin ME, 2017, J CLIN ONCOL S, V35, P5005; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Toss A, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.09.06; Tsao CK, 2012, CURR OPIN UROL, V22, P167, DOI 10.1097/MOU.0b013e3283523b8b; Usher JL, 2016, J CLIN ONCOLOGY S, V34; Vale CL, 2016, LANCET ONCOL, V17, P243, DOI 10.1016/S1470-2045(15)00489-1; Welti J, 2016, EUR UROL, V70, P599, DOI 10.1016/j.eururo.2016.03.049; Zhu Y, 2017, EUR UROL	68	6	6	1	9	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	2					155	163		10.1080/14737159.2018.1427068			9	Pathology	Pathology	FU3KC	WOS:000423748800005	29319382	Green Accepted			2019-10-28	
J	Wang, KK; Yang, ZH; Zhu, T; Shi, Y; Rubenstein, R; Tyndall, JA; Manley, GT				Wang, Kevin K.; Yang, Zhihui; Zhu, Tian; Shi, Yuan; Rubenstein, Richard; Tyndall, J. Adrian; Manley, Geoff T.			An update on diagnostic and prognostic biomarkers for traumatic brain injury	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Biomarkers; traumatic brain injury; diagnostics; theranostics; neurotrauma	FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; ALPHA-II-SPECTRIN; SERUM NEUROFILAMENT LIGHT; NEURON-SPECIFIC ENOLASE; REPETITIVE HEAD TRAUMA; CENTRAL-NERVOUS-SYSTEM; DIFFUSE AXONAL INJURY; 2ND IMPACT SYNDROME; CEREBROSPINAL-FLUID	Introduction: Traumatic brain injury (TBI) is a major worldwide neurological disorder of epidemic proportions. To date, there are still no FDA-approved therapies to treat any forms of TBI. Encouragingly, there are emerging data showing that biofluid-based TBI biomarker tests have the potential to diagnose the presence of TBI of different severities including concussion, and to predict outcome.Areas covered: The authors provide an update on the current knowledge of TBI biomarkers, including protein biomarkers for neuronal cell body injury (UCH-L1, NSE), astroglial injury (GFAP, S100B), neuronal cell death (II-spectrin breakdown products), axonal injury (NF proteins), white matter injury (MBP), post-injury neurodegeneration (total Tau and phospho-Tau), post-injury autoimmune response (brain antigen-targeting autoantibodies), and other emerging non-protein biomarkers. The authors discuss biomarker evidence in TBI diagnosis, outcome prognosis and possible identification of post-TBI neurodegernative diseases (e.g. chronic traumatic encephalopathy and Alzheimer's disease), and as theranostic tools in pre-clinical and clinical settings.Expert commentary: A spectrum of biomarkers is now at or near the stage of formal clinical validation of their diagnostic and prognostic utilities in the management of TBI of varied severities including concussions. TBI biomarkers could serve as a theranostic tool in facilitating drug development and treatment monitoring.	[Wang, Kevin K.; Yang, Zhihui; Zhu, Tian] Univ Florida, Program Neurotrauma Neuroprote & Biomarkers Res, Dept Emergency Med, Gainesville, FL 32611 USA; [Wang, Kevin K.; Yang, Zhihui; Zhu, Tian] Univ Florida, Dept Psychiat, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Wang, Kevin K.; Yang, Zhihui; Zhu, Tian] Univ Florida, Dept Neurosci, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32610 USA; [Wang, Kevin K.; Yang, Zhihui; Zhu, Tian] Univ Florida, Dept Chem, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Shi, Yuan] Third Mil Med Univ, Daping Hosp, Dept Pediat, Chongqing, Peoples R China; [Rubenstein, Richard] Suny Downstate Med Ctr, Lab Neurodegenerat Dis & CNS Biomarker Discovery, Dept Neurol, Brooklyn, NY 11203 USA; [Rubenstein, Richard] Suny Downstate Med Ctr, Lab Neurodegenerat Dis & CNS Biomarker Discovery, Dept Physiol Pharmacol, Brooklyn, NY 11203 USA; [Tyndall, J. Adrian] Univ Florida, Dept Emergency Med, Gainesville, FL USA; [Manley, Geoff T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Manley, Geoff T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA	Wang, KK (reprint author), Univ Florida, Program Neurotrauma Neuroprote & Biomarkers Res, Dept Emergency Med, Gainesville, FL 32611 USA.; Wang, KK (reprint author), Univ Florida, Dept Psychiat, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA.; Wang, KK (reprint author), Univ Florida, Dept Neurosci, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32610 USA.; Wang, KK (reprint author), Univ Florida, Dept Chem, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA.	kawangwang17@gmail.com		Wang, Kevin/0000-0002-9343-6473	U.S. DOD TED Seed Project [TED1506]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21NS085455-01, RC2 NS069409, 1U01 NS086090-01]; VAUS Department of Veteran Affairs [I01 RX001859-02]; Florida State/McKnight Brain Institute BSCIRT Fund [110587]; DODUnited States Department of Defense [W81XWH-14-2-0176, W81XWH-13-1-04]; DOD-ArmyUnited States Department of Defense [W81XWH-14-2-0166]; European CommissionEuropean Commission Joint Research Centre [602150-2]	This study is supported in part by U.S. DOD TED Seed Project TED1506 (KK Wang), NIH R21NS085455-01 (KK Wang), VA I01 RX001859-02 Merit Award (KK Wang), and Florida State/McKnight Brain Institute BSCIRT Fund (#110587) (KK Wang), NIH RC2 NS069409 (GT Manley), NIH 1U01 NS086090-01 (GT Manley), DOD Grant W81XWH-14-2-0176 (GT Manley), DOD Grant W81XWH-13-1-04 (GT Manley), DOD-Army grant W81XWH-14-2-0166 (R Rubenstein). European Commission Framework Program 7, FP7-HEALTH-2013-INNOVATION-1 grant #602150-2; (KK Wang; overall PI Andrew Maas, David Menon).	Abbasi Mohsen, 2014, Turk J Emerg Med, V14, P147, DOI 10.5505/1304.7361.2014.74317; Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107; Agoston DV, 2017, BRAIN INJURY, V31, P1195, DOI 10.1080/02699052.2017.1357836; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Ankeny DP, 2006, J NEUROCHEM, V99, P1073, DOI 10.1111/j.1471-4159.2006.04147.x; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Barbosa RR, 2012, J TRAUMA ACUTE CARE, V73, pS307, DOI 10.1097/TA.0b013e3182701885; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Berger RP, 2015, J PEDIATR-US, V166, P383, DOI 10.1016/j.jpeds.2014.10.036; Berger RP, 2011, PM&R, V3, pS31, DOI 10.1016/j.pmrj.2011.03.016; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2004, CHILD ABUSE NEGLECT, V28, P739, DOI 10.1016/j.chiabu.2004.01.007; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bhomia M, 2016, SCI REP, V6; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333; Bonneh-Barkay D, 2010, J NEUROTRAUM, V27, P1215, DOI 10.1089/neu.2010.1310; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Buonora JE, 2015, FRONT NEUROL S1, V6, P503; Cantu RC, 2011, YB SPORTS MED, V2011, P26; Cervellin G, 2012, CLIN BIOCHEM, V45, P408, DOI 10.1016/j.clinbiochem.2012.01.006; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Colasanti T, 2010, AUTOIMMUN REV, V9, P807, DOI 10.1016/j.autrev.2010.07.008; Cox AL, 2006, J NEUROIMMUNOL, V174, P180, DOI 10.1016/j.jneuroim.2006.01.007; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; D'Andrea MR, 2005, MED HYPOTHESES, V64, P458, DOI 10.1016/j.mehy.2004.08.024; Dambinova SA, 2003, CLIN CHEM, V49, P1752, DOI 10.1373/49.10.1752; Dambinova SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042362; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; De Oliveira CO, 2007, J NEUROTRAUM, V24, P1331, DOI 10.1089/neu.2006.0159; DEBER CM, 1991, CLIN BIOCHEM, V24, P113, DOI 10.1016/0009-9120(91)90421-A; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Di Pietro V, 2017, J NEUROTRAUM, V34, P1948, DOI 10.1089/neu.2016.4857; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; DOD DVBIC, 2017, DOD DVBIC REP DOD RE, V1-5; Duan YL, 2012, TRANSL NEURODEGENER, V1, DOI 10.1186/2047-9158-1-24; Egea-Guerrero JJ, 2013, J NEUROTRAUM, V30, P1762, DOI 10.1089/neu.2012.2606; Elovic E, 2006, J HEAD TRAUMA REHAB, V21, P426, DOI 10.1097/00001199-200609000-00044; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Ferrari Maurizio, 2008, EJIFCC, V19, P68; Filippidis AS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.8.FOCUS10185; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Glushakova OY, 2012, TOXICOL SCI, V130, P158, DOI 10.1093/toxsci/kfs224; Goldstein L. E., 2012, SCI TRANSL MED, V4; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Goryunova A V, 2007, Neurosci Behav Physiol, V37, P761, DOI 10.1007/s11055-007-0079-3; Hedegaard CJ, 2009, IMMUNOLOGY, V128, pe451, DOI 10.1111/j.1365-2567.2008.02999.x; Hoffman SW, 2009, CLIN NEUROPSYCHOL, V23, P1400, DOI 10.1080/13854040903369433; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kang JH, 2012, J NEUROTRAUM, V29, P90, DOI 10.1089/neu.2011.1936; Kellermann I, 2016, CLIN NEUROL NEUROSUR, V145, P79, DOI 10.1016/j.clineuro.2016.04.005; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kiechle K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084977; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Kobeissy FH, 2011, PM&R, V3, pS139, DOI 10.1016/j.pmrj.2011.02.012; Kochanek PM, 2011, J TRAUMA, V71, pS15, DOI 10.1097/TA.0b013e31822117fe; Kochanek PM, 2015, J NEUROTRAUM, Vneu.2015, P4113; Korley FK, 2016, J NEUROTRAUM, V33, P215, DOI 10.1089/neu.2015.3949; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lancaster E, 2012, NAT REV NEUROL, V8, P380, DOI 10.1038/nrneurol.2012.99; Lee JY, 2015, J KOREAN NEUROSURG S, V58, P93, DOI 10.3340/jkns.2015.58.2.93; Lee PC, 2012, NEUROLOGY, V79, P2061, DOI 10.1212/WNL.0b013e3182749f28; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; Li Y, 2015, J NEUROL SCI, V359, P280, DOI 10.1016/j.jns.2015.08.035; Liliang PC, 2010, RESUSCITATION, V81, P1205, DOI 10.1016/j.resuscitation.2010.05.016; Liu MD, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3389/fincel.2015.00168, 10.3389/fncel.2015.00168]; Liu MD, 2014, CHIN J TRAUMATOL, V17, P317, DOI 10.3760/cma.j.issn.1008-1275.2014.06.003; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Macher H, 2012, CLIN CHIM ACTA, V414, P12, DOI 10.1016/j.cca.2012.08.001; Maier B, 2005, J NEUROTRAUM, V22, P822, DOI 10.1089/neu.2005.22.822; Manek R, 2017, MOL NEUROBIOL, V24; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Martinez-Morillo E, 2015, CLIN CHEM LAB MED, V53, P1575, DOI 10.1515/cclm-2014-0908; Massaro AN, 2013, PEDIATR CRIT CARE ME, V14, P310, DOI 10.1097/PCC.0b013e3182720642; McCrory P, 2013, CONS STAT CONC SPORT, pe55; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MECOCCI P, 1995, J NEUROIMMUNOL, V57, P165, DOI 10.1016/0165-5728(94)00180-V; Merlo L, 2014, J NEUROTRAUM, V31, P1375, DOI 10.1089/neu.2014.3385; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mitra B, 2017, J CLIN NEUROSCI, V38, P37, DOI 10.1016/j.jocn.2016.12.009; Mondello S., 2011, TRANSLATIONAL STROKE, V3, P1, DOI DOI 10.3389/FNEUR.2012.00147/ABSTRACT; Mondello S, 2015, J NEUROTRAUM, Vneu.2015, P4132; Mondello S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28203; Mondello S, 2012, BRAIN INJURY, V26, P1629, DOI 10.3109/02699052.2012.700083; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Mountney A, 2015, J NEUROTRAUMA INTERN, Vneu.2015, P4130; Moyron RB, 2017, PROTEOM CLIN APPL, V11, DOI 10.1002/prca.201700095; Muradashvili N, 2013, BRAIN INJURY, V27, P1508, DOI 10.3109/02699052.2013.823562; Nekludov M, 1856, BRAIN INJURY, V31, P2017; Neselius S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081249; Nimer AF, 2015, PLOS ONE, V10; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Oliver JM, 2016, J NEUROTRAUM, V33, P1784, DOI 10.1089/neu.2015.4295; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Ottens AK, 2008, J NEUROCHEM, V104, P1404, DOI 10.1111/j.1471-4159.2007.05086.x; Pandey S., 2017, BRIT J NEUROSURG, V1, P1; Papa L, 2017, J NEUROTRAUMA NEU, V2017, P4994; Papa L, 2015, NEUROCRIT CARE, V22, P52, DOI 10.1007/s12028-014-0028-2; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pearson WS, 2012, WEST J EMERG MED, V13, P289, DOI 10.5811/westjem.2012.3.11559; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/neu.2004.21.1553; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Ponomarenko NA, 2006, IMMUNOL LETT, V103, P45, DOI 10.1016/j.imlet.2005.10.006; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Rodrigues Filho EM, 2014, REV BRASILEIRA TERAP, V26, P1; Rodrigues Filho EM, 1639, J NEUROTRAUM, V31, P2014; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schiff L, 2012, MOL DIAGN THER, V16, P79, DOI 10.2165/11631580-000000000-00000; Schulte S, 2014, J ATHL TRAINING, V49, P830, DOI 10.4085/1062-6050-49.3.33; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Shear DA, 2015, J NEUROTRAUM, Vneu.2015, P4115; Siman R, 2013, FRONT NEUROL, V18, P10; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Sorokina EG, 2010, ZH NEVROL PSIKHIATR, V110, P30; Stein DM, 2011, NEUROCRIT CARE, V14, P200, DOI 10.1007/s12028-010-9496-1; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Stovitz SD, 2017, CURR SPORT MED REP, V16, P50, DOI 10.1249/JSR.0000000000000326; Svetlov SI, 2012, NATO RES TECHNOL ORG, V207; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2013, J NEUROTRAUM, V30, P1426, DOI 10.1089/neu.2012.2752; Tanriverdi F, 2010, EUR J ENDOCRINOL, V162, P861, DOI 10.1530/EJE-09-1024; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2017, ACTA NEUROCHIR, V159, P209, DOI 10.1007/s00701-016-3046-3; Tomkins O., 2011, CARDIOVASC PSYCHIAT, V2011, P1; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Vartanian MG, 1996, DEV BRAIN RES, V95, P169, DOI 10.1016/S0165-3806(96)00073-9; Verfaillie CJ, 2010, CLIN CHEM LAB MED, V48, P891, DOI 10.1515/CCLM.2010.159; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner Amy K, 2013, Pathophysiology, V20, P39, DOI 10.1016/j.pathophys.2012.02.007; Wang KKW, 2016, J NEUROTRAUM, V33, P1270, DOI 10.1089/neu.2015.3881; Wang KKW, 2013, PROC SPIE, V8723, DOI 10.1117/12.2020030; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Wilkinson Charles W, 2012, Front Neurol, V3, P11, DOI 10.3389/fneur.2012.00011; Winston CN, 2016, AM J PATHOL, V186, P552, DOI 10.1016/j.ajpath.2015.11.006; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yang J, 2015, CLIN BIOCHEM, V48, P843, DOI 10.1016/j.clinbiochem.2015.05.015; Yang Z, 2018, CURR PHYS M IN PRESS; Yang ZH, 2015, TRENDS NEUROSCI, V38, P364, DOI 10.1016/j.tins.2015.04.003; Yang ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11178; Yang ZH, 2014, J CEREBR BLOOD F MET, V34, P1444, DOI 10.1038/jcbfm.2014.105; Yokobori S, 2015, WORLD NEUROSURG, V83, P867, DOI 10.1016/j.wneu.2013.03.012; Yurgel VC, 2007, J NEUROTRAUM, V24, P1172, DOI 10.1089/neu.2006.0160; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zhang ZF, 2014, EURASIP J AUDIO SPEE, DOI 10.1186/1687-4722-2014-15; Zhang ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092698; Zhang ZY, 2014, PEPTIDES, V60, P13, DOI 10.1016/j.peptides.2014.07.016; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027; Zurek J, 2011, ACTA NEUROCHIR, V154, P103; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2; Zurek J, 2011, BRAIN INJURY, V25, P221, DOI 10.3109/02699052.2010.541895	199	23	23	3	26	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	2					165	180		10.1080/14737159.2018.1428089			16	Pathology	Pathology	FU3KC	WOS:000423748800006	29338452	Green Accepted			2019-10-28	
J	Gastaldi, M; Nosadini, M; Spatola, M; Sartori, S; Franciotta, D				Gastaldi, Matteo; Nosadini, Margherita; Spatola, Marianna; Sartori, Stefano; Franciotta, Diego			N-methyl-D-aspartate receptor encephalitis: laboratory diagnostics and comparative clinical features in adults and children	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Autoimmune encephalitis; cell-based assay; immunohistochemistry; immunosuppressive therapies; neuroimmunology; neuropsychiatric disorders; paraneoplastic neurological syndrome	ANTI-NMDAR ENCEPHALITIS; HERPES-SIMPLEX ENCEPHALITIS; AUTOIMMUNE ENCEPHALITIS; LIMBIC ENCEPHALITIS; STATUS EPILEPTICUS; CASE SERIES; NEUROMYELITIS-OPTICA; INSTITUTIONAL COHORT; DOPAMINE-2 RECEPTOR; MOVEMENT-DISORDERS	Introduction: N-methyl-D-aspartate receptor (NMDAR) encephalitis is the most common autoimmune encephalitis due to autoantibodies against neuronal surface antigens, can affect both children and adults, leading to neurological and neuropsychological sequelae. However, it is potentially treatable and the prompt start of immunotherapy associates with better prognosis. Conversely, misdiagnosis can be harmful. The detection of NMDAR antibodies in serum and cerebrospinal fluid plays a pivotal role in the diagnostic work-up. Reliable methods for NMDAR antibody detection are thus fundamental to assure accurate diagnosis and allow early treatments.Areas covered: This review recapitulates the pathogenic mechanisms of NMDAR encephalitis as a model of antibody mediated synaptopathy, and gives insights into the related state-of-the-art laboratory testing. The differences in clinical presentations, tumor associations and responses to treatments between adults and children are also described.Expert commentary: The relevance of NMDAR encephalitis has placed neuroimmunology laboratories in a crucial position, but methods for NMDAR antibody detection are awaiting thorough and consensus-based standardizations. In the next few years, this process, along with novel insights into the pathogenic mechanisms, could improve the disease management and clarify the still pending role of NMDAR antibodies in healthy people and in other more common neuropsychiatric disorders.	[Gastaldi, Matteo; Franciotta, Diego] IRCCS Mondino Fdn, Lab Neuroimmunol, Pavia, Italy; [Gastaldi, Matteo] IRCCS Mondino Fdn, Dept Brain & Behav Sci, Pavia, Italy; [Gastaldi, Matteo] Univ Pavia, Pavia, Italy; [Nosadini, Margherita; Sartori, Stefano] Univ Hosp Padua, Dept Womens & Childrens Hlth, Paediat Neurol & Neurophysiol Unit, Padua, Italy; [Spatola, Marianna] Univ Lausanne UNIL, Dept Clin Neurosci, Lausanne, Switzerland; [Spatola, Marianna] IDIBAPS Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain	Franciotta, D (reprint author), IRCCS Mondino Fdn, Via Mondino 2, I-27100 Pavia, Italy.	diego.franciotta@mondino.it	Gastaldi, Matteo/K-8398-2016; Franciotta, Diego/K-8262-2016	Franciotta, Diego/0000-0002-3014-3913; Spatola, Marianna/0000-0003-2548-0429	Italian Ministry of Health 'Ricerca Corrente'Ministry of Health, Italy	This work was supported by the Italian Ministry of Health 'Ricerca Corrente' 2017-2019 Grant to IRCCS Mondino Foundation.	[Anonymous], 2007, THYROID, V17, P1027, DOI 10.1089/thy.2007.1526; Armangue T, 2015, NEUROLOGY, V85, P1736, DOI 10.1212/WNL.0000000000002125; Armangue T, 2014, CURR OPIN NEUROL, V27, P361, DOI 10.1097/WCO.0000000000000087; Armangue T, 2014, ANN NEUROL, V75, P317, DOI 10.1002/ana.24083; Armangue T, 2013, J PEDIATR-US, V162, P850, DOI 10.1016/j.jpeds.2012.10.011; Arnulf I, 2012, LANCET NEUROL, V11, P918, DOI 10.1016/S1474-4422(12)70187-4; BARLOW DJ, 1986, NATURE, V322, P747, DOI 10.1038/322747a0; Bartolini L, 2017, J NEUROL, V264, P647, DOI 10.1007/s00415-017-8407-1; Bien CG, 2005, BRAIN, V128, P454, DOI 10.1093/brain/awh415; Boronat A, 2013, ANN NEUROL, V73, P120, DOI 10.1002/ana.23756; Cortese A, 2016, J NEUROL SCI, V363, P182, DOI 10.1016/j.jns.2016.02.022; Cutolo M, 2006, ANN NY ACAD SCI, V1089, P538, DOI 10.1196/annals.1386.043; Dahm L, 2014, ANN NEUROL, V76, P82, DOI 10.1002/ana.24189; Dale RC, 2017, CURR OPIN NEUROL, V30, P334, DOI 10.1097/WCO.0000000000000443; Dale RC, 2014, NEUROLOGY, V83, P142, DOI 10.1212/WNL.0000000000000570; Dale RC, 2013, DEV MED CHILD NEUROL, V55, P191, DOI 10.1111/dmcn.12036; Dale RC, 2012, BRAIN, V135, P3453, DOI 10.1093/brain/aws256; Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050; Dalmau J, 2011, LANCET NEUROL, V10, P63, DOI 10.1016/S1474-4422(10)70253-2; Dalmau J, 2008, LANCET NEUROL, V7, P1091, DOI 10.1016/S1474-4422(08)70224-2; Darnell RB, 1996, P NATL ACAD SCI USA, V93, P4529, DOI 10.1073/pnas.93.10.4529; De Silvestro G, 2009, J CLIN APHERESIS, V24, P1, DOI 10.1002/jca.20184; De Tiege X, 2003, NEUROLOGY, V61, P241, DOI 10.1212/01.WNL.0000073985.71759.7C; Demeestere I, 2016, J CLIN ONCOL, V34, P2568, DOI 10.1200/JCO.2015.65.8864; Diamond B, 2013, ANNU REV IMMUNOL, V31, P345, DOI 10.1146/annurev-immunol-020711-075041; Duan BC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004365; Ehrenreich H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00181; Eschler DC, 2011, CLIN REV ALLERG IMMU, V41, P190, DOI 10.1007/s12016-010-8245-8; Florance NR, 2009, ANN NEUROL, V66, P11, DOI 10.1002/ana.21756; Gable MS, 2012, CLIN INFECT DIS, V54, P899, DOI 10.1093/cid/cir1038; Gastaldi M, 2017, CLIN BIOCHEM, V50, P354, DOI 10.1016/j.clinbiochem.2016.11.023; Gastaldi M, 2016, NEUROTHERAPEUTICS, V13, P147, DOI 10.1007/s13311-015-0410-6; Gleichman AJ, 2012, J NEUROSCI, V32, P11082, DOI 10.1523/JNEUROSCI.0064-12.2012; Gordon-Lipkin E, 2017, J CHILD NEUROL, V32, P930, DOI 10.1177/0883073817720340; Granerod J, 2010, LANCET INFECT DIS, V10, P835, DOI 10.1016/S1473-3099(10)70222-X; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Gresa-Arribas N, 2016, NEUROLOGY, V86, P2235, DOI 10.1212/WNL.0000000000002775; Gresa-Arribas N, 2014, LANCET NEUROL, V13, P167, DOI 10.1016/S1474-4422(13)70282-5; Hachiya Y, 2013, J NEUROIMMUNOL, V265, P128, DOI 10.1016/j.jneuroim.2013.09.017; Hammer C, 2014, MOL PSYCHIATR, V19, P1143, DOI 10.1038/mp.2013.110; Hilderink M, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000126; Ho ACC, 2017, DEV MED CHILD NEUROL, V59, P1256, DOI 10.1111/dmcn.13579; Huang Q, 2016, J NEUROL, V263, P2446, DOI 10.1007/s00415-016-8282-1; Hughes EG, 2010, J NEUROSCI, V30, P5866, DOI 10.1523/JNEUROSCI.0167-10.2010; Hutchinson M, 2008, NEUROLOGY, V71, P1291, DOI 10.1212/01.wnl.0000327606.50322.f0; Iizuka T, 2008, NEUROLOGY, V70, P504, DOI 10.1212/01.wnl.0000278388.90370.c3; Iizuka T, 2016, JAMA NEUROL, V73, P706, DOI 10.1001/jamaneurol.2016.0232; Iizuka T, 2010, J NEUROL, V257, P1686, DOI 10.1007/s00415-010-5604-6; Irani SR, 2010, BRAIN, V133, P2734, DOI 10.1093/brain/awq213; Irani SR, 2010, BRAIN, V133, P1655, DOI 10.1093/brain/awq113; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; Jezequel J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01700-3; Johnson N, 2010, NEUROLOGY, V75, P1480, DOI 10.1212/WNL.0b013e3181f8831a; Kahn I, 2017, J CHILD NEUROL, V32, P243, DOI 10.1177/0883073816675557; Kayser MS, 2013, JAMA NEUROL, V70, P1133, DOI 10.1001/jamaneurol.2013.3216; Kim SH, 2013, JAMA NEUROL, V70, P1110, DOI 10.1001/jamaneurol.2013.3071; Kreye J, 2016, BRAIN, V139, P2641, DOI 10.1093/brain/aww208; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199; Kurian MA, 2011, LANCET NEUROL, V10, P721, DOI 10.1016/S1474-4422(11)70141-7; Lai MZ, 2010, LANCET NEUROL, V9, P776, DOI 10.1016/S1474-4422(10)70137-X; Lai MZ, 2009, ANN NEUROL, V65, P424, DOI 10.1002/ana.21589; Lancaster E, 2011, NEUROLOGY, V77, P1698, DOI 10.1212/WNL.0b013e3182364a44; Lancaster E, 2016, J CLIN NEUROL, V12, P1, DOI 10.3988/jcn.2016.12.1.1; Lancaster E, 2015, ANN NEUROL, V77, P183, DOI 10.1002/ana.24233; Lancaster E, 2010, LANCET NEUROL, V9, P67, DOI 10.1016/S1474-4422(09)70324-2; Lee WJ, 2016, NEUROTHERAPEUTICS, V13, P824, DOI 10.1007/s13311-016-0442-6; Lee WJ, 2016, NEUROLOGY, V86, P1683, DOI 10.1212/WNL.0000000000002635; Linnoila JJ, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000245; Looney RJ, 2006, BEST PRACT RES CL HA, V19, P3, DOI 10.1016/j.beha.2005.01.032; Marchant A, 2005, CLIN EXP IMMUNOL, V141, P10, DOI 10.111/j.1365.2249.2005.02799.x; Martinez-Hernandez E, 2011, NEUROLOGY, V77, P589, DOI 10.1212/WNL.0b013e318228c136; Masdeu JC, 2016, TRENDS NEUROSCI, V39, P300, DOI 10.1016/j.tins.2016.02.006; Matricardi S, 2016, J NEUROL, V263, P765, DOI 10.1007/s00415-016-8056-9; McCracken L, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000404; McDonald V, 2010, J THROMB HAEMOST, V8, P1201, DOI 10.1111/j.1538-7836.2010.03818.x; McKeon A, 2013, NEUROHOSPITALIST, V3, P53, DOI 10.1177/1941874412453339; Meyfroidt G, 2017, LANCET NEUROL, V16, P721, DOI 10.1016/S1474-4422(17)30259-4; Mikasova L, 2012, BRAIN, V135, P1606, DOI 10.1093/brain/aws092; Moghaddam B, 2012, NEUROPSYCHOPHARMACOL, V37, P4, DOI 10.1038/npp.2011.181; Mohammad SS, 2014, MOVEMENT DISORD, V29, P1539, DOI 10.1002/mds.25999; Mohammad SS, 2014, MOVEMENT DISORD, V29, P117, DOI 10.1002/mds.25623; Nosadini M, 2017, DEV MED CHILD NEUROL, V59, P796, DOI 10.1111/dmcn.13448; Nosadini M, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000188; Nosadini M, 2015, EXPERT REV NEUROTHER, V15, P1391, DOI 10.1586/14737175.2015.1115720; Nosadini M, 2015, J CHILD NEUROL, V30, P238, DOI 10.1177/0883073813515947; Pellkofer HL, 2011, NEUROLOGY, V76, P1310, DOI 10.1212/WNL.0b013e3182152881; Petit-Pedrol M, 2014, LANCET NEUROL, V13, P276, DOI 10.1016/S1474-4422(13)70299-0; Planaguma J, 2016, ANN NEUROL, V80, P388, DOI 10.1002/ana.24721; Planaguma J, 2015, BRAIN, V138, P94, DOI 10.1093/brain/awu310; Puoti G, 2012, LANCET NEUROL, V11, P618, DOI 10.1016/S1474-4422(12)70063-7; Quek AML, 2012, ARCH NEUROL-CHICAGO, V69, P582, DOI 10.1001/archneurol.2011.2985; Sabater L, 2014, LANCET NEUROL, V13, P575, DOI [10.1016/S1474-4421(14)70051-1, 10.1016/S1474-4422(14)70051-1]; Sanders J, 2002, THYROID, V12, P1043, DOI 10.1089/105072502321085135; Schabitz WR, 2014, NEUROLOGY, V83, P2309, DOI 10.1212/WNL.0000000000001072; Schmitt SE, 2012, NEUROLOGY, V79, P1094, DOI 10.1212/WNL.0b013e3182698cd8; Schroder C, 2003, TRANSPL IMMUNOL, V12, P19, DOI 10.1016/S0966-3274(03)00059-5; Solis N, 2016, J CLIN VIROL, V83, P26, DOI 10.1016/j.jcv.2016.08.292; Solomon T, 2012, J INFECTION, V64, P347, DOI 10.1016/j.jinf.2011.11.014; Spatola M, 2015, NEUROLOGY, V85, P464, DOI 10.1212/WNL.0000000000001717; Suppiej A, 2016, BRAIN DEV-JPN, V38, P613, DOI 10.1016/j.braindev.2016.01.009; Tardieu M, 2013, HAND CLINIC, V112, P1087, DOI 10.1016/B978-0-444-52910-7.00026-X; Titulaer MJ, 2013, NEUROLOGY, V81, P1058, DOI 10.1212/WNL.0b013e3182a4a49c; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Tse L, 2015, CURR NEUROPHARMACOL, V13, P395, DOI 10.2174/1570159X13999150424113345; van Baalen A, 2017, NEUROPEDIATRICS, V48, P5, DOI 10.1055/s-0036-1597271; Venancio P, 2014, PEDIATR INFECT DIS J, V33, P882, DOI 10.1097/INF.0000000000000408; Zhang L, 2017, EPILEPSY BEHAV, V68, P57, DOI 10.1016/j.yebeh.2016.12.019; Zinkernagel RM, 2001, NEW ENGL J MED, V345, P1331, DOI 10.1056/NEJMra012493; Zuliani L, 2017, NEUROL SCI, V38, pS225, DOI 10.1007/s10072-017-3032-4; Zuliani L, 2012, J NEUROL NEUROSUR PS, V83, P638, DOI 10.1136/jnnp-2011-301237	110	3	3	0	7	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	2					181	193		10.1080/14737159.2018.1431124			13	Pathology	Pathology	FU3KC	WOS:000423748800007	29376438				2019-10-28	
J	Lucchi, NW; Ndiaye, D; Britton, S; Udhayakumar, V				Lucchi, Naomi W.; Ndiaye, Daouda; Britton, Sumudu; Udhayakumar, Venkatachalam			Expanding the malaria molecular diagnostic options: opportunities and challenges for loop-mediated isothermal amplification tests for malaria control and elimination	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Malaria; diagnosis; elimination; LAMP; molecular tests; loop mediated isothermal amplification	HISTIDINE-RICH PROTEIN-2; PLASMODIUM-FALCIPARUM; IMPORTED MALARIA; HIGH-THROUGHPUT; ASYMPTOMATIC MALARIA; HIGH-SENSITIVITY; NESTED-PCR; LAMP ASSAY; PERFORMANCE; IDENTIFICATION	Introduction: The loop-mediated isothermal amplification (LAMP) technique holds substantial promise as an alternative easy-to-use molecular test for malaria parasite detection. Several modifications to the initial malaria LAMP assay have been made in an effort to make the LAMP platform more field-friendly.Areas covered: A PubMed literature search was performed using the following search terms: malaria,' loop mediated isothermal amplification', LAMP', molecular tests' and diagnostics'. The authors review the currently reported malaria LAMP assays and discuss what requirements would be needed to make malaria LAMP assays field-usable, especially in the context of malaria elimination.Expert commentary: Expanding the malaria LAMP tests as options for use in malaria control programs will require addressing some important challenges such as the need for simplified sample preparation steps; ready to use kits that require no cold chain; the use of a non-subjective results readout and preferably cost-effectiveness. Two malaria LAMP kits are now CE-marked and commercially available: the Loopamp MALARIA kit and the Illumigene malaria LAMP. Malaria LAMP tests, like other molecular tests, will likely be utilized in very specific studies such as: to evaluate detect and treat' strategies; in controlled malaria infection trials or drug efficacy trials and as confirmatory test in reference laboratories.	[Lucchi, Naomi W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30333 USA; [Ndiaye, Daouda] UCAD, Lab Parasitol & Mycol, Dakar, Senegal; [Britton, Sumudu] Queensland Inst Med Res QIMR Berghofer Med Res In, Dept Clin Trop Med, Brisbane, Qld, Australia; [Britton, Sumudu] Univ Queensland, Sch Med, Brisbane, Qld, Australia	Lucchi, NW (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30333 USA.	frd9@cdc.gov					Abdul-Ghani R, 2012, ACTA TROP, V122, P233, DOI 10.1016/j.actatropica.2012.02.004; [Anonymous], 2017, WORLD MALARIA REPORT; Aydin-Schmidt B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169037; Aydin-Schmidt B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103905; Beshir KB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15031-2; Bousema T, 2014, NAT REV MICROBIOL, V12, P833, DOI 10.1038/nrmicro3364; Britton S, 2016, AM J TROP MED HYG, V95, P120, DOI 10.4269/ajtmh.15-0670; Britton S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004443; Britton S, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0848-3; Campillo A, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2037-z; Coleman RE, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-121; Cook J, 2015, J INFECT DIS, V211, P1476, DOI 10.1093/infdis/jiu655; Cook J, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0573-y; Cullen KA, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6502a1; Das S, 2017, AM J TROP MED HYG, V97, P1540, DOI 10.4269/ajtmh.17-0245; de Gier B, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1711-5; Golassa L, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-352; Han ET, 2007, J CLIN MICROBIOL, V45, P2521, DOI 10.1128/JCM.02117-06; Han ET, 2013, EXPERT REV MOL DIAGN, V13, P205, DOI [10.1586/erm.12.144, 10.1586/ERM.12.144]; Harris I, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-254; Hayashida K, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-016-1949-8; Hayashida K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003578; Hopkins H, 2013, J INFECT DIS, V208, P645, DOI 10.1093/infdis/jit184; Imwong M, 2014, J CLIN MICROBIOL, V52, P3303, DOI 10.1128/JCM.01057-14; Kongkasuriyachai D, 2017, METHODS MOL BIOL, V1572, P431, DOI 10.1007/978-1-4939-6911-1_28; LaBarre P, 2010, IEEE ENG MED BIO, P1097, DOI 10.1109/IEMBS.2010.5627346; Landier J, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1399-y; Lau YL, 2016, AM J TROP MED HYG, V94, P336, DOI 10.4269/ajtmh.15-0569; Lee CS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060751; Lucchi NW, 2016, SCI REP-UK, V6, DOI 10.1038/srep36808; Lucchi NW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151437; Lucchi NW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013733; Menegon M, 2017, INFECT GENET EVOL, V55, P131, DOI 10.1016/j.meegid.2017.09.004; Mohon A, 2016, DIAGN MICR INFEC DIS, V85, P149, DOI 10.1016/j.diagmicrobio.2015.11.009; Mohon A, 2014, ACTA TROP, V134, P52, DOI 10.1016/j.actatropica.2014.02.016; Mornand P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180758; Morris U, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0731-2; Mosha JF, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-221; Notomi T, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e63; Okell LC, 2009, J INFECT DIS, V200, P1509, DOI 10.1086/644781; Oriero EC, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0926-6; Oriero EC, 2015, EXPERT REV MOL DIAGN, V15, P1419, DOI 10.1586/14737159.2015.1090878; Parr JB, 2017, J INFECT DIS, V216, P36, DOI 10.1093/infdis/jiw538; Patel JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054986; Perera RS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171126; Polley SD, 2013, J INFECT DIS, V208, P637, DOI 10.1093/infdis/jit183; Poole CB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169011; Poon LLM, 2006, CLIN CHEM, V52, P303; Rees E, 2017, TRAVEL MED INFECT DI, V17, P35, DOI 10.1016/j.tmaid.2017.04.004; Rogier E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172139; Roth JM, 2016, CRIT REV CL LAB SCI, V53, P87, DOI 10.3109/10408363.2015.1084991; Ruas R, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1952-3; Rypien C, 2017, J CLIN MICROBIOLOGY; Sema M, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0559-9; Singh R, 2017, J VECTOR DIS, V54, P54; Sanchez BS, 2017, ENFERM INFEC MICR CL, V35, P348, DOI 10.1016/j.eimc.2016.11.014; Stresman GH, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-265; Sturrock HJW, 2015, AM J TROP MED HYG, V93, P139, DOI 10.4269/ajtmh.14-0256; Sturrock HJW, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001467; Sturrock HJW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063830; Tatem AJ, 2017, LANCET INFECT DIS, V17, P98, DOI 10.1016/S1473-3099(16)30326-7; The Malera Refresh Consultative Panel on Tools for Malaria Elimination, 2017, PLOS MED, V14; Wang B, 2014, J CLIN MICROBIOL, V52, P1838, DOI 10.1128/JCM.03615-13; WHO, 2014, WHO EV REV GROUP MAL; WHO, 2017, FRAM MAL EL; World Health Organization, 2016, WORLD MALARIA REPORT; Yongkiettrakul S, 2014, PARASITOL INT, V63, P777, DOI 10.1016/j.parint.2014.06.004	67	3	3	2	14	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	2					195	203		10.1080/14737159.2018.1431529			9	Pathology	Pathology	FU3KC	WOS:000423748800008	29353522				2019-10-28	
J	Coffin, CM; Coulomb-L'Hermine, A; Cohen, M; Scheimberg, I; Dehner, LP				Coffin, Cheryl M.; Coulomb-L'Hermine, Aurore; Cohen, Marta; Scheimberg, Irene; Dehner, Louis P.			In Memoriam: Liliane Boccon-Gibod, MD, 1941-2017	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Biographical-Item									[Coffin, Cheryl M.] Vanderbilt Univ, Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Coulomb-L'Hermine, Aurore] Hop Armand Trousseau, Dept Pathol & Cytol, Paris, France; [Cohen, Marta] Sheffield Childrens Hosp, Dept Histopathol, Sheffield, S Yorkshire, England; [Scheimberg, Irene] Bart Hlth NHS Trust, Dept Pathol, London, England; [Dehner, Louis P.] Washington Univ, Pathol & Immunol, St Louis, MO USA	Coffin, CM (reprint author), POB 92, Surry, ME 04684 USA.	ccoffin@hotmail.com	Cohen, Marta/X-2014-2019	Cohen, Marta/0000-0001-5534-444X			BOCCONGIBOD L, PUBLICATION LIST	1	0	0	0	1	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JAN-FEB	2018	21	1					3	5		10.1177/1093526617753892			3	Pathology; Pediatrics	Pathology; Pediatrics	FU1PW	WOS:000423622900001	29378495				2019-10-28	
J	Pawel, BR				Pawel, Bruce R.			SMARCB1-deficient Tumors of Childhood: A Practical Guide	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Review						SMARCB1; pediatric neoplasms; rhabdoid; oncology; immunohistochemistry	RENAL MEDULLARY CARCINOMA; MALIGNANT RHABDOID TUMOR; EXTRASKELETAL MYXOID CHONDROSARCOMA; CENTRAL-NERVOUS-SYSTEM; NATIONAL-WILMS-TUMOR; DIAGNOSTIC IMMUNOHISTOCHEMICAL MARKER; CRIBRIFORM NEUROEPITHELIAL TUMOR; SMARCB1/INI1 PROTEIN EXPRESSION; SICKLE-CELL TRAIT; SSX-FUSION-TYPE	The SMARCB1 gene (INI1, BAF47) is a member of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex, involved in the epigenetic regulation of gene transcription. SMARCB1 acts as a tumor suppressor gene, and loss of function of both alleles gives rise to SMARCB1-deficient tumors. The prototypical SMARCB1-deficient tumor is the malignant rhabdoid tumor (MRT) which was first described in the kidney but also occurs in soft tissue, viscera, and the brain (where it is referred to as atypical teratoid rhabdoid tumor or AT/RT). These are overwhelmingly tumors of the very young, and most follow an aggressive and ultimately lethal course. Morphologically, most but not all contain a population of "rhabdoid'' cells, which are large cells with abundant cytoplasm, perinuclear spherical inclusions, and eccentric vesicular nuclei with large inclusion-like nucleoli. MRT immunohistochemistry reveals complete loss of SMARCB1 nuclear expression, and molecular analysis confirms biallelic SMARCB1 inactivation in the vast majority. Rare AT/RTs have loss of SMARCA4, another SWI/SNF member, rather than SMARCB1. With the widespread adoption of SMARCB1 immunohistochemistry, an increasing number of SMARCB1-deficient tumors outside of the MRT-AT/RT spectrum have been described. In addition to MRT and AT/RT, pediatric tumors with complete loss of SMARCB1 expression include cribriform neuroepithelial tumor, renal medullary carcinoma, and epithelioid sarcoma. Tumors with variable loss of SMARCB1 expression include subsets of epithelioid malignant peripheral nerve sheath tumor, schwannomas arising in schwannomatosis, subsets of chordomas, myoepithelial carcinomas, and sinonasal carcinomas. Variable and reduced expression of SMARCB1 is characteristic of synovial sarcoma. In this review, the historical background, clinical characteristics, morphology, immunohistochemical features, and molecular genetics most germane to these tumors are summarized. In addition, familial occurrence of these tumors (the rhabdoid tumor predisposition syndrome) is discussed. It is hoped that this review may provide practical guidance to pathologists encountering tumors that have altered expression of SMARCB1.	[Pawel, Bruce R.] Univ Penn, Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Div Anat Pathol, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA; [Pawel, Bruce R.] Univ Penn, Perelman Sch Med, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA	Pawel, BR (reprint author), Univ Penn, Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Div Anat Pathol, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA.; Pawel, BR (reprint author), Univ Penn, Perelman Sch Med, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	pawelb@email.chop.edu					Agaimy A, 2017, AM J SURG PATHOL, V41, P458, DOI 10.1097/PAS.0000000000000797; Agaimy A, 2014, ADV ANAT PATHOL, V21, P394, DOI 10.1097/PAP.0000000000000038; Agaimy A, 2014, AM J SURG PATHOL, V38, P1274, DOI 10.1097/PAS.0000000000000236; Agaram NP, 2014, HUM PATHOL, V45, P1084, DOI 10.1016/j.humpath.2014.01.007; Al-Ibraheemi Alyaa, 2015, Surg Pathol Clin, V8, P399, DOI 10.1016/j.path.2015.05.009; Alaggio R, 2009, PATHOL RES PRACT, V205, P451, DOI 10.1016/j.prp.2009.01.003; Alvarez O, 2015, PEDIATR BLOOD CANCER, V62, P1694, DOI 10.1002/pbc.25592; Amin MB, 2014, AM J SURG PATHOL, V38, P871, DOI 10.1097/PAS.0000000000000222; Antonescu CR, 2010, GENE CHROMOSOME CANC, V49, P1114, DOI 10.1002/gcc.20819; Arnold MA, 2013, PEDIATR DEVEL PATHOL, V16, P301, DOI 10.2350/12-12-1287-CR.1; Arnold MA, 2013, HUM PATHOL, V44, P881, DOI 10.1016/j.humpath.2012.08.014; Bartelheim K, 2014, CANCER GENET-NY, V207, P379, DOI 10.1016/j.cancergen.2014.04.005; BECKWITH JB, 1978, CANCER-AM CANCER SOC, V41, P1937, DOI 10.1002/1097-0142(197805)41:5<1937::AID-CNCR2820410538>3.0.CO;2-U; Bergh P, 1999, CANCER-AM CANCER SOC, V85, P2596, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2596::AID-CNCR16>3.0.CO;2-K; Biegel JA, 2002, CLIN CANCER RES, V8, P3461; Biegel JA, 1996, GENE CHROMOSOME CANC, V16, P94, DOI 10.1002/(SICI)1098-2264(199606)16:2<94::AID-GCC3>3.0.CO;2-Y; Biegel JA, 1999, CANCER RES, V59, P74; Bishop JA, 2014, AM J SURG PATHOL, V38, P1282, DOI 10.1097/PAS.0000000000000285; Boudjemaa S, 2015, PEDIATR DEVEL PATHOL, V18, P401, DOI 10.2350/14-07-1533-CR.1; Bourdeaut F, 2014, CANCER GENET-NY, V207, P346, DOI 10.1016/j.cancergen.2014.10.004; Calderaro J, 2012, HISTOPATHOLOGY, V61, P428, DOI 10.1111/j.1365-2559.2012.04228.x; Caltabiano R, 2017, CHILD NERV SYST, V33, P933, DOI 10.1007/s00381-017-3340-2; Cheng JX, 2008, MODERN PATHOL, V21, P647, DOI 10.1038/modpathol.2008.44; Coindre JM, 2003, CANCER-AM CANCER SOC, V98, P2700, DOI 10.1002/cncr.11840; DAVIS CJ, 1995, AM J SURG PATHOL, V19, P1, DOI 10.1097/00000478-199501000-00001; de Bruijn DRH, 2007, GENE CHROMOSOME CANC, V46, P107, DOI 10.1002/gcc.20399; Drilon AD, 2008, CANCER-AM CANCER SOC, V113, P3364, DOI 10.1002/cncr.23978; Dufour C, 2012, CANCER-AM CANCER SOC, V118, P3812, DOI 10.1002/cncr.26684; Dunham C, 2015, CHILD NERV SYST, V31, P1729, DOI 10.1007/s00381-015-2735-1; Dykhuizen EC, 2013, NATURE, V497, P624, DOI 10.1038/nature12146; Eaton KW, 2011, PEDIATR BLOOD CANCER, V56, P7, DOI 10.1002/pbc.22831; Erlandson RA, 1998, HUM PATHOL, V29, P1372, DOI 10.1016/S0046-8177(98)90005-3; Ferrari A, 2015, ANN ONCOL, V26, P567, DOI 10.1093/annonc/mdu562; Fleming AJ, 2012, BRAIN PATHOL, V22, P625, DOI 10.1111/j.1750-3639.2011.00561.x; Foulkes WD, 2017, CLIN CANCER RES, V23, pE62, DOI 10.1158/1078-0432.CCR-17-0595; Fowler DJ, 2006, FETAL PEDIATR PATHOL, V25, P159, DOI 10.1080/15513810600908388; Fuller CE, 2001, HUM PATHOL, V32, P1102, DOI 10.1053/hupa.2001.28252; Fuller CE, 2016, SEMIN DIAGN PATHOL, V33, P427, DOI 10.1053/j.semdp.2016.08.003; Gessi M, 2015, J NEUROPATH EXP NEUR, V74, P970, DOI 10.1097/NEN.0000000000000239; Gleason BC, 2007, AM J SURG PATHOL, V31, P1813, DOI 10.1097/PAS.0b013e31805f6775; Guillou L, 1997, AM J SURG PATHOL, V21, P130, DOI 10.1097/00000478-199702000-00002; Guillou L, 2001, HUM PATHOL, V32, P105, DOI 10.1053/hupa.2001.21130; HAAS JE, 1981, HUM PATHOL, V12, P646, DOI 10.1016/S0046-8177(81)80050-0; Hasegawa T, 2001, MODERN PATHOL, V14, P655, DOI 10.1038/modpathol.3880368; Hasselblatt M, 2016, ACTA NEUROPATHOL, V132, P149, DOI 10.1007/s00401-016-1574-9; Hasselblatt M, 2009, J NEUROPATH EXP NEUR, V68, P1249, DOI 10.1097/NEN.0b013e3181c06a51; Hollmann TJ, 2011, AM J SURG PATHOL, V35, pE47, DOI 10.1097/PAS.0b013e31822b325b; Hoot AC, 2004, AM J SURG PATHOL, V28, P1485, DOI 10.1097/01.pas.0000141390.14548.34; Ito J, 2016, HUM PATHOL, V47, P32, DOI 10.1016/j.humpath.2015.09.010; Jagdis A, 2009, AM J SURG PATHOL, V33, P1743, DOI 10.1097/PAS.0b013e3181b7ed36; Jo VY, 2017, AM J SURG PATHOL, V41, P1013, DOI 10.1097/PAS.0000000000000849; Jo VY, 2015, HEAD NECK PATHOL, V9, P32, DOI 10.1007/s12105-015-0618-0; Judkins AR, 2005, J NEUROPATH EXP NEUR, V64, P391, DOI 10.1093/jnen/64.5.391; Judkins AR, 2004, AM J SURG PATHOL, V28, P644, DOI 10.1097/00000478-200405000-00013; Kadoch C, 2013, CELL, V153, P71, DOI 10.1016/j.cell.2013.02.036; Kalimuthu SN, 2016, J CLIN PATHOL, V69, P484, DOI 10.1136/jclinpath-2016-203650; Kang YN, 2014, MODERN PATHOL, V27, P55, DOI 10.1038/modpathol.2013.115; Kohashi K, 2008, AM J SURG PATHOL, V32, P1168, DOI 10.1097/PAS.0b013e318161781a; Kohashi K, 2015, HUM PATHOL, V46, P225, DOI 10.1016/j.humpath.2014.10.010; Kohashi K, 2013, HUM PATHOL, V44, P526, DOI 10.1016/j.humpath.2012.06.014; Kohashi K, 2010, MODERN PATHOL, V23, P981, DOI 10.1038/modpathol.2010.71; Kosemehmetoglu K, 2009, MODERN PATHOL, V22, P872, DOI 10.1038/modpathol.2009.47; Ladanyi M, 2002, CANCER RES, V62, P135; Le Loarer F, 2015, NAT GENET, V47, P1200, DOI 10.1038/ng.3399; Le Loarer F, 2014, GENE CHROMOSOME CANC, V53, P475, DOI 10.1002/gcc.22159; Lee RS, 2012, J CLIN INVEST, V122, P2983, DOI 10.1172/JCI64400; Liu QY, 2013, AM J SURG PATHOL, V37, P368, DOI 10.1097/PAS.0b013e3182770406; Lopez-Terrada D, 2014, MODERN PATHOL, V27, P472, DOI 10.1038/modpathol.2013.80; Machen SK, 1998, HISTOPATHOLOGY, V33, P501; Margol AS, 2014, CANCER GENET-NY, V207, P358, DOI 10.1016/j.cancergen.2014.07.004; Mobley BC, 2010, ACTA NEUROPATHOL, V120, P745, DOI 10.1007/s00401-010-0767-x; Morgenstern DA, 2010, PEDIATR BLOOD CANCER, V54, P29, DOI 10.1002/pbc.22231; Ogino S, 2000, ADV ANAT PATHOL, V7, P181, DOI 10.1097/00125480-200007030-00007; Palmer HE, 1999, ARCH PEDIAT ADOL MED, V153, P1107, DOI 10.1001/archpedi.153.10.1107; Palmer HE, 1981, AM SOC CLIN ONCOL AB, P406; PARHAM DM, 1994, AM J SURG PATHOL, V18, P1010, DOI 10.1097/00000478-199410000-00005; Patil S, 2008, BRAIN PATHOL, V18, P517, DOI 10.1111/j.1750-3639.2008.00155.x; Pawel BR, 2010, PEDIAT DEV PATHOL, V13, P133; PEREZATAYDE AR, 1994, AM J SURG PATHOL, V18, P1030, DOI 10.1097/00000478-199410000-00006; Piotrowski A, 2014, NAT GENET, V46, P182, DOI 10.1038/ng.2855; Plotkin SR, 2013, AM J MED GENET A, V161A, P405, DOI 10.1002/ajmg.a.35760; Prieto-Granada CN, 2016, AM J SURG PATHOL, V40, P479, DOI 10.1097/PAS.0000000000000564; Rao P, 2012, AM J SURG PATHOL, V36, P583, DOI 10.1097/PAS.0b013e3182417d78; Rekhi B, 2017, APMIS, V125, P679, DOI 10.1111/apm.12702; Rekhi B, 2016, ANN DIAGN PATHOL, V21, P39, DOI 10.1016/j.anndiagpath.2015.12.003; Rekhi B, 2015, APMIS, V123, P618, DOI 10.1111/apm.12395; Roberts CWM, 2009, CANCER BIOL THER, V8, P412, DOI 10.4161/cbt.8.5.8019; RORKE LB, 1995, J NEURO-ONCOL, V24, P21, DOI 10.1007/BF01052653; Saito T, 2013, INT J CLIN EXP PATHO, V6, P2272; Schaefer IM, 2016, MODERN PATHOL, V29, P4, DOI 10.1038/modpathol.2015.134; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Smith MJ, 2015, NEUROLOGY, V84, P141, DOI 10.1212/WNL.0000000000001129; Smith MJ, 2014, CANCER GENET-NY, V207, P373, DOI 10.1016/j.cancergen.2014.04.001; Smith MJ, 2012, HUM MOL GENET, V21, P5239, DOI 10.1093/hmg/dds370; Smith NE, 2014, AM J SURG PATHOL, V38, P858, DOI 10.1097/PAS.0000000000000179; Sredni ST, 2015, PEDIATR DEVEL PATHOL, V18, P49, DOI 10.2350/14-07-1531-MISC.1; Sullivan LM, 2013, MODERN PATHOL, V26, P385, DOI 10.1038/modpathol.2012.175; Sullivan LM, 2012, AM J SURG PATHOL, V36, P73, DOI 10.1097/PAS.0b013e31822cfa7e; Swartz MA, 2002, UROLOGY, V60, P1083, DOI 10.1016/S0090-4295(02)02154-4; ten Heuvel SE, 2009, APPL IMMUNOHISTO M M, V17, P189, DOI 10.1097/PAI.0b013e31818a6f5c; Terry J, 2007, AM J SURG PATHOL, V31, P240, DOI 10.1097/01.pas.0000213330.71745.39; Thway K, 2016, ADV ANAT PATHOL, V23, P41, DOI 10.1097/PAP.0000000000000102; Thway K, 2014, ANN DIAGN PATHOL, V18, P369, DOI 10.1016/j.anndiagpath.2014.09.002; Trobaugh-Lotrario AD, 2009, PEDIATR BLOOD CANCER, V52, P328, DOI 10.1002/pbc.21834; Van Houdt JKJ, 2012, NAT GENET, V44, P445, DOI 10.1038/ng.1105; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vokuhl C, 2016, GENE CHROMOSOME CANC, V55, P925, DOI 10.1002/gcc.22390; WEEKS DA, 1991, AM J SURG PATHOL, V15, P1042, DOI 10.1097/00000478-199111000-00003; WEEKS DA, 1989, AM J SURG PATHOL, V13, P439, DOI 10.1097/00000478-198906000-00001; White FV, 1999, AM J SURG PATHOL, V23, P249, DOI 10.1097/00000478-199903000-00001; WICK MR, 1995, SEMIN DIAGN PATHOL, V12, P233; Wieczorek D, 2013, HUM MOL GENET, V22, P5121, DOI 10.1093/hmg/ddt366; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931; Zhou SB, 2015, ADV MATER SCI ENG, DOI 10.1155/2015/208473	114	9	10	0	1	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JAN-FEB	2018	21	1					6	28		10.1177/1093526617749671			23	Pathology; Pediatrics	Pathology; Pediatrics	FU1PW	WOS:000423622900002	29280680				2019-10-28	
J	Bove, KE; Sheridan, R; Fei, L; Anders, R; Chung, CT; Cummings, OW; Finegold, MJ; Finn, L; Ranganathan, S; Kim, G; Lovell, M; Magid, MS; Melin-Aldana, H; Russo, P; Shehata, B; Wang, L; White, F; Chen, Z; Spino, C; Magee, JC				Bove, K. E.; Sheridan, R.; Fei, L.; Anders, R.; Chung, C. T.; Cummings, O. W.; Finegold, M. J.; Finn, L.; Ranganathan, S.; Kim, G.; Lovell, M.; Magid, M. S.; Melin-Aldana, H.; Russo, P.; Shehata, B.; Wang, L.; White, F.; Chen, Z.; Spino, C.; Magee, J. C.			Hepatic Hilar Lymph Node Reactivity at Kasai Portoenterostomy for Biliary Atresia: Correlations With Age, Outcome, and Histology of Proximal Biliary Remnant	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						biliary atesia; Hilar lymph node; germinal center reaction; biliary remnant; Kasai procedure; outcome	CONGENITAL-RUBELLA SYNDROME; HUMAN-PAPILLOMAVIRUS; FIBROUS REMNANTS; ETIOLOGY; CYTOMEGALOVIRUS; ROTAVIRUS; INFANTS; TISSUES; INJURY; FETAL	We hypothesized that if infection is the proximate cause of congenital biliary atresia, an appropriate response to antigen would occur in lymph nodes contiguous with the biliary remnant. We compared the number of follicular germinal centers (GC) in 79 surgically excised hilar lymph nodes (LN) and 27 incidentally discovered cystic duct LNs in 84 subjects at the time of hepatic portoenterostomy (HPE) for biliary atresia (BA) to autopsy controls from the pancreaticobiliary region of non-septic infants >3 months old at death. All 27 control LN lacked GC, a sign in infants of a primary response to antigenic stimulation. GC were found in 53% of 106 LN in 56 of 84 subjects. Visible surgically excised LN contiguous with the most proximal biliary remnants had 1 or more well-formed reactive GC in only 26/51 subjects. Presence of GC and number of GC/LN was unrelated to age at onset of jaundice or to active fibroplasia in the biliary remnant but was related to older age at HPE. Absent GC in visible and incidentally removed cystic duct LNs predicted survival with the native liver at 2 and 3 years after HPE, P = .03, but significance was lost at longer intervals. The uncommon inflammatory lesions occasionally found in remnants could be secondary either to bile-induced injury or secondary infection established as obstruction evolves. The absence of consistent evidence of antigenic stimulation in LN contiguous with the biliary remnant supports existence of at least 1 major alternative to infection in the etiology of biliary atresia.	[Bove, K. E.; Sheridan, R.] Cincinnati Childrens Hosp Med Ctr, Div Pathol & Lab Med, Cincinnati, OH 45229 USA; [Fei, L.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Anders, R.] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA; [Chung, C. T.] Hosp Sick Children, Div Pathol, Toronto, ON, Canada; [Cummings, O. W.] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; [Finegold, M. J.] Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA; [Finn, L.] Seattle Childrens Hosp, Dept Pathol, Seattle, WA USA; [Ranganathan, S.] UPMC, Dept Pathol, Childrens Hosp Pittsburgh, Pittsburgh, PA USA; [Kim, G.] Univ Calif San Francisco, Dept Anat Pathol, San Francisco, CA 94143 USA; [Lovell, M.] Childrens Hosp Colorado, Dept Pathol, Aurora, CO USA; [Magid, M. S.] Mt Sinai Med Ctr, Kravis Childrens Hosp, Dept Pathol, New York, NY 10029 USA; [Melin-Aldana, H.] Ann & Robert H Lurie Childrens Hosp, Dept Pathol, Chicago, IL USA; [Russo, P.] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Shehata, B.] Childrens Healthcare Atlanta, Dept Pathol, Atlanta, GA USA; [Wang, L.] Childrens Hosp Los Angeles, Dept Pathol, Los Angeles, CA 90027 USA; [White, F.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Chen, Z.] Quest Diagnost, Hlth Informat, Madison, NJ USA; [Spino, C.] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Magee, J. C.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA	Bove, KE (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Pathol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	kevin.bove@cchmc.org			National Institute of Diabetes, Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U01, DK 62445, DK 62497, DK 62470, DK 62456, DK 84536, DK 84575, DK 62500, DK 62503, DK 62466, DK 62453, DK 62452, DK 84538, DK 62436]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by U01 grants from the National Institute of Diabetes, Digestive and Kidney Diseases (DK 62445 [Mount Sinai School of Medicine], DK 62497[Cincinnati Children's Hospital Medical Center], DK 62470 [Children's Healthcare of Atlanta], DK62481 [The Children's Hospital of Philadelphia], DK 62456 [The University of Michigan], DK 84536 [Riley Hospital for Children], DK 84575 [Seattle Children's Hospital], DK 62500 [UCSF Children's Hospital], DK 62503 [Johns Hopkins School of Medicine], DK 62466 [Children's Hospital of Pittsburgh of UPMC], DK 62453 [Children's Hospital Colorado], DK 62452 [Washington University School of Medicine], DK 84538 [Children's Hospital Los Angeles], and DK 62436 [Ann & Robert H Lurie Children's Hospital of Chicago]).	Arva NC, 2015, PATHOL RES PRACT, V211, P252, DOI 10.1016/j.prp.2014.12.003; Bezerra JA, 2014, JAMA-J AM MED ASSOC, V311, P1750, DOI 10.1001/jama.2014.2623; Yam-Puc JC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00188; Coots A, 2012, J SURG RES, V177, P275, DOI 10.1016/j.jss.2012.05.082; Domiati-Saad R, 2000, PEDIATR DEVEL PATHOL, V3, P367, DOI 10.1007/s100240010045; Drut R, 1998, J PEDIATR GASTR NUTR, V27, P530, DOI 10.1097/00005176-199811000-00007; ESTERLY JR, 1969, ARCH PATHOL, V87, P380; Feldman AG, 2012, SEMIN PEDIATR SURG, V21, P192, DOI 10.1053/j.sempedsurg.2012.05.003; Fenner EK, 2014, PEDIATR RES, V76, P72, DOI 10.1038/pr.2014.46; Fjaer RB, 2005, PEDIATR TRANSPLANT, V9, P68, DOI 10.1111/j.1399-3046.2005.00257.x; GAUTIER M, 1981, ARCH PATHOL LAB MED, V105, P397; GAUTIER M, 1976, J PEDIATR-US, V89, P704, DOI 10.1016/S0022-3476(76)80787-1; GAUTIER M, 1979, ARCH FR PEDIATR, V36, pR3; GLASER JH, 1984, J PEDIATR-US, V105, P912, DOI 10.1016/S0022-3476(84)80076-1; Harpavat S, 2016, J PEDIATR GASTR NUTR, V62, P799, DOI 10.1097/MPG.0000000000001097; Hertel PM, 2012, CURR OPIN GASTROEN, V28, P10, DOI 10.1097/MOG.0b013e32834c7ae4; KYRIAZIS AA, 1971, ARCH PATHOL, V91, P444; Mack CL, 2012, SEMIN LIVER DIS, V32, P307, DOI 10.1055/s-0032-1329899; Makori N, 2003, CLIN DIAGN LAB IMMUN, V10, P140, DOI 10.1128/CDLI.10.1.140-153.2003; Nakamura K, 2013, J HEPATO-BIL-PAN SCI, V20, P459, DOI 10.1007/s00534-013-0604-4; Petersen C, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-128; Rauschenfels S, 2009, EUR J PEDIATR, V168, P469, DOI 10.1007/s00431-008-0774-2; RiepenhoffTalty M, 1996, J INFECT DIS, V174, P8, DOI 10.1093/infdis/174.1.8; Scheuer Peter J, 2002, Clin Liver Dis, V6, P335, DOI 10.1016/S1089-3261(02)00009-0; Shivakumar P, 2014, J HEPATOL, V60, P370, DOI 10.1016/j.jhep.2013.09.021; SINGER DB, 1967, J PEDIATR-US, V71, P665, DOI 10.1016/S0022-3476(67)80202-6; SINGER DB, 1969, AM J DIS CHILD, V118, P54, DOI 10.1001/archpedi.1969.02100040056010; TAN CEL, 1994, J PEDIATR SURG, V29, P1459, DOI 10.1016/0022-3468(94)90144-9; Zani A, 2015, J PEDIATR SURG, V50, P1739, DOI 10.1016/j.jpedsurg.2015.03.001; Zhang DY, 2004, HEPATOLOGY, V39, P954, DOI 10.1002/hep.20135; Zheng S, 2008, EUR J PEDIATR SURG, V18, P98, DOI 10.1055/s-2008-1038360	31	2	2	0	0	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JAN-FEB	2018	21	1					29	40		10.1177/1093526617707851			12	Pathology; Pediatrics	Pathology; Pediatrics	FU1PW	WOS:000423622900003	28474973	Bronze			2019-10-28	
J	Cromwell, S; Chiasson, DA; Cassidy, D; Somers, GR				Cromwell, Susan; Chiasson, David A.; Cassidy, Debra; Somers, Gino R.			Improving Autopsy Report Turnaround Times by Implementing Lean Management Principles	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						autopsy; turnaround time; efficiency; lean management principles; improvement; value stream mapping	QUALITY IMPROVEMENT; WORKFLOW; HEALTH; CARE	The autopsy is an integral part of the service of a large academic pathology department. Timely reporting is central to providing good service and is beneficial for many stakeholders, including the families, the clinical team, the hospital, and the wider community. The current study aimed to improve hospital-consented autopsy reporting times (turnaround time, TAT) by using lean principles modified for a healthcare setting, with an aim of signing out 90% of autopsies in 90 days. An audit of current and historical TATs was performed, and a working group incorporating administrative, technical, and professional staff constructed a value stream map documenting the steps involved in constructing an autopsy report. Two areas of delay were noted: examination of the microscopy and time taken to sign-out the report after the weekly autopsy conference. Several measures were implemented to address these delays, including visual tracking using a whiteboard and individualized tracking sheets, weekly whiteboard huddles, and timelier scheduling of clinicopathologic conference rounds. All measures resulted in an improvement of TATs. In the 30 months prior to the institution of lean, 37% of autopsies (53/144) were signed out in 90 days, with a wide variation in reporting times. In the 30 months following the institution of lean, this improved to 74% (136/185) (P <. 0001, Fisher exact test), with a marked reduction in variability. Further, the time from autopsy to presentation at weekly clinicopathological rounds was also reduced (median: 73 days prior to lean; 63 days post-lean). The application of lean principles to autopsy sign-out workflow can significantly improve TATs and reduce variability, without changing staffing levels or significantly altering scheduling structure.	[Cromwell, Susan; Chiasson, David A.; Cassidy, Debra; Somers, Gino R.] Hosp Sick Children, Div Pathol, Dept Paediat Lab Med, Toronto, ON, Canada; [Chiasson, David A.; Somers, Gino R.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	Somers, GR (reprint author), Hosp Sick Children, Div Pathol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	gino.somers@sickkids.ca					Amaratunga T, 2016, J AM COLL RADIOL, V13, P1088, DOI 10.1016/j.jacr.2016.02.033; Burton EC, 2002, AM J MED QUAL, V17, P56, DOI 10.1177/106286060201700203; Burton JL, 2007, LANCET, V369, P1471, DOI 10.1016/S0140-6736(07)60376-6; Cameron DB, 2016, CURR OPIN PEDIATR, V28, P348, DOI 10.1097/MOP.0000000000000346; Cankovic M, 2009, J MOL DIAGN, V11, P390, DOI 10.2353/jmoldx.2009.090002; Evans-Lacko S, 2016, LANCET, V387, P1356, DOI 10.1016/S0140-6736(16)30090-3; Fine Benjamin A, 2009, Healthc Q, V12, P32; Knowles S, 2013, J CLIN PATHOL, V66, P635, DOI 10.1136/jclinpath-2013-201624; Lyon A, 2004, ARCH DIS CHILD, V89, pF284, DOI 10.1136/adc.2003.037333; Napoles Leyda, 2006, Clin Leadersh Manag Rev, V20, pE4; Pollanen MS, 2016, CAN J PATHOL, V8, P4; Rutledge J, 2016, NEW ENGL J MED, V374, P1993, DOI 10.1056/NEJMc1602596; Schultz SR, 2016, RADIOL MANAGE, V38, P32; Schultz Stacy R, 2016, Radiol Manage, V38, P23; Serrano L, 2010, ADV ANAT PATHOL, V17, P215, DOI 10.1097/PAP.0b013e3181d98c81; Shojania K G, 2002, Evid Rep Technol Assess (Summ), P1; Siebert JR, 2009, ARCH PATHOL LAB MED, V133, P1932, DOI 10.1043/1543-2165-133.12.1932; Valdez-Dapena M, 1983, PERINATAL AUTOPSY MA; van Eeghen C, 2016, J AM BOARD FAM MED, V29, P385, DOI 10.3122/jabfm.2016.03.150186; Weinstock Donna, 2008, J Med Pract Manage, V23, P339; Wong Agnes M F, 2016, Healthc Q, V19, P36	21	1	1	1	8	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JAN-FEB	2018	21	1					41	47		10.1177/1093526617707581			7	Pathology; Pediatrics	Pathology; Pediatrics	FU1PW	WOS:000423622900004	28478740	Bronze			2019-10-28	
J	Kovach, AE; Pacheco, MC				Kovach, Alexandra E.; Pacheco, M. Cristina			Ganglion Cells Are Frequently Present in Pediatric Mucosal Colorectal Biopsies: H&E Sections and Calretinin Immunohistochemistry in the Evaluation of Children With Chronic Constipation	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						Hirschsprung; ganglion cells; calretinin immunohistochemistry; constipation; pediatrics; GI	SEGMENT HIRSCHSPRUNG DISEASE; RECTAL SUCTION BIOPSY	Hirschsprung disease (HD) rarely presents as chronic constipation after the newborn period. At our institution, calretinin immunohistochemistry (CAL) is frequently requested by clinicians on rectal mucosal biopsies (RMBs) taken during colono-scopy in older children in whom suspicion for HD is low. We hypothesized that review of these biopsies would frequently reveal ganglion cells (GCs). We reviewed features of mucosal biopsies (November 2013 to September 2015) from children >= 1 year of age on which clinicians had requested CAL on at least one specimen. A total of 93 biopsies with paired CAL from 83 patients were suitable for study (ages 1-18 years, M:F 1.2). Submitted clinical indication was constipation in 62 patients (75%). GCs were found within or subjacent to muscularis mucosa in 63 biopsies (68%), 12 (19%) of which were designated from a specific anatomic site, eg, 2 or 3 cm. In 25 of 63 (40%) cases, GCs were identified on one of the first 3 sections (median 5th, range 1st-54th). Forty-six cases (73%) contained no or < 0.5mm of submucosa (SM, range 0-2 mm). All but one case (62/63, 98%) with identified GCs showed positive CAL staining; a single case showed equivocal staining. Among the 30 biopsies with no observed GCs, none (0%) had > 1 mm of SM, and 21 (70%) had no SM. CAL was positive in 28 (93%) and equivocal/weak in 2 (7%); no additional work-up for HD was pursued. The data suggest that H&E sections of RMBs can exclude HD at a specified site in many cases and provide the basis for a future study examining the utility of CAL in RMBs without SM as a means for excluding HD.	[Kovach, Alexandra E.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Div Pediat Pathol,Monroe Carell Jr Childrens Hosp, 11236 Doctors Off Tower,2200 Childrens Way, Nashville, TN 37232 USA; [Pacheco, M. Cristina] Seattle Childrens Hosp, Pediat Pathol, Seattle, WA USA	Kovach, AE (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Div Pediat Pathol,Monroe Carell Jr Childrens Hosp, 11236 Doctors Off Tower,2200 Childrens Way, Nashville, TN 37232 USA.	alexandra.kovach@vanderbilt.edu					Alizai NK, 1998, PEDIATR SURG INT, V13, P121, DOI 10.1007/s003830050264; Brady AC, 2016, J PEDIATR SURG, V51, P966, DOI 10.1016/j.jpedsurg.2016.02.064; Cass D, 1986, Prog Pediatr Surg, V20, P199; Coffie JM, 2007, J PEDIAT GASTOENTERO, V44, P198; DALE G, 1979, LANCET, V1, P347; Lourencao PLTD, 2014, J PEDIATR GASTR NUTR, V58, P603, DOI 10.1097/MPG.0000000000000263; Gonzalo DH, 2013, ARCH PATHOL LAB MED, V137, P1099, DOI 10.5858/arpa.2012-0220-OA; Guinard-Samuel V, 2009, MODERN PATHOL, V22, P1379, DOI 10.1038/modpathol.2009.110; Kapur RR, 2009, PEDIATR DEVEL PATHOL, V12, P6, DOI 10.2350/08-02-0424.1; Kapur RP, 2014, PEDIATR DEVEL PATHOL, V17, P28, DOI 10.2350/13-10-1387-OA.1; Kapur RP, 2009, SEMIN PEDIAT SURG, V18, P212, DOI 10.1053/j.sempedsurg.2009.07.003; Kapur RP, 1999, CRIT REV CL LAB SCI, V36, P225, DOI 10.1080/10408369991239204; Keyzer-Dekker CMG, 2016, EUR J PEDIATR SURG, V26, P100, DOI 10.1055/s-0035-1566099; Kobayashi H, 2002, PEDIATR SURG INT, V18, P753, DOI 10.1007/s00383-002-0876-2; Maerzheuser S, 2012, CLIN PEDIATR, V51, P1087, DOI 10.1177/0009922812458354; Moore BG, 1996, DIS COLON RECTUM, V39, P817, DOI 10.1007/BF02054450; Nurko S, 2014, AM FAM PHYSICIAN, V90, P82; Pacheco MC, 2008, PEDIATR DEVEL PATHOL, V11, P274, DOI 10.2350/07-09-0343.1; Tafazzoli K, 2005, EUR J PEDIATR SURG, V15, P159, DOI 10.1055/s-2005-837601; WALTERS JRF, 1993, GASTROENTEROLOGY, V104, P1381, DOI 10.1016/0016-5085(93)90346-E; Warren M, 2016, PEDIATR DEVEL PATHOL, V19, P87, DOI 10.2350/15-01-1602-OA.1	21	1	1	0	1	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JAN-FEB	2018	21	1					48	53		10.1177/1093526617704594			6	Pathology; Pediatrics	Pathology; Pediatrics	FU1PW	WOS:000423622900005	28508695				2019-10-28	
J	Armes, JE; Williams, M; Price, G; Wallis, T; Gallagher, R; Matsika, A; Joy, C; Galea, M; Gardener, G; Leach, R; Swagemakers, SMA; Tearle, R; Stubbs, A; Harraway, J; van der Spek, PJ; Venter, DJ				Armes, Jane E.; Williams, Mark; Price, Gareth; Wallis, Tristan; Gallagher, Renee; Matsika, Admire; Joy, Christopher; Galea, Melanie; Gardener, Glenn; Leach, Rick; Swagemakers, Sigrid M. A.; Tearle, Rick; Stubbs, Andrew; Harraway, James; van der Spek, Peter J.; Venter, Deon J.			Application of Whole Genome Sequencing Technology in the Investigation of Genetic Causes of Fetal, Perinatal, and Early Infant Death	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						COL2A1; fetal death; perinatal death; perlecan; RYR1; whole genome sequencing	CONGENITAL HEART-DISEASE; SCHWARTZ-JAMPEL-SYNDROME; LEMLI-OPITZ SYNDROME; LINK PROTEIN; MUTATIONS; CRIM1; IDENTIFICATION; ZEBRAFISH; DYSPLASIA; PERLECAN	Death in the fetal, perinatal, and early infant age-group has a multitude of causes, a proportion of which is presumed to be genetic. Defining a specific genetic aberration leading to the death is problematic at this young age, due to limited phenotype-genotype correlation inherent in the underdeveloped phenotype, the inability to assess certain phenotypic traits after death, and the problems of dealing with rare disorders. In this study, our aim was to increase the yield of identification of a defined genetic cause of an early death. Therefore, we employed whole genome sequencing and bioinformatic filtering techniques as a comprehensive, unbiased genetic investigation into 16 fetal, perinatal, and early infant deaths, which had undergone a full autopsy. A likely genetic cause was identified in two cases (in genes; COL2A1 and RYR1) and a speculative genetic cause in a further six cases (in genes: ARHGAP35, BBS7, CASZ1, CRIM1, DHCR7, HADHB, HAPLN3, HSPG2, MYO18B, and SRGAP2). This investigation indicates that whole genome sequencing is a significantly enabling technology when determining genetic causes of early death.	[Armes, Jane E.; Williams, Mark; Price, Gareth; Wallis, Tristan; Gallagher, Renee; Matsika, Admire; Joy, Christopher; Galea, Melanie; Harraway, James; Venter, Deon J.] Mater Hlth, Dept Pathol, South Brisbane, Qld, Australia; [Armes, Jane E.; Williams, Mark; Gardener, Glenn; Venter, Deon J.] Univ Queensland, Mater Res Inst, Brisbane, Qld, Australia; [Armes, Jane E.; Venter, Deon J.] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [Gardener, Glenn] Mater Hlth, Ctr Maternal Fetal Med, South Brisbane, Qld, Australia; [Leach, Rick; Tearle, Rick] Complete Genom Inc, Mountain View, CA USA; [Swagemakers, Sigrid M. A.; Stubbs, Andrew; van der Spek, Peter J.] Erasmus MC, Dept Bioinformat, Rotterdam, Netherlands; [Tearle, Rick] Univ Adelaide, Sch Anim & Vet Sci, Davies Res Ctr, Fac Sci, Roseworthy, SA, Australia; [van der Spek, Peter J.] Erasmus MC, Dept Pathol, Rotterdam, Netherlands	Armes, JE (reprint author), ICPMR Westmead Hosp, Tissue Pathol & Diagnost Oncol, Westmead, NSW 2145, Australia.	jane.armes@health.nsw.gov.au	Price, Gareth/A-4832-2017; Williams, Mark/F-1961-2015	Price, Gareth/0000-0003-2439-8650; Gardener, Glenn/0000-0002-8123-0718; Matsika, Admire/0000-0002-4418-7394; Williams, Mark/0000-0002-1294-1110			AKL KF, 1977, CLIN PEDIATR, V16, P665, DOI 10.1177/000992287701600717; Basiri Keivan, 2015, Adv Biomed Res, V4, P163, DOI 10.4103/2277-9175.162538; Beales PL, 2003, AM J HUM GENET, V72, P1187, DOI 10.1086/375178; Beleggia F, 2015, HUM MOL GENET, V24, P2267, DOI 10.1093/hmg/ddu744; Birney E, 2015, NATURE, V526, P52, DOI 10.1038/526052a; Castillo A, 2014, EUR J MED GENET, V57, P654, DOI 10.1016/j.ejmg.2014.08.009; Charrier C, 2012, CELL, V149, P923, DOI 10.1016/j.cell.2012.03.034; Chiu HS, 2012, GENESIS, V50, P711, DOI 10.1002/dvg.22032; Crotti L, 2013, JAMA-J AM MED ASSOC, V309, P1473, DOI 10.1001/jama.2013.3219; Daoud H, 2016, CAN MED ASSOC J, V188, pE254, DOI 10.1503/cmaj.150823; Deveault C, 2011, HUM MUTAT, V32, P610, DOI 10.1002/humu.21480; Drmanac R, 2010, SCIENCE, V327, P78, DOI 10.1126/science.1181498; Erikson GA, 2016, CELL, V165, P1002, DOI 10.1016/j.cell.2016.03.022; Fish JE, 2011, DEVELOPMENT, V138, P1409, DOI 10.1242/dev.060046; Giedion A, 1997, EUR J PEDIATR, V156, P214, DOI 10.1007/s004310050587; Gurung R, 2017, GENETICS, V205, P725, DOI 10.1534/genetics.116.192864; Hennekam RCM, 2012, HUM MUTAT, V33, P884, DOI 10.1002/humu.22048; Hiltemann S, 2014, GIGASCIENCE, V3, DOI 10.1186/2047-217X-3-1; Huang RT, 2016, GENE, V595, P62, DOI 10.1016/j.gene.2016.09.044; Ito Y, 2008, DEV BIOL, V319, P34, DOI 10.1016/j.ydbio.2008.03.042; Iyer S, 2016, HISTOL HISTOPATHOL, V31, P1049, DOI 10.14670/HH-11-766; Kalb S, 2012, CLIN GENET, V81, P598, DOI 10.1111/j.1399-0004.2011.01750.x; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lockhart M, 2011, BIRTH DEFECTS RES A, V91, P535, DOI 10.1002/bdra.20810; Malfatti Edoardo, 2015, J Neuromuscul Dis, V2, P219; Mammoto A, 2009, NATURE, V457, P1103, DOI 10.1038/nature07765; Neubauer J, 2017, EUR J HUM GENET, V25, P404, DOI 10.1038/ejhg.2016.199; Ogawa H, 2004, MATRIX BIOL, V23, P287, DOI 10.1016/j.matbio.2004.07.001; Pennisi DJ, 2012, PLACENTA, V33, P175, DOI 10.1016/j.placenta.2011.12.014; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rodgers KD, 2007, HUM MOL GENET, V16, P515, DOI 10.1093/hmg/ddl484; Saisawat P, 2012, KIDNEY INT, V81, P196, DOI 10.1038/ki.2011.315; SILENGO MC, 1983, PEDIATR RADIOL, V13, P106, DOI 10.1007/BF02390113; Sojka S, 2014, DEVELOPMENT, V141, P3040, DOI 10.1242/dev.106518; Spicer AP, 2003, J BIOL CHEM, V278, P21083, DOI 10.1074/jbc.M213100200; Stum M, 2006, HUM MUTAT, V27, P1082, DOI 10.1002/humu.20388; Terrone G, 2014, NEUROLOGY, V82, pE1, DOI 10.1212/01.wnl.0000438217.31437.72; VANALLEN MI, 1987, AM J MED GENET, V28, P529, DOI 10.1002/ajmg.1320280302; Wilkin DJ, 1999, AM J MED GENET, V85, P105, DOI 10.1002/(SICI)1096-8628(19990716)85:2<105::AID-AJMG2>3.3.CO;2-Q; Willig LK, 2015, LANCET RESP MED, V3, P377, DOI 10.1016/S2213-2600(15)00139-3; Witsch-Baumgartner M, 2005, Hum Mutat, V25, P412, DOI 10.1002/humu.9328	41	3	3	2	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JAN-FEB	2018	21	1					54	67		10.1177/1093526617715528			14	Pathology; Pediatrics	Pathology; Pediatrics	FU1PW	WOS:000423622900006	28641477				2019-10-28	
J	Wu, KY; Treece, AL; Russo, PA; Wen, JW				Wu, Katherine Y.; Treece, Amanda L.; Russo, Pierre A.; Wen, Jessica W.			An Atypical Presentation of Alagille Syndrome	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						Alagille syndrome; cholestasis; CK7; JAG1; jaundice	CHOLEDOCHAL CYSTS; JAG1 MUTATIONS; CHOLESTASIS; DIAGNOSIS; FEATURES; PAUCITY	Alagille syndrome is a multisystem disorder classically involving the liver, heart, vertebrae, facial features, and the eyes. In this case report, we document a case of Alagille syndrome with an atypical clinical and histopathologic presentation and subsequent identification of a novel JAG1 missense mutation. This case highlights that there may be both atypical clinical and pathologic findings in mutation-proven Alagille syndrome and that the diagnosis of Alagille syndrome should be considered in cases of ongoing bile duct damage in the setting of early-onset jaundice, cholestasis, hepatosplenomegaly, posterior embryotoxon in the eyes, and butterfly vertebrae.	[Wu, Katherine Y.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Treece, Amanda L.] Childrens Hosp Colorado, Dept Pathol & Lab Med, Aurora, CO USA; [Russo, Pierre A.] Childrens Hosp Philadelphia, Div Anat Pathol, Philadelphia, PA 19104 USA; [Wen, Jessica W.] Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA	Wu, KY (reprint author), Childrens Hosp Philadelphia, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	wuky@email.chop.edu					Byrne JA, 2007, LAB INVEST, V87, P1138, DOI 10.1038/labinvest.3700677; Deutsch GH, 2001, PEDIATR DEVEL PATHOL, V4, P559, DOI 10.1007/s10024001-0102-6; Emerick KM, 1999, HEPATOLOGY, V29, P822, DOI 10.1002/hep.510290331; Ernst LM, 2007, PEDIATR DEVEL PATHOL, V10, P383, DOI 10.2350/06-09-0171.1; Goldman Matthew, 2011, Curr Gastroenterol Rep, V13, P193, DOI 10.1007/s11894-010-0169-1; Guegan K, 2012, CLIN GENET, V82, P33, DOI 10.1111/j.1399-0004.2011.01749.x; HADCHOUEL M, 1978, ARCH PATHOL LAB MED, V102, P402; Hartley JL, 2013, CLIN LIVER DIS, V17, P279, DOI 10.1016/j.cld.2012.12.004; HASHIDA Y, 1988, Pediatric Pathology, V8, P1; Jurkiewicz D, 2014, J APPL GENET, V55, P329, DOI 10.1007/s13353-014-0212-2; Kamath BM, 2012, J MED GENET, V49, P138, DOI 10.1136/jmedgenet-2011-100544; Leonard LD, 2014, EUR J HUM GENET, V22, DOI 10.1038/ejhg.2013.140; Nguyen KD, 2014, WORLD J GASTROENTERO, V20, P9418, DOI 10.3748/wjg.v20.i28.9418; Park DH, 2005, GASTROINTEST ENDOSC, V62, P360, DOI 10.1016/j.gie.2005.04.026; Sakhuja P, 2015, CLIN CASE REP, V3, P24, DOI 10.1002/ccr3.138; Singham J, 2009, CAN J SURG, V52, P506; Spinner NB, 1993, GENEREVIEWS R; Turnpenny PD, 2012, EUR J HUM GENET, V20, P251, DOI 10.1038/ejhg.2011.181; Vajro P, 2012, CLIN RES HEPATOL GAS, V36, P275, DOI 10.1016/j.clinre.2012.03.019; Warthen DM, 2006, HUM MUTAT, V27, P436, DOI 10.1002/humu.20310; Zakim D, 2003, HEPATOLOGY TXB LIVER	21	0	0	0	1	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JAN-FEB	2018	21	1					79	83		10.1177/1093526616686902			5	Pathology; Pediatrics	Pathology; Pediatrics	FU1PW	WOS:000423622900008	29187043				2019-10-28	
J	Pogoriler, J; O'Neill, AF; Voss, SD; Shamberger, RC; Perez-Atayde, AR				Pogoriler, Jennifer; O'Neill, Allison F.; Voss, Stephan D.; Shamberger, Robert C.; Perez-Atayde, Antonio R.			Hepatocellular Carcinoma in Fanconi-Bickel Syndrome	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						hepatoblastoma; hepatocellular adenoma; dysplastic nodule; glycogenosis; glycogen storage disease; electron microscopy	GLUCOSE-TRANSPORTER; GLUT2 MUTATIONS; GENE; ADENOMAS	Fanconi-Bickel syndrome is a rare autosomal recessive disorder due to mutations in the facilitative glucose transporter 2 (GLUT2 or SLC2A2) gene resulting in excessive glycogen storage predominantly in the liver and kidney. Previous case reports of this condition have described liver biopsies with glycogen storage and variable steatosis and/or fibrosis. Unlike in other types of glycogen storage disease, hepatocellular adenomas and carcinomas have not been described to date in this syndrome. A 6-year-old boy with consanguineous parents had short stature, poorly controlled rickets, hepatosplenomegaly, and renal tubular dysfunction clinically consistent with Fanconi-Bickel Syndrome. Sequencing of the SLC2A2 gene showed a homozygous variant of unknown significance [c.474A > C (p.Arg158Ser)] causing a missense mutation in an evolutionarily conserved residue. An incidental single hepatic lesion was discovered on imaging, and subsequent resection showed a 2.6 cm well-differentiated hepatocellular carcinoma with moderate atypia, diffuse immunoreactivity for glypican-3, and nuclear b-catenin, and with focal complete loss of the reticulin framework. The non-neoplastic liver showed marked glycogen accumulation with mild periportal fibrosis, rare bridging fibrosis, and no regenerative or adenomatous nodules. By electron microscopy, tumor cells had pleomorphic nuclei, prominent nucleoli, and scant cytoplasm with numerous mitochondria. Well-developed canaliculi were occasionally seen. The non-neoplastic liver showed glycogenosis with abundant cytoplasmic free (non-membrane bound) glycogen. Hepatocellular carcinoma should be considered as a possible complication of Fanconi-Bickel syndrome. This well differentiated carcinoma did not appear to be associated with hepatic adenomatosis as has been described in some hepatocellular carcinomas associated with other hepatic glycogen storage disorders. The nuclear beta-catenin immunoreactivity indicates a role for the Wnt signaling pathway in the pathogenesis of this tumor.	[Pogoriler, Jennifer; Perez-Atayde, Antonio R.] Harvard Med Sch, Boston Childrens Hosp, Dept Pathol, Boston, MA USA; [O'Neill, Allison F.] Harvard Med Sch, Dana Farber Canc Inst, Div Pediat Oncol, Boston, MA USA; [Voss, Stephan D.] Harvard Med Sch, Boston Childrens Hosp, Dept Radiol, Boston, MA USA; [Shamberger, Robert C.] Harvard Med Sch, Boston Childrens Hosp, Dept Surg, Boston, MA USA; [Pogoriler, Jennifer] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	Perez-Atayde, AR (reprint author), Boston Childrens Hosp, Dept Pathol, 300 Longwood Ave, Boston, MA 02118 USA.	antonio.perezatayde@childrens.harvard.edu					Al-Haggar M., 2011, CASE REP NEPHROL, V2011; Al-Haggar Mohammad, 2012, World J Nephrol, V1, P63, DOI 10.5527/wjn.v1.i3.63; Al-Haggar M, 2012, CLIN EXP NEPHROL, V16, P604, DOI 10.1007/s10157-012-0603-9; Andersson EA, 2013, DIABETES, V62, P3610, DOI 10.2337/db13-0362; Baheti AD, 2015, J CLIN IMAG SCI, V5, DOI 10.4103/2156-7514.163991; Borglykke A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050418; Calderaro J, 2013, J HEPATOL, V58, P350, DOI 10.1016/j.jhep.2012.09.030; de Moor RA, 2000, ARCH DIS CHILD, V82, P479, DOI 10.1136/adc.82.6.479; Demo E, 2007, J HEPATOL, V46, P492, DOI 10.1016/j.jhep.2006.09.022; Gopalakrishnan A, 2011, CLIN EXP NEPHROL, V15, P745, DOI 10.1007/s10157-011-0456-7; Grunert SC, 2012, MOL GENET METAB, V105, P433, DOI 10.1016/j.ymgme.2011.11.200; Hadipour Fatemeh, 2013, Indian J Hum Genet, V19, P84, DOI 10.4103/0971-6866.112906; Kakar S, 2014, MODERN PATHOL, V27, P1499, DOI 10.1038/modpathol.2014.50; Karamizadeh Z, 2012, J GENET, V91, P359, DOI 10.1007/s12041-012-0198-7; Kehar M, 2014, INDIAN J PEDIATR, V81, P1237, DOI 10.1007/s12098-014-1487-3; Kishnani Priya S, 2014, Genet Med, V16, pe1; Mannstadt M, 2012, J CLIN ENDOCR METAB, V97, pE1978, DOI 10.1210/jc.2012-1279; Manzia TM, 2011, TRANSPL P, V43, P1181, DOI 10.1016/j.transproceed.2011.01.129; Raft MB, 2015, HISTOPATHOLOGY, V66, P910, DOI 10.1111/his.12539; Resaz R, 2014, DIS MODEL MECH, V7, P1083, DOI 10.1242/dmm.014878; Sakellariou S, 2012, HISTOPATHOLOGY, V60, pE58, DOI 10.1111/j.1365-2559.2011.04153.x; Santer R, 1998, EUR J PEDIATR, V157, P783, DOI 10.1007/s004310050937; Santer R, 2002, HUM GENET, V110, P21, DOI 10.1007/s00439-001-0638-6; Santer R, 1997, NAT GENET, V17, P324, DOI 10.1038/ng1197-324; Sotelo N, 2008, ANN HEPATOL, V7, P163, DOI 10.1016/S1665-2681(19)31875-7; Sun BD, 2009, MOL GENET METAB, V97, P267, DOI 10.1016/j.ymgme.2009.04.003; Thorens B, 2015, DIABETOLOGIA, V58, P221, DOI 10.1007/s00125-014-3451-1; Wang HL, 2008, ARCH PATHOL LAB MED, V132, P1723, DOI 10.1043/1543-2165-132.11.1723	28	2	2	0	1	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JAN-FEB	2018	21	1					84	90		10.1177/1093526617693540			7	Pathology; Pediatrics	Pathology; Pediatrics	FU1PW	WOS:000423622900009	28382841				2019-10-28	
J	Abdulghani, S; Moretti, F; Nikkels, PGJ; Khung-Savatovsky, S; Hurteau-Miller, J; Grynspan, D				Abdulghani, Sahar; Moretti, Felipe; Nikkels, Peter G. J.; Khung-Savatovsky, Suonavy; Hurteau-Miller, Julie; Grynspan, David			Growth Restriction, Osteopenia, Placental Massive Perivillous Fibrin Deposition With (or Without) Intervillous Histiocytes and Renal Tubular Dysgenesis-An Emerging Complex	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						placenta; fetal; massive perivillous fibrin; chronic intervillosistis; renal tubular dysgenesis; intrauterine growth restriction		We describe a case of a pregnancy complicated by early onset asymmetric growth restriction with anhydramnios with termination occurring at 21 weeks. Fetal autopsy showed demineralization of bones and renal tubular dysgenesis. Placental pathology showed features of massive perivillous fibrin deposition and chronic histiocytic intervillositis. We review prior documentation of this association and briefly discuss potential pathogenesis.	[Abdulghani, Sahar] King Saud Univ Hosp, Riyadh, Saudi Arabia; [Moretti, Felipe] Ottawa Hosp, Dept Obstet & Gynecol, Ottawa, ON, Canada; [Moretti, Felipe; Hurteau-Miller, Julie] Univ Ottawa, Ottawa, ON, Canada; [Nikkels, Peter G. J.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Khung-Savatovsky, Suonavy] Hosp Robert Debre, AP HP, Fetal Pathol Dept, Paris, France; [Hurteau-Miller, Julie] Childrens Hosp Eastern Ontario, Dept Diagnost Imaging, Ottawa, ON, Canada; [Grynspan, David] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Pathol & Lab Med, Ottawa, ON, Canada	Grynspan, D (reprint author), Univ Ottawa, Ottawa, ON, Canada.; Grynspan, D (reprint author), Childrens Hosp Eastern Ontario, Dept Pathol & Lab Med, Ottawa, ON, Canada.	dgrynspan@cheo.on.ca					Adams-Chapman Ira, 2002, J Perinatol, V22, P236, DOI 10.1038/sj.jp.7210685; Katzman PJ, 2002, PEDIATR DEVEL PATHOL, V5, P159, DOI 10.1007/s10024-001-0195-y; Khung-Savatovsky S, 2007, 8 M INT SKEL DYSPL S; Leong MY, 2013, PEDIATR DEVEL PATHOL, V16, P447, DOI 10.2350/13-09-1376-LET.1; Linn RL, 2013, PEDIATR DEVEL PATHOL, V16, P378, DOI 10.2350/13-06-1351-CR.1; Maroun LL, 2013, 59 PAED PATH SOC ANN; Nikkel PGJ, 2007, 8 M INT SKEL DYSPL S; Thompson KS, 2001, PEDIAT DEV PATHOL, V4, P412; Weber MA, 2006, PEDIATR DEVEL PATHOL, V9, P234, DOI 10.2350/06-01-0019.1	9	0	1	0	0	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JAN-FEB	2018	21	1					91	94		10.1177/1093526617697061			4	Pathology; Pediatrics	Pathology; Pediatrics	FU1PW	WOS:000423622900010	29187034				2019-10-28	
J	Metts, JL; Park, SI; Briones, MA; Keller, FG				Metts, Jonathan L.; Park, Sunita I.; Briones, Michael A.; Keller, Frank G.			Hemophagocytic Lymphohistiocytosis Secondary to T Cell/Histiocyte-rich Large B Cell Lymphoma in an Adolescent Male	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						oncology; lymphoma; histiocytosis; hemophagocytic lymphohistiocytosis; pediatric; hematopathology	DIAGNOSIS; FEATURES; CHILDREN	Hemophagocytic Lymphohistiocytosis (HLH) is a hyperinflammatory disorder that may be encountered as a primary or secondary phenomenon. HLH secondary to lymphoma has been described, more frequently in adults than in children. T-cell/Histiocyte-rich B-cell lymphoma (THRLBCL) is a large B-cell lymphoma that resides in a microenvironment of robust host immune response and has previously been associated with HLH in adults. Here, we describe the first case of HLH secondary to THRLBCL in an adolescent patient.	[Metts, Jonathan L.; Briones, Michael A.; Keller, Frank G.] Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Dept Pediat, Atlanta, GA USA; [Metts, Jonathan L.; Park, Sunita I.; Briones, Michael A.; Keller, Frank G.] Emory Univ, Atlanta, GA 30322 USA; [Metts, Jonathan L.] All Childrens Hosp, Canc & Blood Disorders Inst, St Petersburg, FL 33701 USA; [Park, Sunita I.] Childrens Healthcare Atlanta, Dept Pathol, Atlanta, GA USA	Metts, JL (reprint author), Johns Hopkins All Childrens Hosp, Canc & Blood Disorders Inst, 601 5th St South, St Petersburg, FL 33701 USA.	jmetts1@jhmi.edu					Abramson JS, 2006, ONCOLOGIST, V11, P384, DOI 10.1634/theoncologist.11-4-384; Chandrakasan S, 2013, J PEDIATR-US, V163, P1253, DOI 10.1016/j.jpeds.2013.06.053; Chen BJ, 2013, CLIN CANCER RES, V19, P3462, DOI 10.1158/1078-0432.CCR-13-0855; Devitt Katherine, 2014, Leuk Res Rep, V3, P42, DOI 10.1016/j.lrr.2014.05.004; Geng LY, 2015, INT J CLIN EXP MED, V8, P14656; George MR, 2014, J BLOOD MED, V5, P69, DOI 10.2147/JBM.S46255; Han AR, 2007, ANN HEMATOL, V86, P493, DOI 10.1007/s00277-007-0278-6; Hartmann S, 2015, BRIT J HAEMATOL, V169, P415, DOI 10.1111/bjh.13310; Hartmann S, 2013, INT J CANCER, V133, P2609, DOI 10.1002/ijc.28273; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Hu YX, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13512; Jordan MB, 2011, BLOOD, V118, P4041, DOI 10.1182/blood-2011-03-278127; Lehmberg K, 2015, BRIT J HAEMATOL, V170, P539, DOI 10.1111/bjh.13462; Mitterer M, 1999, ANN ONCOL, V10, P231, DOI 10.1023/A:1008212516595; Monti S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004-07-2947; Otrock ZK, 2015, AM J HEMATOL, V90, P220, DOI 10.1002/ajh.23911; Riviere S, 2014, AM J MED, V127, P1118, DOI 10.1016/j.amjmed.2014.04.034; Tiemann M, 2005, LEUKEMIA LYMPHOMA, V46, P1295, DOI 10.1080/10428190500083326; Tousseyn T, 2011, VIRCHOWS ARCH, V459, P557, DOI 10.1007/s00428-011-1165-z; Trottestam H, 2011, BLOOD, V118, P4577, DOI 10.1182/blood-2011-06-356261; Van Loo P, 2010, HAEMATOL-HEMATOL J, V95, P440, DOI 10.3324/haematol.2009.009647; Weitzman S, 2011, HEMATOL-AM SOC HEMAT, P178, DOI 10.1182/asheducation-2011.1.178	22	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JAN-FEB	2018	21	1					95	99		10.1177/1093526617699137			5	Pathology; Pediatrics	Pathology; Pediatrics	FU1PW	WOS:000423622900011	29187030				2019-10-28	
J	Huho, AN; Issaq, N; Iacobas, I; Elghetany, TM; Lopez-Terrada, D; Fisher, KE; Punia, JN				Huho, Albert N.; Issaq, Niveen; Iacobas, Ionela; Elghetany, Tarek M.; Lopez-Terrada, Dolores; Fisher, Kevin E.; Punia, Jyotinder N.			A Rare Case of Pediatric Chronic Myelogenous Leukemia Presenting With Severe Thrombocytosis Without Leukocytosis	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						pediatric; thrombocytosis; BCR/ABL1; chronic myelogenous leukemia; essential thrombocythemia; normal white blood cell count	CHRONIC MYELOID-LEUKEMIA; BCR-ABL; CML; BREAKPOINTS; FEATURES; CHILDREN; ONSET; GENE	Pediatric chronic myelogenous leukemia is uncommon. We report a pediatric patient with chronic myelogenous leukemia presenting with a normal white blood cell count and no circulating immature myeloid cells. The patient presented with extreme thrombocytosis (platelet count range: 2175-3064 x 10(9)/L) noted incidentally. No splenomegaly was found. Examination of the bone marrow aspirate revealed normal cellularity and normal myeloid: erythroid ratio with marked megakaryocytic hyperplasia. Molecular studies on the bone marrow aspirate detected both the major BCR/ABL1 p210 fusion transcript (9280 copies; p210/ABL1 ratio: 38.2%) and the minor p190 transcript (below limit of quantitation). The platelet count normalized within 2 weeks after treatment with the second-generation tyrosine kinase inhibitor dasatinib. Follow-up after 3 months revealed a 1.87 log reduction in p210 transcripts compared to diagnosis and no detectable p190 transcripts. This case highlights the need to include BCR/ABL1 fusion testing to accurately diagnose pediatric patients presenting with isolated thrombocytosis.	[Huho, Albert N.; Issaq, Niveen; Elghetany, Tarek M.; Lopez-Terrada, Dolores; Fisher, Kevin E.; Punia, Jyotinder N.] Baylor Coll Med, Dept Pathol & Immunol, 6621 Fannin St,Suite AB1-195, Houston, TX 77030 USA; [Huho, Albert N.; Issaq, Niveen; Elghetany, Tarek M.; Lopez-Terrada, Dolores; Fisher, Kevin E.; Punia, Jyotinder N.] Texas Childrens Hosp, 6621 Fannin St,Suite AB1-195, Houston, TX 77030 USA; [Iacobas, Ionela] Texas Childrens Hosp, Texas Childrens Canc & Hematol Ctr, Houston, TX 77030 USA	Punia, JN (reprint author), Baylor Coll Med, Dept Pathol & Immunol, 6621 Fannin St,Suite AB1-195, Houston, TX 77030 USA.; Punia, JN (reprint author), Texas Childrens Hosp, 6621 Fannin St,Suite AB1-195, Houston, TX 77030 USA.	punia@bcm.edu					Arana-Trejo RM, 2002, CLIN LAB HAEMATOL, V24, P145, DOI 10.1046/j.1365-2257.2002.00413.x; Bennour A, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0348-z; Cervantes F, 1996, LEUKEMIA, V10, P1241; Emilia G, 1998, CANCER GENET CYTOGEN, V101, P75, DOI 10.1016/S0165-4608(97)00263-X; Hijiya N, 2016, BLOOD, V127, P392, DOI 10.1182/blood-2015-06-648667; Hsu HC, 2004, J LAB CLIN MED, V143, P125, DOI 10.1016/j.lab.2003.10.007; INOKUCHI K, 1994, INTERNAL MED, V33, P189, DOI 10.2169/internalmedicine.33.189; INOKUCHI K, 1991, LEUKEMIA RES, V15, P1067, DOI 10.1016/0145-2126(91)90113-8; Jabbour E, 2015, CL LYMPH MYELOM LEUK, V15, P797, DOI 10.1016/j.clml.2015.09.008; Krumbholz M, 2012, GENE CHROMOSOME CANC, V51, P1045, DOI 10.1002/gcc.21989; Kucine N, 2014, HAEMATOLOGICA, V99, P620, DOI 10.3324/haematol.2013.092684; Mantadakis E, 2008, INDIAN PEDIATR, V45, P669; Meissner RD, 1998, BRIT J HAEMATOL, V103, P224, DOI 10.1046/j.1365-2141.1998.00945.x; Millot F, 2005, PEDIATRICS, V116, P140, DOI 10.1542/peds.2004-2473; Teofili L, 2010, HAEMATOL-HEMATOL J, V95, P65, DOI [10.3324/haemotol.2009.007542, 10.3324/haematol.2009.007542]; Vardiman JW, 2008, WHO CLASSIFICATION T, P32; Wertheim JA, 2003, BLOOD, V102, P2220, DOI 10.1182/blood-2003-01-0062	17	2	2	0	2	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JAN-FEB	2018	21	1					100	104		10.1177/1093526617698601			5	Pathology; Pediatrics	Pathology; Pediatrics	FU1PW	WOS:000423622900012	29187020	Bronze			2019-10-28	
J	Yang, Q; Stefanovici, C; Mujawar, Q; El-Matary, W				Yang, Qi; Stefanovici, Camelia; Mujawar, Quais; El-Matary, Wael			Esophageal Squamous Papilloma in a Pediatric Patient With Helicobacter pylori Gastritis	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Letter									[Yang, Qi; Stefanovici, Camelia; Mujawar, Quais; El-Matary, Wael] Hlth Sci Ctr, Winnipeg, MB, Canada; [Yang, Qi; Stefanovici, Camelia] Univ Manitoba, Dept Pathol, Winnipeg, MB, Canada; [Stefanovici, Camelia] Diagnost Serv Manitoba, Pathol, Winnipeg, MB, Canada; [Mujawar, Quais; El-Matary, Wael] Univ Manitoba, Dept Pediat, Sect Pediat Gastroenterol, Winnipeg, MB, Canada	Yang, Q (reprint author), 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	qyang3@manitoba-physicians.ca		EL-MATARY, WAEL/0000-0001-6417-7583; Mujawar, Quais/0000-0002-0181-5434			CARR NJ, 1994, AM J GASTROENTEROL, V89, P245; Lopukhov P. D., 2016, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P71; Szanto Imre, 2005, Orvosi Hetilap, V146, P547	3	0	0	0	0	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JAN-FEB	2018	21	1					105	106		10.1177/1093526617701798			2	Pathology; Pediatrics	Pathology; Pediatrics	FU1PW	WOS:000423622900013	28382843	Bronze			2019-10-28	
J	Siddiqui, I; Somers, GR				Siddiqui, Iram; Somers, Gino R.			Paediatric GI Biopsies: How Many Levels Are Necessary?	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Letter									[Siddiqui, Iram; Somers, Gino R.] Univ Toronto, Hosp Sick Children, Dept Pathol, Toronto, ON, Canada; [Siddiqui, Iram; Somers, Gino R.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	Siddiqui, I (reprint author), DPLM Hosp Sick Children, Dept Pathol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	iram.siddiqui@sickkids.ca					Fine Benjamin A, 2009, Healthc Q, V12, P32; Noffsinger A, 2007, AFIP ATLAS NONTUMOR, P680	2	0	0	0	0	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JAN-FEB	2018	21	1					107	108		10.1177/1093526617707850			2	Pathology; Pediatrics	Pathology; Pediatrics	FU1PW	WOS:000423622900014	28478741	Bronze			2019-10-28	
J	Watanabe, H				Watanabe, Hiromitsu			Honorary Member, Akihiro Ito MD., Ph. D., 1938-2017 In Memoriam	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Biographical-Item									[Watanabe, Hiromitsu] Hiroshima Univ, Hiroshima, Japan	Watanabe, H (reprint author), Hiroshima Univ, Hiroshima, Japan.							0	0	0	0	1	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	1					1	1		10.1293/tox.2018-M1			1	Pathology; Toxicology	Pathology; Toxicology	FT4TH	WOS:000423147300001		Bronze			2019-10-28	
J	Iguchi, T; Sakurai, K; Tamai, S; Mori, K				Iguchi, Takuma; Sakurai, Ken; Tamai, Satoshi; Mori, Kazuhiko			Circulating liver-specific microRNAs in cynomolgus monkeys	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Review						cynomolgus monkeys; microRNA; next-generation sequencing; drug-induced liver injury	ACETAMINOPHEN OVERDOSE; HEPATIC-NECROSIS; N-ACETYLCYSTEINE; KIDNEY INJURY; BIOMARKERS; PARACETAMOL; TOXICITY; PLASMA; IDENTIFICATION; RAT	Circulating microRNAs (miRNAs) can potentially be used as sensitive and specific biomarkers for tissue injury. However, the usefulness of circulating miRNAs as safety biomarkers in nonclinical toxicological studies using nonhuman primates is debatable owing to the limited information on organ-specific miRNAs. Therefore, a systematic investigation was performed to address this point. We identified organ-specific miRNAs from cynomolgus monkeys by next-generation sequencing analysis, which revealed that miR-122 was only abundant in the liver, whereas miR-192 was abundant in the liver, stomach, intestines, and kidney. The sequences of these miRNAs were identical to their human counterparts. Next, the absolute miR-122 and miR-192 levels were qualified by quantitative reverse transcription polymerase chain reaction (RT-qPCR) to determine the circulating levels of the miRNAs. No significant differences in the levels of circulating miRNAs between sexes were noted, and there was greater interindividual variation in miR-122 (20-fold variation) than in miR-192 (8-fold variation), based on their dynamic ranges. Finally, we evaluated the fluctuation in circulating liver-specific miRNAs in a monkey model of acetaminophen-induced hepatotoxicity. Acetaminophen with L-buthionine-(S, R)-sulfoximine induced hepatotoxicity in all the animals, which was characterized histopathologically by centrilobular necrosis and vacuolation of hepatocytes. Circulating miR-122 and miR-192 levels increased more than ALT levels after 24 h, indicating that circulating miR-122 and miR-192 may serve as sensitive biomarkers for the detection of hepatotoxicity in cynomolgus monkeys. This review describes the fundamental profiles of circulating liver-specific miRNAs in cynomolgus monkeys and focusses on their organ specificity, circulating levels, and fluctuations in drug-induced hepatotoxicity.	[Iguchi, Takuma; Sakurai, Ken; Tamai, Satoshi; Mori, Kazuhiko] Daiichi Sankyo Co Ltd, Med Safety Res Labs, Edogawa Ku, 1-16-13 Kita Kasai, Tokyo 1348630, Japan	Iguchi, T (reprint author), Daiichi Sankyo Co Ltd, Med Safety Res Labs, Edogawa Ku, 1-16-13 Kita Kasai, Tokyo 1348630, Japan.	iguchi.takuma.kz@daiichisankyo.co.jp					Akiyama H, 2015, ANAL BIOCHEM, V472, P75, DOI 10.1016/j.ab.2014.11.012; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Bala S, 2012, HEPATOLOGY, V56, P1946, DOI 10.1002/hep.25873; Bhaskaran M, 2014, VET PATHOL, V51, P759, DOI 10.1177/0300985813502820; Bland JM, 1996, BRIT MED J, V312, P1079; Calvano J, 2016, TOXICOL APPL PHARM, V312, P53, DOI 10.1016/j.taap.2015.11.015; Carlsson HE, 2004, AM J PRIMATOL, V63, P225, DOI 10.1002/ajp.20054; Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282; Chen X, 2012, TRENDS CELL BIOL, V22, P125, DOI 10.1016/j.tcb.2011.12.001; Church RJ, 2016, TOXICOL SCI, V150, P3, DOI 10.1093/toxsci/kfv260; Corsten MF, 2010, CIRC-CARDIOVASC GENE, V3, P499, DOI 10.1161/CIRCGENETICS.110.957415; DAVIDSON DG, 1966, BRIT MED J, V2, P497, DOI 10.1136/bmj.2.5512.497; DAVIS DC, 1974, LIFE SCI, V14, P2099, DOI 10.1016/0024-3205(74)90092-7; Dear JW, 2014, BRIT J CLIN PHARMACO, V77, P904, DOI 10.1111/bcp.12214; Emoto C, 2013, CURR DRUG METAB, V14, P239; Heard KJ, 2008, NEW ENGL J MED, V359, P285, DOI 10.1056/NEJMct0708278; Heinloth AN, 2004, TOXICOL SCI, V80, P193, DOI 10.1093/toxsci/kfh145; Hinson Jack A, 2010, Handb Exp Pharmacol, P369, DOI 10.1007/978-3-642-00663-0_12; Hornby RJ, 2014, EXPERT REV CLIN PHAR, V7, P349, DOI 10.1586/17512433.2014.904201; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Iguchi T, 2017, INT J TOXICOL, V36, P220, DOI 10.1177/1091581817704975; Kalabat DY, 2017, TOXICOL PATHOL, V45, P302, DOI 10.1177/0192623316644992; Koenig EM, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2958-x; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI [10.1373/clinchem.2009.131737, 10.1373/clinchem.2009.131797]; Lewis PJS, 2011, HEPATOLOGY, V54, P1767, DOI 10.1002/hep.24538; Malentacchi F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112293; Masubuchi Y, 2005, J HEPATOL, V42, P110, DOI 10.1016/j.jhep.2004.09.015; MCJUNKIN B, 1976, JAMA-J AM MED ASSOC, V236, P1874, DOI 10.1001/jama.236.16.1874; MINERS JO, 1984, BIOCHEM PHARMACOL, V33, P2995, DOI 10.1016/0006-2952(84)90599-9; Moldovan L, 2014, J CELL MOL MED, V18, P371, DOI 10.1111/jcmm.12236; Momen-Heravi F, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0623-9; Ohshima K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013247; Platt R, 2008, PHARMACOEPIDEM DR S, V17, P1175, DOI 10.1002/pds.1668; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; Pritchard CC, 2012, NAT REV GENET, V13, P358, DOI 10.1038/nrg3198; Ramachandran R, 2009, J CLIN PATHOL, V62, P481, DOI 10.1136/jcp.2008.058248; RUMACK BH, 1975, PEDIATRICS, V55, P871; Sakurai K, 2016, J APPL TOXICOL, V36, P1614, DOI 10.1002/jat.3326; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; Smith A, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2956-z; SMOLAREK TA, 1990, DRUG METAB DISPOS, V18, P659; Starckx S, 2013, TOXICOL PATHOL, V41, P795, DOI 10.1177/0192623312464436; Tamai S, 2017, J TOXICOL SCI, V42, P73, DOI 10.2131/jts.42.73; TEE LBG, 1987, BIOCHEM PHARMACOL, V36, P1041, DOI 10.1016/0006-2952(87)90412-6; Thulin P, 2014, LIVER INT, V34, P367, DOI 10.1111/liv.12322; Tian ZM, 2008, GENOME RES, V18, P404, DOI 10.1101/gr.6587008; Tsujiura M, 2010, BRIT J CANCER, V102, P1174, DOI 10.1038/sj.bjc.6605608; Turchinovich A., 2013, Frontiers in Genetics, V4, P119, DOI 10.3389/fgene.2013.00119; Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254; Veeranagouda Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142708; Vliegenthart ADB, 2015, SCI REP-UK, V5, DOI 10.1038/srep15501; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Wang WJ, 2015, BIOMARK MED, V9, P1177, DOI 10.2217/bmm.15.86; Watanabe Toshiyuki, 2003, J Toxicol Sci, V28, P455, DOI 10.2131/jts.28.455; Yamaura Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030250; Yan GM, 2011, NAT BIOTECHNOL, V29, P1019, DOI 10.1038/nbt.1992; Zhang LL, 2017, INT UROL NEPHROL, V49, P541, DOI 10.1007/s11255-016-1485-7	58	2	2	0	2	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	1					3	13		10.1293/tox.2017-0036			11	Pathology; Toxicology	Pathology; Toxicology	FT4TH	WOS:000423147300002	29479135	Green Published, Bronze			2019-10-28	
J	Hamada, C				Hamada, Chikuma			Statistical analysis for toxicity studies	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Review						decision tree; parametric method; nonparametric method and multiple comparison		Generally, multiple statistical analysis methods can be applied for certain kind of data, and conclusion could differ, depending on the selected statistical method. Therefore, it is necessary to fully understand the performance of each statistical method and to examine which method is appropriate to use and to standardize statistical methods for toxicity studies to be carried out routinely. Several viewpoints for selecting appropriate statistical methods are discussed in this review paper. According to the distribution form, i.e., whether a distribution has a bell shape without outliers or not, either a parametric or a nonparametric approach should be selected. The nonparametric approach is also available for categorical data. Depending on the design and purpose of a study, several forms of statistical analysis are available. Assuming dose dependency, comparisons with a control are conducted by Williams test (nonparametric: Shirley-Williams test). When a dose dependent relationship is not expected, comparisons with the control are conducted by Dunnett test (nonparametric: Steel test). All possible pairwise comparisons among groups are conducted by Tukey test (nonparametric: Steel-Dwass test). If we are interested in several specific comparisons among groups, the Bonferroni-adjusted Student's t-test (nonparametric: the Bonferroni-adjusted Wilcoxon test) can be used.	[Hamada, Chikuma] Tokyo Univ Sci, Dept Informat & Comp Technol, Fac Engn, Katsushika Ku, 6-3-1 Niijuku, Tokyo 1258585, Japan	Hamada, C (reprint author), Tokyo Univ Sci, Dept Informat & Comp Technol, Fac Engn, Katsushika Ku, 6-3-1 Niijuku, Tokyo 1258585, Japan.	hamada@rs.kagu.tus.ac.jp					DUNCAN DB, 1975, BIOMETRICS, V31, P339, DOI 10.2307/2529425; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096; DUNNETT CW, 1980, J AM STAT ASSOC, V75, P789, DOI 10.2307/2287160; Hamada C, 1998, DRUG INF J, V32, P201, DOI 10.1177/009286159803200128; Hamada C, 1997, DRUG INF J, V31, P413; Hamada C, 2012, STAT PRESENTATION WR; Hamada Chikuma, 1998, Journal of Toxicological Sciences, V23, P173; Hothorn AL, 1997, DRUG INF J, V31, P327; TUKEY JW, 1949, BIOMETRICS, V5, P99, DOI 10.2307/3001913; Uesaka H, 1995, HDB STAT MED, P77; WILLIAMS DA, 1972, BIOMETRICS, V28, P519, DOI 10.2307/2556164; YAMAZAKI M, 1981, Journal of Takeda Research Laboratories, V40, P163	12	5	5	0	4	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	1					15	22		10.1293/tox.2017-0050			8	Pathology; Toxicology	Pathology; Toxicology	FT4TH	WOS:000423147300003	29479136	Green Published, Bronze			2019-10-28	
J	Ichii, O; Horino, T				Ichii, Osamu; Horino, Taro			MicroRNAs associated with the development of kidney diseases in humans and animals	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Review						microRNA; kidney disease; acute kidney injury; chronic kidney disease; biomarker; exosome	PROMOTES RENAL FIBROSIS; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; INDUCED COLLAGEN EXPRESSION; CLINICAL-PRACTICE GUIDELINE; UP-REGULATION; MESENCHYMAL TRANSITION; LUPUS NEPHRITIS; DOWN-REGULATION; BIOMARKERS; IDENTIFICATION	Mature microRNAs (miRNAs) are single-stranded RNAs with approximately 18-25 bases, and their sequences are highly conserved among animals. miRNAs act as posttranscriptional regulators by binding mRNAs, and their main function involves the degradation of their target mRNAs. Recent studies revealed altered expression of miRNAs in the kidneys during the progression of acute kidney injury (AKI) and chronic kidney disease (CKD) in humans and experimental rodent models by using high-throughput screening techniques including microarray and small RNA sequencing. Particularly, miR-21 seems to be strongly associated with renal pathogenesis both in the glomerulus and tubulointerstitium. Furthermore, abundant evidence has been gathered showing the involvement of miRNAs in renal fibrosis. Because of the complex morphofunctional organization of the mammalian kidneys, it is crucial both to determine the exact localization of the kidney cells that express the miRNAs, which has been addressed mainly using in situ hybridization methods, and to identify precisely which mRNAs are bound and degraded by these miRNAs, which has been studied mostly through in vitro analysis. To discover novel biomarker candidates, miRNA levels in urine supernatant, sediment, and exosomal fraction were comprehensively investigated in different types of kidney disease, including drug-induced AKI, ischemia-induced AKI, diabetic nephropathy, lupus nephritis, and IgA nephropathy. Recent studies also demonstrated the therapeutic effect of miRNA and/or anti-miRNA administrations. The intent of this review is to illustrate the state-of-the-art research in the field of miRNAs associated with renal pathogenesis, especially focusing on AKI and CKD in humans and animal models.	[Ichii, Osamu] Hokkaido Univ, Dept Vet Basic Sci, Anat Lab, Fac Vet Med,Kita Ku, Kita 18 Nishi 9, Sapporo, Hokkaido 0600818, Japan; [Horino, Taro] Kochi Univ, Kochi Med Sch, Dept Endocrinol Metab & Nephrol, Nanko Ku, Oko Cho, Kochi 7838505, Japan	Ichii, O (reprint author), Hokkaido Univ, Dept Vet Basic Sci, Anat Lab, Fac Vet Med,Kita Ku, Kita 18 Nishi 9, Sapporo, Hokkaido 0600818, Japan.	ichi-o@vetmed.hokudai.ac.jp			JSPS KAKENHI GrantMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [24688033, 26461231, 15H05634]	This manuscript has not been published or presented elsewhere in part or in entirety and is not under consideration by another journal. Both authors approved the manuscript and agreed to its submission to your esteemed journal. There are no conflicts of interest to declare. This work was partially supported by JSPS KAKENHI Grant Numbers 24688033, 26461231, and 15H05634.	Aguado-Fraile E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127175; Aguado-Fraile E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044305; Alipour MR, 2013, MOL BIOL REP, V40, P6477, DOI 10.1007/s11033-013-2763-4; Alvarez ML, 2012, KIDNEY INT, V82, P1024, DOI 10.1038/ki.2012.256; Amrouche L, 2017, J AM SOC NEPHROL, V28, P479, DOI 10.1681/ASN.2016010045; [Anonymous], 2012, CLIN PRACTICE GUIDEB; Bhatt K, 2015, J AM SOC NEPHROL, V26, P1588, DOI 10.1681/ASN.2014050463; Bhatt K, 2010, MOL MED, V16, P409, DOI 10.2119/molmed.2010.00002; Boggs RM, 2007, GENE, V404, P25, DOI 10.1016/j.gene.2007.08.015; Cardenas-Gonzalez M, 2017, CLIN CHEM, V63, P1515, DOI 10.1373/clinchem.2017.274175; Chau BN, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003205; Chung ACK, 2010, J AM SOC NEPHROL, V21, P1317, DOI 10.1681/ASN.2010020134; Delic D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150154; DuJ, 2013, PLOS ONE, V8; Eissa S, 2016, BIOMED PHARMACOTHER, V83, P92, DOI 10.1016/j.biopha.2016.06.018; Eissa S, 2016, J DIABETES COMPLICAT, V30, P1585, DOI 10.1016/j.jdiacomp.2016.07.012; Fang Y, 2013, AM J PHYSIOL-RENAL, V304, pF1274, DOI 10.1152/ajprenal.00287.2012; Gebeshuber CA, 2013, NAT MED, V19, P481, DOI 10.1038/nm.3142; Glowacki F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058014; Guclu A, 2017, J SURG RES, V207, P241, DOI 10.1016/j.jss.2016.08.067; Gutierrez-Escolano A, 2015, RENAL FAILURE, V37, P1498, DOI 10.3109/0886022X.2015.1077322; Hennino MF, 2016, SCI REP-UK, V6, DOI 10.1038/srep27209; Hsu YC, 2016, SCI REP-UK, V6, DOI 10.1038/srep30575; Huang YH, 2015, INT J MOL MED, V35, P311, DOI 10.3892/ijmm.2014.2008; Huang ZB, 2017, BIOMED RES INT, DOI 10.1155/2017/7298160; Ichii O, 2008, KIDNEY INT, V74, P339, DOI 10.1038/ki.2008.182; Ichii O, 2017, SCI REP-UK, V7, DOI 10.1038/srep40340; Ichii O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110383; Ichii O, 2014, RES VET SCI, V96, P299, DOI 10.1016/j.rvsc.2014.01.003; Ichii O, 2012, KIDNEY INT, V81, P280, DOI 10.1038/ki.2011.345; Inker LA, 2014, AM J KIDNEY DIS, V63, P713, DOI 10.1053/j.ajkd.2014.01.416; Ito H, 2012, J AM SOC NEPHROL, V23, P1797, DOI 10.1681/ASN.2012020126; Jin WW, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-90; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; Joo MS, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.427; Kaimori JY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06111-4; Kato M, 2007, P NATL ACAD SCI USA, V104, P3432, DOI 10.1073/pnas.0611192104; Kato M, 2011, KIDNEY INT, V80, P358, DOI 10.1038/ki.2011.43; Kato M, 2010, J BIOL CHEM, V285, P34004, DOI 10.1074/jbc.M110.165027; Kato M, 2009, NAT CELL BIOL, V11, P881, DOI 10.1038/ncb1897; Khurana R, 2017, RNA, V23, P142, DOI 10.1261/rna.058834.116; Koga K, 2015, DIABETOLOGIA, V58, P2169, DOI 10.1007/s00125-015-3642-4; Kolling M, 2017, MOL THER, V25, P165, DOI 10.1016/j.ymthe.2016.08.001; Kriegel AJ, 2012, PHYSIOL GENOMICS, V44, P259, DOI 10.1152/physiolgenomics.00173.2011; Kumar D, 2015, ONCOTARGET, V6, P3280, DOI 10.18632/oncotarget.2462; Lai JY, 2015, J AM SOC NEPHROL, V26, P805, DOI 10.1681/ASN.2013121274; Lan HY, 2003, J AM SOC NEPHROL, V14, P1535, DOI 10.1097/01.ASN.0000067632.04658.B8; Lan YF, 2012, J AM SOC NEPHROL, V23, P2012, DOI 10.1681/ASN.2012050438; Lee CG, 2014, KIDNEY INT, V86, P943, DOI 10.1038/ki.2014.117; Lee HW, 2017, J BIOL CHEM, V292, P732, DOI 10.1074/jbc.M116.753822; Li R, 2013, KIDNEY INT, V84, P1129, DOI 10.1038/ki.2013.272; Li ZH, 2016, J NEPHROL, V29, P27, DOI 10.1007/s40620-015-0217-x; Lin CL, 2014, J AM SOC NEPHROL, V25, P1698, DOI 10.1681/ASN.2013050527; Liu XL, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-96; Liu XJ, 2015, AM J NEPHROL, V42, P168, DOI 10.1159/000439185; Loboda A, 2016, MEDIAT INFLAMM, DOI 10.1155/2016/8319283; Lorenzen JM, 2014, J AM SOC NEPHROL, V25, P2717, DOI 10.1681/ASN.2013121329; Loyer X, 2014, CIRC RES, V114, P345, DOI 10.1161/CIRCRESAHA.113.300858; Lu J, 2012, NEPHROLOGY, V17, P346, DOI 10.1111/j.1440-1797.2012.01573.x; Lv LL, 2013, AM J PHYSIOL-RENAL, V305, pF1220, DOI 10.1152/ajprenal.00148.2013; Min QH, 2017, J CLIN LAB ANAL, V2017; Mohan A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154055; Morizane R, 2014, SCI REP-UK, V4, DOI 10.1038/srep04578; Mousavi MZ, 2015, ANALYST, V140, P4097, DOI 10.1039/c5an00145e; Muralidharan J, 2017, AM J PHYSIOL-RENAL, V312, pF982, DOI 10.1152/ajprenal.00569.2016; Oba S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013614; Oni L, 2017, PHARMACOL THERAPEUT, V174, P55, DOI 10.1016/j.pharmthera.2017.02.018; Palevsky PM, 2013, AM J KIDNEY DIS, V61, P649, DOI 10.1053/j.ajkd.2013.02.349; Pavkovic M, 2016, TOXICOL SCI, V152, P205, DOI 10.1093/toxsci/kfw077; Perez-Hernandez J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138618; Putta S, 2012, J AM SOC NEPHROL, V23, P458, DOI 10.1681/ASN.2011050485; Qin W, 2011, J AM SOC NEPHROL, V22, P1462, DOI 10.1681/ASN.2010121308; Ramachandran K, 2013, CLIN CHEM, V59, P1742, DOI 10.1373/clinchem.2013.210245; Ramezani A, 2015, EUR J CLIN INVEST, V45, P394, DOI 10.1111/eci.12420; Ranganathan P, 2015, AM J PHYSIOL-RENAL, V309, pF551, DOI 10.1152/ajprenal.00076.2015; Recio C, 2017, J AM SOC NEPHROL, V28, P575, DOI 10.1681/ASN.2016020237; Saikumar J, 2012, TOXICOL SCI, V129, P256, DOI 10.1093/toxsci/kfs210; Schley G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145042; Shukla P, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2036-9; Sole C, 2015, NEPHROL DIAL TRANSPL, V30, P1488, DOI 10.1093/ndt/gfv128; Sun L, 2011, J PATHOL, V225, P364, DOI 10.1002/path.2961; Sun YQ, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh186; Szeto CC, 2012, DIS MARKERS, V33, P137, DOI 10.3233/DMA-2012-0914; Tian ZM, 2008, GENOME RES, V18, P404, DOI 10.1101/gr.6587008; Timoneda O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055402; Timoneda O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044413; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Veeranagouda Y, 2017, METHODS MOL BIOL, V1641, P349, DOI 10.1007/978-1-4939-7172-5_20; Veeranagouda Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142708; Wang B, 2012, J AM SOC NEPHROL, V23, P252, DOI 10.1681/ASN.2011010055; Wang B, 2011, DIABETES, V60, P280, DOI 10.2337/db10-0892; Wang G, 2011, DIS MARKERS, V30, P171, DOI 10.3233/DMA-2011-0766; Wang Q, 2008, FASEB J, V22, P4126, DOI 10.1096/fj.08-112326; Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405; Wei QQ, 2016, J AM SOC NEPHROL, V27, P2784, DOI 10.1681/ASN.2015080870; Xiong MX, 2012, AM J PHYSIOL-RENAL, V302, pF369, DOI 10.1152/ajprenal.00268.2011; Xu XL, 2012, KIDNEY INT, V82, P1167, DOI 10.1038/ki.2012.241; Yuan J, 2015, AM J TRANSPLANT, V15, P1682, DOI 10.1111/ajt.13161; Zarjou A, 2011, AM J PHYSIOL-RENAL, V301, pF793, DOI 10.1152/ajprenal.00273.2011; Zhao BH, 2016, J AM SOC NEPHROL, V27, P2597, DOI 10.1681/ASN.2015030300; Zheng ZJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep37492; Zhong X, 2011, J AM SOC NEPHROL, V22, P1668, DOI 10.1681/ASN.2010111168; Zhou H, 2013, J AM SOC NEPHROL, V24, P1073, DOI 10.1681/ASN.2012080849; Zhou Q, 2010, J BIOL CHEM, V285, P40019, DOI 10.1074/jbc.M110.141341; Zhou XB, 2016, REGUL TOXICOL PHARM, V78, P78, DOI 10.1016/j.yrtph.2016.04.001; Zhu S, 2012, NAT MED, V18, P1077, DOI 10.1038/nm.2815; Zou YF, 2017, EXP BIOL MED, V242, P657, DOI 10.1177/1535370216685005	107	16	18	0	12	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	1					23	34		10.1293/tox.2017-0051			12	Pathology; Toxicology	Pathology; Toxicology	FT4TH	WOS:000423147300004	29479137	Green Published, Bronze			2019-10-28	
J	Kuroda, H; Kinomoto, T; Ogawa, S; Kawabe, M; Suguro, M; Naraoka, H; Takamatsu, K; Oishi, Y				Kuroda, Hiroyuki; Kinomoto, Toshiko; Ogawa, Shuji; Kawabe, Mayumi; Suguro, Mayuko; Naraoka, Hitoshi; Takamatsu, Kazuhiko; Oishi, Yuji			Progression process and safety assessment adaptation of endometrial lesions in ENU-induced 2-stage uterine carcinogenicity in a Tg-rasH2 mouse model	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Review						acotiamide-HH; endometrial adenocarcinoma; carcinogenicity; rasH2 mouse	ETHYL-N-NITROSOUREA; P53-DEFICIENT CBA MICE; GENE RASH2 MICE; TRANSGENIC MICE; DONRYU RATS; RAPID INDUCTION; ADENOCARCINOMAS; ETHINYLESTRADIOL; TUMORS	Although acotiamide hydrochloride hydrate (acotiamide-HH) has not been reported to have genotoxic findings in any of the genotoxicity studies or treatment-related toxicological findings in reproductive and developmental studies, suspicious uterine tumorigenesis was observed in the results of a long-term rat carcinogenicity study. To clarify the uterine tumorigenesis of acotiamide-HH, we performed a 2-stage uterine carcinogenicity model in the transgenic rasH2 mouse initiated by N-Ethyl-N-nitrosourea (ENU). This model facilitated the short-term detection of uterine carcinogenic potential, and it appears to be a very useful testing method for assessing the safety of chemicals that may affect uterine tumorigenesis. However, there have not been many reports on this model, and accumulation of case studies using this model is recommended to support its usability. In this study, we performed this carcinogenesis model to not only confirm uterine tumorigenesis of acotiamide-HH but also to confirm the reliability of the model. The results of this study revealed that the endometrial adenocarcinoma found in the long-term rat carcinogenicity study possibly arose spontaneously. Also, we confirmed early induction of a uterine tumor as in previous reports and confirmed that 26 weeks is the appropriate treatment period for this rasH2 mouse model according to time-course observations of uterine tumor development.	[Kuroda, Hiroyuki] Zeria Pharmaceut Co Ltd, R&D PLANNING, Chuo Ku, 10-11 Nihonbashi Kobuna Cho, Tokyo 1038351, Japan; [Kinomoto, Toshiko; Ogawa, Shuji] Zeria Pharmaceut Co Ltd, Cent Res Labs, 2512-1 Aza Numagami, Kumagaya, Saitama 3600111, Japan; [Kawabe, Mayumi; Suguro, Mayuko] DIMS Inst Med Sci Inc, 64 Goura,Azai Cho, Ichinomiya, Aichi 4910113, Japan; [Naraoka, Hitoshi; Takamatsu, Kazuhiko] Astellas Pharma Inc, Tsukuba Res Ctr, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan; [Oishi, Yuji] Osaka City Univ, Dept Mol Pathol, Abeno Ku, 1-4-3 Asahi Machi, Osaka, Osaka 5458585, Japan	Kuroda, H (reprint author), Zeria Pharmaceut Co Ltd, R&D PLANNING, Chuo Ku, 10-11 Nihonbashi Kobuna Cho, Tokyo 1038351, Japan.	hiroyuki-kuroda@zeria.co.jp					Alden CL, 2011, VET PATHOL, V48, P772, DOI 10.1177/0300985811400445; ANDOLU J, 1994, JPN J CANCER RES, V85, P789, DOI 10.1111/j.1349-7006.1994.tb02949.x; [Anonymous], 2013, REP DEL RES EV LIC D; Kuroda H, 2016, FUNDAM TOXICOL SCI, V3, P19; Kuroda H, 2015, FUNDAM TOXICOL SCI, V2, P117; MacDonald J, 2004, TOXICOL SCI, V77, P188, DOI 10.1093/toxsci/kfh037; Mitsumori K, 2000, CARCINOGENESIS, V21, P1039, DOI 10.1093/carcin/21.5.1039; Mitsumori K, 2000, TOXICOL SCI, V58, P43, DOI 10.1093/toxsci/58.1.43; Mitsumori K, 1998, TOXICOL PATHOL, V26, P520, DOI 10.1177/019262339802600408; NAGAOKA T, 1994, TOXICOL PATHOL, V22, P261, DOI 10.1177/019262339402200304; NAGAOKA T, 1990, J CANCER RES CLIN, V116, P623, DOI 10.1007/BF01637084; TAKAHASHI M, 1995, CANCER LETT, V95, P85, DOI 10.1016/0304-3835(95)03867-V; Takahashi M, 2001, CANCER LETT, V165, P123, DOI 10.1016/S0304-3835(00)00709-6; Takaoka M, 2003, TOXICOL PATHOL, V31, P191, DOI 10.1080/01926230390183670; Watanabe T, 2003, TOXICOL PATHOL, V31, P496, DOI 10.1080/01926230390226014; Watanabe T, 2002, CANCER LETT, V188, P39, DOI 10.1016/S0304-3835(02)00158-1	16	0	0	1	1	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	1					35	41		10.1293/tox.2017-0035			7	Pathology; Toxicology	Pathology; Toxicology	FT4TH	WOS:000423147300005	29479138	Bronze, Green Published			2019-10-28	
J	Toita, R; Kawano, T; Fujita, S; Murata, M; Kang, JH				Toita, Riki; Kawano, Takahito; Fujita, Satoshi; Murata, Masaharu; Kang, Jeong-Hun			Increased hepatic inflammation in a normal-weight mouse after long-term high-fat diet feeding	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						body mass index; calorie dense food; hepatic disease; inflammation; obesity	ADIPOSE-TISSUE; LIVER-DISEASE; INSULIN-RESISTANCE; OBESE MICE; METABOLIC SYNDROME; ADIPOCYTE DEATH; OVERWEIGHT; STEATOSIS; VALUES; DAMAGE	Among five C57BL/6 mice fed a high-fat diet (HFD) for 12 weeks, one mouse showed a body weight (BW) similar to normal diet (ND)-fed mice. We compared obesity-related parameters of three groups (ND-fed mice, one HFD-fed normal-weight mouse, and HFD-fed overweight mice), including visceral fat weight, serum levels of total cholesterol (TC), glucose, and aminotransferases (AST and ALT), adipocyte size, percentage of crown-like structures, severity of hepatic steatosis, and number of inflammatory foci. Compared to ND-fed mice, the HFD-fed normal-weight mouse exhibited a similar visceral fat weight, similar serum levels of glucose and aminotransferases, and a similar percentage of crown-like structures. On the other hand, the serum TC level, adipocyte size, and hepatic steatosis severity of the HFD-fed normal-weight mouse were intermediate between those of ND-fed mice and HFD-fed overweight mice. Interestingly, the number of hepatic inflammatory foci in the HFD-fed normal-weight mouse was remarkably increased compared with those in HFD-fed overweight mice. These results suggest that having BW or serum ALT levels within normal ranges may not guarantee absence of hepatic inflammation and that the HFD-fed normal-weight mouse can be used as an animal model for the study of liver inflammation, particularly in patients with normal BWs and/or serum ALT values.	[Toita, Riki; Fujita, Satoshi] Natl Inst Adv Ind Sci & Technol, Biomed Res Inst, 1-8-31 Midorigaoka, Ikeda, Osaka 5638577, Japan; [Kawano, Takahito; Murata, Masaharu] Kyushu Univ, Dept Adv Med Initiat, Fac Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan; [Kang, Jeong-Hun] Natl Cerebral & Cardiovasc Ctr, Res Inst, Div Biopharmaceut & Pharmacokinet, 5-7-1 Fujishiro Dai, Suita, Osaka 5658565, Japan	Toita, R (reprint author), Natl Inst Adv Ind Sci & Technol, Biomed Res Inst, 1-8-31 Midorigaoka, Ikeda, Osaka 5638577, Japan.; Kang, JH (reprint author), Natl Cerebral & Cardiovasc Ctr, Res Inst, Div Biopharmaceut & Pharmacokinet, 5-7-1 Fujishiro Dai, Suita, Osaka 5658565, Japan.	toita-r@aist.go.jp; jrjhkang@ncvc.go.jp	Fujita, Satoshi/L-8237-2018; Toita, Riki/C-5710-2014	Fujita, Satoshi/0000-0002-1139-7002; Toita, Riki/0000-0001-9700-4531; Kang, Jeong-Hun/0000-0001-9229-3063	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP16K21212, JP17K01386]	This work was supported by JSPS KAKENHI Grant Numbers JP16K21212 and JP17K01386.	Alkhouri N, 2010, J BIOL CHEM, V285, P3428, DOI 10.1074/jbc.M109.074252; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1016/S0002-9270(99)00433-5; Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071; Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200; Coenen KR, 2007, DIABETES, V56, P564, DOI 10.2337/db06-1375; Czaja AJ, 2014, WORLD J GASTROENTERO, V20, P2515, DOI 10.3748/wjg.v20.i10.2515; Fracanzani AL, 2008, HEPATOLOGY, V48, P792, DOI 10.1002/hep.22429; Fraulob JC, 2010, J CLIN BIOCHEM NUTR, V46, P212, DOI 10.3164/jcbn.09-83; Gallou-Kabani C, 2007, OBESITY, V15, P1996, DOI 10.1038/oby.2007.238; Ghadir MR, 2010, HEPAT MON, V10, P285; Gotoh K, 2013, NEPHROL DIAL TRANSPL, V28, P1120, DOI 10.1093/ndt/gfs440; Gowda S, 2009, PAN AFR MED J, V3, P1; Hariri N, 2010, NUTR RES REV, V23, P270, DOI 10.1017/S0954422410000168; Hooper L, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7666; Hwang LL, 2010, OBESITY, V18, P463, DOI 10.1038/oby.2009.273; Kew MC, 2000, LANCET, V355, P591, DOI 10.1016/S0140-6736(99)00219-6; Lavie CJ, 2009, J AM COLL CARDIOL, V53, P1925, DOI 10.1016/j.jacc.2008.12.068; Liedtke C, 2013, FIBROGENESIS TISSUE, V6, DOI 10.1186/1755-1536-6-19; Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132; Machado MV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127991; Mofrad P, 2003, HEPATOLOGY, V37, P1286, DOI 10.1053/jhep.2003.50229; Mulder P, 2015, INFLAMM CELL SIGNAL, V2, pe804, DOI DOI 10.14800/ICS.804; Murano I, 2008, J LIPID RES, V49, P1562, DOI 10.1194/jlr.M800019-JLR200; Nettschwander-Tetri BA, 2010, HEPATOLOGY, V52, P913, DOI 10.1002/hep.23784; Omagari K, 2002, J GASTROEN HEPATOL, V17, P1098, DOI 10.1046/j.1440-1746.2002.02846.x; Parlee SD, 2014, METHOD ENZYMOL, V537, P93, DOI 10.1016/B978-0-12-411619-1.00006-9; SATTAR N, 2014, BMJ-BRIT MED J, V349, DOI DOI 10.1136/BMJ.G4596; Stranges S, 2004, HEPATOLOGY, V39, P754, DOI 10.1002/hep.20149; Strauss RS, 2000, J PEDIATR-US, V136, P727, DOI 10.1067/mpd.2000.102940; Strissel KJ, 2007, DIABETES, V56, P2910, DOI 10.2337/db07-0767; Sun BC, 2012, J HEPATOL, V56, P704, DOI 10.1016/j.jhep.2011.09.020; Tandra S, 2011, J HEPATOL, V55, P654, DOI 10.1016/j.jhep.2010.11.021; Toita R, 2016, BIOMATERIALS, V110, P81, DOI 10.1016/j.biomaterials.2016.09.018	33	1	1	0	3	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	1					43	47		10.1293/tox.2017-0038			5	Pathology; Toxicology	Pathology; Toxicology	FT4TH	WOS:000423147300006	29479139	Bronze, Green Published			2019-10-28	
J	Konishi, S; Kotera, T; Koga, M; Ueda, M				Konishi, Shizuka; Kotera, Takashi; Koga, Masaaki; Ueda, Makoto			Spontaneous hypertrophic cardiomyopathy in a cynomolgus macaque (Macaca fascicularis)	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						cynomolgus macaque; hypertrophic cardiomyopathy; disarray; vacuolation; autophagy	VACUOLAR CARDIOMYOPATHY; HEART-FAILURE; AUTOPHAGY; DISEASE; ASSOCIATION; CARDIOLOGY; STATEMENT	The term cardiomyopathy is used to describe heart disease resulting from an abnormality in the myocardium. It is rare in cynomolgus macaques (Macaca fascicularis). Here, we report a case of hypertrophic cardiomyopathy in an 11-year-old male cynomolgus macaque. Macroscopically, the interventricular septum (IVS) and the left ventricular (LV) and right ventricular (RV) walls of the heart were thickened. Histologically, cardiomyocytes showed hypertrophy and disarray with interstitial fibrosis, and some myocytes showed karyomegaly and vacuoles. On the basis of these morphological characteristics, the present case was diagnosed as hypertrophic cardiomyopathy. Immunohistochemically, the cardiomyocytes in the affected regions were positive for the autophagic markers LC3 and p62/SQSTM1 (p62). The accumulation of autophagosomes in hypertrophied cardiomyocytes was demonstrated. The mechanism of accumulation of autophagosomes seems to be a secondary effect due to stress. To our knowledge, this is the first report of spontaneous hypertrophic cardiomyopathy in a cynomolgus macaque.	[Konishi, Shizuka; Kotera, Takashi; Koga, Masaaki; Ueda, Makoto] Nippon Shinyaku Co Ltd, Pharmacokinet & Safety Assessment Dept, Minami Ku, 14 Nishinosho Monguchi Cho, Kyoto 6018550, Japan	Konishi, S (reprint author), Nippon Shinyaku Co Ltd, Pharmacokinet & Safety Assessment Dept, Minami Ku, 14 Nishinosho Monguchi Cho, Kyoto 6018550, Japan.	s.konishi@po.nippon-shinyaku.co.jp					Allison LC, 2014, HYPERTROPHIC CARDIOM; Chamanza R, 2010, TOXICOL PATHOL, V38, P642, DOI 10.1177/0192623310368981; Daniels BH, 2013, AM J SURG PATHOL, V37, P1014, DOI 10.1097/PAS.0b013e3182863fa8; Estes M L, 1987, Am J Med, V82, P447, DOI 10.1016/0002-9343(87)90444-X; FOX RI, 1993, SEMIN ARTHRITIS RHEU, V23, P82, DOI 10.1016/S0049-0172(10)80012-5; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lyon AR, 2016, EUR J HEART FAIL, V18, P8, DOI 10.1002/ejhf.424; Maron BJ, 2006, CIRCULATION, V113, P1807, DOI 10.1161/CIRCULATIONAHA.106.174287; Miller L.M., 2017, PATHOLOGIC BASIS VET, P561, DOI 10.1016/B978-0-323-35775-3.00010-2; Nagueh SF, 2014, CIRCULATION, V130, P1081, DOI 10.1161/CIRCULATIONAHA.114.009789; Nef HM, 2007, EUR HEART J, V28, P2456, DOI 10.1093/eurheartj/ehl570; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Sadakari N, 1997, JUNTENDO MED J, V43, P613; Schoen JF, 2010, ROBBINS COTRAN PATHO, P530; Terman A, 2005, CARDIOVASC RES, V68, P355, DOI 10.1016/j.cardiores.2005.08.014; Vidal JD, 2010, TOXICOL PATHOL, V38, P297, DOI 10.1177/0192623309358906; Zabka TS, 2009, TOXICOL PATHOL, V37, P814, DOI 10.1177/0192623309345692	18	0	0	0	1	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	1					49	54		10.1293/tox.2017-0027			6	Pathology; Toxicology	Pathology; Toxicology	FT4TH	WOS:000423147300007	29479140	Green Published, Bronze			2019-10-28	
J	Yasuno, K; Honda, K; Hakamata, S; Kai, K; Mori, K				Yasuno, Kyohei; Honda, Kumi; Hakamata, Shinobu; Kai, Kiyonori; Mori, Kazuhiko			Minimal change disease of the kidney in a young Sprague Dawley rat	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						kidney; minimal change disease; nephrin; podocyte; rat	PUROMYCIN AMINONUCLEOSIDE NEPHROSIS; NEPHRIN; EXPRESSION; CHILDHOOD; PROTEINURIA; PODOCYTE; ALBUMIN; LESIONS; MODELS; MARKER	Minimal change disease (MCD) can be experimentally induced in rats, but spontaneous cases have not been reported. Herein, we present a case of MCD in rats that resembled the phenotypes of human MCD. A 9-week-old male Sprague Dawley rat developed continuous albuminuria for 2 weeks and was sacrificed at 11 weeks of age. Histological testing revealed no glomerular or renal tubular abnormalities on light microscopy. Immunofluorescence revealed absence of immunoglobulin G or immunoglobulin M deposition in the glomerulus. Extensive foot process effacement of glomerular podocytes was observed by electron microscopy, with rearrangement of the actin cytoskeleton at the base of the fused foot processes. The rat did not show desmin-positive podocytes, and the nephrin showed a normal liner pattern of distribution along the glomerular capillary loop throughout the glomeruli. These pathological characteristics corresponded to those of human MCD, and the glomerular lesion was considered a rare case of rat MCD.	[Yasuno, Kyohei; Honda, Kumi; Hakamata, Shinobu; Kai, Kiyonori; Mori, Kazuhiko] Daiichi Sankyo Co Ltd, Med Safety Res Labs, Edogawa Ku, 1-16-13 Kita Kasai, Tokyo 1348630, Japan	Yasuno, K (reprint author), Daiichi Sankyo Co Ltd, Med Safety Res Labs, Edogawa Ku, 1-16-13 Kita Kasai, Tokyo 1348630, Japan.						Bazzi C, 1997, AM J KIDNEY DIS, V30, P404, DOI 10.1016/S0272-6386(97)90286-9; BOHLIN AB, 1984, ACTA PAEDIATR SCAND, V73, P631, DOI 10.1111/j.1651-2227.1984.tb09987.x; Chugh SS, 2012, AM J KIDNEY DIS, V59, P284, DOI 10.1053/j.ajkd.2011.07.024; DIAMOND JR, 1986, AM J PATHOL, V122, P481; FLOEGE J, 1992, LAB INVEST, V67, P486; Frazier KS, 2012, TOXICOL PATHOL, V40, P14, DOI 10.1177/0192623312438736; Furukawa S, 2017, J TOXICOL PATHOL, V30, P79, DOI 10.1293/tox.2016-0047; Hingorani SR, 2004, PEDIATR NEPHROL, V19, P300, DOI 10.1007/s00467-003-1346-3; HOPPER J, 1970, MEDICINE, V49, P321, DOI 10.1097/00005792-197007000-00004; Inokuchi S, 1996, KIDNEY INT, V50, P1278, DOI 10.1038/ki.1996.439; Kakimoto T, 2014, J ENDOCRINOL, V222, P43, DOI 10.1530/JOE-14-0164; Kawakami H, 2012, NEPHROL DIAL TRANSPL, V27, P1324, DOI 10.1093/ndt/gfr492; Khan KNM, 2013, HASCHEK AND ROUSSEAUX'S HANDBOOK OF TOXICOLOGIC PATHOLOGY, VOL 1-3, 3RD EDITION, P1667; Maruyama M, 2007, CLIN NEPHROL, V68, P73; Nair R, 2004, AM J KIDNEY DIS, V44, P618, DOI 10.1053/j.ajkd.2004.05.044; OLSON JL, 1981, LAB INVEST, V44, P271; Olson JL., HEPTINSTALLS PATHOLO, P125; Patrakka J, 2001, J AM SOC NEPHROL, V12, P289; Patrakka J, 2007, TRENDS MOL MED, V13, P396, DOI 10.1016/j.molmed.2007.06.006; Pippin JW, 2009, AM J PHYSIOL-RENAL, V296, pF213, DOI 10.1152/ajprenal.90421.2008; Rivera A, 2001, ULTRASTRUCT PATHOL, V25, P313, DOI 10.1080/019131201753136340; Russo LM, 2007, KIDNEY INT, V71, P504, DOI 10.1038/sj.ki.5002041; SIMMS HS, 1957, J GERONTOL, V12, P244, DOI 10.1093/geronj/12.3.244; Tonomura Y, 2010, TOXICOLOGY, V273, P53, DOI 10.1016/j.tox.2010.04.015; WHITE RHR, 1970, LANCET, V1, P1353	25	0	0	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	1					55	59		10.1293/tox.2017-0052			5	Pathology; Toxicology	Pathology; Toxicology	FT4TH	WOS:000423147300008	29479141	Green Published, Bronze			2019-10-28	
J	Ono, Y; Sato, H; Miyazaki, T; Fujiki, K; Kume, E; Tanaka, M				Ono, Yuko; Sato, Hiroko; Miyazaki, Toshiko; Fujiki, Katsuya; Kume, Eisuke; Tanaka, Masaharu			Quality assessment of long-term stored formalin-fixed paraffin embedded tissues for histopathological evaluation	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						FFPE tissue; long-term storage; hematoxylin and eosin; histopathological examination; quality assessment; reconstruction		Histopathological examination of formalin-fixed paraffin-embedded (FFPE) tissues that had been stored for 30 years was conducted, and reconstructivity of the results was verified. These FFPE tissues, which were from all organs of male and female rats, were re-sectioned and histopathologically examined using hematoxylin and eosin (HE) staining. In particular, the stainability and morphology of HE sections and reproducibility of microscopic findings in the liver and kidney demonstrated in the original final reports were evaluated. Although the stainability of hematoxylin was slightly weaker and some morphological artifacts were observed in tissues in re-prepared slides, these deteriorations in the quality of HE sections were considered to be permissible for histopathological examination so long as control sections were also prepared. Most microscopic findings recorded in the original final reports were confirmed using re-prepared HE sections in the present study. While some focal findings, which were judged to be either incidental or spontaneous in nature, were not observed in the sections as expected, this was not considered to be a problem in reconstructing the results of the original histopathological examination because most findings related to the test articles were generally observed diffusely or multifocally in each organ. We concluded that results of the original histopathological examinations could be reconstructed using paraffin blocks that had been stored for up to 30 years.	[Ono, Yuko; Sato, Hiroko; Miyazaki, Toshiko; Fujiki, Katsuya; Kume, Eisuke; Tanaka, Masaharu] Mitsubishi Tanabe Pharma Corp, Innovat Res Div, Safety Res Labs, Sohya Ku, 2-2-50 Kawagishi, Toda, Saitama 3358505, Japan	Ono, Y (reprint author), Mitsubishi Tanabe Pharma Corp, Innovat Res Div, Safety Res Labs, Sohya Ku, 2-2-50 Kawagishi, Toda, Saitama 3358505, Japan.	oono.yuuko@ma.mt-pharma.co.jp					Asano Y, 2001, JPN J HISTOTECH, V10, P9; OECD (Organisation for Economic Co-operation and Development), 2007, OECD SER PRINC GOOD; Okazaki K, 2002, JPN J HISTOTECH, V11, P25; Wakita R, 1993, JPN J HISTOTECH, V2, P75	4	0	0	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	1					61	64		10.1293/tox.2017-0046			4	Pathology; Toxicology	Pathology; Toxicology	FT4TH	WOS:000423147300009	29479142	Green Published, Bronze			2019-10-28	
J	Chisada, S; Hirako, A; Sugiyama, A				Chisada, Shin-ichi; Hirako, Ayano; Sugiyama, Akihiko			Ocular lesions in leptin receptor-deficient medaka (Oryzias latipes)	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						cataract; hyperglycemia; leptin receptor-deficient medaka; retinopathy; vascular dilatation	PIGMENT EPITHELIAL-CELLS; OBESE GENE-PRODUCT; GENOMIC CHARACTERIZATION; MORPHOLOGICAL-CHANGES; DIABETIC-RETINOPATHY; TISSUE DISTRIBUTION; EXPRESSION; RATS; COMPLICATIONS; INHIBITION	Ocular lesions in leptin receptor-deficient medaka were examined histopathologically at 10, 28, and 37 weeks post hatching. Leptin receptor-deficient medaka at 28 and 37 weeks old showed hyperglycemia and hypoinsulinemia. Histopathologically, vacuolation, swelling, fragmentation, and liquefaction of the lens fibers and dilatation of the retinal central veins, retinal capillaries, iridal veins and capillaries, and choroidal veins were observed in leptin receptor-deficient medaka at 28 and 37 weeks old. Thinning of the total retina, pigment epithelial layer, layer of rods and cones, outer granular layer, outer plexiform layer, inner granular layer, and inner plexiform layer was observed in leptin receptor-deficient medaka at 28 and 37 weeks compared with in control medaka. These histopathological characteristics in leptin receptor-deficient medaka are similar to characteristics in ocular lesions of rodent models for type II diabetes mellitus, making leptin receptor-deficient medaka a useful model of diabetic cataract and retinopathy.	[Chisada, Shin-ichi] Kyorin Univ, Sch Med, Dept Prevent Med & Publ Hlth, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan; [Hirako, Ayano; Sugiyama, Akihiko] Tottori Univ, Joint Dept Vet Med, Fac Agr, Minami 4-101 Koyama Cho, Tottori, Tottori 6808553, Japan	Sugiyama, A (reprint author), Tottori Univ, Joint Dept Vet Med, Fac Agr, Minami 4-101 Koyama Cho, Tottori, Tottori 6808553, Japan.	sugiyama@muses.tottori-u.ac.jp					Andoh T, 2002, GEN COMP ENDOCR, V125, P365, DOI 10.1006/gcen.2001.7760; Banks WA, 2004, DIABETES, V53, P1253, DOI 10.2337/diabetes.53.5.1253; Ayala-Pena VB, 2016, BBA-MOL CELL RES, V1863, P1134, DOI 10.1016/j.bbamcr.2016.02.010; BERNTHPETERSEN P, 1983, ACTA OPHTHALMOL, V61, P406; Bronson-Castain KW, 2009, RETINA-J RET VIT DIS, V29, P618, DOI 10.1097/IAE.0b013e31819a988b; Chisada S, 2014, GEN COMP ENDOCR, V195, P9, DOI 10.1016/j.ygcen.2013.10.008; Christoffersen N, 2004, ACTA OPHTHALMOL SCAN, V82, P591, DOI 10.1111/j.1600-0420.2004.00326.x; Dag A, 2016, EXP CLIN ENDOCR DIAB, V124, P167, DOI 10.1055/s-0035-1559781; Dong LY, 2013, MAR DRUGS, V11, P960, DOI 10.3390/md11030960; Du M, 2013, DIABETOLOGIA, V56, P2318, DOI 10.1007/s00125-013-2986-x; GARNER A, 1993, EYE, V7, P250, DOI 10.1038/eye.1993.58; Kakehashi A, 2006, DIABETES-METAB RES, V22, P455, DOI 10.1002/dmrr.638; Kim DI, 2015, INT J BIOCHEM CELL B, V59, P41, DOI 10.1016/j.biocel.2014.11.018; Kim DI, 2014, ARCH BIOCHEM BIOPHYS, V560, P36, DOI 10.1016/j.abb.2014.07.021; Kim J, 2012, EXP DIABETES RES, DOI 10.1155/2012/210821; Kono K, 2013, AM J NEPHROL, V37, P167, DOI 10.1159/000346808; Kristinsson JK, 1997, BRIT J OPHTHALMOL, V81, P274, DOI 10.1136/bjo.81.4.274; Kubo E, 2001, EXP EYE RES, V73, P375, DOI 10.1006/exer.2001.1046; Kurokawa T, 2008, GEN COMP ENDOCR, V158, P108, DOI 10.1016/j.ygcen.2008.06.003; Kurokawa T, 2009, GEN COMP ENDOCR, V161, P229, DOI 10.1016/j.ygcen.2009.01.008; Kusari J, 2010, INVEST OPHTH VIS SCI, V51, P1044, DOI 10.1167/iovs.08-3293; Lai AKW, 2013, J DIABETES RES, DOI 10.1155/2013/106594; Lechner J, 2017, VISION RES IN PRESS; Li XY, 2013, NEUROCHEM RES, V38, P669, DOI 10.1007/s11064-012-0966-z; Lu ZY, 2003, JPN J OPHTHALMOL, V47, P28, DOI 10.1016/S0021-5155(02)00631-7; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MORI Y, 1992, PANCREAS, V7, P569, DOI 10.1097/00006676-199209000-00010; Mustafi D, 2009, PROG RETIN EYE RES, V28, P289, DOI 10.1016/j.preteyeres.2009.05.003; Olsen AS, 2010, WOUND REPAIR REGEN, V18, P532, DOI 10.1111/j.1524-475X.2010.00613.x; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Ronnestad I, 2010, GEN COMP ENDOCR, V168, P55, DOI 10.1016/j.ygcen.2010.04.010; Sayin N, 2015, WORLD J DIABETES, V6, P92, DOI 10.4239/wjd.v6.i1.92; Shinohara M, 2000, Int J Exp Diabetes Res, V1, P89, DOI 10.1155/EDR.2000.89; Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004; Taniguchi Y, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-12-r116; Thiraphatthanavong P, 2014, OXID MED CELL LONGEV, DOI 10.1155/2014/789406; Tojo C, 1996, ENDOCR J, V43, P233, DOI 10.1507/endocrj.43.233; Wang BX, 2014, CURR DIABETES REV, V10, P131, DOI 10.2174/1573399810666140508121012; Whiting DR, 2011, DIABETES RES CLIN PR, V94, P311, DOI 10.1016/j.diabres.2011.10.029; Yang JH, 2013, INVEST OPHTH VIS SCI, V54, P3844, DOI 10.1167/iovs.12-11309; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	41	0	0	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	1					65	72		10.1293/tox.2017-0042			8	Pathology; Toxicology	Pathology; Toxicology	FT4TH	WOS:000423147300010	29479143	Green Published, Bronze			2019-10-28	
J	Cho, YM; Mizuta, Y; Akagi, J; Toyoda, T; Sone, M; Ogawa, K				Cho, Young-Man; Mizuta, Yasuko; Akagi, Jun-ichi; Toyoda, Takeshi; Sone, Mizuki; Ogawa, Kumiko			Size-dependent acute toxicity of silver nanoparticles in mice	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						silver nanoparticles; size dependence; acute toxicity; intraperitoneal administration; BALB/c mice	CYTOTOXICITY; RATS; GENOTOXICITY; CELLS	In this study, we aimed to evaluate changes in the acute toxicity of intraperitoneally administered silver nanoparticles (AgNPs) of varying sizes in BALB/c mice. Seven-week-old female BALB/c mice were intraperitoneally administered AgNPs measuring 10, 60, or 100 nm in diameter (0.2 mg/mouse) and then sacrificed 1, 3, or 6 h after treatment. In mice administered 10 nm AgNPs, reduced activity and piloerection were observed at 5 h post administration, and lowered body temperature was observed at 6 h post administration, with histopathological changes of congestion, vacuolation, single cell necrosis, and focal necrosis in the liver; congestion in the spleen; and apoptosis in the thymus cortex. These histopathological changes were not evident following administration of either 60 or 100 nm AgNPs. These results suggested that smaller AgNPs, e.g., those measuring 10 nm in diameter, had higher acute toxicity in mice.	[Cho, Young-Man; Mizuta, Yasuko; Akagi, Jun-ichi; Toyoda, Takeshi; Sone, Mizuki; Ogawa, Kumiko] Natl Inst Hlth Sci, Div Pathol, Biol Safety Res Ctr, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan	Cho, YM (reprint author), Natl Inst Hlth Sci, Div Pathol, Biol Safety Res Ctr, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.	ymcho@nihs.go.jp		Cho, Young-Man/0000-0002-2895-467X	Ministry of Health, Labour and Welfare, JapanMinistry of Health, Labour and Welfare, Japan	We thank Ms. Ayako Saikawa and Ms. Yoshimi Komatsu for their expert technical assistance with the processing of histological materials. This work was supported by a Grant-in-Aid from the Ministry of Health, Labour and Welfare, Japan.	Elkhawass EA, 2014, INT J PHARM PHARM SC, V7, P94; Gao XG, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0265-6; Gliga AR, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-11; Hackenberg S, 2011, TOXICOL LETT, V201, P27, DOI 10.1016/j.toxlet.2010.12.001; Kang SJ, 2012, TOXICOL APPL PHARM, V258, P89, DOI 10.1016/j.taap.2011.10.011; Kawata K, 2009, ENVIRON SCI TECHNOL, V43, P6046, DOI 10.1021/es900754q; Kim JS, 2013, NANOTOXICOLOGY, V7, P953, DOI 10.3109/17435390.2012.676099; Kim YR, 2010, PSYCHIAT INVEST, V7, P1, DOI 10.4306/pi.2010.7.1.1; Lankveld DPK, 2010, BIOMATERIALS, V31, P8350, DOI 10.1016/j.biomaterials.2010.07.045; Lu WT, 2010, CHEM PHYS LETT, V487, P92, DOI 10.1016/j.cplett.2010.01.027; Majdalawieh A, 2014, J NANOSCI NANOTECHNO, V14, P4757, DOI 10.1166/jnn.2014.9526; Mikklesen HS, 2011, SURVEY BASIC KNOWLED; Panacek A, 2006, J PHYS CHEM B, V110, P16248, DOI 10.1021/jp063826h; Park J, 2011, CHEM COMMUN, V47, P4382, DOI 10.1039/c1cc10357a; Park K, 2013, J TOXICOL ENV HEAL A, V76, P1246, DOI 10.1080/15287394.2013.849635; Park K, 2011, ARCH PHARM RES, V34, P153, DOI 10.1007/s12272-011-0118-z; Park MVDZ, 2011, BIOMATERIALS, V32, P9810, DOI 10.1016/j.biomaterials.2011.08.085; Quang HT, 2013, ADV NAT SCI-NANOSCI, V4, P1; Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002; Samberg ME, 2010, ENVIRON HEALTH PERSP, V118, P407, DOI 10.1289/ehp.0901398; Singh RP, 2012, TOXICOL LETT, V213, P249, DOI 10.1016/j.toxlet.2012.07.009; Suliman YA, 2015, ENVIRON TOXICOL, V30, P149, DOI 10.1002/tox.21880; Sung JH, 2009, TOXICOL SCI, V108, P452, DOI 10.1093/toxsci/kfn246; Tang JL, 2009, J NANOSCI NANOTECHNO, V9, P4924, DOI 10.1166/jnn.2009.1269; Vance ME, 2015, BEILSTEIN J NANOTECH, V6, P1769, DOI 10.3762/bjnano.6.181; You J, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-26	26	14	14	1	10	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	1					73	80		10.1293/tox.2017-0043			8	Pathology; Toxicology	Pathology; Toxicology	FT4TH	WOS:000423147300011	29479144	Green Published, Bronze			2019-10-28	
J	Fujii, E; Yamazaki, M; Kawai, S; Ohtani, Y; Watanabe, T; Kato, A; Suzuki, M				Fujii, Etsuko; Yamazaki, Masaki; Kawai, Shigeto; Ohtani, Yoshimi; Watanabe, Takeshi; Kato, Atsuhiko; Suzuki, Masami			A simple method for histopathological evaluation of organoids	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						organoid; pathological method; morphology; single cross section	COLON; CELLS; TUMOR	In vitro-cultured 3D structures called organoids have become important tools for biological research, but there is little information concerning simple and efficient methods to evaluate organoid morphology. To address this issue, we attempted to establish a simple method by applying conventional histopathology that enables observation of multiple organoids on a single cross section, maintains good morphology, and is applicable to various histopathological stains. By centrifugation in unsolidified agarose solution, we were able to accumulate the organoids onto a single plane. The morphology was well preserved, and the various morphological types and sizes of organoid structures were identified. This method was also applicable for special staining, immunohistochemistry, and immunofluorescence staining. This method makes it possible to utilize the advantages of conventional pathological methods when studying organoids.	[Fujii, Etsuko; Kawai, Shigeto; Suzuki, Masami] Univ Tokyo, Komaba Open Lab, Forerunner Pharma Res Co Ltd, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan; [Fujii, Etsuko; Yamazaki, Masaki; Kato, Atsuhiko; Suzuki, Masami] Chugai Pharmaceut Co Ltd, 200 Kajiwara, Kamakura, Kanagawa 2478530, Japan; [Ohtani, Yoshimi; Watanabe, Takeshi] Chugai Res Inst Med Sci Inc, 1-135 Komakado, Gotemba, Shizuoka 4128513, Japan	Fujii, E (reprint author), Univ Tokyo, Komaba Open Lab, Forerunner Pharma Res Co Ltd, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan.; Fujii, E (reprint author), Chugai Pharmaceut Co Ltd, 200 Kajiwara, Kamakura, Kanagawa 2478530, Japan.	fujiietk@chugai-pharm.co.jp	Yamazaki, Masaki/V-6997-2019	Yamazaki, Masaki/0000-0002-2079-0084			Carneiro K, 2015, BIRTH DEFECTS RES C, V105, P1, DOI 10.1002/bdrc.21089; Drost J, 2017, DEVELOPMENT, V144, P968, DOI 10.1242/dev.140566; Eiraku M, 2008, CELL STEM CELL, V3, P519, DOI 10.1016/j.stem.2008.09.002; Kaushik G, 2017, STEM CELLS, V35, P51, DOI 10.1002/stem.2502; Kobayashi S, 2012, STEM CELLS, V30, P2631, DOI 10.1002/stem.1257; Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125; Ohta Y, 2014, FRONT MED, V1, DOI 10.3389/fmed.2014.00014; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; SATO Y, 1986, AM J PATHOL, V125, P431; Susaki EA, 2016, CELL CHEM BIOL, V23, P137, DOI 10.1016/j.chembiol.2015.11.009; Suzuki Masami, 2002, J Toxicol Sci, V27, P165, DOI 10.2131/jts.27.165; Willyard C, 2015, NATURE, V523, P520, DOI 10.1038/523520a; Yamazaki M, 2015, ACTA HISTOCHEM CYTOC, V48, P159, DOI 10.1267/ahc.15019	14	0	0	0	1	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	1					81	85		10.1293/tox.2017-0060			5	Pathology; Toxicology	Pathology; Toxicology	FT4TH	WOS:000423147300012	29479145	Bronze, Green Published			2019-10-28	
J	Corro, C; Moch, H				Corro, Claudia; Moch, Holger			Biomarker discovery for renal cancer stem cells	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Review						cancer stem cells; tumor-initiating cells; renal cell carcinoma; biomarkers	ACUTE MYELOID-LEUKEMIA; PROGENITOR CELLS; SIDE POPULATION; ALDEHYDE DEHYDROGENASE; INITIATING CELLS; CD133 EXPRESSION; PROGNOSTIC VALUE; DRUG-RESISTANCE; CULTURE-SYSTEMS; CD44 EXPRESSION	Characterised by high intra- and inter-tumor heterogeneity, metastatic renal cell carcinoma (RCC) is resistant to chemo- and radiotherapy. Therefore, the development of new prognostic and diagnostic markers for RCC patients is needed. Cancer stem cells (CSCs) are a small population of neoplastic cells within a tumor which present characteristics reminiscent of normal stem cells. CSCs are characterised by unlimited cell division, maintenance of the stem cell pool (self-renewal), and capability to give rise to all cell types within a tumor; and contribute to metastasis in vivo (tumourigenicity), treatment resistance and recurrence. So far, many studies have tried to establish unique biomarkers to identify CSC populations in RCC. At the same time, different approaches have been developed with the aim to isolate CSCs. Consequently, several markers were found to be specifically expressed in CSCs and cancer stem-like cells derived from RCC such as CD105, ALDH1, OCT4, CD133, and CXCR4. However, the contribution of genetic and epigenetic mechanisms, and tumor microenvironment, to cellular plasticity have made the discovery of unique biomarkers a very difficult task. In fact, contrasting results regarding the applicability of such markers to the isolation of renal CSCs have been reported in the literature. Therefore, a better understanding of the mechanism underlying CSC may help dissecting tumor heterogeneity and drug treatment efficiency.	[Corro, Claudia; Moch, Holger] Univ Hosp Zurich, Dept Pathol & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland	Corro, C (reprint author), Univ Hosp Zurich, Dept Pathol & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	Claudia.Corro@usz.ch		Corro', Claudia/0000-0002-5507-3667			Abbaszadegan MR, 2017, J CELL PHYSIOL, V232, P2008, DOI 10.1002/jcp.25759; Abourbih S, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-298; Addla SK, 2008, AM J PHYSIOL-RENAL, V295, pF680, DOI 10.1152/ajprenal.90286.2008; Angelotti ML, 2012, STEM CELLS, V30, P1714, DOI 10.1002/stem.1130; Arik D, 2017, PATHOL ONCOL RES, V23, P409, DOI 10.1007/s12253-016-0128-8; Ashkenazi R, 2008, NEOPLASIA, V10, P1170, DOI 10.1593/neo.08572; Atay Safinur, 2014, Commun Integr Biol, V7, pe28231, DOI 10.4161/cib.28231; Baccelli I, 2012, J CELL BIOL, V198, P281, DOI 10.1083/jcb.201202014; Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Baracca A, 2003, BBA-BIOENERGETICS, V1606, P137, DOI 10.1016/S0005-2728(03)00110-5; Basakran NS, 2015, SAUDI MED J, V36, P273, DOI 10.15537/smj.2015.3.9622; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Bertoncello Ivan, 2004, Methods Mol Biol, V263, P181; Bhatt JR, 2014, NAT REV UROL, V11, P517, DOI [10.1038/nruro1.2014.194, 10.1038/nrurol.2014.194]; Bielecka ZF, 2017, BIOL REV, V92, P1505, DOI 10.1111/brv.12293; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bourkoula E, 2014, STEM CELLS, V32, P1239, DOI 10.1002/stem.1605; Breyer MD, 2016, NAT REV DRUG DISCOV, V15, P568, DOI 10.1038/nrd.2016.67; Bruno S, 2006, AM J PATHOL, V169, P2223, DOI 10.2353/ajpath.2006.060498; Busillo JM, 2007, BBA-BIOMEMBRANES, V1768, P952, DOI 10.1016/j.bbamem.2006.11.002; Bussolati B, 2005, AM J PATHOL, V166, P545, DOI 10.1016/S0002-9440(10)62276-6; Bussolati B, 2008, FASEB J, V22, P3696, DOI 10.1096/fj.08-102590; Bussolati B, 2015, NAT REV NEPHROL, V11, P695, DOI 10.1038/nrneph.2015.126; Bussolati B, 2013, CANCER LETT, V338, P141, DOI 10.1016/j.canlet.2012.05.007; Cabarcas SM, 2011, INT J CANCER, V129, P2315, DOI 10.1002/ijc.26312; Campbell SC, 2013, RENAL CELL CARCINOMA; Carnero A, 2016, BIOESSAYS, V38, pS65, DOI 10.1002/bies.201670911; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chen KG, 2005, PIGM CELL RES, V18, P102, DOI 10.1111/j.1600-0749.2005.00214.x; Cheng B, 2016, ONCOTARGET, V7, P65862, DOI 10.18632/oncotarget.11672; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Corti S, 2006, STEM CELLS, V24, P975, DOI 10.1634/stemcells.2005-0217; Dallas NA, 2008, CLIN CANCER RES, V14, P1931, DOI 10.1158/1078-0432.CCR-07-4478; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911-009-9109-9; Debeb BG, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-180; Dekel B, 2006, CANCER RES, V66, P6040, DOI 10.1158/0008-5472.CAN-05-4528; Delahunt B, 2001, HUM PATHOL, V32, P590, DOI 10.1053/hupa.2001.24984; Deng S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010277; Drost J, 2016, NAT PROTOC, V11, P347, DOI 10.1038/nprot.2016.006; Egeblad M, 2010, CURR OPIN CELL BIOL, V22, P697, DOI 10.1016/j.ceb.2010.08.015; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Fang XF, 2010, CELL MOL IMMUNOL, V7, P100, DOI 10.1038/cmi.2009.119; Feng G, 2014, UROL ONCOL, V32; Fonsatti E, 2004, J TRANSL MED, V2, P18, DOI DOI 10.1186/1479-5876-2-18; Frew IJ, 2015, ANNU REV PATHOL-MECH, V10, P263, DOI 10.1146/annurev-pathol-012414-040306; Galleggiante V, 2014, J UROLOGY, V192, P1831, DOI 10.1016/j.juro.2014.06.070; Gao MQ, 2010, ONCOGENE, V29, P2672, DOI 10.1038/onc.2010.35; Gassenmaier M, 2013, STEM CELLS, V31, P1467, DOI 10.1002/stem.1407; Gerstung M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1814; Golebiewska A, 2011, CELL STEM CELL, V8, P136, DOI 10.1016/j.stem.2011.01.007; Goodell MA, 2005, CURR PROTOC CYTOM, V9, P9; Grange C, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-2025-z; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Greve B, 2012, CYTOM PART A, V81A, P284, DOI 10.1002/cyto.a.22022; Grosse-Gehling P, 2013, J PATHOL, V229, P355, DOI 10.1002/path.4086; Hermann PC, 2010, SEMIN CANCER BIOL, V20, P77, DOI 10.1016/j.semcancer.2010.03.004; Hill RP, 2006, CANCER RES, V66, P1891, DOI 10.1158/0008-5472.CAN-05-3450; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Hu P, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00116; Hu YB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125625; Huang B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068293; Huling J, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0339-7; Humphreys BD, 2015, AM J PHYSIOL-RENAL, V308, pF29, DOI 10.1152/ajprenal.00538.2014; Humphreys BD, 2014, CURR OPIN NEPHROL HY, V23, P25, DOI 10.1097/01.mnh.0000437332.31418.e0; Jaggupilli A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/708036; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Jung T, 2009, NEOPLASIA, V11, P1093, DOI 10.1593/neo.09822; Kalisky T, 2011, NAT METHODS, V8, P311, DOI [10.1038/nmeth0411-311, 10.1038/nmeth0411-308]; KASTAN MB, 1990, BLOOD, V75, P1947; Kern SE, 2007, CANCER RES, V67, P8985, DOI 10.1158/0008-5472.CAN-07-1971; Khan MI, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165718; Khan MI, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0177-z; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kretzschmar K, 2012, CELL, V148, P33, DOI 10.1016/j.cell.2012.01.002; Kumar D, 2015, ONCOTARGET, V6, P3280, DOI 10.18632/oncotarget.2462; Kurosawa H, 2007, J BIOSCI BIOENG, V103, P389, DOI 10.1263/jbb.103.389; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lazzeri E, 2007, J AM SOC NEPHROL, V18, P3128, DOI 10.1681/ASN.2007020210; Li XT, 2015, SCI REP-UK, V5, DOI 10.1038/srep13157; Li Z, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-17; Lichner Z, 2015, ONCOTARGET, V6, P5567, DOI 10.18632/oncotarget.1901; Lin RZ, 2013, MOL CELL BIOCHEM, V383, P13, DOI 10.1007/s11010-013-1746-z; Liu C, 2011, CANCER RES, V71, P5950, DOI 10.1158/0008-5472.CAN-11-1035; Lu JZ, 2013, ONCOL LETT, V5, P1903, DOI 10.3892/ol.2013.1270; Ma CY, 2016, CANCER SCI, V107, P700, DOI 10.1111/cas.12917; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Maeda K, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071025; Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563; Messer J, 2013, ADV EXP MED BIOL, V779, P291, DOI 10.1007/978-1-4614-6176-0_13; Micucci C, 2015, BRIT J CANCER, V113, P1178, DOI 10.1038/bjc.2015.338; Mikami S, 2015, INT J CANCER, V136, P1504, DOI 10.1002/ijc.29137; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; Moch H., 2016, WHO CLASSIFICATION T, V8, P400; Moch H., 2014, WORLD CANC REPORT 20; Moch H, 2015, CURR DRUG TARGETS, V16, P125, DOI 10.2174/1389450116666150126110632; Moch H, 2013, SEMIN CANCER BIOL, V23, P3, DOI 10.1016/j.semcancer.2012.06.006; Moghbeli M, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0069-6; Myszczyszyn A, 2015, STEM CELL REV REP, V11, P919, DOI 10.1007/s12015-015-9611-y; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; Nishizawa S, 2012, CANCER RES, V72, P2844, DOI 10.1158/0008-5472.CAN-11-3062; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oliver JA, 2016, STEM CELL REP, V6, P757, DOI 10.1016/j.stemcr.2016.03.008; Oliver JA, 2009, J AM SOC NEPHROL, V20, P2315, DOI 10.1681/ASN.2008111203; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Ozbek Emin, 2012, Arch Ital Urol Androl, V84, P7; Park EK, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.313; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Pauli C, 2017, CANCER DISCOV, V7, P462, DOI 10.1158/2159-8290.CD-16-1154; Peired AJ, 2016, STEM CELLS INT, DOI 10.1155/2016/4798639; Peired AJ, 2016, STEM CELLS INT, DOI 10.1155/2016/8342625; Peng L, 2016, ONCOTARGET, V7, P42007, DOI 10.18632/oncotarget.9751; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Pleniceanu O, 2010, STEM CELLS, V28, P1649, DOI 10.1002/stem.486; Pode-Shakked N, 2009, J CELL MOL MED, V13, P1792, DOI 10.1111/j.1582-4934.2008.00607.x; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4; Resetkova E, 2010, BREAST CANCER RES TR, V123, P97, DOI 10.1007/s10549-009-0619-3; Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Ronconi E, 2009, J AM SOC NEPHROL, V20, P322, DOI 10.1681/ASN.2008070709; Rosenberg ME, 2007, J AM SOC NEPHROL, V18, P3018, DOI 10.1681/ASN.2007101106; Rycaj K, 2015, CANCER RES, V75, P4003, DOI 10.1158/0008-5472.CAN-15-0798; Sagrinati C, 2006, J AM SOC NEPHROL, V17, P2443, DOI 10.1681/ASN.2006010089; Sahlberg SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094621; Salcido CD, 2010, BRIT J CANCER, V102, P1636, DOI 10.1038/sj.bjc.6605668; Saroufim A, 2014, BRIT J CANCER, V110, P1778, DOI 10.1038/bjc.2014.71; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Song L, 2017, ONCOTARGET, V8, P31977, DOI 10.18632/oncotarget.16667; SPEICHER MR, 1994, AM J PATHOL, V145, P356; Struckmann K, 2008, J PATHOL, V214, P464, DOI 10.1002/path.2310; Sun CY, 2012, J CANCER RES CLIN, V138, P1619, DOI 10.1007/s00432-012-1237-8; Thapa R, 2016, STEM CELLS INT, DOI 10.1155/2016/2087204; Thoma CR, 2014, ADV DRUG DELIVER REV, V69, P29, DOI 10.1016/j.addr.2014.03.001; Ueda K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075463; Varna M, 2015, CLIN CANCER RES, V21, P916, DOI 10.1158/1078-0432.CCR-14-0666; Vieyra DS, 2009, STEM CELLS DEV, V18, P1155, DOI 10.1089/scd.2008.0391; Vikram R, 2009, RADIOGRAPHICS, V29, P741, DOI 10.1148/rg.293085190; Vikram R, 2009, RADIOGRAPHICS, V29, P757; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wang M, 2014, BRIT J CANCER, V110, P1199, DOI 10.1038/bjc.2014.14; Weiswald LB, 2015, NEOPLASIA, V17, P1, DOI 10.1016/j.neo.2014.12.004; Wilson BJ, 2014, CANCER RES, V74, P4196, DOI 10.1158/0008-5472.CAN-14-0582; World Health Organization Classification of Tumours, 2004, PATHOLOGY GENETICS T; Xiao W, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0507-3; Yamashita M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146501; YUHAS JM, 1977, CANCER RES, V37, P3639; Yun EJ, 2016, CLIN CANCER RES, V22, P670, DOI 10.1158/1078-0432.CCR-15-0190; Zhang YH, 2013, J SURG ONCOL, V108, P414, DOI 10.1002/jso.23402; Zhong Li-ye, 2011, Nan Fang Yi Ke Da Xue Xue Bao, V31, P854; Zhong Y, 2010, CANCER LETT, V299, P150, DOI 10.1016/j.canlet.2010.08.013; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	161	13	14	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	JAN	2018	4	1					3	18		10.1002/cjp2.91			16	Pathology	Pathology	FT7OU	WOS:000423343200001	29416873	DOAJ Gold, Green Published			2019-10-28	
J	Bollweg, BC; Silva-Flannery, L; Spivey, P; Hale, GL				Bollweg, Brigid C.; Silva-Flannery, Luciana; Spivey, Pamela; Hale, Gillian L.			Optimization of commercially available Zika virus antibodies for use in a laboratory-developed immunohistochemical assay	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						Zika virus; immunohistochemistry; antibody; pathology; placenta; fetal demise; microcephaly	CHIKUNGUNYA; INFECTION; PATHOLOGY; BRAZIL; BRAIN	Zika virus (ZIKV) infection during pregnancy can cause adverse fetal outcomes and severe irreversible congenital birth defects including microcephaly. Immunohistochemistry (IHC) is a valuable diagnostic tool for detecting ZIKV antigens in tissues from cases of fetal loss in women infected with ZIKV, and for providing insights into disease pathogenesis. As a result, there is increasing demand for commercially available ZIKV antibodies for use in IHC assays. ZIKV antibodies were selected and obtained from commercial sources to include both mouse and rabbit hosts, and a variety of antigenic targets. Pretreatment conditions and antibody concentrations resulting in optimal immunohistochemical staining were determined using ZIKV cell control and polymerase chain reaction (PCR)-confirmed ZIKV case control material (fetal brain tissue). Cross-reactivity of the antibodies against other flaviviruses (dengue virus serogroups 1-4, yellow fever virus, Japanese encephalitis virus, West Nile virus) and chikungunya virus was also evaluated. Immunostaining using the commercially available antibodies was compared to a previously validated ZIKV IHC assay used for primary diagnosis. Four antibodies demonstrated optimal staining similar to the previously validated ZIKV IHC assay. Two of the four antibodies cross-reacted with dengue virus, while the other two antibodies showed no cross-reactivity with dengue, other flaviviruses, or chikungunya virus. Differences in the cross-reactivity profiles could not be entirely explained by the antigenic target. Commercially available ZIKV antibodies can be optimized for use in IHC testing to aid in ZIKV diagnostic testing and an evaluation of tissue tropism.	[Bollweg, Brigid C.; Silva-Flannery, Luciana; Spivey, Pamela; Hale, Gillian L.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, 1600 Clifton Rd NE,MS G32, Atlanta, GA 30329 USA	Hale, GL (reprint author), Ctr Dis Control & Prevent, Infect Dis Pathol Branch, 1600 Clifton Rd NE,MS G32, Atlanta, GA 30329 USA.	cwx4@cdc.gov					Azevedo RSS, 2016, J CLIN VIROL, V85, P56, DOI 10.1016/j.jcv.2016.10.024; Bhatnagar J, 2017, EMERG INFECT DIS, V23, P405, DOI 10.3201/eid2303.161499; Buchwalow I, 2011, SCI REP-UK, V1, DOI 10.1038/srep00028; de Noronha L, 2016, MEM I OSWALDO CRUZ, V111, P287, DOI 10.1590/0074-02760160085; Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715; Furuya-Kanamori L, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1417-2; Gould EA, 2008, LANCET, V371, P500, DOI 10.1016/S0140-6736(08)60238-X; Jain J, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0543-1; Kawiecki AB, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0749-x; Landry ML, 2017, ARCH PATHOL LAB MED, V141, P60, DOI 10.5858/arpa.2016-0406-SA; Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952; Lindenbach BD, 2003, ADV VIRUS RES, V59, P23, DOI 10.1016/S0065-3527(03)59002-9; Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2; Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1; Miller MA, 2005, J VET DIAGN INVEST, V17, P461, DOI 10.1177/104063870501700509; Ramos-Vara JA, 2005, VET PATHOL, V42, P405, DOI 10.1354/vp.42-4-405; Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338; Ritter JM, 2017, ARCH PATHOL LAB MED, V141, P49, DOI 10.5858/arpa.2016-0397-SA; Rubin EJ, 2016, NEW ENGL J MED, V374, P984, DOI 10.1056/NEJMe1601862; Strauss JH, 2001, CELL, V105, P5, DOI 10.1016/S0092-8674(01)00291-4; Vilches-Moure JG, 2005, J VET DIAGN INVEST, V17, P346, DOI 10.1177/104063870501700407	21	5	5	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA		2056-4538		J PATHOL CLIN RES	J. Pathol. Clin. Res.	JAN	2018	4	1					19	25		10.1002/cjp2.84			7	Pathology	Pathology	FT7OU	WOS:000423343200002	29416874	DOAJ Gold, Green Published			2019-10-28	
J	Farquhar, N; Thornton, S; Coupland, SE; Coulson, JM; Sacco, JJ; Krishna, Y; Heimann, H; Taktak, A; Cebulla, CM; Abdel-Rahman, MH; Kalirai, H				Farquhar, Neil; Thornton, Sophie; Coupland, Sarah E.; Coulson, Judy M.; Sacco, Joseph J.; Krishna, Yamini; Heimann, Heinrich; Taktak, Azzam; Cebulla, Colleen M.; Abdel-Rahman, Mohamed H.; Kalirai, Helen			Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						BAP1; uveal melanoma; prognosis; mutation; immunohistochemistry; cytoplasm; Golgi	DEPENDENT PROBE AMPLIFICATION; BRCA1-ASSOCIATED PROTEIN-1; TUMOR-SUPPRESSOR; UBIQUITIN HYDROLASE; MONOSOMY 3; MUTATIONS; DISEASE; SF3B1; IMMUNOHISTOCHEMISTRY; ANTIBODIES	Uveal melanoma (UM) is a rare aggressive intraocular tumour with a propensity for liver metastases, occurring in similar to 50% of patients. The tumour suppressor BAP1 is considered to be key in UM progression. Herein, we present the largest study to date investigating cellular expression patterns of BAP1 protein in 165 UMs, correlating these patterns to prognosis. Full clinical, histological, genetic, and follow-up data were available for all patients. BAP1 gene sequencing was performed on a subset of 26 cases. An independent cohort of 14 UMs was examined for comparison. Loss of nuclear BAP1 (nBAP1) protein expression was observed in 54% (88/165) UMs. nBAP1 expression proved to be a significant independent prognostic parameter: it identified two subgroups within monosomy 3 (M3) UM, which are known to have a high risk of metastasis. Strikingly, nBAP1-positiveM3 UMs were associated with prolonged survival compared to nBAP1-negative M3 UMs (Log rank, p=0.014). nBAP1 protein loss did not correlate with a BAP1 mutation in 23% (6/26) of the UMs analysed. Cytoplasmic BAP1 protein (cBAP1) expression was also observed in UM: although appearing 'predominantly diffuse' in most nBAP1-negative UM, a distinct 'focal perinuclear' expression pattern - localized immediately adjacent to the cis Golgi - was seen in 31% (18/59). These tumours tended to carry loss-of-function BAP1 mutations. Our study demonstrates loss of nBAP1 expression to be the strongest prognostic marker in UM, confirming its importance in UM progression. Our data suggest that non-genetic mechanisms account for nBAP1 loss in a small number of UMs. In addition, we describe a subset of nBAP1-negative UM, in which BAP1 is sequestered in perinuclear bodies, most likely within Golgi, warranting further mechanistic investigation.	[Farquhar, Neil; Thornton, Sophie; Coupland, Sarah E.; Sacco, Joseph J.; Heimann, Heinrich; Taktak, Azzam; Kalirai, Helen] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Canc Med, Liverpool Ocular Oncol Res Grp, Liverpool, Merseyside, England; [Coupland, Sarah E.; Krishna, Yamini] Royal Liverpool Univ Hosp, Dept Cellular Pathol, Liverpool, Merseyside, England; [Coulson, Judy M.] Univ Liverpool, Inst Translat Med, Dept Cellular & Mol Physiol, Liverpool, Merseyside, England; [Sacco, Joseph J.] Clatterbridge Canc Ctr, Dept Med Oncol, Clatterbridge, England; [Heimann, Heinrich] Royal Liverpool Univ Hosp, Liverpool Ocular Oncol Ctr, Liverpool, Merseyside, England; [Taktak, Azzam] Royal Liverpool Univ Hosp, Dept Med Phys & Clin Engn, Liverpool, Merseyside, England; [Cebulla, Colleen M.; Abdel-Rahman, Mohamed H.] Ohio State Univ, Havener Eye Inst, Dept Ophthalmol & Visual Sci, Columbus, OH 43210 USA; [Abdel-Rahman, Mohamed H.] Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA	Coupland, SE (reprint author), Dept Mol & Clin Canc Med, 3rd Floor William Henry Duncan Bldg, Liverpool L7 8TX, Merseyside, England.	s.e.coupland@liverpool.ac.uk	; Abdel-Rahman, Mohamed/A-8197-2013	Thornton, Sophie/0000-0001-7693-7279; Coupland, Sarah/0000-0002-1464-2069; Abdel-Rahman, Mohamed/0000-0002-9493-7894	Fight for Sight UK [1497/98]; Eye Tumour Research Fund; RLBUHT; NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [K08EY022672]; Ohio Lions Eye Research Foundation; Patti Blow Fund	Finally, we would like to acknowledge funding from Fight for Sight UK (1497/98) and from the Eye Tumour Research Fund, RLBUHT, who are funding the PhD studentships of Neil Farquhar and Sophie Thornton, respectively. Colleen Cebulla is supported by NEI Award Number K08EY022672. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding institutions. Additional funds were provided by the Ohio Lions Eye Research Foundation and the Patti Blow Fund.	Abdel-Rahman MH, 2012, EXP EYE RES, V100, P26, DOI 10.1016/j.exer.2012.04.010; Abdel-Rahman MH, 2011, J MED GENET, V48, P856, DOI 10.1136/jmedgenet-2011-100156; Al-Shamsi HO, 2016, J GASTROINTEST ONCOL, V7, P556, DOI 10.21037/jgo.2016.03.05; Bhattacharya S, 2015, SCI REP-UK, V5, DOI 10.1038/srep18462; Bononi A, 2017, NATURE, V546, P549, DOI 10.1038/nature22798; Caines R, 2015, MOL VIS, V21, P1; Carvajal RD, 2017, BRIT J OPHTHALMOL, V101, P38, DOI 10.1136/bjophthalmol-2016-309034; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Damato B, 2012, EYE, V26, P1157, DOI 10.1038/eye.2012.126; Damato B, 2007, OPHTHALMOLOGY, V114, P1925, DOI 10.1016/j.ophtha.2007.06.012; Damato B, 2011, PROG RETIN EYE RES, V30, P285, DOI 10.1016/j.preteyeres.2011.05.003; Damato B, 2009, INVEST OPHTH VIS SCI, V50, P3048, DOI 10.1167/iovs.08-3165; DeParis SW, 2016, INVEST OPHTH VIS SCI, V57, P6116, DOI 10.1167/iovs.16-19654; Dono M, 2014, BRIT J CANCER, V110, P1058, DOI 10.1038/bjc.2013.804; Dopierala J, 2010, INVEST OPHTH VIS SCI, V51, P4898, DOI 10.1167/iovs.09-5004; Dvinge H, 2016, NAT REV CANCER, V16, P413, DOI 10.1038/nrc.2016.51; Eletr ZM, 2011, CELL BIOCHEM BIOPHYS, V60, P3, DOI 10.1007/s12013-011-9184-6; FINSTAD CL, 1991, J HISTOCHEM CYTOCHEM, V39, P1603, DOI 10.1177/39.12.1682363; Gammon B, 2013, J CUTAN PATHOL, V40, P538, DOI 10.1111/cup.12133; Hakiri S, 2015, CANCER SCI, V106, P990, DOI 10.1111/cas.12698; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Hausler T, 2005, INT J CANCER, V116, P909, DOI 10.1002/ijc.21086; HORSMAN DE, 1990, CANCER GENET CYTOGEN, V45, P249, DOI 10.1016/0165-4608(90)90090-W; Ismail IH, 2014, CANCER RES, V74, P4282, DOI 10.1158/0008-5472.CAN-13-3109; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kalirai H, 2014, BRIT J CANCER, V111, P1373, DOI 10.1038/bjc.2014.417; Kilic E, 2005, INVEST OPHTH VIS SCI, V46, P2253, DOI 10.1167/iovs.04-1460; KLIMAN HJ, 1995, AM J PATHOL, V146, P166; Koopmans AE, 2014, MODERN PATHOL, V27, P1321, DOI 10.1038/modpathol.2014.43; Lake SL, 2012, INVEST OPHTH VIS SCI, V53, P2647, DOI 10.1167/iovs.12-9584; Machida YJ, 2009, J BIOL CHEM, V284, P34179, DOI 10.1074/jbc.M109.046755; Martin M, 2013, NAT GENET, V45, P933, DOI 10.1038/ng.2674; Mashtalir N, 2014, MOL CELL, V54, P392, DOI 10.1016/j.molcel.2014.03.002; McCarthy C, 2016, PIGM CELL MELANOMA R, V29, P60, DOI 10.1111/pcmr.12433; Misaghi S, 2009, MOL CELL BIOL, V29, P2181, DOI 10.1128/MCB.01517-08; Nishikawa H, 2009, CANCER RES, V69, P111, DOI 10.1158/0008-5472.CAN-08-3355; Ouwendijk WJD, 2012, J NEUROVIROL, V18, P172, DOI 10.1007/s13365-012-0095-0; Pilarski R, 2014, GENE CHROMOSOME CANC, V53, P177, DOI 10.1002/gcc.22129; Pins A, 2015, HUM PATHOL, V46, P239, DOI 10.1016/j.humpath.2014.10.015; Prescher G, 1996, LANCET, V347, P1222; Rai K, 2016, CLIN GENET, V89, P285, DOI 10.1111/cge.12630; Rai K, 2017, GENE CHROMOSOME CANC, V56, P168, DOI 10.1002/gcc.22424; Righi L, 2016, J THORAC ONCOL, V11, P2006, DOI 10.1016/j.jtho.2016.06.020; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Royer-Bertrand B, 2016, AM J HUM GENET, V99, P1190, DOI 10.1016/j.ajhg.2016.09.008; Sahtoe DD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10292; Schueren F, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006196; SISLEY K, 1992, GENE CHROMOSOME CANC, V5, P197, DOI 10.1002/gcc.2870050304; Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912; Tschentscher F, 2001, CANCER RES, V61, P3439; van de Nes JAP, 2016, AM J SURG PATHOL, V40, P796, DOI 10.1097/PAS.0000000000000645; van Essen TH, 2014, BRIT J OPHTHALMOL, V98, P1738, DOI 10.1136/bjophthalmol-2014-305047; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Virgili G, 2007, OPHTHALMOLOGY, V114, P2309, DOI 10.1016/j.ophtha.2007.01.032; Woodman SE, 2012, CANCER J, V18, P148, DOI 10.1097/PPO.0b013e31824bd256; Yavuzyigitoglu S, 2016, OPHTHALMOLOGY, V123, P1118, DOI 10.1016/j.ophtha.2016.01.023; Yonekawa Y, 2012, HEMATOL ONCOL CLIN N, V26, P1169, DOI 10.1016/j.hoc.2012.08.004; Yu H, 2010, MOL CELL BIOL, V30, P5071, DOI 10.1128/MCB.00396-10; Zhang XK, 2015, INT J CLIN EXP PATHO, V8, P5035	60	11	11	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA		2056-4538		J PATHOL CLIN RES	J. Pathol. Clin. Res.	JAN	2018	4	1					26	38		10.1002/cjp2.86			13	Pathology	Pathology	FT7OU	WOS:000423343200003	29416875	DOAJ Gold, Green Published			2019-10-28	
J	Grigoriadis, A; Gazinska, P; Pai, T; Irhsad, S; Wu, Y; Millis, R; Naidoo, K; Owen, J; Gillett, CE; Tutt, A; Coolen, ACC; Pinder, SE				Grigoriadis, Anita; Gazinska, Patrycja; Pai, Trupti; Irhsad, Sheeba; Wu, Yin; Millis, Rosemary; Naidoo, Kalnisha; Owen, Julie; Gillett, Cheryl E.; Tutt, Andrew; Coolen, Anthonius C. C.; Pinder, Sarah E.			Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						immune and stromal tumour-environment; multivariate distant metastasis free survival analysis; lymph nodes; triple negative breast cancers; lymph node positive breast cancer	TUMOR-INFILTRATING LYMPHOCYTES; SURVIVAL; TISSUE; CHEMOTHERAPY; LOBULITIS; WOMEN; TRIAL; RISK	The prognostic importance of lymph node (LN) status and tumour-infiltrating lymphocytes (TILs), is well established, particularly TILs in triple negative breast cancers (TNBCs). So far, few studies have interrogated changes in involved and uninvolved LNs and evaluated if their morphological patterns add valuable information for the prediction of disease progression in breast cancer. In a cohort of 309 patients enriched for TNBCs (170/309), we histologically characterised immune and stromal features in primary tumours and associated involved and uninvolved axillary LNs on routine haematoxylin and eosin stained sections. Of the 309 patients, 143 had LN-positive disease. Twenty-five histopathological features were assessed, including the degree of TIL presence, quantitative and qualitative assessment of germinal centres (GCs) and sinus histiocytosis. Multivariate and cross-validated proportional hazard regression analyses were used to identify optimal covariate sets for prediction of distant metastasis-free survival (DMFS). The degree of intratumoural and peritumoural immune infiltrate was associated with architectural changes in both uninvolved and involved LNs. By including clinicopathological characteristics as well as tumour and LN histopathological features in L2-regularised proportional hazard models, the prediction of 5-year DMFS was improved by 3-15% over the baseline in all cancers and in TNBCs. In LN-positive cancers, the combination of Salgado's classification, lymphocytic lobulitis, size and number of GCs in the uninvolved LNs and location of GCs in the involved LNs carried significant prognostic information. From these features, a multivariate cross-validation-stable risk signature was constructed, which identified low-risk groups within both LN-positive breast cancers and the LN-positive TNBCs group with a 10-year DMFS probability of 78 and 87%, respectively. This study illustrates that, by incorporating histopathological patterns of involved and uninvolved LNs combined with primary tumour immune and stromal features, the prediction of developing distant metastasis in LN-positive breast cancers can be estimated more accurately.	[Grigoriadis, Anita; Gazinska, Patrycja; Irhsad, Sheeba; Wu, Yin; Tutt, Andrew] Kings Coll London, Guys Hosp, Fac Life Sci & Med, Breast Canc Now Res Unit,Innovat Hub,Canc Ctr, London, England; [Grigoriadis, Anita; Gazinska, Patrycja; Pai, Trupti; Irhsad, Sheeba; Millis, Rosemary; Owen, Julie; Gillett, Cheryl E.; Tutt, Andrew; Pinder, Sarah E.] Kings Coll London, Sch Canc & Pharmaceut Sci, CRUK Kings Hlth Partners Ctr, Innovat Hub,Canc Ctr,Guys Hosp, London, England; [Grigoriadis, Anita; Pai, Trupti] Kings Coll London, Guys Hosp, Ctr Canc, Innovat Hub,Canc Bioinformat, London SE1 9RT, England; [Pai, Trupti] Tata Mem Hosp, Dept Pathol, Tata Mem Ctr, Bombay, Maharashtra, India; [Wu, Yin] Kings Coll London, Guys Hosp, Peter Gorer Dept Immunobiol, Borough Wing, London, England; [Naidoo, Kalnisha; Tutt, Andrew] Inst Canc Res, Breast Canc Now, London, England; [Coolen, Anthonius C. C.] Kings Coll London, Inst Math & Mol Biomed, Hodgkin Bldg,Guys Campus, London, England	Grigoriadis, A (reprint author), Kings Coll London, Guys Hosp, Ctr Canc, Innovat Hub,Canc Bioinformat, London SE1 9RT, England.	anita.grigoriadis@kcl.ac.uk		Grigoriadis, Anita/0000-0003-3434-201X	Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award; Experimental Cancer Centre at King's College London; Breast Cancer Now Unit at King's College London; National Institute for Health Research Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust; King's College London	Patient samples and data were provided by King's Health Partners Cancer Biobank, which is supported by the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award and the Experimental Cancer Centre at King's College London. We thank Professor Agamemnon Grigoriadis for helping with the figures. PG, SI, AG, and AT were supported by Breast Cancer Now Unit (former known as Breakthrough Breast Cancer Research) funding at King's College London and by the National Institute for Health Research Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London.	CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; CULTER S J, 1963, Cancer, V16, P1589; Degnim AC, 2014, BREAST CANCER RES TR, V144, P539, DOI 10.1007/s10549-014-2896-8; Denkert C, 2015, J CLIN ONCOL, V33, P983, DOI 10.1200/JCO.2014.58.1967; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Fan J, 2010, BORROWING STRENGTH T; Gazinska P, 2013, MODERN PATHOL, V26, P955, DOI 10.1038/modpathol.2012.244; Gu-Trantien C, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26066; Gulbahce HE, 2014, HUM PATHOL, V45, P78, DOI 10.1016/j.humpath.2013.08.008; Hermsen BBJ, 2005, J PATHOL, V206, P220, DOI 10.1002/path.1774; Irshad S, 2012, BREAST CARE, V7, P273, DOI 10.1159/000341529; Kohrt HE, 2005, PLOS MED, V2, P904, DOI 10.1371/journal.pmed.0020284; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; McGale P, 2014, LANCET, V383, P2127, DOI 10.1016/S0140-6736(14)60488-8; Moons KGM, 2004, J CLIN EPIDEMIOL, V57, P1262, DOI 10.1016/j.jclinepi.2004.01.020; Pruneri G, 2016, BREAST CANCER RES TR, V158, P323, DOI 10.1007/s10549-016-3863-3; Riedel A, 2016, NAT IMMUNOL, V17, P1118, DOI 10.1038/ni.3492; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Simon RM, 2011, BRIEF BIOINFORM, V12, P203, DOI 10.1093/bib/bbr001; van Houwelingen HC, 2006, STAT MED, V25, P3201, DOI 10.1002/sim.2353; Weaver DL, 2011, NEW ENGL J MED, V364, P412, DOI 10.1056/NEJMoa1008108; Witten DM, 2010, STAT METHODS MED RES, V19, P29, DOI 10.1177/0962280209105024	24	2	2	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA		2056-4538		J PATHOL CLIN RES	J. Pathol. Clin. Res.	JAN	2018	4	1					39	54		10.1002/cjp2.87			16	Pathology	Pathology	FT7OU	WOS:000423343200004	29416876	DOAJ Gold, Green Published			2019-10-28	
J	Zepp, M; Kovacheva, M; Altankhuyag, M; Westphal, G; Berger, I; Gather, KS; Hilbig, H; Neuhaus, J; Hansch, GM; Armbruster, FP; Berger, MR				Zepp, Michael; Kovacheva, Marineta; Altankhuyag, Munkhtsetseg; Westphal, Gabriela; Berger, Irina; Gather, Katharina S.; Hilbig, Heidegard; Neuhaus, Jochen; Haensch, Gertrud M.; Armbruster, Franz P.; Berger, Martin R.			IDK1 is a rat monoclonal antibody against hypoglycosylated bone sialoprotein with application as biomarker and therapeutic agent in breast cancer skeletal metastasis	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						hypoglycosylated bone sialoprotein; biomarker; immunohistochemical method; immunocytochemistry	COLONY FORMATION; FACTOR-H; OSTEOPONTIN; EXPRESSION; BINDING; GLYCOPROTEINS; DENOSUMAB; MIGRATION; CELLS; MODEL	Changes in glycosylation are salient features of cancer cells. Here, we report on the diagnostic and therapeutic properties of IDK1, an antibody against tumour associated, hypoglycosylated bone sialoprotein (hypo-BSP). The affinity of the rat monoclonal antibody IDK1 for hypo-BSP, as determined by microscale thermophoresis, was three orders of magnitude higher than for mature BSP, whereas the mouse monoclonal antibody used had similar affinity for both BSP forms. IDK1 showed no activity against the proliferation or migration of normal or cancer cells growing in vitro. In vivo, however, IDK1 caused dose-dependent regression of soft tissue and skeletal lesions in nude rats harbouring human MDA-MB-231 cells. At optimal dose, 80% of the treated rats showed complete remission of all tumour lesions. Analysis of BSP expression in vitro by fluorescence-activated cell sorting (FACS) and immunocytochemistry showed basal levels of this protein, which were visible only in a fraction of these cells. Cells of the metastatic cell lines MDA-MB-231 and PC-3 were more often positive for hypo-BSP. In addition, there was co-expression of both forms in some cells, but almost no co-localization; rather, hypo-BSP was present in the nucleus, and mature BSP was detected extra-cellularly. Normal osteoblasts and osteoclasts were negative for hypo-BSP. Breast cancer tissue, however, showed strong expression of mature BSP, which was present intra-cellularly as well as in vesicles outside cells. Hypo-BSP was present mainly in lesions from skeletal sites, thus explaining the antineoplastic activity of IDK1, which was high in lesions growing in the vicinity of the skeleton but low in lesions growing subcutaneously. Finally, hypo-BSP was detected in specimens from breast cancer patients, with a significantly greater intensity in skeletal metastases as compared to the respective primary cancers. In conclusion, IDK-1 is an antibody with diagnostic and therapeutic applications in skeletal metastases of breast cancer.	[Zepp, Michael; Kovacheva, Marineta; Berger, Martin R.] German Canc Res Ctr, Toxicol & Chemotherapy Unit, Neuenheimer Feld 581, D-69120 Heidelberg, Germany; [Altankhuyag, Munkhtsetseg; Westphal, Gabriela; Berger, Irina] Klinikum Kassel, Inst Pathol, Kassel, Germany; [Gather, Katharina S.; Hilbig, Heidegard] Univ Leipzig, Inst Anat, Leipzig, Germany; [Neuhaus, Jochen] Univ Hosp, Urol Clin, Leipzig, Germany; [Haensch, Gertrud M.] Univ Hosp Heidelberg, Inst Immunol, Heidelberg, Germany; [Armbruster, Franz P.] Immundiagnostik AG, Bensheim, Germany	Berger, MR (reprint author), German Canc Res Ctr, Toxicol & Chemotherapy Unit, Neuenheimer Feld 581, D-69120 Heidelberg, Germany.	m.berger@dkfz.de			Federal Ministry for Education and ResearchFederal Ministry of Education & Research (BMBF) [0315855]	This study was supported by a grant from the Federal Ministry for Education and Research (#0315855).	Adwan H, 2004, INT J ONCOL, V24, P1235; Adwan H, 2004, CANCER GENE THER, V11, P109, DOI 10.1038/sj.cgt.7700659; Bauerle T, 2008, NEOPLASIA, V10, P511, DOI 10.1593/neo.08220; Bauerle T, 2011, INT J CANCER, V128, P2453, DOI 10.1002/ijc.25563; Bauerle T, 2005, INT J CANCER, V115, P177, DOI 10.1002/ijc.20840; Bellahcene A, 1996, INT J CANCER, V69, P350; Bellahcene A, 1998, THYROID, V8, P637, DOI 10.1089/thy.1998.8.637; Bellahcene A, 2008, NAT REV CANCER, V8, P212, DOI 10.1038/nrc2345; Chen SH, 2000, CANCER RES, V60, P3013; Cornelissen LAM, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6020026; Dapunt U, 2015, J LEUKOCYTE BIOL, V98, P575, DOI 10.1189/jlb.3VMA1014-482R; Diel IJ, 1999, CLIN CANCER RES, V5, P3914; Fedarko NS, 2000, J BIOL CHEM, V275, P16666, DOI 10.1074/jbc.M001123200; Fortunato F, 2007, J PATHOL, V213, P441, DOI 10.1002/path.2243; Gillespie MT, 1997, INT J CANCER, V73, P812; Kailemia MJ, 2017, ANAL BIOANAL CHEM, V409, P395, DOI 10.1007/s00216-016-9880-6; Karadag A, 2006, J BONE MINER RES, V21, P1627, DOI 10.1359/JBMR.060710; Kirwan A, 2015, BIOMED RES INT, DOI 10.1155/2015/490531; Kovacheva M, 2014, ONCOTARGET, V5, P5510, DOI 10.18632/oncotarget.2132; Kruger TE, 2014, CRIT REV ONCOL HEMAT, V89, P330, DOI 10.1016/j.critrevonc.2013.08.013; Lipton A, 2016, EUR J CANCER, V53, P75, DOI 10.1016/j.ejca.2015.09.011; Mukhopadhyay P, 2011, BBA-REV CANCER, V1815, P224, DOI 10.1016/j.bbcan.2011.01.001; Parente R, 2017, CELL MOL LIFE SCI, V74, P1605, DOI 10.1007/s00018-016-2418-4; Pervaiz A, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0607-x; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Reufsteck C, 2012, CLIN EXP METASTAS, V29, P441, DOI 10.1007/s10585-012-9462-8; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; Sanmamed MF, 2016, ANN ONCOL, V27, P1190, DOI 10.1093/annonc/mdw041; Schieferdecker A, 2014, ONCOTARGET, V5, P6647, DOI 10.18632/oncotarget.2160; Uccello M, 2011, J CANCER RES THER, V7, P115, DOI 10.4103/0973-1482.82912; Waltregny D, 1998, J NATL CANCER I, V90, P1000, DOI 10.1093/jnci/90.13.1000; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200; Zepp M, 2012, BREAST CANC CURRENT, P453	34	3	3	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	JAN	2018	4	1					55	68		10.1002/cjp2.88			14	Pathology	Pathology	FT7OU	WOS:000423343200005	29416877	DOAJ Gold, Green Published			2019-10-28	
J	Chui, MH; Have, C; Hoang, LN; Shaw, P; Lee, CH; Clarke, BA				Chui, M. Herman; Have, Cherry; Hoang, Lien N.; Shaw, Patricia; Lee, Cheng-Han; Clarke, Blaise A.			Genomic profiling identifies GPC5 amplification in association with sarcomatous transformation in a subset of uterine carcinosarcomas	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						carcinosarcoma; Malignant Mixed Mullerian Tumour; copy number alterations; gene amplification; transdifferentiation; epithelial-mesenchymal transition	ENDOMETRIAL CARCINOMA; OVARIAN-CANCER; TRANSITION; GENES	Uterine carcinosarcoma, also known as Malignant Mixed Mullerian Tumour, is a high-grade biphasic neoplasm composed of sarcomatous elements thought to originate via transdifferentiation from high-grade endometrial carcinoma. To identify molecular factors contributing to the histogenesis of this tumour, we analyzed DNA extracted from matched carcinoma and sarcoma components from 12 cases of carcinosarcoma by a molecular inversion probe microarray to assess genomic copy number alterations (CNAs) and allelic imbalances. Widespread CNAs were identified in tumours with serous histology in the carcinoma component (9/12), while the remaining three cases with endometrioid carcinoma were near-diploid. Quantification of the extent of genomic aberrations revealed a significant increase in sarcoma relative to carcinoma in tumours with well-delineated histologic components. Focal amplification of 13q31.3 was identified in 6/12 profiled tumours, of which four harboured the aberration exclusively in the sarcoma component. This result was verified by fluorescence in situ hybridization against GPC5, the only gene situated within the minimal region of amplification. In a validation cohort composed of 97 carcinosarcomas and other uterine sarcomas, amplification of GPC5 (GPC5/CEP13 ratio >= 2.2) was identified in 11/97 (11.3%) cases (9/64 carcinosarcoma, 1/3 rhabdomyosarcoma, 1/21 leiomyosarcoma, 0/8 adenosarcoma, 0/1 undifferentiated endometrial sarcoma) and an additional 4 (2.8%) cases had low level gains (GPC5/CEP13 ratio >= 1.5 but <2.2). The functional relevance of Glypican-5, the gene product of GPC5, in regulating differentiation and lineage commitment was demonstrated in an endometrial carcinoma cell line in vitro. In conclusion, we identified GPC5 amplification as a molecular event mediating epithelial-mesenchymal transdifferentiation in a subset of uterine carcinosarcomas.	[Chui, M. Herman; Have, Cherry; Shaw, Patricia; Clarke, Blaise A.] Univ Toronto, Univ Hlth Network, Dept Pathol, Toronto, ON, Canada; [Hoang, Lien N.; Lee, Cheng-Han] Univ British Columbia, BC Canc Agcy, Dept Pathol, Vancouver, BC, Canada	Chui, MH (reprint author), Univ Hlth Network, Dept Pathol, 200 Elizabeth St,11th Floor, Toronto, ON, Canada.	michaelherman.chui@utoronto.ca			PSI Resident Research Grant; United States and Canadian Academy of Pathology	This work was funded by a PSI Resident Research Grant awarded to MHC and was acknowledged with the 2017 Stowell-Orbison Award by the United States and Canadian Academy of Pathology.	Bayani J, 2008, NEOPLASIA, V10, P1057, DOI 10.1593/neo.08584; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Byrne Jennifer A, 2012, Genes Cancer, V3, P87, DOI 10.1177/1947601912456287; Chui MH, 2013, INT J CANCER, V132, P1487, DOI 10.1002/ijc.27745; Cope L, 2013, GYNECOL ONCOL, V128, P500, DOI 10.1016/j.ygyno.2012.11.031; Faruqi SA, 2002, CANCER GENET CYTOGEN, V138, P44, DOI 10.1016/S0165-4608(01)00658-6; Foster JM, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0079-z; Garg K, 2009, J CLIN PATHOL, V62, P679, DOI 10.1136/jcp.2009.064949; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gutierrez J, 2010, MOL CELL BIOL, V30, P1634, DOI 10.1128/MCB.01164-09; Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681; Haupt LM, 2009, J CELL PHYSIOL, V220, P780, DOI 10.1002/jcp.21825; Jones S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6006; Kuhn E, 2014, AM J SURG PATHOL, V38, P660, DOI 10.1097/PAS.0000000000000166; Kuhn E, 2012, JNCI-J NATL CANCER I, V104, P1503, DOI 10.1093/jnci/djs345; Li J, 2017, NEOPLASIA, V19, P100, DOI 10.1016/j.neo.2016.12.009; McCluggage WG, 2016, MODERN PATHOL, V29, pS78, DOI 10.1038/modpathol.2015.137; McConechy MK, 2015, J PATHOL CLIN RES, V1, P173, DOI 10.1002/cjp2.18; Seidman JD, 2003, INT J GYNECOL PATHOL, V22, P75, DOI 10.1097/01.PGP.0000040089.04359.AD; Tseng JH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03972-7; Williamson D, 2007, CANCER RES, V67, P57, DOI 10.1158/0008-5472.CAN-06-1650; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Zhao SM, 2016, P NATL ACAD SCI USA, V113, P12238, DOI 10.1073/pnas.1614120113	23	4	4	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	JAN	2018	4	1					69	78		10.1002/cjp2.89			10	Pathology	Pathology	FT7OU	WOS:000423343200006	29416878	DOAJ Gold, Green Published			2019-10-28	
J	Brun, LVC; Roux, JJ; Sopoh, GE; Aguiar, J; Eddyani, M; Meyers, WM; Stubbe, D; Akpo, MTA; Portaels, F; de Jong, BC				Brun, Luc V. C.; Roux, Jean Jacques; Sopoh, Ghislain E.; Aguiar, Julia; Eddyani, Miriam; Meyers, Wayne M.; Stubbe, Dirk; Akpo, Marie T. Akele; Portaels, Francoise; de Jong, Bouke C.			Subcutaneous Granulomatous Inflammation due to Basidiobolomycosis: Case Reports of 3 Patients in Buruli Ulcer Endemic Areas in Benin	CASE REPORTS IN PATHOLOGY			English	Article							SPLENDORE-HOEPPLI PHENOMENON; GASTROINTESTINAL BASIDIOBOLOMYCOSIS; SOUTHERN BENIN; ITRACONAZOLE; HAPTOSPORUS; ZYGOMYCOSIS; DIAGNOSIS; DISEASE	Background. Basidiobolomycosis is a rare subcutaneous mycosis, which can be mistaken for several other diseases, such as soft tissue tumors, lymphoma, or Buruli ulcer in the preulcerative stage. Microbiological confirmation by PCR for Basidiobolus ranarum and culture yield the most specific diagnosis, yet they are not widely available in endemic areas and with varying sensitivity. A combination of histopathological findings, namely, granulomatous inflammation with giant cells, septate hyphal fragments, and the Splendore-Hoeppli phenomenon, can confirm basidiobolomycosis in patients presenting with painless, hard induration of soft tissue. Case Presentations. We report on three patients misdiagnosed as suffering from Buruli ulcer, who did not respond to Buruli treatment. Histopathological review of the tissue sections from these patients suggests basidiobolomycosis. All patients had been lost to follow-up, and none received antifungal therapy. On visiting the patients at their homes, two were reported to have died of unknown causes. The third patient was found alive and well and had experienced local spontaneous healing. Conclusion. Basidiobolomycosis is a rare subcutaneous fungal disease mimicking preulcerative Buruli ulcer. We stress the importance of the early recognition by clinicians and pathologists of this treatable disease, so patients can timely receive antifungal therapy.	[Brun, Luc V. C.] Univ Parakou, Sch Med, Dept Pathol, 03 BP 333, Parakou, Benin; [Roux, Jean Jacques] Hosp Chambery, Dept Pathol, Pl Lucien Biset, F-73000 Chambery, France; [Sopoh, Ghislain E.] Buruli Ulcer Treatment Ctr, Allada, Benin; [Sopoh, Ghislain E.] Reg Inst Publ Hlth, Ouidah, Benin; [Aguiar, Julia] Nutr Ctr Gbemontin, Zagnanado, Benin; [Eddyani, Miriam; Portaels, Francoise; de Jong, Bouke C.] Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium; [Meyers, Wayne M.] Armed Forces Inst Pathol, Washington, DC USA; [Stubbe, Dirk] Sci Inst Publ Hlth, BCCM IHEM Biomed Fungi & Yeasts Collect, Brussels, Belgium; [Akpo, Marie T. Akele] Univ Abomey Calavi, Sch Med, Dept Pathol, Cotonou, Benin	Brun, LVC (reprint author), Univ Parakou, Sch Med, Dept Pathol, 03 BP 333, Parakou, Benin.	luc.brun2013@gmail.com		Brun, luc Valere C./0000-0002-6024-3982	SOFI fund from ERC [311725 INTERRUPTB]; UBS Optimus Foundation; Medicor Foundation; SOFI fund from the EWI Ministry	This research was supported by the UBS Optimus and the Medicor Foundations, as well as the SOFI funds from the EWI Ministry and ERC starting Grant 311725 INTERRUPTB to Bouke C. de Jong. The authors are grateful to the families of the patients, who agreed on the publication of this case report. They are also grateful to Paulin Deguenon and Michel Assogbaga from the Nutritional health center "Gbemontin" of Zagnanado and to Thierry Kinkpe for their support.	[Anonymous], 2011, J MYCOLOGIE MED, V21, P221; Atadokpede F, 2017, ANN DERMATOL VENER, V144, P250, DOI 10.1016/j.annder.2016.10.017; Atadokpede F., 2015, ANN DERMATOL VENEROL, V142; Aujoulat I, 2003, TROP MED INT HEALTH, V8, P750, DOI 10.1046/j.1365-3156.2003.01089.x; Barreiros HM, 2013, J DERMATOL CASE REP, V7, P29, DOI 10.3315/jdcr.2013.1134; BASSET A, 1972, Annales de la Societe Belge de Medecine Tropicale, V52, P307; BITTENCOURT AL, 1982, AM J TROP MED HYG, V31, P370, DOI 10.4269/ajtmh.1982.31.370; Charlier P, 2012, AFR HEALTH SCI, V12, P443, DOI 10.4314/ahs.v12i4.7; CHATURVEDI VP, 1984, SABOURAUDIA, V22, P185; CLEMMENSEN OJ, 1991, J CUTAN PATHOL, V18, P293, DOI 10.1111/j.1600-0560.1991.tb01239.x; COREMANS-PELSENEER J, 1972, Annales de la Societe Belge de Medecine Tropicale, V52, P315; Costa Jackson M. L., 2004, An. Bras. Dermatol., V79, P329, DOI 10.1590/S0365-05962004000300009; El-Shabrawi M., 2017, MICROBIOLOGY RES J I, V19, P1; El-Shabrawi MH, 2014, MYCOSES, V57, P138, DOI 10.1111/myc.12231; El-Shabrawi MHF, 2011, J MED MICROBIOL, V60, P1395, DOI 10.1099/jmm.0.028613-0; Gryganskyi AP, 2013, PERSOONIA, V30, P94, DOI 10.3767/003158513X666330; GUGNANI HC, 1980, MYKOSEN, V23, P260; Hussein MR, 2008, J CUTAN PATHOL, V35, P979, DOI 10.1111/j.1600-0560.2008.01045.x; Johnson R C, 2004, Med Trop (Mars), V64, P145; KAMALAM A, 1982, MYKOSEN, V25, P508; Kang JW, 2010, OTOLARYNG HEAD NECK, V142, P456, DOI 10.1016/j.otohns.2009.08.007; Khan ZU, 2001, J CLIN MICROBIOL, V39, P2360, DOI 10.1128/JCM.39.6.2360-2363.2001; Khot PD, 2009, EXPERT REV ANTI-INFE, V7, P1201, DOI 10.1586/ERI.09.104; Kibadi K, 2009, TROP MED INT HEALTH, V14, P1110, DOI 10.1111/j.1365-3156.2009.02324.x; Kombate K, 2012, MED SANTE TROP, V22, P145, DOI 10.1684/mst.2012.0047; Mahe A, 1996, ANN DERMATOL VENER, V123, P182; Mathew R, 2005, INT J DERMATOL, V44, P572, DOI 10.1111/j.1365-4632.2004.02419.x; Mendoza L, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a019562; Nasimfar A., 2016, PAEDIATR INT CHILD H, P1; Nelson RT, 1998, MYCOLOGIA, V90, P761, DOI 10.2307/3761316; Pasha TM, 1997, GASTROENTEROLOGY, V112, P250, DOI 10.1016/S0016-5085(97)70242-7; Rose SR, 2013, MED MYCOL CASE REP, V2, P11, DOI 10.1016/j.mmcr.2012.11.001; Rothhardt JE, 2011, MOLECULAR DETECTION OF HUMAN FUNGAL PATHOGENS, P723; Saka B, 2010, Bull Soc Pathol Exot, V103, P293, DOI 10.1007/s13149-010-0090-8; Sangare A., 2000, MED AFR NOIRE, V47, P8; Sethi Pulkit, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2015-214097; Sivaraman, 1999, INT J DERMATOL, V38, P920, DOI 10.1046/j.1365-4362.1999.00871.x; SPEARE R, 1985, AUST VET J, V62, P209, DOI 10.1111/j.1751-0813.1985.tb07308.x; Vianna LMD, 2005, REV SOC BRAS MED TRO, V38, P348, DOI 10.1590/S0037-86822005000400014; YOSHIKAWA Y, 1988, THORAX, V43, P157, DOI 10.1136/thx.43.2.157	40	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									1351694	10.1155/2018/1351694			6	Pathology	Pathology	FT3YE	WOS:000423084900001	29545962	DOAJ Gold, Green Published			2019-10-28	
J	Chiang, W; Tynski, Z				Chiang, Way; Tynski, Zofia			Primary Peritoneal Angiosarcoma Metastatic to Liver and Bone without History of Radiation Therapy	CASE REPORTS IN PATHOLOGY			English	Article							PACLITAXEL	Angiosarcoma is a rare vascular soft tissue tumor of endothelial origin most commonly seen in the elderly as a primary cutaneous head and neck malignancy. Furthermore, a peritoneal angiosarcoma is an exceedingly rare entity. This is the second case of primary peritoneal angiosarcoma reported in literature that is not associated with prior radiotherapy. Herein, we describe a case of primary peritoneal angiosarcoma metastatic to both the liver and bone in a male patient with metachronous renal cell carcinoma and parathyroid adenoma.	[Chiang, Way] Clarion Hosp, Dept Family Med, 1 Hosp Dr, Clarion, PA 16214 USA; [Tynski, Zofia] Clarion Hosp, Dept Pathol, 1 Hosp Dr, Clarion, PA 16214 USA	Tynski, Z (reprint author), Clarion Hosp, Dept Pathol, 1 Hosp Dr, Clarion, PA 16214 USA.	ztynski@clarionhospital.org		Tynski, Zofia/0000-0001-7105-408X	Lake Erie Consortium for Osteopathic Medical Training (LECOMT); Lake Erie College of Osteopathic Medicine (LECOM)	The authors thank Dr. Jan Silverman, Chair and Director of Anatomic Pathology at Allegheny Health Network, for diagnostic assistance. This study was supported by the Lake Erie College of Osteopathic Medicine (LECOM) and the Lake Erie Consortium for Osteopathic Medical Training (LECOMT).	Abeloff MD, 2008, ABELOFFS CLIN ONCOLO; Chen G, 2016, ONCOL LETT, V11, P2445, DOI 10.3892/ol.2016.4277; Chudecka-Glaz A, 2014, GYNECOL OBSTET INVES, V77, P68, DOI 10.1159/000356690; Guo TH, 2011, GENE CHROMOSOME CANC, V50, P25, DOI 10.1002/gcc.20827; Hung Jennifer, 2013, Sarcoma, P798403, DOI 10.1155/2013/798403; Illert B, 2009, INT J COLORECTAL DIS, V24, P465, DOI 10.1007/s00384-008-0563-4; Litvan J, 2014, ANTICANCER RES, V34, P5001; Penel N, 2008, J CLIN ONCOL, V26, P5269, DOI 10.1200/JCO.2008.17.3146; Seo C. J., 2017, BMJ CASE REPORTS, V2017; Skubitz KM, 2005, CANCER, V104, P361, DOI 10.1002/cncr.21140; Spiker A, 2017, CANC ANGIOSARCOMA; Verma S, 2008, CANCER TREAT REV, V34, P339, DOI 10.1016/j.ctrv.2008.01.005; WESTENBERG AH, 1989, EUR J SURG ONCOL, V15, P175	13	0	0	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									1257284	10.1155/2018/1257284			5	Pathology	Pathology	FT3YD	WOS:000423084700001	29545961	DOAJ Gold, Green Published			2019-10-28	
J	Zhou, DX; Yang, K; Wu, YY; Luan, JJ				Zhou, Dexi; Yang, Kui; Wu, Yuanyuan; Luan, Jiajie			Histone deacetylases inhibition: a potential diagnostic and therapeutic target for cancers	HUMAN PATHOLOGY			English	Letter							MODEL		[Luan, Jiajie] Wannan Med Coll, Yijishan Hosp, Lab Clin Pharm, Wuhu 241001, Anhui, Peoples R China; Wannan Med Coll, Yijishan Hosp, Dept Pharm, Wuhu 241001, Anhui, Peoples R China	Luan, JJ (reprint author), Wannan Med Coll, Yijishan Hosp, Lab Clin Pharm, Wuhu 241001, Anhui, Peoples R China.	luanjiajie757@163.com					Huang PY, 2017, ONCOTARGET, V8, P2694, DOI 10.18632/oncotarget.13738; Klieser E, 2017, HUM PATHOL, V65, P41, DOI 10.1016/j.humpath.2017.02.009; Ler SY, 2015, ONCOL REP, V34, P2238, DOI 10.3892/or.2015.4263; Marampon F, 2017, CANCER LETT, V397, P1, DOI 10.1016/j.canlet.2017.03.028; Oya Y, 2017, J NUTR BIOCHEM, V42, P7, DOI 10.1016/j.jnutbio.2016.12.015; Pfister SX, 2017, NAT REV DRUG DISCOV, V16, P241, DOI 10.1038/nrd.2016.256; Phi JH, 2017, ONCOTARGET, V8, P56747, DOI 10.18632/oncotarget.18132; Promod ST, LEUKEMIA; Stojanovic N, 2017, ONCOGENE, V36, P1804, DOI 10.1038/onc.2016.344; Yuan ZG, 2017, BIOORGAN MED CHEM, V25, P4100, DOI 10.1016/j.bmc.2017.05.058	10	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						166	167		10.1016/j.humpath.2017.07.017			2	Pathology	Pathology	FS7TV	WOS:000422612600020	28882696				2019-10-28	
J	Neureiter, D; Kiesslich, T				Neureiter, Daniel; Kiesslich, Tobias			Histone deacetylases inhibition: a potential diagnostic and therapeutic target for cancers-reply	HUMAN PATHOLOGY			English	Letter									[Neureiter, Daniel] Paracelsus Med Univ, Inst Pathol, Salzburger Landeskliniken SALK, A-5020 Salzburg, Austria; [Kiesslich, Tobias] Paracelsus Med Univ, Dept Internal Med 1, Salzburger Landeskliniken SALK, A-5020 Salzburg, Austria; [Kiesslich, Tobias] Paracelsus Med Univ, Inst Physiol & Pathophysiol, Lab Tumour Biol & Expt Therapies, A-5020 Salzburg, Austria	Neureiter, D (reprint author), Paracelsus Med Univ, Inst Pathol, Salzburger Landeskliniken SALK, A-5020 Salzburg, Austria.	d.neureiter@salk.at		Kiesslich, Tobias/0000-0001-5403-9478			de Lera AR, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0271-9; Klieser E, 2017, HUM PATHOL, V65, P41, DOI 10.1016/j.humpath.2017.02.009; Ler SY, 2015, ONCOL REP, V34, P2238, DOI 10.3892/or.2015.4263; Quint K, 2011, VIRCHOWS ARCH, V459, P129, DOI 10.1007/s00428-011-1103-0; Swierczynski S, 2015, EXPERT OPIN BIOL TH, V15, P651, DOI 10.1517/14712598.2015.1025047; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738	6	0	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						167	168		10.1016/j.humpath.2017.07.016			2	Pathology	Pathology	FS7TV	WOS:000422612600021	28873357				2019-10-28	
J	Chen, C; Ji, Q				Chen, Chen; Ji, Qiu			Net1, a therapeutic potential target for cancer	HUMAN PATHOLOGY			English	Letter							TRANSFORMING GENE-1; TUMOR-GROWTH; ANGIOGENESIS; CARCINOMA		[Chen, Chen; Ji, Qiu] Binhu Hosp Hefei City, Dept PIVAS, Hefei 230601, Anhui, Peoples R China	Ji, Q (reprint author), Binhu Hosp Hefei City, Dept PIVAS, Hefei 230601, Anhui, Peoples R China.	Qiujibinhu@126.com		Chen, Chen/0000-0001-5389-6275			Ahmad HM, 2014, FEBS J, V281, P3904, DOI 10.1111/febs.12926; Ding CB, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0524-2; Fang L, 2015, MOL MED REP, V12, P7439, DOI 10.3892/mmr.2015.4385; Ye K, 2014, TUMOR BIOL, V35, P11219, DOI 10.1007/s13277-014-2454-3; Zhang YT, 2017, HUM PATHOL, V65, P113, DOI 10.1016/j.humpath.2017.04.021	5	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						168	168		10.1016/j.humpath.2017.07.018			1	Pathology	Pathology	FS7TV	WOS:000422612600022	28882700				2019-10-28	
J	An, HJ; Ko, GH; Lee, JH; Lee, JS; Kim, DC; Yang, JW; Kim, MH; Kim, JP; Jung, EJ; Song, DH				An, Hyo Jung; Ko, Gyung Hyuck; Lee, Jeong-Hee; Lee, Jong Sil; Kim, Dong Chul; Yang, Jung Wook; Kim, Min Hye; Kim, Jin Pyeong; Jung, Eun Jung; Song, Dae Hyun			Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Programmed death-ligand 1; Carcinoma, papillary; Thyroid; Lymph nodes; Neoplasm metastasis	CELL-CARCINOMA; PD-L1 EXPRESSION; IMMUNE EVASION; T-CELLS; CANCER; IMMUNOTHERAPY; FAMILY	Background: The immunotherapeutic role of programmed death-ligand 1 (PD-L1) in life expectancy in many cancers has been highlighted. However, data regarding PD-L1 expression in papillary thyroid carcinoma (PTC) are limited. In this study, we describe the PD-L1 and programmed cell death protein 1 (PD-1) expressions in PTC and analyze their correlation with lymph node (LN) metastasis. Methods: Clinicopathological data were obtained from 116 patients with PTC who were treated in Gyeongsang National University Hospital, Jinju, Korea in 2009. Tissue microarray blocks were made using representative paraffin blocks of classical PTCs excluding follicular variants. Two pathologists graded the proportion and intensity of PD-L1 and PD-1 expression in both tumor and inflammatory cells. According to their proportions, positive PTC cells were scored as negative (0%), grade 1 (1%-50%), and grade 2 (51%-100%). Similarly, positive inflammatory cells were graded as negative (0%), grade 1 (1%-10%), and grade 2 (11%-20%). The intensity of each protein expression was simplified as positive or negative. Results: A statistically significant correlation exists between the proportions of PD-1 and PD-L1 expression both in papillary carcinoma (p = .001) and peritumoral lymphoid cells in the thyroid (p < .001). In addition, the proportion of PD-L1 expression in PTC cells was closely related to metastatic LNs (p = .036). Conclusions: PD-L1 is a valuable predictive marker for LN metastasis in PTC. Immunomodulating therapies that inhibit PD-L1 might be an option for patients with LN metastasis.	[An, Hyo Jung; Song, Dae Hyun] Gyeongsang Natl Univ, Dept Pathol, Changwon Hosp, Chang Won, South Korea; [Ko, Gyung Hyuck; Lee, Jeong-Hee; Lee, Jong Sil; Kim, Dong Chul; Kim, Jin Pyeong; Jung, Eun Jung; Song, Dae Hyun] Gyeongsang Natl Univ, Sch Med, Jinju, South Korea; [Ko, Gyung Hyuck; Lee, Jeong-Hee; Lee, Jong Sil; Kim, Dong Chul; Kim, Jin Pyeong; Jung, Eun Jung; Song, Dae Hyun] Gyeongsang Inst Hlth Sci, Jinju, South Korea; [Ko, Gyung Hyuck; Lee, Jeong-Hee; Lee, Jong Sil; Kim, Dong Chul; Yang, Jung Wook; Kim, Min Hye] Gyeongsang Natl Univ Hosp, Dept Pathol, Jinju, South Korea; [Kim, Jin Pyeong] Gyeongsang Natl Univ, Changwon Hosp, Dept Otorhinolaryngol, Chang Won, South Korea; [Jung, Eun Jung] Gyeongsang Natl Univ, Changwon Hosp, Dept Surg, Chang Won, South Korea	Song, DH (reprint author), Gyeongsang Natl Univ, Sch Med, Dept Pathol, 15 Jinju Daero 816Beon Gil, Jinju 52727, South Korea.	golgy@hanmail.net			Gyeongsang National University	This work was funded by the research promotion program of Gyeongsang National University, 2016.	Bastman JJ, 2016, J CLIN ENDOCR METAB, V101, P2863, DOI 10.1210/jc.2015-4227; Botti G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020459; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Chen N, 2017, CANCER IMMUNOL IMMUN, V66, P1175, DOI 10.1007/s00262-017-2005-z; Chovanec M, 2017, ONCOTARGET, V8, P21794, DOI 10.18632/oncotarget.15585; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Fontugne J, 2017, ONCOTARGET, V8, P24644, DOI 10.18632/oncotarget.15602; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; French JD, 2012, J CLIN ENDOCR METAB, V97, pE934, DOI 10.1210/jc.2011-3428; Gravelle P, 2017, ONCOTARGET, V8, P44960, DOI 10.18632/oncotarget.16680; Han J, 2017, J PATHOL TRANSL MED, V51, P40, DOI 10.4132/jptm.2016.08.31; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Jiang YB, 2017, ONCOTARGET, V8, P30175, DOI 10.18632/oncotarget.15621; Jin SY, 2017, ONCOTARGET, V8, P38850, DOI 10.18632/oncotarget.16407; Juarez-Salcedo LM, 2017, CRIT REV ONCOL HEMAT, V113, P52, DOI 10.1016/j.critrevonc.2017.02.027; Motoshima T, 2017, BMC UROL, V17, DOI 10.1186/s12894-016-0195-x; Ness N, 2017, ONCOTARGET, V8, P26789, DOI 10.18632/oncotarget.15817; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Nixon IJ, 2016, THYROID, V26, P373, DOI 10.1089/thy.2015.0315; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Park IH, 2017, ONCOTARGET, V8, P32722, DOI 10.18632/oncotarget.16281; Song DH, 2016, ONCOL LETT, V11, P998, DOI 10.3892/ol.2015.3988; Thompson RH, 2007, CLIN CANCER RES, V13, p709S, DOI 10.1158/1078-0432.CCR-06-1868; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zhou YJ, 2017, ONCOTARGET, V8, P51210, DOI 10.18632/oncotarget.17214	26	4	4	1	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JAN	2018	52	1					9	13		10.4132/jptm.2017.07.26			5	Pathology	Pathology	FS7VE	WOS:000422616200002	28994272	DOAJ Gold, Green Published			2019-10-28	
J	Kong, JS; Kim, HJ; Kim, MJ; Kim, A; Lee, D; Han, K; Park, S; Koh, JS; Myung, JK				Kong, Joon Seog; Kim, Hyeon Jin; Kim, Min-Jung; Kim, Areumnuri; Lee, Dalnim; Han, Kanghee; Park, Sunhoo; Koh, Jae Soo; Myung, Jae Kyung			The Significance of TROP2 Expression in Predicting BRAF Mutations in Papillary Thyroid Carcinoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						TROP2; BRAF mutation; Papillary thyroid carcinoma	CELL-LINES; CANCER; ACID	Background: Trophoblast antigen 2 (TROP2) is a human trophoblast cell-surface glycoprotein that is overexpressed in several types of epithelial cancers, and is suggested to be associated with an unfavorable prognosis. BRAF mutations are the most common genetic alteration in papillary thyroid carcinoma (PTC). We evaluated the correlation between TROP2 expression and BRAF mutation in PTC. Methods: First, we carried out pyrosequencing for BRAF mutations and immunohistochemistry for TROP2 expression with a tissue microarray consisting of 52 PTC cases. Membranous staining in at least 5% of tumor cells was designated as positive staining and we analyzed the relationship between TROP2 expression and diverse clinicopathological factors, including BRAF mutation. Second, we tested TROP2 mRNA expression in three thyroid cancer cell lines with BRAF mutations (BCPAP, SNU790, and 8505C) and a normal thyroid cell line. Additionally, we checked TROP2 protein levels in a normal thyroid cell line after introduction of the BRAF V600E mutation. Results: In this study, 21 of 26 cases with BRAF mutation showed TROP2 immunoreactivity, whereas all 26 cases without BRAF mutation showed no immunoreactivity for TROP2 with a statistically significant difference (p < .001). Upregulation of TROP2 mRNA was observed in all three thyroid cancer cell lines, but not in the normal thyroid cell line. Interestingly, however, the TROP2 expression was increased in the normal thyroid cell line after introduction of the BRAF V600E mutation. Conclusions: Based on these results, we concluded that TROP2 expression is significantly associated with BRAF mutation and that TROP2 immunohistochemistry could be used for predicting BRAF mutations or diagnosing papillary thyroid carcinoma.	[Kong, Joon Seog; Han, Kanghee; Park, Sunhoo; Koh, Jae Soo; Myung, Jae Kyung] Korea Canc Ctr Hosp, Dept Pathol, 75 Nowon Ro, Seoul 01812, South Korea; [Kim, Hyeon Jin; Kim, Min-Jung; Kim, Areumnuri; Lee, Dalnim; Park, Sunhoo; Myung, Jae Kyung] Korea Inst Radiol & Med Sci, Natl Radiat Emergency Med Ctr, Lab Radiat Exposure & Therapeut, Seoul, South Korea	Myung, JK (reprint author), Korea Canc Ctr Hosp, Dept Pathol, 75 Nowon Ro, Seoul 01812, South Korea.	tontos016@naver.com	Kim, Hyeonjin/M-3761-2019	Lee, Darrall/0000-0002-6990-4441	Korea Institute of Radiological and Medical Sciences (KIRAMS) - Ministry of Science, ICT and Future Planning, Republic of Korea [1711045543, 1711045540/50476-2017]	This study was supported by a grant from the Korea Institute of Radiological and Medical Sciences (KIRAMS), funded by the Ministry of Science, ICT and Future Planning, Republic of Korea (1711045543; 1711045540/50476-2017).	Addati T, 2015, CYTOPATHOLOGY, V26, P303, DOI 10.1111/cyt.12196; Ahmed N, 2003, BRIT J CANCER, V89, P374, DOI 10.1038/sj.bjc.6601098; Bignotti E, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-22; Bignotti E, 2010, EUR J CANCER, V46, P944, DOI 10.1016/j.ejca.2009.12.019; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Cubas R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-253; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Fang YJ, 2009, INT J COLORECTAL DIS, V24, P875, DOI 10.1007/s00384-009-0725-z; Fong D, 2008, BRIT J CANCER, V99, P1290, DOI 10.1038/sj.bjc.6604677; Fong D, 2008, MODERN PATHOL, V21, P186, DOI 10.1038/modpathol.3801001; Guan GF, 2015, INT J CLIN EXP PATHO, V8, P10995; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Koh CS, 2007, MOL CELL ENDOCRINOL, V264, P118, DOI 10.1016/j.mce.2006.10.017; LIPINSKI M, 1981, P NATL ACAD SCI-BIOL, V78, P5147, DOI 10.1073/pnas.78.8.5147; Liu HY, 2017, APPL IMMUNOHISTO M M, V25, P525, DOI 10.1097/PAI.0000000000000332; McDougall ARA, 2015, DEV DYNAM, V244, P99, DOI 10.1002/dvdy.24242; Muhlmann G, 2009, J CLIN PATHOL, V62, P152, DOI 10.1136/jcp.2008.060590; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Shvartsur Anna, 2015, Genes Cancer, V6, P84; Simms A, 2016, DIAGN CYTOPATHOL, V44, P26, DOI 10.1002/dc.23382; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978	23	5	5	0	2	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JAN	2018	52	1					14	20		10.4132/jptm.2017.10.17			7	Pathology	Pathology	FS7VE	WOS:000422616200003	29228520	DOAJ Gold, Green Published			2019-10-28	
J	Koc, N; Ayas, S; Arinkan, SA				Koc, Nermin; Ayas, Selcuk; Arinkan, Sevcan Arzu			Comparison of the Classical Method and SEE-FIM Protocol in Detecting Microscopic Lesions in Fallopian Tubes with Gynecological Lesions	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						SEE-FIM method; Classical method; Fallopian tube lesions	TUBAL INTRAEPITHELIAL CARCINOMA; ENDOMETRIOID CARCINOMA; SEROUS TUMORS; OVARIAN; CANCER; ADENOCARCINOMA; ASSOCIATION; HYPERPLASIA; FIMBRIA; UTERUS	Background: The objective of this study was to compare the classical method and Sectioning and Extensively Examining the Fimbriated End Protocol (SEE-FIM) in detecting microscopic lesions in fallopian tubes with gynecological lesions. Methods: From a total of 1,118 cases, 582 with various parts of both fallopian tubes sampled in three-ring-shape sections and 536 sampled with the SEE-FIM protocol were included in this study. Pathological findings of cases with endometrial carcinoma, non-uterine pelvic malignant tumor, ovarian borderline tumors, premalignancy, and benign lesions were compared. Results: We detected two tubal infiltrative carcinomas among 40 uterine endometrioid adenocarcinomas, 15 serous tubal intraepithelial carcinomas in 39 non-uterine pelvic serous high-grade carcinoma cases, seven papillary tubal hyperplasias in 13 serous borderline tumor cases, and 11 endometriotic foci and four adenomatoid tumors among all cases sampled with the SEE-FIM protocol. Using the classical method, we detected only one serous tubal intraepithelial carcinoma in 113 non-uterine pelvic serous high-grade carcinoma cases and two papillary tubal hyperplasia cases in 31 serous borderline tumors. We did not identify additional findings in 185 uterine endometrioid carcinoma cases, and neither endometriotic focus nor adenomatoid tumor was shown in other lesions by the classical method. Conclusions: Benign, premalignant, and malignant lesions can possibly be missed using the classical method. The SEE-FIM protocol should be considered especially in cases of endometrial carcinoma, non-uterine pelvic serous cancers, or serous borderline ovarian tumors. For other lesions, at least a detailed examination of the fimbrial end should be undertaken.	[Koc, Nermin] Zeynep Kamil Matern & Pediat Res & Training Hosp, Dept Pathol, Istanbul, Turkey; [Ayas, Selcuk; Arinkan, Sevcan Arzu] Zeynep Kamil Matern & Pediat Res & Training Hosp, Dept Obstet & Gynecol, TR-34660 Istanbul, Turkey	Arinkan, SA (reprint author), Zeynep Kamil Matern & Pediat Res & Training Hosp, Dept Obstet & Gynecol, TR-34660 Istanbul, Turkey.	pataraa96@gmail.com					BLOSS JD, 1993, GYNECOL ONCOL, V50, P347, DOI 10.1006/gyno.1993.1223; Carcangiu ML, 2006, AM J SURG PATHOL, V30, P1222, DOI 10.1097/01.pas.0000202161.80739.ac; Clement PB, 2007, ADV ANAT PATHOL, V14, P241, DOI 10.1097/PAP.0b013e3180ca7d7b; Culton LK, 2006, AM J SURG PATHOL, V30, P844, DOI 10.1097/01.pas.0000209839.00467.05; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Kuhn E, 2012, INT J GYNECOL PATHOL, V31, P416, DOI 10.1097/PGP.0b013e31824cbeb4; Kulac I, 2013, J GYNECOL ONCOL, V24, P114, DOI 10.3802/jgo.2013.24.2.114; Kurman RJ, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P1, DOI 10.1007/978-1-4419-0489-8; Kurman RJ, 2011, AM J SURG PATHOL, V35, P1605, DOI 10.1097/PAS.0b013e318229449f; Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003; Longacre TA, 2007, HUM PATHOL, V38, P1160, DOI 10.1016/j.humpath.2006.11.010; Medeiros F, 2006, AM J SURG PATHOL, V30, P230, DOI 10.1097/01.pas.0000180854.28831.77; Mehrad M, 2010, ADV ANAT PATHOL, V17, P293, DOI 10.1097/PAP.0b013e3181ecdee1; Modesitt SC, 2002, OBSTET GYNECOL, V100, P788, DOI 10.1016/S0029-7844(02)02149-X; Przybycin CG, 2010, AM J SURG PATHOL, V34, P1407, DOI 10.1097/PAS.0b013e3181ef7b16; QUIGLEY JC, 1981, AM J CLIN PATHOL, V76, P627; ROBEY SS, 1989, INT J GYNECOL PATHOL, V8, P214, DOI 10.1097/00004347-198909000-00004; Rosai J., 2011, ROSAI ACKERMANS SURG; Seidman JD, 2002, INT J GYNECOL PATHOL, V21, P101, DOI 10.1097/00004347-200204000-00001; Tang SG, 2012, INT J GYNECOL PATHOL, V31, P103, DOI 10.1097/PGP.0b013e31822ea955; YANAI YI, 1995, INT J GYNECOL PATHOL, V14, P107; Yates MS, 2011, CANCER PREV RES, V4, P463, DOI 10.1158/1940-6207.CAPR-10-0266; Yemelyanova A, 2011, MODERN PATHOL, V24, P1248, DOI 10.1038/modpathol.2011.85	23	4	4	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JAN	2018	52	1					21	27		10.4132/jptm.2016.06.17			7	Pathology	Pathology	FS7VE	WOS:000422616200004	27539290	DOAJ Gold, Green Published			2019-10-28	
J	Chung, Y; Wi, YC; Kim, Y; Bang, SS; Yang, JH; Jang, K; Min, KW; Paik, SS				Chung, Yumin; Wi, Young Chan; Kim, Yeseul; Bang, Seong Sik; Yang, Jung-Ho; Jang, Kiseok; Min, Kyueng-Whan; Paik, Seung Sam			The Smad4/PTEN Expression Pattern Predicts Clinical Outcomes in Colorectal Adenocarcinoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Smad4; PTEN; Prognosis; Colon neoplasms; Humans	TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL CARCINOMA; COLON-CANCER; MOLECULAR SUBTYPES; PTEN EXPRESSION; TGF-BETA; MUTATIONS; BREAST; PATHWAY; CARCINOGENESIS	Background: Smad4 and PTEN are prognostic indicators for various tumor types. Smad4 regulates tumor suppression, whereas PTEN inhibits cell proliferation. We analyzed and compared the performance of Smad4 and PTEN for predicting the prognosis of patients with colorectal adenocarcinoma. Methods: Combined expression patterns based on Smad4+/- and PTEN+/- status were evaluated by immunostaining using a tissue microarray of colorectal adenocarcinoma. The relationships between the protein expression and clinicopathological variables were analyzed. Results: Smad4-/PTEN- status was most frequently observed in metastatic adenocarcinoma, followed by primary adenocarcinoma and tubular adenoma (p < .001). When Smad4-/PTEN- and Smad4+/PTEN+ groups were compared, Smad4-/PTEN- status was associated with high N stage (p = .018) and defective mismatch repair proteins (p = .006). Significant differences in disease-free survival and overall survival were observed among the three groups (Smad4+/PTEN+, Smad4-/PTEN+ or Smad4+/PTEN-, and Smad4-/PTEN-) (all p < .05). Conclusions: Concurrent loss of Smad4 and PTEN may lead to more aggressive disease and poor prognosis in patients with colorectal adenocarcinoma compared to the loss of Smad4 or PTEN alone.	[Chung, Yumin; Wi, Young Chan; Kim, Yeseul; Bang, Seong Sik; Jang, Kiseok; Min, Kyueng-Whan; Paik, Seung Sam] Hanyang Univ, Coll Med, Dept Pathol, Seoul, South Korea; [Yang, Jung-Ho] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Pathol, Seoul, South Korea	Min, KW (reprint author), Hanyang Univ, Coll Med, Guri Hosp, Dept Pathol, 153 Gyeongchun Ro, Guri 11923, South Korea.; Paik, SS (reprint author), Hanyang Univ, Coll Med, Seoul Hosp, Dept Pathol, 222-1 Wangsimni Ro, Seoul 04763, South Korea.	kyueng@gmail.com; sspaik@hanyang.ac.kr					Ahmed S, 2017, J CLIN MED, V6, DOI 10.3390/jcm6010005; Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI 10.1053/j.gastro.2009.12.064; Chen KL, 2011, CLIN EXP METASTAS, V28, P751, DOI 10.1007/s10585-011-9407-7; Choi D, 2009, WORLD J GASTROENTERO, V15, P2258, DOI 10.3748/wjg.15.2258; Chow JYC, 2008, CANCER BIOL THER, V7, P1694, DOI 10.4161/cbt.7.10.6665; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Davies MA, 1999, CANCER RES, V59, P2551; Dicuonzo G, 2001, CLIN CANCER RES, V7, P4049; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Haeger SM, 2016, ONCOGENE, V35, P577, DOI 10.1038/onc.2015.112; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jang KS, 2010, HISTOPATHOLOGY, V56, P229, DOI 10.1111/j.1365-2559.2009.03468.x; Jing FF, 2015, INT J ONCOL, V46, P1582, DOI 10.3892/ijo.2015.2844; Kechagioglou P, 2014, ANTICANCER RES, V34, P1387; Lee HS, 2003, J PATHOL, V200, P39, DOI 10.1002/path.1288; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu J, 2015, CELL REP, V10, P1599, DOI 10.1016/j.celrep.2015.02.014; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Park SH, 2017, J PATHOL TRANSL MED, V51, P205, DOI 10.4132/jptm.2017.03.08; Peltomaki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060; Peppercorn J, 2008, CANCER INVEST, V26, P1, DOI 10.1080/07357900701784238; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Risinger JI, 1997, CANCER RES, V57, P4736; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Sahlberg SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094621; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Tachibana M, 2002, CANCER-AM CANCER SOC, V94, P1955, DOI 10.1002/cncr.10410; Teng Y, 2006, CANCER RES, V66, P6972, DOI 10.1158/0008-5472.CAN-06-0507; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Valcz G, 2012, PATHOL ONCOL RES, V18, P371, DOI 10.1007/s12253-011-9454-z; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wang XX, 2015, AGING-US, V7, P1032, DOI 10.18632/aging.100855; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xu X, 2010, ONCOGENE, V29, P674, DOI 10.1038/onc.2009.375; Xu XL, 2006, J CLIN INVEST, V116, P1843, DOI 10.1172/JCI27282; Yan P, 2016, CLIN CANCER RES, V22, P3037, DOI 10.1158/1078-0432.CCR-15-0939; Yang L, 2003, WORLD J GASTROENTERO, V9, P35, DOI 10.3748/wjg.v9.i1.35; Zhang LL, 2015, J BIOL CHEM, V290, P15018, DOI 10.1074/jbc.M115.641407; Zhao YS, 2017, THORAC CANCER, V8, P203, DOI 10.1111/1759-7714.12425	43	5	5	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JAN	2018	52	1					37	44		10.4132/jptm.2017.10.20			8	Pathology	Pathology	FS7VE	WOS:000422616200006	29056035	DOAJ Gold, Green Published			2019-10-28	
J	Han, K; Ha, HJ; Kong, JS; Myung, JK; Park, S; Kim, JS; Shin, MS; Seol, HS; Koh, JS; Lee, SS				Han, Kanghee; Ha, Hwa-Jeong; Kong, Joon Seog; Myung, Jae Kyung; Park, Sunhoo; Kim, Jung-Soon; Shin, Myung-Soon; Seol, Hye Sil; Koh, Jae Soo; Lee, Seung-Sook			Importance of Individual Ghost Cells in Fine-Needle Aspiration Cytology Diagnosis of Pilomatricoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Pilomatricoma; Fine-needle aspiration cytology; Ghost cells	FDG PET/CT; FEATURES; TUMOR	Background: Although histological diagnosis of pilomatricoma is not difficult because of its unique histological features, cytological diagnosis through fine-needle aspiration cytology (FNAC) is often problematic due to misdiagnoses as malignancy. Methods: We reviewed the cytological features of 14 cases of histologically-proven pilomatricoma from Korea Cancer Center Hospital, with a discussion on the diagnostic pitfalls of FNAC. Results: Among 14 cases of pilomatricoma, 10 (71.4%) were correctly diagnosed through FNAC, and two (14.3%) were misdiagnosed as carcinoma. Cytologically, all cases had easily recognizable clusters of basaloid cells and foreign body-type multinucleated cells. Although ghost cells were also found in all cases, some were inconspicuous and hardly recognizable due to their small numbers. Conclusions: An accurate diagnosis of pilomatricoma in FNAC is feasible with consideration of clinical information and close examination of ghost cells.	[Han, Kanghee; Ha, Hwa-Jeong; Kong, Joon Seog; Park, Sunhoo; Kim, Jung-Soon; Shin, Myung-Soon; Seol, Hye Sil; Koh, Jae Soo] Korea Inst Radiol & Med Sci KIRAMS, Dept Pathol, Korea Canc Ctr Hosp, 75 Nowon Ro, Seoul 01812, South Korea; [Myung, Jae Kyung; Lee, Seung-Sook] Korea Inst Radiol & Med Sci KIRAMS, Lab Radiat Pathol, Seoul, South Korea	Lee, SS (reprint author), Korea Inst Radiol & Med Sci KIRAMS, Dept Pathol, Korea Canc Ctr Hosp, 75 Nowon Ro, Seoul 01812, South Korea.	sslee@kirams.re.kr			Korea Institute of Radiological and Medical Science (KIRAMS) - Ministry of Science, ICT and Future planning, republic of Korea [1711045543, 1711045540/50476-2017]	This study was supported by a grant from the Korea Institute of Radiological and Medical Science (KIRAMS), funded by the Ministry of Science, ICT and Future planning, republic of Korea (1711045543; 1711045540/50476-2017).	Agrawal L, 2010, INDIAN J CANCER, V47, P483, DOI 10.4103/0019-509X.73565; Al-Khateeb TH, 2007, J ORAL MAXIL SURG, V65, P261, DOI 10.1016/j.joms.2005.07.018; Bansal C, 2011, J CYTOL, V28, P1, DOI 10.4103/0970-9371.76940; Bhatt MK, 2012, CLIN NUCL MED, V37, P684, DOI 10.1097/RLU.0b013e3182443cbe; Cigliano B, 2005, EUR J PEDIATR, V164, P673, DOI 10.1007/s00431-005-1730-z; Domanski HA, 1997, ACTA CYTOL, V41, P771; Fletcher CD, 2013, DIAGNOSTIC HISTOPATH, P1707; Gupta M, 2014, DIAGN CYTOPATHOL, V42, P906, DOI 10.1002/dc.23192; Ieni A, 2012, Indian J Dermatol, V57, P152, DOI 10.4103/0019-5154.94295; Jung YS, 2007, OTOLARYNG HEAD NECK, V137, P845, DOI 10.1016/j.otohns.2007.06.735; Kumaran N, 2006, J PEDIATR SURG, V41, P1755, DOI 10.1016/j.jpedsurg.2006.05.005; Lan MY, 2003, ARCH OTOLARYNGOL, V129, P1327, DOI 10.1001/archotol.129.12.1327; LeBoit PE, 2006, WHO CLASSIFICATION T, P153; Lemos MM, 2001, CANCER CYTOPATHOL, V93, P252, DOI 10.1002/cncr.9038; Nori J, 2013, J RADIOL CASE REP, V7, P43, DOI 10.3941/jrcr.v7i10.1651; Pirouzmanesh A, 2003, PLAST RECONSTR SURG, V112, P1784, DOI 10.1097/01.PRS.0000091160.54278.64; Rosenbaum SJ, 2006, EUR RADIOL, V16, P1054, DOI 10.1007/s00330-005-0088-y; Sharma A, 2014, J CLIN DIAGN RES, V8, pHC13, DOI [10.7860/JCDR/2014/9696.5064, 10.7860/JCDR/2014/8999.4877]; Singh S, 2007, CYTOPATHOLOGY, V18, P260, DOI 10.1111/j.1365-2303.2006.00354.x; Szturz P, 2014, NUCL MED REV, V17, P94, DOI 10.5603/NMR.2014.0024; Tay JK, 2014, AM J OTOLARYNG, V35, P452, DOI 10.1016/j.amjoto.2013.12.007; Wang J, 2002, DIAGN CYTOPATHOL, V27, P167, DOI 10.1002/dc.10161	22	2	2	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JAN	2018	52	1					45	50		10.4132/jptm.2017.10.18			6	Pathology	Pathology	FS7VE	WOS:000422616200007	29370510	DOAJ Gold, Green Published			2019-10-28	
J	Koc, N; Arinkan, SA; Ozbay, NO; Selcuk, S				Koc, Nermin; Arinkan, Sevcan Arzu; Ozbay, Nurver Ozel; Selcuk, Selcuk			Colloid Carcinoma of the Uterine Cervix and Its Immunohistochemical Analysis: A Case Report	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Colloid carcinoma; Cervix uteri; Neoplasms	GLANDULAR LESIONS; INTESTINAL-TYPE; EXPRESSION; ADENOCARCINOMA; MORPHOLOGY; BENIGN; MUC5AC; CDX2; MUC2	Colloid carcinoma, which is a very rare tumor of the uterine cervix, is composed of an excessive amount of mucus and a relative paucity of tumoral glandular cells within them. Herein, we report a rare case of colloid carcinoma of the cervix with adenocarcinoma in situ (AIS), intestinal and usual types, and endocervical adenocarcinoma (usual type) components. We also discuss the morphological and immunohistochemical characteristics of this tumor. A 51-year-old woman was referred to our outpatient clinic with the symptom of genital bleeding lasting for 5 months. She had a cervix surrounded by an irregular tumor with a diameter of 5 cm. The colloid carcinoma cells were positive for MUC2, MUC5AC, and cytokeratin (CK) 7, focal positive for CDX2, and negative for MUC6 and CK20. Also, the intestinal type AIS showed a similar staining pattern. Colloid carcinoma cells producing mucin showed an intestinal phenotype and AIS. The intestinal type can be considered as a precursor lesion of colloid carcinoma.	[Koc, Nermin] Zeynep Kamil Matern & Pediat Res & Training Hosp, Dept Pathol, Istanbul, Turkey; [Arinkan, Sevcan Arzu; Selcuk, Selcuk] Zeynep Kamil Matern & Pediat Res & Training Hosp, Dept Obstet & Gynecol, TR-34660 Istanbul, Turkey; [Ozbay, Nurver Ozel] Fatih Sultan Mehmet Res & Training Hosp, Dept Pathol, Istanbul, Turkey	Arinkan, SA (reprint author), Zeynep Kamil Matern & Pediat Res & Training Hosp, Dept Obstet & Gynecol, TR-34660 Istanbul, Turkey.	pataraa96@gmail.com					Baker AC, 2006, ARCH PATHOL LAB MED, V130, P1510; Bu XD, 2010, WORLD J GASTROENTERO, V16, P4089, DOI 10.3748/wjg.v16.i32.4089; HURT WG, 1977, AM J OBSTET GYNECOL, V129, P304, DOI 10.1016/0002-9378(77)90788-8; Ishida M, 2014, INT J GYNECOL PATHOL, V33, P248, DOI 10.1097/PGP.0b013e31829366d0; Kurman RJ, 2014, WHO CLASSIFICATION T; McCluggage WG, 2008, INT J GYNECOL PATHOL, V27, P92, DOI 10.1097/pgp.0b013e31815698e7; Riethdorf L, 2000, VIRCHOWS ARCH, V437, P365, DOI 10.1007/s004280000273; Shintaku M, 2010, PATHOL INT, V60, P119, DOI 10.1111/j.1440-1827.2009.02485.x; Sullivan LM, 2008, AM J SURG PATHOL, V32, P1608, DOI 10.1097/PAS.0b013e31816d71c4; WALKER AN, 1987, PATHOL ANNU, V22, P277; Young RH, 2002, HISTOPATHOLOGY, V41, P185, DOI 10.1046/j.1365-2559.2002.01462.x	11	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JAN	2018	52	1					56	60		10.4132/jptm.2017.04.08			5	Pathology	Pathology	FS7VE	WOS:000422616200009	29370509	DOAJ Gold, Green Published			2019-10-28	
J	Ekemen, S; Yapicier, O; Boler, HD; Ince, U				Ekemen, Suheyla; Yapicier, Ozlem; Boler, Hatice Deniz; Ince, Umit			An Extremely Rare Case of Back and Hip Pain due to the Metastasis of Late Recurrent Myxopapillary Ependymoma to the Inguinal Lymph Node	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article							CAUDA-EQUINA	Myxopapillary ependymomas (ME) are rare and slowly growing gliomas usually with spinal cord localization originating from the ectopic ependymal residues. They are commonly located in the conus medullaris, cauda equina and filum terminale. ME is known to be more aggressive in childhood, but has a good prognosis in adults with a very low metastasis risk.(1,2) If successfully excised, ME are usually cured completely. However, in adults, ME at the sacrococcygeal region metastasizing to organs outside central nervous system has rarely been reported so far.(3-5) Herein, we report an extremely rare case of an inguinal lymph node metastasis developed 19 years after removal of primary ME at the sacrococcygeal region, which presented with unusually severe back and hip pain. Because the metastasis of ME to the lymph node after such a long time is rare, our case may contribute to improving the differential diagnosis of extremely rare metastatic ME cases and identifying their unexpected role in the pain of unknown origin.	[Ekemen, Suheyla] Acibadem Univ, Fac Med, Lab Acibadem Pathol, Kayisdagi St 32,B Block,8F, TR-34752 Istanbul, Turkey; [Yapicier, Ozlem; Ince, Umit] Acibadem Univ, Fac Med, Dept Pathol, Istanbul, Turkey; [Boler, Hatice Deniz] Acibadem Univ, Fac Med, Dept Gen Surg, Istanbul, Turkey	Ekemen, S (reprint author), Acibadem Univ, Fac Med, Lab Acibadem Pathol, Kayisdagi St 32,B Block,8F, TR-34752 Istanbul, Turkey.	suheylaekemen@gmail.com	ince, umit/T-8783-2017	ince, umit/0000-0002-6113-661X			BARDALES RH, 1994, DIAGN CYTOPATHOL, V10, P47, DOI 10.1002/dc.2840100113; Fujimori T, 2013, GLOB SPINE J, V3, P33, DOI 10.1055/s-0032-1329888; HELWIG EB, 1984, AM J CLIN PATHOL, V81, P156, DOI 10.1093/ajcp/81.2.156; KRAMER GWPM, 1988, J NEUROSURG, V68, P474, DOI 10.3171/jns.1988.68.3.0474; Lee Kyung-Jae, 2012, J Clin Med Res, V4, P61, DOI 10.4021/jocmr678w; Satti Mohammed, 2005, Ann Diagn Pathol, V9, P215, DOI 10.1016/j.anndiagpath.2005.04.015; Vega-Orozco R, 2011, DIAGN CYTOPATHOL, V39, P689, DOI 10.1002/dc.21535; Wang H, 2014, J CLIN NEUROSCI, V21, P569, DOI 10.1016/j.jocn.2013.05.028; Weber DC, 2015, NEURO-ONCOLOGY, V17, P588, DOI 10.1093/neuonc/nou293; WIGHT DGD, 1973, J CLIN PATHOL, V26, P929, DOI 10.1136/jcp.26.12.929	10	0	0	1	3	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JAN	2018	52	1					67	70		10.4132/jptm.2017.11.09			4	Pathology	Pathology	FS7VE	WOS:000422616200012	29166763	DOAJ Gold, Green Published			2019-10-28	
J	Yassin, DF; Al-Abbadi, MA				Yassin, Dima F.; Al-Abbadi, Mousa A.			Cytology Formation: "A Neutrophilic Happy New Year"	ACTA CYTOLOGICA			English	Editorial Material									[Yassin, Dima F.; Al-Abbadi, Mousa A.] Sheikh Khalifa Med City, Dept Pathol & Lab Med, Abu Dhabi, U Arab Emirates	Al-Abbadi, MA (reprint author), Sheikh Khalifa Med City, Dept Pathol & Lab Med, Abu Dhabi, U Arab Emirates.	alabbadima@yahoo.com; malabbadi@seha.ae					Al-Quran SZ, 2004, ARCH PATHOL LAB MED, V128, P1309; Allen RC, 2015, J IMMUNOL RES, DOI 10.1155/2015/794072; Leliefeld PHC, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1250-4; Yang F, 2017, INFLAMMATION, V40, P311, DOI 10.1007/s10753-016-0458-4	4	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.	JAN-FEB	2018	62	1					1	2		10.1159/000466680			2	Pathology	Pathology	FS4QW	WOS:000419778600001	29301126				2019-10-28	
J	Shabalova, I				Shabalova, Irina			Gaining an Accurate Diagnosis: A Multidisciplinary Approach	ACTA CYTOLOGICA			English	Editorial Material									[Shabalova, Irina] Russian Med Acad Continuous Profess Educ, Dept Clin Lab Diagnost, Moscow, Russia	Shabalova, I (reprint author), Russian Med Acad Postgrad Educ, Dept Lab Med, 3rd Vladimirskaja 32-31,Apt 129, RU-111397 Moscow, Russia.	irenshab@inbox.ru					Gupta V, 2017, ACTA CYTOL, DOI [10.1159/000480064, DOI 10.1159/000480064.]; Shabalova IP, 1985, PROBL ONCOL, V7, P727	2	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.	JAN-FEB	2018	62	1					3	3		10.1159/000481655			1	Pathology	Pathology	FS4QW	WOS:000419778600002	29073594	Bronze			2019-10-28	
J	Gupta, V; Bhake, A				Gupta, Vivek; Bhake, Arvind			Assessment of Clinically Suspected Tubercular Lymphadenopathy by Real-Time PCR Compared to Non-Molecular Methods on Lymph Node Aspirates	ACTA CYTOLOGICA			English	Article						Tubercular lymphadenopathy; Real-time PCR; Non-molecular methods; Lymph node aspirates; Clinical cytology	MYCOBACTERIUM-TUBERCULOSIS; LYMPHADENITIS; DIAGNOSIS; SPECIMENS; CULTURE; STRAINS	Background: The diagnosis of tubercular lymphadenitis (TBLN) is challenging. This study assesses the role of diagnostic intervention with real-time PCR in clinically suspected tubercular lymphadenopathy in relation to cytology and microbiological methods. Methods: The cross-sectional study involved 214 patients, and PCR, cytology, and Ziehl-Neelsen (ZN) staining was performed on aspirates. The findings were compared with culture on Lowenstein-Jensen medium. The overall concordance of cytology and PCR, both individually and combined, was calculated.. 2 and Phi values were assessed between cytology, PCR, and culture. Results: A cytological diagnosis of tuberculosis (TB), reactive lymphoid hyperplasia, and suppurative lymphadenitis was made in 71, 112, and 6 patients, respectively. PCR and culture were positive in 40% of the cases. Among the TBLN patients, PCR showed higher positivity in necrosis and culture showed higher positivity in necrotizing granuloma. Positive ZN staining was observed in 29.6% of the TBLN cases, with an overall positivity of 11%. PCR could additionally detect 82 cases missed by ZN staining. The overall concordance rate for either diagnostic modality, i.e., PCR or cytology, was highest (75%), and for PCR alone was 74%. Phi values were observed to be 0.47 between PCR and culture. Conclusion: Real-time PCR for Mycobacterium tuberculosis complex on aspirates offers a definitive and comparable diagnosis of TBLN. Including this approach as the primary investigation in the work-up of TBLN could reduce the burden of TB. (c) 2017 S. Karger AG, Basel	[Gupta, Vivek; Bhake, Arvind] Jawaharlal Nehru Med Coll, Dept Pathol, Sawangi Meghe 442002, Wardha, India	Gupta, V (reprint author), Jawaharlal Nehru Med Coll, Dept Pathol, Sawangi Meghe 442002, Wardha, India.	dr_vivek_gupta@yahoo.com	GUPTA, VIVEK/D-6916-2016	GUPTA, VIVEK/0000-0002-7830-4616	International Society of Infectious Diseases, USA	This study was funded by the International Society of Infectious Diseases, USA.	Aljafari AS, 2004, CYTOPATHOLOGY, V15, P44, DOI 10.1111/j.1365-2303.2003.00119.x; Alonso H, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-422; Bales CE, 2006, KOSS DIAGNOSTIC CYTO, P1570; Central Tuberculosis Division Directorate General of Health Services, 2007, TB IND 2007 REV NAT, V13, P10; Chien HP, 2000, INT J TUBERC LUNG D, V4, P866; Churukian CJ, 2008, THEORY PRACTICE HIST, P247; Cortez-Herrera E, 2008, BRAZ ARCH BIOL TECHN, V51, P685, DOI 10.1590/S1516-89132008000400006; Derese Y, 2012, J INFECT DEV COUNTR, V6, P53, DOI 10.3855/jidc.2050; Gopinath K, 2009, J APPL MICROBIOL, V107, P425, DOI 10.1111/j.1365-2672.2009.04218.x; Green M. R., 2012, MOL CLONING LAB MANU, P64; GUPTA PR, 2004, LUNG INDIA, V21, P50; Gupta V., 2017, ACTA CYTOL; Gupta V, 2017, INDIAN J TUBERC; Ishaq S, 2015, EUR J BIOMED PHARM S, V2, P336; Kartikranjan M, 2014, INT J MOD RES REV, V2, P354; Lashiram RS, 2010, J INDIAN ACAD CLIN M, V11, P31; Mittal P, 2011, DIAGN CYTOPATHOL, V39, P822, DOI 10.1002/dc.21472; Pahwa R, 2005, J MED MICROBIOL, V54, P873, DOI 10.1099/jmm.0.45904-0; Pravez M, 2012, IBRAHIM MED COLL J, V6, P46; Purohit MR, 2009, INT J INFECT DIS, V13, P600, DOI 10.1016/j.ijid.2008.06.046; Ramanathan VD, 1999, INDIAN J MED RES, V109, P212; Raoot A, 2013, INDIAN J TUBERC, P124; Ravilone M, 2016, 20 WHO; Sharma SK, 2004, INDIAN J MED RES, V120, P316; Tiwari RP, 2007, TUBERCULOSIS, V87, P193, DOI 10.1016/j.tube.2006.07.005; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578; Waard JH, 2007, TUBERCULOSIS, P401; WHO, 2016, GLOB TUB REP 2016	28	2	2	1	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.	JAN-FEB	2018	62	1					4	11		10.1159/000480064			8	Pathology	Pathology	FS4QW	WOS:000419778600003	28946148				2019-10-28	
J	Renshaw, AA; Gould, EW				Renshaw, Andrew A.; Gould, Edwin W.			Characteristics of False-Negative Thyroid Fine-Needle Aspirates	ACTA CYTOLOGICA			English	Article						Thyroid; Neoplasia; Resection; Cytology; Fine-needle aspiration; Diagnosis; Risk of malignancy	TERM-FOLLOW-UP; PAPILLARY CARCINOMA; BIOPSY; NODULES; DIAGNOSIS; CYTOLOGY; DISEASE; EXPERIENCE; MANAGEMENT; MALIGNANCY	Introduction: False-negative thyroid fine-needle aspirates (FNA) are not well characterized. Methods: We correlated the results of all thyroid aspirations from 1997 to 2016 with histologic follow-up. Results: There were 13,733 aspirates, 2,112 (15.3%) resections, and 678 malignancies (32.1%). Eighteen (2.7%) false-negative cases were identified (interpretation, n = 6; sampling, n = 7; and new nodules, n = 5). Interpretive false-negative cases were significantly less likely when the indeterminate rate was greater than 13% (p = 0.01). Interpretive errors involved rare cells with poorly developed features of malignancy. Sampling errors were not associated with scant cellularity in the specimen. The majority of false-negative cases were not resected because of a clinical suspicion of malignancy. The sensitivity of FNA for 9-mm papillary carcinomas was 44.3%. Conclusion: In this cohort, the false-negative rate of thyroid FNA was 2.7% and the risk of malignancy for a benign diagnosis was 3.5%. Interpretative errors involved rare cells with poorly developed features of malignancy. There is little evidence that either the false-negative rate or the risk of malignancy of a benign thyroid FNA is different in patients who do and do not undergo resection. (C) 2017 S. Karger AG, Basel	[Renshaw, Andrew A.] Baptist Hosp Miami, Dept Pathol, 8900 N Kendall Dr, Miami, FL 33176 USA; Miami Canc Inst, Miami, FL USA	Renshaw, AA (reprint author), Baptist Hosp Miami, Dept Pathol, 8900 N Kendall Dr, Miami, FL 33176 USA.	andrewr@baptisthealth.net					Alexander EK, 2012, NEW ENGL J MED, V367, P705, DOI 10.1056/NEJMoa1203208; Ali SZ, 2010, BETHESDA SYSTEM REPO; ALTAVILLA G, 1990, ACTA CYTOL, V34, P251; Amrikachi M, 2001, ARCH PATHOL LAB MED, V125, P484; Baloch ZW, 1998, THYROID, V8, P565, DOI 10.1089/thy.1998.8.565; Baloch ZW, 2000, DIAGN CYTOPATHOL, V23, P425, DOI 10.1002/1097-0339(200012)23:6<425::AID-DC14>3.0.CO;2-3; Barroeta JE, 2006, ENDOCR PATHOL, V17, P61, DOI 10.1385/EP:17:1:61; BOEY J, 1986, WORLD J SURG, V10, P623, DOI 10.1007/BF01655540; BOEY J, 1984, WORLD J SURG, V8, P458, DOI 10.1007/BF01654913; Caplan RH, 2000, AM J MANAG CARE, V6, P1134; CARAWAY NP, 1993, DIAGN CYTOPATHOL, V9, P345, DOI 10.1002/dc.2840090320; Chehade J M, 2001, Endocr Pract, V7, P237; DWARAKANATHAN AA, 1993, AM J SURG, V166, P350, DOI 10.1016/S0002-9610(05)80330-7; EINHORN J, 1962, ACTA RADIOL DIAGN, V58, P321, DOI 10.3109/00016926209169574; Erdogan MF, 1998, THYROID, V8, P1087, DOI 10.1089/thy.1998.8.1087; Faquin WC, 2003, MODERN PATHOL, V16, p64A; Frates MC, 2006, J CLIN ENDOCR METAB, V91, P3411, DOI 10.1210/jc.2006-0690; Gabalec F, 2009, EUR J ENDOCRINOL, V161, P933, DOI 10.1530/EJE-09-0514; GARDINER GW, 1986, J OTOLARYNGOL, V15, P161; GHARIB H, 1993, CLIN LAB MED, V13, P699, DOI 10.1016/S0272-2712(18)30434-7; GHARIB H, 1993, ANN INTERN MED, V118, P282, DOI 10.7326/0003-4819-118-4-199302150-00007; GOELLNER JR, 1987, ACTA CYTOL, V31, P587; HALL TL, 1989, CANCER, V63, P718, DOI 10.1002/1097-0142(19890215)63:4<718::AID-CNCR2820630420>3.0.CO;2-N; HAMAKER RC, 1983, ARCH OTOLARYNGOL, V109, P225; HAMBURGER JI, 1989, ARCH PATHOL LAB MED, V113, P1035; HAMBURGER JI, 1987, ARCH INTERN MED, V147, P97, DOI 10.1001/archinte.147.1.97; HAWKINS F, 1987, CANCER, V59, P1206, DOI 10.1002/1097-0142(19870315)59:6<1206::AID-CNCR2820590629>3.0.CO;2-7; Jo VY, 2013, DIAGN CYTOPATHOL, V41, P871, DOI 10.1002/dc.22976; KHAFAGI F, 1988, MED J AUSTRALIA, V149, P302, DOI 10.5694/j.1326-5377.1988.tb120629.x; Lee S, 2013, J AM COLL SURGEONS, V217, P81, DOI 10.1016/j.jamcollsurg.2013.03.014; Londero SC, 2013, THYROID, V23, P1159, DOI 10.1089/thy.2012.0595; Marchevsky AM, 2010, DIAGN CYTOPATHOL, V38, P252, DOI 10.1002/dc.21185; Marhefka GD, 2009, ACTA CYTOL, V53, P517, DOI 10.1159/000325378; Torre EM, 2007, ACTA CYTOL, V51, P850; Merchant SH, 2000, THYROID, V10, P489, DOI 10.1089/thy.2000.10.489; MILLER JM, 1979, JAMA-J AM MED ASSOC, V241, P481, DOI 10.1001/jama.241.5.481; NATHAN AR, 1988, CANCER, V62, P1337, DOI 10.1002/1097-0142(19881001)62:7<1337::AID-CNCR2820620716>3.0.CO;2-9; Nayar R, 2009, CANCER CYTOPATHOL, V117, P195, DOI 10.1002/cncy.20029; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Nou E, 2014, J CLIN ENDOCR METAB, V99, P510, DOI 10.1210/jc.2013-3160; Oertel YC, 2007, THYROID, V17, P1061, DOI 10.1089/thy.2007.0159; Orlandi A, 2005, THYROID, V15, P274, DOI 10.1089/thy.2005.15.274; Ravetto C, 2000, CANCER CYTOPATHOL, V90, P357, DOI 10.1002/1097-0142(20001225)90:6<357::AID-CNCR6>3.0.CO;2-4; Renshaw AA, 2005, CANCER CYTOPATHOL, V105, P217, DOI 10.1002/cncr.21281; Renshaw AA, 2002, AM J CLIN PATHOL, V118, P518; Renshaw AA, 2002, AM J CLIN PATHOL, V118, P208, DOI 10.1309/QDLD-FTY3-M8ED-CX6U; Renshaw AA, CANC CYTOPA IN PRESS; Renshaw A, 2010, CANCER CYTOPATHOL, V118, P190, DOI 10.1002/cncy.20092; Renshaw AA, 2007, AM J CLIN PATHOL, V128, P370, DOI 10.1309/07TL3V58337TXHMC; Renshaw AA, 2015, CANCER CYTOPATHOL, V123, P237, DOI 10.1002/cncy.21520; Renshaw AA, 2013, ARCH PATHOL LAB MED, V137, P1627, DOI 10.5858/arpa.2012-0575-OA; Renshaw AA, 2011, DIAGN CYTOPATHOL, V39, P471, DOI 10.1002/dc.21411; Renshaw AA, 2012, DIAGN CYTOPATHOL, V40, pE13, DOI 10.1002/dc.21492; Renshaw AA, 2013, CANCER CYTOPATHOL, V121, P175, DOI 10.1002/cncy.21236; SILVERMAN JF, 1986, CANCER, V57, P1164, DOI 10.1002/1097-0142(19860315)57:6<1164::AID-CNCR2820570617>3.0.CO;2-S; Vivero M, CANC CYTOPA IN PRESS; Wilbur CD, 2015, BETHESDA SYSTEM REPO; Wu HHJ, 2003, DIAGN CYTOPATHOL, V29, P262, DOI 10.1002/dc.10388; Yang J, 2007, CANCER CYTOPATHOL, V111, P306, DOI 10.1002/cncr.22955; Yassa L, 2007, CANCER CYTOPATHOL, V111, P508, DOI 10.1002/cncr.23116	60	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.	JAN-FEB	2018	62	1					12	18		10.1159/000481722			7	Pathology	Pathology	FS4QW	WOS:000419778600004	29130950				2019-10-28	
J	Possati-Resende, JC; Vazquez, FD; Biot, ST; Mauad, EC; Talarico, T; Fregnani, JHTG; Longatto, A				Possati-Resende, Julio Cesar; Vazquez, Fabiana de Lima; Biot, Sinval Tadeu; Mauad, Edmundo Carvalho; Talarico, Thais; Tavares Guerreiro Fregnani, Jose Humberto; Longatto-Filho, Adhemar			Organized Cervical Cancer Screening Program in Barretos, Brazil: Experience in 18 Municipalities of Sao Paulo State	ACTA CYTOLOGICA			English	Article						Cervical cancer screening; Cervical cytology; Cervix; Cytology; Cervical screening programs	PERFORMANCE; WOMEN; RODEO; TEAM	Objectives: The aim of this report is to demonstrate the Barretos Cancer Hospital initiative of organizational, laboratorial, and human resources training in the implementation of an organized cervical screening program in low-resource settings. Methods: We developed a computational program to report all epidemiological, clinical, and laboratorial findings, and to trace all necessary information to recruit women for regular screening or for referral for complementary exams after liquid-based Pap test analyses. Results: All Pap tests were collected in liquid medium and in 2014 more than 160,000 tests were analyzed and 2,900 colposcopy examinations were performed. From 2012 to 2015, the percentage of exams collected increased from 54.6% in 2012 to 62.4% in 2013, 68.4% in 2014, and 71% in 2015. Per 1,000 Pap tests, 0.4 cases of invasive cancer were diagnosed; for in situ carcinoma, 1.9 cases were identified. More importantly, between 2011 and 2015, 89.4% of all carcinomas were detected at clinical stage 0 or I (in situ carcinoma), and only 5% at stages III and IV. Conclusions: Since the organized system was implemented, 98% of women have attended their recall for colposcopy. So far, we have not reached the target of 70% of women for this proposal, as recommended by the international standards. (C) 2017 S. Karger AG, Basel	[Possati-Resende, Julio Cesar; Biot, Sinval Tadeu; Mauad, Edmundo Carvalho; Tavares Guerreiro Fregnani, Jose Humberto] Barretos Canc Hosp, Canc Prevent Dept, Rua Antenor Duarte Villella 1331, BR-14784400 Barretos, SP, Brazil; [Vazquez, Fabiana de Lima; Tavares Guerreiro Fregnani, Jose Humberto] Barretos Canc Hosp, Teaching & Res Inst, Barretos, Brazil; [Vazquez, Fabiana de Lima; Talarico, Thais; Longatto-Filho, Adhemar] Barretos Canc Hosp, Mol Oncol Ctr, Barretos, Brazil; [Longatto-Filho, Adhemar] Univ Sao Paulo, Sch Med, Lab Med Invest LIM 14, Sao Paulo, Brazil; [Longatto-Filho, Adhemar] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal; [Longatto-Filho, Adhemar] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal	Vazquez, FD (reprint author), Barretos Canc Hosp, Canc Prevent Dept, Rua Antenor Duarte Villella 1331, BR-14784400 Barretos, SP, Brazil.	fabilivazquez@gmail.com	Longatto-Filho, Adhemar/N-3397-2019; longatto-filho, adhemar/D-7039-2013; Fregnani, Jose H/H-4238-2012; Possati-Resende, Julio Cesar/C-8575-2016	Longatto-Filho, Adhemar/0000-0002-5779-9752; longatto-filho, adhemar/0000-0002-5779-9752; Fregnani, Jose H/0000-0002-5235-6469; Possati-Resende, Julio Cesar/0000-0002-7869-3885			Alfaro KM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2360-7; Costa RFA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138945; Branca M, 2015, ACTA CYTOL, V59, P361, DOI 10.1159/000441515; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fregnani JHTG, 2013, ACTA CYTOL, V57, P69, DOI 10.1159/000343046; Hakama M, 1986, SCREENING CANC UTERI, P76; INCA, 2016, COORD GER AC ESTR CO; Instituto Brasileiro de Geografia e Estatistica, 2014, CONT REG; Instituto Nacional de Cancer, 2012, MAN GEST QUAL LAB CI; Instituto Nacional de Cancer, 2011, ATL MORT CANC; Instituto Nacional de Cancer (INCA), 2016, EST 2016 INC CANC BR; Instituto Nacional de Cancer Jose Alencar Gomes da Silva-INCA/ Ministerio da Saude, 2011, PROGR NAC CONTR CANC; Hidalgo JLT, 2016, EUR J CANCER PREV, V25, P423, DOI 10.1097/CEJ.0000000000000201; Lorenzi AT, 2013, GYNECOL ONCOL, V131, P131, DOI 10.1016/j.ygyno.2013.07.092; Macinko J, 2003, HEALTH SERV RES, V38, P831, DOI 10.1111/1475-6773.00149; Mauad EC, 2009, RURAL REMOTE HEALTH, V9; Mauad EC, 2010, DIAGN CYTOPATHOL, V38, P727, DOI 10.1002/dc.21287; Miller Anthony B., 2000, International Journal of Cancer, V86, P440, DOI 10.1002/(SICI)1097-0215(20000501)86:3<440::AID-IJC22>3.0.CO;2-A; Possati-Resende JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134445; Rossi PG, 2015, BRIT J CANCER, V112, P667, DOI 10.1038/bjc.2015.11; Sankaranarayanan R, 1988, CANC SURVIVAL DEV CO, P15; Stein MD, 2013, AM J CLIN PATHOL, V140, P567, DOI 10.1309/AJCPWL36JXMRESFH; World Health Organization, 2002, NAT CANC CONTR PROGR	24	1	1	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.	JAN-FEB	2018	62	1					19	27		10.1159/000480446			9	Pathology	Pathology	FS4QW	WOS:000419778600005	29069645	Bronze			2019-10-28	
J	de Oliveira, GG; Eleuterio, RMN; Goncalves, AKS; Giraldo, PC; Eleuterio, J				de Oliveira, Geilson Gomes; Nunes Eleuterio, Renata Mirian; Silveira Goncalves, Ana Katherine; Giraldo, Paulo Cesar; Eleuterio Jr, Jose			Atypical Squamous Cells in Liquid-Based Cervical Cytology: Microbiology, Inflammatory Infiltrate, and Human Papillomavirus-DNA Testing	ACTA CYTOLOGICA			English	Article						Atypical squamous cells of undetermined significance; Infection human papillomavirus; Cytology	FOLLOW-UP; MANAGEMENT; WOMEN; HPV	Objective: The aim of this study was to assess the correlation between atypical squamous cells (ASC) and inflammatory infiltrate and vaginal microbiota using cervical liquid-based cytological (SurePath (R)) and high-risk human papillomavirus (HR-HPV) tests. Study Design: A cross-sectional study was conducted using a 6-year database from a laboratory in Fortaleza (Brazil). Files from 1,346 ASC cases were divided into subgroups and results concerning inflammation and vaginal microorganisms diagnosed by cytology were compared with HR-HPV test results. Results: An absence of specific microorganisms (ASM) was the most frequent finding (ASC of undetermined significance, ASC-US = 74%; ASC - cannot exclude high-grade squamous intraepithelial lesion, ASC-H = 68%), followed by bacterial vaginosis (ASC-US = 20%; ASCH = 25%) and Candida spp. (ASC-US = 6%; ASC-H = 5%). Leukocyte infiltrate was present in 71% of ASC-US and 85% of ASC-H (p = 0.0040), and in these specific cases HR-HPV tests were positive for 65 and 64%, respectively. A positive HR-HPV test was relatively more frequent when a specific microorganism was present, and Candida spp. was associated with HR-HPV-positive results (p = 0.0156), while an ASM was associated with negative HR-HPV results (p = 0.0370). Conclusion: ASC-US is associated with an absence of inflammation or vaginosis, while ASC-H smears are associated with Trichomonas vaginalis and inflammatory infiltrate. A positive HR-HPV is associated with Candida spp. in ASC cytology. (C) 2017 S. Karger AG, Basel	[de Oliveira, Geilson Gomes; Eleuterio Jr, Jose] Univ Fed Ceara, Fac Med, Dept Pathol, Fortaleza, Ceara, Brazil; [Nunes Eleuterio, Renata Mirian; Eleuterio Jr, Jose] Univ Fed Ceara, Dept Pharm, Fortaleza, Ceara, Brazil; [Silveira Goncalves, Ana Katherine; Eleuterio Jr, Jose] Univ Fed Rio Grande do Norte, Dept Obstet & Gynecol, Natal, RN, Brazil; [Giraldo, Paulo Cesar; Eleuterio Jr, Jose] Univ Estadual Campinas, Dept Obstet & Gynecol, Campinas, SP, Brazil; [Eleuterio Jr, Jose] Univ Fed Ceara, Fac Med, Dept Maternal & Child Hlth, Fortaleza, Ceara, Brazil	de Oliveira, GG (reprint author), Univ Fed Ceara, Rua Aluisio Borba 132,Casa 4, BR-60813730 Fortaleza, Ceara, Brazil.	geilson.ce@gmail.com	Eleuterio, Jose/K-5027-2019	Eleuterio, Jose/0000-0003-4617-7269			Barcelos Ana Cristina Macedo, 2011, Infect Dis Obstet Gynecol, V2011, P904674, DOI 10.1155/2011/904674; Bazán-Ruiz Susy, 2016, Rev. chil. obstet. ginecol., V81, P32; Bhatla N, 2013, INDIAN J MED RES, V137, P533; Bukhari M, 2010, DIAGN CYTOPATHOL, V40, P35; Donders GGG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0086266; Eleuterio Jr J, 2012, DST J BRAS DOENCAS S, V24, P122; Eleutério Junior José, 2004, Rev. Bras. Ginecol. Obstet., V26, P221, DOI 10.1590/S0100-72032004000300008; Gaitán Duarte Hernando, 2004, Rev. salud pública, V6, P253; Ghosh I, 2016, J CLIN DIAGN RES, V10, pXE1, DOI 10.7860/JCDR/2016/15305.7173; Gupta S, 2007, DIAGN CYTOPATHOL, V35, P677, DOI 10.1002/dc.20719; Jahic Mahira, 2016, Med Arch, V70, P296; Kero K, 2017, EUR J CLIN MICROBIOL, V36, P2215, DOI 10.1007/s10096-017-3048-y; Levi JE, 2014, OJOG, V4, P470, DOI DOI 10.4236/0J0G.2014.48068; Linhares IM, 2010, REV ASSOC MED BRAS, V56, P370, DOI 10.1590/S0104-42302010000300026; Longatto A, 2006, INT J GYNECOL CANCER, V16, P955, DOI 10.1111/j.1525-1438.2006.00582.x; Lopez-Alegria F, 2015, SAO PAULO MED J, V133, P480, DOI 10.1590/1516-3180.2014.9142511; Nasser H, 2011, ACTA CYTOL, V55, P251, DOI 10.1159/000323320; Nayar R, 2015, CANCER CYTOPATHOL, V123, P271, DOI 10.1002/cncy.21521; Paba P, 2015, J LOW GENIT TRACT DI, V19, P203, DOI 10.1097/LGT.0000000000000078; da Silva MGP, 2013, REV PANAM SALUD PUBL, V34, P107; Reboucas K, 2014, J BRAS DOENCAS SEX T, V26, P5; Schiffman M, 2015, GYNECOL ONCOL, V138, P573, DOI 10.1016/j.ygyno.2015.06.040; Silva C, 2014, SAO PAULO MED J, V132, P92, DOI 10.1590/1516-3180.2014.1322579; Tafurt-Cardona Yaliana, 2012, Rev. salud pública, V14, P53; Vidal Borras Emilio, 2010, Rev Cubana Obstet Ginecol, V36, P594; Watson M, 2015, CANCER CAUSE CONTROL, V26, P759, DOI 10.1007/s10552-015-0549-9; Won Kyu-Hee, 2015, Obstet Gynecol Sci, V58, P117, DOI 10.5468/ogs.2015.58.2.117; Zhang D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178033	28	1	1	1	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.	JAN-FEB	2018	62	1					28	33		10.1159/000481654			6	Pathology	Pathology	FS4QW	WOS:000419778600006	29130974				2019-10-28	
J	Sinha, P; Srivastava, P; Srivastava, A				Sinha, Parul; Srivastava, Pritika; Srivastava, Anand			Comparison of Visual Inspection with Acetic Acid and the Pap Smear for Cervical Cancer Screening	ACTA CYTOLOGICA			English	Article						Pap smear; Visual inspection with acetic acid; The Bethesda System; Cervical cancer screening	LOW-RESOURCE SETTINGS; CYTOLOGY; HEALTH; TOOLS; VILI	Objective: To evaluate the efficacy of visual inspection with acetic acid (VIA) in the early detection of cervical cancer and compare it with the Pap smear. Study Design: This was a cross-sectional study conducted over a period of 3 months. A total of 316 patients who attended the Gynecology Outpatient Department of Era's Lucknow Medical College and Hospital, fulfilled the inclusion criteria, and gave their informed consent were included. Results: VIA was found positive in 38 patients (12.6%). Pap smear was positive in 31 patients (10.3%). Twenty-eight patients had a positive VIA and a positive Pap smear, 3 had a negative VIA and a positive Pap smear, 10 had a positive VIA and a negative Pap smear, and 34 had a negative VIA and a negative Pap smear. Conclusion: The sensitivity of VIA and the Pap smear was found to be nearly equal, 93.3 and 93.8%, respectively. The Pap smear was found to be more specific than VIA, i.e., 72.9 versus 60%. In terms of test accuracy, the Pap smear was found to have greater test accuracy, i.e., 77.3 versus 66.7% for VIA. (C) 2017 S. Karger AG, Basel	[Sinha, Parul; Srivastava, Pritika] Eras Lucknow Med Coll, Dept Obstet & Gynaecol, Lucknow 226003, Uttar Pradesh, India; [Srivastava, Anand] King Georges Med Univ, Dept Resp Med, Lucknow, Uttar Pradesh, India	Sinha, P (reprint author), Eras Lucknow Med Coll, Dept Obstet & Gynaecol, Lucknow 226003, Uttar Pradesh, India.	drparulanand@gmail.com					Belinson JL, 2001, OBSTET GYNECOL, V98, P441, DOI 10.1016/S0029-7844(01)01454-5; Bhattacharyya Ashish Kumar, 2015, J Midlife Health, V6, P53, DOI 10.4103/0976-7800.158942; Campos NG, 2012, INT J CANCER, V130, P2672, DOI 10.1002/ijc.26269; Denny L, 2005, JAMA-J AM MED ASSOC, V294, P2173, DOI 10.1001/jama.294.17.2173; Diaz M, 2008, BRIT J CANCER, V99, P230, DOI 10.1038/sj.bjc.6604462; Ferlay J, 2013, IARC CANCERBASE; Goldie SJ, 2005, NEW ENGL J MED, V353, P2158, DOI 10.1056/NEJMsa044278; Harshini V, 2013, INDIAN J PHARM BIOL, V1, P55; Huh WK, 2015, GYNECOL ONCOL, V136, P178, DOI 10.1016/j.ygyno.2014.12.022; Ibrahim A, 2012, IN J WOMENS HEALTH, V4, P67, DOI 10.2147/IJWH.S28406; Jeronimo J, 2005, REV PANAM SALUD PUBL, V17, P1; Kitchener HC, 2006, VACCINE, V24, P63, DOI 10.1016/j.vaccine.2006.05.113; Longatto A, 2012, VIRCHOWS ARCH, V460, P577, DOI 10.1007/s00428-012-1242-y; Naaz U, 2016, J SURG PAKISTAN, V21, P18; Omole-Ohonsi A, 2013, AFR J MED HLTH SCI, V12, P25; Paovonen J, 2009, LANCET, V374, P301, DOI 10.1016/S0140-6736(09)61248-4; Saleh HS, 2014, MIDDLE EAST FERTIL S, V19, P187, DOI 10.1016/j.mefs.2013.10.003; Sankaranarayanan R, 2005, INT J GYNECOL OBSTET, V89, pS4, DOI 10.1016/j.ijgo.2005.01.009; Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516; Sarian LO, 2005, J MED SCREEN, V12, P142, DOI 10.1258/0969141054855328; Shastri SS, 2014, JNCI-J NATL CANCER I, P106; Syrjanen K, 2008, ACTA CYTOL, V52, P641, DOI 10.1159/000325616; Vadehra K, 2006, J I MED, V28, P36; Veena R, 2012, IOSR J DENT MED SCI, V1, P1; Villa LL, 2006, BRIT J CANCER, V95, P1459, DOI 10.1038/sj.bjc.6603469; World Health Organization, 2013, GUID SCREEN TREATM P	26	4	4	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.	JAN-FEB	2018	62	1					34	38		10.1159/000484036			5	Pathology	Pathology	FS4QW	WOS:000419778600007	29136626				2019-10-28	
J	Desai, KM; Angadi, PV; Kale, AD; Hallikerimath, S				Desai, Karishma M.; Angadi, Punnya V.; Kale, Alka D.; Hallikerimath, Seema			Modified Alcohol-Formalin Cell Block Technique in Head and Neck Pathology Diagnosis	ACTA CYTOLOGICA			English	Article						Modified alcohol-formalin; Cell block; Fine-needle aspiration; Head and neck pathology	FINE-NEEDLE-ASPIRATION; CYTOLOGY; EFFUSIONS	Objectives: Cell block preparation is a recognized technique in histopathological diagnosis. This technique aids in maintaining an intact architecture and reducing the diagnostic errors associated with fine-needle aspiration cytology. Numerous techniques have been put forth, but the need for an optimal technique for routine use in the laboratory still persists. The aim of our study was to establish a cell block technique which aids in the accurate diagnosis of head and neck pathology. Methodology: A modified cell block technique was developed using alcohol-formalin as a fixative. Forty fine-needle aspiration fluids from clinically and radiologically diagnosed cases of head and neck pathology were used as samples. The cell block sections were compared with the cytology smears to determine the utility of the technique. Results: The cell blocks presented with better preservation of the architectural framework and enabled a quick diagnosis. Cellular clumping was negligible, and nuclear as well as cellular details were maintained similar to tissue sections. It led to the integration of conventional techniques using 10% neutral buffered formalin with that of the 10% alcohol-formalin technique. Conclusion: Modified cell block technique can be used as a simple and effective tool in the routine diagnosis of head and neck pathology. (C) 2017 S. Karger AG, Basel	[Desai, Karishma M.; Angadi, Punnya V.; Kale, Alka D.; Hallikerimath, Seema] KLE Univ, Dept Oral Pathol & Microbiol, KLE VK Inst Dent Sci & Hosp, Belagavi 590010, Karnataka, India	Desai, KM (reprint author), KLE Univ, Dept Oral Pathol & Microbiol, KLE VK Inst Dent Sci & Hosp, Belagavi 590010, Karnataka, India.	drdesaikarishma@gmail.com		Desai, Karishma/0000-0002-3281-731X			DEKKER A, 1978, AM J CLIN PATHOL, V70, P855; Koss LG, DIAGNOSTIC CYTOLOGY, V1, P1; KUNG ITM, 1989, PATHOLOGY, V21, P143, DOI 10.3109/00313028909059552; Moschetta M, 2014, G CHIR, V35, P171, DOI 10.11138/gchir/2014.35.7.171; Musso C, 2005, ACTA CYTOL, V49, P22, DOI 10.1159/000326090; Nathan NA, 2000, AM J CLIN PATHOL, V114, P599, DOI 10.1309/G035-P2MM-D1TM-T5QE; Orell SR, 2003, CYTOPATHOLOGY, V14, P173, DOI 10.1046/j.1365-2303.2003.00078.x; Shobha SN, 2013, INT J HLTH SCI RES, V3, P32; Udasimath S, 2012, J CLIN DIAGN RES, V6, P1280; VELLIOS F, 1954, AM J CLIN PATHOL, V24, P676, DOI 10.1093/ajcp/24.6.676; Zanoni D S, 2012, Open Vet J, V2, P19	11	3	3	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.	JAN-FEB	2018	62	1					39	43		10.1159/000484195			5	Pathology	Pathology	FS4QW	WOS:000419778600008	29136629				2019-10-28	
J	Hamasaki, M; Chang, KHF; Nabeshima, K; Tauchi-Nishi, PS				Hamasaki, Makoto; Chang, Karen H. F.; Nabeshima, Kazuki; Tauchi-Nishi, Pamela S.			Intraoperative Squash and Touch Preparation Cytology of Brain Lesions Stained with H+E and Diff-Quik(TM) : A 20-Year Retrospective Analysis and Comparative Literature Review	ACTA CYTOLOGICA			English	Review						Cytology; Intraoperative brain assessment; Brain; Neoplasm; Squash preparation; Touch preparation	CENTRAL-NERVOUS-SYSTEM; SMEAR TECHNIQUE; FROZEN-SECTIONS; DIAGNOSIS; ACCURACY; TUMORS; EXPERIENCE; BIOPSIES; PITFALLS; UTILITY	Objective: Squash preparation (SP) is a rapid technique for the intraoperative assessment of brain lesions. Only a few studies have employed touch preparation (TP) cytology and Diff-Quik(TM) (DQ) staining in conjunction with SP. Our study aimed to assess the diagnostic efficacy of SP of brain lesions at our institution, ascertain the additional effect of TP and DQ staining, examine factors affecting the sensitivity and specificity of our methods, and compare our findings with those of previous investigations. Study Design: Our database was searched for all SP/TP of brain lesions examined from January 1996 to December 2016. Results: During this 20-year study period, our search revealed 400 brain lesions diagnosed by SP/TP cytology. There were 338 (84.5%) neoplasms and 62 (15.5%) nonneoplastic lesions. The most common neoplasms were glioblastoma multiforme (24.6%), metastatic cancer (18.3%), meningioma (16.9%), astrocytoma (11.5%), lymphoma (8.3%), oligoastrocytoma (3.3%), and pituitary adenoma (3.3%). There was discordance between the SP/TP and histological diagnoses in 19/338 (5.6%) cases, i.e., 12 misclassifications of tumor subtype and 7 sampling errors. No false-positive cases were detected. Conclusion: Brain SP/TP stained with H+E/DQ demonstrated high sensitivity (97.9%), specificity (100%), and overall diagnostic accuracy (95.3%). The combined methods, in particular, aided in the diagnosis of brain tumors prone to smearing artifacts and certain metastatic malignancies. (C) 2017 S. Karger AG, Basel	[Hamasaki, Makoto; Nabeshima, Kazuki] Fukuoka Univ Hosp, Dept Pathol, Fukuoka, Japan; [Hamasaki, Makoto; Nabeshima, Kazuki] Sch Med, Fukuoka, Japan; [Chang, Karen H. F.; Tauchi-Nishi, Pamela S.] Queens Med Ctr, Hawaii Pathologists Lab, 1301 Punchbowl St, Honolulu, HI 96813 USA; [Tauchi-Nishi, Pamela S.] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA	Tauchi-Nishi, PS (reprint author), Queens Med Ctr, Hawaii Pathologists Lab, 1301 Punchbowl St, Honolulu, HI 96813 USA.	pnishi@queens.org					Asha T, 1989, Indian J Pathol Microbiol, V32, P152; Bleggi-Torres LF, 2001, DIAGN CYTOPATHOL, V24, P293, DOI 10.1002/dc.1062; CAHILL EM, 1985, ACTA CYTOL, V29, P279; Chand P, 2016, J CYTOL, V33, P93, DOI 10.4103/0970-9371.182530; Di Stefano D, 1998, ACTA CYTOL, V42, P346, DOI 10.1159/000331614; Firlik KS, 1999, J NEUROSURG, V91, P454, DOI 10.3171/jns.1999.91.3.0454; Ghosal N, 2011, DIAGN CYTOPATHOL, V39, P582, DOI 10.1002/dc.21432; Goel D, 2007, CYTOPATHOLOGY, V18, P300, DOI 10.1111/j.1365-2303.2007.00484.x; GUARDA LA, 1990, DIAGN CYTOPATHOL, V6, P235, DOI 10.1002/dc.2840060403; Iqbal M, 2006, ACTA CYTOL, V50, P608, DOI 10.1159/000326028; Jaiswal S, 2012, DIAGN CYTOPATHOL, V40, P104, DOI 10.1002/dc.21506; Kishore S, 2016, ANN PATHOL LAB MED, V3, P61; Krishnani N, 2012, CYTOPATHOLOGY, V23, P308, DOI 10.1111/j.1365-2303.2011.00905.x; MARSHALL LF, 1973, J NEUROSURG, V39, P82, DOI 10.3171/jns.1973.39.1.0082; MARTINEZ AJ, 1988, MODERN PATHOL, V1, P378; Mitra S, 2010, J CYTOL, V27, P81, DOI 10.4103/0970-9371.71870; MOURIQUAND C, 1987, ACTA CYTOL, V31, P756; Narang V, 2015, J CYTOL, V32, P153, DOI 10.4103/0970-9371.168835; Roessler K, 2002, ACTA CYTOL, V46, P667, DOI 10.1159/000326973; Savargaonkar P, 2001, ANN CLIN LAB SCI, V31, P133; Shah AB, 1998, ACTA CYTOL, V42, P1149, DOI 10.1159/000332104; Sharma S, 2011, J CYTOL, V28, P147, DOI 10.4103/0970-9371.86339; Shukla Kaushambi, 2006, Indian J Pathol Microbiol, V49, P483; Sidawy MK, 1997, AM J CLIN PATHOL, V108, pS56; Tambouret RH, 2014, CAP TODAY; TORRES LFB, 1993, ACTA CYTOL, V37, P34; Weihsin HU, 2014, J CLIN DIAGN RES, V8, pZD29, DOI [10.7860/JCDR/2014/7888.5351, 10.7860/JCDR/2014/10142.4921]; WILLEMS JGMS, 1984, ACTA CYTOL, V28, P243	28	1	1	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.	JAN-FEB	2018	62	1					44	53		10.1159/000480063			10	Pathology	Pathology	FS4QW	WOS:000419778600009	28977789				2019-10-28	
J	Glass, R; Rosen, L; Chau, K; Sheikh-Fayyaz, S; Farmer, P; Coutsouvelis, C; Slim, F; Brenkert, R; Das, K; Raab, S; Cocker, R				Glass, Ryan; Rosen, Lisa; Chau, Karen; Sheikh-Fayyaz, Sylvat; Farmer, Peter; Coutsouvelis, Constantinos; Slim, Farah; Brenkert, Ryan; Das, Kasturi; Raab, Stephen; Cocker, Rubina			Analysis of the Cytomorphological Features in Atypical Urine Specimens following Application of The Paris System for Reporting Urinary Cytology	ACTA CYTOLOGICA			English	Article						Urine cytology; Atypical urothelial cells; Paris System	HOPKINS HOSPITAL TEMPLATE; UROTHELIAL TISSUE FRAGMENTS; TO-CYTOPLASMIC RATIO; TERTIARY CARE CENTER; CELL GROUPS; SAMPLES; NEOPLASIA; RECOMMENDATIONS; MORPHOLOGISTS; ACCURACY	Background: This study investigates the use of The Paris System (TPS) for Reporting Urinary Cytopathology and examines the performance of individual and combined morphological features in atypical urine cytologies. Methods: We reviewed 118 atypical cytologies with subsequent bladder biopsies for the presence of several morphological features and reclassified them into Paris System categories. The sensitivity and specificity of individual and combined features were calculated along with the risk of malignancy. Results: An elevated nuclear-to-cytoplasmic ratio was only predictive of malignancy if seen in single cells, while irregular nuclear borders, hyperchromasia, and coarse granular chromatin were predictive in single cells and in groups. Identification of coarse chromatin alone yielded a malignancy risk comparable to 2-feature combinations. The use of TPS criteria identified the specimens at a higher risk of malignancy. Conclusion: Our findings support the use of TPS criteria, suggesting that the presence of coarse chromatin is more specific than other individual features, and confirming that cytologic atypia is more worrisome in single cells than in groups. (C) 2017 S. Karger AG, Basel	[Glass, Ryan] Northwell Hlth, Staten Isl Univ Hosp, Dept Pathol, Staten Isl, NY USA; [Rosen, Lisa] Northwell Hlth, Feinstein Inst, Manhasset, NY USA; [Chau, Karen; Sheikh-Fayyaz, Sylvat; Farmer, Peter; Coutsouvelis, Constantinos; Slim, Farah; Brenkert, Ryan; Das, Kasturi; Cocker, Rubina] Northwell Hlth, Cytopathol Div, North Shore Hosp, Lake Success, NY USA; [Raab, Stephen] Univ Mississippi, Dept Pathol, Jackson, MS USA	Cocker, R (reprint author), North Shore LIJ Med Grp, 6 Ohio Dr, Lake Success, NY 11092 USA.	rcocker@nshs.edu					Barkan G, 2016, J AM SOC CYTOPATHOL, V5, pS87; Bostwick DG, 2014, DIAGN CYTOPATHOL, V42, P1034, DOI 10.1002/dc.23159; Cowan ML, 2017, CANCER CYTOPATHOL, V125, P427, DOI 10.1002/cncy.21843; Deshpande V, 2005, CANCER CYTOPATHOL, V105, P468, DOI 10.1002/cncr.21317; Glass RE, 2016, CANCER CYTOPATHOL, V124, P188, DOI 10.1002/cncy.21630; Granados R, 2017, ACTA CYTOL, V61, P71, DOI 10.1159/000452092; Granados R, 2016, DIAGN CYTOPATHOL, V44, P582, DOI 10.1002/dc.23489; Layfield L, 2016, J AM SOC CYTOPATHOL, V5, pS22; Layfield LJ, 2004, DIAGN CYTOPATHOL, V30, P24, DOI 10.1002/dc.10401; Mai KT, 2014, DIAGN CYTOPATHOL, V42, P555, DOI 10.1002/dc.23069; McCroskey Zulfia, 2015, J Am Soc Cytopathol, V4, P183, DOI 10.1016/j.jasc.2014.11.002; Miki Y, 2017, CYTOPATHOLOGY, V28, P88, DOI 10.1111/cyt.12367; Miller S, 2016, J AM SOC CYTOPATHOL, V5, pS23; Mokhtar GA, 2010, UROL ANNALS, V2, P100, DOI 10.4103/0974-7796.68857; Nassar H, 2003, DIAGN CYTOPATHOL, V28, P115, DOI 10.1002/dc.10245; Nasuti JF, 2001, ACTA CYTOL, V45, P147, DOI 10.1159/000327297; Olson Matthew T, 2014, J Am Soc Cytopathol, V3, P156, DOI 10.1016/j.jasc.2014.02.003; Onur I, 2015, CANCER CYTOPATHOL, V123, P186, DOI 10.1002/cncy.21519; Onur I, 2015, CANCER CYTOPATHOL, V123, P180, DOI 10.1002/cncy.21501; Rosenthal D, 2016, PARIS SYSTEM REPORTI; Rosenthal DL, 2013, CANCER CYTOPATHOL, V121, P15, DOI 10.1002/cncy.21255; Vaickus LJ, 2015, CANCER CYTOPATHOL, V123, P524, DOI 10.1002/cncy.21585; VandenBussche CJ, 2013, CANCER CYTOPATHOL, V121, P21, DOI 10.1002/cncy.21254; Wojcik Eva M, 2015, J Am Soc Cytopathol, V4, P30, DOI 10.1016/j.jasc.2014.08.001; Wu HH, 2015, DIAGN CYTOPATHOL, V43, P593, DOI 10.1002/dc.23257; Zhang MJL, 2016, CANCER CYTOPATHOL, V124, P669, DOI 10.1002/cncy.21735	26	3	3	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.	JAN-FEB	2018	62	1					54	61		10.1159/000481278			8	Pathology	Pathology	FS4QW	WOS:000419778600010	29151086				2019-10-28	
J	Renshaw, AA; Gould, EW				Renshaw, Andrew A.; Gould, Edwin W.			High-Grade Urothelial Carcinoma on Urine Cytology Resembling Umbrella Cells	ACTA CYTOLOGICA			English	Article						Urine; High-grade urothelial carcinoma; Diagnosis; Cytospin; Umbrella cells	PARIS SYSTEM; PATIENT-MANAGEMENT; ATYPICAL CATEGORY; ACCURACY; INSTITUTION; MALIGNANCY; SPECIMENS; IMPACT	Context: High-grade urothelial carcinoma (UC) cells have many appearances on urine cytology, but according to The Paris System, they can be easily distinguished from umbrella cells. Objective: We aimed to define the incidence and appearance of high-grade UC cells that resemble umbrella cells in Cytospin preparations on urine cytology. Results: Cytospin preparations from 331 cases with biopsy follow-up (230 benign/low-grade and 101 malignant [22 carcinoma in situ, 52 papillary, 19 invasive UC, 8 other] cases) were reviewed. A total of 18 cases with malignant cells resembling umbrella cells were identified (17.8% of the malignant cases) and were the only type of malignant cell in 3% of the cases. Two patterns were identified. Tumor cells were either identifiable by at least 20 abnormal cells which were large, had abundant cytoplasm but an elevated nuclear-to-cytoplasmic ratio, and markedly enlarged, round-to-elongated nucleoli, or else rare cells with abundant cytoplasm but obviously malignant nuclei. Cells without nucleoli or obviously malignant nuclei were not specific. Conclusions: Malignant cells resembling umbrella cells can be seen in up to 17% of urine cytology specimens. (C) 2017 S. Karger AG, Basel	[Renshaw, Andrew A.] Baptist Hosp Miami, Dept Pathol, 8900 N Kendall Dr, Miami, FL 33176 USA; Miami Canc Inst, Miami, FL USA	Renshaw, AA (reprint author), Baptist Hosp Miami, Dept Pathol, 8900 N Kendall Dr, Miami, FL 33176 USA.	andrewr@baptisthealth.net					Bastacky S, 1999, CANCER CYTOPATHOL, V87, P118, DOI 10.1002/(SICI)1097-0142(19990625)87:3<118::AID-CNCR4>3.0.CO;2-N; Bhatia Alka, 2006, Cytojournal, V3, P28, DOI 10.1186/1742-6413-3-28; Bostwick DG, 2014, DIAGN CYTOPATHOL, V42, P1034, DOI 10.1002/dc.23159; Brimo Fadi, 2015, J Am Soc Cytopathol, V4, P232, DOI 10.1016/j.jasc.2015.01.003; Brimo F, 2009, AM J CLIN PATHOL, V132, P785, DOI 10.1309/AJCPPRZLG9KT9AXL; Chau KR, 2015, CANCER CYTOPATHOL, V123, P10, DOI 10.1002/cncy.21477; Cowan ML, 2017, CANCER CYTOPATHOL, V125, P427, DOI 10.1002/cncy.21843; Deshpande V, 2005, CANCER CYTOPATHOL, V105, P468, DOI 10.1002/cncr.21317; Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001; Feasel P, 2014, J AM SOC CYTOPATHOL, V3, ps30; Fenelus M, 2012, J AM SOC CYTOPATHOL, V1, ps24; Glass R, 2016, DIAGN CYTOPATHOL, V44, P477, DOI 10.1002/dc.23468; Glass RE, 2016, CANCER CYTOPATHOL, V124, P188, DOI 10.1002/cncy.21630; Granados R, 2017, ACTA CYTOL, V61, P71, DOI 10.1159/000452092; Halling KC, 2003, EXPERT REV MOL DIAGN, V3, P507, DOI 10.1586/14737159.3.4.507; Hassan M, 2016, AM J CLIN PATHOL, V146, P384, DOI [10.1093/ajcp/aqw127, 10.1093/AJCP/AQW127]; Joudi AM, 2016, CANCER CYTOPATHOL, V124, P811, DOI 10.1002/cncy.21764; Malviya K, 2017, ACTA CYTOL, V61, P145, DOI 10.1159/000464270; Matsumoto K, 2014, ASIAN PAC J CANCER P, V15, P2251, DOI 10.7314/APJCP.2014.15.5.2251; McCroskey Zulfia, 2015, J Am Soc Cytopathol, V4, P183, DOI 10.1016/j.jasc.2014.11.002; Piaton E, 2014, CYTOPATHOLOGY, V25, P27, DOI 10.1111/cyt.12050; Rosenthal D, 2016, PARIS SYSTEM REPORTI; Sternberg I, 2011, CYTOPATHOLOGY, V22, P329, DOI 10.1111/j.1365-2303.2010.00827.x; Straccia P, 2016, CANCER CYTOPATHOL, V124, P519, DOI 10.1002/cncy.21709; Nu TNT, 2014, CANCER CYTOPATHOL, V122, P796, DOI 10.1002/cncy.21449; Wu HH, 2015, DIAGN CYTOPATHOL, V43, P593, DOI 10.1002/dc.23257; Yafi F. A., 2015, UROL ONCOL, V33, pe25, DOI DOI 10.1016/J.UR0L0NC.2014.06.008; Yafi FA, 2014, UROL ONCOL-SEMIN ORI, V32, DOI 10.1016/j.urolonc.2012.09.011	28	1	1	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.	JAN-FEB	2018	62	1					62	67		10.1159/000481908			6	Pathology	Pathology	FS4QW	WOS:000419778600011	29130942				2019-10-28	
J	Chantziantoniou, N; Mukherjee, M; Donnelly, AD; Pantanowitz, L; Austin, RM				Chantziantoniou, Nikolaos; Mukherjee, Maheswari; Donnelly, Amber D.; Pantanowitz, Liron; Austin, R. Marshall			Digital Applications in Cytopathology: Problems, Rationalizations, and Alternative Approaches	ACTA CYTOLOGICA			English	Article						Digital cytopathology; Static digital imaging; Telecytology; Virtual microscopy; Whole-slide imaging; Z-Stacking	FINE-NEEDLE-ASPIRATION; IMMEDIATE ASSESSMENT; VIRTUAL MICROSCOPY; CERVICAL SMEARS; TELECYTOLOGY; CYTOLOGY; REPRODUCIBILITY; SPECIMENS; IMAGE; TELECYTOPATHOLOGY	Objective: The aim of this work was to raise awareness of problems using digital applications for examining, teaching, and applying telecytology at King Abdulaziz Medical City (KAMC), Riyadh, Saudi Arabia; University of Nebraska Medical Center (UNMC), Omaha, NE, USA; and University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA. The objective was to rationalize problems and propose alternative digital approaches. Study Design: We sought to identify solutions to improve the following: (a) interpretive examination scores at KAMC for complex cytological templates (i.e., high-grade squamous intraepithelial lesions [HSIL]) when using static digital images (SDI) of cells in regions of interest (ROI); (b) visualization of cells in 3D clusters when teaching at UNMC using 2D and 3D whole-slide imaging (WSI); and (c) visualization of cells through streaming telecytology at UPMC. Results: Composite SDI (CSDI) improved test scores for complex interpretations (i.e., HSIL) by converging diagnostic criteria from multiple ROI. Multiplane focusing through z-stacked WSI facilitated the teaching of cytological entities characterized by 3D cell clusters and consultative telecytology through robotic cell analysis. Conclusions: Adequately visualized cytomorphology and multiplane focusing are essential for virtual cytopathology examinations, teaching, or consultative telecytology. Visualization of diagnostic criteria through 2D or 3D imaging is critical. Panoptiq panoramic WSI with integrated z-stacked video clips enables optimal applied telecytology. (C) 2017 S. Karger AG, Basel	[Chantziantoniou, Nikolaos] Qatar Fdn, Sidra Med, Cytopathol Sect, Dept Pathol, Doha, Qatar; [Mukherjee, Maheswari; Donnelly, Amber D.] Univ Nebraska Med Ctr, Coll Allied Hlth Profess, Cytotechnol Educ, Omaha, NE USA; [Pantanowitz, Liron] Univ Pittsburgh, Med Ctr, Shadyside Hosp, Dept Pathol, Pittsburgh, PA USA; [Austin, R. Marshall] Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Pathol Dept, Pittsburgh, PA 15213 USA	Chantziantoniou, N (reprint author), Sidra Med, Dept Pathol, Educ City North Campus,POB 26999,Al Luqta St, Doha, Qatar.	nchantziantoniou@sidra.org					Agarwal S, 2016, CANCER CYTOPATHOL, V124, P213, DOI 10.1002/cncy.21636; Bott MJ, 2015, ANN THORAC SURG, V100, P201, DOI 10.1016/j.athoracsur.2015.02.090; Buxbaum JL, 2012, DIGEST DIS SCI, V57, P3092, DOI 10.1007/s10620-012-2275-4; Cai Guoping, 2010, J Pathol Inform, V1, DOI 10.4103/2153-3539.63826; Collins BT, 2013, ACTA CYTOL, V57, P221, DOI 10.1159/000350718; Donnelly Amber D, 2016, J Am Soc Cytopathol, V5, P235, DOI 10.1016/j.jasc.2016.02.001; Donnelly AD, 2012, CYTOJOURNAL, V9, DOI 10.4103/1742-6413.95827; Eichhorn JH, 2008, AM J CLIN PATHOL, V129, P686, DOI 10.1309/GRAV16QP8JR5XTPF; El-Gabry E., 2014, DIAGN HISTOPATHOL, V20, P456, DOI DOI 10.1016/J.MPDHP.2014.10.006; Evered A, 2011, CYTOPATHOLOGY, V22, P82, DOI 10.1111/j.1365-2303.2010.00758.x; Farahani N, 2015, PATHOL LAB MED INT, V7, P23, DOI 10.2147/PLMI.S59826; Georgoulakis J, 2011, DIAGN CYTOPATHOL, V39, P495, DOI 10.1002/dc.21419; Giansanti D, 2013, TELEMED E-HEALTH, V19, P991, DOI 10.1089/tmj.2013.0108; Heimann A, 2012, DIAGN CYTOPATHOL, V40, P575, DOI 10.1002/dc.21582; Jialdasani R, 2006, J TELEMED TELECARE, V12, P311, DOI 10.1258/135763306778558132; Kaplan KJ, 2010, CANCER CYTOPATHOL, V118, P115, DOI 10.1002/cncy.20079; Kern I, 2012, J TELEMED TELECARE, V18, P86, DOI 10.1258/jtt.2011.110418; Khalbuss WE, 2011, PATHOL RES INT, V2011; Khurana Kamal K, 2012, J Pathol Inform, V3, P36, DOI 10.4103/2153-3539.101803; Kim C, 2015, J AM SOC CYTOPATHOL, V4, pS66; Lee ES, 2003, AM J CLIN PATHOL, V119, P356, DOI 10.1309/7YTVAG4XNR48T75H; Marchevsky AM, 2003, DIAGN CYTOPATHOL, V28, P147, DOI 10.1002/dc.10247; Marotti JD, 2012, ACTA CYTOL, V56, P548, DOI 10.1159/000339546; Modery Judith, 2012, J Pathol Inform, V3, P6, DOI 10.4103/2153-3539.93403; Monaco SE, 2015, DIAGN CYTOPATHOL, V43, P1, DOI 10.1002/dc.23223; Mori I, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-S1-S15; Mukherjee Maheswari S, 2016, J Pathol Inform, V7, P8, DOI 10.4103/2153-3539.177682; Pantanowitz L, 2011, CYTOPATHOLOGY, V22, P73, DOI 10.1111/j.1365-2303.2011.00852.x; Pantanowitz L, 2015, JASC, V4, pS66; Pantanowitz L, 2009, CYTOJOURNAL, V6, DOI 10.4103/1742-6413.48606; Pinco J, 2009, ARCH PATHOL LAB MED, V133, P57, DOI 10.1043/1543-2165-133.1.57; Pradhan Dinesh, 2016, J Pathol Inform, V7, P26, DOI 10.4103/2153-3539.181770; Syed M, 2014, J PATHOL INFORM, V5, pS25; Thrall Michael, 2011, J Pathol Inform, V2, P51, DOI 10.4103/2153-3539.91129; Tsilalis T, 2012, TELEMED E-HEALTH, V18, P516, DOI 10.1089/tmj.2011.0167; Wilbur DC, 2011, ACTA CYTOL, V55, P227, DOI 10.1159/000324734; Wright AM, 2013, ARCH PATHOL LAB MED, V137, P618, DOI 10.5858/arpa.2012-0430-OA; Yamashiro K, 2009, DIAGN CYTOPATHOL, V37, P727, DOI 10.1002/dc.21078	38	1	1	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.	JAN-FEB	2018	62	1					68	76		10.1159/000484434			9	Pathology	Pathology	FS4QW	WOS:000419778600012	29183021				2019-10-28	
J	Vassilakos, P; Catarino, R; Petignat, P				Vassilakos, Pierre; Catarino, Rosa; Petignat, Patrick			Use of Automated Analysis of Cervical Cytology for the Detection of High-Grade Squamous Intraepithelial Lesions in Human Papillomavirus-Positive Women: A Future Practice?	ACTA CYTOLOGICA			English	Letter									[Vassilakos, Pierre] Geneva Univ Hosp, Geneva Fdn Med Educ & Res, Geneva, Switzerland; [Vassilakos, Pierre; Catarino, Rosa; Petignat, Patrick] Geneva Univ Hosp, Div Gynecol, Dept Gynecol & Obstet, Geneva, Switzerland	Catarino, R (reprint author), Geneva Univ Hosp, Div Gynecol, Blvd Cluse 30, CH-1205 Geneva, Switzerland.	rosapintocatarino@gmail.com					Schiffman M, 2017, INT J CANCER, V140, P718, DOI 10.1002/ijc.30456; Vassilakos P, 2002, BRIT J CANCER, V86, P382, DOI 10.1038/sj/bjc/6600073; Wilbur DC, 2017, ACTA CYTOL, V61, P345, DOI 10.1159/000477374	3	0	0	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.	JAN-FEB	2018	62	1					77	77		10.1159/000481909			1	Pathology	Pathology	FS4QW	WOS:000419778600013	29136620				2019-10-28	
J	Pai, RK; Pai, RK				Pai, Reetesh K.; Pai, Rish K.			Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy	MODERN PATHOLOGY			English	Article							TOTAL MESORECTAL EXCISION; COLORECTAL LIVER METASTASES; PREDICTS POOR-PROGNOSIS; SIGNET-RING CELL; ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA; AMERICAN-JOINT-COMMITTEE; ADVANCED RECTAL-CANCER; ACELLULAR MUCIN POOLS; DUCTAL ADENOCARCINOMA; PREOPERATIVE CHEMORADIATION	Neoadjuvant therapy is increasingly used to treat patients with a wide variety of malignancies. Histologic evaluation of treated specimens provides important prognostic information and may guide subsequent chemotherapy. Neoadjuvant therapy is commonly employed in the treatment of locally advanced rectal adenocarcinoma, hepatic colorectal metastases, esophageal/esophagogastric junction carcinoma, and pancreatic ductal adenocarcinoma. Numerous tumor regression schemes have been used in these tumors and standardized approaches to evaluate these specimens are needed. In this review, the various tumor regression scoring systems that have been used in these organs are described and their associations with clinical outcomes are discussed. Recommendations regarding how to handle and report the histologic findings in these resections specimens are provided.	[Pai, Reetesh K.] Univ Pittsburgh, Med Ctr, Dept Pathol, 200 Lothrop St,Room A610, Pittsburgh, PA 15213 USA; [Pai, Rish K.] Mayo Clin, Dept Lab Med & Pathol, Scottsdale, AZ USA	Pai, RK (reprint author), Univ Pittsburgh, Med Ctr, Dept Pathol, 200 Lothrop St,Room A610, Pittsburgh, PA 15213 USA.	pair@upmc.edu					Adam R, 2008, J CLIN ONCOL, V26, P1635, DOI 10.1200/JCO.2007.13.7471; Adsay NV, 2014, AM J SURG PATHOL, V38, P480, DOI 10.1097/PAS.0000000000000165; Agoston AT, 2015, AM J SURG PATHOL, V39, P1085, DOI 10.1097/PAS.0000000000000420; Ajani JA, 2015, J NATL COMPR CANC NE, V13, P194, DOI 10.6004/jnccn.2015.0028; Albers MB, 2014, PANCREAS, V43, P648, DOI 10.1097/MPA.0000000000000070; Allen PJ, 2017, ANN SURG, V265, P185, DOI 10.1097/SLA.0000000000001763; Alnaji RM, 2016, J GASTROINTEST SURG, V20, P1541, DOI 10.1007/s11605-016-3177-0; Ambrosini-Spaltro A, 2006, VIRCHOWS ARCH, V448, P442, DOI 10.1007/s00428-005-0137-6; Arbman G, 1996, BRIT J SURG, V83, P375, DOI 10.1002/bjs.1800830326; Bateman AC, 2009, HISTOPATHOLOGY, V54, P713, DOI 10.1111/j.1365-2559.2009.03292.x; Becker K, 2003, CANCER-AM CANCER SOC, V98, P1521, DOI 10.1002/cncr.11660; Benson AB, 2015, J NATL COMPR CANC NE, V13, P719, DOI 10.6004/jnccn.2015.0087; Berger AC, 2005, J CLIN ONCOL, V23, P4330, DOI 10.1200/JCO.2005.05.017; Bhatti AH, 2014, INT J SURG, V12, P1123, DOI 10.1016/j.ijsu.2014.07.267; Birbeck KF, 2002, ANN SURG, V235, P449, DOI 10.1097/00000658-200204000-00001; Blazer DG, 2008, J CLIN ONCOL, V26, P5344, DOI 10.1200/JCO.2008.17.5299; Brouquet A, 2013, CANCER-AM CANCER SOC, V119, P2778, DOI 10.1002/cncr.28097; Campbell F, 2009, HISTOPATHOLOGY, V55, P277, DOI 10.1111/j.1365-2559.2009.03376.x; Castoro C, 2011, ANN SURG ONCOL, V18, P3743, DOI 10.1245/s10434-011-1753-9; Cecil TD, 2004, DIS COLON RECTUM, V47, P1145, DOI 10.1007/s10350-004-0086-6; Chang GJ, 2007, J NATL CANCER I, V99, P433, DOI 10.1093/jnci/djk092; Chang HHL, 2012, AM J SURG PATHOL, V36, P570, DOI 10.1097/PAS.0b013e31824057e7; Chao YK, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001407; Chatterjee D, 2013, HISTOPATHOLOGY, V63, P841, DOI 10.1111/his.12234; Chatterjee D, 2012, CANCER-AM CANCER SOC, V118, P3182, DOI 10.1002/cncr.26651; Chatterjee D, 2012, AM J SURG PATHOL, V36, P552, DOI 10.1097/PAS.0b013e318240c1c0; Chatterjee D, 2012, AM J SURG PATHOL, V36, P409, DOI 10.1097/PAS.0b013e31824104c5; Chetty R, 2012, HUM PATHOL, V43, P1917, DOI 10.1016/j.humpath.2012.01.020; Chirieac LR, 2005, CLIN CANCER RES, V11, P2229, DOI 10.1158/1078-0432.CCR-04-1840; Chirieac LR, 2005, CANCER-AM CANCER SOC, V103, P1347, DOI 10.1002/cncr.20916; Cloyd JM, 2016, CANCER-AM CANCER SOC, V122, P2671, DOI 10.1002/cncr.30117; Davies AR, 2014, J CLIN ONCOL, V32, P2983, DOI 10.1200/JCO.2014.55.9070; Dworak O, 1997, INT J COLORECTAL DIS, V12, P19, DOI 10.1007/s003840050072; Enlow JM, 2013, ANN THORAC SURG, V96, P1927, DOI 10.1016/j.athoracsur.2013.06.047; Esposito I, 2008, ANN SURG ONCOL, V15, P1651, DOI 10.1245/s10434-008-9839-8; Estrella JS, 2012, CANCER-AM CANCER SOC, V118, P268, DOI 10.1002/cncr.26243; EVANS DB, 1992, ARCH SURG-CHICAGO, V127, P1335; Fathi A, 2015, J GASTROINTEST ONCOL, V6, P418, DOI 10.3978/j.issn.2078-6891.2015.053; Fernandez FG, 2005, J AM COLL SURGEONS, V200, P845, DOI 10.1016/j.jamcollsurg.2005.01.024; Fischer LK, 2016, HISTOPATHOLOGY, V68, P210, DOI 10.1111/his.12732; Frankel WL, 2015, MODERN PATHOL, V28, pS95, DOI 10.1038/modpathol.2014.128; Gabriel E, 2016, JAMA SURG, V151, P234, DOI 10.1001/jamasurg.2015.4068; Gillen S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000267; Groth SS, 2010, J THORAC CARDIOV SUR, V139, P612, DOI 10.1016/j.jtcvs.2009.07.017; Gu Y, 2006, CANCER-AM CANCER SOC, V106, P1017, DOI 10.1002/cncr.21693; Hartman DJ, 2012, ARCH PATHOL LAB MED, V136, P100, DOI 10.5858/arpa.2011-0144-RA; Heestand GM, 2015, J CLIN ONCOL, V33, P1770, DOI 10.1200/JCO.2014.59.7930; Heger U, 2014, ANN SURG ONCOL, V21, P1739, DOI 10.1245/s10434-013-3462-z; Heinrich S, 2008, J CLIN ONCOL, V26, P2526, DOI 10.1200/JCO.2007.15.5556; Hermann RM, 2006, DIS ESOPHAGUS, V19, P329, DOI 10.1111/j.1442-2050.2006.00589.x; Hornick JL, 2006, AM J SURG PATHOL, V30, P28, DOI 10.1097/01.pas.0000174011.29816.fa; House MG, 2007, J GASTROINTEST SURG, V11, P1549, DOI 10.1007/s11605-007-0243-7; Hur C, 2013, CANCER-AM CANCER SOC, V119, P1149, DOI 10.1002/cncr.27834; ISHIKAWA O, 1989, J SURG ONCOL, V40, P143, DOI 10.1002/jso.2930400303; Jang R, 2015, J NATL COMPR CANC NE, V13, P229, DOI 10.6004/jnccn.2015.0029; Kakar S, 2016, AJCC CANC STAGING MA, P337; Kalimuthu SN, 2016, J CLIN PATHOL, V69, P463, DOI 10.1136/jclinpath-2016-203604; Kapiteijn E, 2001, NEW ENGL J MED, V345, P638, DOI 10.1056/NEJMoa010580; Karamitopoulou E, 2014, AM J SURG PATHOL, V38, P1551, DOI 10.1097/PAS.0000000000000255; Khorana AA, 2017, J ONCOL PRACT, V13, P388, DOI 10.1200/JOP.2017.023044; Knijn N, 2013, HISTOPATHOLOGY, V63, P149, DOI 10.1111/his.12124; Kok NFM, 2015, ANN SURG, V261, pE15, DOI 10.1097/SLA.0000000000000459; Langer R, 2009, MODERN PATHOL, V22, P1555, DOI 10.1038/modpathol.2009.123; Le Scodan R, 2009, ANN ONCOL, V20, P1387, DOI 10.1093/annonc/mdp015; Lee SM, 2016, AM J SURG PATHOL, V40, P1653, DOI 10.1097/PAS.0000000000000738; Lindebjerg J, 2011, HISTOPATHOLOGY, V59, P18, DOI 10.1111/j.1365-2559.2011.03888.x; Liu L, 2015, AM J SURG PATHOL, V39, P1395, DOI 10.1097/PAS.0000000000000491; Luna RA, 2015, J GASTROINTEST SURG, V19, P1201, DOI 10.1007/s11605-015-2821-4; Maas M, 2015, INT J CANCER, V137, P212, DOI 10.1002/ijc.29355; Maas M, 2010, LANCET ONCOL, V11, P835, DOI 10.1016/S1470-2045(10)70172-8; Mace AG, 2015, DIS COLON RECTUM, V58, P32, DOI 10.1097/DCR.0000000000000266; MANDARD AM, 1994, CANCER, V73, P2680, DOI 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C; Manfredi S, 2006, ANN SURG, V244, P254, DOI 10.1097/01.sla.0000217629.94941.cf; Maru DM, 2010, AM J SURG PATHOL, V34, P1287, DOI 10.1097/PAS.0b013e3181eb2f7b; Mathur A, 2014, AM SURGEON, V80, P353; Merkow RP, 2012, ARCH SURG-CHICAGO, V147, P505, DOI 10.1001/archsurg.2011.2215; Meyer JE, 2010, CANCER-AM CANCER SOC, V116, P4354, DOI 10.1002/cncr.25432; MORIKAWA E, 1994, DIS COLON RECTUM, V37, P219, DOI 10.1007/BF02048158; Nafteux PR, 2014, ANN SURG, V260, P1023, DOI 10.1097/SLA.0000000000000689; Nagtegaal ID, 2002, J CLIN ONCOL, V20, P1729, DOI 10.1200/JCO.2002.07.010; Nagtegaal ID, 2002, EUR J CANCER, V38, P964, DOI 10.1016/S0959-8049(02)00056-4; Newell KJ, 2001, ARCH PATHOL LAB MED, V125, P642; Njei B, 2016, J GASTROEN HEPATOL, V31, P1141, DOI 10.1111/jgh.13289; O'Connell JB, 2003, AM SURGEON, V69, P866; Okano K, 2000, CANCER, V89, P267, DOI 10.1002/1097-0142(20000715)89:2<267::AID-CNCR10>3.0.CO;2-1; Park SY, 2011, HISTOPATHOLOGY, V59, P650, DOI 10.1111/j.1365-2559.2011.03980.x; Patel VR, 2014, ANN THORAC SURG, V98, P1064, DOI 10.1016/j.athoracsur.2014.04.099; Peyre CG, 2008, ANN SURG, V248, P549, DOI 10.1097/SLA.0b013e318188c474; Poultsides GA, 2012, ANN SURG ONCOL, V19, P2797, DOI 10.1245/s10434-012-2335-1; QUIRKE P, 1986, LANCET, V2, P996; Quirke P, 2003, LANCET ONCOL, V4, P695, DOI 10.1016/S1470-2045(03)01248-8; Raoof M, 2016, BRIT J SURG, V103, P1731, DOI 10.1002/bjs.10218; Rau BM, 2012, SURGERY, V152, pS103, DOI 10.1016/j.surg.2012.05.015; Rizk NP, 2007, J CLIN ONCOL, V25, P507, DOI 10.1200/JCO.2006.08.0101; Rodel C, 2005, J CLIN ONCOL, V23, P8688, DOI 10.1200/JCO.2005.02.1329; Rodel C, 2016, BEST PRACT RES CL GA, V30, P629, DOI 10.1016/j.bpg.2016.06.004; Roland CL, 2015, ANN SURG ONCOL, V22, P1168, DOI 10.1245/s10434-014-4192-6; Rosenberg R, 2008, J SURG ONCOL, V97, P8, DOI 10.1002/jso.20844; Roy P, 2012, J SURG ONCOL, V105, P130, DOI 10.1002/jso.22073; Rubbia-Brandt L, 2007, ANN ONCOL, V18, P299, DOI 10.1093/annonc/mdl386; Rubbia-Brandt U, 2006, J AM COLL SURGEONS, V202, P199, DOI 10.1016/j.jamcollsurg.2005.09.010; Ruffato A, 2016, ANN THORAC SURG, V101, P1915, DOI 10.1016/j.athoracsur.2015.12.008; Ryan R, 2005, HISTOPATHOLOGY, V47, P141, DOI 10.1111/j.1365-2559.2005.02176.x; Shia J, 2004, AM J SURG PATHOL, V28, P215, DOI 10.1097/00000478-200402000-00009; Shia J, 2002, AM J SURG PATHOL, V26, P863, DOI 10.1097/00000478-200207000-00004; Shia J, 2011, AM J SURG PATHOL, V35, P127, DOI 10.1097/PAS.0b013e318200cf78; SHIROUZU K, 1995, CANCER, V76, P388, DOI 10.1002/1097-0142(19950801)76:3<388::AID-CNCR2820760307>3.0.CO;2-Y; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Smith FM, 2015, TECH COLOPROCTOL, V19, P159, DOI 10.1007/s10151-015-1272-y; Smith FM, 2014, COLORECTAL DIS, V16, P610, DOI 10.1111/codi.12608; Smith FM, 2014, DIS COLON RECTUM, V57, P311, DOI 10.1097/DCR.0b013e3182a84eba; Strobel O, 2012, SURGERY, V152, pS33, DOI 10.1016/j.surg.2012.05.029; Tempero MA, 2014, J NATL COMPR CANC NE, V12, P1083, DOI 10.6004/jnccn.2014.0106; Tepper JE, 2001, J CLIN ONCOL, V19, P157, DOI 10.1200/JCO.2001.19.1.157; Tong DKH, 2010, ANN SURG ONCOL, V17, P2184, DOI 10.1245/s10434-010-0995-2; Tsai CJ, 2011, CANCER-AM CANCER SOC, V117, P3713, DOI 10.1002/cncr.25973; Turrini O, 2009, EJSO-EUR J SURG ONC, V35, P1306, DOI 10.1016/j.ejso.2009.06.005; Van den Broeck A, 2009, EJSO-EUR J SURG ONC, V35, P600, DOI 10.1016/j.ejso.2008.12.006; Varadhachary GR, 2008, J CLIN ONCOL, V26, P3487, DOI 10.1200/JCO.2007.15.8642; Verbeke C, 2015, CANCER TREAT REV, V41, P17, DOI 10.1016/j.ctrv.2014.11.002; Verbeke CS, 2006, BRIT J SURG, V93, P1232, DOI 10.1002/bjs.5397; Vigano L, 2017, J HEPATOL, V67, P84, DOI 10.1016/j.jhep.2017.02.031; Vigano L, 2013, ANN SURG, V258, P731, DOI 10.1097/SLA.0b013e3182a6183e; Wang C, 2005, J SURG ONCOL, V91, P167, DOI 10.1002/jso.20278; Wang JS, 2012, CANCER-AM CANCER SOC, V118, P3801, DOI 10.1002/cncr.26717; Wang KL, 2006, CANCER-AM CANCER SOC, V107, P1467, DOI 10.1002/cncr.22179; Wibe A, 2002, BRIT J SURG, V89, P327, DOI 10.1046/j.0007-1323.2001.02024.x; Wu SG, 2016, ONCOTARGET, V7, P22497, DOI 10.18632/oncotarget.8113; Wu TT, 2007, AM J SURG PATHOL, V31, P58, DOI 10.1097/01.pas.0000213312.36306.cc; Yao YF, 2011, J CLIN PATHOL, V64, P1073, DOI 10.1136/jclinpath-2011-200190; Yoon HH, 2010, MAYO CLIN PROC, V85, P1080, DOI 10.4065/mcp.2010.0421; Zhao Q, 2012, ANN DIAGN PATHOL, V16, P29, DOI 10.1016/j.anndiagpath.2011.08.005	132	4	5	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					4	23		10.1038/modpathol.2017.87			20	Pathology	Pathology	FS4MK	WOS:000419766500001	28776577	Bronze			2019-10-28	
J	Cheng, L; Lopez-Beltran, A; Massari, F; MacLennan, GT; Montironi, R				Cheng, Liang; Lopez-Beltran, Antonio; Massari, Francesco; MacLennan, Gregory T.; Montironi, Rodolfo			Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine	MODERN PATHOLOGY			English	Article							RESOLUTION MELTING ANALYSIS; CIRCULATING TUMOR DNA; METASTATIC MELANOMA; MALIGNANT-MELANOMA; LIQUID BIOPSIES; CLINICAL-IMPLICATIONS; P.V600E MUTATIONS; MUTANT MELANOMA; MEK INHIBITION; DOUBLE-BLIND	Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy with BRAF and MEK inhibitors is associated with significant long-term treatment benefit in patients with BRAF V600-mutated melanoma. Therefore, molecular testing for BRAF mutations is a priority in determining the course of therapy. A literature search was performed using MEDLINE/PubMed and scientific congress databases using the terms 'BRAF,' 'mutation,' and 'cancer/tumor.' These results were filtered to include manuscripts that focused on diagnostic tests for determining BRAF mutation status. Numerous BRAF testing methods were identified, including DNA-based companion diagnostic tests and DNA-and protein-based laboratory-developed tests. Herein we review the characteristics of each method and highlight the strengths and weaknesses that should be considered before use and when interpreting results for each patient. Molecular profiling has shown that mutation load increases with melanoma tumor progression and that unique patterns of genetic changes and evolutionary trajectories for different melanoma subtypes can occur. Discordance in the BRAF mutational status between primary and metastatic lesions, as well as intratumoral heterogeneity, is known to occur. Additionally, the development of acquired resistance to combination BRAF and MEK inhibitor therapy is still a formidable obstacle. Therefore, tumor heterogeneity and the development of acquired resistance have important implications for molecular testing and ultimately the treatment of patients with advanced-stage melanoma. Overall, this information may help community oncologists more accurately and effectively interpret results of diagnostic tests within the context of recent data characterizing melanoma tumor progression.	[Cheng, Liang] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Lopez-Beltran, Antonio] Univ Cordoba, Fac Med, Unit Anat Pathol, Cordoba, Spain; [Lopez-Beltran, Antonio] Champalimaud Clin Ctr, Lisbon, Portugal; [Massari, Francesco] St Orsola Marcello Malpighi Hosp, Div Oncol, Bologna, Italy; [MacLennan, Gregory T.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [MacLennan, Gregory T.] Univ Hosp Cleveland, Med Ctr, Cleveland, OH 44106 USA; [Montironi, Rodolfo] Polytech Univ Marche Reg Ancona, United Hosp, Sch Med, Inst Pathol Anat & Histopathol, Ancona, Italy	Cheng, L (reprint author), Indiana Univ Sch Med, Dept Pathol & Lab Med, IUHPL, 350 West 11th St,Room 4010, Indianapolis, IN 46202 USA.	liang_cheng@yahoo.com	Massari, Francesco/K-7239-2016	Massari, Francesco/0000-0001-6476-6871	Novartis Pharmaceuticals CorporationNovartis	We wish to acknowledge Amanda Kauffman, Heather Edens, and William Fazzone of ArticulateScience LLC, Hamilton, NJ, for providing editorial support and medical writing assistance, funded by Novartis Pharmaceuticals Corporation.	Agah A, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh159; American Cancer Society, MEL SKIN CANC ACS; [Anonymous], 2016, ZELB VEM SUMM PROD C; [Anonymous], 2013, THXID BRAF PACK INS; [Anonymous], 2016, TAF DABR PACK INS; [Anonymous], 2016, ZELB VEM PACK INS; Anwar MAF, 2016, J SURG RES, V203, P407, DOI 10.1016/j.jss.2016.04.029; Armbruster David A, 2008, Clin Biochem Rev, V29 Suppl 1, pS49; Ascierto PA, 2016, LANCET ONCOL, V17, P1248, DOI 10.1016/S1470-2045(16)30122-X; Ascierto PA, 2013, J CLIN ONCOL, V31, P3205, DOI 10.1200/JCO.2013.49.8691; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Bastian BC, 2014, ANNU REV PATHOL-MECH, V9, P239, DOI 10.1146/annurev-pathol-012513-104658; Bradish JR, 2015, MODERN PATHOL, V28, P480, DOI 10.1038/modpathol.2014.136; Bradish JR, 2014, HUM PATHOL, V45, P1315, DOI 10.1016/j.humpath.2014.04.001; Bradish JR, 2013, FUTURE ONCOL, V9, P245, DOI [10.2217/fon.12.179, 10.2217/FON.12.179]; Burotto M, 2014, CANCER-AM CANCER SOC, V120, P3446, DOI 10.1002/cncr.28864; Calapre L, 2017, CANCER LETT, V404, P62, DOI 10.1016/j.canlet.2017.06.030; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chau CH, 2008, CLIN CANCER RES, V14, P5967, DOI 10.1158/1078-0432.CCR-07-4535; Chen D, 2014, SCI REP-UK, V4, DOI 10.1038/srep04168; Chen G, 2016, JAMA ONCOL, V2, P1056, DOI 10.1001/jamaoncol.2016.0509; Cheng L, 2013, MOL SURG PATHOLOGY; Cheng L, 2013, MOL GENETIC PATHOLOG; Chiappetta C, 2015, APPL IMMUNOHISTO M M, V23, P172, DOI 10.1097/PAI.0000000000000071; Colomba E, 2013, J MOL DIAGN, V15, P94, DOI 10.1016/j.jmoldx.2012.09.001; Colombino M, 2012, J CLIN ONCOL, V30, P2522, DOI 10.1200/JCO.2011.41.2452; *COSMIC, CAT SOM MUT CANC; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Gramont A, 2015, NAT REV CLIN ONCOL, V12, P197, DOI 10.1038/nrclinonc.2014.202; Dummer R, 2015, ANN ONCOL, V26, pV126, DOI 10.1093/annonc/mdv297; Dummer R, 2016, ANN ONCOL, P126; Dunstan RW, 2011, TOXICOL PATHOL, V39, P988, DOI 10.1177/0192623311419163; Ebert PJR, 2016, IMMUNITY, V44, P609, DOI 10.1016/j.immuni.2016.01.024; Eriksson H, 2015, JAMA DERMATOL, V151, P410, DOI 10.1001/jamadermatol.2014.3689; Fedorenko IV, 2013, ONCOGENE, V32, P3009, DOI 10.1038/onc.2012.453; Fiskus W, 2016, ANNU REV MED, V67, P29, DOI 10.1146/annurev-med-090514-030732; Garbe C, 2016, EUR J CANCER, V63, P201, DOI 10.1016/j.ejca.2016.05.005; Gatter K, 2017, ARCH PATHOL LAB MED, V141, P746, DOI 10.5858/arpa.2017-0053-ED; Girotti MR, 2016, CANCER DISCOV, V6, P286, DOI 10.1158/2159-8290.CD-15-1336; Goodwin S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/nrg.2016.49; Harrington CT, 2013, ARCH PATHOL LAB MED, V137, P1296, DOI 10.5858/arpa.2012-0463-RA; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Heinzerling L, 2013, BRIT J CANCER, V109, P2833, DOI 10.1038/bjc.2013.622; Hu-Lieskovan S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4691; Huang SK, 2016, MOL ONCOL, V10, P450, DOI 10.1016/j.molonc.2015.12.008; Hugdahl E, 2016, BRIT J CANCER, V114, P801, DOI 10.1038/bjc.2016.44; Huynh Kelly, 2016, Critical Reviews in Oncogenesis, V21, P141, DOI 10.1615/CritRevOncog.2016016075; Ihle MA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-13; Johnson DB, 2014, J CLIN ONCOL, V32, P3697, DOI 10.1200/JCO.2014.57.3535; Jurkowska M, 2015, INT J CLIN EXP PATHO, V8, P8487; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Long GV, 2017, ANN ONCOL, V28, P1631, DOI 10.1093/annonc/mdx176; Long GV, 2016, J CLIN ONCOL, V34, P871, DOI 10.1200/JCO.2015.62.9345; Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4; Long GV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6694; Long GV, 2013, AM J SURG PATHOL, V37, P61, DOI 10.1097/PAS.0b013e31826485c0; Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327; Long GV, 2016, J CLIN ONCOL, P34; Lopez-Rios F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053733; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Manfredi L, 2016, ACTA DERM-VENEREOL, V96, P630, DOI 10.2340/00015555-2326; Manzano JL, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.07; Marin C, 2014, ARCH PATHOL LAB MED, V138, P71, DOI 10.5858/arpa.2013-0031-OA; McArthur G, SOC MEL RES ANN M BO; McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9; Merkel EA, 2017, LAB INVEST, V97, P630, DOI 10.1038/labinvest.2016.147; Merlino G, 2016, PIGM CELL MELANOMA R, V29, P404, DOI 10.1111/pcmr.12475; Miller VA, 2016, CLIN ADV HEMATOL ONC, V14, P305; Moriceau G, 2015, CANCER CELL, V27, P240, DOI 10.1016/j.ccell.2014.11.018; National Comprehensive Cancer Network (NCCN), PRACT GUID ONC MEL V; Ossio R, 2017, NAT REV CANCER, V17, P393, DOI 10.1038/nrc.2017.43; Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14; Pearlstein MV, 2014, J CUTAN PATHOL, V41, P724, DOI 10.1111/cup.12364; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Qu K, 2013, J MOL DIAGN, V15, P790, DOI 10.1016/j.jmoldx.2013.07.003; Reed GH, 2007, PHARMACOGENOMICS, V8, P597, DOI 10.2217/14622416.8.6.597; Ribas A, 2011, NAT REV CLIN ONCOL, V8, P426, DOI 10.1038/nrclinonc.2011.69; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Robert C, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw435.37; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Roche Diagnostics Inc, COB 4800 BRAF V600 M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santiago-Walker A, 2016, CLIN CANCER RES, V22, P567, DOI 10.1158/1078-0432.CCR-15-0321; Schadendorf D, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.3; Schiller JH, 1996, CLIN CANCER RES, V2, P29; Schirosi L, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2951-4; Shain AH, 2016, NAT REV CANCER, V16, P345, DOI 10.1038/nrc.2016.37; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Sholl LM, 2016, ARCH PATHOL LAB MED, V140, P355, DOI 10.5858/arpa.2015-0278-CP; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Siravegna G, 2017, NAT REV CLIN ONCOL, V14, P531, DOI 10.1038/nrclinonc.2017.14; Su MY, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002196; Thierry AR, 2014, NAT MED, V20, P430, DOI 10.1038/nm.3511; Treece AL, 2017, ARCH PATHOL LAB MED, V141, P658, DOI 10.5858/arpa.2016-0280-CP; Ugurel S, 2016, EUR J CANCER, V53, P125, DOI 10.1016/j.ejca.2015.09.013; US FDA, LIST CLEAR APPR COMP; US Food and Drug Administration, PRINC COD IN VITR CO, P1; US Food and Drug Administration, CLIA LDT FAQS, P1; US Food and Drug Administration, LAB DEV TESTS, P1; US Food and Drug Administration, DISC PAP LAB DEV TES, P1; Ventana Medical Systems Inc, EV BRAF V600E MUT IM; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7; Welsh SJ, 2016, EUR J CANCER, V62, P76, DOI 10.1016/j.ejca.2016.04.005; Xi LQ, 2016, CLIN CANCER RES, V22, P5480, DOI 10.1158/1078-0432.CCR-16-0613; Xue YH, 2017, NAT MED, V23, P929, DOI 10.1038/nm.4369; Yancovitz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029336; Yang GA, 2005, J INVEST DERMATOL, V125, P1242, DOI 10.1111/j.0022-202X.2005.23931.x	110	36	36	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					24	38		10.1038/modpathol.2017.104			15	Pathology	Pathology	FS4MK	WOS:000419766500002	29148538	Green Published			2019-10-28	
J	Bartels, S; Christgen, M; Luft, A; Persing, S; Jodecke, K; Lehmann, U; Kreipe, H				Bartels, Stephan; Christgen, Matthias; Luft, Angelina; Persing, Sascha; Joedecke, Kai; Lehmann, Ulrich; Kreipe, Hans			Estrogen receptor (ESR1) mutation in bone metastases from breast cancer	MODERN PATHOLOGY			English	Article							CLINICAL ONCOLOGY/COLLEGE; AMERICAN SOCIETY; RESISTANCE; RECOMMENDATIONS; DEPRIVATION; GUIDELINES; PATTERNS; VERSION; UPDATE; DNA	Activating mutations of estrogen receptor alpha gene (ESR1) in breast cancer can cause endocrine resistance of metastatic tumor cells. The skeleton belongs to the metastatic sides frequently affected by breast cancer. The prevalence of ESR1 mutation in bone metastasis and the corresponding phenotype are not known. In this study bone metastases from breast cancer (n= 231) were analyzed for ESR1 mutation. In 27 patients (12%) (median age 73 years, range: 55-82 years) activating mutations of ESR1 were detected. The most frequent mutation was p. D538G (53%), no mutations in exon 4 (K303) or 7 (S463) were found. Lobular breast cancer was present in 52% of mutated cases (n= 14) and in 49% of all samples (n= 231), respectively. Mutated cancers constantly displayed strong estrogen receptor expression. Progesterone receptor was positive in 78% of the mutated cases (n= 21). From 194 estrogen receptor-positive samples, 14% had ESR1 mutated. Except for one mutated case, no concurrent HER2 overexpression was noted. Metastatic breast cancer with activating mutations of ESR1 had a higher Ki67 labeling index than primary luminal cancers (median 30%, ranging from 5 to 60% with 85% of cases revealing >= 20% Ki67-positive cells). From those patients from whom information on endocrine therapy was available (n= 7), two had received tamoxifen only, 4 tamoxifen followed by aromatase inhibitors and one patient had been treated with aromatase inhibitors only. We conclude that ESR1 mutation is associated with estrogen receptor expression and high proliferative activity and affects about 14% of estrogen receptor-positive bone metastases from breast cancer.	[Bartels, Stephan; Christgen, Matthias; Luft, Angelina; Persing, Sascha; Joedecke, Kai; Lehmann, Ulrich; Kreipe, Hans] Hannover Med Sch, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany	Kreipe, H (reprint author), Hannover Med Sch, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Kreipe.Hans@MH-Hannover.de		Bartels, Stephan/0000-0002-8903-2345	Deutsche KrebshilfeDeutsche Krebshilfe [1097154]	This study was supported by a grant from the Deutsche Krebshilfe to HK (Grant Number 1097154)	Bado I, 2017, ONCOGENE; Bartels S, 2016, ONCOTARGET, V7, P30084, DOI 10.18632/oncotarget.8310; Bartels S, 2015, METHODS MOL BIOL, V1315, P103, DOI 10.1007/978-1-4939-2715-9_8; BORST MJ, 1993, SURGERY, V114, P637; Carlson RW, 2012, J NATL COMPR CANC NE, V10, P821, DOI 10.6004/jnccn.2012.0086; Fribbens C, 2016, J CLIN ONCOL, V34, P2961, DOI 10.1200/JCO.2016.67.3061; Gaedcke J, 2007, MODERN PATHOL, V20, P864, DOI 10.1038/modpathol.3800830; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0021; Gellert P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13294; Gelsomino L, 2016, BREAST CANCER RES TR, V157, P253, DOI 10.1007/s10549-016-3829-5; Gluz O, 2016, J CLIN ONCOL, V34, P2341, DOI 10.1200/JCO.2015.63.5383; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48; HOWLADER N, 2014, JNCI-J NATL CANCER I, V106, P1, DOI DOI 10.1093/JNCI/DJU055; JAIN SJ, 1993, EUR J CANCER, V29A, P2155, DOI 10.1016/0959-8049(93)90053-I; Jeselsohn R, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0591-8; Ma CX, 2015, NAT REV CANCER, V15, P261, DOI 10.1038/nrc3920; Merenbakh-Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008-5472.CAN-13-1197; Patani N, 2014, MOL CELL ENDOCRINOL, V382, P683, DOI 10.1016/j.mce.2013.09.038; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Sefrioui D, 2015, INT J CANCER, V137, P2513, DOI 10.1002/ijc.29612; Sundaresan TK, 2016, CLIN CANCER RES, V22, P1103, DOI 10.1158/1078-0432.CCR-15-1031; Takeshita T, 2016, ONCOTARGET, V7, P32504, DOI 10.18632/oncotarget.8839; Thomssen C, 2011, BREAST CARE, V6, P299, DOI 10.1159/000331459; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Wang PL, 2016, CLIN CANCER RES, V22, P1130, DOI 10.1158/1078-0432.CCR-15-1534; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Wolters R, 2015, BREAST CANCER RES TR, V152, P357, DOI 10.1007/s10549-015-3484-2; Yardley DA, 2016, BREAST CANCER-TARGET, V8, P73, DOI 10.2147/BCTT.S97963; Zhang QX, 1997, CANCER RES, V57, P1244	29	8	9	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					56	61		10.1038/modpathol.2017.95			6	Pathology	Pathology	FS4MK	WOS:000419766500004	28799536	Bronze			2019-10-28	
J	Carmon, M; Zilber, S; Gekhtman, D; Olsha, O; Hadar, T; Golomb, E				Carmon, Moshe; Zilber, Sofia; Gekhtman, David; Olsha, Oded; Hadar, Tal; Golomb, Eliahu			Hygroscopic sonographically detectable clips form characteristic breast and lymph node pseudocysts	MODERN PATHOLOGY			English	Article							NEOADJUVANT CHEMOTHERAPY; INTRAOPERATIVE ULTRASOUND; CANCER PATIENTS; MARKER CLIPS; LOCALIZATION; BIOPSY; SURGERY	The use of hygroscopic sonographically detectable clips (HSDCs) has dramatically increased during the last years, especially in breast cancer patients who undergo neoadjuvant chemotherapy. The aims of this study are to define the appearance of HSDC sites in histopathological specimens, and to enable pathologists to recognize these sites and differentiate them from other lesions. We examined 124 breast cancer specimens in which the application of HSDCs was documented, 88 breast tissues and 36 lymph nodes, and analyzed the appearance of the clip site in these tissues. The clip site was clearly detected histologically in 79/88 (90%) of the breast specimens and in 29/36 (81%) of lymph node specimens. In most of the specimens, the HSDC site had a specific characteristic appearance of a pseudocyst, lined by layers of epithelioid histiocytes, sometimes with pseudopapillary formation, and with minimal or no fibrosis. This was the appearance in 69 of the breast specimens and in 23 of the lymph node specimens. In other specimens, scarring, scattered foamy macrophages and abundant siderophages were the predominant findings, as usually found in sites of other clips. As non-palpable breast lesions become more frequent, clips play a major role in the treatment of breast cancer, making them an important component of the communication among radiologists, surgeons, pathologists, and oncologists. HSDCs in tissues have a characteristic appearance with an epithelioid component. Pathologists should be able to recognize this finding, differentiate it from other breast lesions and include it in the pathology report.	[Carmon, Moshe; Olsha, Oded; Hadar, Tal] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Breast Hlth Unit, 12 Beyth St,POB 3235, IL-91031 Jerusalem, Israel; [Zilber, Sofia; Golomb, Eliahu] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Dept Pathol, Jerusalem, Israel; [Gekhtman, David] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Dept Breast Imaging, Jerusalem, Israel	Carmon, M (reprint author), Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Breast Hlth Unit, 12 Beyth St,POB 3235, IL-91031 Jerusalem, Israel.	carmonm@gmail.com					Ahmed M, 2014, BREAST CANCER RES TR, V145, P1, DOI 10.1007/s10549-014-2926-6; Aracava MM, 2014, EUR J RADIOL, V83, P516, DOI 10.1016/j.ejrad.2013.12.017; Bossi D, 2015, AM J SURG, V209, P950; Boughey JC, 2016, ANN SURG, V263, P802, DOI 10.1097/SLA.0000000000001375; Carmon M, 2017, J ULTRAS MED, V36, P401, DOI 10.7863/ultra.16.02053; Caudle AS, 2015, JAMA SURG, V150, P137, DOI 10.1001/jamasurg.2014.1086; Dash N, 1999, AM J ROENTGENOL, V173, P911, DOI 10.2214/ajr.173.4.10511147; Eby PR, 2010, ACAD RADIOL, V17, P340, DOI 10.1016/j.acra.2009.10.017; Gittleman MA, 2003, AM J SURG, V186, P386, DOI 10.1016/S0002-9610(03)00277-0; Goorts B, 2017, BREAST CANCER RES TR, V163, P83, DOI 10.1007/s10549-017-4155-2; Guarda LA, 2005, AM J SURG PATHOL, V29, P814, DOI 10.1097/01.pas.0000161324.59219.ca; Langhans L, 2017, JAMA SURG, V152, P378, DOI 10.1001/jamasurg.2016.4751; Liberman L, 1999, AM J ROENTGENOL, V173, P1315, DOI 10.2214/ajr.173.5.10541111; Ngo C, 2007, ANN SURG ONCOL, V14, P2485, DOI 10.1245/s10434-007-9420-x; Olsha O, 2007, BREAST J, V13, P627, DOI 10.1111/j.1524-4741.2007.00495.x; Olsha O, 2011, ANN SURG ONCOL, V18, P447, DOI 10.1245/s10434-010-1280-0; Ramos M, 2014, INT J SURG, V12, P572, DOI 10.1016/j.ijsu.2014.04.003; Ramos M, 2013, BREAST, V22, P520, DOI 10.1016/j.breast.2012.10.006; Rogers L.W., 2005, SEMIN BREAST DIS, V8, P127; Sakamoto N, 2017, BREAST CANCER-TOKYO, V24, P585, DOI 10.1007/s12282-016-0741-0; Seow James Han-Su, 2012, Australas J Ultrasound Med, V15, P149, DOI 10.1002/j.2205-0140.2012.tb00198.x; Youn I, 2015, J BREAST CANCER, V18, P44, DOI 10.4048/jbc.2015.18.1.44	22	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					62	67		10.1038/modpathol.2017.96			6	Pathology	Pathology	FS4MK	WOS:000419766500005	28799535				2019-10-28	
J	Arbajian, E; Koster, J; von Steyern, FV; Mertens, F				Arbajian, Elsa; Koster, Jan; von Steyern, Fredrik Vult; Mertens, Fredrik			Inflammatory leiomyosarcoma is a distinct tumor characterized by near-haploidization, few somatic mutations, and a primitive myogenic gene expression signature	MODERN PATHOLOGY			English	Article							INTEGRIN ALPHA-7	Inflammatory leiomyosarcoma is a soft-tissue tumor resembling conventional leiomyosarcoma, but with a prominent intrinsic inflammatory component. Previous studies have suggested that inflammatory leiomyosarcoma differs genetically from leiomyosarcoma, but in-depth analyses are lacking. Here we provide a comprehensive picture of the genome and transcriptome of inflammatory leiomyosarcoma by combining cytogenetic, single-nucleotide polymorphism array, mRNA-sequencing, and whole-exome sequencing data. The results show that inflammatory leiomyosarcoma has a specific genetic profile characterized by near-haploidization with or without subsequent whole-genome doubling. Consistently, both parental copies of chromosomes 5 and 22 are preserved. Apart from recurrent mutation of the NF1 gene, additional somatic events that could serve as driver mutations were not found at either the nucleotide or the genome level. Furthermore, no fusion transcripts were identified. Global gene expression profiling revealed particularly prominent differential expression of genes, including ITGA7, MYF5, MYF6, MYOD1, MYOG, and PAX7, involved in muscle development and function, providing strong argument for grouping inflammatory leiomyosarcoma with myogenic sarcomas, rather than with myofibroblastic lesions. Combined with previously published data, there are now 10 cases of inflammatory leiomyosarcoma with confirmed near-haploid genotype. These patients differ from leiomyosarcoma patients in being younger (median 41 years), showing a male predominance (9:1), and few relapses (1 of 8 informative patients). Thus, the clinical, morphological, and genetic data provide compelling support for inflammatory leiomyosarcoma being a distinct subtype of myogenic tumors.	[Arbajian, Elsa; Mertens, Fredrik] Lund Univ, Dept Lab Med, Div Clin Genet, SE-22184 Lund, Sweden; [Koster, Jan] Skane Univ Hosp, Dept Pathol, Lund, Sweden; [von Steyern, Fredrik Vult] Lund Univ, Dept Orthoped & Clin Sci, Lund, Sweden; [von Steyern, Fredrik Vult] Skane Univ Hosp, Lund, Sweden	Mertens, F (reprint author), Lund Univ, Dept Lab Med, Div Clin Genet, SE-22184 Lund, Sweden.	fredrik.mertens@med.lu.se		Arbajian, Elsa/0000-0002-1484-0073; Mertens, Fredrik/0000-0002-6278-5232	Swedish Cancer SocietySwedish Cancer Society; Swedish Childhood Cancer Foundation; Region Skane	This study was supported by grants from the Swedish Cancer Society, The Swedish Childhood Cancer Foundation, and Region Skane.	Buddingh EP, 2011, CLIN CANCER RES, V17, P2110, DOI 10.1158/1078-0432.CCR-10-2047; Castiglioni A, 2014, STEM CELL REP, V2, P92, DOI 10.1016/j.stemcr.2013.12.006; Chang A, 2005, INT J SURG PATHOL, V13, P185, DOI 10.1177/106689690501300210; Cunha LL, 2014, ENDOCR-RELAT CANCER, V21, pR85, DOI 10.1530/ERC-13-0431; Dal Cin P, 1998, J PATHOL, V185, P112; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; Hinz B, 2012, AM J PATHOL, V180, P1340, DOI 10.1016/j.ajpath.2012.02.004; Holmfeldt L, 2013, NAT GENET, V45, P242, DOI 10.1038/ng.2532; Hsia LT, 2016, P NATL ACAD SCI USA, V113, pE2162, DOI 10.1073/pnas.1603534113; Iyer MK, 2011, BIOINFORMATICS, V27, P2903, DOI 10.1093/bioinformatics/btr467; Karn T, 2015, CURR CANCER DRUG TAR, V15, P652, DOI 10.2174/156800961508151001101209; Mandahl N, 2012, GENE CHROMOSOME CANC, V51, P536, DOI 10.1002/gcc.21947; McGowan-Jordan J., 2016, INT SYSTEM HUMAN CYT; Merchant W, 1995, HISTOPATHOLOGY, V27, P525, DOI 10.1111/j.1365-2559.1995.tb00323.x; Mertens F, 2016, GENE CHROMOSOME CANC, V55, P291, DOI 10.1002/gcc.22335; Ming XY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13568; Nicorici D., 2014, BIORXIV; Nord KH, 2012, NEOPLASIA, V14, P807, DOI 10.1593/neo.12930; Safavi S, 2015, ONCOTARGET, V6, P42793, DOI 10.18632/oncotarget.6000; Sincennes MC, 2016, STEM CELL TRANSL MED, V5, P282, DOI 10.5966/sctm.2015-0266; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Walther C, 2016, GENE CHROMOSOME CANC, V55, P3, DOI 10.1002/gcc.22285; Walther C, 2015, LAB INVEST, V95, P1071, DOI 10.1038/labinvest.2015.83; Zheng SY, 2016, CANCER CELL, V29, P723, DOI 10.1016/j.ccell.2016.04.002	24	1	1	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					93	100		10.1038/modpathol.2017.113			8	Pathology	Pathology	FS4MK	WOS:000419766500008	28884746	Bronze			2019-10-28	
J	Keller, MD; Neppl, C; Irmak, Y; Hall, SR; Schmid, RA; Langer, R; Berezowska, S				Keller, Manuel D.; Neppl, Christina; Irmak, Yasin; Hall, Sean R.; Schmid, Ralph A.; Langer, Rupert; Berezowska, Sabina			Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases	MODERN PATHOLOGY			English	Article							DEATH-LIGAND 1; LUNG-CANCER; NSCLC; IMMUNOHISTOCHEMISTRY; ADENOCARCINOMAS; IMMUNOTHERAPY; PEMBROLIZUMAB; PATHOLOGIST; NIVOLUMAB; SAFETY	Immunohistochemical assessment of programmed cell death (PD)-ligand 1 (PD-L1) expression in lung cancer in the context of therapeutically targeting the PD1/ PD-L1 axis is still controversially discussed. This includes the comparability of antibody clones, prognostic value, and discrepancies between primary tumors and metastases. We assessed tumoral PD-L1 expression using clones E1L3N and SP142 in 372 primary resected pulmonary squamous cell carcinomas, including 40 paired N2 lymph node metastases, in relation with clinico-pathological parameters. PD-L1 expression was negative (< 1%) in 163/372 (44%, E1L3N) or 231/370 patients (62%, SP142). Positivity of 1- < 50% was observed in 135 (36%, E1L3N) or 92 patients (25%, SP142) and >= 50% in 74 (20%, E1L3N) or 47 patients (13%, SP142). PD-L1 staining correlated significantly between both antibodies (r=0.781; P < 0.001). Scores correlated significantly between full-slide sections (N=40) and tissue microarrays, and between primaries and N2 metastases (P < 0.001 all). CD8(+) tumor infiltrating lymphocyte counts positively correlated with PD-L1 expression (P < 0.001). PD-L1 >= 50% showed the best prognostic discrimination using the split-sample validation method. It was associated with shorter disease-specific survival in the observation group (E1L3N: P= 0.035, SP142: P= 0.002) and validation group (E1L3N: P= 0.024, SP142: P= 0.101) and shorter time to recurrence (observation group: E1L3N: P= 0.056, SP142: P < 0.001; validation group: E1L3N: P=0.036, SP142: P= 0.247). Multivariate analysis showed that PD-L1 expression >= 50% determined by clone E1L3N was an independent prognostic factor in the observation group regarding disease-specific survival (HR= 2.768; 95% CI= 1.149-6.666; P= 0.023) and time to recurrence (HR= 2.164; 95% CI= 1.056-4.436; P= 0.035) and in the validation group (disease-specific survival: HR= 1.978; 95% CI= 0.928-4.214; P= 0.077 and time to recurrence: HR= 1.571; 95% CI= 0.838-2.944; P= 0.159). High PD-L1 expression was associated with adverse prognosis in pulmonary squamous cell carcinoma. Clone E1L3N was more sensitive than SP142 and superior regarding prognostication. PD-L1 expression correlated significantly between primary tumor and N2 metastases, rendering mediastinal lymph node metastases adequate for immunohistochemical assessment.	[Keller, Manuel D.; Neppl, Christina; Irmak, Yasin; Langer, Rupert; Berezowska, Sabina] Univ Bern, Inst Pathol, Murtenstr 31, CH-3008 Bern, Switzerland; [Hall, Sean R.; Schmid, Ralph A.] Univ Hosp Bern, Div Gen Thorac Surg, Inselspital, Bern, Switzerland; [Hall, Sean R.; Schmid, Ralph A.] Univ Bern, Dept Clin Res, Bern, Switzerland	Berezowska, S (reprint author), Univ Bern, Inst Pathol, Murtenstr 31, CH-3008 Bern, Switzerland.	sabina.berezowska@pathology.unibe.ch		Langer, Rupert/0000-0001-9491-3609; Berezowska, Sabina/0000-0001-5442-9791	Tissue Bank Bern at the Institute of Pathology, University of Bern	The authors gratefully acknowledge the Translational Research Unit of the Institute of Pathology for excellent technical support, and the support of the Tissue Bank Bern at the Institute of Pathology, University of Bern, in acquiring patient tissue, and the Cancer registry Bern for support acquiring survival data.	Adam J, 2017, J THORAC ONCOL, V12, pS11; Altman DG, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001216; Antonia S, 2016, LANCET ONCOL, V17, P299, DOI 10.1016/S1470-2045(15)00544-6; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Champiat S, 2014, J THORAC ONCOL, V9, P144, DOI 10.1097/JTO.0000000000000074; Chen DS, 2012, CLIN CANCER RES, V18, P6580, DOI 10.1158/1078-0432.CCR-12-1362; Dislich B, 2017, CANCER IMMUNOL IMMUN, V66, P777, DOI 10.1007/s00262-017-1982-2; Du LL, 2017, HEMATOL ONCOL CLIN N, V31, P131, DOI 10.1016/j.hoc.2016.08.004; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gazdar AF, 2016, J THORAC ONCOL, V11, P287, DOI 10.1016/j.jtho.2015.10.009; Gniadek TJ, 2017, MODERN PATHOL, V30, P530, DOI 10.1038/modpathol.2016.213; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Irmak Y., 2016, THESIS; Keller M., 2017, THESIS; Kerr KM, 2016, ARCH PATHOL LAB MED, V140, P249, DOI 10.5858/arpa.2015-0303-SA; Kim MY, 2015, LUNG CANCER, V88, P24, DOI 10.1016/j.lungcan.2015.01.016; Langer CJ, 2016, J THORAC ONCOL, V11, P2066, DOI 10.1016/j.jtho.2016.08.138; McLaughlin JF, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.8064; Mino-Kenudson M, 2016, CANCER BIOL MED, V13, P157, DOI 10.20892/j.issn.2095-3941.2016.0009; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rehman JA, 2017, MODERN PATHOL, V30, P340, DOI 10.1038/modpathol.2016.186; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Rizvi NA, 2015, LANCET ONCOL, V16, P257, DOI 10.1016/S1470-2045(15)70054-9; Sanmamed MF, 2014, CANCER J, V20, P256, DOI 10.1097/PPO.0000000000000061; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Sobin LH, 2009, INT UNION CANC UICC, P138; Sun JM, 2016, J THORAC ONCOL, V11, P1003, DOI 10.1016/j.jtho.2016.04.007; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Travis WD, 2015, WHO CLASSIFICATION T; Tsao MS, 2017, ANN ONCOL, V28, P882, DOI 10.1093/annonc/mdx003; Uruga H, 2017, J THORAC ONCOL, V12, P458, DOI 10.1016/j.jtho.2016.10.015; Zlobec I, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-104	36	6	6	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					101	110		10.1038/modpathol.2017.111			10	Pathology	Pathology	FS4MK	WOS:000419766500009	28884747				2019-10-28	
J	Rekhtman, N; Pietanza, CM; Sabari, J; Montecalvo, J; Wang, HJ; Habeeb, O; Kadota, K; Adusumilli, P; Rudin, CM; Ladanyi, M; Travis, WD; Joubert, P				Rekhtman, Natasha; Pietanza, Catherine M.; Sabari, Joshua; Montecalvo, Joseph; Wang, Hangjun; Habeeb, Omar; Kadota, Kyuichi; Adusumilli, Prasad; Rudin, Charles M.; Ladanyi, Marc; Travis, William D.; Joubert, Philippe			Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations	MODERN PATHOLOGY			English	Article							TRANSCRIPTION FACTOR-I; LUNG ADENOCARCINOMA; POLYCLONAL NAPSIN; TUMORS; DIFFERENTIATION; CLASSIFICATION; CANCER; MUTATION; SUBSETS; CAUTION	Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a highly aggressive malignancy, which was recently found to comprise three major genomic subsets: small cell carcinoma-like, non-small cell carcinoma (predominantly adenocarcinoma)-like, and carcinoid-like. To further characterize adenocarcinoma-like subset, here we analyzed the expression of exocrine marker napsin A, along with TTF-1, in a large series of LCNECs (n=112), and performed detailed clinicopathologic and genomic analysis of napsin A-positive cases. For comparison, we analyzed napsin A expression in other lung neuroendocrine neoplasms (177 carcinoids, 37 small cell carcinomas) and 60 lung adenocarcinomas. We found that napsin A was expressed in 15% of LCNEC (17/112), whereas all carcinoids and small cell carcinomas were consistently negative. Napsin A reactivity in LCNEC was focal in 12/17 cases, and weak or moderate in intensity in all cases, which was significantly lower in the extent and intensity than seen in adenocarcinomas (P < 0.0001). The combination of TTF-1-diffuse/napsin A-negative or focal was typical of LCNEC but was rare in adenocarcinoma, and could thus serve as a helpful diagnostic clue. The diagnosis of napsin A-positive LCNECs was confirmed by classic morphology, diffuse labeling for at least one neuroendocrine marker, most consistently synaptophysin, and the lack of distinct adenocarcinoma component. Genomic analysis of 14 napsin A-positive LCNECs revealed the presence of mutations typical of lung adenocarcinoma (KRAS and/or STK11) in 11 cases. In conclusion, LCNECs are unique among lung neuroendocrine neoplasms in that some of these tumors exhibit low-level expression of exocrine marker napsin A, and harbor genomic alterations typical of adenocarcinoma. Despite the apparent close biological relationship, designation of adeno-like LCNEC as a separate entity from adenocarcinoma is supported by their distinctive morphology, typically diffuse expression of neuroendocrine marker(s) and aggressive behavior. Further studies are warranted to assess the clinical utility and optimal method of identifying adenocarcinoma-like and other subsets of LCNEC in routine practice.	[Rekhtman, Natasha; Montecalvo, Joseph; Wang, Hangjun; Habeeb, Omar; Kadota, Kyuichi; Ladanyi, Marc; Travis, William D.; Joubert, Philippe] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Pietanza, Catherine M.; Sabari, Joshua; Rudin, Charles M.] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, New York, NY 10065 USA; [Adusumilli, Prasad] Mem Sloan Kettering Canc Ctr, Dept Thorac Surg, New York, NY 10065 USA; [Ladanyi, Marc] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Pietanza, Catherine M.] Merck Res Labs, Rahway, NJ USA; [Wang, Hangjun] McGill Univ, Jewish Gen Hosp, Dept Pathol, Montreal, PQ, Canada; [Habeeb, Omar] Wellington Hosp, Wellington, New Zealand; [Kadota, Kyuichi] Kagawa Univ, Dept Diagnost Pathol, Takamatsu, Kagawa, Japan; [Joubert, Philippe] Quebec Heart & Lung Inst, Dept Pathol, Quebec City, PQ, Canada	Rekhtman, N (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.	rekhtman@mskcc.org	Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465	Fiona and Stanley Druckenmiller Center for Lung Cancer Research; NIH/NCI Cancer Center Support Grant [P30 CA008748]	This study was supported in part by the grant from the Fiona and Stanley Druckenmiller Center for Lung Cancer Research (to NR). This research was also made possible by infrastructure support by the NIH/NCI Cancer Center Support Grant P30 CA008748.	Agoff SN, 2000, MODERN PATHOL, V13, P238, DOI 10.1038/modpathol.3880044; Augustyn A, 2014, P NATL ACAD SCI USA, V111, P14788, DOI 10.1073/pnas.1410419111; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bishop JA, 2010, HUM PATHOL, V41, P20, DOI 10.1016/j.humpath.2009.06.014; Brasch F, 2003, J BIOL CHEM, V278, P49006, DOI 10.1074/jbc.M306844200; CHEJFEC G, 1985, CANCER, V56, P2683, DOI 10.1002/1097-0142(19851201)56:11<2683::AID-CNCR2820561127>3.0.CO;2-L; Chen F, 2017, ONCOGENE, V36, P1384, DOI 10.1038/onc.2016.303; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; den Bakker MA, 2010, HISTOPATHOLOGY, V56, P356, DOI 10.1111/j.1365-2559.2010.03486.x; Fernandez-Cuesta L, 2015, J THORAC ONCOL, V10, pS185; Folpe AL, 1999, MODERN PATHOL, V12, P5; Ionescu DN, 2007, AM J SURG PATHOL, V31, P26, DOI 10.1097/01.pas.0000213319.04919.97; Iyoda A, 2007, ANN THORAC SURG, V84, P702, DOI 10.1016/j.athoracsur.2007.03.093; Jiang SX, 1998, AM J SURG PATHOL, V22, P526, DOI 10.1097/00000478-199805000-00002; Karlsson A, 2017, J THORAC ONCOL, V12, P1257, DOI 10.1016/j.jtho.2017.05.008; Karlsson A, 2015, ONCOTARGET, V6, P22028, DOI 10.18632/oncotarget.4314; Kaufmann O, 2000, HISTOPATHOLOGY, V36, P415; Kosari F, 2014, ONCOGENE, V33, P3776, DOI 10.1038/onc.2013.359; Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099222; Masai K, 2013, APPL IMMUNOHISTO M M, V21, P292, DOI 10.1097/PAI.0b013e31826fd4f3; Miyoshi T, 2017, CLIN CANCER RES, V23, P757, DOI 10.1158/1078-0432.CCR-16-0355; Moreira AL, 2014, HUM PATHOL, V45, P213, DOI 10.1016/j.humpath.2013.10.011; Mukhopadhyay S, 2012, AM J CLIN PATHOL, V138, P703, DOI 10.1309/AJCPKVBXTI9O3TEM; Ordonez NG, 2012, AM J SURG PATHOL, V36, P396, DOI 10.1097/PAS.0b013e31823b13e2; Pelosi G, 2003, CANCER-AM CANCER SOC, V97, P2487, DOI 10.1002/cncr.11376; Quinn AM, 2017, AM J SURG PATHOL, V41, P263, DOI 10.1097/PAS.0000000000000767; Rekhtman N, 2016, CLIN CANCER RES, V22, P3618, DOI 10.1158/1078-0432.CCR-15-2946; Rekhtman N, 2015, ARCH PATHOL LAB MED, V139, P434, DOI 10.5858/arpa.2014-0452-LE; Rekhtman N, 2013, MODERN PATHOL, V26, P511, DOI 10.1038/modpathol.2012.195; Rekhtman N, 2010, ARCH PATHOL LAB MED, V134, P1628, DOI 10.1043/2009-0583-RAR.1; Rossi G, 2014, VIRCHOWS ARCH, V464, P61, DOI 10.1007/s00428-013-1501-6; Sakai Y, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-47; Sarkaria IS, 2011, ANN THORAC SURG, V92, P1180, DOI 10.1016/j.athoracsur.2011.05.027; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; Travis WD, 1998, HUM PATHOL, V29, P272, DOI 10.1016/S0046-8177(98)90047-8; Travis WD, 2015, WHO CLASSIFICATION T, P69; Turner BM, 2012, ARCH PATHOL LAB MED, V136, P163, DOI 10.5858/arpa.2011-0320-OA; Yamada K, 2014, PATHOL INT, V64, P28, DOI 10.1111/pin.12127; Zhang C, 2014, AM J CLIN PATHOL, V142, P320, DOI 10.1309/AJCPGA0IUA8BHQEZ	39	10	10	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					111	121		10.1038/modpathol.2017.110			11	Pathology	Pathology	FS4MK	WOS:000419766500010	28884744	Green Accepted			2019-10-28	
J	Vivero, M; Bueno, R; Chirieac, LR				Vivero, Marina; Bueno, Raphael; Chirieac, Lucian R.			Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma	MODERN PATHOLOGY			English	Article							CLINICAL CHARACTERISTICS; HOMOZYGOUS DELETION; ASBESTOS EXPOSURE; SEQUENCING DATA; BAP1 MUTATIONS; SURVIVAL; CANCER; EXPERIENCE; CHILDHOOD; RADIATION	Pleural diffuse malignant mesothelioma typically presents during the seventh decade of life and has poor prognosis. Recent epidemiologic studies have shown differences between young and older mesothelioma patients, but the biology of pleural mesothelioma in young patients is poorly understood. We studied the clinicopathologic and genetic characteristics in pleural mesothelioma patients aged 35 years and younger. Thirty-six consecutive pleural mesothelioma patients aged 35 years and younger were compared with 48 older patients. We examined demographic and clinical characteristics, histologic type, growth patterns, mitotic index, and nuclear grade on hematoxylin and eosin-stained slides, BAP1 protein expression by immunohistochemistry, and CDKN2A and NF2 deletions by fluorescence in situ hybridization. Clinicopathologic and cytogenetic results were compared between young and older groups, and correlated with overall survival. Young patients were more frequently women, reported less asbestos exposure, and had a greater frequency of prior therapeutic radiation and family history of breast cancer than older patients (P < 0.05 each). There were no histologic differences between young and older patients (all P > 0.05). CDKN2A deletion was less prevalent in young patients (P = 0.01), loss of BAP1 protein expression less frequent in young patients (P = 0.06), and NF2 deletion rates similar between groups (P > 0.05 each). Median overall survival was 40 vs 26 months (P = 0.10) in young and older patients, respectively, and 47 vs 31 months (P = 0.04) when comparing patients with epithelioid histology only. High mitotic index and non-epithelioid histology were the only characteristics associated with a poor overall survival in young patients. Young patients with pleural mesothelioma have an equal sex distribution and are more likely to have a history of mantle radiation, family history of breast cancer, and lower rates of CDKN2A deletion than older patients. Our results suggest that pleural mesothelioma in young patients has distinctive clinical and genetic characteristics, despite some similarities to pleural mesothelioma in older patients.	[Vivero, Marina; Chirieac, Lucian R.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Amory 3,75 Francis St, Boston, MA 02115 USA; [Bueno, Raphael] Harvard Med Sch, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Vivero, M (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Amory 3,75 Francis St, Boston, MA 02115 USA.	mvivero@partners.org			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA120528]		Abo RP, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1211; ANTMAN K, 1988, J CLIN ONCOL, V6, P147, DOI 10.1200/JCO.1988.6.1.147; Baumann F, 2015, CARCINOGENESIS, V36, P76, DOI 10.1093/carcin/bgu227; Borczuk AC, 2016, CANCER BIOL THER, V17, P328, DOI 10.1080/15384047.2016.1145850; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; BRENNER J, 1981, MED PEDIATR ONCOL, V9, P367, DOI 10.1002/mpo.2950090409; Centers for Disease Control, WORK REL LUNG DIS SU; Chiosea S, 2008, MODERN PATHOL, V21, P742, DOI 10.1038/modpathol.2008.45; Chirieac LR, 2013, J CLIN ONCOL, V31, P4544, DOI 10.1200/JCO.2013.49.9616; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; COGGON D, 1995, OCCUP ENVIRON MED, V52, P775, DOI 10.1136/oem.52.11.775; Dacic S, 2008, VIRCHOWS ARCH, V453, P627, DOI 10.1007/s00428-008-0689-3; Delgermaa V, 2011, B WORLD HEALTH ORGAN, V89, P716, DOI 10.2471/BLT.11.086678; Factor RE, 2009, CANCER CYTOPATHOL, V117, P247, DOI 10.1002/cncy.20036; FRAIRE AE, 1988, CANCER, V62, P838, DOI 10.1002/1097-0142(19880815)62:4<838::AID-CNCR2820620433>3.0.CO;2-9; Galateau-Salle F, 2015, WHO CLASSIFICATION T, P156; GRUNDY GW, 1972, CANCER, V30, P1216, DOI 10.1002/1097-0142(197211)30:5<1216::AID-CNCR2820300511>3.0.CO;2-5; Illei PB, 2003, CLIN CANCER RES, V9, P2108; Kadota K, 2012, MODERN PATHOL, V25, P260, DOI 10.1038/modpathol.2011.146; KANE MJ, 1990, CANCER, V65, P1449, DOI 10.1002/1097-0142(19900315)65:6<1449::AID-CNCR2820650633>3.0.CO;2-0; LAW MR, 1983, THORAX, V38, P744, DOI 10.1136/thx.38.10.744; Lopez-Rios F, 2006, CANCER RES, V66, P2970, DOI 10.1158/0008-5472.CAN-05-3907; McDonald JC, 2001, ANN OCCUP HYG, V45, P519, DOI 10.1016/S0003-4878(01)00047-3; Moran CA, 2008, HISTOPATHOLOGY, V52, P824, DOI 10.1111/j.1365-2559.2008.03029.x; Murthy SS, 1999, J CELL PHYSIOL, V180, P150, DOI 10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H; National Cancer Institute, 1975, SURV EP END RES PROG; Neumann V, 2001, INT ARCH OCC ENV HEA, V74, P383, DOI 10.1007/s004200100240; Pugh TJ, 2016, GENET MED, V18, P712, DOI 10.1038/gim.2015.156; Reid A, 2007, CHEST, V131, P376, DOI 10.1378/chest.06-1690; Roushdy-Hammady I, 2001, LANCET, V357, P444, DOI 10.1016/S0140-6736(00)04013-7; Sholl LM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87062; SPIRTAS R, 1988, INT J CANCER, V41, P525, DOI 10.1002/ijc.2910410409; SPIRTAS R, 1994, OCCUP ENVIRON MED, V51, P804, DOI 10.1136/oem.51.12.804; Stathopoulos J, 2005, ANTICANCER RES, V25, P3671; Sugarbaker DJ, 2011, EUR J CARDIO-THORAC, V40, P298, DOI 10.1016/j.ejcts.2010.12.024; Sugarbaker DJ, 1999, J THORAC CARDIOV SUR, V117, P54, DOI 10.1016/S0022-5223(99)70469-1; Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912; Teta MJ, 2007, CANCER, V109, P1432, DOI 10.1002/cncr.22526; Teta MJ, 2008, EUR J CANCER PREV, V17, P525, DOI 10.1097/CEJ.0b013e3282f0c0a2; Thomas A, 2015, ONCOTARGET, V6, P16766, DOI 10.18632/oncotarget.4414; Yoshikawa Y, 2012, CANCER SCI, V103, P868, DOI 10.1111/j.1349-7006.2012.02223.x; Zauderer MG, 2013, J THORAC ONCOL, V8, P1430, DOI 10.1097/JTO.0b013e31829e7ef9	42	3	3	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					122	131		10.1038/modpathol.2017.108			10	Pathology	Pathology	FS4MK	WOS:000419766500011	28884745	Green Accepted			2019-10-28	
J	Graham, RP; Yeh, MM; Lam-Himlin, D; Roberts, LR; Terracciano, L; Cruise, MW; Greipp, PT; Zreik, RT; Jain, D; Zaid, N; Salaria, SN; Jin, L; Wang, XK; Rustin, JG; Kerr, SE; Sukov, WR; Solomon, DA; Kakar, S; Waterhouse, E; Gill, RM; Ferrell, L; Alves, VAF; Nart, D; Yilmaz, F; Roessler, S; Longerich, T; Schirmacher, P; Torbenson, MS				Graham, Rondell P.; Yeh, Matthew M.; Lam-Himlin, Dora; Roberts, Lewis R.; Terracciano, Luigi; Cruise, Michael W.; Greipp, Patricia T.; Zreik, Riyam T.; Jain, Dhanpat; Zaid, Nida; Salaria, Safia N.; Jin, Long; Wang, Xiaoke; Rustin, Jeanette G.; Kerr, Sarah E.; Sukov, William R.; Solomon, David A.; Kakar, Sanjay; Waterhouse, Emily; Gill, Ryan M.; Ferrell, Linda; Alves, Venancio A. F.; Nart, Deniz; Yilmaz, Funda; Roessler, Stephanie; Longerich, Thomas; Schirmacher, Peter; Torbenson, Michael S.			Molecular testing for the clinical diagnosis of fibrolamellar carcinoma	MODERN PATHOLOGY			English	Article							HEPATOCELLULAR-CARCINOMA; FUSION GENE; LIVER; AMPLIFICATION; DNAJB1-PRKACA; FEATURES	Fibrolamellar carcinoma has a distinctive morphology and immunophenotype, including cytokeratin 7 and CD68 co-expression. Despite the distinct findings, accurate diagnosis of fibrolamellar carcinoma continues to be a challenge. Recently, fibrolamellar carcinomas were found to harbor a characteristic somatic gene fusion, DNAJB1-PRKACA. A break-apart fluorescence in situ hybridization (FISH) assay was designed to detect this fusion event and to examine its diagnostic performance in a large, multicenter, multinational study. Cases initially classified as fibrolamellar carcinoma based on histological features were reviewed from 124 patients. Upon central review, 104 of the 124 cases were classified histologically as typical of fibrolamellar carcinoma, 12 cases as 'possible fibrolamellar carcinoma' and 8 cases as 'unlikely to be fibrolamellar carcinoma'. PRKACA FISH was positive for rearrangement in 102 of 103 (99%) typical fibrolamellar carcinomas, 9 of 12 'possible fibrolamellar carcinomas' and 0 of 8 cases 'unlikely to be fibrolamellar carcinomas'. Within the morphologically typical group of fibrolamellar carcinomas, two tumors with unusual FISH patterns were also identified. Both cases had the fusion gene DNAJB1-PRKACA, but one also had amplification of the fusion gene and one had heterozygous deletion of the normal PRKACA locus. In addition, 88 conventional hepatocellular carcinomas were evaluated with PRKACA FISH and all were negative. These findings demonstrate that FISH for the PRKACA rearrangement is a clinically useful tool to confirm the diagnosis of fibrolamellar carcinoma, with high sensitivity and specificity. A diagnosis of fibrolamellar carcinoma is more accurate when based on morphology plus confirmatory testing than when based on morphology alone.	[Graham, Rondell P.; Roberts, Lewis R.; Greipp, Patricia T.; Jin, Long; Wang, Xiaoke; Rustin, Jeanette G.; Kerr, Sarah E.; Sukov, William R.; Torbenson, Michael S.] Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA; [Yeh, Matthew M.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Lam-Himlin, Dora] Mayo Clin, Dept Lab Med & Pathol, Scottsdale, AZ USA; [Terracciano, Luigi] Univ Hosp Basel, Inst Pathol, Div Mol Pathol, Basel, Switzerland; [Cruise, Michael W.] Cleveland Clin, Dept Pathol, Cleveland, OH 44106 USA; [Zreik, Riyam T.] Baylor Scott & White Mem Hosp, Dept Pathol, Temple, TX USA; [Jain, Dhanpat] Yale, Dept Pathol, New Haven, CT USA; [Zaid, Nida; Salaria, Safia N.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Solomon, David A.; Kakar, Sanjay; Waterhouse, Emily; Gill, Ryan M.; Ferrell, Linda] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Alves, Venancio A. F.] Univ Sao Paulo, Inst Canc Estado Sao Paulo, Fac Med, Sao Paulo, Brazil; [Nart, Deniz; Yilmaz, Funda] Ege Univ, Dept Pathol, Izmir, Turkey; [Roessler, Stephanie; Schirmacher, Peter] Univ Hosp, Inst Pathol, Heidelberg, Germany; [Longerich, Thomas] Univ Hosp RWTH, Inst Pathol, Aachen, Germany	Torbenson, MS (reprint author), Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA.	torbenson.michael@mayo.edu	Barbet, Funda Yilmaz/V-9938-2017; Yilmaz, Funda/O-9646-2018; Roessler, Stephanie/J-8432-2019	Barbet, Funda Yilmaz/0000-0003-1837-6498; Yilmaz, Funda/0000-0003-1837-6498; Roessler, Stephanie/0000-0002-5333-5942; Graham, Rondell/0000-0002-8686-4867; Roberts, Lewis/0000-0001-7885-8574; Zreik, Riyam/0000-0002-4102-3562	NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30 DK026743]		Abbott JJ, 2006, MODERN PATHOL, V19, P1512, DOI 10.1038/modpathol.3800695; Cornella H, 2015, GASTROENTEROLOGY, V148, P806, DOI 10.1053/j.gastro.2014.12.028; Duan FH, 2012, GENE CHROMOSOME CANC, V51, P662, DOI 10.1002/gcc.21953; El-Serag HB, 2004, HEPATOLOGY, V39, P798, DOI 10.1002/hep.20096; Graham RP, 2016, MODERN PATHOL, V29, P607, DOI 10.1038/modpathol.2016.59; Graham RP, 2016, HISTOPATHOLOGY, V68, P686, DOI 10.1111/his.12799; Graham RP, 2015, MODERN PATHOL, V28, P822, DOI 10.1038/modpathol.2015.4; Honeyman JN, 2014, SCIENCE, V343, P1010, DOI 10.1126/science.1249484; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Malouf G, 2009, J CLIN PATHOL, V62, P519, DOI 10.1136/jcp.2008.062620; Martin-Subero JI, 2005, GENE CHROMOSOME CANC, V43, P414, DOI 10.1002/gcc.20187; Oikawa T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9070; Ross HM, 2011, MODERN PATHOL, V24, P390, DOI 10.1038/modpathol.2010.207; Terracciano LM, 2004, ARCH PATHOL LAB MED, V128, P222; Torbenson M, 2007, ADV ANAT PATHOL, V14, P217, DOI 10.1097/PAP.0b013e3180504913; Torbenson M, 2012, SCIENTIFICA, DOI 10.6064/2012/743790; Tornoczky T, 2012, PATHOL ONCOL RES, V18, P545, DOI 10.1007/s12253-011-9468-6; VANEYKEN P, 1990, HISTOPATHOLOGY, V17, P101; Vivekanandan P, 2009, HUM PATHOL, V40, P293, DOI 10.1016/j.humpath.2008.08.003; Ward SC, 2011, SEMIN LIVER DIS, V31, P61, DOI 10.1055/s-0031-1272835; Ward SC, 2010, MODERN PATHOL, V23, P1180, DOI 10.1038/modpathol.2010.105; Wood LD, 2013, MODERN PATHOL, V26, P1586, DOI 10.1038/modpathol.2013.68	22	9	9	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					141	149		10.1038/modpathol.2017.103			9	Pathology	Pathology	FS4MK	WOS:000419766500013	28862261	Green Published			2019-10-28	
J	Zhao, L; Westerhoff, M; Pai, RK; Choi, WT; Gao, ZH; Hart, J				Zhao, Lei; Westerhoff, Maria; Pai, Rish K.; Choi, Won-Tak; Gao, Zu-Hua; Hart, John			Centrilobular ductular reaction correlates with fibrosis stage and fibrosis progression in non-alcoholic steatohepatitis	MODERN PATHOLOGY			English	Article							FATTY LIVER-DISEASE; NATURAL-HISTORY; PROGENITOR CELLS; CYTOKERATIN 7; EXPRESSION; REGENERATION; MORTALITY; BIOPSIES; HEPATOCYTES; ASSOCIATION	There is increasing interest in the role of ductular reaction as part of the pathogenesis and characteristic histology of non-alcoholic steatohepatitis. However, earlier studies did not separately assess the contribution of periportal and centrilobular zone ductular reaction over the spectrum of non-alcoholic steatohepatitis, and their clinical significance remains unclear. We herein analyzed the character of ductular reaction in each hepatic zone in non-alcoholic steatohepatitis biopsies and for the first time evaluated the prognostic value of ductular reaction in baseline biopsies as a predictor of progression of fibrosis in subsequent biopsies. A total of 90 non-alcoholic steatohepatitis liver biopsies were included in the cohort. The relationships among ductular reaction, grade, stage, and other common histopathologic findings in non-alcoholic steatohepatitis were analyzed in a cross-sectional manner. Among these patients, a total of 47 patients underwent sequential liver biopsies in the absence of effective treatment. The frequency of ductular reaction and the other histopathologic parameters in the initial biopsies were analyzed as predictors of progression of fibrosis in the second biopsies in a longitudinal analysis. Centrilobular ductular reaction was identified in 90% of patients and 38% of centrilobular zones. The prevalence of centrilobular ductular reaction increased as non-alcoholic steatohepatitis grade increased (P = 0.0002) and also as stage of fibrosis increased (P < 0.0001) in the cross-sectional study. In the longitudinal study, the frequency of centrilobular ductular reaction in the initial biopsies was significantly higher in the group of progressors and correlated with the rate of fibrosis progression (P = 0.02). Centrilobular ductular reaction is common in non-alcoholic steatohepatitis and its presence correlates significantly with increasing necroinflammatory activity and fibrosis stage. Development of centrilobular ductular reaction appears to predict progression of fibrosis in subsequent biopsies.	[Zhao, Lei] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Westerhoff, Maria] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Pai, Rish K.] Mayo Clin, Dept Lab Med, Scottsdale, AZ USA; [Pai, Rish K.] Mayo Clin, Dept Pathol, Scottsdale, AZ USA; [Choi, Won-Tak] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Gao, Zu-Hua] McGill Univ, Dept Pathol, Montreal, PQ, Canada; [Hart, John] Univ Chicago, Dept Pathol, 5841 S Maryland Ave,E-607D,MC 6101, Chicago, IL 60637 USA	Hart, J (reprint author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,E-607D,MC 6101, Chicago, IL 60637 USA.	john.hart@uchospitals.edu					Adams LA, 2005, J HEPATOL, V42, P132, DOI 10.1016/j.jhep.2004.09.012; Angulo P, 2010, HEPATOLOGY, V51, P373, DOI 10.1002/hep.23521; Argo CK, 2009, CLIN LIVER DIS, V13, P511, DOI 10.1016/j.cld.2009.07.005; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1016/S0002-9270(99)00433-5; Brunt EM, 2004, SEMIN LIVER DIS, V24, P3; Clouston AD, 2005, HEPATOLOGY, V41, P809, DOI 10.1002/hep.20650; Clouston AD, 2009, HEPATOLOGY, V49, P1424, DOI 10.1002/hep.22893; Desmet VJ, 2011, VIRCHOWS ARCH, V458, P251, DOI 10.1007/s00428-011-1048-3; Ekstedt M, 2006, HEPATOLOGY, V44, P865, DOI 10.1002/hep.21327; Fassio E, 2004, HEPATOLOGY, V40, P820, DOI 10.1002/hep.20410; Fleming KE, 2013, LIVER INT, V33, P525, DOI 10.1111/liv.12099; GEBHARDT R, 1989, CARCINOGENESIS, V10, P1917, DOI 10.1093/carcin/10.10.1917; Gill RM, 2011, AM J SURG PATHOL, V35, P1400, DOI 10.1097/PAS.0b013e3182254283; Gouw ASH, 2011, HEPATOLOGY, V54, P1853, DOI 10.1002/hep.24613; Harrison SA, 2003, AM J GASTROENTEROL, V98, P2042, DOI 10.1016/S0002-9270(03)00622-1; Hui AY, 2005, ALIMENT PHARM THER, V21, P407, DOI 10.1111/j.1365-2036.2005.02334.x; Itoh T, 2014, HEPATOLOGY, V59, P1617, DOI 10.1002/hep.26753; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Krings G, 2014, AM J SURG PATHOL, V38, P205, DOI 10.1097/PAS.0000000000000099; Lamers WH, 1999, J HISTOCHEM CYTOCHEM, V47, P1507, DOI 10.1177/002215549904701202; Loomba R, 2012, HEPATOLOGY, V56, P943, DOI 10.1002/hep.25772; Lowes KN, 1999, AM J PATHOL, V154, P537, DOI 10.1016/S0002-9440(10)65299-6; Marchesini G, 2016, HEPATOLOGY, V63, P2032, DOI 10.1002/hep.28392; Matsukuma S, 2012, HISTOPATHOLOGY, V61, P857, DOI 10.1111/j.1365-2559.2012.04278.x; McPherson S, 2015, J HEPATOL, V62, P1148, DOI 10.1016/j.jhep.2014.11.034; Nettschwander-Tetri BA, 2010, HEPATOLOGY, V52, P913, DOI 10.1002/hep.23784; Pai RK, 2010, MODERN PATHOL, V23, P1650, DOI 10.1038/modpathol.2010.175; Richardson MM, 2007, GASTROENTEROLOGY, V133, P80, DOI 10.1053/j.gastro.2007.05.012; Roskams TA, 2004, HEPATOLOGY, V39, P1739, DOI 10.1002/hep.20130; Sedlaczek N, 2001, AM J PATHOL, V158, P1239, DOI 10.1016/S0002-9440(10)64074-6; Sicklick JK, 2006, AM J PHYSIOL-GASTR L, V291, pG575, DOI 10.1152/ajpgi.00102.2006; Singh S, 2015, CLIN GASTROENTEROL H, V13, P643, DOI 10.1016/j.cgh.2014.04.014; Skoien R, 2013, LIVER INT, V33, P624, DOI 10.1111/liv.12100; Soderberg C, 2010, HEPATOLOGY, V51, P595, DOI 10.1002/hep.23314; Stepanova M, 2013, DIGEST DIS SCI, V58, P3017, DOI 10.1007/s10620-013-2743-5; Strazzabosco M, 2012, J HEPATOL, V56, P1159, DOI 10.1016/j.jhep.2011.09.022; Turanyi E, 2010, HISTOPATHOLOGY, V57, P607, DOI 10.1111/j.1365-2559.2010.03668.x; Wong VWS, 2010, GUT, V59, P969, DOI 10.1136/gut.2009.205088; Younossi ZM, 2011, HEPATOLOGY, V53, P1874, DOI 10.1002/hep.24268	39	2	2	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					150	159		10.1038/modpathol.2017.115			10	Pathology	Pathology	FS4MK	WOS:000419766500014	28862262				2019-10-28	
J	Wu, MK; Vujanic, GM; Fahiminiya, S; Watanabe, N; Thorner, PS; O'Sullivan, MJ; Fabian, MR; Foulkes, WD				Wu, Mona K.; Vujanic, Gordan M.; Fahiminiya, Somayyeh; Watanabe, Noriko; Thorner, Paul S.; O'Sullivan, Maureen J.; Fabian, Marc R.; Foulkes, William D.			Anaplastic sarcomas of the kidney are characterized by DICER1 mutations	MODERN PATHOLOGY			English	Article							PLEUROPULMONARY BLASTOMA; CYSTIC NEPHROMA; WILMS-TUMORS; GERM-LINE; PINEALOBLASTOMA; HETEROZYGOSITY; MECHANISMS; FEATURES; ENTITY	Anaplastic sarcoma of the kidney is a rare tumor (<= 25 reported cases) characterized by the presence of cysts, and solid areas composed of bundles of undifferentiated spindle cells, showing marked cellular anaplasia (usually accompanied by TP53 overexpression). These tumors often feature prominent areas of cartilage or chondroid material. Germline mutations in DICER1, encoding the microRNA (miRNA) processor DICER1, cause an eponymous syndrome. Recent reports suggest that anaplastic sarcoma of the kidney should be included in DICER1 syndrome as germline DICER1 mutations are associated with the occurrence of such tumors. Therefore, we sought to determine the following: (1) what proportion of anaplastic sarcoma of the kidney have DICER1 mutations; (2) whether the identified mutations affect both alleles of DICER1 (ie, are biallelic); (3) whether somatic missense mutations in the DICER1 RNase IIIb domain impact miRNA generation; and (4) whether TP53 alteration always occurs in these tumors. DICER1 mutations were evaluated by Sanger sequencing and next-generation sequencing in nine tumor/normal pairs. Impact of DICER1 mutations on miRNA generation was evaluated via an in vitro DICER1 cleavage assay. TP53 status was assessed by immunohistochemistry and next-generation sequencing. Eight of the nine cases had at least one RNase IIIb DICER1 mutation that impacted the generation of miRNAs. There were six tumors with truncating DICER1 mutations and in four of them, the mutation found in the tumor was also detected in adjacent normal tissue, and therefore was likely to be either mosaic or germline in origin. Analysis of mutation phase revealed that two of three tumors had biallelic DICER1 mutations. Six of nine anaplastic sarcomas of the kidney had aberrant TP53 immunohistochemisty with damaging TP53 mutations identified in three cases. Taken together, these data suggest that the great majority of anaplastic sarcomas of the kidney have DICER1 mutations and confirm that these tumors are part of the DICER1 syndrome.	[Wu, Mona K.; Foulkes, William D.] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Dept Med Genet, Montreal, PQ, Canada; [Vujanic, Gordan M.] Cardiff Univ, Sch Med, Dept Cellular Pathol, Univ Hosp Wales, Cardiff, S Glam, Wales; [Vujanic, Gordan M.] Sidra Med & Res Ctr, Dept Pathol, Doha, Qatar; [Fahiminiya, Somayyeh; Foulkes, William D.] McGill Univ, Res Inst, Hlth Ctr, Montreal, PQ, Canada; [Fahiminiya, Somayyeh] McGill Univ, Montreal, PQ, Canada; [Fahiminiya, Somayyeh] Genome Quebec Innovat Ctr, Montreal, PQ, Canada; [Watanabe, Noriko] Nihon Univ, Sch Med, Dept Pathol, Tokyo, Japan; [Thorner, Paul S.] Hosp Sick Children, Dept Pediat Lab Med, Toronto, ON, Canada; [Thorner, Paul S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [O'Sullivan, Maureen J.] Our Ladys Childrens Hosp, Histol Lab, Dublin 12, Ireland; [O'Sullivan, Maureen J.] Univ Dublin, Trinity Coll, Dublin 2, Ireland; [O'Sullivan, Maureen J.] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin 12, Ireland; [Fabian, Marc R.] McGill Univ, Segal Canc Ctr, Jewish Gen Hosp, Dept Oncol,Lady Davis Inst Med Res, Montreal, PQ, Canada; [Foulkes, William D.] McGill Univ, Dept Oncol, Program Canc Genet, Montreal, PQ, Canada; [Foulkes, William D.] McGill Univ, Dept Human Genet, Program Canc Genet, Montreal, PQ, Canada	Foulkes, WD (reprint author), Jewish Gen Hosp, Lady Davis Inst, Dept Med Genet, 3755 Chemin Cote St Catherine Montreal, Montreal, PQ, Canada.	william.foulkes@mcgill.ca		O'Sullivan, Maureen/0000-0001-5838-1609	Alex's Lemonade Stand; Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [FDN-148390]; CIHR grantCanadian Institutes of Health Research (CIHR) [MOP-130425]; Fonds de Recherche du Quebec-Sante (FRQS) award	We thank the Drs N Benlimame, M Bayat, and D Grehan for performing the immunohistochemistry, and Dr A Spatz for his interpretation of the staining. We thank Drs R Grant and C Goudie for their clinical contribution to this study, and John R Priest for reading the manuscript. WDF is supported by Alex's Lemonade Stand and a Canadian Institutes for Health Research (CIHR) Grant (FDN-148390); MRF by a CIHR grant (MOP-130425), and MKW by a Fonds de Recherche du Quebec-Sante (FRQS) award.	Antonescu C, 1997, MODERN PATHOL, V10, P391; Argani P, 2000, AM J SURG PATHOL, V24, P1087, DOI 10.1097/00000478-200008000-00006; Arnold MM, 1995, MODERN PATHOL, V8, P409; Bahubeshi A, 2010, J MED GENET, V47, P863, DOI 10.1136/jmg.2010.081216; Cajaiba MM, 2016, HUM PATHOL, V48, P81, DOI 10.1016/j.humpath.2015.08.022; de Kock L, 2016, J MED GENET, V53, P43, DOI 10.1136/jmedgenet-2015-103428; de Kock L, 2014, ACTA NEUROPATHOL, V128, P583, DOI 10.1007/s00401-014-1318-7; de Kock L, 2014, ACTA NEUROPATHOL, V128, P111, DOI 10.1007/s00401-014-1285-z; Delahunt B, 1998, CANCER, V82, P427; Doros LA, 2014, MODERN PATHOL, V27, P1267, DOI 10.1038/modpathol.2013.242; Faria PA, 1996, PEDIATR PATHOL LAB M, V16, P1005, DOI 10.1080/15513819609168724; Foulkes WD, 2014, NAT REV CANCER, V14, P662, DOI 10.1038/nrc3802; Gomi K, 2010, HUM PATHOL, V41, P1495, DOI 10.1016/j.humpath.2010.03.008; Heravi-Moussavi A, 2012, NEW ENGL J MED, V366, P234, DOI 10.1056/NEJMoa1102903; Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334; Palculict TB, 2016, J MED GENET, V53, P385, DOI 10.1136/jmedgenet-2015-103311; Pugh TJ, 2014, ONCOGENE, V33, P5295, DOI 10.1038/onc.2014.150; Rakheja D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5802; Sabbaghian N, 2012, J MED GENET, V49, P417, DOI 10.1136/jmedgenet-2012-100898; Seki M, 2014, CANCER RES, V74, P2742, DOI 10.1158/0008-5472.CAN-13-2470; Slade I, 2011, J MED GENET, V48, P273, DOI 10.1136/jmg.2010.083790; Vujanic GM, 2007, AM J SURG PATHOL, V31, P1459, DOI 10.1097/PAS.0b013e31804d43a4; Wang YM, 2015, NEOPLASIA, V17, P650, DOI 10.1016/j.neo.2015.08.003; Watanabe N, 2013, PEDIATR INT, V55, pE129, DOI 10.1111/ped.12167; Wu MK, 2016, ENDOCR-RELAT CANCER, V23, pL1, DOI 10.1530/ERC-15-0460; Wu MK, 2013, J PATHOL, V230, P154, DOI 10.1002/path.4196; Wu MK, 2016, HUM PATHOL, V53, P114, DOI 10.1016/j.humpath.2016.03.002; Wu MK, 2016, PEDIATR BLOOD CANCER, V63, P1272, DOI 10.1002/pbc.25959; Yoshida M, 2017, HUM PATHOL, V61, P205, DOI 10.1016/j.humpath.2016.06.024	29	9	9	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					169	178		10.1038/modpathol.2017.100			10	Pathology	Pathology	FS4MK	WOS:000419766500016	28862265	Bronze			2019-10-28	
J	Skala, SL; Xiao, H; Udager, AM; Dhanasekaran, SM; Shukla, S; Zhang, Y; Landau, C; Shao, LN; Roulston, D; Wang, LS; Siddiqui, J; Cao, XH; Magi-Galluzzi, C; Zhang, M; Osunkoya, AO; Smith, SC; McKenney, JK; Betz, BL; Myers, JL; Chinnaiyan, AM; Tomlins, SA; Mehra, R				Skala, Stephanie L.; Xiao, Hong; Udager, Aaron M.; Dhanasekaran, Saravana M.; Shukla, Sudhanshu; Zhang, Yang; Landau, Carrie; Shao, Lina; Roulston, Diane; Wang, Lisha; Siddiqui, Javed; Cao, Xuhong; Magi-Galluzzi, Cristina; Zhang, Miao; Osunkoya, Adeboye O.; Smith, Steven C.; McKenney, Jesse K.; Betz, Bryan L.; Myers, Jeffrey L.; Chinnaiyan, Arul M.; Tomlins, Scott A.; Mehra, Rohit			Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays	MODERN PATHOLOGY			English	Article							BREAK-APART FISH; GENE-FUSION; MOLECULAR ANALYSIS; FEATURES; T(6/11); ENTITY; TUMOR; ADENOCARCINOMA; CLASSIFICATION; REARRANGEMENTS	Renal cell carcinomas with MITF aberrations demonstrate a wide morphologic spectrum, highlighting the need to consider these entities within the differential diagnosis of renal tumors encountered in clinical practice. Herein, we describe our experience with application of clinical fluorescence in situ hybridization (FISH) assays for detection of TFE3 and TFEB gene aberrations from 85 consecutive renal cell carcinoma cases submitted to our genitourinary FISH service. Results from 170 FISH assays performed on these tumors were correlated with available clinicopathologic findings. Ninety-eight percent of renal tumors submitted for FISH evaluation were from adult patients. Thirty-one (37%) tumors were confirmed to demonstrate MITF aberrations (21 TFE3 translocation, 4 TFEB translocation, and 6 TFEB amplification cases). Overall, renal cell carcinomas with MITF aberrations demonstrated morphologic features overlapping with clear cell, papillary, or clear cell papillary renal cell carcinomas. Renal cell carcinomas with MITF aberrations were significantly more likely to demonstrate dual (eosinophilic and clear) cytoplasmic tones (P = 0.030), biphasic TFEB translocation renal cell carcinoma-like morphology (P = 0.002), psammomatous calcifications (P = 0.002), and nuclear pseudoinclusions (P = 0.001) than renal cell carcinomas without MITF aberrations. Notably, 7/9 (78%) renal cell carcinomas exhibiting subnuclear clearing and linear nuclear array (6 of which showed high World Health Organization/International Society of Urological Pathology nucleolar grade) demonstrated TFE3 translocation, an association that was statistically significant when compared with renal cell carcinomas without MITF aberrations (P = 0.009). In this cohort comprising consecutive cases, TFEB-amplified renal cell carcinomas were more commonly identified than renal cell carcinomas with TFEB translocations, and four (67%) of these previously unreported TFEB-amplified renal cell carcinomas demonstrated oncocytic and papillary features with a high World Health Organization/International Society of Urological Pathology nucleolar grade. In summary, TFE3 and TFEB FISH evaluation aids in identification and accurate classification of renal cell carcinomas with MITF aberrations, including TFEB-amplified renal cell carcinoma, which may demonstrate aggressive behavior.	[Skala, Stephanie L.; Xiao, Hong; Udager, Aaron M.; Shao, Lina; Roulston, Diane; Betz, Bryan L.; Myers, Jeffrey L.; Chinnaiyan, Arul M.; Tomlins, Scott A.; Mehra, Rohit] Univ Michigan Hlth Syst, Dept Pathol, Room 2G332 UH,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA; [Xiao, Hong; Zhang, Yang; Landau, Carrie; Shao, Lina; Roulston, Diane] Univ Michigan Hlth Syst, Clin Cytogenet Lab, Ann Arbor, MI 48109 USA; [Dhanasekaran, Saravana M.; Shukla, Sudhanshu; Wang, Lisha; Siddiqui, Javed; Cao, Xuhong; Chinnaiyan, Arul M.; Tomlins, Scott A.; Mehra, Rohit] Michigan Ctr Translat Pathol, Ann Arbor, MI USA; [Magi-Galluzzi, Cristina; McKenney, Jesse K.] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA; [Zhang, Miao] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Osunkoya, Adeboye O.] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; [Osunkoya, Adeboye O.] Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA; [Smith, Steven C.] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA; [Chinnaiyan, Arul M.; Tomlins, Scott A.; Mehra, Rohit] Univ Michigan Hlth Syst, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA; [Chinnaiyan, Arul M.] Howard Hughes Med Inst, Ann Arbor, MI USA	Mehra, R (reprint author), Univ Michigan Hlth Syst, Dept Pathol, Room 2G332 UH,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mrohit@med.umich.edu		Dhanasekaran, saravana mohan/0000-0002-0489-2224; Udager, Aaron/0000-0002-8254-5404	Howard Hughes Medical InstituteHoward Hughes Medical Institute		Argani P, 2002, AM J SURG PATHOL, V26, P1553, DOI 10.1097/00000478-200212000-00003; Argani P, 2003, ONCOGENE, V22, P5374, DOI 10.1038/sj.onc.1206686; Argani P, 2003, AM J SURG PATHOL, V27, P750, DOI 10.1097/00000478-200306000-00005; Argani P, 2001, AM J PATHOL, V159, P179, DOI 10.1016/S0002-9440(10)61684-7; Argani P, 2007, AM J SURG PATHOL, V31, P1149, DOI 10.1097/PAS.0b013e318031ffff; Argani P, 2017, AM J SURG PATHOL, V41, P655, DOI 10.1097/PAS.0000000000000835; Argani P, 2016, AM J SURG PATHOL, V40, P1484, DOI 10.1097/PAS.0000000000000720; Argani P, 2016, AM J SURG PATHOL, V40, P723, DOI 10.1097/PAS.0000000000000631; Argani P, 2015, SEMIN DIAGN PATHOL, V32, P103, DOI 10.1053/j.semdp.2015.02.003; Argani P, 2012, AM J SURG PATHOL, V36, P1516, DOI 10.1097/PAS.0b013e3182613d8f; Chen FJ, 2016, CELL REP, V14, P2476, DOI 10.1016/j.celrep.2016.02.024; Chen YB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13131; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014; Durinck S, 2015, NAT GENET, V47, P13, DOI 10.1038/ng.3146; Falzarano SM, 2016, AM J SURG PATHOL, V40, P989, DOI 10.1097/PAS.0000000000000632; Green WM, 2013, AM J SURG PATHOL, V37, P1150, DOI 10.1097/PAS.0b013e31828a69ae; Gupta S, 2017, MODERN PATHOL, V30, P998, DOI 10.1038/modpathol.2017.24; Hora M, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-245; Inamura K, 2012, AM J SURG PATHOL, V36, P35, DOI 10.1097/PAS.0b013e3182293ec3; Lilleby Wolfgang, 2015, J Med Case Rep, V9, P281, DOI 10.1186/s13256-015-0749-7; Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917; Mehra R, 2008, CANCER RES, V68, P3584, DOI 10.1158/0008-5472.CAN-07-6154; Mehra R, 2007, CANCER RES, V67, P7991, DOI 10.1158/0008-5472.CAN-07-2043; Mehra R, 2007, MODERN PATHOL, V20, P538, DOI 10.1038/modpathol.3800769; Mehra R, 2016, CANCER DISCOV, V6, P1258, DOI 10.1158/2159-8290.CD-16-0267; Meyer PN, 2007, AM J CLIN PATHOL, V128, P70, DOI 10.1309/LR5G1VMXPY3G0CUK; Moch H, 2016, WHO CLASSIFICATION T, P14; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Mosquera JM, 2011, DIAGN MOL PATHOL, V20, P129, DOI 10.1097/PDM.0b013e31820e9c67; Parihar A, 2015, INT J SURG PATHOL, V23, P234, DOI 10.1177/1066896914562280; Peckova K, 2014, ANN DIAGN PATHOL, V18, P351, DOI 10.1016/j.anndiagpath.2014.10.002; Petersson F, 2012, HUM PATHOL, V43, P726, DOI 10.1016/j.humpath.2011.07.001; Rao Q, 2013, INT J CLIN EXP PATHO, V6, P1452; Rao Q, 2013, AM J SURG PATHOL, V37, P804, DOI 10.1097/PAS.0b013e31827e17cb; Rao Q, 2012, AM J SURG PATHOL, V36, P1327, DOI 10.1097/PAS.0b013e31825aafb5; Schmidt LS, 2016, SEMIN ONCOL, V43, P566, DOI 10.1053/j.seminoncol.2016.09.001; Smith NE, 2014, AM J SURG PATHOL, V38, P604, DOI 10.1097/PAS.0000000000000203; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Suarez-Vilela D, 2011, INT J SURG PATHOL, V19, P506, DOI 10.1177/1066896909340531; Sukov WR, 2012, AM J SURG PATHOL, V36, P663, DOI 10.1097/PAS.0b013e31824dd972; Udager AM, 2016, ARCH PATHOL LAB MED, V140, P1026, DOI 10.5858/arpa.2016-0218-RA; Udager AM, 2014, PROSTATE, V74, P1199, DOI 10.1002/pros.22836; Udager AM, 2014, CANCER J, V20, P29, DOI 10.1097/PPO.0000000000000017; Williamson SR, 2017, HUM PATHOL, V62, P175, DOI 10.1016/j.humpath.2016.10.024; Williamson SR, 2017, AM J SURG PATHOL, V41, P287, DOI 10.1097/PAS.0000000000000776; Williamson SR, 2013, MODERN PATHOL, V26, P697, DOI 10.1038/modpathol.2012.204; Xia Q, 2016, MODERN PATHOL, V30, P416; Zhong MH, 2012, AM J SURG PATHOL, V36, P654, DOI 10.1097/PAS.0b013e31824f24a6	49	14	16	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					179	197		10.1038/modpathol.2017.99			19	Pathology	Pathology	FS4MK	WOS:000419766500017	28840857				2019-10-28	
J	Li, H; Wang, ZZ; Xiao, W; Yan, LB; Guan, W; Hu, ZQ; Wu, LL; Huang, QH; Wang, J; Xu, H; Zhang, X; Ye, ZQ				Li, Heng; Wang, Zhize; Xiao, Wei; Yan, Libin; Guan, Wei; Hu, Zhiquan; Wu, Lily; Huang, Qihong; Wang, Ji; Xu, Hua; Zhang, Xu; Ye, Zhangqun			Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients	MODERN PATHOLOGY			English	Article							WORKING GROUP 3; RESISTANCE; VARIANTS; RECOMMENDATIONS; PROGRESSION; MECHANISMS; EXPRESSION; DEPLETION; AR-V7	Androgen-deprivation therapy has been the standard treatment for metastatic and locally advanced prostate cancer, but the majority of patients will progress to castration-resistant prostate cancer within 2-3 years. Unlike the case in breast cancer, no clinically validated biomarker has been used to predict the outcomes of androgen-deprivation therapy. To evaluate androgen-receptor splice variant-7 (AR-V7) detection in newly diagnosed advanced prostate cancer and describe the distinctive prognosis of this novel molecular subtype, this study retrospectively enrolled 168 newly diagnosed prostate cancer patients from 2003 to 2015 who received androgen-deprivation therapy. AR-V7 immunohistochemical staining was performed with a monoclonal antibody, and AR-V7 expression was determined using Immune-Reactive Score data. The association between nuclear AR-V7 expression and prognosis was determined. Multiple cause-specific Cox regression and stratified cumulative incidences were used to analyze the prognosis risk. Among the 168 patients, 32 (19%) were AR-V7-positive. Compared with the AR-V7-negative patients, the AR-V7-positive patients had significantly lower prostate-specific antigen response rates (P < 0.001) to androgen-deprivation therapy and a much shorter time to castration-resistant prostate cancer (P < 0.0001). In Kaplan-Meier analysis, the AR-V7-positive group showed markedly lower castration-resistant prostate cancer progression-free survival (P < 0.0001) and much lower cancer-specific (P < 0.0001) and overall survival (P < 0.0001) both in all enrolled patients and in patients with metastases. AR-V7 positivity was a significant predictor of castration-resistant prostate cancer progression in multiple Cox regression (hazard ratio: 4.826; 95% CI: 2.960-7.869; P < 0.001). AR-V7 immunohistochemical detection in newly diagnosed prostate cancer patients who are planning to receive androgen-deprivation therapy, especially those with metastases, is necessary and valuable for prognostic assessment. AR-V7-positive prostate cancer should be considered a novel prostate cancer subtype that should be distinguished upon initial biopsy. The main limitation of this study is its observational nature.	[Li, Heng; Wang, Zhize; Yan, Libin; Guan, Wei; Hu, Zhiquan; Xu, Hua; Ye, Zhangqun] Huazhong Univ Sci & Technol, Dept Urol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; [Li, Heng; Wang, Zhize; Yan, Libin; Guan, Wei; Hu, Zhiquan; Xu, Hua] Huazhong Univ Sci & Technol, Hubei Inst Urol, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Xiao, Wei] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Translat Med Ctr, Wuhan, Hubei, Peoples R China; [Wu, Lily] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Wu, Lily] UCLA, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA; [Huang, Qihong] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA; [Wang, Ji] Univ Minnesota, Hormel Inst, Dept Cell Death & Canc Genet, 801 16th Ave NE, Austin, MN 55912 USA; [Zhang, Xu] Chinese Peoples Liberat Army Gen Hosp, PLA Med Sch, Dept Urol, State Key Lab Kidney Dis, Beijing, Peoples R China	Xu, H (reprint author), Huazhong Univ Sci & Technol, Dept Urol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.	xuhua@hust.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [31372562, 81470935, 81402098, 81402105, 81402087]; Chenguang Program of Wuhan Science and Technology Bureau [2015070404010199]; National High Technology Research and Development Program 863National High Technology Research and Development Program of China [2014AA020607]	This work was supported by the National Natural Science Foundation of China (Grant Numbers 31372562, 81470935, 81402098, 81402105, and 81402087), the Chenguang Program of Wuhan Science and Technology Bureau (Grant Number 2015070404010199), and The National High Technology Research and Development Program 863 (Grant Number 2014AA020607). We thank all investigators and staff at the participating institutions, team members of the pathology department of Tongji Hospital and, above all, the patients, without whom this work would not have been possible.	Antonarakis ES, 2015, JAMA ONCOL, V1, P582, DOI 10.1001/jamaoncol.2015.1341; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Chandrasekar T, 2015, TRANSL ANDROL UROL, V4, P365, DOI 10.3978/j.issn.2223-4683.2015.05.02; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Choudhury AD, 2012, EUR UROL, V62, P577, DOI 10.1016/j.eururo.2012.05.054; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; Geethakumari PR, 2016, ONCOLOGY-NY, V30, P187; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232; Hussain M, 2006, J CLIN ONCOL, V24, P3984, DOI 10.1200/JCO.2006.06.4246; Nuzzo PV, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-625; Onstenk W, 2015, EUR UROL, V68, P939, DOI 10.1016/j.eururo.2015.07.007; Qu YY, 2015, SCI REP-UK, V5, DOI 10.1038/srep07654; Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Welti J, 2016, EUR UROL, V70, P599, DOI 10.1016/j.eururo.2016.03.049; Zhang XT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027970	24	10	10	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					198	208		10.1038/modpathol.2017.74			11	Pathology	Pathology	FS4MK	WOS:000419766500018	29076496				2019-10-28	
J	Slattery, ML; Lee, FY; Pellatt, AJ; Mullany, LE; Stevens, JR; Samowitz, WS; Wolff, RK; Herrick, JS				Slattery, Martha L.; Lee, Frances Y.; Pellatt, Andrew J.; Mullany, Lila E.; Stevens, John R.; Samowitz, Wade S.; Wolff, Roger K.; Herrick, Jennifer S.			Infrequently expressed miRNAs in colorectal cancer tissue and tumor molecular phenotype (vol 30, pg 1152, 2017)	MODERN PATHOLOGY			English	Correction														NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA163683]		Slattery ML, 2017, MODERN PATHOL, V30, P1152, DOI 10.1038/modpathol.2017.38	1	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					209	209		10.1038/modpathol.2017.118			1	Pathology	Pathology	FS4MK	WOS:000419766500019	29302080	Other Gold, Green Accepted			2019-10-28	
J	Furie, MB				Furie, Martha B.			A New Scope and a New Editorial Team for The American Journal of Pathology	AMERICAN JOURNAL OF PATHOLOGY			English	Editorial Material									[Furie, Martha B.] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA	Furie, MB (reprint author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.						Furie MB, 2012, AM J PATHOL, V180, P2184, DOI 10.1016/j.ajpath.2012.04.003	1	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					2	3		10.1016/j.ajpath.2017.10.008			2	Pathology	Pathology	FQ8SS	WOS:000418634100001	29132929	Bronze			2019-10-28	
J	Otero, JJ				Otero, Jose J.			Neural Regeneration a Century after Ramon y Cajal's Decree	AMERICAN JOURNAL OF PATHOLOGY			English	Editorial Material							MIGRATION		[Otero, Jose J.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA	Otero, JJ (reprint author), Ohio State Univ, 4171 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	jose.otero@osumc.edu		Otero, Jose/0000-0003-0680-4520	NIH National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL132355]	Supported by NIH National Heart, Lung, and Blood Institute grant R01HL132355 (J.J.O)	Filous AR, 2018, AM J PATHOL, V188, P53, DOI 10.1016/j.ajpath.2017.09.005; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Leferink PS, 2018, AM J PATHOL, V188, P39, DOI 10.1016/j.ajpath.2017.08.030; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; Peng L, 2018, AM J PATHOL, V188, P23, DOI 10.1016/j.ajpath.2017.09.004; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; Ramon y Cajal S, 1926, DEGENERATION REGENER; Sinnaeve J, 2018, AM J PATHOL, V188, P29, DOI 10.1016/j.ajpath.2017.08.029; Youn YH, 2018, AM J PATHOL, V188, P11, DOI 10.1016/j.ajpath.2017.08.031	9	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					4	5		10.1016/j.ajpath.2017.09.003			2	Pathology	Pathology	FQ8SS	WOS:000418634100002	29030050				2019-10-28	
J	Hsieh, T; Vaickus, MH; Remick, DG				Hsieh, Terry; Vaickus, Max H.; Remick, Daniel G.			Enhancing Scientific Foundations to Ensure Reproducibility A New Paradigm	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CANCER-RESEARCH; SEX-DIFFERENCES; STROKE; EFFICACY; QUALITY; NXY-059; SCIENCE; CELLS; BIAS	Progress in science is dependent on a strong foundation of reliable results. The publish or perish paradigm in research, coupled with an increase in retracted articles from the peer-reviewed literature, is beginning to erode the trust of both the scientific community and the public. The NIH is combating errors by requiring investigators to follow new guidelines addressing scientific premise, experimental design, biological variables, and authentication of reagents. Herein, we discuss how implementation of NIH guidelines will help investigators proactively address pitfalls of experimental design and methods. Careful consideration of the variables contributing to reproducibility helps ensure robust results. The NIH, investigators, and journals must collaborate to ensure that quality science is funded, explored, and published.	[Hsieh, Terry; Vaickus, Max H.; Remick, Daniel G.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA	Remick, DG (reprint author), Boston Univ, Sch Med, 670 Albany St,Floor 4,Room 405, Boston, MA 02118 USA.	remickd@bu.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01GM82962, R21AI112887, R01GM97320, T32HL 007501, T32GM86308, R21AA022122, T32HL 007035, T32007309, R01GM117519]	Supported by NIH grants R01GM82962 (D.G.R.), R21AI112887 (D.G.R.), R01GM97320 (D.G.R.), T32HL 007501 (D.G.R.), T32GM86308 (D.G.R.), R21AA022122 (D.G.R.), R21AI112887 (D.G.R.), T32HL 007035 (T.H.), T32007309 (T.H.), and R01GM117519 (D.G.R.).	Anguera MC, 2012, CELL STEM CELL, V11, P75, DOI 10.1016/j.stem.2012.03.008; Bebarta V, 2003, ACAD EMERG MED, V10, P684, DOI 10.1111/j.1553-2712.2003.tb00056.x; Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a; Bordeaux J, 2010, BIOTECHNIQUES, V48, P197, DOI 10.2144/000113382; Carey Benedict, 2015, NEW YORK TIMES  0606, V6, pD1; Fanelli D, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001563; Festing Michael F W, 2002, ILAR J, V43, P244; Hess KR, 2011, CANCER RES, V71, P625, DOI 10.1158/0008-5472.CAN-10-3296; Hirst JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098856; Kadioglu A, 2011, J INFECT DIS, V204, P1971, DOI 10.1093/infdis/jir657; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824; Klein SL, 2015, P NATL ACAD SCI USA, V112, P5257, DOI 10.1073/pnas.1502843112; Kong BY, 2016, J INVEST DERMATOL, V136, P12, DOI 10.1038/JID.2015.298; LOZANOTORRES X, 2016, FASEB J S1, V30; Macleod MR, 2008, STROKE, V39, P2824, DOI 10.1161/STROKEAHA.108.515957; Macleod MR, 2005, J CEREBR BLOOD F MET, V25, P713, DOI 10.1038/sj.jcbfm.9600064; Prendergast BJ, 2014, NEUROSCI BIOBEHAV R, V40, P1, DOI 10.1016/j.neubiorev.2014.01.001; Richardson SS, 2015, P NATL ACAD SCI USA, V112, P13419, DOI 10.1073/pnas.1516958112; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sena E, 2007, TRENDS NEUROSCI, V30, P433, DOI 10.1016/j.tins.2007.06.009; Shah K, 2014, AM J PHYSIOL-CELL PH, V306, pC3, DOI 10.1152/ajpcell.00281.2013; Shuaib A, 2007, NEW ENGL J MED, V357, P562, DOI 10.1056/NEJMoa070240; van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245; Vasilevsky NA, 2013, PEERJ, V1, DOI 10.7717/peerj.148; Vesterinen HM, 2010, MULT SCLER J, V16, P1044, DOI 10.1177/1352458510379612; Yang Z, 2014, ELIFE, V3, DOI 10.7554/eLife.03711; Yoon DY, 2014, SURGERY, V156, P508, DOI 10.1016/j.surg.2014.07.001	28	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					6	10		10.1016/j.ajpath.2017.08.028			5	Pathology	Pathology	FQ8SS	WOS:000418634100003	28958817	Green Published			2019-10-28	
J	Youn, YH; Han, YG				Youn, Yong Ha; Han, Young-Goo			Primary Cilia in Brain Development and Diseases	AMERICAN JOURNAL OF PATHOLOGY			English	Review							PLANAR CELL POLARITY; BARDET-BIEDL-SYNDROME; NEURAL STEM-CELLS; INTRAFLAGELLAR TRANSPORT PROTEINS; MAMMALIAN CEREBRAL-CORTEX; CYSTIC KIDNEY-DISEASE; PROGENITOR POOL; RADIAL GLIA; MOUSE MODEL; HIPPOCAMPAL NEUROGENESIS	The primary cilium, a sensory appendage that is present in most mammalian cells, plays critical roles in signaling pathways and cell cycle progression. Mutations that affect the structure or function of primary cilia result in ciliopathies, a group of developmental and degenerative diseases that affect almost all organs and tissues. Our understanding of the constituents, development, and function of primary cilia has advanced considerably in recent years, revealing pathogenic mechanisms that potentially underlie ciliopathies. In the brain, the primary cilia are crucial for early patterning, neurogenesis, neuronal maturation and survival, and tumorigenesis, mostly through regulating cell cycle progression, Hedgehog signaling, and WNT signaling. We review these advances in our knowledge of primary cilia, focusing on brain development, and discuss the mechanisms that may underlie brain abnormalities in ciliopathies.	[Youn, Yong Ha; Han, Young-Goo] St Jude Childrens Res Hosp, Neurobiol & Brain Tumor Program, Dept Dev Neurobiol, 262 Danny Thomas Pl, Memphis, TN 38105 USA	Han, YG (reprint author), St Jude Childrens Res Hosp, Neurobiol & Brain Tumor Program, Dept Dev Neurobiol, 262 Danny Thomas Pl, Memphis, TN 38105 USA.	young-goo.han@stjude.org	Han, Young-Goo/N-2664-2018	Han, Young-Goo/0000-0002-4008-294X	Sontag Foundation Distinguished Scientist Award; Whitehall Foundation; American Lebanese Syrian Associated CharitiesAmerican Lebanese Syrian Associated Charities (ALSAC); NIH/NCI Cancer Center Core Support grant [CA021765]	Supported by The Sontag Foundation Distinguished Scientist Award (Y.-G.H.), a Whitehall Foundation Research grant (Y.-G.H.), American Lebanese Syrian Associated Charities (Y.-G.H.), and NIH/NCI Cancer Center Core Support grant CA021765 (St. Jude Children's Research Hospital).	Abdelhamed ZA, 2013, HUM MOL GENET, V22, P1358, DOI 10.1093/hmg/dds546; Aguilar A, 2012, P NATL ACAD SCI USA, V109, P16951, DOI 10.1073/pnas.1201408109; Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Amador-Arjona A, 2011, J NEUROSCI, V31, P9933, DOI 10.1523/JNEUROSCI.1062-11.2011; Ansley SJ, 2003, NATURE, V425, P628, DOI 10.1038/nature02030; Balmer S, 2015, DEV CELL, V34, P705, DOI 10.1016/j.devcel.2015.07.016; Bangs F, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028175; Besse L, 2011, DEVELOPMENT, V138, P2079, DOI 10.1242/dev.059808; Bielas SL, 2009, NAT GENET, V41, P1032, DOI 10.1038/ng.423; Boutin C, 2014, P NATL ACAD SCI USA, V111, pE3129, DOI 10.1073/pnas.1404988111; Braun DA, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028191; Breunig JJ, 2008, P NATL ACAD SCI USA, V105, P13127, DOI 10.1073/pnas.0804558105; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Cano DA, 2004, DEVELOPMENT, V131, P3457, DOI 10.1242/dev.01189; Chih B, 2012, NAT CELL BIOL, V14, P61, DOI 10.1038/ncb2410; Chizhikov VV, 2007, J NEUROSCI, V27, P9780, DOI 10.1523/JNEUROSCI.5586-06.2007; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Corbit KC, 2008, NAT CELL BIOL, V10, P70, DOI 10.1038/ncb1670; Davenport JR, 2007, CURR BIOL, V17, P1586, DOI 10.1016/j.cub.2007.08.034; Deane JA, 2001, CURR BIOL, V11, P1586, DOI 10.1016/S0960-9822(01)00484-5; Dehay C, 2007, NAT REV NEUROSCI, V8, P438, DOI 10.1038/nrn2097; Dowdle WE, 2011, AM J HUM GENET, V89, P94, DOI 10.1016/j.ajhg.2011.06.003; Fietz SA, 2010, NAT NEUROSCI, V13, P690, DOI 10.1038/nn.2553; Florio M, 2015, SCIENCE, V347, P1465, DOI 10.1126/science.aaa1975; Fotaki V, 2006, J NEUROSCI, V26, P9282, DOI 10.1523/JNEUROSCI.2673-06.2006; Gabriel E, 2016, EMBO J, V35, P803, DOI 10.15252/embj.201593679; Garcia-Gonzalo FR, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028134; Garcia-Gonzalo FR, 2011, NAT GENET, V43, P776, DOI 10.1038/ng.891; Gerdes JM, 2007, NAT GENET, V39, P1350, DOI 10.1038/ng.2007.12; Glickstein SB, 2009, J NEUROSCI, V29, P9614, DOI 10.1523/JNEUROSCI.2284-09.2009; Goetz SC, 2012, CELL, V151, P847, DOI 10.1016/j.cell.2012.10.010; Gradilone SA, 2013, CANCER RES, V73, P2259, DOI 10.1158/0008-5472.CAN-12-2938; Graser S, 2007, J CELL BIOL, V179, P321, DOI 10.1083/jcb.200707181; Green JA, 2010, CELL MOL LIFE SCI, V67, P3287, DOI 10.1007/s00018-010-0425-4; Guadiana SM, 2013, J NEUROSCI, V33, P2626, DOI 10.1523/JNEUROSCI.2906-12.2013; Guirao B, 2010, NAT CELL BIOL, V12, P341, DOI 10.1038/ncb2040; Han YG, 2003, CURR BIOL, V13, P1679, DOI 10.1016/j.cub.2003.08.034; Han YG, 2008, NAT NEUROSCI, V11, P277, DOI 10.1038/nn2059; Han YG, 2010, CURR OPIN NEUROBIOL, V20, P58, DOI 10.1016/j.conb.2009.12.002; Han YG, 2009, NAT MED, V15, P1062, DOI 10.1038/nm.2020; Hansen DV, 2010, NATURE, V464, P554, DOI 10.1038/nature08845; Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053; Higginbotham H, 2013, NAT NEUROSCI, V16, P1000, DOI 10.1038/nn.3451; Huang P, 2009, DEVELOPMENT, V136, P3089, DOI 10.1242/dev.041343; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Inoko A, 2012, J CELL BIOL, V197, P391, DOI 10.1083/jcb.201106101; Jacoby M, 2009, NAT GENET, V41, P1027, DOI 10.1038/ng.427; Jin H, 2010, CELL, V141, P1208, DOI 10.1016/j.cell.2010.05.015; Jonassen JA, 2008, J CELL BIOL, V183, P377, DOI 10.1083/jcb.200808137; Jones C, 2008, NAT GENET, V40, P69, DOI 10.1038/ng.2007.54; Joo K, 2013, P NATL ACAD SCI USA, V110, P5987, DOI 10.1073/pnas.1220927110; Karam A, 2015, NEUROBIOL DIS, V80, P15, DOI 10.1016/j.nbd.2015.05.008; Keryer G, 2011, J CLIN INVEST, V121, P4372, DOI 10.1172/JCI57552; Kim S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9087; Kim S, 2011, NAT CELL BIOL, V13, P351, DOI 10.1038/ncb2183; Kumamoto N, 2012, NAT NEUROSCI, V15, P399, DOI 10.1038/nn.3042; Laclef C, 2015, HUM MOL GENET, V24, P4997, DOI 10.1093/hmg/ddv221; Lancaster MA, 2011, NAT MED, V17, P726, DOI 10.1038/nm.2380; Lange C, 2009, CELL STEM CELL, V5, P320, DOI 10.1016/j.stem.2009.05.026; Lechtreck KF, 2009, J CELL BIOL, V187, P1117, DOI 10.1083/jcb.200909183; Li AQ, 2011, NAT CELL BIOL, V13, P402, DOI 10.1038/ncb2218; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Vuong LT, 2014, DEVELOPMENT, V141, P3222, DOI 10.1242/dev.106229; Liu AM, 2005, DEVELOPMENT, V132, P3103, DOI 10.1242/dev.01894; Mairet-Coello G, 2012, DEVELOPMENT, V139, P475, DOI 10.1242/dev.067314; Martinez-Cerdeno V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030178; May SR, 2005, DEV BIOL, V287, P378, DOI 10.1016/j.ydbio.2005.08.050; Mirzadeh Z, 2010, J NEUROSCI, V30, P2600, DOI 10.1523/JNEUROSCI.3744-09.2010; Nachury MV, 2007, CELL, V129, P1201, DOI 10.1016/j.cell.2007.03.053; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Nonaka-Kinoshita M, 2013, EMBO J, V32, P1817, DOI 10.1038/emboj.2013.96; Ocbina PJR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006839; Oh EC, 2013, J AM SOC NEPHROL, V24, P10, DOI 10.1681/ASN.2012050526; Ohata S, 2015, J NEUROSCI, V35, P11153, DOI 10.1523/JNEUROSCI.0686-15.2015; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Phua SC, 2017, CELL, V168, P264, DOI 10.1016/j.cell.2016.12.032; Pilaz LJ, 2009, P NATL ACAD SCI USA, V106, P21924, DOI 10.1073/pnas.0909894106; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Reillo I, 2011, CEREB CORTEX, V21, P1674, DOI 10.1093/cercor/bhq238; RIEDER CL, 1979, J ULTRA MOL STRUCT R, V68, P173, DOI 10.1016/S0022-5320(79)90152-7; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; Ross AJ, 2005, NAT GENET, V37, P1135, DOI 10.1038/ng1644; Sang LY, 2011, CELL, V145, P513, DOI 10.1016/j.cell.2011.04.019; Sawamoto K, 2006, SCIENCE, V311, P629, DOI 10.1126/science.1119133; Schmidt KN, 2012, J CELL BIOL, V199, P1083, DOI 10.1083/jcb.201202126; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Singla V, 2010, DEV CELL, V18, P410, DOI 10.1016/j.devcel.2009.12.022; Snedeker J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173258; Spassky N, 2008, DEV BIOL, V317, P246, DOI 10.1016/j.ydbio.2008.02.026; Stahl R, 2013, CELL, V153, P535, DOI 10.1016/j.cell.2013.03.027; Stottmann RW, 2009, DEV BIOL, V335, P166, DOI 10.1016/j.ydbio.2009.08.023; Tanos BE, 2013, GENE DEV, V27, P163, DOI 10.1101/gad.207043.112; Taschner M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a028092; Thauvin-Robinet C, 2014, NAT GENET, V46, P905, DOI 10.1038/ng.3031; Theil T, 1999, DEVELOPMENT, V126, P3561; Tole S, 2000, DEV BIOL, V217, P254, DOI 10.1006/dbio.1999.9509; Tong CK, 2014, P NATL ACAD SCI USA, V111, P12438, DOI 10.1073/pnas.1321425111; TUCKER RW, 1979, CELL, V17, P527, DOI 10.1016/0092-8674(79)90261-7; Wang L, 2016, NAT NEUROSCI, V19, P888, DOI 10.1038/nn.4307; Waters AM, 2011, PEDIATR NEPHROL, V26, P1039, DOI 10.1007/s00467-010-1731-7; Wei Q, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3750; Wei Q, 2012, NAT CELL BIOL, V14, P950, DOI 10.1038/ncb2560; Wheway G, 2013, DEV BIOL, V377, P55, DOI 10.1016/j.ydbio.2013.02.015; Willaredt MA, 2008, J NEUROSCI, V28, P12887, DOI 10.1523/JNEUROSCI.2084-08.2008; Wilson SL, 2012, DEV NEUROBIOL, V72, P1196, DOI 10.1002/dneu.20985; Yang Y, 2013, EMBO REP, V14, P741, DOI 10.1038/embor.2013.80; Ye X, 2014, P NATL ACAD SCI USA, V111, P2164, DOI 10.1073/pnas.1318737111	108	14	14	1	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					11	22		10.1016/j.ajpath.2017.08.031			12	Pathology	Pathology	FQ8SS	WOS:000418634100004	29030052	Green Published			2019-10-28	
J	Peng, L; Bonaguidi, MA				Peng, Lei; Bonaguidi, Michael A.			Function and Dysfunction of Adult Hippocampal Neurogenesis in Regeneration and Disease	AMERICAN JOURNAL OF PATHOLOGY			English	Review							TRAUMATIC BRAIN-INJURY; TRANSIENT GLOBAL-ISCHEMIA; NEURAL STEM-CELLS; RAT DENTATE GYRUS; GRANULE CELLS; INCREASES NEUROGENESIS; ENHANCES NEUROGENESIS; ENRICHED ENVIRONMENT; SYNAPTIC PLASTICITY; COGNITIVE FUNCTION	The hippocampus is the only known brain region where physiological neurogenesis continues into adulthood across mammalian species and in humans. However, disease and injury can change the level of adult hippocampal neurogenesis, which plays an important role in regulating cognitive and emotional abilities. Alterations in hippocampal neurogenesis can mediate treatment of mental illness or affect the brain's capacity for repair and regeneration. In the present review, we evaluate how adult neurogenesis contributes to the repair and regeneration of hippocampal circuitry in the face of diseases and injuries. We also discuss possible future directions for harnessing adult neurogenesis for therapeutic use.	[Peng, Lei; Bonaguidi, Michael A.] Univ Southern Calif, Keck Sch Med, Broad Calif Inst Regenerat Med CIRM Ctr, 1425 San Pablo St,Broad CIRM Ctr 412, Los Angeles, CA 90033 USA; [Peng, Lei] Univ Southern Calif, Keck Sch Med, Dept Stem Cell Biol & Regenerat Med, Los Angeles, CA 90033 USA; [Bonaguidi, Michael A.] Univ Southern Calif, Keck Sch Med, Neurosci Grad Program, Los Angeles, CA 90033 USA; [Bonaguidi, Michael A.] Univ Southern Calif, Keck Sch Med, Zilkha Neurogenet Inst, Dept Stem Cell Biol & Regenerat Med, 1425 San Pablo St,Broad CIRM Ctr 412, Los Angeles, CA 90033 USA; [Bonaguidi, Michael A.] Univ Southern Calif, Keck Sch Med, Zilkha Neurogenet Inst, Dept Gerontol, 1425 San Pablo St,Broad CIRM Ctr 412, Los Angeles, CA 90033 USA; [Bonaguidi, Michael A.] Univ Southern Calif, Keck Sch Med, Zilkha Neurogenet Inst, Dept Biomed Engn, 1425 San Pablo St,Broad CIRM Ctr 412, Los Angeles, CA 90033 USA	Bonaguidi, MA (reprint author), Univ Southern Calif, Keck Sch Med, Broad Calif Inst Regenerat Med CIRM Ctr, 1425 San Pablo St,Broad CIRM Ctr 412, Los Angeles, CA 90033 USA.; Bonaguidi, MA (reprint author), Univ Southern Calif, Keck Sch Med, Zilkha Neurogenet Inst, Dept Stem Cell Biol & Regenerat Med, 1425 San Pablo St,Broad CIRM Ctr 412, Los Angeles, CA 90033 USA.; Bonaguidi, MA (reprint author), Univ Southern Calif, Keck Sch Med, Zilkha Neurogenet Inst, Dept Gerontol, 1425 San Pablo St,Broad CIRM Ctr 412, Los Angeles, CA 90033 USA.; Bonaguidi, MA (reprint author), Univ Southern Calif, Keck Sch Med, Zilkha Neurogenet Inst, Dept Biomed Engn, 1425 San Pablo St,Broad CIRM Ctr 412, Los Angeles, CA 90033 USA.	mbonagui@usc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R00NS080913]; L.K. Whittier Foundation	Supported by NIH grant R00NS080913 and the L.K. Whittier Foundation (M.A.B.).	ALTMAN J, 1962, SCIENCE, V135, P1127, DOI 10.1126/science.135.3509.1127; Ardizzone TD, 2007, STROKE, V38, P1621, DOI 10.1161/STROKEAHA.106.478966; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Cho KO, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7606; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Cuadrado-Tejedor M, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00182; Dietrich J, 2006, ADV EXP MED BIOL, V557, P191; Duman CH, 2008, BRAIN RES, V1199, P148, DOI 10.1016/j.brainres.2007.12.047; Duman RS, 2012, PHILOS T R SOC B, V367, P2475, DOI 10.1098/rstb.2011.0357; Duman RS, 2000, BIOL PSYCHIAT, V48, P732, DOI 10.1016/S0006-3223(00)00935-5; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gil JMAC, 2005, NEUROBIOL DIS, V20, P744, DOI 10.1016/j.nbd.2005.05.006; Girgis F, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00008; GOULD E, 1992, J NEUROSCI, V12, P3642; Hattiangady B, 2004, NEUROBIOL DIS, V17, P473, DOI 10.1016/j.nbd.2004.08.008; Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265; Hosford BE, 2016, J NEUROSCI, V36, P11013, DOI 10.1523/JNEUROSCI.1371-16.2016; Iyengar SS, 2015, EXP NEUROL, V264, P135, DOI 10.1016/j.expneurol.2014.11.009; Jacobs BL, 2000, MOL PSYCHIATR, V5, P262, DOI 10.1038/sj.mp.4000712; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Koyama R, 2012, NAT MED, V18, P1271, DOI 10.1038/nm.2850; Krook-Magnuson E, 2014, ENEURO, V1, DOI 10.1523/ENEURO.0005-14.2014; Liu JL, 1998, J NEUROSCI, V18, P7768; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Malberg JE, 2000, J NEUROSCI, V20, P9104; Marti HH, 2000, NEWS PHYSIOL SCI, V15, P225; Mathern GW, 2002, EPILEPSIA, V43, P68, DOI 10.1046/j.1528-1157.43.s.5.28.x; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Mu YL, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-85; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Parent JM, 2006, HIPPOCAMPUS, V16, P321, DOI 10.1002/hipo.20166; Parent JM, 1997, J NEUROSCI, V17, P3727; Raber J, 2004, ANN NEUROL, V55, P381, DOI 10.1002/ana.10853; Rai KS, 2007, EUR J NEUROSCI, V26, P1765, DOI 10.1111/j.1460-9568.2007.05820.x; RAKIC P, 1981, J COMP NEUROL, V196, P99, DOI 10.1002/cne.901960109; Revest JM, 2009, MOL PSYCHIATR, V14, P959, DOI 10.1038/mp.2009.15; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Roh JK, 2008, CURR STEM CELL RES T, V3, P185, DOI 10.2174/157488808785740352; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Sierra A, 2015, CELL STEM CELL, V16, P488, DOI 10.1016/j.stem.2015.04.003; Small SA, 2004, P NATL ACAD SCI USA, V101, P7181, DOI 10.1073/pnas.0400285101; Smith LK, 2015, NAT MED, V21, P932, DOI 10.1038/nm.3898; Snyder JS, 2011, NATURE, V476, P458, DOI 10.1038/nature10287; Spalding KL, 2005, CELL, V122, P133, DOI 10.1016/j.cell.2005.04.028; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Steiner B, 2006, REGEN MED, V1, P15, DOI 10.2217/17460751.1.1.15; Tanaka R, 2004, STROKE, V35, P1454, DOI 10.1161/01.STR.0000126480.40967.b3; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569; Wang XT, 2016, J NEUROTRAUM, V33, P721, DOI 10.1089/neu.2015.4097	59	10	12	2	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					23	28		10.1016/j.ajpath.2017.09.004			6	Pathology	Pathology	FQ8SS	WOS:000418634100005	29030053	Bronze, Green Published			2019-10-28	
J	Sinnaeve, J; Mobley, BC; Ihrie, RA				Sinnaeve, Justine; Mobley, Bret C.; Ihrie, Rebecca A.			Space Invaders Brain Tumor Exploitation of the Stem Cell Niche	AMERICAN JOURNAL OF PATHOLOGY			English	Review							GLIOBLASTOMA RECURRENCE PATTERNS; SUBVENTRICULAR ZONE; VASCULAR NICHE; CEREBROSPINAL-FLUID; ADULT NEUROGENESIS; RADIATION-THERAPY; MALIGNANT GLIOMAS; GERMINAL ZONE; GROWTH; MIGRATION	Increasing evidence indicates that the adult neurogenic niche of the ventricular-subventricular zone (V-SVZ), beyond serving as a potential site of origin, affects the outcome of malignant brain cancers. Glioma contact with this niche predicts worse prognosis, suggesting a supportive role for the V-SVZ environment in tumor initiation or progression. In this review, we describe unique components of the V-SVZ that may permit or promote tumor growth within the region. Cell-cell interactions, soluble factors, and extracellular matrix composition are discussed, and the role of the niche in future therapies is explored. The purpose of this review is to highlight niche intrinsic factors that may promote or support malignant cell growth and maintenance, and point out how we might leverage these features to improve patient outcome.	[Sinnaeve, Justine; Ihrie, Rebecca A.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; [Mobley, Bret C.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Mobley, Bret C.] Vanderbilt Univ, Med Ctr, Dept Microbiol, Nashville, TN 37232 USA; [Mobley, Bret C.] Vanderbilt Univ, Med Ctr, Dept Immunol, Nashville, TN 37232 USA; [Ihrie, Rebecca A.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN 37232 USA	Ihrie, RA (reprint author), Vanderbilt Univ, 2220 Pierce Ave,761 PRB, Nashville, TN 37232 USA.	rebecca.ihrie@vanderbilt.edu		Ihrie, Rebecca/0000-0003-0439-0141; Sinnaeve, Justine/0000-0001-9303-7969	NIH/National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS096238]; Department of Defense Idea Development [W81XWH-16-1-0171]; Vanderbilt-Ingram Cancer Center (VICC) [P30 CA68485]; VICC Michael David Greene Brain Cancer Fund gift; Southeastern Brain Tumor Foundation [SBTA-0001199]	Supported by NIH/National Institute of Neurological Diseases and Stroke grant R01NS096238 (R.A.I.), Department of Defense Idea Development Award W81XWH-16-1-0171 (R.A.I.), Vanderbilt-Ingram Cancer Center (VICC) Ambassadors Award and Discovery Award P30 CA68485 (R.A.I.), a VICC Michael David Greene Brain Cancer Fund gift (R.A.I.), and Ann Faulkenberry Memorial Award SBTA-0001199 from the Southeastern Brain Tumor Foundation (R.A.I.).	Aboody KS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005365; Achanta P, 2012, STEM CELLS, V30, P2548, DOI 10.1002/stem.1214; Achari R, 2017, CLIN ONCOL-UK, V29, P335, DOI 10.1016/j.clon.2017.01.010; Adeberg S, 2014, INT J RADIAT ONCOL, V90, P886, DOI 10.1016/j.ijrobp.2014.07.027; Akers JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078115; Andreu-Agullo C, 2009, NAT NEUROSCI, V12, P1514, DOI 10.1038/nn.2437; Bago JR, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah6510; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Bonaguidi MA, 2012, CURR OPIN NEUROBIOL, V22, P754, DOI 10.1016/j.conb.2012.03.013; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Caretti V, 2014, ACTA NEUROPATHOL, V128, P605, DOI 10.1007/s00401-014-1307-x; Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009; Chen LD, 2015, RADIOTHER ONCOL, V116, P294, DOI 10.1016/j.radonc.2015.07.032; Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021; Chhieng DC, 2002, DIAGN CYTOPATHOL, V26, P209, DOI 10.1002/dc.10013; Crouch EE, 2015, J NEUROSCI, V35, P4528, DOI 10.1523/JNEUROSCI.1188-14.2015; DELBIGIO MR, 1995, GLIA, V14, P1, DOI 10.1002/glia.440140102; Dennis CV, 2016, NEUROPATH APPL NEURO, V42, P621, DOI 10.1111/nan.12337; Doetsch F, 1997, J NEUROSCI, V17, P5046; Elias LAB, 2007, NATURE, V448, P901, DOI 10.1038/nature06063; Ernst A, 2014, CELL, V156, P1072, DOI 10.1016/j.cell.2014.01.044; Falk A, 2002, J NEUROSCI RES, V69, P757, DOI 10.1002/jnr.10410; Fonseca RS, 2016, STEM CELLS DEV, V25, P542, DOI 10.1089/scd.2015.0319; Fuentealba LC, 2015, CELL, V161, P1644, DOI 10.1016/j.cell.2015.05.041; Fuentealba LC, 2012, CELL STEM CELL, V10, P698, DOI 10.1016/j.stem.2012.05.012; Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246; Goffart N, 2017, NEURO-ONCOLOGY, V19, P66, DOI 10.1093/neuonc/now136; Goffart N, 2015, NEURO-ONCOLOGY, V17, P81, DOI 10.1093/neuonc/nou144; Guichet PO, 2015, STEM CELLS, V33, P21, DOI 10.1002/stem.1767; Hingtgen SD, 2010, STEM CELLS, V28, P832, DOI 10.1002/stem.313; Hoglinger GU, 2014, J COMP NEUROL, V522, P2336, DOI 10.1002/cne.23537; Iacoangeli M, 2012, ONCOTARGETS THER, V5, P449, DOI 10.2147/OTT.S39429; Ihrie RA, 2011, NEURON, V71, P250, DOI 10.1016/j.neuron.2011.05.018; Iuchi T, 2014, INT J RADIAT ONCOL, V88, P793, DOI 10.1016/j.ijrobp.2013.12.011; Jafri NF, 2013, NEURO-ONCOLOGY, V15, P91, DOI 10.1093/neuonc/nos268; Jeon JY, 2008, EXP MOL MED, V40, P84, DOI 10.3858/emm.2008.40.1.84; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jungk C, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0710-7; Kelsch W, 2007, PLOS BIOL, V5, P2501, DOI 10.1371/journal.pbio.0050300; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kim SK, 2006, CLIN CANCER RES, V12, P5550, DOI 10.1158/1078-0432.CCR-05-2508; Kimura M, 2013, NEURORADIOL J, V26, P542, DOI 10.1177/197140091302600507; Kokovay E, 2012, CELL STEM CELL, V11, P220, DOI 10.1016/j.stem.2012.06.016; Kokovay E, 2010, CELL STEM CELL, V7, P163, DOI 10.1016/j.stem.2010.05.019; Kroonen J, 2011, INT J CANCER, V129, P574, DOI 10.1002/ijc.25709; Kunze A, 2009, P NATL ACAD SCI USA, V106, P11336, DOI 10.1073/pnas.0813160106; Lai A, 2011, J CLIN ONCOL, V29, P4482, DOI 10.1200/JCO.2010.33.8715; Lathia JD, 2010, CELL STEM CELL, V6, P421, DOI 10.1016/j.stem.2010.02.018; Leelatian N, 2017, CYTOM PART B-CLIN CY, V92, P68, DOI 10.1002/cyto.b.21481; Lehtinen MK, 2011, NEURON, V69, P893, DOI 10.1016/j.neuron.2011.01.023; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Lim DA, 2007, NEURO-ONCOLOGY, V9, P424, DOI 10.1215/15228517-2007-023; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; Liu SC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147306; Liu S, 2016, ONCOTARGET, V7, P17920, DOI 10.18632/oncotarget.7472; Llorens-Bobadilla E, 2015, CELL STEM CELL, V17, P329, DOI 10.1016/j.stem.2015.07.002; Lorente M, 2009, GLIA, V57, P1374, DOI 10.1002/glia.20856; Malik M, 2015, INT J RADIAT ONCOL, V93, pS111, DOI 10.1016/j.ijrobp.2015.07.265; McClenahan FK, 2016, DEV CELL, V38, P548, DOI 10.1016/j.devcel.2016.07.017; Mercier F, 2002, J COMP NEUROL, V451, P170, DOI 10.1002/cne.10342; Merkle FT, 2007, SCIENCE, V317, P381, DOI 10.1126/science.1144914; Mirzadeh Z, 2008, CELL STEM CELL, V3, P265, DOI 10.1016/j.stem.2008.07.004; Mistry AM, 2017, J NEURO-ONCOL, V132, P341, DOI 10.1007/s11060-017-2374-3; Mistry AM, 2017, J NEURO-ONCOL, V131, P125, DOI 10.1007/s11060-016-2278-7; Nestler U, 2015, ACTA NEUROCHIR, V157, P179, DOI 10.1007/s00701-014-2271-x; Nourallah B, 2017, CLIN ONCOL-UK, V29, P26, DOI 10.1016/j.clon.2016.09.005; Ohata S, 2016, TRENDS NEUROSCI, V39, P543, DOI 10.1016/j.tins.2016.05.004; Ottone C, 2014, NAT CELL BIOL, V16, P1045, DOI 10.1038/ncb3045; Paez-Gonzalez P, 2014, NAT NEUROSCI, V17, P934, DOI 10.1038/nn.3734; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Panagiotakos G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000588; Paredes MF, 2016, SCIENCE, V354, DOI 10.1126/science.aaf7073; Perry A, 2009, BRAIN PATHOL, V19, P81, DOI 10.1111/j.1750-3639.2008.00167.x; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Piccirillo SGM, 2015, CANCER RES, V75, P194, DOI 10.1158/0008-5472.CAN-13-3131; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Qin EY, 2017, CELL, V170, P845, DOI 10.1016/j.cell.2017.07.016; Radbruch A, 2012, NEURO-ONCOLOGY, V14, P222, DOI 10.1093/neuonc/nor200; Ramirez-Castillejo C, 2006, NAT NEUROSCI, V9, P331, DOI 10.1038/nn1657; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Sawamoto K, 2006, SCIENCE, V311, P629, DOI 10.1126/science.1119133; Seri B, 2004, J COMP NEUROL, V478, P359, DOI 10.1002/cne.20288; Shah K, 2005, ANN NEUROL, V57, P34, DOI 10.1002/ana.20306; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Shen Q, 2008, CELL STEM CELL, V3, P289, DOI 10.1016/j.stem.2008.07.026; Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414; Silva-Vargas V, 2016, CELL STEM CELL, V19, P643, DOI 10.1016/j.stem.2016.06.013; Silva-Vargas V, 2013, CURR OPIN NEUROBIOL, V23, P935, DOI 10.1016/j.conb.2013.09.004; Siyahhan B, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.1189; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Sonoda Y, 2014, NEUROL MED-CHIR, V54, P302, DOI 10.2176/nmc.oa.2013-0226; Soroceanu L, 2007, P NATL ACAD SCI USA, V104, P3466, DOI 10.1073/pnas.0611271104; Soumier A, 2010, EUR NEUROPSYCHOPHARM, V20, P336, DOI 10.1016/j.euroneuro.2009.11.007; Staflin K, 2007, J NEUROSCI RES, V85, P2147, DOI 10.1002/jnr.21344; Stummer W, 1998, NEUROSURGERY, V42, P518, DOI 10.1097/00006123-199803000-00017; Tamura Masaru, 1993, Neurologia Medico-Chirurgica, V33, P77, DOI 10.2176/nmc.33.77; Tavazoie M, 2008, CELL STEM CELL, V3, P279, DOI 10.1016/j.stem.2008.07.025; Thouvenot E, 2008, J PROTEOME RES, V7, P4409, DOI 10.1021/pr8003858; Tong CK, 2014, CELL STEM CELL, V14, P500, DOI 10.1016/j.stem.2014.01.014; Venkatesh HS, 2015, CELL, V161, P803, DOI 10.1016/j.cell.2015.04.012; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang YX, 2015, P NATL ACAD SCI USA, V112, P9704, DOI 10.1073/pnas.1511694112; Watkins S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5196; Wei W, 2016, CANCER CELL, V29, P563, DOI 10.1016/j.ccell.2016.03.012; Willard N, 2015, CLIN NEUROPATHOL, V34, P330, DOI 10.5414/NP300882; Xavier ALR, 2015, J NEUROSCI, V35, P11848, DOI 10.1523/JNEUROSCI.1217-15.2015; Yin J, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002152; Young KM, 2007, J NEUROSCI, V27, P8286, DOI 10.1523/JNEUROSCI.0476-07.2007; Zong H, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020610	113	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					29	38		10.1016/j.ajpath.2017.08.029			10	Pathology	Pathology	FQ8SS	WOS:000418634100006	29024634	Bronze, Green Published			2019-10-28	
J	Leferink, PS; Heine, VM				Leferink, Prisca S.; Heine, Vivi M.			The Healthy and Diseased Microenvironments Regulate Oligodendrocyte Properties Implications for Regenerative Medicine	AMERICAN JOURNAL OF PATHOLOGY			English	Review							PELIZAEUS-MERZBACHER-DISEASE; CENTRAL-NERVOUS-SYSTEM; VANISHING WHITE-MATTER; ANTERIOR MEDULLARY VELUM; X-LINKED ADRENOLEUKODYSTROPHY; PROGENITOR-CELL PROLIFERATION; IPSC-DERIVED OLIGODENDROCYTES; BONE MORPHOGENETIC PROTEINS; MULTIPLE-SCLEROSIS LESIONS; EMBRYONIC STEM-CELLS	White matter disorders are characterized by deficient myelin or myelin loss, Lead to a range of neurologic dysfunctions, and can result in early death. Oligodendrocytes, which are responsible for white matter formation, are the first targets for treatment. However, many studies indicate that failure of white matter repair goes beyond the intrinsic incapacity of oligodendrocytes to (re)generate myelin and that failed interactions with neighboring cells or factors in the diseased microenvironment can underlie white matter defects. Moreover, most of the white matter disorders show specific white matter pathology caused by different disease mechanisms. Herein, we review the factors within the cellular and the extracellular microenvironment regulating oligodendrocyte properties and discuss stem cell tools to identify microenvironmental factors of importance to the development of improved regenerative medicine for patients with white matter disorders.	[Leferink, Prisca S.; Heine, Vivi M.] Vrije Univ Amsterdam, Med Ctr, Dept Pediat Child Neurol, Amsterdam, Netherlands; [Heine, Vivi M.] Vrije Univ Amsterdam, Amsterdam Neurosci, Ctr Neurogen & Cognit Res, Dept Complex Trait Genet, Amsterdam, Netherlands	Heine, VM (reprint author), Vrije Univ Amsterdam, Med Ctr, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	vm.heine@vumc.nl	Heine, Vivi/F-1741-2011	Heine, Vivi/0000-0003-4416-3875	ZonMw (The Netherlands Organisation for Health Research and Development) VITA (part of The Innovational Research Incentives Scheme) [91712343]; ZonMw TAS IDB [116005006]; E-Rare Joint Call project [9003037601]; European Leukodystrophy Association Research grant [2014-012L1]	Supported by ZonMw (The Netherlands Organisation for Health Research and Development) VITA (part of The Innovational Research Incentives Scheme) research grant 91712343 (V.M.H.), ZonMw TAS IDB (part of the Translational Adult Stem Cell Research Program) project 116005006 (V.M.H.), E-Rare Joint Call project 9003037601 (V.M.H.), and European Leukodystrophy Association Research grant 2014-012L1 (V.M.H.).	Alsanie WF, 2013, STEM CELLS DEV, V22, P2459, DOI 10.1089/scd.2012.0520; Altevogt BM, 2004, J NEUROSCI, V24, P4313, DOI 10.1523/JNEUROSCI.3303-03.2004; Ambrosini E, 2005, J NEUROPATH EXP NEUR, V64, P706, DOI 10.1097/01.jnen.0000173893.01929.fc; Armstrong RC, 2002, J NEUROSCI, V22, P8574; Baarine M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143238; Baas D, 1997, GLIA, V19, P324, DOI 10.1002/(SICI)1098-1136(199704)19:4<324::AID-GLIA5>3.0.CO;2-X; Baas D, 2002, P NATL ACAD SCI USA, V99, P2907, DOI 10.1073/pnas.052482299; Back SA, 2005, NAT MED, V11, P966, DOI 10.1038/nm1279; Baker BM, 2012, J CELL SCI, V125, P3015, DOI 10.1242/jcs.079509; Baron W, 2014, GLIA, V62, P927, DOI 10.1002/glia.22650; Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; BARRES BA, 1993, CURR BIOL, V3, P489, DOI 10.1016/0960-9822(93)90039-Q; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; Barros CS, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005108; Baxi EG, 2014, GLIA, V62, P1513, DOI 10.1002/glia.22697; Bechler ME, 2015, CURR BIOL, V25, P2411, DOI 10.1016/j.cub.2015.07.056; Blaschuk KL, 2000, DEVELOPMENT, V127, P1961; Boutin ME, 2018, J NEUROSCI METH, V299, P55, DOI 10.1016/j.jneumeth.2017.01.014; Bugiani M, 2006, NEUROLOGY, V67, P273, DOI 10.1212/01.wnl.0000223832.66286.e4; Bugiani M, 2013, BRAIN, V136, P209, DOI 10.1093/brain/aws320; Bugiani M, 2011, J NEUROPATH EXP NEUR, V70, P69, DOI 10.1097/NEN.0b013e318203ae74; Butt AM, 1997, J NEUROCYTOL, V26, P327, DOI 10.1023/A:1018556702353; Butt AM, 1997, J NEUROSCI RES, V48, P588; Butt AM, 1997, MOL CELL NEUROSCI, V8, P311, DOI 10.1006/mcne.1996.0590; Calza L, 2010, J MOL ENDOCRINOL, V44, P13, DOI 10.1677/JME-09-0067; CARSON MJ, 1993, NEURON, V10, P729, DOI 10.1016/0896-6273(93)90173-O; Choe Y, 2014, J NEUROSCI, V34, P14973, DOI 10.1523/JNEUROSCI.1156-14.2014; Clemente D, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00268; Cohen RI, 1996, J NEUROSCI, V16, P6433; Colognato H, 2007, DEVELOPMENT, V134, P1723, DOI 10.1242/dev.02819; Davis H, 2012, ACS CHEM NEUROSCI, V3, P31, DOI 10.1021/cn200082q; Demerens C, 1996, P NATL ACAD SCI USA, V93, P9887, DOI 10.1073/pnas.93.18.9887; Dheen ST, 2007, CURR MED CHEM, V14, P1189; Domingues HS, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00071; Dooves S, 2016, J INHERIT METAB DIS, V39, P513, DOI 10.1007/s10545-016-9925-1; Dooves S, 2016, J CLIN INVEST, V126, P1512, DOI 10.1172/JCI83908; Douvaras P, 2015, NAT PROTOC, V10, P1143, DOI 10.1038/nprot.2015.075; Durand B, 2000, BIOESSAYS, V22, P64; Emery B, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020461; Eyermann C, 2012, J NEUROCHEM, V120, P928, DOI 10.1111/j.1471-4159.2011.07600.x; Feigenson K, 2011, ASN NEURO, V3, DOI 10.1042/AN20110004; Franklin RJM, 2014, GLIA, V62, P1905, DOI 10.1002/glia.22622; Frost E, 1996, DEV NEUROSCI-BASEL, V18, P266, DOI 10.1159/000111416; Fruhbeis C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001604; Galvez-Contreras AY, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00258; Garcion E, 2001, DEVELOPMENT, V128, P2485; Goldman SA, 2015, DEVELOPMENT, V142, P3983, DOI 10.1242/dev.126409; Goldman SA, 2012, SCIENCE, V338, P491, DOI 10.1126/science.1218071; Grinspan JB, 2015, VITAM HORM, V99, P195, DOI 10.1016/bs.vh.2015.05.005; Gudz TI, 2006, J NEUROSCI, V26, P2458, DOI 10.1523/JNEUROSCI.4054-05.2006; Gupta N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004373; Hagemann TL, 2006, J NEUROSCI, V26, P11162, DOI 10.1523/JNEUROSCI.3260-06.2006; Hagemann TL, 2013, J NEUROSCI, V33, P18698, DOI 10.1523/JNEUROSCI.3693-13.2013; Hamilton NB, 2017, GLIA, V65, P309, DOI 10.1002/glia.23093; HAMILTON SP, 1994, GLIA, V11, P326, DOI 10.1002/glia.440110405; Hogberg HT, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt365; Hu JG, 2009, J NEUROSCI RES, V87, P2854, DOI 10.1002/jnr.22111; Huang JK, 2011, NAT NEUROSCI, V14, P45, DOI 10.1038/nn.2702; Itoh T, 2002, J NEUROCHEM, V81, P390, DOI 10.1046/j.1471-4159.2002.00866.x; Ivanov DP, 2017, SCI REP-UK, V7, DOI 10.1038/srep41160; Izrael M, 2007, MOL CELL NEUROSCI, V34, P310, DOI 10.1016/j.mcn.2006.11.008; Jang J, 2011, ANN NEUROL, V70, P402, DOI 10.1002/ana.22486; Jones EV, 2014, NEURAL PLAST, DOI 10.1155/2014/321209; Karadottir R, 2008, NAT NEUROSCI, V11, P450, DOI 10.1038/nn2060; Karim SA, 2007, GLIA, V55, P341, DOI 10.1002/glia.20465; Karim SA, 2010, GLIA, V58, P1727, DOI 10.1002/glia.21043; Kerman BE, 2015, DEVELOPMENT, V142, P2213, DOI 10.1242/dev.116517; Kerrisk ME, 2014, PROG BRAIN RES, V214, P101, DOI 10.1016/B978-0-444-63486-3.00005-0; Kessaris N, 2006, NAT NEUROSCI, V9, P173, DOI 10.1038/nn1620; Kondo T, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0337-0; Kondo Yoichi, 2009, V549, P175, DOI 10.1007/978-1-60327-931-4_12; LAENG P, 1994, J NEUROSCI RES, V39, P613, DOI 10.1002/jnr.490390602; Lampron A, 2015, J EXP MED, V212, P481, DOI 10.1084/jem.20141656; Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125; Laterza C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3597; Le Dreau G, 2012, DEV NEUROBIOL, V72, P1471, DOI 10.1002/dneu.22015; Lee S, 2012, NAT METHODS, V9, P917, DOI 10.1038/nmeth.2105; Leiton CV, 2015, J NEUROCHEM, V135, P522, DOI 10.1111/jnc.13241; Li HL, 2016, BRAIN RES, V1641, P111, DOI 10.1016/j.brainres.2015.10.013; Liddelow S, 2015, CELL, V162, P1170, DOI 10.1016/j.cell.2015.08.029; Lin SC, 2004, NAT NEUROSCI, V7, P24, DOI 10.1038/nn1162; Lu JF, 1997, P NATL ACAD SCI USA, V94, P9366, DOI 10.1073/pnas.94.17.9366; Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055; Luyt K, 2007, J NEUROCHEM, V100, P822, DOI 10.1111/j.1471-4159.2006.04255.x; Luzi P, 2004, NEUROCHEM RES, V29, P881, DOI 10.1023/B:NERE.0000021233.79076.72; Marques S, 2016, SCIENCE, V352, P1326, DOI 10.1126/science.aaf6463; Marteyn A, 2016, STEM CELLS, V34, P984, DOI 10.1002/stem.2263; Matsuda N, 2009, J NEUROSCI, V29, P14185, DOI 10.1523/JNEUROSCI.1863-09.2009; Maysami S, 2006, J NEUROIMMUNOL, V178, P17, DOI 10.1016/j.jneuroim.2006.05.021; Mendell JR, 2006, PEDIATR DEVEL PATHOL, V9, P427, DOI 10.2350/06-07-0127.1; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Messing A, 2012, J NEUROSCI, V32, P5017, DOI 10.1523/JNEUROSCI.5384-11.2012; Miller BA, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-28; Monzel AS, 2017, STEM CELL REP, V8, P1144, DOI 10.1016/j.stemcr.2017.03.010; Nevin ZS, 2017, AM J HUM GENET, V100, P617, DOI 10.1016/j.ajhg.2017.03.005; Nualart-Marti A, 2013, BBA-BIOMEMBRANES, V1828, P69, DOI 10.1016/j.bbamem.2012.01.024; Numasawa-Kuroiwa Y, 2014, STEM CELL REP, V2, P648, DOI 10.1016/j.stemcr.2014.03.007; O'Meara RW, 2011, J SIGNAL TRANSDUCT, V2011, DOI DOI 10.1155/2011/354091; Olabarria M, 2015, ACTA NEUROPATHOL, V130, P469, DOI 10.1007/s00401-015-1469-1; Olsen IM, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-25; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; Ortega JA, 2013, FRONT CELL NEUROSCI, V7, DOI [10.3389/fncel.2013.00254, 10.3389/fnce1.2013.00254]; Orthmann-Murphy JL, 2008, J MOL NEUROSCI, V35, P101, DOI 10.1007/s12031-007-9027-5; Pang Y, 2010, NEUROSCIENCE, V166, P464, DOI 10.1016/j.neuroscience.2009.12.040; Pang Y, 2013, BRAIN BEHAV, V3, P503, DOI 10.1002/brb3.152; Piaton G, 2010, J NEUROCHEM, V114, P1243, DOI 10.1111/j.1471-4159.2010.06831.x; Pouya A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027925; Quinlan RA, 2007, EXP CELL RES, V313, P2077, DOI 10.1016/j.yexcr.2007.04.004; RASKIND WH, 1991, AM J HUM GENET, V49, P1355; Relucio J, 2012, GLIA, V60, P1451, DOI 10.1002/glia.22365; Relucio J, 2009, J NEUROSCI, V29, P11794, DOI 10.1523/JNEUROSCI.0888-09.2009; Schiffmann R, 2009, NEUROLOGY, V72, P750, DOI 10.1212/01.wnl.0000343049.00540.c8; Schnadelbach O, 2000, MOL CELL NEUROSCI, V15, P288, DOI 10.1006/mcne.1999.0819; Shi Y, 2017, NAT REV DRUG DISCOV, V16, P115, DOI 10.1038/nrd.2016.245; Simons M, 2002, J CELL BIOL, V157, P327, DOI 10.1083/jcb.200110138; Siskova Z, 2006, MOL CELL NEUROSCI, V33, P150, DOI 10.1016/j.mcn.2006.07.001; Siskova Z, 2009, MOL CELL NEUROSCI, V42, P234, DOI 10.1016/j.mcn.2009.07.005; Skripuletz T, 2013, BRAIN, V136, P147, DOI 10.1093/brain/aws262; Sloane JA, 2010, P NATL ACAD SCI USA, V107, P11555, DOI 10.1073/pnas.1006496107; Sosunov AA, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0425-9; Srinivasan P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099640; Stamatovic SM, 2008, CURR NEUROPHARMACOL, V6, P179, DOI 10.2174/157015908785777210; Stoffels JMJ, 2013, BRAIN, V136, P116, DOI 10.1093/brain/aws313; Tanaka KF, 2007, GLIA, V55, P617, DOI 10.1002/glia.20486; Tawk M, 2011, J NEUROSCI, V31, P3729, DOI 10.1523/JNEUROSCI.4270-10.2011; Taylor AM, 2005, NAT METHODS, V2, P599, DOI 10.1038/NMETH777; Thomas AM, 2014, INTEGR BIOL-UK, V6, P694, DOI 10.1039/c4ib00009a; Thomson CE, 2008, EUR J NEUROSCI, V28, P1518, DOI 10.1111/j.1460-9568.2008.06415.x; Tokumoto YM, 2001, EMBO J, V20, P5261, DOI 10.1093/emboj/20.18.5261; Tomassy GS, 2014, SCIENCE, V344, P319, DOI 10.1126/science.1249766; Tripathi RB, 2011, J NEUROSCI, V31, P6809, DOI 10.1523/JNEUROSCI.6474-10.2011; Tsai HH, 2016, SCIENCE, V351, P379, DOI 10.1126/science.aad3839; Uchida N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004371; Urbanski MM, 2016, SCI REP-UK, V6, DOI 10.1038/srep33751; van der Knaap MS, 2016, NEUROL-CLIN PRACT, V6, P506, DOI 10.1212/CPJ.0000000000000289; vanderKnaap MS, 1997, NEUROLOGY, V48, P845, DOI 10.1212/WNL.48.4.845; Vigano F, 2013, NAT NEUROSCI, V16, P1370, DOI 10.1038/nn.3503; Vondran MW, 2010, GLIA, V58, P848, DOI 10.1002/glia.20969; Wake H, 2011, SCIENCE, V333, P1647, DOI 10.1126/science.1206998; Wang LC, 2016, NEUROCHEM RES, V41, P3289, DOI 10.1007/s11064-016-2061-3; Wang S, 2013, CELL STEM CELL, V12, P252, DOI 10.1016/j.stem.2012.12.002; Wang YP, 2011, J NEUROSCI, V31, P6053, DOI 10.1523/JNEUROSCI.5524-09.2011; Werner H, 1998, BRAIN PATHOL, V8, P771, DOI 10.1111/j.1750-3639.1998.tb00200.x; Windrem MS, 2004, NAT MED, V10, P93, DOI 10.1038/nm974; WOOD PM, 1986, NATURE, V320, P756, DOI 10.1038/320756a0; Woodward Karen J., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000677; Wu MZ, 2012, J NEUROSCI, V32, P6651, DOI 10.1523/JNEUROSCI.4876-11.2012; Zeger M, 2007, GLIA, V55, P400, DOI 10.1002/glia.20469	148	5	5	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					39	52		10.1016/j.ajpath.2017.08.030			14	Pathology	Pathology	FQ8SS	WOS:000418634100007	29024633	Bronze			2019-10-28	
J	Filous, AR; Schwab, JM				Filous, Angela R.; Schwab, Jan M.			Determinants of Axon Growth, Plasticity, and Regeneration in the Context of Spinal Cord Injury	AMERICAN JOURNAL OF PATHOLOGY			English	Review							CHONDROITIN SULFATE PROTEOGLYCANS; CENTRAL-NERVOUS-SYSTEM; LEUKEMIA INHIBITORY FACTOR; REPULSIVE GUIDANCE MOLECULE; OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; RETINAL GANGLION-CELLS; CNS GLIAL SCAR; NEURITE OUTGROWTH; FUNCTIONAL RECOVERY; IN-VIVO	The mechanisms that underlie recovery after injury of the central nervous system have rarely been definitively established. Axon regrowth remains the major prerequisite for plasticity, regeneration, circuit formation, and eventually functional recovery. The attributed functional relevance of axon regrowth, however, will depend on several subsequent conditional neurobiological modifications, including myelination and synapse formation, but also pruning of aberrant connectivity. Despite the ability to revamp axon outgrowth by altering an increasing number of extracellular and intracellular targets, disentangling which axons are responsible for the recovery of function from those that are functionally silent, or even contributing to aberrant functions, represents a pertinent void in our understanding, challenging the intuitive translational link between anatomical and functional regeneration. Anatomic hallmarks of regeneration are not static and are largely activity dependent. Herein, we survey mechanisms leading to the formation of dystrophic growth cone at the injured axonal tip, the subsequent axonal dieback, and the molecular determinants of axon growth, plasticity, and regeneration in the context of spinal cord injury.	[Filous, Angela R.; Schwab, Jan M.] Ohio State Univ, Dept Neurol, Spinal Cord Injury Div, Dept Neurol, Columbus, OH 43210 USA; [Schwab, Jan M.] Ohio State Univ, Wexner Med Ctr, Dept Neurosci, Columbus, OH 43210 USA; [Schwab, Jan M.] Ohio State Univ, Wexner Med Ctr, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Schwab, Jan M.] Ohio State Univ, Wexner Med Ctr, Ctr Brain & Spinal Cord Repair, Spinal Cord Injury Med, Columbus, OH 43210 USA	Filous, AR; Schwab, JM (reprint author), Ohio State Univ, Wexner Med Ctr, Spinal Cord Injury Med, 395 W 12th Ave,Floor 7, Columbus, OH 43210 USA.	angela.filous@osumc.edu; jan.schwab@osumc.edu		Schwab, Jan/0000-0001-6784-4919	National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services [90SI50200100]; Wings for Life Spinal Cord Research Foundation; Era-Net-NEURON Program of the European Union [SILENCE] [01EW170A]; Era-Net-NEURON Program of the European Union [SCI-NET] [01EW1710]; W.E. Hunt and C.M. Curtis Endowment; Craig H. Neilsen Foundation (Encino, CA)	Supported by the National Institute on Disability, Independent Living, and Rehabilitation Research grant 90SI50200100 (J.M.S.); Wings for Life Spinal Cord Research Foundation (J.M.S.); the Era-Net-NEURON Program of the European Union [SILENCE (#01EW170A) and SCI-NET (#01EW1710); J.M.S.]; the W.E. Hunt and C.M. Curtis Endowment (J.M.S.); and the Craig H. Neilsen Foundation (Encino, CA; A.F.). J.M.S. is a Discovery Theme Initiative Scholar (The Ohio State University).	Aboul-Enein F, 2006, ACTA NEUROPATHOL, V111, P539, DOI 10.1007/s00401-006-0047-y; AGUAYO AJ, 1981, J EXP BIOL, V95, P231; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Apostolova I, 2006, J NEUROSCI, V26, P7849, DOI 10.1523/JNEUROSCI.1526-06.2006; Bagnard D, 2004, MOL CELL NEUROSCI, V25, P722, DOI 10.1016/j.mcn.2003.12.007; Ben-Zvi A, 2008, J NEUROSCI, V28, P12427, DOI 10.1523/JNEUROSCI.3573-08.2008; Benson MD, 2005, P NATL ACAD SCI USA, V102, P10694, DOI 10.1073/pnas.0504021102; Blesch A, 1999, J NEUROSCI, V19, P3556; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bradbury EJ, 2011, BRAIN RES BULL, V84, P306, DOI 10.1016/j.brainresbull.2010.06.015; Bradke F, 2012, NAT REV NEUROSCI, V13, P183, DOI 10.1038/nrn3176; Bundesen LQ, 2003, J NEUROSCI, V23, P7789; Busch SA, 2010, J NEUROSCI, V30, P255, DOI 10.1523/JNEUROSCI.3705-09.2010; Busch SA, 2009, J NEUROSCI, V29, P9967, DOI 10.1523/JNEUROSCI.1151-09.2009; Cafferty WBJ, 2001, J NEUROSCI, V21, P7161, DOI 10.1523/JNEUROSCI.21-18-07161.2001; Cao ZX, 2006, J NEUROSCI, V26, P5565, DOI 10.1523/JNEUROSCI.0815-06.2006; CARLSTEDT T, 1985, BRAIN RES, V347, P188, DOI 10.1016/0006-8993(85)90911-4; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chauvet N, 1998, EXP NEUROL, V151, P1, DOI 10.1006/exnr.1998.6784; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; ChenKinon, 2017, EXP NEUROL, V292, P135, DOI 10.1016/j.expneurol.2017.03.012; Cregg JM, 2014, EXP NEUROL, V253, P197, DOI 10.1016/j.expneurol.2013.12.024; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Davies SJA, 1997, NATURE, V390, P680; Di Maio A, 2011, J NEUROSCI, V31, P4569, DOI 10.1523/JNEUROSCI.4638-10.2011; Dickendesher TL, 2012, NAT NEUROSCI, V15, P703, DOI 10.1038/nn.3070; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Duan YT, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3110pe6; Erturk A, 2007, J NEUROSCI, V27, P9169, DOI 10.1523/JNEUROSCI.0612-07.2007; Evans TA, 2014, EXP NEUROL, V254, P109, DOI 10.1016/j.expneurol.2014.01.013; Fabes J, 2007, EUR J NEUROSCI, V26, P2496, DOI 10.1111/j.1460-9568.2007.05859.x; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Filous AR, 2014, J NEUROSCI, V34, P16369, DOI 10.1523/JNEUROSCI.1309-14.2014; Filous AR, 2010, DEV NEUROBIOL, V70, P826, DOI 10.1002/dneu.20820; Fisher D, 2011, J NEUROSCI, V31, P14051, DOI 10.1523/JNEUROSCI.1737-11.2011; FRIEDE RL, 1980, J NEUROL SCI, V44, P181, DOI 10.1016/0022-510X(80)90126-4; Gao Y, 2003, J NEUROSCI, V23, P11770; Geoffroy CG, 2014, CURR OPIN NEUROBIOL, V27, P31, DOI 10.1016/j.conb.2014.02.012; Gilbert RJ, 2005, MOL CELL NEUROSCI, V29, P545, DOI 10.1016/j.mcn.2005.04.006; Giraudon P, 2004, J IMMUNOL, V172, P1246, DOI 10.4049/jimmunol.172.2.1246; Gitler D, 1998, NEURON, V20, P1123, DOI 10.1016/S0896-6273(00)80494-8; Gitler D, 2002, J NEUROBIOL, V52, P267, DOI 10.1002/neu.10084; Guth L, 1999, ANN NY ACAD SCI, V890, P366, DOI 10.1111/j.1749-6632.1999.tb08017.x; Gutilla EA, 2016, EXP NEUROL, V279, P27, DOI 10.1016/j.expneurol.2016.02.013; Hagino S, 2003, GLIA, V42, P130, DOI 10.1002/glia.10207; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Hawthorne AL, 2011, J NEUROSCI, V31, P5605, DOI 10.1523/JNEUROSCI.6663-10.2011; He ZG, 2016, NEURON, V90, P437, DOI 10.1016/j.neuron.2016.04.022; Hollis ER, 2016, NAT NEUROSCI, V19, P697, DOI 10.1038/nn.4282; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Kaneko S, 2006, NAT MED, V12, P1380, DOI 10.1038/nm1505; Kang SS, 2013, NEUROBIOL DIS, V49, P68, DOI 10.1016/j.nbd.2012.08.020; Keough MB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11312; Kerr BJ, 2005, GLIA, V51, P73, DOI 10.1002/glia.20177; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kikuchi K, 2003, J BIOL CHEM, V278, P42985, DOI 10.1074/jbc.M302395200; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; Kottis V, 2002, J NEUROCHEM, V82, P1566, DOI 10.1046/j.1471-4159.2002.01146.x; Lacroix S, 2002, J COMP NEUROL, V454, P213, DOI 10.1002/cne.10407; Lang BT, 2015, NATURE, V518, P404, DOI 10.1038/nature13974; Lee JK, 2010, NEURON, V66, P663, DOI 10.1016/j.neuron.2010.05.002; Lee JK, 2009, J NEUROSCI, V29, P8649, DOI 10.1523/JNEUROSCI.1864-09.2009; Leibinger M, 2009, J NEUROSCI, V29, P14334, DOI 10.1523/JNEUROSCI.2770-09.2009; LI Y, 1995, EXP NEUROL, V134, P102, DOI 10.1006/exnr.1995.1041; Liu K, 2010, NAT NEUROSCI, V13, P1075, DOI 10.1038/nn.2603; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; LU X, 1991, J NEUROSCI, V11, P972; Mandolesi G, 2004, FASEB J, V18, P1934, DOI 10.1096/fj.04-1805fje; Matthews RT, 2002, J NEUROSCI, V22, P7536; McKeon RJ, 1999, J NEUROSCI, V19, P10778; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MCQUARRIE IG, 1973, ARCH NEUROL-CHICAGO, V29, P53, DOI 10.1001/archneur.1973.00490250071008; McTigue DM, 2006, J NEUROPATH EXP NEUR, V65, P406, DOI 10.1097/01.jnen.0000218447.32320.52; Monnier PP, 2003, MOL CELL NEUROSCI, V22, P319, DOI 10.1016/S1044-7431(02)00035-0; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; MONTIGRAZIADEI GA, 1980, BRAIN RES, V189, P343, DOI 10.1016/0006-8993(80)90095-5; MORRIS JH, 1972, Z ZELLFORSCH MIK ANA, V124, P103, DOI 10.1007/BF00981944; MORRISON EE, 1995, NEUROSCI LETT, V198, P213, DOI 10.1016/0304-3940(95)11943-Q; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Neumann S, 2005, P NATL ACAD SCI USA, V102, P16848, DOI 10.1073/pnas.0508538102; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; Nishiyama A, 1999, J NEUROPATH EXP NEUR, V58, P1113, DOI 10.1097/00005072-199911000-00001; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Pan JZ, 2002, J NEUROSCI RES, V68, P315, DOI 10.1002/jnr.10215; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Pasterkarnp RJ, 2006, PHILOS T R SOC B, V361, P1499, DOI 10.1098/rstb.2006.1892; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Qiu J, 2005, J NEUROSCI, V25, P1645, DOI 10.1523/JNEUROSCI.3269-04.2005; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Ramon, 1928, DEGENERATION REGENER; Reza JN, 1999, MOL CELL NEUROSCI, V14, P317, DOI 10.1006/mcne.1999.0786; RUDGE JS, 1990, J NEUROSCI, V10, P3594; Ruschel J, 2015, SCIENCE, V348, P347, DOI 10.1126/science.aaa2958; Sachs HH, 2010, EXP NEUROL, V223, P516, DOI 10.1016/j.expneurol.2010.01.019; Sahly I, 2006, J COMP NEUROL, V494, P705, DOI 10.1002/cne.20690; Schwab JM, 2005, EUR J NEUROSCI, V21, P1569, DOI 10.1111/j.1460-9568.2005.03962.x; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; Shen YJ, 2009, SCIENCE, V326, P592, DOI 10.1126/science.1178310; Siebert JR, 2011, J NEUROCHEM, V119, P176, DOI 10.1111/j.1471-4159.2011.07370.x; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Silver J, 2010, NEURON, V66, P619, DOI 10.1016/j.neuron.2010.05.028; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; SPIRA ME, 1993, J NEUROBIOL, V24, P300, DOI 10.1002/neu.480240304; Spira ME, 2003, J COMP NEUROL, V457, P293, DOI 10.1002/cne.10569; Steinmetz MP, 2005, J NEUROSCI, V25, P8066, DOI 10.1523/JNEUROSCI.2111-05.2005; Sun F, 2010, CURR OPIN NEUROBIOL, V20, P510, DOI 10.1016/j.conb.2010.03.013; Suzuki K, 2008, NAT IMMUNOL, V9, P17, DOI 10.1038/ni1553; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Tom VJ, 2004, J NEUROSCI, V24, P6531, DOI 10.1523/JNEUROSCI.0994-04.2004; Tuszynski MH, 2012, NEURON, V74, P777, DOI 10.1016/j.neuron.2012.05.006; Udina E, 2008, EXP NEUROL, V210, P238, DOI 10.1016/j.expneurol.2007.11.007; Wang BA, 2005, CURR PROTEIN PEPT SC, V6, P473, DOI 10.2174/138920305774329340; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Williams PR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6683; YAWO H, 1983, SCIENCE, V222, P1351, DOI 10.1126/science.6658457; Yick LW, 2004, J NEUROTRAUM, V21, P932, DOI 10.1089/neu.2004.21.932; Yick LW, 2000, NEUROREPORT, V11, P1063, DOI 10.1097/00001756-200004070-00032; Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701; Zhao RR, 2013, NEUROSCI BULL, V29, P477, DOI 10.1007/s12264-013-1359-2; Zigmond RE, 2012, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00062	126	12	12	2	30	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					53	62		10.1016/j.ajpath.2017.09.005			10	Pathology	Pathology	FQ8SS	WOS:000418634100008	29030051				2019-10-28	
J	Krupar, R; Hautmann, MG; Pathak, RR; Varier, I; McLaren, C; Gaag, D; Hellerbrand, C; Evert, M; Laban, S; Idel, C; Sandulache, V; Perner, S; Bosserhoff, AK; Sikora, AG				Krupar, Rosemarie; Hautmann, Matthias G.; Pathak, Ravi R.; Varier, Indu; McLaren, Cassandra; Gaag, Doris; Hellerbrand, Claus; Evert, Matthias; Laban, Simon; Idel, Christian; Sandulache, Vlad; Perner, Sven; Bosserhoff, Anja K.; Sikora, Andrew G.			Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma	AMERICAN JOURNAL OF PATHOLOGY			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; CD8(+) T-CELLS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; RECTAL-CANCER; BREAST-CANCER; RADIATION; LACTATE; GLUCOSE-TRANSPORTER-1; 2-DEOXY-D-GLUCOSE	Tumor immune microenvironment and tumor metabolism are major determinants of chemoradiotherapy response. The interdependency and prognostic significance of specific immune and metabolic phenotypes in head and neck squamous cell carcinoma (HNSCC) were assessed and changes in reactive oxygen species were evaluated as a mechanism of treatment response in tumor spheroid/immunocyte co-cultures. Pretreatment tumor biopsies were immunohistochemically characterized in 73 HNSCC patients treated by definitive chemoradiotherapy and correlated with survival. The prognostic significance of CD8A, GLUT1, and COX5B gene expression was analyzed within The Cancer Genome Atlas database. HNSCC spheroids were co-cultured in vitro with peripheral blood mononuclear cells (PBMCs) in the presence of the glycolysis inhibitor 2-deoxyglucose and radiation treatment followed by PBMC chemotaxis determination via fluorescence microscopy. In the chemoradiotherapy-treated HNSCC cohort, mitochondrial-rich (COX5B) metabolism correlated with increased and glucose-dependent (GLUT1) metabolism with decreased intratumoraL CD8/CD4 ratios. High CD8/CD4, together with mitochondrialrich or glucose-independent metabolism, was associated with improved short-term survival. The Cancer Genome Atlas analysis confirmed that patients with a favorable immune and metabolic gene signature (high CD8A, high COX5B, low GLUT1) had improved short- and Long-term survival. In vitro, 2-deoxyglucose and radiation synergistically up-regulated reactive oxygen species-dependent PBMC chemotaxis to HNSCC spheroids. These results suggest that glucose-independent tumor metabolism is associated with CD8-dominant antitumor immune infiltrate, and together, these contribute to improved chemoradiotherapy response in HNSCC.	[Krupar, Rosemarie; Idel, Christian; Perner, Sven] Univ Med Ctr Schleswig Holstein, Pathol, Campus Lubeck,Ratzebtirger Allee 160,Bldg 50, D-23538 Lubeck, Germany; [Krupar, Rosemarie; Idel, Christian; Perner, Sven] Leibniz Ctr Med & Biosci, Res Ctr Borstel, Ratzebtirger Allee 160,Bldg 50, D-23538 Lubeck, Germany; [Hautmann, Matthias G.] Univ Hosp Regensburg, Dept Radiotherapy, Regensburg, Germany; [Krupar, Rosemarie; Pathak, Ravi R.; McLaren, Cassandra; Sandulache, Vlad; Sikora, Andrew G.] Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA; [Varier, Indu] Tulane Univ, Dept Pediat, New Orleans, LA USA; [Gaag, Doris; Evert, Matthias] Univ Regensburg, Inst Pathol, Regensburg, Germany; [Laban, Simon] Univ Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Ulm, Germany; [Idel, Christian] Univ Hosp Schleswig Holstein, Dept Otorhinolaryngol, Lubeck, Germany; [Hellerbrand, Claus; Bosserhoff, Anja K.] Friedrich Alexander Univ Erlangen Nurnberg, Inst Biochem, Erlangen, Germany	Krupar, R (reprint author), Univ Med Ctr Schleswig Holstein, Pathol, Campus Lubeck,Ratzebtirger Allee 160,Bldg 50, D-23538 Lubeck, Germany.; Krupar, R (reprint author), Leibniz Ctr Med & Biosci, Res Ctr Borstel, Ratzebtirger Allee 160,Bldg 50, D-23538 Lubeck, Germany.	rosemarie.krupar@uksh.de		Bosserhoff, Anja/0000-0001-8147-394X; Sandulache, Vlad/0000-0002-9205-385X	German Cancer AidDeutsche Krebshilfe; German Research FoundationGerman Research Foundation (DFG) [KFO262, 190230491]; Foundation Tumor Research Head and Neck (Stiftung Tumorforschung Kopf Hals)	Supported by the German Cancer Aid (R.K.), the German Research Foundation (KFO262) grant 190230491 (R.K.), and the Foundation Tumor Research Head and Neck (Stiftung Tumorforschung Kopf Hals) (R.K.).	Aarstad HJ, 2015, APMIS, V123, P305, DOI 10.1111/apm.12356; Anitei MG, 2014, CLIN CANCER RES, V20, P1891, DOI 10.1158/1078-0432.CCR-13-2830; Ashcraft KA, 2015, INT J RADIAT ONCOL, V93, P892, DOI 10.1016/j.ijrobp.2015.07.2283; Balermpas P, 2014, BRIT J CANCER, V110, P501, DOI 10.1038/bjc.2013.640; Bhatt AN, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1368-9; Brenner JC, 2010, HEAD NECK-J SCI SPEC, V32, P417, DOI 10.1002/hed.21198; CANTONI O, 1986, BIOCHIM BIOPHYS ACTA, V867, P135, DOI 10.1016/0167-4781(86)90073-4; Cho Y, 2003, CANCER RES, V63, P1555; Coleman MC, 2008, FREE RADICAL BIO MED, V44, P322, DOI 10.1016/j.freeradbiomed.2007.08.032; Cook JA, 2004, SEMIN RADIAT ONCOL, V14, P259, DOI 10.1016/j.semradonc.2004.04.001; Curry JM, 2013, CELL CYCLE, V12, P1371, DOI 10.4161/cc.24092; Dang C, 2006, ONCOL REP, V16, P513; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; Fokas E, 2012, CANCER METAST REV, V31, P823, DOI 10.1007/s10555-012-9394-4; Gao SP, 2015, ONCOTARGET, V6, P43363, DOI 10.18632/oncotarget.6222; Goldkorn T, 1998, J CELL SCI, V111, P3209; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Gregoire V, 2010, ANN ONCOL, V21, pv184, DOI 10.1093/annonc/mdq185; Groussard C, 2000, J APPL PHYSIOL, V89, P169; Hara-Chikuma M, 2012, J EXP MED, V209, P1743, DOI 10.1084/jem.20112398; Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457; Huang Y, 2015, ONCOTARGET, V6, P17462, DOI 10.18632/oncotarget.3958; Kalia VK, 2009, J CANCER RES THER, V5, P57, DOI 10.4103/0973-1482.55145; Krupar R, 2014, VIRCHOWS ARCH, V465, P299, DOI 10.1007/s00428-014-1630-6; Leach JK, 2001, CANCER RES, V61, P3894; Lennicke C, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0118-6; Li SJ, 2013, CELL PHYSIOL BIOCHEM, V32, P624, DOI 10.1159/000354466; Lynam-Lennon N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100738; Maleki S, 2011, HEAD NECK PATHOL, V5, P117, DOI 10.1007/s12105-011-0247-1; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Mims J, 2015, RADIAT RES, V183, P291, DOI 10.1667/RR13828.1; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; Sattler UGA, 2010, RADIOTHER ONCOL, V94, P102, DOI 10.1016/j.radonc.2009.11.007; Sattler UGA, 2009, INT J RADIAT BIOL, V85, P963, DOI 10.3109/09553000903258889; Sawayama H, 2014, ANN SURG ONCOL, V21, P1756, DOI 10.1245/s10434-013-3371-1; Senyilmaz Deniz, 2015, F1000Prime Rep, V7, P41, DOI 10.12703/P7-41; Shim BY, 2013, INT J COLORECTAL DIS, V28, P375, DOI 10.1007/s00384-012-1542-3; Shimura T, 2014, RADIOTHER ONCOL, V112, P302, DOI 10.1016/j.radonc.2014.07.015; Shutt DC, 2010, CANCER BIOL THER, V9, P853, DOI 10.4161/cbt.9.11.11632; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Starska K, 2015, TUMOR BIOL, V36, P2309, DOI 10.1007/s13277-014-2838-4; Sun SY, 2010, CANCER BIOL THER, V9, P109, DOI 10.4161/cbt.9.2.10583; Tominaga H, 2004, J RADIAT RES, V45, P181, DOI 10.1269/jrr.45.181; Tong CCL, 2012, IMMUNOL RES, V54, P266, DOI 10.1007/s12026-012-8306-6; URANO M, 1995, CANCER RES, V55, P2490; Walenta S, 2004, CURR MED CHEM, V11, P2195, DOI 10.2174/0929867043364711	49	5	5	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					72	83		10.1016/j.ajpath.2017.09.013			12	Pathology	Pathology	FQ8SS	WOS:000418634100010	29107073				2019-10-28	
J	Puri, P; Schaefer, CM; Bushnell, D; Taglienti, ME; Kreidberg, JA; Yoder, BK; Bates, CM				Puri, Pawan; Schaefer, Caitlin M.; Bushnell, Daniel; Taglienti, Mary E.; Kreidberg, Jordan A.; Yoder, Bradley K.; Bates, Carlton M.			Ectopic Phosphorylated Creb Marks Dedifferentiated Proximal Tubules in Cystic Kidney Disease	AMERICAN JOURNAL OF PATHOLOGY			English	Article							PROTEIN-KINASE-A; MAMMALIAN KIDNEY; RENAL INJURY; CELLS; CILIA; CYSTOGENESIS; DISRUPTION; EXPRESSION; PKD1; TUBULOGENESIS	Ectopic cAMP signaling is pathologic in poLycystic kidney disease; however, its spatiotemporal actions are unclear. We characterized the expression of phosphorylated Creb (p-Creb), a target and mediator of cAMP signaling, in developing and cystic kidney models. We also examined tubule-specific effects of cAMP analogs in cystogenesis in embryonic kidney explants. In wild-type mice, p-Creb marked nephron progenitors (NP), early epithelial NP derivatives, ureteric bud, and cortical stroma; p-Creb was present in differentiated thick ascending Limb of Henle, collecting duct, and stroma; however, it disappeared in mature NP-derived proximal tubules. In Six2cre;Frs2 alpha(Fl/Fl) mice, a renal cystic model, ectopic p-Creb stained proximal tubule-derived cystic segments that lost the differentiation marker Lotus tetragonolobus lectin. Furthermore, lotus tetragonolobus lectin-negative/p-Creb-positive cyst segments (re)-expressed Ncam1, Pax2, and Sox9 markers of immature nephron structures and dedifferentiated proximal tubules after acute kidney injury. These dedifferentiation markers were co-expressed with p-Creb in renal cysts in Itf88 knockout mice subjected to ischemia and Six2cre;Frs2 alpha(Fl/Fl) mice, other renal cystogenesis models. 8-Br-cAMP addition to wild-type embryonic kidney explants induced proximal tubular cystogenesis and p-Creb expression; these effects were blocked by co-addition of protein kinase A inhibitor. Thus p-Creb/cAMP signaling is appropriate in NP and early nephron derivatives, but disappears in mature proximal tubules. Moreover, ectopic p-Creb expression/cAMP signaling marks dedifferentiated proximal tubular cystic segments. Furthermore, proximal tubules are predisposed to become cystic after cAMP stimulation.	[Puri, Pawan; Schaefer, Caitlin M.; Bushnell, Daniel; Bates, Carlton M.] Univ Pittsburgh, Dept Pediat, Div Nephrol, Sch Med, Pittsburgh, PA 15224 USA; [Taglienti, Mary E.; Kreidberg, Jordan A.] Boston Childrens Hosp, Dept Urol, Boston, MA USA; [Taglienti, Mary E.; Kreidberg, Jordan A.] Harvard Med Sch, Dept Surg, Boston, MA USA; [Yoder, Bradley K.] Univ Alabama Birmingham, Dept Pediat, Dept Cell Dev & Integrat Biol, Birmingham, AL USA; [Bates, Carlton M.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Div Nephrol, Med Ctr, Pittsburgh, PA 15224 USA	Puri, P; Bates, CM (reprint author), Univ Pittsburgh, Childrens Hosp Pittsburgh, UPMC, Div Nephrol,Dept Pediat,Sch Med, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	ppuri@tuskegee.edu; batescm@upmc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [4R01DK095748-04, P30 DK074038]	Supported by NIH grants 4R01DK095748-04 (C.M.B.) and P30 DK074038	Abbate M, 1999, AM J PHYSIOL-RENAL, V277, pF454; Arany I, 2005, KIDNEY INT, V68, P1573, DOI 10.1111/j.1523-1755.2005.00569.x; Arany I, 2008, AM J PHYSIOL-RENAL, V294, pF577, DOI 10.1152/ajprenal.00487.2007; Bergmann C, 2015, PEDIATR NEPHROL, V30, P15, DOI 10.1007/s00467-013-2706-2; Calvet JP, 2015, POLYCYSTIC KIDNEY DISEASE, P169; Chang-Panesso M, 2017, NAT REV NEPHROL, V13, P39, DOI 10.1038/nrneph.2016.169; Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126; Chen L, 2015, J CLIN INVEST, V125, P2399, DOI 10.1172/JCI80467; Di Giovanni V, 2015, DEV BIOL, V400, P82, DOI 10.1016/j.ydbio.2015.01.018; Fain PR, 2005, KIDNEY INT, V67, P1256, DOI 10.1111/j.1523-1755.2005.00203.x; Gallegos TF, 2012, DEV BIOL, V364, P11, DOI 10.1016/j.ydbio.2012.01.014; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gupta IR, 1999, J BIOL CHEM, V274, P26305, DOI 10.1074/jbc.274.37.26305; Hanaoka K, 2000, J AM SOC NEPHROL, V11, P1179; Harris PC, 2014, J CLIN INVEST, V124, P2315, DOI 10.1172/JCI72272; Harris PC, 2010, J AM SOC NEPHROL, V21, P1073, DOI 10.1681/ASN.2010030328; Hildebrandt F, 2005, NAT REV GENET, V6, P928, DOI 10.1038/nrg1727; [Institute for Laboratory Animal Research Division on Earth and Life Studies National Research Council of the National Academies Committee for the Update of the Guide for the Care and Use of Laboratory Animals], 2011, GUID CAR US LAB AN; Jonassen JA, 2012, J AM SOC NEPHROL, V23, P641, DOI 10.1681/ASN.2011080829; Kim I, 2009, J AM SOC NEPHROL, V20, P2556, DOI 10.1681/ASN.2009030271; Kobayashi A, 2008, CELL STEM CELL, V3, P169, DOI 10.1016/j.stem.2008.05.020; Lancaster MA, 2010, TRENDS MOL MED, V16, P349, DOI 10.1016/j.molmed.2010.05.004; Li W, 2014, DEV DYNAM, V243, P853, DOI [10.1002/DVDY.24134, 10.1002/dvdy.24134]; Li XG, 2008, NAT MED, V14, P863, DOI 10.1038/nm1783; Lin YS, 2007, GENESIS, V45, P554, DOI 10.1002/dvg.20327; Little M. H., 2012, COLD SPRING HARB PER, V4; Magenheimer BS, 2006, J AM SOC NEPHROL, V17, P3424, DOI 10.1681/ASN.2006030295; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Mantamadiotis T, 2012, BIOESSAYS, V34, P293, DOI 10.1002/bies.201100133; Marciano DK, 2011, DEVELOPMENT, V138, P2099, DOI 10.1242/dev.056564; Masai I, 2005, DEVELOPMENT, V132, P1539, DOI 10.1242/dev.01714; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Peters DJM, 2001, LANCET, V358, P1439, DOI 10.1016/S0140-6736(01)06531-X; Piontek KB, 2004, J AM SOC NEPHROL, V15, P3035, DOI 10.1097/01.ASN.0000144204.01352.86; Puri P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36736; Puri P, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.104414; Qin S, 2012, J AM SOC NEPHROL, V23, P1309, DOI 10.1681/ASN.2011030277; Sakai D, 2006, DEVELOPMENT, V133, P1323, DOI 10.1242/dev.02297; Sharma N, 2013, J AM SOC NEPHROL, V24, P456, DOI 10.1681/ASN.2012020154; Sims-Lucas S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065993; Sims-Lucas S, 2012, J AM SOC NEPHROL, V23, P607, DOI 10.1681/ASN.2011020165; Stewart R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024714; Swenson-Fields KI, 2013, KIDNEY INT, V83, P855, DOI 10.1038/ki.2012.446; Takakura A, 2009, HUM MOL GENET, V18, P2523, DOI 10.1093/hmg/ddp147; Takakura A, 2008, J AM SOC NEPHROL, V19, P2351, DOI 10.1681/ASN.2007101139; Tan YC, 2011, BBA-MOL BASIS DIS, V1812, P1202, DOI 10.1016/j.bbadis.2011.03.002; Tran PV, 2014, J AM SOC NEPHROL, V25, P2201, DOI 10.1681/ASN.2013070735; Villanueva S, 2006, AM J PHYSIOL-REG I, V290, pR861, DOI 10.1152/ajpregu.00384.2005; Weimbs T, 2007, AM J PHYSIOL-RENAL, V293, pF1423, DOI 10.1152/ajprenal.00275.2007; Weimbs T, 2011, J AM SOC NEPHROL, V22, P793, DOI 10.1681/ASN.2011030284; Winyard P, 2011, BBA-MOL BASIS DIS, V1812, P1256, DOI 10.1016/j.bbadis.2011.04.012; Xu JS, 2006, J BIOL CHEM, V281, P38894, DOI 10.1074/jbc.M609339200; Ye H, 2016, J AM SOC NEPHROL, V27, P1312, DOI 10.1681/ASN.2015010057; Yoder BK, 2007, J AM SOC NEPHROL, V18, P1381, DOI 10.1681/ASN.2006111215	54	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					84	94		10.1016/j.ajpath.2017.09.015			11	Pathology	Pathology	FQ8SS	WOS:000418634100011	29107072	Bronze, Green Published			2019-10-28	
J	Singal, SS; Nygard, K; Dhruv, MR; Biggar, K; Shehab, MA; Li, SSC; Jansson, T; Gupta, MB				Singal, Sahil S.; Nygard, Karen; Dhruv, Manthan R.; Biggar, Kyle; Shehab, Majida A.; Li, Shawn S. -C.; Jansson, Thomas; Gupta, Madhulika B.			Co-Localization of Insulin-Like Growth Factor Binding Protein-1, Casein Kinase-2 beta, and Mechanistic Target of Rapamycin in Human Hepatocellular Carcinoma Cells as Demonstrated by Dual Immunofluorescence and in Situ Proximity Ligation Assay	AMERICAN JOURNAL OF PATHOLOGY			English	Article							KINASE CK2; IGFBP-1 PHOSPHORYLATION; SUBCELLULAR-LOCALIZATION; LEUCINE DEPRIVATION; MAMMALIAN TARGET; EXPRESSION; HYPOXIA; CULTURE	Insulin-like growth factor binding protein (IGFBP)-1 influences fetal growth by modifying insulin-like growth factor-I (IGF-I) bioavailability. IGFBP-1 phosphorylation, which markedly increases its affinity for IGF-I, is regulated by mechanistic target of rapamycin (mTOR) and casein kinase (CSNK)-2. However, the underlying molecular mechanisms remain unknown. We examined the cellular localization and potential interactions of IGFBP-1, CSNK-2 beta, and mTOR as a prerequisite for protein-protein interaction. Analysis of dual immunofluorescence images indicated a potential perinuclear co-localization between IGFBP-1 and CSNK-2 beta and a nuclear co-localization between CSNK-2 beta and mTOR. Proximity ligation assay (PLA) indicated proximity between IGFBP-1 and CSNK-2 beta as well as mTOR and CSNK-2 beta but not between mTOR and IGFBP-1. Three-dimensional rendering of the PLA images validated that IGFBP-1 and CSNK-2 beta interactions were in the perinuclear region and mTOR and CSNK-2 beta interactions were also predominantly perinuclear rather than nuclear as indicated by mTOR and CSNK-2 beta co-localization. Compared with control, hypoxia and rapamycin treatment showed markedly amplified PLA signals for IGFBP-1 and CSNK-2 beta (approximately 18-fold, P = 0.0002). Stable isotope labeling with multiple reaction monitoring-mass spectrometry demonstrated that hypoxia and rapamycin treatment increased IGFBP-1 phosphorylation at Ser98/Ser101/Ser119/Ser174 but most considerably (106-fold) at Ser169. We report interactions between CSNK-2 beta and IGFBP-1 as well as mTOR and CSNK-2 beta, providing strong evidence of a mechanistic link between mTOR and IGF-I signaling, two critical regulators of cell growth via CSNK-2.	[Singal, Sahil S.; Biggar, Kyle; Li, Shawn S. -C.; Gupta, Madhulika B.] Univ Western Ontario, Dept Biochem, London, ON, Canada; [Dhruv, Manthan R.; Shehab, Majida A.; Gupta, Madhulika B.] Univ Western Ontario, Dept Pediat, London, ON, Canada; [Nygard, Karen] Univ Western Ontario, Biotron Lab, London, ON, Canada; [Biggar, Kyle] Carleton Univ, Inst Biochem, Ottawa, ON, Canada; [Jansson, Thomas] Univ Colorado, Dept Obstet & Gynecol, Anschutz Med Campus, Aurora, CO USA; [Gupta, Madhulika B.] Childrens Hlth Res Inst, VRL Room A5-136 WC,800 Commissioners Rd E, London, ON N6C 2V5, Canada	Gupta, MB (reprint author), Childrens Hlth Res Inst, VRL Room A5-136 WC,800 Commissioners Rd E, London, ON N6C 2V5, Canada.	mbgupta@uwo.ca			Natural Science and Engineering Council of Canada Discovery grants [RGPIN-2016-04752, RGPIN-2015-05000]; Lawson Health Research Institute [HRF0512]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD 078313]	Supported by the Natural Science and Engineering Council of Canada Discovery grants RGPIN-2016-04752 and RGPIN-2015-05000 and Lawson Health Research Institute grant HRF0512 (M.B.G.) and, in part, NIH grant HD 078313 (M.B.G. and T.J.).	Abu Shehab M, 2014, ENDOCRINOLOGY, V155, P1327, DOI 10.1210/en.2013-1759; Abu Shehab M, 2010, J PROTEOME RES, V9, P1873, DOI 10.1021/pr900987n; Cao JY, 2014, MOL CELL BIOL, V34, P246, DOI 10.1128/MCB.00968-13; Damerill I, 2016, MOL ENDOCRINOL, V30, P201, DOI 10.1210/me.2015-1194; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003; Gupta MB, 2015, J CELL COMMUN SIGNAL, V9, P111, DOI 10.1007/s12079-015-0266-x; Han VKM, 1996, HORM RES, V45, P160, DOI 10.1159/000184780; JONES JI, 1993, GROWTH REGULAT, V3, P37; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Malkani N, 2016, MOL CELL ENDOCRINOL, V425, P48, DOI 10.1016/j.mce.2015.12.006; Martina NA, 1997, J CLIN ENDOCR METAB, V82, P1894, DOI 10.1210/jc.82.6.1894; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Montenarh M, 2014, ADV CLIN EXP MED, V23, P153, DOI 10.17219/acem/37040; Mottet D, 2005, INT J CANCER, V117, P764, DOI 10.1002/ijc.21268; Mounier C, 2006, ENDOCRINOLOGY, V147, P2383, DOI 10.1210/en.2005-0902; Nissum M, 2009, MOL CELL PROTEOMICS, V8, P1424, DOI 10.1074/mcp.M800571-MCP200; Olsten MEK, 2005, MOL CELL BIOCHEM, V274, P115, DOI 10.1007/s11010-005-3072-6; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Peracchia G, 1999, PLANT MOL BIOL, V40, P199, DOI 10.1023/A:1006196530079; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Popovici RM, 2001, J CLIN ENDOCR METAB, V86, P2653, DOI 10.1210/jc.86.6.2653; Seferovic MD, 2016, DIS MARKERS, DOI 10.1155/2016/7124186; Seferovic MD, 2011, J PROTEOME RES, V10, P1495, DOI 10.1021/pr100879z; Seferovic MD, 2009, ENDOCRINOLOGY, V150, P220, DOI 10.1210/en.2008-0657; Turowec JP, 2010, METHOD ENZYMOL, V484, P471, DOI [10.1016/S0076-6879(10)84023-6, 10.1016/B978-0-12-381298-8.00023-X]; Veis A, 1997, CRIT REV ORAL BIOL M, V8, P360, DOI 10.1177/10454411970080040101	29	3	3	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					111	124		10.1016/j.ajpath.2017.09.009			14	Pathology	Pathology	FQ8SS	WOS:000418634100013	29037858	Bronze, Green Published			2019-10-28	
J	Mangus, LM; Beck, SE; Queen, SE; Brill, SA; Shirk, EN; Pate, KAM; Muth, DC; Adams, RJ; Gama, L; Clements, JE; Mankowski, JL				Mangus, Lisa M.; Beck, Sarah E.; Queen, Suzanne E.; Brill, Samuel A.; Shirk, Erin N.; Pate, Kelly A. Metcalf; Muth, Dillon C.; Adams, Robert J.; Gama, Lucio; Clements, Janice E.; Mankowski, Joseph L.			Lymphocyte-Dominant Encephalitis and Meningitis in Simian Immunodeficiency Virus-Infected Macaques Receiving Antiretroviral Therapy	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; RECONSTITUTION INFLAMMATORY SYNDROME; CHRONIC HIV-INFECTION; IMMUNE RECONSTITUTION; CEREBROSPINAL-FLUID; NEUROCOGNITIVE IMPAIRMENT; HIV-1-INFECTED PATIENTS; CEREBRAL INJURY; VIRAL LOAD; BRAIN	A retrospective neuropathologic review of 30 SIV-infected pigtailed macaques receiving combination antiretroviral therapy (cART) was conducted. Seventeen animals with lymphocyte-dominant inflammation in the brain and/or meninges that clearly was morphologically distinct from prototypic SIV encephalitis and human immunodeficiency virus encephalitis were identified. Central nervous system (CNS) infiltrates in cART-treated macaques primarily comprised CD20(+) B cells and CD3(+) T cells with fewer CD68(+) macrophages. Inflammation was associated with low levels of SIV RNA in the brain as shown by in situ hybridization, and generally was observed in animals with episodes of cerebrospinal fluid (CSF) viral rebound or sustained plasma and CSF viremia during treatment. Although the lymphocytic CNS inflammation in these macaques shared morphologic characteristics with uncommon immune-mediated neurologic disorders reported in treated HIV patients, including CNS immune reconstitution inflammatory syndrome and neurosymptomatic CSF escape, the high prevalence of CNS lesions in macaques suggests that persistent adaptive immune responses in the CNS also may develop in neuroasymptomatic or mildly impaired HIV patients yet remain unrecognized given the tack of access to CNS tissue for histopathologic evaluation. Continued investigation into the mechanisms and outcomes of CNS inflammation in cART-treated, SIV-infected macaques will advance our understanding of the consequences of residual CNS HIV replication in patients on cART, including the possible contribution of adaptive immune responses to HIV-associated neurocognitive disorders.	[Mangus, Lisa M.; Beck, Sarah E.; Queen, Suzanne E.; Brill, Samuel A.; Shirk, Erin N.; Pate, Kelly A. Metcalf; Muth, Dillon C.; Adams, Robert J.; Gama, Lucio; Clements, Janice E.; Mankowski, Joseph L.] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD 21205 USA; [Clements, Janice E.; Mankowski, Joseph L.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Clements, Janice E.; Mankowski, Joseph L.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	Mankowski, JL (reprint author), Johns Hopkins Univ, Dept Mol & Comparat Pathobiol, 733 N Broadway,BRB 819, Baltimore, MD 21205 USA.	jmankows@jhmi.edu		Muth, Dillon/0000-0003-4550-3755	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS097221, R01NS089482, R01NS077869, T32OD011089, P40OD0131117, P01MH070306, K01OD021323, K01OD018244]; Johns Hopkins University Center for AIDS Research grant [P30AI094189]	Supported by NIH grants R01NS097221 (J.L.M.), R01NS089482 (J.L.M.), R01NS077869 (J.E.C., J.L.M.), T32OD011089 (J.L.M.), P40OD0131117 (R.J.A.), P01MH070306 (J.E.C.), K01OD021323 (S.E.B.), K01OD018244 (K.A.M.P.), and the Johns Hopkins University Center for AIDS Research grant P30AI094189 (S.E.B., K.A.M.P). Antiretroviral compounds and latency-reversing agents were provided by Abbvie, Amazonia Fitomedicamentos, Bristol-Meyers Squibb, Gilead, Janssen, Merck, and ViiV Healthcare.	Abdulle S, 2005, HIV MED, V6, P164, DOI 10.1111/j.1468-1293.2005.00281.x; Anderson AM, 2015, JAIDS-J ACQ IMM DEF, V69, P29, DOI 10.1097/QAI.0000000000000532; Anderson CM, 2016, J CELL BIOCHEM, V117, P2201, DOI 10.1002/jcb.25606; Anthony IC, 2003, BRAIN, V126, P1058, DOI 10.1093/brain/awg118; Beck SE, 2015, EUR J PHARMACOL, V759, P303, DOI 10.1016/j.ejphar.2015.03.018; Becker JT, 2015, INT J EPIDEMIOL, V44, P1506, DOI 10.1093/ije/dyu092; Bonnan M, 2015, J NEUROIMMUNOL, V285, P41, DOI 10.1016/j.jneuroim.2015.05.015; Budka H, 1991, BRAIN PATHOL, V1, P143, DOI 10.1111/j.1750-3639.1991.tb00653.x; Budka H, 1991, BRAIN PATHOL, V1, P163, DOI 10.1111/j.1750-3639.1991.tb00656.x; Burdo TH, 2013, IMMUNOL REV, V254, P102, DOI 10.1111/imr.12068; Burdo TH, 2013, AIDS, V27, P1387, DOI 10.1097/QAD.0b013e32836010bd; Canestri A, 2010, CLIN INFECT DIS, V50, P773, DOI 10.1086/650538; Cassol E, 2014, AIDS, V28, P1579, DOI 10.1097/QAD.0000000000000303; Clements JE, 2002, J INFECT DIS, V186, P905, DOI 10.1086/343768; Dickens Alex M, 2015, AIDS, V29, P559, DOI 10.1097/QAD.0000000000000580; Ellis RJ, 2011, AIDS, V25, P1747, DOI 10.1097/QAD.0b013e32834a40cd; Gama L, 2017, AIDS, V31, P5, DOI 10.1097/QAD.0000000000001267; Gelman BB, 2015, CURR HIV-AIDS REP, V12, P272, DOI 10.1007/s11904-015-0266-8; Gongvatana A, 2013, J NEUROVIROL, V19, P209, DOI 10.1007/s13365-013-0162-1; Gray F, 2013, BRAIN PATHOL, V23, P525, DOI 10.1111/bpa.12038; Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727; Johnson T, 2010, ANN NY ACAD SCI, V1184, P106, DOI 10.1111/j.1749-6632.2009.05111.x; Johnson TP, 2014, CURR OPIN HIV AIDS, V9, P572, DOI 10.1097/COH.0000000000000107; Johnson TP, 2013, P NATL ACAD SCI USA, V110, P13588, DOI 10.1073/pnas.1308673110; KAISER R, 1989, J NEUROL, V236, P157, DOI 10.1007/BF00314332; Kamat A, 2012, JAIDS-J ACQ IMM DEF, V60, P234, DOI 10.1097/QAI.0b013e318256f3bc; Lackner P, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-79; Le T, 2013, NEW ENGL J MED, V368, P218, DOI 10.1056/NEJMoa1110187; Lescure FX, 2013, CLIN INFECT DIS, V57, P101, DOI 10.1093/cid/cit175; Lindzen E, 2008, J NEUROVIROL, V14, P569, DOI 10.1080/13550280802304753; Mankowski J, 2002, J INFECT DIS S2, V186, P208; Martin-Blondel G, 2011, BRAIN, V134, P928, DOI 10.1093/brain/awq365; MCARTHUR JC, 1989, ANN NEUROL, V26, P601, DOI 10.1002/ana.410260504; MCARTHUR JC, 1993, NEUROLOGY, V43, P2245, DOI 10.1212/WNL.43.11.2245; McCutchan JA, 2012, NEUROLOGY, V78, P485, DOI 10.1212/WNL.0b013e3182478d64; Miller RF, 2004, ACTA NEUROPATHOL, V108, P17, DOI 10.1007/s00401-004-0852-0; Moir S, 2010, BLOOD, V116, P5571, DOI 10.1182/blood-2010-05-285528; Peluso MJ, 2012, AIDS, V26, P1765, DOI 10.1097/QAD.0b013e328355e6b2; Queen SE, 2011, J VIROL, V85, P9167, DOI 10.1128/JVI.00366-11; Ringelstein A, 2009, AIDS, V23, P1435, DOI 10.1097/QAD.0b013e32832c4101; Robertson J, 2006, CLIN INFECT DIS, V42, P1639, DOI 10.1086/503903; Rodriguez-Porcel F, 2013, FRONT NEUROL, V4, DOI [10.3389/fneur.2013.00183, 10.3389/fneur.2013.00012]; Roh D, 2013, J NEUROVIROL, V19, P190, DOI 10.1007/s13365-013-0161-2; Rushing EJ, 2008, J NEUROPATH EXP NEUR, V67, P819, DOI 10.1097/NEN.0b013e318181b4da; Saylor D, 2016, NAT REV NEUROL, V12, P234, DOI 10.1038/nrneurol.2016.27; Spudich SS, 2016, CURR OPIN HIV AIDS, V11, P226, DOI 10.1097/COH.0000000000000243; Valcour V, 2012, J INFECT DIS, V206, P275, DOI 10.1093/infdis/jis326; Venkataramana A, 2006, NEUROLOGY, V67, P383, DOI 10.1212/01.wnl.0000227922.22293.93; Zink MC, 2010, J INFECT DIS, V202, P161, DOI 10.1086/653213; Zink MC, 1999, J VIROL, V73, P10480; Zink MC, 1997, AM J PATHOL, V151, P793	51	2	2	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					125	134		10.1016/j.ajpath.2017.08.035			10	Pathology	Pathology	FQ8SS	WOS:000418634100014	29229308	Green Published, Bronze			2019-10-28	
J	Ashar, HK; Mueller, NC; Rudd, JM; Snider, TA; Achanta, M; Prasanthi, M; Pulavendran, S; Thomas, PG; Ramachandran, A; Malayer, JR; Ritchey, JW; Rajasekhar, R; Chow, VTK; Esmon, CT; Teluguakula, N				Ashar, Harshini K.; Mueller, Nathan C.; Rudd, Jennifer M.; Snider, Timothy A.; Achanta, Mallika; Prasanthi, Maram; Pulavendran, Sivasami; Thomas, Paul G.; Ramachandran, Akhilesh; Malayer, Jerry R.; Ritchey, Jerry W.; Rajasekhar, Rachakatla; Chow, Vincent T. K.; Esmon, Charles T.; Teluguakula, Narasaraju			The Role of Extracellular Histones in Influenza Virus Pathogenesis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; MICE; INFECTION; PNEUMONIA; MEDIATORS; INFLAMMATION; AGGREGATION; ACTIVATION; NECROSIS	Although exaggerated host immune responses have been implicated in influenza-induced lung pathogenesis, the etiologic factors that contribute to these events are not completely understood. We previously demonstrated that neutrophil extracellular traps exacerbate pulmonary injury during influenza pneumonia. Histones are the major protein components of neutrophil extracellular traps and are known to have cytotoxic effects. Here, we examined the role of extracellular histones in Lung pathogenesis during influenza. Mice infected with influenza virus displayed high accumulation of extracellular histones, with widespread pulmonary microvascular thrombosis. Occluded pulmonary blood vessels with vascular thrombi often exhibited endothelial necrosis surrounded by hemorrhagic effusions and pulmonary edema. Histones released during influenza induced cytotoxicity and showed strong binding to platelets within thrombi in infected mouse lungs. Nasal wash samples from influenza-infected patients also showed increased accumulation of extracellular histones, suggesting a possible clinical relevance of elevated histones in pulmonary injury. Although histones inhibited influenza growth in vitro, in vivo treatment with histones did not yield antiviral effects and instead exacerbated lung pathology. Blocking with antihistone antibodies caused a marked decrease in lung pathology in lethal influenza-challenged mice and improved protection when administered in combination with the antiviral agent oseltamivir. These findings support the pathogenic effects of extracellular histones in that pulmonary injury during influenza was exacerbated. Targeting histones provides a novel therapeutic approach to influenza pneumonia.	[Ashar, Harshini K.; Mueller, Nathan C.; Rudd, Jennifer M.; Snider, Timothy A.; Achanta, Mallika; Prasanthi, Maram; Pulavendran, Sivasami; Ramachandran, Akhilesh; Malayer, Jerry R.; Ritchey, Jerry W.; Teluguakula, Narasaraju] Oklahoma State Univ, Ctr Vet Hlth Sci, Stillwater, OK 74078 USA; [Thomas, Paul G.] St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Rajasekhar, Rachakatla] Arkansas Coll Osteopath Med, Dept Anat, Ft Smith, AR USA; [Chow, Vincent T. K.] Natl Univ Singapore, Natl Univ Hlth Syst, Sch Med, Dept Microbiol & Immunol, Singapore, Singapore; [Esmon, Charles T.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma Med Res Fdn, Coagulat Biol Lab, Oklahoma City, OK USA; [Esmon, Charles T.] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Dept Pathol, Oklahoma City, OK 73190 USA	Teluguakula, N (reprint author), Oklahoma State Univ, 264 McElroy Hall, Stillwater, OK 74078 USA.	narasa@okstate.edu	Thomas, Paul G./H-1063-2018	Thomas, Paul G./0000-0001-7955-0256; Malayer, Jerry/0000-0002-6955-8374; Snider, Timothy/0000-0002-2659-835X	National Institute of General Medical Sciences NIH award [P20GM103648]; Oklahoma Center for the Advancement of Science & Technology grant; Center for Veterinary Health Sciences, Oklahoma State University grant; National Heart, Lung & Blood Institute NIH grant [UM1 HL120877]	Supported by National Institute of General Medical Sciences NIH award P20GM103648; an Oklahoma Center for the Advancement of Science & Technology grant; a Center for Veterinary Health Sciences, Oklahoma State University grant (N.T.); and National Heart, Lung & Blood Institute NIH grant UM1 HL120877 (C.T.E.).	Abrams ST, 2013, AM J RESP CRIT CARE, V187, P160, DOI 10.1164/rccm.201206-1037OC; Allam R, 2012, J AM SOC NEPHROL, V23, P1375, DOI 10.1681/ASN.2011111077; Anand SX, 2003, THROMB HAEMOSTASIS, V90, P377, DOI 10.1160/TH03-05-0268; Andre P, 2002, CIRCULATION, V106, P896, DOI 10.1161/01.CIR.0000028962.04520.01; Audrey-Ann L, 2014, EUR J INFLAMM, V12, P117; Dharan NJ, 2009, JAMA-J AM MED ASSOC, V301, P1034, DOI 10.1001/jama.2009.294; Estenssoro E, 2010, AM J RESP CRIT CARE, V182, P41, DOI [10.1164/rccm.201001-0037OC, 10.1164/201001-0037OC]; Fuchs TA, 2012, ARTERIOSCL THROM VAS, V32, P1777, DOI 10.1161/ATVBAHA.111.242859; Fuchs TA, 2011, BLOOD, V118, P3708, DOI 10.1182/blood-2011-01-332676; Harms PW, 2010, AM J CLIN PATHOL, V134, P27, DOI 10.1309/AJCP35KOZSAVNQZW; Hoeksema M, 2015, INNATE IMMUN-LONDON, V21, P736, DOI 10.1177/1753425915593794; Ilyushina NA, 2006, ANTIVIR RES, V70, P121, DOI 10.1016/j.antiviral.2006.01.012; Ivan FX, 2012, FUNCT INTEGR GENOMIC, V12, P105, DOI 10.1007/s10142-011-0247-y; Kash JC, 2015, AM J PATHOL, V185, P1528, DOI 10.1016/j.ajpath.2014.08.030; Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496; LeCount ER, 1919, J AMER MED ASSOC, V72, P1519, DOI 10.1001/jama.1919.02610210015003; Lee DY, 2009, J INVEST DERMATOL, V129, P2489, DOI 10.1038/jid.2009.106; Li J, 2014, J CLIN INVEST, V124, P1483, DOI 10.1172/JCI72305; Mauad T, 2010, AM J RESP CRIT CARE, V181, P72, DOI 10.1164/rccm.200909-1420OC; Moorthy AN, 2016, ONCOTARGET, V7, P19327, DOI 10.18632/oncotarget.8451; Moorthy AN, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00056; Moscona A, 2005, NEW ENGL J MED, V353, P2633, DOI 10.1056/NEJMp058291; Narasaraju T, 2010, AM J RESP CELL MOL, V42, P732, DOI 10.1165/rcmb.2008-0423OC; Narasaraju T, 2016, J INFECT PULM DIS, P2; Narasaraju TA, 2014, CURR MOL MED, V14, P1; Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013; Ng HH, 2012, EXP MOL PATHOL, V92, P287, DOI 10.1016/j.yexmp.2012.03.003; Nguyen JT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031006; Nie Q, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0381-y; Oshansky CM, 2014, AM J RESP CRIT CARE, V189, P449, DOI 10.1164/rccm.201309-1616OC; Peiris JSM, 2009, TRENDS IMMUNOL, V30, P574, DOI 10.1016/j.it.2009.09.004; Ramos I, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00361; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; Sharma G, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.52; Shieh WJ, 2010, AM J PATHOL, V177, P166, DOI 10.2353/ajpath.2010.100115; Short KR, 2014, LANCET INFECT DIS, V14, P57, DOI 10.1016/S1473-3099(13)70286-X; Smee DF, 2010, ANTIMICROB AGENTS CH, V54, P126, DOI 10.1128/AAC.00933-09; Suzuki Hiroshi, 2003, Journal of Infection and Chemotherapy, V9, P195; Taubenberger JK, 2008, ANNU REV PATHOL-MECH, V3, P499, DOI 10.1146/annurev.pathol.3.121806.154316; Traylor ZP, 2013, INFLUENZA OTHER RESP, V7, P472, DOI 10.1111/j.1750-2659.2012.00414.x; Le VB, 2015, AM J RESP CRIT CARE, V191, P804, DOI 10.1164/rccm.201406-1031OC; Wang H, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1840-4; Wildhagen KCAA, 2015, THROMB RES, V136, P542, DOI 10.1016/j.thromres.2015.06.035; Xu J, 2011, J IMMUNOL, V187, P2626, DOI 10.4049/jimmunol.1003930; Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053; Xu T, 2006, AM J RESP CRIT CARE, V174, P1011, DOI 10.1164/rccm.200511-1751OC; Yacoub D, 2010, ARTERIOSCL THROM VAS, V30, P2424, DOI 10.1161/ATVBAHA.110.216143; Yang Y, 2016, CELL MOL IMMUNOL, V13, P432, DOI 10.1038/cmi.2016.1; Yokoyama T, 2010, INTERNAL MED, V49, P427, DOI 10.2169/internalmedicine.49.3022; Zarnegar B, 2004, P NATL ACAD SCI USA, V101, P8108, DOI 10.1073/pnas.0402629101; Zhang YL, 2015, ANESTHESIOLOGY, V122, P127, DOI 10.1097/ALN.0000000000000429	51	7	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					135	148		10.1016/j.ajpath.2017.09.014			14	Pathology	Pathology	FQ8SS	WOS:000418634100015	29107075	Green Published, Bronze			2019-10-28	
J	Yu, JG; Zanotti, S; Walia, B; Jellison, E; Sanjay, A; Canalis, E				Yu, Jungeun; Zanotti, Stefano; Walia, Bhavita; Jellison, Evan; Sanjay, Archana; Canalis, Ernesto			The Hajdu Cheney Mutation Is a Determinant of B-Cell Allocation of the Splenic Marginal Zone	AMERICAN JOURNAL OF PATHOLOGY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION COMPLEXES; INTRACELLULAR DOMAIN; OSTEOCLAST SURVIVAL; NOTCH2 MUTATIONS; B1B CELLS; ACTIVATION; FATE; MICE; ANTIBODIES	The neurogenic locus notch homolog protein (Notch)-2 receptor is a determinant of B-cell allocation, and gain-of-NOTCH2-function mutations are associated with Hajdu-Cheney syndrome (HCS), a disease presenting with osteoporosis and acro-osteolysis. We generated a mouse model reproducing the HCS mutation (Notch2HCS), and heterozygous global mutant mice displayed gain-of-Notch2 function. In the mutant spleen, the characteristic perifollicular rim marking the marginal zone (MZ), which is the interface between the nonlymphoid red pulp and the lymphoid white pulp, merged with components of the white pulp. As a consequence, the MZ of Notch2HCS mice occupied most of the splenic structure. To explore the mechanisms involved, lymphocyte populations from the bone marrow and spleen were harvested from heterozygous Notch2HCS mice and sex-matched control Littermates and analyzed by flow cytometry. Notch2HCS mice had an increase in CD21/35(high)CD23(-) splenic MZ B cells of approximately fivefold and a proportional decrease in splenic follicular B cells (CD21/35(int)CD23(+)) at 1, 2, and 12 months of age. Western blot analysis revealed that Notch2HCS mutant splenocytes had increased phospho-Akt and phospho-Jun N-terminal kinase, and gene expression analysis of splenic CD19(+) B cells demonstrated induction of Hest and Hes5 in Notch2HCS mutants. Anti-Notch2 antibodies decreased MZ B cells in control and Notch2HCS mice. In conclusion, Notch2HCS mutant mice have increased mature B cells in the MZ of the spleen.	[Yu, Jungeun; Zanotti, Stefano; Sanjay, Archana; Canalis, Ernesto] UConn Hlth, UConn Musculoskeletal Inst, Dept Orthopaed Surg, Farmington, CT 06030 USA; [Zanotti, Stefano; Canalis, Ernesto] UConn Hlth, UConn Musculoskeletal Inst, Dept Med, Farmington, CT 06030 USA; [Walia, Bhavita] UConn Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; [Jellison, Evan] UConn Hlth, Dept Immunol, Farmington, CT 06030 USA	Sanjay, A; Canalis, E (reprint author), UConn Hlth, Dept Orthopaed Surg, Farmington, CT 06030 USA.	asanjay@uchc.edu; canalis@uchc.edu	Walia, Bhavita/I-7177-2019	Walia, Bhavita/0000-0001-5361-4506	National Institute of Diabetes and Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK045227]	Supported by National Institute of Diabetes and Digestive and Kidney Diseases grant DK045227 (E.C.).	Adami G, 2016, BONE, V92, P150, DOI 10.1016/j.bone.2016.08.025; Adapala NS, 2014, J CELL BIOCHEM, V115, P1277, DOI 10.1002/jcb.24779; Adapala NS, 2010, J BIOL CHEM, V285, P36745, DOI 10.1074/jbc.M110.124628; AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Aste-Amezaga M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009094; Canalis E, 2017, ENDOCRINOLOGY, V158, P730, DOI 10.1210/en.2016-1787; Canalis E, 2016, CURR OSTEOPOROS REP, V14, P126, DOI 10.1007/s11914-016-0311-6; Canalis E, 2016, J BIOL CHEM, V191, P1538, DOI 10.1074/jbc.M115.685453; CHENEY WD, 1965, AMER J ROENTGENOL RA, V94, P595; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Descatoire M, 2014, J EXP MED, V211, P986, DOI 10.1084/jem.20132203; Duggan SP, 2016, CELL SIGNAL, V28, P1, DOI 10.1016/j.cellsig.2015.10.006; Gibb DR, 2010, J EXP MED, V207, P623, DOI 10.1084/jem.20091990; Gibson DG, 2009, NAT METHODS, V6, P343, DOI [10.1038/nmeth.1318, 10.1038/NMETH.1318]; Gray MJ, 2012, EUR J HUM GENET, V20, P122, DOI 10.1038/ejhg.2011.125; Guinamard R, 2000, NAT IMMUNOL, V1, P31; HAJDU N, 1948, BRIT J RADIOL, V21, P42, DOI 10.1259/0007-1285-21-241-42; Hammad H, 2017, NAT IMMUNOL, V18, P313, DOI 10.1038/ni.3657; Hampel F, 2011, BLOOD, V118, P6321, DOI 10.1182/blood-2010-12-325944; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Huntzicker EG, 2015, HEPATOLOGY, V61, P942, DOI 10.1002/hep.27566; Ilagan MXG, 2013, CANCER CELL, V23, P267, DOI 10.1016/j.ccr.2013.02.020; Isidor B, 2011, NAT GENET, V43, P306, DOI 10.1038/ng.778; Jheon AH, 2016, J BONE MINER RES, V31, P152, DOI 10.1002/jbmr.2591; Jin WJ, 2016, CELL SIGNAL, V28, P357, DOI 10.1016/j.cellsig.2016.01.016; Kiel MJ, 2012, J EXP MED, V209, P1553, DOI 10.1084/jem.20120910; Kovall RA, 2008, ONCOGENE, V27, P5099, DOI 10.1038/onc.2008.223; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; Lafkas D, 2015, NATURE, V528, P127, DOI 10.1038/nature15715; Largaespada D, 2013, CANCER CELL, V23, P269, DOI 10.1016/j.ccr.2013.03.001; Lee SY, 2009, CANCER SCI, V100, P920, DOI 10.1111/j.1349-7006.2009.01130.x; Li K, 2008, J BIOL CHEM, V283, P8046, DOI 10.1074/jbc.M800170200; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; LORTAN J, 1985, ADV EXP MED BIOL, V186, P593; Majewski J, 2011, HUM MUTAT, V32, P1114, DOI 10.1002/humu.21546; MANKARIOUS S, 1988, J LAB CLIN MED, V112, P634; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e37; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, P2089, DOI 10.1093/nar/30.9.2089; Phan TG, 2005, J IMMUNOL, V174, P4567, DOI 10.4049/jimmunol.174.8.4567; Pillai S, 2005, ANNU REV IMMUNOL, V23, P161, DOI 10.1146/annurev.immunol.23.021704.115728; Pillai S, 2009, NAT REV IMMUNOL, V9, P767, DOI 10.1038/nri2656; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Rossi D, 2012, J EXP MED, V209, P1537, DOI 10.1084/jem.20120904; Ryeom SW, 2011, J CLIN INVEST, V121, P508, DOI 10.1172/JCI45976; Saito T, 2003, IMMUNITY, V18, P675, DOI 10.1016/S1074-7613(03)00111-0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Simonetti G, 2013, J EXP MED, V210, P2887, DOI 10.1084/jem.20131026; Simpson MA, 2011, NAT GENET, V43, P303, DOI 10.1038/ng.779; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793; Ward JM, 2006, EXP TOXICOL PATHOL, V57, P377, DOI 10.1016/j.etp.2006.01.007; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; Witt CM, 2003, MOL CELL BIOL, V23, P8637, DOI 10.1128/MCB.23.23.8637-8650.2003; Witt CM, 2003, J IMMUNOL, V171, P2783, DOI 10.4049/jimmunol.171.6.2783; Wu Y, 2010, NATURE, V464, P1052, DOI 10.1038/nature08878; Yan MH, 2010, NATURE, V463, pE6, DOI 10.1038/nature08751; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zanotti S, 2016, ENDOCR REV, V37, P223, DOI 10.1210/er.2016-1002; Zanotti S, 2010, MOL CELL BIOL, V30, P886, DOI 10.1128/MCB.01285-09; Zhao W, 2013, OSTEOPOROSIS INT, V24, P2275, DOI 10.1007/s00198-013-2298-5; Zouali M, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00063	65	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					149	159		10.1016/j.ajpath.2017.09.010			11	Pathology	Pathology	FQ8SS	WOS:000418634100016	29037852	Green Published, Bronze			2019-10-28	
J	Chan, W; Almasieh, M; Catrinescu, MM; Levin, LA				Chan, Wesley; Almasieh, Mohammadali; Catrinescu, Maria-Magdalena; Levin, Leonard A.			Cobalamin-Associated Superoxide Scavenging in Neuronal Cells Is a Potential Mechanism for Vitamin B-12-Deprivation Optic Neuropathy	AMERICAN JOURNAL OF PATHOLOGY			English	Article							RETINAL GANGLION-CELLS; IN-VIVO; GLAUCOMA WORLDWIDE; INTRINSIC-FACTOR; SPINAL-CORD; COMPLEX-I; DEFICIENCY; RECEPTOR; METALLOCORROLES; IDENTIFICATION	Chronic deficiency of vitamin B-12 is the only nutritional deficiency definitively proved to cause optic neuropathy and loss of vision. The mechanism by which this occurs is unknown. Optic neuropathies are associated with death of retinal ganglion cells (RGCs), neurons that project their axons along the optic nerve to the brain. Injury to RGC axons causes a burst of intracellular superoxide, which then signals RGC apoptosis. Vitamin B-12 (cobalamin) was recently shown to be a superoxide scavenger, with a rate constant similar to superoxide dismutase. Given that vitamin B-12 deficiency causes an optic neuropathy through unknown mechanisms and that it is a potent superoxide scavenger, we tested whether cobalamin, a vitamin B-12 vitamer, would be neuroprotective in vitro and in vivo. We found that cobalamin scavenged superoxide in neuronal cells in vitro treated with the reduction-oxidation cycling agent menadione. In vivo confocal scanning laser ophthaLmoscopy demonstrated that optic nerve transection in Long-Evans rats increased superoxide levels in RGCs. The RGC superoxide burst was significantly reduced by intravitreal cobalamin and resulted in increased RGC survival. These data demonstrate that cobalamin may function as an endogenous neuroprotectant for RGCs through a superoxide-associated mechanism.	[Chan, Wesley; Almasieh, Mohammadali; Catrinescu, Maria-Magdalena; Levin, Leonard A.] Univ Montreal, Maisonneuve Rosemont Hosp Res Ctr, Montreal, PQ, Canada; [Chan, Wesley; Almasieh, Mohammadali; Catrinescu, Maria-Magdalena; Levin, Leonard A.] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada; [Almasieh, Mohammadali; Catrinescu, Maria-Magdalena; Levin, Leonard A.] McGill Univ, Dept Ophthalmol, 5252 Blvd Maisonneuve W, Montreal, PQ H4A 3S5, Canada; [Almasieh, Mohammadali; Catrinescu, Maria-Magdalena; Levin, Leonard A.] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [Levin, Leonard A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA	Levin, LA (reprint author), McGill Univ, Dept Ophthalmol, 5252 Blvd Maisonneuve W, Montreal, PQ H4A 3S5, Canada.	leonard.levin@mcgill.ca			Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Canadian Foundation for InnovationCanada Foundation for Innovation; Canadian Research Chairs programCanada Research Chairs; Fonds de Recherche en Ophtalmologie de l'Universite de Montreal; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 EY017970, R21 EY025074, P30 EY016665]; Retina Research Foundation; Research to Prevent BlindnessResearch to Prevent Blindness (RPB)	Supported by Canadian Institutes for Health Research; the Canadian Foundation for Innovation; the Canadian Research Chairs program; Fonds de Recherche en Ophtalmologie de l'Universite de Montreal; NIH grants R21 EY017970, R21 EY025074, and P30 EY016665; the Retina Research Foundation; and Research to Prevent Blindness. L.A.L. is the Canada Research Chair in Translational Visual Science.	Alpers DH, 2013, BIOCHIMIE, V95, P989, DOI 10.1016/j.biochi.2012.12.006; Banerjee R, 2006, ACS CHEM BIOL, V1, P149, DOI 10.1021/cb6001174; Baracca A, 2005, ARCH NEUROL-CHICAGO, V62, P730, DOI 10.1001/archneur.62.5.730; Birch CS, 2009, FREE RADICAL BIO MED, V47, P184, DOI 10.1016/j.freeradbiomed.2009.04.023; Bonafede L, 2015, INVEST OPHTH VIS SCI, V56, P7875, DOI 10.1167/iovs.15-17857; Buccellato FR, 1999, FASEB J, V13, P297; Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003; Catrinescu MM, 2012, EXP EYE RES, V97, P31, DOI 10.1016/j.exer.2012.02.006; CHESTER EM, 1980, ACTA NEUROL SCAND, V61, P9; Chew EY, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12914; Cohen H, 1936, LANCET, V2, P1202; Danesh-Meyer HV, 2008, INVEST OPHTH VIS SCI, V49, P1879, DOI 10.1167/iovs.07-1127; Dassanayake RS, 2016, J INORG BIOCHEM, V163, P81, DOI 10.1016/j.jinorgbio.2016.07.009; Davis BM, 2016, ACTA NEUROPATHOL, V132, P807, DOI 10.1007/s00401-016-1609-2; Dirani M, 2011, CLIN EXP OPHTHALMOL, V39, P623, DOI 10.1111/j.1442-9071.2011.02530.x; Eckshtain M, 2009, DALTON T, P7879, DOI 10.1039/b911278b; Forkink Marleen, 2015, Methods Mol Biol, V1264, P161, DOI 10.1007/978-1-4939-2257-4_15; Froese DS, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001651; Fyfe JC, 2004, BLOOD, V103, P1573, DOI 10.1182/blood-2003-08-2852; Gherasim C, 2013, BIOCHIMIE, V95, P1023, DOI 10.1016/j.biochi.2013.02.003; Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177; Gross Z, 1999, ANGEW CHEM INT EDIT, V38, P2366, DOI 10.1002/(SICI)1521-3773(19990816)38:16<2366::AID-ANIE2366>3.0.CO;2-W; Gruber K, 2011, CHEM SOC REV, V40, P4346, DOI 10.1039/c1cs15118e; Hamel CP, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-7; HERBERT V, 1988, AM J CLIN NUTR, V48, P852, DOI 10.1093/ajcn/48.3.852; Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001; Johnson Felicity, 2005, Molecular Aspects of Medicine, V26, P340, DOI 10.1016/j.mam.2005.07.006; Kanamori A, 2010, BRAIN, V133, P2612, DOI 10.1093/brain/awq105; Kanamori A, 2010, J NEUROCHEM, V114, P488, DOI 10.1111/j.1471-4159.2010.06781.x; Kerrison JB, 1997, CLIN NEUROSCI, V4, P295; Kozyraki R, 1999, NAT MED, V5, P656, DOI 10.1038/9504; Krishnamoorthy RR, 2013, INVEST OPHTH VIS SCI, V54, P5712, DOI 10.1167/iovs.13-12085; Ku CA, 2016, OPHTHALMIC GENET, V37, P404, DOI 10.3109/13816810.2015.1121500; Kussmaul L, 2006, P NATL ACAD SCI USA, V103, P7607, DOI 10.1109/pnas.0510977103; Larner AJ, 2004, INT J CLIN PRACT, V58, P977, DOI 10.1111/j.1368-5031.2004.00306.x; Lerner-Ellis JP, 2006, NAT GENET, V38, P93, DOI 10.1038/ng1683; Levin LA, 2015, J NEURO-OPHTHALMOL, V35, P152, DOI 10.1097/WNO.0000000000000250; Levin Leonard A, 2007, Trans Am Ophthalmol Soc, V105, P379; Lieven CJ, 2012, APOPTOSIS, V17, P591, DOI 10.1007/s10495-012-0714-5; Lieven CJ, 2006, INVEST OPHTH VIS SCI, V47, P1477, DOI 10.1167/iovs.05-0921; Mc Guire PJ, 2009, MOL GENET METAB, V98, P173, DOI 10.1016/j.ymgme.2009.06.007; Moreira ES, 2011, FREE RADICAL BIO MED, V51, P876, DOI 10.1016/j.freeradbiomed.2011.05.034; Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178; Newman NJ, 2006, AM J OPHTHALMOL, V141, P1061, DOI 10.1016/j.ajo.2005.12.045; Nguyen SM, 2003, ANTIOXID REDOX SIGN, V5, P629, DOI 10.1089/152308603770310293; Oh RC, 2003, AM FAM PHYSICIAN, V67, P979; Quadros EV, 2013, BIOCHIMIE, V95, P1008, DOI 10.1016/j.biochi.2013.02.004; Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; Reig AJ, 2012, INORG CHEM, V51, P2867, DOI 10.1021/ic202052g; Richard E, 2009, HUM MUTAT, V30, P1558, DOI 10.1002/humu.21107; Robinson KM, 2006, P NATL ACAD SCI USA, V103, P15038, DOI 10.1073/pnas.0601945103; Rovira C, 2001, INORG CHEM, V40, P11, DOI 10.1021/ic000143m; Scalabrino G, 2006, TRENDS MOL MED, V12, P247, DOI 10.1016/j.molmed.2006.04.008; Schlieve CR, 2006, EXP EYE RES, V83, P1252, DOI 10.1016/j.exer.2006.07.002; Scott CJ, 2010, BRAIN RES, V1306, P142, DOI 10.1016/j.brainres.2009.10.004; SellesNavarro I, 1996, INVEST OPHTH VIS SCI, V37, P2002; Steinsapir K D, 1999, Curr Opin Ophthalmol, V10, P340, DOI 10.1097/00055735-199910000-00011; Suarez-Moreira E, 2009, J AM CHEM SOC, V131, P15078, DOI 10.1021/ja904670x; Thompson AF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145270; Trip SA, 2005, ANN NEUROL, V58, P383, DOI 10.1002/ana.20575; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Veber D, 2008, J NEUROSCI RES, V86, P1380, DOI 10.1002/jnr.21599; Watanabe F, 2007, EXP BIOL MED, V232, P1266, DOI 10.3181/0703-MR-67; WAXMAN SG, 1978, NEUROLOGY, V28, P27, DOI 10.1212/WNL.28.9_Part_2.27; Weisfeld-Adams JD, 2015, MOL GENET METAB, V114, P537, DOI 10.1016/j.ymgme.2015.01.012; Whatham A, 2008, OPHTHAL PHYSL OPT, V28, P1, DOI 10.1111/j.1475-1313.2007.00531.x; Yuki K, 2011, INVEST OPHTH VIS SCI, V52, P4143, DOI 10.1167/iovs.10-6294; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	70	8	8	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					160	172		10.1016/j.ajpath.2017.08.032			13	Pathology	Pathology	FQ8SS	WOS:000418634100017	29037851	Green Published			2019-10-28	
J	Lai, BB; Zou, JH; Lin, ZY; Qu, ZP; Song, AY; Xu, Y; Gao, X				Lai, Beibei; Zou, Jianghuan; Lin, Zhaoyu; Qu, Zhipeng; Song, Anying; Xu, Ying; Gao, Xiang			Haploinsufficiency of hnRNP U Changes Activity Pattern and Metabolic Rhythms	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CIRCADIAN CLOCK; SUPRACHIASMATIC NUCLEUS; LOCOMOTOR-ACTIVITY; VPAC(2) RECEPTOR; MESSENGER-RNA; IN-VITRO; EXPRESSION; MOUSE; MICE; GENE	The neuropeptides arginine vasopressin (Avp) and vasoactive intestinal polypeptide (Vip) are critical for the communication and coupling of suprachiasmatic nucleus neurons, which organize daily rhythms of physiology and behavior in mammals. However, how these peptides are regulated remains uncharacterized. We found that heterogeneous nuclear ribonucleoprotein U (hnRNP U) is essential for the expression of Avp and Vip. Loss of one copy of the Hnrnpu gene resulted in fragmented locomotor activities and disrupted metabolic rhythms. Hnrnpu(+/-) mice were more active than wild-type mice in the daytime but more inactive at night. These phenotypes were partially rescued by microinfusion of Avp and Vip into free-moving animals. In addition, hnRNP U modulated Avp and Vip via directly binding to their promoters together with brain and muscle Arnt-like protein-1/circadian locomotor output cycles kaput heterodimers. Our work identifies hnRNP U as a novel regulator of the circadian pacemaker and provides new insights into the mechanism of rhythm output.	[Lai, Beibei; Zou, Jianghuan; Lin, Zhaoyu; Qu, Zhipeng; Song, Anying; Gao, Xiang] Nanjing Univ, Collaborat Innovat Ctr Genet & Dev, Model Anim Res Ctr, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China; [Lai, Beibei; Zou, Jianghuan; Lin, Zhaoyu; Qu, Zhipeng; Song, Anying; Gao, Xiang] Nanjing Univ, Collaborat Innovat Ctr Genet & Dev, Model Anim Res Ctr, MOE Key Lab Model Anim Dis Study, Nanjing, Jiangsu, Peoples R China; [Xu, Ying] Soochou Univ, Med Coll, 199 Renai Rd, Suzhou 215123, Peoples R China	Xu, Y (reprint author), Soochou Univ, Med Coll, 199 Renai Rd, Suzhou 215123, Peoples R China.; Gao, X (reprint author), Nanjing Univ, Model Anim Res Ctr, 12 Xuefu Rd, Nanjing 210061, Jiangsu, Peoples R China.	xuying@nicemice.cn; gaoxiang@nju.edu.cn	Xu, Ying/A-3009-2013	Xu, Ying/0000-0002-6689-7768	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [31301217]; Ministry of Science and Technology of the People's Republic of ChinaMinistry of Science and Technology, China [2014BAI02B01, 2015BAI08B02]	Supported by National Natural Science Foundation of China grant 31301217 and Ministry of Science and Technology of the People's Republic of China grants 2014BAI02B01 and 2015BAI08B02 (X.G.).	Abrahamson EE, 2001, BRAIN RES, V916, P172, DOI 10.1016/S0006-8993(01)02890-6; ALBERS HE, 1995, NEUROSCI LETT, V191, P63, DOI 10.1016/0304-3940(95)11559-1; An S, 2013, P NATL ACAD SCI USA, V110, pE4355, DOI 10.1073/pnas.1307088110; Antle MC, 2005, TRENDS NEUROSCI, V28, P145, DOI 10.1016/j.tins.2005.01.003; Aton SJ, 2005, NAT NEUROSCI, V8, P476, DOI 10.1038/nn1419; Bedont JL, 2014, CELL REP, V7, P609, DOI 10.1016/j.celrep.2014.03.060; Buijs RM, 2003, J COMP NEUROL, V464, P36, DOI 10.1002/cne.10765; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Carpinelli MR, 2015, AM J PATHOL, V185, P1867, DOI 10.1016/j.ajpath.2015.03.026; Chen WD, 2015, AM J PATHOL, V185, P3152, DOI 10.1016/j.ajpath.2015.08.003; Colwell CS, 2003, AM J PHYSIOL-REG I, V285, pR939, DOI 10.1152/ajpregu.00200.2003; Cutler DJ, 2003, EUR J NEUROSCI, V17, P197, DOI 10.1046/j.1460-9568.2003.02425.x; Dardente H, 2004, MOL BRAIN RES, V124, P143, DOI 10.1016/j.molbrainres.2004.01.010; De Leersnyder H, 2006, TRENDS ENDOCRIN MET, V17, P291, DOI 10.1016/j.tem.2006.07.007; Earnest DJ, 1999, SCIENCE, V283, P693, DOI 10.1126/science.283.5402.693; Georg B, 2007, BRAIN RES, V1135, P52, DOI 10.1016/j.brainres.2006.12.001; Han S, 2012, NATURE, V489, P385, DOI 10.1038/nature11356; Harmar AJ, 2002, CELL, V109, P497, DOI 10.1016/S0092-8674(02)00736-5; Hatori M, 2014, ELIFE, V3, DOI 10.7554/eLife.03357; Herzog ED, 2007, NAT REV NEUROSCI, V8, P790, DOI 10.1038/nrn2215; Huang TN, 2014, NAT NEUROSCI, V17, P240, DOI 10.1038/nn.3626; Hughes ATL, 2008, J BIOL RHYTHM, V23, P211, DOI 10.1177/0748730408316290; Hughes ATL, 2008, J NEUROCHEM, V106, P1646, DOI 10.1111/j.1471-4159.2008.05520.x; Hurst WJ, 2002, BIOCHEM BIOPH RES CO, V298, P133, DOI 10.1016/S0006-291X(02)02346-X; Lee JE, 2010, MOL CELL PROTEOMICS, V9, P285, DOI 10.1074/mcp.M900362-MCP200; Li JD, 2009, AM J PHYSIOL-REG I, V296, pR824, DOI 10.1152/ajpregu.90463.2008; Matsuoka Y, 2009, ONCOL REP, V22, P249, DOI 10.3892/or_00000431; Maywood ES, 2006, CURR BIOL, V16, P599, DOI 10.1016/j.cub.2006.02.023; McGlincy NJ, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r54; Miller BH, 2007, P NATL ACAD SCI USA, V104, P3342, DOI 10.1073/pnas.0611724104; Onishi Y, 2008, MOL CELL BIOL, V28, P3477, DOI 10.1128/MCB.02227-07; Orozco-Solis R, 2016, CELL METAB, V23, P467, DOI 10.1016/j.cmet.2016.02.003; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; PIGGINS HD, 1995, J NEUROSCI, V15, P5612; Qu ZP, 2016, ELIFE, V5, DOI 10.7554/eLife.17171; Rahrmann EP, 2014, AM J PATHOL, V184, P2082, DOI 10.1016/j.ajpath.2014.04.006; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Roshon MJ, 2005, TRANSGENIC RES, V14, P179, DOI 10.1007/s11248-004-8147-8; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; SATINOFF E, 1993, AM J PHYSIOL, V265, pR1216; Schibler U, 1998, NATURE, V393, P620, DOI 10.1038/31337; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; SHINOHARA K, 1995, P NATL ACAD SCI USA, V92, P7396, DOI 10.1073/pnas.92.16.7396; STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Tamaru T, 2003, NEUROSCI LETT, V341, P111, DOI 10.1016/S0304-3940(03)00181-2; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Thierry G, 2012, AM J MED GENET A, V158A, P1633, DOI 10.1002/ajmg.a.35423; Tousson E, 2004, J NEUROSCI, V24, P2983, DOI 10.1523/JNEUROSCI.5044-03.2004; van der Horst GTJ, 1999, NATURE, V398, P627; van Someren V, 2000, ARCH DIS CHILD, V83, P76, DOI 10.1136/adc.83.1.76; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Vizlin-Hodzic D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028049; Vizlin-Hodzic D, 2011, CELL REPROGRAM, V13, P13, DOI 10.1089/cell.2010.0075; VOGELBAUM MA, 1993, J NEURAL TRANSP PLAS, V4, P239, DOI 10.1155/NP.1993.239; Wang XH, 2010, EMBO J, V29, P1389, DOI 10.1038/emboj.2010.34; Xiao R, 2012, MOL CELL, V45, P656, DOI 10.1016/j.molcel.2012.01.009; Ye JQ, 2015, P NATL ACAD SCI USA, V112, pE3020, DOI 10.1073/pnas.1508461112; Zhao J, 2009, HUM MOL GENET, V18, P3090, DOI 10.1093/hmg/ddp250	59	0	0	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					173	183		10.1016/j.ajpath.2017.09.017			11	Pathology	Pathology	FQ8SS	WOS:000418634100018	29128567	Bronze			2019-10-28	
J	Semango, G; Heinhuis, B; Plantinga, TS; Blokx, WAM; Kibiki, G; Sonda, T; Mavura, D; Masenga, EJ; Nyindo, M; van der Ven, AJAM; Joosten, LAB				Semango, George; Heinhuis, Bas; Plantinga, Theo S.; Blokx, Willeke A. M.; Kibiki, Gibson; Sonda, Tolbert; Mavura, Daudi; Masenga, Elisante J.; Nyindo, Mramba; van der Ven, Andre J. A. M.; Joosten, Leo A. B.			Exploring the Role of IL-32 in HIV-Related Kaposi Sarcoma	AMERICAN JOURNAL OF PATHOLOGY			English	Article							PROINFLAMMATORY CYTOKINE; RHEUMATOID-ARTHRITIS; INTERLEUKIN-32; EXPRESSION; IL-32-GAMMA; CANCER; CELLS; INFLAMMATION; HERPESVIRUS; ACTIVATION	The intracellular proinflammatory mediator IL-32 is associated with tumor progression; however, the mechanisms remain unknown. We studied IL-32 mRNA expression as well as expression of other proinflammatory cytokines and mediators, including IL-1 alpha, IL-1 beta, IL-6, IL-8, tumor necrosis factor (TNF)-alpha, the proangiogenic and antiapoptotic enzyme cyclooxygenase-2, the IL-8 receptor C-X-C chemokine receptor (CXCR) 1, and the intracellular kinase focal adhesion kinase-1. The interaction of IL-32 expression with expression of IL-6, TNF-alpha, IL-8, and cyclooxygenase-2 was also investigated. Biopsy specimens of 11 HIV-related, 7 non-HIV-related Kaposi sarcoma (KS), and 7 normal skin tissues (NSTs) of Dutch origin were analyzed. RNA was isolated from the paraffin material, and gene expression levels of IL-32 alpha, beta, and gamma isoforms, IL1a, IL1b, IL6, IL8, TNFA, PTGS2, CXCR1, and PTK2 were determined using real-time quantitative PCR. Significantly higher expression of IL-32 beta and IL-32 gamma isoforms was observed in HIV-related KS biopsy specimens compared with non-HIV-related KS and NST. The splicing ratio of the IL-32 isoforms showed IL-32 gamma as the highest expressed isoform, followed by IL-32 beta, in HIV-related KS cases compared with non-HIV-related KS and NST. Our data suggest a possible survival mechanism by the splicing of IL-32 gamma to IL-32 beta and also IL-6, IL-8, and CXCR1 signaling pathways to reverse the proapoptotic effect of the IL-32 gamma isoform, leading to tumor cell survival and thus favoring tumor progression.	[Semango, George; Nyindo, Mramba] Kilimanjaro Christian Med Univ Coll, Moshi, Tanzania; [Semango, George] Nelson Mandela African Inst Sci & Technol, Sch Life Sci, Arusha, Tanzania; [Heinhuis, Bas; van der Ven, Andre J. A. M.; Joosten, Leo A. B.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [Plantinga, Theo S.; Blokx, Willeke A. M.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, Nijmegen, Netherlands; [Heinhuis, Bas; van der Ven, Andre J. A. M.; Joosten, Leo A. B.] Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Infect Dis, Nijmegen, Netherlands; [Kibiki, Gibson; Sonda, Tolbert] Kilimanjaro Clin Res Inst, Moshi, Tanzania; [Mavura, Daudi; Masenga, Elisante J.] Reg Dermatol Training Ctr, Moshi, Tanzania	Semango, G (reprint author), Nelson Mandela African Inst Sci & Technol, POB 447, Arusha, Tanzania.	george.semango@nm-aist.ae.tz	van der Ven, A.J.A.M./H-8102-2014; Plantinga, Theo S./A-6895-2015; Blokx, W.A.M./L-4205-2015	van der Ven, A.J.A.M./0000-0003-1833-3391; Plantinga, Theo S./0000-0003-4990-6084; Blokx, Willeke/0000-0002-4647-8830	Department of Internal Medicine, Radboud University Medical Center (Nijmegen, the Netherlands); HIV Research Trust	Supported by the Department of Internal Medicine, Radboud University Medical Center (Nijmegen, the Netherlands; A.J.A.M.v.d.V. and L.A.B.J.). The HIV Research Trust supported part of travel costs to the Netherlands to work on the project (G.S.).	Calabrese F, 2008, AM J RESP CRIT CARE, V178, P894, DOI 10.1164/rccm.200804-646OC; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Dinarello CA, 2006, ANN RHEUM DIS, V65, P61, DOI 10.1136/ard.2006.058511; Goda C, 2006, INT IMMUNOL, V18, P233, DOI 10.1093/intimm/dxh339; Heinhuis B, 2013, CYTOKINE, V64, P433, DOI 10.1016/j.cyto.2013.05.002; Heinhuis B, 2012, J BIOL CHEM, V287, P5733, DOI 10.1074/jbc.M111.288290; Heinhuis B, 2011, P NATL ACAD SCI USA, V108, P4962, DOI 10.1073/pnas.1016005108; Heinhuis B, 2010, ANN RHEUM DIS, V69, P1866, DOI 10.1136/ard.2009.127399; Joosten LAB, 2006, P NATL ACAD SCI USA, V103, P3298, DOI 10.1073/pnas.0511233103; Joosten LAB, 2013, CELL MOL LIFE SCI, V70, P3883, DOI 10.1007/s00018-013-1301-9; Jung MY, 2011, J IMMUNOL, V186, P6848, DOI 10.4049/jimmunol.1003996; Kim SH, 2005, IMMUNITY, V22, P131, DOI 10.1016/j.immuni.2004.12.003; Lee S, 2011, IMMUNOLOGY, V132, P410, DOI 10.1111/j.1365-2567.2010.03377.x; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Netea MG, 2006, PLOS MED, V3, P1310, DOI 10.1371/journal.pmed.0030277; Nishida A, 2009, J BIOL CHEM, V284, P17868, DOI 10.1074/jbc.M900368200; Nold MF, 2008, J IMMUNOL, V181, P557, DOI 10.4049/jimmunol.181.1.557; Nold-Petry CA, 2014, J IMMUNOL, V192, P589, DOI 10.4049/jimmunol.1202802; Nold-Petry CA, 2009, P NATL ACAD SCI USA, V106, P3883, DOI 10.1073/pnas.0813334106; Oh JH, 2011, ONCOGENE, V30, P3345, DOI 10.1038/onc.2011.52; Plantinga TS, 2013, CARCINOGENESIS, V34, P1529, DOI 10.1093/carcin/bgt092; Seo EH, 2008, J MICROBIOL BIOTECHN, V18, P1606; Sharma-Walia N, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000777; Sturzl M, 1997, INT J CANCER, V72, P68; Sturzl M, 2001, ADV CANCER RES, V81, P125, DOI 10.1016/S0065-230X(01)81004-6; Yun HM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.166; Zhang YJ, 2008, MOL CANCER THER, V7, P712, DOI 10.1158/1535-7163.MCT-07-2036	27	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					196	203		10.1016/j.ajpath.2017.08.033			8	Pathology	Pathology	FQ8SS	WOS:000418634100020	29037857	Bronze			2019-10-28	
J	Kawamata, F; Nishihara, H; Homma, S; Kato, Y; Tsuda, M; Konishi, Y; Wang, L; Kohsaka, S; Liu, C; Yoshida, T; Tanino, M; Tanaka, S; Kawamura, H; Kamiyama, T; Taketomi, A				Kawamata, Futoshi; Nishihara, Hiroshi; Homma, Shigenori; Kato, Yasutaka; Tsuda, Masumi; Konishi, Yuji; Wang, Lei; Kohsaka, Shinji; Liu, Cheng; Yoshida, Tadashi; Tanino, Mishie; Tanaka, Shinya; Kawamura, Hideki; Kamiyama, Toshiya; Taketomi, Akinobu			Chorionic Gonadotropin-beta Modulates Epithelial-Mesenchymal Transition in Colorectal Carcinoma Metastasis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SERUM HCG-BETA; PROGNOSTIC-FACTORS; TGF-BETA; CANCER; EXPRESSION; CA-72-4; ANGIOGENESIS; CEA	Ectopic production of free beta human chorionic gonadotropin (hCG beta) has been associated with aggressive behavior in non-trophoblastic tumors. hCG beta shares common evolutionary sequences with transforming growth factor-beta (TGF-beta), which represents a major driving force of epithelial-to-mesenchymal transition (EMT). In this study, we examined the biological roles of hCG beta during EMT and its clinical significance in colorectal cancer (CRC) progression. Eighty CRC specimens and 54 preoperative serum samples were analyzed. beta-overexpressing human CRC cell lines were examined for invasiveness and tumorigenicity, and the expression of EMT-associated genes was investigated. In human CRC, histologic hCG beta positivity [13/80 (16.3%)] was lower than serologic hCG beta positivity [13/54 (24.1%)]. However, it was significantly correlated with several clinicopathological features and unfavorable outcome (P < 0.05). hCG beta-overexpressing cell lines had increased invasiveness, migratory ability, and metastatic potential in mice (P < 0.01). Western blot, PCR, and microarray analyses showed hCG beta altered expression of EMT-related genes, including E-cadherin, phosphorylated SMAD2, SNAIL, and TWIST. hCG beta-induced SNAIL and TWIST overexpression levels were reversible by type I and type II TGF-beta receptor inhibitors (P < 0.05). hCG beta thus induces EMT via the TGF-beta signaling pathway, and it may represent a molecular target in CRC treatment.	[Kawamata, Futoshi; Homma, Shigenori; Konishi, Yuji; Yoshida, Tadashi; Kawamura, Hideki; Kamiyama, Toshiya; Taketomi, Akinobu] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol Surg 1, Sapporo, Hokkaido, Japan; [Nishihara, Hiroshi; Wang, Lei] Hokkaido Univ, Grad Sch Med, Dept Translat Pathol, Sapporo, Hokkaido, Japan; [Kato, Yasutaka; Tsuda, Masumi; Tanaka, Shinya] Hokkaido Univ, Grad Sch Med, Dept Canc Pathol, Sapporo, Hokkaido, Japan; [Kohsaka, Shinji] Univ Tokyo, Grad Sch Med, Dept Cellular Signaling, Tokyo, Japan; [Liu, Cheng] QIMR Berghofer Med Res Inst, Conjoint Gastroenterol Lab, Brisbane, Qld, Australia	Nishihara, H (reprint author), Hokkaido Univ, Grad Sch Med, Dept Translat Pathol, Kita Ku, Kita 14,Nishi 7, Sapporo, Hokkaido 0608638, Japan.	hnishihara@s5.dion.ne.jp	Tanaka, Shinya/D-3586-2011		Uehara Memorial FoundationUehara Memorial Foundation [201430015]	Supported by the Uehara Memorial Foundation Fellowship grant 201430015 (F.K.).	Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Berndt S, 2013, FASEB J, V27, P1309, DOI 10.1096/fj.12-213686; Butler SA, 2000, BRIT J CANCER, V82, P1553; Carpelan-Holmstrom M, 2004, TUMOR BIOL, V25, P228, DOI 10.1159/000081385; Cole LA, 2012, REPROD BIOL ENDOCRIN, V10, DOI 10.1186/1477-7827-10-24; Elmansuri AZ, 2016, ONCOTARGET, V7, P27094, DOI 10.18632/oncotarget.8314; Eveno C, 2011, AM J PATHOL, V178, P1861, DOI 10.1016/j.ajpath.2010.12.019; FUJII D, 1986, SOMAT CELL MOLEC GEN, V12, P281, DOI 10.1007/BF01570787; Gulubova M, 2010, INT J COLORECTAL DIS, V25, P591, DOI 10.1007/s00384-010-0906-9; Harmon RL, 2005, INT SEMIN SURG ONCOL, V2, P3, DOI DOI 10.1186/1477-7800-2-3; Itoh S, 2007, MOL CANCER RES, V5, P667, DOI 10.1158/1541-7786.MCR-06-0282; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]; Kido A, 1996, SURG TODAY, V26, P966, DOI 10.1007/BF00309954; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEHNERT SA, 1988, DEVELOPMENT, V104, P263; Liu XQ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.221697; Louhimo J, 2004, INT J CANCER, V111, P929, DOI 10.1002/ijc.20321; Louhimo J, 2004, ONCOLOGY-BASEL, V66, P126, DOI 10.1159/000077438; Louhimo J, 2002, INT J CANCER, V101, P545, DOI 10.1002/ijc.90009; Lundin M, 2000, ANTICANCER RES, V20, P4949; Lundin M, 2001, INT J CANCER, V95, P18, DOI 10.1002/1097-0215(20010120)95:1<18::AID-IJC1003>3.0.CO;2-5; Mahabir R, 2014, NEURO-ONCOLOGY, V16, P671, DOI 10.1093/neuonc/not239; Moulton HM, 2002, CLIN CANCER RES, V8, P2044; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SHOUSHA S, 1986, DIS COLON RECTUM, V29, P558, DOI 10.1007/BF02554253; Sobin LH, 2010, CANCER-AM CANCER SOC, V116, P5336, DOI 10.1002/cncr.25537; Swallow CJ, 2004, CANCER RES, V64, P6402, DOI 10.1158/0008-5472.CAN-04-1117; West NJ, 2009, INT J COLORECTAL DIS, V24, P731, DOI 10.1007/s00384-009-0690-6; Yamada T, 2008, BIOCHEM BIOPH RES CO, V368, P575, DOI 10.1016/j.bbrc.2008.01.121; YAMAGUCHI A, 1989, BRIT J CANCER, V60, P382, DOI 10.1038/bjc.1989.289	30	5	5	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					204	215		10.1016/j.ajpath.2017.08.034			12	Pathology	Pathology	FQ8SS	WOS:000418634100021	29037859	Bronze			2019-10-28	
J	Jin, R; Xiao, AY; Song, ZF; Yu, SY; Li, J; Cui, MZ; Li, GH				Jin, Rong; Xiao, Adam Y.; Song, Zifang; Yu, Shiyong; Li, Jarvis; Cui, Mei-Zhen; Li, Guohong			Platelet CD40 Mediates Leukocyte Recruitment and Neointima Formation after Arterial Denudation Injury in Atherosclerosis-Prone Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							MONOCYTE RECRUITMENT; ENDOTHELIAL-CELLS; IN-VITRO; LIGAND; INFLAMMATION; ACTIVATION; PROGRESSION; INHIBITION; EXPRESSION; DEPOSITION	The role of platelets in the development of thrombosis and abrupt closure after angioplasty is well recognized. However, the direct impact of platelets on neointima formation after arterial injury remains undetermined. Herein, we show that neointima formation after carotid artery wire injury reduces markedly in CD40(-/-) apolipoprotein E-deficient (apoE(-/-)) mice but only slightly in CD40 ligand(-/-)apoE(-/-) mice, compared with apoE(-/-) mice. Wild-type and CD40-deficient platelets were isolated from blood of apoE(-/-) and CD40(-/-)apoE(-/-) mice, respectively. The i.v. injection of thrombin-activated platelets into CD40(-/-)apoE(-/-)mice was performed every 5 days, starting at 2 days before wire injury. Injection of wild-type platelets promoted neointima formation, which was associated with increased inflammation by stimulating leukocyte recruitment via up-regulation of circulating platelet surface P-selectin expression and the formation of platelet-leukocyte aggregates. It was also associated with further promoting the luminal deposition of platelet-derived regulated on activation normal T cell expressed and secreted/chemokine (C-C motif) ligand 5 and expression of monocyte chemoattractant protein-1 and vascular cell adhesion molecule 1 in wire-injured carotid arteries. Remarkably, all these inflammatory actions by activated platelets were abrogated by lack of CD40 on injected platelets. Moreover, injection of wild-type platelets inhibited endothelial recovery in wire-injured carotid arteries, but this effect was also abrogated by lack of CD40 on injected platelets. Results suggest that platelet CD40 plays a pivotal role in neointima formation after arterial injury and might represent an attractive target to prevent restenosis after vascular interventions.	[Jin, Rong; Li, Guohong] Louisiana State Univ, Hlth Sci Ctr, Dept Neurosurg, Shreveport, LA 71105 USA; [Xiao, Adam Y.; Li, Guohong] Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71105 USA; [Jin, Rong; Song, Zifang; Yu, Shiyong; Li, Guohong] Penn State Univ, Dept Neurosurg, Hershey, PA USA; [Li, Jarvis] Caddo Magnet High Sch, Shreveport, LA USA; [Cui, Mei-Zhen] Univ Tennessee, Coll Vet Med, Dept Biomed & Diagnost Sci, Knoxville, TN USA	Li, GH (reprint author), Penn State Coll Med, BMR, 500 Univ Dr,C3830G, Hershey, PA 17033 USA.	guohongli@pennstatehealth.psu.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS088719]; Louisiana State University Health Sciences Foundation	Supported by NIH grant NS088719 (G.L.) and the Louisiana State University Health Sciences Foundation Fund for Schumpert Endowed Chair (G.L.).	Ancuta P, 2003, J EXP MED, V197, P1701, DOI 10.1084/jem.20022156; Andre P, 2002, NAT MED, V8, P247, DOI 10.1038/nm0302-247; Antoniades C, 2009, J AM COLL CARDIOL, V54, P669, DOI 10.1016/j.jacc.2009.03.076; Beaulieu LM, 2014, ARTERIOSCL THROM VAS, V34, P552, DOI 10.1161/ATVBAHA.113.302700; Chandrasekar B, 2000, J AM COLL CARDIOL, V35, P555, DOI 10.1016/S0735-1097(99)00596-3; Cipollone F, 2005, DIABETOLOGIA, V48, P1216, DOI 10.1007/s00125-005-1750-2; Donners MMPC, 2008, BLOOD, V111, P4596, DOI 10.1182/blood-2007-05-088906; Fuentes E, 2013, PLATELETS, V24, P255, DOI 10.3109/09537104.2012.690113; Garlichs CD, 2001, CIRCULATION, V104, P2395, DOI 10.1161/hc4501.099312; Gerdes N, 2016, ARTERIOSCL THROM VAS, V36, P482, DOI 10.1161/ATVBAHA.115.307074; Green TD, 2012, J LEUKOCYTE BIOL, V92, P633, DOI 10.1189/jlb.1211604; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Hassan GS, 2012, IMMUNOBIOLOGY, V217, P521, DOI 10.1016/j.imbio.2011.03.010; Hassan GS, 2009, TRENDS IMMUNOL, V30, P165, DOI 10.1016/j.it.2009.01.004; HAWRYLOWICZ CM, 1991, J EXP MED, V174, P785, DOI 10.1084/jem.174.4.785; Hay C, 2001, ARTERIOSCL THROM VAS, V21, P1948, DOI 10.1161/hq1201.100256; Heeschen C, 2003, NEW ENGL J MED, V348, P1104, DOI 10.1056/NEJMoa022600; Ho YC, 2016, SCI REP-UK, V6, DOI 10.1038/srep25374; Jeremy JY, 2010, CURR VASC PHARMACOL, V8, P198, DOI 10.2174/157016110790887027; Kawai T, 2000, NAT MED, V6, P114, DOI 10.1038/72162; Kopp CW, 2003, STROKE, V34, P2560, DOI 10.1161/01.STR.0000094425.06242.64; Li G, 2008, AM J PATHOL, V172, P1141, DOI 10.2353/ajpath.2008.070633; Li Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130814; Lievens D, 2010, BLOOD, V116, P4317, DOI 10.1182/blood-2010-01-261206; Linden MD, 2010, INT J BIOCHEM CELL B, V42, P1762, DOI 10.1016/j.biocel.2010.07.012; Lo Sasso G, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0901-1; Lutgens E, 2000, P NATL ACAD SCI USA, V97, P7464, DOI 10.1073/pnas.97.13.7464; Lutgens E, 1999, NAT MED, V5, P1313, DOI 10.1038/15271; Lutgens E, 2010, J EXP MED, V207, P391, DOI 10.1084/jem.20091293; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; MOVAT HZ, 1955, ARCH PATHOL, V60, P289; Pankratz S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101723; Papapanagiotou A, 2016, CURR PHARM DESIGN, V22, P4493, DOI 10.2174/1381612822666160607064118; Prasad KSS, 2003, P NATL ACAD SCI USA, V100, P12367, DOI 10.1073/pnas.2032886100; Prasad KSS, 2003, CURR OPIN HEMATOL, V10, P356, DOI 10.1097/00062752-200309000-00006; Projahn D, 2012, J LEUKOCYTE BIOL, V92, P1167, DOI 10.1189/jlb.0312151; Sanguigni V, 2005, CIRCULATION, V111, P412, DOI 10.1161/01.CIR.0000153810.81187.7D; Schober A, 2005, ANTIOXID REDOX SIGN, V7, P1249, DOI 10.1089/ars.2005.7.1249; Schober A, 2002, CIRCULATION, V106, P1523, DOI 10.1161/01.CIR.0000028590.02477.6F; Schonbeck U, 2000, P NATL ACAD SCI USA, V97, P7458, DOI 10.1073/pnas.97.13.7458; Song Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101617; Song ZF, 2012, ARTERIOSCL THROM VAS, V32, P50, DOI 10.1161/ATVBAHA.111.238329; Song ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023239; Totani L, 2010, ARTERIOSCL THROM VAS, V30, P2357, DOI 10.1161/ATVBAHA.110.207480; van Gils JM, 2009, J LEUKOCYTE BIOL, V85, P195, DOI 10.1189/jlb.0708400; Versari D, 2007, CURR PHARM DESIGN, V13, P1811, DOI 10.2174/138161207780831239; von Hundelshausen P, 2001, CIRCULATION, V103, P1772, DOI 10.1161/01.CIR.103.13.1772; Zirlik A, 2007, CIRCULATION, V115, P1571, DOI 10.1161/CIRCULATIONAHA.106.683201	48	3	3	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					252	263		10.1016/j.ajpath.2017.09.007			12	Pathology	Pathology	FQ8SS	WOS:000418634100025	29037856	Green Published, Bronze			2019-10-28	
J	[Anonymous]				[Anonymous]			Inhibition of Glycogen Synthase Kinase 3 beta Blocks Mesomesenchymal Transition and Attenuates Streptococcus pneumonia - Mediated Pleural Injury in Mice (vol 187, pg 2461, 2017)	AMERICAN JOURNAL OF PATHOLOGY			English	Correction														NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL115466, HL130133]; University of Texas Health Science Center at Tyler; The Texas Lung Injury Institute	Supported by NIH grants HL115466 (T.A.T.) and HL130133 (T.A.T.), Seed grant funding from the University of Texas Health Science Center at Tyler (T.A.T.), and The Texas Lung Injury Institute (T.A.T.).	Boren J, 2017, AM J PATHOL, V187, P2461, DOI 10.1016/j.ajpath.2017.07.007	1	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					264	264		10.1016/j.ajpath.2017.10.003			1	Pathology	Pathology	FQ8SS	WOS:000418634100026	29249253	Green Published, Bronze			2019-10-28	
J	[Anonymous]				[Anonymous]			Expression of Transforming Growth Factor-beta 1 by Pancreatic Stellate Cells and Its Implications for Matrix Secretion and Turnover in Chronic Pancreatitis (vol 160, pg 1787, 2002)	AMERICAN JOURNAL OF PATHOLOGY			English	Correction																Shek FWT, 2002, AM J PATHOL, V160, P1787, DOI 10.1016/S0002-9440(10)61125-X	1	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					265	265		10.1016/j.ajpath.2017.10.002			1	Pathology	Pathology	FQ8SS	WOS:000418634100027	29249254				2019-10-28	
J	Zehnbauer, B; Essex, EH; Chauhant, C				Zehnbauer, Barbara; Essex, Emily H.; Chauhant, Chhavi			Navigating the Peer Review Process	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Editorial Material									[Zehnbauer, Barbara] Emory Univ, Sch Med, Dept Pathol, 961 Castle Falls Dr NE, Atlanta, GA 30329 USA; [Essex, Emily H.; Chauhant, Chhavi] Amer Soc Invest Pathol, Rockville, MD USA	Zehnbauer, B (reprint author), Emory Univ, Sch Med, 961 Castle Falls Dr NE, Atlanta, GA 30329 USA.	bzehnba@emory.edu						0	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JAN	2018	20	1					1	3		10.1016/j.jmoldx.2017.10.003			3	Pathology	Pathology	FR2DY	WOS:000418878400001	29249242				2019-10-28	
J	Ding, Y; Miyamoto, H; Rothberg, PG				Ding, Yi; Miyamoto, Hiroshi; Rothberg, Paul G.			Is Tubulocystic Renal Cell Carcinoma Real? Genomic Analysis Confirms the World Health Organization Classification	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Editorial Material							COLLECTING DUCT CARCINOMA; MOLECULAR CHARACTERIZATION; KIDNEY		[Ding, Yi; Miyamoto, Hiroshi; Rothberg, Paul G.] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA	Rothberg, PG (reprint author), Univ Rochester, Med Ctr, Dept Pathol & Lab Med, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	paul_rothberg@urmc.rochester.edu		Miyamoto, Hiroshi/0000-0001-7610-7769			Amin MB, 2009, AM J SURG PATHOL, V33, P384, DOI 10.1097/PAS.0b013e3181872d3f; Chappell WH, 2011, ONCOTARGET, V2, P135; Deshmukh M, 2011, INDIAN J PATHOL MICR, V54, P127, DOI 10.4103/0377-4929.77363; Elfiky AA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-133; Vera-Badillo FE, 2012, INT J UROL, V19, P894, DOI 10.1111/j.1442-2042.2012.03079.x; Lawrie CH, 2018, J MOL DIAGN, V20, P34, DOI 10.1016/j.jmoldx.2017.09.002; Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917; MacLennan GT, 1997, UROLOGY, V50, P679, DOI 10.1016/S0090-4295(97)00335-X; MASSON P, 1970, HUMAN TUMORS HISTOLO; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Osunkoya AO, 2009, AM J SURG PATHOL, V33, P1103, DOI 10.1097/PAS.0b013e3181a13e7b; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Spector Y, 2013, MOL ONCOL, V7, P732, DOI 10.1016/j.molonc.2013.03.002; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Xu Q, 2016, CANCERS, V8, DOI 10.3390/cancers8060057; Yang XJ, 2008, AM J SURG PATHOL, V32, P177, DOI 10.1097/PAS.0b013e318150df1d; Youssef YM, 2011, EUR UROL, V59, P721, DOI 10.1016/j.eururo.2011.01.004; Zhou M, 2009, AM J SURG PATHOL, V33, P1840, DOI 10.1097/PAS.0b013e3181be22d1	18	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JAN	2018	20	1					28	30		10.1016/j.jmoldx.2017.10.004			3	Pathology	Pathology	FR2DY	WOS:000418878400003	29155049	Bronze			2019-10-28	
J	Joseph, L				Joseph, Loren			Telomere Diagnostics for Pancreatic Neoplasms and Cysts	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Editorial Material							INTRAEPITHELIAL NEOPLASIA; LESIONS		[Joseph, Loren] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA USA	Joseph, L (reprint author), Beth Israel Deaconess Med Ctr, Dept Pathol, Res West 763,330 Brookline Ave, Boston, MA 02215 USA.	ljjoseph@bidmc.harvard.edu					Basturk O, 2017, MODERN PATHOL, DOI [10.1038/modpathol.2017, DOI 10.1038/MODPATHOL.2017]; Cawthon RM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkn1027; Hata T, 2018, J MOL DIAGN, V20, P46, DOI 10.1016/j.jmoldx.2017.09.006; Hata T, 2016, CLIN CANCER RES, V22, P5141, DOI 10.1158/1078-0432.CCR-16-0311; Hong SM, 2011, MODERN PATHOL, V24, P256, DOI 10.1038/modpathol.2010.181; Shi CJ, 2009, MOL CANCER RES, V7, P230, DOI 10.1158/1541-7786.MCR-08-0206; Singhi AD, 2018, GUT, V67, P2131, DOI 10.1136/gutjnl-2016-313586; van Heek NT, 2002, AM J PATHOL, V161, P1541, DOI 10.1016/S0002-9440(10)64432-X; Yu J, 2017, GUT, V66, P1677, DOI 10.1136/gutjnl-2015-311166	9	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JAN	2018	20	1					31	33		10.1016/j.jmoldx.2017.11.001			3	Pathology	Pathology	FR2DY	WOS:000418878400004	29155048	Bronze			2019-10-28	
J	Lawrie, CH; Armesto, M; Fernandez-Mercado, M; Arestin, M; Manterola, L; Goicoechea, I; Larrea, E; Caffarel, MM; Araujo, AM; Sole, C; Sperga, M; Alvarado-Cabrero, I; Michal, M; Hes, O; Lopez, JI				Lawrie, Charles H.; Armesto, Maria; Fernandez-Mercado, Marta; Arestin, Maria; Manterola, Lorea; Goicoechea, Ibai; Larrea, Erika; Caffarel, Maria M.; Araujo, Angela M.; Sole, Carla; Sperga, Maris; Alvarado-Cabrero, Isabel; Michal, Michal; Hes, Ondrej; Lopez, Jose I.			Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							BREAST-CANCER CELLS; MICRORNA EXPRESSION; SMALL NUCLEOLAR; DOWN-REGULATION; KIDNEY CANCER; TUMORS; CLASSIFICATION; DIAGNOSIS; PROFILES; SUBTYPES	Tubulocystic renal cell carcinoma (TC-RCC) is a rare recently described renal neoplasm characterized by gross, microscopic, and immunohistochemical differences from other renal tumor types and was recently classified as a distinct entity. However, this distinction remains controversial particularly because some genetic studies suggest a close relationship with papillary RCC (PRCC). The molecular basis of this disease remains largely unexplored. We therefore performed noncoding (nc) RNA/miRNA expression analysis and targeted next-generation sequencing mutational profiling on 13 TC-RCC cases (11 pure, two mixed TC-RCC/PRCC) and compared with other renal neoplasms. The expression profile of miRNAs and other ncRNAs in TC-RCC was distinct and validated 10 differentially expressed miRNAs by quantitative RT-PCR, including miR-155 and miR-34a, that were significantly down-regulated compared with PRCC cases (n = 22). With the use of targeted next-generation sequencing we identified mutations in 14 different genes, most frequently (>60% of TC-RCC cases) in ABL1 and PDFGRA genes. These mutations were present in <5% of clear cell RCC, PRCC, or chromophobe RCC cases (n > 600) of The Cancer Genome Atlas database. In summary, this study is by far the Largest moLecular study of TC-RCC cases and the first to investigate either ncRNA expression or their genomic profile. These results add molecular evidence that TC-RCC is indeed a distinct entity from PRCC and other renal neoplasms.	[Lawrie, Charles H.; Armesto, Maria; Fernandez-Mercado, Marta; Arestin, Maria; Manterola, Lorea; Goicoechea, Ibai; Larrea, Erika; Caffarel, Maria M.; Araujo, Angela M.; Sole, Carla] Biodonostia Res Inst, Mol Oncol Grp, San Sebastian, Spain; [Lawrie, Charles H.; Caffarel, Maria M.] Basque Fdn Sci, IKERBASQUE, Bilbao, Spain; [Lawrie, Charles H.] Univ Oxford, Radcliffe Dept Med, Oxford, England; [Sperga, Maris] Riga Stradins Univ, Dept Pathol, Riga, Latvia; [Alvarado-Cabrero, Isabel] Mexican Oncol Hosp, Dept Pathol, Mexico City, DF, Mexico; [Michal, Michal; Hes, Ondrej] Charles Univ Hosp, Dept Pathol, Plzen, Czech Republic; [Lopez, Jose I.] Univ Basque Country, Cruces Univ Hosp, Dept Pathol, Baracaldo, Bizkaia, Spain; [Lopez, Jose I.] BioCruces Res Inst, Baracaldo, Bizkaia, Spain	Lawrie, CH (reprint author), Biodonostia Res Inst, San Sebastian 20014, Spain.	charles.lawrie@biodonostia.org	Lopez, Jose Ignacio/L-3884-2019; Goicoechea, Ibai/T-8243-2017	Lopez, Jose Ignacio/0000-0003-0842-5348; Goicoechea, Ibai/0000-0002-5329-2225; Manterola, Lorea/0000-0003-0660-916X; Alvarado-Cabrero, Isabel/0000-0003-4000-9280	IKERBASQUE Foundation for Science, Ministry of Economy & Competitiveness of Spanish central government; Fondo Europeo de Desarrollo Regional (FEDER)European Union (EU) [PI12/00663, PTE13/00048, DTS14/00109, PI15/00275]; Department of Economic Development & Competitiveness; Department of Health of Basque government; Spanish Association Against Cancer (AECC); Provincial Council of Guipuzcoa (DFG); Instituto de Salud "Carlos III" (ISCIII) grant [PI16/00169]; IKERBASQUE Foundation for Science; ISCIII Ministry of Economy & Competitiveness of Spanish central government; Ministry of Economy & Competitiveness of the Spanish central government	Supported by the IKERBASQUE Foundation for Science, Ministry of Economy & Competitiveness of Spanish central government, and Fondo Europeo de Desarrollo Regional (FEDER) grants PI12/00663, PTE13/00048, DTS14/00109, and PI15/00275 (C.H.L.); Department of Economic Development & Competitiveness and the Department of Health of Basque government (C.H.L.); Spanish Association Against Cancer (AECC) (C.H.L., M.F.-M., and I.G.); the Provincial Council of Guipuzcoa (DFG) (C.H.L. and M.F.-M.); Instituto de Salud "Carlos III" (ISCIII) grant PI16/00169 (M.F.-M.); IKERBASQUE Foundation for Science (M.M.C.); ISCIII Ministry of Economy & Competitiveness of Spanish central government (M.M.C.); and the Ministry of Economy & Competitiveness of the Spanish central government (E.L.).	Al-Ali BM, 2012, ANTICANCER RES, V32, P3727; Amin MB, 2009, AM J SURG PATHOL, V33, P384, DOI 10.1097/PAS.0b013e3181872d3f; Azoulay S, 2007, VIRCHOWS ARCH, V451, P905, DOI 10.1007/s00428-007-0483-7; Chen DQ, 2015, MOL MED REP, V12, P1399, DOI 10.3892/mmr.2015.3496; Chen N, 2014, J CLIN PATHOL, V67, P1006, DOI 10.1136/jclinpath-2014-202363; Chow TFF, 2010, J UROLOGY, V183, P743, DOI 10.1016/j.juro.2009.09.086; Duns G, 2013, GENE CHROMOSOME CANC, V52, P165, DOI 10.1002/gcc.22016; Ge YZ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000767; Geurts-Giele WRR, 2013, VIRCHOWS ARCH, V462, P249, DOI 10.1007/s00428-012-1346-4; Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019; Guttilla IK, 2009, J BIOL CHEM, V284, P23204, DOI 10.1074/jbc.M109.031427; Hora M, 2011, WORLD J UROL, V29, P349, DOI 10.1007/s00345-010-0614-7; Huang Y, 2009, EJSO-EUR J SURG ONC, V35, P1119, DOI 10.1016/j.ejso.2009.04.010; Juan D, 2010, UROLOGY, V75, P835, DOI 10.1016/j.urology.2009.10.033; Kuroda N, 2013, POL J PATHOL, V64, P233, DOI 10.5114/PJP.2013.39329; Lawrie CH, 2008, LEUKEMIA, V22, P1440, DOI 10.1038/sj.leu.2405083; Lawrie CH, 2014, J PATHOL, V232, P32, DOI 10.1002/path.4296; Lopez JI, 2013, PATHOL RES PRACT, V209, P137, DOI 10.1016/j.prp.2013.01.007; Lopez-Beltran A, 2006, EUR UROL, V49, P798, DOI 10.1016/j.eururo.2005.11.035; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Malavaki CJ, 2013, FEBS J, V280, P2477, DOI 10.1111/febs.12163; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Morris MR, 2017, NAT REV NEPHROL, V13, P47, DOI 10.1038/nrneph.2016.168; Munari E, 2014, HUM PATHOL, V45, P1130, DOI 10.1016/j.humpath.2014.01.013; Nagashima Y, 2004, PATHOL INT, V54, P377, DOI 10.1111/j.1440-1827.2004.01648.x; Nakada C, 2008, J PATHOL, V216, P418, DOI 10.1002/path.2437; Neal CS, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-64; O'Hara AJ, 2008, BLOOD, V111, P2347, DOI 10.1182/blood-2007-08-104463; O'Hara AJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000389; Petillo D, 2009, INT J ONCOL, V35, P109, DOI 10.3892/ijo_00000318; Qu Y, 2013, INT J CANCER, V133, P544, DOI 10.1002/ijc.28056; Ronchetti D, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.41; Sauna ZE, 2011, NAT REV GENET, V12, P683, DOI 10.1038/nrg3051; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Slaby O, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-90; Smith SC, 2016, AM J SURG PATHOL, V40, P1457, DOI 10.1097/PAS.0000000000000719; Song T, 2011, ASIAN PAC J CANCER P, V12, P1307; Sourbier C, 2014, CANCER CELL, V26, P840, DOI 10.1016/j.ccell.2014.10.005; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Srinivasan D, 2009, CELL SIGNAL, V21, P1143, DOI 10.1016/j.cellsig.2009.03.003; Steiner P, 2013, VIRCHOWS ARCH, V462, P183, DOI 10.1007/s00428-012-1367-z; Su H, 2014, ONCOGENE, V33, P1348, DOI 10.1038/onc.2013.89; Sun XH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156324; Terada T, 2012, HISTOL HISTOPATHOL, V27, P297, DOI 10.14670/HH-27.297; Tran T, 2016, HISTOPATHOLOGY, V68, P850, DOI 10.1111/his.12840; Tickoo SK, 2011, ADV ANAT PATHOL, V18, P120, DOI 10.1097/PAP.0b013e31820cb3dd; Truong LD, 2011, ARCH PATHOL LAB MED, V135, P92, DOI 10.1043/2010-0478-RAR.1; Ulamec M, 2016, APPL IMMUNOHISTO M M, V24, P521, DOI 10.1097/PAI.0000000000000213; Valleron W, 2012, LEUKEMIA, V26, P2052, DOI 10.1038/leu.2012.111; von Brandenstein M, 2012, AM J PATHOL, V180, P1787, DOI 10.1016/j.ajpath.2012.01.014; Wang J, 2015, TRENDS CANCER, V1, P110, DOI 10.1016/j.trecan.2015.07.004; Weng LH, 2010, J PATHOL, V222, P41, DOI 10.1002/path.2736; White NMA, 2011, J UROLOGY, V186, P1077, DOI 10.1016/j.juro.2011.04.110; Williams GT, 2012, NAT REV CANCER, V12, P84, DOI 10.1038/nrc3195; Wu XW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035661; Xu X, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-109; Yamamura S, 2012, CARCINOGENESIS, V33, P294, DOI 10.1093/carcin/bgr286; Yang XJ, 2008, AM J SURG PATHOL, V32, P177, DOI 10.1097/PAS.0b013e318150df1d; Yousem SA, 2013, CHEST, V143, P1679, DOI 10.1378/chest.12-1917; Zhou M, 2009, AM J SURG PATHOL, V33, P1840, DOI 10.1097/PAS.0b013e3181be22d1	61	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JAN	2018	20	1					34	45		10.1016/j.jmoldx.2017.09.002			12	Pathology	Pathology	FR2DY	WOS:000418878400005	29056573				2019-10-28	
J	Chang, KTE; Goytain, A; Tucker, T; Karsan, A; Lee, CH; Nielsen, TO; Ng, TL				Chang, Kenneth T. E.; Goytain, Angela; Tucker, Tracy; Karsan, Aly; Lee, Cheng-Han; Nielsen, Torsten O.; Ng, Tony L.			Development and Evaluation of a Pan-Sarcoma Fusion Gene Detection Assay Using the NanoString nCounter Platform	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							EXTRASKELETAL MYXOID CHONDROSARCOMA; POLYMERASE-CHAIN-REACTION; ROUND-CELL SARCOMAS; INFLAMMATORY MYOFIBROBLASTIC TUMOR; ENDOMETRIAL STROMAL SARCOMA; GRADE FIBROMYXOID SARCOMA; IN-SITU HYBRIDIZATION; ANEURYSMAL BONE-CYST; EWING-LIKE-SARCOMA; SYNOVIAL SARCOMA	The NanoString nCounter assay is a high-throughput hybridization technique using target-specific probes that can be customized to test for numerous fusion transcripts in a single assay using RNA from formalin-fixed, paraffin-embedded material. We designed a NanoString assay targeting 174 unique fusion junctions in 25 sarcoma types. The study cohort comprised 212 cases, 96 of which showed fusion gene expression by the NanoString assay, including all 20 Ewing sarcomas, 11 synovial sarcomas, and 5 myxoid Liposarcomas tested. Among these 96 cases, 15 showed fusion expression not identified by standard cLinicaL assay, including EWSR1-FLI1, EWSR1-ERG, BC0R-CCNB3, ZC3H7B-BC0R, HEY1-NC0A2, CIC-DUX4, C0L1A1-PDGFB, MYH9-USP6, YAP1-TFE3, and IRF2BP2-CDX1 fusions. There were no false-positive results; however, four cases were false negative when compared with clinically available fluorescence in situ hybridization or RT-PCR testing. When batched as six cases, the per-sample reagent cost was less than conventional techniques, such as fluorescence in situ hybridization, with technologist hands-on time of 1.2 hours per case and assay time of 36 hours. In summary, the NanoString nCounter Sarcoma Fusion CodeSet reliably and cost-effectively identifies fusion genes in sarcomas using formalin-fixed, paraffin-embedded material, including many fusions missed by standard clinical assays, and can serve as a first-line clinical diagnostic test for sarcoma fusion gene identification, replacing multiple individual clinical assays.	[Chang, Kenneth T. E.] KK Womens & Childrens Hosp, Dept Pathol & Lab Med, Singapore, Singapore; [Chang, Kenneth T. E.] Duke NUS Med Sch, Singapore, Singapore; [Goytain, Angela; Karsan, Aly; Lee, Cheng-Han; Nielsen, Torsten O.; Ng, Tony L.] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada; [Tucker, Tracy; Karsan, Aly; Lee, Cheng-Han; Nielsen, Torsten O.; Ng, Tony L.] British Columbia Canc Agcy, Dept Pathol, Vancouver, BC, Canada; [Lee, Cheng-Han; Nielsen, Torsten O.; Ng, Tony L.] Vancouver Gen Hosp, Dept Pathol, Vancouver, BC, Canada	Ng, TL (reprint author), Vancouver Gen Hosp, Dept Pathol & Lab Med, 855 W 12th Ave, Vancouver, BC V5Z 1L3, Canada.	tony.ng@vch.ca			Canadian Cancer Society [701582]; Terry Fox Foundation Strategic Health Research Training Program in Cancer Research at the Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [TGT-53912]; VIVA-KKH Pediatric Brain and Solid Tumor Program [KRDUK16V0100]	Supported by the Canadian Cancer Society grant 701582 (T.O.N.). K.T.E.C. was a visiting fellow in the Terry Fox Foundation Strategic Health Research Training Program in Cancer Research at the Canadian Institutes of Health Research (TGT-53912). The work in Singapore was funded by the VIVA-KKH Pediatric Brain and Solid Tumor Program grant KRDUK16V0100 (K.T.E.C.).	Agaram NP, 2015, GENE CHROMOSOME CANC, V54, P63, DOI 10.1002/gcc.22216; Agaram NP, 2014, HUM PATHOL, V45, P1084, DOI 10.1016/j.humpath.2014.01.007; Amary MFC, 2007, HISTOPATHOLOGY, V51, P559, DOI 10.1111/j.1365-2559.2007.02812.x; Antonescu CR, 1998, DIAGN MOL PATHOL, V7, P24, DOI 10.1097/00019606-199802000-00005; Antonescu CR, 1998, CANCER, V83, P1504, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1504::AID-CNCR5>3.0.CO;2-B; Antonescu CR, 2001, CLIN CANCER RES, V7, P3977; Antonescu CR, 2007, GENE CHROMOSOME CANC, V46, P1051, DOI 10.1002/gcc.20491; Antonescu CR, 2015, AM J SURG PATHOL, V39, P957, DOI 10.1097/PAS.0000000000000404; Antonescu CR, 2013, GENE CHROMOSOME CANC, V52, P775, DOI 10.1002/gcc.22073; Antonescu CR, 2010, GENE CHROMOSOME CANC, V49, P1114, DOI 10.1002/gcc.20819; Attwooll C, 1999, ONCOGENE, V18, P7599, DOI 10.1038/sj.onc.1203156; Barr FG, 2002, CANCER RES, V62, P4704; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Barr FG, 2007, J MOL DIAGN, V9, P437, DOI 10.2353/jmoldx.2007.070080; Bode-Lesniewska B, 2007, GENE CHROMOSOME CANC, V46, P961, DOI 10.1002/gcc.20478; Brandal P, 2008, GENE CHROMOSOME CANC, V47, P558, DOI 10.1002/gcc.20559; Brandal P, 2009, GENE CHROMOSOME CANC, V48, P1051, DOI 10.1002/gcc.20706; Bridge JA, 2012, HUM PATHOL, V43, P1524, DOI 10.1016/j.humpath.2012.01.019; Chen QR, 2007, J MOL DIAGN, V9, P80, DOI 10.2353/jmoldx.2007.060111; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Dahlen A, 2004, BIOCHEM BIOPH RES CO, V325, P1318, DOI 10.1016/j.bbrc.2004.10.172; DEALAVA E, 1995, AM J PATHOL, V147, P1584; Demicco EG, 2013, ADV ANAT PATHOL, V20, P264, DOI 10.1097/PAP.0b013e31829c2c7b; FLIGMAN I, 1995, AM J PATHOL, V147, P1592; Gambarotti M, 2016, HISTOPATHOLOGY, V69, P624, DOI 10.1111/his.12985; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Giacomini CP, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003464; Graham C, 2012, HUM PATHOL, V43, P180, DOI 10.1016/j.humpath.2011.04.023; Guillou L, 2007, AM J SURG PATHOL, V31, P1387, DOI 10.1097/PAS.0b013e3180321959; Guillou L, 2010, VIRCHOWS ARCH, V456, P201, DOI 10.1007/s00428-009-0853-4; Hisaoka M, 2004, GENE CHROMOSOME CANC, V40, P325, DOI 10.1002/gcc.20044; Horn H, 2014, PATHOL RES PRACT, V210, P804, DOI 10.1016/j.prp.2014.09.009; Hosaka T, 2002, J MOL DIAGN, V4, P164, DOI 10.1016/S1525-1578(10)60698-8; Isphording A, 2013, HUM PATHOL, V44, P837, DOI 10.1016/j.humpath.2012.08.007; Italiano A, 2016, LANCET ONCOL, V17, P532, DOI 10.1016/S1470-2045(15)00583-5; Italiano A, 2012, GENE CHROMOSOME CANC, V51, P207, DOI 10.1002/gcc.20945; JEON IS, 1995, ONCOGENE, V10, P1229; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kubo T, 2009, ANTICANCER RES, V29, P2357; Ladanyi M, 2001, ONCOGENE, V20, P48, DOI 10.1038/sj.onc.1204074; LEE W, 1993, AM J PATHOL, V143, P15; Llombart B, 2009, HISTOPATHOLOGY, V54, P860, DOI 10.1111/j.1365-2559.2009.03310.x; Llombart-Bosch A, 2000, DIAGN MOL PATHOL, V9, P137, DOI 10.1097/00019606-200009000-00003; Loke BN, 2017, J CLIN PATHOL, V70, P697, DOI 10.1136/jclinpath-2016-204247; Lovly CM, 2014, CANCER DISCOV, V4, P889, DOI 10.1158/2159-8290.CD-14-0377; Machado I, 2013, VIRCHOWS ARCH, V463, P837, DOI 10.1007/s00428-013-1499-9; Maire G, 2002, CANCER GENET CYTOGEN, V134, P156, DOI 10.1016/S0165-4608(01)00617-3; Mertens F, 2005, LAB INVEST, V85, P408, DOI 10.1038/labinvest.3700230; Mertens F, 2009, SEMIN ONCOL, V36, P312, DOI 10.1053/j.seminoncol.2009.06.004; Micci F, 2006, CANCER RES, V66, P107, DOI 10.1158/0008-5472.CAN-05-2485; Micci F, 2003, CANCER GENET CYTOGEN, V144, P119, DOI 10.1016/S0165-4608(03)00025-6; Mikami T, 2015, J ORAL MAXIL SURG, V73, P1505, DOI 10.1016/j.joms.2015.02.010; Moller E, 2008, GENE CHROMOSOME CANC, V47, P21, DOI 10.1002/gcc.20501; Nakanishi Y, 2006, J CLIN PATHOL, V59, P1108, DOI 10.1136/jcp.2005.026245; Ng TL, 2007, J MOL DIAGN, V9, P459, DOI 10.2353/jmoldx.2007.070009; Nilsson G, 1999, CANCER RES, V59, P3180; O'Brien KP, 1998, GENE CHROMOSOME CANC, V23, P187, DOI 10.1002/(SICI)1098-2264(199810)23:2<187::AID-GCC13>3.0.CO;2-L; Oliveira AM, 2005, ONCOGENE, V24, P3419, DOI 10.1038/sj.onc.1208506; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Ouchi K, 2015, PEDIATR BLOOD CANCER, V62, P909, DOI 10.1002/pbc.25424; Panagopoulos I, 2006, INT J CANCER, V118, P1181, DOI 10.1002/ijc.21490; Panagopoulos I, 2002, GENE CHROMOSOME CANC, V35, P340, DOI 10.1002/gcc.10127; Panagopoulos I, 2013, GENE CHROMOSOME CANC, V52, P733, DOI 10.1002/gcc.22068; Panagopoulos I, 2013, GENE CHROMOSOME CANC, V52, P610, DOI 10.1002/gcc.22057; Panagopoulos I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039354; Parker D, 2014, CLIN MED INSIGHTS-ON, V8, P145, DOI 10.4137/CMO.S19236; Patel KU, 2008, HUM PATHOL, V39, P184, DOI 10.1016/j.humpath.2007.06.009; Patel NR, 2015, HISTOPATHOLOGY, V67, P699, DOI 10.1111/his.12697; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Pierron G, 2012, NAT GENET, V44, P461, DOI 10.1038/ng.1107; Powers MP, 2010, MODERN PATHOL, V23, P1307, DOI 10.1038/modpathol.2010.118; Przybyl J, 2012, TUMOR BIOL, V33, P2245, DOI 10.1007/s13277-012-0486-0; Puls F, 2014, HISTOPATHOLOGY, V65, P917, DOI 10.1111/his.12517; Puls F, 2014, AM J SURG PATHOL, V38, P1307, DOI 10.1097/PAS.0000000000000223; Safar A, 1998, DIAGN MOL PATHOL, V7, P283, DOI 10.1097/00019606-199810000-00008; Shing DC, 2003, CANCER RES, V63, P4568; Sjogren H, 2000, CANCER RES, V60, P6832; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Storlazzi CT, 2003, GENE CHROMOSOME CANC, V37, P195, DOI 10.1002/gcc.10210; Suehara Y, 2012, CLIN CANCER RES, V18, P6599, DOI 10.1158/1078-0432.CCR-12-0838; Sugita S, 2014, AM J SURG PATHOL, V38, P1571, DOI 10.1097/PAS.0000000000000286; Sumegi J, 2011, MODERN PATHOL, V24, P333, DOI 10.1038/modpathol.2010.201; Sumegi J, 2010, GENE CHROMOSOME CANC, V49, P224, DOI 10.1002/gcc.20731; Szuhai K, 2009, CLIN CANCER RES, V15, P2259, DOI 10.1158/1078-0432.CCR-08-2184; Takeuchi K, 2011, CLIN CANCER RES, V17, P3341, DOI 10.1158/1078-0432.CCR-11-0063; Tanas MR, 2009, ADV ANAT PATHOL, V16, P383, DOI 10.1097/PAP.0b013e3181bb6b86; TAYLOR C, 1993, BRIT J CANCER, V67, P128, DOI 10.1038/bjc.1993.22; Turc-Carel C, 1995, Curr Top Pathol, V89, P73; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; Wang J, 1999, DIAGN MOL PATHOL, V8, P113, DOI 10.1097/00019606-199909000-00002; Wang L, 2007, J MOL DIAGN, V9, P498, DOI 10.2353/jmoldx.2007.070053; Wang L, 2012, GENE CHROMOSOME CANC, V51, P127, DOI 10.1002/gcc.20937; Wang WL, 2009, MODERN PATHOL, V22, P1201, DOI 10.1038/modpathol.2009.85; Wang XK, 2014, NAT GENET, V46, P666, DOI 10.1038/ng.2989; Werner H, 2007, CANCER LETT, V247, P84, DOI 10.1016/j.canlet.2006.03.027; Williams A, 2011, VIRCHOWS ARCH, V458, P291, DOI 10.1007/s00428-010-1039-9; Yamaguchi S, 2005, GENE CHROMOSOME CANC, V43, P217, DOI 10.1002/gcc.20171; Yokoyama Y, 2012, BIOCHEM BIOPH RES CO, V425, P353, DOI 10.1016/j.bbrc.2012.07.095	100	14	14	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JAN	2018	20	1					63	77		10.1016/j.jmoldx.2017.09.007			15	Pathology	Pathology	FR2DY	WOS:000418878400008	29104083	Other Gold			2019-10-28	
J	Roth, JM; de Bes, L; Sawa, P; Omweri, G; Osoti, V; Oberheitmann, B; Schallig, HDFH; Mens, PF				Roth, Johanna M.; de Bes, Laura; Sawa, Patrick; Omweri, George; Osoti, Victor; Oberheitmann, Boris; Schallig, Henk D. F. H.; Mens, Petra F.			Plasmodium Detection and Differentiation by Direct-on-Blood PCR Nucleic Acid Lateral Flow Immunoassay Development, Validation, and Evaluation	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							ISOTHERMAL AMPLIFICATION LAMP; RAPID DIAGNOSTIC-TEST; MALARIA ELIMINATION; SENSITIVITY; PERFORMANCE; STRATEGIES; PARASITES; TESTS; FIELD; ASSAY	Decreasing malaria transmission warrants the search for highly sensitive point-of-care diagnostics, especially in resource-limited settings. The direct-on-blood PCR nucleic add lateral flow immunoassay (db-PCR-NALFIA) is a simplified PCR-based technique with a lateral flow readout that does not require sample preparation. Two duplex db-PCR-NALFIAs were developed: a pan-Plasmodium/Plasmodium falciparum (pan/P. falciparum) and a pan-Plasmodium/Plasmodium vivax (pan/P. vivax) assay. Confirmed positive samples (n = 61) and negative controls (n = 40) were used for laboratory validations. A prospective field evaluation of the pan/P. falciparum assay was performed in Kenya (n = 300). In the laboratory validation, sensitivity and specificity of the pan/P. falciparum assay were 100% (95% CI, 94.1%-100%) and 100% (95% CI, 91.2%-100%), respectively. Sensitivity and specificity of the pan/P. vivax assay were 100% (95% CI, 94.1%-100%) and 97.5% (95% CI, 86.8%-99.9%), respectively. In Kenya, sensitivity of the pan/P. falciparum db-PCR-NALFIA was 97.2% (95% CI, 93.0%-99.2%) and specificity was 74.2% (95% CI 67.0%-81.0%) compared with reference standard microscopy. When using real-time quantitative PCR as a reference standard, sensitivity was 84.5% (95% CI 78.7%-89.3%) and specificity was 85.4% (95% CI, 77.1%-91.6%). Db-PCR-NALFIA is a sensitive, specific, and easy method for the detection and species differentiation of Plasmodium. This test is especially of interest for malaria control or elimination programs in low-transmission settings that require accurate detection of low parasite densities.	[Roth, Johanna M.; de Bes, Laura; Schallig, Henk D. F. H.; Mens, Petra F.] Acad Med Ctr, Dept Med Microbiol, Amsterdam, Netherlands; [Sawa, Patrick; Omweri, George; Osoti, Victor] Int Ctr Insect Physiol & Ecol, Human Hlth Div, Mbita Point, Kenya; [Oberheitmann, Boris] Q Bioanalyt GmbH, Bremerhaven, Germany	Roth, JM (reprint author), Acad Med Ctr, Dept Med Microbiol, Lab Clin Parasitol L1 247, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.m.roth@amc.uva.nl			EUEuropean Union (EU) [FP7-Health-2013.0-1, 601714]	Supported by the EU-funded FP7-Health-2013.0-1 project DIAGMAL (translation of the direct-on-blood PCR-NALFIA system into an innovative near point-of-care diagnostic for malaria) grant 601714 (H.D.F.H.S.).	Altman DG, 1991, PRACTICAL STAT MED R; Baltzell KA, 2013, AM J TROP MED HYG, V88, P289, DOI 10.4269/ajtmh.2012.12-0095; Banoo S, 2010, NAT REV MICROBIOL, pS17, DOI 10.1038/nrmicro1523; Britton S, 2016, PLOS NEGLECT TROP D, V10, P1; Canier L, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-405; Cook J, 2015, J INFECT DIS, V211, P1476, DOI 10.1093/infdis/jiu655; Cook J, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0573-y; Cotter C, 2013, LANCET, V382, P900, DOI 10.1016/S0140-6736(13)60310-4; Golassa L, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1070-1; Hermsen CC, 2001, MOL BIOCHEM PARASIT, V118, P247, DOI 10.1016/S0166-6851(01)00379-6; Holden MJ, 2011, EXPERT REV MOL DIAGN, V11, P741, DOI [10.1586/erm.11.50, 10.1586/ERM.11.50]; Hopkins H, 2013, J INFECT DIS, V208, P645, DOI 10.1093/infdis/jit184; Kattenberg JH, 2012, TROP MED INT HEALTH, V17, P550, DOI 10.1111/j.1365-3156.2012.02975.x; Kitchen RR, 2010, METHODS, V50, P231, DOI 10.1016/j.ymeth.2010.01.025; Lucchi NW, 2016, SCI REP-UK, V6, DOI 10.1038/srep36808; Marx V, 2015, NAT METHODS, V12, P393, DOI 10.1038/nmeth.3369; Mens PF, 2012, J CLIN MICROBIOL, V50, P3520, DOI 10.1128/JCM.01426-12; Mens PF, 2008, DIAGN MICR INFEC DIS, V61, P421, DOI 10.1016/j.diagmicrobio.2008.03.009; Mens PF, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-279; Mixson-Hayden Tonya, 2010, BMC Res Notes, V3, P88, DOI 10.1186/1756-0500-3-88; Mohon A, 2014, ACTA TROP, V134, P52, DOI 10.1016/j.actatropica.2014.02.016; Moody A, 2002, CLIN MICROBIOL REV, V15, P66, DOI 10.1128/CMR.15.1.66-78.2002; Moonen B, 2010, LANCET, V376, P1592, DOI 10.1016/S0140-6736(10)61269-X; Murray CK, 2008, CLIN MICROBIOL REV, V21, P97, DOI 10.1128/CMR.00035-07; Niemz A, 2011, TRENDS BIOTECHNOL, V29, P240, DOI 10.1016/j.tibtech.2011.01.007; Oguike MC, 2011, INT J PARASITOL, V41, P677, DOI 10.1016/j.ijpara.2011.01.004; Okell LC, 2009, J INFECT DIS, V200, P1509, DOI 10.1086/644781; Oriero EC, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0926-6; Ouedraogo AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008410; Proux S, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-323; Roth JM, 2016, CRIT REV CL LAB SCI, V53, P87, DOI 10.3109/10408363.2015.1084991; Rougemont M, 2004, J CLIN MICROBIOL, V42, P5636, DOI 10.1128/JCM.42.12.5636-5643.2004; Schneider P, 2007, AM J TROP MED HYG, V76, P470, DOI 10.4269/ajtmh.2007.76.470; Schrader C, 2012, J APPL MICROBIOL, V113, P1014, DOI 10.1111/j.1365-2672.2012.05384.x; Shokoples SE, 2009, J CLIN MICROBIOL, V47, P975, DOI 10.1128/JCM.01858-08; SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B; The malERA. Consultative Group, 2011, PLOS MED, V8; Vallejo AF, 2015, PLOS NEGLECT TROP D, V9, P1; Wang CW, 2009, PARASITOL INT, V58, P478, DOI 10.1016/j.parint.2009.07.004; WHO, 2010, BAS MAL MICR 1; Wongsrichanalai C, 2007, AM J TROP MED HYG, V77, P119, DOI 10.4269/ajtmh.2007.77.119; World Health Organization, 2015, GUID TREATM MAL	42	3	3	1	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JAN	2018	20	1					78	86		10.1016/j.jmoldx.2017.09.004			9	Pathology	Pathology	FR2DY	WOS:000418878400009	29056574	Bronze			2019-10-28	
J	Capone, GL; Putignano, AL; Saavedra, ST; Paganini, I; Sestini, R; Gensini, F; De Rienzo, I; Papi, L; Porfirio, B				Capone, Gabriele Lorenzo; Putignano, Anna Laura; Saavedra, Sharon Trujillo; Paganini, Irene; Sestini, Roberta; Gensini, Francesca; De Rienzo, Irene; Papi, Laura; Porfirio, Berardino			Evaluation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Mutation Detection	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							HEREDITARY BREAST; CANCER; PANEL; GENES; VALIDATION; GUIDELINES; GENETICS	The efficiency of a novel targeted next-generation sequencing (NGS) test, the Devyser BRCA kit, for a comprehensive analysis of all 48 coding exons of the high-risk breast/ovarian cancer susceptibility genes BRCA1 and BRCA2 has been assessed. The new assay intended to detect nucleotide substitutions, small deletions/insertions, and large deletions/duplications. To document the false-negative and false-positive rates of the NGS assay in the hands of end users, 48 samples with previously identified 444 small variants and seven gross rearrangements were analyzed, showing 100% concordance with gold standards. Furthermore, all other 43 variants (42 single-nucleotide variation or insertion/deletion variation and one copy number variation, whose significance is or may be of clinical value), which were called by the NGS assay in a prospectively analyzed 179-sample set, were confirmed by Sanger sequencing or multiplex ligation probe amplification, according to their nature. We conclude that the Devyser BRCA kit performed satisfactorily for use in a clinical laboratory.	[Capone, Gabriele Lorenzo; Putignano, Anna Laura; Saavedra, Sharon Trujillo; Paganini, Irene; Sestini, Roberta; Gensini, Francesca; De Rienzo, Irene; Papi, Laura; Porfirio, Berardino] Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Med Genet Unit, Viale Gaetano Pieraccini 6, I-50139 Florence, Italy	Papi, L (reprint author), Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Med Genet Unit, Viale Gaetano Pieraccini 6, I-50139 Florence, Italy.	laura.papi@unifi.it	Porfirio, Berardino/I-1988-2012	Porfirio, Berardino/0000-0003-4646-2502; Papi, Laura/0000-0003-4552-9517	Ricerca d'Ateneo	Supported by institutional funding from Ricerca d'Ateneo (L.P. and B.P.).	Augello C, 2006, ANN ONCOL, V17, pVII30, DOI 10.1093/annonc/mdl946; Axilbund JE, 2016, J CLIN ONCOL, V34, P1433, DOI 10.1200/JCO.2015.65.5522; Bosdet IE, 2013, J MOL DIAGN, V15, P796, DOI 10.1016/j.jmoldx.2013.07.004; Castera L, 2014, EUR J HUM GENET, V22, P1305, DOI 10.1038/ejhg.2014.16; Cavanagh H, 2015, HERED CANCER CLIN PR, V13, DOI 10.1186/s13053-015-0038-x; Chong HK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097408; Domchek SM, 2013, J CLIN ONCOL, V31, P1267, DOI 10.1200/JCO.2012.46.9403; Gargis AS, 2012, NAT BIOTECHNOL, V30, P1033, DOI 10.1038/nbt.2403; George A, 2017, NAT REV CLIN ONCOL, V14, P284, DOI 10.1038/nrclinonc.2016.191; Gradishar WJ, 2017, J NATL COMPR CANC NE, V15, P433, DOI 10.6004/jnccn.2017.0044; Jalkh N, 2012, HERED CANCER CLIN PR, V10, DOI 10.1186/1897-4287-10-7; Judkins T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1224-y; Kalari Krishna R., 2006, In Silico Biology, V6, P237; Kang HP, 2016, PEERJ, V4, DOI 10.7717/peerj.2162; Lincoln SE, 2015, J MOL DIAGN, V17, P533, DOI 10.1016/j.jmoldx.2015.04.009; Metcalfe KA, 2013, BRIT J CANCER, V109, P777, DOI 10.1038/bjc.2013.309; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Robson M, 2014, J CLIN ONCOL, V32, P1987, DOI [10.1200/JCO.014.56.0474, 10.1200/JCO.2014.56.0474]; Stanislaw C, 2016, CANCER BIOL MED, V13, P55, DOI 10.28092/j.issn.2095-3941.2016.0002; Strom CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136419; Thompson ER, 2016, J CLIN ONCOL, V34, P1455, DOI 10.1200/JCO.2015.63.7454; Wallace AJ, 2016, EUR J HUM GENET, V24, pS10, DOI 10.1038/ejhg.2016.94; Yurgelun MB, 2015, J CLIN ONCOL, V33, P3092, DOI 10.1200/JCO.2015.60.8596	23	1	1	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JAN	2018	20	1					87	94		10.1016/j.jmoldx.2017.09.005			8	Pathology	Pathology	FR2DY	WOS:000418878400010	29061375	Bronze			2019-10-28	
J	Conroy, JM; Pabla, S; Glenn, ST; Burgher, B; Nesline, M; Papanicolau-Sengos, A; Andreas, J; Giamo, V; Lenzo, FL; Hyland, FCL; Omilian, A; Bshara, W; Qin, MC; He, J; Puzanov, I; Ernstoff, MS; Gardner, M; Galluzzi, L; Morrison, C				Conroy, Jeffrey M.; Pabla, Sarabjot; Glenn, Sean T.; Burgher, Blake; Nesline, Mary; Papanicolau-Sengos, Antonios; Andreas, Jonathan; Giamo, Vincent; Lenzo, Felicia L.; Hyland, Fiona C. L.; Omilian, Angela; Bshara, Wiam; Qin, Moachun; He, Ji; Puzanov, Igor; Ernstoff, Marc S.; Gardner, Mark; Galluzzi, Lorenzo; Morrison, Carl			Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							CANCER-THERAPY; CHEMOTHERAPY; INFILTRATE; QUALITY	We have developed a next-generation sequencing assay to quantify biomarkers of the host immune response in formalin-fixed, paraffin-embedded (FFPE) tumor specimens. This assay aims to provide clinicians with a comprehensive characterization of the immunologic tumor microenvironment as a guide for therapeutic decisions on patients with solid tumors. The assay relies on RNA-sequencing (seq) to semi-quantitatively measure the levels of 43 transcripts related to anticancer immune responses and 11 transcripts that reflect the relative abundance of tumor-infiltrating lymphocytes, as well as on DNA-seq to estimate mutational burden. The assay has a clinically relevant 5-day turnaround time and can be conducted on as little as 2.5 ng of RNA and 1.8 ng of genomic DNA extracted from three to five standard FFPE sections. The standardized next-generation sequencing workflow produced sequencing reads adequate for clinical testing of matched RNA and DNA from several samples in a single run. Assay performance for gene-specific sensitivity, Linearity, dynamic range, and detection threshold was estimated across a wide range of actual and artificial FFPE samples selected or generated to address preanalytical variability linked to specimen features (eg, tumor-infiltrating lymphocyte abundance, percentage of necrosis), and analytical variability linked to assay features (eg, batch size, run, day, operator). Analytical precision studies demonstrated that the assay is highly reproducible and accurate compared with established orthogonal approaches.	[Conroy, Jeffrey M.; Pabla, Sarabjot; Glenn, Sean T.; Burgher, Blake; Nesline, Mary; Papanicolau-Sengos, Antonios; Andreas, Jonathan; Giamo, Vincent; Lenzo, Felicia L.; Qin, Moachun; He, Ji; Gardner, Mark; Morrison, Carl] OmniSeq Inc, 700 Ellicott St, Buffalo, NY 14203 USA; [Conroy, Jeffrey M.; Morrison, Carl] Roswell Pk Canc Inst, Ctr Personalized Med, Buffalo, NY 14263 USA; [Glenn, Sean T.] Roswell Pk Canc Inst, Ctr Canc Genet & Genom, Buffalo, NY 14263 USA; [Omilian, Angela; Bshara, Wiam] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA; [Puzanov, Igor; Ernstoff, Marc S.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA; [Hyland, Fiona C. L.] Thermo Fisher Sci, Clin Next Generat Sequencing Div, San Francisco, CA USA; [Galluzzi, Lorenzo] Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY USA; [Galluzzi, Lorenzo] Sandra & Edward Meyer Canc Ctr, New York, NY USA; [Galluzzi, Lorenzo] Univ Paris Descartes Paris V, Paris, France	Morrison, C (reprint author), OmniSeq Inc, 700 Ellicott St, Buffalo, NY 14203 USA.	carl.morrison@omniseq.com		Pabla, Sarabjot/0000-0002-7746-9144	National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA16056]	We thank Elizabeth Brese and Monica Murphy (Roswell Park Cancer Institute) for shared resources (funded by National Cancer Institute P30CA16056) and technical expertise in procuring the formalin-fixed, paraffin-embedded samples used in this study.	Buque A, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008814; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Danilova L, 2016, P NATL ACAD SCI USA, V113, pE7769, DOI 10.1073/pnas.1607836113; Dobbin KK, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0179-0; Fucikova J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00402; Galluzzi L, 2017, TRENDS IMMUNOL, V38, P539, DOI 10.1016/j.it.2017.05.007; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Gargis AS, 2012, NAT BIOTECHNOL, V30, P1033, DOI 10.1038/nbt.2403; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Masucci GV, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0178-1; Ott PA, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0218-5; Paluch BE, 2017, ONCOTARGET, V8, P3197, DOI 10.18632/oncotarget.13691; Plebani M, 2014, CLIN CHEM LAB MED, V52, P951, DOI 10.1515/cclm-2014-0142; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Senovilla L, 2012, ONCOIMMUNOLOGY, V1, P1323, DOI 10.4161/onci.22009; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36	18	10	10	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JAN	2018	20	1					95	109		10.1016/j.jmoldx.2017.10.001			15	Pathology	Pathology	FR2DY	WOS:000418878400011	29061374	Bronze			2019-10-28	
J	Pellegrini, C; Di Nardo, L; Cipolloni, G; Martorelli, C; De Padova, M; Antonini, A; Maturo, MG; Del Regno, L; Strafella, S; Micantonio, T; Leocata, P; Peris, K; Fargnoli, MC				Pellegrini, Cristina; Di Nardo, Lucia; Cipolloni, Gianluca; Martorelli, Claudia; De Padova, Marina; Antonini, Ambra; Maturo, Maria Giovanna; Del Regno, Laura; Strafella, Sara; Micantonio, Tamara; Leocata, Pietro; Peris, Ketty; Fargnoli, Maria Concetta			Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype Findings from Molecular and Immunohistochemical Analysis	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							CUTANEOUS MELANOMA; CLINICOPATHOLOGICAL FEATURES; PRONE FAMILIES; RISK; VARIANTS; POPULATION; CDKN2A; GENE; METAANALYSIS; EXPRESSION	Data on somatic heterogeneity and germline-somatic interaction in multiple primary melanoma (MPM) patients are limited. We investigated the mutational status of BRAF, NRAS, and TERT promoter genes in 97 melanomas of 44 MPM patients and compared molecular and immunohistochemical findings. We further evaluated the association of somatic alterations with the germline MC1R genotype. Mutations in BRAF gene were identified in 41.2% (40/97) of melanomas, in NRAS in 2.1% (2/97), and in TERT promoter in 19.6% (19/97). Distribution of BRAF mutations did not differ across multiple melanomas (P = 0.85), whereas TERT promoter changes decreased from first to subsequent melanomas (P = 0.04). Intrapatient discrepancy of BRAF mutations among multiple tumors was detected in 14 of 44 MPM patients (32%) and of BRAF/NRAS/TERT promoter genes in 20 of 44 (45%). We observed a high rate of agreement between allele-specific TaqMan assay and immunohistochemistry in BRAF(V600E) detection (kappa = 0.83, P < 0.01) with 86 of 97 melanomas (88.7%) presenting similar BRAF status. Germline MC1R variants were identified in 81.4% (35/43) of MPM patients with no association of MC1R genotype with somatic mutations or with intrapatient concordance of somatic mutational profile. Our results support the genetic diversity of multiple melanomas and show that somatic heterogeneity is not influenced by inherited MC1R variants. Immunohistochemistry may be useful as an initial screening test.	[Pellegrini, Cristina; Di Nardo, Lucia; Martorelli, Claudia; Antonini, Ambra; Maturo, Maria Giovanna; Strafella, Sara; Micantonio, Tamara; Fargnoli, Maria Concetta] Univ Aquila, Dept Dermatol, Via Vetoio, I-67100 Laquila, Italy; [De Padova, Marina; Leocata, Pietro] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy; [De Padova, Marina; Leocata, Pietro] Univ Aquila, Dept Life Hlth & Environm Sci, Laquila, Italy; [Cipolloni, Gianluca] S Salvatore Hosp, Dept Pathol, Laquila, Italy; [Del Regno, Laura; Peris, Ketty] Catholic Univ, Inst Dermatol, Rome, Italy	Fargnoli, MC (reprint author), Univ Aquila, Dept Dermatol, Via Vetoio, I-67100 Laquila, Italy.	mariaconcetta.fargnoli@univaq.it	Di Nardo, Lucia/L-1384-2018	Di Nardo, Lucia/0000-0002-2087-7526	Italian Ministry of the University and Scientific Research (PRIN) [2012JJX494]	Supported by the Italian Ministry of the University and Scientific Research (PRIN) 2012 grant 2012JJX494.	Anwar MAF, 2016, J SURG RES, V203, P407, DOI 10.1016/j.jss.2016.04.029; Bradford PT, 2010, ARCH DERMATOL, V146, P265, DOI 10.1001/archdermatol.2010.2; Bruno W, 2017, ONCOTARGET, V8, P8069, DOI 10.18632/oncotarget.14094; Busam KJ, 2013, AM J SURG PATHOL, V37, P413, DOI 10.1097/PAS.0b013e318271249e; Chen YL, 2014, INT J SURG, V12, P659, DOI 10.1016/j.ijsu.2014.05.066; Colombino M, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-117; Colombino M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-202; Robles-Espinoza CD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12064; Edlundh-Rose E, 2006, MELANOMA RES, V16, P471, DOI 10.1097/01.cmr.0000232300.22032.86; Egberts F, 2016, J MOL DIAGN, V18, P75, DOI 10.1016/j.jmoldx.2015.07.010; Ellerhorst JA, 2011, CLIN CANCER RES, V17, P229, DOI 10.1158/1078-0432.CCR-10-2276; Fargnoli MC, 2008, J INVEST DERMATOL, V128, P2485, DOI 10.1038/jid.2008.67; Ferrone CR, 2005, JAMA-J AM MED ASSOC, V294, P1647, DOI 10.1001/jama.294.13.1647; Goldstein AM, 2005, CANCER EPIDEM BIOMAR, V14, P2208, DOI 10.1158/1055-9965.EPI-05-0321; Griewank KG, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju246; Hacker E, 2013, J INVEST DERMATOL, V133, P1027, DOI 10.1038/jid.2012.385; Hacker E, 2010, J INVEST DERMATOL, V130, P241, DOI 10.1038/jid.2009.182; Heidenreich B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4401; Heinzerling L, 2013, BRIT J CANCER, V108, P2164, DOI 10.1038/bjc.2013.143; Hoiom V, 2009, PIGM CELL MELANOMA R, V22, P196, DOI 10.1111/j.1755-148X.2008.00526.x; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Ihle MA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-13; Kakavand H, 2014, PATHOLOGY, V46, P193, DOI 10.1097/PAT.0000000000000077; Kanetsky PA, 2006, CANCER RES, V66, P9330, DOI 10.1158/0008-5472.CAN-06-1634; Kim SY, 2015, J AM ACAD DERMATOL, V72, P1036, DOI 10.1016/j.jaad.2015.02.1113; Landi MT, 2006, SCIENCE, V313, P521, DOI 10.1126/science.1127515; Landi MT, 2005, J NATL CANCER I, V97, P998, DOI 10.1093/jnci/dji176; Lee JH, 2011, BRIT J DERMATOL, V164, P776, DOI 10.1111/j.1365-2133.2010.10185.x; Lo JA, 2014, SCIENCE, V346, P945, DOI 10.1126/science.1253735; Massil D, 2015, MODERN PATHOL, V28, P487, DOI 10.1038/modpathol.2014.137; Murali R, 2012, ANN SURG ONCOL, V19, P1024, DOI 10.1245/s10434-011-2058-8; Nagore E, 2017, PIGM CELL MELANOMA R, V30, P273, DOI 10.1111/pcmr.12567; Nagore E, 2016, INT J CANCER, V139, P75, DOI 10.1002/ijc.30042; Nikolaou V, 2014, BRIT J DERMATOL, V170, P11, DOI [10.1111/bjd.12712, 10.1111/bjd.12492]; Ofner R, 2017, J CANCER RES CLIN, V143, P613, DOI 10.1007/s00432-016-2322-1; Pastorino L, 2008, PIGM CELL MELANOMA R, V21, P700, DOI 10.1111/j.1755-148X.2008.00512.x; Pellegrini C, 2017, MELANOMA RES, V27, P258, DOI 10.1097/CMR.0000000000000323; Peris K, 2004, J INVEST DERMATOL, V122, P1327, DOI 10.1111/j.0022-202X.2004.22532.x; Populo H, 2014, J INVEST DERMATOL, V134, P2251, DOI 10.1038/jid.2014.163; Puntervoll HE, 2013, J MED GENET, V50, P264, DOI 10.1136/jmedgenet-2012-101455; Roh MR, 2017, AM J CANCER RES, V7, P134; Savoia P, 2012, J EUR ACAD DERMATOL, V26, P882, DOI 10.1111/j.1468-3083.2011.04181.x; Scherer D, 2010, J INVEST DERMATOL, V130, P2844, DOI 10.1038/jid.2010.242; Siskind V, 2011, J INVEST DERMATOL, V131, P461, DOI 10.1038/jid.2010.298; Stratigos AJ, 2006, J INVEST DERMATOL, V126, P1842, DOI 10.1038/sj.jid.5700292; Taylor NJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119920; Tetzlaff MT, 2015, HUM PATHOL, V46, P1101, DOI 10.1016/j.humpath.2015.04.012; Thomas NE, 2015, JAMA ONCOL, V1, P359, DOI 10.1001/jamaoncol.2015.0493; Thomas NE, 2010, J INVEST DERMATOL, V130, P1463, DOI 10.1038/jid.2009.410; Tschandl P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069639; Uguen A, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0359-0; Wangari-Talbot Janet, 2013, Frontiers in Genetics, V3, DOI 10.3389/fgene.2012.00330; Yazdi AS, 2003, J INVEST DERMATOL, V121, P1160, DOI 10.1046/j.1523-1747.2003.12559.x; Youlden DR, 2014, JAMA DERMATOL, V150, P526, DOI 10.1001/jamadermatol.2013.9852	54	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JAN	2018	20	1					110	122		10.1016/j.jmoldx.2017.10.002			13	Pathology	Pathology	FR2DY	WOS:000418878400012	29061376	Bronze			2019-10-28	
J	Montgomery, ND; Selitsky, SR; Patel, NM; Hayes, DN; Parker, JS; Weck, KE				Montgomery, Nathan D.; Selitsky, Sara R.; Patel, Nirali M.; Hayes, D. Neil; Parker, Joel S.; Weck, Karen E.			Identification of Germline Variants in Tumor Genomic Sequencing Analysis	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Letter									[Montgomery, Nathan D.; Patel, Nirali M.; Weck, Karen E.] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Campus Box 7525, Chapel Hill, NC 27599 USA; [Montgomery, Nathan D.; Selitsky, Sara R.; Patel, Nirali M.; Hayes, D. Neil; Parker, Joel S.; Weck, Karen E.] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Campus Box 7525, Chapel Hill, NC 27599 USA	Weck, KE (reprint author), Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Campus Box 7525, Chapel Hill, NC 27599 USA.	kweck@unc.edu		Patel, Nirali/0000-0002-2683-4789	University Cancer Research Fund, Lineberger Comprehensive Cancer Center	Supported in part by the University Cancer Research Fund, Lineberger Comprehensive Cancer Center.	Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Li MM, 2017, J MOL DIAGN, V19, P4, DOI 10.1016/j.jmoldx.2016.10.002; Seifert BA, 2016, CLIN CANCER RES, V22, P4087, DOI 10.1158/1078-0432.CCR-16-0015; Trosman JR, 2015, J NATL COMPR CANC NE, V13, P311, DOI 10.6004/jnccn.2015.0043	4	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JAN	2018	20	1					123	125		10.1016/j.jmoldx.2017.09.008			3	Pathology	Pathology	FR2DY	WOS:000418878400013	29249243				2019-10-28	
J	Takata, K; Miyata-Takata, T; Sato, Y; Iwamuro, M; Okada, H; Tari, A; Yoshino, T				Takata, Katsuyoshi; Miyata-Takata, Tomoko; Sato, Yasuharu; Iwamuro, Masaya; Okada, Hiroyuki; Tari, Akira; Yoshino, Tadashi			Gastrointestinal follicular lymphoma: Current knowledge and future challenges	PATHOLOGY INTERNATIONAL			English	Review						duodenum; gastrointestinal follicular lymphoma; MALT lymphoma	B-CELL LYMPHOMA; NON-HODGKIN-LYMPHOMA; HELICOBACTER-PYLORI; IMMUNE-RESPONSES; SERUM; REGRESSION; RISK; ERADICATION; EXPRESSION; DUODENUM	The gastrointestinal (GI) tract is the most commonly involved site of extranodal follicular lymphoma (FL). GI-FL shows very indolent clinical behavior and localized at GI tract without any progression or transformation compared to nodal FL. The most frequently involved site of the GI tract was the duodenum followed by the jejunum and ileum, and only 15% of FL arising in the second part of the duodenum were localized there without scattered very small daughter lesions in other GI tract examined by double-balloon endoscopy. The typical macroscopic appearance of GI-FL was multiple white nodules. Microscopically, neoplastic cells were small- to medium-sized lymphoid cells and formed neoplastic follicles. Most of the cases (>95%) were histologically Grade 1 to 2 (low grade). Several pathological and molecular characteristics were seen in GI-FL (especially duodenal FL) compared with nodal FL: immunoglobulin heavy chain deviation to VH4 and VH5; memory B-cell immunophenotype; and molecular features shared by mucosa-associated lymphoid tissue lymphoma. Considering the pathological and molecular uniqueness of this disease, GI-FL should be separately managed from nodal FL.	[Takata, Katsuyoshi] British Columbia Canc Res Ctr, Dept Lymphoid Canc Res, 675W 10th Ave, Vancouver, BC V5Z 1L2, Canada; [Takata, Katsuyoshi; Miyata-Takata, Tomoko; Sato, Yasuharu; Yoshino, Tadashi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathol, Okayama, Japan; [Iwamuro, Masaya; Okada, Hiroyuki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Okayama, Japan; [Tari, Akira] Hiroshima Red Cross Hosp, Dept Internal Med, Hiroshima, Japan; [Tari, Akira] Atom Bomb Survivors Hosp, Hiroshima, Japan	Takata, K (reprint author), British Columbia Canc Res Ctr, Dept Lymphoid Canc Res, 675W 10th Ave, Vancouver, BC V5Z 1L2, Canada.; Takata, K (reprint author), Okayama Univ, Dept Pathol, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	katsuyoshi.t@h5.dion.ne.jp					Agace WW, 2006, NAT REV IMMUNOL, V6, P682, DOI 10.1038/nri1869; Cappione AJ, 2004, J IMMUNOL, V172, P4298, DOI 10.4049/jimmunol.172.7.4298; Charbonneau B, 2012, CYTOKINE, V60, P882, DOI 10.1016/j.cyto.2012.08.028; Conconi A, 2012, BRIT J HAEMATOL, V157, P188, DOI 10.1111/j.1365-2141.2012.09054.x; Cook DN, 2000, IMMUNITY, V12, P495, DOI 10.1016/S1074-7613(00)80201-0; Cui W, 2011, PATHOL INT, V61, P737, DOI 10.1111/j.1440-1827.2011.02736.x; DRAGOSICS B, 1985, CANCER, V55, P1060, DOI 10.1002/1097-0142(19850301)55:5<1060::AID-CNCR2820550523>3.0.CO;2-8; Edlefsen KL, 2014, INT J CANCER, V135, P913, DOI 10.1002/ijc.28724; Franco V, 2004, HISTOPATHOLOGY, V44, P381, DOI 10.1111/j.1365-2559.2004.01857.x; Green MR, 2015, P NATL ACAD SCI USA, V112, pE1116, DOI 10.1073/pnas.1501199112; Green MR, 2013, BLOOD, V121, P1604, DOI 10.1182/blood-2012-09-457283; Hangai S, 2013, ANN HEMATOL, V92, P993, DOI 10.1007/s00277-012-1654-4; Hayashi H, 2013, INTERNAL MED, V52, P2611, DOI 10.2169/internalmedicine.52.0552; Huckhagel T, 2013, VIRCHOWS ARCH, V463, P849, DOI 10.1007/s00428-013-1481-6; Iwamuro M, 2016, WORLD J GASTROENTERO, V22, P1674, DOI 10.3748/wjg.v22.i4.1674; Iwamuro M, 2015, INTERNAL MED, V54, P1741, DOI 10.2169/internalmedicine.54.4390; Iwamuro M, 2014, INTERNAL MED, V53, P1397, DOI 10.2169/internalmedicine.53.2433; Iwamuro M, 2014, CLIN BIOCHEM, V47, P191, DOI 10.1016/j.clinbiochem.2013.11.026; Kagami Y, 2001, LEUKEMIA, V15, P148, DOI 10.1038/sj.leu.2402002; Kodama M, 2008, ENDOSCOPY, V40, P343, DOI 10.1055/s-2007-995365; KRAJ P, 1995, J IMMUNOL, V154, P6406; LEBRUN DP, 1992, AM J PATHOL, V140, P1327; Mamessier E, 2014, HAEMATOLOGICA, V99, P481, DOI 10.3324/haematol.2013.094474; Mir MA, 2015, BLOOD, V125, P992, DOI 10.1182/blood-2014-06-583369; Misdraji J, 1997, AM J SURG PATHOL, V21, P484, DOI 10.1097/00000478-199704000-00016; Miyata-Takata T, 2015, SCI REP-UK, V5, DOI 10.1038/srep18434; Miyata-Takata T, 2014, PATHOL INT, V64, P527, DOI 10.1111/pin.12197; Montoto S, 2007, J CLIN ONCOL, V25, P2426, DOI 10.1200/JCO.2006.09.3260; Ohnishi N, 2016, CANCER SCI, V107, P1687, DOI 10.1111/cas.13031; Purdue MP, 2013, BLOOD, V122, P951, DOI 10.1182/blood-2013-01-481077; Sato Y, 2008, J CLIN PATHOL, V61, P377, DOI 10.1136/jcp.2007.049825; Schmatz AI, 2011, J CLIN ONCOL, V29, P1445, DOI 10.1200/JCO.2010.32.9193; Swerdlow SH, 2017, WHO CLASSIFICATION T, V2; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Takata K, 2014, CANCER SCI, V105, P608, DOI 10.1111/cas.12392; Takata K, 2013, MODERN PATHOL, V26, P22, DOI 10.1038/modpathol.2012.127; Takata K, 2011, CANCER SCI, V102, P1532, DOI 10.1111/j.1349-7006.2011.01980.x; Takata K, 2009, MODERN PATHOL, V22, P940, DOI 10.1038/modpathol.2009.51; Tamura M, 2011, PATHOL INT, V61, P742, DOI 10.1111/j.1440-1827.2011.02748.x; Tari A, 2016, SCAND J GASTROENTERO, V51, P321, DOI 10.3109/00365521.2015.1087589; Toyoda H, 2001, GASTROINTEST ENDOSC, V54, P92, DOI 10.1067/mge.2001.114963; van Vollenhoven RF, 1999, J RHEUMATOL, V26, P1727; Watanabe N, 2008, GASTROENTEROLOGY, V134, P642, DOI 10.1053/j.gastro.2007.12.007; Yaguchi T, 2010, DIGEST ENDOSC, V22, P316, DOI 10.1111/j.1443-1661.2010.01011.x; Yamamoto S, 2010, J GASTROENTEROL, V45, P370, DOI 10.1007/s00535-009-0182-z; Yoshino T, 2000, AM J SURG PATHOL, V24, P688, DOI 10.1097/00000478-200005000-00007	46	5	5	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JAN	2018	68	1					1	6		10.1111/pin.12621			6	Pathology	Pathology	FR5JQ	WOS:000419103200001	29292593				2019-10-28	
J	Sugita, S; Hirano, H; Hatanaka, Y; Fujita, H; Kubo, T; Kikuchi, N; Ito, Y; Sugawara, T; Segawa, K; Hisai, H; Yamashita, K; Nobuoka, T; Matsuno, Y; Hasegawa, T				Sugita, Shintaro; Hirano, Hiroshi; Hatanaka, Yutaka; Fujita, Hiromi; Kubo, Terufumi; Kikuchi, Noriaki; Ito, Yumika; Sugawara, Taro; Segawa, Keiko; Hisai, Hiroyuki; Yamashita, Kentaro; Nobuoka, Takayuki; Matsuno, Yoshihiro; Hasegawa, Tadashi			Image analysis is an excellent tool for quantifying Ki-67 to predict the prognosis of gastrointestinal stromal tumor patients	PATHOLOGY INTERNATIONAL			English	Article						gastrointestinal stromal tumor; image analysis; Ki-67; prognostic factor; quantitation	INDEX; MANAGEMENT; EXPRESSION; GIST; KI67	We investigated the quantification of Ki-67 staining using digital image analysis (IA) as a complementary prognostic factor to the modified National Institutes of Health (NIH) classification in patients with gastrointestinal stromal tumor (GIST). We examined 92 patients, focusing on the correlation between age, sex, primary tumor site, tumor size, predominant histologic type, mitotic index, modified NIH classification (low/intermediate vs high), Ki-67 quantitation, and recurrence-free survival (RFS). We compared two IA processes for whole slide imaging (WSI) and manually captured image (MCI) methods. A Ki-67 quantitation cutoff was determined by receiver operator characteristics curve analysis. In the survival analysis, the high-risk group of a modified NIH classification, a mitotic count >5 per 20 high-powered fields, and Ki-67 cutoffs of 6% and 8% obtained by IA of the WSI and MCI methods, respectively, had an adverse impact on RFS. On multivariate analysis, each Ki-67 quantitation method strongly predicted prognosis, more strongly than the modified NIH classification. In addition, Ki-67 quantitation using IA of the MCI method could stratify low or intermediate risk and high risk GIST patients. Thus, IA is an excellent tool for quantifying Ki-67 to predict the prognosis of GIST patients, and this semiautomated approach may be preferable for patient care.	[Sugita, Shintaro; Hirano, Hiroshi; Fujita, Hiromi; Kubo, Terufumi; Kikuchi, Noriaki; Ito, Yumika; Sugawara, Taro; Segawa, Keiko; Hasegawa, Tadashi] Sapporo Med Univ, Dept Surg Pathol, Sch Med, Sapporo, Hokkaido, Japan; [Hatanaka, Yutaka; Matsuno, Yoshihiro] Hokkaido Univ Hosp, Dept Surg Pathol, Sapporo, Hokkaido, Japan; [Hisai, Hiroyuki] Japanese Red Cross Date Gen Hosp, Dept Gastroenterol, Date, Hokkaido, Japan; [Yamashita, Kentaro] Sapporo Med Univ, Dept Gastroenterol Rheumatol & Clin Immunol, Sch Med, Sapporo, Hokkaido, Japan; [Nobuoka, Takayuki] Sapporo Med Univ, Dept Surg Oncol & Sci, Sch Med, Sapporo, Hokkaido, Japan	Hasegawa, T (reprint author), Sapporo Med Univ, Sch Med, Dept Surg Pathol, Chuo Ku, South 1 West 16, Sapporo, Hokkaido 0608543, Japan.	hasetada@sapmed.ac.jp					Neto RA, 2012, ACTA CIR BRAS, V27, P315, DOI 10.1590/S0102-86502012000500007; Carrillo R, 1997, HUM PATHOL, V28, P160, DOI 10.1016/S0046-8177(97)90100-3; Neves Lúcio Roberto de Oliveira das, 2009, Arq. Gastroenterol., V46, P116, DOI 10.1590/S0004-28032009000200008; Demetri GD, 2010, J NATL COMPR CANC NE, V8, pS1; Faria MHG, 2006, NEUROPATHOLOGY, V26, P519, DOI 10.1111/j.1440-1789.2006.00724.x; Farris AB, 2017, ARCH PATHOL LAB MED, V141, P542, DOI 10.5858/arpa.2016-0265-SA; Hasegawa T, 2007, PATHOL INT, V57, P121, DOI 10.1111/j.1440-1827.2006.02068.x; Joensuu H, 2008, HUM PATHOL, V39, P1411, DOI 10.1016/j.humpath.2008.06.025; Kemmerling R, 2014, ONCOL LETT, V7, P745, DOI 10.3892/ol.2014.1802; Nagasako Yoshihide, 2003, Gastric Cancer, V6, P168, DOI 10.1007/s10120-003-0246-3; Ogino J, 2013, PATHOL INT, V63, P102, DOI 10.1111/pin.12038; Patil DT, 2011, ARCH PATHOL LAB MED, V135, P1298, DOI 10.5858/arpa.2011-0022-RA; Yoshioka T, 2015, BREAST CANCER-TOKYO, V22, P185, DOI 10.1007/s12282-013-0474-2; Zhao WY, 2014, INT J CLIN EXP PATHO, V7, P2298	14	2	2	3	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JAN	2018	68	1					7	11		10.1111/pin.12611			5	Pathology	Pathology	FR5JQ	WOS:000419103200002	29131458				2019-10-28	
J	Owada, Y; Tamura, T; Tanoi, T; Ozawa, Y; Shimizu, Y; Hisakura, K; Matsuzaka, T; Shimano, H; Nakano, N; Sakashita, S; Matsukawa, T; Isoda, H; Ohkohchi, N				Owada, Yohei; Tamura, Takafumi; Tanoi, Tomohito; Ozawa, Yusuke; Shimizu, Yoshio; Hisakura, Katsuji; Matsuzaka, Takashi; Shimano, Hitoshi; Nakano, Noriyuki; Sakashita, Shingo; Matsukawa, Toshiya; Isoda, Hiroko; Ohkohchi, Nobuhiro			Novel non-alcoholic steatohepatitis model with histopathological and insulin-resistant features	PATHOLOGY INTERNATIONAL			English	Article						insulin resistance; Liver X receptor; mouse model; NAFLD activity score; non-alcoholic steatohepatitis	FATTY LIVER-DISEASE; NECROSIS-FACTOR-ALPHA; DIET-INDUCED OBESITY; ANIMAL-MODELS; CHRONIC EXPOSURE; RECEPTOR LEVELS; MICE; INTERLEUKIN-6; CELLS; NASH	Although several non-alcoholic steatohepatitis (NASH) models have been reported to date, few of these models fully reflect the histopathology and pathophysiology of human NASH. The aim of this study was to establish a novel NASH model by feeding a high-fat (HF) diet and administering both carbon tetrachloride (CCl4) and the Liver X receptor agonist T0901317. Male C57BL/6J mice were divided into four groups (each n=5): HF, HF+CCl4, HF+T0901317, and the novel NASH model (HF+CCl4+T0901317). CCl4 (0.1mL/kg) and T0901317 (2.5mg/kg) were intraperitoneally administered four times and five times, respectively. The livers of the novel NASH model group presented a whitish colour. The serum levels of TNF- and IL-6 were significantly increased in the novel NASH model group, and mice in this group exhibited histopathological features and insulin resistance reflective of NASH, i.e., macrovesicular hepatic steatosis, ballooning hepatocytes, Mallory-Denk bodies, lobular inflammation and fibrosis. The novel NASH model group presented significantly upregulated expression levels of mRNAs related to lipogenesis, oxidative stress, fibrosis and steatosis and significantly downregulated expression levels of mRNAs related to triglyceride export. We successfully established a novel experimental NASH model that exhibits similar histopathology and pathophysiology to human NASH.	[Owada, Yohei; Tamura, Takafumi; Tanoi, Tomohito; Ozawa, Yusuke; Shimizu, Yoshio; Hisakura, Katsuji; Ohkohchi, Nobuhiro] Univ Tsukuba, Dept Gastrointestinal & Hepatobiliary Pancreat Su, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan; [Matsuzaka, Takashi; Shimano, Hitoshi] Univ Tsukuba, Dept Endocrinol & Metab, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan; [Shimano, Hitoshi] Univ Tsukuba, Int Inst Integrat Sleep Med WPI IIIS, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan; [Shimano, Hitoshi] Japan Agcy Med Res & Dev AMED, AMED CREST, Chiyoda Ku, 1-7-1 Ohte Machi, Tokyo 1000004, Japan; [Nakano, Noriyuki; Sakashita, Shingo] Univ Tsukuba, Dept Diagnost Pathol, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan; [Matsukawa, Toshiya; Isoda, Hiroko] Univ Tsukuba, Grad Sch Environm Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058572, Japan	Ohkohchi, N (reprint author), Univ Tsukuba, Dept Gastrointestinal & Hepatobiliary Pancreat Su, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	nokochi3@md.tsukuba.ac.jp	Shimano, Hitoshi/V-1761-2019	Shimano, Hitoshi/0000-0002-5562-5572; Isoda, Hiroko/0000-0002-1399-9541	Ministry of Education, Culture, Sports, Science, and Technology of Japan, KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26861059, 16K10489]	This study is supported by the Ministry of Education, Culture, Sports, Science, and Technology of Japan, KAKENHI, No. 26861059 and No. 16K10489.	Abd El-Kader SM, 2015, WORLD J HEPATOL, V7, P846, DOI 10.4254/wjh.v7.i6.846; Abiru S, 2006, LIVER INT, V26, P39, DOI 10.1111/j.1478-3231.2005.01191.x; Bowe JE, 2014, J ENDOCRINOL, V222, pG13, DOI 10.1530/JOE-14-0182; Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chitturi S, 2004, J GASTROEN HEPATOL, V19, P368, DOI 10.1111/j.1440-1746.2003.03252.x; Chitturi S, 2002, HEPATOLOGY, V35, P373, DOI 10.1053/jhep.2002.30692; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; Deng QG, 2005, HEPATOLOGY, V42, P905, DOI 10.1002/hep.20877; Diehl AM, 2005, HEPATOL RES, V33, P138, DOI 10.1016/j.hepres.2005.09.022; Eguchi Y, 2012, J GASTROENTEROL, V47, P586, DOI 10.1007/s00535-012-0533-z; Gao MM, 2013, AAPS J, V15, P258, DOI 10.1208/s12248-012-9429-3; Guillen N, 2009, PHYSIOL GENOMICS, V37, P187, DOI 10.1152/physiolgenomics.90339.2008; Havel PJ, 2004, DIABETES, V53, pS143, DOI 10.2337/diabetes.53.2007.S143; Ip E, 2004, HEPATOLOGY, V39, P1286, DOI 10.1002/hep.20170; Ito M, 2007, HEPATOL RES, V37, P50, DOI 10.1111/j.1872-034X.2007.00008.x; Kanemaki T, 1998, HEPATOLOGY, V27, P1296, DOI 10.1002/hep.510270515; Kanno K, 2003, BIOCHEM BIOPH RES CO, V308, P177, DOI 10.1016/S0006-291X(03)01357-3; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Klover PJ, 2003, DIABETES, V52, P2784, DOI 10.2337/diabetes.52.11.2784; Larter CZ, 2008, J GASTROEN HEPATOL, V23, P1635, DOI 10.1111/j.1440-1746.2008.05543.x; Larter CZ, 2007, J GASTROEN HEPATOL, V22, P1353, DOI 10.1111/j.1440-1746.2007.05004.x; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161; Medici V, 2010, OBESITY, V18, P2268, DOI 10.1038/oby.2010.95; Muir K, 2013, CANCER RES, V73, P4722, DOI 10.1158/0008-5472.CAN-12-3797; Nakagawa H, 2015, WORLD J HEPATOL, V7, P2110, DOI 10.4254/wjh.v7.i17.2110; Nishikawa S, 2007, EXP ANIM TOKYO, V56, P263, DOI 10.1538/expanim.56.263; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391; Senn JJ, 2003, J BIOL CHEM, V278, P13740, DOI 10.1074/jbc.M210689200; Stojsavljevic S, 2014, WORLD J GASTROENTERO, V20, P18070, DOI 10.3748/wjg.v20.i48.18070; Takahashi Y, 2012, WORLD J GASTROENTERO, V18, P2300, DOI 10.3748/wjg.v18.i19.2300; Tanoi T, 2016, HEPATOL RES, V46, P697, DOI 10.1111/hepr.12607; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Tilg H, 2010, HEPATOLOGY, V52, P1836, DOI 10.1002/hep.24001; Tomita K, 2006, GUT, V55, P415, DOI 10.1136/gut.2005.071118; Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x; Wunderlich FT, 2010, CELL METAB, V12, P237, DOI 10.1016/j.cmet.2010.06.011	39	4	4	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JAN	2018	68	1					12	22		10.1111/pin.12612			11	Pathology	Pathology	FR5JQ	WOS:000419103200003	29154469	Green Published, Other Gold			2019-10-28	
J	Nagasaki, A; Ogawa, I; Sato, Y; Takeuchi, K; Kitagawa, M; Ando, T; Sakamoto, S; Shrestha, M; Uchisako, K; Koizumi, K; Toratani, S; Konishi, M; Takata, T				Nagasaki, Atsuhiro; Ogawa, Ikuko; Sato, Yukiko; Takeuchi, Kengo; Kitagawa, Masae; Ando, Toshinori; Sakamoto, Shinnichi; Shrestha, Madhu; Uchisako, Kaori; Koizumi, Koichi; Toratani, Shigeaki; Konishi, Masaru; Takata, Takashi			Central mucoepidermoid carcinoma arising from glandular odontogenic cyst confirmed by analysis of MAML2 rearrangement: A case report	PATHOLOGY INTERNATIONAL			English	Article						Central mucoepidermoid carcinoma; CRTC3-MAML2; Glandular odontogenic cyst	IN-SITU HYBRIDIZATION; FUSION TRANSCRIPT; CLINICOPATHOLOGICAL SIGNIFICANCE	Central mucoepidermoid carcinoma (MEC) poses a diagnostic challenge because of its rarity and histological overlap with glandular odontogenic cyst (GOC). In MEC of both salivary glands and jaws, MAML2 arrangement has been well known as the specific gene alteration. We report a case of central MEC arising from GOC diagnosed by MAML2 fusion gene. A 57-year-old male presented a multilocular cystic lesion in left molar region of the mandible. Histopathologically, multiple cysts lined by thin cuboidal or non-keratinized squamous epithelium with small duct-like structures, mucous cells and ciliated cells were present. It was diagnosed as GOC. The recurrent lesion after nine years showed the proliferation of many cystic and solid nests composed of epidermoid, mucous and intermediated cells. Nested PCR revealed CRTC3-MAML2 fusion gene in the recurrent lesion, but not in the primary one. Similarly, MAML-2 rearrangement by FISH analysis was positive in the recurrent lesion, while negative for the primary one, thus confirming the diagnosis of central MEC arising from GOC. Analysis of MAML2 rearrangement can be used as a supportive evidence to distinguish central MEC from GOC.	[Nagasaki, Atsuhiro; Ando, Toshinori; Sakamoto, Shinnichi; Shrestha, Madhu; Takata, Takashi] Hiroshima Univ, Dept Oral & Maxillofacial Pathobiol, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan; [Ogawa, Ikuko; Kitagawa, Masae] Hiroshima Univ Hosp, Ctr Oral Clin Examinat, Hiroshima, Japan; [Sato, Yukiko; Takeuchi, Kengo] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Pathol, Tokyo, Japan; [Takeuchi, Kengo] Canc Inst Hosp, Pathol Project Mol Targets, Japanese Fdn Canc Res, Tokyo, Japan; [Uchisako, Kaori; Koizumi, Koichi; Toratani, Shigeaki] Hiroshima Univ, Dept Mol Oral Med & Maxillofacial Surg, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan; [Konishi, Masaru] Hiroshima Univ, Dept Oral & Maxillofacial Radiol, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan	Takata, T (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Oral & Maxillofacial Pathobiol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	ttakata@hiroshima-u.ac.jp					Argyris PP, 2015, HISTOPATHOLOGY, V66, P791, DOI 10.1111/his.12526; Atarbashi Moghadam S, 2014, J Dent (Shiraz), V15, P86; Bell D, 2010, ANN DIAGN PATHOL, V14, P396, DOI 10.1016/j.anndiagpath.2010.05.009; Bulut E, 2016, J CRANIOFAC SURG, V27, pE150, DOI 10.1097/SCS.0000000000002396; EVERSOLE LR, 1975, CANCER-AM CANCER SOC, V35, P270, DOI 10.1002/1097-0142(197501)35:1<270::AID-CNCR2820350134>3.0.CO;2-Y; Fowler CB, 2011, HEAD NECK PATHOL, V5, P364, DOI 10.1007/s12105-011-0298-3; Fujimaki M, 2011, HUM PATHOL, V42, P2052, DOI 10.1016/j.humpath.2011.02.021; Garcia JJ, 2011, HUM PATHOL, V42, P2001, DOI 10.1016/j.humpath.2011.02.028; He Y, 2012, OR SURG OR MED OR PA, V114, P424, DOI 10.1016/j.oooo.2011.12.021; Khan HA, 2010, HEAD NECK PATHOL, V4, P261, DOI 10.1007/s12105-010-0191-5; Nakayama T, 2009, MODERN PATHOL, V22, P1575, DOI 10.1038/modpathol.2009.126; Noda H, 2013, CANCER SCI, V104, P85, DOI 10.1111/cas.12039; Okabe M, 2006, CLIN CANCER RES, V12, P3902, DOI 10.1158/1078-0432.CCR-05-2376; Okumura Y, 2011, HISTOPATHOLOGY, V59, P90, DOI 10.1111/j.1365-2559.2011.03890.x; Pires FR, 2004, ORAL ONCOL, V40, P545, DOI 10.1016/j.oraloncology.2003.11.007; Stenman G, 2014, ORAL ONCOL, V50, P683, DOI 10.1016/j.oraloncology.2014.04.008; Tajima S, 2017, MED MOL MORPHOL, V50, P117, DOI 10.1007/s00795-015-0120-5; Takeda Yasunori, 2005, J Oral Sci, V47, P77, DOI 10.2334/josnusd.47.77; Tilson MP, 2014, HEAD NECK PATHOL, V8, P59, DOI 10.1007/s12105-013-0475-7; Zhou CX, 2012, AM J SURG PATHOL, V36, P18, DOI 10.1097/PAS.0b013e31822be0df	20	1	1	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JAN	2018	68	1					31	35		10.1111/pin.12609			5	Pathology	Pathology	FR5JQ	WOS:000419103200005	29131467				2019-10-28	
J	Tajima, S; Maeda, I; Aida, Y; Kazama, A; Koizumi, H; Doi, M; Endo, A; Chosokabe, M; Kishimoto, K; Ono, T; Tsugawa, K; Takagi, M				Tajima, Shinya; Maeda, Ichiro; Aida, Yoshio; Kazama, Akio; Koizumi, Hirotaka; Doi, Masatomo; Endo, Akira; Chosokabe, Motohiro; Kishimoto, Keiko; Ono, Takafumi; Tsugawa, Koichiro; Takagi, Masayuki			Nuclear inverse polarity papillary lesions lacking myoepithelial cells: A report of two cases	PATHOLOGY INTERNATIONAL			English	Article						calponin; lack of myoepithelial cells; non-apocrine papillary lesion; nuclear inverse polarity; p63	BREAST-CANCER; BENIGN; TUMOR; CARCINOMAS; EXPRESSION	Here, cases of a 68- (Case 1) and a 44-year-old (Case 2) female are presented. They had an abnormality in the breast, and came to our hospital for further examination and treatment. Radiologically, malignancy could not completely excluded so breast excision was performed. Histologically, both cases revealed papillary neoplastic lesions lined by fibrovascular core and nuclear inverse polarity without atypia. Loss of myoepithelial cells was observed by HE, p63, and calponin. Previous report indicate CK5/6, ER, p63 and MUC3 are important for distinguishing between papillary lesions according to the differential index (based on Allred score) of ([ER total score]+[MUC3 total score])/([CK5/6 total score]+[p63 total score]+1). Based on this analysis, our two cases had benign lesions. However, based on immunopositivity for cell-cycle marker Cyclin-D1, Case 1 was negative, and Case 2 was about 70% positive. Additionally, the Ki-67 index was <1% in both cases, and no evidence of disease was observed after a maximum 62 months of follow-up in both cases, despite lack of additional treatment. Thus, we propose that lack of myoepithelial cells in papillary lesions do not necessarily indicate malignancy and are thought to be, at the most, uncertain malignant potential.	[Tajima, Shinya; Maeda, Ichiro; Aida, Yoshio; Kazama, Akio; Koizumi, Hirotaka; Doi, Masatomo; Endo, Akira; Chosokabe, Motohiro; Takagi, Masayuki] St Marianna Univ Sch Med, Dept Pathol, Kawasaki, Kanagawa, Japan; [Kishimoto, Keiko; Ono, Takafumi] St Marianna Univ Sch Med, Dept Radiol, Kawasaki, Kanagawa, Japan; [Tsugawa, Koichiro] St Marianna Univ Sch Med, Dept Breast & Endocrine Surg, Kawasaki, Kanagawa, Japan	Tajima, S (reprint author), St Marianna Univ Sch Med, Dept Pathol, Miyamae Ku, 2-16-1 Sugao, Kawasaki, Kanagawa 2168511, Japan.	stajima0829@gmail.com					Adriance MC, 2005, BREAST CANCER RES, V7, P190, DOI 10.1186/bcr1286; Ahlin C, 2007, HISTOPATHOLOGY, V51, P491, DOI 10.1111/j.1365-2559.2007.02798.x; Allred DC, 1998, MODERN PATHOL, V11, P155; Cserni G, 2008, HISTOPATHOLOGY, V52, P253, DOI 10.1111/j.1365-2559.2007.02902.x; de Azambuja E, 2007, BRIT J CANCER, V96, P1504, DOI 10.1038/sj.bjc.6603756; Foschini MP, 2017, AM J SURG PATHOL, V41, P887, DOI 10.1097/PAS.0000000000000853; Furuya C, 2012, PATHOL INT, V62, P381, DOI 10.1111/j.1440-1827.2012.02811.x; Grin A, 2009, AM J SURG PATHOL, V33, P1615, DOI 10.1097/PAS.0b013e3181aec446; Gudjonsson T, 2002, J CELL SCI, V115, P39; Hilson JB, 2010, AM J SURG PATHOL, V34, P896, DOI 10.1097/PAS.0b013e3181dd60d3; Lacroix-Triki M, 2003, VIRCHOWS ARCH, V442, P548, DOI 10.1007/s00428-003-0808-0; Loh SF, 2015, J CLIN PATHOL, V68, P187, DOI 10.1136/jclinpath-2014-202331; Man YG, 2003, BREAST CANCER RES, V5, pR231, DOI 10.1186/bcr653; Moriya T, 2009, PATHOLOGY, V41, P68, DOI 10.1080/00313020802563544; Pathmanathan N, 2010, MODERN PATHOL, V23, P1021, DOI 10.1038/modpathol.2010.81; Rakha EA, 2005, MODERN PATHOL, V18, P1295, DOI 10.1038/modpathol.3800445; Saddik M, 1999, ARCH PATHOL LAB MED, V123, P152; Seal M, 2009, VIRCHOWS ARCH, V455, P477, DOI 10.1007/s00428-009-0834-7; Tramm T, 2011, AM J SURG PATHOL, V35, P202, DOI 10.1097/PAS.0b013e31820598a2	19	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JAN	2018	68	1					36	40		10.1111/pin.12610			5	Pathology	Pathology	FR5JQ	WOS:000419103200006	29127687	Other Gold			2019-10-28	
J	Shimizu, A; Takahashi, T; Kushima, R; Sentani, K; Yasui, W; Matsuno, Y				Shimizu, Ai; Takahashi, Toshiyuki; Kushima, Ryoji; Sentani, Kazuhiro; Yasui, Wataru; Matsuno, Yoshihiro			An extremely rare case of Epstein-Barr virus-associated gastric carcinoma with differentiation to neuroendocrine carcinoma	PATHOLOGY INTERNATIONAL			English	Article						epstein-Barr virus-associated gastric carcinoma (EBVGC); mixed adenoneuroendocrine carcinoma (MANEC); neuroendocrine differentiation	LYMPHOID STROMA; CHROMOGRANIN-A; REG-IV; EXPRESSION; ADENOCARCINOMA; INFECTION; CANCER	Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVGC) is defined as a neoplasm comprising monoclonal proliferation of EBV-infected gastric epithelial cells. Although the typical histology is gastric carcinoma with lymphoid stroma (GCLS), the histologic features of the tumor vary. We report herein the case of a 78-year-old man with multiple simultaneous EBVGCs revealing different histopathologic morphologies; one was mixed adenoneuroendocrine carcinoma (MANEC), and the other was GCLS. Both tumor types exhibited positive results for EBV in situ hybridization. To the best of our knowledge, this represents the first report of EBVGC showing neuroendocrine differentiation. Immunohistochemistry also revealed a loss of gastrointestinal features, including CDX2, MUC5AC, and MUC6 expression, among tumor cells from the neuroendocrine component of the MANEC. We describe the pathologic features of this rare neoplasm and discuss the mechanisms underlying the neuroendocrine differentiation of EBVGC cells, along with providing a brief review of the literature.	[Shimizu, Ai; Takahashi, Toshiyuki] Hokkaido Gastroenterol Hosp, Dept Pathol, Sapporo, Hokkaido, Japan; [Shimizu, Ai; Matsuno, Yoshihiro] Hokkaido Univ Hosp, Dept Pathol, Sapporo, Hokkaido, Japan; [Kushima, Ryoji] Shiga Univ Med Sci, Div Diagnost Pathol, Dept Clin Lab Med, Otsu, Shiga, Japan; [Sentani, Kazuhiro; Yasui, Wataru] Hiroshima Univ, Dept Mol Pathol, Inst Biomed & Hlth Sci, Hiroshima, Japan	Takahashi, T (reprint author), Hokkaido Gastroenterol Hosp, Dept Pathol, Higashi Ku, Honcho 1-1-2-10, Sapporo, Hokkaido 0650041, Japan.	ricoh@hgh.or.jp					Barua RR, 2006, J GASTROENTEROL, V41, P733, DOI 10.1007/s00535-006-1841-y; Domori K, 2014, GASTRIC CANCER, V17, P263, DOI 10.1007/s10120-013-0281-7; Fukayama M, 2011, PATHOL RES PRACT, V207, P529, DOI 10.1016/j.prp.2011.07.004; Gurzu S, 2015, WORLD J GASTROENTERO, V21, P1329, DOI 10.3748/wjg.v21.i4.1329; Hirano N, 2007, HISTOL HISTOPATHOL, V22, P641, DOI 10.14670/HH-22.641; Kim L, 2012, PATHOL INT, V62, P351, DOI 10.1111/j.1440-1827.2012.02806.x; Lauwers G, 2010, WHO CLASSIFICATION T, P48; Matsuda I, 2015, INT J CLIN EXP PATHO, V8, P11766; Nishikawa J, 2014, CANCERS, V6, P2259, DOI 10.3390/cancers6042259; OOI A, 1988, CANCER, V62, P1096, DOI 10.1002/1097-0142(19880915)62:6<1096::AID-CNCR2820620612>3.0.CO;2-T; Oue N, 2005, J PATHOL, V207, P185, DOI 10.1002/path.1827; Qvigstad G, 2000, HISTOCHEM J, V32, P551, DOI 10.1023/A:1004102312006; Sentani K, 2010, PATHOL INT, V60, P291, DOI 10.1111/j.1440-1827.2010.02519.x; Shinozaki-Ushiku A, 2015, INT J ONCOL, V46, P1421, DOI 10.3892/ijo.2015.2856; Solcia E, 2010, WHO CLASSIFICATION T, P64; Speck O, 2015, APPL IMMUNOHISTO M M, V23, P633, DOI 10.1097/PAI.0000000000000122; Ushiku T, 2010, PATHOL INT, V60, P551, DOI 10.1111/j.1440-1827.2010.02557.x; WATANABE H, 1976, CANCER, V38, P232, DOI 10.1002/1097-0142(197607)38:1<232::AID-CNCR2820380135>3.0.CO;2-4	18	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JAN	2018	68	1					41	46		10.1111/pin.12613			6	Pathology	Pathology	FR5JQ	WOS:000419103200007	29244230				2019-10-28	
J	Sunagawa, K; Uchino, Y; Ishimoto, S; Nakamura, S; Honma, T; Nakanishi, Y; Hatta, Y; Miyazaki, Y; Sakurai, H; Hao, H; Sugitani, M				Sunagawa, Keishin; Uchino, Yoshihito; Ishimoto, Shinichirou; Nakamura, Shigeki; Honma, Taku; Nakanishi, Yoko; Hatta, Yoshihiro; Miyazaki, Yoshitsugu; Sakurai, Hiroyuki; Hao, Hiroyuki; Sugitani, Masahiko			Mycotic pseudoaneurysm of a pulmonary artery branch caused by Cladosporium	PATHOLOGY INTERNATIONAL			English	Article						Cladosporium sp; PCR; Pulmonary artery pseudoaneurysm	TISSUE; FUNGI; ANEURYSMS	We report the case of a 53-year-old male with a history of acute myelogenous leukemia, who suffered the rupturing of a right-sided pulmonary artery pseudoaneurysm combined with pneumonia. He underwent a right-sided lower lobectomy. The resected lung tissue demonstrated a mycotic pseudoaneurysm of a pulmonary artery branch together with a filamentous fungal infection. Pseudoaneurysms are caused by the breaching of all layers of a blood vessel wall. The extravasated blood is trapped by the surrounding extravascular tissue or clots. Cladosporium was detected during a polymerase chain reaction-based analysis followed by DNA sequencing of formalin-fixed paraffin-embedded lung tissue samples. Although previous cases of pulmonary artery pseudoaneurysms caused by fungal infections, e.g., Candida or Aspergillus sp., have been reported, to the best of our knowledge this is the first case to involve cladosporiosis.	[Sunagawa, Keishin] Showa Univ, Dept Pathol, Shinagawa Ku, Tokyo 1428555, Japan; [Sunagawa, Keishin; Honma, Taku; Nakanishi, Yoko; Hao, Hiroyuki; Sugitani, Masahiko] Nihon Univ, Dept Pathol, Sch Med, Itabashi Ku, Tokyo, Japan; [Sunagawa, Keishin] Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo, Japan; [Uchino, Yoshihito; Hatta, Yoshihiro] Nihon Univ, Dept Hematol & Rheumatol, Sch Med, Itabashi Ku, Tokyo, Japan; [Ishimoto, Shinichirou; Sakurai, Hiroyuki] Nihon Univ, Dept Resp Surg, Sch Med, Itabashi Ku, Tokyo, Japan; [Nakamura, Shigeki; Miyazaki, Yoshitsugu] Natl Inst Infect Dis, Dept Chemotherapy & Mycoses, Shinjuku Ku, Tokyo, Japan	Sunagawa, K (reprint author), Showa Univ, Dept Pathol, Shinagawa Ku, Tokyo 1428555, Japan.	sunagawa.keishin@gmail.com					Ahmad RAR, 2014, J THORAC CARDIOV SUR, V148, pE221, DOI 10.1016/j.jtcvs.2014.06.084; AJELLO L, 1986, European Journal of Epidemiology, V2, P243, DOI 10.1007/BF00419488; Al-Doory Y., 1984, MOULD ALLERGY; BARENFANGER J, 1989, CHEST, V95, P1158, DOI 10.1378/chest.95.5.1158; BARTTER T, 1988, CHEST, V94, P1065, DOI 10.1378/chest.94.5.1065; CHUNG CW, 1995, CHEST, V108, P1164, DOI 10.1378/chest.108.4.1164; Crous PW, 2007, STUD MYCOL, P33, DOI 10.3114/sim.2007.58.02; Francis W., 1997, PHAEOHYPHMYCOSIS IN; Jang JH, 2012, ANN LAB MED, V32, P126, DOI 10.3343/alm.2012.32.2.126; Kantarcioglu AS, 2002, MYCOSES, V45, P500, DOI 10.1046/j.1439-0507.2002.00811.x; Kerry OD, 1993, P INT S NEWP OR CAB; Kimura M, 1998, ARCH PATHOL LAB MED, V122, P1107; Kocovski L, 2014, CARDIOVASC PATHOL, V23, P50, DOI 10.1016/j.carpath.2013.07.003; Lau A, 2007, J CLIN MICROBIOL, V45, P380, DOI 10.1128/JCM.01862-06; Revankar SG, 2007, MYCOSES, V50, P91, DOI 10.1111/j.1439-0507.2006.01331.x; Revankar SG, 2010, CLIN MICROBIOL REV, V23, P884, DOI 10.1128/CMR.00019-10; Rinaldi MG, 1996, DERMATOL CLIN, V14, P147, DOI 10.1016/S0733-8635(05)70335-1; Sandoval-Denis M, 2016, PERSOONIA, V36, P281, DOI 10.3767/003158516X691951; Sundaram C, 2014, INDIAN J PATHOL MICR, V57, P217, DOI 10.4103/0377-4929.134666; White T. J., 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1	20	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JAN	2018	68	1					47	52		10.1111/pin.12615			6	Pathology	Pathology	FR5JQ	WOS:000419103200008	29193597				2019-10-28	
J	Kumagai, M; Yamada, S; Kurose, N; Nakada, S; Aikawa, A; Futatsuya, C; Mizutani, K; Shioya, A; Minato, H				Kumagai, Motona; Yamada, Sohsuke; Kurose, Nozomu; Nakada, Satoko; Aikawa, Akane; Futatsuya, Chizuru; Mizutani, Ken-ichi; Shioya, Akihiro; Minato, Hiroshi			Benign mesothelial nodules reflux within acquired cutaneous lymphangiectasia associated with huge ovarian clear cell carcinoma	PATHOLOGY INTERNATIONAL			English	Letter									[Kumagai, Motona; Yamada, Sohsuke; Kurose, Nozomu; Nakada, Satoko; Aikawa, Akane; Futatsuya, Chizuru; Mizutani, Ken-ichi; Shioya, Akihiro; Minato, Hiroshi] Kanazawa Med Univ, Dept Pathol & Lab Med, Kanazawa, Ishikawa, Japan; [Yamada, Sohsuke; Kurose, Nozomu; Nakada, Satoko; Aikawa, Akane] Kanazawa Med Univ Hosp, Dept Pathol, Kanazawa, Ishikawa, Japan; [Minato, Hiroshi] Ishikawa Prefectural Cent Hosp, Dept Diagnost Pathol, Kanazawa, Ishikawa, Japan	Kumagai, M (reprint author), Kanazawa Med Univ, Dept Pathol & Lab Med, Kanazawa, Ishikawa, Japan.			/0000-0001-5709-1968			Agaimy A, 2011, AM J SURG PATHOL, V35, P152, DOI 10.1097/PAS.0b013e31820273f5; BROOKS JSJ, 1990, AM J CLIN PATHOL, V93, P741, DOI 10.1093/ajcp/93.6.741; Hwang HC, 2016, AM J SURG PATHOL, V40, P120, DOI 10.1097/PAS.0000000000000529; Tomasini C, 2008, AM J DERMATOPATH, V30, P140, DOI 10.1097/DAD.0b013e31816373ad; Vilela DS, 1998, HISTOPATHOLOGY, V33, P570	5	1	1	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JAN	2018	68	1					53	55		10.1111/pin.12619			3	Pathology	Pathology	FR5JQ	WOS:000419103200009	29222819				2019-10-28	
J	Tahara, S; Takeyari, M; Morii, E				Tahara, Shinichiro; Takeyari, Misa; Morii, Eiichi			Usefulness of cytological analysis in the diagnosis of pancreatic undifferentiated rhabdoid carcinoma	PATHOLOGY INTERNATIONAL			English	Letter									[Tahara, Shinichiro; Takeyari, Misa; Morii, Eiichi] Osaka Univ, Dept Pathol, Grad Sch Med, Yamada Oka 2-2, Suita, Osaka 5650871, Japan	Tahara, S (reprint author), Osaka Univ, Dept Pathol, Grad Sch Med, Yamada Oka 2-2, Suita, Osaka 5650871, Japan.				Project MEET, Osaka University Graduate School of Medicine; Ministry of Education, Culture, Sports, Science and Technology, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [T17K195550]	This work was supported by Project MEET, Osaka University Graduate School of Medicine, and grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan (T17K195550).	Agaimy A, 2015, MODERN PATHOL, V28, P248, DOI 10.1038/modpathol.2014.100; Asoda S, 2009, J JPN SOC ORAL TUMOR, V21, P255; Disibio G, 2008, ARCH PATHOL LAB MED, V132, P931, DOI 10.1043/1543-2165(2008)132[931:MPOCRF]2.0.CO;2; Fukushima N, 2010, WHO CLASSIFICATION T, P292; Nishii T, 2012, J JPN PANC SOC, V27, P54	5	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JAN	2018	68	1					56	58		10.1111/pin.12616			3	Pathology	Pathology	FR5JQ	WOS:000419103200010	29235210				2019-10-28	
J	de Boer, WB; Ee, H; Kumarasinghe, MP				de Boer, Willem B.; Ee, Hooi; Kumarasinghe, Marian P.			Neoplastic Lesions of Gastric Adenocarcinoma and Proximal Polyposis Syndrome (GAPPS) Are Gastric Phenotype	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						polyposis; gastric; hereditary; gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)	FAMILIAL ADENOMATOUS POLYPOSIS; PROMOTER 1B; DYSPLASIA; APC; CLASSIFICATION; STOMACH; CANCER	Neoplastic lesions of gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) are gastric phenotype. GAPPS was reported in 2011 as a new autosomal dominant gastric polyposis syndrome characterized by involvement of the gastric body/fundus with sparing of the antrum by multiple polyps, reported to be primarily fundic gland polyps (FGPs), with progression to dysplasia and adenocarcinoma of intestinal type. Our series consists of 51 endoscopic biopsies and 5 gastrectomy specimens from 25 patients belonging to a previously defined GAPPS family. Slides were reviewed and further stains performed. Endoscopy was abnormal in 15 of the 25 patients: carpeting polyposis of the gastric body and fundus in 14 and a gastric mass without polyposis in one. The most common polypoid lesion (seen in 12 patients) was a disorganized proliferation of specialized/oxyntic glands high up in the mucosa involving the attenuated foveolar region around the gastric pits, which we have termed "hyperproliferative aberrant pits". Well developed FGP were seen in 10 patients. Established neoplastic lesions seen in 9 patients were: (1) discrete gastric adenomas, (2) multifocal "flat" dysplasia in the setting of hyperproliferative aberrant pits +/- FGPs, (3) adenomatous tissue associated with adenocarcinoma. All cases of dysplasia were of gastric phenotype based on morphology and mucin immunohistochemistry. In conclusion: (1) the spectrum of gastric pathology associated with GAPPS is wider than previously reported, (2) the earliest microscopic clue is the finding of hyperproliferative aberrant pits, and (3) the dysplasia is gastric phenotype and the subsequent adenocarcinoma may follow the gastric pathway of carcinogenesis.	[de Boer, Willem B.; Kumarasinghe, Marian P.] QE 2 Med Ctr, PathWest Lab Med, Perth, WA, Australia; [de Boer, Willem B.; Kumarasinghe, Marian P.] Univ Western Australia, Perth, WA, Australia; [Ee, Hooi] Sir Charles Gairdner Hosp, Dept Gastroenterol, Perth, WA, Australia	de Boer, WB (reprint author), QE II Med Ctr, Dept Anat Pathol, PathWest, Hosp Ave, Perth, WA 6009, Australia.	bastiaan.deboer@health.wa.gov.au					Abraham SC, 2002, AM J SURG PATHOL, V26, P1276, DOI 10.1097/01.PAS.0000024542.83286.45; Arnason T, 2014, HISTOPATHOLOGY, V65, P353, DOI 10.1111/his.12393; Brown IS, 2010, MODERN PATHOL, V23, P834, DOI 10.1038/modpathol.2010.59; Carneiro F, 2012, PATHOLOGE, V33, P231, DOI 10.1007/s00292-012-1677-6; Lagarde A, 2010, J MED GENET, V47, P721, DOI 10.1136/jmg.2010.078964; Li J, 2016, AM J HUM GENET, V98, P830, DOI 10.1016/j.ajhg.2016.03.001; Park DY, 2008, AM J SURG PATHOL, V32, P524, DOI 10.1097/PAS.0b013e31815b890e; Pavicic W, 2014, GENE CHROMOSOME CANC, V53, P857, DOI 10.1002/gcc.22197; RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0; Rohlin A, 2011, ONCOGENE, V30, P4977, DOI 10.1038/onc.2011.201; Rugge M, 2000, AM J SURG PATHOL, V24, P167, DOI 10.1097/00000478-200002000-00001; Snow AK, 2015, CLIN GENET, V88, P360, DOI 10.1111/cge.12503; Valente P, 2015, GASTRIC CANCER, V18, P720, DOI 10.1007/s10120-014-0416-5; Worthley DL, 2012, GUT, V61, P774, DOI 10.1136/gutjnl-2011-300348; Yanaru-Fujisawa R, 2012, GUT, V61, P1103, DOI 10.1136/gutjnl-2011-301384	15	2	2	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					1	8		10.1097/PAS.0000000000000924			8	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200002	29112017				2019-10-28	
J	Kossai, M; El Zein, S; Wassef, M; Guichard, JP; Pouliquen, C; Herman, P; Verillaud, B; Classe, M				Kossai, Myriam; El Zein, Sophie; Wassef, Michel; Guichard, Jean-Pierre; Pouliquen, Christelle; Herman, Philippe; Verillaud, Benjamin; Classe, Marion			Olfactory Epithelial Hamartoma A New Subtype of Sinonasal Hamartoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						sinonasal hamartoma; olfactory epithelium; olfactory epithelial hamartoma; olfactory receptor cells; olfactory cleft	ADENOMATOID HAMARTOMAS; SEROMUCINOUS HAMARTOMA; MYOEPITHELIAL CELLS; NASAL POLYPOSIS; THE-LITERATURE; NASOPHARYNX; CLEFTS; TRACT; NOSE; IMMUNOHISTOPATHOLOGY	Sinonasal epithelial hamartomas occurring in adults are classified as seromucinous hamartoma (SMH) or respiratory epithelial adenomatoid hamartoma (REAH). We describe herein a novel subtype of adult sinonasal hamartoma that contains olfactory epithelium, a histologic feature not previously reported in the literature. Our pathology department database was retrospectively searched for sinonasal hamartomas containing areas of olfactory epithelium. Six relevant cases (3 male and 3 female patients; age, 30 to 77 y) were retrieved, and available pathology slides and clinical and imaging data from patient charts were reviewed. Five of the lesions were unilateral solitary, polypoid, pedunculated masses, 38 to 80 mm in length, lodged in the nasal olfactory cleft. The sixth lesion was associated with bilateral nasal polyposis, and its precise localization was not known. All patients were treated by transnasal endoscopic surgery. None of the 3 patients who had received adequate follow-up evaluation exhibited recurrence. Histologically, all lesions resembled SMH or REAH, with areas of olfactory epithelium comprising olfactory receptors and sustentacular and basal cells. Olfactory epithelium was observed at the lesion surface or in invaginated gland-like structures, and it contained focal aggregates of filamentous cell processes. Some olfactory receptor cells or cell processes were also present in the seromucinous gland component of lesions. Olfactory receptor cells expressed CD56 (neural cell adhesion molecule), and the filamentous aggregates contained CD56, neurofilaments, and synaptophysin. Aside from SMH and REAH, we have described a third subtype of adult sinonasal hamartoma-olfactory epithelial hamartoma-which shares the benign character of the other 2.	[Kossai, Myriam; El Zein, Sophie; Wassef, Michel; Classe, Marion] Lariboisiere Hosp, AP HP, Dept Pathol, Paris, France; [Guichard, Jean-Pierre] Lariboisiere Hosp, AP HP, Dept Neuroradiol, Paris, France; [Herman, Philippe; Verillaud, Benjamin] Lariboisiere Hosp, AP HP, Dept Otolaryngol Head & Neck Surg, Paris, France; [Kossai, Myriam; El Zein, Sophie; Wassef, Michel; Classe, Marion] Paris Diderot Univ, Fac Med, Paris, France; [Pouliquen, Christelle] Tenon Hosp, AP HP, Dept Pathol, Paris, France	Wassef, M (reprint author), Lariboisiere Hosp, Dept Pathol, 2 Rue Ambroise Pare, F-75475 Paris 10, France.	michel.wassef@aphp.fr					Al Hawat A, 2015, EUR ARCH OTO-RHINO-L, V272, P2867, DOI 10.1007/s00405-014-3401-z; Ambrosini-Spaltro A, 2010, VIRCHOWS ARCH, V457, P727, DOI 10.1007/s00428-010-0984-7; BAILLIE EE, 1974, ORAL SURG ORAL MED O, V38, P760, DOI 10.1016/0030-4220(74)90397-1; BOON LM, 1994, HUM MOL GENET, V3, P1583, DOI 10.1093/hmg/3.9.1583; Chuang SS, 2000, HISTOPATHOLOGY, V36, P376; Nguyen DT, 2014, AM J RHINOL ALLERGY, V28, pE187, DOI 10.2500/ajra.2014.28.4085; Eerola I, 2003, AM J HUM GENET, V73, P1240, DOI 10.1086/379793; Figures MR, 2010, OTOLARYNG HEAD NECK, V143, P165, DOI 10.1016/j.otohns.2009.11.014; Flavin R, 2005, INT J PEDIATR OTORHI, V69, P87, DOI 10.1016/j.ijporl.2004.07.010; Fleming KE, 2012, HEAD NECK PATHOL, V6, P395, DOI 10.1007/s12105-012-0339-6; Gauchotte G, 2013, AM J SURG PATHOL, V37, P1678, DOI 10.1097/PAS.0000000000000092; GRAEMECOOK F, 1992, HEAD NECK-J SCI SPEC, V14, P321, DOI 10.1002/hed.2880140413; Holbrook EH, 2011, LARYNGOSCOPE, V121, P1687, DOI 10.1002/lary.21856; Hua X, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-70; Huang CC, 2015, HEAD NECK-J SCI SPEC, V37, pE15, DOI 10.1002/hed.23748; Kazmierczak B, 1996, ONCOGENE, V12, P515; Khan RA, 2011, HEAD NECK PATHOL, V5, P241, DOI 10.1007/s12105-011-0269-8; Lee JT, 2013, AM J RHINOL ALLERGY, V27, P322, DOI 10.2500/ajra.2013.27.3905; Lima NB, 2006, RHINOLOGY, V44, P264; Lorentz C, 2012, EUR ARCH OTO-RHINO-L, V269, P847, DOI 10.1007/s00405-011-1713-9; McDermott MB, 1998, AM J SURG PATHOL, V22, P425, DOI 10.1097/00000478-199804000-00006; Muhlmeier G, 2014, HNO, V62, P813, DOI 10.1007/s00106-014-2914-5; NAKASHIMA T, 1991, EUR ARCH OTO-RHINO-L, V248, P370; NAKASHIMA T, 1985, LARYNGOSCOPE, V95, P391; Nguyen DT, 2014, LARYNGOSCOPE, V124, P2461, DOI 10.1002/lary.24778; Ozolek JA, 2006, AM J SURG PATHOL, V30, P1576, DOI 10.1097/01.pas.0000213344.55605.77; Patel RM, 2014, CLIN ANAT, V27, P54, DOI 10.1002/ca.22338; Roffman E, 2006, AM J RHINOL, V20, P586, DOI 10.2500/ajr.2006.20.2947; Seol JG, 2010, AM J NEURORADIOL, V31, P277, DOI 10.3174/ajnr.A1755; Stewart DR, 2014, HUM GENET, V133, P1443, DOI 10.1007/s00439-014-1474-9; Stricker TP, 2010, ROBBINS COTRAN PATHO, P259; Vira D, 2011, LARYNGOSCOPE, V121, P2706, DOI 10.1002/lary.22399; Weinreb I, 2010, HEAD NECK PATHOL, V4, P77, DOI 10.1007/s12105-009-0159-5; Weinreb I, 2009, HISTOPATHOLOGY, V54, P205, DOI 10.1111/j.1365-2559.2008.03198.x; WENIG BM, 1995, ANN OTO RHINOL LARYN, V104, P639, DOI 10.1177/000348949510400809; Wigglesworth JS, 1992, OXFORD TXB PATHOLOGY, P790; Young B., 2006, WHEATERS FUNCTIONAL; ZARBO RJ, 1983, LARYNGOSCOPE, V93, P494	38	4	4	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					9	17		10.1097/PAS.0000000000000967			9	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200003	29076871				2019-10-28	
J	El Hallani, S; Udager, AM; Bell, D; Fonseca, I; Thompson, LDR; Assaad, A; Agaimy, A; Luvison, AM; Miller, C; Seethala, RR; Chiosea, S				El Hallani, Soufiane; Udager, Aaron M.; Bell, Diana; Fonseca, Isabel; Thompson, Lester D. R.; Assaad, Adel; Agaimy, Abbas; Luvison, Alyssa M.; Miller, Caitlyn; Seethala, Raja R.; Chiosea, Simion			Epithelial-Myoepithelial Carcinoma Frequent Morphologic and Molecular Evidence of Preexisting Pleomorphic Adenoma, Common HRAS Mutations in PLAG1-intact and HMGA2-intact Cases, and Occasional TP53, FBXW7, and SMARCB1 Alterations in High-grade Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						epithelial-myoepithelial carcinoma; carcinoma ex pleomorphic adenoma; PLAG1; HMGA2	SALIVARY DUCT CARCINOMA; PHOSPHOINOSITIDE 3-KINASE P110-ALPHA; HMGA2 REARRANGEMENTS; CELL CARCINOMA; GLAND TUMORS; MUTATIONS; RAS; FUSION; PLAG1; TUMORIGENESIS	We hypothesized that there is a relationship between the preexisting pleomorphic adenoma [PA]), histologic grade of epithelial-myoepithelial carcinomas (EMCAs), and genetic alterations. EMCAs (n=39) were analyzed for morphologic and molecular evidence of preexisting PA (PLAG1, HMGA2 status by fluorescence in situ hybridization, FISH, and FGFR1-PLAG1 fusion by next-generation sequencing, NGS). Twenty-three EMCAs were further analyzed by NGS for mutations and copy number variation in 50 cancer-related genes. On the basis of combined morphologic and molecular evidence of PA, the following subsets of EMCA emerged: (a) EMCAs with morphologic evidence of preexisting PA, but intact PLAG1 and HMGA2 (12/39, 31%), (b) Carcinomas with PLAG1 alterations (9/39, 23%), or (c) HMGA2 alterations (10/39, 26%), and (d) de novo carcinomas, without morphologic or molecular evidence of PA (8/39, 21%). Twelve high-grade EMCAs (12/39, 31%) occurred across all subsets. The median disease-free survival was 80 months (95% confidence interval, 77-84mo). Disease-free survival and other clinicopathologic parameters did not differ by the above defined subsets. HRAS mutations were more common in EMCAs with intact PLAG1 and HMGA2 (7/9 vs. 1/14, P<0.001). Other genetic abnormalities (TP53 [n=2], FBXW7 [n=1], SMARCB1 deletion [n=1]) were seen only in high-grade EMCAs with intact PLAG1 and HMGA2. We conclude that most EMCAs arose ex PA (31/39, 80%) and the genetic profile of EMCA varies with the absence or presence of preexisting PA and its cytogenetic signature. Progression to higher grade EMCA with intact PLAG1 and HMGA2 correlates with the presence of TP53, FBXW7 mutations, or SMARCB1 deletion.	[El Hallani, Soufiane; Luvison, Alyssa M.; Miller, Caitlyn; Seethala, Raja R.; Chiosea, Simion] Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA USA; [Udager, Aaron M.] Michigan Med, Dept Pathol, Ann Arbor, MI USA; [Bell, Diana] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Fonseca, Isabel] Univ Lisbon, Fac Med, Pathol Anat Inst, Lisbon, Portugal; [Fonseca, Isabel] Inst Portugues Oncol Francisco Gentil, Serv Anat Patol, Lisbon, Portugal; [Thompson, Lester D. R.] Southern Calif Permanente Med Grp, Dept Pathol, Woodland Hills, CA USA; [Assaad, Adel] Virginia Mason Hosp, Dept Pathol, Seattle, WA USA; [Agaimy, Abbas] Univ Hosp, Inst Pathol, Erlangen, Germany	Chiosea, S (reprint author), Presbyterian Univ Hosp, A610-2,200 Lothrop St, Pittsburgh, PA 15213 USA.	chioseasi@upmc.edu	Thompson, Lester D. R./J-8404-2016; Fonseca, Isabel/A-7396-2008	Thompson, Lester D. R./0000-0003-3714-1432; Fonseca, Isabel/0000-0002-1359-6494; Chiosea, Simion/0000-0002-5766-8779	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA047904, P50 CA097190]		Agaimy A, 2014, ADV ANAT PATHOL, V21, P394, DOI 10.1097/PAP.0000000000000038; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Alos L, 1999, VIRCHOWS ARCH, V434, P291, DOI 10.1007/s004280050344; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Augello C, 2006, J CELL PHYSIOL, V207, P654, DOI 10.1002/jcp.20601; Bahrami A, 2013, HISTOPATHOLOGY, V63, P250, DOI 10.1111/his.12152; Bahrami A, 2012, HEAD NECK PATHOL, V6, P328, DOI 10.1007/s12105-012-0353-8; Barasch N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171265; Beadling C, 2016, J MOL DIAGN, V18, P165, DOI 10.1016/j.jmoldx.2015.10.002; Brock EJ, 2016, MINI-REV MED CHEM, V16, P358, DOI 10.2174/1389557515666151001154002; BULLERDIEK J, 1993, CANCER GENET CYTOGEN, V65, P27, DOI 10.1016/0165-4608(93)90054-P; Burke JE, 2012, P NATL ACAD SCI USA, V109, P15259, DOI 10.1073/pnas.1205508109; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; Chetty R, 2000, HISTOPATHOLOGY, V37, P260, DOI 10.1046/j.1365-2559.2000.00976.x; Chiosea SI, 2016, CANCER-AM CANCER SOC, V122, P3136, DOI 10.1002/cncr.30179; Chiosea SI, 2014, HEAD NECK PATHOL, V8, P146, DOI 10.1007/s12105-013-0506-4; CORIO RL, 1982, ORAL SURG ORAL MED O, V53, P280, DOI 10.1016/0030-4220(82)90304-8; Cros J, 2013, ANN ONCOL, V24, P2624, DOI 10.1093/annonc/mdt338; Daa T, 2001, APMIS, V109, P316, DOI 10.1034/j.1600-0463.2001.d01-126.x; DONATH K, 1972, VIRCHOWS ARCH A, V356, P16, DOI 10.1007/BF00543554; Edge DRB SB, 2009, AJCC CANC STAGING HD; FONSECA I, 1993, VIRCHOWS ARCH A, V422, P389, DOI 10.1007/BF01605458; Grasso C, 2015, J MOL DIAGN, V17, P53, DOI 10.1016/j.jmoldx.2014.09.008; Griffith CC, 2014, HISTOPATHOLOGY, V65, P854, DOI 10.1111/his.12454; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Katabi N, 2015, HUM PATHOL, V46, P26, DOI 10.1016/j.humpath.2014.08.017; Liu XM, 2011, HUM MUTAT, V32, P894, DOI 10.1002/humu.21517; NIELSEN LL, 1991, CANCER RES, V51, P3762; Rettig EM, 2016, CANCER PREV RES, V9, P265, DOI 10.1158/1940-6207.CAPR-15-0316; Roy P, 2010, AM J SURG PATHOL, V34, P1258, DOI 10.1097/PAS.0b013e3181e366d2; Roy S, 2014, J MOL DIAGN, V16, P11, DOI 10.1016/j.jmoldx.2013.08.005; Seethala RR, 2007, AM J SURG PATHOL, V31, P44, DOI 10.1097/01.pas.0000213314.74423.d8; Seethala RR, 2009, ARCH PATHOL LAB MED, V133, P950, DOI 10.1043/1543-2165-133.6.950; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Stenman G, 2013, HEAD NECK PATHOL, V7, pS12, DOI 10.1007/s12105-013-0462-z; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Weinreb I, 2014, GENE CHROMOSOME CANC, V53, P845, DOI 10.1002/gcc.22195; Williams L, 2015, AM J SURG PATHOL, V39, P705, DOI 10.1097/PAS.0000000000000413; Xu WS, 2016, SEMIN CANCER BIOL, V36, P62, DOI 10.1016/j.semcancer.2015.09.005	40	5	5	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					18	27		10.1097/PAS.0000000000000933			10	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200004	29135520	Green Accepted			2019-10-28	
J	Mills, AM; Gradecki, SE; Horton, BJ; Blackwell, R; Moskaluk, CA; Mandell, JW; Mills, SE; Cathro, HP				Mills, Anne M.; Gradecki, Sarah E.; Horton, Bethany J.; Blackwell, Rebecca; Moskaluk, Christopher A.; Mandell, James W.; Mills, Stacey E.; Cathro, Helen P.			Diagnostic Efficiency in Digital Pathology A Comparison of Optical Versus Digital Assessment in 510 Surgical Pathology Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						digital pathology; digital imaging; efficiency; whole slide imaging	LABORATORY QUALITY CENTER; VIRTUAL MICROSCOPY; SURGICAL PATHOLOGY; FROZEN-SECTION; SLIDE IMAGES; WHOLE; ROUTINE; VALIDATION; DERMATOPATHOLOGY; CONSULTATION	Prior work has shown that digital images and microscopic slides can be interpreted with comparable diagnostic accuracy. Although accuracy has been well-validated, the interpretative time for digital images has scarcely been studied and concerns about efficiency remain a major barrier to adoption. We investigated the efficiency of digital pathology when compared with glass slide interpretation in the diagnosis of surgical pathology biopsy and resection specimens. Slides were pulled from 510 surgical pathology cases from 5 organ systems (gastrointestinal, gynecologic, liver, bladder, and brain). Original diagnoses were independently confirmed by 2 validating pathologists. Diagnostic slides were scanned using the Philips IntelliSite Pathology Solution. Each case was assessed independently on digital and optical by 3 reading pathologists, with a >= 6 week washout period between modalities. Reading pathologists recorded assessment times for each modality; digital times included time to load the case. Diagnostic accuracy was determined based on whether a rendered diagnosis differed significantly from the original diagnosis. Statistical analysis was performed to assess for differences in interpretative times across modalities. All 3 reading pathologists showed comparable diagnostic accuracy across optical and digital modalities (mean major discordance rates with original diagnosis: 4.8% vs. 4.4%, respectively). Mean assessment times ranged from 1.2 to 9.1 seconds slower on digital versus optical. The slowest reader showed a significant learning effect during the course of the study so that digital assessment times decreased over time and were comparable with optical times by the end of the series. Organ site and specimen type did not significantly influence differences in interpretative times. In summary, digital image reading times compare favorably relative to glass slides across a variety of organ systems and specimen types. Mean increase in assessment time is 4 seconds/case. This time can be minimized with experience and may be further balanced by the improved ease of electronic chart access allowed by digital slide viewing, as well as quantitative assessments which can be expedited on digital images.	[Mills, Anne M.; Gradecki, Sarah E.; Blackwell, Rebecca; Moskaluk, Christopher A.; Mandell, James W.; Mills, Stacey E.; Cathro, Helen P.] Univ Virginia, Dept Pathol, 3rd Floor HEP,Room 3001,1215 Lee St, Charlottesville, VA 22908 USA; [Horton, Bethany J.] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA	Mills, AM (reprint author), Univ Virginia, Dept Pathol, 3rd Floor HEP,Room 3001,1215 Lee St, Charlottesville, VA 22908 USA.	amm7r@virginia.edu		Mills, Anne/0000-0002-2686-4857; Gradecki, Sarah/0000-0002-7574-9011	Philips Digital Pathology Solutions	A.M.M., R.B., C.A.M., J.W.M., S.E.M., and H.P.C. received compensation in the form of salary support from Philips Digital Pathology Solutions for their work in the Multi-Center Clinical Validation Study by Philips. They did not receive compensation for their efforts in this side study. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Al Habeeb Ayman, 2012, J Pathol Inform, V3, P2, DOI 10.4103/2153-3539.93399; Al-Janabi S, 2012, HUM PATHOL, V43, P2318, DOI 10.1016/j.humpath.2012.03.027; Al-Janabi S, 2012, HUM PATHOL, V43, P702, DOI 10.1016/j.humpath.2011.06.017; Al-Janabi S, 2012, J CLIN PATHOL, V65, P152, DOI 10.1136/jclinpath-2011-200277; Bauer TW, 2014, ARCH PATHOL LAB MED, V138, P1459, DOI 10.5858/arpa.2013-0541-OA; Bauer TW, 2013, ARCH PATHOL LAB MED, V137, P518, DOI 10.5858/arpa.2011-0678-OA; Becht E, 2016, ADV IMMUNOL, V130, P95, DOI 10.1016/bs.ai.2015.12.002; Camparo P, 2012, APMIS, V120, P298, DOI 10.1111/j.1600-0463.2011.02872.x; Campbell WS, 2012, HUM PATHOL, V43, P1739, DOI 10.1016/j.humpath.2011.12.023; Chargari C, 2011, PATHOL RES PRACT, V207, P366, DOI 10.1016/j.prp.2011.03.005; Cornish TC, 2012, ADV ANAT PATHOL, V19, P152, DOI 10.1097/PAP.0b013e318253459e; Evans MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091142; Fallon MA, 2010, ARCH PATHOL LAB MED, V134, P1020, DOI 10.1043/2009-0320-OA.1; Gage JC, 2013, HUM PATHOL, V44, P2542, DOI 10.1016/j.humpath.2013.06.015; Gould PV, 2012, ANAL CELL PATHOL, V35, P85, DOI 10.3233/ACP-2011-0026; Jukic DM, 2011, ARCH PATHOL LAB MED, V135, P372, DOI 10.1043/2009-0678-OA.1; Kirilovsky A, 2016, INT IMMUNOL, V28, P373, DOI 10.1093/intimm/dxw021; Krishnamurthy S, 2013, ARCH PATHOL LAB MED, V137, P1733, DOI 10.5858/arpa.2012-0437-OA; Lopez AM, 2009, SEMIN DIAGN PATHOL, V26, P177, DOI 10.1053/j.semdp.2009.09.004; Molnar B, 2003, J CLIN PATHOL, V56, P433, DOI 10.1136/jcp.56.6.433; Mukhopadhyay S, 1992, AM J SURG P IN PRESS; Nielsen PS, 2010, HUM PATHOL, V41, P1770, DOI 10.1016/j.humpath.2010.05.015; Pantanowitz L, 2013, ARCH PATHOL LAB MED, V137, P1710, DOI 10.5858/arpa.2013-0093-CP; Slodkowska J, 2009, FOLIA HISTOCHEM CYTO, V47, P679, DOI 10.2478/v10042-010-0009-z; Thrall MJ, 2015, ARCH PATHOL LAB MED, V139, P656, DOI 10.5858/arpa.2014-0073-OA; van der Post RS, 2013, HISTOPATHOLOGY, V63, P114, DOI 10.1111/his.12131; Velez N, 2008, HUM PATHOL, V39, P1341, DOI 10.1016/j.humpath.2008.01.006; Wilbur DC, 2009, ARCH PATHOL LAB MED, V133, P1949, DOI 10.1043/1543-2165-133.12.1949	28	6	6	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					53	59		10.1097/PAS.0000000000000930			7	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200007	28877052				2019-10-28	
J	Shain, AF; Kwok, S; Folkins, AK; Kong, CS				Shain, Alana F.; Kwok, Shirley; Folkins, Ann K.; Kong, Christina S.			Utility of p16 Immunohistochemistry in Evaluating Negative Cervical Biopsies Following High-risk Pap Test Results	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						LAST project; p16; high-risk Pap; negative biopsy	HUMAN-PAPILLOMAVIRUS; INTRAEPITHELIAL LESIONS; CLINICAL-PRACTICE; WOMEN; RECOMMENDATIONS; CYTOLOGY	The Lower Anogenital Squamous Terminology (LAST) Standardization Project for human papilloma virus (HPV)-associated lesions specifically recommends the use of p16 immunohistochemistry (IHC) as an adjunct to morphologic assessment of cervical biopsies interpreted as negative or low-grade squamous intraepithelial lesion (LSIL) from patients with prior high-risk Pap test results (high-grade squamous intraepithelial lesion [HSIL], atypical squamous cells cannot exclude HSIL, atypical glandular cells [AGC], or HPV16(+) atypical squamous cells of undetermined significance [ASC-US]). The impetus for this recommendation is to increase detection of missed high-grade disease. However, the quality of evidence supporting this recommendation was lower than that for the other LAST recommendations addressing improved consistency in the diagnosis of HSIL with the use of p16. A database search spanning 10 years identified 341 cases (encompassing 736 discrete biopsy specimens) interpreted as negative for dysplasia from 330 patients with a prior high-risk Pap result (atypical squamous cells cannot exclude HSIL, HSIL, atypical glandular cells, not otherwise specified [AGC-NOS], atypical endocervical cells-NOS [AEC-NOS], and AEC-favor neoplastic). p16 IHC was performed and detected missed abnormalities in 11/341 (3.2%) cases. The abnormalities corresponded to missed foci of HSIL (cervical intraepithelial neoplasia [CIN] 2) (n=1), SIL-indeterminate grade (n=7), atypical squamous metaplasia (n=2), and LSIL [CIN1]) (n=1). Subsequent histologic follow-up identified HSIL or greater in 6/8 (75%) p16(+) cases versus 20/79 (25.3%) p16(-) cases (P=0.0079). p16 IHC performed on biopsies interpreted as negative from patients with prior high-risk Pap test results increased the detection rate of missed SIL. A p16(+) result also significantly increased the likelihood of HSIL on subsequent biopsy. Although further studies are required to determine what percentage of missed HSIL justifies the additional cost, improved detection of HSIL in high-risk patients may lead to fewer diagnostic procedures and fewer patients lost to follow-up .	[Shain, Alana F.; Kwok, Shirley; Folkins, Ann K.; Kong, Christina S.] Stanford Univ, Dept Pathol, Sch Med, 300 Pasteur Dr,Room L235, Stanford, CA 94305 USA	Kong, CS (reprint author), Stanford Univ, Dept Pathol, Sch Med, 300 Pasteur Dr,Room L235, Stanford, CA 94305 USA.	ckong@stanford.edu					Bergeron C, 2010, AM J CLIN PATHOL, V133, P395, DOI 10.1309/AJCPXSVCDZ3D5MZM; Carrigg A, 2013, AM J CLIN PATHOL, V139, P422, DOI 10.1309/AJCP6BSD0SNGQLHQ; Clinton LK, 2015, AM J CLIN PATHOL, V144, P844, DOI 10.1309/AJCPUXLP7XD8OQYY; Darragh TM, 2012, ARCH PATHOL LAB MED, V136, P1266, DOI 10.5858/arpa.LGT200570; Dijkstra MG, 2010, J CLIN PATHOL, V63, P972, DOI 10.1136/jcp.2010.078634; Galgano MT, 2010, AM J SURG PATHOL, V34, P1077, DOI 10.1097/PAS.0b013e3181e8b2c4; Katki HA, 2013, J LOW GENIT TRACT DI, V17, pS69, DOI 10.1097/LGT.0b013e31828543b1; Katki HA, 2011, LANCET ONCOL, V12, P663, DOI 10.1016/S1470-2045(11)70145-0; Massad LS, 2013, J LOW GENIT TRACT DI, V17, pS1, DOI 10.1097/LGT.0b013e318287d329; Ordi J, 2009, INT J GYNECOL PATHOL, V28, P90, DOI 10.1097/PGP.0b013e31817e9ac5; Shah AA, 2014, AM J CLIN PATHOL, V141, P342, DOI 10.1309/AJCPDXD41YLVAZZN; Stoler MH, 2011, AM J CLIN PATHOL, V135, P468, DOI 10.1309/AJCPZ5JY6FCVNMOT; Wheeler CM, 2006, J INFECT DIS, V194, P1291, DOI 10.1086/507909	13	2	2	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					69	75		10.1097/PAS.0000000000000960			7	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200009	29112019				2019-10-28	
J	Kobel, M; Hoang, LN; Tessier-Cloutier, B; Meng, B; Soslow, RA; Stewart, CJR; Lee, CH				Koebel, Martin; Hoang, Lien N.; Tessier-Cloutier, Basile; Meng, Bo; Soslow, Robert A.; Stewart, Colin J. R.; Lee, Cheng-Han			Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						endometrial cancer; undifferentiated carcinoma; ARID1A; ARID1B; SMARCA4; SMARCB1	MALIGNANT RHABDOID TUMORS; SMALL-CELL CARCINOMA; METHYLTRANSFERASE EZH2; HYPERCALCEMIC TYPE; EXPRESSION; INHIBITION; MUTATION; OVARY; INSIGHTS; ARID1A	Undifferentiated endometrial carcinoma is an aggressive type of endometrial carcinoma that typically presents with advanced stage disease and rapid clinical progression. In contrast to dedifferentiated endometrial carcinoma, undifferentiated carcinoma lacks a concurrent differentiated (typically low-grade endometrioid) carcinoma component, though the undifferentiated component of dedifferentiated carcinoma is similar histologically and immunophenotypically to pure undifferentiated carcinoma. We recently identified 3 mutually exclusive mechanisms of switch/sucrose nonfermentable (SWI/SNF) complex inactivation (BRG1 inactivation, INI1 inactivation or ARID1A/ARID1B co-inactivation) that are associated with histologic dedifferentiation in the majority of dedifferentiated endometrial carcinoma. In the current study, we aimed to determine by immunohistochemistry whether these patterns of SWI/SNF inactivation also occur in undifferentiated endometrial carcinomas. Of the 34 undifferentiated carcinomas examined, 17 (50%) exhibited SWI/SNF complex inactivation, with 11 tumors showing complete loss of both ARID1A and ARID1B, 5 showing complete loss of BRG1 and 1 showing complete loss of INI1. Ten of the remaining 17 undifferentiated carcinomas showed the following alterations: 5 tumors (15%) showed loss of ARID1A only with intact ARID1B, BRG1, and INI1 expression, 4 tumors (12%) showed mutated patterns of p53 staining with intact SWI/SNF protein expression, and 1 tumor (3%) harbored a POLE exonuclease domain mutation (P286R). SWI/SNF complex-inactivated tumors presented more frequently with extrauterine disease spread than those with intact expression (88% vs. 41%, respectively). In addition, patients with SWI/SNF complex-inactivated tumors had a significantly worse disease-specific survival (P=0.02). The findings here demonstrate frequent SWI/SNF complex inactivation in undifferentiated endometrial carcinomas, which has future implications regarding therapies that target chromatin remodelling and epigenetic control.	[Koebel, Martin] Calgary Lab Serv, Dept Pathol & Lab Med, Calgary, AB, Canada; [Koebel, Martin] Univ Calgary, Calgary, AB, Canada; [Meng, Bo; Lee, Cheng-Han] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada; [Hoang, Lien N.; Tessier-Cloutier, Basile; Lee, Cheng-Han] Vancouver Gen Hosp, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Lee, Cheng-Han] British Columbia Canc Agcy, Dept Pathol, Room 3225,600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada; [Soslow, Robert A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Stewart, Colin J. R.] Univ Western Australia, King Edward Mem Hosp, Dept Histopathol, Perth, WA, Australia; [Stewart, Colin J. R.] Univ Western Australia, Sch Womens & Infants Hlth, Perth, WA, Australia	Lee, CH (reprint author), British Columbia Canc Agcy, Dept Pathol, Room 3225,600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	chenghanlee@gmail.com		Kobel, Martin/0000-0002-6615-2037	Cancer Research Society of Canada [20313]; Royal Alexandra Hospital foundation; Alberta Cancer Foundation; Calgary Laboratory Services Internal Research Competition [RS14-513]; MSK Cancer Center Support Grant [P30 CA008748]	Supported in part by research funds from Cancer Research Society of Canada (20313), Royal Alexandra Hospital foundation, Alberta Cancer Foundation, Calgary Laboratory Services Internal Research Competition (RS14-513). R.A.S. is supported in part by the MSK Cancer Center Support Grant P30 CA008748. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Alimova I, 2013, NEURO-ONCOLOGY, V15, P149, DOI 10.1093/neuonc/nos285; Altrabulsi B, 2005, AM J SURG PATHOL, V29, P1316, DOI 10.1097/01.pas.0000171003.72352.9a; Alver BH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14648; Chan-Penebre E, 2017, MOL CANCER THER, V16, P850, DOI 10.1158/1535-7163.MCT-16-0678; Coatham M, 2016, MODERN PATHOL, V29, P1586, DOI 10.1038/modpathol.2016.156; Espinosa I, 2017, AM J SURG PATHOL, V41, P1121, DOI 10.1097/PAS.0000000000000873; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Guan B, 2011, AM J SURG PATHOL, V35, P625, DOI 10.1097/PAS.0b013e318212782a; Hoang LN, 2016, HISTOPATHOLOGY, V69, P560, DOI 10.1111/his.12989; Hoang LN, 2014, INT J GYNECOL PATHOL, V33, P483, DOI 10.1097/PGP.0b013e31829ff239; Isphording A, 2013, HUM PATHOL, V44, P837, DOI 10.1016/j.humpath.2012.08.007; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Karnezis AN, 2016, MODERN PATHOL, V29, P302, DOI 10.1038/modpathol.2015.155; Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110; Kobel M, 2016, J PATHOL CLIN RES, V2, P247, DOI 10.1002/cjp2.53; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; Meng B, 2014, GYNECOL ONCOL, V134, P15, DOI 10.1016/j.ygyno.2014.05.006; Moreno N, 2016, ANTICANCER RES, V36, P3883; Ramalingam P, 2017, HISTOPATHOLOGY, V70, P359, DOI 10.1111/his.13091; Ramalingam P, 2016, INT J GYNECOL PATHOL, V35, P410, DOI 10.1097/PGP.0000000000000248; Rosa-Rosa JM, 2016, MODERN PATHOL, V29, P1390, DOI 10.1038/modpathol.2016.132; Silva EG, 2006, INT J GYNECOL PATHOL, V25, P52, DOI 10.1097/01.pgp.0000183048.22588.18; Silva EG, 2007, PATHOLOGY, V39, P134, DOI 10.1080/00313020601159494; Stewart CJR, 2015, PATHOLOGY, V47, P439, DOI 10.1097/PAT.0000000000000270; Tafe LJ, 2010, MODERN PATHOL, V23, P781, DOI 10.1038/modpathol.2010.41; Wang XF, 2014, CLIN CANCER RES, V20, P21, DOI 10.1158/1078-0432.CCR-13-0280; Wang YM, 2017, J PATHOL, V242, P371, DOI 10.1002/path.4912	27	9	11	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					76	83		10.1097/PAS.0000000000000941			8	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200010	28863077				2019-10-28	
J	Hognas, G; Kivinummi, K; Kallio, HML; Hieta, R; Ruusuvuori, P; Koskenalho, A; Kesseli, J; Tammela, TLJ; Riikonen, J; Ilvesaro, J; Kares, S; Hirvikoski, PP; Laurila, M; Mirtti, T; Nykter, M; Kujala, PM; Visakorpi, T; Tolonen, T; Bova, GS				Hognas, Gunilla; Kivinummi, Kati; Kallio, Heini M. L.; Hieta, Reija; Ruusuvuori, Pekka; Koskenalho, Antti; Kesseli, Juha; Tammela, Teuvo L. J.; Riikonen, Jarno; Ilvesaro, Joanna; Kares, Saara; Hirvikoski, Pasi P.; Laurila, Marita; Mirtti, Tuomas; Nykter, Matti; Kujala, Paula M.; Visakorpi, Tapio; Tolonen, Teemu; Bova, G. Steven			Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						prostate cancer; tissue processing; tissue fixation; histology; immunostaining; DNA quality; RNA quality; DNA yield; RNA yield; PAXgene	FORMALIN; DNA; PRESERVATION; MORPHOLOGY; ALIGNMENT; SAMPLES; SYSTEM	Advances in prostate cancer biology and diagnostics are dependent upon high-fidelity integration of clinical, histomorphologic, and molecular phenotypic findings. In this study, we compared fresh frozen, formalin-fixed paraffin-embedded (FFPE), and PAXgene-fixed paraffin-embedded (PFPE) tissue preparation methods in radical prostatectomy prostate tissue from 36 patients and performed a preliminary test of feasibility of using PFPE tissue in routine prostate surgical pathology diagnostic assessment. In addition to comparing histology, immunohistochemistry, and general measures of DNA and RNA integrity in each fixation method, we performed functional tests of DNA and RNA quality, including targeted Miseq RNA and DNA sequencing, and implemented methods to relate DNA and RNA yield and quality to quantified DNA and RNA picogram nuclear content in each tissue volume studied. Our results suggest that it is feasible to use PFPE tissue for routine robot-assisted laparoscopic prostatectomy surgical pathology diagnostics and immunohistochemistry, with the benefit of significantly improvedDNA and RNA quality and RNA picogram yield per nucleus as compared with FFPE tissue. For fresh frozen, FFPE, and PFPE tissues, respectively, the average Genomic Quality Numbers were 7.9, 3.2, and 6.2, average RNA Quality Numbers were 8.7, 2.6, and 6.3, average DNA picogram yields per nucleus were 0.41, 0.69, and 0.78, and average RNA picogram yields per nucleus were 1.40, 0.94, and 2.24. These findings suggest that where DNA and/or RNA analysis of tissue is required, and when tissue size is small, PFPE may provide important advantages over FFPE. The results also suggest several interesting nuances including potential avenues to improve RNA quality in FFPE tissues and confirm recent suggestions that some DNA sequence artifacts associated with FFPE can be avoided.	[Hognas, Gunilla; Kivinummi, Kati; Kallio, Heini M. L.; Hieta, Reija; Ruusuvuori, Pekka; Koskenalho, Antti; Kesseli, Juha; Tammela, Teuvo L. J.; Nykter, Matti; Visakorpi, Tapio; Bova, G. Steven] Univ Tampere, Fac Med & Life Sci, Prostate Canc Res Ctr, Tampere, Finland; [Hognas, Gunilla; Kivinummi, Kati; Kallio, Heini M. L.; Hieta, Reija; Ruusuvuori, Pekka; Koskenalho, Antti; Kesseli, Juha; Tammela, Teuvo L. J.; Nykter, Matti; Visakorpi, Tapio; Bova, G. Steven] Univ Tampere, BioMediTech Inst, POB 100, FI-33014 Tampere, Finland; [Tammela, Teuvo L. J.; Riikonen, Jarno] Univ Tampere, Dept Urol, Tampere, Finland; [Ilvesaro, Joanna; Kares, Saara; Laurila, Marita; Kujala, Paula M.; Visakorpi, Tapio; Tolonen, Teemu] Tampere Univ Hosp, Dept Pathol, Fimlab Labs, Tampere, Finland; [Ruusuvuori, Pekka] Tampere Univ Technol, Signal Proc Lab, Pori, Finland; [Hirvikoski, Pasi P.] Oulu Univ Hosp, Dept Pathol, Oulu, Finland; [Mirtti, Tuomas] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland; [Mirtti, Tuomas] Helsinki Univ Hosp, HUSLAB, Dept Pathol, Helsinki, Finland	Bova, GS (reprint author), Univ Tampere, BioMediTech Inst, POB 100, FI-33014 Tampere, Finland.	g.steven.bova@uta.fi		Kallio, Heini M.L./0000-0003-4345-1787; Mirtti, Tuomas/0000-0003-0455-9891; Visakorpi, Tapio/0000-0002-5004-0364; Nykter, Matti/0000-0001-6956-2843	Cancer Society of Finland; Academy of FinlandAcademy of Finland; Finnish Cancer Institute; K. Albin Johansson Foundation; Finnish-Norwegian Medical Foundation	Supported by Cancer Society of Finland, Academy of Finland, Finnish Cancer Institute, K. Albin Johansson Foundation, Finnish-Norwegian Medical Foundation. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Advanced Analytical Technologies, ADV AN TECHN DOC RNA; Agilent Technologies, 2015, HERC 2 FUS DNA POL U; Belloni B, 2013, J CLIN PATHOL, V66, P124, DOI 10.1136/jclinpath-2012-200983; Carrick DM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127353; Costello M, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1443; Do HD, 2015, CLIN CHEM, V61, P64, DOI 10.1373/clinchem.2014.223040; Faust GG, 2014, BIOINFORMATICS, V30, P2503, DOI 10.1093/bioinformatics/btu314; Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010; Gillard M, 2015, AM J TRANSL RES, V7, P1227; Greagg MA, 1999, P NATL ACAD SCI USA, V96, P9045, DOI 10.1073/pnas.96.16.9045; Gundisch S, 2014, VIRCHOWS ARCH, V465, P509, DOI 10.1007/s00428-014-1624-4; Illumina, ILLUMINA TECHNICAL N; Kap M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027704; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim S, 2017, J MOL DIAGN, V19, P137, DOI 10.1016/j.jmoldx.2016.09.006; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Mathieson W, 2016, AM J CLIN PATHOL, V146, P25, DOI 10.1093/ajcp/aqw023; Mizumachi T, 2008, PROSTATE, V68, P408, DOI 10.1002/pros.20697; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Reznik E, 2016, ELIFE, V5, DOI 10.7554/eLife.10769; Staff S, 2013, J CLIN PATHOL, V66, P807, DOI 10.1136/jclinpath-2012-201283; Wikipedia contributors, 2017, C VAL	23	3	3	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					103	115		10.1097/PAS.0000000000000961			13	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200013	28984675	Green Accepted			2019-10-28	
J	Pina-Oviedo, S; Miranda, RN; Medeiros, LJ				Pina-Oviedo, Sergio; Miranda, Roberto N.; Medeiros, L. Jeffrey			Cancer Therapy-associated Lymphoproliferative Disorders An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						Epstein-Barr virus; immunodeficiency; iatrogenic; lymphomas; chemotherapy	EPSTEIN-BARR-VIRUS; CHRONIC LYMPHOCYTIC-LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; CHRONIC MYELOID-LEUKEMIA; B-CELL LYMPHOMA; BONE-MARROW-TRANSPLANTATION; PLASMABLASTIC LYMPHOMA; SECONDARY MALIGNANCIES; FOLLICULAR LYMPHOMA; FLUDARABINE	We describe the clinicopathologic features of 17 patients who had a hematologic malignancy of various types, were treated, and subsequently developed a lymphoproliferative disorder (LPD). There were 10 men and 7 women with a median age of 59 years (range, 36 to 83 y). The primary hematologic neoplasms included: 5 chronic lymphocytic leukemia/small lymphocytic lymphoma, 3 plasma cell myeloma, 2 acute monoblastic leukemia, and 1 case each of mixed-phenotype acute leukemia, chronic myeloid leukemia, splenic marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, T-cell prolymphocytic leukemia, and peripheral T-cell lymphoma. All patients were treated with chemotherapy with or without therapeutic antibodies; 3 also underwent autologous stem cell transplantation. The mean interval from initiation of therapy for initial hematologic malignancy to onset of LPD was 66 months (range, 3 to 299 mo). Ten (59%) LPDs were extranodal and 7 (41%) involved nodal tissues. The histologic diagnoses included: 8 diffuse large B-cell lymphoma, 4 classical Hodgkin lymphoma, 3 polymorphic LPD, 1 lymphomatoid granulomatosis, and 1 Epstein-Barr virus (EBV)(+) mucocutaneous ulcer. Fourteen cases were EBV+. Following the onset of LPD, chemotherapy was administered to 10 (59%) patients. With a median follow-up of 100 months (range, 5 to 328 mo), 8 (47%) patients are alive and 9 (53%) died. One (6%) patient with lymphomatoid granulomatosis underwent spontaneous remission. On the basis of the clinicopathologic features and high prevalence of EBV infection in this cohort, we believe that these LPDs show similarities with other types of immunodeficiency-associated LPDs. We suggest that cancer therapy-associated LPD be included in future classification systems for immunodeficiency-associated LPDs.	[Pina-Oviedo, Sergio; Miranda, Roberto N.; Medeiros, L. Jeffrey] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd,Unit 0072, Houston, TX 77030 USA	Medeiros, LJ (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd,Unit 0072, Houston, TX 77030 USA.	ljmedeiros@mdanderson.org	Medeiros, L. Jeffrey/AAB-1018-2019				Abruzzo LV, 2002, AM J SURG PATHOL, V26, P630, DOI 10.1097/00000478-200205000-00009; Bhamidipati PK, 2013, CL LYMPH MYELOM LEUK, V13, P342, DOI 10.1016/j.clml.2012.10.002; Briz M, 1997, BRIT J HAEMATOL, V98, P485, DOI 10.1046/j.1365-2141.1997.2153034.x; Castillo JJ, 2017, LEUKEMIA LYMPHOMA, V58, P773, DOI 10.1080/10428194.2016.1217527; Cheminant M, 2012, BRIT J HAEMATOL, V158, P644, DOI 10.1111/j.1365-2141.2012.09202.x; Cutucache CE, 2013, INT IMMUNOPHARMACOL, V17, P35, DOI 10.1016/j.intimp.2013.05.021; Dhalla F, 2015, CURR OPIN ALLERGY CL, V15, P505, DOI 10.1097/ACI.0000000000000215; Dhalla F, 2014, J CLIN IMMUNOL, V34, P277, DOI 10.1007/s10875-014-9995-5; Fong D, 2005, BRIT J HAEMATOL, V129, P199, DOI 10.1111/j.1365-2141.2005.05426.x; Foo WC, 2010, HUM PATHOL, V41, P1802, DOI 10.1016/j.humpath.2010.04.019; Forconi F, 2015, BLOOD, V126, P573, DOI 10.1182/blood-2015-03-567388; Friman V, 2016, HEMATOL ONCOL, V34, P121, DOI 10.1002/hon.2323; Gaulard P, 2008, WHO CLASSIFICATION T, P350; Hauke RJ, 1998, BONE MARROW TRANSPL, V21, P1271, DOI 10.1038/sj.bmt.1701258; Higuchi M, 2015, INT J HEMATOL, V102, P482, DOI 10.1007/s12185-015-1802-4; Inui Y, 2015, LEUKEMIA LYMPHOMA, V56, P3045, DOI 10.3109/10428194.2015.1022769; Izumiya S, 2012, ONCOL LETT, V3, P1203, DOI 10.3892/ol.2012.670; Jain P, 2013, LEUKEMIA LYMPHOMA, V54, P2540, DOI 10.3109/10428194.2013.773995; Jones RJ, 2016, CLIN CANCER RES, V22, P4901, DOI 10.1158/1078-0432.CCR-15-2242; Kilner MF, 2013, BMJ CASE REP, DOI 10. 1136/bcr-2013-200079 .; Kluin-Nelemans HC, 2008, BLOOD, V112, P1039, DOI 10.1182/blood-2008-02-138800; Knowles DM, 1999, MODERN PATHOL, V12, P200; Krishnan B, 2007, CANCER EPIDEM BIOMAR, V16, P377, DOI 10.1158/1055-9965.EPI-06-1069; Lazzarino M, 1999, BRIT J HAEMATOL, V107, P877, DOI 10.1046/j.1365-2141.1999.01765.x; Leguay T, 2007, LEUKEMIA, V21, P2208, DOI 10.1038/sj.leu.2404758; Leone G, 2011, CURR OPIN ONCOL, V23, P672, DOI 10.1097/CCO.0b013e32834bcc2a; Loo EY, 2013, AM J SURG PATHOL, V37, P1290, DOI 10.1097/PAS.0b013e31828e6564; Malaguarnera L, 2010, CRIT REV ONCOL HEMAT, V74, P40, DOI 10.1016/j.critrevonc.2009.06.002; Menter T, 2014, HEMATOL ONCOL, V32, P47, DOI 10.1002/hon.2054; Miao Y, 2016, HUM PATHOL, V58, P72, DOI 10.1016/j.humpath.2016.07.025; Miranda MB, 2016, LEUKEMIA, V30, P1255, DOI 10.1038/leu.2016.20; Morscio J, 2016, J HEMATOP, V9, P113, DOI 10.1007/s12308-016-0273-8; Natkunam Y, 2017, AM J CLIN PATHOL, V147, P124, DOI 10.1093/ajcp/aqw200; Niesvizky R, 1999, NEW ENGL J MED, V341, P55, DOI 10.1056/NEJM199907013410112; Orlandi E, 2001, BRIT J HAEMATOL, V112, P373, DOI 10.1046/j.1365-2141.2001.02579.x; Peniket AJ, 1998, BONE MARROW TRANSPL, V22, P307, DOI 10.1038/sj.bmt.1701335; Powell JL, 2004, BONE MARROW TRANSPL, V33, P651, DOI 10.1038/sj.bmt.1704402; Seggewiss R, 2005, BLOOD, V105, P2473, DOI 10.1182/blood-2004-07-2527; Sohani AR, 2010, J CLIN ONCOL, V28, pE69, DOI 10.1200/JCO.2009.24.4194; Swerdlow SH, 2008, WHO CLASSIFICATION T; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tadmor T, 2016, HEMATOL ONCOL; Tarazona R, 2017, CANCER IMMUNOL IMMUN, V66, P233, DOI 10.1007/s00262-016-1882-x; Verma D, 2011, BLOOD, V118, P4353, DOI 10.1182/blood-2011-06-362889; Weisenburger DD, 2016, BR J HAEMATOL; Wu JZ, 2014, INT J CLIN EXP PATHO, V7, P4400	46	6	6	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					116	129		10.1097/PAS.0000000000000954			14	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200014	29112013				2019-10-28	
J	Bishop, JA; Cowan, ML; Shum, CH; Westra, WH				Bishop, Justin A.; Cowan, Morgan L.; Shum, Chung H.; Westra, William H.			MAML2 Rearrangements in Variant Forms of Mucoepidermoid Carcinoma Ancillary Diagnostic Testing for the Ciliated and Warthin-like Variants	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						mucoepidermoid carcinoma; MAML2; cilia; Warthin tumor; Warthin-like	IN-SITU-HYBRIDIZATION; PAROTID-GLAND; SALIVARY-GLAND; FUSION TRANSCRIPT; CELL CARCINOMA; THYROID-GLAND; TUMOR; TRANSLOCATION; ADENOCARCINOMA; MECT1-MAML2	Mucoepidermoid carcinoma (MEC) is the most common salivary gland malignancy. Recent studies have shown that most MECs harbor gene fusions involving MAML2-an alteration that appears to be specific for MEC, a finding that could be diagnostically useful. While most cases of MEC are histologically straightforward, uncommon variants can cause considerable diagnostic difficulty. We present 2 variants of MEC for which MAML2 studies were crucial in establishing a diagnosis: a previously undescribed ciliated variant, and the recently described Warthin-like variant. All cases of ciliated and Warthin-like MEC were retrieved from the archives of The Johns Hopkins Hospital. Break-apart fluorescence in situ hybridization for MAML2 was performed on all cases. One ciliated MEC and 6 Warthin-like MECs were identified. The ciliated MEC presented as a 4.6 cm cystic lymph node metastasis originating from the tongue base in a 47-year-old woman. The Warthin-like MECs presented as parotid masses ranging in size from 1.2 to 3.3 (mean, 2.7 cm) in 4 women and 2 men. The ciliated MEC consisted of macrocystic spaces punctuated by tubulopapillary proliferations of squamoid cells and ciliated columnar cells. The Warthin-like MECs were comprised of cystic spaces lined by multilayered oncocytic to squamoid cells surrounded by a circumscribed cuff of lymphoid tissue with germinal centers. In these cases, the Warthin-like areas dominated the histologic picture. Conventional MEC, when present, represented a minor tumor component. MAML2 rearrangements were identified in all cases. Warthin-like MEC, and now a ciliated form of MEC, are newly described variants of a common salivary gland carcinoma. Unfamiliarity with these novel forms, unanticipated cellular features (eg, cilia), and morphologic overlap with mundane benign processes (eg, developmental ciliated cysts, Warthin tumor) or other carcinomas (eg, ciliated human papillomavirus-related carcinoma) may render these variants susceptible to misdiagnosis. These unusual variants appear to consistently harbor MAML2 fusionsa finding that establishes a clear link to conventional MEC and provides a valuable adjunct in establishing the diagnosis.	[Bishop, Justin A.; Cowan, Morgan L.; Westra, William H.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21231 USA; [Bishop, Justin A.; Westra, William H.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA; [Bishop, Justin A.; Westra, William H.] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21231 USA; [Shum, Chung H.] Dahl Chase Pathol Associates, Bangor, ME USA	Bishop, JA (reprint author), Johns Hopkins Univ, Sch Med, 401 N Broadway,Weinberg 2249, Baltimore, MD 21231 USA.	jbishop@jhmi.edu			National Institute of Dental and Craniofacial ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01 DE013152-11]	Supported in parts by the National Institute of Dental and Craniofacial Research (R01 DE013152-11). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Ando M, 2008, PATHOL INT, V58, P741, DOI 10.1111/j.1440-1827.2008.02303.x; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; BATSAKIS JG, 1987, ANN OTO RHINOL LARYN, V96, P234, DOI 10.1177/000348948709600221; Behboudi A, 2006, GENE CHROMOSOME CANC, V45, P470, DOI 10.1002/gcc.20306; Bell D, 2008, GENE CHROMOSOME CANC, V47, P309, DOI 10.1002/gcc.20534; Birkeland AC, 2017, ORAL ONCOL, V68, P5, DOI 10.1016/j.oraloncology.2017.02.025; Bishop JA, 2015, AM J SURG PATHOL, V39, P1591, DOI 10.1097/PAS.0000000000000521; Bishop JA, 2014, HEAD NECK PATHOL, V8, P298, DOI 10.1007/s12105-014-0541-9; Bishop JA, 2012, AM J SURG PATHOL, V36, P1874, DOI 10.1097/PAS.0b013e318265fb2b; BULLERDIEK J, 1988, CANCER GENET CYTOGEN, V35, P129, DOI 10.1016/0165-4608(88)90131-8; CHAN WY, 1993, HUM PATHOL, V24, P1107, DOI 10.1016/0046-8177(93)90191-I; Chiosea SI, 2012, LARYNGOSCOPE, V122, P1690, DOI 10.1002/lary.22419; Cibas ES, 2014, CYTOLOGY DIAGNOSTIC; Eichhorn JH, 1996, INT J GYNECOL PATHOL, V15, P248, DOI 10.1097/00004347-199607000-00010; GADIENT SE, 1975, ORAL SURG ORAL MED O, V40, P391, DOI 10.1016/0030-4220(75)90426-0; Garcia JJ, 2011, HUM PATHOL, V42, P2001, DOI 10.1016/j.humpath.2011.02.028; Gattuso P, 2015, DIFFERENTIAL DIAGNOS; HENDRICKSON MR, 1983, INT J GYNECOL PATHOL, V2, P1, DOI 10.1097/00004347-198301000-00001; Isayeva T, 2013, HEAD NECK PATHOL, V7, P135, DOI 10.1007/s12105-012-0411-2; Ishibashi K, 2015, AM J SURG PATHOL, V39, P1479, DOI 10.1097/PAS.0000000000000507; Jour G, 2013, HEAD NECK PATHOL, V7, P224, DOI 10.1007/s12105-012-0417-9; Jung YH, 2010, J KOREAN MED SCI, V25, P1683, DOI 10.3346/jkms.2010.25.11.1683; Luk PP, 2016, OR SURG OR MED OR PA, V121, P530, DOI 10.1016/j.oooo.2016.01.003; LUMERMAN H, 1975, ORAL SURG ORAL MED O, V39, P953, DOI 10.1016/0030-4220(75)90117-6; Manisha M, 2012, INDIAN J PATHOL MICR, V55, P392, DOI 10.4103/0377-4929.101756; Mardi Kavita, 2007, Indian J Pathol Microbiol, V50, P331; MARK J, 1990, CANCER GENET CYTOGEN, V46, P35, DOI 10.1016/0165-4608(90)90006-V; Martins C, 2004, J MOL DIAGN, V6, P205, DOI 10.1016/S1525-1578(10)60511-9; Mitani Y, 2016, CLIN CANCER RES, V22, P725, DOI 10.1158/1078-0432.CCR-15-2867-T; MORINAGA S, 1986, ACTA PATHOL JAPON, V36, P1905; Okabe M, 2006, CLIN CANCER RES, V12, P3902, DOI 10.1158/1078-0432.CCR-05-2376; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Radkay-Gonzalez L, 2016, HEAD NECK PATHOL, V10, P167, DOI 10.1007/s12105-015-0653-x; Saade RE, 2016, JAMA OTOLARYNGOL, V142, P234, DOI 10.1001/jamaoto.2015.3270; Seethala RR, 2016, AM J SURG PATHOL, V40, P1151, DOI 10.1097/PAS.0000000000000676; Seethala RR, 2010, AM J SURG PATHOL, V34, P1106, DOI 10.1097/PAS.0b013e3181de3021; Skalova A, 2013, AM J SURG PATHOL, V37, P1743, DOI 10.1097/PAS.0000000000000065; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Smolka W, 2015, ARCH MED SCI, V11, P691, DOI 10.5114/aoms.2015.52379; Weinreb I, 2014, GENE CHROMOSOME CANC, V53, P845, DOI 10.1002/gcc.22195; Williamson JD, 2000, AM J CLIN PATHOL, V114, P564, DOI 10.1309/GUT1-F58A-V4WV-0D8P; Winnes M, 2006, J MOL DIAGN, V8, P394, DOI 10.2353/jmoldx.2006.060020; Yamada S, 2002, PATHOL INT, V52, P653, DOI 10.1046/j.1440-1827.2002.01408.x; Yu CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep30149	44	7	8	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					130	136		10.1097/PAS.0000000000000932			7	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200015	28877061	Green Accepted			2019-10-28	
J	McCluggage, WG; Irving, JA; Chong, AS; Clarke, BA; Young, RH; Foulkes, WD; Rivera, B				McCluggage, W. Glenn; Irving, Julie A.; Chong, Anne-Sophie; Clarke, Blaise A.; Young, Robert H.; Foulkes, William D.; Rivera, Barbara			Ovarian Microcystic Stromal Tumors Are Characterized by Alterations in the Beta-Catenin-APC Pathway and May be an Extracolonic Manifestation of Familial Adenomatous Polyposis	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Letter							MUTATION; CTNNB1; NEOPLASM		[McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland; [Irving, Julie A.] Univ British Columbia, Dept Pathol, Victoria, BC, Canada; [Irving, Julie A.] Royal Jubilee Hosp, Dept Lab Med Pathol & Med Genet, Victoria, BC, Canada; [Chong, Anne-Sophie; Foulkes, William D.; Rivera, Barbara] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [Clarke, Blaise A.] Univ Toronto, Univ Hlth Network, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Young, Robert H.] Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA; [Young, Robert H.] Harvard Med Sch, Dept Pathol, Boston, MA USA	McCluggage, WG (reprint author), Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland.		; Rivera, Barbara/D-7407-2018	Clarke, Blaise/0000-0002-2585-8391; Rivera, Barbara/0000-0001-9434-6288			Afgan E, 2016, NUCLEIC ACIDS RES, V44, pW3, DOI 10.1093/nar/gkw343; Bi R, 2015, HISTOPATHOLOGY, V67, P872, DOI 10.1111/his.12722; Hu PJ, 2012, GENE CHROMOSOME CANC, V51, P283, DOI 10.1002/gcc.20953; Irving JA, 2015, AM J SURG PATHOL, V39, P1420, DOI 10.1097/PAS.0000000000000482; Irving JA, 2009, AM J SURG PATHOL, V33, P367, DOI 10.1097/PAS.0b013e31818479c3; Kang YN, 2015, INT J GYNECOL PATHOL, V34, P121, DOI 10.1097/PGP.0000000000000122; Lee SH, 2015, GENE CHROMOSOME CANC, V54, P353, DOI 10.1002/gcc.22233; Liu C, 2016, INT J GYNECOL PATHOL, V35, P561, DOI 10.1097/PGP.0000000000000289; Maeda D, 2011, AM J SURG PATHOL, V35, P1429, DOI 10.1097/PAS.0b013e31822d6c71; Podduturi V, 2015, INT J GYNECOL PATHOL, V34, P541, DOI 10.1097/PGP.0000000000000198; Yang H, 2015, NAT PROTOC, V10, P1556, DOI 10.1038/nprot.2015.105	11	2	2	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					137	139		10.1097/PAS.0000000000000981			3	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200016	29076875				2019-10-28	
J	Leivo, MZ; Sahoo, D; Hamilton, Z; Mirsadraei, L; Shabaik, A; Parsons, JK; Kader, AK; Derweesh, I; Kane, C; Hansel, DE				Leivo, Mariah Z.; Sahoo, Debashis; Hamilton, Zachary; Mirsadraei, Leili; Shabaik, Ahmed; Parsons, John K.; Kader, Andrew K.; Derweesh, Ithaar; Kane, Christopher; Hansel, Donna E.			Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						urinary bladder; substaging; carcinoma; progression	PT1 UROTHELIAL CARCINOMA; LAMINA PROPRIA INVASION; MUSCULARIS MUCOSA INVASION; PROGNOSTIC-SIGNIFICANCE; PROGRESSION; SERIES; DEPTH; RECURRENCE; MICROARRAY; TUMORS	Urothelial carcinoma of the bladder invasive into lamina propria on biopsy or transurethral resection of bladder tumor, termed "T1" disease, progresses to muscularis propria invasion in a subset of patients. Prior studies have proposed histopathologic metrics to predict progression, although methods vary widely and it is unclear which method is most robust. This poses a challenge since recent World Health Organization and American Joint Commission on Cancer editions encourage some attempt to substratify T1 disease. To address this critical problem, we analyzed T1 specimens to test which T1 quantification method is best to predict progression and to then establish the optimal cut-off. Progression was analyzed for all patients or for patients with definitive muscularis propria only. Multivariate analysis and outcomes modeling controlled for additional histopathologic features. Our results suggest that aggregate linear length of invasive carcinoma (ALLICA) measured by optical micrometer is far superior to other methods (P=3.067x10(-6)) and could be applied to 100% of specimens. ALLICA retained significance in multivariate analysis and eliminated contribution of other histopathologic features to progression. The best cut-off for ALLICA using a 30% false-positive threshold was 2.3mm and using a 10% false-positive threshold at 25 mm, although the latter severely limited patients who could achieve this threshold. After comparison of all proposed methods of T1 quantification, we recommend the adoption of the ALLICA measurement and a cut-off of 2.3 mm as the best predictor of progression, acknowledging that additional nonhistopathologic methods may be required to increase broad applicability and further reduce the false-positive threshold.	[Leivo, Mariah Z.; Mirsadraei, Leili; Shabaik, Ahmed; Hansel, Donna E.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Sahoo, Debashis] Univ Calif San Diego, Dept Comp Sci & Engn, La Jolla, CA 92093 USA; [Hamilton, Zachary; Parsons, John K.; Kader, Andrew K.; Derweesh, Ithaar; Kane, Christopher; Hansel, Donna E.] Univ Calif San Diego, Dept Urol, La Jolla, CA 92093 USA	Hansel, DE (reprint author), 9500 Gilman Dr,MC 0612, La Jolla, CA 92093 USA.	dhansel@ucsd.edu					Amin MB, 2016, AJCC CANC STAGING MA; Bertz S, 2011, HISTOPATHOLOGY, V59, P722, DOI 10.1111/j.1365-2559.2011.03989.x; Brimo F, 2013, HUM PATHOL, V44, P95, DOI 10.1016/j.humpath.2012.04.020; Chang WC, 2012, AM J SURG PATHOL, V36, P454, DOI 10.1097/PAS.0b013e31823dafd3; Cheng L, 2009, MODERN PATHOL, V22, pS70, DOI 10.1038/modpathol.2009.1; Descotes F, 2014, BJU INT, V113, P333, DOI 10.1111/bju.12364; Gendy R, 2016, BJU INT, V117, P54, DOI 10.1111/bju.13265; Hajian-Tilaki K, 2013, CASP J INTERN MED, V4, P627; Hermann GG, 1998, J UROLOGY, V159, P91, DOI 10.1016/S0022-5347(01)64021-7; Holmang S, 1997, J UROLOGY, V157, P800, DOI 10.1016/S0022-5347(01)65044-4; Hu ZH, 2014, ANN DIAGN PATHOL, V18, P49, DOI 10.1016/j.anndiagpath.2013.11.002; Lee JY, 2012, KOREAN J UROL, V53, P317, DOI 10.4111/kju.2012.53.5.317; Li G, 2016, SCI REP-UK, V6, DOI 10.1038/srep27586; Mhawech P, 2002, EUR UROL, V42, P459, DOI 10.1016/S0302-2838(02)00368-8; Mhawech-Fauceglia P, 2007, BJU INT, V100, P1182, DOI 10.1111/j.1464-410X.2007.07090.x; Moch H, 2015, WHO CLASSIFICATION T; Munari E, 2015, HISTOPATHOLOGY, V66, P262, DOI 10.1111/his.12499; Nepple Kenneth G, 2009, Can Urol Assoc J, V3, pS188; Orsola A, 2005, EUR UROL, V48, P231, DOI 10.1016/j.eururo.2005.04.013; Orsola A, 2015, BRIT J CANCER, V112, P468, DOI 10.1038/bjc.2014.633; Otto W, 2017, INT UROL NEPHROL, V49, P431, DOI 10.1007/s11255-016-1491-9; Ozyalvacli ME, 2015, CUAJ-CAN UROL ASSOC, V9, pE126, DOI 10.5489/cuaj.2523; Patriarca C, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0466-6; Rose M, 2014, CARCINOGENESIS, V35, P727, DOI 10.1093/carcin/bgt375; Roupret M, 2013, J UROLOGY, V189, P2069, DOI 10.1016/j.juro.2012.11.120; Soukup V, 2014, UROL INT, V92, P150, DOI 10.1159/000355358; van de Putte EEF, 2016, WORLD J UROL, V34, P157, DOI 10.1007/s00345-015-1636-y; van Rhijn BWG, 2012, EUR UROL, V61, P378, DOI 10.1016/j.eururo.2011.10.026; Wettstein MS, 2015, DIS MARKERS, P1, DOI 10.1155/2015/785461	29	7	7	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					E1	E10		10.1097/PAS.0000000000000964			10	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200001	29076872				2019-10-28	
J	Palmer, MV				Palmer, Mitchell V.			Emerging Understanding of Tuberculosis and the Granuloma by Comparative Analysis in Humans, Cattle, Zebrafish, and Nonhuman Primates	VETERINARY PATHOLOGY			English	Editorial Material						bovine; granuloma; mycobacteria; nonhuman primate; tuberculosis; zebrafish	MYCOBACTERIUM-BOVIS INFECTION; DELTA T-CELLS; IMMUNE-RESPONSES; RAPID DETECTION; I PROCOLLAGEN; EXPRESSION; PATHOLOGY; ANTIBODY; ASSAY		[Palmer, Mitchell V.] USDA, Infect Bacterial Dis Livestock, Natl Anim Dis Ctr, Ames, IA USA	Palmer, MV (reprint author), Natl Anim Dis Ctr, Infect Bacterial Dis Livestock, 1920 Dayton Ave, Ames, IA 50010 USA.	mitchell.palmer@ars.usda.gov	Palmer, Mitchell/R-7091-2018	Palmer, Mitchell/0000-0002-5902-3333			Ameni Gobena, 2012, Vet Med Int, V2012, P457872, DOI 10.1155/2012/457872; Aranday-Cortes E, 2013, TRANSBOUND EMERG DIS, V60, P525, DOI 10.1111/j.1865-1682.2012.01370.x; Buddle BM, 2009, NEW ZEAL VET J, V57, P173, DOI 10.1080/00480169.2009.36899; Davis JM, 2009, CELL, V136, P37, DOI 10.1016/j.cell.2008.11.014; Gideon HP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004603; Greenwald R, 2009, CLIN VACCINE IMMUNOL, V16, P605, DOI 10.1128/CVI.00038-09; HEIN WR, 1991, IMMUNOL TODAY, V12, P30, DOI 10.1016/0167-5699(91)90109-7; Johnson L, 2007, TUBERCULOSIS, V87, P71, DOI 10.1016/j.tube.2006.04.002; Johnson L, 2006, VET IMMUNOL IMMUNOP, V111, P219, DOI 10.1016/j.vetimm.2006.01.016; Lin PL, 2014, NAT MED, V20, P75, DOI 10.1038/nm.3412; Lin PL, 2009, INFECT IMMUN, V77, P4631, DOI 10.1128/IAI.00592-09; Lyashchenko KP, 2013, CLIN VACCINE IMMUNOL, V20, P907, DOI 10.1128/CVI.00120-13; Lyashchenko KP, 2012, CLIN VACCINE IMMUNOL, V19, P1269, DOI 10.1128/CVI.00163-12; Martinot AJ, 2017, VET PATHOL; Maue AC, 2005, INFECT IMMUN, V73, P6659, DOI 10.1128/IAI.73.10.6659-6667.2005; McGill JL, 2014, VET IMMUNOL IMMUNOP, V159, P133, DOI 10.1016/j.vetimm.2014.02.010; Meijer AH, 2016, SEMIN IMMUNOPATHOL, V38, P261, DOI 10.1007/s00281-015-0522-4; Mustafa T, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-535; Palmer MV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167471; Rhodes SG, 2000, IMMUNOLOGY, V99, P195, DOI 10.1046/j.1365-2567.2000.00944.x; Salguero FJ, 2016, TRANSBOUND EMERG DIS; Shu D, 2014, VET IMMUNOL IMMUNOP, V160, P81, DOI 10.1016/j.vetimm.2014.03.017; Vordermeier HM, 2016, VET IMMUNOL IMMUNOP, V181, P10, DOI 10.1016/j.vetimm.2016.02.003; Wangoo A, 2005, J COMP PATHOL, V133, P223, DOI 10.1016/j.jcpa.2005.05.001; WANGOO A, 1995, J CLIN PATHOL, V48, P339, DOI 10.1136/jcp.48.4.339; Waters W.R, 2011, CLIN DEV IMMUNOL, V2011, DOI DOI 10.1155/2011/768542; Waters W Ray, 2011, Vet Med Int, V2011, P953985, DOI 10.4061/2011/953985; WOOD PR, 1990, RES VET SCI, V49, P46, DOI 10.1016/S0034-5288(18)31044-0	28	2	2	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		8	10		10.1177/0300985817712795			3	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300002	29254474	Bronze			2019-10-28	
J	Raskin, RE				Raskin, Rose E.			Diagnostic Tools and Dilemmas With Equine Leukemias	VETERINARY PATHOLOGY			English	Editorial Material							HORSES		[Raskin, Rose E.] Purdue Univ, Dept Comparat Pathobiol, 725 Harrison St, W Lafayette, IN 47907 USA	Raskin, RE (reprint author), Purdue Univ, Dept Comparat Pathobiol, 725 Harrison St, W Lafayette, IN 47907 USA.	rraskin@purdue.edu					Al-Rukibat R, 1998, CASE PRESENTATION SL; Barrell EA, 2017, J VET DIAGN INVEST, V29, P529, DOI 10.1177/1040638717707724; Cooper CJ, 2017, VET PATHOL; McClure JT, 2001, J VET INTERN MED, V15, P144, DOI 10.1892/0891-6640(2001)015<0144:ICOLIH>2.3.CO;2; Meichner K, 2017, VET CLIN PATH, V46, P64, DOI 10.1111/vcp.12435; Ringger NC, 1997, AUST VET J, V75, P329, DOI 10.1111/j.1751-0813.1997.tb15702.x	6	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		11	13		10.1177/0300985817738315			3	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300003	29254473	Bronze			2019-10-28	
J	Martinot, AJ				Martinot, Amanda J.			Microbial Offense vs Host Defense: Who Controls the TB Granuloma?	VETERINARY PATHOLOGY			English	Review						tuberculosis; Mycobacterium tuberculosis; Mycobacterium marinum; in vivo; virulence; granuloma; mice; zebrafish; transposon mutagenesis; caseous necrosis	MYCOBACTERIUM-TUBERCULOSIS INFECTION; NECROSIS-FACTOR-ALPHA; FUNCTIONAL-CHARACTERIZATION; PHTHIOCEROL DIMYCOCEROSATE; CYNOMOLGUS MACAQUES; CYTOKINE RESPONSE; SECRETION SYSTEM; BACTERIAL-GROWTH; VIRULENCE FACTOR; IMMUNE-RESPONSE	The granuloma is the hallmark of tuberculosis and simultaneously signifies acquisition of an infection and induction of a host immune response. But who benefits more from the development of the granuloma, the host or the pathogen? Is microbe or man dictating disease course and progression? Mycobacterial diseases affect humans and animals alike, and the concepts presented in this review reflect host-pathogen interactions that influence not only mycobacterial granulomas in humans and animals but also other infectious granulomatous diseases that are encountered in veterinary medicine. Current dogma supports that an organized granuloma is a mark of an adequate and restrictive host immune response. However, the formation of a granuloma also provides a niche for the maturation, growth, and persistence of numerous infectious agents, and these pathogens devote some portion of their genetic machinery to ensuring these structures' form. An understanding of pathogens' contributions to granuloma formation can aid the development of host-directed therapies and other antimicrobial and antiparasitic therapies that can tip this balance in favor of a restrictive host response and eliminationnot just containmentof the infectious organism. This review discusses animal models that have aided our understanding of pathogens' contribution to the host response and how mycobacterial virulence genes direct host pathology in ways that may aid disease transmission and/or persistence in the form of latent infection.	[Martinot, Amanda J.] Harvard Med Sch, Ctr Virol & Vaccine Res, Beth Israel Deaconess Med Ctr, E CLS 1024-B7, Boston, MA 02115 USA	Martinot, AJ (reprint author), Harvard Med Sch, Ctr Virol & Vaccine Res, Beth Israel Deaconess Med Ctr, E CLS 1024-B7, Boston, MA 02115 USA.	amartino@bidmc.harvard.edu					ADAMS DO, 1976, AM J PATHOL, V84, P164; Aguilo JI, 2013, CELL MICROBIOL, V15, P1994, DOI 10.1111/cmi.12169; Anbazhagan P, 2014, TUBERCULOSIS, V94, P405, DOI 10.1016/j.tube.2014.03.003; Arora G, 2014, J BIOL CHEM, V289, P25149, DOI 10.1074/jbc.M114.597682; Barber DL, 2011, J IMMUNOL, V186, P1598, DOI 10.4049/jimmunol.1003304; BEKIERKUNST A, 1969, J BACTERIOL, V100, P95; Berthet FX, 1998, SCIENCE, V282, P759, DOI 10.1126/science.282.5389.759; Bigi F, 2004, MICROBES INFECT, V6, P182, DOI 10.1016/j.micinf.2003.10.010; Braibant M, 2000, FEMS MICROBIOL REV, V24, P449, DOI 10.1016/S0168-6445(00)00034-6; Brodin P, 2006, INFECT IMMUN, V74, P88, DOI 10.1128/IAI.74.1.88-98.2006; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; Cambier CJ, 2014, NATURE, V505, P218, DOI 10.1038/nature12799; Capuano SV, 2003, INFECT IMMUN, V71, P5831, DOI 10.1128/IAI.71.10.5831-5844.2003; Capyk JK, 2009, J BIOL CHEM, V284, P35534, DOI 10.1074/jbc.M109.072132; Carpenter SM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005380; Castell A, 2005, PROTEIN SCI, V14, P1850, DOI 10.1110/ps.051442305; Chang JC, 2007, J INFECT DIS, V196, P788, DOI 10.1086/520089; Chang JC, 2009, J BACTERIOL, V191, P5232, DOI 10.1128/JB.00452-09; Chen JM, 2012, J BACTERIOL, V194, P884, DOI 10.1128/JB.06417-11; Choudhuri BS, 2002, BIOCHEM J, V367, P279, DOI 10.1042/BJ20020615; Clay H, 2008, IMMUNITY, V29, P283, DOI 10.1016/j.immuni.2008.06.011; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Comas I, 2010, NAT GENET, V42, P498, DOI 10.1038/ng.590; Cooper AM, 2015, COLD SPRING HARB PER, V5; Coscolla M, 2015, CELL HOST MICROBE, V18, P538, DOI 10.1016/j.chom.2015.10.008; Cosma CL, 2006, INFECT IMMUN, V74, P3125, DOI 10.1128/IAI.02061-05; Cox JS, 1999, NATURE, V402, P79; Cronan MR, 2016, IMMUNITY, V45, P861, DOI 10.1016/j.immuni.2016.09.014; Cronan MR, 2014, DIS MODEL MECH, V7, P777, DOI 10.1242/dmm.016089; Davis JM, 2009, CELL, V136, P37, DOI 10.1016/j.cell.2008.11.014; Day TA, 2014, INFECT IMMUN, V82, P5214, DOI 10.1128/IAI.01340-13; de Mendonca-Lima L, 2003, CELL MICROBIOL, V5, P65, DOI 10.1046/j.1462-5822.2003.00237.x; Di Luca M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052059; Dorhoi A, 2014, SEMIN IMMUNOL, V26, P203, DOI 10.1016/j.smim.2014.04.003; Drage MG, 2010, NAT STRUCT MOL BIOL, V17, P1088, DOI 10.1038/nsmb.1869; Egen JG, 2008, IMMUNITY, V28, P271, DOI 10.1016/j.immuni.2007.12.010; Ehlers S, 1999, FEMS IMMUNOL MED MIC, V23, P149, DOI 10.1016/S0928-8244(98)00130-8; Ermann J, 2015, NAT REV RHEUMATOL, V11, P541, DOI 10.1038/nrrheum.2015.71; Farrow MF, 2008, J BACTERIOL, V190, P1783, DOI 10.1128/JB.01046-07; Flynn JL, 2003, TUBERCULOSIS, V83, P116, DOI 10.1016/S1472-9792(02)00059-8; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; Frank DJ, 2014, J BIOL CHEM, V289, P30417, DOI 10.1074/jbc.M114.602771; Gaur RL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004376; Gengenbacher M, 2012, FEMS MICROBIOL REV, V36, P514, DOI 10.1111/j.1574-6976.2012.00331.x; Griffin JE, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002251; Groschel MI, 2016, NAT REV MICROBIOL, V14, P677, DOI 10.1038/nrmicro.2016.131; Grzegorzewicz AE, 2016, J BIOL CHEM, V291, P18867, DOI 10.1074/jbc.M116.739227; Harari A, 2011, NAT MED, V17, P372, DOI 10.1038/nm.2299; Healy C, 2016, TUBERCULOSIS, V97, P154, DOI 10.1016/j.tube.2015.10.003; Houben D, 2012, CELL MICROBIOL, V14, P1287, DOI 10.1111/j.1462-5822.2012.01799.x; Hunter RL, 2006, AM J PATHOL, V168, P1249, DOI 10.2353/ajpath.2006.050848; Hunter RL, 2007, TUBERCULOSIS, V87, P267, DOI 10.1016/j.tube.2006.11.003; Hunter RL, 2016, TUBERCULOSIS, V97, P8, DOI 10.1016/j.tube.2015.11.010; Jain M, 2007, P NATL ACAD SCI USA, V104, P5133, DOI 10.1073/pnas.0610634104; Joshi SA, 2012, CHEM BIOL, V19, P372, DOI 10.1016/j.chembiol.2012.01.008; Kalscheuer R, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.MGM2-0002-2013; Kalscheuer R, 2010, P NATL ACAD SCI USA, V107, P21761, DOI 10.1073/pnas.1014642108; Kaushal D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9533; Keane J, 2005, RHEUMATOLOGY, V44, P714, DOI 10.1093/rheumatology/keh567; Kendall SL, 2007, MOL MICROBIOL, V65, P684, DOI 10.1111/j.1365-2958.2007.05827.x; Kiran D, 2016, SEMIN IMMUNOPATHOL, V38, P167, DOI 10.1007/s00281-015-0537-x; Klepp LI, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-3; Kocincova D, 2004, FEMS MICROBIOL LETT, V231, P191, DOI 10.1016/S0378-1097(03)00964-9; Kramnik I, 2016, SEMIN IMMUNOPATHOL, V38, P221, DOI 10.1007/s00281-015-0538-9; Kumar A, 2013, ACTA CRYSTALLOGR D, V69, P2543, DOI 10.1107/S0907444913026371; Lam SH, 2004, DEV COMP IMMUNOL, V28, P9, DOI 10.1016/S0145-305X(03)00103-4; Lam THJ, 2008, MICROB PATHOGENESIS, V45, P12, DOI 10.1016/j.micpath.2008.01.006; Lazar-Molnar E, 2010, P NATL ACAD SCI USA, V107, P13402, DOI 10.1073/pnas.1007394107; Lee W, 2013, J BIOL CHEM, V288, P6788, DOI 10.1074/jbc.M112.445056; Lewis KN, 2003, J INFECT DIS, V187, P117, DOI 10.1086/345862; Lin PL, 2006, INFECT IMMUN, V74, P3790, DOI 10.1128/IAI.00064-06; Lin PL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005739; Liu Z, 2013, J BIOL CHEM, V288, P18473, DOI 10.1074/jbc.M113.466912; Logunova N, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005672; Mahajan S, 2012, J IMMUNOL, V188, P5593, DOI 10.4049/jimmunol.1103038; Mann S, 2006, FEBS J, V273, P4778, DOI 10.1111/j.1742-4658.2006.05479.x; Martinot AJ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005351; Matsunaga I, 2004, J EXP MED, V200, P1559, DOI 10.1084/jem.20041429; MEDLAR E M, 1956, J Lancet, V76, P82; Millington KA, 2011, P NATL ACAD SCI USA, V108, P5730, DOI 10.1073/pnas.1015153108; Mishra BB, 2013, NAT IMMUNOL, V14, P52, DOI 10.1038/ni.2474; Mishra BB, 2010, CELL MICROBIOL, V12, P1046, DOI 10.1111/j.1462-5822.2010.01450.x; Munoz-Elias EJ, 2006, CELL MICROBIOL, V8, P10, DOI 10.1111/j.1462-5822.2005.00648.x; Nienaber L, 2015, FEBS J, V282, P2708, DOI 10.1111/febs.13313; NORTH RJ, 1993, AM J PATHOL, V142, P1959; Novotny L, 2010, J FISH DIS, V33, P947, DOI 10.1111/j.1365-2761.2010.01202.x; Oehlers SH, 2015, NATURE, V517, P612, DOI 10.1038/nature13967; Orme IM, 2014, SEMIN IMMUNOL, V26, P601, DOI 10.1016/j.smim.2014.09.009; Pandey AK, 2008, P NATL ACAD SCI USA, V105, P4376, DOI 10.1073/pnas.0711159105; Pang XH, 2013, J BACTERIOL, V195, P66, DOI 10.1128/JB.01067-12; Parish T, 2007, J BACTERIOL, V189, P3721, DOI 10.1128/JB.01740-06; Park SW, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002264; Pasricha R, 2014, PATHOG DIS, V72, P188, DOI 10.1111/2049-632X.12200; Pena JC, 2015, INFECT IMMUN, V83, P852, DOI 10.1128/IAI.02850-14; Prigozhin DM, 2013, J BIOL CHEM, V288, P31549, DOI 10.1074/jbc.M113.510792; Purushotham G, 2015, MOL MICROBIOL, V98, P586, DOI 10.1111/mmi.13144; Raghavan S, 2008, NATURE, V454, P717, DOI 10.1038/nature07219; Rajagopalan M, 2010, J BIOL CHEM, V285, P15816, DOI 10.1074/jbc.M109.040097; Ramon-Garcia S, 2009, ANTIMICROB AGENTS CH, V53, P3675, DOI 10.1128/AAC.00550-09; Rengarajan J, 2008, P NATL ACAD SCI USA, V105, P264, DOI 10.1073/pnas.0710601105; Rogerson BJ, 2006, IMMUNOLOGY, V118, P195, DOI 10.1111/j.1365-2567.2006.02355.x; Rousseau C, 2004, CELL MICROBIOL, V6, P277, DOI 10.1111/j.1462-5822.2004.00368.x; Russell DG, 2009, NAT IMMUNOL, V10, P943, DOI 10.1038/ni.1781; Saini NK, 2016, MICROB PATHOGENESIS, V100, P43, DOI 10.1016/j.micpath.2016.08.038; Saini NK, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-200; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Savvi S, 2008, J BACTERIOL, V190, P3886, DOI 10.1128/JB.01767-07; Seidel M, 2007, J BIOL CHEM, V282, P14729, DOI 10.1074/jbc.M700271200; Shukla S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004471; Siegrist MS, 2010, METHOD MOL BIOL, V465, P311; Singh V, 2012, CELL HOST MICROBE, V12, P669, DOI 10.1016/j.chom.2012.09.012; Smith CM, 2016, MBIO, V7, DOI [10.1128/mbio.01516-16, 10.1128/mBio.01516-16]; Spigelman M, 2015, TUBERCULOSIS, V95, pS145, DOI 10.1016/j.tube.2015.02.022; Srivastava S, 2013, J IMMUNOL, V191, P1016, DOI 10.4049/jimmunol.1301236; Sulzenbacher G, 2006, EMBO J, V25, P1436, DOI 10.1038/sj.emboj.7601048; Tang Q, 2014, MOL MICROBIOL, V94, P1006, DOI 10.1111/mmi.12817; Tian J, 2005, MOL MICROBIOL, V57, P859, DOI 10.1111/j.1365-2958.2005.04741.x; Tiwari B, 2014, FEBS J, V281, P1556, DOI 10.1111/febs.12723; van der Geize R, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002181; van Pinxteren LAH, 2000, EUR J IMMUNOL, V30, P3689, DOI 10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.3.CO;2-W; Venugopal A, 2011, CELL HOST MICROBE, V9, P21, DOI 10.1016/j.chom.2010.12.004; Bianco MV, 2011, VIRULENCE, V2, P233, DOI 10.4161/viru.2.3.15888; Volkman HE, 2010, SCIENCE, V327, P466, DOI 10.1126/science.1179663; Volkman HE, 2004, PLOS BIOL, V2, P1946, DOI 10.1371/journal.pbio.0020367; Wang F, 2007, CHEM BIOL, V14, P543, DOI 10.1016/j.chembiol.2007.04.005; Woodworth JS, 2011, J IMMUNOL, V186, P1627, DOI 10.4049/jimmunol.1002911; Zhang CQ, 2015, J CLIN LAB ANAL, V29, P375, DOI 10.1002/jcla.21782; Zhang XL, 2015, FASEB J, V29, P4804, DOI 10.1096/fj.15-270843; Zhang YJJ, 2013, CELL, V155, P1296, DOI 10.1016/j.cell.2013.10.045	129	3	3	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		14	26		10.1177/0300985817705177			13	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300004	28749750	Bronze			2019-10-28	
J	Stimmer, L; Fovet, CM; Serguera, C				Stimmer, Lev; Fovet, Claire-Maelle; Serguera, Che			Experimental Models of Autoimmune Demyelinating Diseases in Nonhuman Primates	VETERINARY PATHOLOGY			English	Review						experimental autoimmune encephalomyelitis; animal models; nonhuman primate; ADEM; NMO; multiple sclerosis; neuro-inflammation; demyelination; review	MYELIN OLIGODENDROCYTE GLYCOPROTEIN; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS LESIONS; BLOOD-BRAIN-BARRIER; HUMAN MYELIN/OLIGODENDROCYTE GLYCOPROTEIN; CD8(+) T-CELLS; RHESUS-MONKEYS; COMMON MARMOSETS; BASIC-PROTEIN	Human idiopathic inflammatory demyelinating diseases (IIDD) are a heterogeneous group of autoimmune inflammatory and demyelinating disorders of the central nervous system (CNS). These include multiple sclerosis (MS), the most common chronic IIDD, but also rarer disorders such as acute disseminated encephalomyelitis (ADEM) and neuromyelitis optica (NMO). Great efforts have been made to understand the pathophysiology of MS, leading to the development of a few effective treatments. Nonetheless, IIDD still require a better understanding of the causes and underlying mechanisms to implement more effective therapies and diagnostic methods. Experimental autoimmune encephalomyelitis (EAE) is a commonly used animal model to study the pathophysiology of IIDD. EAE is principally induced through immunization with myelin antigens combined with immune-activating adjuvants. Nonhuman primates (NHP), the phylogenetically closest relatives of humans, challenged by similar microorganisms as other primates may recapitulate comparable immune responses to that of humans. In this review, the authors describe EAE models in 3 NHP species: rhesus macaques (Macaca mulatta), cynomolgus macaques (Macaca fascicularis), and common marmosets (Callithrix jacchus), evaluating their respective contribution to the understanding of human IIDD. EAE in NHP is a heterogeneous disease, including acute monophasic and chronic polyphasic forms. This diversity makes it a versatile model to use in translational research. This clinical variability also creates an opportunity to explore multiple facets of immune-mediated mechanisms of neuro-inflammation and demyelination as well as intrinsic protective mechanisms. Here, the authors review current insights into the pathogenesis and immunopathological mechanisms implicated in the development of EAE in NHP.	[Stimmer, Lev] CEA, INSERM, Platform Expt Pathol U1169 US27, Mol Imaging Res Ctr, 8 Route Panorama, F-92265 Fontenay Aux Roses, France; [Fovet, Claire-Maelle] CEA, INSERM, Platform Gen Surg U1169 US27, Mol Imaging Res Ctr, Fontenay Aux Roses, France; [Serguera, Che] CEA, INSERM, US27, Mol Imaging Res Ctr, Fontenay Aux Roses, France	Stimmer, L (reprint author), CEA, INSERM, Platform Expt Pathol U1169 US27, Mol Imaging Res Ctr, 8 Route Panorama, F-92265 Fontenay Aux Roses, France.	lev.stimmer@cea.fr		Serguera, Che/0000-0002-9210-0636			Aggarwal S, 2011, TRENDS CELL BIOL, V21, P585, DOI 10.1016/j.tcb.2011.06.004; Anderson AC, 2000, J EXP MED, V191, P761, DOI 10.1084/jem.191.5.761; Axisa PP, 2016, CURR OPIN NEUROL, V29, P345, DOI 10.1097/WCO.0000000000000319; Axthelm MK, 2011, ANN NEUROL, V70, P362, DOI 10.1002/ana.22449; Axthelm MK, 2004, J NEUROPATH EXP NEUR, V63, P750, DOI 10.1093/jnen/63.7.750; Babbe H, 2000, J EXP MED, V192, P393, DOI 10.1084/jem.192.3.393; Baker D, 2014, MULT SCLER RELAT DIS, V3, P555, DOI 10.1016/j.msard.2014.05.002; Barcellos LF, 2006, HUM MOL GENET, V15, P2813, DOI 10.1093/hmg/ddl223; Bauchet AL, 2013, STUDY INFLAMMATORY P, P261; Beecham AH, 2013, NAT GENET, V45, P1353, DOI 10.1038/ng.2770; Behan PO, 2014, MULT SCLER RELAT DIS, V3, P565, DOI 10.1016/j.msard.2014.06.003; Belbasis L, 2015, LANCET NEUROL, V14, P263, DOI 10.1016/S1474-4422(14)70267-4; Berer K, 2011, MOL IMMUNOL, V48, P1332, DOI 10.1016/j.molimm.2010.10.025; Bettelli E, 2003, J EXP MED, V197, P1073, DOI 10.1084/jem.20021603; Bettelli E, 2006, J CLIN INVEST, V116, P2393, DOI 10.1172/JCI28334; Billiau A, 2001, J LEUKOCYTE BIOL, V70, P849; Boche D, 2013, NEUROPATH APPL NEURO, V39, P3, DOI 10.1111/nan.12011; Brok HPM, 2002, J IMMUNOL, V169, P6554, DOI 10.4049/jimmunol.169.11.6554; BRUCK W, 1995, ANN NEUROL, V38, P788, DOI 10.1002/ana.410380514; Carter CJ, 2012, IMMUNOPHARM IMMUNOT, V34, P21, DOI 10.3109/08923973.2011.572262; Clements CS, 2003, P NATL ACAD SCI USA, V100, P11059, DOI 10.1073/pnas.1833158100; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Constantinescu CS, 2011, BRIT J PHARMACOL, V164, P1079, DOI 10.1111/j.1476-5381.2011.01302.x; Day Michael J., 2005, P25, DOI 10.1007/0-387-25518-4_3; de Rosbo NK, 2000, J NEUROIMMUNOL, V110, P83, DOI 10.1016/S0165-5728(00)00306-4; de Vos AF, 2002, J IMMUNOL, V169, P5415, DOI 10.4049/jimmunol.169.10.5415; Delarasse C, 2003, J CLIN INVEST, V112, P544, DOI 10.1172/JCI200315861; Dendrou CA, 2015, NAT REV IMMUNOL, V15, P545, DOI 10.1038/nri3871; deRosbo NK, 1997, EUR J IMMUNOL, V27, P3059, DOI 10.1002/eji.1830271144; Desai RA, 2016, ANN NEUROL, V79, P591, DOI 10.1002/ana.24607; Du L, 2016, MOL NEUROBIOL; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; Fotheringham Julie, 2005, Herpes, V12, P4; Friese MA, 2006, BRAIN, V129, P1940, DOI 10.1093/brain/awl083; Furlan R, 2003, BRAIN, V126, P285, DOI 10.1093/brain/awg031; Garcia-Vallejo JJ, 2014, J EXP MED, V211, P1457, DOI 10.1084/jem.20122192; Genain CP, 1995, J CLIN INVEST, V96, P2966, DOI 10.1172/JCI118368; Genain CP, 2001, IMMUNOL REV, V183, P159, DOI 10.1034/j.1600-065x.2001.1830113.x; GLANZMANN E, 1927, SCHWEIZ MED WSCHR, V57, P145; Haanstra KG, 2015, J IMMUNOL, V194, P1454, DOI 10.4049/jimmunol.1402563; Haanstra KG, 2013, J NEUROIMMUNE PHARM, V8, P1251, DOI 10.1007/s11481-013-9487-z; Haanstra KG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071549; Han HJ, 2013, BIOFACTORS, V39, P233, DOI 10.1002/biof.1076; Hardy TA, 2016, LANCET NEUROL, V15, P967, DOI 10.1016/S1474-4422(16)30043-6; Harrington CJ, 1998, IMMUNITY, V8, P571, DOI 10.1016/S1074-7613(00)80562-2; Hickey WF, 2001, GLIA, V36, P118, DOI 10.1002/glia.1101; Holmoy T, 2008, CURR OPIN INFECT DIS, V21, P271, DOI 10.1097/QCO.0b013e3282f88b48; Hoppmann N, 2015, BRAIN, V138, P902, DOI 10.1093/brain/awu408; Housley WJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9223; Huseby ES, 2001, J EXP MED, V194, P669, DOI 10.1084/jem.194.5.669; Jagessar SA, 2008, J NEUROPATH EXP NEUR, V67, P326, DOI 10.1097/NEN.0b013e31816a6851; Jagessar SA, 2012, EUR J IMMUNOL, V42, P217, DOI 10.1002/eji.201141863; Jorg S, 2016, CELL MOL LIFE SCI, V73, P4611, DOI 10.1007/s00018-016-2311-1; Johns TG, 1999, J NEUROCHEM, V72, P1, DOI 10.1046/j.1471-4159.1999.0720001.x; KABAT EA, 1946, SCIENCE, V104, P362, DOI 10.1126/science.104.2703.362; Kaliyaperumal S, 2013, AM J PATHOL, V183, P1910, DOI 10.1016/j.ajpath.2013.08.007; Kanzaki A, 1994, Rinsho Shinkeigaku, V34, P511; Kap YS, 2008, J IMMUNOL, V180, P1326, DOI 10.4049/jimmunol.180.3.1326; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Krishnamoorthy G, 2006, J CLIN INVEST, V116, P2385, DOI 10.1172/JCI28330; Ladewig G, 2009, EXP NEUROL, V220, P207, DOI 10.1016/j.expneurol.2009.08.027; Lange C, 2011, BRAIN BEHAV IMMUN, V25, P120, DOI 10.1016/j.bbi.2010.09.004; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Larochelle C, 2011, FEBS LETT, V585, P3770, DOI 10.1016/j.febslet.2011.04.066; Lassmann H, 2004, TRENDS IMMUNOL, V25, P132, DOI 10.1016/j.it.2004.01.007; LEBAR R, 1986, CLIN EXP IMMUNOL, V66, P423; LININGTON C, 1987, J NEUROIMMUNOL, V17, P61, DOI 10.1016/0165-5728(87)90031-2; Loeffler C, 2011, NEUROPATHOLOGY, V31, P230, DOI 10.1111/j.1440-1789.2010.01167.x; Love S, 2006, J CLIN PATHOL, V59, P1151, DOI 10.1136/jcp.2005.031195; Lunemann JD, 2007, CURR NEUROL NEUROSCI, V7, P253, DOI 10.1007/s11910-007-0038-y; Maggi P, 2014, ANN NEUROL, V76, P594, DOI 10.1002/ana.24242; Marta CB, 2005, P NATL ACAD SCI USA, V102, P13992, DOI 10.1073/pnas.0504979102; MASSACESI L, 1995, ANN NEUROL, V37, P519, DOI 10.1002/ana.410370415; Mayer MC, 2012, THER ADV NEUROL DISO, V5, P147, DOI 10.1177/1756285611433772; Mazzarino P, 2005, EUR J IMMUNOL, V35, P3240, DOI 10.1002/eji.200535343; McFarland HI, 1999, J IMMUNOL, V162, P2384; MCRAE BL, 1995, J EXP MED, V182, P75, DOI 10.1084/jem.182.1.75; Meinl E, 2011, J NEUROL SCI, V306, P180, DOI 10.1016/j.jns.2010.08.009; Monteyne P, 1998, CURR OPIN NEUROL, V11, P287, DOI 10.1097/00019052-199808000-00002; NAMER IJ, 1994, EUR NEUROL, V34, P224, DOI 10.1159/000117043; NIBLACK GD, 1977, IMMUNOLOGY, V32, P257; Nunez-Iglesias MJ, 2010, PHARMACOL BIOCHEM BE, V97, P350, DOI 10.1016/j.pbb.2010.09.002; Owens T, 2001, NAT MED, V7, P161, DOI 10.1038/84603; Pesic M, 2013, J CLIN INVEST, V123, P1192, DOI 10.1172/JCI67233; PETTE M, 1990, P NATL ACAD SCI USA, V87, P7968, DOI 10.1073/pnas.87.20.7968; PHAMDINH D, 1994, J NEUROCHEM, V63, P2353; Popescu BFG, 2012, ANNU REV PATHOL-MECH, V7, P185, DOI 10.1146/annurev-pathol-011811-132443; Raine CS, 1999, ANN NEUROL, V46, P144, DOI 10.1002/1531-8249(199908)46:2<144::AID-ANA3>3.0.CO;2-K; Ransohoff RM, 2012, NAT NEUROSCI, V15, P1074, DOI 10.1038/nn.3168; Reboldi A, 2009, NAT IMMUNOL, V10, P514, DOI 10.1038/ni.1716; Reindl M, 2013, NAT REV NEUROL, V9, P455, DOI 10.1038/nrneurol.2013.118; Reindl M, 2006, J NEUROIMMUNOL, V180, P50, DOI 10.1016/j.jneuroim.2006.06.028; Rivers TM, 1935, J EXP MED, V61, P689, DOI 10.1084/jem.61.5.689; ROSE LM, 1987, CLIN IMMUNOL IMMUNOP, V44, P93, DOI 10.1016/0090-1229(87)90055-9; ROSE LM, 1991, CLIN IMMUNOL IMMUNOP, V59, P1, DOI 10.1016/0090-1229(91)90077-N; Sasaki K, 2014, J IMMUNOL, V192, P3029, DOI 10.4049/jimmunol.1302911; Skalsky RL, 2016, J VIROL, V90, P9350, DOI 10.1128/JVI.01123-16; Sobel RA, 2008, GREENFIELDS NEUROPAT, P1513; Stys PK, 2012, NAT REV NEUROSCI, V13, P507, DOI 10.1038/nrn3275; Su SB, 2005, J IMMUNOL, V175, P6303, DOI 10.4049/jimmunol.175.10.6303; 't Hart BA, 2005, J NEUROIMMUNOL, V168, P1, DOI 10.1016/j.jneuroim.2005.05.017; 't Hart BA, 1998, AM J PATHOL, V153, P649, DOI 10.1016/S0002-9440(10)65606-4; 't Hart BA, 2016, MULT SCLER J, V22, P559, DOI 10.1177/1352458515591862; 't Hart BA, 2015, EUR J PHARMACOL, V759, P14, DOI 10.1016/j.ejphar.2015.03.030; 't Hart BA, 2015, ANN CLIN TRANSL NEUR, V2, P581, DOI 10.1002/acn3.194; 't Hart BA, 2011, TRENDS MOL MED, V17, P119, DOI 10.1016/j.molmed.2010.11.006; 't Hart BA, 2009, TRENDS MOL MED, V15, P235, DOI 10.1016/j.molmed.2009.04.001; t'Hart BA, 2005, J IMMUNOL, V175, P4761; T'Hart BA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00145; Tardieu M, 2004, EUR J PAEDIATR NEURO, V8, P239, DOI 10.1016/j.ejpn.2004.05.006; TSUKADA N, 1988, ACTA NEUROPATHOL, V77, P39, DOI 10.1007/BF00688241; Tsunoda I, 2007, AM J PATHOL, V171, P1563, DOI 10.2353/ajpath.2007.070147; Van Epps HL, 2005, J EXP MED, V202, P4, DOI 10.1084/jem.2021fta; van Zwam M, 2010, J NEUROIMMUNOL, V225, P112, DOI 10.1016/j.jneuroim.2010.04.021; van Zwam M, 2009, J PATHOL, V217, P543, DOI 10.1002/path.2476; van Zwam M, 2009, J MOL MED, V87, P273, DOI 10.1007/s00109-008-0421-4; VANLAMBALGEN R, 1987, CLIN EXP IMMUNOL, V68, P100; Vatanen T, 2016, CELL, V165, P1551, DOI 10.1016/j.cell.2016.05.056; von Budingen HC, 2004, EUR J IMMUNOL, V34, P2072, DOI 10.1002/eji.200324843; von Herrath MG, 2003, NAT REV MICROBIOL, V1, P151, DOI 10.1038/nrmicro754; Wiendl H, 2002, BIODRUGS, V16, P183, DOI 10.2165/00063030-200216030-00003; Xu HP, 2003, J NEUROIMMUNOL, V142, P47, DOI 10.1016/S0165-5728(03)00258-3; Yang YH, 2009, J EXP MED, V206, P1549, DOI 10.1084/jem.20082584	123	5	5	1	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		27	41		10.1177/0300985817712794			15	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300005	28583039				2019-10-28	
J	Richter, KR; Nasr, AN; Mexas, AM				Richter, Kristen R.; Nasr, Amirah N.; Mexas, Angela M.			Cytokine Concentrations Measured by Multiplex Assays in Canine Peripheral Blood Samples	VETERINARY PATHOLOGY			English	Review						dog; cytokines; multiplex assays; inflammatory mediators; plasma; serum	MONOCYTE CHEMOTACTIC PROTEIN-1; SERUM ADIPOKINE CONCENTRATIONS; IDIOPATHIC PULMONARY-FIBROSIS; ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; MITRAL-VALVE DISEASE; RACING SLED DOGS; TNF-ALPHA; ATOPIC-DERMATITIS; HEALTHY DOGS	Cytokines are known to play important roles in a wide range of pathologic conditions spanning all organ systems in every species studied. As our knowledge of the physiology of individual cytokines expands and our ability to measure multiple cytokines in smaller biological samples increases, we gain more insight into the significance and function of each cytokine and the importance of cytokine networks. Previous studies that reported measurements of cytokine concentrations from serum or plasma in dogs with infectious, autoimmune, metabolic, endocrine, and neoplastic diseases yield an appreciation for the complexity of cytokine control and potential applications for cytokine measurements in the diagnosis, prognosis, and therapy of a variety of disease conditions. In this review, we highlight the benefits of multiplex cytokine analysis, summarize clinical and experimental reports that have used this technology in dogs, and discuss the strengths and limitations of data analysis for the interpretation of results in these studies. We describe how differences in technical acuity, data reporting tactics, statistical analysis, study population selection criteria, and cross-sectional experimental design methods may affect interpretation of results from this technology. We also suggest methods for analysis in future studies, such as reporting median fluorescence intensity values, analyzing the proportion of patients above population medians, and performing longitudinal studies.	[Richter, Kristen R.; Nasr, Amirah N.; Mexas, Angela M.] Midwestern Univ, Coll Vet Med, 19555 N 59th Ave, Glendale, AZ 85308 USA	Mexas, AM (reprint author), Midwestern Univ, Coll Vet Med, 19555 N 59th Ave, Glendale, AZ 85308 USA.	amexas@midwestern.edu			Midwestern University; MWU's Vice President for Research & Strategic Initiatives' One Health Research Award	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors (A.M.M.) and (K.R.) are supported by intramural funds from Midwestern University for the production of scholarly work that advances knowledge and improves the health of animals and people. Specifically, this study was supported by MWU's Vice President for Research & Strategic Initiatives' One Health Research Award.	BAARSCH MJ, 1991, J IMMUNOL METHODS, V140, P15, DOI 10.1016/0022-1759(91)90121-U; Barthelemy A, 2015, VET J, V205, P410, DOI 10.1016/j.tvjl.2015.05.012; Bastarache JA, 2011, J IMMUNOL METHODS, V367, P33, DOI 10.1016/j.jim.2011.01.005; Bastien BC, 2015, VET IMMUNOL IMMUNOP, V163, P174, DOI 10.1016/j.vetimm.2014.12.003; Becher B, 2017, NAT REV IMMUNOL, V17, P49, DOI 10.1038/nri.2016.123; Breen EJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep26996; Breen EJ, 2015, CYTOKINE, V71, P188, DOI 10.1016/j.cyto.2014.10.030; Brondum L, 2016, SCAND J CLIN LAB INV, V76, P601, DOI 10.1080/00365513.2016.1230882; Brown AL, 2015, EXP PARASITOL, V157, P185, DOI 10.1016/j.exppara.2015.08.002; Calvalido J, 2016, VET IMMUNOL IMMUNOP, V182, P106, DOI 10.1016/j.vetimm.2016.10.009; Cameron MJ, 2003, ADV EXP MED BIOL, V520, P8; Chen XT, 2015, AM J DENT, V28, P9; Cho KD, 2014, J VET INTERN MED, V28, P429, DOI 10.1111/jvim.12270; Christopher-Hennings J, 2013, J VET DIAGN INVEST, V25, P671, DOI 10.1177/1040638713507256; CHRISTOPOULOS TK, 1995, ANAL CHEM, V67, P4290, DOI 10.1021/ac00119a014; Cosgrove SB, 2013, VET DERMATOL, V24, P587, DOI 10.1111/vde.12088; Cosgrove SB, 2013, VET DERMATOL, V24, P479, DOI 10.1111/vde.12047; de Lima VMF, 2007, VET IMMUNOL IMMUNOP, V115, P189, DOI 10.1016/j.vetimm.2006.10.003; DeClue AE, 2012, J VET INTERN MED, V26, P624, DOI 10.1111/j.1939-1676.2012.00895.x; Dinarello CA, 2007, EUR J IMMUNOL, V37, pS34, DOI 10.1002/eji.200737772; Dolinay T, 2012, AM J RESP CRIT CARE, V185, P1225, DOI 10.1164/rccm.201201-0003OC; Dossus L, 2009, J IMMUNOL METHODS, V350, P125, DOI 10.1016/j.jim.2009.09.001; Dvir E, 2012, VET PARASITOL, V190, P185, DOI 10.1016/j.vetpar.2012.06.007; Eirmann LA, 2009, INT J APPL RES VET M, V7, P196; Ellington AA, 2009, CLIN CHEM, V55, P1092, DOI 10.1373/clinchem.2008.120717; Elshal MF, 2006, METHODS, V38, P317, DOI 10.1016/j.ymeth.2005.11.010; Estrela-Lima A, 2016, VET COMP ONCOL, V14, P88, DOI 10.1111/vco.12070; Fan SL, 2016, CLIN CHIM ACTA, V460, P203, DOI 10.1016/j.cca.2016.07.002; Felix AOC, 2013, VET PARASITOL, V193, P312, DOI 10.1016/j.vetpar.2012.11.012; Floras ANK, 2014, J VET INTERN MED, V28, P1447, DOI 10.1111/jvim.12409; Fowler BL, 2011, VET IMMUNOL IMMUNOP, V144, P167, DOI 10.1016/j.vetimm.2011.07.011; Frank L, 2015, VET IMMUNOL IMMUNOP, V167, P104, DOI 10.1016/j.vetimm.2015.07.010; Fung HL, 2014, ACTA TROP, V135, P67, DOI 10.1016/j.actatropica.2014.03.010; Gelaleti GB, 2012, VET IMMUNOL IMMUNOP, V146, P106, DOI 10.1016/j.vetimm.2012.02.005; German AJ, 2009, DOMEST ANIM ENDOCRIN, V37, P214, DOI 10.1016/j.domaniend.2009.07.001; Goddard A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150113; Gogos CA, 2000, J INFECT DIS, V181, P176, DOI 10.1086/315214; Guedes PMM, 2009, VET IMMUNOL IMMUNOP, V130, P43, DOI 10.1016/j.vetimm.2009.01.004; Harris G, 2013, METHODS MOL BIOL, V1061, P265, DOI 10.1007/978-1-62703-589-7_16; Helsel DR, 2006, CHEMOSPHERE, V65, P2434, DOI 10.1016/j.chemosphere.2006.04.051; Hofer J, 2011, VET COMP ONCOL, V9, P290, DOI 10.1111/j.1476-5829.2011.00267.x; de Andres PJ, 2013, VET IMMUNOL IMMUNOP, V152, P245, DOI 10.1016/j.vetimm.2012.12.010; Johnson V, 2016, VET IMMUNOL IMMUNOP, V180, P15, DOI 10.1016/j.vetimm.2016.08.010; Karlsson I, 2012, REPROD DOMEST ANIM, V47, P337, DOI 10.1111/rda.12034; Karlsson I, 2016, VET IMMUNOL IMMUNOP, V170, P41, DOI 10.1016/j.vetimm.2016.01.005; Keppel KE, 2008, VET IMMUNOL IMMUNOP, V123, P337, DOI 10.1016/j.vetimm.2008.02.008; Khaled AR, 2002, NAT REV IMMUNOL, V2, P817, DOI 10.1038/nri931; Kilpatrick S, 2014, VET J, V200, P197, DOI 10.1016/j.tvjl.2014.01.007; Kim AY, 2015, J VET SCI, V16, P333, DOI 10.4142/jvs.2015.16.3.333; Kim HS, 2016, J VET INTERN MED, V30, P1589, DOI 10.1111/jvim.14570; Kjelgaard-Hansen M, 2011, J VET INTERN MED, V25, P76, DOI 10.1111/j.1939-1676.2010.0642.x; Leng SX, 2008, J GERONTOL A-BIOL, V63, P879, DOI 10.1093/gerona/63.8.879; Leonard WJ, 2001, NAT REV IMMUNOL, V1, P200, DOI 10.1038/35105066; Lin A, 2015, METHOD MOL BIOL, V1318; Luiza-Silva M, 2011, J INFECT DIS, V204, P873, DOI 10.1093/infdis/jir439; Lynch HE, 2014, J IMMUNOL METHODS, V409, P62, DOI 10.1016/j.jim.2014.04.011; Machado VS, 2015, PATHOL RES PRACT, V211, P677, DOI 10.1016/j.prp.2015.06.011; Maciel GS, 2014, REPROD DOMEST ANIM, V49, P701, DOI 10.1111/rda.12360; Maiolini A, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-23; Majewska A, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0805-6; Mayer I, 2015, VET ARHIV, V85, P369; McCann TM, 2007, J SMALL ANIM PRACT, V48, P619, DOI 10.1111/j.1748-5827.2007.00335.x; Morel PA, 2016, CYTOKINE; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; Neumann S., 2012, Comparative Clinical Pathology, V21, P539, DOI 10.1007/s00580-010-1126-y; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Nielsen LN, 2013, VET J, V198, P424, DOI 10.1016/j.tvjl.2013.07.030; O'Connell KE, 2014, AUTOIMMUNITY, V47, P505, DOI 10.3109/08916934.2014.930734; O'Neill S, 2012, VET IMMUNOL IMMUNOP, V148, P276, DOI 10.1016/j.vetimm.2012.06.027; Otto CM, 1997, J VET INTERN MED, V11, P65, DOI 10.1111/j.1939-1676.1997.tb00075.x; Paek J, 2014, J VET INTERN MED, V28, P1760, DOI 10.1111/jvim.12437; Paim FC, 2013, KOREAN J PARASITOL, V51, P133, DOI 10.3347/kjp.2013.51.1.133; Perry JA, 2011, VET COMP ONCOL, V9, P55, DOI 10.1111/j.1476-5829.2010.00235.x; do Nascimento PRP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073873; Quaranta A, 2006, BEHAV BRAIN RES, V166, P236, DOI 10.1016/j.bbr.2005.08.001; Quaranta A, 2008, BEHAV BRAIN RES, V186, P256, DOI 10.1016/j.bbr.2007.08.014; Rancan L, 2013, AM J VET RES, V74, P155, DOI 10.2460/ajvr.74.1.155; Raphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011; Riggs C, 2013, VET IMMUNOL IMMUNOP, V156, P229, DOI 10.1016/j.vetimm.2013.09.019; Roels E, 2015, RES VET SCI, V101, P57, DOI 10.1016/j.rvsc.2015.05.020; Roels E, 2015, VET J, V206, P75, DOI 10.1016/j.tvjl.2015.06.001; ROSENBAUM JT, 1995, BRIT J OPHTHALMOL, V79, P970, DOI 10.1136/bjo.79.11.970; Rountree W, 2014, J IMMUNOL METHODS, V409, P72, DOI 10.1016/j.jim.2014.01.007; Safra N, 2016, VET IMMUNOL IMMUNOP, V179, P32, DOI 10.1016/j.vetimm.2016.08.003; Saridomichelakis MN, 2016, VET J, V207, P29, DOI 10.1016/j.tvjl.2015.09.016; Sasso LA, 2012, MICROFLUID NANOFLUID, V13, P603, DOI 10.1007/s10404-012-0980-0; Schett G, 2013, NAT MED, V19, P822, DOI 10.1038/nm.3260; SCHULTE W, 2013, MEDIAT INFLAMM, V1659, P2013; Shen P, 2015, NAT REV IMMUNOL, V15, P441, DOI 10.1038/nri3857; Siniscalchi M, 2014, LATERALITY, V19, P522, DOI 10.1080/1357650X.2013.867971; Strasser A, 2000, J VET MED A, V47, P181, DOI 10.1046/j.1439-0442.2000.00278.x; Titmarsh HF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137377; Vignali DAA, 2000, J IMMUNOL METHODS, V243, P243, DOI 10.1016/S0022-1759(00)00238-6; Vilek J, 2003, CYTOKINE HDB, P3, DOI DOI 10.1016/B978-012689663-3/50005-3; Vitelli-Avelar DM, 2008, SCAND J IMMUNOL, V68, P516, DOI 10.1111/j.1365-3083.2008.02167.x; von Pfeil DJF, 2015, CAN VET J, V56, P1252; Wakshlag JJ, 2010, AM J VET RES, V71, P1207, DOI 10.2460/ajvr.71.10.1207; West NR, 2015, NAT REV IMMUNOL, V15, P615, DOI 10.1038/nri3896; WHICHER JT, 1990, CLIN CHEM, V36, P1269; Whitcomb BW, 2008, PAEDIATR PERINAT EP, V22, P597, DOI 10.1111/j.1365-3016.2008.00969.x; Wynn JL, 2016, P NATL ACAD SCI USA, V113, pE2627, DOI 10.1073/pnas.1515793113; Yazwinski M, 2013, J VET INTERN MED, V27, P371, DOI 10.1111/jvim.12046; Zois NE, 2012, VET J, V192, P106, DOI 10.1016/j.tvjl.2011.05.009; Zygner W, 2015, VET PARASITOL, V211, P23, DOI 10.1016/j.vetpar.2015.04.023; Zygner W, 2014, PARASITOL RES, V113, P1499, DOI 10.1007/s00436-014-3792-1	105	2	2	1	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		53	67		10.1177/0300985817725388			15	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300007	28812527				2019-10-28	
J	Durward-Akhurst, SA; Valberg, SJ				Durward-Akhurst, S. A.; Valberg, S. J.			Immune-Mediated Muscle Diseases of the Horse	VETERINARY PATHOLOGY			English	Review						horse; immunologic; inflammation; musculoskeletal; myositis	HENOCH-SCHONLEIN PURPURA; COMPLEX CLASS-I; MHC CLASS-I; INFLAMMATORY MYOPATHIES; MUSCULAR-DYSTROPHY; SARCOCYSTIS-FAYERI; EXPRESSION; MYOSITIS; INFECTION; ANTIGENS	In horses, immune-mediated muscle disorders can arise from an overzealous immune response to concurrent infections or potentially from an inherent immune response to host muscle antigens. Streptococcus equi ss. equi infection or vaccination can result in infarctive purpura hemorrhagica (IPH) in which vascular deposition of IgA-streptococcal M protein complexes produces ischemia and complete focal infarction of skeletal muscle and internal organs. In Quarter Horse-related breeds with immune-mediated myositis, an apparent abnormal immune response to muscle antigens results in upregulation of major histocompatibility complex class (MHC) I and II on muscle cell membranes, lymphocytic infiltration of lumbar and gluteal myofibers, and subsequent gross muscle atrophy. Rarely, an inflammatory event results in myositis with subsequent systemic calcinosis characterized by a pathognomonic hyperphosphatemia and high fatality rate. This review presents an overview of these immune-mediated myopathies and highlights clinical and pathological features as well as the suspected pathophysiology.	[Durward-Akhurst, S. A.] Univ Minnesota, Coll Vet Med, Dept Vet Populat Med, St Paul 1365 Gortner Ave, St Paul, MN 55108 USA; [Valberg, S. J.] Michigan State Univ, Dept Large Anim Clin Sci, E Lansing, MI 48824 USA	Durward-Akhurst, SA (reprint author), Univ Minnesota, Coll Vet Med, Dept Vet Populat Med, St Paul 1365 Gortner Ave, St Paul, MN 55108 USA.	durwa004@umn.edu		Durward-Akhurst, Sian/0000-0003-3034-1554			Aleman M, 2016, NEUROMUSCULAR DISORD, V26, P85, DOI 10.1016/j.nmd.2015.09.014; APPLEYARD ST, 1985, LANCET, V1, P361; Barrott MJ, 2004, EQUINE VET EDUC, V16, P58; BARTOCCIONI E, 1994, CLIN EXP IMMUNOL, V95, P166; Beech J, 2000, EQUINE VET EDUC, V12, P208; Carter T, 2013, NEPHROL NURS J, V40, P431; Cawthorn R J, 1990, J Vet Diagn Invest, V2, P342; Confalonieri P, 2003, J NEUROIMMUNOL, V142, P130, DOI 10.1016/S0165-5728(03)00255-8; Creus KK, 2009, AUTOIMMUN REV, V8, P627, DOI 10.1016/j.autrev.2009.02.026; Durward-Akhurst SA, 2016, J VET INTERN MED, V30, P1313, DOI 10.1111/jvim.14371; Durward-Akhurst SA, 2016, PLANT AN GEN C 24; Durward-Akhurst S, 2016, EQUINE CLINICAL IMMUNOLOGY, P91; Evans J, 2004, J VET INTERN MED, V18, P679, DOI 10.1892/0891-6640(2004)18<679:CIMACR>2.0.CO;2; Fales-Williams A, 2008, J VET DIAGN INVEST, V20, P692, DOI 10.1177/104063870802000533; GALAN JE, 1985, J IMMUNOL, V135, P3134; Gardner-Medwin JMM, 2002, LANCET, V360, P1197, DOI 10.1016/S0140-6736(02)11279-7; GUNSON DE, 1977, VET PATHOL, V14, P325, DOI 10.1177/030098587701400403; Herd HR, 2015, VET PATHOL, V52, P1191, DOI 10.1177/0300985815584073; Hewer E, 2008, PATHOL RES PRACT, V204, P609, DOI 10.1016/j.prp.2008.03.006; Hilton H, 2008, J VET INTERN MED, V22, P1061, DOI 10.1111/j.1939-1676.2008.0115.x; Hohlfield R, 2004, MYOLOGY BASIC CLIN, P889; Huang L, 2001, MOL CELL ENDOCRINOL, V181, P199, DOI 10.1016/S0303-7207(01)00486-5; Jain A, 2007, ARCH PATHOL LAB MED, V131, P1070; Kaese Heather J., 2005, Journal of the American Veterinary Medical Association, V226, P1893, DOI 10.2460/javma.2005.226.1893; KARPATI G, 1988, ANN NEUROL, V23, P64, DOI 10.1002/ana.410230111; KAUFFMANN RH, 1980, AM J MED, V69, P859, DOI 10.1016/S0002-9343(80)80011-8; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Lewis SS, 2007, J VET INTERN MED, V21, P495, DOI 10.1892/0891-6640(2007)21[495:SIMIH]2.0.CO;2; Llach F, 1999, KIDNEY INT, V56, pS31, DOI 10.1046/j.1523-1755.1999.07316.x; Mallicote M, 2015, VET CLIN N AM-EQUINE, V31, P27, DOI 10.1016/j.cveq.2014.11.003; MCDOUALL RM, 1989, J NEUROL SCI, V89, P213, DOI 10.1016/0022-510X(89)90023-3; Morita T, 2002, VET PATHOL, V39, P512, DOI 10.1354/vp.39-4-512; Niaudet P, 1998, PEDIATR NEPHROL, V12, P238, DOI 10.1007/s004670050446; Paciello O, 2007, NEUROMUSCULAR DISORD, V17, P313, DOI 10.1016/j.nmd.2007.01.012; Pellegrini-Masini A, 2004, JAVMA-J AM VET MED A, V225, P722, DOI 10.2460/javma.2004.225.722; Pellegrini- Masini A, 2004, J AM VET MED ASSOC, V225, P699; PUCHE RC, 1978, CALC TISS RES, V26, P61, DOI 10.1007/BF02013235; Pumarola M, 2004, MUSCLE NERVE, V29, P782, DOI 10.1002/mus.20043; Pusterla N, 2003, VET REC, V153, P118, DOI 10.1136/vr.153.4.118; Quist EM, 2011, VET PATHOL, V48, pE52, DOI 10.1177/0300985811414034; Rezaie W, 2009, Indian J Nephrol, V19, P115, DOI 10.4103/0971-4065.57109; Saulsbury FT, 2010, CURR OPIN RHEUMATOL, V22, P598, DOI 10.1097/BOR.0b013e32833af608; Schott HC, 2007, VET CLIN N AM-EQUINE, V23, P593, DOI 10.1016/j.cveq.2007.10.002; Schott HC, 1997, P 43 ANN CONV AM ASS, P345; Shelton GD, 2007, NEUROMUSCULAR DISORD, V17, P663, DOI 10.1016/j.nmd.2007.06.466; SOMEKH E, 1983, ARCH DIS CHILD, V58, P929, DOI 10.1136/adc.58.11.929; Sponseller BT, 2005, JAVMA-J AM VET MED A, V227, P1800, DOI 10.2460/javma.2005.227.1800; Sweeney CR, 2005, J VET INTERN MED, V19, P123; Sykes JE, 2011, J VET INTERN MED, V25, P1277, DOI 10.1111/j.1939-1676.2011.00828.x; Tan JY, 2010, CAN VET J, V51, P993; TINLING SP, 1980, J PARASITOL, V66, P458, DOI 10.2307/3280748; TRAUBDARGATZ JL, 1994, J AM VET MED ASSOC, V205, P1574; Valberg S J, 1999, Equine Vet J Suppl, P533; Valberg SJ, 2014, ATHLETIC HORSE PRINC; Valberg SJ, 2015, LARGE ANIMAL INTERNA; Wang L, 2003, CLIN RHEUMATOL, V22, P140, DOI 10.1007/s10067-002-0676-z; Watson KE, 1997, CIRCULATION, V96, P1755, DOI 10.1161/01.CIR.96.6.1755; Wiendl H, 2005, TRENDS IMMUNOL, V26, P373, DOI 10.1016/j.it.2005.05.003; Wu XH, 2007, J IMMUNOL, V179, P4939, DOI 10.4049/jimmunol.179.7.4939	59	7	7	1	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		68	75		10.1177/0300985816688755			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300008	28129093	Bronze			2019-10-28	
J	Vogel, P; Janke, L; Gravano, DM; Lu, MF; Sawant, DV; Bush, D; E, SY; Vignali, DAA; Pillai, A; Rehg, JE				Vogel, Peter; Janke, Laura; Gravano, David M.; Lu, Meifen; Sawant, Deepali V.; Bush, Dorothy; E, Shuyu; Vignali, Dario A. A.; Pillai, Asha; Rehg, Jerold E.			Globule Leukocytes and Other Mast Cells in the Mouse Intestine	VETERINARY PATHOLOGY			English	Article						graft-vs-host; Heligmosomoides bakeri; mast cell; mouse; Treg; Trichuris muris; immunohistochemistry	REGULATORY T-CELLS; TRICHINELLA-SPIRALIS INFECTION; INNATE LYMPHOID-CELLS; ALLERGIC AIRWAY INFLAMMATION; RAT GASTROINTESTINAL MUCOSA; TISSUE-SPECIFIC EXPRESSION; HOST PROTECTIVE IMMUNITY; TUMOR-SUPPRESSOR ARF; HELIGMOSOMOIDES-POLYGYRUS; NIPPOSTRONGYLUS-BRASILIENSIS	Only 2 major mast cell (MC) subtypes are commonly recognized in the mouse: the large connective tissue mast cells (CTMCs) and the mucosal mast cells (MMCs). Interepithelial mucosal inflammatory cells, most commonly identified as globule leukocytes (GLs), represent a third MC subtype in mice, which we term interepithelial mucosal mast cells (ieMMCs). This term clearly distinguishes ieMMCs from lamina proprial MMCs (lpMMCs) while clearly communicating their common MC lineage. Both lpMMCs and ieMMCs are rare in normal mouse intestinal mucosa, but increased numbers of ieMMCs are seen as part of type 2 immune responses to intestinal helminth infections and in food allergies. Interestingly, we found that increased ieMMCs were consistently associated with decreased mucosal inflammation and damage, suggesting that they might have a role in controlling helminth-induced immunopathology. We also found that ieMMC hyperplasia can develop in the absence of helminth infections, for example, in Treg-deficient mice, Arf null mice, some nude mice, and certain graft-vs-host responses. Since tuft cell hyperplasia plays a critical role in type 2 immune responses to intestinal helminths, we looked for (but did not find) any direct relationship between ieMMC and tuft cell numbers in the intestinal mucosa. Much remains to be learned about the differing functions of ieMMCs and lpMMCs in the intestinal mucosa, but an essential step in deciphering their roles in mucosal immune responses will be to apply immunohistochemistry methods to consistently and accurately identify them in tissue sections.	[Vogel, Peter; Janke, Laura; Lu, Meifen; Bush, Dorothy; Rehg, Jerold E.] St Jude Childrens Res Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Gravano, David M.] Univ Calif Merced, Merced, CA USA; [Sawant, Deepali V.; Vignali, Dario A. A.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA; [E, Shuyu; Pillai, Asha] Univ Miami, Sch Med, Miami, FL USA	Vogel, P (reprint author), St Jude Childrens Res Hosp, 262 Danny Thomas Pl, Memphis, TN 38105 USA.	peter.vogel@stjude.org	Rehg, Jerold/N-8111-2018; Janke, Laura/N-8121-2018; Vogel, Peter/N-2490-2018	Janke, Laura/0000-0002-9871-6239; Vogel, Peter/0000-0002-7535-0545	American Lebanese Syrian Associated Charities (ALSAC)American Lebanese Syrian Associated Charities (ALSAC)	The author(s) received the following financial support for the research, authorship, and/or publication of this article: This work was funded by the American Lebanese Syrian Associated Charities (ALSAC).	AKPAVIE SO, 1989, ANAT HISTOL EMBRYOL, V18, P87, DOI 10.1111/j.1439-0264.1989.tb00584.x; ALIZADEH H, 1984, J PARASITOL, V70, P767, DOI 10.2307/3281760; Artis D, 2004, J IMMUNOL, V173, P5626, DOI 10.4049/jimmunol.173.9.5626; Artis D, 2006, INT J PARASITOL, V36, P723, DOI 10.1016/j.ijpara.2006.02.011; AUSTEN KF, 1984, HOSP PRACT, V19, P135; Bancroft AJ, 1998, J IMMUNOL, V160, P3453; BANSEMIR AD, 1994, J PARASITOL, V80, P24, DOI 10.2307/3283340; BEFUR D, 1986, T ROY SOC TROP MED H, V80, P735, DOI 10.1016/0035-9203(86)90372-X; BEFUS AD, 1982, J IMMUNOL, V128, P2475; BEFUS D, 1986, J PEDIATR GASTR NUTR, V5, P517, DOI 10.1097/00005176-198607000-00002; Behnke J, 2010, TRENDS PARASITOL, V26, P524, DOI 10.1016/j.pt.2010.07.001; BEHNKE JM, 1993, PARASITE IMMUNOL, V15, P415, DOI 10.1111/j.1365-3024.1993.tb00626.x; Bell LV, 2008, PARASITE IMMUNOL, V30, P163, DOI 10.1111/j.1365-3024.2007.01017.x; Ben-Smith A, 2003, J HELMINTHOL, V77, P133, DOI 10.1079/JOH2003173; Bennett CL, 2001, NAT GENET, V27, P20; Betts CJ, 1999, PARASITE IMMUNOL, V21, P45, DOI 10.1046/j.1365-3024.1999.00200.x; BIENENSTOCK J, 1983, MONOGR ALLERGY, V18, P124; BIENENSTOCK J, 1982, J ALLERGY CLIN IMMUN, V70, P407, DOI 10.1016/0091-6749(82)90001-X; Bischoff SC, 1996, HISTOPATHOLOGY, V28, P1, DOI 10.1046/j.1365-2559.1996.262309.x; Bisset SA, 1996, VET PARASITOL, V61, P249, DOI 10.1016/0304-4017(95)00836-5; Blankenhaus B, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003913; Blankenhaus B, 2011, J IMMUNOL, V186, P4295, DOI 10.4049/jimmunol.1001920; BROIDE DH, 1989, J IMMUNOL, V143, P1591; CANTIN M, 1972, LAB INVEST, V27, P495; CARR KE, 1968, Z ZELLFORSCH MIK ANA, V86, P153, DOI 10.1007/BF00348521; CARR KE, 1967, J ANAT, V101, P793; Caughey GH, 2011, ADV EXP MED BIOL, V716, P212, DOI 10.1007/978-1-4419-9533-9_12; Chen F, 2012, NAT MED, V18, P260, DOI 10.1038/nm.2628; COLLAN Y, 1972, SCAND J GASTROENTERO, V7, P1; CRAIG SS, 1989, IMMUNOL RES, V8, P130, DOI 10.1007/BF02919075; CROWLE PK, 1981, INFECT IMMUN, V33, P54; D'Elia R, 2009, J IMMUNOL, V182, P2340, DOI 10.4049/jimmunol.0802767; Dawicki W, 2007, CURR OPIN IMMUNOL, V19, P31, DOI 10.1016/j.coi.2006.11.006; De Winter BY, 2012, BBA-MOL BASIS DIS, V1822, P66, DOI 10.1016/j.bbadis.2011.03.016; Donaldson LE, 1996, INT IMMUNOL, V8, P559, DOI 10.1093/intimm/8.4.559; DOUCH PGC, 1986, VET PARASITOL, V20, P315, DOI 10.1016/0304-4017(86)90129-9; DVORAK AM, 1978, LANCET, V1, P498; Ehrlich P, 1878, BEITRAGE THEORIE PRA; Elliott DE, 2008, J IMMUNOL, V181, P2414, DOI 10.4049/jimmunol.181.4.2414; Elliott DE, 2012, CURR OPIN GASTROEN, V28, P551, DOI 10.1097/MOG.0b013e3283572f73; Else KJ, 1998, INT J PARASITOL, V28, P1145, DOI 10.1016/S0020-7519(98)00087-3; ELSE KJ, 1992, IMMUNOLOGY, V75, P232; ENERBACK L, 1985, BIOCHEM J, V227, P661, DOI 10.1042/bj2270661; ENERBACK L, 1987, INT ARCH ALLER A IMM, V82, P249, DOI 10.1159/000234199; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P303, DOI 10.1111/apm.1966.66.3.303; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; Enerback L., 1981, MONOGR ALLERGY, V17, P222; Faulkner H, 1997, EUR J IMMUNOL, V27, P2536, DOI 10.1002/eji.1830271011; FERGUSON A, 1987, ANN ALLERGY, V59, P40; Fernando J, 2013, J IMMUNOL, V191, P4505, DOI 10.4049/jimmunol.1202723; Filbey KJ, 2014, IMMUNOL CELL BIOL, V92, P436, DOI 10.1038/icb.2013.109; Finkelman FD, 2001, J ALLERGY CLIN IMMUN, V107, P772, DOI 10.1067/mai.2001.114989; Finlay CM, 2014, IMMUNOL REV, V259, P206, DOI 10.1111/imr.12164; Fleming JO, 2015, PARASITE IMMUNOL, V37, P277, DOI 10.1111/pim.12175; Fleming JO, 2011, MULT SCLER J, V17, P743, DOI 10.1177/1352458511398054; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; GALLI SJ, 1990, LAB INVEST, V62, P5; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Galli SJ, 2008, J DERMATOL SCI, V49, P7, DOI 10.1016/j.jdermsci.2007.09.009; Galli SJ, 2016, ALLERGOL INT, V65, P3, DOI 10.1016/j.alit.2015.09.002; Galli SJ, 2010, EUR J IMMUNOL, V40, P1843, DOI 10.1002/eji.201040559; GAMBLE HR, 1992, VET PARASITOL, V41, P211, DOI 10.1016/0304-4017(92)90081-J; Gerbe F, 2016, NATURE, V529, P226, DOI 10.1038/nature16527; Gerbe F, 2012, CELL MOL LIFE SCI, V69, P2907, DOI 10.1007/s00018-012-0984-7; Godfraind C, 1998, J IMMUNOL, V160, P3989; Grainger JR, 2010, J EXP MED, V207, P2331, DOI 10.1084/jem.20101074; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Grimbaldeston MA, 2006, CURR OPIN IMMUNOL, V18, P751, DOI 10.1016/j.coi.2006.09.011; Groschwitz KR, 2013, AM J PHYSIOL-GASTR L, V304, pG479, DOI 10.1152/ajpgi.00186.2012; Gurish MF, 2006, J ALLERGY CLIN IMMUN, V117, P1285, DOI 10.1016/j.jaci.2006.04.017; Gurish MF, 1997, BLOOD, V90, P382; Gurish MF, 2012, IMMUNITY, V37, P25, DOI 10.1016/j.immuni.2012.07.003; HA TY, 1983, INFECT IMMUN, V41, P445; Halim TYF, 2016, INT IMMUNOL, V28, P13, DOI 10.1093/intimm/dxv050; Hamilton MJ, 2014, INFLAMM BOWEL DIS, V20, P2364, DOI 10.1097/MIB.0000000000000142; Hamilton MJ, 2011, P NATL ACAD SCI USA, V108, P290, DOI 10.1073/pnas.1005758108; Hang L, 2013, J IMMUNOL, V191, P1927, DOI 10.4049/jimmunol.1201457; HARGIS AM, 1983, VET PATHOL, V20, P71, DOI 10.1177/030098588302000108; Harrison GBL, 1999, INT J PARASITOL, V29, P459, DOI 10.1016/S0020-7519(98)00221-5; HAYDEN DW, 1975, AM J VET RES, V36, P1605; Hayes KS, 2004, IMMUNOL REV, V201, P75, DOI 10.1111/j.0105-2896.2004.00193.x; Hepworth MR, 2012, P NATL ACAD SCI USA, V109, P6644, DOI 10.1073/pnas.1112268109; Herbert DR, 2009, J EXP MED, V206, P2947, DOI 10.1084/jem.20091268; Hershko AY, 2010, IMMUNOL LETT, V128, P98, DOI 10.1016/j.imlet.2009.10.013; HILDERSON H, 1995, VET PARASITOL, V56, P107, DOI 10.1016/0304-4017(94)00656-W; Howitt MR, 2016, SCIENCE, V351, P1329, DOI 10.1126/science.aaf1648; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; HUNTLEY JF, 1990, PARASITE IMMUNOL, V12, P85, DOI 10.1111/j.1365-3024.1990.tb00938.x; HUNTLEY JF, 1984, PARASITE IMMUNOL, V6, P371, DOI 10.1111/j.1365-3024.1984.tb00809.x; HUNTLEY JF, 1985, J CLIN PATHOL, V38, P375, DOI 10.1136/jcp.38.4.375; HUNTLEY JF, 1984, IMMUNOLOGY, V53, P525; IRANI AMA, 1987, J IMMUNOL, V138, P4381; Jamur Maria Celia, 2011, Front Biosci (Schol Ed), V3, P1390; JENKINS D, 1994, T ROY SOC TROP MED H, V88, P269, DOI 10.1016/0035-9203(94)90074-4; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KATZ HR, 1985, J ALLERGY CLIN IMMUN, V76, P250, DOI 10.1016/0091-6749(85)90638-4; Kearney AY, 2015, AGING-US, V7, P613, DOI 10.18632/aging.100813; KELLY JD, 1972, INT ARCH ALLER A IMM, V43, P497, DOI 10.1159/000230865; KENT JF, 1952, ANAT REC, V112, P91, DOI 10.1002/ar.1091120107; KENT JF, 1966, ANAT RECORD, V156, P439, DOI 10.1002/ar.1091560408; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kim BS, 2015, COLD SPRING HARB PER, V7; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; KING SJ, 1984, IMMUNOLOGY, V51, P653; KITAGAWA H, 1988, JPN J VET RES, V36, P83; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1977, NATURE, V268, P442, DOI 10.1038/268442a0; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; Kitamura Y, 2007, P JPN ACAD B-PHYS, V83, P164, DOI 10.2183/pjab.83.164; Knight PA, 2002, AM J PATHOL, V161, P771, DOI 10.1016/S0002-9440(10)64236-8; Knight PA, 2000, J EXP MED, V192, P1849, DOI 10.1084/jem.192.12.1849; Knight PA, 2007, AM J PATHOL, V171, P1237, DOI 10.2353/ajpath.2007.061245; KONNO A, 1995, VET IMMUNOL IMMUNOP, V48, P105, DOI 10.1016/0165-2427(94)05412-L; Kuijk LM, 2012, MOL IMMUNOL, V51, P210, DOI 10.1016/j.molimm.2012.03.020; Kurashima Y, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.7; Kurashima Y, 2013, EUR J IMMUNOL, V43, P3108, DOI 10.1002/eji.201343782; La Flamme AC, 2003, INFECT IMMUN, V71, P4996, DOI 10.1128/IAI.71.9.4996-5004.2003; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Lawrence CE, 2004, GASTROENTEROLOGY, V127, P155, DOI 10.1053/j.gastro.2004.04.004; LAWRENCE JA, 1977, RES VET SCI, V23, P239, DOI 10.1016/S0034-5288(18)33161-8; LEE TDG, 1982, INT ARCH ALLER A IMM, V67, P302, DOI 10.1159/000233037; Liu Q, 2009, INFECT IMMUN, V77, P5347, DOI 10.1128/IAI.01170-08; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Maizels RM, 2012, EXP PARASITOL, V132, P76, DOI 10.1016/j.exppara.2011.08.011; da Silva EZM, 2014, J HISTOCHEM CYTOCHEM, V62, P698, DOI 10.1369/0022155414545334; MARSHALL JS, 1987, BRIT J DERMATOL, V117, P29, DOI 10.1111/j.1365-2133.1987.tb04087.x; Maruyama H, 2000, J IMMUNOL, V164, P3749, DOI 10.4049/jimmunol.164.7.3749; MAYRHOFER G, 1981, INT ARCH ALLER A IMM, V64, P320, DOI 10.1159/000232710; McDermott JR, 2003, P NATL ACAD SCI USA, V100, P7761, DOI 10.1073/pnas.1231488100; McSorley HJ, 2013, INT J PARASITOL, V43, P301, DOI 10.1016/j.ijpara.2012.11.011; McSorley HJ, 2012, EUR J IMMUNOL, V42, P2667, DOI 10.1002/eji.201142161; Miller HRP, 1996, VET IMMUNOL IMMUNOP, V54, P331, DOI 10.1016/S0165-2427(96)05696-6; Miller HRP, 2002, IMMUNOLOGY, V105, P375, DOI 10.1046/j.1365-2567.2002.01375.x; MILLER HRP, 1971, IMMUNOLOGY, V20, P277; MILLER HRP, 1988, IMMUNOLOGY, V65, P559; MITCHELL LA, 1983, PARASITE IMMUNOL, V5, P1, DOI 10.1111/j.1365-3024.1983.tb00718.x; MURRAY M, 1968, LAB INVEST, V19, P222; MURRAY M, 1971, EXP PARASITOL, V30, P58, DOI 10.1016/0014-4894(71)90070-1; NAWA Y, 1985, PARASITE IMMUNOL, V7, P429, DOI 10.1111/j.1365-3024.1985.tb00088.x; NEWLANDS GFJ, 1987, IMMUNOLOGY, V62, P629; Nussbaum JC, 2013, NATURE, V502, P245, DOI 10.1038/nature12526; OKU Y, 1984, IMMUNOLOGY, V53, P337; Onah Denis Nnabuike, 2000, Korean Journal of Parasitology, V38, P209; Palomares O, 2014, GENES IMMUN, V15, P511, DOI 10.1038/gene.2014.45; Patel N, 2009, INT J PARASITOL, V39, P13, DOI 10.1016/j.ijpara.2008.08.003; Pennock JL, 2006, CHEM IMMUNOL ALLERGY, V90, P128, DOI 10.1159/000088885; Pillai AB, 2009, BLOOD, V113, P4458, DOI 10.1182/blood-2008-06-165506; Rausch S, 2009, EUR J IMMUNOL, V39, P3066, DOI 10.1002/eji.200939644; Ray A, 2010, MUCOSAL IMMUNOL, V3, P216, DOI 10.1038/mi.2010.4; Reber LL, 2015, MUCOSAL IMMUNOL, V8, P444, DOI 10.1038/mi.2014.131; Reber LL, 2012, TRENDS IMMUNOL, V33, P613, DOI 10.1016/j.it.2012.09.008; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; Robinson N, 2010, VET RES, V41, DOI 10.1051/vetres/2010009; Rodgers DT, 2014, IMMUNOLOGY, V141, P457, DOI 10.1111/imm.12208; Roediger B, 2015, ADV IMMUNOL, V125, P111, DOI 10.1016/bs.ai.2014.09.004; Roka R, 2007, NEUROGASTROENT MOTIL, V19, P57, DOI 10.1111/j.1365-2982.2006.00851.x; RUITENBER EJ, 1976, NATURE, V264, P258, DOI 10.1038/264258a0; Ruitenberg E J, 1979, Adv Exp Med Biol, V114, P687; RUITENBERG EJ, 1979, BRIT J EXP PATHOL, V60, P246; RUITENBERG EJ, 1980, BRIT J EXP PATHOL, V61, P285; RUITENBERG EJ, 1979, INT ARCH ALLER A IMM, V60, P302, DOI 10.1159/000232355; RUITENBERG EJ, 1980, INT ARCH ALLER A IMM, V62, P104, DOI 10.1159/000232500; Ryan JJ, 2007, CRIT REV IMMUNOL, V27, P15, DOI 10.1615/CritRevImmunol.v27.i1.20; Sawant DV, 2014, J IMMUNOL, V192, P2904, DOI 10.4049/jimmunol.1202502; SCUDAMORE CL, 1995, J EXP MED, V182, P1871, DOI 10.1084/jem.182.6.1871; Scudamore CL, 1997, AM J PATHOL, V150, P1661; Scudamore CL, 1998, EUR J CELL BIOL, V75, P321, DOI 10.1016/S0171-9335(98)80065-4; Sethi A, 2015, BIOL BLOOD MARROW TR, V21, pS346, DOI 10.1016/j.bbmt.2014.11.550; Setiawan T, 2007, INFECT IMMUN, V75, P4655, DOI 10.1128/IAI.00358-07; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Smith KA, 2016, MUCOSAL IMMUNOL, V9, P428, DOI 10.1038/mi.2015.73; Smith P, 2007, J IMMUNOL, V178, P4557, DOI 10.4049/jimmunol.178.7.4557; Spoor Melanie S, 2011, Vet Clin Pathol, V40, P136, DOI 10.1111/j.1939-165X.2011.00328.x; STANKIEWICZ M, 1993, J PARASITOL, V79, P940, DOI 10.2307/3283734; STANKIEWICZ M, 1994, INT J PARASITOL, V24, P307, DOI 10.1016/0020-7519(94)90045-0; STANKIEWICZ M, 1995, INT J PARASITOL, V25, P389, DOI 10.1016/0020-7519(94)00104-V; Stear MJ, 1996, PARASITOL TODAY, V12, P438, DOI 10.1016/0169-4758(96)10069-7; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; STEVENS RL, 1986, J IMMUNOL, V137, P291; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; TAKEUCHI A, 1969, ANAT RECORD, V164, P79, DOI 10.1002/ar.1091640106; Tian L, 2011, BLOOD, V118, P1845, DOI 10.1182/blood-2011-04-346056; TONER PG, 1965, ACTA ANAT, V61, P321; Traves PG, 2012, ONCOIMMUNOLOGY, V1, P946, DOI 10.4161/onci.19948; Traves PG, 2011, J IMMUNOL, V187, P6527, DOI 10.4049/jimmunol.1004070; Tsai M, 2015, CURR OPIN IMMUNOL, V36, P80, DOI 10.1016/j.coi.2015.07.001; URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513; URBAN JF, 1995, J IMMUNOL, V154, P4675; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; van der Merwe M, 2013, J IMMUNOL, V191, P5764, DOI 10.4049/jimmunol.1302191; Van Meulder F, 2013, INFECT IMMUN, V81, P1798, DOI 10.1128/IAI.01298-12; van Riet E, 2007, IMMUNOBIOLOGY, V212, P475, DOI 10.1016/j.imbio.2007.03.009; von Moltke J, 2016, NATURE, V529, P221, DOI 10.1038/nature16161; WAHID FN, 1994, PARASITOLOGY, V108, P461, DOI 10.1017/S0031182000076022; Wastling JM, 1997, IMMUNOLOGY, V90, P308, DOI 10.1046/j.1365-2567.1997.00155.x; Welle M, 1997, J LEUKOCYTE BIOL, V61, P233; Weng MQ, 2007, J IMMUNOL, V179, P4721, DOI 10.4049/jimmunol.179.7.4721; WIGGIN CJ, 1990, AM J VET RES, V51, P825; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; WINGREN U, 1983, HISTOCHEM J, V15, P571, DOI 10.1007/BF01954148; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; WOODBURY RG, 1984, NATURE, V312, P450, DOI 10.1038/312450a0; Xing W, 2011, P NATL ACAD SCI USA, V108, P14210, DOI 10.1073/pnas.1111048108; Yang ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059441; Yazdanbakhsh M, 2004, CLIN REV ALLERG IMMU, V26, P15, DOI 10.1385/CRIAI:26:1:15; Yetil A, 2015, ONCOTARGET, V6, P3563, DOI 10.18632/oncotarget.2969; YURT RW, 1977, J BIOL CHEM, V252, P518; ZAJAC AM, 1990, VET PARASITOL, V36, P221, DOI 10.1016/0304-4017(90)90034-9; Zaph C, 2014, PARASITE IMMUNOL, V36, P439, DOI 10.1111/pim.12090; Zhao YP, 2013, J LEUKOCYTE BIOL, V94, P1103, DOI 10.1189/jlb.0213064	216	4	4	1	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		76	97		10.1177/0300985817705174			22	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300009	28494703	Bronze			2019-10-28	
J	Matsumoto, I; Uchida, K; Nakashima, K; Hiyoshi, S; Chambers, JK; Tsujimoto, H; Nakayama, H				Matsumoto, I.; Uchida, K.; Nakashima, K.; Hiyoshi, S.; Chambers, J. K.; Tsujimoto, H.; Nakayama, H.			IgA Antibodies Against Gliadin and Tissue Transglutaminase in Dogs With Chronic Enteritis and Intestinal T-Cell Lymphoma	VETERINARY PATHOLOGY			English	Article						celiac disease; dogs; gliadin; inflammatory bowel disease; intestinal lymphoma; lymphoplasmacytic enteritis; tissue transglutaminase	INFLAMMATORY-BOWEL-DISEASE; IRISH-SETTER DOGS; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURALLY-OCCURRING ENTEROPATHY; ENDOSCOPIC BIOPSY SAMPLES; CELIAC-DISEASE; GASTROINTESTINAL INFLAMMATION; SENSITIVE ENTEROPATHY; ALIMENTARY LYMPHOMA; RECEPTOR GENE	Molecular clonality analysis of T-cell receptor (TCR) genes for diagnosing T-cell lymphoma is widely used in veterinary medicine. However, differentiating chronic enteritis (CE) from intestinal lymphoma is challenging because of the incompatibility between histopathologic and clonality analysis results. On the basis of findings that canine intestinal T-cell lymphoma and celiac disease share some common features, we conducted serologic examinations in combination with histopathologic and T-cell receptor clonality analyses in 48 dogs diagnosed with either CE or intestinal lymphoma. Immunoglobulin A (IgA) and immunoglobulin G (IgG) antibodies against gliadin and tissue transglutaminase (tTG) were quantitatively measured using ELISA. The conditions were classified according to the histopathologic diagnosis, clonality analysis, and combined histopathologic/clonality analysis. Histopathologic analysis showed that dogs with intestinal lymphoma were likely to have high levels of serum IgA antibodies against gliadin and tTG, and serum IgG antibodies against tTG. No correlation between the diagnosed groups and control group was observed in the results of the clonality analysis and histopathologic/clonality analysis. It is interesting that dogs with intestinal lymphoma had a higher serum IgA titer against gliadin and tTG than did dogs with CE. These results suggest an association between repetitive inflammatory stimulation by gliadin peptides and subsequent intestinal lymphoma in dogs.	[Matsumoto, I.; Uchida, K.; Chambers, J. K.; Nakayama, H.] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Pathol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan; [Nakashima, K.] Japan Small Anim Med Ctr, Tokorozawa, Saitama, Japan; [Hiyoshi, S.; Tsujimoto, H.] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Internal Med, Bunkyo Ku, Tokyo, Japan	Uchida, K (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Pathol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	auchidak@mail.ecc.u-tokyo.ac.jp		Matsumoto, Isao/0000-0002-7400-961X; Nakashima, Ko/0000-0002-4823-4821	KEKENHI [26660235]	This study was supported by a Grant-in-Aid for Challenging Exploratory Research (KEKENHI No. 26660235).	Bakakos P, 2001, J ALLERGY CLIN IMMUN, V107, P1089, DOI 10.1067/mai.2001.114651; BATT RM, 1984, RES VET SCI, V37, P339, DOI 10.1016/S0034-5288(18)31875-7; BATT RM, 1987, DIGEST DIS SCI, V32, P184, DOI 10.1007/BF01297107; Bevan S, 1999, J MED GENET, V36, P687; Boer A, 2008, BRIT J DERMATOL, V159, P394, DOI 10.1111/j.1365-2133.2008.08670.x; Camarca A, 2009, J IMMUNOL, V182, P4158, DOI 10.4049/jimmunol.0803181; Carrasco V, 2015, VET PATHOL, V52, P668, DOI 10.1177/0300985814559398; Coyle KA, 2004, VET PATHOL, V41, P141, DOI 10.1354/vp.41-2-141; Dahlbom I, 2005, CLIN DIAGN LAB IMMUN, V12, P254, DOI 10.1128/CDLI.12.2.254-258.2005; Dandrieux JR, 2008, AM J VET RES, V69, P1279, DOI 10.2460/ajvr.69.10.1279; Day MJ, 2008, J COMP PATHOL, V138, pS1, DOI 10.1016/j.jcpa.2008.01.001; Ferrara F, 2010, CLIN EXP IMMUNOL, V159, P217, DOI 10.1111/j.1365-2249.2009.04054.x; Fukushima K, 2009, J VET MED SCI, V71, P1673, DOI 10.1292/jvms.001673; Gieger T, 2011, VET CLIN N AM-SMALL, V41, P419, DOI 10.1016/j.cvsm.2011.02.001; Goto-Koshino Y, 2015, VET IMMUNOL IMMUNOP, V165, P81, DOI 10.1016/j.vetimm.2015.03.005; HALL EJ, 1992, GUT, V33, P198, DOI 10.1136/gut.33.2.198; Hiyoshi S, 2015, VET IMMUNOL IMMUNOP, V165, P138, DOI 10.1016/j.vetimm.2015.03.009; Hogberg L, 2003, SCAND J GASTROENTERO, V38, P61, DOI 10.1080/00365520310000456; Kleinschmidt S, 2006, VET PATHOL, V43, P1000, DOI 10.1354/vp.43-6-1000; Lenhardt A, 2004, DIGEST LIVER DIS, V36, P730, DOI 10.1016/j.dld.2004.06.017; Maeda S, 2016, VET PATHOL, V53, P102, DOI 10.1177/0300985815591081; Maeda S, 2013, J VET INTERN MED, V27, P47, DOI 10.1111/jvim.12023; March JB, 2003, DIGEST DIS SCI, V48, P608, DOI 10.1023/A:1022565522441; Nakashima K, 2015, VET J, V205, P28, DOI 10.1016/j.tvjl.2015.05.001; Oberhuber G, 1999, EUR J GASTROEN HEPAT, V11, P1185, DOI 10.1097/00042737-199910000-00019; Olivero D, 2011, VET IMMUNOL IMMUNOP, V144, P337, DOI 10.1016/j.vetimm.2011.08.011; Ozaki K, 2006, VET PATHOL, V43, P339, DOI 10.1354/vp.43-3-339; Polvi A, 1998, TISSUE ANTIGENS, V52, P543, DOI 10.1111/j.1399-0039.1998.tb03085.x; Polvi A, 1997, TISSUE ANTIGENS, V49, P236, DOI 10.1111/j.1399-0039.1997.tb02744.x; Rostom A, 2006, GASTROENTEROLOGY, V131, P1981, DOI 10.1053/j.gastro.2006.10.004; Samaroo D, 2010, SCHIZOPHR RES, V118, P248, DOI 10.1016/j.schres.2009.08.009; Shewry P.R., 1992, COELIAC DIS, P305; Sugai E, 2010, DIGEST LIVER DIS, V42, P352, DOI 10.1016/j.dld.2009.07.011; Valli V, 2002, HISTOPATHOLOGICAL CL; Villalta D, 2010, CLIN CHEM, V56, P464, DOI 10.1373/clinchem.2009.128132; Vincenzetti S, 2006, VET RES COMMUN, V30, P219, DOI 10.1007/s11259-006-0045-z; Washabau RJ, 2010, J VET INTERN MED, V24, P10, DOI 10.1111/j.1939-1676.2009.0443.x; Willard MD, 2008, J VET INTERN MED, V22, P1084, DOI 10.1111/j.1939-1676.2008.0149.x; Woodward J, 2013, THER ADV CHRONIC DIS, V4, P77, DOI 10.1177/2040622312473174	39	3	3	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		98	107		10.1177/0300985817690212			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300010	29254476	Bronze			2019-10-28	
J	Jeffery, U; LeVine, DN				Jeffery, Unity; LeVine, Dana N.			Canine Neutrophil Extracellular Traps Enhance Clot Formation and Delay Lysis	VETERINARY PATHOLOGY			English	Article						dogs; cell-free DNA; coagulation; fibrinolysis; neutrophil extracellular traps; thrombosis	MEDIATED HEMOLYTIC-ANEMIA; THROMBIN GENERATION; VEIN-THROMBOSIS; DOGS; DNA; THROMBOEMBOLISM; MICROPARTICLES; AUTOIMMUNITY; DEGRADATION; MECHANISMS	Autoimmune diseases increase the risk of thrombosis. Neutrophil extracellular traps (NETs) are webs of DNA and protein that may mediate thrombosis in autoimmune diseases. Human and murine studies show NET-releasing neutrophils within a thrombus promote its growth, but it is unclear to what extent NET fragments released into circulation during inflammation are prothrombotic. This study hypothesized that canine NETs promote clot formation and impair lysis even in the absence of neutrophils. NETs were prepared from PMA-stimulated neutrophils and added to fibrinogen and thrombin or to recalcified pooled canine platelet-poor plasma, tissue factor, and tissue plasminogen activator. Clot formation and lysis were measured spectrophotometrically. NETs did not alter fibrin clot formation, but NETs increased maximum clot formation velocity (P = .001) and delayed lysis (P = .009) of plasma clots compared with supernatants from nonstimulated neutrophils. DNase digestion of NETs reduced their effect on clot lysis but not maximum clot formation velocity. This suggested impaired lysis was principally mediated by DNA within NETs but that NET proteins were principally responsible for increased speed of clot formation. Previous reports suggested elastase or histones might be responsible for the effect of NETs on clot formation. Elastase activity was greatly reduced by plasma, and addition of histones to plasma did not increase formation velocity, suggesting these proteins were not responsible for increasing maximum formation velocity. This study showed that NETs enhanced clot formation and impaired clot lysis in canine platelet-poor plasma. These in vitro findings suggest both NET proteins and DNA may contribute to thrombosis in inflammatory disease.	[Jeffery, Unity] Iowa State Univ, Coll Vet Med, Dept Vet Microbiol & Preventat Med, Ames, IA USA; [LeVine, Dana N.] Iowa State Univ, Coll Vet Med, Dept Vet Clin Sci, Ames, IA USA	Jeffery, U (reprint author), Texas A&M Univ, Coll Vet Med, Dept Vet Pathobiol, College Stn, TX 77840 USA.	ujeffery@cvm.tamu.edu					Ammollo CT, 2011, J THROMB HAEMOST, V9, P1795, DOI 10.1111/j.1538-7836.2011.04422.x; Barrientos L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00166; Behnen M, 2014, J IMMUNOL, V193, P1954, DOI 10.4049/jimmunol.1400478; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Carr AP, 2002, J VET INTERN MED, V16, P504, DOI 10.1892/0891-6640(2002)016<0504:PFFMAT>2.3.CO;2; Celinska-Lowenhoff M, 2014, THROMB HAEMOSTASIS, V112, P287, DOI 10.1160/TH13-11-0980; Fuchs TA, 2012, BLOOD, V120, P1157, DOI 10.1182/blood-2012-02-412197; Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107; Gould TJ, 2015, ARTERIOSCL THROM VAS, V35, P2544, DOI 10.1161/ATVBAHA.115.306035; Gould TJ, 2014, ARTERIOSCL THROM VAS, V34, P1977, DOI 10.1161/ATVBAHA.114.304114; Habets KLL, 2013, EUR J CLIN INVEST, V43, P746, DOI 10.1111/eci.12101; Huang YM, 2015, ARTHRITIS RHEUMATOL, V67, P2780, DOI 10.1002/art.39239; Jeffery U, 2015, VET IMMUNOL IMMUNOP, V168, P262, DOI 10.1016/j.vetimm.2015.10.014; Kolaczkowska E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7673; Laurenson MP, 2010, J VET INTERN MED, V24, P1298, DOI 10.1111/j.1939-1676.2010.0593.x; Leffler J, 2014, CLIN EXP RHEUMATOL, V32, P66; Leffler J, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4264; Massberg S, 2010, NAT MED, V16, P887, DOI 10.1038/nm.2184; Niccolai E, 2015, SEMIN THROMB HEMOST, V41, P413, DOI 10.1055/s-0035-1549850; OHLSSON K, 1971, SCAND J CLIN LAB INV, V28, P251, DOI 10.3109/00365517109095696; Respess M, 2012, J VET INTERN MED, V26, P230, DOI 10.1111/j.1939-1676.2012.00893.x; Saffarzadeh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032366; Saghazadeh A, 2016, CRIT REV ONCOL HEMAT, V99, P272, DOI 10.1016/j.critrevonc.2016.01.007; Sur Chowdhury Chanchal, 2014, Arthritis Res Ther, V16, pR122, DOI 10.1186/ar4579; Szczepaniak P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125069; Varju I, 2015, THROMB HAEMOSTASIS, V113, P1289, DOI 10.1160/TH14-08-0669; von Bruhl ML, 2012, J EXP MED, V209, P819, DOI 10.1084/jem.20112322; Yang CF, 2015, INT J CLIN EXP PATHO, V8, P14075; Yeromonahos C, 2010, BIOPHYS J, V99, P2018, DOI 10.1016/j.bpj.2010.04.059; Yipp BG, 2013, BLOOD, V122, P2784, DOI 10.1182/blood-2013-04-457671; Yusuf HR, 2015, THROMB RES, V135, P50, DOI 10.1016/j.thromres.2014.10.012; Zhang SG, 2014, INTERNAL MED, V53, P2763, DOI 10.2169/internalmedicine.53.2570; Zucker M, 2014, J THROMB HAEMOST, V12, P1121, DOI 10.1111/jth.12600	33	4	4	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		116	123		10.1177/0300985817699860			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300012	28346125	Bronze			2019-10-28	
J	Pasolini, MP; Pagano, TB; Costagliola, A; De Biase, D; Lamagna, B; Auletta, L; Fatone, G; Greco, M; Coluccia, P; Veneziano, V; Pirozzi, C; Raso, GM; Santoro, P; Manna, G; Papparella, S; Paciello, O				Pasolini, Maria P.; Pagano, Teresa B.; Costagliola, Alessandro; De Biase, Davide; Lamagna, Barbara; Auletta, Luigi; Fatone, Gerardo; Greco, Michele; Coluccia, Pierpaolo; Veneziano, Veneziano; Pirozzi, Claudio; Raso, Giuseppina Mattace; Santoro, Pasquale; Manna, Giuseppe; Papparella, Serenella; Paciello, Orlando			Inflammatory Myopathy in Horses With Chronic Piroplasmosis	VETERINARY PATHOLOGY			English	Article						equine; piroplasmosis; myositis; skeletal muscle; autoimmunity	BABESIA-CABALLI INFECTIONS; NECROSIS-FACTOR-ALPHA; CLASS-II ANTIGENS; COMPLEX CLASS-I; THEILERIA-EQUI; QUANTITATIVE DETECTION; LEISHMANIA-INFANTUM; MOLECULAR MIMICRY; INTERFERON-GAMMA; IMMUNE-RESPONSE	Horses affected by chronic piroplasmosis may develop poor performance and muscle atrophy. Here we investigate the pathological and immunopathological aspects of myopathy occurring in chronic equine piroplasmosis. The study included 16 horses serologically positive for equine piroplasms presenting with clinical signs and supporting serum biochemical evidence of a myopathy. Skeletal muscle was evaluated by histopathology, immunohistochemistry, indirect immunofluorescence, and molecular detection of piroplasms and inflammatory cytokines in skeletal muscle. Histologic lesions included muscle fiber atrophy (100% of cases), degenerative changes (13/16, 81%), and perivascular perimysial and endomysial lymphocytic infiltrates (81% of cases). In 15 cases (94%), muscle fibers had strong immunostaining for major histocompatibility complex classes I and II. T lymphocyte populations were mainly CD3+, CD8+, and CD4+ in equal proportions, with a lower number of CD79+ cells. The serum from affected horses was tested by indirect immunofluorescence for binding of IgG, IgM, or IgA to sections of normal equine muscle to detect circulating autoantibodies against muscle antigen(s). In all cases, distinct sarcolemmal staining was detected in sections incubated with serum from affected horses, in contrast to sections incubated with phosphate-buffered saline or equine control sera. Reverse transcription polymerase chain reaction (RT-PCR) testing of muscles from affected animals revealed a significant increase of interferon-, interleukin-12, and tumor necrosis factor- gene expression compared to healthy controls. Theileria equi or Babesia caballi was not detected in samples of affected muscle by RT-PCR. Thus, inflammatory myopathy associated with equine piroplasmosis may involve an autoimmune pathogenesis with upregulation of inflammatory cytokines that may cause myofiber atrophy and degeneration.	[Pasolini, Maria P.; Lamagna, Barbara; Fatone, Gerardo; Greco, Michele; Coluccia, Pierpaolo] Univ Naples Federico II, Dept Vet Med & Anim Prod, Surg Unit, Naples, Italy; [Pagano, Teresa B.; Costagliola, Alessandro; De Biase, Davide; Papparella, Serenella; Paciello, Orlando] Univ Naples Federico II, Dept Vet Med & Anim Prod, Unit Pathol, Via Delpino 1, I-80137 Naples, Italy; [Veneziano, Veneziano] Univ Naples Federico II, Dept Vet Med & Anim Prod, Unit Parasitol, Naples, Italy; [Pirozzi, Claudio; Raso, Giuseppina Mattace] Univ Naples Federico II, Dept Pharm, Naples, Italy; [Santoro, Pasquale] Vet Diagnost Lab Di Lab, Naples, Italy; [Manna, Giuseppe] Ist Zooprofilatt Sperimentale M Aleandri, Natl Reference Ctr Equine Dis, Rome, Italy; [Auletta, Luigi] IRCCS SDN, Via Emanuele Gianturco, Naples, Italy	Costagliola, A; Paciello, O (reprint author), Univ Naples Federico II, Dept Vet Med & Anim Prod, Unit Pathol, Via Delpino 1, I-80137 Naples, Italy.	alex_vet@hotmail.it; paciello@unina.it		Pirozzi, Claudio/0000-0002-3409-5744; VENEZIANO, Vincenzo/0000-0003-2496-4034; De Biase, Davide/0000-0002-8118-9807			ADACHI K, 1992, J VET MED SCI, V54, P1081, DOI 10.1292/jvms.54.1081; Aleman M, 2008, NEUROMUSCULAR DISORD, V18, P277, DOI 10.1016/j.nmd.2008.01.001; Bach JF, 1998, IMMUNOL REV, V164, P139, DOI 10.1111/j.1600-065X.1998.tb01216.x; Bailey SR, 2001, J VET PHARMACOL THER, V24, P209, DOI 10.1046/j.1365-2885.2001.00329.x; BANERJEE D P, 1977, Tropical Animal Health and Production, V9, P153, DOI 10.1007/BF02236589; Bhoora R, 2010, VET PARASITOL, V168, P201, DOI 10.1016/j.vetpar.2009.11.011; Boldbaatar D, 2005, VET PARASITOL, V127, P29, DOI 10.1016/j.vetpar.2004.08.021; BOSE R, 1992, INT J PARASITOL, V22, P627, DOI 10.1016/0020-7519(92)90011-9; Camacho AT, 2005, TROP ANIM HEALTH PRO, V37, P293, DOI 10.1007/s11250-005-5691-z; Costagliola A, 2016, BIOMED RES INT, DOI 10.1155/2016/8016186; Cunha CW, 2006, CLIN VACCINE IMMUNOL, V13, P297, DOI 10.1128/CVI.13.2.297-300.2006; Dalakas MC, 2011, NEUROPATH APPL NEURO, V37, P226, DOI 10.1111/j.1365-2990.2010.01153.x; DALAKAS MC, 1986, JAMA-J AM MED ASSOC, V256, P2381, DOI 10.1001/jama.256.17.2381; DALAKAS MC, 1986, NEUROLOGY, V36, P569, DOI 10.1212/WNL.36.4.569; Das L, 2013, APPL IMMUNOHISTO M M, V21, P539, DOI 10.1097/PAI.0b013e31827d7f16; De Paepe B, 2015, INT J MOL SCI, V16, P18683, DOI 10.3390/ijms160818683; de Waal DT, 2004, EQUINE BABESIOSIS IN; DEWAAL DT, 1987, ONDERSTEPOORT J VET, V54, P561; Durward-Akhurst SA, 2016, J VET INTERN MED, V30, P1313, DOI 10.1111/jvim.14371; Englund P, 2001, AM J PATHOL, V159, P1263, DOI 10.1016/S0002-9440(10)62513-8; Evans J, 2004, J VET INTERN MED, V18, P679, DOI 10.1892/0891-6640(2004)18<679:CIMACR>2.0.CO;2; Figarella-Branger D, 2003, MUSCLE NERVE, V28, P659, DOI 10.1002/mus.10462; Froelich Sonja, 2012, Journal of Parasitology Research, P852591, DOI 10.1155/2012/852591; Frost RA, 2003, ENDOCRINOLOGY, V144, P1770, DOI 10.1210/en.2002-220808; FUJINAMI RS, 1989, IMMUNOL RES, V8, P3, DOI 10.1007/BF02918552; Ghirardello A, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926-013-0335-1; Goes TS, 2007, VET IMMUNOL IMMUNOP, V116, P215, DOI 10.1016/j.vetimm.2006.12.011; Grandi G, 2011, VECTOR-BORNE ZOONOT, V11, P955, DOI 10.1089/vbz.2010.0193; Grundtman C, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2139; Gummow B, 1996, J S AFR VET ASSOC, V67, P204; Hailat NQ, 1997, VET PARASITOL, V69, P1, DOI 10.1016/S0304-4017(96)01100-4; Hall DT, 2011, AGING-US, V3, P702, DOI 10.18632/aging.100358; Hanafusa Y, 1998, J VET MED SCI, V60, P1127, DOI 10.1292/jvms.60.1127; Hankel S, 2006, VET IMMUNOL IMMUNOP, V113, P1, DOI 10.1016/j.vetimm.2006.03.025; Heerden J. van, 1996, Equine Veterinary Education, V8, P3; Iwai LK, 2005, J AUTOIMMUN, V24, P111, DOI 10.1016/j.jaut.2005.01.006; Jubb KVF, 2015, PATHOLOGY OF DOMESTI, V1, P229; KALOVIDOURIS AE, 1995, J RHEUMATOL, V22, P1698; Kim C, 2008, VET PARASITOL, V151, P158, DOI 10.1016/j.vetpar.2007.10.023; Kumar V, 2009, ROBBINS COTRAN PATHO; Laus F, 2013, J VET MED SCI, V75, P715, DOI 10.1292/jvms.12-0449; LEONMONZON M, 1993, MUSCLE NERVE, V16, P408, DOI 10.1002/mus.880160411; Elisa BDL, 2016, TICKS TICK-BORNE DIS, V7, P462, DOI 10.1016/j.ttbdis.2016.01.011; Lewis SS, 2007, J VET INTERN MED, V21, P495, DOI 10.1892/0891-6640(2007)21[495:SIMIH]2.0.CO;2; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165; Lundberg I, 1995, J NEUROIMMUNOL, V63, P9, DOI 10.1016/0165-5728(95)00122-0; MATTHYS P, 1991, INT J CANCER, V49, P77, DOI 10.1002/ijc.2910490115; Mehlhorn H, 1998, PARASITOL RES, V84, P467, DOI 10.1007/s004360050431; Moretti A, 2010, VET J, V184, P346, DOI 10.1016/j.tvjl.2009.03.021; Mosaad Youssef M, 2003, Egypt J Immunol, V10, P19; Nuttall GHF, 1910, CENT BAKTERIOLO PARA, V56, P524; Ohsugi Y, 2007, BIOL PHARM BULL, V30, P2001, DOI 10.1248/bpb.30.2001; Oldfors A, 2006, NEUROLOGY, V66, pS49, DOI 10.1212/01.wnl.0000192127.63013.8d; Paciello O, 2007, NEUROMUSCULAR DISORD, V17, P313, DOI 10.1016/j.nmd.2007.01.012; Paciello O, 2010, MUSCLE NERVE, V41, P355, DOI 10.1002/mus.21502; Paciello O, 2009, FOLIA HISTOCHEM CYTO, V47, P143, DOI 10.2478/v10042-009-0066-3; Paciello O, 2009, NEUROMUSCULAR DISORD, V19, P124, DOI 10.1016/j.nmd.2008.10.013; Phipps L. P., 1996, Equine Veterinary Education, V8, P33; Pumarola M, 2004, MUSCLE NERVE, V29, P782, DOI 10.1002/mus.20043; Ribeiro MFB, 1999, VET RES COMMUN, V23, P385, DOI 10.1023/A:1006389725759; Riihimaki M, 2008, BMC VET RES, V4, DOI 10.1186/1746-6148-4-8; Rothschild C, 2007, EQUINE INFECT DIS, P465; Sakkas LI, 2008, CLIN BIOCHEM, V41, P65, DOI 10.1016/j.clinbiochem.2007.10.008; Sanchez-Matamoros A, 2013, CYTOKINE, V61, P50, DOI 10.1016/j.cyto.2012.10.004; Ternblay JN, 2007, J ALLERGY CLIN IMMUN, V120, P659, DOI 10.1016/j.jaci.2007.04.044; van der Pas J, 2004, J NEUROL NEUROSUR PS, V75, P136; Varadhachary AS, 2010, CURR OPIN RHEUMATOL, V22, P651, DOI 10.1097/BOR.0b013e32833f108a; Vattemi G, 2014, AUTOIMMUN HIGHLIGHTS, V5, P77, DOI 10.1007/s13317-014-0062-2; Wise LN, 2013, J VET INTERN MED, V27, P1334, DOI 10.1111/jvim.12168; Wu XH, 2007, J IMMUNOL, V179, P4939, DOI 10.4049/jimmunol.179.7.4939; Xu YT, 2003, J VET MED SCI, V65, P1015, DOI 10.1292/jvms.65.1015	71	2	2	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		133	143		10.1177/0300985817716262			11	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300014	28718360				2019-10-28	
J	Ferrari, CR; Cooley, J; Mujahid, N; Costa, LR; Wills, RW; Johnson, ME; Swiderski, CE				Ferrari, Claudenir R.; Cooley, Jim; Mujahid, Nisma; Costa, Lais R.; Wills, Robert W.; Johnson, Melanie E.; Swiderski, Cyprianna E.			Horses With Pasture Asthma Have Airway Remodeling That Is Characteristic of Human Asthma	VETERINARY PATHOLOGY			English	Article						airway remodeling; disease models; animal; horses; summer pasture-associated recurrent airway obstruction (SPARAO); heaves; equine asthma; lungs; terminal bronchiolar remodeling	OBSTRUCTIVE PULMONARY-DISEASE; GOBLET CELL HYPERPLASIA; MESSENGER-RNA EXPRESSION; ELASTIC FIBER CONTENT; THIN-SECTION CT; SMOOTH-MUSCLE; ANIMAL-MODELS; MUCUS ACCUMULATION; BASEMENT-MEMBRANE; MODERATE ASTHMA	Severe equine asthma, formerly recurrent airway obstruction (RAO), is the horse counterpart of human asthma, affecting horses maintained indoors in continental climates. Equine pasture asthma, formerly summer pasture RAO, is clinically similar but affects grazing horses during hot, humid conditions in the southeastern United States and United Kingdom. To advance translational relevance of equine pasture asthma to human asthma, histologic features of airway remodeling in human asthma were scored in lung lobes from 15 pasture asthma-affected and 9 control horses of mixed breeds. All noncartilaginous airways were scored using a standardized grading rubric (0-3) in hematoxylin and eosin (HE) and Movat's pentachrome-stained sections; 15 airways were chosen randomly from each lobe for analysis. Logistic regression identified disease, age, and lobe effects on probability of histologic outcomes. Airway smooth muscle (odds ratio [OR] = 2.5, P < .001), goblet cell hyperplasia/metaplasia (OR = 37.6, P < .0001), peribronchiolar elastic system fibers (OR = 4.2, P < .001), peribronchiolar fibrosis (OR = 3.8, P = .01), airway occlusion by mucus/inflammation (OR = 4.2, P = .04), and airway adventitial inflammation (OR = 3.0, P = .01) were significantly greater in diseased airways. A novel complex tissue disorganization, designated terminal bronchiolar remodeling, was overrepresented in diseased airways (OR = 3.7, P < .0001). Distribution of terminal bronchiolar remodeling corresponded to putative sites of air trapping in human asthma, at secondary pulmonary lobules. Age (>15 years) was an independent risk factor for increased peribronchiolar fibrosis, elastic system fibers, and terminal bronchiolar remodeling. Remodeling differed significantly between lung lobes, congruent with nonhomogeneous remodeling in human asthma. Equine pasture asthma recapitulates airway remodeling in human asthma in a manner not achieved in induced animal asthma models, endorsing its translational relevance for human asthma investigation.	[Ferrari, Claudenir R.; Mujahid, Nisma; Costa, Lais R.; Johnson, Melanie E.; Swiderski, Cyprianna E.] Mississippi State Univ, Coll Vet Med, Dept Clin Sci, 240 Wise Ctr Dr, Mississippi State, MS 39762 USA; [Ferrari, Claudenir R.; Cooley, Jim; Wills, Robert W.; Johnson, Melanie E.] Mississippi State Univ, Coll Vet Med, Dept Pathobiol & Populat Med, Starkville, MS USA	Swiderski, CE (reprint author), Mississippi State Univ, Coll Vet Med, Dept Clin Sci, 240 Wise Ctr Dr, Mississippi State, MS 39762 USA.	swiderski@cvm.msstate.edu			Office of Graduate Research; Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University; Department of Population and Preventative Medicine, College of Veterinary Medicine, Mississippi State University	Financial support for this research and its publication was provided by the Office of Graduate Research and the Departments of Clinical Sciences and Population and Preventative Medicine, College of Veterinary Medicine, Mississippi State University.	AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Al-Muhsen S, 2011, J ALLERGY CLIN IMMUN, V128, P451, DOI 10.1016/j.jaci.2011.04.047; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Bai TR, 2005, CLIN SCI, V108, P463, DOI 10.1042/CS20040342; Beadle RE, 2002, EQUINE VET J, V34, P389, DOI 10.2746/042516402776249119; BEAUMONT F, 1985, ALLERGY, V40, P181, DOI 10.1111/j.1398-9995.1985.tb00214.x; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bentley J Kelley, 2008, Proc Am Thorac Soc, V5, P89, DOI 10.1513/pats.200705-063VS; BERGSTEN G, 1974, ACTA VET SCAND, P1; Bittar HET, 2015, ANNU REV PATHOL-MECH, V10, P511, DOI 10.1146/annurev-pathol-012414-040343; BOCK P, 1984, ANAT EMBRYOL, V170, P145, DOI 10.1007/BF00318999; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865, DOI 10.1164/ajrccm.152.3.7663797; Bousquet J, 1996, AM J RESP CRIT CARE, V153, P1648, DOI 10.1164/ajrccm.153.5.8630616; Bullone M, 2015, MOL IMMUNOL, V66, P97, DOI 10.1016/j.molimm.2014.12.005; Busacker A, 2009, CHEST, V135, P48, DOI 10.1378/chest.08-0049; Carroll N, 1996, EUR RESPIR J, V9, P709, DOI 10.1183/09031936.96.09040709; Carroll NG, 2000, AM J RESP CRIT CARE, V161, P244, DOI 10.1164/ajrccm.161.1.9805005; Centers for Disease Control and Prevention, 2016, DAT STAT SURV; CHERNIACK RM, 1995, CLIN CHEST MED, V16, P567; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910, DOI 10.1164/ajrccm.153.3.8630572; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Choe MM, 2006, AM J RESP CELL MOL, V35, P306, DOI 10.1165/rcmb.2005-0443OC; Chu H. W., 2002, Clinical and Experimental Allergy, V32, P1558, DOI 10.1046/j.1365-2222.2002.01477.x; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Corren J, 2008, CURR ALLERGY ASTHM R, V8, P533, DOI 10.1007/s11882-008-0097-4; Costa LRR, 2006, AM J VET RES, V67, P1635, DOI 10.2460/ajvr.67.9.1635; Costa LR, 2016, MANAGING SUMMER PAST; Costa LRR, 2000, AM J VET RES, V61, P167, DOI 10.2460/ajvr.2000.61.167; Dixon PM, 1995, EQUINE VET J, V27, P416, DOI 10.1111/j.2042-3306.1995.tb04421.x; Duca L, 2004, CRIT REV ONCOL HEMAT, V49, P235, DOI 10.1016/j.critrevonc.2003.09.007; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Fahy J V, 2000, Curr Opin Pulm Med, V6, P15, DOI 10.1097/00063198-200001000-00004; Fahy JV, 2002, CHEST, V122, p320S, DOI 10.1378/chest.122.6_suppl.320S; Faul JL, 1997, EUR RESPIR J, V10, P301, DOI 10.1183/09031936.97.10020301; Fitzpatrick AM, 2012, CURR OPIN ALLERGY CL, V12, P193, DOI 10.1097/ACI.0b013e32835090ac; Fleming L, 2015, EUR RESPIR J, V46, P1322, DOI 10.1183/13993003.00780-2015; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; FOLEY FD, 1966, AM REV RESPIR DIS, V93, P17; Fulop T, 1998, PATHOL BIOL, V46, P497; Furness MC, 2010, VET PATHOL, V47, P982, DOI 10.1177/0300985810375051; GALLIVAN GJ, 1990, CAN J VET RES, V54, P99; Gerber V, 2004, J VET INTERN MED, V18, P92, DOI 10.1892/0891-6640(2004)18<92:AMIRAO>2.0.CO;2; Gillespie J. R., 1969, Advances in Veterinary Science, V13, P59; GILLESPIE JR, 1966, J APPL PHYSIOL, V21, P416; GILLESPIE JR, 1964, AM J PHYSIOL, V207, P1067; Girodet PO, 2016, AM J RESP CRIT CARE, V193, P627, DOI 10.1164/rccm.201507-1404OC; Global Initiative for Asthma, 2017 REP GLOB STRAT; GODFREY RWA, 1995, EUR RESPIR J, V8, P922; Gonem S, 2016, J ALLERGY CLIN IMMUN, V137, P417, DOI 10.1016/j.jaci.2015.06.027; Gordon IO, 2013, J ASTHMA, V50, P634, DOI 10.3109/02770903.2013.794239; Grainge CL, 2011, NEW ENGL J MED, V364, P2006, DOI 10.1056/NEJMoa1014350; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Gupta S, 2014, J ALLERGY CLIN IMMUN, V133, P729, DOI 10.1016/j.jaci.2013.09.039; Haley KJ, 1998, AM J RESP CRIT CARE, V158, P565, DOI 10.1164/ajrccm.158.2.9705036; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Hartley RA, 2016, J ALLERGY CLIN IMMUN, V137, P1413, DOI 10.1016/j.jaci.2016.02.001; Hassan M, 2010, J ALLERGY CLIN IMMUN, V125, P1037, DOI 10.1016/j.jaci.2010.02.031; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Hayes D, 2013, CLIN RESPIR J, V7, P135, DOI 10.1111/j.1752-699X.2012.00294.x; Hein WR, 2003, NAT REV IMMUNOL, V3, P79, DOI 10.1038/nri977; Herszberg B, 2006, J ALLERGY CLIN IMMUN, V118, P382, DOI 10.1016/j.jaci.2006.03.044; HOGG JC, 1993, J ALLERGY CLIN IMMUN, V92, P1, DOI 10.1016/0091-6749(93)90029-F; Holgate ST, 2010, CLIN SCI, V118, P439, DOI 10.1042/CS20090474; HORNER WE, 1991, INT ARCH ALLER A IMM, V94, P359; Horohov DW, 2005, VET IMMUNOL IMMUNOP, V108, P237, DOI 10.1016/j.vetimm.2005.07.013; Hoshino M, 1998, THORAX, V53, P21, DOI 10.1136/thx.53.1.21; Houghton AM, 2015, MATRIX BIOL, V44-46, P167, DOI 10.1016/j.matbio.2015.02.002; Huang JTJ, 2016, EUR RESPIR J, V48, P1215, DOI 10.1183/13993003.01125-2016; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; James AL, 2012, AM J RESP CRIT CARE, V185, P1058, DOI 10.1164/rccm.201110-1849OC; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Jucker M, 2010, NAT MED, V16, P1210, DOI 10.1038/nm.2224; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; KAUP FJ, 1990, EQUINE VET J, V22, P349, DOI 10.1111/j.2042-3306.1990.tb04288.x; Kirschvink N, 2008, CURR DRUG TARGETS, V9, P470, DOI 10.2174/138945008784533525; Kraft M, 1999, EUR RESPIR J, V14, P1403, DOI 10.1183/09031936.99.14614039; Kumar RK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00312; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; Kuyper LM, 2003, AM J MED, V115, P6, DOI 10.1016/S0002-9343(03)00241-9; Laurent F, 2000, EUR RADIOL, V10, P1404, DOI 10.1007/s003300000504; Leclere M, 2011, RESPIROLOGY, V16, P1027, DOI 10.1111/j.1440-1843.2011.02033.x; LITTLEJOHN A, 1982, ONDERSTEPOORT J VET, V49, P211; LITTLEJOHN A, 1981, ONDERSTEPOORT J VET, V48, P37; Lugo J, 2006, VET J, V172, P293, DOI 10.1016/j.tvjl.2005.04.018; Mair TS, 1996, VET REC, V138, P89, DOI 10.1136/vr.138.4.89; Martin JG, 2000, EUR RESPIR J, V16, P349, DOI 10.1034/j.1399-3003.2000.16b25.x; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; Maud T, 1999, AM J RESP CRIT CARE, V160, P968; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Michalik M, 2009, MED SCI MONITOR, V15, pBR194; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Mithieux SM, 2005, ADV PROTEIN CHEM, V70, P437, DOI 10.1016/S0065-3233(05)70013-9; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; Mujahid NB, 2011, J EQUINE VET SCI, V31, P246; Mullane K, 2011, BIOCHEM PHARMACOL, V82, P567, DOI 10.1016/j.bcp.2011.06.038; NOWELL JA, 1971, AM REV RESPIR DIS, V103, P313; NYMAN G, 1991, EQUINE VET J, V23, P253, DOI 10.1111/j.2042-3306.1991.tb03713.x; OHRUI T, 1992, AM REV RESPIR DIS, V146, P1501, DOI 10.1164/ajrccm/146.6.1501; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517, DOI 10.1164/ajrccm.163.2.2004039; Park CS, 1997, RADIOLOGY, V203, P361, DOI 10.1148/radiology.203.2.9114089; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; Pascual RM, 2009, J ALLERGY CLIN IMMUN, V124, P883, DOI 10.1016/j.jaci.2009.09.047; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Perrin S, 2014, NATURE, V507, P423, DOI 10.1038/507423a; PIRIE M, 1990, EQUINE VET J, V22, P338, DOI 10.1111/j.2042-3306.1990.tb04286.x; Pirie RS, 2016, EQUINE VET J, V48, P403, DOI 10.1111/evj.12586; Range F, 2007, VET PATHOL, V44, P901, DOI 10.1354/vp.44-6-901; Ray A, 2016, J CLIN INVEST, V126, P2394, DOI 10.1172/JCI84144; Reddel CJ, 2012, PULM PHARMACOL THER, V25, P144, DOI 10.1016/j.pupt.2012.02.001; Robinson NE, 2003, AM J VET RES, V64, P550, DOI 10.2460/ajvr.2003.64.550; Robinson NE, 1996, BRIT VET J, V152, P283, DOI 10.1016/S0007-1935(96)80101-1; Rodgers UR, 2005, PATHOL BIOL, V53, P390, DOI 10.1016/j.patbio.2004.12.022; Roy SR, 2010, J ALLERGY CLIN IMMUN, V125, P636, DOI 10.1016/j.jaci.2009.11.046; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138, DOI 10.1164/ajrccm/143.1.138; Sagar S, 2015, EUR J PHARMACOL, V759, P272, DOI 10.1016/j.ejphar.2015.03.037; Seahorn TL, 1996, J AM VET MED ASSOC, V208, P248; Seahorn TL, 1997, AM J VET RES, V58, P1408; SEAHORN TL, 1993, J AM VET MED ASSOC, V202, P779; Setlakwe EL, 2014, AM J PHYSIOL-LUNG C, V307, pL252, DOI 10.1152/ajplung.00019.2014; Shimura S, 1996, EUR RESPIR J, V9, P1395, DOI 10.1183/09031936.96.09071395; Slejko JF, 2014, J ALLERGY CLIN IMMUN, V133, P1579, DOI 10.1016/j.jaci.2013.10.028; Stern E J, 1993, J Thorac Imaging, V8, P273, DOI 10.1097/00005382-199323000-00003; Sullivan SD, 2007, ALLERGY, V62, P126, DOI 10.1111/j.1398-9995.2006.01254.x; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; Swartz MA, 2001, P NATL ACAD SCI USA, V98, P6180, DOI 10.1073/pnas.111133298; Swiderski CE, 2017, J EQUINE VET SCI, V52, P29, DOI 10.1016/j.jevs.2017.03.219; Szelenyi I, 2000, INFLAMM RES, V49, P639, DOI 10.1007/s000110050642; Teague WG, 2014, J ASTHMA, V51, P677, DOI 10.3109/02770903.2014.914535; Tillie-Leblond I, 2008, ALLERGY, V63, P533, DOI 10.1111/j.1398-9995.2008.01656.x; Tyler W S, 1971, Equine Vet J, V3, P84; Webb WR, 2006, RADIOLOGY, V239, P322, DOI 10.1148/radiol.2392041968; Weibel ER, 1963, MORPHOMETRY HUMAN LU; Wenzel S E, 2005, Exp Lung Res, V31 Suppl 1, P22; Wenzel S, 2006, AM J RESP CRIT CARE, V174, P1173, DOI 10.1164/rccm.2609002; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; WIGGS BR, 1990, J APPL PHYSIOL, V69, P849; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363; Yamauchi Kohei, 2007, Allergol Int, V56, P321, DOI 10.2332/allergolint.R-07-151; YANAI M, 1992, J APPL PHYSIOL, V72, P1016; Zhang SL, 1999, LAB INVEST, V79, P395; Zosky GR, 2007, CLIN EXP ALLERGY, V37, P973, DOI 10.1111/j.1365-2222.2007.02740.x	146	2	2	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		144	158		10.1177/0300985817741729			15	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300015	29254472	Bronze			2019-10-28	
J	Cooper, CJ; Keller, SM; Arroyo, LG; Hewson, J; Kenney, D; Bienzle, D				Cooper, Carina J.; Keller, Stefan M.; Arroyo, Luis G.; Hewson, Joanne; Kenney, Daniel; Bienzle, Dorothee			Acute Leukemia in Horses	VETERINARY PATHOLOGY			English	Article						acute lymphocytic leukemia; acute lymphoblastic leukemia; acute myeloid leukemia; bone marrow; CD172a; equine; immunohistochemistry; ionized calcium-binding adapter molecule-1; allograft inflammatory factor-1	ACUTE MYELOMONOCYTIC LEUKEMIA; WORLD-HEALTH-ORGANIZATION; ACUTE MYELOID-LEUKEMIA; INTRAVASCULAR LEUKOSTASIS; MONOCYTIC LEUKEMIA; 2016 REVISION; CLASSIFICATION; SECONDARY; LYMPHOMA; DIFFERENTIATION	Leukemia is broadly divided into acute and chronic lymphocytic and myeloid types based on the proportion of blasts, morphology of cells, and expression of specific antigens on neoplastic cells. Classifying leukemia in horses can be challenging if blasts predominate and since few antibodies to identify cell types are available. The objective of this study was to describe in detail the clinical and pathologic features of acute leukemia in horses. Twelve horses ranging from 0.2 to 25.9 years of age were diagnosed with acute leukemia. Six cases were classified as acute lymphocytic leukemia (ALL) based on predominance of blasts, lack of granulocytic or monocytic differentiation, and detection of CD3, CD20, and/or CD79a antigens by immunohistochemistry. Six other cases were classified as acute myeloid leukemia (AML) with myelomonocytic (n = 4), basophilic (n = 1), and eosinophilic (n = 1) differentiation based on > 20% bone marrow blasts and partial leukocytic differentiation. Reactivity with antibodies to Iba-1/AIF-1, CD172a, and CD163 was determined for all cases of AML. Eleven horses had thrombocytopenia, 10 had neutropenia, 8 had anemia, all had blasts on blood films, and none had leukocytosis. Ten horses had increased serum acute phase proteins. Bone marrow cellularity ranged from 30% to 100%, and the proportion of blasts ranged from 80% to 100% and 30% to 60% in ALL and AML, respectively. Horses were severely ill at diagnosis and euthanized within days or weeks. Unique features of acute leukemia in horses compared to other species were variable lymphocyte antigen expression (ALL) and frequent inflammation (ALL and AML).	[Cooper, Carina J.; Arroyo, Luis G.; Hewson, Joanne; Kenney, Daniel] Univ Guelph, Dept Clin Studies, Guelph, ON, Canada; [Keller, Stefan M.; Bienzle, Dorothee] Univ Guelph, Dept Pathobiol, 50 Stone Rd E, Guelph, ON N1G 2W1, Canada	Bienzle, D (reprint author), Univ Guelph, Dept Pathobiol, 50 Stone Rd E, Guelph, ON N1G 2W1, Canada.	dbienzle@uoguelph.ca		Bienzle, Dorothee/0000-0002-2301-2931			Abramson JS, 2006, ONCOLOGIST, V11, P384, DOI 10.1634/theoncologist.11-4-384; Achten-Weiler M, 2016, VET QUART, V36, P105, DOI 10.1080/01652176.2015.1110427; Adaszek L, 2011, ZOONOSES PUBLIC HLTH, V58, P514, DOI 10.1111/j.1863-2378.2011.01394.x; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Barrell EA, 2017, J VET DIAGN INVEST, V29, P529, DOI 10.1177/1040638717707724; BERNINI JC, 1995, CANCER, V75, P110, DOI 10.1002/1097-0142(19950101)75:1<110::AID-CNCR2820750118>3.0.CO;2-I; BIENZLE D, 1993, CAN VET J, V34, P36; BLUE J, 1987, J AM VET MED ASSOC, V190, P1562; BOUDREAUX MK, 1984, VET PATHOL, V21, P544, DOI 10.1177/030098588402100521; BUECHNERMAXWELL V, 1994, J VET INTERN MED, V8, P258, DOI 10.1111/j.1939-1676.1994.tb03229.x; BURKHARDT E, 1984, VET PATHOL, V21, P394, DOI 10.1177/030098588402100405; DASCANIO JJ, 1992, J VET INTERN MED, V6, P225, DOI 10.1111/j.1939-1676.1992.tb00343.x; Delcambre GH, 2016, PEERJ, V4, DOI 10.7717/peerj.1601; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; DURANDO MM, 1994, EQUINE VET J, V26, P83, DOI 10.1111/j.2042-3306.1994.tb04339.x; Durham AC, 2013, VET PATHOL, V50, P86, DOI 10.1177/0300985812451603; Esteves CL, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0525-2; Forbes G, 2011, AUST VET J, V89, P269, DOI 10.1111/j.1751-0813.2011.00790.x; Furness MC, 2016, CAN VET J, V57, P1067; Hunger SP, 2015, NEW ENGL J MED, V373, P1541, DOI 10.1056/NEJMra1400972; Ibrahim S, 2012, VET IMMUNOL IMMUNOP, V145, P7, DOI 10.1016/j.vetimm.2011.07.021; Invernizzi R, 2015, MEDITERR J HEMATOL I, V7, DOI 10.4084/MJHID.2015.035; Jagannathan-Bogdan M, 2013, DEVELOPMENT, V140, P2463, DOI 10.1242/dev.083147; Johansson AM, 2007, J VET INTERN MED, V21, P1126, DOI 10.1892/0891-6640(2007)21[1126:CGLIAH]2.0.CO;2; Koch TG, 2006, J VET INTERN MED, V20, P1251, DOI 10.1892/0891-6640(2006)20[1251:LEATEG]2.0.CO;2; Kohler C, 2007, CELL TISSUE RES, V330, P291, DOI 10.1007/s00441-007-0474-7; KOHN CW, 1990, AM J VET RES, V51, P1198; Lee S, 2015, EUR REV MED PHARMACO, V19, P2934; LESTER GD, 1993, J VET INTERN MED, V7, P360, DOI 10.1111/j.1939-1676.1993.tb01031.x; Maverakis E, 2012, CLIN REV ALLERG IMMU, V42, P135, DOI 10.1007/s12016-010-8248-5; McGurrin MKJ, 2004, JAVMA-J AM VET MED A, V224, P83, DOI 10.2460/javma.2004.224.83; Meyer J, 2006, VET PATHOL, V43, P914, DOI 10.1354/vp.43-6-914; Miller CA, 2015, J VET DIAGN INVEST, V27, P86, DOI 10.1177/1040638714561653; MONTEITH CN, 1995, CAN VET J, V36, P765; MORI T, 1991, VET PATHOL, V28, P344, DOI 10.1177/030098589102800415; Pavlidis NA, 2002, ONCOLOGIST, V7, P279; Rendle DI, 2007, EQUINE VET J, V39, P522, DOI 10.2746/042516407X2163271; Riley RS, 2009, J CLIN LAB ANAL, V23, P259, DOI 10.1002/jcla.20305; Ringger NC, 1997, AUST VET J, V75, P329, DOI 10.1111/j.1751-0813.1997.tb15702.x; Roode SC, 2015, CHROMOSOME RES, V23, P681, DOI 10.1007/s10577-015-9475-7; SPIER SJ, 1986, J AM VET MED ASSOC, V188, P861; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Thomsen JH, 2013, OXID MED CELL LONGEV, DOI 10.1155/2013/523652; Valli V., 2015, JUBB KENNEDY PALMERS, V3, P102; Weiss DJ, 2001, VET CLIN PATH, V30, P67, DOI 10.1111/j.1939-165X.2001.tb00261.x	45	5	5	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		159	172		10.1177/0300985817720983			14	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300016	28812528	Bronze			2019-10-28	
J	Yamada, N; Hashimoto, N; Kamiie, J; Doi, T; Sato, J; Inoue, T; Shirota, K; Tsuchitani, M				Yamada, Naoaki; Hashimoto, Nanako; Kamiie, Junichi; Doi, Takuya; Sato, Junko; Inoue, Takeshi; Shirota, Kinji; Tsuchitani, Minoru			Relationship Between Immunoglobulin Deposition and Early Lesions of Progressive Glomerulonephropathy in Young Common Marmosets	VETERINARY PATHOLOGY			English	Article						glomerulonephropathy; glomerulonephritis; immunoglobulin M; immunohistochemistry; kidney; ultrastructure; marmoset; IgM nephropathy; minimal change disease	CALLITRICHID IGM NEPHROPATHY; CALLITHRIX-JACCHUS; DISEASE	The authors previously investigated progressive glomerulonephropathy in 2- to 11-year-old common marmosets and characterized age-related changes of the renal glomeruli and development of tubulointerstitial lesions. In this study, immunoglobulin deposition and ultrastructural changes of the glomeruli were investigated in 5 young marmosets from 6 months to 3 years of age with pre-onset or early glomerulonephropathy. In all animals, the foot processes of podocytes were effaced, and IgM was deposited into the glomeruli. In glomeruli without glomerular basement membrane (GBM) alteration, IgM was the only immunoglobulin type deposited in the glomeruli. In cases with more advanced lesions of reticulation and thickening of GBM, IgA and IgG deposits were also observed. Therefore, the authors conclude that IgM may be the primary or earliest immunoglobulin deposited in this nephropathy, whereas IgA and IgG deposition may be connected to the progression of the glomerular lesions. IgM deposition and foot process effacement of podocytes occur early in the life of affected marmosets.	[Yamada, Naoaki; Doi, Takuya; Sato, Junko; Tsuchitani, Minoru] LSI Medience Corp, Dept Pathol, Nonclin Res Ctr, Kashima Lab, 14-1 Sunayama, Kamisu, Ibaraki 3140255, Japan; [Hashimoto, Nanako; Inoue, Takeshi] Cent Inst Expt Anim, Marmoset Res Dept, Kawasaki Ku, Kawasaki, Kanagawa, Japan; [Kamiie, Junichi; Shirota, Kinji] Azabu Univ, Lab Vet Pathol, Chuo Ku, Sagamihara, Kanagawa, Japan	Yamada, N (reprint author), LSI Medience Corp, Dept Pathol, Nonclin Res Ctr, Kashima Lab, 14-1 Sunayama, Kamisu, Ibaraki 3140255, Japan.	yamada.naoaki@mn.medience.co.jp					Barratt TM, 1989, TXB NEPHROLOGY, V1, P625; Brack M, 1999, NEPHRON, V82, P221, DOI 10.1159/000045406; BRACK M, 1995, NEPHRON, V69, P286, DOI 10.1159/000188472; BRACK M, 1995, LAB ANIM, V29, P54, DOI 10.1258/002367795780740366; Herlitz LC, 2014, CLIN J AM SOC NEPHRO, V9, P1033, DOI 10.2215/CJN.11951113; Isobe K, 2012, VET PATHOL, V49, P839, DOI 10.1177/0300985811427151; Suzuki S, 1996, CLIN NEPHROL, V46, P287; TUCKER MJ, 1984, LAB ANIM, V18, P351, DOI 10.1258/002367784780865397; Vanikar Aruna, 2013, J Nephropathol, V2, P98, DOI 10.12860/JNP.2013.16; Yamada N, 2013, TOXICOL PATHOL, V41, P1106, DOI 10.1177/0192623313478206	10	3	3	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		173	176		10.1177/0300985817712556			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300017	28578628				2019-10-28	
J	Friedenberg, SG; Brown, DL; Meurs, KM; Law, JM				Friedenberg, S. G.; Brown, D. L.; Meurs, K. M.; Law, J. McHugh			Lymphocyte Subsets in the Adrenal Glands of Dogs With Primary Hypoadrenocorticism	VETERINARY PATHOLOGY			English	Article						Addison's disease; hypoadrenocorticism; endocrine diseases; adrenal gland; immunophenotype; lymphocyte subsets; dogs	ASSOCIATION; ZEB1	Primary hypoadrenocorticism, or Addison's disease, is an autoimmune condition common in certain dog breeds that leads to the destruction of the adrenal cortex and a clinical syndrome involving anorexia, gastrointestinal upset, and electrolyte imbalances. Previous studies have demonstrated that this destruction is strongly associated with lymphocytic-plasmacytic inflammation and that the lymphocytes are primarily T cells. In this study, we used both immunohistochemistry and in situ hybridization to characterize the T-cell subtypes involved. We collected postmortem specimens of 5 dogs with primary hypoadrenocorticism and 2 control dogs and, using the aforementioned techniques, showed that the lymphocytes are primarily CD4+ rather than CD8+. These findings have important implications for improving our understanding of the pathogenesis and in searching for the underlying causative genetic polymorphisms.	[Friedenberg, S. G.; Meurs, K. M.] North Carolina State Univ, Dept Clin Sci, Coll Vet Med, Raleigh, NC USA; [Friedenberg, S. G.] Univ Minnesota, Coll Vet Med, Dept Vet Clin Sci, St Paul, MN 55108 USA; [Brown, D. L.] WIL Res, Hillsborough, NC USA; [Law, J. McHugh] North Carolina State Univ, Dept Populat Hlth & Pathobiol, Coll Vet Med, Raleigh, NC USA	Friedenberg, SG (reprint author), Univ Minnesota, Coll Vet Med, Dept Vet Clin Sci, St Paul, MN 55108 USA.	fried255@umn.edu	Friedenberg, Steven/L-2681-2019	Friedenberg, Steven/0000-0002-7510-2322; Meurs, Kathryn/0000-0002-7707-3799	National Institutes of Health T32 training award [5T32OD11130-07]; American Kennel Club Canine Health Foundation; Poodle Club of America Foundation	The author(s) received the following financial support for the research, authorship, and/or publication of this article: This study was funded in part by a National Institutes of Health T32 training award provided to SGF (5T32OD11130-07). Additional funding was provided by the American Kennel Club Canine Health Foundation and the Poodle Club of America Foundation.	Boag AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143458; Boag AM, 2014, TOP COMPANION ANIM M, V29, P96, DOI 10.1053/j.tcam.2015.01.001; BOUJON CE, 1994, J COMP PATHOL, V111, P287, DOI 10.1016/S0021-9975(05)80007-6; Bratland E, 2011, MOL CELL ENDOCRINOL, V336, P180, DOI 10.1016/j.mce.2010.12.015; Frank CB, 2013, J COMP PATHOL, V149, P268, DOI 10.1016/j.jcpa.2012.11.242; Gamba CO, 2014, RES VET SCI, V97, P554, DOI 10.1016/j.rvsc.2014.09.016; HADLOW WJ, 1953, AM J PATHOL, V29, P353; Hughes AM, 2010, TISSUE ANTIGENS, V75, P684, DOI 10.1111/j.1399-0039.2010.01440.x; Karihtala P, 2013, BREAST CANCER RES TR, V138, P81, DOI 10.1007/s10549-013-2442-0; Ma CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994; Massey J, 2013, IMMUNOGENETICS, V65, P291, DOI 10.1007/s00251-013-0680-2; SCHAER M, 1986, J AM ANIM HOSP ASSOC, V22, P789; Van Lanen K, 2014, TOP COMPANION ANIM M, V29, P88, DOI 10.1053/j.tcam.2014.10.001	13	2	2	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		177	181		10.1177/0300985816684914			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300018	28005496	Green Accepted, Bronze			2019-10-28	
J	Ohfuji, S				Ohfuji, Susumu			Hepatic Mastocytosis in Japanese Black Cattle	VETERINARY PATHOLOGY			English	Article						bovine; cattle; liver; mast cells; mastocytosis; portal veins; vasculopathy	SYSTEMIC MASTOCYTOSIS; CUTANEOUS MASTOCYTOSIS; BONE-MARROW; MAST-CELLS; DIAGNOSIS	In 5 Japanese Black steers (2-2.4 years old) that originated from 5 different feedlots, the livers were found at slaughter to have multiple nodular or cordlike lesions (5 steers) and an extensive fibrotic area (1 steer). Microscopic changes included extensive fibroplasia in the portal tracts and chronic proliferative endophlebitis-like lesions confined to the portal vein branches. Fibroplasia was much more prominent in the macroscopic fibrotic lesion of 1 steer. Portal vein branches presented irregular variciform dilation of the vascular lumen and fibroplastic changes in the subendothelial areas that showed occasional hemorrhage and were simultaneously infiltrated with large numbers of mast cells and moderate to large numbers of eosinophils. Within these subendothelial regions, not only did mast cells exhibit cytologically atypical features, but they also formed multifocal nodules. The venous lesions may represent a variant of mastocytosis with specific involvement of the hepatic portal vein branches in cattle.	[Ohfuji, Susumu] Diagnost Anim Pathol Off, Dept Histopathol, Nishino 11-9-20-25, Sapporo, Hokkaido 0630041, Japan	Ohfuji, S (reprint author), Diagnost Anim Pathol Off, Dept Histopathol, Nishino 11-9-20-25, Sapporo, Hokkaido 0630041, Japan.	ssmohfuji@yc5.so-net.ne.jp					Bohm A, 2007, J ALLERGY CLIN IMMUN, V120, P192, DOI 10.1016/j.jaci.2007.03.015; BUNDZA A, 1982, VET PATHOL, V19, P453, DOI 10.1177/030098588201900412; CHEVILLE NF, 1972, VET PATHOL, V9, P394, DOI 10.1177/030098587200900601; Chiu A, 2009, MODERN PATHOL, V22, P657, DOI 10.1038/modpathol.2009.53; Horny HP, 2007, PATHOBIOLOGY, V74, P121, DOI 10.1159/000101711; Johnson MR, 2009, MODERN PATHOL, V22, P50, DOI 10.1038/modpathol.2008.141; Kirsch R, 2008, MODERN PATHOL, V21, P1508, DOI 10.1038/modpathol.2008.158; Li S, 2013, VET PATHOL, V50, P842, DOI 10.1177/0300985813476055; LUND JE, 1978, VET PATHOL, V15, P64, DOI 10.1177/030098587801500108; MAXIE M.D., 2007, JUBB KENNEDY PALMERS, V3, P1; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; Meuten D. J., 2002, TUMORS DOMESTIC ANIM, P105; MICAN JM, 1995, HEPATOLOGY, V22, P1163, DOI 10.1016/0270-9139(95)90625-8; Mylonakis ME, 2006, VET CLIN PATH, V35, P311, DOI 10.1111/j.1939-165X.2006.tb00137.x; OHFUJI S, 1992, VET PATHOL, V29, P265, DOI 10.1177/030098589202900315; Palyada KS, 2008, VET DERMATOL, V19, P184, DOI 10.1111/j.1365-3164.2008.00666.x; Safyan EL, 1997, AM J GASTROENTEROL, V92, P1197; Sandes AF, 2013, SAO PAULO MED J, V131, P264, DOI 10.1590/1516-3180.2013.1314590; VANVLEET JF, 1995, THOMSONS SPECIAL VET, P175; Wygrecka M, 2013, AM J PATHOL, V182, P2094, DOI 10.1016/j.ajpath.2013.02.013; YAM LT, 1986, AM J MED, V80, P819, DOI 10.1016/0002-9343(86)90622-4	21	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		182	186		10.1177/0300985817736115			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300019	29050542	Bronze			2019-10-28	
J	Reindel, JF				Reindel, James F.			Pathology for Toxicologists: Principles and Practices of Laboratory Animal Pathology for Study Personnel	VETERINARY PATHOLOGY			English	Book Review									[Reindel, James F.] MPI Res, Diplomate Amer Coll Vet Pathologists, Mattawan, MI 49071 USA	Reindel, JF (reprint author), MPI Res, Diplomate Amer Coll Vet Pathologists, Mattawan, MI 49071 USA.						MCINNES E, 2017, PATHOLOGY TOXICOLOGI	1	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		187	188		10.1177/0300985817742144			2	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300020		Bronze			2019-10-28	
J	Amory, JK				Amory, John K.			Introduction to Drug Disposition and Pharmacokinetics	VETERINARY PATHOLOGY			English	Book Review									[Amory, John K.] Univ Washington, Sch Med, Seattle, WA 98195 USA	Amory, JK (reprint author), Univ Washington, Sch Med, Seattle, WA 98195 USA.						CURRY SH, 2017, INTRO DRUG DISPOSITI	1	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		188	188		10.1177/0300985817742143			1	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300021		Bronze			2019-10-28	
J	Serra, S; Chetty, R				Serra, Stefano; Chetty, Runjan			Rnf43	JOURNAL OF CLINICAL PATHOLOGY			English	Article							TRADITIONAL SERRATED ADENOMA; RECURRENT MUTATIONS; DRIVER MUTATIONS; GASTRIC-CANCER; WNT; LIGASE; GENE; ADENOCARCINOMA; LANDSCAPE; CARCINOMA	RNF43 (E3 ubiquitin-protein ligase RNF43 or RING-type E3 ubiquitin transferase RNF43) functions as a tumor suppressor, by exerting a predominant negative feedback mechanism in the Wnt/beta-catenin signaling pathway. RNF43 inhibits Wnt/beta-catenin signaling by ubiquitinating Frizzled receptor and targeting it to the lysosomal pathway for degradation. Loss of function of RNF43 results in decrease/lack of degradation of Frizzled with enhancement of Wnt/beta-catenin signaling pathway. Mutations of RNF43 have been reported in different cancers. We describe the structure of RNF43, its function and most frequent mutations in different cancers.	Univ Hlth Network, Lab Med Program, Dept Anat Pathol, Toronto, ON, Canada; Univ Toronto, Toronto, ON, Canada	Serra, S (reprint author), Toronto Gen Hosp, Univ Hlth Network, Dept Pathol, Toronto, ON M5G 2C4, Canada.	stefano.serra@uhn.ca					Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bond CE, 2016, ONCOTARGET, V7, P70589, DOI 10.18632/oncotarget.12130; Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600; Fennell LJ, 2017, FAM CANC; Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Hashimoto T, 2017, AM J SURG PATHOL, V41, P1188, DOI 10.1097/PAS.0000000000000877; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Jiang XM, 2015, MOL CELL, V58, P522, DOI 10.1016/j.molcel.2015.03.015; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Loregger A, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aac6757; Min BH, 2016, J PATHOL, V240, P304, DOI 10.1002/path.4777; Miyamoto K, 2008, PROTEOMICS, V8, P2907, DOI 10.1002/pmic.200800083; Ong CK, 2012, NAT GENET, V44, P690, DOI 10.1038/ng.2273; Planas-Paz L, 2016, NAT CELL BIOL, V18, P467, DOI 10.1038/ncb3337; Ryland GL, 2013, J PATHOL, V229, P469, DOI 10.1002/path.4134; Sekine S, 2017, MODERN PATHOL, V30, P1144, DOI 10.1038/modpathol.2017.39; Sekine S, 2016, J PATHOL, V239, P133, DOI 10.1002/path.4709; Shinada K, 2011, BIOCHEM BIOPH RES CO, V404, P143, DOI 10.1016/j.bbrc.2010.11.082; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sugiura T, 2008, EXP CELL RES, V314, P1519, DOI 10.1016/j.yexcr.2008.01.013; Takahashi N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086582; Tan MC, 2015, J AM COLL SURGEONS, V220, P845, DOI 10.1016/j.jamcollsurg.2014.11.029; Tsai JH, 2016, AM J SURG PATHOL, V40, P1352, DOI 10.1097/PAS.0000000000000664; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108; Yagyu R, 2004, INT J ONCOL, V25, P1343; Zebisch M, 2015, PROG BIOPHYS MOL BIO, V118, P112, DOI 10.1016/j.pbiomolbio.2015.04.006; Zebisch M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3787	31	1	3	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					1	6		10.1136/jclinpath-2017-204763			6	Pathology	Pathology	FP8TS	WOS:000417919600002	29018044	Green Published			2019-10-28	
J	Rubio, CA; Puppa, G; de Petris, G; Kis, L; Schmidt, PT				Rubio, Carlos A.; Puppa, Giacomo; de Petris, Giovanni; Kis, Lorand; Schmidt, Peter T.			The third pathway of colorectal carcinogenesis	JOURNAL OF CLINICAL PATHOLOGY			English	Review							LYMPHOID-TISSUE GALT; DOME-TYPE CARCINOMA; COLONIC CARCINOGENESIS; ULCERATIVE-COLITIS; SERRATED ADENOMAS; ADENOCARCINOMA; MUCOSA; RATS; EPITHELIUM; PHENOTYPE	Aims The majority of the colorectal carcinomas (CRC) arise in a vast mucosal area built with columnar cells and mucus-producing goblet cells. These carcinomas evolve via the conventional (tubular/villous) adenoma-carcinoma pathway, or the serrated adenoma-carcinoma pathway. Much less frequently CRC arise in the gut-associated lymphoid tissue (GALT) mucosal domain via the third pathway of colorectal carcinogenesis. Methods All publications on human colorectal GALT carcinomas in the literature were reviewed. Results Only 23 GALT-carcinomas found in 20 patients are in record. The GALT carcinomas were detected at surveillance colonoscopic biopsy in 11 patients (four had ulcerative colitis, two were members of a Lynch syndrome family, two of a CRC family, one had familial adenomatous polyposis (FAP), one prior colon adenomas and one a submucosal tumour), or at diagnostic colonoscopic biopsy in the remaining nine patients (three had rectal bleedings, two abdominal pains, one diverticular disease and one protracted constipation. In three, no ground disease or symptoms were provided). In six of the 23 GALT carcinomas, the luminal surface showed tumour cells, ulcerations or no descriptions were given. Ten (66.7%) of the remaining 15 GALT carcinomas showed on top, adenomas (n=8) or high-grade dysplasia (n=2). Conclusions The low frequency of GALT carcinomas might be explained by the fact that the colorectal mucosal areas occupied by GALT domains are minute. The finding that two-thirds of the 15 remaining GALT carcinomas (vide supra) were covered by high-grade dysplasia or by conventional adenomas strongly suggest that conventional non-invasive neoplasias might have preceded the majority of the GALT carcinomas in record.	[Rubio, Carlos A.; Kis, Lorand] Karolinska Inst, Dept Pathol, S-17176 Stockholm, Sweden; [Rubio, Carlos A.; Kis, Lorand] Univ Hosp, Stockholm, Sweden; [Puppa, Giacomo] Geneva Univ Hosp, Div Gastroenterol & Hepatol, Geneva, Switzerland; [de Petris, Giovanni] Arizona Gastroenterol Associates, Dept Gastrointestinal Pathol, Scottsdale, AZ USA; [Schmidt, Peter T.] Karolinska Inst, Ctr Digest Dis, Karolinska Univ Hosp, Dept Med Solna, Stockholm, Sweden	Rubio, CA (reprint author), Karolinska Inst, Dept Pathol, S-17176 Stockholm, Sweden.	carlos.rubio@ki.se					Asmussen L, 2008, J CLIN PATHOL, V61, P482, DOI 10.1136/jcp.2007.047621; Autenrieth IB, 1996, J MED MICROBIOL, V44, P285, DOI 10.1099/00222615-44-4-285; Ball CB, 1903, BRIT MED J, V1903, P413; Butler JE, 2013, J LEUKOCYTE BIOL, V94, P259, DOI 10.1189/jlb.0313120; Clouston AD, 2000, HISTOPATHOLOGY, V37, P567, DOI 10.1046/j.1365-2559.2000.01018-3.x; Coyne JD, 2012, COLORECTAL DIS, V14, pE360, DOI 10.1111/j.1463-1318.2011.02795.x; De Petris G, 1999, ARCH PATHOL LAB MED, V123, P720; DEASY JM, 1983, J SURG ONCOL, V24, P36, DOI 10.1002/jso.2930240109; DUKES CE, 1954, ANN ROY COLL SURG, V14, P389; Elmore SA, 2006, TOXICOL PATHOL, V34, P687, DOI 10.1080/01926230600939989; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Helander HF, 2014, SCAND J GASTROENTERO, V49, P681, DOI 10.3109/00365521.2014.898326; Hickey P, 2016, ACG ANN SCI M LAS VE; JACKMAN RJ, 1951, SURG GYNECOL OBSTET, V93, P327; Jass JR, 2000, HISTOPATHOLOGY, V36, P116; Kannuna H, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0305-1; LIEBLER EM, 1988, VET PATHOL, V25, P503, DOI 10.1177/030098588802500614; LONGACRE TA, 1990, AM J SURG PATHOL, V14, P524, DOI 10.1097/00000478-199006000-00003; Nascimbeni R, 1999, AM J SURG PATHOL, V23, P1256, DOI 10.1097/00000478-199910000-00011; Neutra MR, 2001, NAT IMMUNOL, V2, P1004, DOI 10.1038/ni1101-1004; O'Brien M J, 1996, Surg Oncol Clin N Am, V5, P513; O'Brien MJ, 2015, HISTOPATHOLOGY, V66, P49, DOI 10.1111/his.12564; Perse M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/473964; Puppa G, 2012, CASE REP PATHOL, V2012, P1; Rabeneck L, CANC DIS CONTROL PRI; Rubio C A, 1987, In Vivo, V1, P61; Rubio CA, 2003, GASTROENTEROLOGY, V124, P2000, DOI 10.1016/S0016-5085(03)00573-0; RUBIO CA, 1984, DIS COLON RECTUM, V27, P182, DOI 10.1007/BF02555670; Rubio CA, 2002, HISTOPATHOLOGY, V40, P577, DOI 10.1046/j.1365-2559.2002.t01-2-01294.x; Rubio CA, 2017, BR J MED MED RES, V21, P1; Rubio CA, 2017, J CLIN PATHOL, V70, P301, DOI 10.1136/jclinpath-2016-204037; Rubio CA, 2017, ANTICANCER RES, V37, P1039, DOI 10.21873/anticanres.11414; Rubio CA, 2017, ANTICANCER RES, V37, P15, DOI 10.21873/anticanres.11284; Rubio CA, 2016, ANTICANCER RES, V36, P5385, DOI 10.21873/anticanres.11113; Rubio CA, 2013, VIRCHOWS ARCH, V463, P637, DOI 10.1007/s00428-013-1474-5; Rubio CA, 2013, WORLD J GASTRO ENDOS, V5, P293, DOI 10.4253/wjge.v5.i6.293; Rubio CA, 2010, ANTICANCER RES, V30, P3019; Stewart CJR, 2008, HISTOPATHOLOGY, V53, P231, DOI 10.1111/j.1365-2559.2008.03061.x; Takagi W, 2015, ENDOSC INT OPEN, V3, pE359, DOI 10.1055/s-0034-1392019; Torlakovic EE, 2008, AM J SURG PATHOL, V32, P21, DOI 10.1097/PAS.0b013e318157f002; Yamada M, 2013, CLIN GASTROENTEROL H, V11, pA30, DOI 10.1016/j.cgh.2012.11.009; Yamada M, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-21	42	5	5	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					7	11		10.1136/jclinpath-2017-204660			5	Pathology	Pathology	FP8TS	WOS:000417919600003	28751521				2019-10-28	
J	Murng, SHK; Thomas, M				Murng, Sai H. K.; Thomas, Moira			Clinical associations of the positive anti Ro52 without Ro60 autoantibodies: undifferentiated connective tissue diseases	JOURNAL OF CLINICAL PATHOLOGY			English	Article							IGA ANTITISSUE TRANSGLUTAMINASE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PRIMARY SJOGRENS-SYNDROME; AUTOANTIGEN RO52; ANTIBODIES; ANTI-RO52; EXPRESSION; MARKER; TRIM21; CLASSIFICATION	Aims Autoantibodies targeting Ro52 and Ro60 antigens are historically reported as anti SSA/Ro. In general anti SSA/Ro results are either anti Ro52+Ro60+ or anti Ro52-Ro60+ antibodies. Anti Ro52 without anti Ro60 (Ro52+Ro60-) antibodies are often not reported routinely. This study intends to review the potential significance of these autoantibodies in the management of connective tissue diseases. . Method A retrospective survey of Ro52+Ro60- was carried out as part of the service evaluation of extractable nuclear antigen antibodies (ENA) reporting from the immunology laboratory, the NHS Greater Glasgow and Clyde (GGC), UK. The clinical documents and laboratory results of 97 patients with Ro52+Ro60- and 100 patients with Ro52+Ro60+ were reviewed. Results Seventy-one patients (73%) with anti Ro52+Ro60- antibodies have been diagnosed with autoimmune conditions including undifferentiated connective tissue diseases (n=14, 14%), systemic lupus erythematosus (n=10, 10%), Sjogren's syndrome (n=10, 10%) and rheumatoid arthritis (n=13, 13%). Twenty-three patients (24%) with anti Ro52+Ro60-antibodies have no autoimmune features but were found to have significant clinical conditions including malignancies. In contrast, 87 patients (87%) with anti Ro52+Ro60+ antibodies have autoimmune conditions including Sjogren's syndrome (n=34, 34%), systemic lupus erythematosus (SLE; n=23, 23%), undifferentiated connective tissue diseases (n=12, 12%) and rheumatoid arthritis (n=6, 6%). Conclusion Anti Ro52 without anti Ro60 (Ro52+Ro60-) antibodies should be reported. In the majority of patients these autoantibodies were associated with various autoimmune diseases. Anti Ro52+Ro60- antibodies were also found in patients with significant clinical conditions including malignancies even though there was no suggestion of autoimmunity at the time of testing.	[Murng, Sai H. K.; Thomas, Moira] Queen Elizabeth Univ Hosp, Dept Immunol, NHS Greater Glasgow & Clyde, Glasgow G51 4TF, Lanark, Scotland	Murng, SHK (reprint author), Queen Elizabeth Univ Hosp, Dept Immunol, NHS Greater Glasgow & Clyde, Glasgow G51 4TF, Lanark, Scotland.	sai.murng@ggc.scot.nhs.uk					Aqrawi LA, 2014, CLIN EXP IMMUNOL, V177, P244, DOI 10.1111/cei.12341; Aziz KA, 2004, SAUDI MED J, V25, P442; BENCHETRIT E, 1992, AM J REPROD IMMUNOL, V28, P256, DOI 10.1111/j.1600-0897.1992.tb00809.x; Brauner S, 2015, J INTERN MED, V278, P323, DOI 10.1111/joim.12375; Cavazzana I, 2001, CLIN EXP RHEUMATOL, V19, P403; CHARLES PJ, 1992, CLIN EXP RHEUMATOL, V10, P507; Dugar M, 2010, POSTGRAD MED J, V86, P79, DOI 10.1136/pgmj.2009.089656; Fitch-Rogalsky C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093812; Foss S, 2015, IMMUNOL REV, V268, P328, DOI 10.1111/imr.12363; Fukuda-Kamitani T, 2002, BIOCHEM BIOPH RES CO, V295, P774, DOI 10.1016/S0006-291X(02)00750-7; Ghillani P, 2011, AUTOIMMUN REV, V10, P509, DOI 10.1016/j.autrev.2011.03.004; Granito A, 2007, ALIMENT PHARM THER, V26, P831, DOI 10.1111/j.1365-2036.2007.03433.x; Hanly JG, 2010, J IMMUNOL METHODS, V358, P75, DOI 10.1016/j.jim.2010.04.005; HARMON CE, 1984, ARTHRITIS RHEUM, V27, P166, DOI 10.1002/art.1780270207; Hervier B, 2009, RHEUMATOLOGY, V48, P964, DOI 10.1093/rheumatology/kep145; Higgs R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011776; Hudson M, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3763; Jauharoh SNA, 2012, BIOCHEM BIOPH RES CO, V417, P582, DOI 10.1016/j.bbrc.2011.12.010; Keech CL, 1996, CLIN EXP IMMUNOL, V104, P255, DOI 10.1046/j.1365-2249.1996.16726.x; Kong HJ, 2007, J IMMUNOL, V179, P26, DOI 10.4049/jimmunol.179.1.26; Thai LH, 2014, AUTOIMMUN REV, V13, P313, DOI 10.1016/j.autrev.2013.11.003; Langguth DM, 2007, J CLIN PATHOL, V60, P670, DOI 10.1136/jcp.2006.040360; Lock RJ, 1999, J CLIN PATHOL, V52, P274, DOI 10.1136/jcp.52.4.274; Menendez A, 2013, SCI WORLD J, DOI 10.1155/2013/832789; Menendez A, 2013, AUTOIMMUNITY, V46, P32, DOI 10.3109/08916934.2012.732131; Almagro RM, 2016, REUMATOL CLIN, V12, P256, DOI 10.1016/j.reuma.2015.10.010; Meyer O, 2002, ANN MED INTERNE, V153, P520; Mosca A, 2006, AUTOIMMUN REV, V6, P1, DOI 10.1016/j.autrev.2006.03.004; Mosca M, 1998, LUPUS, V7, P95, DOI 10.1191/096120398678919787; Mosca M, 1999, CLIN EXP RHEUMATOL, V17, P615; Narayanan K, 2010, Med J Armed Forces India, V66, P102, DOI 10.1016/S0377-1237(10)80118-2; Oke V, 2012, J AUTOIMMUN, V39, P77, DOI 10.1016/j.jaut.2012.01.014; Peene I, 2002, ANN RHEUM DIS, V61, P929, DOI 10.1136/ard.61.10.929; Peene I, 2000, CLIN RHEUMATOL, V19, P291, DOI 10.1007/s100670070048; Pollock W, 1999, J CLIN PATHOL, V52, P684, DOI 10.1136/jcp.52.9.684; Retamozo S, 2012, CLIN EXP RHEUMATOL, V30, P686; Rutjes SA, 1997, CLIN EXP IMMUNOL, V109, P32, DOI 10.1046/j.1365-2249.1997.4081308.x; Samasca G, 2011, CLIN LAB, V57, P695; Sanders JSF, 2006, RHEUMATOLOGY, V45, P724, DOI 10.1093/rheumatology/kei272; Sayed Sohair K, 2012, Egypt J Immunol, V19, P41; Schulte-Pelkum J, 2009, AUTOIMMUN REV, V8, P632, DOI 10.1016/j.autrev.2009.02.010; Shoenfeld Y, 2005, AUTOIMMUNITY, V38, P1, DOI 10.1080/14756360400021882; Takahata M, 2008, MOL IMMUNOL, V45, P2045, DOI 10.1016/j.molimm.2007.10.023; Venables PJW, 2004, BEST PRACT RES CL RH, V18, P313, DOI 10.1016/j.berh.2004.02.010; Villegas-Zambrano N, 2009, ANN NY ACAD SCI, V1173, P60, DOI 10.1111/j.1749-6632.2009.04650.x; Wada K, 2006, BIOCHEM BIOPH RES CO, V339, P415, DOI 10.1016/j.bbrc.2005.11.029; Wodkowski M, 2015, CLIN EXP RHEUMATOL, V33, pS131; Yoshimi R, 2012, INT J RHEUMATOL, V2012, P1; Yoshimi R, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/606195	49	4	4	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					12	19		10.1136/jclinpath-2015-203587			8	Pathology	Pathology	FP8TS	WOS:000417919600004	28663326				2019-10-28	
J	McCahon, D; Roalfe, A; Fitzmaurice, DA				McCahon, Deborah; Roalfe, Andrea; Fitzmaurice, David A.			An evaluation of a coagulation system (Xprecia Stride) for utilisation in anticoagulation management	JOURNAL OF CLINICAL PATHOLOGY			English	Article							PATIENT SELF-MANAGEMENT; POINT-OF-CARE; ORAL ANTICOAGULATION; PROTHROMBIN TIME; COAGUCHEK-S; GUIDELINES; WARFARIN; TRIAL	Aim To evaluate the reliability and performance of the Xprecia Stride coagulometer under the conditions in which it is most likely to be used. Methods The performance of the Xprecia Stride coagulometer was compared with a local laboratory and the CoaguChek systems routinely used for international normalised ratio (INR) estimation within one primary and one secondary care based anticoagulation clinic in Birmingham. Anticoagulation clinic personnel were trained to use the Xprecia Stride. Patients attending the clinics were eligible if aged >= 18 years and had received warfarin for at least 3 months. Consenting participants provided capillary blood samples for parallel testing on the Xprecia Stride and CoaguChek systems. At the secondary care clinic, a venous blood sample was also collected for laboratory INR estimation. INR results were compared using linear regression analysis and Bland-Altman plots. Results A total of 102 laboratory and 205 parallel coagulometer INR tests were performed. Linear regression revealed strong correlation between the Xprecia Stride and the laboratory (r=0.83) and between the Xprecia Stride and CoaguChek systems (r=0.92). Within the therapeutic range, agreement between the systems was very good with 87% of the Xprecia Stride and laboratory INR results and 93% of the Xprecia Stride and CoaguChek INR results being within 0.5 INR units of each other. Conclusion INRs tested using the Xprecia Stride system showed good agreement with the laboratory and CoaguChek systems. Findings indicate that in the hands of the intended users the Xprecia Stride is accurate, reliable and acceptable for use in a routine clinical setting.	[McCahon, Deborah; Roalfe, Andrea] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England; [McCahon, Deborah] Univ Bristol, Social & Community Med, Bristol, Avon, England; [Fitzmaurice, David A.] Univ Warwick, Warwick Clin Trials, Coventry, W Midlands, England	McCahon, D (reprint author), Ctr Acad Primary Care, Social & Community Med, Canynge Hall,39 Whatley Rd, Bristol BS8 2PS, Avon, England.	deborah.mccahon@bristol.ac.uk			Siemens Healthcare	The study was funded by Siemens Healthcare.	[Anonymous], 2008, 07026 CEP; Braun S, 2007, THROMB HAEMOSTASIS, V97, P310, DOI 10.1160/TH06-03-0181; Briggs C, 2012, BRIT J HAEMATOL, V158, P679, DOI 10.1111/j.1365-2141.2012.09207.x; Chitolie A, 1995, EVALUATION THROMBOLY; Fitzmaurice DA, 2005, BRIT J HAEMATOL, V131, P156, DOI 10.1111/j.1365-2141.2005.05739.x; Garcia-Alamino Josep M, 2010, Cochrane Database Syst Rev, pCD003839, DOI 10.1002/14651858.CD003839.pub2; Gardiner C, 2006, BRIT J HAEMATOL, V132, P598, DOI 10.1111/j.1365-2141.2005.05899.x; Gardiner C, 2005, BRIT J HAEMATOL, V128, P242, DOI 10.1111/j.1365-2141.2004.05300.x; Hobbs FDR, 1999, J CLIN PATHOL, V52, P494, DOI 10.1136/jcp.52.7.494; Jackson Shane L, 2004, Aust J Rural Health, V12, P137, DOI 10.1111/j.1440-1854.2004.00585.x; Jackson SL, 2005, J CLIN PHARM THER, V30, P345, DOI 10.1111/j.1365-2710.2005.00656.x; Jackson SL, 2004, CLIN LAB HAEMATOL, V26, P49, DOI 10.1111/j.0141-9854.2003.00578.x; KAPIOTIS S, 1995, THROMB RES, V77, P563, DOI 10.1016/0049-3848(95)00031-3; Keeling D, 2011, BRIT J HAEMATOL, V154, P311, DOI 10.1111/j.1365-2141.2011.08753.x; McCahon D, 2007, J CLIN PATHOL, V60, P1263, DOI 10.1136/jcp.2006.044008; Murray ET, 1999, J CLIN PATHOL, V52, P842, DOI 10.1136/jcp.52.11.842; Nam MH, 2008, ANN CLIN LAB SCI, V38, P37; National Institute for Health and Clinical Excellence, 2014, ATR FIBR MAN ATR FIB; Roche Diagnostics International Ltd, 2014, ACC PREC OR ANT MON; Sander KJ, 1989, EVALUATION NYCOMED T; Shiach CR, 2002, BRIT J HAEMATOL, V119, P370, DOI 10.1046/j.1365-2141.2002.03888.x; Sunderji R, 2005, AM J CLIN PATHOL, V123, P184, DOI 10.1309/P2Y3VM4AXPVUDAW3; Williams VK, 2007, PATHOLOGY, V39, P575, DOI 10.1080/00313020701684797	23	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					20	26		10.1136/jclinpath-2017-204456			7	Pathology	Pathology	FP8TS	WOS:000417919600005	28611189				2019-10-28	
J	Leadbeatter, S; James, R				Leadbeatter, Stephen; James, Ryk			How can we ensure that the coroner's autopsy is not an invasion of human rights?	JOURNAL OF CLINICAL PATHOLOGY			English	Article								Background Despite public inquiries, and some changes to legislation following high-profile multiple homicides that were not detected by autopsy, coroners continue to rely largely on the autopsy. Regardless of the extent of quality failings and excess deaths at some hospitals, not detected through the coroner system, the autopsy is scarcely used by hospitals to monitor standards and educate. Objective To explore when a compulsory medicolegal autopsy should, and should not, be used. Method Two hundred and thirty-six cases referred to a senior coroner were evaluated by pathologists with long experience of forensic, coronial and hospital autopsies, using detailed antecedent medical and circumstantial information: after their advice, the senior coroner decided what kind of autopsy provided sufficient information for his purposes. Results In nearly 40% (n=88) of deaths where the senior coroner accepted jurisdiction, issues raised could be resolved through analysis of medical records and antecedent information, supplemented only by detailed external examination of the body. Conclusions Timely provision of sufficient information allows informed decisions about the requirement for, and nature and extent of, medical investigations into a death: unnecessary post mortem dissection is avoided, protecting the rights, under Articles 8 and 9 of the Human Rights Act 1998, of the bereaved to privacy, family life and religious practice. Although improvements in healthcare can undoubtedly result from detailed coroners' inquiries, those deaths where the matters investigated relate only to the accuracy of a natural cause of death or sit with a healthcare provider's internal quality assurance, should be investigated by the healthcare system in collaboration with the bereaved.	[Leadbeatter, Stephen; James, Ryk] Cardiff Univ, Wales Inst Forens Med, Heath Pk, Cardiff CF14 4XN, S Glam, Wales	James, R (reprint author), Cardiff Univ, Wales Inst Forens Med, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	jamesd5@cardiff.ac.uk					Alcolado JC, 2004, BRIT MED J, V328, P165, DOI 10.1136/bmj.328.7432.165-a; [Anonymous], 2006, COR AUT DO WE DES BE; [Anonymous], 2004, CM6159; [Anonymous], 1994, 9416 EL; [Anonymous], 2015, REV FORENSIC PATHOLO; [Anonymous], 2001, ROYAL LIVERPOOL CHIL; [Anonymous], 2 ANN REP 2014 2015; [Anonymous], 2003, REV FORENSIC PATHOLO; [Anonymous], 2006, CM6943; [Anonymous], 2001, CM52071, V1; [Anonymous], 1989, REPORT WORKING PARTY; [Anonymous], 1971, CMND4810; Berry C, 2007, B ROY COLL PATHOL, V139, P72; General Medical Council, 2013, FIN COMM ARR CONFL I; House of Commons constitutional affairs committee, 2006, REF COR SYST DEATH C; James DS, 1997, J ROY COLL PHYS LOND, V31, P296; Palmer RN, 2011, J ROY SOC MED, V104, P97, DOI 10.1258/jrsm.2010.11k006; Pounder D, 2011, J ROY SOC MED, V104, P19, DOI 10.1258/jrsm.2010.100207; Sheppard MN, 2004, BRIT MED J, V328, P406, DOI 10.1136/bmj.328.7436.406; 2003, CM5831; 2003, CM5854	21	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					27	+		10.1136/jclinpath-2017-204323			8	Pathology	Pathology	FP8TS	WOS:000417919600006	28645945				2019-10-28	
J	Soljic, M; Mrklic, I; Tomic, S; Omrcen, T; Sutalo, N; Bevanda, M; Vrdoljak, E				Soljic, Martina; Mrklic, Ivana; Tomic, Snjezana; Omrcen, Tomislav; Sutalo, Nikica; Bevanda, Milenko; Vrdoljak, Eduard			Prognostic value of vitamin D receptor and insulin-like growth factor receptor 1 expression in triple-negative breast cancer	JOURNAL OF CLINICAL PATHOLOGY			English	Article							IGF-I; CELLS; THERAPY; RECOMMENDATIONS; ASSOCIATION; CARCINOMAS; PATHWAYS; SUBTYPES	Aim Triple-negative breast cancer (TNBC) is characterised by shorter overall survival and an early peak of distant recurrences with still no specific targeted treatment available. Vitamin D receptor (VDR) and insulin-like growth factor receptor 1 (IGFR) have recently been described as potential new targets for anticancer therapy, yet their roles in TNBCs are still to be explored. In this study we investigated VDR and IGFR expression in patients with TNBC and compared them with clinical and pathological parameters and survival to possibly demonstrate their prognostic and therapeutic relevance. Methods The study included 96 patients with TNBC. Clinical and pathological parameters were compared with the immunohistochemical expression of VDR and IGFR. Results Positive VDR immunostaining was present in 27% of tumours and inversely correlated with higher mitotic score, histological grade and higher proliferation index measured by Ki-67 and related to the increased overall survival (OS). Out of 96 patients with TNBC, 35.5% of tumours were IGFR positive and correlated with higher mitotic score and Ki-67, and strongly correlated with shorter disease-free survival (DFS). Patients with VDR-negative and IGF-positive tumours had significantly lower DFS and OS. Conclusion Approximately one third of TNBCs express VDR and/or IGFR. Their expression is linked with the recurrence of the disease and survival, which make them possible targets for treatment and a prognostic tool for dividing TNBCs into more homogeneous subgroups.	[Soljic, Martina] Clin Hosp Mostar, Dept Thorac Surg, Bijeli Brijeg Bb, Mostar 88000, Bosnia & Herceg; [Mrklic, Ivana; Tomic, Snjezana] Split Univ Hosp Ctr, Dept Pathol Forens Med & Cytol, Split, Croatia; [Omrcen, Tomislav; Vrdoljak, Eduard] Split Univ Hosp Ctr, Dept Oncol & Radiotherapy, Split, Croatia; [Sutalo, Nikica] Clin Hosp Mostar, Dept Gen Surg, Mostar, Bosnia & Herceg; [Bevanda, Milenko] Clin Hosp Mostar, Dept Internal Med, Mostar, Bosnia & Herceg	Soljic, M (reprint author), Clin Hosp Mostar, Dept Thorac Surg, Bijeli Brijeg Bb, Mostar 88000, Bosnia & Herceg.	msoljic@gmail.com					Aaltonen KE, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-794; Ameri P, 2013, CLIN ENDOCRINOL, V79, P457, DOI 10.1111/cen.12268; Arnaldez FI, 2012, HEMATOL ONCOL CLIN N, V26, P527, DOI 10.1016/j.hoc.2012.01.004; Bartucci M, 2001, CANCER RES, V61, P6747; Boyle P, 2012, ANN ONCOL, V23, P7, DOI 10.1093/annonc/mds187; Buttigliero C, 2011, ONCOLOGIST, V16, P1215, DOI 10.1634/theoncologist.2011-0098; Chen HX, 2013, CHIN J CANCER, V32, P242, DOI 10.5732/cjc.012.10263; Chiang KC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040606; Creighton CJ, 2008, J CLIN ONCOL, V26, P4078, DOI 10.1200/JCO.2007.13.4429; Davison Z, 2011, NEOPLASIA, V13, P504, DOI 10.1593/neo.101590; Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196; Dowsett M, 2011, J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FREAKE HC, 1984, CANCER RES, V44, P1677; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Greene FL, 2009, TNM CLASSIFICATION M, P181; Grotsky DA, 2013, J CELL BIOL, V200, P187, DOI 10.1083/jcb.201204053; Hammond MEH, 2010, J ONCOL PRACT, V6, P195, DOI 10.1200/JOP.777003; Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113; Lakhani S. R., 2012, WHO CLASSIFICATION T, P8; Litzenburger BC, 2011, CLIN CANCER RES, V17, P2314, DOI 10.1158/1078-0432.CCR-10-1903; Lopes N, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3178; Lopes N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-483; Mrklic I, 2013, PATHOL RES PRACT, V209, P296, DOI 10.1016/j.prp.2013.02.012; Mrklic I, 2013, ACTA HISTOCHEM, V115, P344, DOI 10.1016/j.acthis.2012.09.006; Nag S, 2014, CURR BREAST CANCER R, V6, P275, DOI 10.1007/s12609-014-0165-9; Pal SK, 2011, BREAST CANCER RES TR, V125, P627, DOI 10.1007/s10549-010-1293-1; Park YH, 2011, ANN ONCOL, V22, P1554, DOI 10.1093/annonc/mdq617; Peppone LJ, 2012, ANN SURG ONCOL, V19, P2590, DOI 10.1245/s10434-012-2297-3; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rainville Christa, 2009, Cases J, V2, P8390, DOI 10.4076/1757-1626-2-8390; Rozen F, 1997, J NATL CANCER I, V89, P652, DOI 10.1093/jnci/89.9.652; SEPPLORENZINO L, 1994, CELL GROWTH DIFFER, V5, P1077; Swami S, 2003, BREAST CANCER RES TR, V80, P49, DOI 10.1023/A:1024487118457; Thakkar A, 2016, BREAST CANCER RES TR, V157, P77, DOI 10.1007/s10549-016-3807-y; Wang YJ, 2010, ARCH BIOCHEM BIOPHYS, V494, P166, DOI 10.1016/j.abb.2009.11.029; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2; Wu XY, 2015, ONCOL RES, V22, P129, DOI 10.3727/096504015X14267282610894; Yerushalmi R, 2012, BREAST CANCER RES TR, V132, P131, DOI 10.1007/s10549-011-1529-8	39	1	1	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					34	39		10.1136/jclinpath-2016-204222			6	Pathology	Pathology	FP8TS	WOS:000417919600007	28663327				2019-10-28	
J	Doutre, S; Omar, T; Goumbri-Lompo, O; Kelly, H; Clavero, O; Zan, S; Chikandiwa, A; Sawadogo, B; Delany-Moretlwe, S; Costes, V; Mayaud, P; Segondy, M				Doutre, Sylviane; Omar, Tanvier; Goumbri-Lompo, Olga; Kelly, Helen; Clavero, Omar; Zan, Souleymane; Chikandiwa, Admire; Sawadogo, Bernard; Delany-Moretlwe, Sinead; Costes, Valerie; Mayaud, Philippe; Segondy, Michel		HARP Study Grp	Cervical intraepithelial neoplasia (CIN) in African women living with HIV: role and effect of rigorous histopathological review by a panel of pathologists in the HARP study endpoint determination	JOURNAL OF CLINICAL PATHOLOGY			English	Review							INTEROBSERVER VARIATION; DIAGNOSIS; LESIONS; TERMINOLOGY; COLPOSCOPY; DYSPLASIA; AGREEMENT; CANCER	AIMS To analyse the effect of the expert end-point committee (EPC) review on histological endpoint classification of cervical intraepithelial neoplasia (CIN). Methods A cohort of women living with HIV were recruited in Burkina Faso (BF) and South Africa (SA) and followed over 18 months. Four-quadrant cervical biopsies were obtained in women with abnormalities detected by at least one screening test. A central review by a panel of five pathologists was organised at baseline and at endline. Results At baseline the prevalence of high-grade CIN (CIN2+) was 5.1% (28/554) in BF and 23.3% (134/574) in SA by local diagnosis, and 5.8% (32/554) in BF and 22.5% (129/574) in SA by the EPC. At endline the prevalence of CIN2+ was 2.3% (11/483) in BF and 9.4% (47/501) in SA by local diagnosis, and 1.4% (7/483) in BF and 10.2% (51/501) in SA by EPC. The prevalence of borderline CIN1/2 cases was 2.8% (32/1128) and 0.8% (8/984) at baseline and endline. Overall agreement between local diagnosis and final diagnosis for distinguishing CIN2+ from <= CIN1 was 91.2% (kappa=0.82) and 88.9% (kappa=0.71) for BF at baseline and endline, and 92.7% (kappa=0.79) and 98.7% (kappa=0.97) for SA at baseline and endline. Among the CIN1/2 cases, 12 (37.5%) were graded up to CIN2 and 20 (62.5%) were graded down to CIN1 at baseline, and 3 (37.5%) were graded up to CIN2 and 5 (62.5%) were graded down to CIN1 at endline. Conclusions This study highlights the importance of a centralised rigorous re-reading with exchange of experiences among pathologists from different settings.	[Doutre, Sylviane; Costes, Valerie; Segondy, Michel] Univ Hosp CHU, Dept Biol & Pathol, Montpellier, France; [Omar, Tanvier] Natl Hlth Lab Serv Johannesburg, Dept Pathol, Johannesburg, South Africa; [Goumbri-Lompo, Olga] Univ Teaching Hosp Yalgado, Dept Pathol, Ouagadougou, Burkina Faso; [Kelly, Helen; Mayaud, Philippe] London Sch Hyg & Trop Med, Dept Clin Res, London, England; [Clavero, Omar] Catalan Inst Oncol, Dept Pathol, Barcelona, Spain; [Zan, Souleymane] Univ Teaching Hosp Yalgado, Dept Gynaecol, Ouagadougou, Burkina Faso; [Chikandiwa, Admire; Delany-Moretlwe, Sinead; Mayaud, Philippe] Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa; [Sawadogo, Bernard] Univ Ouagadougou, Ctr Recherches Int Sante CRIS, Ouagadougou, Burkina Faso; [Costes, Valerie; Segondy, Michel] Univ Montpellier, Pathogenesis & Control Chron Infect, INSERM, EFS, Montpellier, France	Segondy, M (reprint author), St Eloi Hosp, Dept Biol & Pathol, Virol Lab, F-34295 Montpellier 05, France.	m-segondy@chu-montpellier.fr		MAYAUD, Philippe/0000-0001-5730-947X	European Commission (EC)European Commission Joint Research CentreEuropean Community (EC) [HEALTH-2010-F2-265396]	The research leading to these results has received funding from the European Commission (EC) 7th Framework Programme under grant agreement No. HEALTH-2010-F2-265396.	Basu P, 2013, INT J GYNECOL PATHOL, V32, P509, DOI 10.1097/PGP.0b013e31827b26b1; Bergeron C, 2010, AM J CLIN PATHOL, V133, P395, DOI 10.1309/AJCPXSVCDZ3D5MZM; Cai B, 2007, AM J SURG PATHOL, V31, P1854, DOI 10.1097/PAS.0b013e318058a544; Carreon JD, 2007, INT J GYNECOL PATHOL, V26, P441, DOI 10.1097/pgp.ob013e31805152ab; Darragh TM, 2012, J LOW GENIT TRACT DI, V16, P205, DOI 10.1097/LGT.0b013e31825c31dd; Denny L, 2012, CANCER EPIDEM BIOMAR, V21, P1434, DOI 10.1158/1055-9965.EPI-12-0334; DEVET HCW, 1990, J CLIN EPIDEMIOL, V43, P1395, DOI 10.1016/0895-4356(90)90107-Z; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Firnhaber C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053494; ISMAIL SM, 1989, BRIT MED J, V298, P707, DOI 10.1136/bmj.298.6675.707; ISMAIL SM, 1990, HISTOPATHOLOGY, V16, P371, DOI 10.1111/j.1365-2559.1990.tb01141.x; Kelly HA, 2017, AIDS, V31, P273, DOI 10.1097/QAD.0000000000001301; McCluggage WG, 1996, J CLIN PATHOL, V49, P833, DOI 10.1136/jcp.49.10.833; Muwonge R, 2016, CANCER CAUSE CONTROL, V27, P1437, DOI 10.1007/s10552-016-0823-5; Stoler MH, 2015, AM J SURG PATHOL, V39, P729, DOI 10.1097/PAS.0000000000000381; Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500; Strander B, 2005, ACTA OBSTET GYN SCAN, V84, P1013, DOI 10.1111/j.0001-6349.2005.00895.x; Waxman AG, 2012, OBSTET GYNECOL, V120, P1465, DOI [10.1097/AOG.0b013e31827001d5, http://10.1097/AOG.0b013e31827001d5]	18	2	2	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					40	45		10.1136/jclinpath-2017-204512			6	Pathology	Pathology	FP8TS	WOS:000417919600008	28600294				2019-10-28	
J	El Jabbour, T; Ross, JS; Sheehan, CE; Affolter, KE; Geiersbach, KB; Boguniewicz, A; Ainechi, S; Bronner, MP; Jones, DM; Lee, H				El Jabbour, Tony; Ross, Jeffrey S.; Sheehan, Christine E.; Affolter, Kajsa E.; Geiersbach, Katherine B.; Boguniewicz, Ann; Ainechi, Sanaz; Bronner, Mary P.; Jones, David M.; Lee, Hwajeong			PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry	JOURNAL OF CLINICAL PATHOLOGY			English	Article							DEATH-LIGAND 1; ANTI-PD-L1 ANTIBODY; BRAF MUTATION; SAFETY; HETEROGENEITY; MORPHOLOGY; MPDL3280A; BLOCKADE; PATTERNS; MELANOMA	Aims Routine application of PD-L1 immunohistochemistry (IHC) in colorectal cancer (CRC) is limited due to lack of standardized scoring criteria, antibody clones, and intratumoral staining heterogeneity. We assessed PD-L1 protein expression on full face CRC tissue sections and applied two algorithms based on the published clinical trials that support the recent FDA approval for immune checkpoint inhibitors (ICPI) therapy in non-small cell lung cancer (NSCLC). Methods PD-L1/CD274 IHC (Roche/Ventana, clone SP142) was performed on representative tumour blocks from 52 mismatch repair-deficient (MMR-D) and 52 MMR-proficient (MMR-P) CRCs. Membranous PD-L1 expression was scored for the tumour cell (TC) and tumour-infiltrating immune cell (IC) components. PD-L1 positivity status was determined based on the published NSCLC clinical trials that utilized the Ventana SP142 assay. Hybrid capture-based comprehensive genomic profiling (CGP) was performed on a separate set of 2268 clinically advanced CRCs and the frequency of PD-L1/PD-L2 amplification was determined. Results PD-L1 expression in the TC and IC correlated with MMR-D (p=0.013, p<0.0001), T stage (p=0.036, p=0.0036) and clinical stage (p=0.022, p=0.0037). PD-L1 positivity status correlated with MMR-D by two algorithms. Five of 2268 (<1%) advansced CRCs demonstrated amplification of either the PD-L1 or PD-L2 genes by CGP. Conclusions PD-L1 expression in TC and IC is associated with advanced stage and MMR-D. PD-L1 positivity status by the published algorithm is associated with MMR-D. PD-L1 amplification is extremely uncommon in CRC. Evaluation of whole tissue section and incorporation of IC staining enhance the sensitivity to screen patients who may benefit from ICPI therapy.	[El Jabbour, Tony; Ross, Jeffrey S.; Sheehan, Christine E.; Boguniewicz, Ann; Ainechi, Sanaz; Jones, David M.; Lee, Hwajeong] Albany Med Coll, Anat Pathol, Albany, NY 12208 USA; [Ross, Jeffrey S.] Fdn Med, Cambridge, MA USA; [Affolter, Kajsa E.; Geiersbach, Katherine B.; Bronner, Mary P.] Univ Utah, Dept Pathol, Salt Lake City, UT USA; [Geiersbach, Katherine B.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA	Lee, H (reprint author), Albany Med Coll, 47 New Scotland Ave,MC81, Albany, NY 12208 USA.	LeeH5@mail.amc.edu					[Anonymous], TECENTRIQ CANC IMM C; [Anonymous], 2017, VENTANA PD L1 SP 142; Bilgin B, 2017, CURR MED RES OPIN, V33, P749, DOI 10.1080/03007995.2017.1279132; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Chen DS, 2012, CLIN CANCER RES, V18, P6580, DOI 10.1158/1078-0432.CCR-12-1362; DAKO, PD L1 IHC 22C3 PHARM; Droeser RA, 2013, EUR J CANCER, V49, P2233, DOI 10.1016/j.ejca.2013.02.015; Edge SB, 2010, AJCC CANC STAGING MA, P143; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; George T. J., 2016, ASCO M S, V34, P3587; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Ilie M, 2016, ANN ONCOL, V27, P147, DOI 10.1093/annonc/mdv489; Inaguma S, 2017, MODERN PATHOL, V30, P278, DOI 10.1038/modpathol.2016.185; Kerr KM, 2015, J THORAC ONCOL, V10, P985, DOI 10.1097/JTO.0000000000000526; Kim JH, 2016, BRIT J CANCER, V115, P490, DOI 10.1038/bjc.2016.211; Lal N, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.976052; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lee LH, 2016, MODERN PATHOL, V29, P1433, DOI 10.1038/modpathol.2016.139; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Mansfield AS, 2016, CLIN CANCER RES, V22, P2177, DOI 10.1158/1078-0432.CCR-15-2246; Masugi Y, 2017, GUT, V66, P1463, DOI 10.1136/gutjnl-2016-311421; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Prall F, 2016, HISTOPATHOLOGY, V69, P158, DOI 10.1111/his.12915; Rehman JA, 2017, MODERN PATHOL, V30, P340, DOI 10.1038/modpathol.2016.186; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rosenbaum MW, 2016, MODERN PATHOL, V29, P1104, DOI 10.1038/modpathol.2016.95; Salem ME, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.11517; Schats KA, 2017, HISTOPATHOLOGY, V70, P253, DOI 10.1111/his.13056; Sheng J, 2016, SCI REP, V6; Shia J, 2017, MODERN PATHOL, V30, P599, DOI 10.1038/modpathol.2016.198; Sunshine J, 2015, CURR OPIN PHARMACOL, V23, P32, DOI 10.1016/j.coph.2015.05.011; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332; Zhu HL, 2015, INT J CLIN EXP PATHO, V8, P9351	40	6	6	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					46	51		10.1136/jclinpath-2017-204525			6	Pathology	Pathology	FP8TS	WOS:000417919600009	28667193				2019-10-28	
J	Gomez, LC; Sottile, ML; Guerrero-Gimenez, ME; Zoppino, FCM; Redondo, AL; Gago, FE; Orozco, JI; Tello, OM; Roque, M; Nadin, SB; Marzese, DM; Vargas-Roig, LM				Gomez, Laura C.; Sottile, Mayra L.; Guerrero-Gimenez, Martin E.; Zoppino, Felipe C. M.; Redondo, Analia L.; Gago, Francisco E.; Orozco, Javier I.; Tello, Olga M.; Roque, Maria; Nadin, Silvina B.; Marzese, Diego M.; Vargas-Roig, Laura M.			TP73 DNA methylation and upregulation of Delta Np73 are associated with an adverse prognosis in breast cancer	JOURNAL OF CLINICAL PATHOLOGY			English	Article							SQUAMOUS-CELL CARCINOMA; POOR-PROGNOSIS; LUNG-CANCER; HISTOLOGIC GRADE; GENE-EXPRESSION; P73 ISOFORMS; HUMAN TUMORS; IN-VIVO; P53; TAP73	Aim Accumulated evidence suggests that aberrant methylation of the TP73 gene and increased levels of Delta Np73 in primary tumours correlate with poor prognosis. However, little is known regarding the transcriptional and functional regulation of the TP73 gene in breast cancer. The aim of the present study was to determine the expression of the Delta Np73 isoform, its relationship with DNA methylation of TP73 and their clinical prognostic significance in breast cancer patients. Methods TP73 gene methylation was studied in TCGA datasets and in 70 invasive ductal breast carcinomas (IDCs). The expression of p73 isoforms was evaluated by immunohistochemistry (IHC) and Western blot and correlated with clinicopathological variables and clinical outcome. Results We observed that the methylation of diverse CpG islands of TP73 differed significantly between molecular subtypes. An inverse correlation was found between p73 protein expression and the methylation status of the TP73 gene. The expression of exon 3' of p73 (only expressed in Delta Np73) was significantly higher in patients with wild-type p53. Immunohistochemical analysis revealed that all p73 isoforms were localised in both the nuclear and cytoplasmic compartments. We confirmed a positive association between the expression of Delta Np73 and high histological grade. Conclusions Our findings suggest that high expression of Delta Np73 could be used to determine the aggressiveness of IDCs and could be incorporated in the pathologist's report.	[Orozco, Javier I.; Marzese, Diego M.] Providence St Johns Hlth Ctr, John Wayne Canc Inst, Dept Translat Mol Med, Santa Monica, CA 90401 USA; [Gomez, Laura C.; Sottile, Mayra L.; Redondo, Analia L.; Nadin, Silvina B.; Vargas-Roig, Laura M.] Natl Sci & Tech Res Council CONICET, Tumor Biol Lab, Inst Med & Expt Biol Cuyo IMBECU, Mendoza, Argentina; [Gomez, Laura C.; Roque, Maria] Natl Univ Cuyo, Fac Exact Sci, Mendoza, Argentina; [Guerrero-Gimenez, Martin E.; Zoppino, Felipe C. M.] IMBECU CONICET, Oncol Lab, Mendoza, Argentina; [Guerrero-Gimenez, Martin E.; Zoppino, Felipe C. M.; Redondo, Analia L.; Orozco, Javier I.; Vargas-Roig, Laura M.] Natl Univ Cuyo, Sch Med, Mendoza, Argentina; [Gago, Francisco E.; Orozco, Javier I.; Tello, Olga M.] Gineco Mamario Inst, Mendoza, Argentina; [Roque, Maria] IHEM CONICET, Mendoza, Argentina	Marzese, DM (reprint author), Providence St Johns Hlth Ctr, John Wayne Canc Inst, Dept Translat Mol Med, Santa Monica, CA 90401 USA.; Vargas-Roig, LM (reprint author), Inst Med & Expt Biol Cuyo, CC 855, RA-5500 Mendoza, Argentina.	marzesed@jwci.org; vargasl@mendoza-conicet.ar		Zoppino, Felipe Carlos Martin/0000-0002-3348-8319	National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI); Ministry of Health of Argentina; CONICET, ArgentinaConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [PIP 27913]; National University of Cuyo, Argentina [06-J463]; Associates for Breast and Prostate Cancer Studies (ABCs) [887377001-40000]; Fashion Footwear Association of New York (FFANY) foundation [88737700160000]	This work was supported by the National Cancer Institute, Ministry of Health of Argentina (LMV-R), CONICET, Argentina Grant: PIP 27913 (LMV-R), and National University of Cuyo, Argentina Grant: 06-J463 (LMV-R); the Associates for Breast and Prostate Cancer Studies (ABCs) (Grant ID: 887377001-40000) award (DM and JIO) and the Fashion Footwear Association of New York (FFANY) (Grant ID: 88737700160000) foundation (DMM).	Bansal C, 2014, J CANCER RES THER, V10, P839, DOI 10.4103/0973-1482.140979; Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721; Belloni L, 2006, ONCOGENE, V25, P3606, DOI 10.1038/sj.onc.1209321; Biswas S, 2017, PHARMACOL THERAPEUT, V173, P118, DOI 10.1016/j.pharmthera.2017.02.011; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Bozzetti C, 2007, J CLIN ONCOL, V25, P1451, DOI 10.1200/JCO.2006.09.2023; Branham MT, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.17; Bunjobpo W, 2014, CELL DEATH DIFFER, V21, P1240, DOI 10.1038/cdd.2014.41; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Chowdhury B, 2017, J BIOL ENG, V11, DOI 10.1186/s13036-017-0052-9; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; Conforti F, 2012, AGING-US, V4, P202, DOI 10.18632/aging.100441; Dai XF, 2015, AM J CANCER RES, V5, P2929; Daskalos A, 2011, CANCER LETT, V300, P79, DOI 10.1016/j.canlet.2010.09.009; Di CX, 2013, CELL CYCLE, V12, P1861, DOI 10.4161/cc.24967; Di Vinci A, 2009, INT J ONCOL, V34, P449, DOI 10.3892/ijo_00000169; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Guan M, 2005, J CLIN PATHOL, V58, P1175, DOI 10.1136/jcp.2005.026955; Gyorffy B, 2016, INT J CANCER, V138, P87, DOI 10.1002/ijc.29684; Holm K, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0685-5; Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590; Inoue T, 2002, J BIOL CHEM, V277, P15053, DOI 10.1074/jbc.M200248200; Jaffe AE, 2012, INT J EPIDEMIOL, V41, P200, DOI 10.1093/ije/dyr238; Lai J, 2014, MOL CELLS, V37, P605, DOI 10.14348/molcells.2014.0154; Lai J, 2014, ONCOTARGET, V5, P6909, DOI 10.18632/oncotarget.2230; Liu SS, 2006, CLIN CANCER RES, V12, P3922, DOI 10.1158/1078-0432.CCR-05-2573; Lo Iacono M, 2011, J THORAC ONCOL, V6, P473, DOI 10.1097/JTO.0b013e31820b86b0; Lucena-Araujo AR, 2008, BRIT J HAEMATOL, V142, P74, DOI 10.1111/j.1365-2141.2008.07160.x; Lucena-Araujo AR, 2015, BLOOD, V126, P2302, DOI 10.1182/blood-2015-01-623330; Maisse C, 2004, CELL DEATH DIFFER, V11, P685, DOI 10.1038/sj.cdd.4401376; Marzese DM, 2012, J MOL DIAGN, V14, P613, DOI 10.1016/j.jmoldx.2012.07.001; Marzese DM, 2010, MOL CELL PROBE, V24, P271, DOI 10.1016/j.mcp.2010.05.002; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Moelans CB, 2015, CELL ONCOL, V38, P397, DOI 10.1007/s13402-015-0241-9; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Nadin SB, 2014, CELL STRESS CHAPERON, V19, P493, DOI 10.1007/s12192-013-0475-2; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Puig P, 2003, CLIN CANCER RES, V9, P5642; Rakha EA, 2008, J CLIN ONCOL, V26, P3153, DOI 10.1200/JCO.2007.15.5986; Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004; ROSEN PP, 1979, ANN CLIN LAB SCI, V9, P144; Rufini Alessandro, 2011, Genes Cancer, V2, P491, DOI 10.1177/1947601911408890; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Uramoto H, 2004, CLIN CANCER RES, V10, P6905, DOI 10.1158/1078-0432.CCR-04-0290; Ushiku T, 2007, INT J CANCER, V120, P60, DOI 10.1002/ijc.22275; Vilgelm A, 2008, ONCOGENE, V27, P2170, DOI 10.1038/sj.onc.1210862; Vilgelm AE, 2010, ONCOGENE, V29, P5861, DOI 10.1038/onc.2010.319; Vilgelm AE, 2010, MOL CANCER THER, V9, P693, DOI 10.1158/1535-7163.MCT-09-0912; Yan PS, 2000, CLIN CANCER RES, V6, P1432; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zhu WP, 2015, ONCOL LETT, V9, P2090, DOI 10.3892/ol.2015.3052	52	2	2	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					52	58		10.1136/jclinpath-2017-204499			7	Pathology	Pathology	FP8TS	WOS:000417919600010	28743687				2019-10-28	
J	Lo, RCL; Chan, KKS; Chok, KSH; Ng, IOL				Lo, Regina Cheuk-lam; Chan, Kristy Kwan-shuen; Chok, Kenneth Siu-ho; Ng, Irene Oi-lin			Liver allograft biopsies with histological cholestasis: a clinicopathological study of 254 cases from a single centre	JOURNAL OF CLINICAL PATHOLOGY			English	Article							HEPATITIS-B IMMUNOGLOBULIN; INTRAHEPATIC CHOLESTASIS; BILIARY COMPLICATIONS; RISK-FACTORS; TRANSPLANTATION; REJECTION; LAMIVUDINE	Aims Liver allograft biopsy is important in the management of liver transplant (LT) recipients. Cholestasis is an indicator of liver dysfunction, and histological evidence of cholestasis can be observed in a wide range of pathological entities in the post-LT setting. In this study, we describe the clinicopathological features and significance of liver allograft biopsies with histological cholestasis over 11 years in our centre. Methods Liver allograft biopsies performed in Queen Mary Hospital, Hong Kong from 2004 to 2014 showing histological cholestasis were retrieved from the pathology archive. Clinical and pathological data were retrospectively reviewed and analyzed. Results Among the 254 biopsies from 167 patients, large duct obstruction (LDO) and acute cellular rejection (ACR) were the two main aetiologies associated with cholestasis. There was a decrease in sepsis as a cause over the study duration. In cases showing cholestasis at 6 months or more after LT, LDO was more common than ACR. Over half (61%) of the 254 biopsies showed mild cholestasis. Severe panacinar cholestasis was more often observed in LDO. Mild cholestasis was most commonly observed regardless of the severity of ACR. Severe cholestasis was associated with poorer 1-year and 3-year graft survival and patient survival, as well as higher 3-month and 6-month post-biopsy mortality. Conclusion Histological cholestasis and its severity in liver allograft biopsies has clinical and prognostic significance. Our study summarizes our previous experience and provides further insights into the management of post-LT patients.	[Lo, Regina Cheuk-lam; Chan, Kristy Kwan-shuen; Ng, Irene Oi-lin] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Lo, Regina Cheuk-lam; Chok, Kenneth Siu-ho; Ng, Irene Oi-lin] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Hong Kong, Peoples R China; [Chok, Kenneth Siu-ho] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Lo, RCL (reprint author), Univ Hong Kong, Dept Pathol, Queen Mary Hosp, Room 216A,Univ Pathol Bldg, Pokfulam, Hong Kong, Peoples R China.; Ng, IOL (reprint author), Univ Hong Kong, Dept Pathol, Queen Mary Hosp, Room 217B,Univ Pathol Bldg, Pokfulam, Hong Kong, Peoples R China.	reginalo@pathology.hku.hk; iolng@hku.hk	Lo, Cheuk Lam Regina/E-9874-2010	Lo, Cheuk Lam Regina/0000-0001-6213-0343; Chok, Kenneth Siu ho/0000-0001-7921-3807; Ng, Irene Oi-lin/0000-0001-7532-2029			Ben-Ari Z, 2003, LIVER TRANSPLANT, V9, P1005, DOI 10.1053/jlts.2003.50212; Blair JE, 2005, LIVER TRANSPLANT, V11, P1452, DOI 10.1002/lt.20624; Corbani A, 2008, CLIN LIVER DIS, V12, P111, DOI 10.1016/j.cld.2007.11.001; Demetris A J, 1997, Ann Transplant, V2, P27; Demetris AJ, 1997, HEPATOLOGY, V25, P658; Feng S, 2015, AM J TRANSPLANT, V15; Heneghan M A, 2001, Semin Gastrointest Dis, V12, P133; Hernandez Maria Del Pilar, 2015, Gastroenterol Hepatol (N Y), V11, P741; Hirschfield GM, 2010, GASTROENTEROLOGY, V139, P1481, DOI 10.1053/j.gastro.2010.09.004; Hori T, 2016, ANN GASTROENTEROL, V29, P454, DOI 10.20524/aog.2016.0069; Kerkar N, 2011, CLIN TRANSPLANT, V25, pE584, DOI 10.1111/j.1399-0012.2011.01494.x; Kochhar G, 2013, WORLD J GASTROENTERO, V19, P2841, DOI 10.3748/wjg.v19.i19.2841; Loomba R, 2008, CLIN GASTROENTEROL H, V6, P696, DOI 10.1016/j.cgh.2008.02.055; Mejia GA, 2016, TRANSPL P, V48, P665, DOI 10.1016/j.transproceed.2016.02.033; Perkins JD, 2006, LIVER TRANSPLANT, V12, P886; Rao WS, 2009, TRANSPL INT, V22, P387, DOI 10.1111/j.1432-2277.2008.00784.x; Watt KDS, 2010, AM J TRANSPLANT, V10, P1420, DOI 10.1111/j.1600-6143.2010.03126.x	17	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					72	78		10.1136/jclinpath-2017-204334			7	Pathology	Pathology	FP8TS	WOS:000417919600013	28751522				2019-10-28	
J	Lee, J; Harrison, CN				Lee, Joe; Harrison, Claire N.			Hb Baden: a rare high affinity haemoglobin variant and its management	JOURNAL OF CLINICAL PATHOLOGY			English	Article							ERYTHROCYTOSIS; DIAGNOSIS	Haemoglobin Baden is a rare variant haemoglobin which has only recently been clinically and functionally characterised. We present the case of a young adult male patient who presented with an erythrocytosis but was clinically asymptomatic. His mother was also diagnosed retrospectively having presented with erythrocytosis being treated with regular venesections. We discuss the management plan and potential significance of being a carrier of this rare haemoglobin variant.	[Lee, Joe; Harrison, Claire N.] Guys Hosp, Dept Haematol, London, England	Lee, J (reprint author), Guys & St Thomas NHS Fdn Trust, Haematol Dept, Guys Hosp, Haematol, London SE1 9RT, England.	joe.lee@kcl.ac.uk					Abdulmalik O, 2010, AM J HEMATOL, V85, P848, DOI 10.1002/ajh.21831; DIVOKY V, 1992, BIOCHIM BIOPHYS ACTA, V1180, P173, DOI 10.1016/0925-4439(92)90065-U; Fairbanks V, 1971, MAYO CLIN P; Klarskov K, 1998, BIOCHEMISTRY-US, V37, P5995, DOI 10.1021/bi972498w; McMullin MF, 2007, BRIT J HAEMATOL, V138, P821, DOI 10.1111/j.1365-2141.2007.06741.x; McMullin MF, 2012, THER ADV HEMATOL, V3, P391, DOI 10.1177/2040620712458947; Percy MJ, 2009, HAEMATOL-HEMATOL J, V94, P1321, DOI 10.3324/haematol.2009.008037; Thom CS, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a011858; WEATHERALL DJ, 1977, BRIT J HAEMATOL, V35, P177, DOI 10.1111/j.1365-2141.1977.tb00575.x	9	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					79	80		10.1136/jclinpath-2017-204586			2	Pathology	Pathology	FP8TS	WOS:000417919600014	28768701				2019-10-28	
J	Mohamed, OE; Jones, J; Osman, H; Huissoon, AP				Mohamed, Omar E.; Jones, Julie; Osman, Husam; Huissoon, Aarnoud P.			Unexplained abnormal liver function in patients with primary antibody deficiency: could it be chronic hepatitis E infection?	JOURNAL OF CLINICAL PATHOLOGY			English	Article							COMMON VARIABLE IMMUNODEFICIENCY; E VIRUS-INFECTION; IMMUNE-RESPONSES	Data from recent studies suggest rising incidence rate of hepatitis E virus (HEV) infection in the UK. HEV infection may take a severe and persistent course in immunocompromised patients, including transplant recipients on immunosuppressives, patients with HIV, haematological malignancies and in idiopathic CD4(+) T lymphocytopenia. The prevalence of HEV in primary antibody deficiency (PAD) disorders is still unknown. The aim of this study was to investigate HEV infection in 27 patients with PAD with unexplained, persistently elevated liver enzymes. Although all the 27 patients tested negative for HEV-RNA, we would still strongly recommend that HEV should be considered in any immunodeficient patient with impaired liver function.	[Mohamed, Omar E.; Jones, Julie; Huissoon, Aarnoud P.] Heartlands Hosp, West Midlands Immunodeficiency Ctr, Birmingham, W Midlands, England; [Osman, Husam] Heartlands Hosp, Dept Virol, Birmingham, W Midlands, England; [Osman, Husam] Publ Hlth Lab Birmingham, Birmingham, W Midlands, England	Mohamed, OE (reprint author), Birmingham Heartlands Hosp, Dept Allergy & Immunol, Birmingham B9 5SS, W Midlands, England.	omar.mohamed@heartofengland.nhs.uk					Bateman EAL, 2012, CLIN EXP IMMUNOL, V170, P202, DOI 10.1111/j.1365-2249.2012.04643.x; Borish L, 2011, J ALLERGY CLIN IMMUN, V127, P541, DOI 10.1016/j.jaci.2010.11.004; Boxall E, 2006, TRANSFUSION MED, V16, P79, DOI 10.1111/j.1365-3148.2006.00652.x; Colson P, 2008, CLIN MICROBIOL INFEC, V14, P1176, DOI 10.1111/j.1469-0691.2008.02102.x; Durandy A, 2013, NAT REV IMMUNOL, V13, P519, DOI 10.1038/nri3466; ESID Registry, WORK DEF CLIN DIAGN; Hewitt PE, 2014, LANCET, V384, P1766, DOI 10.1016/S0140-6736(14)61034-5; Kamar N, 2008, NEW ENGL J MED, V358, P811, DOI 10.1056/NEJMoa0706992; Mallet V, 2010, ANN INTERN MED, V153, P85, DOI 10.7326/0003-4819-153-2-201007200-00257; Ollier L, 2009, ANN INTERN MED, V150, P430, DOI 10.7326/0003-4819-150-6-200903170-00026; Pischke S, 2012, INFECT DIS REP, V4, P114, DOI 10.4081/idr.2012.e28; Salzer U, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4032; Srivastava R, 2011, J GASTROEN HEPATOL, V26, P306, DOI 10.1111/j.1440-1746.2010.06356.x; Srivastava R, 2007, VIRAL IMMUNOL, V20, P56, DOI 10.1089/vim.2006.0053; Suneetha PV, 2012, HEPATOLOGY, V55, P695, DOI 10.1002/hep.24738; Wong GK, 2016, J CLIN PATHOL, V69, P672, DOI 10.1136/jclinpath-2015-203351; Woodward JM, 2015, AM J GASTROENTEROL, V110, P320, DOI 10.1038/ajg.2014.432	17	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					81	83		10.1136/jclinpath-2017-204627			3	Pathology	Pathology	FP8TS	WOS:000417919600015					2019-10-28	
J	Yannakou, CK; Jones, K; Ryland, GL; Thompson, ER; Reid, G; McBean, M; Trainer, A; Westerman, D; Blombery, P				Yannakou, Costas K.; Jones, Kate; Ryland, Georgina L.; Thompson, Ella R.; Reid, Gareth; McBean, Michelle; Trainer, Alison; Westerman, David; Blombery, Piers			Incidental detection of germline variants of potential clinical significance by massively parallel sequencing in haematological malignancies	JOURNAL OF CLINICAL PATHOLOGY			English	Article							ACMG RECOMMENDATIONS; EXOME	Massively parallel sequencing (MPS) technology has become routinely available for diagnosis, prognostication and therapeutic decision-making in haematological malignancies. However, increased throughput and wider coverage of genes can have unintended consequences. Germline variants of potential clinical significance (GVPCSs) detected during cancer testing may have implications for patients and families beyond the biological evaluation of a specific tumour. 721 reports generated from MPS panels used in the routine testing of myeloid and lymphoid malignancies were reviewed and variants within genes of potential germline relevance (TP53, RUNX1, GATA2 and WT1 in all contexts and CBL, KRAS and NRAS in the setting of juvenile myelomonocytic leukaemia) were analysed. A variant allele fraction threshold of >= 33.09% for considering germline origin of variants within cancer samples was established. The detection rate of incidental, pathogenic germline variants was 0.42%. Patient education and confirmatory germline sample testing of GVPCSs in appropriate circumstances are recommended.	[Yannakou, Costas K.; Jones, Kate; Ryland, Georgina L.; Thompson, Ella R.; Reid, Gareth; McBean, Michelle; Trainer, Alison; Westerman, David; Blombery, Piers] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Yannakou, Costas K.; Thompson, Ella R.; Trainer, Alison; Westerman, David; Blombery, Piers] Univ Melbourne, Melbourne, Vic, Australia	Yannakou, CK (reprint author), Peter MacCallum Canc Ctr, Dept Mol Haematol, Pathol Level 4,305 Grattan St, Melbourne, Vic 3000, Australia.	costas.yannakou@petermac.org					Churpek JE, 2016, BLOOD; Cykowski MD, 2013, J NEURO-ONCOL, V115, P477, DOI 10.1007/s11060-013-1249-5; FUNCHAIN P, 2015, J CLIN ONCOL S, V33; Green RC, 2013, GENET MED, V15, P565, DOI 10.1038/gim.2013.73; Jones S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7161; Kalia SS, 2017, GENET MED, V19, P249, DOI 10.1038/gim.2016.190; Kohlmann W, 2016, BLOOD, V128, P2497, DOI 10.1182/blood-2016-06-716704; Richards CS, 2008, GENET MED, V10, P294, DOI 10.1097/GIM.0b013e31816b5cae; Walsh T, 2010, P NATL ACAD SCI USA, V107, P12629, DOI 10.1073/pnas.1007983107; Yushak ML, 2016, CANCER-AM CANCER SOC, V122, P1588, DOI 10.1002/cncr.29951	10	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					84	87		10.1136/jclinpath-2017-204481			4	Pathology	Pathology	FP8TS	WOS:000417919600016	28801348				2019-10-28	
J	van Schaijik, B; Davis, PF; Wickremesekera, AC; Tan, ST; Itinteang, T				van Schaijik, Bede; Davis, Paul F.; Wickremesekera, Agadha C.; Tan, Swee T.; Itinteang, Tinte			Subcellular localisation of the stem cell markers OCT4, SOX2, NANOG, KLF4 and c-MYC in cancer: a review	JOURNAL OF CLINICAL PATHOLOGY			English	Article							NUCLEAR-LOCALIZATION; TRANSCRIPTION FACTOR; GENES OCT4; EXPRESSION; PLURIPOTENT; IDENTIFICATION; PROTEIN; FIBROBLASTS; CYTOPLASM; PRODUCT	The stem cell markers octamer-binding transcription factor 4, sex-determining region Y-box 2, NANOG, Kruppel-like factor 4 and c-MYC are key factors in inducing pluripotency in somatic cells, and they have been used to detect cancer stem cell subpopulations in a range of cancer types. Recent literature has described the subcellular localisation of these markers and their potential implications on cellular function. This is a relatively complex and unexplored area of research, and the extent of the effect that subcellular localisation has on cancer development and growth is largely unknown. This review analyses this area of research in the context of the biology of stem cells and cancer and explores the potential modulating effect of subcellular localisation of these proteins as supported by the literature.	[van Schaijik, Bede; Davis, Paul F.; Wickremesekera, Agadha C.; Tan, Swee T.; Itinteang, Tinte] Gillies McIndoe Res Inst, Wellington 6242, New Zealand; [Wickremesekera, Agadha C.] Wellington Reg Hosp, Dept Neurosurg, Wellington, New Zealand; [Tan, Swee T.] Hutt Hosp, Wellington Reg Plast, Maxillofacial & Burns Unit, Wellington, New Zealand	Itinteang, T (reprint author), Gillies McIndoe Res Inst, Wellington 6242, New Zealand.	tinte@gmri.org.nz					Alexander RE, 2014, HUM PATHOL, V45, P27, DOI 10.1016/j.humpath.2013.08.006; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; Atlasi Y, 2008, STEM CELLS, V26, P3068, DOI 10.1634/stemcells.2008-0530; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Baillie R, 2016, J CLIN PATHOL, V69, P742, DOI 10.1136/jclinpath-2015-203599; Baltus GA, 2009, STEM CELLS, V27, P2175, DOI 10.1002/stem.168; Bhartiya D, 2012, STEM CELLS DEV, V21, P1, DOI 10.1089/scd.2011.0311; Bradshaw A, 2016, FRONT SURG, V3, DOI 10.3389/fsurg.2016.00021; Cauffman G, 2006, STEM CELLS, V24, P2685, DOI 10.1634/stemcells.2005-0611; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chang DF, 2009, STEM CELLS, V27, P812, DOI 10.1634/stemcells.2008-0657; Chen YJ, 2008, CANCER BIOL THER, V7, P777, DOI 10.4161/cbt.7.5.5768; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502; Do JT, 2004, STEM CELLS, V22, P941, DOI 10.1634/stemcells.22-6-941; Ezeh UI, 2005, CANCER-AM CANCER SOC, V104, P2255, DOI 10.1002/cncr.21432; Gu TT, 2012, AM J PATHOL, V181, P652, DOI 10.1016/j.ajpath.2012.04.008; Guo Y, 2011, HISTOPATHOLOGY, V59, P763, DOI 10.1111/j.1365-2559.2011.03993.x; Jeong CH, 2010, STEM CELLS, V28, P2141, DOI 10.1002/stem.540; Kafri M, 2016, CELL REP, V14, P22, DOI 10.1016/j.celrep.2015.12.015; Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005; Le Magnen C, 2013, EUR J CANCER, V49, P955, DOI 10.1016/j.ejca.2012.09.023; Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143; Liu Y, 2013, BIOCHEM BIOPH RES CO, V436, P162, DOI 10.1016/j.bbrc.2013.05.067; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Luo WR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056324; Ma MQ, 2014, INT J CLIN EXP PATHO, V7, P6679; McBride KM, 2002, EMBO J, V21, P1754, DOI 10.1093/emboj/21.7.1754; McCaughan F, 2010, AM J RESP CRIT CARE, V182, P83, DOI 10.1164/rccm.201001-0005OC; Munro MJ, 2017, J CLIN PATHOL; Neumann J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-518; Oka M, 2013, J BIOL CHEM, V288, P15085, DOI 10.1074/jbc.M112.448837; Pan GJ, 2004, J BIOL CHEM, V279, P37013, DOI 10.1074/jbc.M405117200; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Ram R, 2017, FRONT SURG, V4, DOI 10.3389/fsurg.2017.00012; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; ROYDS JA, 1992, GRAEF ARCH CLIN EXP, V230, P366, DOI 10.1007/BF00165947; ROYDS JA, 1992, J PATHOL, V166, P225, DOI 10.1002/path.1711660304; Saigusa S, 2009, ANN SURG ONCOL, V16, P3488, DOI 10.1245/s10434-009-0617-z; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; Shan JJ, 2012, HEPATOLOGY, V56, P1004, DOI 10.1002/hep.25745; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SIKORA K, 1985, BRIT J CANCER, V52, P171, DOI 10.1038/bjc.1985.174; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tang Y, 2011, CELL REPROGRAM, V13, P99, DOI 10.1089/cell.2010.0072; Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863; Yang G, 2005, CANCER-AM CANCER SOC, V103, P1186, DOI 10.1002/cncr.20905; Yang WC, 2009, BIOTECHNOL BIOENG, V104, P1047, DOI 10.1002/bit.22517; Yu HH, 2016, FRONT SURG, V3, DOI 10.3389/fsurg.2016.00046; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zeineddine D, 2014, AM J STEM CELLS, V3, P74; Zhang JH, 2009, CIRC RES, V104, pE30, DOI 10.1161/CIRCRESAHA.108.192237	54	24	24	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					88	91		10.1136/jclinpath-2017-204815			4	Pathology	Pathology	FP8TS	WOS:000417919600017	29180509				2019-10-28	
J	Hopkins, D; Varma, M				Hopkins, Daniel; Varma, Murali			Crouching tiger, hidden dragon	JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material							INTERTUBULAR GROWTH; SEMINOMAS; TUMORS		[Hopkins, Daniel; Varma, Murali] Univ Hosp Wales, Dept Cellular Pathol, Cardiff, S Glam, Wales	Varma, M (reprint author), Univ Hosp Wales, Dept Histopathol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	varmam@Cardiff.ac.uk					Berney DM, 2016, HISTOPATHOLOGY, V69, P7, DOI 10.1111/his.12958; Browne TJ, 2005, HUM PATHOL, V36, P640, DOI 10.1016/j.humpath.2005.03.011; Henley JD, 2004, AM J SURG PATHOL, V28, P1163, DOI 10.1097/01.pas.0000132742.12221.82; Sen S, 2009, DIAGN HISTOPATHOL, V15, P104; Williamson SR, 2017, HISTOPATHOLOGY, V70, P335, DOI 10.1111/his.13102	5	0	0	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					92	U118		10.1136/jclinpath-2017-204691			3	Pathology	Pathology	FP8TS	WOS:000417919600018	28903996				2019-10-28	
J	Palomino, J; Hanell, A				Palomino, Jhonel; Hanell, Anders			Computer graphics for the microscopist	JOURNAL OF CLINICAL PATHOLOGY			English	Letter							PATHOLOGY		[Palomino, Jhonel; Hanell, Anders] Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden	Hanell, A (reprint author), Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden.	anders.hanell@ki.se	Hanell, Anders/E-4776-2011	Hanell, Anders/0000-0001-9369-3886	Mattson Foundation via the Swedish Brain Foundation [PS2015-0060]; Swedish Armed Forces, RD	This work was supported by the Mattson Foundation via the Swedish Brain Foundation (PS2015-0060) and the Swedish Armed Forces, R&D.	Clarke EL, 2017, HISTOPATHOLOGY, V70, P153, DOI 10.1111/his.13079; Cromey DW, 2010, SCI ENG ETHICS, V16, P639, DOI 10.1007/s11948-010-9201-y; Driman DK, 2017, HISTOPATHOLOGY, V70, P840, DOI 10.1111/his.13146; Ghaznavi F, 2013, ANNU REV PATHOL-MECH, V8, P331, DOI 10.1146/annurev-pathol-011811-120902; Helliwell TR, 2017, HISTOPATHOLOGY, V71, P496, DOI 10.1111/his.13241; Park S, 2012, CLIN LAB MED, V32, P557, DOI 10.1016/j.cll.2012.07.006; Shaw SL, 2013, METHOD CELL BIOL, V114, P317, DOI 10.1016/B978-0-12-407761-4.00013-0; Weinstein RS, 2009, HUM PATHOL, V40, P1057, DOI 10.1016/j.humpath.2009.04.006	8	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1							e1	10.1136/jclinpath-2017-204861			2	Pathology	Pathology	FP8TS	WOS:000417919600001	29146884				2019-10-28	
J	Rosty, C				Rosty, Christophe			The Role of the Surgical Pathologist in the Diagnosis of Gastrointestinal Polyposis Syndromes	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						Peutz-Jeghers syndrome; juvenile polyposis syndrome; Cowden syndrome; familial adenomatous polyposis; MUTYH-associated polyposis; polymerase proofreading-associated polyposis; NTHL1-associated polyposis; serrated polyposis syndrome	PEUTZ-JEGHERS-SYNDROME; MUTYH-ASSOCIATED POLYPOSIS; HAMARTOMA TUMOR SYNDROME; GENOTYPE-PHENOTYPE CORRELATIONS; FAMILIAL ADENOMATOUS POLYPOSIS; HIGH CANCER-RISK; SERRATED POLYPOSIS; JUVENILE POLYPOSIS; COWDEN-SYNDROME; COLORECTAL-CANCER	Polyps of the gastrointestinal tract are very common lesions and most frequently sporadic in nature. Some polyp subtypes are associated with rare hereditary polyposis syndromes, including juvenile polyposis syndrome, Peutz-Jeghers syndrome, and Cowden syndrome. However, many sporadic benign lesions of the gastrointestinal tract can mimic some of these syndromic hamartomatous polyps. The role of the surgical pathologist is to raise the possibility of a hereditary condition in case of suggestive polyp histology and to look for clinical information to support the suspected diagnosis. In this review, the clinical presentation and the pathology associated with these rare hamartomatous polyposis syndromes are discussed in an attempt to provide pathologists clues in suggesting one such syndrome on the basis of histologic findings and clinical context. Identification of affected individuals is important because of the increased gastrointestinal and other malignancies. Recently, new adenomatous polyposis syndromes have been discovered, expanding the genetic causes of patient diagnosed with multiple colonic adenomas. By being aware of the clinical phenotype and the tumor spectrum associated with gastrointestinal polyposis syndromes, surgical pathologists can play a critical role in recommending genetic counseling when suspicious of such a diagnosis. This may lead to the identification of a genetic cause and appropriate surveillance of affected family members to screen for associated malignancies.	[Rosty, Christophe] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [Rosty, Christophe] Univ Melbourne, Dept Pathol, Genet Epidemiol Lab, Carlton, Vic, Australia	Rosty, C (reprint author), 5-38 Bishop St, Kelvin Grove, Qld 4059, Australia.	c.rosty@uq.edu.au		Rosty, Christophe/0000-0001-7671-2651			Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Aretz S, 2007, J MED GENET, V44, P702, DOI 10.1136/jmg.2007.052506; Beggs AD, 2010, GUT, V59, P975, DOI 10.1136/gut.2009.198499; Blumenthal GM, 2008, EUR J HUM GENET, V16, P1289, DOI 10.1038/ejhg.2008.162; Boparai KS, 2010, GUT, V59, P1222, DOI 10.1136/gut.2009.200741; Boparai KS, 2010, GUT, V59, P1094, DOI 10.1136/gut.2009.185884; Borowsky J, 2015, MODERN PATHOL, V28, p149A; Brosens LAA, 2005, GUT, V54, P1034, DOI 10.1136/gut.2004.053843; Brosens LAA, 2007, GUT, V56, P965, DOI 10.1136/gut.2006.116913; Brosens LAA, 2016, INT J SURG PATHOL, V24, P185, DOI 10.1177/1066896915620013; BRUWER A, 1954, P STAFF M MAYO CLIN, V29, P168; Buchanan DD, 2017, GUT, V66, P1170, DOI 10.1136/gutjnl-2016-312773; Carballal S, 2016, GUT, V65, P1829, DOI 10.1136/gutjnl-2015-309647; Clendenning M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066705; COBURN MC, 1995, ANN SURG ONCOL, V2, P386, DOI 10.1007/BF02306370; Crowder CD, 2012, AM J SURG PATHOL, V36, P1178, DOI 10.1097/PAS.0b013e3182597f41; Eng C, 2000, J MED GENET, V37, P828, DOI 10.1136/jmg.37.11.828; Friedl W, 2002, HUM GENET, V111, P108, DOI 10.1007/s00439-002-0748-9; Gala MK, 2014, GASTROENTEROLOGY, V146, P520, DOI 10.1053/j.gastro.2013.10.045; Galiatsatos P, 2006, AM J GASTROENTEROL, V101, P385, DOI 10.1111/j.1572-0241.2006.00375.x; GAYTHER SA, 1994, HUM MOL GENET, V3, P53, DOI 10.1093/hmg/3.1.53; Giardiello FM, 2006, CLIN GASTROENTEROL H, V4, P408, DOI 10.1016/j.cgh.2005.11.005; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Gonzalez RS, 2017, HISTOPATHOLOGY, V70, P918, DOI 10.1111/his.13149; Guarinos C, 2014, CLIN CANCER RES, V20, P1158, DOI 10.1158/1078-0432.CCR-13-1490; Heald B, 2010, GASTROENTEROLOGY, V139, P1927, DOI 10.1053/j.gastro.2010.06.061; Howe JR, 1998, ANN SURG ONCOL, V5, P751, DOI 10.1007/BF02303487; JEGHERS H, 1949, NEW ENGL J MED, V241, P993, DOI 10.1056/NEJM194912222412501; Lam-Himlin D, 2010, AM J SURG PATHOL, V34, P1656, DOI 10.1097/PAS.0b013e3181f2b1f1; Latchford AR, 2011, FAM CANCER, V10, P455, DOI 10.1007/s10689-011-9442-1; Latchford AR, 2012, DIS COLON RECTUM, V55, P1038, DOI 10.1097/DCR.0b013e31826278b3; Li J, 2016, AM J HUM GENET, V98, P830, DOI 10.1016/j.ajhg.2016.03.001; LLOYD KM, 1963, ANN INTERN MED, V58, P136, DOI 10.7326/0003-4819-58-1-136; Ma CQ, 2014, AM J SURG PATHOL, V38, P1618, DOI 10.1097/PAS.0000000000000283; MARRA G, 1994, J CLIN GASTROENTEROL, V18, P42, DOI 10.1097/00004836-199401000-00011; Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461; Morak M, 2014, EUR J HUM GENET, V22, P1334, DOI 10.1038/ejhg.2014.15; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nelen MR, 1999, EUR J HUM GENET, V7, P267, DOI 10.1038/sj.ejhg.5200289; Nielsen M, 2011, CRIT REV ONCOL HEMAT, V79, P1, DOI 10.1016/j.critrevonc.2010.05.011; Nielsen M, 2009, GASTROENTEROLOGY, V136, P471, DOI 10.1053/j.gastro.2008.10.056; Pai RK, 2016, AM J SURG PATHOL, V40, pE17, DOI 10.1097/PAS.0000000000000620; Palles C, 2013, NAT GENET, V45, P136, DOI 10.1038/ng.2503; Parry S, 2017, NEW ZEAL MED J, V130, P57; Pilarski R, 2013, JNCI-J NATL CANCER I, V105, P1607, DOI 10.1093/jnci/djt277; Rex DK, 2012, AM J GASTROENTEROL, V107, P1315, DOI 10.1038/ajg.2012.161; Riegert-Johnson DL, 2010, HERED CANCER CLIN PR, V8, DOI 10.1186/1897-4287-8-6; Rittershaus AC, 2011, ARCH PATHOL LAB MED, V135, P1311, DOI 10.5858/arpa.2011-0038-RA; Rivera B, 2015, NEW ENGL J MED, V373, P1985, DOI 10.1056/NEJMc1506878; Rivero-Sanchez L, 2017, ENDOSCOPY, V49, P44, DOI 10.1055/s-0042-115640; Rosty C, 2011, PATHOLOG RES INT, V2011, DOI DOI 10.4061/2011/157073; Rosty C, 2013, AM J SURG PATHOL, V37, P434, DOI 10.1097/PAS.0b013e318270f748; Rosty C, 2012, AM J SURG PATHOL, V36, P876, DOI 10.1097/PAS.0b013e31824e133f; Shaco-Levy R, 2016, HUM PATHOL, V49, P39, DOI 10.1016/j.humpath.2015.10.002; Snover DC, 2010, WHO CLASSIFICATION T, P160; Spier I, 2015, INT J CANCER, V137, P320, DOI 10.1002/ijc.29396; Spjut H, 1977, Pathol Annu, V12 Pt 1, P147; Stanich PP, 2014, WORLD J GASTROENTERO, V20, P1833, DOI 10.3748/wjg.v20.i7.1833; Stanich PP, 2011, MAYO CLIN PROC, V86, P489, DOI 10.4065/mcp.2010.0816; STARINK TM, 1986, CLIN GENET, V29, P222; Syngal S, 2015, AM J GASTROENTEROL, V110, P223, DOI 10.1038/ajg.2014.435; Tan MH, 2012, CLIN CANCER RES, V18, P400, DOI 10.1158/1078-0432.CCR-11-2283; Tan MH, 2011, AM J HUM GENET, V88, P42, DOI 10.1016/j.ajhg.2010.11.013; Taupin Douglas, 2015, Hum Genome Var, V2, P15013, DOI 10.1038/hgv.2015.13; Tse JY, 2013, MODERN PATHOL, V26, P1235, DOI 10.1038/modpathol.2013.44; van Herwaarden YJ, 2015, ENDOSCOPY, V47, P1043, DOI 10.1055/s-0034-1392411; van Lier MGF, 2010, AM J GASTROENTEROL, V105, P1258, DOI 10.1038/ajg.2009.725; van Lier MGF, 2011, GUT, V60, P141, DOI 10.1136/gut.2010.223750; VEALE A. M. O., 1966, J MED GENET, V3, P5, DOI 10.1136/jmg.3.1.5; Vemulapalli KC, 2012, GASTROINTEST ENDOSC, V75, P1206, DOI 10.1016/j.gie.2012.01.033; Vogel T, 2000, INT J COLORECTAL DIS, V15, P118, DOI 10.1007/s003840050245; Vogt S, 2009, GASTROENTEROLOGY, V137, P1976, DOI 10.1053/j.gastro.2009.08.052; WEARY PE, 1972, ARCH DERMATOL, V106, P682, DOI 10.1001/archderm.106.5.682; Weren RDA, 2015, NAT GENET, V47, P668, DOI 10.1038/ng.3287; Win AK, 2016, INT J CANCER, V139, P1557, DOI 10.1002/ijc.30197; Worthley DL, 2012, GUT, V61, P774, DOI 10.1136/gutjnl-2011-300348; Yan HHN, 2017, GUT, V66, P1645, DOI 10.1136/gutjnl-2016-311849; Young JP, 2010, NAT REV GASTRO HEPAT, V7, P594, DOI 10.1038/nrgastro.2010.166; Zhou XP, 2003, AM J HUM GENET, V73, P404, DOI 10.1086/377109	79	4	4	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	JAN	2018	25	1					1	13		10.1097/PAP.0000000000000173			13	Pathology	Pathology	FP9AX	WOS:000417940800001	28901964				2019-10-28	
J	Monaco, S; Mehrad, M; Dacic, S				Monaco, Sara; Mehrad, Mitra; Dacic, Sanja			Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						biopsy; cytology; effusion; fluids; immunohistochemistry; mesothelioma; p16	9P21 HOMOZYGOUS DELETION; IN-SITU HYBRIDIZATION; PLEURAL MESOTHELIOMA; EFFUSION CYTOLOGY; P16 FISH; SARCOMATOID MESOTHELIOMA; BAP1 IMMUNOHISTOCHEMISTRY; CONTROLLED-TRIAL; CDKN2A; PROLIFERATIONS	Mesothelial proliferations can be diagnostically challenging in small specimens, such as body fluid cytology and small tissue biopsies. A great morphologic challenge for pathologists is the separation of benign reactive mesothelial proliferations from malignant mesotheliomas. Reactive mesothelial proliferations may have histologic features that resemble malignancy including increased cellularity, cytologic atypia, and mitoses. Recent advances in mesothelioma genetics resulted in identification of BAP1 mutations and p16 deletions as features of malignant mesotheliomas. Hence, BAP1 immunohistochemistry and fluorescence in situ hybridization for p16 emerged as 2 most common diagnostically helpful ancillary studies used on limited samples when the question is whether the proliferation is malignant or benign. In contrast, separation of mesothelioma from other malignancies is relatively straight forward using morphology and immunohistochemical stains. The choice of antibody panel to be applied in an individual case is driven by morphology, either epithelioid or sarcomatoid. This brief review will focus on morphology and ancillary testing of mainly pleural mesothelial proliferations.	[Monaco, Sara; Dacic, Sanja] Univ Pittsburgh, Dept Pathol, 200 Lothrop St, Pittsburgh, PA 15213 USA; [Mehrad, Mitra] Vanderbilt Univ, Dept Pathol, Nashville, TN USA	Dacic, S (reprint author), Univ Pittsburgh, Dept Pathol, 200 Lothrop St, Pittsburgh, PA 15213 USA.	dacics@upmc.edu					Attanoos RL, 2003, HISTOPATHOLOGY, V43, P231, DOI 10.1046/j.1365-2559.2003.01686.x; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Chiosea S, 2008, MODERN PATHOL, V21, P742, DOI 10.1038/modpathol.2008.45; Chirieac LR, 2011, AM J CANCER RES, V1, P14; Churg A, 2000, AM J SURG PATHOL, V24, P1183; Churg A, 2016, ARCH PATHOL LAB MED, V140, P318, DOI 10.5858/arpa.2015-0240-SA; Churg A, 2012, ARCH PATHOL LAB MED, V136, P1217, DOI 10.5858/arpa.2012-0112-RA; Galateau-Salle F, 2015, WHO CLASSIFICATION T, P160; Gao L, 2012, CYTOJOURNAL, V9, DOI 10.4103/1742-6413.99170; Guo GW, 2015, CANCER RES, V75, P264, DOI 10.1158/0008-5472.CAN-14-1008; Henderson DW, 2013, J CLIN PATHOL, V66, P847, DOI 10.1136/jclinpath-2012-201303; Hida T, 2015, CANCER SCI, V106, P1635, DOI 10.1111/cas.12769; Hirao T, 2002, CARCINOGENESIS, V23, P1127, DOI 10.1093/carcin/23.7.1127; Hjerpe A, 2015, CYTOPATHOLOGY, V26, P142, DOI 10.1111/cyt.12250; Husain AN, 2013, ARCH PATHOL LAB MED, V137, P647, DOI 10.5858/arpa.2012-0214-OA; Hwang HC, 2016, AM J SURG PATHOL, V40, P120, DOI 10.1097/PAS.0000000000000529; Ikeda K, 2011, DIAGN CYTOPATHOL, V39, P395, DOI 10.1002/dc.21398; Illei PB, 2003, CLIN CANCER RES, V9, P2108; Kadota K, 2012, MODERN PATHOL, V25, P260, DOI 10.1038/modpathol.2011.146; Kadota K, 2011, J THORAC ONCOL, V6, P896, DOI 10.1097/JTO.0b013e318211127a; Kao SCH, 2011, J THORAC ONCOL, V6, P602, DOI 10.1097/JTO.0b013e31820ce2c7; Klebe S, 2008, MODERN PATHOL, V21, P1084, DOI 10.1038/modpathol.2008.125; Klebe S, 2010, MODERN PATHOL, V23, P470, DOI 10.1038/modpathol.2009.180; Krasinskas AM, 2010, MODERN PATHOL, V23, P531, DOI 10.1038/modpathol.2009.186; Lopez-Rios F, 2006, CANCER RES, V66, P2970, DOI 10.1158/0008-5472.CAN-05-3907; Maskell NA, 2003, LANCET, V361, P1326, DOI 10.1016/S0140-6736(03)13079-6; Matsumoto S, 2013, CANCER CYTOPATHOL, V121, P415, DOI 10.1002/cncy.21269; McGregor SM, 2015, HUM PATHOL, V46, P1670, DOI 10.1016/j.humpath.2015.06.024; Metintas M, 2016, RESPIRATION, V91, P156, DOI 10.1159/000443483; Monaco SE, 2011, AM J CLIN PATHOL, V135, P619, DOI 10.1309/AJCPP5R2ZJZKCLWN; Nabeshima K, 2016, DIAGN CYTOPATHOL, V44, P774, DOI 10.1002/dc.23501; Ordonez NG, 2012, MODERN PATHOL, V25, P1011, DOI 10.1038/modpathol.2012.39; Paintal A, 2013, CANCER CYTOPATHOL, V121, P703, DOI 10.1002/cncy.21342; Savic S, 2010, CHEST, V138, P137, DOI 10.1378/chest.09-1951; Sheffield BS, 2015, AM J SURG PATHOL, V39, P977, DOI 10.1097/PAS.0000000000000394; Shi M, 2011, AM J SURG PATHOL, V35, P878, DOI 10.1097/PAS.0b013e318218985b; STERRETT GF, 1987, ACTA CYTOL, V31, P185; Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912; Tochigi N, 2013, ARCH PATHOL LAB MED, V137, P632, DOI 10.5858/arpa.2012-0108-OA; Travis WD, 2015, WHO CLASSIFICATION T; Travis WD, 2010, ARCH PATHOL LAB MED, V134, P1645, DOI 10.1043/2010-0086-RAR.1; Wadt KAW, 2015, CLIN GENET, V88, P267, DOI 10.1111/cge.12501; Walts AE, 2016, DIAGN CYTOPATHOL, V44, P599, DOI 10.1002/dc.23491; Weinbreck N, 2007, MODERN PATHOL, V20, P617, DOI 10.1038/modpathol.3800775; Wu D, 2013, AM J CLIN PATHOL, V139, P39, DOI 10.1309/AJCPT94JVWIHBKRD; Yoshikawa Y, 2012, CANCER SCI, V103, P868, DOI 10.1111/j.1349-7006.2012.02223.x; Zauderer MG, 2013, J THORAC ONCOL, V8, P1430, DOI 10.1097/JTO.0b013e31829e7ef9	47	6	6	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	JAN	2018	25	1					24	30		10.1097/PAP.0000000000000180			7	Pathology	Pathology	FP9AX	WOS:000417940800003	29227332				2019-10-28	
J	Valasek, MA; Pai, RK				Valasek, Mark A.; Pai, Reetesh K.			An Update on the Diagnosis, Grading, and Staging of Appendiceal Mucinous Neoplasms	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						appendix; mucinous neoplasm; mucinous adenocarcinoma; pseudomyxoma peritonei; low-grade appendiceal mucinous neoplasm; LAMN; signet ring cell carcinoma; mucinous carcinoma peritonei	HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; DISSEMINATED PERITONEAL ADENOMUCINOSIS; SIGNET-RING CELLS; OF-THE-LITERATURE; PSEUDOMYXOMA-PERITONEI; CLINICOPATHOLOGICAL ANALYSIS; SYSTEMIC CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; INTESTINAL METAPLASIA; SINGLE-INSTITUTION	Despite advances in our understanding of appendiceal mucinous neoplasms and their relationship to the pseudomyxoma peritonei syndrome, the classification of mucinous tumors of the appendix is still confusing. This review will provide an update on the various classification systems that have been recently proposed for appendiceal mucinous neoplasia, with a particular emphasis on how to handle and report the histologic findings for these tumors using the newly published Peritoneal Surface Oncology Group International (PSOGI) and American Joint Committee on Cancer (AJCC) eighth edition guidelines. A simplified approach to diagnostic reporting of appendiceal mucinous neoplasms based on the 3-tier AJCC grading scheme is detailed and specific criteria for assessing grade in appendiceal mucinous neoplasia will be outlined. In addition, histologic mimics of appendiceal mucinous neoplasia and how to distinguish these mimics from mucinous neoplasia will be discussed. Finally, despite improvements in diagnostic terminology, significant challenges in classifying appendiceal mucinous neoplasia persist and diagnostic strategies will be detailed to assist practicing pathologists in these challenging scenarios.	[Valasek, Mark A.] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; [Pai, Reetesh K.] Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA USA	Pai, RK (reprint author), Univ Pittsburgh, Presbyterian Hosp, Dept Pathol, 200 Lothrop St,Room A-610, Pittsburgh, PA 15213 USA.	pair@upmc.edu					Agrawal AK, 2014, CURR ONCOL, V21, pE155, DOI 10.3747/co.21.1695; Arnason T, 2015, ARCH PATHOL LAB MED, V139, P518, DOI 10.5858/arpa.2014-0246-OA; Asare EA, 2016, CANCER-AM CANCER SOC, V122, P213, DOI 10.1002/cncr.29744; Baratti D, 2008, ANN SURG ONCOL, V15, P526, DOI 10.1245/s10434-007-9691-2; Barrios P, 2016, CLIN TRANSL ONCOL, V18, P437, DOI 10.1007/s12094-015-1413-9; Bijelic L, 2012, GASTROENT RES PRACT, V2012; Bradley RF, 2006, AM J SURG PATHOL, V30, P551, DOI 10.1097/01.pas.0000202039.74837.7d; Carr NJ, 2010, WHO CLASSIFICATION T, P122; Carr NJ, 2016, AM J SURG PATHOL, V40, P14, DOI 10.1097/PAS.0000000000000535; Carr NJ, 2012, J CLIN PATHOL, V65, P919, DOI 10.1136/jclinpath-2012-200843; Chua TC, 2012, J CLIN ONCOL, V30, P2449, DOI 10.1200/JCO.2011.39.7166; Chuaqui RF, 1996, HUM PATHOL, V27, P165, DOI 10.1016/S0046-8177(96)90370-6; Davison JM, 2014, MODERN PATHOL, V27, P1521, DOI 10.1038/modpathol.2014.37; Davison JM, 2014, AM J SURG PATHOL, V38, P583, DOI 10.1097/PAS.0000000000000194; Gleeson EM, 2017, AM J CLIN ONCOL; Hsu M, 2009, AM J SURG PATHOL, V33, P1515, DOI 10.1097/PAS.0b013e3181abe31b; Jhuang JY, 2012, HUM PATHOL, V43, P1148, DOI 10.1016/j.humpath.2011.09.021; Lamps LW, 2000, MODERN PATHOL, V13, P495, DOI 10.1038/modpathol.3880086; Lieu CH, 2012, ANN ONCOL, V23, P652, DOI 10.1093/annonc/mdr279; Liu X, 2014, CLIN CHEM, V60, P1004, DOI 10.1373/clinchem.2014.225565; Liu Y, 2016, ANN SURG ONCOL, V23, P1625, DOI 10.1245/s10434-015-5056-4; McKenne JK, 2008, AM J SURG PATHOL, V32, P645, DOI 10.1097/PAS.0b013e31815b486d; Misdraji J, 2004, MODERN PATHOL, V17, P1447, DOI 10.1038/modpathol.3800212; Misdraji J, 2003, AM J SURG PATHOL, V27, P1089, DOI 10.1097/00000478-200308000-00006; Misdraji J, 2014, AM J SURG PATHOL, V38, P698, DOI 10.1097/PAS.0000000000000167; Mizuta Y, 2005, PANCREATOLOGY, V5, P470, DOI 10.1159/000086551; Nishikawa G, 2013, BRIT J CANCER, V108, P951, DOI 10.1038/bjc.2013.47; Noguchi R, 2015, CANCER MED-US, V4, P1809, DOI 10.1002/cam4.542; Nummela P, 2015, INT J CANCER, V136, pE282, DOI 10.1002/ijc.29245; Overman MJ, 2013, ANN SURG, V257, P1072, DOI 10.1097/SLA.0b013e318269d680; Overman MJ, 2017, AJCC CANC STAGING MA, P237; Pai RK, 2009, AM J SURG PATHOL, V33, P1425, DOI 10.1097/PAS.0b013e3181af6067; Pai RK, 2014, HUM PATHOL, V45, P227, DOI 10.1016/j.humpath.2013.10.021; Remorgida V, 2007, OBSTET GYNECOL SURV, V62, P461, DOI 10.1097/01.ogx.0000268688.55653.5c; Ronnett BM, 1997, INT J GYNECOL PATHOL, V16, P1, DOI 10.1097/00004347-199701000-00001; RONNETT BM, 1995, AM J SURG PATHOL, V19, P1390, DOI 10.1097/00000478-199512000-00006; Ronnett BM, 2001, CANCER, V92, P85, DOI 10.1002/1097-0142(20010701)92:1<85::AID-CNCR1295>3.0.CO;2-R; Rosenberger LH, 2012, J GASTROINTEST SURG, V16, P762, DOI 10.1007/s11605-012-1823-8; Shapiro JF, 2010, CANCER-AM CANCER SOC, V116, P316, DOI 10.1002/cncr.24715; Shetty S, 2013, AM SURGEON, V79, P1171; Singhi AD, 2014, HUM PATHOL, V45, P1737, DOI 10.1016/j.humpath.2014.04.018; Sio TT, 2014, J HUM GENET, V59, P124, DOI 10.1038/jhg.2013.132; Sirintrapun SJ, 2014, HUM PATHOL, V45, P1597, DOI 10.1016/j.humpath.2014.03.007; Sugarbaker PH, 2008, TUMORI, V94, P732; Sugarbaker PH, 2010, J SURG ONCOL, V102, P576, DOI 10.1002/jso.21679; Szych C, 1999, AM J PATHOL, V154, P1849, DOI 10.1016/S0002-9440(10)65442-9; Taggart MW, 2013, AM J SURG PATHOL, V37, P1192, DOI 10.1097/PAS.0b013e318282649b; Teixeira MR, 1997, CANCER GENET CYTOGEN, V93, P157, DOI 10.1016/S0165-4608(96)00186-0; Vyas M, 2017, PATHOL RES PRACT, V213, P39, DOI 10.1016/j.prp.2016.10.011; Yamana I, 2012, SURG TODAY, V42, P363, DOI 10.1007/s00595-012-0152-6; Yantiss RK, 2007, AM J SURG PATHOL, V31, P1742, DOI 10.1097/PAS.0b013e31806bee6d; Yantiss RK, 2009, AM J SURG PATHOL, V33, P248, DOI 10.1097/PAS.0b013e31817ec31e; YOUNG RH, 1991, AM J SURG PATHOL, V15, P415, DOI 10.1097/00000478-199105000-00001	53	8	10	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	JAN	2018	25	1					38	60		10.1097/PAP.0000000000000178			23	Pathology	Pathology	FP9AX	WOS:000417940800005	29016471				2019-10-28	
J	Fadare, O; Roma, AA; Parkash, V; Zheng, WX; Walavalkar, V				Fadare, Oluwole; Roma, Andres A.; Parkash, Vinita; Zheng, Wenxin; Walavalkar, Vighnesh			Does a p53 "Wild-type" Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma?	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						p53; endometrial serous carcinoma; immunohistochemistry; wild-type	EXONUCLEASE DOMAIN MUTATIONS; CLEAR-CELL CARCINOMA; LI-FRAUMENI-SYNDROME; MUTANT P53; INTRAEPITHELIAL CARCINOMA; PAPILLARY CARCINOMA; UTERINE CORPUS; IMMUNOHISTOCHEMICAL ANALYSIS; GLANDULAR DYSPLASIA; PROTEIN EXPRESSION	An aberrant p53 immunophenotype may be identified in several histotypes of endometrial carcinoma, and is accordingly recognized to lack diagnostic specificity in and of itself. However, based on the high frequency with which p53 aberrations have historically been identified in endometrial serous carcinoma, a mutation-type immunophenotype is considered to be highly sensitive for the histotype. Using an illustrative case study and a review of the literature, we explore a relatively routine diagnostic question: whether the negative predictive value of a wild-type p53 immunophenotype for serous carcinoma is absolute, that is, whether a p53-wild type immunophenotype is absolutely incompatible with a diagnosis of serous carcinoma. The case is an advanced stage endometrial carcinoma that was reproducibly classified by pathologists from 3 institutions as serous carcinoma based on its morphologic features. By immunohistochemistry, the tumor was p53-wild type (DO-7 clone), diffusely positive for p16 (block positivity), and showed retained expression of PTEN, MSH2, MSH6, MLH1, and PMS2. Next generation sequencing showed that there indeed was an underlying mutation in TP53 (D393fs*78, R213*). The tumor was microsatellite stable, had a low mutational burden (4 mutations per MB), and displayed no mutations in the exonuclease domain of DNA polymerase epsilon (POLE) gene. Other genomic alterations included RB1 mutation (R46fs*19), amplifications in MYST3 and CRKL, and ARID1A deletion (splice site 5125-94_5138del108). A review of the recent literature identified 5 studies in which a total of 259 cases of serous carcinoma were whole-exome sequenced. The average TP53 mutational rate in endometrial serous carcinoma was only 75% (range, 60 to 88). A total of 12 (33%) of 36 immunohistochemical studies reported a p53-aberrant rate of <80% in endometrial serous carcinoma. We discuss in detail several potential explanations that may underlie the scenario of serous carcinoma-like morphology combined with p53-wild-type immunophenotype, including analytic limitations, a nonserous histotype displaying morphologic mimicry of serous carcinoma, and true biological phenomena (including the possibility of a TP53-independent pathway of endometrial serous carcinogenesis). Ultimately, our central thematic question is provisionally answered in the negative. At present, the available data would not support a categorical conclusion that a p53 alteration is a necessary and obligate component in the genesis and/or diagnosis of endometrial serous carcinoma. On the basis of their collective experience, the authors proffer some recommendations on the use of p53 immunohistochemistry in the histotyping of endometrial carcinomas.	[Fadare, Oluwole; Roma, Andres A.; Walavalkar, Vighnesh] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; [Parkash, Vinita] Yale Sch Med, Dept Pathol, New Haven, CT USA; [Zheng, Wenxin] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA	Fadare, O (reprint author), UC San Diego Hlth, Div Anat Pathol, 9300 Campus Point Dr,Suite 1-200,MC 7723, La Jolla, CA 92037 USA.	oluwole.fadare@gmail.com					Alessandro DS, 2015, GYNECOL ONCOL REP, V12, P3, DOI 10.1016/j.gore.2015.01.005; Alkushi A, 2010, INT J GYNECOL PATHOL, V29, P343, DOI 10.1097/PGP.0b013e3181cd6552; Allo G, 2014, MODERN PATHOL, V27, P255, DOI 10.1038/modpathol.2013.144; Alsner J, 2008, ACTA ONCOL, V47, P600, DOI 10.1080/02841860802047411; Altman AD, 2015, GYNECOL ONCOL, V139, P268, DOI 10.1016/j.ygyno.2015.09.001; Alvarez T, 2012, AM J SURG PATHOL, V36, P753, DOI 10.1097/PAS.0b013e318247b7bb; Ambros RA, 1996, MODERN PATHOL, V9, P1165; Bakhsh S, 2016, HISTOPATHOLOGY, V68, P916, DOI 10.1111/his.12878; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bellone S, 2017, GYNECOL ONCOL, V144, P146, DOI 10.1016/j.ygyno.2016.11.023; Bernardini MQ, 2016, GYNECOL ONCOL, V141, P148, DOI 10.1016/j.ygyno.2016.02.002; Blom R, 1998, GYNECOL ONCOL, V68, P18, DOI 10.1006/gyno.1997.4892; Boruta DM, 2009, GYNECOL ONCOL, V115, P142, DOI 10.1016/j.ygyno.2009.06.011; BUR ME, 1992, AM J CLIN PATHOL, V98, P81, DOI 10.1093/ajcp/98.1.81; Busmanis I, 2005, ANN ACAD MED SINGAP, V34, P421; Chen WQ, 2017, INT J GYNECOL PATHOL, V36, P128, DOI 10.1097/PGP.0000000000000291; Chiesa-Vottero AG, 2007, INT J GYNECOL PATHOL, V26, P328, DOI 10.1097/01.pgp.0000235065.31301.3e; Clement PB, 2004, ADV ANAT PATHOL, V11, P117, DOI 10.1097/00125480-200405000-00001; Daniilidou K, 2013, J BUON, V18, P195; Danks MK, 1998, CELL DEATH DIFFER, V5, P678, DOI 10.1038/sj.cdd.4400408; Darvishian T, 2004, AM J SURG PATHOL, V28, P1568, DOI 10.1097/00000478-200412000-00004; Demopoulos RI, 1999, INT J GYNECOL PATHOL, V18, P233, DOI 10.1097/00004347-199907000-00008; Edmondson RJ, 2017, GYNECOL ONCOL, V146, P327, DOI 10.1016/j.ygyno.2017.05.014; Egan JA, 2004, INT J GYNECOL PATHOL, V23, P119, DOI 10.1097/01.pgp.0000116616.98868.ee; Espinosa I, 2017, AM J SURG PATHOL, V41, P1121, DOI 10.1097/PAS.0000000000000873; Fadare O, 2013, MODERN PATHOL, V26, P1101, DOI 10.1038/modpathol.2013.35; Fadare O, 2009, INT J CLIN EXP PATHO, V2, P411; Fang M, 2014, ONCOGENE, V33, P1336, DOI 10.1038/onc.2013.62; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gilks CB, 2013, AM J SURG PATHOL, V37, P874, DOI 10.1097/PAS.0b013e31827f576a; Haley SL, 2011, ANN DIAGN PATHOL, V15, P402, DOI 10.1016/j.anndiagpath.2011.05.006; Halperin R, 2001, EUR J GYNAECOL ONCOL, V22, P122; Hamel NW, 1996, GYNECOL ONCOL, V62, P192, DOI 10.1006/gyno.1996.0214; Hamilton CA, 2006, BRIT J CANCER, V94, P642, DOI 10.1038/sj.bjc.6603012; Han GM, 2013, MODERN PATHOL, V26, P1594, DOI 10.1038/modpathol.2013.102; Hayano T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114491; HENDRICKSON M, 1982, AM J SURG PATHOL, V6, P93, DOI 10.1097/00000478-198203000-00002; Hernandez-Monge Jesus, 2016, Genes Cancer, V7, P278, DOI 10.18632/genesandcancer.120; Hirschowitz L, 2009, HISTOPATHOLOGY, V55, P478, DOI 10.1111/j.1365-2559.2009.03390.x; Hoang LN, 2017, AM J SURG PATHOL, V41, P245, DOI 10.1097/PAS.0000000000000764; Hoang LN, 2014, HISTOPATHOLOGY, V64, P585, DOI 10.1111/his.12286; Howitt BE, 2015, JAMA ONCOL, V1, P1319, DOI 10.1001/jamaoncol.2015.2151; Hui P, 2005, MODERN PATHOL, V18, P75, DOI 10.1038/modpathol.3800271; Hussein YR, 2015, MODERN PATHOL, V28, P505, DOI 10.1038/modpathol.2014.143; Idrees MT, 2006, HISTOPATHOLOGY, V49, P75, DOI 10.1111/j.1365-2559.2006.02447.x; INOUE M, 1994, AM J CLIN PATHOL, V102, P665, DOI 10.1093/ajcp/102.5.665; Jarboe EA, 2009, MODERN PATHOL, V22, P345, DOI 10.1038/modpathol.2008.197; Jia L, 2008, CLIN CANCER RES, V14, P2263, DOI 10.1158/1078-0432.CCR-07-4837; Jia L, 2015, MODERN PATHOL, V28, P118, DOI 10.1038/modpathol.2014.76; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; KHALIFA MA, 1994, GYNECOL ONCOL, V53, P84, DOI 10.1006/gyno.1994.1092; Khoury MP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000927; Kihara A, 2016, HISTOPATHOLOGY, V69, P374, DOI 10.1111/his.12971; KING SA, 1995, CANCER, V75, P2700, DOI 10.1002/1097-0142(19950601)75:11<2700::AID-CNCR2820751110>3.0.CO;2-I; Kobel M, 2016, J PATHOL CLIN RES, V2, P247, DOI 10.1002/cjp2.53; KOHLER MF, 1992, CANCER RES, V52, P1622; Kommoss F, 2017, AM J SURG PATHOL, V41, P161, DOI 10.1097/PAS.0000000000000757; Kounelis S, 2000, MODERN PATHOL, V13, P379, DOI 10.1038/modpathol.3880062; Kovalev S, 1998, HUM PATHOL, V29, P613, DOI 10.1016/S0046-8177(98)80012-9; Kuhn E, 2012, JNCI-J NATL CANCER I, V104, P1503, DOI 10.1093/jnci/djs345; Kurnit KC, 2017, MODERN PATHOL, V30, P1032, DOI 10.1038/modpathol.2017.15; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lax SF, 2000, CANCER-AM CANCER SOC, V88, P814, DOI 10.1002/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.3.CO;2-L; Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455; Lee EJ, 2010, GYNECOL ONCOL, V116, P533, DOI 10.1016/j.ygyno.2009.11.018; Li C, 2007, MODERN PATHOL, V20, P1263, DOI 10.1038/modpathol.3800960; McCluggage WG, 2005, INT J GYNECOL PATHOL, V24, P307, DOI 10.1097/01.pgp.0000167113.86586.65; McCluggage WG, 2011, HISTOPATHOLOGY, V59, P786, DOI 10.1111/j.1365-2559.2011.03907.x; McConechy MK, 2016, CLIN CANCER RES, V22, P2865, DOI 10.1158/1078-0432.CCR-15-2233; McConechy MK, 2012, J PATHOL, V228, P20, DOI 10.1002/path.4056; Meng B, 2014, GYNECOL ONCOL, V134, P15, DOI 10.1016/j.ygyno.2014.05.006; Mhawech-Fauceglia P, 2010, AM J CLIN PATHOL, V133, P899, DOI 10.1309/AJCPQDQXJ4FNRFQB; Nafisi H, 2015, INT J GYNECOL PATHOL, V34, P424, DOI 10.1097/PGP.0000000000000179; Nofech-Mozes S, 2008, MODERN PATHOL, V21, P1147, DOI 10.1038/modpathol.2008.108; OKAMOTO A, 1991, CANCER RES, V51, P5632; Oliner J. D., 2016, COLD SPRING HARB PER, P6; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; PRAT J, 1994, CANCER, V74, P1778, DOI 10.1002/1097-0142(19940915)74:6<1778::AID-CNCR2820740621>3.0.CO;2-5; Ragni N, 2005, EUR J OBSTET GYN R B, V123, P111, DOI 10.1016/j.ejogrb.2005.03.018; Ramalingam P, 2016, INT J GYNECOL PATHOL, V35, P410, DOI 10.1097/PGP.0000000000000248; REINARTZ JJ, 1994, HUM PATHOL, V25, P1075, DOI 10.1016/0046-8177(94)90068-X; Russo A, 2005, J CLIN ONCOL, V23, P7518, DOI 10.1200/JCO.2005.00.471; Saegusa M, 1997, J CANCER RES CLIN, V123, P429, DOI 10.1007/BF01372546; Schmitz MJ, 2000, GYNECOL ONCOL, V77, P439, DOI 10.1006/gyno.2000.5814; Schultheis AM, 2016, INT J GYNECOL PATHOL, V35, P289, DOI 10.1097/PGP.0000000000000243; Semczuk A, 2005, ONCOLOGY-BASEL, V69, P317, DOI 10.1159/000089764; Senturk S, 2014, P NATL ACAD SCI USA, V111, pE3287, DOI 10.1073/pnas.1321640111; SHERMAN ME, 1995, HUM PATHOL, V26, P1268, DOI 10.1016/0046-8177(95)90204-X; Shirole NH, 2016, ELIFE, V5, DOI 10.7554/eLife.17929; Sho T, 2014, INT J GYNECOL CANCER, V24, P102, DOI 10.1097/IGC.0000000000000029; Sholl Andrew B, 2012, Gynecol Oncol Case Rep, V3, P11, DOI 10.1016/j.gynor.2012.10.005; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Skomedal H, 1999, J PATHOL, V187, P556, DOI 10.1002/(SICI)1096-9896(199904)187:5<556::AID-PATH294>3.0.CO;2-Y; Sorbe B, 2016, ONCOL LETT, V11, P2283, DOI 10.3892/ol.2016.4178; Soslow RA, 1998, INT J GYNECOL PATHOL, V17, P129, DOI 10.1097/00004347-199804000-00006; Stewart RL, 1998, HISTOPATHOLOGY, V33, P440, DOI 10.1046/j.1365-2559.1998.00499.x; Suh YA, 2011, CANCER RES, V71, P7168, DOI 10.1158/0008-5472.CAN-11-0459; Talhouk A, 2016, Gynecol Oncol Res Pract, V3, P14, DOI 10.1186/s40661-016-0035-4; Tashiro H, 1997, AM J PATHOL, V150, P177; Taskin OC, 2016, APPL IMMUNOHISTOCHEM; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Togami S, 2015, PATHOL ONCOL RES, V21, P487, DOI 10.1007/s12253-014-9854-y; Trahan S, 2005, HUM PATHOL, V36, P1316, DOI 10.1016/j.humpath.2005.09.015; TSUDA H, 1992, JPN J CANCER RES, V83, P1184, DOI 10.1111/j.1349-7006.1992.tb02743.x; Uppendahl L, 2017, CURR OPIN OBSTET GYN, V29, P35, DOI 10.1097/GCO.0000000000000342; Vang R, 2016, INT J GYNECOL PATHOL, V35, P48, DOI 10.1097/PGP.0000000000000207; Vasil'eva E V, 2005, Arkh Patol, V67, P25; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang XJ, 2012, FEBS LETT, V586, P1390, DOI 10.1016/j.febslet.2012.02.049; Xue De-bin, 2010, Chinese Journal of Pathology, V39, P671, DOI 10.3760/cma.j.issn.0529-5807.2010.10.006; Yan ZJ, 2010, APPL IMMUNOHISTO M M, V18, P75, DOI 10.1097/PAI.0b013e3181b1d10e; Zaino R., 2014, WHO CLASSIFICATION T, P125; Zhang X, 2009, AM J PATHOL, V174, P2000, DOI 10.2353/ajpath.2009.081085; Zhang YX, 2013, INT J GYNECOL PATHOL, V32, P476, DOI 10.1097/PGP.0b013e31826ddc4e; Zhao SM, 2013, P NATL ACAD SCI USA, V110, P2916, DOI 10.1073/pnas.1222577110; Zheng WX, 2011, AM J SURG PATHOL, V35, pE1, DOI 10.1097/PAS.0b013e318202772e; Zheng WX, 2004, INT J SURG PATHOL, V12, P207, DOI 10.1177/106689690401200302	120	0	0	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	JAN	2018	25	1					61	70		10.1097/PAP.0000000000000171			10	Pathology	Pathology	FP9AX	WOS:000417940800006	28945609				2019-10-28	
